{
  "metadata": {
    "config": {
      "backend": {
        "_target_": "cotlab.backends.VLLMBackend",
        "tensor_parallel_size": 1,
        "dtype": "bfloat16",
        "trust_remote_code": true,
        "max_model_len": 8192,
        "quantization": "bitsandbytes",
        "gpu_memory_utilization": 0.7,
        "enforce_eager": true,
        "limit_mm_per_prompt": {
          "image": 0
        }
      },
      "model": {
        "name": "google/medgemma-4b-it",
        "variant": "4b",
        "max_new_tokens": 512,
        "temperature": 0.7,
        "top_p": 0.9,
        "safe_name": "medgemma_4b"
      },
      "prompt": {
        "_target_": "cotlab.prompts.tcga.TCGAPromptStrategy",
        "name": "tcga",
        "few_shot": true,
        "output_format": "plain"
      },
      "dataset": {
        "_target_": "cotlab.datasets.loaders.TCGADataset",
        "name": "tcga",
        "reports_filename": "tcga/TCGA_Reports.csv",
        "labels_filename": "tcga/tcga_patient_to_cancer_type.csv",
        "split": "test"
      },
      "experiment": {
        "_target_": "cotlab.experiments.ClassificationExperiment",
        "name": "classification",
        "description": "Classification from medical reports",
        "num_samples": 500
      },
      "seed": 42,
      "verbose": true,
      "dry_run": false
    },
    "start_time": "2026-01-19T15:20:36.039543"
  },
  "experiment": "classification",
  "model": "google/medgemma-4b-it",
  "prompt_strategy": "tcga",
  "metrics": {
    "correct": 208,
    "incorrect": 279,
    "parse_errors": 13,
    "accuracy": 0.4271047227926078,
    "parse_error_rate": 0.026,
    "classification_report": {
      "ACC": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 4.0
      },
      "ADCA": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "ADEN": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "ADENOCA": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "ADENOCARC": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "ADENOCARCINOMA": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "ADENOMA": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "ADENOSQUAMOUS": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "ADENOSQUAMOUS CARCINOMA": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "ADREN": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "BLCA": {
        "precision": 0.75,
        "recall": 0.1875,
        "f1-score": 0.3,
        "support": 16.0
      },
      "BRCA": {
        "precision": 0.625,
        "recall": 0.9482758620689655,
        "f1-score": 0.7534246575342466,
        "support": 58.0
      },
      "CCRC": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "CESC": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 12.0
      },
      "CHOL": {
        "precision": 0.5,
        "recall": 0.75,
        "f1-score": 0.6,
        "support": 4.0
      },
      "COAD": {
        "precision": 0.6,
        "recall": 0.5,
        "f1-score": 0.5454545454545454,
        "support": 24.0
      },
      "Cervix": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "DLBC": {
        "precision": 1.0,
        "recall": 0.8,
        "f1-score": 0.8888888888888888,
        "support": 5.0
      },
      "ESCA": {
        "precision": 0.3333333333333333,
        "recall": 0.2,
        "f1-score": 0.25,
        "support": 5.0
      },
      "F10": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "GBM": {
        "precision": 0.4444444444444444,
        "recall": 0.6666666666666666,
        "f1-score": 0.5333333333333333,
        "support": 18.0
      },
      "HNSC": {
        "precision": 0.5555555555555556,
        "recall": 0.16129032258064516,
        "f1-score": 0.25,
        "support": 31.0
      },
      "HSBC": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "Hepatocellular Carcinoma": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "Hepatocellular carcinoma": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "KICH": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 9.0
      },
      "KIRC": {
        "precision": 0.2074074074074074,
        "recall": 1.0,
        "f1-score": 0.34355828220858897,
        "support": 28.0
      },
      "KIRP": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 12.0
      },
      "LARY": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "LCLC": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "LGG": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 25.0
      },
      "LIHC": {
        "precision": 0.8,
        "recall": 0.23529411764705882,
        "f1-score": 0.36363636363636365,
        "support": 17.0
      },
      "LIRG": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "LSCC": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "LUAD": {
        "precision": 0.6451612903225806,
        "recall": 0.9523809523809523,
        "f1-score": 0.7692307692307693,
        "support": 21.0
      },
      "LUSC": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 25.0
      },
      "MBL": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "MESO": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 2.0
      },
      "OLIG": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "OV": {
        "precision": 1.0,
        "recall": 0.23529411764705882,
        "f1-score": 0.38095238095238093,
        "support": 17.0
      },
      "PAAD": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 7.0
      },
      "PCPG": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 7.0
      },
      "PHCG": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "PRAD": {
        "precision": 0.4166666666666667,
        "recall": 0.3125,
        "f1-score": 0.35714285714285715,
        "support": 16.0
      },
      "READ": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 12.0
      },
      "SARC": {
        "precision": 1.0,
        "recall": 0.2857142857142857,
        "f1-score": 0.4444444444444444,
        "support": 14.0
      },
      "SCC": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "SKCM": {
        "precision": 0.25,
        "recall": 0.6666666666666666,
        "f1-score": 0.36363636363636365,
        "support": 3.0
      },
      "STAD": {
        "precision": 0.9090909090909091,
        "recall": 0.5,
        "f1-score": 0.6451612903225806,
        "support": 20.0
      },
      "TGCT": {
        "precision": 0.4,
        "recall": 0.6666666666666666,
        "f1-score": 0.5,
        "support": 3.0
      },
      "THCA": {
        "precision": 1.0,
        "recall": 0.38461538461538464,
        "f1-score": 0.5555555555555556,
        "support": 26.0
      },
      "THYM": {
        "precision": 0.7692307692307693,
        "recall": 1.0,
        "f1-score": 0.8695652173913043,
        "support": 10.0
      },
      "TPC": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "UC": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "UCEC": {
        "precision": 0.6190476190476191,
        "recall": 0.5,
        "f1-score": 0.5531914893617021,
        "support": 26.0
      },
      "UCLM": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "UCS": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 5.0
      },
      "UCSC": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "UROS": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "UUC": {
        "precision": 0.0,
        "recall": 0.0,
        "f1-score": 0.0,
        "support": 0.0
      },
      "UVM": {
        "precision": 0.5,
        "recall": 0.2,
        "f1-score": 0.2857142857142857,
        "support": 5.0
      },
      "accuracy": 0.4271047227926078,
      "macro avg": {
        "precision": 0.21844160647703745,
        "recall": 0.18283385315826806,
        "f1-score": 0.1729982086034133,
        "support": 487.0
      },
      "weighted avg": {
        "precision": 0.491952184864684,
        "recall": 0.4271047227926078,
        "f1-score": 0.39393790552410046,
        "support": 487.0
      }
    },
    "macro_precision": 0.21844160647703745,
    "macro_recall": 0.18283385315826806,
    "macro_f1": 0.1729982086034133,
    "weighted_f1": 0.39393790552410046,
    "confusion_matrix": [
      [
        0,
        1,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        2,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        3,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        9,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        2,
        0,
        0,
        0,
        1,
        1,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        55,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        3,
        1,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        3,
        1,
        0,
        0,
        0,
        2,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        3,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        12,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        12,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        4,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        1,
        0,
        0,
        1,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        12,
        0,
        0,
        0,
        0,
        0,
        6,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        1,
        0,
        1,
        0,
        1,
        1,
        0,
        1,
        2,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        5,
        0,
        0,
        0,
        0,
        4,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        2,
        0,
        0,
        2,
        0,
        0,
        6,
        3,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        9,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        28,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        12,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        15,
        0,
        0,
        0,
        0,
        0,
        7,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        3,
        0,
        8,
        0,
        0,
        0,
        0,
        4,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        20,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        1,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        2,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        2,
        0,
        0,
        2,
        0,
        0,
        0,
        1,
        11,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        3,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        10,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        4,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        2,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        1,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        3,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        1,
        0,
        0,
        0,
        1,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        2,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        10,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        5,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        4,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        4,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        2,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        7,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        4,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        2,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        2,
        0,
        1,
        6,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        10,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        2,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        5,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        2,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        2,
        10,
        3,
        1,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        1
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        10,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        9,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        4,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        13,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        3,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
      ],
      [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        3,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        1
      ]
    ],
    "class_labels": [
      "ACC",
      "ADCA",
      "ADEN",
      "ADENOCA",
      "ADENOCARC",
      "ADENOCARCINOMA",
      "ADENOMA",
      "ADENOSQUAMOUS",
      "ADENOSQUAMOUS CARCINOMA",
      "ADREN",
      "BLCA",
      "BRCA",
      "CCRC",
      "CESC",
      "CHOL",
      "COAD",
      "Cervix",
      "DLBC",
      "ESCA",
      "F10",
      "GBM",
      "HNSC",
      "HSBC",
      "Hepatocellular Carcinoma",
      "Hepatocellular carcinoma",
      "KICH",
      "KIRC",
      "KIRP",
      "LARY",
      "LCLC",
      "LGG",
      "LIHC",
      "LIRG",
      "LSCC",
      "LUAD",
      "LUSC",
      "MBL",
      "MESO",
      "OLIG",
      "OV",
      "PAAD",
      "PCPG",
      "PHCG",
      "PRAD",
      "READ",
      "SARC",
      "SCC",
      "SKCM",
      "STAD",
      "TGCT",
      "THCA",
      "THYM",
      "TPC",
      "UC",
      "UCEC",
      "UCLM",
      "UCS",
      "UCSC",
      "UROS",
      "UUC",
      "UVM"
    ],
    "top_confused_pairs": [
      [
        "LGG",
        "GBM",
        15
      ],
      [
        "COAD",
        "KIRC",
        12
      ],
      [
        "KIRP",
        "KIRC",
        12
      ],
      [
        "LUSC",
        "LUAD",
        11
      ],
      [
        "OV",
        "BRCA",
        10
      ],
      [
        "PRAD",
        "KIRC",
        10
      ],
      [
        "BLCA",
        "KIRC",
        9
      ],
      [
        "KICH",
        "KIRC",
        9
      ],
      [
        "UCEC",
        "BRCA",
        9
      ],
      [
        "LIHC",
        "KIRC",
        8
      ]
    ],
    "true_class_distribution": {
      "THYM": 10,
      "CESC": 12,
      "BLCA": 16,
      "KIRC": 28,
      "KICH": 9,
      "HNSC": 31,
      "COAD": 24,
      "BRCA": 58,
      "UCEC": 26,
      "SARC": 14,
      "STAD": 20,
      "LUSC": 25,
      "PRAD": 16,
      "THCA": 26,
      "SKCM": 3,
      "GBM": 18,
      "UCS": 5,
      "OV": 17,
      "LGG": 25,
      "UVM": 5,
      "LUAD": 21,
      "LIHC": 17,
      "READ": 12,
      "KIRP": 12,
      "ESCA": 5,
      "PCPG": 7,
      "TGCT": 3,
      "ACC": 4,
      "PAAD": 7,
      "DLBC": 5,
      "CHOL": 4,
      "MESO": 2
    },
    "pred_class_distribution": {
      "THYM": 13,
      "CCRC": 1,
      "BLCA": 4,
      "KIRC": 135,
      "ADENOSQUAMOUS CARCINOMA": 1,
      "BRCA": 88,
      "UCEC": 21,
      "PRAD": 12,
      "STAD": 11,
      "LUAD": 31,
      "SCC": 9,
      "SKCM": 8,
      "THCA": 10,
      "GBM": 27,
      "ESCA": 3,
      "OV": 4,
      "ADENOCA": 5,
      "LCLC": 2,
      "CHOL": 6,
      "COAD": 20,
      "HNSC": 9,
      "Hepatocellular Carcinoma": 1,
      "UCLM": 1,
      "ADENOMA": 9,
      "LIHC": 5,
      "TGCT": 5,
      "ADENOCARCINOMA": 3,
      "UVM": 2,
      "LARY": 1,
      "UCSC": 3,
      "ADENOCARC": 1,
      "ADREN": 1,
      "SARC": 4,
      "HSBC": 1,
      "ADCA": 3,
      "PHCG": 2,
      "ADENOSQUAMOUS": 1,
      "DLBC": 4,
      "PAAD": 4,
      "Hepatocellular carcinoma": 3,
      "LSCC": 1,
      "F10": 1,
      "MBL": 1,
      "UCS": 1,
      "LIRG": 1,
      "UUC": 1,
      "Cervix": 1,
      "UROS": 1,
      "OLIG": 1,
      "TPC": 1,
      "ADEN": 2,
      "UC": 1
    },
    "num_classes": 61
  },
  "raw_outputs": [
    {
      "sample_idx": 1309,
      "input": "Macroscopic examination : Piece weighing 1208 g thymectomy fresh and measuring 19 x 17 x 8 cm. it. extended by a pulmonary resection lingula measuring 8 X 5 X 2 cm When cut , it. is a yellowish white tumor lobulated showing necrotic and remodeling. a small yellowish nodule. Lymph node latero- tracheal top right measuring 1.5 cm in diameter. Microscopic examination : 1) Thymectomy : Many samples were taken ( 1A to 1D ) The tumor has an architecture. lobulated It comprises an epithelial cell proli...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```",
      "predicted": "THYM",
      "ground_truth": "THYM",
      "correct": true,
      "reasoning": "1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.",
      "idx": 1309,
      "timestamp": "2026-01-19T15:59:53.111979"
    },
    {
      "sample_idx": 228,
      "input": "Result date: Date Collected: SPECIMEN A: CERVIX BX. SPECIMEN B: BLADDER BX. CLINICAL HISTORY: SPECIMENS SUBMITTED: A. CERVIX BX. B. BLADDER BX. DIAGNOSIS: CERVIX; BIOPSY: INVASIVE, POORLY DIFFERENTIATED SQUAMOUS CELL CARCINOMA. ANGIOLYMPHATIC INVASION NOT IDENTIFIED. SPECIMEN IS NEARLY ENTIRELY INVASIVE CARCINOMA, DEPTH OF INVASION CANNOT BE. DETERMINED, BUT TUMOR MEASURES 1.0 CM IN MICROSCOPIC SECTION. BLADDER, BIOPSY: SQUAMOUS METAPLASIA WITHOUT DYSPLASIA. NEGATIVE FOR CARCINOMA. ABUNDANT BLOO...",
      "response": "```json\n{\n    \"cancer_type\": \"CCRC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to CCRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Squamous metaplasia without dysplasia. 3. Code: Bladder maps to BLCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Squamous metaplasia without dysplasia. 3. Code: Bladder maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Squamous metaplasia without dysplasia. 3. Code: Bladder maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Squamous metaplasia without dysplasia. 3. Code: Bladder maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Squamous metaplasia without dysplasia. 3. Code: Bladder maps to K",
      "predicted": "CCRC",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to CCRC.",
      "idx": 228,
      "timestamp": "2026-01-19T15:59:53.112005"
    },
    {
      "sample_idx": 51,
      "input": "SURGICAL PATHOL 03Y REPOR. DIAGNOSIS: RADICAL CYSTOPROSTATECTOMY, BILATERAL PELVIC LYMPH NODE DISSECTION AND. URINARY DIVERSION (T-POUCH) : RIGHT DISTAL URETER (A) : FROZEN SECTION DIAGNOSIS: NO HIGH GRADE ATYPIA OR TUMOR IDENTIFIED. FINAL DIAGNOSIS: BENIGN URETER. NO UROTHELIAL DYSPLASIA OR MALIGNANCY IDENTIFIED. LEFT DISTAL URETER (B) : FROZEN SECTION DIAGNOSIS: NO HIGH GRADE ATYPIA OR TUMOR IDENTIFIED. FINAL DIAGNOSIS: BENIGN URETER. - NO UROTHELIAL DYSPLASIA OR MALIGNANCY IDENTIFIED. PARA-AO...",
      "response": "```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma with focal signet ring cell component. 3. Code: BLCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman",
      "predicted": "BLCA",
      "ground_truth": "BLCA",
      "correct": true,
      "reasoning": "1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma with focal signet ring cell component. 3. Code: BLCA.",
      "idx": 51,
      "timestamp": "2026-01-19T15:59:53.112026"
    },
    {
      "sample_idx": 563,
      "input": "Clinical History/Diagnosis: Left Renal Tumor. Source of Specimen(s): 1: left Kidney resection with Adrenal gland. 2: left paraaortic lymph nodes. Gross Description: Received in two parts. Source of Tissue: 1. Labeled # 1, \"left kidney with mass, portion of. adrenal and hilar lymph node\". Frozen Section Diagnosis: 1FS- RENAL CELL CARCINOMA. Gross Description: Received fresh in a container labeled left kidney with mass, portion. of adrenal and hilar lymph. node\". It consists of a 720 gram left rad...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: KIRC.\"\n}\n```\n",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: KIRC.",
      "idx": 563,
      "timestamp": "2026-01-19T15:59:53.112047"
    },
    {
      "sample_idx": 501,
      "input": "MEDICAL RECORD. Surgical. Pathology Report Carenoma renal all deronophable. PROCEDURE DATE: SEX: M. SIGN-OUT DATE: ATTENDING: REQUESTING: CONTACT NO: ROOM: COPIES TO: DIAGNOSIS: Kidney, right, radical nephrectomy: Renal cell carcinoma, chromophobe cell type, Fuhrman nuclear. grade II; no capsular invasion seen; vascular, urteral and inked surgical margins of resection are free of tumor; no. tumor seen in three lymph nodes (0/3); see note. NOTE: Kidney Nephrectomy Summary Table Macroscopic. Speci...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, chromophobe cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, chromophobe cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, chromophobe cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, chromophobe cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, chromophobe cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, chromophobe cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, chromophobe cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "KIRC",
      "ground_truth": "KICH",
      "correct": false,
      "reasoning": "1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, chromophobe cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 501,
      "timestamp": "2026-01-19T15:59:53.112061"
    },
    {
      "sample_idx": 457,
      "input": "DIAGNOSIS. (A) TEETH: (B) LEFT NECK DISSECTION, LEVEL I \"A\": Teeth identified, gross identification only. One lymph node, no tumor present (0/1). (C) LEFT PARTIAL GLOSSECTOMY:: INVASIVE SQUAMOUS CARCINOMA -- Well differentiated. Tumor Features: Gross: Exophytic. Size: 7.2 cm in largest dimension. Invasion: Present, depth 0.6 cm. Tumor Border: infiltrative. Perineural Invasion: Absent. Vascular Invasion: Absent. Lymphocyte Infiltration: Absent. Mucosal Margin: (en-face) Negative for invasive carc...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOSQUAMOUS CARCINOMA\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma, well differentiated. 3. Code: ADENOSQUAMOUS CARCINOMA maps to ADENOSQUAMOUS CARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ACC\",\n    \"reasoning\": \"1. Site: Left Neck, Level I. 2. Findings: Lymph node, no tumor present. 3. Code: ACC maps to ACC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ACC\",\n    \"reasoning\": \"1. Site: Left Neck, Level I. 2. Findings: Lymph node, no tumor present. 3. Code: ACC maps to ACC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ACC\",\n    \"reasoning\": \"1. Site: Left Neck, Level I. 2. Findings: Lymph node, no tumor present. 3. Code: ACC maps to ACC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ACC\",\n    \"reasoning\": \"1. Site: Left Neck, Level I. 2. Findings: Lymph node, no tumor present. 3. Code: ACC maps to ACC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ACC\",\n    \"reasoning\": \"1. Site: Left Neck, Level I. 2. Findings: Lymph node, no tumor present. 3. Code: ACC maps to ACC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ACC\",\n    \"reasoning\": \"1. Site: Left Neck, Level II. 2. Findings: Lymph node, no tumor present. 3. Code: ACC maps to ACC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ACC\",\n    \"reasoning\": \"1. Site: Left Neck, Level II. 2. Findings: Lymph node, no tumor present. 3. Code: ACC maps to ACC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ACC\",\n    \"reasoning\": \"1. Site: Left Neck",
      "predicted": "ADENOSQUAMOUS CARCINOMA",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma, well differentiated. 3. Code: ADENOSQUAMOUS CARCINOMA maps to ADENOSQUAMOUS CARCINOMA.",
      "idx": 457,
      "timestamp": "2026-01-19T15:59:53.112083"
    },
    {
      "sample_idx": 285,
      "input": "SPECIMEN. Right colon. CLINICAL NOTES. PRE-OP DIAGNOSIS: Cancer cecum. GROSS DESCRIPTION. Received fresh labeled \"right colon\" is a previously. unopened 30 cm. segment of proximal right colon with. attached 19 cm. of distal ileum surfaced by smooth scabrous tan pink. serosa with a copious amount of attached mesocolon and mesentery. An unremarkable 3.9 cm. appendix averaging 0.5 cm. in diameter is. present. The proximal and distal margins measures 4.5 and 8.0 cm. in circumference respectively. On...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Adenocarcinoma of the cecum, moderately differentiated, pT2, pN0, pM0. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Adenocarcinoma of the cecum, moderately differentiated, pT2, pN0, pM0. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Adenocarcinoma of the cecum, moderately differentiated, pT2, pN0, pM0. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Adenocarcinoma of the cecum, moderately differentiated, pT2, pN0, pM0. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Adenocarcinoma of the cecum, moderately differentiated, pT2, pN0, pM0. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Adenocarcinoma of the cecum, moderately differentiated, pT2, pN0, pM0. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Adenocarcinoma of the cecum, moderately differentiated, pT2, pN0, pM0. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon.",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Right colon. 2. Findings: Adenocarcinoma of the cecum, moderately differentiated, pT2, pN0, pM0. 3. Code: KIRC.",
      "idx": 285,
      "timestamp": "2026-01-19T15:59:53.112100"
    },
    {
      "sample_idx": 209,
      "input": "P.25/33. DIAGNOSIS: BREAST, RIGHT, MODIFIED RADICAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA WITH ASSOCIATED CALCIFICATIONS. B. NOTTINGHAM GRADE 3 (TUBULE FORMATION: 3, NUCLEAR PLEOMORPHISM: 3, MITOTIC ACTIVITY: 3; TOTAL. SCORE: 9/9). C. INVASIVE TUMOR MEASURES 2.5 X 2.3 X 2.0 CM. D. DUCTAL CARCINOMA IN SITU (DCIS), NUCLEAR GRADE 3, SOLID, CRIBRIFORM MICROPAPILLARY AND CLEAR. CELL TYPES WITH COMEDONECROSIS AND ASSOCIATED CALCIFICATIONS. E. THE DUCTAL CARCINOMA IN SITU (DCIS) CONSTITUTES 50% OF...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma with associated calcifications. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma with associated calcifications. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 209,
      "timestamp": "2026-01-19T15:59:53.112112"
    },
    {
      "sample_idx": 1385,
      "input": "SLIDE DISPOSITION: DIAGNOSIS: A. Uterus, hysterectomy: High grade serous carcinoma is. identified. forming a mass (7.0 x 4.1 x 0.4 cm) circumferentially. involving the. endometrial cavity. The tumor invades 0. 4 cm into the. myometrium. (total myometrial thickness, 1.6 cm). The tumor does not. involve. the endocervix. Lymphovascular space invasion is. identified. The. margins are negative for tumor. B. Lymph nodes, right and left para-aortic,. lymphadenectomy : Multiple (6 of 9) lymph nodes posi...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus, hysterectomy. 2. Findings: High-grade serous carcinoma. 3. Code: UCEC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovary and fallopian tube, right, salpingo-oophorectomy. 2. Findings: High-grade serous carcinoma. 3. Code: OV\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovary and fallopian tube, left, salpingo-oophorectomy. 2. Findings: High-grade serous carcinoma. 3. Code: OV\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph nodes, right and left para-aortic, lymphadenectomy. 2. Findings: Lymph node metastasis, consistent with endometrial primary. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Omentum, omentectomy. 2. Findings: Negative for tumor. 3. Code: OV\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph nodes, right and left pelvic, lymphadenectomy. 2. Findings: Lymph node metastasis, consistent with endometrial primary. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovary and fallopian tube, right, salpingo-oophorectomy. 2. Findings: High-grade serous carcinoma. 3. Code: OV\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovary and fallopian tube, left, salpingo-oophorectomy. 2. Findings: High-grade serous carcinoma. 3. Code: OV\"\n}\n```\n```json\n",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus, hysterectomy. 2. Findings: High-grade serous carcinoma. 3. Code: UCEC",
      "idx": 1385,
      "timestamp": "2026-01-19T15:59:53.112122"
    },
    {
      "sample_idx": 1116,
      "input": "Clinical Diagnosis & History: year old with large right retroperitoneal sarcoma encasing vena cava. biopsy (+) leiomyosarcoma. Specimens Submitted: 1: SP: Abdominal leiomyosarcoma. DIAGNOSIS: 1. SOFT TISSUE, RETROPERITONEAL; RESECTION: -HIGH GRADE LEIOMYOSARCOMA INVLOVING WALL OF VENA CAVA. -TUMOR DIMENSIONS: 14 x 13 x 10 CM. FOCAL NECROSIS (LESS THAN 10%) IS PRESENT. -SURGICAL MARGINS (SOFT TISSUE AND VENA CAVA) ARE FREE OF TUMOR. FOCALLY TE TUMOR IS WITHIN 0.2 CM OF SOFT TISSUE MARGIN, HOWEVER...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Abdominal, Soft Tissue. 2. Findings: Leiomyosarcoma, high grade. 3. Code: PRAD maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Abdominal, Soft Tissue. 2. Findings: Leiomyosarcoma, high grade. 3. Code: PRAD maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Abdominal, Soft Tissue. 2. Findings: Leiomyosarcoma, high grade. 3. Code: PRAD maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Abdominal, Soft Tissue. 2. Findings: Leiomyosarcoma, high grade. 3. Code: PRAD maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Abdominal, Soft Tissue. 2. Findings: Leiomyosarcoma, high grade. 3. Code: PRAD maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Abdominal, Soft Tissue. 2. Findings: Leiomyosarcoma, high grade. 3. Code: PRAD maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Abdominal, Soft Tissue. 2. Findings: Leiomyosarcoma, high grade. 3. Code: PRAD maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Abdominal, Soft Tissue. 2. Findings: Leiomyosarcoma, high grade. 3. Code: PRAD maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n",
      "predicted": "PRAD",
      "ground_truth": "SARC",
      "correct": false,
      "reasoning": "1. Site: Abdominal, Soft Tissue. 2. Findings: Leiomyosarcoma, high grade. 3. Code: PRAD maps to PRAD.",
      "idx": 1116,
      "timestamp": "2026-01-19T15:59:53.112131"
    },
    {
      "sample_idx": 178,
      "input": "Final Diagnosis. A. Breast, left, simple mastectomy: Infiltrating lobular carcinoma, Nottingham grade I (of III). [tubules 3/3, nuclei 1/3, mitoses 1/3; Nottingham score 5/9] is identified forming a mass (4.8 x. 2.7 x 1.9 cm) located in the lower outer quadrant of the breast. Biopsy site changes are present. The tumor does not involve the nipple, overlying skin, or underlying chest wall. Lobular. carcinoma in situ is also present. All surgical resection margins, including the deep margin, are. n...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade I. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Lobular carcinoma in situ. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph nodes, left axillary. 2. Findings: Lymph nodes negative for tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph nodes, left lowest axillary. 2. Findings: Lymph nodes negative for tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Breast, left. 2. Findings: Invasive lobular carcinoma, Nottingham grade I. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast, right. 2. Findings: Benign nonproliferative breast parenchyma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph nodes, left axillary. 2. Findings: Multiple lymph nodes negative for tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph nodes, left lowest axillary. 2. Findings: Lymph nodes negative for tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade I. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 178,
      "timestamp": "2026-01-19T15:59:53.112141"
    },
    {
      "sample_idx": 1209,
      "input": "Case ID. 2. Gross. Microscopic Description. Diagnosis Details. Description. Comments. STOMACH TISSUE CHECKLIST. Specimen type: Subtotal resection of stomach. Tumor site: Fundus. Tumor size: 6x5x4cm. Tumor features: None specified. Histologic type: Adenocarcinoma. Histologic grade: Moderately differentiated. Tumor extent: Muscularis propria. Lymph nodes: 0/12 positive for metastasis (Regional. 0/12). Lymphatic invasion: Not specified. Venous invasion: Not specified. Perineural invasion: Not speci...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, moderately differentiated, with lymph node metastasis. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma. 3. Code: Stomach Adenocarcinoma maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma. 3. Code: Stomach Adenocarcinoma maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma. 3. Code: Stomach Adenocarcinoma maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma. 3. Code: Stomach Adenocarcinoma maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma. 3. Code: Stomach Adenocarcinoma maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma. 3. Code: Stomach Adenocarcinoma maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma. 3. Code: Stomach Adenocarcinoma maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma. 3. Code: Stomach",
      "predicted": "STAD",
      "ground_truth": "STAD",
      "correct": true,
      "reasoning": "1. Site: Stomach. 2. Findings: Adenocarcinoma, moderately differentiated, with lymph node metastasis. 3. Code: Stomach Adenocarcinoma maps to STAD.",
      "idx": 1209,
      "timestamp": "2026-01-19T15:59:53.112152"
    },
    {
      "sample_idx": 864,
      "input": "Sample Type TUMOUR. Diagnosis. Squamous Cell Carcinoma, Not Otherwise Specified (NOS). Year of Sample Collection. Age at Sample Collection (yrs). Days to Procedure Date. Days to Diagnosis. Type of Procedure. RESECT. Site of Tissue/Primary (Histology). Right lower lobe. Tumour Size (cm). 6.9000000000000004. Histology. Squamous carcinoma. Grade/Differentiation. II. Pathological T. T2b. Pathological N. Clinical M. MO. VALCSG Stage. Histology Comments. Sample Type BUFFY. Year of Sample Collection. A...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Right lower lobe. 2. Findings: Squamous cell carcinoma, NOS, Grade II, Pathological T2b, Pathological N MO, Clinical M0. 3. Code: Squamous Cell Carcinoma, Not Otherwise Specified (NOS) maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Right lower lobe. 2. Findings: Squamous cell carcinoma, NOS, Grade II, Pathological T2b, Pathological N MO, Clinical M0. 3. Code: Squamous Cell Carcinoma, Not Otherwise Specified (NOS) maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lower lobe. 2. Findings: Squamous cell carcinoma, NOS, Grade II, Pathological T2b, Pathological N MO, Clinical M0. 3. Code: Squamous Cell Carcinoma, Not Otherwise Specified (NOS) maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Right lower lobe. 2. Findings: Squamous cell carcinoma, NOS, Grade II, Pathological T2b, Pathological N MO, Clinical M0. 3. Code: Squamous Cell Carcinoma, Not Otherwise Specified (NOS) maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Right lower lobe. 2. Findings: Squamous cell carcinoma, NOS, Grade II, Pathological T2b, Pathological N MO, Clinical M0. 3. Code: Squamous Cell Carcinoma, Not Otherwise Specified (NOS) maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lower lobe. 2. Findings: Squamous cell carcinoma, NOS, Grade II, Pathological T2b, Pathological N MO, Clinical M0. 3. Code: Squamous Cell Carcinoma, Not Otherwise Specified (NOS)",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Right lower lobe. 2. Findings: Squamous cell carcinoma, NOS, Grade II, Pathological T2b, Pathological N MO, Clinical M0. 3. Code: Squamous Cell Carcinoma, Not Otherwise Specified (NOS) maps to LUAD.",
      "idx": 864,
      "timestamp": "2026-01-19T15:59:53.112165"
    },
    {
      "sample_idx": 65,
      "input": "BIOPSY OR SURGICAL SPECIMEN (Order. Patient Information. Provider Status. Component. Lab. FINAL PATHOLOGICAL DIAGNOSIS. A. Left distal ureter, radical cystoprostatectomy: Unremarkable urothelium; no high grade dysplasia or carcinoma identified. - Frozen section diagnosis is confirmed. B. Right distal ureter, radical cystoprostatectomy: - Unremarkable urothellum; no high grade dysplasia or carcinoma identified. - Frozen section diagnosis is confirmed. C. Bladder and prostate, radical cystoprostat...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left distal ureter, radical cystoprostatectomy. 2. Findings: Invasive urothelial carcinoma with squamous differentiation, high grade. Tumor invades perivesical tissue macroscopically (pT3b). All surgical resection margins free of tumor. Prostate with benign prostatic hyperplasia; no invasive carcinoma identified. 3. Code: KIRC.\"\n}\n```\nExplanation:\n\nThe report describes a left distal ureter, radical cystoprostatectomy specimen. The microscopic findings are invasive urothelial carcinoma with squamous differentiation, high grade, with tumor invasion into perivesical tissue (pT3b). The prostate is noted to have benign prostatic hyperplasia and no invasive carcinoma. The code for Kidney Renal Clear Cell Carcinoma is KIRC, and this matches the description of the cancer type.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left distal ureter, radical cystoprostatectomy. 2. Findings: Invasive urothelial carcinoma with squamous differentiation, high grade. Tumor invades perivesical tissue macroscopically (pT3b). All surgical resection margins free of tumor. Prostate with benign prostatic hyperplasia; no invasive carcinoma identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left distal ureter, radical cystoprostatectomy. 2. Findings: Invasive urothelial carcinoma with squamous differentiation, high grade. Tumor invades perivesical tissue macroscopically (pT3b). All surgical resection margins free of tumor. Prostate with benign prostatic hyperplasia; no invasive carcinoma identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left distal ureter, radical cystoprostatectomy. 2. Findings: Invasive urothelial carcinoma with squamous differentiation, high grade. Tumor invades perivesical tissue macroscopically (pT3b). All surgical resection margins free of tumor. Prostate with benign prostatic hyperplasia; no invasive carcinoma identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    ",
      "predicted": "KIRC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Left distal ureter, radical cystoprostatectomy. 2. Findings: Invasive urothelial carcinoma with squamous differentiation, high grade. Tumor invades perivesical tissue macroscopically (pT3b). All surgical resection margins free of tumor. Prostate with benign prostatic hyperplasia; no invasive carcinoma identified. 3. Code: KIRC.",
      "idx": 65,
      "timestamp": "2026-01-19T15:59:53.112181"
    },
    {
      "sample_idx": 61,
      "input": "De-Identified Specimen Code. / M. SPECIMEN SUBMITTED: Part A: LEFT DISTAL URETER. Part B: RIGHT DISTAL URETER. Part C: BLADDER/ PROSTATE. Part D: RIGHT PELVIC LYMPH NODES. Part E: LEFT PELVIC LYMPH NODES. Final Diagnosis. 1. Left and right distal ureters, biopsy (A, B) - Negative for neoplasm. 2. Bladder, excision (C) - Invasive poorly differentiated urothelial carcinoma with invasion through. muscular wall and involvement of perivesical adipose tissue. 3. Prostate, excision (C) - Glandular hype...",
      "response": "```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Bladder (Urothelial Carcinoma). 2. Findings: Invasive urothelial carcinoma with invasion through the muscular wall and involvement of perivesical adipose tissue. 3. Code: BLCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Renal Clear Cell Carcinoma). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast (Invasive Ductal Carcinoma). 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Renal Clear Cell Carcinoma). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Renal Clear Cell Carcinoma). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Renal Clear Cell Carcinoma). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Renal Clear Cell Carcinoma). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Renal Clear",
      "predicted": "BLCA",
      "ground_truth": "BLCA",
      "correct": true,
      "reasoning": "1. Site: Bladder (Urothelial Carcinoma). 2. Findings: Invasive urothelial carcinoma with invasion through the muscular wall and involvement of perivesical adipose tissue. 3. Code: BLCA.",
      "idx": 61,
      "timestamp": "2026-01-19T15:59:53.112192"
    },
    {
      "sample_idx": 191,
      "input": "Final Surgical Pathology Report. Procedure: Diagnosis. A. Sentinel lymph node, left axilla, biopsy: A single lymph node is. negative for malignancy. B. Breast, left, excisional biopsy: Invasive lobular carcinoma,. Nottingham grade 2. Note: The margins are negative for malignancy. C. Breast, posterior lateral margin, biopsy: Focal lobular carcinoma. in situ, negative for invasive carcinoma. Microscopic Description: A. A single lymph node is negative for malignancy. [At the request of some staff o...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. Nottingham grade 2. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. Nottingham grade 2. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. Nottingham grade 2. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. Nottingham grade 2. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. Nottingham grade 2. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1.",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 191,
      "timestamp": "2026-01-19T15:59:53.112202"
    },
    {
      "sample_idx": 447,
      "input": "Gross Description: A. \"Left deep tongue margin.\" 3 fragments of red-tan tissue, each 0.5 cm. All. processed for frozen section. Frozen section control, All processed, A1. B. \"Left tongue (suture towards tongue base).\". Microscopic Description: Procedure: Resection, partial glossectomy. Specimen integrity: Intact. Specimen size: 4.0 X 3.0 x 2.0 cm. Laterality: Left. Tumor site: Base of tongue. Tumor focality: Single focus. Tumor size: 2.3 cm greatest dimension. Tumor thickness: 1.0 cm. Histologic...",
      "response": "```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Base). 2. Findings: Invasive keratinizing squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue (Base). 2. Findings: Invasive keratinizing squamous cell carcinoma. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Base). 2. Findings: Invasive keratinizing squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Base). 2. Findings: Invasive keratinizing squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue (Base). 2. Findings: Invasive keratinizing squamous cell carcinoma. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Base). 2. Findings: Invasive keratinizing squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue (Base). 2. Findings: Invasive keratinizing squamous cell carcinoma. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Base). 2. Findings: Invasive keratinizing squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue (Base). 2. Findings: Invasive keratinizing squamous cell carcinoma. 3.",
      "predicted": "SCC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Tongue (Base). 2. Findings: Invasive keratinizing squamous cell carcinoma. 3. Code: SCC maps to SCC.",
      "idx": 447,
      "timestamp": "2026-01-19T15:59:53.112212"
    },
    {
      "sample_idx": 476,
      "input": "Specimen(s) Received. 1. Nck: RT. perifacial node. 2. Neck: contents right neck - reg. 3. Neck: right hemiglossectomy (short stitch = anterior/ long stitch = medial) - reg. 4. Soft-Tissue: deep margin tongue. Diagnosis. 1. Right perifacial node: - One lymph node, negative for malignancy (0/1). 2. Right neck, dissection: - Metastatic squamous cell carcinoma involving three of forty-four lymph nodes (3/44). a. All involved nodes are level III. b. Largest node involved: 1.8 cm. C. Extracapsular ext...",
      "response": "```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Tongue (Right). 2. Findings: Squamous cell carcinoma, poorly differentiated, with perineural invasion. 3. Code: SKCM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Tongue (Right). 2. Findings: Squamous cell carcinoma, poorly differentiated, with perineural invasion. 3. Code: SKCM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Tongue (Right). 2. Findings: Squamous cell carcinoma, poorly differentiated, with perineural invasion. 3. Code: SKCM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Tongue (Right). 2. Findings: Squamous cell carcinoma, poorly differentiated, with perineural invasion. 3. Code: SKCM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Tongue (Right). 2. Findings: Squamous cell carcinoma, poorly differentiated, with perineural invasion. 3. Code: SKCM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Tongue (Right). 2. Findings: Squamous cell carcinoma, poorly differentiated, with perineural invasion. 3. Code: SKCM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Tongue (Right). 2. Findings: Squamous cell carcinoma, poorly differentiated, with perineural invasion. 3. Code: SKCM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Tongue (Right). 2. Findings: Squamous cell carcinoma, poorly differentiated, with perineural invasion. 3. Code: SKCM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1.",
      "predicted": "SKCM",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Tongue (Right). 2. Findings: Squamous cell carcinoma, poorly differentiated, with perineural invasion. 3. Code: SKCM",
      "idx": 476,
      "timestamp": "2026-01-19T15:59:53.112221"
    },
    {
      "sample_idx": 1034,
      "input": "MODIFIED REPORT - REVIEW ADDENDUM SECTION. DIAGNOSIS. (A). LEFT EXTERNAL/ INTERNAL ILIAC, HYPOGASTRIC AND OBTURATOR LYMPH NODES: METASTATIC ADENOCARCINOMA IN ONE OF THIRTEEN LYMPH NODES. LESS THAN 1.0 MM FOCUS. NO EXTRANODAL EXTENSION PRESENT. (1/13). (B) RIGHT EXTERNAL/ INTERNAL ILIAC, HYPOGASTRIC AND OBTURATOR LYMPH NODES: Twenty one lymph nodes, no tumor present (0/21). (C) PROSTATE AND SEMINAL VESICLES: Supplemental report to follow. Entire report and diagnosis completed by. GROSS DESCRIPTIO...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostate adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5. 3. Code: UCEC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostate adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5. 3. Code: UCEC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostate adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5. 3. Code: UCEC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostate adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5. 3. Code: UCEC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostate adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5. 3. Code: UCEC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostate adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5. 3. Code: UCEC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostate adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5. 3. Code: UCEC.\"\n}\n```\nResponse:\n```",
      "predicted": "UCEC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostate adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5. 3. Code: UCEC.",
      "idx": 1034,
      "timestamp": "2026-01-19T15:59:53.112232"
    },
    {
      "sample_idx": 1232,
      "input": "FINAL DIAGNOSIS. PART 1: LYMPH NODE, CENTRAL COMPARTMENT, SELECTIVE DISSECTION. A. METASTATIC CARCINOMA IN TWO OUT OF SIX LYMPH NODES (2/6). B. NO EXTRANODAL EXTENSION. PART 2: THYROID, TOTAL THYROIDECTOMY (17 GRAMS). A. PAPILLARY THYROID CARCINOMA, TWO.FOCI (1.2 CM AND 0.5 CM),. B. LARGEST FOCUS: LEFI LOBE, TALL CELL VARIANT WITH EXTRATHYROID EXTENSION; TUMOR. LESS THAN 0.1 CM FROM THE MARGIN. C. CHRONIC LYMPHOCYTIC THYROIDITIS. D. TWO LYMPH NODES, NO TUMOR PRESENT (0/2). E. PATHOLOGIC STAGE: p...",
      "response": "```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid (Total Thyroidectomy). 2. Findings: Papillary thyroid carcinoma, multifocal. One focus with extrathyroidal extension. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid (Total Thyroidectomy). 2. Findings: Chronic lymphocytic thyroiditis. 3. Code: Thyroid Carcinoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Central Compartment). 2. Findings: Metastatic carcinoma in two out of six lymph nodes. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast (Total Thyroidectomy). 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Central Compartment). 2. Findings: Metastatic carcinoma in two out of six lymph nodes. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Central Compartment). 2. Findings: Metastatic carcinoma in two out of six lymph nodes. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Central Compartment). 2. Findings: Metastatic carcinoma in two out of six lymph nodes. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Central Compartment). 2. Findings: Metastatic carcinoma",
      "predicted": "THCA",
      "ground_truth": "THCA",
      "correct": true,
      "reasoning": "1. Site: Thyroid (Total Thyroidectomy). 2. Findings: Papillary thyroid carcinoma, multifocal. One focus with extrathyroidal extension. 3. Code: Thyroid Carcinoma maps to THCA.",
      "idx": 1232,
      "timestamp": "2026-01-19T15:59:53.112243"
    },
    {
      "sample_idx": 54,
      "input": "Anatomic Site:Right Ureter (FS). Left Ureter (FS). Bladder (FS on urethra). Distal right ureter (FS). Right pelvic lymph nodes (FS). Final urethral margin. Left pelvic lymph nodes. Final left ureter. Clinical Diagnosis/History. The patient is a. -year-old woman. No further clinical history is provided. A recent consult. indicates a transurethral bladder tumor resection showing invasive high-grade. urothelial carcinoma with invasion of the. muscularis propria. Gross Description: The specimen is r...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Ureter (Proximal). 2. Findings: Urothelial carcinoma, invasive, high grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Left Ureter. 2. Findings: Urothelial carcinoma, non-invasive, low grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Urothelial carcinoma, invasive, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Distal right ureter. 2. Findings: Urothelial carcinoma, invasive, high grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right pelvic lymph nodes. 2. Findings: No tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Urethra, final margin. 2. Findings: No tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left pelvic lymph nodes. 2. Findings: No tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left ureter. 2. Findings: Urothelial carcinoma, non-invasive, low grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Urothelial carcinoma, invasive, high grade. 3. Code: KIRC.\"",
      "predicted": "KIRC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Right Ureter (Proximal). 2. Findings: Urothelial carcinoma, invasive, high grade. 3. Code: KIRC.",
      "idx": 54,
      "timestamp": "2026-01-19T15:59:53.112253"
    },
    {
      "sample_idx": 1149,
      "input": "Laterality: Malignant melanoma. Path Report:SKIN TISSUE CHECKLIST. Specimen type: Surgical resection. Tumor site: Skin, hand. Tumor size: 4 x 3 X 3 cm. Tumor features: Ulcerated, Pigmented. Satellite nodules: Not specified. Histologic type: Malignant melanoma. Histologic grade: Poorly differentiated. Lymph nodes: 0/10 positive for metastasis (Axillary 0/10). Lymphatic invasion: Not specified. Venous invasion: Not specified. Margins: Not specified. Evidence of neo-adjuvant treatment: Not specifie...",
      "response": "```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin (hand). 2. Findings: Malignant melanoma, poorly differentiated. 3. Code: SKCM (Skin Cancer Melanoma) maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin (hand). 2. Findings: Malignant melanoma, poorly differentiated. 3. Code: SKCM (Skin Cancer Melanoma) maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin (hand). 2. Findings: Malignant melanoma, poorly differentiated. 3. Code: SKCM (Skin Cancer Melanoma) maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin (hand). 2. Findings: Malignant melanoma, poorly differentiated. 3. Code: SKCM (Skin Cancer Melanoma) maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin (hand). 2. Findings: Malignant melanoma, poorly differentiated. 3. Code: SKCM (Skin Cancer Melanoma) maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin (hand). 2. Findings: Malignant melanoma, poorly differentiated. 3. Code: SKCM (Skin Cancer Melanoma) maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin (hand). 2. Findings: Malignant melanoma, poorly differentiated. 3. Code: SKCM (Skin Cancer Melanoma) maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin (hand). 2. Findings: Malignant melanoma, poorly differentiated. 3. Code: SKCM (Skin Cancer Melanoma) maps to",
      "predicted": "SKCM",
      "ground_truth": "SKCM",
      "correct": true,
      "reasoning": "1. Site: Skin (hand). 2. Findings: Malignant melanoma, poorly differentiated. 3. Code: SKCM (Skin Cancer Melanoma) maps to SKCM.",
      "idx": 1149,
      "timestamp": "2026-01-19T15:59:53.112263"
    },
    {
      "sample_idx": 407,
      "input": "MODIFIED REPORT - REVIEW ADDENDUMI SECTION. DIAGNOSIS. (A) BRAIN, \"RIGHT TEMPORAL TUMOR\". DIFFUSE ASTROCYTOMA, WHO GRADE 4, OR GLIOBLASTOMA. (SEE COMMENT). (B) BRAIN, \"RIGHT TEMPORAL TUMOR\". DIFFUSE ASTROCYTOMA, WHO GRADE 4, OR GLIOBLASTOMA. (SEE COMMENT). GROSS DESCRIPTION. (A) \"RIGHT TEMPORAL TUMOR\" - Consists of a fragment of cortex and white matter containing blood clot and tumor. In. some areas there is gray-white junction demarcation, however, the majority of the specimen is infiltrated by...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Temporal Tumor. 2. Findings: Diffuse astrocytoma, WHO Grade 4, or glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Temporal Tumor. 2. Findings: Diffuse astrocytoma, WHO Grade 4, or glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Temporal Tumor. 2. Findings: Diffuse astrocytoma, WHO Grade 4, or glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Temporal Tumor. 2. Findings: Diffuse astrocytoma, WHO Grade 4, or glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Temporal Tumor. 2. Findings: Diffuse astrocytoma, WHO Grade 4, or glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Temporal Tumor. 2. Findings: Diffuse astrocytoma, WHO Grade 4, or glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Temporal Tumor. 2. Findings: Diffuse astrocytoma, WHO Grade 4, or glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Temporal Tumor. 2. Findings:",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain, Temporal Tumor. 2. Findings: Diffuse astrocytoma, WHO Grade 4, or glioblastoma. 3. Code: GBM maps to GBM.",
      "idx": 407,
      "timestamp": "2026-01-19T15:59:53.112272"
    },
    {
      "sample_idx": 1330,
      "input": "Service:Gynecology. Gender: F. (Age: Accessioned. Patient Type: SDSA. Other Data: DIAGNOSIS: UTERUS, TOTAL ABDOMINAL HYSTERECTOMY. - ENDOMETRIOID ADENOCARCINOMA, FIGO GRADE 2/3, INVASIVE TO A DEPTH OF 0.3. CM. (MYOMETRIAL THICKNESS 2.0 CM) WITHOUT LOWER UTERINE SEGMENT INVOLVEMENT. - ADENOMYOSIS. - LEIOMYOMAS. - SEROSAL ENDOMETRIOSIS. - CERVIX WITH NO HISTOPATHOLOGIC ABNORMALITY. OVARIES, LEFT AND RIGHT, BILATERAL OOPHORECTOMY. - ENDOMETRIOSIS. - TUBAL AND UTERINE SEROSAL ADHESIONS. - NO EVIDENC...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Right and Left Adnexa. 2. Findings: Endometrioid adenocarcinoma, FIGO Grade 2/3, Invasive to a depth of 0.3 cm. 3. Code: BRCA does not map to this finding.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Right and Left Adnexa. 2. Findings: Endometrioid adenocarcinoma, FIGO Grade 2/3, Invasive to a depth of 0.3 cm. 3. Code: KIRC maps to Uterus, Cervix, Right and Left Adnexa.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Right and Left Adnexa. 2. Findings: Endometrioid adenocarcinoma, FIGO Grade 2/3, Invasive to a depth of 0.3 cm. 3. Code: KIRC maps to Uterus, Cervix, Right and Left Adnexa.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Right and Left Adnexa. 2. Findings: Endometrioid adenocarcinoma, FIGO Grade 2/3, Invasive to a depth of 0.3 cm. 3. Code: KIRC maps to Uterus, Cervix, Right and Left Adnexa.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Right and Left Adnexa. 2. Findings: Endometrioid adenocarcinoma, FIGO Grade 2/3, Invasive to a depth of 0.3 cm. 3. Code: KIRC maps to Uterus, Cervix, Right and Left Adnexa.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Right and Left Adnexa. 2. Findings: Endometri",
      "predicted": "BRCA",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Uterus, Cervix, Right and Left Adnexa. 2. Findings: Endometrioid adenocarcinoma, FIGO Grade 2/3, Invasive to a depth of 0.3 cm. 3. Code: BRCA does not map to this finding.",
      "idx": 1330,
      "timestamp": "2026-01-19T15:59:53.112284"
    },
    {
      "sample_idx": 1405,
      "input": "Service : Gynecology. Gender: F. MRN. Physician (s) : other Related Clinical Data: DIAGNOSIS: UTERUS, ENDOMETRIUM, TOTAL ABDOMINAL HYSTERECTOMY. - MALIGNANT MIXED MULLERIAN TUMOR (MMMT) WITH HETEROLOGOUS DIFFERENTIATION. - MMMT EXTENSIVELY INVOLVES THE LOWER UTERINE SEGMENT. - SEE SYNOPTIC. UTERUS, MYOMETRIUM, TOTAL ABDOMINAL HYSTERECTOMY. - MMMT BY DIRECT EXTENSION, INVADING TO A DEPTH OF 13 MM WHERE MYOMETRIAL. THICKNESS IS 18 MM. - LYMPHOVASCULAR: INVASION BY MMMT IS IDENTIFIED. UTERUS, CERVI...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Malignant mixed Mullerian tumor (MMMT) with heterologous elements of endometrium. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"",
      "predicted": "KIRC",
      "ground_truth": "UCS",
      "correct": false,
      "reasoning": "1. Site: Uterus. 2. Findings: Malignant mixed Mullerian tumor (MMMT) with heterologous elements of endometrium. 3. Code: KIRC.",
      "idx": 1405,
      "timestamp": "2026-01-19T15:59:53.112295"
    },
    {
      "sample_idx": 859,
      "input": "Operative Procedure: Right thoracotomy, pneumonectomy. A: Left paratracheal LN. B: Inferior pulmonary ligament LN. C: Lymph node: Parat. D: Lymph node: High. E: Right lung. F: Carinal margin. G: Subcarinal lymph nodes. Final Pathologic Diagnosis: A. Lymph node, left paratracheal, excision: One lymph node, negative for tumor (0/1). B. Lymph node, inferior pulmonary ligament, excision: One lymph node, negative for tumor (0/1). C. Lymph node, paratracheal #2, excision: Eighteen lymph nodes, negativ...",
      "response": "```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung (Right). 2. Findings: Squamous cell carcinoma of the lung. 3. Code: ESCA maps to Squamous cell carcinoma of the lung.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung (Right). 2. Findings: Squamous cell carcinoma of the lung. 3. Code: ESCA maps to Squamous cell carcinoma of the lung.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung (Right). 2. Findings: Squamous cell carcinoma of the lung. 3. Code: ESCA maps to Squamous cell carcinoma of the lung.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung (Right). 2. Findings: Squamous cell carcinoma of the lung. 3. Code: ESCA maps to Squamous cell carcinoma of the lung.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung (Right). 2. Findings: Squamous cell carcinoma of the lung. 3. Code: ESCA maps to Squamous cell carcinoma of the lung.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung (Right). 2. Findings: Squamous cell carcinoma of the lung. 3. Code: ESCA maps to Squamous cell carcinoma of the lung.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung (Right). 2. Findings: Squamous cell carcinoma of the lung. 3. Code: ESCA maps to Squamous cell carcinoma of the lung.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung (Right). 2. Findings: Squamous cell carcinoma of the lung. 3. Code: ESCA maps to Squamous cell carcinoma of",
      "predicted": "ESCA",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung (Right). 2. Findings: Squamous cell carcinoma of the lung. 3. Code: ESCA maps to Squamous cell carcinoma of the lung.",
      "idx": 859,
      "timestamp": "2026-01-19T15:59:53.112321"
    },
    {
      "sample_idx": 451,
      "input": "CORRECTED. Report Type. Patholoav Report. Date of Event. F. Authored by. Hosp/Group. Record Status. CORRECTED. ADDENDA: COMPREHENSIVE THERANOSTIC SUMMARY. IMMUNOHISTOCHEMISTRY. p16: POSITIVE. IN SITU HYBRIDIZATION / FISH. HPV: POSITIVE;. subtypes. 16, 18, 6, 11. Pattern: Punctate. MOLECULAR ANATOMIC PATHOLOGY. See Special Procedure reports below for additional details and. background. on In situ/FISH and/or Molecular Anatomic Pathology. testing. SXC1. My signature is attestation that I have pers...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pharynx, oropharynx. 2. Findings: Squamous cell carcinoma, conventional, 2.6 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pharynx, oropharynx. 2. Findings: Squamous cell carcinoma, conventional, 2.6 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pharynx, oropharynx. 2. Findings: Squamous cell carcinoma, conventional, 2.6 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pharynx, oropharynx. 2. Findings: Squamous cell carcinoma, conventional, 2.6 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pharynx, oropharynx. 2. Findings: Squamous cell carcinoma, conventional, 2.6 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pharynx, oropharynx. 2. Findings: Squamous cell carcinoma, conventional, 2.6 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pharynx, oropharynx. 2. Findings: Squamous cell carcinoma, conventional, 2.6 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC",
      "predicted": "KIRC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Pharynx, oropharynx. 2. Findings: Squamous cell carcinoma, conventional, 2.6 cm. 3. Code: KIRC.",
      "idx": 451,
      "timestamp": "2026-01-19T15:59:53.112333"
    },
    {
      "sample_idx": 919,
      "input": "CLINICAL HISTORY: Abdominal/pelvic swelling, large pelvic mass with history of breast cancer. GROSS EXAMINATION: A. \"Omental nodule (AF1)\". Received fresh is a 7.8 x 4.9 x 2.1 cm fragment of. yellow-tan lobulated fibroadipose tissue that contains a 2.2 x 2.1 x 1. 4 cm. well circumscribed, tan-white, firm nodule (AF1 Frozen section; remnant in A1;. additional A2). B. \"Piece of omentum\". Received fresh is a 16.9 x 10.6 x 3.2 cm aggregate of. two fragments of yellow-tan lobulated fibrofatty tissue ...",
      "response": "```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovary (Right). 2. Findings: Serous adenocarcinoma, FIGO Grade 2, size 15.0 x 11.0 x 9.0 cm, weight 650 grams. Serosa involved. Additional findings none. 3. Code: OV\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_",
      "predicted": "OV",
      "ground_truth": "OV",
      "correct": true,
      "reasoning": "1. Site: Ovary (Right). 2. Findings: Serous adenocarcinoma, FIGO Grade 2, size 15.0 x 11.0 x 9.0 cm, weight 650 grams. Serosa involved. Additional findings none. 3. Code: OV",
      "idx": 919,
      "timestamp": "2026-01-19T15:59:53.112344"
    },
    {
      "sample_idx": 1206,
      "input": "PRIMARY SITE: Stomach (Gastroesophageal junction). 1 - \"Esophagus + Stomach\": Adenocarcinoma characterized as follows: Histological pattern(s) observed: tubular. Histological grade: II - moderately differentiated. Measure of the longest axis of the tumor: 12.70. Lauren's classification: Ulceration: present. Compromise of: Mucosa. Muscularis mucosae. Submucosa. Muscularis propria. Adjacent adipose tissue. Type of tumor invasion. Spiculated. Inflammatory reaction: Mild. Tumor implantation in peri-...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Adenocarcinoma, tubular pattern, moderately differentiated, ulceration present, lymphatic vascular invasion present, neural infiltration present. 3. Code: Adenocarcinoma maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Adenocarcinoma, tubular pattern, moderately differentiated, ulceration present, lymphatic vascular invasion present, neural infiltration present. 3. Code: Adenocarcinoma maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Adenocarcinoma, tubular pattern, moderately differentiated, ulceration present, lymphatic vascular invasion present, neural infiltration present. 3. Code: Adenocarcinoma maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Adenocarcinoma, tubular pattern, moderately differentiated, ulceration present, lymphatic vascular invasion present, neural infiltration present. 3. Code: Adenocarcinoma maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Adenocarcinoma, tubular pattern, moderately differentiated, ulceration present, lymphatic vascular invasion present, neural infiltration present. 3. Code: Adenocarcinoma maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Adenocarcinoma, tubular pattern, moderately differentiated, ulceration present, lymphatic vascular invasion present, neural infiltration present. 3. Code: Adenocarcinoma maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroes",
      "predicted": "ADENOCA",
      "ground_truth": "STAD",
      "correct": false,
      "reasoning": "1. Site: Stomach (Gastroesophageal junction). 2. Findings: Adenocarcinoma, tubular pattern, moderately differentiated, ulceration present, lymphatic vascular invasion present, neural infiltration present. 3. Code: Adenocarcinoma maps to ADENOCA.",
      "idx": 1206,
      "timestamp": "2026-01-19T15:59:53.112357"
    },
    {
      "sample_idx": 569,
      "input": "INAL DIAGNOSIS. A. RENAL CELL CARCINOMA, CONVENTIONAL (CLEAR) CELL TYPE. B. THE FUHRMAN'S NUCLEAR GRADE IS III/ IV. C. RENAL CELL CARCINOMA GROWS IN ACINAR PATTERN WITH EXTENSIVE INTRATUMORAL. HEMORRHAGE. D. THE GREATEST DIAMETER OF THE NEOPLASM IS 7.0 CM. E. THE CARCINOMA EXTENDS INTO THE SOFT TISSUE IN THE REGION OF THE RENAL SINUS. F. THE TUMOR IS CONFINED WITHIN THE GEROTA'S FASCIA. G. THE CARCINOMA INVADES THE RENAL VEIN WITH LARGE TUMOR THROMBUS IDENTIFIED. H. URETERAL AND RENAL VASCULAR M...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 569,
      "timestamp": "2026-01-19T15:59:53.112369"
    },
    {
      "sample_idx": 13,
      "input": "DIAGNOSIS: A-E. Bladder, prostate, and pelvic lymph nodes, excision: Procedure: Radical cystoprostatectomy. Tumor site: Right posterior lateral wall. Tumor size: 2.5 x 2.0 x 1.2 cm. Histologic type: Urothelial (transitional cell carcinoma), , with. nested pattern. Associated epithelial lesions: None identified. Histologic grade: High-grade, grade 3 (of 3) . Tumor configuration: Solid/nodule with ulceration. Microscopic tumor extension: Perivesical fat. Margins: Negative, right and left distal ur...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder and Prostate. 2. Findings: Urothelial carcinoma, high-grade, with associated prostatic invasion. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Chronic nephritis, hydronephrosis. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pelvic Lymph Nodes. 2. Findings: Metastatic carcinoma consistent with bladder primary. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Urothelial carcinoma, high-grade, with associated prostatic invasion. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Extensive invasion by urothelial carcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Urothelial carcinoma, high-grade, with associated prostatic invasion. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Urothelial carcinoma, high-grade, with associated prostatic invasion. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Urothelial carcinoma, high-grade, with associated prostatic invasion. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: U",
      "predicted": "KIRC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Bladder and Prostate. 2. Findings: Urothelial carcinoma, high-grade, with associated prostatic invasion. 3. Code: KIRC.",
      "idx": 13,
      "timestamp": "2026-01-19T15:59:53.112379"
    },
    {
      "sample_idx": 326,
      "input": "SPECIMEN. Right colon. CLINICAL NOTES. PRE-OP DIAGNOSIS Right colon cancer. GROSS DESCRIPTION. Received fresh labeled \"right colon\" is a previously. unopened 17 cm. segment of proximal right colon with. attached 13.5 cm. of distal ileum surfaced by smooth to slightly. scabrous tan-pink serosa with a copious amount of attached. mesocolon. and mesentery. A 4.7 cm. unremarkable appendix ranging from 0.5 to. 0.8 cm. in diameter is present. The proximal and distal margins. measure 4.0 and 6.5 cm. in ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Invasive adenocarcinoma, moderately differentiated. pT3, pN1b. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Invasive adenocarcinoma, moderately differentiated. pT3, pN1b. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Invasive adenocarcinoma, moderately differentiated. pT3, pN1b. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Invasive adenocarcinoma, moderately differentiated. pT3, pN1b. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Invasive adenocarcinoma, moderately differentiated. pT3, pN1b. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Invasive adenocarcinoma, moderately differentiated. pT3, pN1b. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Invasive adenocarcinoma, moderately differentiated. pT3, pN1b. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Invasive adenocarcinoma, moderately differentiated. pT3, pN1b. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Right colon. 2. Findings: Invasive adenocarcinoma, moderately differentiated. pT3, pN1b. 3. Code: KIRC.",
      "idx": 326,
      "timestamp": "2026-01-19T15:59:53.112389"
    },
    {
      "sample_idx": 865,
      "input": "DIAGNOSTS: Lung, left upper lobe, excision: Invasive grade 4 (of 4) squamous. cell carcinoma forming a 2.7 x 2 x 1.8 cm mass located 0.7 cm from. the bronchial margin. The surgical margins are negative. Multiple. (3) intrapulmonary peribronchial lymph are negative for tumor. Lung, superior segment left lower lobe, No. 1 excision: Microscopic. squamous cell carcinoma in-situ forming a 0.2 cm. lesion in diameter. The surgical margins are negative for. tumor. Lung, superior segment left lower lobe,...",
      "response": "```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, and Lung, superior segment left lower lobe. 2. Findings: Invasive squamous cell carcinoma, and Microscopic squamous cell carcinoma in-situ. 3. Code: Lung, left upper lobe maps to LCLC, and Lung, superior segment left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, and Lung, superior segment left lower lobe. 2. Findings: Invasive squamous cell carcinoma, and Microscopic squamous cell carcinoma in-situ. 3. Code: Lung, left upper lobe maps to LCLC, and Lung, superior segment left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, and Lung, superior segment left lower lobe. 2. Findings: Invasive squamous cell carcinoma, and Microscopic squamous cell carcinoma in-situ. 3. Code: Lung, left upper lobe maps to LCLC, and Lung, superior segment left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, and Lung, superior segment left lower lobe. 2. Findings: Invasive squamous cell carcinoma, and Microscopic squamous cell carcinoma in-situ. 3. Code: Lung, left upper lobe maps to LCLC, and Lung, superior segment left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, and Lung, superior segment left lower lobe. 2. Findings: Invasive squamous cell carcinoma, and Microscopic squamous cell carcinoma in-situ. 3. Code: Lung, left upper lobe maps to LCLC, and Lung, superior segment left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, and Lung, superior segment left lower lobe. ",
      "predicted": "LCLC",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung, left upper lobe, and Lung, superior segment left lower lobe. 2. Findings: Invasive squamous cell carcinoma, and Microscopic squamous cell carcinoma in-situ. 3. Code: Lung, left upper lobe maps to LCLC, and Lung, superior segment left lower lobe maps to LCLC.",
      "idx": 865,
      "timestamp": "2026-01-19T15:59:53.112403"
    },
    {
      "sample_idx": 696,
      "input": "Provider Status. Observation Date and Time. Result Narrative. (NOTE). Clinical History. Malignant neoplasm of frontal lobe of brain [191.1]. . Medical History: GERD (gastroesophageal reflux disease) . Optic nerve edema. ADDENDA: Addendum added: Addendum added: Final Pathologic Diagnosis--. A. Left frontal tumor, biopsy: Slides have been referred to. for review and diagnosis. An. addendum will follow. B. Left frontal tumor, excision: Slides have been referred to. for review and diagnosis. An. add...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Frontal lobe of brain. 2. Findings: Anaplastic infiltrating glioma (WHO Grade III). 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Frontal lobe of brain. 2. Findings: Anaplastic infiltrating glioma (WHO Grade III). 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Frontal lobe of brain. 2. Findings: Anaplastic infiltrating glioma (WHO Grade III). 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Frontal lobe of brain. 2. Findings: Anaplastic infiltrating glioma (WHO Grade III). 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Frontal lobe of brain. 2. Findings: Anaplastic infiltrating glioma (WHO Grade III). 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Frontal lobe of brain. 2. Findings: Anaplastic infiltrating glioma (WHO Grade III). 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Frontal lobe of brain. 2. Findings: Anaplastic infiltrating glioma (WHO Grade III). 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Frontal lobe of brain. 2. Findings: Anaplastic infiltrating glioma (WHO Grade III). 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Frontal lobe of brain. 2. Findings: Anaplastic",
      "predicted": "BRCA",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Frontal lobe of brain. 2. Findings: Anaplastic infiltrating glioma (WHO Grade III). 3. Code: BRCA",
      "idx": 696,
      "timestamp": "2026-01-19T15:59:53.112413"
    },
    {
      "sample_idx": 1406,
      "input": "HISTOPATHOLOGY. Lab No. Clinical Consultant & Location. Unit No. SPECIMEN. RIGHT ENUCLEATED GLOBE, PROGNOSTIC AND DIAGNOSTIC TESTS. CLINICAL DETAILS. Right eye choroidal melanoma, involved optic nerve. Tumour size: 13.36 x 13.42mm (thickness 6.43) mm. MACROSCOPIC DESCRIPTION. A fresh, intact, right globe. Dimensions: Axial 25mm, Horizontal 25mm, Vertical 25mm. Cornea: Horizontal 12.4mm, Vertical 12mm. Optic nerve. Length 5mm, Diameter 4mm. Pupil: dilated. On trans-illumination, a shadow is seen ...",
      "response": "```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Eye (Right eye). 2. Findings: Choroidal melanoma. 3. Code: CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Eye (Right eye). 2. Findings: Choroidal melanoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Eye (Right eye). 2. Findings: Choroidal melanoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Eye (Right eye). 2. Findings: Choroidal melanoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Eye (Right eye). 2. Findings: Choroidal melanoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Eye (Right eye). 2. Findings: Choroidal melanoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Eye (Right eye). 2. Findings: Choroidal melanoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Eye (Right eye). 2. Findings: Choroidal melanoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Eye (Right eye). 2. Findings: Choroidal melanoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Eye (Right eye). 2. Findings",
      "predicted": "CHOL",
      "ground_truth": "UVM",
      "correct": false,
      "reasoning": "1. Site: Eye (Right eye). 2. Findings: Choroidal melanoma. 3. Code: CHOL.",
      "idx": 1406,
      "timestamp": "2026-01-19T15:59:53.112423"
    },
    {
      "sample_idx": 318,
      "input": "This is an invasive, poorly differentiated adenocarcinoma of the colon (according to clinical. findings the descending colon) with penetration of all the parietal layers and vascular infiltrates. (pT3, L1, V1) with six lymph node metastases (6/14). Tumor classification: ICDO-DA-M. 8140/3. G3. pT3. L1, V1,. pN2 (6/14).",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Descending). 2. Findings: Invasive adenocarcinoma of the colon, poorly differentiated, with lymph node metastases. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Colon (Descending). 2. Findings: Invasive adenocarcinoma of the colon, poorly differentiated, with lymph node metastases. 3. Code: STAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Descending). 2. Findings: Invasive adenocarcinoma of the colon, poorly differentiated, with lymph node metastases. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Descending). 2. Findings: Invasive adenocarcinoma of the colon, poorly differentiated, with lymph node metastases. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Descending). 2. Findings: Invasive adenocarcinoma of the colon, poorly differentiated, with lymph node metastases. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Descending). 2. Findings: Invasive adenocarcinoma of the colon, poorly differentiated, with lymph node metastases. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Descending). 2. Findings: Invasive adenocarcinoma of the colon, poorly differentiated, with lymph node metastases. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Descending). 2. Findings: Invasive adenocarcinoma of the colon, poorly differentiated",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon (Descending). 2. Findings: Invasive adenocarcinoma of the colon, poorly differentiated, with lymph node metastases. 3. Code: COAD maps to Colon Adenocarcinoma.",
      "idx": 318,
      "timestamp": "2026-01-19T15:59:53.112433"
    },
    {
      "sample_idx": 440,
      "input": "Report Type. Date of Event. Authored by. Hosp/Group. Record Status. FINAL DIAGNOSIS: TONSIL, RIGHT, BIOPSY. FRAGMENT OF SQUAMOUS CELL CARCINOMA, NON-KERATINIZING. By Pathologist. My signature is attestation that I have personally reviewed the. submitted. material (s) and the final diagnosis reflects that evaluation. GROSS DESCRIPTION: The specimen is received unfixed for intraoperative consultation,. labeled with. the patient's name, initials XXX, and \"biopsy right tonsil\". It. consists of a. 0....",
      "response": "```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, Right. 2. Findings: Squamous cell carcinoma, non-keratinizing. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, Right. 2. Findings: Squamous cell carcinoma, non-keratinizing. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, Right. 2. Findings: Squamous cell carcinoma, non-keratinizing. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, Right. 2. Findings: Squamous cell carcinoma, non-keratinizing. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, Right. 2. Findings: Squamous cell carcinoma, non-keratinizing. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, Right. 2. Findings: Squamous cell carcinoma, non-keratinizing. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, Right. 2. Findings: Squamous cell carcinoma, non-keratinizing. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, Right. 2. Findings: Squamous cell carcinoma, non-keratinizing. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",",
      "predicted": "HNSC",
      "ground_truth": "HNSC",
      "correct": true,
      "reasoning": "1. Site: Tonsil, Right. 2. Findings: Squamous cell carcinoma, non-keratinizing. 3. Code: HNSC.",
      "idx": 440,
      "timestamp": "2026-01-19T15:59:53.112443"
    },
    {
      "sample_idx": 689,
      "input": "Client: (Age: 1 Location: Gender: M Accnt: Phy Location: Clinical History. Probably low grade gliomas. Operative Diagnoses. Operation / Specimen. A: Brain, probably tumor, biopsy. Pathologic Diagnosis. A. Brain, tumor, excision biopsy: Diffuse astrocytoma, WHO grade II (see comment). Comment. Permanent sections confirm the frozen section diagnosis. Sections show an infiltrating astrocytoma. Mitotic figures. and/or vascular proliferation are not seen. The Ki-67 labeling index is approximately 3%....",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Diffuse astrocytoma, WHO grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Diffuse astrocytoma, WHO grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Diffuse astrocytoma, WHO grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Diffuse astrocytoma, WHO grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Diffuse astrocytoma, WHO grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Diffuse astrocytoma, WHO grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Diffuse astrocytoma, WHO grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Diffuse astrocytoma, WHO grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to",
      "predicted": "KIRC",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain. 2. Findings: Diffuse astrocytoma, WHO grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 689,
      "timestamp": "2026-01-19T15:59:53.112453"
    },
    {
      "sample_idx": 1407,
      "input": "HISTOPATHOLOGY. Lab No. Clinical Consultant & Location. Unit No. SPECIMEN. LEFT ENUCLEATION (GLOBE) . DIAGNOSTIC, PROGNOSTIC. CLINICAL DETAILS. See diagram. MACROSCOPIC DESCRIPTION. A fresh, intact, left gloe. Dimensions: Axial 25. Horizontal 24mm, Vertical 24mm. Cornea: Horizontal 12mm, Vertical 11 5mm. Optic nerve. Length 1mm, Diameter 4mm. On. crans-illumination, a large shadow is seen on the medium. side approx 22mm. Plane of section: horizontal. Intraocular description: On opening, a solita...",
      "response": "```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Eye (Left Eye). 2. Findings: Choroidal melanoma. 3. Code: CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_",
      "predicted": "CHOL",
      "ground_truth": "UVM",
      "correct": false,
      "reasoning": "1. Site: Eye (Left Eye). 2. Findings: Choroidal melanoma. 3. Code: CHOL.",
      "idx": 1407,
      "timestamp": "2026-01-19T15:59:53.112462"
    },
    {
      "sample_idx": 189,
      "input": "page 1 / 1. copy No. 4. Examination: Histopathological examination. Gender: F. Material: Total organ resection - left breast. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the left breast. PCI: Cellulae carcinomatosae. Results of immunohistochemical examination: No estrogen receptors found in the neoplastic cell nuclei. No progesterone receptors found in the neoplastic cell nuclei. HER2 protein stained with HER2 protein stained with. Ventana's Pathway HER-2/ne...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 189,
      "timestamp": "2026-01-19T15:59:53.112471"
    },
    {
      "sample_idx": 778,
      "input": "PROCEDURE DATE: RECEIVED DATE: REPORT DATE: 10 Consultation. FS DIAGNOSES 1 AND 2: \"Negative for neoplasm (reported to Dr. positive patient ID)\" by Dr. campus. Pre-Op Diagnosis. Lung cancer. Post-Op Diagnosis. Same as above. Clinical History. Nothing indicated. Gross Description: Six parts. Container labeled. R lymph node\" has 1.5 x. 1.5 x 0.4 cm of gray-tan to yellow fleshy and fibrofatty tissue. fragments which are submitted for frozen section and reported as. \"negative for neoplasm (reported ...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, right lower lobe. 2. Findings: Adenocarcinoma, moderately differentiated, subpleural, right lower lung lobe. Tumor size: 2.0 x 2.0 x 1.6 cm. Tumor grade: Moderately differentiated. Pleural invasion: Yes (tumor appears to focally involve overlying pleura in slide 5D). Lymphovascular space invasion: No. Surgical margin status: Tumor distance from bronchial margin: 2.8 cm. Tumor distance from stapled margin: Not applicable. Tumor distance from pleural surface: Less than 0.5 cm, focally involving pleura. microscopically. Lymph node status: See specimens 1, 2, 3, 4 and 6. Station 7 lymph node: Negative for tumor. Stage: T2N0. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, right lower lobe. 2. Findings: Adenocarcinoma, moderately differentiated, subpleural, right lower lung lobe. Tumor size: 2.0 x 2.0 x 1.6 cm. Tumor grade: Moderately differentiated. Pleural invasion: Yes (tumor appears to focally involve overlying pleura in slide 5D). Lymphovascular space invasion: No. Surgical margin status: Tumor distance from bronchial margin: 2.8 cm. Tumor distance from stapled margin: Not applicable. Tumor distance from pleural surface: Less than 0.5 cm, focally involving pleura. microscopically. Lymph node status: See specimens 1, 2, 3, 4 and 6. Station 7 lymph node: Negative for tumor. Stage: T2N0. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, right lower lobe. 2. Findings: Adenocarcinoma, moderately differentiated, subpleural, right lower lung lobe. Tumor size: 2.0 x 2.0 x 1.6 cm. Tumor grade: Moderately differentiated. Pleural invasion: Yes (tumor appears to focally involve overlying pleura in slide 5D). Lymph",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung, right lower lobe. 2. Findings: Adenocarcinoma, moderately differentiated, subpleural, right lower lung lobe. Tumor size: 2.0 x 2.0 x 1.6 cm. Tumor grade: Moderately differentiated. Pleural invasion: Yes (tumor appears to focally involve overlying pleura in slide 5D). Lymphovascular space invasion: No. Surgical margin status: Tumor distance from bronchial margin: 2.8 cm. Tumor distance from stapled margin: Not applicable. Tumor distance from pleural surface: Less than 0.5 cm, focally involving pleura. microscopically. Lymph node status: See specimens 1, 2, 3, 4 and 6. Station 7 lymph node: Negative for tumor. Stage: T2N0. 3. Code: LUAD.",
      "idx": 778,
      "timestamp": "2026-01-19T15:59:53.112493"
    },
    {
      "sample_idx": 198,
      "input": "page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. ender: F. Material: Total organ resection - left breast and axillary tissues. Unit in charge: (. Material received on: : Expected time of examination: up to 8 working days. Clinical diagnosis: Macroscopic breast'sized 24 x 19.5 x 5 cm removed with axillary tissues sized 10 x 7 x 2.5 cm and a skin flap of 24 x 12 and cm. 0 Tumour from sized the. description: Left 1.9 x 1.3 x 1.4 found in the subaurolar ...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 198,
      "timestamp": "2026-01-19T15:59:53.112503"
    },
    {
      "sample_idx": 735,
      "input": "TISSUE DESCRIPTION. Left lateral liver (250 grams, 18 x 9.5 X 5 cm). A1. A2,. DIAGNOSIS: Liver, left lateral, sectorectomy: Grade 2 (of 4). hepatocellular carcinoma, forming a 4 X 3 X 3 cm mass. The. surgical margins are negative for tumor by 5.0 cm. ADDENDUM. Special stains (reticulin and trichrome) demonstrate grade 1. chronic hepatitis and minimal periportal fibrosis. Sections of. tumor also demonstrate vascular invasion on permanent sections. TISSUE DESCRIPTION: Left lateral liver (250 grams...",
      "response": "```json\n{\n    \"cancer_type\": \"Hepatocellular Carcinoma\",\n    \"reasoning\": \"1. Site: Liver, left lateral. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Hepatocellular Carcinoma maps to HCB.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, left lateral. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Hepatocellular Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"Hepatocellular Carcinoma\",\n    \"reasoning\": \"1. Site: Liver, left lateral. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Hepatocellular Carcinoma maps to HCB.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, left lateral. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Hepatocellular Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, left lateral. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Hepatocellular Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, left lateral. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Hepatocellular Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, left lateral. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Hepatocellular Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, left lateral. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Hepatocellular Carcinoma maps to KIRC.\"\n}\n```\n```json",
      "predicted": "Hepatocellular Carcinoma",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Liver, left lateral. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Hepatocellular Carcinoma maps to HCB.",
      "idx": 735,
      "timestamp": "2026-01-19T15:59:53.112514"
    },
    {
      "sample_idx": 704,
      "input": "Service Date: Soc. Sec. #: Client: FINAL PATHOLOGIC DIAGNOSIS. A. Brain, left temporal lobe, excision: Anaplastic Astrocytoma, WHO grade III; see. comment. B. Brain, left temporal lobe, excision: Anaplastic Astrocytoma, WHO grade III; see. comment. COMMENT: H&E sections of this astrocytoma show multiple areas of increased cellularity and mitotic activity (up to. 4 MF/10 HPF), consistent with an anaplastic astrocytoma, WHO grade III. Immunohistochemistry for. IDH-1 (R132H mutant protein), p53, an...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Temporal Lobe). 2. Findings: Anaplastic Astrocytoma, WHO grade III. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Temporal Lobe). 2. Findings: Anaplastic Astrocytoma, WHO grade III. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Temporal Lobe). 2. Findings: Anaplastic Astrocytoma, WHO grade III. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Temporal Lobe). 2. Findings: Anaplastic Astrocytoma, WHO grade III. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Temporal Lobe). 2. Findings: Anaplastic Astrocytoma, WHO grade III. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Temporal Lobe). 2. Findings: Anaplastic Astrocytoma, WHO grade III. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Temporal Lobe). 2. Findings: Anaplastic Astrocytoma, WHO grade III. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Temporal Lobe). 2. Findings: Anaplastic Astrocytoma, WHO grade III. 3. Code: GBM maps",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain (Left Temporal Lobe). 2. Findings: Anaplastic Astrocytoma, WHO grade III. 3. Code: GBM maps to GBM.",
      "idx": 704,
      "timestamp": "2026-01-19T15:59:53.112523"
    },
    {
      "sample_idx": 1236,
      "input": "LABORATORY MEDICINE PROGRAM. Facility: Specimen(s) Received. 1. Thyroid: RIGHT HEMI THYROID STITCH UPPER POLE FOR TUMOUR BANK. Diagnosis. Papillary carcinoma, follicular variant 4.0 cm, right: Thyrold. No pathological diagnosis: Parathyroid, right. -Right hemithyroidectomy specimen. Comment. This case has been seen in consultation with Dr. and she agrees with the interpretation and diagnosis. Synoptic Data. Clinical History: Other: BRCA1 mutation. Procedure: Right hemithyroidectomy. Fresh. Speci...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, follicular variant, right lobe. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, follicular variant, right lobe. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, follicular variant, right lobe. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, follicular variant, right lobe. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, follicular variant, right lobe. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, follicular variant, right lobe. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, follicular variant, right lobe. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, follicular variant, right lobe. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1.",
      "predicted": "BRCA",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Thyroid. 2. Findings: Papillary carcinoma, follicular variant, right lobe. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1236,
      "timestamp": "2026-01-19T15:59:53.112533"
    },
    {
      "sample_idx": 541,
      "input": "SPECIMEN. Right kidney. CLINICAL NOTES. PRE-OP DIAGNOSIS: Right renal mass. GROSS DESCRIPTION. The specimen is received unfixed, labeled \"right kidney\". and consists of a radical nephrectomy specimen measuring. 16. x 9 x 7 cm. On cut section the specimen contains a kidney measuring. 12.5 x 7.7 cm. On the central portion of the kidney there is a. yellow tumor in the renal cortex measuring 5 x 3.2 cm. A portion of. the specimen is taken for research purposes. Sections after. fixation. RS-8. MICROS...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Clear cell type renal cell carcinoma, Furhman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Clear cell type renal cell carcinoma, Furhman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Clear cell type renal cell carcinoma, Furhman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Clear cell type renal cell carcinoma, Furhman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Clear cell type renal cell carcinoma, Furhman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Clear cell type renal cell carcinoma, Furhman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Clear cell type renal cell carcinoma, Furhman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Clear cell",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Right kidney. 2. Findings: Clear cell type renal cell carcinoma, Furhman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 541,
      "timestamp": "2026-01-19T15:59:53.112544"
    },
    {
      "sample_idx": 88,
      "input": "page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - right breast. Unit in charge: I. Material collected on: I. aterial received on: Expected time of examination: up to 8 working days. Clinical diagnosis: Macroscopic description: Right breast Sized 20 x 14 x 5 cm removed along with axillary tissues sized 10 x 5 x 3 cm and a skin flap of 18 x 10 cm. Tumour. found in the upper outer quadrant, located 3 cm fro...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 88,
      "timestamp": "2026-01-19T15:59:53.112553"
    },
    {
      "sample_idx": 940,
      "input": "FINAL DIAGNOSIS: PART 1: OMENTUM, OMENTECTOMY -. ADIPOSE TISSUE WITH REACTIVE LYMPHOID AGGREGATES, NO NEOPLASM IDENTIFIED. PART 2: ADNEXA, LEFT, SALPINGO-OOPHORECTOMY -. A. POORLY DIFFERENTIATED ADENOCARCINOMA OF LEFT OVARY, PREDOMINANTLY PAPILLARY SEROUS. TYPE WITH AREAS OF CLEAR CELL AND ENDOMETRIOID CARCINOMA, 18 CM. B. NEOPLASM EXTENDS THROUGH OVARIAN CAPSULE AND ONTO THE SURFACE. C. LYMPHOVASCULAR INVASION IDENTIFIED. D. PATHOLOGIC STAGE: pT2c, NX, MX. E. UNREMARKABLE FALLOPIAN TUBE. PART 3...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Papillary serous adenocarcinoma, moderately differentiated (6-7 pts). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Papillary serous adenocarcinoma, moderately differentiated (6-7 pts). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Papillary serous adenocarcinoma, moderately differentiated (6-7 pts). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Papillary serous adenocarcinoma, moderately differentiated (6-7 pts). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Papillary serous adenocarcinoma, moderately differentiated (6-7 pts). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Papillary serous adenocarcinoma, moderately differentiated (6-7 pts). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Papillary serous adenocarcinoma, moderately differentiated (6-7 pts). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Papillary serous adenocarcinoma, moderately differentiated (6-7 pts). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2.",
      "predicted": "BRCA",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Ovary. 2. Findings: Papillary serous adenocarcinoma, moderately differentiated (6-7 pts). 3. Code: BRCA.",
      "idx": 940,
      "timestamp": "2026-01-19T15:59:53.112563"
    },
    {
      "sample_idx": 1098,
      "input": "SPECIMEN. A. Sigmoid and upper rectum. B. Appendix. CLINICAL NOTES. PRE-OP DIAGNOSIS: Sigmoid cancer. GROSS DESCRIPTION. A. Received fresh, subsequently fixed in formalin labeled. \"sigmoid and upper rectum\" is a rectosigmoid colon,. partially covered with abundant yellow lobular fat. The specimen. is. 38.5. The proximal end is inked blue and is previously stapled. The. distal end is also stapled and is inked black. The serosa is. pink-tan smooth glistening and partially covered with abundant. ye...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid and upper rectum. 2. Findings: Invasive adenocarcinoma, moderately differentiated, invasive of visceral peritoneum. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Appendix. 2. Findings: Unremarkable appendix. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid and upper rectum. 2. Findings: Moderately differentiated invasive adenocarcinoma, invasive of visceral peritoneum. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid and upper rectum. 2. Findings: Moderately differentiated invasive adenocarcinoma, invasive of visceral peritoneum. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid and upper rectum. 2. Findings: Moderately differentiated invasive adenocarcinoma, invasive of visceral peritoneum. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid and upper rectum. 2. Findings: Moderately differentiated invasive adenocarcinoma, invasive of visceral peritoneum. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid and upper rectum. 2. Findings: Moderately differentiated invasive adenocarcinoma, invasive of visceral peritoneum. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid and upper rectum. 2. Findings: Moderately differentiated invasive adenocarcinoma, invasive of visceral peritoneum. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\":",
      "predicted": "KIRC",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Sigmoid and upper rectum. 2. Findings: Invasive adenocarcinoma, moderately differentiated, invasive of visceral peritoneum. 3. Code: KIRC.",
      "idx": 1098,
      "timestamp": "2026-01-19T15:59:53.112573"
    },
    {
      "sample_idx": 255,
      "input": "Component. (note). Accession # : PATHOLOGIC DIAGNOSIS. A. LYMPH NODE, LEFT PARAMETRIAL, BIOPSY: - ONE LYMPH NODE WITH NO EVIDENCE MALIGNANCY (0/1). B. UTERUS, CERVIX, RADICAL HYSTERECTOMY: - INVASIVE POORLY DIFFERENTIATED CERVICAL SQUAMOUS. CARCINOMA pT1b2N1. - TUMOR EXTENDS INTO LOWER UTERINE SEGMENT. - TUMOR NOT PRESENT AT INKED MARGINS. - LYMPHOVASCULAR SPACE INVASION IDENTIFIED. - PERINEURAL INVASION IDENTIFIED. - FOCAL SQUAMOUS CARCINOMA IN-SITU. - FOURTEEN LYMPH NODES WITH NO EVIDENCE OF M...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive poorly differentiated squamous cell carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix. 2. Findings: Invasive poorly differentiated squamous cell carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Lymph Node, Left Parametrial. 2. Findings: No evidence of malignancy. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix. 2. Findings: Invasive poorly differentiated squamous cell carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Lymph Node, Left Parametrial. 2. Findings: No evidence of malignancy. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Soft Tissue, Left Parametrium. 2. Findings: No evidence of malignancy. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Fallopian Tube and Ovary, Left. 2. Findings: Benign inclusion cyst. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Lymph Node, Left Parametrial. 2. Findings: No evidence of malignancy. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Soft Tissue, Left Parametrium. 2. Findings: No evidence of malignancy. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type",
      "predicted": "BRCA",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Cervix. 2. Findings: Invasive poorly differentiated squamous cell carcinoma. 3. Code: BRCA",
      "idx": 255,
      "timestamp": "2026-01-19T15:59:53.112582"
    },
    {
      "sample_idx": 775,
      "input": "Acct / Reg #: DIAGNOSIS. DIAGNOSIS: A. Lymph node, level 9L, excision: Total number of lymph nodes received: One (1). Total number of lymph nodes containing metastatic carcinoma: Zero (0). B. Lymph node, level 5, excision: Total number of lymph nodes received: One (1). Total number of lymph nodes containing metastatic carcinoma: Zero (0). Frozen section diagnosis confirmed. C. Lymph node, level 7, excision: Total number of lymph nodes received: Two (2). Total number of lymph nodes containing met...",
      "response": "```json\n{\n    \"cancer_type\": \"UCLM\",\n    \"reasoning\": \"1. Site: Lung (Left). 2. Findings: Adenocarcinoma, poorly differentiated, 4.5 cm, unifocal, pleural invasion, lymphovascular invasion, confined to lung, not identified. 3. Code: UCLM maps to UCLM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCLM\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated, 4.5 cm, unifocal, pleural invasion, lymphovascular invasion, confined to lung, not identified. 3. Code: UCLM maps to UCLM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCLM\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated, 4.5 cm, unifocal, pleural invasion, lymphovascular invasion, confined to lung, not identified. 3. Code: UCLM maps to UCLM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2",
      "predicted": "UCLM",
      "ground_truth": "LUAD",
      "correct": false,
      "reasoning": "1. Site: Lung (Left). 2. Findings: Adenocarcinoma, poorly differentiated, 4.5 cm, unifocal, pleural invasion, lymphovascular invasion, confined to lung, not identified. 3. Code: UCLM maps to UCLM.",
      "idx": 775,
      "timestamp": "2026-01-19T15:59:53.112594"
    },
    {
      "sample_idx": 161,
      "input": "BREAST TISSUE CHECKLIST. Specimen type: Radical mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 1.8 x 1 x 1 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal and lobular carcinoma. Histologic grade: Tumor extent: Not specified. Lymph nodes: 7/7 positive for metastasis (Regional 7/7). Right,Jupper. Extracapsular invasion of the lymph nodes: Not specified. inner. Margins: Not specified. quadrant. Nottingham Histologic Score. Tubule formation: Not speci...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal and lobular carcinoma",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 161,
      "timestamp": "2026-01-19T15:59:53.112603"
    },
    {
      "sample_idx": 1130,
      "input": "SPECIMEN(S): A: Left axillary sentinel lymph node. B: Left breast. C: Right breast. FINAL DIAGNOSIS: A. Lymph node, left axillary sentinel, biopsy. - No evidence of malignancy in one lymph node (0/1). B. Breast, left, mastectomy: - Leiomyosarcoma, intermediate grade. - Tumor measures 5.5 x 5.2 x 4.5 cm. - Biopsy site changes with hemorrhage. - Margin widely negative (all greater than 1.8 cm). - Fat necrosis. - Cysts with apocrine metaplasia. - See microscopic for discussion and tumor synoptic. C...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Leiomyosarcoma, intermediate grade. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left axillary sentinel lymph node. 2. Findings: Lymph node, left axillary sentinel, biopsy. No evidence of malignancy in one lymph node (0/1). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Right breast. 2. Findings: Simple ductal hyperplasia without atypia. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Simple ductal hyperplasia without atypia. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Simple ductal hyperplasia without atypia. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Simple ductal hyperplasia without atypia. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Simple ductal hyperplasia without atypia. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Simple ductal hyperplasia without atypia. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Simple ductal hyperplasia without atypia. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BR",
      "predicted": "BRCA",
      "ground_truth": "SARC",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Leiomyosarcoma, intermediate grade. 3. Code: BRCA",
      "idx": 1130,
      "timestamp": "2026-01-19T15:59:53.112612"
    },
    {
      "sample_idx": 600,
      "input": "AMENDEDICORRECTED REPORT: Amended date: Reason: Spelling / Typographical Edit. This report being amended is to make correction to a typographical error on diagnostic line 'C' of Part 2, \"THE GREATEST. DIMENSION OF THE NEOPLASM IS 3.0 cm\", which is corrected to read as, \"THE GREATEST DIMENSION OF THE. NEOPLASM IS 7.5 cm\". in the Final Diagnosis field. While it was correctly stated in the Case Synopsis field. This Amended/Corrected Report reflects NO change to the previously rendered diagnoses. Th...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left). 2. Findings: Papillary renal cell carcinoma, Type I, Fuhrman Grade II, Greatest dimension of the neoplasm is 7.5 cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left). 2. Findings: Papillary renal cell carcinoma, Type I, Fuhrman Grade II, Greatest dimension of the neoplasm is 7.5 cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left). 2. Findings: Papillary renal cell carcinoma, Type I, Fuhrman Grade II, Greatest dimension of the neoplasm is 7.5 cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left). 2. Findings: Papillary renal cell carcinoma, Type I, Fuhrman Grade II, Greatest dimension of the neoplasm is 7.5 cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left). 2. Findings: Papillary renal cell carcinoma, Type I, Fuhrman Grade II, Greatest dimension of the neoplasm is 7.5 cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left). 2. Findings: Papillary renal cell carcinoma, Type I, Fuhrman Grade II, Greatest dimension of the neoplasm is 7.5 cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Kidney (Left). 2. Findings: Papillary renal cell carcinoma, Type I, Fuhrman Grade II, Greatest dimension of the neoplasm is 7.5 cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 600,
      "timestamp": "2026-01-19T15:59:53.112624"
    },
    {
      "sample_idx": 1287,
      "input": "PATIENT HISTORY: CHIEF COMPLAINT/ PRE-OP/ POST-OP DIAGNOSIS: Metastatic thyroid cancer. PROCEDURE: Total thyroidectomy, excision lymph node. SPECIFIC CLINICAL QUESTION: Not 'answered. OUTSIDE TISSUE DIAGNOSIS: Not answered. PRIOR MALIGNANCY: Not answered. CHEMORADIATION THERAPY: Not answered. ORGAN TRANSPLANT: Not answered. IMMUNOSUPPRESSION: Not answered. OTHER DISEASES: Not answered. ADDENDA: Addendum. Molecular Anatomic Pathology Testing: Block 1D: A. HRAS codon 61 mutation IDENTIFIED. B. Mut...",
      "response": "```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Total thyroidectomy. 2. Findings: Angioinvasive follicular carcinoma, 2.8 cm. pT2, pNX, pM1. 3. Code: THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Total thyroidectomy. 2. Findings: Nodular thyroid hyperplasia. 3. Code: THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Total thyroidectomy. 2. Findings: Loss of heterozygosity at chromosome 22q. 3. Code: UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"READ\",\n    \"reasoning\": \"1. Site: Total thyroidectomy. 2. Findings: Loss of heterozygosity at chromosome 1p, 1p35.1, 1p36.21, 3p25.3, 3p26.3, 5q23.2, 5q23.3, 9p21.3, 9p22.2, 10q23.31, 10q23.31, 17p13.1, 17p13.1, 22q12.2, 22q12.2. 3. Code: READ.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Total thyroidectomy. 2. Findings: Nodular thyroid hyperplasia. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Total thyroidectomy. 2. Findings: pT2, pNX, pM1. 3. Code: OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Total thyroidectomy. 2. Findings: Angioinvasive follicular carcinoma, ",
      "predicted": "THCA",
      "ground_truth": "THCA",
      "correct": true,
      "reasoning": "1. Site: Total thyroidectomy. 2. Findings: Angioinvasive follicular carcinoma, 2.8 cm. pT2, pNX, pM1. 3. Code: THCA.",
      "idx": 1287,
      "timestamp": "2026-01-19T15:59:53.112639"
    },
    {
      "sample_idx": 1266,
      "input": "Case type: Surgical Case. DIAGNOSIS. 8340/3. (A) LEFT THYROID LOBE AND ISTHMUS: PAPILLARY THYROID CARCINOMA, FOLLICULAR VARIANT CQCF: carcinoma, papillary, theroid. Location: Left lobe. Multi-focal: No. Size = 2.2 cm. Extrathyroidal extension: Absent. Lymphovascular invasion: Present. Resection Margins: Negative. Lymph nodes: No lymph nodes present. GROSS DESCRIPTION. (A) LEFT THYROID LOBE AND ISTHMUS - A hemithyroidectomy specimen (4.0 : x 1.5 x 1.5 cm) contains a well-. circumscribed pink-tan ...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe and Isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant, Fuhrman Grade II, Extrathyroidal extension: Absent, Lymphovascular invasion: Present, Resection Margins: Negative, Lymph nodes: No lymph nodes present. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe and Isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant, Fuhrman Grade II, Extrathyroidal extension: Absent, Lymphovascular invasion: Present, Resection Margins: Negative, Lymph nodes: No lymph nodes present. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe and Isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant, Fuhrman Grade II, Extrathyroidal extension: Absent, Lymphovascular invasion: Present, Resection Margins: Negative, Lymph nodes: No lymph nodes present. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe and Isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant, Fuhrman Grade II, Extrathyroidal extension: Absent, Lymphovascular invasion: Present, Resection Margins: Negative, Lymph nodes: No lymph nodes present. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe and Isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant, Fuhrman Grade II, Extrathyroidal extension: Absent, Lymphovascular invasion: Present, Resection Margins: Negative, Lymph nodes: No lymph nodes present. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"",
      "predicted": "THYM",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Left Thyroid Lobe and Isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant, Fuhrman Grade II, Extrathyroidal extension: Absent, Lymphovascular invasion: Present, Resection Margins: Negative, Lymph nodes: No lymph nodes present. 3. Code: THYM maps to THYM.",
      "idx": 1266,
      "timestamp": "2026-01-19T15:59:53.112654"
    },
    {
      "sample_idx": 740,
      "input": "TISSUE DESCRIPTION. Right lobe liver (22 x 14.3 X 9.5 cm) and gallbladder (7.5 X 3.5. X 1.5 cm) and submitted en bloc (1,475 grams) . A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, A11, A12,. A13, A14, A15, A16, A17, A18, A19,A20, A21, A22, A23, A24, A25,. A26, A27, A28, A29, A30, A31, A32, A33, A34. DIAGNOSIS: Liver, right lobe, hepatectomy: Grade 2 (of 4) hepatocellular. carcinoma forming a 12 X 11 X 8 cm mass. No vascular invasion. is identified. Surgical margins are free by 1 cm. Gallbladder, hepa...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Right lobe). 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, right lobe, hepatectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Gallbladder. 2. Findings: Mild chronic cholecystitis. 3. Code: Gallbladder maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Right lobe). 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, right lobe, hepatectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Right lobe). 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, right lobe, hepatectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Right lobe). 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, right lobe, hepatectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Right lobe). 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, right lobe, hepatectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Right lobe). 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, right lobe, hepatectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Right lobe). 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, right",
      "predicted": "KIRC",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Liver (Right lobe). 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, right lobe, hepatectomy maps to KIRC.",
      "idx": 740,
      "timestamp": "2026-01-19T15:59:53.112664"
    },
    {
      "sample_idx": 1182,
      "input": "Case ID. Subject. STOMACH TISSUE CHECKLIST. Specimen type: Gastrectomy. Tumor site: Stomach. Tumor size: 8 X 5 X 1.7 cm. Tumor features: None specified. Histologic type: Adenocarcinoma. Histologic grade: Poorly differentiated. Tumor extent: Adjacent structures (specify) -. Esophagus, lesser omentum. Lymph nodes: 0/5 positive for metastasis. (Regional 0/5). Lymphatic invasion: Not specified. Venous invasion: Not specified. Perineural invasion: Not specified. Margins: Uninvolved. Evidence of neo-a...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site",
      "predicted": "ADENOMA",
      "ground_truth": "STAD",
      "correct": false,
      "reasoning": "1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: ADENOMA",
      "idx": 1182,
      "timestamp": "2026-01-19T15:59:53.112673"
    },
    {
      "sample_idx": 393,
      "input": "CLINICAL HISTORY. has experienced. On imaging. there is a large right temporoparietal mass with rim-enhancement and. prominent. associated vasogenic edema. OPERATIVE DIAGNOSES. Operation/Specimen A: Brain, right parietal tumor, excision biopsy. PATHOLOGICAL DIAGNOSIS: A and B. Brain, right parietal, excisional biopsies: A. Glioblastoma. B. MIB-1 proliferation index: > 8%. See Microscopy Description and Comment. COMMENT. The neoplasm is a glioblastoma with brisk mitotic activity, a high MIB-1. pr...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Right Parietal). 2. Findings: Glioblastoma, high grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Right Parietal). 2. Findings: Glioblastoma, high grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Right Parietal). 2. Findings: Glioblastoma, high grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Right Parietal). 2. Findings: Glioblastoma, high grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Right Parietal). 2. Findings: Glioblastoma, high grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Right Parietal). 2. Findings: Glioblastoma, high grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Right Parietal). 2. Findings: Glioblastoma, high grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Right Parietal). 2. Findings: Glioblastoma, high grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Right Parietal). 2. Findings: Glioblastoma, high grade. 3. Code: KIRC.\"\n}\n```",
      "predicted": "KIRC",
      "ground_truth": "GBM",
      "correct": false,
      "reasoning": "1. Site: Brain (Right Parietal). 2. Findings: Glioblastoma, high grade. 3. Code: KIRC.",
      "idx": 393,
      "timestamp": "2026-01-19T15:59:53.112683"
    },
    {
      "sample_idx": 142,
      "input": "SPECIMENS: A. SLN #1 RIGHT AXILLA. B. RIGHT BREAST. C. RIGHT BREAST UPPER OUTER QUADRANT. D. RIGHT BREAST LATERAL FLAP. E. LEFT BREAST AND AXILLARY TAIL. F. ADDITIONAL AXILLARY CONTENTS. SPECIMEN(S): A. SLN #1 RIGHT AXILLA. B. RIGHT BREAST. C. RIGHT BREAST UPPER OUTER QUADRANT. D. RIGHT BREAST LATERAL FLAP. E. LEFT BREAST AND AXILLARY TAIL. F. ADDITIONAL AXILLARY CONTENTS. GROSS DESCRIPTION: A. SLN #1 RIGHT AXILLA. Received fresh labeled with the patient's identification and \"SLN #1 right axilla...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, mainly pleomorphic type, SBR Grade 3, solid growth pattern, LCIS. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, mainly pleomorphic type, SBR Grade 3, solid growth pattern, LCIS. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, mainly pleomorphic type, SBR Grade 3, solid growth pattern, LCIS. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, mainly pleomorphic type, SBR Grade 3, solid growth pattern, LCIS. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, mainly pleomorphic type, SBR Grade 3, solid growth pattern, LCIS. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, mainly pleomorphic type, SBR Grade 3, solid growth pattern, LCIS. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, mainly pleomorphic type, SBR Grade 3, solid growth pattern, LCIS. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings:",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive lobular carcinoma, mainly pleomorphic type, SBR Grade 3, solid growth pattern, LCIS. 3. Code: BRCA.",
      "idx": 142,
      "timestamp": "2026-01-19T15:59:53.112692"
    },
    {
      "sample_idx": 93,
      "input": "IGA-EW-A2FW-01A-PR. Pathologic Interpretation: A. SENTINEL NODE # 1 COUNT. - No malignancy seen in one lymph node (0/1). . Keratin immunostain to follow. B. SUSPICIOUS LYMPH NODE RIGHT BREAST: - No malignancy seen in one lymph node (0/1). - Keratin immunostain to follow. c. SENTINEL NODE # 2 COUNT. - No malignancy seen in one lymph node (0/1). - Keratin immunostaln to follow. D. SENTINEL NODE # 3 COUNT. - No malignancy seen in one lymph node (0/1). - Keratin immunostain to follow. E. SENTINEL NO...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, poorly differentiated, Nottingham grade 2 (3 +2+1 = 6), papiliary type, 2.8 cm in greatest. dimension. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nExplanation:\nThe pathology report describes an invasive ductal carcinoma in the breast. The key findings are the presence of a poorly differentiated, high-grade invasive carcinoma with a Nottingham grade of 2 and a size of 2.8 cm. This aligns with the description of Breast Invasive Carcinoma in the provided TCGA codes. Therefore, the correct TCGA code is BRCA.\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, poorly differentiated, Nottingham grade 2 (3 +2+1 = 6), papiliary type, 2.8 cm in greatest. dimension. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, poorly differentiated, Nottingham grade 2 (3 +2+1 = 6), papiliary type, 2.8 cm in greatest. dimension. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, poorly differentiated, Nottingham grade 2 (3 +2+1 = 6), papiliary type, 2.8 cm in greatest. dimension. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, poorly differentiated, Nottingham grade 2 (3 +2+1 = 6), papiliary type, 2.8 cm in greatest. dimension. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, poorly differentiated, Nottingham grade 2 (3 +2+1 = 6), papiliary type, 2.8 cm in greatest. dimension. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 93,
      "timestamp": "2026-01-19T15:59:53.112704"
    },
    {
      "sample_idx": 466,
      "input": "SURGICAL PATHOLOGY REVISED REPORT. Diagnosis: A: Right palate lesion, biopsy. - Invasive moderately differentiated squamous cell carcinoma. Clinical History: -year-old male with a palate mass. Gross Description: Received is one appropriately labeled container, additionally. labeled \"right palate lesion. It holds multiple pale tan soft. tissue fragments in aggregate measuring 1.4 X 1.0 X 0.6 cm. Tissue is taken by Dr. in. for the. and the remaining tissue is submitted in block A1,. Addendum. Adde...",
      "response": "```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Palate. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Palate. 2. Findings: Squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Palate. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Palate. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Palate. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Palate. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Palate. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Palate. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Palate. 2. Findings: Invasive squamous cell carcinoma. 3. Code: H",
      "predicted": "HNSC",
      "ground_truth": "HNSC",
      "correct": true,
      "reasoning": "1. Site: Palate. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC maps to HNSC.",
      "idx": 466,
      "timestamp": "2026-01-19T15:59:53.112714"
    },
    {
      "sample_idx": 592,
      "input": "FINAL DIAGNOSIS: PART 1: BONE, BONE AND 12 TH BONE RIB, PARTIAL MARROW RESECTION: WITH NO EVIDENCE - OF MALIGNANCY. 3.8. CM. PART RADICAL. KIDNEY, 2: LEFT, NEPHRECTOMY CONVENTIONAL - (CLEAR CELL) TYPE, FUHRMAN NUCLEAR GRADE THE III/IV, RENAL SINUS. OR. A. RENAL GREATEST CELL DIMENSION. CARCINOMA, WITHIN THE RENAL CAPSULE, WITH NO EVIDENCE OF INVASION OF. B. TUMOR PERI-NEPHRIC IS NO CONFINED EVIDENCE ADIPOSE OF TISSUE. ANGIOLYMPHATIC TUMOR. INVASION. C. D. THERE ALL NON-NEOPLASTIC SURGICAL IS MAR...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 592,
      "timestamp": "2026-01-19T15:59:53.112724"
    },
    {
      "sample_idx": 163,
      "input": "FINAL DIAGNOSIS: PART 1: LEFT AXILLARY SENTINEL LYMPH NODE #1, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR TUMOR (0/1). PART 2: BREAST, LEFT, SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA, NOTTINGHAM GRADE 3, (TUBULE FORMATION - 3, NUCLEAR GRADE -. 3, MITOTIC RATE - 3, TOTAL SCORE: 9/9). B. INVASIVE CARCINOMA MEASURES 1.8 CM IN GREATEST DIMENSION (SLIDE 2B). C. DUCTAL CARCINOMA IN SITU (DCIS), NUCLEAR GRADE 3, SOLID AND MICROPAPILLARY TYPES WITH. COMEDO NECROSIS AND ASSOCIATED CALCIFICATIONS. ...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Grade 3. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Grade 3. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Grade 3. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Grade 3. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Grade 3. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Grade 3. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Grade 3. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Grade 3. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1.",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Grade 3. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 163,
      "timestamp": "2026-01-19T15:59:53.112734"
    },
    {
      "sample_idx": 1397,
      "input": "LOC: U#: AGE/SX: RM/BED: REG DR: TLOC: DIS: SPEC #: Obtained: CLINICAL HISTORY: GRADE II ENDOMETRIAL CANCER;. OUCI,. PECIMEN/PROCEDURE: 1. LYMPH NODE - RIGHT PELVIC; LAP.ASST'D VAGINAL HYSTERECTOMY/LNI. 2. LYMPH NODE - RIGHT PA'T AORTIC. 3. LYMPH NODE - RIGHT OCMMON ILIAC. 4. LYMPH NODE - LEFT PARA-AORTIC. 5. LYMPH NODE - LEFT PELVIC. 6. LYMPH NODE - LEFT COMMON ILIAC. 7. UTERUS - WITH CERVIX, BILATERAL TUBES AND OVARIES. IMPRESSION: 1). LYMPH NODES, RIGHT PELVIC, REGIONAL DISSECTION: Nine benig...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus (with cervix, bilateral tubes and ovaries). 2. Findings: Endometrial adenocarcinoma, endometrioid type, FIGO grade II, nuclear grade 2. The tumor involves the endometrium and extends into the myometrium. 3. Code: KIRC.\"\n}\n```\nExplanation:\n\n1.  **Anatomic Site:** The specimen is a uterus with cervix, bilateral tubes, and ovaries.\n2.  **Histological Findings:** The report describes endometrial adenocarcinoma, specifically endometrioid type, with a FIGO grade II and nuclear grade 2. It also mentions the tumor extending into the myometrium.\n3.  **TCGA Code Selection:** Based on the description, the most appropriate TCGA code is KIRC, which stands for Kidney Renal Clear Cell Carcinoma. This is because the report describes a tumor in the uterus, which is not a kidney. The report describes a tumor in the uterus.\nThe correct code is KIRC, which corresponds to Kidney Renal Clear Cell Carcinoma.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus (with cervix, bilateral tubes and ovaries). 2. Findings: Endometrial adenocarcinoma, endometrioid type, FIGO grade II, nuclear grade 2. The tumor involves the endometrium and extends into the myometrium. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus (with cervix, bilateral tubes and ovaries). 2. Findings: Endometrial adenocarcinoma, endometrioid type, FIGO grade II, nuclear grade 2. The tumor involves the endometrium and extends into the myometrium. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus (with cervix, bilateral tubes and ovaries). 2. Findings: Endometrial adenocarcinoma, endometrioid type, FIGO grade II, nuclear grade 2. The tumor involves the endometrium and extends into the myometrium. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type",
      "predicted": "KIRC",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Uterus (with cervix, bilateral tubes and ovaries). 2. Findings: Endometrial adenocarcinoma, endometrioid type, FIGO grade II, nuclear grade 2. The tumor involves the endometrium and extends into the myometrium. 3. Code: KIRC.",
      "idx": 1397,
      "timestamp": "2026-01-19T15:59:53.112748"
    },
    {
      "sample_idx": 206,
      "input": "AP Surgical Pathology: Final. CLINICAL HISTORY: Probable metastatic breast CA -. year-old white female presenting. with left femur fracture ? pathologic, has large 6 cm breast mass in left. breast. GROSS EXAMINATION: A. \"Left breast biopsy\", in formalin. An irregular fragment of yellow. fibro-adipose tissue measuring 5 x 2.5 x 2 cm in approximate dimensions. The. specimen has previously been sectioned and a portion submitted for ER-PR. evaluation. The margins of the specimen were not inked as th...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 206,
      "timestamp": "2026-01-19T15:59:53.112757"
    },
    {
      "sample_idx": 1374,
      "input": "Specimens Submitted: 1: SP: Uterus, cervix, bilateral tubes and ovaries (. 2: SP: Omentum. 3: SP: Right peri-aortic lymph node. 4: SP: Left peri-aortic lymph node. 5: SP: Left external iliac lymph node. 6 : SP: Left common iliac lymph node. 7: SP: Left obturator lymph node. 8: SP: Left hypogastric lymph node. 9: SP: Right external iliac lymph node. 10: SP: Right obturator lymph node. DIAGNOSIS: 1). UTERUS, CERVIX, VALLOPIAN TUBES AND OVARIES; TOTAL HYSTERECTOMY. AND BILATERAL SALPINGO-OOPHORECTO...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, bilateral tubes and ovaries. 2. Findings: Papillary serous carcinoma of the endometrium arising in an atrophic polyp. Tumor invades through more than half of the myometrial thickness. Vascular invasion is present. No endocervical invasion identified. 3. Code: UTERUS, CERVIX, VALLOPIAN TUBES AND OVARIES maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Omentum. 2. Findings: Benign fibroadipose tissue. 3. Code: OMENTUM maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right peri-aortic lymph node. 2. Findings: Four benign lymph nodes. 3. Code: LYMPH NODE, RIGHT PERICOLIC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left peri-aortic lymph node. 2. Findings: One benign lymph node. 3. Code: LYMPH NODE, LEFT PERIAORTIC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left external iliac lymph node. 2. Findings: Metastatic carcinoma in one of one lymph node. 3. Code: LYMPH NODE, LEFT EXTERNAL ILIAC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left common iliac lymph node. 2. Findings: Metastatic carcinoma in three of six lymph nodes. 3. Code: LYMPH NODE, LEFT COMMON ILIAC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left obturator lymph node. 2. Findings: Metastatic carcinoma in one or two lymph nodes. 3. Code: LYMPH NODE",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus, cervix, bilateral tubes and ovaries. 2. Findings: Papillary serous carcinoma of the endometrium arising in an atrophic polyp. Tumor invades through more than half of the myometrial thickness. Vascular invasion is present. No endocervical invasion identified. 3. Code: UTERUS, CERVIX, VALLOPIAN TUBES AND OVARIES maps to UCEC.",
      "idx": 1374,
      "timestamp": "2026-01-19T15:59:53.112772"
    },
    {
      "sample_idx": 1380,
      "input": "Client. History/Clinical Dx: Endometrial cancer. Postoperative Dx: Same, pending pathology examination. Specimen(s) Received: A: Uterus, cervix, tubes and ovaries. B: Left peivic lymph nodes. C: Left aortic lymph nodes. D: Right pelvic lymph nodes. E: Right caval lymph nodes. DIAGNOSIS: A. Uterus, cervix, tubes and ovaries: ENDOMETRIAL ADENOCARCINOMA. Tumor Information: Operative procedure: TAH-BSO with node sampling. Histologic type: Endometriold. Histologic grade(FIGO): Grade 1. Nuclear grade:...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, tubes and ovaries. 2. Findings: Endometrial adenocarcinoma, grade 1, nuclear grade 2, tumor size 2.4 x 2.0 x 1.8 cm. Extent of invasion: Less than 50% (2 mm of invasion). Lympho/vascular invasion: Not identified. Serosa: Free of tumor. Parametrium: Free of tumor. Cervical Involvement: Absent. Right adnexa: No evidence of tumor. Left adnexa: No evidence of tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"",
      "predicted": "KIRC",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Uterus, cervix, tubes and ovaries. 2. Findings: Endometrial adenocarcinoma, grade 1, nuclear grade 2, tumor size 2.4 x 2.0 x 1.8 cm. Extent of invasion: Less than 50% (2 mm of invasion). Lympho/vascular invasion: Not identified. Serosa: Free of tumor. Parametrium: Free of tumor. Cervical Involvement: Absent. Right adnexa: No evidence of tumor. Left adnexa: No evidence of tumor. 3. Code: KIRC.",
      "idx": 1380,
      "timestamp": "2026-01-19T15:59:53.112788"
    },
    {
      "sample_idx": 928,
      "input": "DIAGNOSIS: 1. SMALL BOWEL ADHESION, LYSIS: -Fibrous adhesion. -Necrotic cellular debris with fragments of high-grade. adenocarcinoma. 2. OMENTUM, PARTIAL OMENTECTOMY AND FROZEN SECTION #1: -Adenocarcinoma, high nuclear grade, consistent with mullerian. origin. 3. OVARY AND FALLOPIAN TUBE, LEFT, SALPINGO-OOPHORECTOMY: -Left ovary: -Papillary adenocarcinoma, high nuclear grade (nuclear grade. grade 3), consistent with mullerian-derived adenocarcinoma,. papillary serous type. -Left fallopian tube: ...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary and Fallopian Tube (Left). 2. Findings: Papillary adenocarcinoma, mullerian-derived, papillary serous type. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary and Fallopian Tube (Right). 2. Findings: Papillary adenocarcinoma, mullerian-derived, papillary serous type. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Diaphragm. 2. Findings: Papillary adenocarcinoma, mullerian-derived, papillary serous type. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Bladder Peritoneum. 2. Findings: Adenocarcinoma, papillary serous type, mullerian-derived. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary and Fallopian Tube (Left). 2. Findings: Papillary adenocarcinoma, mullerian-derived, papillary serous type. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary and Fallopian Tube (Right). 2. Findings: Papillary adenocarcinoma, mullerian-derived, papillary serous type. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Papillary adenocarcinoma, mullerian-derived, papillary serous type. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Left External Iliac Lymph Node. 2. Findings: Adenocarcinoma, papillary serous type, mullerian-derived. 3. Code: BRCA\"\n}\n```\n```json",
      "predicted": "BRCA",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Ovary and Fallopian Tube (Left). 2. Findings: Papillary adenocarcinoma, mullerian-derived, papillary serous type. 3. Code: BRCA",
      "idx": 928,
      "timestamp": "2026-01-19T15:59:53.112798"
    },
    {
      "sample_idx": 1301,
      "input": "Result date: Surgical Procedure. Contributor system: Surgical Procedure. SPECIMENS SUBMITTED: A. EXTENDED THYMECTOMY. DIAGNOSIS: A. MEDIASTINUM, THYMUS; THYMECTOMY: THYMOMA, TYPE B1 (PREDOMINANTLY CORTICAL). TUMOR SIZE: 5.8 cm. TUMOR INVASION. TUMOR CAPSULE/MEDIASTINAL FAT: INVASION INTO SURROUNDING FAT. PRESENT. PLEURA/PERICARDIUM: NOT PRESENT FOR EVALUATION. LUNG PARENCHYMA: NOT PRESENT FOR EVALUATION. DIAPHRAGM: NOT PRESENT FOR EVALUATION. LYMPH VASCULAR INVASION: NEGATIVE. IMPLANT/DISTANT ME...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, type B1 (predominantly cortical). 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, type B1 (predominantly cortical). 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, type B1 (predominantly cortical). 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, type B1 (predominantly cortical). 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, type B1 (predominantly cortical). 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, type B1 (predominantly cortical). 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, type B1 (predominantly cortical). 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, type B1 (predominantly cortical). 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "THYM",
      "ground_truth": "THYM",
      "correct": true,
      "reasoning": "1. Site: Thymus. 2. Findings: Thymoma, type B1 (predominantly cortical). 3. Code: Thymoma maps to THYM.",
      "idx": 1301,
      "timestamp": "2026-01-19T15:59:53.112808"
    },
    {
      "sample_idx": 747,
      "input": "TISSUE DESCRIPTION: Liver Segments I, II, III and IV (2280 grams, 20 x 19 x 11 cm), separately submitted. left portal lymph node (4.5 x 2.6 x 1.2 cm) and gallbladder (7.5 x 3.5 x 1 cm). A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, C6. DIAGNOSIS: Liver, Segments I, II, III and IV, resection: Grade 3 (of 4) hepatocellular carcinoma,. usual type, forming a single 18.5 x 18 x 11 cm mass. The tumor is located in. Segments I, II, III and IV. The tumor invades into but not through hepatic capsule. The tumor...",
      "response": "```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver, Segments I, II, III and IV. 2. Findings: Hepatocellular carcinoma, Grade 3 (of 4), usual type, forming a single mass. Vascular invasion identified. The tumor is not encapsulated. 30% necrosis. The non-neoplastic liver shows a mild nonspecific chronic inflammatory infiltrate in the portal tracts. The normal liver shows a mild nonspecific chronic inflammatory infiltrate in the portal tracts. but is otherwise unremarkable. The normal liver shows a mild nonspecific chronic inflammatory infiltrate in the portal tracts. but is otherwise unremarkable. Special stains show minimal amounts of hepatic iron of doubtful clinical significance. A PAS-D is unremarkable. 4. Code: Liver, Segments I, II, III and IV, resection maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, Segments I, II, III and IV. 2. Findings: Hepatocellular carcinoma, Grade 3 (of 4), usual type, forming a single mass. Vascular invasion identified. The tumor is not encapsulated. 30% necrosis. The non-neoplastic liver shows a mild nonspecific chronic inflammatory infiltrate in the portal tracts. The normal liver shows a mild nonspecific chronic inflammatory infiltrate in the portal tracts. but is otherwise unremarkable. Special stains show minimal amounts of hepatic iron of doubtful clinical significance. A PAS-D is unremarkable. 4. Code: Liver, Segments I, II, III and IV, resection maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver, Segments I, II, III and IV. 2. Findings: Hepatocellular carcinoma, Grade 3 (of 4), usual type, forming a single mass. Vascular invasion identified. The tumor is not encapsulated. 30% necrosis. The non-neoplastic liver shows a mild nonspecific chronic inflammatory infiltrate in the portal tracts. The normal liver shows a mild nonspecific chronic inflammatory infiltrate in the portal tracts. but is otherwise unremarkable. Special stains show minimal amounts of hepatic iron of doubtful clinical significance. A PAS-D is unremarkable. 4. Code: Liver, Segments I, II, III and IV, resection maps to LIHC.\"\n}",
      "predicted": "LIHC",
      "ground_truth": "LIHC",
      "correct": true,
      "reasoning": "1. Site: Liver, Segments I, II, III and IV. 2. Findings: Hepatocellular carcinoma, Grade 3 (of 4), usual type, forming a single mass. Vascular invasion identified. The tumor is not encapsulated. 30% necrosis. The non-neoplastic liver shows a mild nonspecific chronic inflammatory infiltrate in the portal tracts. The normal liver shows a mild nonspecific chronic inflammatory infiltrate in the portal tracts. but is otherwise unremarkable. The normal liver shows a mild nonspecific chronic inflammatory infiltrate in the portal tracts. but is otherwise unremarkable. Special stains show minimal amounts of hepatic iron of doubtful clinical significance. A PAS-D is unremarkable. 4. Code: Liver, Segments I, II, III and IV, resection maps to LIHC.",
      "idx": 747,
      "timestamp": "2026-01-19T15:59:53.112831"
    },
    {
      "sample_idx": 333,
      "input": "Date Coll: SPECIMEN. Right colon. CLINICAL NOTES. PRE-OP DIAGNOSIS: Carcinoma of the hepatic flexure. GROSS DESCRIPTION. Received fresh labeled \"right colon\" is a previously. unopened, 12 cm segment of proximal right colon with. attached 6 cm of distal ileum surfaced by smooth to scabrous. tan-pink serosa with a moderate amount of attached mesocolon,. mesentery and unremarkable omentum. An unremarkable 6.6 cm appendix. averaging 0.5 cm in diameter is present. The proximal and distal. margins mea...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with mucinous differentiation, pT3, pN0, pM0. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENCA\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with mucinous differentiation, pT3, pN0, pM0. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with mucinous differentiation, pT3, pN0, pM0. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with mucinous differentiation, pT3, pN0, pM0. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with mucinous differentiation, pT3, pN0, pM0. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with mucinous differentiation, pT3, pN0, pM0. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with mucinous differentiation, pT3, pN0, pM0. 3. Code: Colon Adenocarcinoma maps to CO",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with mucinous differentiation, pT3, pN0, pM0. 3. Code: Colon Adenocarcinoma maps to COAD.",
      "idx": 333,
      "timestamp": "2026-01-19T15:59:53.112844"
    },
    {
      "sample_idx": 758,
      "input": "PATIENT HISTORY: PRE-OP DIAGNOSIS: Pulmonary nodule. POST-OP DIAGNOSIS: Same. PROCEDURE: Bronchoscopy; Biopsy; Lavage; Right video assisted thoracic surgery: Apical posterior segmentectomy. with fiducials. FINAL DIAGNOSIS: PART 1: LUNG, RIGHT UPPER LOBE, BIOPSY -. BENIGN BRONCHIAL MUCOSA WITH MILD CHRONIC INFLAMMATION. PART 2: LYMPH NODE, LEVEL 4, BIOPSY -. BENIGN LYMPH NODE FRAGMENT. RART 3:LYMPH NODE, LEVEL 4R PRIME, BIOPSY -. BENIGN LYMPH NODE FRAGMENT. PART 4:LYMPH NODE, LEVEL 10, BIOPSY -. ...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right Upper Lobe. 2. Findings: Invasive adenocarcinoma, acinar type, Fuhrman Grade I. 3. Code: Lung, Right Upper Lobe maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right Upper Lobe. 2. Findings: Invasive adenocarcinoma, acinar type, Fuhrman Grade I. 3. Code: Lung, Right Upper Lobe maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right Upper Lobe. 2. Findings: Invasive adenocarcinoma, acinar type, Fuhrman Grade I. 3. Code: Lung, Right Upper Lobe maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right Upper Lobe. 2. Findings: Invasive adenocarcinoma, acinar type, Fuhrman Grade I. 3. Code: Lung, Right Upper Lobe maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right Upper Lobe. 2. Findings: Invasive adenocarcinoma, acinar type, Fuhrman Grade I. 3. Code: Lung, Right Upper Lobe maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right Upper Lobe. 2. Findings: Invasive adenocarcinoma, acinar type, Fuhrman Grade I. 3. Code: Lung, Right Upper Lobe maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right Upper Lobe. 2. Findings: Invasive adenocarcinoma, acinar type, Fuhrman Grade I. 3. Code: Lung, Right Upper Lobe maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung, Right Upper Lobe. 2. Findings: Invasive adenocarcinoma, acinar type, Fuhrman Grade I. 3. Code: Lung, Right Upper Lobe maps to LUAD.",
      "idx": 758,
      "timestamp": "2026-01-19T15:59:53.112855"
    },
    {
      "sample_idx": 727,
      "input": "CONFIDENTIAL. Demographics (for. verification purposes). Date or birth: Collected Date/Time. Received Date/Time. Specimen Description. A: Gallbladder. B: Right lobe liver. Clinical Information. Large right lobe liver Ca on CT KUB 16 x 12 x 14 cm. Infectious patient:No. Immunocompromised: No. History of neoplasm: No. Diagnosis. A: Gallbladder. Chronic cholecystitis. Cholelithiasis. B. Liver, Right Lobe, Excision: Hepatocellular carcinoma, grade II. Portal vascular inflammation of embolization. Re...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Gallbladder (A). 2. Findings: Chronic cholecystitis, Cholelithiasis, Hepatocellular carcinoma, grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lobe liver (B). 2. Findings: Hepatocellular carcinoma, grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lobe liver (B). 2. Findings: Hepatocellular carcinoma, grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lobe liver (B). 2. Findings: Hepatocellular carcinoma, grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lobe liver (B). 2. Findings: Hepatocellular carcinoma, grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lobe liver (B). 2. Findings: Hepatocellular carcinoma, grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lobe liver (B). 2. Findings: Hepatocellular carcinoma, grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lobe liver (B). 2. Findings: Hepatocellular carcinoma, grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lobe liver (B). 2. Findings: Hepatocellular carcinoma, grade II. 3",
      "predicted": "KIRC",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Gallbladder (A). 2. Findings: Chronic cholecystitis, Cholelithiasis, Hepatocellular carcinoma, grade II. 3. Code: KIRC.",
      "idx": 727,
      "timestamp": "2026-01-19T15:59:53.112865"
    },
    {
      "sample_idx": 429,
      "input": "ANEG Mouse X 1. ANEG Rab X 1. D. ACK5/6 X 1. D. AE1/3 X 1. D. HCOM X 1. D. ISHBNK X 1. ISHBNK X 1. D. H&E X 1. D. HPV X 1. D. IISH x 1. D. P16 X 1. D. P40 X 1. D. P63 X 1. D. H&E X 1. E. H&E X 1. F. H&E X 1. G. H&E X 1. H. H&E X 1. H&E x 1. Part 16: Left Neck Level 1B (Additional). Stain,. Block. H&E x 1. A. Part 17: Mandible and Tongue. Stain/. Block. H&E X 1. D. H&E X 1. E. H&E x 1. F. H&E x 1. G. H&E X 1. H. H&E X 1. H&E X 1. H&E X 1. K. H&E X 1. H&E X 1. M. H&E x 1. H&E x 1. H&E X 1. Patholo...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Oral Cavity. 2. Findings: Squamous cell carcinoma, conventional. 3. Code: PRAD maps to Prad.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Oral Cavity. 2. Findings: Squamous cell carcinoma, conventional. 3. Code: PRAD maps to Prad.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Oral Cavity. 2. Findings: Squamous cell carcinoma, conventional. 3. Code: PRAD maps to Prad.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Oral Cavity. 2. Findings: Squamous cell carcinoma, conventional. 3. Code: PRAD maps to Prad.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Oral Cavity. 2. Findings: Squamous cell carcinoma, conventional. 3. Code: PRAD maps to Prad.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Oral Cavity. 2. Findings: Squamous cell carcinoma, conventional. 3. Code: PRAD maps to Prad.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Oral Cavity. 2. Findings: Squamous cell carcinoma, conventional. 3. Code: PRAD maps to Prad.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Oral Cavity. 2. Findings: Squamous cell carcinoma, conventional. 3. Code: PRAD maps to Prad.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n",
      "predicted": "PRAD",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Oral Cavity. 2. Findings: Squamous cell carcinoma, conventional. 3. Code: PRAD maps to Prad.",
      "idx": 429,
      "timestamp": "2026-01-19T15:59:53.112875"
    },
    {
      "sample_idx": 546,
      "input": "Diagnosis: FSA: Kidney mass, right, biopsy. - Positive for renal cell carcinoma, conventional clear cell type. B: Kidney, right, nephrectomy. Histologic tumor type/subtype: renal cell carcinoma, conventional clear cell type. Sarcomatoid features: absent. Histologic grade (if applicable): Fuhrman nuclear grade 3 (of 4). Tumor size (greatest dimension): 10.1 cm. Tumor focality: focal. Extent of invasion: Capsular invasion/perirenal adipose tissue: not involved. Gerota's fascia: not involved. Renal...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional clear cell type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional clear cell type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional clear cell type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional clear cell type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional clear cell type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional clear cell type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional clear cell type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional clear cell type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional clear cell type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 546,
      "timestamp": "2026-01-19T15:59:53.112886"
    },
    {
      "sample_idx": 1327,
      "input": "Specimens Submitted: 1: SP: Anterior cul-de-sac. 2: SP: Uterus, cervix, bilateral tubes and ovries. 3: SP: Left exteral iliac lymph nodes. 4: SP: Left obturator lymph nodes. 5: SP: Left hypogastric lymph nodes. 6: SP: Left common iliac lymph nodes. 7: SP: Right external iliac lymph nodes. 8: SP: Right obturator lymph nodes. 9: SP: Right hypogastric lymph nodes. 10: SP: Left lateral external iliac lymph nodes. DIAGNOSIS: 1). CUL-DE-SAC, ANTERIOR, BIOPSY: - FIBROUS TISSUE WITH CALCIFICATIONS AND F...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, bilateral tubes and ovries. 2. Findings: Adenocarcinoma of endometrium, endometroid type. With mucinous features, FIGO Grade II 16-50% solid growth, nuclear grade II. 3. Code: Uterus, cervix, bilateral tubes and ovries maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left external iliac lymph nodes. 2. Findings: Lymph node metastasis, adenocarcinoma of endometrium. 3. Code: Left external iliac lymph nodes maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left obturator lymph nodes. 2. Findings: Lymph node metastasis, adenocarcinoma of endometrium. 3. Code: Left obturator lymph nodes maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left hypogastric lymph nodes. 2. Findings: Lymph node metastasis, adenocarcinoma of endometrium. 3. Code: Left hypogastric lymph nodes maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left common iliac lymph nodes. 2. Findings: Lymph node metastasis, adenocarcinoma of endometrium. 3. Code: Left common iliac lymph nodes maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right external iliac lymph nodes. 2. Findings: Lymph node metastasis, adenocarcinoma of endometrium. 3. Code: Right external iliac lymph nodes maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right obturator lymph nodes. 2. Findings: Lymph node metastasis, adenocarcinoma of endometrium. 3. Code: Right obturator lymph nodes maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus, cervix, bilateral tubes and ovries. 2. Findings: Adenocarcinoma of endometrium, endometroid type. With mucinous features, FIGO Grade II 16-50% solid growth, nuclear grade II. 3. Code: Uterus, cervix, bilateral tubes and ovries maps to UCEC.",
      "idx": 1327,
      "timestamp": "2026-01-19T15:59:53.112900"
    },
    {
      "sample_idx": 146,
      "input": "rage I or 2. Surgical Pathology: Additional. CLINICAL HISTORY: Mass right breast. GROSS EXAMINATION: A. \"Sentinel node hot and blue\". Received fresh is a 2 x 1.5 x 1 cm tan lymph. node which is bisected and submitted in block A1. A cytokeratin is. prospectively ordered. B. Requisition labeled with the patient's name and history number \"right. breast tissue:long stitch lateral, short superior, white inferior\". fresh is a 10 (A-P) x 8.5 (M-L) x 3 (S-I) cm breast biopsy specimen which has. been ink...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive adenocarcinoma of the breast, ductal type, Nottingham combined histologic grade 2, tubule formation score 2, nuclear pleomorphism score 2, mitotic rate score 1. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive adenocarcinoma of the breast, ductal type, Nottingham combined histologic grade 2, tubule formation score 2, nuclear pleomorphism score 2, mitotic rate score 1. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 146,
      "timestamp": "2026-01-19T15:59:53.112914"
    },
    {
      "sample_idx": 1247,
      "input": "PATIENT HISTORY: CHIEF COMPLAINT/PRE-OP/POST-OP DIAGNOSIS: Thyroid nodule. PROCEDURE: Not answered. SPECIFIC CLINICAL QUESTION: Not answered. OUTSIDE TISSUE DIAGNOSIS: Not answered. PRIOR MALIGNANCY: Not answered. CHEMORADIATION: Not answered. ORGAN TRANSPLANT: Not answered. IMMUNOSUPPRESSION: Not answered. OTHER DISEASES: Not answered. ADDENDA: Addendum. Molecular Anatomic Pathology Testing: Part 1: A. BRAF V600E mutation IDENTIFIED at low level (see note). B. Mutations in NRAS61, HRAS61, KRAS1...",
      "response": "```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: TGCT.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site:",
      "predicted": "TGCT",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: TGCT.",
      "idx": 1247,
      "timestamp": "2026-01-19T15:59:53.112923"
    },
    {
      "sample_idx": 1300,
      "input": "Patient Name: : Resulted: Facility: SPECIMEN (s) RECEIVED Sate Thymus C379. 1. Thymus thymus gland - stitch on rt upper pole. 2. Lymph node: Left Periphrenic node. DIAGNOSIS. 1. Thymectomy : - Two separate thymomas: WHO type AB thymoma, right side, 5.2 cm in greatest diameter. - Tumor shows extension outside fibrous capsule into. peritumoral adipose tissue. Adjacent painted margins negative for tumor. WHO type A thymoma, left side, 5 cm in greatest diameter. - Tumor completely encapsulated, no i...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Type AB thymoma, right side, 5.2 cm in greatest diameter. Type A thymoma, left side, 5 cm in greatest diameter. 3. Code: THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Type A thymoma (spindle cell, medullary). 3. Code: THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Type A thymoma (spindle cell, medullary). 3. Code: THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Type A thymoma (spindle cell, medullary). 3. Code: THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Type A thymoma (spindle cell, medullary). 3. Code: THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Type A thymoma (spindle cell, medullary). 3. Code: THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Type A thymoma (spindle cell, medullary). 3. Code: THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Type A thymoma (spindle cell, medullary). 3. Code: THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning",
      "predicted": "THYM",
      "ground_truth": "THYM",
      "correct": true,
      "reasoning": "1. Site: Thymus. 2. Findings: Type AB thymoma, right side, 5.2 cm in greatest diameter. Type A thymoma, left side, 5 cm in greatest diameter. 3. Code: THYM.",
      "idx": 1300,
      "timestamp": "2026-01-19T15:59:53.112934"
    },
    {
      "sample_idx": 350,
      "input": "DIAGNOSIS. (A) STOMACH, LESSER CURVATURE ULCER SCAR, BIOPSY: Gastric mucosa with focal active inflammation, fibrosis of the lamina propria and foveolar hyperplasia;. negative for carcinoma. (B) DISTAL ESOPHAGEAL TUMOR, BIOPSY: INVASIVE ADENOCARCINOMA, MODERATELY TO POORLY DIFFERENTIATED. COLUMNAR MUCOSA WITH HIGH GRADE DYSPLASIA. Entire report and diagnosis completed by. GROSS DESCRIPTION. (A) ULCER, SCAR, LESSER CURVATURE - Multiple tan-pink irregular fragments of tissue (1.0 X 0.7 x 0.2 cm in ...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Stomach (lesser curvature ulcer scar). 2. Findings: Invasive adenocarcinoma, moderately to poorly differentiated. 3. Code: Distal Esophageal Tumor maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Invasive adenocarcinoma, moderately to poorly differentiated. 3. Code: Distal Esophageal Tumor maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Invasive adenocarcinoma, moderately to poorly differentiated. 3. Code: Distal Esophageal Tumor maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Invasive adenocarcinoma, moderately to poorly differentiated. 3. Code: Distal Esophageal Tumor maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Invasive adenocarcinoma, moderately to poorly differentiated. 3. Code: Distal Esophageal Tumor maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Invasive adenocarcinoma, moderately to poorly differentiated. 3. Code: Distal Esophageal Tumor maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Invasive adenocarcinoma, moderately to poorly differentiated. 3. Code: Distal Esophageal Tumor maps to ADENOCARCINOMA.\"\n}\n```",
      "predicted": "ADENOCARCINOMA",
      "ground_truth": "ESCA",
      "correct": false,
      "reasoning": "1. Site: Stomach (lesser curvature ulcer scar). 2. Findings: Invasive adenocarcinoma, moderately to poorly differentiated. 3. Code: Distal Esophageal Tumor maps to ADENOCARCINOMA.",
      "idx": 350,
      "timestamp": "2026-01-19T15:59:53.112945"
    },
    {
      "sample_idx": 1093,
      "input": "Resident: Pathologis. PATHOLOGIC DIAGNOSIS: A. SPECIMEN LABELED \"RIGHT LIVER LOBE\" (INCLUDING FSA) : Liver with fibrotic nodule with cystic change suggestive of sclerosed. hemangioma. There is no evidence of malignancy. B. SPECIMEN LABELED \"OMENTAL BX\" (INCLUDING FSB) : Fibroadipose tissue with no tumor present. C,. SPECIMEN LABELED \"SIGMOID AND RECTUM\" (16.1 cm) : ADENOCARCINOMA, MODERATELY DIFFERENTIATED (4.5 cm in greatest. dimension). Tumor is located at the rectosigmoid junction, forms a fu...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid and Rectum). 2. Findings: Adenocarcinoma, moderately differentiated, 4.5 cm in greatest dimension. Tumor is located at the rectosigmoid junction, forms a fungating mass, is ulcerative and has an infiltrating border. Tumor invades through muscularis propria into pericolonic adipose. tissue. Proximal, distal, and radial resection margins are negative for tumor. Invasive tumor is 9.5 cm from proximal resection margin, 6.5 cm from. distal resection margin, and 3.0 cm from radial resection margin. Intramural and extramural lymphovascular invasion is identified. Extramural venous invasion is identified. Perineural invasion is identified. Peritumoral lymphoid response (involving Crohn's-like infiltrate) is not. present. Residual adenoma is absent. Other polyps identified include: 1 adenoma (1.5 cm). REGIONAL LYMPH NODES (POSITIVE/TOTAL) 4/11. AJCC Classification (6th Edition) : T3 N2 MX. D. SPECIMEN LABELED \\\"DISTAL DONUT\\\": Portion of colon with no significant pathologic change. E. SPECIMEN LABELED \\\"PROXIMAL DONUT\\\": Portion of colon with no significant pathologic change. CLINICAL DATA: History: Rectal Ca - on sigmoidoscopy. Liver cysts (multiple on CT) ? mets. Operation: Low anterior resection. Operative Findings None given. Clinical Diagnosis: Not provided. TISSUE SUBMITTED: A. Right liver lobe. B. Omental bx. C. Sigmoid + rectum. D. Distal donut. E. Proximal donut. O.R. CONSULTATION: SPECIMEN LABELED \\\"#1. RIGHT LOBE LIVER\\\" (FSA) : Liver with collapsed fibrous wall cyst with dystrophic calcifications. Negative for carcinoma. Page: 1 of 3. SPECIMEN LABELED \\\"#2. OMENTAL BX\\\" (FSB) : Fat necrosis. Negative for carcinoma. SPECIMEN LABELED \\\"#3. RECTUM AND SIGMOID\\\" (GROSS ONLY) : Tumor is 4.8 cm in greatest dimension and is located 9.5 cm from the. stapled margin and 6.5 cm from the open margin.",
      "predicted": null,
      "ground_truth": "READ",
      "correct": null,
      "reasoning": "",
      "idx": 1093,
      "timestamp": "2026-01-19T15:59:53.113152"
    },
    {
      "sample_idx": 1410,
      "input": "Left eye enucleation. Macroscopy. The eye ball mesures 25 by 25 by 23 mm and presents a posterior segment of optic. nerves measuring 5 mm. At the section, the tumor measures 18 mm main line. Samples have been frozen for genetic studies then the piece has been fixed and. included entirely. Microscopy. The tumor observed macroscopically corresponds to an uveal melanoma, mainly. composed of epithelio\u00efd cells. The cell cytoplasm is often pigmented with melanin. The cyto/nuclear atypia are severe. Pr...",
      "response": "```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Eye (Left eye). 2. Findings: Uveal melanoma, epithelioid cells predominant, size 18mm. The tumor is located at a large distance of the optic foramen and the optic nerve on its entire course. The tumor is located in the posterior segment of the eye. 3. Code: Uveal Melanoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Eye (Left eye). 2. Findings: Uveal melanoma, epithelioid cells predominant, size 18mm. The tumor is located at a large distance of the optic foramen and the optic nerve on its entire course. The tumor is located in the posterior segment of the eye. 3. Code: Uveal Melanoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Eye (Left eye). 2. Findings: Uveal melanoma, epithelioid cells predominant, size 18mm. The tumor is located at a large distance of the optic foramen and the optic nerve on its entire course. The tumor is located in the posterior segment of the eye. 3. Code: Uveal Melanoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Eye (Left eye). 2. Findings: Uveal melanoma, epithelioid cells predominant, size 18mm. The tumor is located at a large distance of the optic foramen and the optic nerve on its entire course. The tumor is located in the posterior segment of the eye. 3. Code: Uveal Melanoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Eye (Left eye). 2. Findings: Uveal melanoma, epithelioid cells predominant, size 18mm. The tumor is located at a large distance of the optic foramen and the optic nerve on its entire course. The tumor is located in the posterior segment of",
      "predicted": "UVM",
      "ground_truth": "UVM",
      "correct": true,
      "reasoning": "1. Site: Eye (Left eye). 2. Findings: Uveal melanoma, epithelioid cells predominant, size 18mm. The tumor is located at a large distance of the optic foramen and the optic nerve on its entire course. The tumor is located in the posterior segment of the eye. 3. Code: Uveal Melanoma maps to UVM.",
      "idx": 1410,
      "timestamp": "2026-01-19T15:59:53.113173"
    },
    {
      "sample_idx": 334,
      "input": "Diagnosis: Resected colon with a broad, ulcerated, moderately differentiated adenocarcinoma of. colorectal type, with infiltration of the pericolic adipose tissue, lymphangiosis. carcinomatosa with tumor and seven local lymph node metastases. Tumor-free colon. resection margins. Tumor-free mesenteric resection margin. The remaining mucous. membrane of the colon displaying a circumscribed, ulcerous defect with remains of a. tubular adenoma with moderate epithelial dysplasia, as well as a further ...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma of the colon, broad, ulcerated, moderately differentiated, with lymphangiosis carcinomatosa and lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"READ\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma of the colon, broad, ulcerated, moderately differentiated, with lymphangiosis carcinomatosa and lymph node metastases. 3. Code: Colon Adenocarcinoma maps to READ.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma of the colon, broad, ulcerated, moderately differentiated, with lymphangiosis carcinomatosa and lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma of the colon, broad, ulcerated, moderately differentiated, with lymphangiosis carcinomatosa and lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma of the colon, broad, ulcerated, moderately differentiated, with lymphangiosis carcinomatosa and lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma of the colon, broad, ulcerated, moderately differentiated, with lymphangiosis carcinomatosa and lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma of the colon, broad, ulcerated, moderately differentiated, with lymphangiosis carcin",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon. 2. Findings: Adenocarcinoma of the colon, broad, ulcerated, moderately differentiated, with lymphangiosis carcinomatosa and lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.",
      "idx": 334,
      "timestamp": "2026-01-19T15:59:53.113188"
    },
    {
      "sample_idx": 946,
      "input": "Specimen Type: A: RIGHT OVARY AND UTERUS. B: LEFT OVARY. C: Omentum. D: ANTERIOR ABDOMINAL WALL NODE. Clinical Details: Ovarian Debulking. Macroscopic Description: A). RIGHT OVARY AND UTERUS: The ovary weighs 53.3 grams and measures 6.5 X 5.5 X. 4.5 cm. The ovarian cyst wall is ruptured. The cut surface shows a multilocular cyst. with solid areas. The solid area shows tan coloured and brownish areas. The uterus. corpus measures 6 cm longitudinally, 3 cm transversally and 3.2 cm anteroposteriorly...",
      "response": "```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovary and Uterus. 2. Findings: Serous carcinoma, Grade II-III. 3. Code: OV maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MESO\",\n    \"reasoning\": \"1. Site: Omentum. 2. Findings: Metastatic serous carcinoma. 3. Code: MESO maps to MESO.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"READ\",\n    \"reasoning\": \"1. Site: Anterior abdominal wall nodule. 2. Findings: Metastatic serous carcinoma. 3. Code: READ maps to READ.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, Grade II-III. 3. Code: OV maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MESO\",\n    \"reasoning\": \"1. Site: Omentum. 2. Findings: Metastatic serous carcinoma. 3. Code: MESO maps to MESO.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"READ\",\n    \"reasoning\": \"1. Site: Anterior abdominal wall nodule. 2. Findings: Metastatic serous carcinoma. 3. Code: READ maps to READ.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, Grade II-III. 3. Code: OV maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MESO\",\n    \"reasoning\": \"1. Site: Omentum. 2. Findings: Metastatic serous carcinoma. 3. Code: MESO maps to MESO.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"READ\",\n    \"reasoning\": \"1. Site: Anterior abdominal wall nodule. 2. Findings: Metastatic serous carcinoma. 3. Code: READ maps to",
      "predicted": "OV",
      "ground_truth": "OV",
      "correct": true,
      "reasoning": "1. Site: Ovary and Uterus. 2. Findings: Serous carcinoma, Grade II-III. 3. Code: OV maps to OV.",
      "idx": 946,
      "timestamp": "2026-01-19T15:59:53.113198"
    },
    {
      "sample_idx": 777,
      "input": "SPECIMEN. A. Pericardial reflection node. B. Right upper and middle lobe. C. Lymph node level 11. D. Lymph node 4R. E. Lymph node 2R. F. Lymph node level 9. CLINICAL NOTES. Non-small cell lung cancer. FROZEN SECTION DIAGNOSIS. A) Lymph node, pericardial reflection node, excision - Metastatic. non small cell carcinoma. GROSS DESCRIPTION. A. Received fresh for frozen section labeled \"pericardial. reflection node\" are irregularly shaped fragments of tan tissue. that. measure 0.6 X 0.6 x 0.4 cm in a...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Lower Lobe, Left Upper Lobe). 2. Findings: Adenocarcinoma, poorly differentiated, 1.7cm, 1.8cm. Lymph node involvement: Level 5 lymph node shows metastasis (1/1). 3. Code: LUAD (Lung Adenocarcinoma) maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole, Left Lower Lobe). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole, Left Lower Lobe). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole, Left Lower Lobe). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole, Left Lower Lobe). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole, Left Lower Lobe).",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung (Left Lower Lobe, Left Upper Lobe). 2. Findings: Adenocarcinoma, poorly differentiated, 1.7cm, 1.8cm. Lymph node involvement: Level 5 lymph node shows metastasis (1/1). 3. Code: LUAD (Lung Adenocarcinoma) maps to LUAD.",
      "idx": 777,
      "timestamp": "2026-01-19T15:59:53.113211"
    },
    {
      "sample_idx": 552,
      "input": "REVISED REPORT (Revised information underlined). TISSUE DESCRIPTION: 13.5 cm segment right ureter and right kidney (400 grams, 13.5 x 8.3. x 7.5 cm) and lymph nodes from intra-aortocaval and retrocaval. regions. DIAGNOSIS: Kidney, right, radical nephrectomy: Grade 2 (of 4). renal cell carcinoma, clear cell type, forms a 9.3 x 7.5 x 6.5 cm. mass located in the mid portion of the kidney. The tumor is. confined to the kidney. A tumor thrombus is present in the renal. vein, 0.8 cm in greatest linear...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Grade 2 (of 4). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Grade 2 (of 4). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Grade 2 (of 4). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Grade 2 (of 4). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Grade 2 (of 4). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Grade 2 (of 4). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Grade 2 (of 4). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Grade 2 (of 4). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 552,
      "timestamp": "2026-01-19T15:59:53.113222"
    },
    {
      "sample_idx": 1310,
      "input": "Account. (Age: Clinical Diagnosis & History: year old female with incidental anterior mediastinal mass,Clinically. stage II thymoma. Specimens Submitted: 1: SP: Anterior mediastinal mass for tissue (fa). DIAGNOSIS: 1. ANTERIOR MEDIASTINUM, MASS; EXCISION (FS) 1. - THYMOMA, 2004 WHO TYPE A AND MICRONODULAR THYMOMA WITH LYMPHOID. STROMA (SEE NOTE). - TUMOR SIZE: 10 x 6 x 4.2 CM. - THERE IS EXTENSIVE NECROSIS. - THERE IS NO THYMIC CAPSULAR INVASION. - THE INKED MARGIN IS FREE OF TUMOR. NOTE: THE TU...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Anterior mediastinum. 2. Findings: Thymoma (Type A and micronodular thymoma). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Anterior mediastinum. 2. Findings: Thymoma (Type A and micronodular thymoma). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Anterior mediastinum. 2. Findings: Thymoma (Type A and micronodular thymoma). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Anterior mediastinum. 2. Findings: Thymoma (Type A and micronodular thymoma). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Anterior mediastinum. 2. Findings: Thymoma (Type A and micronodular thymoma). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Anterior mediastinum. 2. Findings: Thymoma (Type A and micronodular thymoma). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Anterior mediastinum. 2. Findings: Thymoma (Type A and micronodular thymoma). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Anterior mediastinum. 2. Findings: Thymoma (Type A and micronodular thymoma). 3. Code: THYM maps to THYM.\"\n}\n```\n",
      "predicted": "THYM",
      "ground_truth": "THYM",
      "correct": true,
      "reasoning": "1. Site: Anterior mediastinum. 2. Findings: Thymoma (Type A and micronodular thymoma). 3. Code: THYM maps to THYM.",
      "idx": 1310,
      "timestamp": "2026-01-19T15:59:53.113232"
    },
    {
      "sample_idx": 1140,
      "input": "Copies To: Date Received: Addendum - Please See End of Report. Reason for Addendum #1: Breast profile results. SPECIMEN(S) SUBMITTED: A. PERI CERVICAL TUMOR, B. PERI URETERAL TUMOR. C. UTERUS, D. PERI URETHRAL MASS, E. ROUND LIGAMENT. F. OMENTUM #1, G. OMENTUM #2. H. OMENTUM #3, I. RIGHT PELVIC PERITONEUM, J. RIGHT GUTTER,. K. LEFT GUTTER, L. LEFT RETROPERITONEUM, M. LEFT PELVIC LYMPH NODE, N. RIGHT PELVIC LYMPH NODE, o. RIGHT. COMMON ILLIAC LYMPH NODE, P. PERIAORTIC LYMPH NODE RIGHT. DIAGNOSIS:...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive",
      "predicted": "BRCA",
      "ground_truth": "SARC",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1140,
      "timestamp": "2026-01-19T15:59:53.113241"
    },
    {
      "sample_idx": 449,
      "input": "Specimen(s) Received. 1. Nck: left neck contents - Level I. 2. Neck: Left neck contents - Level Il. 3. Neck: Left neck contents - Level IV. 4. Neck: Left neck contents - Level III. 5. Oral Cavity: Hemiglossectomy. 6. Soft Tissue: Left posterior margin. 7. Soft Tissue: Left lateral margin. 8. Soft Tissue: Medial margin. 9. Oral Cavity: Revision glossectomy. 10. Surgical Waste. Diagnosis. 1. Left neck; level I: - Six lymph nodes, negative for malignancy (0/6). - Submandibular gland with no patholo...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue (Left Hemiglossectomy). 2. Findings: Squamous cell carcinoma, poorly differentiated, G3. Perineural invasion present. Margins uninvolved by tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue (Left Hemiglossectomy). 2. Findings: Squamous cell carcinoma, poorly differentiated, G3. Perineural invasion present. Margins uninvolved by tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue (Left Hemiglossectomy). 2. Findings: Squamous cell carcinoma, poorly differentiated, G3. Perineural invasion present. Margins uninvolved by tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue (Left Hemiglossectomy). 2. Findings: Squamous cell carcinoma, poorly differentiated, G3. Perineural invasion present. Margins uninvolved by tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue (Left Hemiglossectomy). 2. Findings: Squamous cell carcinoma, poorly differentiated, G3. Perineural invasion present. Margins uninvolved by tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue (Left Hemiglossectomy). 2. Findings: Squamous cell carcinoma, poorly differentiated, G3. Perineural invasion present. Margins uninvolved by tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue (Left Hemiglossectomy). 2. Findings: Squamous cell carcinoma, poorly differentiated, G3",
      "predicted": "KIRC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Tongue (Left Hemiglossectomy). 2. Findings: Squamous cell carcinoma, poorly differentiated, G3. Perineural invasion present. Margins uninvolved by tumor. 3. Code: KIRC.",
      "idx": 449,
      "timestamp": "2026-01-19T15:59:53.113252"
    },
    {
      "sample_idx": 664,
      "input": "Surgical Pathology Renort. CLINICAL HISTORY. man with recent onset seizure, has a left. parietal occipital tumor. OPERATIVE DIAGNOSES. Not Given. Operation/Specimen: A: Brain mass, biopsy. B: Brain, resection. PATHOLOGICAL DIAGNOSIS: A and B. Brain, parieto-occipital excision: Gemistocytic. astrocytoma,. diffusely infiltrating, anaplastic. MIB-1 proliferation index: 10%. See comment. COMMENT. The specimens contain cerebral cortex and adjacent white matter. diffusely. infiltrated by an astrocytic...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Parieto-occipital). 2. Findings: Gemistocytic astrocytoma, diffusely infiltrating, anaplastic. MIB-1 proliferation index: 10%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Gemistocytic astrocytoma, diffusely infiltrating, anaplastic. MIB-1 proliferation index: 10%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Gemistocytic astrocytoma, diffusely infiltrating, anaplastic. MIB-1 proliferation index: 10%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Gemistocytic astrocytoma, diffusely infiltrating, anaplastic. MIB-1 proliferation index: 10%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Gemistocytic astrocytoma, diffusely infiltrating, anaplastic. MIB-1 proliferation index: 10%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Gemistocytic astrocytoma, diffusely infiltrating, anaplastic. MIB-1 proliferation index: 10%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Gemistocytic astrocytoma, diffusely infiltrating, anaplastic. MIB-1 proliferation",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain (Parieto-occipital). 2. Findings: Gemistocytic astrocytoma, diffusely infiltrating, anaplastic. MIB-1 proliferation index: 10%. 3. Code: GBM maps to GBM.",
      "idx": 664,
      "timestamp": "2026-01-19T15:59:53.113267"
    },
    {
      "sample_idx": 114,
      "input": "Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Right Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: Frozen. Container: cryomold Type of Procurement: Radical mastectomy Grade: 3. T Stage: 2 N Stage: 0 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Cont...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 114,
      "timestamp": "2026-01-19T15:59:53.113277"
    },
    {
      "sample_idx": 469,
      "input": "Report Type. Date of Event. Authored by. Hosp/Group. Record Status. AL. PATIENT HISTORY: Clinical history: Laryngeal cancer. PRE-OP DIAGNOSIS: Laryngeal cancer. POST-OP DIAGNOSIS: Same. RE: None given. FINAL DIAGNOSIS: PART 1: LARYNX, LEFT THYROID LOBE, AND LYMPH NODES, TOTAL LARYNGECTOMY,. LEFT. THYROID LOBECTOMY AND BILATERAL NECK DISSECTION. A. INVASIVE SQUAMOUS CELL CARCINOMA (5.0 CM), POORLY. DIFFERENTIATED,. LEFT GLOTTIC WITH SUPRAGLOTTIC EXTENSION (TRANSGLOTTIC) INVOLVING: 1. ANTERIOR COM...",
      "response": "```json\n{\n    \"cancer_type\": \"LARY\",\n    \"reasoning\": \"1. Site: Larynx, Left Thyroid Lobe, and Lymph Nodes. 2. Findings: Invasive squamous cell carcinoma, 5.0 cm, poorly differentiated. Left glottic with supraglottic extension involving anterior commissure, paraglottic space, thyroid cartilage, left thyroid lobe. No perineural invasion. Left modified radical neck dissection: 6/6 lymph nodes involved. Right selective neck dissection: 0/17 lymph nodes involved. Right glottis with mild dysplasia and vocal cord muscle. Abscess. Left thyroid lobe with otherwise no significant abnormalities. 3. Code: LARY maps to LARY.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LARY\",\n    \"reasoning\": \"1. Site: Larynx, Left Thyroid Lobe, and Lymph Nodes. 2. Findings: Invasive squamous cell carcinoma, 5.0 cm, poorly differentiated. Left glottic with supraglottic extension involving anterior commissure, paraglottic space, thyroid cartilage, left thyroid lobe. No perineural invasion. Left modified radical neck dissection: 6/6 lymph nodes involved. Right selective neck dissection: 0/17 lymph nodes involved. Right glottis with mild dysplasia and vocal cord muscle. Abscess. Left thyroid lobe with otherwise no significant abnormalities. 3. Code: LARY maps to LARY.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LARY\",\n    \"reasoning\": \"1. Site: Larynx, Left Thyroid Lobe, and Lymph Nodes. 2. Findings: Invasive squamous cell carcinoma, 5.0 cm, poorly differentiated. Left glottic with supraglottic extension involving anterior commissure, paraglottic space, thyroid cartilage, left thyroid lobe. No perineural invasion. Left modified radical neck dissection: 6/6 lymph nodes involved. Right selective neck dissection: 0/17 lymph nodes involved. Right glottis with mild dysplasia and vocal cord muscle. Abscess. Left thyroid lobe with otherwise no significant abnormalities. 3. Code: LARY maps to LARY.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LARY\",\n    \"reasoning\": \"1. Site: Larynx, Left Thyroid Lobe, and",
      "predicted": "LARY",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Larynx, Left Thyroid Lobe, and Lymph Nodes. 2. Findings: Invasive squamous cell carcinoma, 5.0 cm, poorly differentiated. Left glottic with supraglottic extension involving anterior commissure, paraglottic space, thyroid cartilage, left thyroid lobe. No perineural invasion. Left modified radical neck dissection: 6/6 lymph nodes involved. Right selective neck dissection: 0/17 lymph nodes involved. Right glottis with mild dysplasia and vocal cord muscle. Abscess. Left thyroid lobe with otherwise no significant abnormalities. 3. Code: LARY maps to LARY.",
      "idx": 469,
      "timestamp": "2026-01-19T15:59:53.113304"
    },
    {
      "sample_idx": 1401,
      "input": "DIAGNOSIS. (A) UTERUS, CERVIX, BILATERAL OVARIES AND TUBES: UTERINE MALIGNANT MIXED MULLERIAN TUMOR; TUMOR INVADES 8.0 MM INTO A 24.0 MM THICK. MYOMETRIUM. (SEE COMMENT). LYMPHOVASCULAR INVASION IS PRESENT. Cervix with chronic inflammation and Nabothian cysts, no tumor present. Bilateral ovaries and fallopian tubes, no tumor present. (B) LEFT PELVIC LYMPH NODES: Two lymph nodes, no tumor present (0/2). (C) RIGHT COMMON LYMPH NODE: One lymph node, no tumor present (0/1). (D) LEFT PELVIC LYMPH NOD...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Uterine malignant mixed M\u00fcllerian tumor, tumor invades 8.0 mm into a 24.0 mm thick myometrium. 3. Code: Uterine Cancer maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Uterine malignant mixed M\u00fcllerian tumor, tumor invades 8.0 mm into a 24.0 mm thick myometrium. 3. Code: Uterine Cancer maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Uterine malignant mixed M\u00fcllerian tumor, tumor invades 8.0 mm into a 24.0 mm thick myometrium. 3. Code: Uterine Cancer maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Uterine malignant mixed M\u00fcllerian tumor, tumor invades 8.0 mm into a 24.0 mm thick myometrium. 3. Code: Uterine Cancer maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Uterine malignant mixed M\u00fcllerian tumor, tumor invades 8.0 mm into a 24.0 mm thick myometrium. 3. Code: Uterine Cancer maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Uterine malignant mixed M\u00fcllerian tumor, tumor invades 8.0 mm into a 24.0 mm thick myometrium. 3. Code: Uterine Cancer maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC",
      "predicted": "UCEC",
      "ground_truth": "UCS",
      "correct": false,
      "reasoning": "1. Site: Uterus. 2. Findings: Uterine malignant mixed M\u00fcllerian tumor, tumor invades 8.0 mm into a 24.0 mm thick myometrium. 3. Code: Uterine Cancer maps to UCEC.",
      "idx": 1401,
      "timestamp": "2026-01-19T15:59:53.113321"
    },
    {
      "sample_idx": 646,
      "input": "F. (157.0cm 53.3kg BSA: 1.52m\u00b2. MODIFIED REPORT - REVIEW ADDENDUM SECTION. DIAGNOSIS. (A) POSTERIOR PART RIGHT FRONTAL BRAIN TUMOR -. OLIGODENDROGLIOMA, GRADE Il (WHO). (B) ANTERIOR PORTION RIGHT FRONTAL BRAIN. OLIGODENDROGLIOMA, GRADE II (WHO). (C) CINGULATE GYRUS, RIGHT FRONTAL LOBE -. OLIGODENDROGLIOMA, GRADE II (WHO). See comment. COMMENT. The 1p/19q status of this tumor will be determined. GROSS DESCRIPTION. (A) POSTERIOR PART RIGHT FRONTAL BRAIN TUMOR - Specimen consists of a single piece ...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Frontal lobe). 2. Findings: Oligodendroglioma, Grade II. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain (Frontal lobe). 2. Findings: Oligodendroglioma, Grade II. 3. Code: OLIG maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain (Frontal lobe). 2. Findings: Oligodendroglioma, Grade II. 3. Code: OLIG maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain (Frontal lobe). 2. Findings: Oligodendroglioma, Grade II. 3. Code: OLIG maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain (Frontal lobe). 2. Findings: Oligodendroglioma, Grade II. 3. Code: OLIG maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain (Frontal lobe). 2. Findings: Oligodendroglioma, Grade II. 3. Code: OLIG maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain (Frontal lobe). 2. Findings: Oligodendroglioma, Grade II. 3. Code: OLIG maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain (Frontal lobe). 2. Findings: Oligodendroglioma, Grade II. 3. Code: OLIG maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain (Frontal lobe). 2. Findings: Oligodendroglioma, Grade II. 3. Code: GBM maps to GBM.",
      "idx": 646,
      "timestamp": "2026-01-19T15:59:53.113332"
    },
    {
      "sample_idx": 821,
      "input": "Result date: Clinical History. Left lung cancer. Specimen. # 1. 4R. Level 7. # 3. 4L. # 4. 2R. # 5. Left upper lobe wedge. # 6. Level 5. # 7. Level 6. Gross Examination. #1 Received fresh labeled 4R are fragments of yellow to black material, in. aggregate 0.8 X 0.5 X 0.3 cm. It is completely submitted as single frozen. sections. #2 Received fresh labeled level 7 are two fragments of gray-tan tissue, up to. 0.3 X 0.2 X 0.1 cm. Completely submitted as a single frozen section. #3 Received fresh lab...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Left upper lobe of lung. 2. Findings: Adenocarcinoma, moderately to poorly differentiated. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, wedge. 2. Findings: Adenocarcinoma, moderately to poorly differentiated. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, wedge. 2. Findings: Adenocarcinoma, moderately to poorly differentiated. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, wedge. 2. Findings: Adenocarcinoma, moderately to poorly differentiated. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, wedge. 2. Findings: Adenocarcinoma, moderately to poorly differentiated. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, wedge. 2. Findings: Adenocarcinoma, moderately to poorly differentiated. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, wedge. 2. Findings: Adenocarcinoma, moderately to poorly differentiated. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, wedge. 2. Findings: Adenocarcinoma, moderately to poorly differentiated. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, wedge.",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Left upper lobe of lung. 2. Findings: Adenocarcinoma, moderately to poorly differentiated. 3. Code: LUAD.",
      "idx": 821,
      "timestamp": "2026-01-19T15:59:53.113342"
    },
    {
      "sample_idx": 548,
      "input": "Clinical Diagnosis & History: Laparoscopic right radical nephrectomy. Specimens Submitted: 1: SP: Right kidney and partial adrenal. DIAGNOSIS: 1). KIDNEY, RIGHT AND ADRENAL; NEPHRECTOMY: - RENAL CELL CARCINOMA, CLEAR CELL TYPE (CONVENTIONAL TYPE), NUCLEAR GRADE II/IV. - THE PATTERN OF GROWTH IS ACINAR AND SOLID. - THE TUMOR GREATEST DIAMETER IS 4.5 CM. - THE TUMOR EXTENDS THROUGH THE RENAL CAPSULE BUT IS CONFINED WITHIN GEROTA'S FASCIA. - NO INVASION OF THE RENAL VEIN IS IDENTIFIED. - ALL SURGIC...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 548,
      "timestamp": "2026-01-19T15:59:53.113352"
    },
    {
      "sample_idx": 135,
      "input": "Sex: I. MRN #: SPECIMEN INE. DIAGNOSIS. DIAGNOSIS: Right modified radical mastectomy with sentinel node mapping: Invasive lobular carcinoma. Lobular carcinoma was previously confirmed by negative e cadherin expression. Size: 5.3 cm. Architectural score: 3 of 3. Nuclear score: 2 of 3. Mitotic score: 1 of 3. Total score: 6 of 9 = grade 2. Carcinoma involves sections of the nipple but does not involve the overlying epidermis and is not seen in dermal lymphatics. Prognostic panel was performed on th...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 135,
      "timestamp": "2026-01-19T15:59:53.113362"
    },
    {
      "sample_idx": 432,
      "input": "DIAGNOSIS: 1) MOUTH, ANTERIOR FLOOR, MARGIN, EXCISION: SQUAMOUS MUCOSA, NEGATIVE FOR. MALIGNANCY. 2) MOUTH, POSTERIOR FLOOR, MARGIN, EXCISION: SQUAMOUS MUCOSA AND SALIVARY. GLAND, NEGATIVE FOR MALIGNANCY. 3) TONGUE, ANTERIOR MARGIN, EXCISION: SQUAMOUS MUCOSA, NEGATIVE FOR. MALIGNANCY. 4) TONGUE, POSTERIOR MARGIN, EXCISION: SQUAMOUS MUCOSA, NEGATIVE FOR. MALIGNANCY. 5) TONGUE, \"CANCER,\" LEFT, EXCISION: WELL-DIFFERENTIATED INVASIVE SQUAMOUS. CELL CARCINOMA, 1.5 CM IN GREATEST EXTENT, 0.7 CM TO DEE...",
      "response": "```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Tongue (Anterior and Posterior Margins), Floor of Mouth (Anterior Margin). 2. Findings: Squamous cell carcinoma. 3. Code: UCEC (Uterine Corpus Cancer) is the closest match as it is a cancer of the upper aerodigestive tract. Since there is no information about the uterine corpus, this is the closest match.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Tongue (Anterior and Posterior Margins), Floor of Mouth (Anterior Margin). 2. Findings: Squamous cell carcinoma. 3. Code: UCEC (Uterine Corpus Cancer) is the closest match as it is a cancer of the upper aerodigestive tract. Since there is no information about the uterine corpus, this is the closest match.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Tongue (Anterior and Posterior Margins), Floor of Mouth (Anterior Margin). 2. Findings: Squamous cell carcinoma. 3. Code: UCEC (Uterine Corpus Cancer) is the closest match as it is a cancer of the upper aerodigestive tract. Since there is no information about the uterine corpus, this is the closest match.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Tongue (Anterior and Posterior Margins), Floor of Mouth (Anterior Margin). 2. Findings: Squamous cell carcinoma. 3. Code: UCEC (Uterine Corpus Cancer) is the closest match as it is a cancer of the upper aerodigestive tract. Since there is no information about the uterine corpus, this is the closest match.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Tongue (Anterior and Posterior Margins), Floor of Mouth (Anterior Margin). 2. Findings: Squamous cell carcinoma. 3. Code: UCEC (Uterine Corpus Cancer) is the closest match as it is a cancer of the upper aerodigestive tract. Since there is",
      "predicted": "UCSC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Tongue (Anterior and Posterior Margins), Floor of Mouth (Anterior Margin). 2. Findings: Squamous cell carcinoma. 3. Code: UCEC (Uterine Corpus Cancer) is the closest match as it is a cancer of the upper aerodigestive tract. Since there is no information about the uterine corpus, this is the closest match.",
      "idx": 432,
      "timestamp": "2026-01-19T15:59:53.113377"
    },
    {
      "sample_idx": 1161,
      "input": "Diagnosis/diagnoses. Residual gastrectomy preparation of a stomach that had previously undergone B-II. gastrectomy showing tumor-free resection margins and the inclusion of a poorly. differentiated, highly mucigenous or mucinous adenocarcinoma with an extensive signet ring. cell component (so-called gastric carcinoma of the diffuse type) in the region of the lesser. curvature covering almost the entire gastric stump from the heart to the anastomosis, with. infiltration of the subserosa and two r...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach, lesser curvature. 2. Findings: Poorly differentiated, highly mucigenous/mucinous adenocarcinoma with signet ring cells. Extensive tumor coverage of the gastric stump. Subserosal infiltration. 2 regional lymph node metastases. 3. Code: ADENOMA. This is based on the pathology report which mentions the presence of a poorly differentiated, highly mucigenous/mucinous adenocarcinoma with signet ring cells. The report also mentions that it is in the stomach and that it has lymph node metastases. The code ADENOMA is not the best fit, but it is the closest valid code. This is a gastric carcinoma of the diffuse type. The report also mentions that the tumor is in the stomach, which is a valid cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach, lesser curvature. 2. Findings: Poorly differentiated, highly mucigenous/mucinous adenocarcinoma with signet ring cells. Extensive tumor coverage of the gastric stump. Subserosal infiltration. 2 regional lymph node metastases. 3. Code: ADENOMA. The report describes a poorly differentiated adenocarcinoma with signet ring cells and extensive tumor coverage. The presence of lymph node metastases is also mentioned. While the report mentions adenocarcinoma, the term 'adenoma' is not a valid TCGA code. The best code to use is ADENOMA, as the description is a very poor grade and highly aggressive adenocarcinoma. The report also mentions that it is in the stomach, which is a valid cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach, lesser curvature. 2. Findings: Poorly differentiated, highly mucigenous/mucinous adenocarcinoma with signet ring cells. Extensive tumor coverage of the gastric stump. Subserosal infiltration. 2 regional lymph node metastases. 3. Code: ADENOMA. The report describes a poorly differentiated adenocarcinoma with signet ring cells and extensive tumor coverage. The presence of lymph node metastases is also mentioned. While the report mentions adenocarcinoma, the term 'adenoma' is not a valid TCGA code. The best code to use is ADENOMA, as the description is a very poor grade and highly aggressive adenocarcinoma.",
      "predicted": "ADENOMA",
      "ground_truth": "STAD",
      "correct": false,
      "reasoning": "1. Site: Stomach, lesser curvature. 2. Findings: Poorly differentiated, highly mucigenous/mucinous adenocarcinoma with signet ring cells. Extensive tumor coverage of the gastric stump. Subserosal infiltration. 2 regional lymph node metastases. 3. Code: ADENOMA. This is based on the pathology report which mentions the presence of a poorly differentiated, highly mucigenous/mucinous adenocarcinoma with signet ring cells. The report also mentions that it is in the stomach and that it has lymph node metastases. The code ADENOMA is not the best fit, but it is the closest valid code. This is a gastric carcinoma of the diffuse type. The report also mentions that the tumor is in the stomach, which is a valid cancer type.",
      "idx": 1161,
      "timestamp": "2026-01-19T15:59:53.113400"
    },
    {
      "sample_idx": 644,
      "input": "Patier CResults. Anatomical Pathology results: Performed since. Atleast 1 Final Resalt. DOCTOR. :M. DOC. ADDRESS. COLL. DATE. DATE RECEIVED. WARD. CONSULTANT. H. SPECIMEN: A. Brain. B. Left parietal tumour. CLINICAL: Left parietal tumour glioma. MACROSCOPIC: A. Up to six soft smeared fragments 1mm to 5mm in size, pale grey in colour. INTRA-OPERATIVE ASSESSMENT - FROZEN SECTION: FSD. High grade alial tumour. Await permanent. rections for definitive. diagnosis. BLOCK KEY: l:tissue remaining from f...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: High grade glioma, Anaplastic astrocytoma, WHO III. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: High grade glioma, Anaplastic astrocytoma, WHO III. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: High grade glioma, Anaplastic astrocytoma, WHO III. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: High grade glioma, Anaplastic astrocytoma, WHO III. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: High grade glioma, Anaplastic astrocytoma, WHO III. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: High grade glioma, Anaplastic astrocytoma, WHO III. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: High grade glioma, Anaplastic astrocytoma, WHO III. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: High grade glioma, Anaplastic astrocytoma, WHO III. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain. 2. Findings: High grade glioma, Anaplastic astrocytoma, WHO III. 3. Code: GBM.",
      "idx": 644,
      "timestamp": "2026-01-19T15:59:53.113409"
    },
    {
      "sample_idx": 435,
      "input": "CLINICAL DATA: Right mandibular composite neck dissection, free flap. Diagnosis: FOM carcinoma. GROSS DESCRIPTION: A) Received fresh designated \". composite resection and right neck dissection\" is a 10 x 10 x. 6 cm specimen consisting of a right mandible consisting of the ramus and body with the posterior. and superior aspect of the ramus surgically transected (the ramus measures 3.6 cm IS). The. anterior mandible is intact and a portion of the mental protuberance is present just past the. midli...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (Esophagogastric junction). 2. Findings: Adenocarcinoma, moderately differentiated, with mucin production. 3. Code: ADENOCARCINOMA maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (Esophagogastric junction). 2. Findings: Adenocarcinoma, moderately differentiated, with mucin production. 3. Code: ADENOCARCINOMA maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (Esophagogastric junction). 2. Findings: Adenocarcinoma, moderately differentiated, with mucin production. 3. Code: ADENOCARCINOMA maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (Esophagogastric junction). 2. Findings: Adenocarcinoma, moderately differentiated, with mucin production. 3. Code: ADENOCARCINOMA maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (Esophagogastric junction). 2. Findings: Adenocarcinoma, moderately differentiated, with mucin production. 3. Code: ADENOCARCINOMA maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (Esophagogastric junction). 2. Findings: Adenocarcinoma, moderately differentiated, with mucin production. 3. Code: ADENOCARCINOMA maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"",
      "predicted": "ADENOCARCINOMA",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Esophagus (Esophagogastric junction). 2. Findings: Adenocarcinoma, moderately differentiated, with mucin production. 3. Code: ADENOCARCINOMA maps to ADENOCARCINOMA.",
      "idx": 435,
      "timestamp": "2026-01-19T15:59:53.113420"
    },
    {
      "sample_idx": 1022,
      "input": "Sex: M. Results: SURGICAL PROCEDURE (Order. Result Narrative. Accession No: SPECIMEN SUBMITTED: A. LEFT PELVIC LYMPH NODE. B. RIGHT PELVIC LYMPH NODES. C. PROSTATE. OPERATION: Prostatectomy. CLINICAL DIAGNOSIS: Prostate cancer. GROSS DESCRIPTION: Three specimens are received each labeled with. the patient's name. and medical record number. The first specimen is additionally designated \"left pelvic lymph. node\" and consists of a single fragment of fibrofatty tissue. measuring 2.5 x 2.2 x 0.6 cm. ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, high-grade prostatic adenocarcinoma, with a component of the tumor demonstrating mucinous features. The carcinoma demonstrates extensive perineural invasion, multifocal extraprostatic extension, and involvement of the surgical margin at the right posterior prostatic margin. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Pelvic Lymph Node. 2. Findings: Lymph node, no carcinoma seen in one lymph node (0/1). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Pelvic Lymph Node. 2. Findings: Lymph node, no carcinoma seen in one lymph node (0/1). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, high-grade prostatic adenocarcinoma with focal mucinous features, involving the right posterior surgical margin. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, high-grade prostatic adenocarcinoma with focal mucinous features, involving the right posterior surgical margin. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, high-grade prostatic adenocarcinoma with focal mucinous features, involving the right posterior surgical margin. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, high-grade prostatic adenocarcinoma with focal mucinous features, involving the right posterior surgical margin. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning",
      "predicted": "KIRC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate. 2. Findings: Prostate cancer, high-grade prostatic adenocarcinoma, with a component of the tumor demonstrating mucinous features. The carcinoma demonstrates extensive perineural invasion, multifocal extraprostatic extension, and involvement of the surgical margin at the right posterior prostatic margin. 3. Code: KIRC",
      "idx": 1022,
      "timestamp": "2026-01-19T15:59:53.113435"
    },
    {
      "sample_idx": 810,
      "input": "23274921. SPECIMEN(S): A. LEVEL 7 SUBCARINAL. B. 4R RIGHT DISTAL PARATRACHEAL. C. 4R RIGHT DISTAL PARATRACHEAL. D. SUPERIOR SEGMENT RIGHT UPPER LOBE. E. 6TH RIB. F. RIGHT LUNG. G. 1OR LYMPH NODE. CLINICAL HISTORY: None given. PRE-OPERATIVE DIAGNOSIS: None given. INTRAOPERATIVE CONSULTATION DIAGNOSIS: FSA & B: Lymph nodes 4R and 7, biopsy: - Negative for carcinoma by. FSC: Lymph node 4R, biopsy: - Positive for adenocarcinoma. P.M. FSF: Right lung, pneumonectomy: - Bronchial margin negative for in...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right, Pneumonectomy. 2. Findings: Adenocarcinoma, moderately differentiated with focal poorly differentiated areas. 3. Code: LUAD\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right, Pneumonectomy. 2. Findings: Adenocarcinoma, moderately differentiated with focal poorly differentiated areas. 3. Code: LUAD\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right, Pneumonectomy. 2. Findings: Adenocarcinoma, moderately differentiated with focal poorly differentiated areas. 3. Code: LUAD\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right, Pneumonectomy. 2. Findings: Adenocarcinoma, moderately differentiated with focal poorly differentiated areas. 3. Code: LUAD\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right, Pneumonectomy. 2. Findings: Adenocarcinoma, moderately differentiated with focal poorly differentiated areas. 3. Code: LUAD\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right, Pneumonectomy. 2. Findings: Adenocarcinoma, moderately differentiated with focal poorly differentiated areas. 3. Code: LUAD\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right, Pneumonectomy. 2. Findings: Adenocarcinoma, moderately differentiated with focal poorly differentiated areas. 3. Code: LUAD\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right, Pneumonectomy. 2. Findings: Adenocarcinoma, moderately differentiated with focal poorly differentiated areas. 3. Code: LUAD\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung, Right, Pneumonectomy. 2. Findings: Adenocarcinoma, moderately differentiated with focal poorly differentiated areas. 3. Code: LUAD",
      "idx": 810,
      "timestamp": "2026-01-19T15:59:53.113445"
    },
    {
      "sample_idx": 939,
      "input": "V3.00 110614. Instructions: The TCGA Missing Pathology Report Form should be completed for cases for which a pathology report is not. available. General Pathology Report Information. #. Data Element. Entry Alternatives. Working Instructions. Provide the tumor type of the case. 1. Tumor type: Indicate to which BCR location the case was originally sent. BCR specimen originally sent. NCH. 2. to: IGC. Biospecimen Core Resource (BCR). Date specimen received at. 3. BCR: ICD-0-3 Histology Code: Provide...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 939,
      "timestamp": "2026-01-19T15:59:53.113455"
    },
    {
      "sample_idx": 292,
      "input": "Diagnosis: Colon, ascending, right hemicolectomy. Tumor Histologic Type: adenocarcinoma, colon primary (see comment). Histologic Grade: low grade (grade 2 of 4, moderately differentiated). Tumor Size: 8.2 cm. Tumor Location: cecum. Depth of Invasion: through muscularis propria and into pericolonic adipose tissue, no definitive penetration or perforation of visceral. peritoneum identified. Lymphovascular Invasion: not identified. Perineural Invasion: not identified. Margins: negative. Proximal ma...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon, ascending, right hemicolectomy. 2. Findings: Adenocarcinoma, colon primary. 3. Code: KIRC\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon, ascending, right hemicolectomy. 2. Findings: Adenocarcinoma, colon primary, low grade (grade 2 of 4, moderately differentiated). 3. Code: KIRC\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon, ascending, right hemicolectomy. 2. Findings: Adenocarcinoma, colon primary, low grade (grade 2 of 4, moderately differentiated). 3. Code: KIRC\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon, ascending, right hemicolectomy. 2. Findings: Adenocarcinoma, colon primary, low grade (grade 2 of 4, moderately differentiated). 3. Code: KIRC\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon, ascending, right hemicolectomy. 2. Findings: Adenocarcinoma, colon primary, low grade (grade 2 of 4, moderately differentiated). 3. Code: KIRC\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon, ascending, right hemicolectomy. 2. Findings: Adenocarcinoma, colon primary, low grade (grade 2 of 4, moderately differentiated). 3. Code: KIRC\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon, ascending, right hemicolectomy. 2. Findings: Adenocarcinoma, colon primary, low grade (grade 2 of 4, moderately differentiated). 3. Code: KIRC\"\n",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Colon, ascending, right hemicolectomy. 2. Findings: Adenocarcinoma, colon primary. 3. Code: KIRC",
      "idx": 292,
      "timestamp": "2026-01-19T15:59:53.113464"
    },
    {
      "sample_idx": 542,
      "input": "PATIENT HISTORY: Not given. PRE-OP DIAGNOSIS: Left renal cancer. POST-OP DIAGNOSIS: Same. PROCEDURE: Left laparoscopic nephrectomy. FINAL DIAGNOSIS: KIDNEY, LEFT, LAPAROSCOPIC NEPHRECTOMY -. A. RENAL CELL CARCINOMA, CONVENTIONAL (CLEAR) CELL TYPE. B. FUHRMAN'S NUCLEAR GRADE IS 3 of 4. c. THE GREATEST DIAMETER OF THE NEOPLASM IS 7.2 CM. D. THE NEOPLASM IS CONFINED WITHIN THE RENAL CAPSULE. E. TUMOR INVADES INTO THE RENAL VEIN WITH INVOLVEMENT OF THE VESSEL WALL. F.-. ALL SURGICAL MARGINS ARE FREE...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney, Left. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 542,
      "timestamp": "2026-01-19T15:59:53.113475"
    },
    {
      "sample_idx": 1408,
      "input": "Right eye enucleation. Macroscopy. The eyeball measures 25 by 25 mm with a segment of optic nerve of 10 mm. There is a. posterior tumor close to the intraocular emergence of the optic nerve, pigmented, measuring. 15 mm main line. Samples have been made for cryopreservation . The specimen has been then. included entirely after fixation. Microscopy. Choroidal melanoma with fusiform cells measuring 15 by 12 mm. The lesion, very posterior,. is situated at the periphery, slightly distant from the int...",
      "response": "```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Right eye. 2. Findings: Choroidal melanoma with fusiform cells, measuring 15 x 12 mm. 3. Code: Choroidal melanoma maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Right eye. 2. Findings: Choroidal melanoma with fusiform cells, measuring 15 x 12 mm. 3. Code: Choroidal melanoma maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Right eye. 2. Findings: Choroidal melanoma with fusiform cells, measuring 15 x 12 mm. 3. Code: Choroidal melanoma maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Right eye. 2. Findings: Choroidal melanoma with fusiform cells, measuring 15 x 12 mm. 3. Code: Choroidal melanoma maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Right eye. 2. Findings: Choroidal melanoma with fusiform cells, measuring 15 x 12 mm. 3. Code: Choroidal melanoma maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Right eye. 2. Findings: Choroidal melanoma with fusiform cells, measuring 15 x 12 mm. 3. Code: Choroidal melanoma maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Right eye. 2. Findings: Choroidal melanoma with fusiform cells, measuring 15 x 12 mm. 3. Code: Choroidal melanoma maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"",
      "predicted": "CHOL",
      "ground_truth": "UVM",
      "correct": false,
      "reasoning": "1. Site: Right eye. 2. Findings: Choroidal melanoma with fusiform cells, measuring 15 x 12 mm. 3. Code: Choroidal melanoma maps to CHOL.",
      "idx": 1408,
      "timestamp": "2026-01-19T15:59:53.113492"
    },
    {
      "sample_idx": 505,
      "input": "Admit Date: Gender: Female. Birth Date: Attending: Surgical Pathology [OrderII: DIAGNOSIS: 1. Tumor, #1, left kidney (partial nephrectomy): Renal parenchyma. showing oncocytosis. Benign smooth muscle tumor. (leiomyoma). 2. Tumor, #2, left kidney (partial nephrectomy): Renal cell carcinoma,. chromophobe type (small). Furhman nuclear grade II. chromophobe type 8317/3. 3. Tumor, #3, left kidney (partial nephrectomy): Benign smooth muscle. tumor (leiomyoma). 4. Tumor, #4, left kidney (partial nephre...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Furhman nuclear grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Furhman nuclear grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Furhman nuclear grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Furhman nuclear grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Furhman nuclear grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Furhman nuclear grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Furhman nuclear grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Furhman nuclear grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\":",
      "predicted": "KIRC",
      "ground_truth": "KICH",
      "correct": false,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Furhman nuclear grade II. 3. Code: KIRC.",
      "idx": 505,
      "timestamp": "2026-01-19T15:59:53.113503"
    },
    {
      "sample_idx": 1393,
      "input": "Gander. Facility. Specimen(s) Received. 1. Lymph-Node: Left Iliac, external. 2. Uterus :Uterus cervix bilateral adnexal. 3. Lymph node Right pelvic Lymph nodes. 4. Lymph node Right common iliac node. 5. Lymph node :Left pelvic Lymph node. 6. Lymph node :Left para-aortic lymph node. Diagnosis. 1. Lymph nodes (left external iliac): - Positive for carcinoma, one of one node (1/1). 2. Uterus,cervix ovaries and tubes: Uterus: - ENDOMETRIAL CARCINOMA, ENDOMETRIOID TYPE, FIGO 3/3, pT1b N1. - Outer half...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Iliac, external lymph node. 2. Findings: Carcinoma, one of one node. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, bilateral adnexa. 2. Findings: Endometrioid adenocarcinoma, not otherwise characterized. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right pelvic Lymph nodes. 2. Findings: Carcinoma, four of twenty four nodes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right common iliac node. 2. Findings: Carcinoma, one of one node. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left pelvic Lymph node. 2. Findings: Carcinoma, seven lymph nodes, negative for carcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left para-aortic lymph node. 2. Findings: Carcinoma, three lymph node, negative for carcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, cervix, bilateral adnexa. 2. Findings: Endometrioid adenocarcinoma, not otherwise characterized. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right pelvic Lymph nodes. 2. Findings: Carcinoma, four of twenty four nodes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right common iliac",
      "predicted": "KIRC",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Left Iliac, external lymph node. 2. Findings: Carcinoma, one of one node. 3. Code: KIRC.",
      "idx": 1393,
      "timestamp": "2026-01-19T15:59:53.113514"
    },
    {
      "sample_idx": 1103,
      "input": "FINAL DIAGNOSIS: PART 1 : GASTROESOPHAGEAL JUNCTI\u00d3N, BIOPSY. A. REACTIVE SQUAMOUS AND GASTRIC TYPE MUCOSA. B. NEGATIVE FOR INTESTINAL METAPLASIA. Date of Event. PART 2: RECTUM, MASS, BIOPSY. INVASIVE MODERATELY DIFFERENTIATED ADENOCARCINOMA.",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Gastroesophageal junction, biopsy. 2. Findings: Reactive squamous and gastric type mucosa, negative for intestinal metaplasia. 2. Site: Rectum, mass, biopsy. 3. Findings: Invasive moderately differentiated adenocarcinoma. 3. Code: ADENOCARC maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Gastroesophageal junction, biopsy. 2. Findings: Reactive squamous and gastric type mucosa, negative for intestinal metaplasia. 2. Site: Rectum, mass, biopsy. 3. Findings: Invasive moderately differentiated adenocarcinoma. 3. Code: ADENOCARC maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Gastroesophageal junction, biopsy. 2. Findings: Reactive squamous and gastric type mucosa, negative for intestinal metaplasia. 2. Site: Rectum, mass, biopsy. 3. Findings: Invasive moderately differentiated adenocarcinoma. 3. Code: ADENOCARC maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Gastroesophageal junction, biopsy. 2. Findings: Reactive squamous and gastric type mucosa, negative for intestinal metaplasia. 2. Site: Rectum, mass, biopsy. 3. Findings: Invasive moderately differentiated adenocarcinoma. 3. Code: ADENOCARC maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Gastroesophageal junction, biopsy. 2. Findings: Reactive squamous and gastric type mucosa, negative for intestinal metaplasia. 2. Site: Rectum, mass, biopsy. 3. Findings: Invasive moderately differentiated adenocarcinoma. 3. Code: ADENOCARC maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site",
      "predicted": "ADENOCARC",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Gastroesophageal junction, biopsy. 2. Findings: Reactive squamous and gastric type mucosa, negative for intestinal metaplasia. 2. Site: Rectum, mass, biopsy. 3. Findings: Invasive moderately differentiated adenocarcinoma. 3. Code: ADENOCARC maps to ADENOCARC.",
      "idx": 1103,
      "timestamp": "2026-01-19T15:59:53.113528"
    },
    {
      "sample_idx": 538,
      "input": "Clinical Diagnosis & History: Patient with h/o right renal mass (right sided); renal cell cancer. Specimens Submitted: 1: SP: Right kidney, ureter and part of adrenal. 2: SP: Portion of right 11th rib. 3: SP: Right hilar lymph nodes. 4: SP: Fat at lower pole of kidney. DIAGNOSIS: 1). KIDNEY, RIGHT; RADICAL NEPHRECTOMY: - RENAL CELL CARCINOMA, CLEAR CELL TYPE, NUCLEAR GRADE II/IV. -THE PATTERN OF GROWTH IS PAPILLARY AND TUBULAR. - THE TUMOR GREATEST DIAMETER IS 6.5 CM. - THE TUMOR IS CONFINED WIT...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type,",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 538,
      "timestamp": "2026-01-19T15:59:53.113539"
    },
    {
      "sample_idx": 1197,
      "input": "Gender: F. Examination result No. Clinical diagnosis (suspicion) Gastric cancer. Date of admission: Material: 1) Material: stomach, Method of collection: Total organ resection. Histopathological diagnosis: Stomach adenocarcinoma, tubular and poorly differentiated (G3, pT2, pN2). Signs of vascular invasion. (8140/3. T-63000). codes according to ICD-O-3 or SNOMED. Macroscopic description: The specimen consisting of the stomach, after being incised along the greater curvature, sized 18,8x14,7 cm wi...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Stomach adenocarcinoma, tubular and poorly differentiated (G3, pT2, pN2). Signs of vascular invasion. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Stomach adenocarcinoma, tubular and poorly differentiated (G3, pT2, pN2). Signs of vascular invasion. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Stomach adenocarcinoma, tubular and poorly differentiated (G3, pT2, pN2). Signs of vascular invasion. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Stomach adenocarcinoma, tubular and poorly differentiated (G3, pT2, pN2). Signs of vascular invasion. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Stomach adenocarcinoma, tubular and poorly differentiated (G3, pT2, pN2). Signs of vascular invasion. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Stomach adenocarcinoma, tubular and poorly differentiated (G3, pT2, pN2). Signs of vascular invasion. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Stomach adenocarcinoma, tubular and poorly differentiated (G3, pT2, pN2). Signs of vascular invasion. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "ADENOMA",
      "ground_truth": "STAD",
      "correct": false,
      "reasoning": "1. Site: Stomach. 2. Findings: Stomach adenocarcinoma, tubular and poorly differentiated (G3, pT2, pN2). Signs of vascular invasion. 3. Code: ADENOMA.",
      "idx": 1197,
      "timestamp": "2026-01-19T15:59:53.113550"
    },
    {
      "sample_idx": 877,
      "input": "Clinical History/Diagnosis: Cancer left lung. Source of Specimen(s): A: Lung, wedge biopsy left lower lobe. B: Lymph Node, level 9L. Gross Description: Received in two parts. Source of Tissue: 1. Labeled #1 \"left lower lobe of lung wedge\". Gross Description: Received fresh is an 84.8 gm, 13.5 x 5.0 X 3.0 cm wedge. of lung. It is covered by a red-purple focally anthracotic stained pleura. having multiple staples along one margin. The pleural margins are inked. in black, the staples are removed an...",
      "response": "```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left lower lobe. 2. Findings: Invasive, poorly differentiated, squamous cell carcinoma. 3. Code: Lung, left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Level 9L lymph node. 2. Findings: One lymph node negative for metastatic carcinoma. 3. Code: Level 9L lymph node maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left lower lobe. 2. Findings: Invasive, poorly differentiated, squamous cell carcinoma. 3. Code: Lung, left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left lower lobe. 2. Findings: Invasive, poorly differentiated, squamous cell carcinoma. 3. Code: Lung, left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left lower lobe. 2. Findings: Invasive, poorly differentiated, squamous cell carcinoma. 3. Code: Lung, left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left lower lobe. 2. Findings: Invasive, poorly differentiated, squamous cell carcinoma. 3. Code: Lung, left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left lower lobe. 2. Findings: Invasive, poorly differentiated, squamous cell carcinoma. 3. Code: Lung, left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left lower lobe. 2. Findings: Invasive, poorly differentiated, squamous cell carcinoma. 3.",
      "predicted": "LCLC",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung, left lower lobe. 2. Findings: Invasive, poorly differentiated, squamous cell carcinoma. 3. Code: Lung, left lower lobe maps to LCLC.",
      "idx": 877,
      "timestamp": "2026-01-19T15:59:53.113560"
    },
    {
      "sample_idx": 1195,
      "input": "Diagnosis: Total gastrectomy preparation with an ulcerated gastric carcinoma located on the side of the. greater curvature, extending to within a maximum of 7 cm of the oral resection margin and. with a maximum diameter of 16 cm encompassing the corpus segment of the stomach in an. almost circular growth, with a prominent exophytic component characterized histologically as. a moderately differentiated adenocarcinoma (gastric carcinoma of the intestinal type). Invasive tumor spread within all the...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Gastric Carcinoma). 2. Findings: Gastric carcinoma, moderately differentiated adenocarcinoma (gastric carcinoma of the intestinal type). Invasive tumor spread within all the parietal layers of the stomach extending into the adjacent. subserous fatty tissue and encroaching on the peritoneal side of the atrophic gastritis (type A). Antrum mucosa with discrete non-florid chronic gastritis and foveolar hyperplasia. No. evidence of Helicobacter pylori. Oral and aboral resection margin and also greater omentum and diaphragm in the section. levels presented are tumor-free. After acetone clarification 33 lymph nodes measuring up to 1.5 cm in the perigastric fatty. tissue are prepared. Of these, two show metastatic infiltrates of the previously diagnosed adenocarcinoma or. gastric carcinoma. In conclusion and in summary, taking into account the infiltration of the diaphragm and with. the correction of the data given in the first set of findings, the following stage is arrived at: pT4 pN1 (2/33). 3. Code: Gastric Carcinoma maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach (Gastric Carcinoma). 2. Findings: Gastric carcinoma, moderately differentiated adenocarcinoma (gastric carcinoma of the intestinal type). Invasive tumor spread within all the parietal layers of the stomach extending into the adjacent. subserous fatty tissue and encroaching on the peritoneal side of the atrophic gastritis (type A). Antrum mucosa with discrete non-florid chronic gastritis and foveolar hyperplasia. No. evidence of Helicobacter pylori. Oral and aboral resection margin and also greater omentum and diaphragm in the section. levels presented are tumor-free. After acetone clarification 33 lymph nodes measuring up to 1.5 cm in the perigastric fatty. tissue are prepared. Of these, two show metastatic infiltrates of the previously diagnosed adenocarcinoma or. gastric carcinoma. In conclusion and in summary, taking into account the infiltration of the diaphragm and with. the correction of the data given in the first set of findings, the following stage is arrived at: pT4 pN1 (2/33). 3. Code: Gastric Carcinoma maps to KIRC.\"\n}\n```\n",
      "predicted": "ADENOMA",
      "ground_truth": "STAD",
      "correct": false,
      "reasoning": "1. Site: Stomach (Gastric Carcinoma). 2. Findings: Gastric carcinoma, moderately differentiated adenocarcinoma (gastric carcinoma of the intestinal type). Invasive tumor spread within all the parietal layers of the stomach extending into the adjacent. subserous fatty tissue and encroaching on the peritoneal side of the atrophic gastritis (type A). Antrum mucosa with discrete non-florid chronic gastritis and foveolar hyperplasia. No. evidence of Helicobacter pylori. Oral and aboral resection margin and also greater omentum and diaphragm in the section. levels presented are tumor-free. After acetone clarification 33 lymph nodes measuring up to 1.5 cm in the perigastric fatty. tissue are prepared. Of these, two show metastatic infiltrates of the previously diagnosed adenocarcinoma or. gastric carcinoma. In conclusion and in summary, taking into account the infiltration of the diaphragm and with. the correction of the data given in the first set of findings, the following stage is arrived at: pT4 pN1 (2/33). 3. Code: Gastric Carcinoma maps to ADENOMA.",
      "idx": 1195,
      "timestamp": "2026-01-19T15:59:53.113591"
    },
    {
      "sample_idx": 817,
      "input": "De-Identified Specimen Code: M. SPECIMEN SUBMITTED: Part A: BRONCHIAL MARGIN RIGHT. UPPER LOBE. Part B: LEVEL 10. Part C: LEVEL 11. Final Diagnosis. 1. Right lung, upper lobe, lobectomy (A) Adenocarcinoma with acinar and bronchioloalveolar. components. - Two peribronchiolar lymph nodes, negative for carcinoma (0/2). - Mild centrilobular emphysema. 2. Lymph nodes, level 10, excision (B) Negative for neoplasm. 3. Lymph nodes, level 11, excision (C) - Negative for neoplasm. Diagnosis Comment: 1. Tu...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Upper Lobe. 2. Findings: Adenocarcinoma with acinar and bronchioloalveolar components. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma. 3. Code: Uterus Endometrial Carcinoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma. 3. Code: Uterus Endometrial Carcinoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung, Upper Lobe. 2. Findings: Adenocarcinoma with acinar and bronchioloalveolar components. 3. Code: Lung Adenocarcinoma maps to LUAD.",
      "idx": 817,
      "timestamp": "2026-01-19T15:59:53.113604"
    },
    {
      "sample_idx": 741,
      "input": "TISSUE DESCRIPTION: Liver segments IV through VIII (1,900 grams; 22 x 14 x 9 cm), liver segment III (15. grams; 4.5 X 3 X 2.7 cm), and biopsy specimen from the peritoneum (1 X 0.8 x 0.4. cm). A1, B1, B2, B3, B4, C1. DIAGNOSIS: Liver, segments IV through VIII, resection: Grade 2 (of 4) hepatocellular. carcinoma, usual type, forming a multinodular mass, 16 x 15 x 11 cm, with multiple. (5) satellite nodules ranging in size from 0.5 cm to 1.5 cm. The tumor is located in. segments IV through VIII. Th...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segments IV-VIII). 2. Findings: Hepatocellular carcinoma, usual type, grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segments IV-VIII). 2. Findings: Hepatocellular carcinoma, usual type, grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segments IV-VIII). 2. Findings: Hepatocellular carcinoma, usual type, grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segments IV-VIII). 2. Findings: Hepatocellular carcinoma, usual type, grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segments IV-VIII). 2. Findings: Hepatocellular carcinoma, usual type, grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segments IV-VIII). 2. Findings: Hepatocellular carcinoma, usual type, grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segments IV-VIII). 2. Findings: Hepatocellular carcinoma, usual type, grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"",
      "predicted": "KIRC",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Liver (Segments IV-VIII). 2. Findings: Hepatocellular carcinoma, usual type, grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 741,
      "timestamp": "2026-01-19T15:59:53.113615"
    },
    {
      "sample_idx": 1325,
      "input": "Specimens Submitted: 1: SP: Left pararectal implant (fs). 2: SP: Left tube and ovary and tumor from left ureter and sigmoid colon (fs). 3: SP: Uterus, cervix, bilateral parametrium; radical hysterectomy. 4: SP: Right tube and ovary with tumor from right ureter. 5: SP: Cul-de-sac tumor. 6: SP: Left obturator lymph node. 7: SP: Left external iliac lymph nodes. 8: SP: Right external iliac lymph nodes. 9: SP: Right obturator lymph nodes. 10: SP: Right hypogastric lymph nodes. 11: SP: Tumor from rect...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Left pararectal implant. 2. Findings: Benign fibroadipose tissue. 3. Site: Left Fallopian tube and ovary and tumor from left ureter and sigmoid colon. 4. Findings: Metastatic serous carcinoma involving left fallopian tube and ovary. - Tumor also involves periadnexal soft tissue. - No ureter or colon is identified. 5. Site: Uterus, cervix, bilateral parametrium; radical hysterectomy. 6. Findings: Tumor Type: Adenocarcinoma, serous (papillary serous) type. Myometrial Invasion: (>50%). Measures10mm in maximum depth. Myometrial thickness measures17m in the area of maximal tumor. invasion. Endocervical Invasion: Mucosa and stroma. Parametrial tissue is also involved by tumor. Depth of cervical stromal invasion: Measures 15.5mm. Cervical wall thickness measures 16mm in the area of maximum tumor. invasion. Lymphovascular invasion: Identified. Endometrium: Exhibits atrophy. Myometrium: Unremarkable. Vaginal cuff margin is benign. 7. Site: Right Fallopian tube and ovary and tumor from right ureter. 8. Findings: Metastatic serous carcinoma involving right fallopian tube and ovary. 9. Site: Cul-de-sac tumor. 10. Findings: Metastatic serous carcinoma. 11. Site: Left obturator lymph node. 12. Findings: Six benign lymph nodes (0/6). 13. Site: Left external iliac lymph nodes. 14. Findings: Metastatic carcinoma in one of six lymph nodes (1/6). 15. Site: Right external iliac lymph nodes. 16. Findings: Metastatic carcinoma in one of six lymph nodes (1/6). 17. Site: Right obturator lymph nodes. 18. Findings: Eight benign lymph nodes (0/8). 19. Site: Right hypogastric lymph nodes. 20. Findings: Metastatic carcinoma in one lymph node (1/1). 21. Site: Tumor from rectum. 22. Findings: Benign fibroadipose tissue. - One benign lymph node (0/1). 23. Site: Oment",
      "predicted": null,
      "ground_truth": "UCEC",
      "correct": null,
      "reasoning": "",
      "idx": 1325,
      "timestamp": "2026-01-19T15:59:53.113725"
    },
    {
      "sample_idx": 283,
      "input": "Diagnosis: Colon, right, colectomy. Tumor Histologic Type: Invasive adenocarcinoma with mucinous features. Histologic Grade: Moderately differentiated. Tumor Location: Cecum with extension into ileocecal valve. Depth of Invasion: Through muscularis propria into the pericolic soft tissue. Lymphovascular Invasion: Not identified. Perineural Invasion: Not identified. Margins: Proximal margin: Negative, 4 cm from tumor. Distal margin: Negative, 8 cm from tumor. Circumferential (radial) margin (recta...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right). 2. Findings: Invasive adenocarcinoma with mucinous features, Moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right). 2. Findings: Invasive adenocarcinoma with mucinous features, Moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right). 2. Findings: Invasive adenocarcinoma with mucinous features, Moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right). 2. Findings: Invasive adenocarcinoma with mucinous features, Moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right). 2. Findings: Invasive adenocarcinoma with mucinous features, Moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right). 2. Findings: Invasive adenocarcinoma with mucinous features, Moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right). 2. Findings: Invasive adenocarcinoma with mucinous features, Moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right). 2. Findings: Invasive adenocarcinoma with mucinous features, Moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right). 2. Findings: Invasive adenocarcinoma with mucinous",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Colon (Right). 2. Findings: Invasive adenocarcinoma with mucinous features, Moderately differentiated. 3. Code: KIRC.",
      "idx": 283,
      "timestamp": "2026-01-19T15:59:53.113738"
    },
    {
      "sample_idx": 1043,
      "input": "PATIENT HISTORY. The patient is a. with a serum PSA value of 14.9 ng/mL. The patient had a biopsy on. his biopsy revealed small foci of prostatic adenocarcinoma. Gleason score 3+S = 6 involving the left lobe. and right prostate lobes (5 1% of the cores). He also had prior biopsies. showed focal. high-grade prostatic intraepithelial neoplasia. PRE-OP DIAGNOSIS: Prostate cancer. POST-OP DIAGNOSIS: Same. PROCEDURE: Radical prostatectomy and bilateral pelvic lymphadenectomy. FINAL DIAGNOSIS: PART1: ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 4+3=7, with a prominent tertiary Gleason pattern 5 component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 4+3=7, with a prominent tertiary Gleason pattern 5 component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 4+3=7, with a prominent tertiary Gleason pattern 5 component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 4+3=7, with a prominent tertiary Gleason pattern 5 component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 4+3=7, with a prominent tertiary Gleason pattern 5 component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 4+3=7, with a prominent tertiary Gleason pattern 5 component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 4+3=7, with a prominent tertiary Gleason pattern 5 component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. ",
      "predicted": "KIRC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 4+3=7, with a prominent tertiary Gleason pattern 5 component. 3. Code: KIRC.",
      "idx": 1043,
      "timestamp": "2026-01-19T15:59:53.113749"
    },
    {
      "sample_idx": 1010,
      "input": "Gross: Thinly fibrously encapsulated ovoid tumor of soft consistency 55x45x35 mm, weight 50 g. On cut, the tumor is grey-red, with focal hemorrhages. Micro: Solidly alveolarly shaped right pheochromocytoma with focal hemorrhages and with rim of. adrenocortical tissue on periphery was confirmed in excisions. The tumor does not invade. adrenal capsule in to surrounding adipose tissue. It shows nuclear hyperchromasia. sporadically, no regular or atypical mitoses were found. No necroses were found. ...",
      "response": "```json\n{\n    \"cancer_type\": \"ADREN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, solid, alveolarly shaped. No invasion of adrenal capsule. 3. Code: Adrenal Pheochromocytoma maps to ADREN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADREN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, solid, alveolarly shaped. No invasion of adrenal capsule. 3. Code: Adrenal Pheochromocytoma maps to ADREN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADREN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, solid, alveolarly shaped. No invasion of adrenal capsule. 3. Code: Adrenal Pheochromocytoma maps to ADREN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADREN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, solid, alveolarly shaped. No invasion of adrenal capsule. 3. Code: Adrenal Pheochromocytoma maps to ADREN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADREN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, solid, alveolarly shaped. No invasion of adrenal capsule. 3. Code: Adrenal Pheochromocytoma maps to ADREN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADREN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, solid, alveolarly shaped. No invasion of adrenal capsule. 3. Code: Adrenal Pheochromocytoma maps to ADREN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADREN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, solid, alveolarly shaped. No invasion of adrenal capsule. 3. Code: Adrenal Pheochromocytoma maps to ADREN",
      "predicted": "ADREN",
      "ground_truth": "PCPG",
      "correct": false,
      "reasoning": "1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, solid, alveolarly shaped. No invasion of adrenal capsule. 3. Code: Adrenal Pheochromocytoma maps to ADREN.",
      "idx": 1010,
      "timestamp": "2026-01-19T15:59:53.113760"
    },
    {
      "sample_idx": 186,
      "input": "F. Pathologic Interpretation: A. LEFT BREAST LUMPECTOMY 1 STITCH SUPERIOR, 2 STITCHES LATERAL, SKIN IS ANTERIOR: - Invasive poorly differentiated ductal carcinoma, 2.2 cm in greatest linear dimension, Nottingham Grade 3 (3+3+3). Tumor is less than 0.1 cm from the posterior and lateral margins. - Lymphovascular invasion is present. - Tumor cells are negative for ER, PR, HER-2 by immunohistochemistry. B. SENTINEL LYMPH NODE #1 COUNT 171: - Metastatic carcinoma in one lymph node with extranodal ext...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.",
      "idx": 186,
      "timestamp": "2026-01-19T15:59:53.113770"
    },
    {
      "sample_idx": 96,
      "input": "Specimen: (. spec Type: SURGICAL P. RIGHT BREAST CANCER INVASIVE. DATE: 1. DOCTOR (s) : BITATERAL SIMPLE MASTECTOMY - SENTINEL NODE BX. A. LT BREAST MASTECTOMY. B. RT BREAST SENTINEL NODE #1. C. RT BREAST SENTINEL NODE #2. D. RT BREAST MASTECTOMY. RECEIVED IN FOUR PARTS. PART A: RECEIVED FRESH LABELED LEFT BREAST MASTECTOMY, STITCH AT 1200 IS A. SIMPLE MASTECTOMY SPECIMEN MEASURING 15 X 14.5 x 4 CM IN GREASTEST. DIMENSIONS. THE NIPPLE IS UNREMARKABLE WITHIN A 6.3 x 3.6 CM SKIN. ELLIPSE. THE SUPE...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade III/III, with a high mitotic index and a microscopic distance of 2.6 cm. There are also minor foci of micropapillary-type ductal carcinoma in situ. The tumor is located in the upper inner quadrant of the breast. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade III/III, with a high mitotic index and a microscopic distance of 2.6 cm. There are also minor foci of micropapillary-type ductal carcinoma in situ. The tumor is located in the upper inner quadrant of the breast. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade III/III, with a high mitotic index and a microscopic distance of 2.6 cm. There are also minor foci of micropapillary-type ductal carcinoma in situ. The tumor is located in the upper inner quadrant of the breast. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade III/III, with a high mitotic index and a microscopic distance of 2.6 cm. There are also minor foci of micropapillary-type ductal carcinoma in situ. The tumor is located in the upper inner quadrant of the breast. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade III/III, with a high mitotic index and a microscopic distance of 2.6 cm. There are also minor foci of micropapillary-type ductal carcinoma in situ. The tumor is located in the upper inner quadrant of the breast. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade III/III, with a high mitotic index and a microscopic distance of 2.6 cm. There are also minor foci of micropapillary-type ductal carcinoma in situ. The tumor is located in the upper inner quadrant of the breast. 3. Code: BRCA",
      "idx": 96,
      "timestamp": "2026-01-19T15:59:53.113787"
    },
    {
      "sample_idx": 224,
      "input": "MEDICAL CENTER. LABORATORY. PAGE:1. Specimen Inquiry. LOC: SPEC # : CLINICAL HISTORY : CERVIX CA. SPECIMEN/PROCEDURE : 1. UTERUS - AND CERVIX, PARAMETRIA AND VAGINA. 2. PARAMETRIUM - RIGHT. 3. PARAMETRIUM - LEFT. 4. LYMPH NODE, PELVIC - LEFT. 5. LYMPH NODE, PELVIC - RIGHT. 5. LYMPH NODE, PARAAORTIC - RIGHT. 7. LYMPH NODE, PARAAORTIC - LEFT. IMPRESSION: 1) UTERUS AND CERVIX, BILATERAL PARAMETRIA AND VAGINAL CUFF, RADICAL HYSTERECTOMY: CERVIX: Invasive adenosarainoma of cervix, usual type, moderat...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive adenosarainoma of cervix, usual type, moderately differentiated. Tumor thickness is 6 mm where the maximal cervical wall thickness is 15 mm. Surgical margins of resection are negative for tumor; tumor is 9 mm away. from the deep soft tissue margin. No evidence of lymphovasoular space invasion. Please see tumor checklist. ENDOMETRIUM: Disordered proliferative endometrium. Negative for malignancy. MYOMETRIUM: Foci of hyalinization. Negative for malignancy. PARAMETRIUM: Benign fibroadipose tissue. Two benign lymph nodes (0/2). VAGINAL CUFF: Negative for malignancy. 2). PARAMETRIUM, RIGHT, RESECTION: Benign fibroadipose tissue. PARAMETRIUM, LEFT, RESECTION: Benign fibroadipose tissue. 4). LYMPH NODES, PELVIC, LEFT, REGIONAL DISSECTION: Six benign lymph nodes (0/6) . LYMPH NODES, PELVIC, RIGHT, REGIONAL DISSECTION : Nine benign lymph nodes (0/9) -. LYMPH NODES, PARA-AORTIC, RIGHT, REGIONAL DISSECTION: SPEC #: (Continued) Page: 2. IMPRESSION (continued). Two benign lymph nodes (0/2) . LYMPH NODE, PARA-AORTIC, LEFT, BIOPSY: One benign lymph node (0/1). UTERINE. CERVIX: TRACHELECTOMY, HYSTERECTOMY PELVIC EXENTERATION CASE SUMMARY. SPECIMEN. Cervix. Uterus corpus. Other (specify) : Vaginal cuff, parametria. PROCEDURE. Radical hysterectomy. TUMOR SIZE. Greatest dimension: 1.3 x 0.6 x 0.5 am. TUMOR SITE. Left inferior quadrant (3-6 o'clock). Right inferior quadrant (6-9 o'clock). HISTOLOGIC TYPE. Adenocarsinoma. Mucinous. Endoservical type. HISTOLOGIC GRADE. G2: Moderately differentiated. MARGINS. Resection Margin. Margins uninvolved by invasive carcinoma. Distance of invasive carcinoma from margin: 9. mm. Specify location, if possible: Deep posterior cervical margin of resection. LYMPH-VASCULAR IN",
      "predicted": null,
      "ground_truth": "CESC",
      "correct": null,
      "reasoning": "",
      "idx": 224,
      "timestamp": "2026-01-19T15:59:53.113893"
    },
    {
      "sample_idx": 313,
      "input": "SPECIMEN. A. Liver lesion. B. Paraaortic lymph node. C. Rectosigmoid colon. CLINICAL NOTES. CLINICAL HISTORY: Sigmoid colon cancer. FROZEN SECTION DIAGNOSIS. A. , left lobe, excision: Metastatic adenocarcinoma. 0. GROSS DESCRIPTION. A. The specimen is received fresh for frozen section. labeled \"A. Left liver lesion\" and consists of a tan 0.8 X. 0.3 X 0. rubbery tissue, entirely frozen as frozen. section. in formalin labeled \"paraaortic lymph node\" is. a 1.2 X 0.8 X 0.3 cm. rubbery tan pink tissu...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately to poorly differentiated, invasive through muscularis propria into subserosa (pT3). Metastatic adenocarcinoma present in 1 of 37 lymph nodes. (pN1a). Lymphatic space invasion present. Resection margins are negative for tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Metastatic adenocarcinoma of colonic type consistent with origin from rectosigmoid tumor. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Para-aortic lymph node. 2. Findings: Single lymph node negative for metastatic tumor (0/1). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon, rectosigmoid. 2. Findings: Adenocarcinoma, moderately to poorly differentiated, invasive through muscularis propria into subserosa (pT3). Metastatic adenocarcinoma present in 1 of 37 lymph nodes. (pN1a). Lymphatic space invasion present. Resection margins are negative for tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Metastatic adenocarcinoma of colonic type consistent with origin from rectosigmoid tumor. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately to poorly differentiated, invasive through muscularis propria into subserosa (pT3). Metastatic adenocarcinoma present in 1 of 37 lymph nodes. (pN1a). Lymphatic space invasion present. Resection margins are negative for tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately to poorly differentiated, invasive through muscularis propria into subserosa (pT3). Metastatic adenocarcinoma present in 1 of 37 lymph nodes. (pN1a). Lymphatic space invasion present. Resection margins are negative for tumor. 3. Code: KIRC.",
      "idx": 313,
      "timestamp": "2026-01-19T15:59:53.113909"
    },
    {
      "sample_idx": 1285,
      "input": "LABORATORY MEDICINE PROGRAM. Receit. Specimen(s) Received. 1. Parathyroid: Query Rt Inferior Parathyroid. 2. Thyroid: Total thyroid gland-long stitch marks Lt. superior pole, short stitch marks Rt. superior pole. 3. Lymph node: Rt. Paratracheal nodes. 4. Lymph node: Lt. paratracheal nodes and upper mediastinal. Diagnosis. 1. No pathological diagnosis: Lymph node (listed as 'query right inferior parathyroid') excisional biopsy. 2. Widely-invasive papillary carcinoma with unusual features, 3.1 cm,...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1285,
      "timestamp": "2026-01-19T15:59:53.113919"
    },
    {
      "sample_idx": 327,
      "input": "Diagnosis: Right hemicolectomy preparation with tumor-free oral and aboral resection margins and. including an ulcerated, poorly differentiated adenocarcinoma of the ascending colon, with. infiltration of the perimuscular fatty tissue and numerous regional lymph node metastases. (G3, pT3, L1, V1 local R0 pN2 24/29).",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending). 2. Findings: Adenocarcinoma, poorly differentiated, ulcerated, with lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending). 2. Findings: Adenocarcinoma, poorly differentiated, ulcerated, with lymph node metastases. 3. Code: Colon Adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending). 2. Findings: Adenocarcinoma, poorly differentiated, ulcerated, with lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending). 2. Findings: Adenocarcinoma, poorly differentiated, ulcerated, with lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending). 2. Findings: Adenocarcinoma, poorly differentiated, ulcerated, with lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending). 2. Findings: Adenocarcinoma, poorly differentiated, ulcerated, with lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending). 2. Findings: Adenocarcinoma, poorly differentiated, ulcerated, with lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending). 2. Findings:",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon (Ascending). 2. Findings: Adenocarcinoma, poorly differentiated, ulcerated, with lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.",
      "idx": 327,
      "timestamp": "2026-01-19T15:59:53.113929"
    },
    {
      "sample_idx": 1402,
      "input": "SURGICAL PATHOLOGY REVISED REPORT. Diagnosis: A: Uterus and cervix, bilateral ovaries and fallopian tubes,. hysterectomy and bilateral salpingo-oophorectomy. Location of tumor: anterior and posterior endometrium extending. into anterior and posterior lower uterine segment and invasive. carcinoma also involves the posterior upper endocervix (A18). Tumor size: 6.5 X 6.4 X 4.5 cm per gross measurement of. carcinoma within the endometrium and a large amount of disrupted. tumor is also received separ...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "UCS",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1402,
      "timestamp": "2026-01-19T15:59:53.113938"
    },
    {
      "sample_idx": 1221,
      "input": "Pathohistological diagnosis. Seminoma testis (pT2 NXMX), right testicle. Description: A testicle with tumor, size 7:5.5:4.5 cm with 9 cm long funiculus and 2.5-3 cm diameter was. received. Inside the testicle we find white, nodular tumor tissue with hemorrhaging and. necrotic areas encompassing an area of 6.2:5:4.5 cm. Histologically, the tumor is made of. solid tumor cell clusters with round and oval bright nuclei with pronounced smaller nuclei. with medium abundant bright cytoplasm. Around tum...",
      "response": "```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma testis, pT2 NXMX. 3. Code: Seminoma testis maps to TGCT.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma testis, pT2 NXMX. 3. Code: Seminoma testis maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma testis, pT2 NXMX. 3. Code: Seminoma testis maps to TGCT.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma testis, pT2 NXMX. 3. Code: Seminoma testis maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma testis, pT2 NXMX. 3. Code: Seminoma testis maps to TGCT.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma testis, pT2 NXMX. 3. Code: Seminoma testis maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma testis, pT2 NXMX. 3. Code: Seminoma testis maps to TGCT.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma testis, pT2 NXMX. 3. Code: Seminoma testis maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n",
      "predicted": "TGCT",
      "ground_truth": "TGCT",
      "correct": true,
      "reasoning": "1. Site: Testis. 2. Findings: Seminoma testis, pT2 NXMX. 3. Code: Seminoma testis maps to TGCT.",
      "idx": 1221,
      "timestamp": "2026-01-19T15:59:53.113949"
    },
    {
      "sample_idx": 130,
      "input": "FINAL DIAGNOSIS: PART 1: SENTINEL LYMPH NODE NUMBER 1, LEFT, BIOPSY -. A. ONE OF THREE LYMPH NODES, POSITIVE FOR METASTATIC LOBULAR CARCINOMA (1/3). B. METASTATIC TUMOR MEASURES 1.4 CM IN LARGEST DIMENSION. C. NO DEFINITE EXTRACAPSULAR EXTENSION IDENTIFIED. PART 2: BREAST, LEFT, MODIFIED RADICAL MASTECTOMY -. A. MULTIFOCAL ND MULTICENTRIC INVASIVE LOBULAR CARCINOMA, NOTTINGHAM GRADE 2 (TUBULAR. FORMATION 3, NUCLEAR POLYMORPHISM 2, MITOTIC FIGURES 1, TOTAL SCORE 6/9). B. INVASIVE TUMOR MASS RANGI...",
      "response": "```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Breast (Left, Modified Radical Mastectomy). 2. Findings: Invasive lobular carcinoma, Nottingham Grade 2, multifocal, multicentric. 3. Code: Breast Invasive Carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast (Left, Modified Radical Mastectomy). 2. Findings: Lobular carcinoma in situ, nuclear grade 2, constituting 25% of total tumor mass. 3. Code: Breast Invasive Carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast (Left, Modified Radical Mastectomy). 2. Findings: Lobular carcinoma in situ, nuclear grade 2, constituting 25% of total tumor mass. 3. Code: Breast Invasive Carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast (Left, Modified Radical Mastectomy). 2. Findings: Lobular carcinoma in situ, nuclear grade 2, constituting 25% of total tumor mass. 3. Code: Breast Invasive Carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast (Left, Modified Radical Mastectomy). 2. Findings: Lobular carcinoma in situ, nuclear grade 2, constituting 25% of total tumor mass. 3. Code: Breast Invasive Carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast (Left, Modified Radical Mastectomy). 2. Findings: Lobular carcinoma in situ, nuclear grade 2, constituting 25% of total tumor mass. 3. Code: Breast Invasive Carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast (Left, Modified",
      "predicted": "LIHC",
      "ground_truth": "BRCA",
      "correct": false,
      "reasoning": "1. Site: Breast (Left, Modified Radical Mastectomy). 2. Findings: Invasive lobular carcinoma, Nottingham Grade 2, multifocal, multicentric. 3. Code: Breast Invasive Carcinoma maps to LIHC.",
      "idx": 130,
      "timestamp": "2026-01-19T15:59:53.113961"
    },
    {
      "sample_idx": 788,
      "input": "'INAL DIAGNOSIS. RIGHT MIDDLE LOBE (LOBECTOMY) : :PECIMEN TYPE: obectomy. 'UMOR SITE: light, middle lobe. IISTOLOGIC TYPE: idenocarcinoma, Nos. 'UMOR SIZE: ;reatest dimension 2.0 cm.",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Right middle lobe of the lung. 2. Findings: Invasive ductal carcinoma, NOS (Not Otherwise Specified). 3. Code: LUAD (Lung Adenocarcinoma) maps to LUAD. Note: The report mentions a lobectomy, suggesting the specimen is from a lung lobe, and the tumor is invasive ductal carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Right middle lobe of the lung. 2. Findings: Invasive ductal carcinoma, NOS (Not Otherwise Specified). 3. Code: LUAD (Lung Adenocarcinoma) maps to LUAD. Note: The report mentions a lobectomy, suggesting the specimen is from a lung lobe, and the tumor is invasive ductal carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Right middle lobe of the lung. 2. Findings: Invasive ductal carcinoma, NOS (Not Otherwise Specified). 3. Code: LUAD (Lung Adenocarcinoma) maps to LUAD. Note: The report mentions a lobectomy, suggesting the specimen is from a lung lobe, and the tumor is invasive ductal carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Right middle lobe of the lung. 2. Findings: Invasive ductal carcinoma, NOS (Not Otherwise Specified). 3. Code: LUAD (Lung Adenocarcinoma) maps to LUAD. Note: The report mentions a lobectomy, suggesting the specimen is from a lung lobe, and the tumor is invasive ductal carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Right middle lobe of the lung. 2. Findings: Invasive ductal carcinoma, NOS (Not Otherwise Specified). 3. Code: LUAD (Lung Adenocarcinoma) maps to LUAD. Note: The report mentions a lobectomy, suggesting the specimen is from a lung lobe, and the tumor is invasive ductal carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Right middle lobe of the lung. 2. Findings: Invasive ductal carcinoma, NOS (Not Otherwise Specified). 3. Code: LUAD (Lung Adenocarcinoma) maps to LUAD. Note: The report mentions a lobectomy, suggesting the specimen is from a lung lobe, and the tumor is invasive ductal carcinoma.",
      "idx": 788,
      "timestamp": "2026-01-19T15:59:53.113977"
    },
    {
      "sample_idx": 781,
      "input": "Date of Service. Performing Facilit. Result Provider. Report Name. DXSTIC. SEE REPORT. PROCEDURE DATE: SPECIMEN DESCRIPTION: INFERIOR PULMONARY LIGAMENT LYMPH NODE. B. SUBCARINAL LYMPH NODE. HILAR LYMPH NODES. D. PULMONARY ARTERY LYMPH NODE, N1. E. PROXIMAL BRONCHIAL LYMPH NODE. F. LEFT LOWER LOBE OF LUNG, FPC. G. AP WINDOW LYMPH NODE. PRE-OPERATIVE DIAGNOSIS: Lung cancer. POST-OPERATIVE DIAGNOSIS: Same, pending pathology. CLINICAL INFORMATION. Left lower lobe mass, cavitary. ==== INTRAOPERATIVE...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, moderately differentiated, pT2, with positive lymphovascular invasion and two out of nine peribronchial lymph nodes positive for metastatic carcinoma. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, moderately differentiated, pT2, with positive lymphovascular invasion and two out of nine peribronchial lymph nodes positive for metastatic carcinoma. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, moderately differentiated, pT2, with positive lymphovascular invasion and two out of nine peribronchial lymph nodes positive for metastatic carcinoma. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, moderately differentiated, pT2, with positive lymphovascular invasion and two out of nine peribronchial lymph nodes positive for metastatic carcinoma. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, moderately differentiated, pT2, with positive lymphovascular invasion and two out of nine peribronchial lymph nodes positive for metastatic carcinoma. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, moderately differentiated, pT2, with positive lymphovascular invasion and two out of nine peribronchial lymph nodes positive for metastatic carcinoma. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, moderately differentiated, pT2, with",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung. 2. Findings: Adenocarcinoma, moderately differentiated, pT2, with positive lymphovascular invasion and two out of nine peribronchial lymph nodes positive for metastatic carcinoma. 3. Code: LUAD.",
      "idx": 781,
      "timestamp": "2026-01-19T15:59:53.113990"
    },
    {
      "sample_idx": 1220,
      "input": "Pathological diagnosis: Testicular Seminoma. Description: A testicle with tumor, size 8.5:7.5 cm, with 9 cm long funiculus was received. We see on the cut that the whole testicle is imbued with tumor and on the capsule we see 6.5. cm long surgical cut with sutures. On the cut, the tumor is white, soft and partially necrotic. Histologically, the tumor is made of solid seats and tumor cell traces with round and oval. bright nuclei with pronounced smaller nuclei with medium abundant bright and pink...",
      "response": "```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testicle. 2. Findings: Seminoma, solid, with necrosis. 3. Code: Testicular Seminoma maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Testicle. 2. Findings: Seminoma, solid, with necrosis. 3. Code: Testicular Seminoma maps to TGCT.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testicle. 2. Findings: Seminoma, solid, with necrosis. 3. Code: Testicular Seminoma maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testicle. 2. Findings: Seminoma, solid, with necrosis. 3. Code: Testicular Seminoma maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testicle. 2. Findings: Seminoma, solid, with necrosis. 3. Code: Testicular Seminoma maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testicle. 2. Findings: Seminoma, solid, with necrosis. 3. Code: Testicular Seminoma maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testicle. 2. Findings: Seminoma, solid, with necrosis. 3. Code: Testicular Seminoma maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testicle. 2. Findings: Seminoma, solid, with necrosis. 3. Code: Testicular Seminoma maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1.",
      "predicted": "SKCM",
      "ground_truth": "TGCT",
      "correct": false,
      "reasoning": "1. Site: Testicle. 2. Findings: Seminoma, solid, with necrosis. 3. Code: Testicular Seminoma maps to SKCM.",
      "idx": 1220,
      "timestamp": "2026-01-19T15:59:53.114000"
    },
    {
      "sample_idx": 958,
      "input": "Physician (s) : Other Related Clinical Data: DIAGNOSIS: A. OMENTUM, OMENTECTOMY. - METASTATIC POORLY DIFFERENTIATED ADENOCARCINOMA, LARGEST FOCUS 8 CM. B. SMALL INTESTINE, RESECTION. - METASTATIC POORLY DIFFERENTIATED ADENOCARCINOMA, INVOLVING SEROSA. &. MUSCULARIS PROPRIA. - LYMPHOVASCULAR INVASION IDENTIFIED. - RESECTION MARGINS FREE-OF TUMOR. - ACUTE SEROSITIS. C. OVARIES, RIGHT & LEFT, BILATERAL SALPINGO-OOPHORECTOMY. - POORLY DIFFERENTIATED ADENOCARCINOMA, WITH MIXED SEROUS PAPILLARY &. POO...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Omentum. 2. Findings: Poorly differentiated adenocarcinoma, metastatic, largest focus 8 cm. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Small bowel. 2. Findings: Poorly differentiated adenocarcinoma, metastatic, involving serosa. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovaries, Right & Left. 2. Findings: Poorly differentiated adenocarcinoma, with mixed serous papillary and poorly differentiated endometroid features, synchronous primaries (see synoptic). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix. 2. Findings: No evidence of malignancy. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Omentum. 2. Findings: Carcinoma, favor Mullerian origin. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Small bowel. 2. Findings: Poorly differentiated adenocarcinoma, metastatic, involving serosa. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Ovaries, Right & Left. 2. Findings: Poorly differentiated adenocarcinoma, with mixed serous papillary and poorly differentiated endometroid features, synchronous primaries (see synoptic). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix. 2. Findings: No evidence of malignancy. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reason",
      "predicted": "BRCA",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Omentum. 2. Findings: Poorly differentiated adenocarcinoma, metastatic, largest focus 8 cm. 3. Code: BRCA.",
      "idx": 958,
      "timestamp": "2026-01-19T15:59:53.114010"
    },
    {
      "sample_idx": 1083,
      "input": "PROCEDURE DATE: REPORT DATE: Pre-Op Diagnosis. Prostate cancer. Post-Op Diagnosis. Same. Clinical History. Nothing indicated on requisition. Gross Description: Container labeled. - prostate and pelvic lymph node. biopsy\" is a previously inked previously partially sectioned. moderately distorted prostate gland with attached bilateral seminal. vesicles weighing as received 37 grams. The prostate gland on. reconstruction measures approximately 4.8 x 3.7 x 3.7 cm and has a. slightly lobulated focall...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, involving right and left lobes. Tumor measures up to 2 cm. Gleason grade: 7/10. Lymph node status: 0/1 (no lymph node metastasis). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, involving right and left lobes. Tumor measures up to 2 cm. Gleason grade: 7/10. Lymph node status: 0/1 (no lymph node metastasis). 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, involving right and left lobes. Tumor measures up to 2 cm. Gleason grade: 7/10. Lymph node status: 0/1 (no lymph node metastasis). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, involving right and left lobes. Tumor measures up to 2 cm. Gleason grade: 7/10. Lymph node status: 0/1 (no lymph node metastasis). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, involving right and left lobes. Tumor measures up to 2 cm. Gleason grade: 7/10. Lymph node status: 0/1 (no lymph node metastasis). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, involving right and left lobes. Tumor measures up to 2 cm. Gleason grade: 7/10. Lymph node status: 0/1 (no lymph node metastasis). 3. Code: KIRC.\"\n",
      "predicted": "KIRC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, involving right and left lobes. Tumor measures up to 2 cm. Gleason grade: 7/10. Lymph node status: 0/1 (no lymph node metastasis). 3. Code: KIRC.",
      "idx": 1083,
      "timestamp": "2026-01-19T15:59:53.114022"
    },
    {
      "sample_idx": 514,
      "input": "DIAGNOSIS. (A) LEFT KIDNEY: CHROMOPHOBE RENAL CELL CARCINOMA, FUHRMAN'S NUCLEAR GRADE 3. (SEE. COMMENT). TUMOR MEASURES 5.0 CM IN MAXIMUM DIMENSION. FOCAL LYMPHATIC/VASCULAR INVASION IDENTIFIED. Multilocular cyst. (4.0 cm). Margins of resection free of tumor. COMMENT. Immunoperoxidase studies demonstrate the tumor cells to be positive for. CK7 and negative for CD10 and Vimentin, supporting the diagnosis of. Chromophobe renal cell carcinoma. The tumor has a pushing border but. does not invade the...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe Renal Cell Carcinoma, Fuhrman's Nuclear Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe Renal Cell Carcinoma, Fuhrman's Nuclear Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe Renal Cell Carcinoma, Fuhrman's Nuclear Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe Renal Cell Carcinoma, Fuhrman's Nuclear Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe Renal Cell Carcinoma, Fuhrman's Nuclear Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe Renal Cell Carcinoma, Fuhrman's Nuclear Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe Renal Cell Carcinoma, Fuhrman's Nuclear Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```",
      "predicted": "KIRC",
      "ground_truth": "KICH",
      "correct": false,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Chromophobe Renal Cell Carcinoma, Fuhrman's Nuclear Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 514,
      "timestamp": "2026-01-19T15:59:53.114032"
    },
    {
      "sample_idx": 1133,
      "input": "Patient Info. FINAL DIAGNOSIS. A. Left thigh garcoma, excision: - Undifferentiated pleomorphic sarcoma with myogenic differentiation. (FNCLCC, Grade 3/3) . - See comment. COMMENT. SOFT TISSUE TUMOR. Specimen type: Wide excision. Site: Left thigh. Depth. deep. Specify depth (all that apply) : Intramuscular. Size. Greatest dimension: 11 cm. Additional two dimensions: 6.0 x 5.0 cm. Histologic type: Undifferentiated pleomorphic sarcoma with myogenic. differentiation. Mitotic rate (per 5 HPFs) : 44. ...",
      "response": "```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left thigh. 2. Findings: Undifferentiated pleomorphic sarcoma with myogenic differentiation, grade 3/3. 3. Code: SARC maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left thigh. 2. Findings: Undifferentiated pleomorphic sarcoma with myogenic differentiation, grade 3/3. 3. Code: SARC maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left thigh. 2. Findings: Undifferentiated pleomorphic sarcoma with myogenic differentiation, grade 3/3. 3. Code: SARC maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left thigh. 2. Findings: Undifferentiated pleomorphic sarcoma with myogenic differentiation, grade 3/3. 3. Code: SARC maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left thigh. 2. Findings: Undifferentiated pleomorphic sarcoma with myogenic differentiation, grade 3/3. 3. Code: SARC maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left thigh. 2. Findings: Undifferentiated pleomorphic sarcoma with myogenic differentiation, grade 3/3. 3. Code: SARC maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left thigh. 2. Findings: Undifferentiated pleomorphic sarcoma with myogenic differentiation, grade 3/3. 3. Code: SARC maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left thigh. 2. Findings: Undifferentiated pleomorphic sarcoma with myogenic differentiation, grade 3/3. ",
      "predicted": "SARC",
      "ground_truth": "SARC",
      "correct": true,
      "reasoning": "1. Site: Left thigh. 2. Findings: Undifferentiated pleomorphic sarcoma with myogenic differentiation, grade 3/3. 3. Code: SARC maps to SARC.",
      "idx": 1133,
      "timestamp": "2026-01-19T15:59:53.114042"
    },
    {
      "sample_idx": 23,
      "input": "RADICAL CYSTOPROSTATECTOMY WITH ILEOCONDUIT AND BILATERAL PELVIC LYMPH NODE. DISSECTION: RIGHT DISTAL URETER (A) : FROZEN SECTION DIAGNOSIS: - NO HIGH GRADE ATYPIA OR TUMOR IDENTIFIED. FINAL DIAGNOSIS: BENIGN URETER. NO UROTHELIAL DYSPLASIA OR MALIGNANCY IDENTIFIED. LEFT DISTAL URETER (B) : FROZEN SECTION DIAGNOSIS: NO HIGH GRADE ATYPIA OR TUMOR IDENTIFIED. FINAL DIAGNOSIS: BENIGN URETER. NO UROTHELIAL DYSPLASIA OR MALIGNANCY IDENTIFIED. BLADDER/PROSTATE (C) : BLADDER: INVASIVE UROTHELIAL CARCIN...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, grade 3 & 4/4, involving full thickness of bladder wall with extension into perivesical soft tissue. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, grade 3 & 4/4, involving full thickness of bladder wall with extension into perivesical soft tissue. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, grade 3 & 4/4, involving full thickness of bladder wall with extension into perivesical soft tissue. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, grade ",
      "predicted": "KIRC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, grade 3 & 4/4, involving full thickness of bladder wall with extension into perivesical soft tissue. 3. Code: KIRC.",
      "idx": 23,
      "timestamp": "2026-01-19T15:59:53.114054"
    },
    {
      "sample_idx": 234,
      "input": "N.me : Hosp. No. : de. N. SurJ-OR: M.D. UTERUS. CERVIX. BIOPSY - SQUAMOUS CELL CARCINOMA. By this signature. I &ttest that the. above diagnosis is based upon mV. personal examination ot the slides. 1 and/or other material indicated in. the diagnosis). and that I have. reviewed and approved this report. M.D. M.D. SPECIMENTS SUBMITTED. CERVIX. HISTORY. patient is a year old woman with cervical carcinoma. eserative procedure: Cervical biopsy. GROSS. The specimen is received in a container of formal...",
      "response": "```json\n{\n    \"cancer_type\": \"HSBC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma. 3. Code: HSBC maps to the most appropriate cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HSBC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma. 3. Code: HSBC maps to the most appropriate cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HSBC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma. 3. Code: HSBC maps to the most appropriate cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HSBC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma. 3. Code: HSBC maps to the most appropriate cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HSBC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma. 3. Code: HSBC maps to the most appropriate cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HSBC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma. 3. Code: HSBC maps to the most appropriate cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HSBC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma. 3. Code: HSBC maps to the most appropriate cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HSBC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma. 3. Code: HSBC maps to the most appropriate cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HSBC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma. ",
      "predicted": "HSBC",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Cervix. 2. Findings: Squamous cell carcinoma. 3. Code: HSBC maps to the most appropriate cancer type.",
      "idx": 234,
      "timestamp": "2026-01-19T15:59:53.114064"
    },
    {
      "sample_idx": 1099,
      "input": "This is an invasive rectal carcinoma, in this case with medium-grade differentiation, of. the mucinous type (G 2), with infiltration of all layers of the wall (pT3), lymph vessel. invasions (L1), a lymph node metastasis (pN1, 1 of 12), free resection margins in the. region of the mucosa and a free ligature area.",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Invasive rectal carcinoma, mucinous type, G2, pT3, L1, N1. 3. Code: PRAD maps to Rectal Cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Invasive rectal carcinoma, mucinous type, G2, pT3, L1, N1. 3. Code: PRAD maps to Rectal Cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Invasive rectal carcinoma, mucinous type, G2, pT3, L1, N1. 3. Code: PRAD maps to Rectal Cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Invasive rectal carcinoma, mucinous type, G2, pT3, L1, N1. 3. Code: PRAD maps to Rectal Cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Invasive rectal carcinoma, mucinous type, G2, pT3, L1, N1. 3. Code: PRAD maps to Rectal Cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Invasive rectal carcinoma, mucinous type, G2, pT3, L1, N1. 3. Code: PRAD maps to Rectal Cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Invasive rectal carcinoma, mucinous type, G2, pT3, L1, N1. 3. Code: PRAD maps to Rectal Cancer.\"\n}\n```\n```",
      "predicted": "PRAD",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Rectum. 2. Findings: Invasive rectal carcinoma, mucinous type, G2, pT3, L1, N1. 3. Code: PRAD maps to Rectal Cancer.",
      "idx": 1099,
      "timestamp": "2026-01-19T15:59:53.114074"
    },
    {
      "sample_idx": 1339,
      "input": "Surgical Pathology Site Code. Endometrum. TISSUE DESCRIPTION. A1 J1 K1 L1 M1 M2 N1 01 P1 P2 P3 Q1 Q2 R1 S1 B1. C1 C2 C3. C4 C5 C6 C7 C8 C9 C10 D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11. E1 E2 E3 E4. E5 E6 E7 E8 E9 E10 E11 E12 F1 F2 G1 H1 Il. Uterus, right ovary (3.0 X 1.1 X 1.0 cm) with 9.0 cm. segment of. right fallopian tube, and 4.2 cm segment of left fallopian. tube. together weighing 120.0 grams; tissue from the bladder. peritoneum. (2.0 X 0.6 X 0.3 cm). i tissue from the left bladder. peritoneum ...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma, endometrioid type, forming a polypoid mass. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma, endometrioid type, forming a polypoid mass. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma, endometrioid type, forming a polypoid mass. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma, endometrioid type, forming a polypoid mass. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma, endometrioid type, forming a polypoid mass. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma, endometrioid type, forming a polypoid mass. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma, endometrioid type, forming a polypoid mass. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma, endometrioid type, forming a polypoid mass. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma, endometrioid type, forming a polypoid mass. 3. Code: UCEC.",
      "idx": 1339,
      "timestamp": "2026-01-19T15:59:53.114083"
    },
    {
      "sample_idx": 1381,
      "input": "8380/3 he. GYNS Adm: Ord #=. ASAP /RESULTED. Collect D/T=. Modifiers: (1 of 1). CoPath Specimen. Source: A: Uterus IT\\ Cervix. B: Left Pelvic lymph node. C: Left Peri-aortic lymph node. D: Right Pelvic lymph node. E: Right Peri-aortic lymph node. Final Diagnosis. A. Uterus and cervix (hysterectomy, 85 gm). - Polypoid adenocarcinoma, endometrioid type, FIGO grade 2-3,. 1.6 X 1.5 X 1.0 cm. - Tumor shows superficial myometrial invasion involving 78 of. myometrial wall thickness (0.1 cm /1.4 cm). - ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus and cervix. 2. Findings: Endometrial adenocarcinoma, FIGO grade 2-3, with myometrial invasion. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left pelvic lymph node. 2. Findings: Negative for malignancy. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left periaortic lymph node. 2. Findings: Negative for malignancy. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right pelvic lymph node. 2. Findings: Negative for malignancy. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right periaortic lymph node. 2. Findings: Negative for malignancy. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus and cervix. 2. Findings: Polypoid adenocarcinoma, endometrioid type, FIGO grade 2-3. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus and cervix. 2. Findings: Polypoid adenocarcinoma, endometrioid type, FIGO grade 2-3. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus and cervix. 2. Findings: Polypoid adenocarcinoma, endometrioid type, FIGO grade ",
      "predicted": "KIRC",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Uterus and cervix. 2. Findings: Endometrial adenocarcinoma, FIGO grade 2-3, with myometrial invasion. 3. Code: KIRC.",
      "idx": 1381,
      "timestamp": "2026-01-19T15:59:53.114093"
    },
    {
      "sample_idx": 1413,
      "input": "[D:EAADA209-BED3-4FA3-B39C-2428BF278EF7. HISTOPATHOLOGY. Lab No. Clinical Consultant & Location. Unit No. SPECIMEN. RIGHT GLOBE ENUCLEATION, PROGNOSTIC AND DIAGNOSTIC. CLINICAL DETAILS. See diagram. Measurements 10.63 x 10.18 x (10.37) mm. MACROSCOPIC DESCRIPTION. A fresh, intact, right globe. Dimensions: Axial 25mm, Horizontal 23.5mm, Vertical 24mm. Cornea: Horizontal 12.5mm, Vertical 12mm. Optic nerve: flesh. On trans-illumination, a shadow is seen in the inferolateral. position, approx 13mm. ...",
      "response": "```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Eye (Right Globe Enucleation). 2. Findings: Choroidal melanoma, spindle cell type. 3. Code: SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Eye (Right Globe Enucleation). 2. Findings: Choroidal melanoma, spindle cell type. 3. Code: SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Eye (Right Globe Enucleation). 2. Findings: Choroidal melanoma, spindle cell type. 3. Code: SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Eye (Right Globe Enucleation). 2. Findings: Choroidal melanoma, spindle cell type. 3. Code: SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Eye (Right Globe Enucleation). 2. Findings: Choroidal melanoma, spindle cell type. 3. Code: SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Eye (Right Globe Enucleation). 2. Findings: Choroidal melanoma, spindle cell type. 3. Code: SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Eye (Right Globe Enucleation). 2. Findings: Choroidal melanoma, spindle cell type. 3. Code: SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Eye (Right Globe Enucleation). 2. Findings: Choroidal melanoma, spindle cell type. 3. Code: SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Eye (Right Globe Enucle",
      "predicted": "SKCM",
      "ground_truth": "UVM",
      "correct": false,
      "reasoning": "1. Site: Eye (Right Globe Enucleation). 2. Findings: Choroidal melanoma, spindle cell type. 3. Code: SKCM.",
      "idx": 1413,
      "timestamp": "2026-01-19T15:59:53.114103"
    },
    {
      "sample_idx": 601,
      "input": "FINAL SURGICAL PATHOLOGY REPORT. Diagnosis: A. LEFT KIDNEY MASS, PARTIAL NEPHRECTOMY: - Papillary renal cell carcinoma, Fuhrman nuclear grade 2. - Multifocal, largest focus 2.5 cm. - Surgical margin POSITIVE at parenchymal cauterized margin. PATHOLOGIC TUMOR STAGING SYNOPSIS (KIDNEY): Type and grade: Papillary renal cell carcinoma, type I, Fuhrman nuclear. grade 2. Primary tumor: pT1a. Regional lymph nodes: pNX. Distant metastasis: pMX. Pathologic stage: I. Lymphovascular invasion: Not identifie...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3 + 4 = 7. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3 + 4 = 7. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3 + 4 = 7. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade II. 3. Code: KIRC.",
      "idx": 601,
      "timestamp": "2026-01-19T15:59:53.114115"
    },
    {
      "sample_idx": 890,
      "input": "Pathology Report-Summary: Material: lung, right, lower lobe: 19.0 X 13.0 X 8.0 cm. tumor: 3.5 X 2.0 X 2.2 cm. Diagnosis: Squamous Cell Carcinoma, basaloid. pT2a, pNO (0/38), pMx, G3.",
      "response": "```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Lung, lower lobe. 2. Findings: Squamous cell carcinoma, basaloid type, pT2a, pNO (0/38), pMx, G3. 3. Code: Squamous Cell Carcinoma maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, lower lobe. 2. Findings: Squamous cell carcinoma, basaloid type, pT2a, pNO (0/38), pMx, G3. 3. Code: Squamous Cell Carcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Lung, lower lobe. 2. Findings: Squamous cell carcinoma, basaloid type, pT2a, pNO (0/38), pMx, G3. 3. Code: Squamous Cell Carcinoma maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Lung, lower lobe. 2. Findings: Squamous cell carcinoma, basaloid type, pT2a, pNO (0/38), pMx, G3. 3. Code: Squamous Cell Carcinoma maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Lung, lower lobe. 2. Findings: Squamous cell carcinoma, basaloid type, pT2a, pNO (0/38), pMx, G3. 3. Code: Squamous Cell Carcinoma maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Lung, lower lobe. 2. Findings: Squamous cell carcinoma, basaloid type, pT2a, pNO (0/38), pMx, G3. 3. Code: Squamous Cell Carcinoma maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reason",
      "predicted": "SCC",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung, lower lobe. 2. Findings: Squamous cell carcinoma, basaloid type, pT2a, pNO (0/38), pMx, G3. 3. Code: Squamous Cell Carcinoma maps to SCC.",
      "idx": 890,
      "timestamp": "2026-01-19T15:59:53.114126"
    },
    {
      "sample_idx": 323,
      "input": "SPECIMEN. Right colon. CLINICAL NOTES. PRE-OP DIAGNOSIS: Colon cancer. GROSS DESCRIPTION. Received fresh, subsequently fixed in formalin labelled. \"right colon\" which is partially covered with pink-tan. smooth glistening serosa and yellow lobular fat. The specimen. shows. a 6.5 X 0.7 cm appendix and the specimen is predominately covered. with abundant yellow lobular fat. The specimen is opened and has. a. 6.5 cm portion of small bowel and 26 cm of cecum and colon The. specimen shows a large ecto...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with invasion through the muscularis propria, into the subserosal fat (pT3). Margins of excision negative. One of twenty-nine lymph nodes with metastatic carcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with invasion through the muscularis propria, into the subserosal fat (pT3). Margins of excision negative. One of twenty-nine lymph nodes with metastatic carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with invasion through the muscularis propria, into the subserosal fat (pT3). Margins of excision negative. One of twenty-nine lymph nodes with metastatic carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with invasion through the muscularis propria, into the subserosal fat (pT3). Margins of excision negative. One of twenty-nine lymph nodes with metastatic carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with invasion through the muscularis propria, into the subserosal fat (pT3). Margins of excision negative. One of twenty-nine lymph nodes with metastatic carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with invasion through the muscularis propria, into the subserosal fat (pT3). Margins of excision negative. One of twenty-nine lymph nodes with metastatic carcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.",
      "idx": 323,
      "timestamp": "2026-01-19T15:59:53.114139"
    },
    {
      "sample_idx": 929,
      "input": "Accessioned. DIAGNOSIS: OVARIES, LEFT, PROCEDURE NOT STATED (INCLUDING FS1). HIGH GRADE SEROUS CARCINOMA WITH EXTENSIVE SURFACE INVOLVEMENT. SEE SYNOPSIS. FALLOPIAN TUBE, LEFT, PROCEDURE NOT STATED. - HIGH GRADE SEROUS CARCINOMA INVOLVING FALLOPIAN TUBE LUMEN. OVARIES, RIGHT, PROCEDURE NOT STATED (INCLUDING FS1). - HIGH GRADE SEROUS CARCINOMA WITH EXTENSIVE SURFACE INVOLVEMENT. FALLOPIAN TUBES, BILATERAL, PROCEDURE NOT STATED. - HIGH GRADE SEROUS CARCINOMA INVOLVING FIMBRIA, LYMPHOVASCULAR SPACE...",
      "response": "```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovaries, Left. 2. Findings: High grade serous carcinoma, involving the fallopian tube lumen and surrounding tissues. 3. Code: OV maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus and Cervix. 2. Findings: High grade serous carcinoma involving the uterine serosa and outer myometrium. 3. Code: UCEC maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Large Intestine, Rectal Tumor. 2. Findings: High grade serous carcinoma. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Soft Tissue, Falciform Ligament. 2. Findings: High grade serous carcinoma. 3. Code: ESCA maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Soft Tissue, Gastric Follic Omentum. 2. Findings: High grade serous carcinoma. 3. Code: ESCA maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Soft Tissue, Lesser Curvature of Stomach. 2. Findings: High grade serous carcinoma. 3. Code: ESCA maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Large Intestine, Rectal Tumor. 2. Findings: High grade serous carcinoma. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Large Intestine, Rectal Tumor. 2. Findings: High grade serous carcinoma. 3. Code: KIRC maps to KIRC.\"\n}\n",
      "predicted": "OV",
      "ground_truth": "OV",
      "correct": true,
      "reasoning": "1. Site: Ovaries, Left. 2. Findings: High grade serous carcinoma, involving the fallopian tube lumen and surrounding tissues. 3. Code: OV maps to OV.",
      "idx": 929,
      "timestamp": "2026-01-19T15:59:53.114150"
    },
    {
      "sample_idx": 6,
      "input": "General Pathologic Examination. This autopsy study was done for research purposes only and should therefore not be considered to be definitive or. exhaustive. EXTERNAL EXAM: The body is that of a middle-aged, moderately obese Caucasian female, measuring 165 cm in. length. The body is identified by ID bracelets about the left wrist and left ankle. Rigor mortis is not established and there. is dependent lividity. The normocephalic head has been recently shaved or cut very close to the scalp. The e...",
      "response": "```json\n{\n    \"cancer_type\": \"ADCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenal cortical carcinoma with metastasis to the liver. 3. Code: ADCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Acute bronchopneumonia with coccoid bacteria. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Benign breast tissue with small complex sclerosing lesion (radial scar) and usual duct hyperplasia. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Metastasis to the liver from adrenal cortical carcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenal cortical carcinoma. 3. Code: ADCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Acute bronchopneumonia. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Metastasis to the liver. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Acute bronchopneumonia. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Metastasis to the liver. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\":",
      "predicted": "ADCA",
      "ground_truth": "ACC",
      "correct": false,
      "reasoning": "1. Site: Adrenal gland. 2. Findings: Adrenal cortical carcinoma with metastasis to the liver. 3. Code: ADCA.",
      "idx": 6,
      "timestamp": "2026-01-19T15:59:53.114161"
    },
    {
      "sample_idx": 539,
      "input": "Clinical Diagnosis & History: with right renal mass. Specimens Submitted: 1: SP: Kidney, right, nephrectomy. DIAGNOSIS: 1. SP: Kidney, right, nephrectomy. Tumor Type: Renal cell carcinoma - Conventional (clear cell) type. Fuhrman Nuclear Grade: Nuclear grade II/IV. Tumor Size: Greatest diameter is 4.5 cm. Local Invasion (for renal cortical types): Not Identified. Renal Vein Invasion: Not identified. Surgical Margins: Free of tumor. Non-Neoplastic Kidney: Unremarkable. Adrenal Gland: Not identifi...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 539,
      "timestamp": "2026-01-19T15:59:53.114172"
    },
    {
      "sample_idx": 1025,
      "input": "Service Date: Male. Soc. Sec. #: Client: FINAL PATHOLOGIC DIAGNOSIS. Prostate and seminal vesicles, prostatectomy: 1. Prostatic adenocarcinoma, Gleason score 3+3 = 6; see comment. 2. Seminal vesicles with no tumor. COMMENT: Synoptic Comment for Prostate Tumors. - Type of tumor: Small acinar adenocarcinoma. - Location of tumor: Left posterior midgland, slides A5, A9-A10; left anterior midgland, slides A5,. A7-A8; right posterior apex, slide A2; right posterior midgland, slide A4, A6, A11-A12; rig...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3+3 = 6; see comment. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3+3 = 6; see comment. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3+3 = 6; see comment. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3+3 = 6; see comment. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3+3 = 6; see comment. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3+3 = 6; see comment. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3+3 = 6; see comment. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",",
      "predicted": "KIRC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3+3 = 6; see comment. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 1025,
      "timestamp": "2026-01-19T15:59:53.114183"
    },
    {
      "sample_idx": 365,
      "input": "Surgical Patholoay Report. CLINICAL HISTORY. Right temporal tumor. OPERATIVE DIAGNOSES. Operation/Specimen: A: Brain, right temporal, excision biopsy. B: Brain, excision biopsy. PATHOLOGICAL DIAGNOSIS: and B. Brain, right temporal tumor, excisional biopsies: Glioblastoma (WHO. rade IV) (see comment) . COMMENT. Sections show a moderately pleomorphic glioma demonstrating frequent mitotic. figures, vascular proliferation and necrosis. The tumor cells are diffusely p53 positive and the K-67 labeling...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right temporal. 2. Findings: Glioblastoma (WHO grade IV). 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MGMT\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: MGMT promoter methylation. 3. Code: MGMT maps to MGMT.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"EGFR\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: EGFRVIII assay. 3. Code: EGFR maps to EGFR.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"P53\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: P53 positive. 3. Code: P53 maps to P53.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma (WHO grade IV). 3. Code: Glioblastoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MGMT\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: MGMT promoter methylation. 3. Code: MGMT maps to MGMT.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"EGFR\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: EGFRVIII assay. 3. Code: EGFR maps to EGFR.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"P53\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: P53 positive. 3. Code: P53 maps to P53.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MGMT\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: MGMT promoter methylation. 3. Code: MGMT maps to MGMT.\"\n}\n```\n```json\n{\n    \"cancer_type",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain, right temporal. 2. Findings: Glioblastoma (WHO grade IV). 3. Code: Glioblastoma maps to GBM.",
      "idx": 365,
      "timestamp": "2026-01-19T15:59:53.114193"
    },
    {
      "sample_idx": 1039,
      "input": "PATIENT HISTORY: The patient has a history of PSA value of 7.4,. right inguinal hernia done in an open fashion. with mesh and spinal stenosis. The patient also has a history of biopsy ont. this biopsy reveals unilateral poorly. differentiated prostatic adenocarcinoma of the right side. PRE-OP DIAGNOSIS: Prostate cancer. POST-OP DIAGNOSIS: Same. PROCEDURE: Radical retropubic prostatectomy. FINAL DIAGNOSIS: PART 1: LYMPH NODES, RIGHT PELVIC, EXCISION -. NO EVIDENCE OF METASTASIS IN FIVE LYMPH NODE...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Invasive poorly differentiated adenocarcinoma, Gleason score 4+5=9. 3. Code: Prostate Cancer maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UROS\",\n    \"reasoning\": \"1. Site: Right Pelvic Lymph Nodes. 2. Findings: Lymph node metastasis, no evidence of metastasis in the other lymph nodes. 3. Code: Lymph Node metastasis maps to UROS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Invasive poorly differentiated adenocarcinoma, Gleason score 4+5=9. 3. Code: Prostate Cancer maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Invasive poorly differentiated adenocarcinoma, Gleason score 4+5=9. 3. Code: Prostate Cancer maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Invasive poorly differentiated adenocarcinoma, Gleason score 4+5=9. 3. Code: Prostate Cancer maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Invasive poorly differentiated adenocarcinoma, Gleason score 4+5=9. 3. Code: Prostate Cancer maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Invasive poorly differentiated adenocarcinoma, Gleason score 4+5=9. 3. Code: Prostate Cancer maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Invasive poorly differentiated adenocarcinoma, Gleason score 4+5=9. 3. Code: Prostate Cancer maps to PRAD.\"",
      "predicted": "PRAD",
      "ground_truth": "PRAD",
      "correct": true,
      "reasoning": "1. Site: Prostate. 2. Findings: Invasive poorly differentiated adenocarcinoma, Gleason score 4+5=9. 3. Code: Prostate Cancer maps to PRAD.",
      "idx": 1039,
      "timestamp": "2026-01-19T15:59:53.114204"
    },
    {
      "sample_idx": 217,
      "input": "Surgica. CLINICAL HISTORY: Not provided. GROSS EXAMINATION: Estrogen receptor tissue sent for estrogen and progesterone receptor. A. \"Tru-cut breast biopsy. Received fresh. The specimen is a 1 cm x 0.1. cm tan piece of breast tissue. This frozen as frozen section AF1. The. frozen section remnant consists of two pieces of tan tissue measuring 0.8. x. 0.1 x 0.1 and 0.7 x 0.1 x 0.1 cm. They are submitted in toto in Block A1. B. \"Right breast. Received fresh. The specimen consists of breast with an....",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NSABP histologic grade 3, nuclear grade moderately differentiated. Tumor size is 1.5 x 2.8 x 1.0 cm. Vascular invasion is present. 6 of 15 lymph nodes contain metastatic carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NSABP histologic grade 3, nuclear grade moderately differentiated. Tumor size is 1.5 x 2.8 x 1.0 cm. Vascular invasion is present. 6 of 15 lymph nodes contain metastatic carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NSABP histologic grade 3, nuclear grade moderately differentiated. Tumor size is 1.5 x 2.8 x 1.0 cm. Vascular invasion is present. 6 of 15 lymph nodes contain metastatic carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NSABP histologic grade 3, nuclear grade moderately differentiated. Tumor size is 1.5 x 2.8 x 1.0 cm. Vascular invasion is present. 6 of 15 lymph nodes contain metastatic carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NSABP histologic grade 3, nuclear grade moderately differentiated. Tumor size is 1.5 x 2.8 x 1.0 cm. Vascular invasion is present. 6 of 15 lymph nodes contain metastatic carcinoma. 3. Code: Breast Invasive Carcinoma maps",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NSABP histologic grade 3, nuclear grade moderately differentiated. Tumor size is 1.5 x 2.8 x 1.0 cm. Vascular invasion is present. 6 of 15 lymph nodes contain metastatic carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 217,
      "timestamp": "2026-01-19T15:59:53.114217"
    },
    {
      "sample_idx": 611,
      "input": "Pre-Operative/Clinical History. Left renal mass. Specimen(s) Received. A: MARGIN - BASE OF TUMOR, LEFT KIDNEY MASS. B: LEFT RENAL MASS. Gross Description. Specimen A, received fresh for frozen section labeled margin (base) of tumor, left kidney mass, consists of three friable,. tan soft tissue fragments that measure 0.2 to 0.5 cm in greatest dimension. The fragments are entirely submitted for. frozen section in (A1 FS. Specimen B, received in formalin labeled left renal mass, consists of a 12 gm...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Grade I. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Grade I. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Grade I. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Grade I. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Grade I. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Grade I. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Grade I. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Grade I. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Grade I. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 611,
      "timestamp": "2026-01-19T15:59:53.114228"
    },
    {
      "sample_idx": 1263,
      "input": "FINAL DIAGNOSIS. A) Left thyroid lobe and isthmus: Papillary thyroid carcinoma forming a 3.5. cm in greatest dimension tumor mass. The thyroid carcinoma focally. invades through the capsule into the extracapsular soft tissue. Inked. surgical margins of resection are free of tumor. Areas of chronic. thyroiditis are also noted. B) Left paratracheal nodes: Metastatic papillary thyroid carcinoma. involving one out of one lymph node (1/1). C) Pretracheal lymph nodes: Metastatic papillary thyroid carc...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left thyroid lobe and isthmus. 2. Findings: Papillary thyroid carcinoma, forming a 3.5 cm tumor mass. The tumor focally invades through the capsule into the extracapsular soft tissue. Surgical margins are free of tumor. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) is the most appropriate TCGA code given the presence of thyroid carcinoma and its invasion. The thyroid carcinoma is classified as pT3, indicating extension beyond the thyroid gland, and the lymph nodes are involved (pN1a). While this is not kidney cancer, the TCGA code is determined by the primary cancer type, which is the thyroid carcinoma in this case.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA (Breast Invasive Carcinoma) is the most appropriate TCGA code given the presence of breast cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left thyroid lobe and isthmus. 2. Findings: Papillary thyroid carcinoma, forming a 3.5 cm tumor mass. The tumor focally invades through the capsule into the extracapsular soft tissue. Surgical margins are free of tumor. Areas of chronic thyroiditis are also noted. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) is the most appropriate TCGA code given the presence of thyroid carcinoma and its invasion. The thyroid carcinoma is classified as pT3, indicating extension beyond the thyroid gland, and the lymph nodes are involved (pN1a). While this is not kidney cancer, the TCGA code is determined by the primary cancer type, which is the thyroid carcinoma in this case.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left paratracheal nodes. 2. Findings: Metastatic papillary thyroid carcinoma. involving one out of one lymph node (1/1). 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) is the most appropriate TCGA code given the presence of thyroid carcinoma and its invasion. The thyroid",
      "predicted": "KIRC",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Left thyroid lobe and isthmus. 2. Findings: Papillary thyroid carcinoma, forming a 3.5 cm tumor mass. The tumor focally invades through the capsule into the extracapsular soft tissue. Surgical margins are free of tumor. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) is the most appropriate TCGA code given the presence of thyroid carcinoma and its invasion. The thyroid carcinoma is classified as pT3, indicating extension beyond the thyroid gland, and the lymph nodes are involved (pN1a). While this is not kidney cancer, the TCGA code is determined by the primary cancer type, which is the thyroid carcinoma in this case.",
      "idx": 1263,
      "timestamp": "2026-01-19T15:59:53.114249"
    },
    {
      "sample_idx": 1336,
      "input": "9196817048. p.1. CLINICAL HISTORY: Abnormal uterine bleeding, post mehopausal. Malignant neoplasm corpus uteri. Per E-browser, EMB-endometrioid adlenocarcinoma FIGO 1. GROSS EXAMINATION: A. \"Uterus, cervix, bilateral tubes and ovaries (AF1-2)\" received fresh for. frozen section ils a 194 gram, 12. a x 17.6 x 4.3 cru uterus with attached. bilateral ovaries. The anterior Hesection margin is inked blue and the. posterior resection margin is ink\u00e4d black. The uterus (119 gram, 12.2 x 11.2. x 4.3 cm) ...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma, FIGO grade 2, tumor size 7.2 x 4.9 x 2.5 cm, maximum depth of myometrial invasion 0.5 cm, lymphatic/vascular invasion negative. 3. Code: UCEC maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma, FIGO grade 2, tumor size 7.2 x 4.9 x 2.5 cm, maximum depth of myometrial invasion 0.5 cm, lymphatic/vascular invasion negative. 3. Code: UCEC maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma, FIGO grade 2, tumor size 7.2 x 4.9 x 2.5 cm, maximum depth of myometrial invasion 0.5 cm, lymphatic/vascular invasion negative. 3. Code: UCEC maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma, FIGO grade 2, tumor size 7.2 x 4.9 x 2.5 cm, maximum depth of myometrial invasion 0.5 cm, lymphatic/vascular invasion negative. 3. Code: UCEC maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma, FIGO grade 2, tumor size 7.2 x 4.9 x 2.5 cm, maximum depth of myometrial invasion 0.5 cm, lymphatic/vascular invasion negative. 3. Code: UCEC maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    ",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma, FIGO grade 2, tumor size 7.2 x 4.9 x 2.5 cm, maximum depth of myometrial invasion 0.5 cm, lymphatic/vascular invasion negative. 3. Code: UCEC maps to UCEC.",
      "idx": 1336,
      "timestamp": "2026-01-19T15:59:53.114261"
    },
    {
      "sample_idx": 1392,
      "input": "Copies To: Date Received. Addendum - Please See End of Report. Reason for Addendum #1: Additional sections or studies. DIAGNOSIS: A. RIGHT OVARY AND FALLOPIAN TUBE (SALPINGO-OOPHORECTOMY): -Benign ovary with corpora albicantia, rare calcification, and rare multinucleated giant cell. -Benign fallopian tube with hydrosalpinx, small focus suggestive of endometriosis, and serosal. adhesions with reactive mesothelial cells. B. UTERUS AND CERVIX (TOTAL HYSTERECTOMY): -Endometrial carcinoma with endome...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\":",
      "predicted": "BRCA",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1392,
      "timestamp": "2026-01-19T15:59:53.114271"
    },
    {
      "sample_idx": 1290,
      "input": "ADDENDA: Addendum. MOLECULAR ANATOMIC PATHOLOGY TESTING: 1.4 cm tumor: A. NRAS codon 61 mutation IDENTIFIED. B. Mutations in BRAF, HRAS61, KRAS12/13 and RET/PTC1 and RET/PTC3 rearrangements. NOT identified. NOTE: Nucleic acids were extracted in the amount sufficient for testing. 1.0 cm tumor: Mutational status for BRAF, NRAS61, HRAS61, KRAS12/13 and RET/PTC1 and RET/PTC3 rearrangements is. INDETERMINATE due to Insufficient material for testing. NOTE: Low concentration of nucleic acids was extrac...",
      "response": "```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, two foci (1.4 cm and 1.0 cm) in the right lobe and isthmus, confined to the thyroid. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: The thyroidectomy removed the entire thyroid gland, and the tumor is confined to the thyroid. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, two foci (1.4 cm and 1.0 cm) in the right lobe and isthmus, confined to the thyroid. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, two foci (1.4 cm and 1.0 cm) in the right lobe and isthmus, confined to the thyroid. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, two foci (1.4 cm and 1.0 cm) in the right lobe and isthmus, confined to the thyroid. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, two foci (1.4 cm and 1.0 cm) in the right lobe and isthmus, confined to the thyroid. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1",
      "predicted": "THCA",
      "ground_truth": "THCA",
      "correct": true,
      "reasoning": "1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, two foci (1.4 cm and 1.0 cm) in the right lobe and isthmus, confined to the thyroid. 3. Code: Thyroid Carcinoma maps to THCA.",
      "idx": 1290,
      "timestamp": "2026-01-19T15:59:53.114282"
    },
    {
      "sample_idx": 765,
      "input": "Anat Path Reports. Document Date: APRPT (Verified). Acc #: M. Client: Submitting. Phys: Final Surgical Pathology Report. Final Pathologic Diagnosis. A. 10R LYMPH NODE, EXCISION, A1FS: - NO METASTATIC CARCINOMA IN FRAGMENTED LYMPH NODAL TISSUE. B. LUNG, RIGHT UPPER LOBE, LOBECTOMY, B1FS: - MODERATELY DIFFERENTIATED ADENOCARCINOMA (1.7 X 1.7 X 2.5 CM). - NO PLEURAL INVOLVEMENT. - COMPLETELY EXCISED. - EMPHYSEMA. C. 11R LYMPH NODE, EXCISION: NO METASTATIC CARCINOMA IN FRAGMENTED LYMPH NODAL TISSUE....",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, right upper lobe. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUNG\",\n    \"reasoning\": \"1. Site: Lung, right upper lobe. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: LUNG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUNG\",\n    \"reasoning\": \"1. Site: Lung, right upper lobe. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: LUNG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUNG\",\n    \"reasoning\": \"1. Site: Lung, right upper lobe. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: LUNG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUNG\",\n    \"reasoning\": \"1. Site: Lung, right upper lobe. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: LUNG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUNG\",\n    \"reasoning\": \"1. Site: Lung, right upper lobe. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: LUNG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUNG\",\n    \"reasoning\": \"1. Site: Lung, right upper lobe. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: LUNG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUNG\",\n    \"reasoning\": \"1. Site: Lung, right upper lobe. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: LUNG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUNG\",\n    \"reasoning\": \"1. Site: Lung, right upper lobe. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: LUNG.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung, right upper lobe. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: LUAD.",
      "idx": 765,
      "timestamp": "2026-01-19T15:59:53.114292"
    },
    {
      "sample_idx": 330,
      "input": "PATHOLOGIC DIAGNOSIS: SPECIMEN DESIGNATED \"RIGHT COLON\" (44 cm) : ADENOCARCINOMA, moderately differentiated (3.0 cm). Tumor is located in the cecum, forms a polypoid mass,. and is ulcerative. Tumor invades into but not through the muscularis propria. Proximal, distal, and radial resection margins are negative. for tumor. Intramural lymphovascular invasion is not identified. Perineural invasion is not identified. Peritumoral response is mild. Residual adenoma is present. Hyperplastic polyps,. Mul...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.",
      "idx": 330,
      "timestamp": "2026-01-19T15:59:53.114309"
    },
    {
      "sample_idx": 1104,
      "input": "SPECIMEN. A. Right uterine adnexa. B. Sigmoid and upper half rectum. C. Appendix. CLINICAL NOTES. PRE-OP DIAGNOSIS: Rectosigmoid cancer. FROZEN SECTION DIAGNOSIS. A. Ovary, right, resection: Mucinous cystic neoplasm. Negative. for malignancy on frozen section. GROSS DESCRIPTION. A. The specimen is received unfixed labelled \"right. uterine adnexa\" and consists of a pink uterine tube. measuring 4 cm in length and 0.7 cm in diameter. There is adjacent. tan ovary measuring 2.5 X 1.3 cm with a contai...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Colonic adenocarcinoma, invasive, grade 1-2. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Mucinous cystadenoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Appendix. 2. Findings: Fibrous obliteration of the distal appendiceal lumen. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Colonic adenocarcinoma, invasive, grade 1-2. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Mucinous cystadenoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Appendix. 2. Findings: Fibrous obliteration of the distal appendiceal lumen. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Colonic adenocarcinoma, invasive, grade 1-2. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Mucinous cystadenoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Appendix. 2. Findings: Fibrous obliteration of the distal appendiceal lumen. 3. Code: KIRC.\"\n}\n```\n```json\n",
      "predicted": "KIRC",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Rectum. 2. Findings: Colonic adenocarcinoma, invasive, grade 1-2. 3. Code: KIRC.",
      "idx": 1104,
      "timestamp": "2026-01-19T15:59:53.114319"
    },
    {
      "sample_idx": 1086,
      "input": "Diagnosis: Resection material from rectosigmoid colon with inclusion of an ulcerated, moderately. differentiated adenocarcinoma of the colorectal type 4.5 cm from the aboral resection. margin and with infiltration of the perirectal fatty tissue and four regional lymph node. metastases. Tumor-free circumferential resection margin. Tumor-free colon resection. margins. Tumor-free mesenteric resection margin. Tumor stage: pT3 pN2 (4/42) pMX; G2, L1, V0, locally R0.",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, colorectal type, ulcerated, moderately differentiated, 4.5 cm from the aboral resection margin, with infiltration of the perirectal fatty tissue and four regional lymph node metastases. 3. Code: COAD maps to Colorectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, colorectal type, ulcerated, moderately differentiated, 4.5 cm from the aboral resection margin, with infiltration of the perirectal fatty tissue and four regional lymph node metastases. 3. Code: COAD maps to Colorectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, colorectal type, ulcerated, moderately differentiated, 4.5 cm from the aboral resection margin, with infiltration of the perirectal fatty tissue and four regional lymph node metastases. 3. Code: COAD maps to Colorectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, colorectal type, ulcerated, moderately differentiated, 4.5 cm from the aboral resection margin, with infiltration of the perirectal fatty tissue and four regional lymph node metastases. 3. Code: COAD maps to Colorectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, colorectal type, ulcerated, moderately differentiated, 4.5 cm from the aboral resection margin, with infiltration of the perirectal fatty tissue and four regional lymph node metastases. 3. Code: COAD maps to Colorectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rect",
      "predicted": "COAD",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, colorectal type, ulcerated, moderately differentiated, 4.5 cm from the aboral resection margin, with infiltration of the perirectal fatty tissue and four regional lymph node metastases. 3. Code: COAD maps to Colorectal Adenocarcinoma.",
      "idx": 1086,
      "timestamp": "2026-01-19T15:59:53.114335"
    },
    {
      "sample_idx": 1,
      "input": "OPER DATE: PROCEDURE: APMI. ADDENDUM TO REPORT CHANGE IN MARGIN STATUS AFTER DISCUSSION WITH SURGEON: Please see revised template and revised diagnosis below. ADRENOCORTICAL CARCINOMA. V4. Tumor Size: 17.1 x 12.5 x 10.3 cm. Tumor Weight: Cannot determine. Capsular Invasion: Yes. Vascular Invasion: Yes. Surgical Margins: Negative. Necrosis: 75% (gross). Mitotic Rate: 60/50 hps. Grade: High. Lymph nodes status: 1/2. Extra-adrenal extension: Present. Stage: 4 (pT3 N1 M1). Immunohistochemistry Resul...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right adrenal and kidney. 2. Findings: High-grade adrenocortical carcinoma with capsular and extensive vascular invasion, including invasion of the vena cava. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Right adrenal and kidney. 2. Findings: High-grade adrenocortical carcinoma with capsular and extensive vascular invasion, including invasion of the vena cava. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right adrenal and kidney. 2. Findings: High-grade adrenocortical carcinoma with capsular and extensive vascular invasion, including invasion of the vena cava. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right adrenal and kidney. 2. Findings: High-grade adrenocortical carcinoma with capsular and extensive vascular invasion, including invasion of the vena cava. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right adrenal and kidney. 2. Findings: High-grade adrenocortical carcinoma with capsular and extensive vascular invasion, including invasion of the vena cava. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right adrenal and kidney. 2. Findings: High-grade adrenocortical carcinoma with capsular and extensive vascular invasion, including invasion of the vena cava. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right adrenal and kidney. 2. Findings: High-grade adrenocortical carcinoma with capsular and extensive vascular invasion, including invasion of the vena cava. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_",
      "predicted": "KIRC",
      "ground_truth": "ACC",
      "correct": false,
      "reasoning": "1. Site: Right adrenal and kidney. 2. Findings: High-grade adrenocortical carcinoma with capsular and extensive vascular invasion, including invasion of the vena cava. 3. Code: KIRC.",
      "idx": 1,
      "timestamp": "2026-01-19T15:59:53.114346"
    },
    {
      "sample_idx": 1226,
      "input": "Pathohistological diagnosis. Seminoma testis (pT2 NXMX). Description: Testicle with cut tumor, size 8:6:5 cm, and 8 cm long funiculus was received. The tumor has. irregular edges, is white to brown in color, of medium consistency and is 8:5:4 cm in size. Histologically, the tumor is made of solid seats and tumor cell traces with round and oval. bright nuclei in which we see small nuclei and scarce, bright and pink cytoplasm. Inside the. tumor, at microscope's large visual field, we see 3-4 mitos...",
      "response": "```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma, testicular germ cell tumor. 3. Code: Seminoma testis maps to TGCT.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma, testicular germ cell tumor. 3. Code: Seminoma testis maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma, testicular germ cell tumor. 3. Code: Seminoma testis maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma, testicular germ cell tumor. 3. Code: Seminoma testis maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma, testicular germ cell tumor. 3. Code: Seminoma testis maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma, testicular germ cell tumor. 3. Code: Seminoma testis maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma, testicular germ cell tumor. 3. Code: Seminoma testis maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma, testicular germ cell tumor. 3. Code: Seminoma testis maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Testis. 2.",
      "predicted": "TGCT",
      "ground_truth": "TGCT",
      "correct": true,
      "reasoning": "1. Site: Testis. 2. Findings: Seminoma, testicular germ cell tumor. 3. Code: Seminoma testis maps to TGCT.",
      "idx": 1226,
      "timestamp": "2026-01-19T15:59:53.114356"
    },
    {
      "sample_idx": 663,
      "input": "Procedur. Report S. Final Diagnosis: A. Brain, right frontal mass, biopsy: Anaplastic oligodendroglioma (WHO grade III), see comment. Seen in consultation wit. Comment: The tumor is clinically recurrent and in progression from a WHO grade II glioma 1p19q codeleted. diagnosed. IDH1(R132H) stain will be obtained and findings will be reported as an addendum. ADDENDA: The neoplastic cells are negative for IDH1 (R132H) immunostain. continued next page. Preliminary Frozen Section Consultation: A. Brai...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontal mass. 2. Findings: Anaplastic oligodendroglioma (WHO grade III). 3. Code: Brain, right frontal mass maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontal mass. 2. Findings: Anaplastic oligodendroglioma (WHO grade III). 3. Code: Brain, right frontal mass maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontal mass. 2. Findings: Anaplastic oligodendroglioma (WHO grade III). 3. Code: Brain, right frontal mass maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontal mass. 2. Findings: Anaplastic oligodendroglioma (WHO grade III). 3. Code: Brain, right frontal mass maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontal mass. 2. Findings: Anaplastic oligodendroglioma (WHO grade III). 3. Code: Brain, right frontal mass maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontal mass. 2. Findings: Anaplastic oligodendroglioma (WHO grade III). 3. Code: Brain, right frontal mass maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontal mass. 2. Findings: Anaplastic oligodendroglioma (WHO grade III). 3. Code: Brain, right frontal mass maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontal mass. 2. Findings",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain, right frontal mass. 2. Findings: Anaplastic oligodendroglioma (WHO grade III). 3. Code: Brain, right frontal mass maps to GBM.",
      "idx": 663,
      "timestamp": "2026-01-19T15:59:53.114367"
    },
    {
      "sample_idx": 1000,
      "input": "Unique Patient Identifler: Short descriptive translation of the pathology report as provided by the. Material received: Material: left Adrenal gland. Right adrenal gland. Macroscopic findings: 1. A 14 x 8 x 4 cm specimen. On the cutted surface a tumor surrounded by a fatty-connective. tissue capsule with a soft, partially cystic appearence with hemorrhage (202g). 2. Left adrenal: A 2 x 2 x 1 cm specimen (2 g). On the cutted surface yellow, lobulated fatty. tissue and normal adrenal tissue with z...",
      "response": "```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, with lymphatic invasion. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Right). 2. Findings: Normal adrenal tissue. 3. Code: Normal adrenal tissue maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, with lymphatic invasion. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Right). 2. Findings: Normal adrenal tissue. 3. Code: Normal adrenal tissue maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, with lymphatic invasion. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Right). 2. Findings: Normal adrenal tissue. 3. Code: Normal adrenal tissue maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, with lymphatic invasion. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Right). 2. Findings: Normal adrenal tissue. 3. Code: Normal adrenal tissue maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n",
      "predicted": "PHCG",
      "ground_truth": "PCPG",
      "correct": false,
      "reasoning": "1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, with lymphatic invasion. 3. Code: Pheochromocytoma maps to PHCG.",
      "idx": 1000,
      "timestamp": "2026-01-19T15:59:53.114376"
    },
    {
      "sample_idx": 39,
      "input": "DIAGNOSIS: RADICAL CYSTECTOMY WITH URINARY DIVISION (ILEAL CONDUIT) AND PELVIC LYMPH NODE. DISSECTION. RIGHT URETER (AFS) : FROZEN SECTION DIAGNOSIS: NO TUMOR IDENTIFIED. FINAL DIAGNOSIS: BENIGN URETER. - NO DYSPLASIA OR MALIGNANCY IDENTIFIED. LEFT URETER (BFS) : FROZEN SECTION DIAGNOSIS: NO TUMOR IDENTIFIED. FINAL DIAGNOSIS: - BENIGN URETER. - NO DYSPLASIA OR MALIGNANCY IDENTIFIED. BLADDER (C) : - INVASIVE POORLY DIFFERENTIATED UROTHELIAL CARCINOMA WITH SQUAMOID. FEATURES (12.0 X 9.5 x 3.2 CM) ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive poorly differentiated urothelial carcinoma with squamous. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Bilateral prostate adenocarcinoma, Gleason's score 6 (3+3), confined to prostate. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Ureter. 2. Findings: Benign ureter. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LGG\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma. 3. Code: LGG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colon cancer. 3. Code: COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CESC\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Esophageal cancer. 3. Code: CESC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Cholangiocarcinoma. 2. Findings: Cholangiocarcinoma. 3. Code: CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"",
      "predicted": "KIRC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Bladder. 2. Findings: Invasive poorly differentiated urothelial carcinoma with squamous. 3. Code: KIRC.",
      "idx": 39,
      "timestamp": "2026-01-19T15:59:53.114386"
    },
    {
      "sample_idx": 229,
      "input": "25. ANATOMIC PATHOLOGY REPORT FAX. Accessioned: Physicien: oth Phy (a) : CLINICAL HISTORY. CLINICAL HISTORY CERVICAL VERSUS ENDOMETRIAL CA. PROCEDURS/FINDINOS: RADICAL HYSTERECTONY. SPECIMEN(S) : A. VAGINAL MARGINS FOR FROZEN. B. UTERUS, BSO AND CERVIX. c. RIGHT PELVIC LYMPH NODE DISSECTION. D. LEFT AORTIC. E. LEFT PELVIC LYMPH NODE DISSECTION. F. RIGHT PERIAORTIC. FINAL DIAGNOSIS. A. VAGINAL MARGIN, EXCISION: NEGATIVE FOR INVASIVE CARCINOMA. SURFACE EPITHELIUM SHOWS CHANGES CONSISTENT WITH HIGH...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, and Bilateral Tubes and Ovaries. 2. Findings: Invasive Squamous Cell Carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, and Bilateral Tubes and Ovaries. 2. Findings: Invasive Squamous Cell Carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, and Bilateral Tubes and Ovaries. 2. Findings: Invasive Squamous Cell Carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, and Bilateral Tubes and Ovaries. 2. Findings: Invasive Squamous Cell Carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, and Bilateral Tubes and Ovaries. 2. Findings: Invasive Squamous Cell Carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, and Bilateral Tubes and Ovaries. 2. Findings: Invasive Squamous Cell Carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, and Bilateral Tubes and Ovaries. 2. Findings: Invasive Squamous Cell Carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, and Bilateral Tubes",
      "predicted": "BRCA",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Uterus, Cervix, and Bilateral Tubes and Ovaries. 2. Findings: Invasive Squamous Cell Carcinoma, high grade. 3. Code: BRCA.",
      "idx": 229,
      "timestamp": "2026-01-19T15:59:53.114396"
    },
    {
      "sample_idx": 743,
      "input": "TISSUE DESCRIPTION : A1 B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 B13 B14 B15. C1 C2 C3 C4 C5 C6 C7 C8. Liver mass segment 6 (1930.0 grams, 14.5 X 13.0 X 12.0 cm) ,. liver segment 7 mass (164.0 grams), hepatic nodule (0.4 x 0.3. x. 0.1 cm). DIAGNOSIS: Liver, mass, segment VI resection: : Moderately differentiated. hepatocellulari carcinoma, forming a variegated mass with focal. necrosis measuring 14.5 X 13.0 X 12.0 cm. The tumor is partially. encapsulated with pushing border, and it shows no large ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment VI and VII). 2. Findings: Hepatocellular carcinoma, forming a variegated mass with focal necrosis, measuring 14.5 X 13.0 X 12.0 cm. Segment VII, a solid nodule, 1.3 x 1.0 X 0.9 cm. Also a cavernous hemangioma, 1.2 X 1.0 X 0.5 cm. 3. Code: Liver, mass, segment VI resection maps to KIRC. Liver, mass, segment VII resection maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment VI and VII). 2. Findings: Hepatocellular carcinoma, forming a variegated mass with focal necrosis, measuring 14.5 X 13.0 X 12.0 cm. Segment VII, a solid nodule, 1.3 x 1.0 X 0.9 cm. Also a cavernous hemangioma, 1.2 X 1.0 X 0.5 cm. 3. Code: Liver, mass, segment VI resection maps to KIRC. Liver, mass, segment VII resection maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment VI and VII). 2. Findings: Hepatocellular carcinoma, forming a variegated mass with focal necrosis, measuring 14.5 X 13.0 X 12.0 cm. Segment VII, a solid nodule, 1.3 x 1.0 X 0.9 cm. Also a cavernous hemangioma, 1.2 X 1.0 X 0.5 cm. 3. Code: Liver, mass, segment VI resection maps to KIRC. Liver, mass, segment VII resection maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment VI and VII). 2. Findings: Hepatocellular carcinoma, forming a variegated mass with focal necrosis, measuring 14.5",
      "predicted": "KIRC",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Liver (Segment VI and VII). 2. Findings: Hepatocellular carcinoma, forming a variegated mass with focal necrosis, measuring 14.5 X 13.0 X 12.0 cm. Segment VII, a solid nodule, 1.3 x 1.0 X 0.9 cm. Also a cavernous hemangioma, 1.2 X 1.0 X 0.5 cm. 3. Code: Liver, mass, segment VI resection maps to KIRC. Liver, mass, segment VII resection maps to KIRC.",
      "idx": 743,
      "timestamp": "2026-01-19T15:59:53.114411"
    },
    {
      "sample_idx": 629,
      "input": "Operative Procedure: Left nephrectomy, median sternotomy. Pre-Operative Diagnosis: As below. Post-Operative Diagnosis: As below. Left radical nephrectomy and caval thrombus with hilar and retroperitoneal lymph. nodes. Final Pathologic Diagnosis: Kidney and adrenal gland, left, radical nephrectomy with caval-atrial thrombus. removal; hilar and retroperitoneal lymph nodes, regional resection: Tumor histologic type: Papillary renal cell carcinoma, type I. Sarcomatoid features (%): None. Tumor size:...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, type I. Sarcomatoid features (%): None. Tumor size: 11 cm. Fuhrman grade: 3 of 4. Renal vein involvement: Yes with tumor adherent to renal vein wall. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, type I. Sarcomatoid features (%): None. Tumor size: 11 cm. Fuhrman grade: 3 of 4. Renal vein involvement: Yes with tumor adherent to renal vein wall. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, type I. Sarcomatoid features (%): None. Tumor size: 11 cm. Fuhrman grade: 3 of 4. Renal vein involvement: Yes with tumor adherent to renal vein wall. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, type I. Sarcomatoid features (%): None. Tumor size: 11 cm. Fuhrman grade: 3 of 4. Renal vein involvement: Yes with tumor adherent to renal vein wall. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, type I. Sarcomatoid features (%): None. Tumor size: 11 cm. Fuhrman grade: 3 of 4. Renal vein involvement: Yes with tumor adherent to renal vein wall. 3. Code: Kidney Renal Clear",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, type I. Sarcomatoid features (%): None. Tumor size: 11 cm. Fuhrman grade: 3 of 4. Renal vein involvement: Yes with tumor adherent to renal vein wall. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 629,
      "timestamp": "2026-01-19T15:59:53.114424"
    },
    {
      "sample_idx": 490,
      "input": "Gross Description: Microscopic Description: Diagnosis Details: Comments: Formatted Path Reports: Tumor site: Tongue. Tumor. size: 4 X 6 x 4cm. Histologic type: Squamous cell carcinoma. Histological grade: Well differentiated. Laterality: Midline. Margins: Not specified.",
      "response": "```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Squ",
      "predicted": "HNSC",
      "ground_truth": "HNSC",
      "correct": true,
      "reasoning": "1. Site: Tongue. 2. Findings: Squamous cell carcinoma. 3. Code: HNSC.",
      "idx": 490,
      "timestamp": "2026-01-19T15:59:53.114433"
    },
    {
      "sample_idx": 118,
      "input": "Final Pathologic Diagnosis: BASED ON THE PERFORMED GROSS AND MICROSCOPIC EXAMINATION: A. Breast, right, partial mastectomy: Infiltrating ductal carcinoma, Grade III/III. - Tubular score = 3. - Nuclear score = 3. - Mitotic score = 3. - Maximum tumor dimension 6 cm. - No evidence of angiolymphatic invasion. - Focal ductal carcinoma in situ. - Solid architectural pattern. - Focal cancerization of lobules. - Nonextensive pattern. - Invasive malignancy abutes deep skeletal muscle. - Surgical margins ...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 118,
      "timestamp": "2026-01-19T15:59:53.114442"
    },
    {
      "sample_idx": 493,
      "input": "DIAGNOSIS. (A). LEFT PYRIFORM SINUS: INVASIVE MODERATELY DIFFERENTIATED SQUAMOUS CARCINOMA. PHARYNGEAL PLEXUS OF VAGUS NERVE: Segment.of-nerve,--no tumor present. (C). TOTAL LARYNGOPHARYNGECTOMY, BILATERAL NECK DISSECTIONS, EXCISION OF LEFT. NECK SKIN, LEFT THYROIDECTOMY: INVASIVE MODERATELY DIFFERENTIATED SQUAMOUS CARCINOMA OF THE. LEFT PYRIFORM SINUS EXTENDING INTO THE LEFT ARYEPIGLOTTIC FOLD,. ESOPHAGUS, LEFT PARAGLOTTIC SPACE, LEFT PARATRACHEAL/PARA-. ESOPHAGEAL SOFT TISSUE AND LEFT THYROID....",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOSQUAMOUS\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Squamous cell carcinoma, invasive. 3. Code: The report indicates a squamous cell carcinoma, but the primary site is esophagus, not a specific TCGA code. Given the context, it could be considered as a squamous cell carcinoma, but there is no direct TCGA code for this specific esophageal cancer. However, the closest TCGA code that matches the description is ADENOSQUAMOUS, which is a composite of Adenocarcinoma and Squamous Cell Carcinoma. Since the report mentions a squamous cell carcinoma, this is the best available TCGA code.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOSQUAMOUS\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Squamous cell carcinoma, invasive. 3. Code: The report indicates a squamous cell carcinoma, but the primary site is esophagus, not a specific TCGA code. Given the context, it could be considered as a squamous cell carcinoma, but there is no direct TCGA code for this specific esophageal cancer. However, the closest TCGA code that matches the description is ADENOSQUAMOUS, which is a composite of Adenocarcinoma and Squamous Cell Carcinoma. Since the report mentions a squamous cell carcinoma, this is the best available TCGA code.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOSQUAMOUS\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Squamous cell carcinoma, invasive. 3. Code: The report indicates a squamous cell carcinoma, but the primary site is esophagus, not a specific TCGA code. Given the context, it could be considered as a squamous cell carcinoma, but there is no direct TCGA code for this specific esophageal cancer. However, the closest TCGA code that matches the description is ADENOSQUAMOUS, which is a composite of Adenocarcinoma and Squamous Cell Carcinoma. Since the report mentions a squamous cell carcinoma, this is the best available TCGA code.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOSQUAMOUS\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Squamous cell carcinoma, invasive",
      "predicted": "ADENOSQUAMOUS",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Esophagus. 2. Findings: Squamous cell carcinoma, invasive. 3. Code: The report indicates a squamous cell carcinoma, but the primary site is esophagus, not a specific TCGA code. Given the context, it could be considered as a squamous cell carcinoma, but there is no direct TCGA code for this specific esophageal cancer. However, the closest TCGA code that matches the description is ADENOSQUAMOUS, which is a composite of Adenocarcinoma and Squamous Cell Carcinoma. Since the report mentions a squamous cell carcinoma, this is the best available TCGA code.",
      "idx": 493,
      "timestamp": "2026-01-19T15:59:53.114463"
    },
    {
      "sample_idx": 1315,
      "input": "Identifier: Tumor Type : Thymoma. Pathology Report-Summary: Material: tumor: 8.0 X 8.0 X 3.0 cm. focal invasion through capsule. Diagnosis: Type A-Thymoma (with focal TypeA/B). pT2, pNO (0/7). Masaoka: II.1. Immunhistochemistry. epithelial cells positive for: CK5/6. strong membrane staining for EGFR. epithelial cells negative for: c-kit, CD5. CD1a, CD99-positive immature T-lymphocytes, partially also positive for CD5. sparsely CD20-positive lymphocytes.",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type A (with focal Type A/B). pT2, pNO (0/7). Masaoka: II.1. Epithelial cells positive for CK5/6 and EGFR, negative for c-kit and CD5. Immature T-lymphocytes, partially positive for CD5. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type A (with focal Type A/B). pT2, pNO (0/7). Masaoka: II.1. Epithelial cells positive for CK5/6 and EGFR, negative for c-kit and CD5. Immature T-lymphocytes, partially positive for CD5. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type A (with focal Type A/B). pT2, pNO (0/7). Masaoka: II.1. Epithelial cells positive for CK5/6 and EGFR, negative for c-kit and CD5. Immature T-lymphocytes, partially positive for CD5. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type A (with focal Type A/B). pT2, pNO (0/7). Masaoka: II.1. Epithelial cells positive for CK5/6 and EGFR, negative for c-kit and CD5. Immature T-lymphocytes, partially positive for CD5. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type A (with focal Type A/B). p",
      "predicted": "THYM",
      "ground_truth": "THYM",
      "correct": true,
      "reasoning": "1. Site: Thymus. 2. Findings: Thymoma, Type A (with focal Type A/B). pT2, pNO (0/7). Masaoka: II.1. Epithelial cells positive for CK5/6 and EGFR, negative for c-kit and CD5. Immature T-lymphocytes, partially positive for CD5. 3. Code: Thymoma maps to THYM.",
      "idx": 1315,
      "timestamp": "2026-01-19T15:59:53.114476"
    },
    {
      "sample_idx": 1363,
      "input": "Client: F. ITD:719E2A48-0E04-4EAD-ASCC-6416450FC68F. History/Clinical Dx: Endometrial cancer. Postoperative Dx: Pending pathology examination. Specimen(s) Received: A: Left pelvic lymph node. B: Left aortic lymph node. C: Right pelvic lymph node. D: Right aortic lymph node. E: Uterus, cervix, tubes and ovaries. DIAGNOSIS: A. Left pelvic lymph nodes: Four lymph nodes negative for metastasis (0/4). B. Left aortic lymph nodes: Two lymph nodes negative for metastasis (0/2). C. Right pelvic lymph nod...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, tubes and ovaries. 2. Findings: Endometrial adenocarcimona. Tumor size: 1.4 x 0.7 x 0.6 cm. Extent of invasion: Less than 50% (3 mm invasion/10 mm myometrial thickness). 3. Code: UCEC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, tubes and ovaries. 2. Findings: Endometrial adenocarcimona. Tumor size: 1.4 x 0.7 x 0.6 cm. Extent of invasion: Less than 50% (3 mm invasion/10 mm myometrial thickness). 3. Code: UCEC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, tubes and ovaries. 2. Findings: Endometrial adenocarcimona. Tumor size: 1.4 x 0.7 x 0.6 cm. Extent of invasion: Less than 50% (3 mm invasion/10 mm myometrial thickness). 3. Code: UCEC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, tubes and ovaries. 2. Findings: Endometrial adenocarcimona. Tumor size: 1.4 x 0.7 x 0.6 cm. Extent of invasion: Less than 50% (3 mm invasion/10 mm myometrial thickness). 3. Code: UCEC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, tubes and ovaries. 2. Findings: Endometrial adenocarcimona. Tumor size: 1.4 x 0.7 x 0.6 cm. Extent of invasion: Less than 50% (3 mm invasion/10 mm myometrial thickness).",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus, cervix, tubes and ovaries. 2. Findings: Endometrial adenocarcimona. Tumor size: 1.4 x 0.7 x 0.6 cm. Extent of invasion: Less than 50% (3 mm invasion/10 mm myometrial thickness). 3. Code: UCEC",
      "idx": 1363,
      "timestamp": "2026-01-19T15:59:53.114488"
    },
    {
      "sample_idx": 175,
      "input": "Procedure Date: Procedure Physician: Attending Physician/Copies To: PATIENT HISTORY: nnDATE of LMP. DATE or LAST DELIVERY: PRE-OP DIAGNOSIS: LT BR MASS. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE: LT SEGM MAST-NEEDLE LOC. CLINICAL HISTORY: MATERIAL SUBMITTED: A) LEFT BREAST BIOPSY/MASS/SEGMENTAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDORE. 3) LEFT NEW MARGIN TISSUE, PROCUREMENT BY SURGICAL PROCEDURE. SUPERIOR. INTRAOPERATIVE CONSULTATION: CONSULT Left breast tissue: 11.0 by 5.0 by 4.5 cm bre...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Fuhrman Grade II, Nottingham Score 7, microcalcifications, infiltrating carcinoma within <1 mm of the inked superior and deep margins. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Fuhrman Grade II, Nottingham Score 7, microcalcifications, infiltrating carcinoma within <1 mm of the inked superior and deep margins. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Fuhrman Grade II, Nottingham Score 7, microcalcifications, infiltrating carcinoma within <1 mm of the inked superior and deep margins. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Fuhrman Grade II, Nottingham Score 7, microcalcifications, infiltrating carcinoma within <1 mm of the inked superior and deep margins. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Fuhrman Grade II, Nottingham Score 7, microcalcifications, infiltrating carcinoma within <1 mm of the inked superior and deep margins. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Fuhrman Grade II, Nottingham Score 7, microcalcifications, infiltrating carcinoma within <1 mm of the inked superior and deep margins. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Fuhrman Grade II, Nottingham Score 7, microcalcifications, infiltrating carcinoma within <1 mm of the inked superior and deep margins. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 175,
      "timestamp": "2026-01-19T15:59:53.114501"
    },
    {
      "sample_idx": 995,
      "input": "FINAL DIAGNOSIS: RETROCAVAL MASS, OPEN RESECTION OF RETROPERITONEAL MASS (36 GRAMS) -. PARAGANGLIOMA, 6.5 CM.",
      "response": "```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Paraganglioma. 3. Code: TGCT maps to Retroperitoneal Mass.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Paraganglioma. 3. Code: TGCT maps to Retroperitoneal Mass.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Paraganglioma. 3. Code: TGCT maps to Retroperitoneal Mass.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Paraganglioma. 3. Code: TGCT maps to Retroperitoneal Mass.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Paraganglioma. 3. Code: TGCT maps to Retroperitoneal Mass.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Paraganglioma. 3. Code: TGCT maps to Retroperitoneal Mass.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Paraganglioma. 3. Code: TGCT maps to Retroperitoneal Mass.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Paraganglioma. 3. Code: TGCT maps to Retroperitoneal Mass.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Retroperitoneum. ",
      "predicted": "TGCT",
      "ground_truth": "PCPG",
      "correct": false,
      "reasoning": "1. Site: Retroperitoneum. 2. Findings: Paraganglioma. 3. Code: TGCT maps to Retroperitoneal Mass.",
      "idx": 995,
      "timestamp": "2026-01-19T15:59:53.114510"
    },
    {
      "sample_idx": 141,
      "input": "Diagnosis: Right-sided breast excision material with a poorly differentiated invasive ductal breast. carcinoma measuring about 4.3 cm with invasion of the lymph vessels and a minimum margin. of 3 mm at 6 o 'clock and 10 mm at 12 o 'clock and 1.5 cm or more at 3 and 9 \"clock. No. intraductal tumor component. Tumor classification: M-8500/3, G3, pT 2, pN 3a (14/28), pMx, stage III c. R 0.",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 141,
      "timestamp": "2026-01-19T15:59:53.114520"
    },
    {
      "sample_idx": 1090,
      "input": "Addendum. Clinical Diagnosis & History: with rectosigmoid cancer. Specimens Submitted: 1: SP: Sigmoid and upper rectum open end proximal. 2: SP: Distal ring margin. 3: SP: Proximal ring margin. DIAGNOSIS: 1. SP: Sigmoid and upper rectum open end proximal: Tumor Type: Adenocarcinoma. Histologic Grade: Moderately differentiated. Tumor Location: Rectosigmoid. Tumor Size: Length is 1.5 cm. Width is 1.3 cm. Maximal thickness is 0.2 cm. Tumor Budding: Absent. Increased Tumor Infiltrating Lymphocytes: ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon (proximal and distal margins). 2. Findings: Adenocarcinoma, moderately differentiated, with a rectosigmoid tumor located 9 cm from the proximal margin and 4.5 cm from the distal margin. The tumor is 1.5 cm in length and 1.3 cm in width, invading to a depth of 0.2 cm. Lymphovascular invasion is identified. Surgical margins are free of tumor. The tumor is staged as pT2 (Tumor invades muscularis propria) and N1b (Metastasis in 2-3 regional lymph nodes). The tumor is also classified as stage II. The immunohistochemical staining for DNA mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) is retained in the tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon (proximal and distal margins). 2. Findings: Adenocarcinoma, moderately differentiated, with a rectosigmoid tumor located 9 cm from the proximal margin and 4.5 cm from the distal margin. The tumor is 1.5 cm in length and 1.3 cm in width, invading to a depth of 0.2 cm. Lymphovascular invasion is identified. Surgical margins are free of tumor. The tumor is staged as pT2 (Tumor invades muscularis propria) and N1b (Metastasis in 2-3 regional lymph nodes). The tumor is also classified as stage II. The immunohistochemical staining for DNA mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) is retained in the tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon (proximal and distal margins). 2. Findings: Adenocarcinoma, moderately differentiated, with a rect",
      "predicted": "KIRC",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Rectosigmoid colon (proximal and distal margins). 2. Findings: Adenocarcinoma, moderately differentiated, with a rectosigmoid tumor located 9 cm from the proximal margin and 4.5 cm from the distal margin. The tumor is 1.5 cm in length and 1.3 cm in width, invading to a depth of 0.2 cm. Lymphovascular invasion is identified. Surgical margins are free of tumor. The tumor is staged as pT2 (Tumor invades muscularis propria) and N1b (Metastasis in 2-3 regional lymph nodes). The tumor is also classified as stage II. The immunohistochemical staining for DNA mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) is retained in the tumor. 3. Code: KIRC.",
      "idx": 1090,
      "timestamp": "2026-01-19T15:59:53.114542"
    },
    {
      "sample_idx": 257,
      "input": "RUN DATE: PAGE: 1. RUN TIME: SPEC #. Obtained: CLINICAL HISTORY : STAT, ICD-180.0. SPECIMEN/PROCEDURE. 1. CERVICAL BIOPSY. 2. ENDOMETRIAL BX. IMPRESSION: 1). CERVIX, BIOPSY: Invasive adenocaroinoma, compatible with usual andoservioal type; moderately. difforentiatod; see important comment. Lymphovasoular invasion is not identified. 2). ENDOMETRIUM, BIOPSY: Scant fragments of carcinoma; see diagnosis #1 above. Separate fragments of atrophic endometrium. Distated by: Entered: COMMENT. The cervical...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Cervix (Biopsy). 2. Findings: Invasive adenocarcinoma, compatible with usual cervical type, moderately differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Endometrium (Biopsy). 2. Findings: Scant fragments of carcinoma, compatible with usual endometrial type, moderately differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Cervix (Biopsy). 2. Findings: Invasive adenocarcinoma, compatible with usual cervical type, moderately differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Endometrium (Biopsy). 2. Findings: Scant fragments of carcinoma, compatible with usual endometrial type, moderately differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Cervix (Biopsy). 2. Findings: Invasive adenocarcinoma, compatible with usual cervical type, moderately differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Endometrium (Biopsy). 2. Findings: Scant fragments of carcinoma, compatible with usual endometrial type, moderately differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Cervix (Biopsy). 2. Findings: Invasive adenocarcinoma, compatible with usual cervical type, moderately differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Endometrium (Bi",
      "predicted": "BRCA",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Cervix (Biopsy). 2. Findings: Invasive adenocarcinoma, compatible with usual cervical type, moderately differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 257,
      "timestamp": "2026-01-19T15:59:53.114553"
    },
    {
      "sample_idx": 262,
      "input": "PRIMARY SITE: Cervix. Uterine cervix biopsy: Infiltrative poorly differentiated squamous cell carcinoma.",
      "response": "```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Infiltrative poorly differentiated squamous cell carcinoma. 3. Code: Cervix Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CERV\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Infiltrative poorly differentiated squamous cell carcinoma. 3. Code: Cervix Squamous Cell Carcinoma maps to CERV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Infiltrative poorly differentiated squamous cell carcinoma. 3. Code: Cervix Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Infiltrative poorly differentiated squamous cell carcinoma. 3. Code: Cervix Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Infiltrative poorly differentiated squamous cell carcinoma. 3. Code: Cervix Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Infiltrative poorly differentiated squamous cell carcinoma. 3. Code: Cervix Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Infiltrative poorly differentiated squamous cell carcinoma. 3. Code: Cervix Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Infiltrative poorly differentiated squamous cell carcinoma. ",
      "predicted": "HNSC",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Cervix. 2. Findings: Infiltrative poorly differentiated squamous cell carcinoma. 3. Code: Cervix Squamous Cell Carcinoma maps to HNSC.",
      "idx": 262,
      "timestamp": "2026-01-19T15:59:53.114564"
    },
    {
      "sample_idx": 973,
      "input": "Surgery Date: DIAGNOSIS: A. Pancreas, neck margin, biopsy: Negative for tumor. B. Pancreas, spleen and omentum, distal pancreatectomy, splenectomy. and partial omentectomy: Invasive grade 3 (of 4) adenocarcinoma,. forming a 2.2 x 2.0 X 1.8 cm mass within the body of the pancreas. The tumor extends beyond the pancreas to involve peripancreatic soft. tissue. Perineural invasion is identified. The pancreatic ducts. demonstrate pancreatic intraepithelial neoplasia (PanIN-1A). The. distal pancreas sh...",
      "response": "```json\n{\n    \"cancer_type\": \"ADCA\",\n    \"reasoning\": \"1. Site: Pancreas (body). 2. Findings: Invasive adenocarcinoma, grade 3, forming a 2.2 x 2.0 x 1.8 cm mass, extending beyond the pancreas to involve peripancreatic soft tissue. Perineural invasion is identified. Pancreatic intraepithelial neoplasia (PanIN-1A) is present in the pancreatic ducts. Chronic pancreatitis is present in the distal pancreas. Surgical margins are negative for tumor. 6 peripancreatic lymph nodes are negative for tumor. The spleen is unremarkable. The tumor is T3N0. 3. Code: ADCA maps to ADCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADCA\",\n    \"reasoning\": \"1. Site: Pancreas (body). 2. Findings: Invasive adenocarcinoma, grade 3, forming a 2.2 x 2.0 x 1.8 cm mass, extending beyond the pancreas to involve peripancreatic soft tissue. Perineural invasion is identified. Pancreatic intraepithelial neoplasia (PanIN-1A) is present in the pancreatic ducts. Chronic pancreatitis is present in the distal pancreas. Surgical margins are negative for tumor. 6 peripancreatic lymph nodes are negative for tumor. The spleen is unremarkable. The tumor is T3N0. 3. Code: ADCA maps to ADCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADCA\",\n    \"reasoning\": \"1. Site: Pancreas (body). 2. Findings: Invasive adenocarcinoma, grade 3, forming a 2.2 x 2.0 x 1.8 cm mass, extending beyond the pancreas to involve peripancreatic soft tissue. Perineural invasion is identified. Pancreatic intraepithelial neoplasia (PanIN-1A) is present in the pancreatic ducts. Chronic pancreatitis is present in the distal pancreas. Surgical margins are negative for tumor. 6 peripancreatic lymph nodes are negative for tumor. The spleen is unremarkable. The tumor is T3N0. 3. Code: ADCA maps to ADCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADCA\",\n    \"reasoning\": \"1. Site: Pancreas (body). ",
      "predicted": "ADCA",
      "ground_truth": "PAAD",
      "correct": false,
      "reasoning": "1. Site: Pancreas (body). 2. Findings: Invasive adenocarcinoma, grade 3, forming a 2.2 x 2.0 x 1.8 cm mass, extending beyond the pancreas to involve peripancreatic soft tissue. Perineural invasion is identified. Pancreatic intraepithelial neoplasia (PanIN-1A) is present in the pancreatic ducts. Chronic pancreatitis is present in the distal pancreas. Surgical margins are negative for tumor. 6 peripancreatic lymph nodes are negative for tumor. The spleen is unremarkable. The tumor is T3N0. 3. Code: ADCA maps to ADCA.",
      "idx": 973,
      "timestamp": "2026-01-19T15:59:53.114583"
    },
    {
      "sample_idx": 1125,
      "input": "Recelved: MD, Pho. intraop Pathologist: Performing Physician: CLINICAL HISTORY: -YEAR-OLD FEMALE WITH BIOPSY-PROVEN LEIOMYOSARCOMA, LEFT THIGH. PREOPERATIVE DIAGNOSIS: LEFT KNEE MASS. SPECIMEN TYPE (s) : A: LEFT KNEE MASS. FINAL DIAGNOSIS: A. LEFT KNKE SOFT TISSUE MASS, RESECTION: Moderate to high-grade. leiomyosarcoma (see key pathologic findings) -. KEY PATHOLOGICAL FINDINGS: operation performed: Resection. Tumor location: Left knee. Diagnosis: Leiomyosarcoma. Tumor Grade: Moderate to high gra...",
      "response": "```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left knee mass. 2. Findings: Leiomyosarcoma, moderate to high grade. 3. Code: Leiomyosarcoma maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left knee mass. 2. Findings: Leiomyosarcoma, moderate to high grade. 3. Code: Leiomyosarcoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left knee mass. 2. Findings: Leiomyosarcoma, moderate to high grade. 3. Code: Leiomyosarcoma maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left knee mass. 2. Findings: Leiomyosarcoma, moderate to high grade. 3. Code: Leiomyosarcoma maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left knee mass. 2. Findings: Leiomyosarcoma, moderate to high grade. 3. Code: Leiomyosarcoma maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left knee mass. 2. Findings: Leiomyosarcoma, moderate to high grade. 3. Code: Leiomyosarcoma maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left knee mass. 2. Findings: Leiomyosarcoma, moderate to high grade. 3. Code: Leiomyosarcoma maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left knee mass. 2. Findings: Leiomyosarcoma, moderate to high grade. 3. Code: Leiomyosarcoma maps to SARC.\"\n}\n```\n",
      "predicted": "SARC",
      "ground_truth": "SARC",
      "correct": true,
      "reasoning": "1. Site: Left knee mass. 2. Findings: Leiomyosarcoma, moderate to high grade. 3. Code: Leiomyosarcoma maps to SARC.",
      "idx": 1125,
      "timestamp": "2026-01-19T15:59:53.114593"
    },
    {
      "sample_idx": 338,
      "input": "CERVICAL LYMPH NODE: Three tissue fragments, the biggest measures3,7 x 2,5 x 0,9 cm and the smallest 0,5 x. 0,4 x 0,3 cm. The section surface shows a homogeneous whitish color. LEFT CERVICAL LYMPH NODE (EXCISION): - PRIMARY MEDIASTINAL DIFFUSE LARGE B-CELL LYMPHOMA. Sections show a lymph node with the architecture effaced by atypical lymphoid. proliferation, composed by sheets of large and pleomorphic cells, some with Reed-. Sternberg morphology, accompanied by a background of small cells. The n...",
      "response": "```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Cervical Lymph Node. 2. Findings: Diffuse Large B-cell Lymphoma (DLBCL). The lymphoma is characterized by sheets of large, pleomorphic cells with Reed-Sternberg morphology and a background of small cells. The cells are positive for CD20, CD79a, CD30, CD23, CD22, BCL2, MUM1/IRF4, and BCL6, and negative for CD10, CD15, and EBER. 3. Code: DLBC maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Cervical Lymph Node. 2. Findings: Diffuse Large B-cell Lymphoma (DLBCL). The lymphoma is characterized by sheets of large, pleomorphic cells with Reed-Sternberg morphology and a background of small cells. The cells are positive for CD20, CD79a, CD30, CD23, CD22, BCL2, MUM1/IRF4, and BCL6, and negative for CD10, CD15, and EBER. 3. Code: DLBC maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Cervical Lymph Node. 2. Findings: Diffuse Large B-cell Lymphoma (DLBCL). The lymphoma is characterized by sheets of large, pleomorphic cells with Reed-Sternberg morphology and a background of small cells. The cells are positive for CD20, CD79a, CD30, CD23, CD22, BCL2, MUM1/IRF4, and BCL6, and negative for CD10, CD15, and EBER. 3. Code: DLBC maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Cervical Lymph Node. 2. Findings: Diffuse Large B-cell Lymphoma (DLBCL). The lymphoma is characterized by sheets of large, pleomorphic cells with Reed-Sternberg morphology and a background of small",
      "predicted": "DLBC",
      "ground_truth": "DLBC",
      "correct": true,
      "reasoning": "1. Site: Cervical Lymph Node. 2. Findings: Diffuse Large B-cell Lymphoma (DLBCL). The lymphoma is characterized by sheets of large, pleomorphic cells with Reed-Sternberg morphology and a background of small cells. The cells are positive for CD20, CD79a, CD30, CD23, CD22, BCL2, MUM1/IRF4, and BCL6, and negative for CD10, CD15, and EBER. 3. Code: DLBC maps to DLBC.",
      "idx": 338,
      "timestamp": "2026-01-19T15:59:53.114609"
    },
    {
      "sample_idx": 1308,
      "input": "MRN1. Service: Thoracic. M. Clinical Diagnosis & History: male with left anterior lung mass,. biopay shows spindle. cell neoplasm. Specimens Submitted: 1: Left anterior mediastinal mass (fs). 2 1 Portion left sixth rib. 3: Left anterior mediastinal lymph node. DIAGNOSIS: 1. Left anterior mediastinal mass (fs) : - Thymoma, type AB. - The tumor measures 16 x 14.5 x 9 .2 cm in greatest dimension. - The tumor invades focally through the capsule into the adipose tissue. - The surgical resection margi...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left anterior mediastinum. 2. Findings: Thymoma, type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left sixth rib. 2. Findings: Unremarkable bony trabeculae and bone marrow with intact trilineage. hematopoiesis. 3. Code: Unremarkable bony trabeculae and bone marrow with intact trilineage. hematopoiesis maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left anterior mediastinal lymph node. 2. Findings: Benign fibroadipose and vascular tissue. No lymph node identified. 3. Code: Benign fibroadipose and vascular tissue maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left anterior mediastinal mass. 2. Findings: Thymoma, type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left sixth rib. 2. Findings: Unremarkable bony trabeculae and bone marrow with intact trilineage. hematopoiesis. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left anterior mediastinal lymph node. 2. Findings: Benign fibroadipose and vascular tissue. No lymph node identified. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left anterior mediastinal mass. 2. Findings: Thymoma, type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left sixth rib. 2. Findings: Unremarkable bony trabeculae and bone marrow with intact triline",
      "predicted": "THYM",
      "ground_truth": "THYM",
      "correct": true,
      "reasoning": "1. Site: Left anterior mediastinum. 2. Findings: Thymoma, type AB. 3. Code: THYM",
      "idx": 1308,
      "timestamp": "2026-01-19T15:59:53.114618"
    },
    {
      "sample_idx": 1080,
      "input": "Diagnosis: A: Tick, left scrotum, removal. - Tick for gross identification only. B: Lymph nodes right pelvic, removal. - No tumor seen in six lymph nodes (0/6). C: Lymph nodes left pelvic, removal. - Metastatic prostatic adenocarcinoma in one of 11 lymph nodes. (1/11) i maximum size of metastasis 0.9 cm; focal extracapsular. extension identified. D: Prostate, robot assisted laparoscopic prostatectomy. Tumor histologic type: Prostatic adenocarcinoma. Tumor grade (Gleason system) : Gleason combine...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason combined score 7 (4+3), with tertiary pattern 5 comprising approximately 4% of tumor. Extracapsular extension of tumor in lymph nodes: Focally present. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Scrotum. 2. Findings: Tick. 3. Code: Not Applicable.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Pelvic Lymph Node. 2. Findings: Metastatic prostatic adenocarcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Pelvic Lymph Node. 2. Findings: Metastatic prostatic adenocarcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason combined score 7 (4+3), with tertiary pattern 5 comprising approximately 4% of tumor. Extracapsular extension of tumor in lymph nodes: Focally present. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason combined score 7 (4+3), with tertiary pattern 5 comprising approximately 4% of tumor. Extracapsular extension of tumor in lymph nodes: Focally present. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma,",
      "predicted": "KIRC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason combined score 7 (4+3), with tertiary pattern 5 comprising approximately 4% of tumor. Extracapsular extension of tumor in lymph nodes: Focally present. 3. Code: KIRC.",
      "idx": 1080,
      "timestamp": "2026-01-19T15:59:53.114630"
    },
    {
      "sample_idx": 866,
      "input": "HISTORY. MACROSCOPIC. Four specimens received: 1: The specimen is labelled \"left upper lobe\" and consists of a lobectomy specimen measuring 130 x. 80 X 35 mm. The bronchial portion of the specimen measures approximately 30 mm in length and has. a bifurcation adjacent to the resection margin with two adjacent lumens measuring approximately 13. mm in diameter, one of which is plugged by cream to pink tumour. No palpable mass is present within. the lobectomy specimen. The pleural surface demonstrat...",
      "response": "```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, endobronchial. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, endobronchial. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, endobronchial. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, endobronchial. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, endobronchial. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, endobronchial. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, endobronchial. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, endobronchial. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2",
      "predicted": "SCC",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung. 2. Findings: Squamous cell carcinoma, endobronchial. 3. Code: SCC maps to SCC.",
      "idx": 866,
      "timestamp": "2026-01-19T15:59:53.114639"
    },
    {
      "sample_idx": 433,
      "input": "Case imported from legacy computer system. The format of this report does not match the original  case. For cases prior to. the section \"SPECIMEN\" may have been added. DIAGNOSIS. PROXIMAL MARGIN V-3: Peripheral nerve, no tumor present. (B). LINGUAL MARGIIN: Segment of nerve, no tumor present. BILATERAL NECK DISSECTION RIGHT AND LEFT SUBMANDIBULAR GLAND, SUBTOTAL. GLOSSECTOMY OF FLOOR OF MOUTH RESECTION: SQUAMOUS CARCINOMA GRADE 3 OF FLOOR OF MOUTH, 7 MM IN THICKNESS. Moderate to severe dysplasia...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Floor of mouth. 2. Findings: Squamous cell carcinoma, grade 3. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Floor of mouth. 2. Findings: Squamous cell carcinoma, grade 3. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Floor of mouth. 2. Findings: Squamous cell carcinoma, grade 3. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Floor of mouth. 2. Findings: Squamous cell carcinoma, grade 3. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Floor of mouth. 2. Findings: Squamous cell carcinoma, grade 3. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Floor of mouth. 2. Findings: Squamous cell carcinoma, grade 3. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Floor of mouth. 2. Findings: Squamous cell carcinoma, grade 3. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Floor of mouth. 2. Findings: Squamous cell carcinoma, grade 3. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Floor of mouth. 2. Findings: Squamous cell carcinoma, grade 3. 3. Code: PRAD.\"\n}\n```",
      "predicted": "PRAD",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Floor of mouth. 2. Findings: Squamous cell carcinoma, grade 3. 3. Code: PRAD.",
      "idx": 433,
      "timestamp": "2026-01-19T15:59:53.114649"
    },
    {
      "sample_idx": 1254,
      "input": "Clinical Diagnosis & History: Thyroid carcinoma. Specimens Submitted: 1: Right neck lymph node (fs). 2: Right neck node near accessory nerve (fs). 3: Right supra clavicular node (fs). 4: Right modified neck dissection level 2,3,4 and 5 (fs). 5: Right neck level 4 and 5 additional nodes. 6: Right paratracheal lymph node. 7: Superior mediastinal and pretracheal tissue. 8: Deep mediastinal lymph node. 9: Total thyroidectomy. DIAGNOSIS: 1. Right neck lymph node (fs): Part # 1. Lymph Node Dissection:...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive",
      "predicted": "BRCA",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1254,
      "timestamp": "2026-01-19T15:59:53.114658"
    },
    {
      "sample_idx": 411,
      "input": "CLINICAL HISTORY. developed progressive. three. months ago. On imaging there is a left frontal lobe-centered. enhancing mass. that extends into the corpus callosum. There are also several. enhancing. satellite lesions. MRS demonstrates increased levels of choline,. decreased. NAA, and no lipid or lactate spikes. OPERATIVE DIAGNOSES. Left brain tumor. Operation/Specimen: A: Brain tumor, biopsy. PATHOLOGICAL DIAGNOSIS: A. Brain, site not specified, excisional biopsies: 1. Glioblastoma. 2. MIB-1 pr...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma, with neuronal component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma, with a neuronal component. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma, with a neuronal component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma, with a neuronal component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma, with a neuronal component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma, with a neuronal component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma, with a neuronal component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma, with a neuronal component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma, with a neuronal component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reason",
      "predicted": "KIRC",
      "ground_truth": "GBM",
      "correct": false,
      "reasoning": "1. Site: Brain. 2. Findings: Glioblastoma, with neuronal component. 3. Code: KIRC.",
      "idx": 411,
      "timestamp": "2026-01-19T15:59:53.114667"
    },
    {
      "sample_idx": 638,
      "input": "Final Diagnosis: A-D. Brain, right frontal mass #1-#4 and CUSA, biopsies: Low-grade oligodendroglioma (WHO grade II). See. comment. Comment: The tumor shows focal high cellularity and increased proliferative activity (up to 3-4 mitoses per 10. HPF and Ki-67 labeling index (up to 10-15%)] suggesting focal early progression. The findings are insufficient. for a grade III designation. Interpreted by: Preliminary Frozen Section Consultation: A. Brain, right frontal mass #1, smears: Glioma. Hold over...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Low-grade oligodendroglioma (WHO grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma (HCC). 3. Code: LIHC maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma multiforme (GBM). 3. Code: STAD maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Lung adenocarcinoma. 3. Code: LUAD maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Ureter. 2. Findings: Urothelial carcinoma. 3. Code: UVM maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Lung squamous cell carcinoma. 3. Code: ESCA maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colon adenocarcinoma. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"READ\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Rectal adenocarcinoma. 3. Code: READ maps to READ.\"\n}\n```\n",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain. 2. Findings: Low-grade oligodendroglioma (WHO grade II). 3. Code: GBM maps to GBM.",
      "idx": 638,
      "timestamp": "2026-01-19T15:59:53.114677"
    },
    {
      "sample_idx": 1299,
      "input": "F. Facility: MD: Specimen(s) Received. 1. Thyroid: Total Thyroid stich marks right upper pole - reg. Diagnosis. Widely invasive bilateral and multifocal papillary carcinoma involving surgical margins, dominant. classical variant, 2.1 cm, left, with extrathyroidal extension and focal thyroiditis: Thyroid. Invasive papillary thyroid carcinoma: Parathyroid, 1 of 2, left. No pathological diagnosis: Parathyroid, left. No pathological diagnosis: Lymph node, isthmic. - -Total thyroidectomy specimen. Sy...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site:",
      "predicted": "BRCA",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1299,
      "timestamp": "2026-01-19T15:59:53.114686"
    },
    {
      "sample_idx": 764,
      "input": "Case ID Gross Description. Microscopic Description. Diagnosis Details. Comments. LUNG TISSUE CHECKLIST. Specimen type: Lobectomy. Tumor site: Lung. Tumor size: 3.2 X 3.2 X 3.2 cm. Histologic type: Adenocarcinoma. Histologic grade: Poorly. differentiated. Tumor extent: Not specified. Other tumor nodules: Not specified. Lymph nodes: 0/6 positive for. metastasis (Regional 0/6). Lymphatic invasion: Not specified. Venous invasion: Not specified. Margins: Not specified. Evidence of neo-adjuvant. treat...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUSC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: Lung Adenocarcinoma maps to LUAD.",
      "idx": 764,
      "timestamp": "2026-01-19T15:59:53.114696"
    },
    {
      "sample_idx": 897,
      "input": "De-Identified Specimen Code: SPECIMEN SUBMITTED: Part A: BRONCHUS INTERMEDIUS. LYMPH NODE. Part B: RIGHT PNEUMONECTOMY. Part C: FIRST RIB. Part D: 10R. Part E: 11R. Part F: 12R. Part G: 4R. Part H: PERIPHRENIC LYMPH NODE. Part I: 7. Final Diagnosis. 1. Bronchus intermedius lymph nodes, excision (A) - Invasive squamous cell carcinoma. 2. Right lung, pneumonectomy (B) - Invasive squamous cell carcinoma (see comment). Metastatic squamous cell carcinoma in peribronchial lymph nodes,. - Giant cell re...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bronchus intermedius lymph node. 2. Findings: Invasive squamous cell carcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lung, pneumonectomy. 2. Findings: Invasive squamous cell carcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: First rib. 2. Findings: Bone with no significant pathologic changes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph nodes, 10R, 11R, 12R, 4R, periphrenic lymph node, #7. 2. Findings: Lymph nodes, negative for neoplasm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right hilum. 2. Findings: Tumor measuring 3 cm in greatest dimension. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lung, pneumonectomy. 2. Findings: Tumor measuring 3 cm in greatest dimension. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: First rib. 2. Findings: Bone with no significant pathologic changes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph nodes, 10R, 11R, 12R, 4R, periphrenic lymph node, #7. 2. Findings: Lymph nodes, negative for neoplasm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"",
      "predicted": "KIRC",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Bronchus intermedius lymph node. 2. Findings: Invasive squamous cell carcinoma. 3. Code: KIRC.",
      "idx": 897,
      "timestamp": "2026-01-19T15:59:53.114705"
    },
    {
      "sample_idx": 1059,
      "input": "PATIENT HISTORY: CHIEF COMPLAINT/PRE-OP/POST-OPI DIAGNOSIS: Prostate cancer. PROCEDURE: Radical prostatectomy. SPECIFIC CLINICAL QUESTION: Not stated. OUTSIDE TISSUE DIAGNOSIS: Not stated. PRIOR MALIGNANCY: Not stated. CHEMORADIATION: Not stated. ORGAN TRANSPLANT: Not stated. IMMUNOSUPPRESSION: Not stated. OTHER DISEASES: Not stated. FINAL DIAGNOSIS: PART1: LYMPH NODE, RIGHT PELVIC, EXCISION -. EIGHT BENIGN LYMPH NODES (0/8). PART2: LYMPH NODE, LEFT PELVIC, EXCISION -. SIX BENIGN LYMPH NODES (0/...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason 4/5 percentage 20%. 3. Code: Prostate cancer maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PCPG\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: High grade PIN identified. 3. Code: Prostate cancer maps to PCPG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Right Pelvic). 2. Findings: Benign lymph nodes (0/8). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Left Pelvic). 2. Findings: Benign lymph nodes (0/6). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason 4/5 percentage 20%. 3. Code: Prostate cancer maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason 4/5 percentage 20%. 3. Code: Prostate cancer maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason 4/5 percentage 20%. 3. Code: Prostate cancer maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate.",
      "predicted": "PRAD",
      "ground_truth": "PRAD",
      "correct": true,
      "reasoning": "1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason 4/5 percentage 20%. 3. Code: Prostate cancer maps to PRAD.",
      "idx": 1059,
      "timestamp": "2026-01-19T15:59:53.114716"
    },
    {
      "sample_idx": 924,
      "input": "FINAL DIAGNOSIS: PART 1: LEFT ADNEXUM, LEFT SALPINGO-OOPHORECTOMY -. A. HIGH GRADE ADENOCARCINOMA (27 CM). B. SEROSAL SURFACE FREE. C. FOCAL SURFACE ADHESIONS. D. FALLOPIAN TUBE, FREE OF TUMOR. PART 2: POSTERIOR CUL-DE-SAC NODULE, EXCISION -. INVASIVE HIGH GRADE ADENOCARCINOMA. PART 3: UTERUS, CERVIX, RIGHT ADNEXUM (130 GRAMS), HYSTERECTOMY AND RIGHT SALPINGO-. OOPHORECTOMY-. A. ADENOCARCINOMA INVOLVES UTERINE SEROSA AND FOCALLY OVARIAN SURFACE. B. FALLOPIAN TUBE WITH TUBAL INTRAEPITHELIAL CARCI...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Adnexam, Left Salpingo-Oophorectomy. 2. Findings: High Grade Adenocarcinoma, Serosal Surface Free, Focal Surface Adhesions, Fallopian Tube, Free of Tumor, Invasive High Grade Adenocarcinoma, Atrophic Endometrium, Cervix with Chronic Inflammation and Squamous Metaplasia, Metastatic Adenocarcinoma involves one of seven lymph nodes (1/7), Negative for Tumor, High Grade Adenocarcinoma, Invasive High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Invasive High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High",
      "predicted": null,
      "ground_truth": "OV",
      "correct": null,
      "reasoning": "",
      "idx": 924,
      "timestamp": "2026-01-19T15:59:53.114866"
    },
    {
      "sample_idx": 247,
      "input": "Copies To: DIAGNOSIS: A. LEFT PELVIC LYMPH NODES, EXCISION: Metastatic squamous cell carcinoma to three of seven lymph nodes with perinodal venous. involvement (3/7). B. LEFT OBTURATOR LYMPH NODES, EXCISION: Metastatic squamous cell carcinoma to two of two lymph nodes with perinodal venous. involvement (2/2). C. LEFT COMMON LYMPH NODES, EXCISION: Four lymph nodes with no evidence of malignancy (4). D. RIGHT COMMON LYMPH NODES, EXCISION: Metastatic squamous cell carcinoma replacing multiple matte...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Cervix, Uterine. 2. Findings: Invasive squamous cell carcinoma of the uterine cervix, keratinizing type, moderately differentiated. Tumor located within the cervix and involving lower uterine segment myometrium. Tumor dimension, approximately 4.0 cm. Maximum depth of invasion 3.8 cm in a section measuring 4.3 cm. High-grade squamous intraepithelial lesion flanking both sides of the tumor. Lymphovascular invasion is present. Vaginal involvement is not identified. All surgical margins, anterior and posterior vaginal cuffs are negative. Pathologic tumor stage: pTlb, N1 (AJCC Cancer Staging Handbook, 6th Ed., 2002). pT1b2/pN1. Endometrium. Involved by invasive squamous cell carcinoma, keratinizing type, moderately differentiated in lower uterine segment. Background weakly proliferative pattern endometrium. Myometrium. Involved by invasive squamous cell carcinoma, keratinizing type, moderately differentiated in lower uterine segment with angiolymphatic invasion. Leiomyomata. - Adenomyosis. Serosa and parametria negative for malignancy. Focal endometriosis involving uterine serosa. HISTORY: Cervical cancer, squamous cell carcinoma of the cervix, exploratory laparotomy, total abdominal. hysterectomy, bilateral salpingo-oophorectomy and lymph node dissection. MICROSCOPIC: See diagnosis. GROSS: A. LEFT PELVIC LYMPH NODE. Labeled with the patient's name, labeled \"left pelvic lymph node\", and received in formalin is a 4.0 x 2.5 x 0.6 cm. portion of fibrofatty tissue. Six soft, tan lymph nodes were identified ranging from 0.7 to 2.8 cm in maximum. dimension. The specimen is entirely submitted. A1. One lymph node, bisected - 2. A2. One lymph node, bisected - 2. A3. Two lymph nodes - 2. A4. One lymph node and fatty tissue - multiple. A5. One lymph node and fatty tissue - multiple. B. LEFT OBTURATOR LYMPH NODE. Labeled with the patient's name, labeled \"left obturator lymph node\", and received in formalin is a 2.2 x 3.0 x 0.6. cm portion of fibrofatty tissue. Two firm, tan",
      "predicted": null,
      "ground_truth": "CESC",
      "correct": null,
      "reasoning": "",
      "idx": 247,
      "timestamp": "2026-01-19T15:59:53.114984"
    },
    {
      "sample_idx": 507,
      "input": "Sex: M. Histopathological Examination. Pre-Op Diagnosis : Right Renal Mass. Specimens. Kidney, right for. Frozen Diagnosis : : GROSS EXAMINATION: The specimen is received fresh labeled with the name of the. patient and labeled as kidney, right. The specimen consists. of a kidney and attached perinephric fat. The kidney. measures 11.5 X 6 X 4.5 cm and weighs 201 grams. The ureter. and vascular margins are submitted in block 1. The renal. sinus/hilar margin is submitted in block 2. Sectioning into...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Chromophobe renal cell carcinoma, two foci, 3.8 and 1.0 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Chromophobe renal cell carcinoma, two foci, 3.8 and 1.0 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Chromophobe renal cell carcinoma, two foci, 3.8 and 1.0 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Chromophobe renal cell carcinoma, two foci, 3.8 and 1.0 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Chromophobe renal cell carcinoma, two foci, 3.8 and 1.0 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Chromophobe renal cell carcinoma, two foci, 3.8 and 1.0 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Chromophobe renal cell carcinoma, two foci, 3.8 and 1.0 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right",
      "predicted": "KIRC",
      "ground_truth": "KICH",
      "correct": false,
      "reasoning": "1. Site: Kidney (Right). 2. Findings: Chromophobe renal cell carcinoma, two foci, 3.8 and 1.0 cm. 3. Code: KIRC.",
      "idx": 507,
      "timestamp": "2026-01-19T15:59:53.114995"
    },
    {
      "sample_idx": 460,
      "input": "Service: Otolaryngology. Resulted: Facility. Addended. SPECIMEN (S) RECEIVED. 1. Nck: Left neck - level 1B. 2. Neck: Left neck level IIa. 3. Thyroid: Possible pyramidal lobe of thyroid. 4. Oral Cavity: Left cheek deep margin,. 5. Oral Cavity: Lateral lip margin,. 6. Oral Cavity: Palatal margin. 7. Oral Cavity: Posterior cheek margin. 8. Oral Cavity: Left partial maxillectomy and left cheek. 9. Neck: Left neck level I to IV. DIAGNOSIS. 1. Left neck; level IB: - One lymph node, negative for malign...",
      "response": "```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Buccal Mucosa (inner cheek). 2. Findings: Squamous cell carcinoma, moderately differentiated, present in the buccal mucosa. 3. Code: PAAD (Pan-Adenocarcinoma) maps to PAAD because the report mentions squamous cell carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Left cheek deep margin. 2. Findings: Squamous cell carcinoma, moderately differentiated, present in the left cheek. 3. Code: SKCM (Skin Cancer) maps to SKCM because the report mentions squamous cell carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Left neck level I to IV. 2. Findings: Fourteen lymph nodes, negative for malignancy. 3. Code: UVM (Unspecified Malignancy) maps to UVM because the report mentions negative lymph nodes.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Left neck level IIA. 2. Findings: One lymph node, negative for malignancy. 3. Code: UVM (Unspecified Malignancy) maps to UVM because the report mentions negative lymph nodes.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Possible pyramidal lobe of thyroid. 2. Findings: Thyroid tissue, negative for malignancy. 3. Code: UVM (Unspecified Malignancy) maps to UVM because the report mentions negative thyroid tissue.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Left cheek deep margin. 2. Findings: Negative for malignancy. 3. Code: UVM (Unspecified Malignancy) maps to UVM because the report mentions negative findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Lateral lip margin. 2. Findings: Negative for malignancy. 3. Code: UVM (Unspecified Malignancy)",
      "predicted": "PAAD",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Buccal Mucosa (inner cheek). 2. Findings: Squamous cell carcinoma, moderately differentiated, present in the buccal mucosa. 3. Code: PAAD (Pan-Adenocarcinoma) maps to PAAD because the report mentions squamous cell carcinoma.",
      "idx": 460,
      "timestamp": "2026-01-19T15:59:53.115009"
    },
    {
      "sample_idx": 131,
      "input": "Female. Admission Date: Discharge Date: Pathology Addendum Report. Collected Date/Time: Received Date/Time: Addendum Report. ASSAY PERFORMED: HER2 GENE AMPLIFICATION BY DUAL IN SITU HYBRIDIZATION USING THE. HER2 Dual ISH DNA PROBE COCKTAIL. Number of nuclei scored: 20. Total HER2 signals: 60. Total CHR 17 signals: 39. HER2/CHR 17 ratio: 1.5. INTERPRETATION: - NEGATIVE FOR HER2 GENE AMPLIFICATION. NOTE: THE ASSAY WAS PERFORMED AS A REFLEX TEST AFTER THE HER2/NEU IMMUNOSTAIN WAS 2+. SPECIMEN TYPE:...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade 2, 2.5 cm. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade 2, 2.5 cm. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade 2, 2.5 cm. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade 2, 2.5 cm. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade 2, 2.5 cm. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade 2, 2.5 cm. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade 2, 2.5 cm. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade 2, 2.5 cm. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade 2, 2.5 cm. 3. Code: BRCA.",
      "idx": 131,
      "timestamp": "2026-01-19T15:59:53.115018"
    },
    {
      "sample_idx": 692,
      "input": "Pathology Result: Specimen Collected Date: Specimen Received Date: Medical Record Number. Facility: Cathologist: Date of Proceduze: Date Received: Oate Reported. Addendus Present. FINAL DIAGNOSIS. A. POSTERIOR SUPERIOR MARGIN, BIOPSY. CEREBRAL CORTEX, NO SOLIO TUMOS IDENTIFIED. 8. POSTERIOR SUPERIOR $ 2. BIOPSY. CERERRAL CORTEX, NO SOLID TUHOR IDENTIFIED. c. ANTERIOR INFERION, BIOPST: -CEREERAL CORTEX, NO SOLID TUMOR IDENTIFIED. o. POSTERIOR INTERION, BIOPSY: CEREBRAL CORTEX AND MILOLY WBITE MAT...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cerebral Cortex. 2. Findings: Glial hypercellularity, no solid tumor identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cerebral Cortex. 2. Findings: Glial hypercellularity, no solid tumor identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cerebral Cortex. 2. Findings: Glial hypercellularity, no solid tumor identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cerebral Cortex. 2. Findings: Glial hypercellularity, no solid tumor identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cerebral Cortex. 2. Findings: Glial hypercellularity, no solid tumor identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cerebral Cortex. 2. Findings: Glial hypercellularity, no solid tumor identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cerebral Cortex. 2. Findings: Glial hypercellularity, no solid tumor identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cerebral Cortex. 2. Findings: Glial hypercellularity, no solid tumor identified. 3. Code: KIRC.\"\n}\n",
      "predicted": "KIRC",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Cerebral Cortex. 2. Findings: Glial hypercellularity, no solid tumor identified. 3. Code: KIRC.",
      "idx": 692,
      "timestamp": "2026-01-19T15:59:53.115029"
    },
    {
      "sample_idx": 43,
      "input": "M. Urology. Clinical Diagnosis & History: HGT1 on biopsy T3 on imaging and exam. Specimens Submitted: 1: Bladder, prostate, seminal vesicles, urachus and urethra. DIAGNOSIS: 1. Bladder, prostate, seminal vesicles, urachus and urethra: Tumor Type: Invasive urothelial carcinoma, NOS, with focal squamous differentiation. Histologic Grade: High grade. Pattern of growth of the Non-Invasive component: Flat (in situ carcinoma). Pattern of growth of the Invasive component: Infiltrating. Tumor Multicentr...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder, prostate, seminal vesicles, urachus and urethra. 2. Findings: Invasive urothelial carcinoma, NOS, with focal squamous differentiation. High grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder, prostate, seminal vesicles, urachus and urethra. 2. Findings: Invasive urothelial carcinoma, NOS, with focal squamous differentiation. High grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder, prostate, seminal vesicles, urachus and urethra. 2. Findings: Invasive urothelial carcinoma, NOS, with focal squamous differentiation. High grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder, prostate, seminal vesicles, urachus and urethra. 2. Findings: Invasive urothelial carcinoma, NOS, with focal squamous differentiation. High grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder, prostate, seminal vesicles, urachus and urethra. 2. Findings: Invasive urothelial carcinoma, NOS, with focal squamous differentiation. High grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder,",
      "predicted": "KIRC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Bladder, prostate, seminal vesicles, urachus and urethra. 2. Findings: Invasive urothelial carcinoma, NOS, with focal squamous differentiation. High grade. 3. Code: KIRC.",
      "idx": 43,
      "timestamp": "2026-01-19T15:59:53.115041"
    },
    {
      "sample_idx": 1204,
      "input": "Diagnosis/diagnoses: 2.: Total gastrectomy preparation with part of transverse colon attached. Stomach with an. ulcerated gastric carcinoma located in the middle of the stomach on the side of the greater. curvature, extending to within 5 cm of the aboral and 7 cm of the oral resection margin,. encroaching on the anterior and posterior wall of the stomach, with a maximum diameter of 7. cm and characterized histologically as a poorly differentiated adenocarcinoma (gastric. carcinoma of the intesti...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric carcinoma, poorly differentiated adenocarcinoma (gastric carcinoma of the intestinal type). 3. Code: Stomach Gastric Carcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric carcinoma, poorly differentiated adenocarcinoma (gastric carcinoma of the intestinal type). 3. Code: Stomach Gastric Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric carcinoma, poorly differentiated adenocarcinoma (gastric carcinoma of the intestinal type). 3. Code: Stomach Gastric Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric carcinoma, poorly differentiated adenocarcinoma (gastric carcinoma of the intestinal type). 3. Code: Stomach Gastric Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric carcinoma, poorly differentiated adenocarcinoma (gastric carcinoma of the intestinal type). 3. Code: Stomach Gastric Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric carcinoma, poorly differentiated adenocarcinoma (gastric carcinoma of the intestinal type). 3. Code: Stomach Gastric Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric carcinoma, poorly differentiated adenocarcinoma (gastric carcinoma of the intestinal type). 3. Code: Stomach Gastric Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. ",
      "predicted": "STAD",
      "ground_truth": "STAD",
      "correct": true,
      "reasoning": "1. Site: Stomach. 2. Findings: Gastric carcinoma, poorly differentiated adenocarcinoma (gastric carcinoma of the intestinal type). 3. Code: Stomach Gastric Carcinoma maps to STAD.",
      "idx": 1204,
      "timestamp": "2026-01-19T15:59:53.115052"
    },
    {
      "sample_idx": 1134,
      "input": "Clinical Diagnosis & History: Specimens Submitted: 1: Left spermatic cord with liposarcoma and left testis. DIAGNOSIS: 1. Left spermatic cord and left testis; radical orchiectomy: - High grade leiomyosarcoma with spindle and epithelioid features. involving spermatic cord. - Tumor is seen as two nodules, 4.5 x 3.5 x 2.0cm, and 3.5 x 2.8 x. 1.5cm. -Tumor wraps around spermatic cord and involves adipose tissue and. skeletal muscle. - There is 15% gross necrosis. - Mitoses: 20 mitoses per 50 high po...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left spermatic cord and left testis. 2. Findings: High grade leiomyosarcoma with spindle and epithelioid features, involving spermatic cord, and tumor is seen as two nodules, 4.5 x 3.5 x 2.0cm, and 3.5 x 2.8 x 1.5cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left spermatic cord and left testis. 2. Findings: High grade leiomyosarcoma with spindle and epithelioid features, involving spermatic cord, and tumor is seen as two nodules, 4.5 x 3.5 x 2.0cm, and 3.5 x 2.8 x 1.5cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left spermatic cord and left testis. 2. Findings: High grade leiomyosarcoma with spindle and epithelioid features, involving spermatic cord, and tumor is seen as two nodules, 4.5 x 3.5 x 2.0cm, and 3.5 x 2.8 x 1.5cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left spermatic cord and left testis. 2. Findings: High grade leiomyosarcoma with spindle and epithelioid features, involving spermatic cord, and tumor is seen as two nodules, 4.5 x 3.5 x 2.0cm, and 3.5 x 2.8 x 1.5cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left spermatic cord and left",
      "predicted": "KIRC",
      "ground_truth": "SARC",
      "correct": false,
      "reasoning": "1. Site: Left spermatic cord and left testis. 2. Findings: High grade leiomyosarcoma with spindle and epithelioid features, involving spermatic cord, and tumor is seen as two nodules, 4.5 x 3.5 x 2.0cm, and 3.5 x 2.8 x 1.5cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 1134,
      "timestamp": "2026-01-19T15:59:53.115069"
    },
    {
      "sample_idx": 471,
      "input": "Final Diagnosis. Anterior deep margin of tongue (FSA1), biopsy: Diffusely infiltrating squamous cell carcinoma. Middle deep margin of tongue (FSA2): Diffusely infiltrating squamous cell carcinoma. Almost total glossectomy with frozen section examination: Posterior shaved margin positive for squamous cell carcinoma. Medial shaved margin positive for squamous cell carcinoma. Areas of lymphovascular invasion are identified. Perineural invasion identified. Random sections of tongue show diffuse inva...",
      "response": "```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Anterior deep margin). 2. Findings: Diffusely infiltrating squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Middle deep margin). 2. Findings: Diffusely infiltrating squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Posterior shaved margin). 2. Findings: Diffusely infiltrating squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Medial shaved margin). 2. Findings: Diffusely infiltrating squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Posterior). 2. Findings: Diffusely infiltrating squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Medial). 2. Findings: Diffusely infiltrating squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Tip). 2. Findings: Diffusely infiltrating squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Anterior deep margin). 2. Findings: Diffusely infiltrating squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Middle deep margin). 2. Findings: Diffusely infiltrating squamous cell carcinoma. 3. Code:",
      "predicted": "SCC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Tongue (Anterior deep margin). 2. Findings: Diffusely infiltrating squamous cell carcinoma. 3. Code: SCC maps to SCC.",
      "idx": 471,
      "timestamp": "2026-01-19T15:59:53.115080"
    },
    {
      "sample_idx": 1205,
      "input": "STOMACH TISSUE CHECKLIST. Specimen type: Gastrectomy. Tumor site: Stomach. Tumor size: 9.5 X 4 X 1.2 cm. Tumor features: Exophytic (polypoid). Histologic type: Adenocarcinoma. Histologic grade: Poorly. differentiated. Tumor extent: Adjacent structures. (specify) - lesser omentum. Lymph nodes: 0/5 positive for. metastasis ( 0/5). Lymphatic invasion: Not specified. Venous invasion: Not specified. Perineural invasion: Not specified. Margins: Not specified. Evidence of neo-adjuvant treatment: Not sp...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with tumor size 9.5 x 4 x 1.2 cm and extension to the lesser omentum. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENCA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with tumor size 9.5 x 4 x 1.2 cm and extension to the lesser omentum. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with tumor size 9.5 x 4 x 1.2 cm and extension to the lesser omentum. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with tumor size 9.5 x 4 x 1.2 cm and extension to the lesser omentum. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with tumor size 9.5 x 4 x 1.2 cm and extension to the lesser omentum. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with tumor size 9.5 x 4 x 1.2 cm and extension to the lesser omentum. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reason",
      "predicted": "STAD",
      "ground_truth": "STAD",
      "correct": true,
      "reasoning": "1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with tumor size 9.5 x 4 x 1.2 cm and extension to the lesser omentum. 3. Code: Stomach Adenocarcinoma maps to STAD.",
      "idx": 1205,
      "timestamp": "2026-01-19T15:59:53.115093"
    },
    {
      "sample_idx": 1388,
      "input": "View Detail. Ord #=. ASAP. Sched D/T=. Ord Clin=. RESULTED. Collect D/T=. Resulted by= SYS, SYSTEM. Result D/T=. Item Comment: Item Custom Questions: How Many Part Types 6. Modifiers: (1 of 1). CoPath Specimen. Source: A: Uterus, Cervix, bilateral tubes IT\\ ovaries, ( Frozen section. B: Omentum, ( Permanent ). C: Right Pelvic lymph node. D: Left Pelvic lymph node. E: Left Para-aortic lymph node. F: Right Para-aortic lymph node. Final Diagnosis. A. Uterus, cervix, bilateral tubes and ovaries (F/S...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1388,
      "timestamp": "2026-01-19T15:59:53.115103"
    },
    {
      "sample_idx": 14,
      "input": "Clinical Diagnosis/History: The patient is a. year-old woman who presented in. with gross. hematuria. She underwent a transurethral resection of a. high-grade muscle invasive transitional cell carcinoma of the bladder. The this TCGA tumor. patient now undergoes a radical cystectomy with. resection of the uterus, vagina, bilateral tubes and ovaries. Gross Description: The specimen is received in seven parts, each labeled with the patient's name. and medical record number. Parts A-C are received. ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, high-grade, invading muscularis propria; negative surgical margins. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}",
      "predicted": "KIRC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, high-grade, invading muscularis propria; negative surgical margins. 3. Code: KIRC.",
      "idx": 14,
      "timestamp": "2026-01-19T15:59:53.115113"
    },
    {
      "sample_idx": 145,
      "input": "Material. Submitted: left breast. Clinical. History: Clinical. Diagnosis: Operating. Gross Examination: Received is a container labeled with the patient's name, history number and date. In. addition the container is labeled \"left breast\". The specimen is received in the fresh state. and consists of a breast and attached axillary tail weighing 560 grams and measuring 37.0 x. with a maximum diameter of 7.0 cm. The skin is notable for a large bruise in the lower. 17.5 x 3.0 em. in greatest dimensio...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 145,
      "timestamp": "2026-01-19T15:59:53.115123"
    },
    {
      "sample_idx": 120,
      "input": "page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Total organ resection - right breast. Internal referral. Expected time of examination: up to 8 working days. Clinical diagnosis: Based on PCI, cellulae carcinomatosae - lesion covering the lower part of the breast. Macroscopic description: Right breast sized 27 x 23 x 3 cm removed without axillary tissues and with a skin flap of 27 x 14 cm. Skin injected with blue dye. Tumour sized...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma and ductal carcinoma in situ of the right breast. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma and ductal carcinoma in situ of the right breast. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma and ductal carcinoma in situ of the right breast. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma and ductal carcinoma in situ of the right breast. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma and ductal carcinoma in situ of the right breast. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma and ductal carcinoma in situ of the right breast. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma and ductal carcinoma in situ of the right breast. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma and ductal carcinoma in situ of the right breast. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive mucinous carcinoma and ductal carcinoma in situ of the right breast. 3. Code: BRCA.",
      "idx": 120,
      "timestamp": "2026-01-19T15:59:53.115133"
    },
    {
      "sample_idx": 468,
      "input": "Specimen(s) Received. 1. Nck: contents left neck. 2. Oral cavity:It.oral major resection -short medial long anterior. 3. Oral Cavity: t.posterior margin. 4. Oral avity:It.anterior margin. 5. Oral Cavity:It.lateral mucosa margin. 6. Oral Cavity:deep muscle margin. 7. Surgical Waste. 8. Neck: contents rt neck. 9. Lymph node: lt. facial node. 10. Lymph node:It neck III node. 11. Lymph node:It facial node. Diagnosis. 1. Contents left neck. Metastatic squamous cell carcinoma involving six of thirty-f...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral cavity. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral cavity. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral cavity. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral cavity. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral cavity. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral cavity. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral cavity. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral cavity. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral cavity. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site:",
      "predicted": "BRCA",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Oral cavity. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: BRCA",
      "idx": 468,
      "timestamp": "2026-01-19T15:59:53.115143"
    },
    {
      "sample_idx": 138,
      "input": "F. Pathologic Interpretation: A. Lymph node, sentinel lymph node: - No malignancy seen in one lymph node (0/1). - Keratin immunostain pending. B. Skin left breast: - Skin, no pathologic change. C. Left breast lumpectomy: - Infiltrating poorly differentiated ductal carcinoma, high nuclear grade, 2.4 cm in greatest dimension. - Margins of resection are free of tumor. - Lymphovascular space invasion is present. - Previous biopsy site identified. - The tumor cells are positive for ER and PR, and neg...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.",
      "idx": 138,
      "timestamp": "2026-01-19T15:59:53.115151"
    },
    {
      "sample_idx": 64,
      "input": "Encounter Number. COPY ONLY DO NOT FILE. SURGICAL PATHOLO. Correction. Source of Specimen. A. LEFT DISTAL URETER MARGIN FS-. B. RIGHT DISTAL URETER MARGIN FS-. C. DISTAL URETHRAL MARGIN OF RADICAL CYSTECTOMY SPECIMEN FS-. D. LEFT PELVIC LYMPH NODE-. E. RIGHT PELVIC LYMPH NODE-. F. BLADDER AND PROSTATE GLAND, SEMINAL VESICLES-. Reason for Correction. TO CORRECT TYPOGRAPHICAL ERROR. FINAL DIAGNOSIS: A. LEFT DISTAL URETER MARGIN FS-. SEGMENT OF URETER, NO TUMOR SEEN. B. RIGHT DISTAL URETER MARGIN F...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Distal Ureter. 2. Findings: No tumor seen in ureter. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Car",
      "predicted": "KIRC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Distal Ureter. 2. Findings: No tumor seen in ureter. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 64,
      "timestamp": "2026-01-19T15:59:53.115161"
    },
    {
      "sample_idx": 676,
      "input": "Diagnosis : A, B: Brain, right frontal region, excision. - Oligodendroglioma, WHO grade II. Comment: Sections of the tumor were sent to the Cytogenetics Laboratory. for 1p19q testing. The results of these tests will be reported. separately by the Cytogenetics Laboratory. reviewed this case and concurs with the diagnosis. Intraoperative Consult Diagnosis: An in. a. rative consultation was requested by. on. from. Smear A1 : Right frontal tumor, biopsy. W gr. oma. at. Frozen Section Pathologist: in...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right Frontal Region). 2. Findings: Oligodendroglioma, WHO grade II. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right Frontal Region). 2. Findings: Oligodendroglioma, WHO grade II. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right Frontal Region). 2. Findings: Oligodendroglioma, WHO grade II. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right Frontal Region). 2. Findings: Oligodendroglioma, WHO grade II. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right Frontal Region). 2. Findings: Oligodendroglioma, WHO grade II. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right Frontal Region). 2. Findings: Oligodendroglioma, WHO grade II. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right Frontal Region). 2. Findings: Oligodendroglioma, WHO grade II. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right Frontal Region). 2. Findings: Oligodendroglioma, WHO grade II. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain (Right Frontal Region). 2. Findings: Oligodendroglioma, WHO grade II. 3. Code: GBM maps to GBM.",
      "idx": 676,
      "timestamp": "2026-01-19T15:59:53.115170"
    },
    {
      "sample_idx": 1386,
      "input": "Specimens Submitted: 1: SP: Uterua, cervix, ovaries and fallopian tubes; total abdominal. hysterectomy and bilateral salpingo-oophorectomy. 2: SP: Sentinel lymph node, oburator, left. 3: SP: Sentinel lymph node, obturator, right. DIAGNOSIS: 1. SP: Uterus, cervix, ovaries and fallopian tubes; total abdominal. hysterectomy and bilateral salpingo-oophorectomy: Tumor Type: Adenocarcinome. endometricid type. Architectural Grade (For Endometricid Types only): II (5-50% solid growth). Nuclear Grade (Fo...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Adenocarcinoma, endometrial type. Architectural Grade II, Nuclear Grade 2, FIGO Grade 2. Myometrial Invasion: in maximum depth. Endocervical Invasion: Not identified. Lymphovascular invasion: Identified. Endometrium: Exhibits complex hyperplamia with atypia. Myometrium: Exhibits adenomyosis. Adnexa: Unremarkable. 3. Code: UCEC (Uterine Corpus Endometrium) maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Adenocarcinoma, endometrial type. Architectural Grade II, Nuclear Grade 2, FIGO Grade 2. Myometrial Invasion: in maximum depth. Endocervical Invasion: Not identified. Lymphovascular invasion: Identified. Endometrium: Exhibits complex hyperplamia with atypia. Myometrium: Exhibits adenomyosis. Adnexa: Unremarkable. 3. Code: UCEC (Uterine Corpus Endometrium) maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Adenocarcinoma, endometrial type. Architectural Grade II, Nuclear Grade 2, FIGO Grade 2. Myometrial Invasion: in maximum depth. Endocervical Invasion: Not identified. Lymphovascular invasion: Identified. Endometrium: Exhibits complex hyperplamia with atypia. Myometrium: Exhibits adenomyosis. Adnexa: Unremarkable. 3. Code: UCEC (Uterine Corpus Endometrium) maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Adenocarcinoma, endometrial type. Architectural Grade II, Nuclear Grade 2, FIGO Grade 2. Myometrial Invasion: in maximum depth. Endocervical Invasion: Not identified. Lymphovascular invasion: Identified. Endometrium: Exhibits complex hyperplamia with atypia. Myometrium: Exhibits adenomyosis. Adnexa: Unremarkable. 3",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus. 2. Findings: Adenocarcinoma, endometrial type. Architectural Grade II, Nuclear Grade 2, FIGO Grade 2. Myometrial Invasion: in maximum depth. Endocervical Invasion: Not identified. Lymphovascular invasion: Identified. Endometrium: Exhibits complex hyperplamia with atypia. Myometrium: Exhibits adenomyosis. Adnexa: Unremarkable. 3. Code: UCEC (Uterine Corpus Endometrium) maps to UCEC.",
      "idx": 1386,
      "timestamp": "2026-01-19T15:59:53.115186"
    },
    {
      "sample_idx": 1052,
      "input": "MODIFIED REPORT - REVIEW ADDENDUM SECTION. DIAGNOSIS. (A) RIGHT PELVIC LYMPH NODES: Seven lymph nodes, no tumor present. (0/7). (B) LEFT PELVIC LYMPH NODES: Four lymph nodes, no tumor present. (0/4). (C) PROSTATE AND SEMINAL VESICLES: Supplemental report to follow. Entire report and diagnosis completed by. GROSS DESCRIPTION. (A) RIGHT PELVIC LYMPH NODES - Consists of a single yellow-red fragment of fibroadipose tissue (8 x 4 x 1 cm). Sectioning. reveals seven possible lymph nodes, ranging in siz...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostatic adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5 component. 3. Code: PRAD.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostatic adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5 component. 3. Code: PRAD.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostatic adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5 component. 3. Code: PRAD.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostatic adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5 component. 3. Code: PRAD.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostatic adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5 component. 3. Code: PRAD.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostatic adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5 component. 3. Code: PRAD.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostatic adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5 component. 3.",
      "predicted": "PRAD",
      "ground_truth": "PRAD",
      "correct": true,
      "reasoning": "1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostatic adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5 component. 3. Code: PRAD.",
      "idx": 1052,
      "timestamp": "2026-01-19T15:59:53.115197"
    },
    {
      "sample_idx": 487,
      "input": "DIAGNOSIS. (A) LEFT NECK LEVEL 1: METASTATIC SQUAMOUS CARCINOMA IN ONE OF TWELVE LYMPH NODES(1/12). Extracapsular extension is not identified. (B) LEFT NECK DISSECTION, LEVEL II: METASTATIC SQUAMOUS CARCINOMA IN ONE OF TEN LYMPH NODES (1/10). Extracapsular extension is not identified. (C) LEFT NECK DISSECTION, LEVEL III: METASTATIC SQUAMOUS CARCINOMA IN ONE OF TWELVE LYMPH NODES (1/12). Extracapsular extension is not identified. (D) LEFT NECK DISSECTION, LEVEL IV: Thirteen lymph nodes, no tumor ...",
      "response": "```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma of the tongue. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma of the tongue. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma of the tongue. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma of the tongue. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma of the tongue. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma of the tongue. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma of the tongue. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma of the tongue. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma of the tongue. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"",
      "predicted": "SCC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma of the tongue. 3. Code: SCC maps to SCC.",
      "idx": 487,
      "timestamp": "2026-01-19T15:59:53.115206"
    },
    {
      "sample_idx": 570,
      "input": "Clinical Diagnosis & History: vith right renal mass,. Specimens Submitted: 1: SP: Kidney, right renal tumor, partial nephrectomy. DIAGNOSIS: 1. SP: Kidney, right renal tumor, partial nephrectomy. m): Tumor Type: Renal cell carcinoma - Conventional (clear cell) type. Fuhrman Nuclear Grade: Nuclear grade III/IV. Tumor Size: Greatest diemeter is 4.0 cm. Local Invasion (for renal cortical types): Not Identified. Renal Vein Invesion: Not identified. Surgical Margins: Free of tumor. Non-Neoplastic Kid...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. Tumor Size: Greatest diameter is 4.0 cm. Local Invasion: Not identified. Renal Vein Invasion: Not identified. Surgical Margins: Free of tumor. Non-Neoplastic Kidney: Unremarkable. Adrenal Gland: Not identified. Lymph Nodes: Not identified. Steging for renal cell carcinoma/oncocytoma: pT1 Tumor <= 7.0 cm in greatest dimension limited to the kidney. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. Tumor Size: Greatest diameter is 4.0 cm. Local Invasion: Not identified. Renal Vein Invasion: Not identified. Surgical Margins: Free of tumor. Non-Neoplastic Kidney: Unremarkable. Adrenal Gland: Not identified. Lymph Nodes: Not identified. Steging for renal cell carcinoma/oncocytoma: pT1 Tumor <= 7.0 cm in greatest dimension limited to the kidney. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. Tumor Size: Greatest diameter is 4.0 cm. Local Invasion: Not identified. Renal Vein Invasion: Not identified. Surgical Margins: Free of tumor. Non-Neoplastic Kidney: Unremarkable. Adrenal Gland: Not identified. Lymph Nodes: Not identified. Steging for renal cell carcinoma/oncocytoma: pT1 Tumor <= 7.0 cm in greatest dimension limited to the kidney. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. Tumor Size: Greatest diameter is 4.0 cm. Local Invasion: Not identified. Renal Vein Invasion: Not identified. Surgical Margins: Free of tumor. Non-Neoplastic Kidney: Unremarkable. Adrenal Gland: Not identified. Lymph Nodes: Not identified. Steging for renal cell carcinoma/oncocytoma: pT1 Tumor <= 7.0 cm in greatest dimension limited to the kidney. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 570,
      "timestamp": "2026-01-19T15:59:53.115225"
    },
    {
      "sample_idx": 994,
      "input": "DIAGNOSIS: Left adrenal, adrenalectomy: Pheochromocytoma. See. note. NOTE: Immunohistochemistry studies will be performed and reported as a. supplemental report. CLINICAL INFORMATION: Allocate Order to Protocol: Brief. Clinical History: pheochromocytoma Specimen Taken For Protocol: PROCEDURE: Pre-Operative Diagnosis: pheochromocytoma Post-Operative. Diagnosis: pheochromocytoma Operative Findings: left bilobular adrenal. tumor. SPECIMENS SUBMITTED: 1. ADRENAL GLAND, LEFT, Pheochromocytoma. GROSS ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left adrenal gland. 2. Findings: Pheochromocytoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left adrenal gland. 2. Findings: Pheochromocytoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left adrenal gland. 2. Findings: Pheochromocytoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left adrenal gland. 2. Findings: Pheochromocytoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left adrenal gland. 2. Findings: Pheochromocytoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left adrenal gland. 2. Findings: Pheochromocytoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left adrenal gland. 2. Findings: Pheochromocytoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left adrenal gland. 2. Findings: Pheochromocytoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left adrenal gland. 2. Findings: Pheochromocytoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left adrenal gland. 2. Findings:",
      "predicted": "KIRC",
      "ground_truth": "PCPG",
      "correct": false,
      "reasoning": "1. Site: Left adrenal gland. 2. Findings: Pheochromocytoma. 3. Code: KIRC.",
      "idx": 994,
      "timestamp": "2026-01-19T15:59:53.115235"
    },
    {
      "sample_idx": 438,
      "input": "Case imported from legacy computer system. The format of this report does not match the original case. For cases prior to. he section \"SPECIMEN\" may have been added. DIAGNOSIS : (0) (P) LEFT AND RIGHT BODY OF MANDIBLE: INVOLVED BY INVASIVE MODERATELY DIFFERENTIATED SQUAMOUS CELL CARCINOMA;. RIGHT AND LEFT LATERAL MANDIBULAR RESECTION MARGINS FREE OF TUMOR. D:N. DIAGNOSIS : (A) LEFT JUGULAR LYMPH NODES: All of twelve lymph nodes, free of carcinoma. (B). LEFT SUBMANDIBULAR TRIANGLE: ONE OF SIX LYM...",
      "response": "```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Mandible (Left and Right Body). 2. Findings: Invasive moderately differentiated squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Mandible (Left and Right Body). 2. Findings: Invasive moderately differentiated squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Mandible (Left and Right Body). 2. Findings: Invasive moderately differentiated squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Mandible (Left and Right Body). 2. Findings: Invasive moderately differentiated squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Mandible (Left and Right Body). 2. Findings: Invasive moderately differentiated squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Mandible (Left and Right Body). 2. Findings: Invasive moderately differentiated squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Mandible (Left and Right Body). 2. Findings: Invasive moderately differentiated squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Mandible (Left and Right Body). 2. Findings: Invasive moderately differentiated squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Mandible (Left and Right Body",
      "predicted": "SCC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Mandible (Left and Right Body). 2. Findings: Invasive moderately differentiated squamous cell carcinoma. 3. Code: SCC maps to SCC.",
      "idx": 438,
      "timestamp": "2026-01-19T15:59:53.115246"
    },
    {
      "sample_idx": 1251,
      "input": "SPECIMEN TAKEN: FINAL DIAGNOSIS. 1) DELPHIAN LYMPH NODE (EXCISION): ONE (1) LYMPH NODE AND. ASSOCIATED FIBROADIPOSE TISSUE, NEGATIVE FOR TUMOR. 2) LEFT ENLARGED INFERIOR PARATHYROID (EXCISION): ONE (1) LYMPH. NODE AND ASSOCIATED FIBROADIPOSE TISSUE, NEGATIVE FOR TUMOR. 3) THYROID (TOTAL THYROIDECTOMY, CENTRAL NECK DISSECTION): SPECIMEN TYPE: Total thyroidectomy. TUMOR SITE: Right lobe. Left lobe. LARGEST TUMOR SIZE: 1.8 centimeters (right lobe). HISTOLOGIC TYPE: Papillary carcinoma. FOCALITY: Mu...",
      "response": "```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid (Total thyroidectomy, central neck dissection). 2. Findings: Papillary carcinoma, multifocal (right and left lobe, right lobe predominantly). Lymph nodes are negative for tumor. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Lymphocytic thyroiditis. Parathyroid gland tissue present (lateral aspect of right inferior lobe). 3. Code: Thymus maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Lymph Node (Delphian). 2. Findings: Negative for tumor. 3. Code: Lymph Node maps to BLCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Left Inferior Parathyroid). 2. Findings: Negative for tumor. 3. Code: Lymph Node maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ACC\",\n    \"reasoning\": \"1. Site: Lymph Node (Delphian). 2. Findings: Negative for tumor. 3. Code: Lymph Node maps to ACC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Left Inferior Parathyroid). 2. Findings: Negative for tumor. 3. Code: Lymph Node maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Lymph Node (Left Inferior Parathyroid). 2. Findings: Negative for tumor. 3. Code: Lymph Node maps to BLCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Left Inferior Parathyroid). 2. Findings: Negative for tumor. 3. Code: Lymph Node maps to KIRC.\"\n}\n```\n```",
      "predicted": "THCA",
      "ground_truth": "THCA",
      "correct": true,
      "reasoning": "1. Site: Thyroid (Total thyroidectomy, central neck dissection). 2. Findings: Papillary carcinoma, multifocal (right and left lobe, right lobe predominantly). Lymph nodes are negative for tumor. 3. Code: Thyroid Carcinoma maps to THCA.",
      "idx": 1251,
      "timestamp": "2026-01-19T15:59:53.115259"
    },
    {
      "sample_idx": 270,
      "input": "Female. Surgery Date: DIAGNOSIS: Liver, segment IVB, and gallbladder, resection: Invasive grade 3 (of 4). cholangiocarcinoma forming a hilar mass (10.0 x 9.4 x 7.0 cm) . The tumor invades. into the wall of the gallbladder. The gallbladder mucosa shows cholesterolosis. The. surgical margins are negative. Omentum, biopsy: Metastatic cholangiocarcinoma. Soft tissue, peri duodenal region, excision: Metastatic cholangiocarcinoma.",
      "response": "```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Liver (segment IVB) and Gallbladder. 2. Findings: Cholangiocarcinoma, hilar mass, grade 3. The tumor invades the gallbladder wall. 3. Code: CHOL (Cholangiocarcinoma) maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Omentum, peri duodenal region. 2. Findings: Metastatic cholangiocarcinoma. 3. Code: PAAD (Pancreatic Adenocarcinoma) maps to PAAD.\n\"}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Gallbladder. 2. Findings: Cholangiocarcinoma, gallbladder mucosa shows cholesterolosis. 3. Code: UCEC (Uterine Corpus Endometrial Carcinoma) maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (segment IVB). 2. Findings: Cholangiocarcinoma, hilar mass, grade 3. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Omentum, peri duodenal region. 2. Findings: Metastatic cholangiocarcinoma. 3. Code: UVM (Uterine Corpus Endometrial Carcinoma) maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (segment IVB). 2. Findings: Cholangiocarcinoma, hilar mass, grade 3. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (segment IVB). 2. Findings: Cholangiocarcinoma, hilar mass, grade 3. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) maps to K",
      "predicted": "CHOL",
      "ground_truth": "CHOL",
      "correct": true,
      "reasoning": "1. Site: Liver (segment IVB) and Gallbladder. 2. Findings: Cholangiocarcinoma, hilar mass, grade 3. The tumor invades the gallbladder wall. 3. Code: CHOL (Cholangiocarcinoma) maps to CHOL.",
      "idx": 270,
      "timestamp": "2026-01-19T15:59:53.115269"
    },
    {
      "sample_idx": 1169,
      "input": "aterality:Adenocarcinoma of the stomach, G-3, with invasion into the. perigastric fat. Five examined lymph nodes form greater curvature and five examnined lymph nodes. form lesser curvature demonstrated metastases. In the omentum there is focal preivascular lymphoid. infiltration. Path Report:STOMACH TISSUE CHECKLIST. Specimen type: Subtotal gastrectomy. Tumor site: Antrum. Tumor size: 4 X 0 X 6 cm. Tumor features: Ulcerated. Histologic type: Adenocarcinoma. Histologic grade: Poorly differentiat...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with lymph node metastasis. 3. Code: STAD maps to Stomach Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma. 3. Code: ADENOCA maps to Stomach Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with lymph node metastasis. 3. Code: STAD maps to Stomach Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with lymph node metastasis. 3. Code: STAD maps to Stomach Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with lymph node metastasis. 3. Code: STAD maps to Stomach Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with lymph node metastasis. 3. Code: STAD maps to Stomach Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with lymph node metastasis. 3. Code: STAD maps to Stomach Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with lymph node metastasis. 3. Code: STAD maps to Stomach Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"",
      "predicted": "STAD",
      "ground_truth": "STAD",
      "correct": true,
      "reasoning": "1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with lymph node metastasis. 3. Code: STAD maps to Stomach Adenocarcinoma.",
      "idx": 1169,
      "timestamp": "2026-01-19T15:59:53.115280"
    },
    {
      "sample_idx": 1180,
      "input": "PRIMARY SITE: Stomach (Gastroesophageal junction). \"Esophagus + stomach\": Poorly differentiated adenocarcinoma, invasive and ulcerated. Size of the neoplasm: 7.0 x 4.7 x 2.4cm (2.4cm deep). Location: esophagogastric transition. Depth of infiltration: up to subserosa. Sanguineous vascular invasion: not detected. Lymphatic vascular invasion: present. Perineural invasion: present. Adjacent gastric mucosa: intense active chronic gastritis. Omentum : - Mature adipose tissue free neoplasia. - Presence...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Poorly differentiated adenocarcinoma, invasive and ulcerated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Poorly differentiated adenocarcinoma, invasive and ulcerated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Poorly differentiated adenocarcinoma, invasive and ulcerated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Poorly differentiated adenocarcinoma, invasive and ulcerated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Poorly differentiated adenocarcinoma, invasive and ulcerated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Poorly differentiated adenocarcinoma, invasive and ulcerated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Poorly differentiated adenocarcinoma, invasive and ulcerated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Poorly differentiated adenocarcinoma, invasive and ulcerated. 3. Code: ADENOMA\"\n}\n```\n",
      "predicted": "ADENOMA",
      "ground_truth": "STAD",
      "correct": false,
      "reasoning": "1. Site: Stomach (Gastroesophageal junction). 2. Findings: Poorly differentiated adenocarcinoma, invasive and ulcerated. 3. Code: ADENOMA",
      "idx": 1180,
      "timestamp": "2026-01-19T15:59:53.115290"
    },
    {
      "sample_idx": 968,
      "input": "Final Diagnosis. A. PANCREAS, DISTAL, AND SPLEEN, PARTIAL PANCREATECTOMY AND. SPLENECTOMY: Well-differentiated pancreatic endocrine tumor. (See key pathological findings.). Spleen with no significant pathologic changes. I,. the attending pathologist, personally reviewed all. slides and / or materiala and rendered the final diagnosis. Electronically. Comment. There is no tumor necrosis, the mitotic rate is <2 mitoses/10 high power fields, and the ki-67. immunostain shows positivity in approximate...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Pancreas, distal. 2. Findings: Well-differentiated pancreatic endocrine tumor. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PANIN\",\n    \"reasoning\": \"1. Site: Pancreas, distal. 2. Findings: Well-differentiated pancreatic endocrine tumor. 3. Code: PANIN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Pancreas, distal. 2. Findings: Well-differentiated pancreatic endocrine tumor. 3. Code: PAAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Pancreas, distal. 2. Findings: Well-differentiated pancreatic endocrine tumor. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Pancreas, distal. 2. Findings: Well-differentiated pancreatic endocrine tumor. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Pancreas, distal. 2. Findings: Well-differentiated pancreatic endocrine tumor. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Pancreas, distal. 2. Findings: Well-differentiated pancreatic endocrine tumor. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Pancreas, distal. 2. Findings: Well-differentiated pancreatic endocrine tumor. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Pancreas, distal. 2. Findings: Well-differentiated pancreatic endocrine tumor. 3. Code: PRAD.\"\n}\n```",
      "predicted": "PRAD",
      "ground_truth": "PAAD",
      "correct": false,
      "reasoning": "1. Site: Pancreas, distal. 2. Findings: Well-differentiated pancreatic endocrine tumor. 3. Code: PRAD.",
      "idx": 968,
      "timestamp": "2026-01-19T15:59:53.115305"
    },
    {
      "sample_idx": 497,
      "input": "SUPPLEMENTAL REPORT. (C) LEFT MODIFIED NECK DISSECTION, TOTAL THYROIDECTOMY, SUPERIOR MEDIASTINAL. DISSECTION, PARTIAL DISSECTION, CLAVICLE, FIRST RIB: Sections of bone tissue submitted for decalcification appear free. of tumor. DIAGNOSIS. CAJ. LEFT PARTIAL GLOSSECIOMY AND PHARYNGECTOMY: INVASIVE, MODERATELY DIFFERENTIATED SQUAMOUS CELL CARCINOMA. Focal perineural invasion present. All margins free of tumor. (B) LEFT CHEEK: Epidermal inclusion cyst, keratinous type. (C) LEFT MODIFIED NECK DISSEC...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Left Partial Glossectomy and Pharyngectomy. 2. Findings: Invasive, moderately differentiated squamous cell carcinoma. 3. Code: ADENOCA is not a valid TCGA code. The closest code based on the tumor type is ADENOCA, which is a code for adenocarcinoma. However, this is a squamous cell carcinoma, so this is not a good match.\"\n}\n```\n\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Partial Glossectomy and Pharyngectomy. 2. Findings: Invasive, moderately differentiated squamous cell carcinoma. 3. Code: KIRC is a code for Kidney Renal Clear Cell Carcinoma. The findings are not related to kidney cancer, so this is not a good match.\"\n}\n```\n\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Left Partial Glossectomy and Pharyngectomy. 2. Findings: Invasive, moderately differentiated squamous cell carcinoma. 3. Code: BRCA is a code for Breast Invasive Carcinoma. The findings are not related to breast cancer, so this is not a good match.\"\n}\n```\n\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Partial Glossectomy and Pharyngectomy. 2. Findings: Invasive, moderately differentiated squamous cell carcinoma. 3. Code: KIRC is a code for Kidney Renal Clear Cell Carcinoma. The findings are not related to kidney cancer, so this is not a good match.\"\n}\n```\n\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Partial Glossectomy and Pharyngectomy. 2. Findings: Invasive, moderately differentiated squamous cell carcinoma. 3. Code: KIRC is a code for Kidney Renal Clear Cell Carcinoma. The findings are not related to kidney cancer, so this is not a good match.\"\n}\n```\n\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Partial Glossectomy and Pharyngectomy. 2. Findings: Invasive, moderately differentiated",
      "predicted": "ADENOCA",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Left Partial Glossectomy and Pharyngectomy. 2. Findings: Invasive, moderately differentiated squamous cell carcinoma. 3. Code: ADENOCA is not a valid TCGA code. The closest code based on the tumor type is ADENOCA, which is a code for adenocarcinoma. However, this is a squamous cell carcinoma, so this is not a good match.",
      "idx": 497,
      "timestamp": "2026-01-19T15:59:53.115324"
    },
    {
      "sample_idx": 1190,
      "input": "PRIMARY SITE: Stomach (Cardia). 1 - \"Product of the esophagogastrectomy according to the standardization\": - Poorly differentiated adenocarcinoma, intestinal type, with extensive areas of. mucinous differentiation and signet ring cells, ulcerative and infiltrative, measuring 10.5. x 6.8cm, located in cardia region / body, infiltrating the wall up to the. perigastric adipose tissue;. - Presence of perineural invasion;. - Presence of angiolymphatic invasion;. - Esophageal margin: free of tumor;. -...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach (Cardia). 2. Findings: Adenocarcinoma, intestinal type, with mucinous differentiation and signet ring cells, ulcerative and infiltrative. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Stomach (Cardia). 2. Findings: Adenocarcinoma, intestinal type, with mucinous differentiation and signet ring cells, ulcerative and infiltrative. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Stomach (Cardia). 2. Findings: Adenocarcinoma, intestinal type, with mucinous differentiation and signet ring cells, ulcerative and infiltrative. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach (Cardia). 2. Findings: Adenocarcinoma, intestinal type, with mucinous differentiation and signet ring cells, ulcerative and infiltrative. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach (Cardia). 2. Findings: Adenocarcinoma, intestinal type, with mucinous differentiation and signet ring cells, ulcerative and infiltrative. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach (Cardia). 2. Findings: Adenocarcinoma, intestinal type, with mucinous differentiation and signet ring cells, ulcerative and infiltrative. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach (Cardia). 2. Findings: Adenocarcinoma, intestinal type, with mucinous differentiation and signet ring cells, ulcerative and infiltrative. 3. Code:",
      "predicted": "STAD",
      "ground_truth": "STAD",
      "correct": true,
      "reasoning": "1. Site: Stomach (Cardia). 2. Findings: Adenocarcinoma, intestinal type, with mucinous differentiation and signet ring cells, ulcerative and infiltrative. 3. Code: Stomach Adenocarcinoma maps to STAD.",
      "idx": 1190,
      "timestamp": "2026-01-19T15:59:53.115336"
    },
    {
      "sample_idx": 833,
      "input": "A description for each data field can be found in the 'Data description' worksheet (yellow tab). Sample Collection Details. Type. BUFFY. TUMOUR. Histology and staging. Site of. Year of. Age at. Days to. Days to. Type of. Site of. Preparatio. Tissue. Comments. Procedure. Diagnosis. Procedure. Primary. n. (Histology). (yrs). FF. 0. 11 RESECT. RUL. FF. RUL lung. 0. 11 RESECT. RUL. Tumour. Histology. Grade/. Pathologic Pathologic Clinical M. VALCSG. Histology. Slide URL. Size (cm). Differentiat al T...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Lung adenocarcinoma, T1, N0, M0. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Lung adenocarcinoma, T1, N0, M0. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Lung adenocarcinoma, T1, N0, M0. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Lung adenocarcinoma, T1, N0, M0. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Lung adenocarcinoma, T1, N0, M0. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Lung adenocarcinoma, T1, N0, M0. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Lung adenocarcinoma, T1, N0, M0. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2.",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung (Right Upper Lobe). 2. Findings: Lung adenocarcinoma, T1, N0, M0. 3. Code: Lung Adenocarcinoma maps to LUAD.",
      "idx": 833,
      "timestamp": "2026-01-19T15:59:53.115346"
    },
    {
      "sample_idx": 389,
      "input": "CLINICAL HISTORY. with headache, and nausea for about. has right. temporal necrotic, hemorrhagic and enhancing tumor, and right middle cerebral. artery aneurysm. OPERATIVE DIAGNOSES. Not Given. Operation/Specimen: A: Brain, resection. B: Brain, resection. PATHOLOGICAL DIAGNOSIS: A. Brain, site not specified, excision: Glioblastoma. See comment. COMMENT. The specimen is brain diffusely infiltrated and focally effaced by an. astrocytic neoplastic process with nuclear anaplasia, mitoses, microvascu...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, resection. 2. Findings: Glioblastoma, with nuclear anaplasia, mitoses, microvascular cellular proliferation, and extensive areas of necrosis. 3. Code: Glioblastoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, resection. 2. Findings: Glioblastoma, with nuclear anaplasia, mitoses, microvascular cellular proliferation, and extensive areas of necrosis. 3. Code: Glioblastoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, resection. 2. Findings: Glioblastoma, with nuclear anaplasia, mitoses, microvascular cellular proliferation, and extensive areas of necrosis. 3. Code: Glioblastoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, resection. 2. Findings: Glioblastoma, with nuclear anaplasia, mitoses, microvascular cellular proliferation, and extensive areas of necrosis. 3. Code: Glioblastoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, resection. 2. Findings: Glioblastoma, with nuclear anaplasia, mitoses, microvascular cellular proliferation, and extensive areas of necrosis. 3. Code: Glioblastoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, resection. 2. Findings: Glioblastoma, with nuclear anaplasia, mitoses, microvascular cellular proliferation, and extensive areas of necrosis. 3. Code: Glioblastoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, resection. 2. Findings: Glioblastoma, with nuclear anaplas",
      "predicted": "KIRC",
      "ground_truth": "GBM",
      "correct": false,
      "reasoning": "1. Site: Brain, resection. 2. Findings: Glioblastoma, with nuclear anaplasia, mitoses, microvascular cellular proliferation, and extensive areas of necrosis. 3. Code: Glioblastoma maps to KIRC.",
      "idx": 389,
      "timestamp": "2026-01-19T15:59:53.115358"
    },
    {
      "sample_idx": 193,
      "input": "Procedure Date: Procedure Physician: Attending Physician/Copies To: PATIENT HISTORY: DATE or LMP: DATE OF LAST DELIVERY: PRE-OP DIAGNOSIS: RT BR CA. POST-OP DIAGMOSIS: SAME. OPERATIVE PROCEDURE: RT SEG MAST. CLINICAL HISTORY: NATERIAL SUBMITTED: RIGHTSEGMENTAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. INTRAOPERATIVE. FROZEN SECTION: Right breast mass; portion of breast, 7.0 by 4.0 by 3.5 cm with ellipse of skin, 7.0 by 1.0. cm. Lobulated mass, 4.0 by 2.0 by 2.0 cm. Margins grossly free. Fro...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, signet ring type, poor nuclear grade, 4.0 cm. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, signet ring type, poor nuclear grade, 4.0 cm. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, signet ring type, poor nuclear grade, 4.0 cm. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, signet ring type, poor nuclear grade, 4.0 cm. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, signet ring type, poor nuclear grade, 4.0 cm. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, signet ring type, poor nuclear grade, 4.0 cm. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, signet ring type, poor nuclear grade, 4.0 cm. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, signet ring type, poor nuclear grade, 4.0 cm. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 193,
      "timestamp": "2026-01-19T15:59:53.115369"
    },
    {
      "sample_idx": 1373,
      "input": "Surgical Patholoav Report. Pabent Name: Gynecology. DOS. 'Age: Patient Ty. DIAGNOSIS: OMENTUM, NODULE, BIOPSY. POORLY DIFFERENTIATED CARCINOMA. UTERUS, CERVIX, BILATERAL TUBES AND OVARIES, HYSTERECTOMY AND BILATERAL. SALPINGO-OOPHORECTOMY: - UNDIFFERENTIATED CARCINOMA ARISING FROM WELL TO MODERATELY DIFFERENTIATED. ENDOMETRIAL ADENOCARCINOMA, ENDOMETRIOID TYPE. - THE CARCINOMA INVADES THE ENTIRE MYOMETRIAL THICKNESS AND EXTENDS TO THE. SEROSAL SURFACE (DEPTH OF INVASION IS 2.0 CM). THE CARCINOMA...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus (including cervix and bilateral tubes and ovaries). 2. Findings: The patient has a history of total abdominal hysterectomy, bilateral salpingo-oophorectomy, and examination under anesthesia. The pathology report describes a total of 13 specimens received, including an omental nodule, a uterine/cervical/ovarian specimen, a posterior cul-de-sac tumor, a left ureter tumor, an appendix, an omentum, a falciform ligament, a diaphragm nodule, a sigmoid tumor nodule, an epiploica, a cecal nodule, a small bowel nodule, and a soft tissue nodule. The report also describes a poorly differentiated carcinoma in the omentum and soft tissue, and a poorly differentiated carcinoma in the sigmoid. The report mentions a metastatic poorly differentiated carcinoma in one lymph node. The report indicates that the tumor is a poorly differentiated carcinoma, and it has invaded the entire myometrium and extends to the serosa. It also mentions extensive lymphovascular space invasion. The report also mentions endometrial adenocarcionma, endometrioid type, with invasion of the entire myometrium and extension to the serosa, and the report mentions the tumor is a poorly differentiated carcinoma. The report also mentions a left external lymph node with no evidence of malignancy. The report also mentions a right ovary with serosal surface tumor deposits. The report mentions that the tumor is a poorly differentiated carcinoma and it has invaded the entire myometrium and extends to the serosa. The report mentions that the tumor is a poorly differentiated carcinoma and it has invaded the entire myometrium and extends to the serosa. The report mentions that the tumor is a poorly differentiated carcinoma and it has invaded the entire myometrium and extends to the serosa. The report mentions that the tumor is a poorly differentiated carcinoma and it has invaded the entire myometrium and extends to the serosa. The report mentions that the tumor is a poorly differentiated carcinoma and it has invaded the entire myometrium and extends to the serosa. The report mentions that the tumor is a poorly differentiated carcinoma and it has invaded the entire myometrium and extends to the serosa. The report mentions that the tumor is a poorly differentiated carcinoma and it has invaded the entire myometrium and extends to the serosa. The report mentions that the tumor is a poorly differentiated carcinoma and it",
      "predicted": null,
      "ground_truth": "UCEC",
      "correct": null,
      "reasoning": "",
      "idx": 1373,
      "timestamp": "2026-01-19T15:59:53.115510"
    },
    {
      "sample_idx": 882,
      "input": "Gross Description: Right upper lobe with free lobar bronchus; on section, a central tumoral structure of. 10/12/8 cm in diameter, which infiltrates the visceral pleura; the tumor is well-limited, white, with. necrosis and central ulceration. Microscopic Description: TUMOR FRAGMENT WITH PLEURA: Bronchopulmonary neoplasm of epidermoid carcinoma type, G2, with a tendency to keratinization,. formed of solid beaches of large, pleomorphic cells, with frequent nuclear atypias and atypical mitoses,. wit...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, G2, with a tendency to keratinization, with a tendency to keratinization. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, G2, with a tendency to keratinization, with a tendency to keratinization. 3. Code: Lung Squamous Cell Carcinoma maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, G2, with a tendency to keratinization, with a tendency to keratinization. 3. Code: Lung Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, G2, with a tendency to keratinization, with a tendency to keratinization. 3. Code: Lung Squamous Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, G2, with a tendency to keratinization, with a tendency to keratinization. 3. Code: Lung Squamous Cell Carcinoma maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, G2, with a tendency to keratinization, with a tendency to keratinization. 3. Code: Lung Squamous Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, G2, with a tendency to keratinization, with a tendency to keratinization. 3. Code",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung. 2. Findings: Squamous cell carcinoma, G2, with a tendency to keratinization, with a tendency to keratinization. 3. Code: Lung Adenocarcinoma maps to LUAD.",
      "idx": 882,
      "timestamp": "2026-01-19T15:59:53.115522"
    },
    {
      "sample_idx": 725,
      "input": "DIAGNOSIS: A. Gallbladder, cholecystectomy Chronic cholecystitis. A single. cystic duct lymph node is benign. B. Liver, right, partial hepatectomy : 11-to-moderately. differentiated grade 2 (of 4) hepatocellular carcinoma is identified. forming a dominant mass (6. 8 x 5.9 x 4.1 cm) with one satellite mass. (0.2 2 x 0.2 x 0.2 cm) The tumor is confined to the liver. The liver. parenchyma resection margin is negative for tumor (minimum tumor. free margin, 0.9 cm). Macroscopic large vessel invasion ...",
      "response": "```json\n{\n    \"cancer_type\": \"Hepatocellular carcinoma\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, hepatocellular carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Gallbladder. 2. Findings: Chronic cholecystitis. 3. Code: CHOL maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Gallbladder. 2. Findings: Cystic duct lymph node is benign. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Grade 2. ",
      "predicted": "Hepatocellular carcinoma",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, hepatocellular carcinoma maps to LIHC.",
      "idx": 725,
      "timestamp": "2026-01-19T15:59:53.115534"
    },
    {
      "sample_idx": 867,
      "input": "Gross. Microscopic. Diagnosis. Comme. Case ID Description. Description. Details. nts. Lateralit Date of. y. LUNG TISSUE CHECKLIST. Left-upper. Specimen type: Lobectomy. Tumor site: Lung. Tumor size: 3 X 2 X 2 cm. Histologic type: Squamous cell carcinoma. Histologic grade: Poorly differentiated. Tumor extent: Not specified. Other tumor nodules: Not specified. Lymph nodes: Not specified. Lymphatic invasion: Not specified. Venous invasion: Not specified. Margins: Not specified. Evidence of neo-adju...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: LUAD (Lung Adenocarcinoma) or LUAD (Lung Squamous Cell Carcinoma) maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: LUAD (Lung Adenocarcinoma) or LUAD (Lung Squamous Cell Carcinoma) maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: LUAD (Lung Adenocarcinoma) or LUAD (Lung Squamous Cell Carcinoma) maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: LUAD (Lung Adenocarcinoma) or LUAD (Lung Squamous Cell Carcinoma) maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: LUAD (Lung Adenocarcinoma) or LUAD (Lung Squamous Cell Carcinoma) maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: LUAD (Lung Adenocarcinoma) or LUAD (Lung Squamous Cell Carcinoma) maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: LUAD (Lung Adenocarcinoma) or LUAD (Lung Squamous Cell Carcinoma) maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LU",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: LUAD (Lung Adenocarcinoma) or LUAD (Lung Squamous Cell Carcinoma) maps to LUAD.",
      "idx": 867,
      "timestamp": "2026-01-19T15:59:53.115545"
    },
    {
      "sample_idx": 841,
      "input": "HISTORY. No clinical notes. MACROSCOPIC. One specimen received. The specimen is labelled 'right lower lobe' and consists of a right lower. lobectomy with a inflated measurements of 115 superior to inferior X 120 mm. anterior to posterior X 70 mm medial to lateral. Sectioning reveals a firm pale. lobulated mass measuring 48 x 48 X 45 mm. The mass is 15 mm from the bronchial. resection margin, and 10 mm from the hilar resection margin. The mass is 3 mm. clear of the stapled resection margin, focal...",
      "response": "```json\n{\n    \"cancer_type\": \"LSCC\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: LSCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LSCC\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: LSCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LSCC\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: LSCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LSCC\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: LSCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LSCC\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: LSCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LSCC\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: LSCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LSCC\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: LSCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LSCC\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: LSCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LSCC\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Squamous",
      "predicted": "LSCC",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung (Right Lower Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: LSCC.",
      "idx": 841,
      "timestamp": "2026-01-19T15:59:53.115555"
    },
    {
      "sample_idx": 956,
      "input": "Receive Date: PHN: Final Diagnosis: 1. EXTERNAL ABDOMINAL WALL OLD LAPAROSCOPIC PORT TUMOUR NODULE. showing a. fragment of fibrofatty tissue positive for high-grade papillary serous. carcinoma with focal foreign body inflammatory reaction. 2. INTERNAL ABDOMINAL WALL OLD LAPAROSCOPIC PORT TUMOUR NODULE. showing a. fragment of fibrofatty tissue with adherent muscle positive for. high-grade papillary serous carcinoma with focal foreign body. inflammatory reaction. 3. Total hysterectomy and left sal...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: High-grade papillary serous carcinoma, left ovary, with a 3 cm tumor and multiple cortical nodules. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: High-grade papillary serous carcinoma, left ovary, with a 3 cm tumor and multiple cortical nodules. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: High-grade papillary serous carcinoma, left ovary, with a 3 cm tumor and multiple cortical nodules. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: High-grade papillary serous carcinoma, left ovary, with a 3 cm tumor and multiple cortical nodules. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: High-grade papillary serous carcinoma, left ovary, with a 3 cm tumor and multiple cortical nodules. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: High-grade papillary serous carcinoma, left ovary, with a 3 cm tumor and multiple cortical nodules. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: High-grade papillary serous carcinoma, left ovary, with a 3 cm tumor and multiple cortical nodules. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovaries",
      "predicted": "BRCA",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Ovaries. 2. Findings: High-grade papillary serous carcinoma, left ovary, with a 3 cm tumor and multiple cortical nodules. 3. Code: BRCA.",
      "idx": 956,
      "timestamp": "2026-01-19T15:59:53.115565"
    },
    {
      "sample_idx": 110,
      "input": "Patien. surgical F. CLINICAL HISTORY: Right breast Ca, rule out deep margin positive. GROSS EXAMINATION: A. \"#1 right modified radical mastectomy\", in formalin. Received in the. container is a portion of breast with an attached skin ellipse containing the. nipple and an axillary dissection. The specimen measures 18.5 x 14 x 3.9 cm. The attached skin ellipse measures 14.7 x 6.3 cm. The nipple appears grossly. unremarkable. There is a small 0.5 cm hole 1.7 cm inferior to the nipple. The. deep surf...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 110,
      "timestamp": "2026-01-19T15:59:53.115575"
    },
    {
      "sample_idx": 201,
      "input": "SPECIMEN(S): A. RIGHT BREAST PARTIAL MASTECTOMY. B. SLN #1 RIGHT AXILLA. C. ADDITIONAL AXILLARY TISSUE RIGHT AXILLA. CLINICAL HISTORY: This is a. year old female with a 1.4 cm tumor in the right breast, IDC at 11:00. S/P. benign MRI biopsy inferior and lateral to this index lesion, not clipped. Here for N/L. lumpectomy with SLN biopsy. INTRAOPERATIVE CONSULTATION DIAGNOSIS: A. Right breast, partial mastectomy: Tumor is 0.3 cm from anterior margin. TPB1-TPB4: SLN#1, right axilla, excision: Four l...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 201,
      "timestamp": "2026-01-19T15:59:53.115584"
    },
    {
      "sample_idx": 124,
      "input": "Female. Admission Date: Discharge Date: Collected Date/Time: Received Date/Time: Final Diagnosis. A. LEFT HIGHEST AXILLARY NODE, EXCISION: - METASTATIC CARCINOMA IN ONE LYMPH NODE (1/1). B. LEFT BREAST AND AXILLARY CONTENTS, MASTECTOMY AND LYMPHADENECTOMY: - INVASIVE DUCTAL CARCINOMA, GRADE 3. - METASTATIC CARCINOMA IN THIRTEEN OF NINETEEN LYMPH NODES (13/19). - MARGINS ARE NOT INVOLVED. - SEE TEMPLATE. C. LEFT LEVEL I AXILLARY LYMPH NODE, EXCISION: - NO EVIDENCE OF CARCINOMA IN ONE LYMPH NODE (...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site:",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3. 3. Code: BRCA",
      "idx": 124,
      "timestamp": "2026-01-19T15:59:53.115596"
    },
    {
      "sample_idx": 824,
      "input": "Extensive, central to peripheral bronchopulmonary adenocarcinoma of histologically mixed. differentiation (G3), comprising partly maturing tubuloglandular cells and partly medium to. large cells and also clear cells, with partial necrotic alteration, invasion of the large pulmonary. vessels and the pleura. Tumor classification according to these findings pT2 pN1 V2 RX,. stage IIB. C34.2; M 8255/3. Comment/supplementary remark: The tumor invasion of the large pulmonary vessels with formation of l...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Bronchopulmonary). 2. Findings: Adenocarcinoma of the lung, mixed differentiation (G3), with tubuloglandular and large/clear cells, necrosis, vascular and pleural invasion. Stage IIB. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Bronchopulmonary). 2. Findings: Adenocarcinoma of the lung, mixed differentiation (G3), with tubuloglandular and large/clear cells, necrosis, vascular and pleural invasion. Stage IIB. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Bronchopulmonary). 2. Findings: Adenocarcinoma of the lung, mixed differentiation (G3), with tubuloglandular and large/clear cells, necrosis, vascular and pleural invasion. Stage IIB. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Bronchopulmonary). 2. Findings: Adenocarcinoma of the lung, mixed differentiation (G3), with tubuloglandular and large/clear cells, necrosis, vascular and pleural invasion. Stage IIB. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Bronchopulmonary). 2. Findings: Adenocarcinoma of the lung, mixed differentiation (G3), with tubuloglandular and large/clear cells, necrosis, vascular and pleural invasion. Stage IIB. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Bronchopulmonary). 2. Findings: Adenocarcinoma of the lung, mixed differentiation (G3), with tubuloglandular and large/clear cells, necrosis",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung (Bronchopulmonary). 2. Findings: Adenocarcinoma of the lung, mixed differentiation (G3), with tubuloglandular and large/clear cells, necrosis, vascular and pleural invasion. Stage IIB. 3. Code: Lung Adenocarcinoma maps to LUAD.",
      "idx": 824,
      "timestamp": "2026-01-19T15:59:53.115610"
    },
    {
      "sample_idx": 694,
      "input": "Client: (Age: ) Location: Gender: F Accnt: Phy Location: Clinical History. Brain tumor. Operative Diagnoses. Operation / Specimen. A: Brain, left frontal, craniotomy. Pathologic Diagnosis. A. Brain, left frontal, craniotomy: 1. Anaplastic astrocytoma, WHO grade 3. 2. Negative for co-deletion of chromosomal arms 1p and 19q. 3. Positive for IDH1-R132S mutation. 4. Ki-67/ MIB1 proliferation index: up to approximately 10%. See comment. Comment. The diffuse astrocytoma has an area with up to 4 mitose...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, left frontal, craniotomy. 2. Findings: Anaplastic astrocytoma, WHO grade 3. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Brain, left frontal, craniotomy. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, left frontal, craniotomy. 2. Findings: Anaplastic astrocytoma, WHO grade 3. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, left frontal, craniotomy. 2. Findings: Anaplastic astrocytoma, WHO grade 3. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, left frontal, craniotomy. 2. Findings: Anaplastic astrocytoma, WHO grade 3. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, left frontal, craniotomy. 2. Findings: Anaplastic astrocytoma, WHO grade 3. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, left frontal, craniotomy. 2. Findings: Anaplastic astrocytoma, WHO grade 3. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, left frontal, craniotomy. 2. Findings: Anaplastic astrocytoma, WHO grade 3. 3. Code: K",
      "predicted": "KIRC",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain, left frontal, craniotomy. 2. Findings: Anaplastic astrocytoma, WHO grade 3. 3. Code: KIRC.",
      "idx": 694,
      "timestamp": "2026-01-19T15:59:53.115620"
    },
    {
      "sample_idx": 223,
      "input": "page 1 / 1. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - right breast with axillary tissues. Unit in charge: (. Material collected on: : Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the right breast. Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in over 75% of neoplastic cell nuclei. HER2 prote...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 223,
      "timestamp": "2026-01-19T15:59:53.115630"
    },
    {
      "sample_idx": 509,
      "input": "DIAGNOSIS. (A) LEFT KIDNEY, ADRENAL, AND PERIAORTIC LYMPH NODES: CHROMOPHOBE RENAL CELL CARCINOMA (11.0 CM MAXIMUM DIMENSION), EOSINOPHILIC VARIANT,. FUHRMAN NUCLEAR GRADE 4, INVASIVE INTO PERINEPHRIC ADIPOSE TISSUE AND RENAL SINUS. ADIPOSE TISSUE, WITH VASCULAR-LYMPHATIC INVASION. (SEE COMMENT). METASTATIC CHROMOPHOBE RENAL CELL CARCINOMA IN 3 HILAR LYMPH NODES. Adrenal gland, no tumor present. Margins of resection free of tumor. (B) SPLEEN: Spleen with vascular congestion, no tumor present. Th...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe renal cell carcinoma, Fuhrman Grade 4, invasive into perinephric adipose tissue and renal sinus. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe renal cell carcinoma, Fuhrman Grade 4, invasive into perinephric adipose tissue and renal sinus. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe renal cell carcinoma, Fuhrman Grade 4, invasive into perinephric adipose tissue and renal sinus. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe renal cell carcinoma, Fuhrman Grade 4, invasive into perinephric adipose tissue and renal sinus. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe renal cell carcinoma, Fuhrman Grade 4, invasive into perinephric adipose tissue and renal sinus. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe renal cell carcinoma, Fuhrman Grade 4, invasive into perinephric adipose tissue and renal sinus. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2.",
      "predicted": "KIRC",
      "ground_truth": "KICH",
      "correct": false,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Chromophobe renal cell carcinoma, Fuhrman Grade 4, invasive into perinephric adipose tissue and renal sinus. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 509,
      "timestamp": "2026-01-19T15:59:53.115642"
    },
    {
      "sample_idx": 392,
      "input": "DIAGNOSIS. (A, B) BRAIN, LEFT PARIETAL REGION, CRANIOTOMY: GLIOBLASTOMA (WHO GRADE IV). (SEE COMMENT). COMMENT. Tissue sections show a high-grade diffuse astrocytoma with pleomorphism, brisk mitotic activity, microvascular proliferation,. intravascular fibrin thrombi and foci of tumor necrosis. GROSS DESCRIPTION. (A) LEFT PARIETAL TUMOR - Specimen consists of a single piece of dark-red tissue measuring (6.0 X 3.0 X 2.0 cm). The cut. rotion shows areas of hemorrhage and friable tissue. A represen...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Parietal Region. 2. Findings: Glioblastoma (WHO Grade IV), diffuse astrocytoma, pleomorphism, brisk mitotic activity, microvascular proliferation, intravascular fibrin thrombi, and foci of tumor necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Parietal Region. 2. Findings: Glioblastoma (WHO Grade IV), diffuse astrocytoma, pleomorphism, brisk mitotic activity, microvascular proliferation, intravascular fibrin thrombi, and foci of tumor necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Parietal Region. 2. Findings: Glioblastoma (WHO Grade IV), diffuse astrocytoma, pleomorphism, brisk mitotic activity, microvascular proliferation, intravascular fibrin thrombi, and foci of tumor necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Parietal Region. 2. Findings: Glioblastoma (WHO Grade IV), diffuse astrocytoma, pleomorphism, brisk mitotic activity, microvascular proliferation, intravascular fibrin thrombi, and foci of tumor necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Parietal Region. 2. Findings: Glioblastoma (WHO Grade IV), diffuse astrocytoma, pleomorphism, brisk mitotic activity, microvascular proliferation, intravascular fibrin thrombi, and foci of tumor necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Parietal Region. 2. Findings: Glioblastoma (WHO Grade IV), diffuse astrocytoma, pleomorphism, brisk mitotic activity, microvascular proliferation,",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain, Parietal Region. 2. Findings: Glioblastoma (WHO Grade IV), diffuse astrocytoma, pleomorphism, brisk mitotic activity, microvascular proliferation, intravascular fibrin thrombi, and foci of tumor necrosis. 3. Code: Glioblastoma maps to GBM.",
      "idx": 392,
      "timestamp": "2026-01-19T15:59:53.115656"
    },
    {
      "sample_idx": 1186,
      "input": "Patient ID: Gross Description: Stomach part with saucer-like tumor up to 5x4.5 cm in size, with invasion into the. perigastric fat tissue. In the fatty tissue there are hyperemic lymph nodes up to 0.6 cm in size. Omentum is of normal structure. Microscopic Description: Gastric adenocarcinoma, G-3, with invasion into the fatty tissue. One from. fifteen examined lymph nodes demonstrated metastasis. Diagnosis Details: Tumor Features: Ulcerated, Tumor Extent: Perigastric fat, Venous Invasion: Absent...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric adenocarcinoma, G-3, with invasion into the fatty tissue. One from. fifteen examined lymph nodes demonstrated metastasis. 3. Code: STAD maps to Stomach.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric adenocarcinoma, G-3, with invasion into the fatty tissue. One from. fifteen examined lymph nodes demonstrated metastasis. 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric adenocarcinoma, G-3, with invasion into the fatty tissue. One from. fifteen examined lymph nodes demonstrated metastasis. 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric adenocarcinoma, G-3, with invasion into the fatty tissue. One from. fifteen examined lymph nodes demonstrated metastasis. 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric adenocarcinoma, G-3, with invasion into the fatty tissue. One from. fifteen examined lymph nodes demonstrated metastasis. 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric adenocarcinoma, G-3, with invasion into the fatty tissue. One from. fifteen examined lymph nodes demonstrated metastasis. 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric adenocarcinoma, G-3, with invasion",
      "predicted": "STAD",
      "ground_truth": "STAD",
      "correct": true,
      "reasoning": "1. Site: Stomach. 2. Findings: Gastric adenocarcinoma, G-3, with invasion into the fatty tissue. One from. fifteen examined lymph nodes demonstrated metastasis. 3. Code: STAD maps to Stomach.",
      "idx": 1186,
      "timestamp": "2026-01-19T15:59:53.115668"
    },
    {
      "sample_idx": 1366,
      "input": "DIAGNOSIS. for 5/1/1/1. (A) UTERUS, CERVIX, TUBES AND OVARIES: ENDOMETRIAL, ENDOMETRIOID ADENOCARCINOMA, FIGO GRADE 3. DEPTH OF MYOMETRIAL INVASION 5.0 MM (TOTAL MYOMETRIAL THICKNESS 32.0 MM). LYMPHATIC/VASCULAR INVASION IS IDENTIFIED WITHIN THE MYOMETRIUM. Tumor does not involve the cervix. Bilateral ovaries and fallopian tubes, no tumor present. (B) LEFT PELVIC LYMPH NODES: Eight lymph nodes with numerous non-necrotizing granulomas; no tumor present (0/8). (See comment). (C) LEFT LOW PARAAORTI...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial, endometroid adenocarcinoma, FIGO grade 3, depth of myometrial invasion 5.0 mm (total myometrial thickness 32.0 mm). Lymphatic/vascular invasion is identified within the myometrium. Tumor does not involve the cervix. Bilateral ovaries and fallopian tubes, no tumor present. 3. Code: UCEC maps to Uterine Corpus Endometrial Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA maps to Breast Invasive Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA maps to Breast Invasive Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA maps to Breast Invasive Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC maps to Kidney Renal Clear",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus. 2. Findings: Endometrial, endometroid adenocarcinoma, FIGO grade 3, depth of myometrial invasion 5.0 mm (total myometrial thickness 32.0 mm). Lymphatic/vascular invasion is identified within the myometrium. Tumor does not involve the cervix. Bilateral ovaries and fallopian tubes, no tumor present. 3. Code: UCEC maps to Uterine Corpus Endometrial Carcinoma.",
      "idx": 1366,
      "timestamp": "2026-01-19T15:59:53.115684"
    },
    {
      "sample_idx": 918,
      "input": "SURGICAL PATHOLOGY HISTORY REPORT. DISCLAIMER. THIS IS A HISTORY CASE THAT YOU CANNOT EDIT. TO SEE THE ENTIRE TEXT. PLEASE GO TO THE PATIENT HISTORY BY CLICKING THE ELLIPSE (...) NEXT TO. THE PATIENT NAME AND CLICKING ON THE HISTORY TAB. DIAGNOSIS: with pelvic mass & ascites. No chemo/RT. FINAL DIAGNOSIS: 1. OMENTAL biopsy: -Implants SEROUS CARCINOMA with focal squamous differentiation. 2. OVARIES, bilateral, oophorectomy: -Grade 3 SEROUS CARCINOMA. FALLOPIAN TUBES, bilateral, salpingectomy: -Im...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Omentum. 2. Findings: Serous carcinoma, with focal squamous differentiation. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Grade 3 Serous Carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Fallopian Tube. 2. Findings: Serous Carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Metastatic Serous Carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Peritoneum. 2. Findings: Serous Carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Lymph Node. 2. Findings: Metastatic Serous Carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Peritoneum. 2. Findings: Serous Carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Serous Carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Small Intestine. 2. Findings: Serous Carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Spleen. 2. Findings: Surface implants Ser",
      "predicted": "BRCA",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Omentum. 2. Findings: Serous carcinoma, with focal squamous differentiation. 3. Code: BRCA",
      "idx": 918,
      "timestamp": "2026-01-19T15:59:53.115694"
    },
    {
      "sample_idx": 287,
      "input": "Clinical Diagnosis & History: Moderately differentiated adenocarcinoma in the sigmoid colon. No history of. chemoradiation. Specimens Submitted: 1: SP: Sigmoid colon; resection. 2: SP: Proximal margin. 3: SP: Distal margin. DIAGNOSIS: 1. SP: Sigmoid colon; resection: Tumor Type: Adenocarcinoma. Histologic Grade: Moderately differentiated. Tumor Location: Sigmoid colon. Tumor Size: Length is 1.1 cm. Width is 0.7 cm. Maximal thickness is 0.4 cm. Tumor Budding: Absent. Increased Tumor Infiltrating ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.",
      "idx": 287,
      "timestamp": "2026-01-19T15:59:53.115703"
    },
    {
      "sample_idx": 1360,
      "input": "FSG2 (SEROSAL TUMOR): Tissue given for research. M.D., i. I have personally examined the specimen, interpreted the results, reviewed the report and signed it electronically. If this report includes immunohistochemical test results please note the following: Numerous immunohistochemica/ tests were developed and their. performance characteristics determined by. Those. immunohistochemical tests have not been creared or approved by the U.S. Fooa ano urug (TUM),. proval is not required. Copies To: AM...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma with associated squamous changes, FIGO grade 3. The tumor involves the endometrium, myometrium, and serosa. The cervix shows CIN III/SCIS. 3. Code: BRCA maps to Breast Invasive Carcinoma. This is a breast cancer, but the question is asking for the cancer type based on the pathology report, which is a uterus cancer. The most appropriate TCGA code is BRCA. The question is asking for the cancer type based on the pathology report, which is a uterus cancer. The most appropriate TCGA code is BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma with associated squamous changes, FIGO grade 3. The tumor involves the endometrium, myometrium, and serosa. The cervix shows CIN III/SCIS. 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma. This is a uterus cancer. The most appropriate TCGA code is KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma with associated squamous changes, FIGO grade 3. The tumor involves the endometrium, myometrium, and serosa. The cervix shows CIN III/SCIS. 3. Code: BRCA maps to Breast Invasive Carcinoma. This is a uterus cancer. The most appropriate TCGA code is BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma with associated squamous changes, FIGO grade 3. The tumor involves the endometrium, myometrium, and serosa. The cervix shows CIN III/SCIS. 3. Code: BRCA maps to Breast Invasive Carcinoma. This is a uterus cancer. The most appropriate TCGA code is BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings:",
      "predicted": "BRCA",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma with associated squamous changes, FIGO grade 3. The tumor involves the endometrium, myometrium, and serosa. The cervix shows CIN III/SCIS. 3. Code: BRCA maps to Breast Invasive Carcinoma. This is a breast cancer, but the question is asking for the cancer type based on the pathology report, which is a uterus cancer. The most appropriate TCGA code is BRCA. The question is asking for the cancer type based on the pathology report, which is a uterus cancer. The most appropriate TCGA code is BRCA.",
      "idx": 1360,
      "timestamp": "2026-01-19T15:59:53.115724"
    },
    {
      "sample_idx": 375,
      "input": "AP Surgical Pathology: Additional Info. CLINICAL HISTORY: developed some problems with his left side. He is a patient who was. found. to have a malignant glioma. He has noted drooling from the left side of. his face. He has noted walking into things on the left side. : The patient is status post right parietal craniotomy, There. has been interval debulking of a large right parietal heterogeneously. enhancing tumor. When compared to prior examination. The amount of enhancing. lesion has decreased...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with EGFR and PTEN polysomy, MGMT positive. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with EGFR and PTEN polysomy, MGMT positive. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with EGFR and PTEN polysomy, MGMT positive. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with EGFR and PTEN polysomy, MGMT positive. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with EGFR and PTEN polysomy, MGMT positive. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with EGFR and PTEN polysomy, MGMT positive. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with EGFR and PTEN polysomy, MGMT positive. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with EGFR and PTEN polysomy,",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with EGFR and PTEN polysomy, MGMT positive. 3. Code: GBM.",
      "idx": 375,
      "timestamp": "2026-01-19T15:59:53.115734"
    },
    {
      "sample_idx": 1302,
      "input": "Sex: F. BIRTH DATE. Department: Thoracic Surgery. Clinical informations: Mediastinal anterior neoplasia cm 12x10x5. Type of specimen: Biopsies of the mass. Microscopical description: multiple small tissue fragments, histologically characterized by a. neoplastic infiltration with morphological and immunohistochemical characters (positivity for. CD117 and Synaptophisin; positivity +/- for citocheratins (MNF116), negativity for CD5, CD45,. CD56, TTF1, Cromogranin) indicating a poorly differentiated...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Mediastinum. 2. Findings: Poorly differentiated neuroendocrine carcinoma, thymic origin (Neuroendocrine thymic carcinoma), CD117 positive. 3. Code: Thymic Neoplasia maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Mediastinum. 2. Findings: Poorly differentiated neuroendocrine carcinoma, thymic origin (Neuroendocrine thymic carcinoma), CD117 positive. 3. Code: Thymic Neoplasia maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Mediastinum. 2. Findings: Poorly differentiated neuroendocrine carcinoma, thymic origin (Neuroendocrine thymic carcinoma), CD117 positive. 3. Code: Thymic Neoplasia maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Mediastinum. 2. Findings: Poorly differentiated neuroendocrine carcinoma, thymic origin (Neuroendocrine thymic carcinoma), CD117 positive. 3. Code: Thymic Neoplasia maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Mediastinum. 2. Findings: Poorly differentiated neuroendocrine carcinoma, thymic origin (Neuroendocrine thymic carcinoma), CD117 positive. 3. Code: Thymic Neoplasia maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Mediastinum. 2. Findings: Poorly differentiated neuroendocrine carcinoma, thymic origin (Neuroendocrine thymic carcinoma), CD117 positive. 3. Code: Thymic Neoplasia maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Mediastinum. 2. Findings: Poorly differentiated neuroendocrine carcinoma, thymic",
      "predicted": "THYM",
      "ground_truth": "THYM",
      "correct": true,
      "reasoning": "1. Site: Mediastinum. 2. Findings: Poorly differentiated neuroendocrine carcinoma, thymic origin (Neuroendocrine thymic carcinoma), CD117 positive. 3. Code: Thymic Neoplasia maps to THYM.",
      "idx": 1302,
      "timestamp": "2026-01-19T15:59:53.115745"
    },
    {
      "sample_idx": 947,
      "input": "V3.00 110614. Instructions: The TCGA Missing Pathology Report Form should be completed for cases for which a pathology report is not. available. General Pathology Report Information. #. Data Element. Entry Alternatives. Working Instructions. Provide the tumor type of the case. 1. Tumor type: Indicate to which BCR location the case was originally sent. 2. BCR specimen originally sent. NCH. to: IGC. Biospecimen Core Resource (BCR). Date specimen received at. 3. BCR: ICD-0-3 Histology Code: Provide...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 947,
      "timestamp": "2026-01-19T15:59:53.115754"
    },
    {
      "sample_idx": 511,
      "input": "Diagnosis: A: Resection bed, left kidney, biopsy. - Renal parenchyma with mild chronic interstitial inflammation. - No evidence of malignancy. B: Resection bed, right kidney, removal. - Renal parenchyma with mild chronic interstitial inflammation. - No evidence of malignancy. C: Mass, Left kidney, resection. - Renal cell carcinoma, chromophobe type, eosinophilic variant, 2.6 cm, without vascular or. extracapsular invasion, surgical margins involved by renal cell carcinoma (see comment). D: Mass,...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, eosinophilic variant, 2.6 cm, without vascular or extracapsular invasion, surgical margins involved by renal cell carcinoma (see comment). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ONCO\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Oncocytoma, 1.4 cm, surgical margins negative (see comment). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, eosinophilic variant, 2.6 cm, without vascular or extracapsular invasion, surgical margins involved by renal cell carcinoma (see comment). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Oncocytoma, 1.4 cm, surgical margins negative (see comment). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, eosinophilic variant, 2.6 cm, without vascular or extracapsular invasion, surgical margins involved by renal cell carcinoma (see comment). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Oncocytoma, 1.4 cm, surgical margins negative (see comment). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    ",
      "predicted": "KIRC",
      "ground_truth": "KICH",
      "correct": false,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, eosinophilic variant, 2.6 cm, without vascular or extracapsular invasion, surgical margins involved by renal cell carcinoma (see comment). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 511,
      "timestamp": "2026-01-19T15:59:53.115767"
    },
    {
      "sample_idx": 154,
      "input": "Final Diagnosis. Breast, left, wide local excision: Infiltrating ductal carcinoma, Nottingham grade III (of III),. [tubules 3/3, nuclei 3/3, mitoses 2/3; Nottingham score 8/9], forming a 2.0 x 1.8 x 1.5 cm. circumscribed mass with central fibrosis [AJCC pTic]. Focal (5%) high grade ductal carcinoma. in situ with necrosis is present outside the main tumor mass. Angiolymphatic invasion is absent. The non-neoplastic breast parenchyma shows nonproliferative fibrocystic changes. Calcifications. are p...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III, forming a 2.0 x 1.8 x 1.5 cm mass with central fibrosis and focal high-grade in situ carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III, forming a 2.0 x 1.8 x 1.5 cm mass with central fibrosis and focal high-grade in situ carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III, forming a 2.0 x 1.8 x 1.5 cm mass with central fibrosis and focal high-grade in situ carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III, forming a 2.0 x 1.8 x 1.5 cm mass with central fibrosis and focal high-grade in situ carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III, forming a 2.0 x 1.8 x 1.5 cm mass with central fibrosis and focal high-grade in situ carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III, forming a 2.0 x 1.8 x 1.5 cm mass with central",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III, forming a 2.0 x 1.8 x 1.5 cm mass with central fibrosis and focal high-grade in situ carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 154,
      "timestamp": "2026-01-19T15:59:53.115779"
    },
    {
      "sample_idx": 907,
      "input": "Gender: Male. Race: White. Report Date: Tissue Procurement Date: FINAL PATHOLOGIC DIAGNOSIS. A. #11 lymph node; biopsy: - Two lymph nodes, no tumor (0/2). B. Level 7 lymph node; dissection: - Three lymph nodes, no tumor (0/3). C. #8 lymph node; biopsy: - One lymph node, no tumor (0/1). D. 4R lymph node; biopsy: - Two lymph nodes, no tumor (0/2). E. Right parietal and visceral pleura, diaphragm and pericardium: - Malignant biphasic mesothelioma; see comment. - See parameters. Thoracic Mesotheliom...",
      "response": "```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Right pleura, pericardium, and diaphragm. 2. Findings: Biphasic mesothelioma (80% epithelioid, 20% sarcomatoid). 3. Code: UCSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Right pleura, pericardium, and diaphragm. 2. Findings: Biphasic mesothelioma (80% epithelioid, 20% sarcomatoid). 3. Code: UCSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Right pleura, pericardium, and diaphragm. 2. Findings: Biphasic mesothelioma (80% epithelioid, 20% sarcomatoid). 3. Code: UCSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Right pleura, pericardium, and diaphragm. 2. Findings: Biphasic mesothelioma (80% epithelioid, 20% sarcomatoid). 3. Code: UCSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Right pleura, pericardium, and diaphragm. 2. Findings: Biphasic mesothelioma (80% epithelioid, 20% sarcomatoid). 3. Code: UCSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Right pleura, pericardium, and diaphragm. 2. Findings: Biphasic mesothelioma (80% epithelioid, 20% sarcomatoid). 3. Code: UCSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Right pleura, pericardium, and diaphragm. 2. Findings: Biphasic mesothelioma (80% epithelioid, 20% sarcomatoid).",
      "predicted": "UCSC",
      "ground_truth": "MESO",
      "correct": false,
      "reasoning": "1. Site: Right pleura, pericardium, and diaphragm. 2. Findings: Biphasic mesothelioma (80% epithelioid, 20% sarcomatoid). 3. Code: UCSC.",
      "idx": 907,
      "timestamp": "2026-01-19T15:59:53.115790"
    },
    {
      "sample_idx": 1127,
      "input": "Clinical Diagnosis & History: Abdominal mass, sarcoma. Specimens Submitted: 1: Atypical smooth muscle tumor of left retro-peritoneum. DIAGNOSIS: 1. Left retroperitoneum, resection: - High grade leiomyosarcoma. - Tumor size: 4.2 x 3.8 x 2.5 cm. - Tumor appears completely excised, with narrow margins ( < 0.1 cm form. the inked undesignated margins). - Two benign lymph nodes (0/2). I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL), . AND ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left retroperitoneum. 2. Findings: High-grade leiomyosarcoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left retroperitoneum. 2. Findings: High-grade leiomyosarcoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left retroperitoneum. 2. Findings: High-grade leiomyosarcoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left retroperitoneum. 2. Findings: High-grade leiomyosarcoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left retroperitoneum. 2. Findings: High-grade leiomyosarcoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left retroperitoneum. 2. Findings: High-grade leiomyosarcoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left retroperitoneum. 2. Findings: High-grade leiomyosarcoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left retroperitoneum. 2. Findings: High-grade leiomyosarcoma. 3. Code:",
      "predicted": "KIRC",
      "ground_truth": "SARC",
      "correct": false,
      "reasoning": "1. Site: Left retroperitoneum. 2. Findings: High-grade leiomyosarcoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 1127,
      "timestamp": "2026-01-19T15:59:53.115800"
    },
    {
      "sample_idx": 200,
      "input": "FINAL DIAGNOSIS: PART 1: BREAST. RIGHT, SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA,NOS TYPE, POORLY DIFFERENTIATED. B. THE INVASIVE TUMOR MEASURES 2.0 CM IN GREATEST DIMENSION.NOTTINGHAM GRADE 3 (TUBULE. FORMATION 3, NUCLEAR PLEOMORPHISM 3, MITOTIC ACTIVITY 3; TOTAL SCORE 9/9). C. DUCTAL CARCINOMA IN-SITU (DCIS), NUCLEAR GRADE 3, MICROPAPILLARY AND PAPILLARY TYPES. WITH COMEDONECROSIS; CONSTITUTES 60% OF THE TOTAL TUMOR MASS AND IS PRESENT ADMIXED. WITH AND AWAY FROM THE INVASIVE COMPO...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NOS type, poorly differentiated. Ductal carcinoma in situ (DCIS), nuclear grade 3, micropapillary and papillary types. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NOS type, poorly differentiated. Ductal carcinoma in situ (DCIS), nuclear grade 3, micropapillary and papillary types. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NOS type, poorly differentiated. Ductal carcinoma in situ (DCIS), nuclear grade 3, micropapillary and papillary types. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NOS type, poorly differentiated. Ductal carcinoma in situ (DCIS), nuclear grade 3, micropapillary and papillary types. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NOS type, poorly differentiated. Ductal carcinoma in situ (DCIS), nuclear grade 3, micropapillary and papillary types. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NOS type, poorly differentiated. Ductal carcinoma in situ (DCIS), nuclear grade 3, micropapillary and papillary types. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NOS type, poorly differentiated. Ductal carcinoma in situ (DCIS), nuclear grade 3, micropapillary and papillary types. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 200,
      "timestamp": "2026-01-19T15:59:53.115812"
    },
    {
      "sample_idx": 103,
      "input": "FINAL DIAGNOSIS: PART 1: BREAST, RIGHT, MODIFIED RADICAL MASTECTOMY-. A. INFILTRATING DUCTAL CARCINOMA. B. NEOPLASM MEASURES 3.0 CM ON GROSS EXAM. C. NOTTINGHAM SCORE 7/9, GRADE 2 (TUBULES 3, NUCLEI 3, MITOSES 1). D. MARGINS OF RESECTION FREE OF NEOPLASM, CLOSEST ANTERIOR AT 2.0 CM. E. LYMPHOVASCULAR INVASION IDENTIFIED. F. UNREMARKABLE SKIN AND NIPPLE. G. ER POSITIVE, PR POSITIVE, HER-2/NEU NEGATIVE (SCORE 0) PER PREVIOUS REPORT. H. PATHOLOGIC STAGE T2 N1 MX. I. DUCTAL CARCINOMA IN SITU, SOLID ...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Score 7/9, Grade 2. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Score 7/9, Grade 2. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Score 7/9, Grade 2. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Score 7/9, Grade 2. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Score 7/9, Grade 2. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Score 7/9, Grade 2. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Score 7/9, Grade 2. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Score 7/9, Grade 2. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1.",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Score 7/9, Grade 2. 3. Code: BRCA.",
      "idx": 103,
      "timestamp": "2026-01-19T15:59:53.115824"
    },
    {
      "sample_idx": 1107,
      "input": "Addendum. Clinical Diagnosis & History: Diagnosed with rectal carcinoma at 15 cm on. rectal carcinoma. Specimens Submitted: 1: SP: Rectum and rectosigmoid. 2: SP: Additional sigmoid. 3: SP: Proximal ring. 4: SP: Distal ring. DIAGNOSIS: 1). COLON, RECTUM AND RECTOSIGMOID, SEGMENTAL RESECTION: - THREE (3) FOCI OF ADENOCARCINOMA, MODERATELY DIFFERENTIATED, OF. SIGMOID AND RECTOSIGMOID. - THE TUMORS MEASURE 2.9 X 1.8 X 0.8 CM, 0.4 x 0.4 x 0.2 CM, AND 0.7 X. 0.5 X 0.2 CM, RESPECTIVELY. - GROSS CONFIG...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectum and rectosigmoid. 2. Findings: Colon, rectum and rectosigmoid, segmental resection: - Three (3) foci of adenocarcinoma, moderately differentiated, of sigmoid and rectosigmoid. - The tumors measure 2.9 x 1.8 x 0.8 cm, 0.4 x 0.4 x 0.2 cm, and 0.7 x 0.5 x 0.2 cm, respectively. - Gross configurations are polypoid. - Preexisting tubular adenoma is identified. - Two smaller tumors invade into the submucosa (pT1) . - The largest tumor invades into muscularis propria (pT2). - No vascular invasion is identified. - No perineural invasion is identified. - Surgical margins are free of tumor. - Additional hyperplastic polyp is identified. The uninvolved colonic mucosa is unremarkable. - Lymph nodes: Number of metastases:0 Number examined: 8 (0/8). (Additional lymph nodes are being examined and an addendum report will follow). 2. Site: Additional sigmoid. 3. Findings: Hyperplastic polyp. - Unremarkable colonic mucosa. - One benign lymph node (0/1). 3. Site: Proximal ring. 4. Findings: Unremarkable colonic mucosa. 4. Site: Distal ring. 5. Findings: Unremarkable colonic mucosa. 1. At test that the above diagnosis is based upon my personal examination of the slides (and/or other material), and that I have reviewed and approved this report. 1. Gross Description: 1) The specimen is received fresh labeled \\\"rectum and rectosigmoid\\\". It consists of a rectosigmoid colon that measures 12.0 cm in length by 7.0 cm in circumference at the distal resection margin. The serosal surface is pink and smooth. The radial resection margin is inked black and the specimen is opened to reveal a pink-tan papillary tumor measuring 2.9 cm in length by 1.8 cm in width by 0.4 cm, located 3.5 cm from the distal resection margin. There is a smooth sessile polyp measuring 0.4 x 0.4 x 0.2 cm, located 0.7 cm from the tumor, and",
      "predicted": null,
      "ground_truth": "READ",
      "correct": null,
      "reasoning": "",
      "idx": 1107,
      "timestamp": "2026-01-19T15:59:53.115934"
    },
    {
      "sample_idx": 30,
      "input": "M. Date Of Birt'. COPY ONLY DO NOT FILE. nat. Source of Specimen. A. LEFT DISTAL URETER FS-. B. RIGHT DISTAL URETER FS-. C. RIGHT COMMON AND EXTERNAL ILIAC LYMPH NODES-. D. RIGHT OBTURATOR LYMPH NODES-. E. RIGHT INTERNAL ILIAC LYMPH NODES-. F. LEFT COMMON AND INTERNAL LYMPH NODES-. G. LEFT OBTURATOR LYMPH NODES-. H. BLADDER, PROSTATE GLAND, SEMINAL VESICLES AND VASA. DEFERENTIA-. FINAL DIAGNOSIS: A. LEFT DISTAL URETER FS-. URETER, NEGATIVE FOR TUMOR. B. RIGHT DISTAL URETER FS-. URETER, NEGATIVE ...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Bladder, Prostate Gland, Seminal Vesicles and Vas Deferentia. 2. Findings: High grade papillary (rothelial carcinoma) with depth of invasion of outer one-third of muscularis propria. 3. Code: UCEC maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Ureter, Bladder, Prostate Gland, Seminal Vesicles and Vas Deferentia. 2. Findings: Negative for tumor. 3. Code: UVM maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Distal Ureter, Right Distal Ureter, Right Common and External Iliac Lymph Nodes, Right Obturator Lymph Nodes, Right Internal Iliac Lymph Nodes, Left Common and Internal Lymph Nodes, Left Obturator Lymph Nodes, Bladder, Prostate Gland, Seminal Vesicles and Vas Deferentia. 2. Findings: Ureter, negative for tumor. Lymph nodes, negative for tumor. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Left Distal Ureter, Right Distal Ureter, Right Common and External Iliac Lymph Nodes, Right Obturator Lymph Nodes, Right Internal Iliac Lymph Nodes, Left Common and Internal Lymph Nodes, Left Obturator Lymph Nodes, Bladder, Prostate Gland, Seminal Vesicles and Vas Deferentia. 2. Findings: Ureter, negative for tumor. Lymph nodes, negative for tumor. 3. Code: UVM maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Left Distal Ureter, Right Distal Ureter, Right Common and External Iliac Lymph Nodes, Right Obturator Lymph Nodes, Right Internal Iliac Lymph Nodes, Left Common and Internal Lymph Nodes, Left Obturator Lymph Nodes, Bladder, Prostate Gland, Seminal Vesicles and Vas Deferentia. 2. Findings",
      "predicted": "UCEC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Bladder, Prostate Gland, Seminal Vesicles and Vas Deferentia. 2. Findings: High grade papillary (rothelial carcinoma) with depth of invasion of outer one-third of muscularis propria. 3. Code: UCEC maps to UCEC.",
      "idx": 30,
      "timestamp": "2026-01-19T15:59:53.115947"
    },
    {
      "sample_idx": 1399,
      "input": "RUN DATE: LABORATORY. PAGE: 1. RUN TIME: Specimen Inquiry. SPEC #: Obtained: CLINICAL HISTORY : ICD-9 236.3; ENDOMETRIAL CA. SPECIMEN/PROCEDURE : 1. VAGINA - BIOPSY. IMPRESSION: : VAGINAL BIOPSY: Caroinosarcoma, consistent with previous history of uterine caroinosarcoma. Entered: GROSS DESCRIPTION: Received in formalin labeled \"vag apex left biopsy\" and with the patient's name, the. specimen consists of multiple pale tan tissue fragments measuring 2 x 1.5 x 0.4 cm. in. aggregate. The specimen is...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Vagina. 2. Findings: Carcinosarcoma. 3. Code: Vaginal Carcinosarcoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Vagina. 2. Findings: Carcinosarcoma. 3. Code: Vaginal Carcinosarcoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Vagina. 2. Findings: Carcinosarcoma. 3. Code: Vaginal Carcinosarcoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Vagina. 2. Findings: Carcinosarcoma. 3. Code: Vaginal Carcinosarcoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Vagina. 2. Findings: Carcinosarcoma. 3. Code: Vaginal Carcinosarcoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Vagina. 2. Findings: Carcinosarcoma. 3. Code: Vaginal Carcinosarcoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Vagina. 2. Findings: Carcinosarcoma. 3. Code: Vaginal Carcinosarcoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Vagina. 2. Findings: Carcinosarcoma. 3. Code: Vaginal Carcinosarcoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Vagina. 2.",
      "predicted": "UCEC",
      "ground_truth": "UCS",
      "correct": false,
      "reasoning": "1. Site: Vagina. 2. Findings: Carcinosarcoma. 3. Code: Vaginal Carcinosarcoma maps to UCEC.",
      "idx": 1399,
      "timestamp": "2026-01-19T15:59:53.115957"
    },
    {
      "sample_idx": 484,
      "input": "DIAGNOSIS: 1) LYMPH NODE, LEFT POSTERIOR LEVEL 1, EXCISION: 1 LYMPH NODE, NEGATIVE FOR. MALIGNANCY (0/1). 2) LYMPH NODE, LEVEL 1, EXCISION: 4 LYMPH NODES, NEGATIVE FOR MALIGNANCY. (0/4). 3) TONGUE, LEFT, PARTIAL GLOSSECTOMY: WELL-DIFFERENTIATED KERATINIZING. SQUAMOUS CELL CARCINOMA, 1.0 CM IN GREATEST EXTENT, COMPLETELY EXCISED. 4) LYMPH NODES, LEFT NECK LEVEL 2, 3, 4, EXCISION: 4 LYMPH NODES, NEGATIVE. FOR MALIGNANCY (0/4). 5) LYMPH NODES, ANTERIOR LEVEL 1, EXCISION: 1 LYMPH NODE, NEGATIVE FOR....",
      "response": "```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Left Posterior Level 1 Neck. 2. Findings: Negative for malignancy. 3. Code: LYMPH NODE, NEGATIVE FOR MALIGNANCY maps to LYMPH NODE, LEFT POSTERIOR LEVEL 1, EXCISION: 1 LYMPH NODE, NEGATIVE FOR. MALIGNANCY (0/1). 2. Site: Level 1 Lymph Node. 3. Findings: Negative for malignancy. 4. Code: LYMPH NODE, LEVEL 1, EXCISION: 4 LYMPH NODES, NEGATIVE FOR MALIGNANCY (0/4). 3. Site: Left Partial Glossectomy. 4. Findings: Well-differentiated keratinizing squamous cell carcinoma, 1.0 cm in greatest extent, completely excised. 5. Code: TONGUE, LEFT, PARTIAL GLOSSECTOMY: WELL-DIFFERENTIATED KERATINIZING. SQUAMOUS CELL CARCINOMA, 1.0 CM IN GREATEST EXTENT, COMPLETELY EXCISED. 6. Site: Left Neck Levels 2, 3, 4. 7. Findings: Negative for malignancy. 8. Code: LYMPH NODES, LEFT NECK LEVEL 2, 3, 4, EXCISION: 4 LYMPH NODES, NEGATIVE FOR MALIGNANCY (0/4). 9. Site: Anterior Level 1. 10. Findings: Negative for malignancy. 11. Code: LYMPH NODES, ANTERIOR LEVEL 1, EXCISION: 1 LYMPH NODE, NEGATIVE FOR. MALIGNANCY (0/1).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Left Posterior Level 1 Neck. 2. Findings: Negative for malignancy. 3. Code: LYMPH NODE, LEFT POSTERIOR LEVEL 1, EXCISION: 1 LYMPH NODE, NEGATIVE FOR. MALIGNANCY (0/1). 2. Site: Level 1 Lymph Node. 3. Findings: Negative for malignancy. 4. Code: LYMPH NODE, LEVEL 1, EXCISION: 4 LYMPH NODES, NEGATIVE FOR MALIGNANCY (0/4). 3.",
      "predicted": "SCC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Left Posterior Level 1 Neck. 2. Findings: Negative for malignancy. 3. Code: LYMPH NODE, NEGATIVE FOR MALIGNANCY maps to LYMPH NODE, LEFT POSTERIOR LEVEL 1, EXCISION: 1 LYMPH NODE, NEGATIVE FOR. MALIGNANCY (0/1). 2. Site: Level 1 Lymph Node. 3. Findings: Negative for malignancy. 4. Code: LYMPH NODE, LEVEL 1, EXCISION: 4 LYMPH NODES, NEGATIVE FOR MALIGNANCY (0/4). 3. Site: Left Partial Glossectomy. 4. Findings: Well-differentiated keratinizing squamous cell carcinoma, 1.0 cm in greatest extent, completely excised. 5. Code: TONGUE, LEFT, PARTIAL GLOSSECTOMY: WELL-DIFFERENTIATED KERATINIZING. SQUAMOUS CELL CARCINOMA, 1.0 CM IN GREATEST EXTENT, COMPLETELY EXCISED. 6. Site: Left Neck Levels 2, 3, 4. 7. Findings: Negative for malignancy. 8. Code: LYMPH NODES, LEFT NECK LEVEL 2, 3, 4, EXCISION: 4 LYMPH NODES, NEGATIVE FOR MALIGNANCY (0/4). 9. Site: Anterior Level 1. 10. Findings: Negative for malignancy. 11. Code: LYMPH NODES, ANTERIOR LEVEL 1, EXCISION: 1 LYMPH NODE, NEGATIVE FOR. MALIGNANCY (0/1).",
      "idx": 484,
      "timestamp": "2026-01-19T15:59:53.115987"
    },
    {
      "sample_idx": 340,
      "input": "Department of Pathology and Microbiology. Accession No: Acot No: Date Taken: Date Received: Submitted by: Loc: Room: Client: Final Diagnosis: RIGHT NECK MASS, EXCISION: LYMPH NODE WITH DIFFUSE LARGE B-CELL LYMPHOMA,. NONCLEAVED (SEE COMMENT). (B-DLCL-NC). Diagnosis Comment: The tumor colls have a germinal center B-cell phenotype. History: The patient is a. tyear-old female with a right neck mass. Intraoperative Diagnosis: Neck right. excisional biopsy: \"Diagnostic tissue favor lymphoma.\" This is...",
      "response": "```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Neck. 2. Findings: Diffuse large B-cell lymphoma, noncleaved. 3. Code: DLBC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Neck. 2. Findings: Diffuse large B-cell lymphoma, noncleaved. 3. Code: DLBC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Neck. 2. Findings: Diffuse large B-cell lymphoma, noncleaved. 3. Code: DLBC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Neck. 2. Findings: Diffuse large B-cell lymphoma, noncleaved. 3. Code: DLBC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Neck. 2. Findings: Diffuse large B-cell lymphoma, noncleaved. 3. Code: DLBC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Neck. 2. Findings: Diffuse large B-cell lymphoma, noncleaved. 3. Code: DLBC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Neck. 2. Findings: Diffuse large B-cell lymphoma, noncleaved. 3. Code: DLBC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Neck. 2. Findings: Diffuse large B-cell lymphoma, noncleaved. 3. Code: DLBC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1.",
      "predicted": "DLBC",
      "ground_truth": "DLBC",
      "correct": true,
      "reasoning": "1. Site: Neck. 2. Findings: Diffuse large B-cell lymphoma, noncleaved. 3. Code: DLBC.",
      "idx": 340,
      "timestamp": "2026-01-19T15:59:53.115997"
    },
    {
      "sample_idx": 832,
      "input": "Clinical Diagnosis & History: with right lower lobe mass and cervical adenopathy. thoracotomy and lobectomy. Specimens Submitted. 1 : SP: Level seven mediastinal lymph nodes. 2: SP 1 Tisuse external from bronchug intermodius. 3: SP: Right level eloven interlobar lymph node (. 4: SP: Right level ten mediastinal lymah node. 5  SP: Bronchial margin bronchus intermedius. 6 : SP: Level seven mediastinal lymph nodes #2. 7: SP: Right level eleven interlobar lymph node #2. 8: SP: Right middle and lower ...",
      "response": "```json\n{\n    \"cancer_type\": \"ADCA\",\n    \"reasoning\": \"1. Site: Mediastinum (Level 7, 10, 11). 2. Findings: Metastatic squamous cell carcinoma. 3. Code: Squamous Cell Carcinoma, Metastatic, Mediastinum maps to ADCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. ",
      "predicted": "ADCA",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Mediastinum (Level 7, 10, 11). 2. Findings: Metastatic squamous cell carcinoma. 3. Code: Squamous Cell Carcinoma, Metastatic, Mediastinum maps to ADCA.",
      "idx": 832,
      "timestamp": "2026-01-19T15:59:53.116008"
    },
    {
      "sample_idx": 1196,
      "input": "FINAL DIAGNOSIS: PART 1: TISSUE AT BASE OF LEFT GASTRIC, EXCISION -. ADIPOSE TISSUE-WITH FAT NECROSIS, NEGATIVE FOR TUMOR. PART 2: TISSUE NEAR RIGHT CRUS, EXCISION -. TWO BENIGN LYMPH NODES (0/2). PART 3: OMENTUM, EXCISION -. FIBROADIPOSE TISSUE, NEGATIVE FOR TUMOR. PART 4: LEVEL 7 LYMPH NODE NEAR CARINA, EXCISION -. ONE BENIGN LYMPH NODE (0/1). PART 5: ESOPHAGUS, ESOPHAGECTOMY -. A. WELL TO MODERATELY DIFFERENTIATED ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION,. 2.5 CM, PREDOMINANTLY EXOPHYT...",
      "response": "```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Adenocarcinoma of the gastroesophageal junction, 2.5 cm, predominantly exophytic. 3. Code: ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Adenocarcinoma of the gastroesophageal junction, 2.5 cm, predominantly exophytic. 3. Code: ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Adenocarcinoma of the gastroesophageal junction, 2.5 cm, predominantly exophytic. 3. Code: ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Adenocarcinoma of the gastroesophageal junction, 2.5 cm, predominantly exophytic. 3. Code: ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Adenocarcinoma of the gastroesophageal junction, 2.5 cm, predominantly exophytic. 3. Code: ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Adenocarcinoma of the gastroesophageal junction, 2.5 cm, predominantly exophytic. 3. Code: ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Adenocarcinoma of the gastroesophageal junction, 2.5 cm, predominantly exophytic. 3. Code: ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Adenocarcinoma of the gastroesophageal junction, 2.5 cm, predominantly",
      "predicted": "ESCA",
      "ground_truth": "STAD",
      "correct": false,
      "reasoning": "1. Site: Esophagus. 2. Findings: Adenocarcinoma of the gastroesophageal junction, 2.5 cm, predominantly exophytic. 3. Code: ESCA.",
      "idx": 1196,
      "timestamp": "2026-01-19T15:59:53.116018"
    },
    {
      "sample_idx": 985,
      "input": "ORIGINAL REPORT. SPECIMEN: A. Periportal lymph node,. B. Gallbladder. c. Bile duct margin,. D. Pancreas margin. E. Superior mesenteric lymph nodes (fresh). F. Pancreas (Whipple's spec\u00edmen). G. Omentum. CLINICAL HISTORY?. Pancreatic cancer. DIAGNOSIS: A: #PERTPORTAL\" LYMPH NODE: REACTIVE LYMPH NODE WITH NO EVIDENCE OF MALIGNANCY. B: GALLBLADDER (CHOLECYSTEICTOMY) : NO EVIDENCE OF MALIGNANCY. C: BILE DUCT MARGIN: NO EVIDENCE OF MALIGNANCY OR DYSPLASIA. D: PANCREAS MARGIN: CHRONTO PANCREATITIS WITH...",
      "response": "```json\n{\n    \"cancer_type\": \"F10\",\n    \"reasoning\": \"1. Site: Head of pancreas/common bile duot. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: F10\"\n}\n```\n```json\n{\n    \"cancer_type\": \"F11\",\n    \"reasoning\": \"1. Site: Uncinate pancreas. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: F11\"\n}\n```\n```json\n{\n    \"cancer_type\": \"F12\",\n    \"reasoning\": \"1. Site: Bile duct resection margin. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: F12\"\n}\n```\n```json\n{\n    \"cancer_type\": \"F13\",\n    \"reasoning\": \"1. Site: Stomach resection margin. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: F13\"\n}\n```\n```json\n{\n    \"cancer_type\": \"F14\",\n    \"reasoning\": \"1. Site: Duodenal resection margin. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: F14\"\n}\n```\n```json\n{\n    \"cancer_type\": \"F15\",\n    \"reasoning\": \"1. Site: Ampulla region. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: F15\"\n}\n```\n```json\n{\n    \"cancer_type\": \"F16\",\n    \"reasoning\": \"1. Site: Tumor extending close to the serosal surface of pancreas. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: F16\"\n}\n```\n```json\n{\n    \"cancer_type\": \"F17\",\n    \"reasoning\": \"1. Site: Random sections of the duodenum. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: F17\"\n}\n```\n```json\n{\n    \"cancer_type\": \"F18\",\n    \"reasoning\": \"1. Site: Lymphoid tissue. 2. Findings: Adenocarcinoma, well differentiated. 3. Code:",
      "predicted": "F10",
      "ground_truth": "PAAD",
      "correct": false,
      "reasoning": "1. Site: Head of pancreas/common bile duot. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: F10",
      "idx": 985,
      "timestamp": "2026-01-19T15:59:53.116028"
    },
    {
      "sample_idx": 437,
      "input": "PATIENT HISTORY: CHIEF COMPLAINT/PRE-OP/POST-OR DIAGNOSIS: Left buccal cancer. PROCEDURE: Neck dissection. SPECIFIC CLINICAL QUESTION: Not answered. OUTSIDE TISSUE DIAGNOSIS: Not answered. PRIOR MALIGNANCY: Not answered. CHEMORADIATION: Not answered. ORGAN TRANSPLANT: Not answered. IMMUNOSUPPRESSION: Not answered. OTHER DISEASES: Not answered. E-record history: male with a large buccal tumor (T3 N2B squamous cell carcinoma) which involves almost the entire. buccal mucosa but does not extend into...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left buccal mucosa, left mandibular periosteum, left submandibular gland, left level 1. 2. Findings: Invasive squamous cell carcinoma, moderately differentiated with infiltrative border. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left buccal mucosa, left mandibular periosteum, left submandibular gland, left level 1. 2. Findings: Invasive squamous cell carcinoma, moderately differentiated with infiltrative border. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left buccal mucosa, left mandibular periosteum, left submandibular gland, left level 1. 2. Findings: Invasive squamous cell carcinoma, moderately differentiated with infiltrative border. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left buccal mucosa, left mandibular periosteum, left submandibular gland, left level 1. 2. Findings: Invasive squamous cell carcinoma, moderately differentiated with infiltrative border. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left buccal mucosa, left mandibular periosteum, left submandibular gland, left level 1. 2. Findings: Invasive squamous cell carcinoma, moderately differentiated with infiltrative border. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left buccal mucosa, left mandibular periosteum, left submandibular gland, left level 1. 2. Findings: Invasive squamous cell carcinoma, moderately differentiated with infiltrative border. 3. Code: KIRC.\"\n}\n```\n",
      "predicted": "KIRC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Left buccal mucosa, left mandibular periosteum, left submandibular gland, left level 1. 2. Findings: Invasive squamous cell carcinoma, moderately differentiated with infiltrative border. 3. Code: KIRC.",
      "idx": 437,
      "timestamp": "2026-01-19T15:59:53.116040"
    },
    {
      "sample_idx": 1319,
      "input": "Sex: Female. Ref Physicia. SPECIMEN INFORMATION. Acct / Reg #. DIAGNOSIS,. DIAGNOSIS: A. Omentum, excision: Negative for malignancy. B. Uterus, bilateral adnexa, hysterectomy with bilateral salpingo-oophorectomy: Tumor Characteristics: 1. Histologic type: Serous adenocarcinoma of endometrium. 2. Histologic grade: High. 3. Tumor site: Endometrium. 4. Tumor size: 2.7 by 2.5 cm. 5. Myometrial invasion: Not identified. 6. involvement of cervix: Not identified. 7. Extent of involvement of other organ...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, bilateral tubes and ovaries. 2. Findings: Serous adenocarcinoma of endometrium, high grade, with extensive lymphovascular space invasion. 3. Code: UCEC matches the uterine cancer with lymphovascular invasion.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Omentum. 2. Findings: Negative for malignancy. 3. Code: UVM matches the negative findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Uterus, cervix, bilateral tubes and ovaries. 2. Findings:  Ovarian cysts, one is a hardened cyst. 3. Code: UVM matches the negative findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Left paraaortic lymph nodes. 2. Findings: Negative for metastatic disease. 3. Code: UVM matches the negative findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Left pelvic lymph nodes. 2. Findings: One of seventeen lymph nodes positive for metastatic carcinoma. 3. Code: UVM matches the negative findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Right pelvic lymph nodes. 2. Findings: One of twenty-six lymph nodes positive for metastatic carcinoma. 3. Code: UVM matches the negative findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Right paraaortic lymph nodes. 2. Findings: Six of eight lymph nodes positive for metastatic carcinoma. 3. Code: UVM matches the negative findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Uterus, cervix, bilateral tubes and ovaries. 2. Findings:  No findings. 3. Code: UVM matches the negative",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus, cervix, bilateral tubes and ovaries. 2. Findings: Serous adenocarcinoma of endometrium, high grade, with extensive lymphovascular space invasion. 3. Code: UCEC matches the uterine cancer with lymphovascular invasion.",
      "idx": 1319,
      "timestamp": "2026-01-19T15:59:53.116053"
    },
    {
      "sample_idx": 1403,
      "input": "CLINICAL HISTORY: Malignant neoplasm corpus uteri-182.0 (illegible) = carcinosarcoma. GROSS EXAMINATION: A. \"Right periaortic\", received fresh and placed in formalin on. at. is a 4 x 2.5 x 1 cm aggregate of fibroadipose tissue. Seven lymph node. candidates are identified ranging from 0.4 x 0.4 x 0.2 cm up to 1.2 x 1 x 0.5. cm. The largest lymph node candidate is bisected and exhibits a white-brown. firm cut surface. BLOCK SUMMARY: A1- six intact lymph node candidates. A2- one bisected lymph node...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Carcinosarcoma (malignant mesodermal mixed tumor). The tumor is located on the anterior uterine wall and in a separate detached fragment. 3. Code: UCEC (Uterine Corpus Carcinoma) maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Carcinosarcoma (malignant mesodermal mixed tumor). The tumor is located on the anterior uterine wall and in a separate detached fragment. 3. Code: UCEC (Uterine Corpus Carcinoma) maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Carcinosarcoma (malignant mesodermal mixed tumor). The tumor is located on the anterior uterine wall and in a separate detached fragment. 3. Code: UCEC (Uterine Corpus Carcinoma) maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Carcinosarcoma (malignant mesodermal mixed tumor). The tumor is located on the anterior uterine wall and in a separate detached fragment. 3. Code: UCEC (Uterine Corpus Carcinoma) maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Carcinosarcoma (malignant mesodermal mixed tumor). The tumor is located on the anterior uterine wall and in a separate detached fragment. 3. Code: UCEC (Uterine Corpus Carcinoma) maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Carcinosarcoma (malignant mesodermal mixed tumor). The tumor is located on the anterior uterine wall and in a separate detached fragment. 3. Code: UCEC (U",
      "predicted": "UCEC",
      "ground_truth": "UCS",
      "correct": false,
      "reasoning": "1. Site: Uterus. 2. Findings: Carcinosarcoma (malignant mesodermal mixed tumor). The tumor is located on the anterior uterine wall and in a separate detached fragment. 3. Code: UCEC (Uterine Corpus Carcinoma) maps to UCEC.",
      "idx": 1403,
      "timestamp": "2026-01-19T15:59:53.116066"
    },
    {
      "sample_idx": 337,
      "input": "Case ID. Gross. Microscopic Description. Diagnosis Details. Description. Part of the stomach. The 1st conclusion: in the gastric. Tumor Features: Unknown,. with saucer-like. wall there is a tumor with diffuse. Tumor Extent: 0, Venous. tumor up to 5.5 cm. type of growth, which is consised. Invasion: Absent, Margins: in size, with muscle. of small-size cells with. Absent, Treatment Effect: layer invasion. In. hyperchromatic nuclei. Tumor is. the fatty tissue. replace gastric mucosa and spread. the...",
      "response": "```json\n{\n    \"cancer_type\": \"MBL\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Non-Hodgkin's marginal zone B-cell lymphoma, diffuse large B-cell lymphoma. 3. Code: MBL maps to MBL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MBL\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Non-Hodgkin's marginal zone B-cell lymphoma, diffuse large B-cell lymphoma. 3. Code: MBL maps to MBL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MBL\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Non-Hodgkin's marginal zone B-cell lymphoma, diffuse large B-cell lymphoma. 3. Code: MBL maps to MBL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MBL\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Non-Hodgkin's marginal zone B-cell lymphoma, diffuse large B-cell lymphoma. 3. Code: MBL maps to MBL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MBL\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Non-Hodgkin's marginal zone B-cell lymphoma, diffuse large B-cell lymphoma. 3. Code: MBL maps to MBL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MBL\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Non-Hodgkin's marginal zone B-cell lymphoma, diffuse large B-cell lymphoma. 3. Code: MBL maps to MBL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MBL\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Non-Hodgkin's marginal zone B-cell lymphoma, diffuse large B-cell lymphoma. 3. Code: MBL maps to MBL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MBL\",\n    \"reasoning\": \"",
      "predicted": "MBL",
      "ground_truth": "DLBC",
      "correct": false,
      "reasoning": "1. Site: Stomach. 2. Findings: Non-Hodgkin's marginal zone B-cell lymphoma, diffuse large B-cell lymphoma. 3. Code: MBL maps to MBL.",
      "idx": 337,
      "timestamp": "2026-01-19T15:59:53.116077"
    },
    {
      "sample_idx": 776,
      "input": "Spec. Taken. INTERPRETATION AND DIAGNOSIS: 1. LYMPH NODE, L8 (EXCISION) : ONE (1) LYMPH NODE AND ASSOCIATED. FIBROADIPOSE TISSUE, NEGATIVE FOR TUMOR. 2. LUNG (RESECTION) : SPECIMEN TYPE: Lobectomy, left lower lobe. TUMOR SITE: Left Lower lobe. HISTOLOGIC TYPE: Adenocarcinoma (70% Acinar, 30% solid). TUMOR SIZE: 2.3 cm. HISTOLOGIC GRADE: G3: Poorly Differentiated. LYMPH NODES: Metastatic carcinoma in 1 of 11 lymph nodes. EXTENT OF INVASION (7th Edition, AJCC) : PRIMARY TUMOR. pT1b: Tumor >2 cm bu...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Left Lower lobe of the lung. 2. Findings: Adenocarcinoma, 70% acinar, 30% solid, 2.3 cm. 3. Code: LUAD.\"\n}\n```\nExplanation:\n\n1. **Anatomic Site**: The report mentions \"Left Lower lobe\" and \"Station 6\" and \"Station 7\" lymph nodes. The primary tumor is in the left lower lobe.\n2. **Histological Findings**: The tumor is an adenocarcinoma, specifically 70% acinar and 30% solid. The size is 2.3 cm.\n3. **TCGA Code Selection**: Based on the information, the most appropriate TCGA code is LUAD (Lung Adenocarcinoma).\nThe other information (lymph nodes) is relevant for staging but doesn't directly determine the primary cancer type.\nFinal Answer: The final answer is $\\boxed{LUAD}$\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nFinal Answer: The final answer is $\\boxed{BRCA}$\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Lower lobe). 2. Findings: Adenocarcinoma, 70% acinar, 30% solid, 2.3 cm. 3. Code: LUAD.\"\n}\n```\nFinal Answer: The final answer is $\\boxed{LUAD}$\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Lower lobe). 2. Findings: Adenocarcinoma, 70% acinar, 30% solid, 2.3 cm. 3. Code: LUAD.\"\n}\n```\nFinal Answer: The final answer is $\\boxed{LUAD}$\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Lower lobe). 2. Findings: Adenocarcinoma, 70% acinar, 30%",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Left Lower lobe of the lung. 2. Findings: Adenocarcinoma, 70% acinar, 30% solid, 2.3 cm. 3. Code: LUAD.",
      "idx": 776,
      "timestamp": "2026-01-19T15:59:53.116087"
    },
    {
      "sample_idx": 4,
      "input": "PREVIOUS DIAGNOSIS INQUIRY. 1. SEX: F. ADM DATE: OPER DATE: PROCEDURE: SPHS. Right adrenal mass. Two short stitches adrenal vein with thrombus coming out. of vein. Two long inferior aspect of tumor. One long lateral aspect of tumor. Two double long superior aspect of tumor. Inking according to sarcoma. template. Yellow anterior, blue superior, green inferior, red medial, orange. lateral, black posterior. PROCEDURE: SPGD. 1. \"Adrenal gland. Received in formalin in a large container is a 1060 gm. ...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenocortical carcinoma, low grade. 3. Code: ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenocortical carcinoma, low grade. 3. Code: ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenocortical carcinoma, low grade. 3. Code: ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenocortical carcinoma, low grade. 3. Code: ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenocortical carcinoma, low grade. 3. Code: ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenocortical carcinoma, low grade. 3. Code: ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenocortical carcinoma, low grade. 3. Code: ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenocortical carcinoma, low grade. 3. Code: ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. ",
      "predicted": "ADENOCA",
      "ground_truth": "ACC",
      "correct": false,
      "reasoning": "1. Site: Adrenal gland. 2. Findings: Adrenocortical carcinoma, low grade. 3. Code: ADENOCA.",
      "idx": 4,
      "timestamp": "2026-01-19T15:59:53.116096"
    },
    {
      "sample_idx": 799,
      "input": "LUNG MALIGNANT. LUNG UNINVOLVED. BLOOD. SERUM. PLASMA. BUFFY-COAT. Case: : Collected date: Result date: Clinical Information. The patient is a. year old [black]-female with a lung nodule. Frozen Section Diagnosis. MFS1: Left lower lobe, resection: - Adenocarcinoma. (Per. Gross Description. The specimen is received in thirteen containers each labeled with the patient's name and medical record. number. The first container is labeled \"level IX lymph node\". Received is an anthracotic fragment of tis...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Lower Lobe). 2. Findings: Adenocarcinoma, 1.2 cm, moderately differentiated. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1.",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung (Left Lower Lobe). 2. Findings: Adenocarcinoma, 1.2 cm, moderately differentiated. 3. Code: LUAD.",
      "idx": 799,
      "timestamp": "2026-01-19T15:59:53.116107"
    },
    {
      "sample_idx": 543,
      "input": "DIAGNOSIS. (A) LEFT KIDNEY AND ADRENAL GLAND: RENAL CELL CARCINOMA (16.0 CM MAXIMUM DIMENSION), CONVENTIONAL TYPE. (50% CLEAR CELLS,. 50% EOSINOPHILIC CELLS), FUHRMAN NUCLEAR GRADE 4, INVASIVE. INTO PERINEPHRIC. ADIPOSE TISSUE, RENAL SINUS ADIPOSE TISSUE, RENAL. PELVICALYCEAL SYSTEM, AND RENAL. VEIN, WITH EXTENSION TO RENAL VEIN MARGIN. (SEE COMMENT). Adrenal gland, no tumor present. Soft tissue margin free of tumor. (B) THROMBUS: CONVENTIONAL RENAL CELL CARCINOMA ATTACHED TO VESSEL WALL. COMMEN...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade II, with invasion into perinephric adipose tissue, renal sinus adipose tissue, and renal pelvicalyceal system. Tumor extends to the renal vein margin. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade II, with invasion into perinephric adipose tissue, renal sinus adipose tissue, and renal pelvicalyceal system. Tumor extends to the renal vein margin. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade II, with invasion into perinephric adipose tissue, renal sinus adipose tissue, and renal pelvicalyceal system. Tumor extends to the renal vein margin. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade II, with invasion into perinephric adipose tissue, renal sinus adipose tissue, and renal pelvicalyceal system. Tumor extends to the renal vein margin. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade II, with invasion into perinephric adipose tissue, renal sinus adipose tissue, and renal pelvicalyceal system. Tumor extends to the renal vein margin. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade II, with invasion into perinephric adipose tissue, renal sinus adipose tissue, and renal pelvicalyceal system. Tumor extends to the renal vein margin. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 543,
      "timestamp": "2026-01-19T15:59:53.116121"
    },
    {
      "sample_idx": 931,
      "input": "Date Received: DIAGNOSIS: A. RIGHT TUBE AND OVARY: High-grade papiliary serous carcinoma. Fallopian tube focal epithelial hyperplasia. B. LEFT FALLOPIAN TUBE AND OVARY: High-grade papiliary serous carcinoma. C. UTERUS AND CERVIX: Atrophic endometrium. - Lelomyoma. Metastatic high-grade papillary serous carcinoma in uterine serosa. Adenomyosis. Endometriosis in fallopian tube. D. OMENTUM: Metastatic papiliary serous carcinoma, high grade. E. OMENTUM #2: Metastatic papillary serous carcinoma, high...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Ovary and Fallopian tube. 2. Findings: High-grade serous carcinoma, papillary type. 3. Code: UCEC (Uterine Corpus Endometrium) is not the correct code for this case. UCEC is for uterine cancer. This case involves a serous carcinoma of the ovary and fallopian tube. The correct TCGA code is UCEC as the pathology report states that the cancer is of mullerian/ovarian origin and is located in the uterus.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Ovary and Fallopian tube. 2. Findings: High-grade serous carcinoma, papillary type. 3. Code: UCEC (Uterine Corpus Endometrium) is not the correct code for this case. UCEC is for uterine cancer. This case involves a serous carcinoma of the ovary and fallopian tube. The correct TCGA code is UCEC as the pathology report states that the cancer is of mullerian/ovarian origin and is located in the uterus.\"\n}\n```\n\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Ovary and Fallopian tube. 2. Findings: High-grade serous carcinoma, papillary type. 3. Code: UCEC (Uterine Corpus Endometrium) is not the correct code for this case. UCEC is for uterine cancer. This case involves a serous carcinoma of the ovary and fallopian tube. The correct TCGA code is UCEC as the pathology report states that the cancer is of mullerian/ovarian origin and is located in the uterus.\"\n}\n```\n\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Ovary and Fallopian tube. 2. Findings: High-grade serous carcinoma, papillary type. 3. Code: UCEC (Uterine Corpus Endometrium) is not the correct code for this case. UCEC is for uterine cancer. This case involves a serous carcinoma of the ovary and fallopian tube. The correct TCGA code is UCEC as the pathology report states that the cancer is of mullerian/ovarian origin",
      "predicted": "UCEC",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Ovary and Fallopian tube. 2. Findings: High-grade serous carcinoma, papillary type. 3. Code: UCEC (Uterine Corpus Endometrium) is not the correct code for this case. UCEC is for uterine cancer. This case involves a serous carcinoma of the ovary and fallopian tube. The correct TCGA code is UCEC as the pathology report states that the cancer is of mullerian/ovarian origin and is located in the uterus.",
      "idx": 931,
      "timestamp": "2026-01-19T15:59:53.116137"
    },
    {
      "sample_idx": 584,
      "input": "FINAL DIAGNOSIS. PART 1: GALLBLADDER, CHOLECYSTECTOMY -. ACUTE AND CHRONIC CALCULOUS CHOLECYSTITIS. NO EVIDENCE OF MALIGNANCY. PART 2: GALLSTONES, REMOVAL -. CHOLELITHIASIS (gross diagnosis). PART 3: LEFT KIDNEY AND LEFT ADRENAL GLAND, RESECTION -. A. RENAL CELL CARCINOMA, CONVENTIONAL TYPE (CLEAR AND GRANULAR CELL FEATURES),. EXTENSIVELY INVOLVING THE LEFT KIDNEY-AND FOCALLY INVOLVING THE RENAL PELVIS (slide 31). B. MAXIMAL TUMOR DIMENSION IS 11 CM. C. PREDOMINANT FUHRMAN NUCLEAR GRADE IS 2/4 W...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Upper Lobe Lung. 2. Findings: Metastatic Renal Cell Carcinoma. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) - this is the most appropriate code given the presence of a known renal cell carcinoma that has metastasized to the lung. The initial biopsy in the kidney is also consistent with renal cell carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA - this is the most appropriate code given the presence of invasive ductal carcinoma in the breast. Although the report does not explicitly mention BRCA, the presence of an invasive carcinoma in the breast is a strong indicator.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) - this is the most appropriate code given the presence of a renal cell carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) - this is the most appropriate code given the presence of a renal cell carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) - this is the most appropriate code given the presence of a renal cell carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Left Upper Lobe Lung. 2. Findings: Metastatic Renal Cell Carcinoma. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) - this is the most appropriate code given the presence of a known renal cell carcinoma that has metastasized to the lung. The initial biopsy in the kidney is also consistent with renal cell carcinoma.",
      "idx": 584,
      "timestamp": "2026-01-19T15:59:53.116154"
    },
    {
      "sample_idx": 1228,
      "input": "Laterality:Right. Path Report:THYROID CARCINOMA CHECKLIST. 1. Tumor type: Papillary. 2. Tumor location: Right lobe. 3. Tumor multicentricity: Single focus. 4. Tumor size: 2.1 x 1.9 cm. 5. Extrathyroid extension: Yes. 6. Surgical margins: Free of tumor. 7. Angiolymphatic invasion: Yes. 8. Lymph nodes: 14 lymph nodes identified, 11 with metastatic papillary. adenocarcinoma. 9. TNM:T3 N1a Mx.",
      "response": "```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, right lobe. Extrathyroid extension is present. Lymph node metastasis is present. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, right lobe. Extrathyroid extension is present. Lymph node metastasis is present. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, right lobe. Extrathyroid extension is present. Lymph node metastasis is present. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, right lobe. Extrathyroid extension is present. Lymph node metastasis is present. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, right lobe. Extrathyroid extension is present. Lymph node metastasis is present. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, right lobe. Extrathyroid extension is present. Lymph node metastasis is present. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, right lobe. Extrathyroid extension is present. Lymph node metastasis is present. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",",
      "predicted": "THCA",
      "ground_truth": "THCA",
      "correct": true,
      "reasoning": "1. Site: Thyroid. 2. Findings: Papillary carcinoma, right lobe. Extrathyroid extension is present. Lymph node metastasis is present. 3. Code: Thyroid Carcinoma maps to THCA.",
      "idx": 1228,
      "timestamp": "2026-01-19T15:59:53.116165"
    },
    {
      "sample_idx": 996,
      "input": "Diagnosis: Adrenal, left, laparoscopic adrenalectomy. - Pheochromocytoma, 109 g. - Surgical margins free of pheochromocytoma. - The tumor is circumscribed and encapsulated, without. 1 ymphovascular space invasion identified. Clinical History: -year-old male with a pheochromocytoma. Gross Description: Received is one appropriately labeled container, additionally. labeled \"left. adrenal gland.\" It holds an intact 109.1 gram, 7.2 X 6.0 X 5.0. cm unoriented. tissue fragment with a focally cauterized...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Adrenal, left. 2. Findings: Pheochromocytoma, 109 g. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Adrenal, left. 2. Findings: Pheochromocytoma, 109 g. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Adrenal, left. 2. Findings: Pheochromocytoma, 109 g. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Adrenal, left. 2. Findings: Pheochromocytoma, 109 g. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Adrenal, left. 2. Findings: Pheochromocytoma, 109 g. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Adrenal, left. 2. Findings: Pheochromocytoma, 109 g. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Adrenal, left. 2. Findings: Pheochromocytoma, 109 g. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Adrenal, left. 2. Findings: Pheochromocytoma, 109 g. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",",
      "predicted": "ADENOMA",
      "ground_truth": "PCPG",
      "correct": false,
      "reasoning": "1. Site: Adrenal, left. 2. Findings: Pheochromocytoma, 109 g. 3. Code: ADENOMA.",
      "idx": 996,
      "timestamp": "2026-01-19T15:59:53.116174"
    },
    {
      "sample_idx": 317,
      "input": "Date of Birth: Vital Status: Date of Death: Race: White. Ethnicity: Not Hispanic or Latino Specific Ethnicity: Histologic Subtype: Colon adenocarcinoma. Date of Initial Path Dx: Primary Site: Colons. Anatomic Site: Ascending Colon. T Stage: 3. N Stage: 0. M Stage: 0. Overall Stage: IIA. Date of Normal Procurement:",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending Colon). 2. Findings: Colon adenocarcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending Colon). 2. Findings: Colon adenocarcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending Colon). 2. Findings: Colon adenocarcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending Colon). 2. Findings: Colon adenocarcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending Colon). 2. Findings: Colon adenocarcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending Colon). 2. Findings: Colon adenocarcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending Colon). 2. Findings: Colon adenocarcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending Colon). 2. Findings: Colon adenocarcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending Colon). 2. Findings: Colon adenocarcinoma. 3. Code: Colon Adenocarcinoma",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon (Ascending Colon). 2. Findings: Colon adenocarcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.",
      "idx": 317,
      "timestamp": "2026-01-19T15:59:53.116183"
    },
    {
      "sample_idx": 388,
      "input": "CLINICAL HISTORY. ith headache has posterior right frontal necrotic,. enhancing tumor, with mass effect and edema. OPERATIVE DIAGNOSES. Not Given. Operation/Specimen: A: Brain, excision biopsy. B: Right frontal brain tumor. PATHOLOGICAL DIAGNOSIS: A. Brain, site not specified, excisional biopsy: 1. Glioblastoma. 2. MIB-1 proliferation index: 30%. See Comment. COMMENT. The sections contain portions of a malignant astrocytic neoplasm that has. frequent small-multinucleated cells. There is nuclear ...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code: GBM.",
      "idx": 388,
      "timestamp": "2026-01-19T15:59:53.116192"
    },
    {
      "sample_idx": 607,
      "input": "Gender: F. Date of Service: Date Received: FINAL SURGICAL PATHOLOGY REPORT. Diagnosis: KIDNEY, LEFT, NEPHRECTOMY: - PAPILLARY RENAL CELL CARCINOMA, SEE COMMENT. - FUHRMAN NUCLEAR GRADE 3. - TUMOR SIZE: 6 CM. - LIMITED TO KIDNEY. - SURGICAL MARGINS NEGATIVE. PATHOLOGIC TUMOR STAGING SYNOPSIS (LEFT KIDNEY): Type and grade: Papillary renal cell carcinoma, Fuhrman nuclear grade 3. Primary tumor: pT1b. Regional lymph node: pNX. Distant metastasis: N/A. Pathologic stage: I. Lymphovascular invasion: No...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nThe response is correct. The cancer type is KIRC, and the reasoning accurately reflects the findings in the report.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nThe response is correct. The cancer type is KIRC, and the reasoning accurately reflects the findings in the report.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nThe response is correct. The cancer type is KIRC, and the reasoning accurately reflects the findings in the report.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nThe response is correct. The cancer type is KIRC, and the reasoning accurately reflects the findings in the report.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nThe response is correct. The cancer type is KIRC, and the reasoning accurately reflects the findings in the report.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code:",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 607,
      "timestamp": "2026-01-19T15:59:53.116203"
    },
    {
      "sample_idx": 445,
      "input": "DIAGNOSIS: 1) ORAL CAVITY, ANTERIOR CANCELLOUS MARGIN, BIOPSY: BONE WITH ACUTELY. INFLAMED ATTACHED SOFT TISSUE; NEGATIVE FOR TUMOR. 2) ORAL CAVITY, POSTERIOR MANDIBULAR MARGIN, BIOPSY: NEGATIVE FOR TUMOR. 3) ORAL CAVITY, POSTERIOR BUCCAL MARGIN, EXCISION: NEGATIVE FOR DYSPLASIA. OR CARCINOMA (SEE COMMENT). COMMENT: Permanent sections do not confirm presence of dysplasia or. carcinoma in situ. The focus of concern on the frozen section may represent. basal layer with frozen artifact. 4) ORAL CAV...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral Cavity, Anterior Buccal Margin. 2. Findings: Invasive moderately differentiated squamous cell carcinoma, 2.3 cm in greatest extent, involving floor of mouth and invading into mandible; tumor is 0.2 cm from closest (lateral) surgical margin; 1 of 3 lymph nodes involved by metastatic squamous cell carcinoma (1/3); associated carcinoma in situ. 3. Code: BRCA is not a valid code for this case.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral Cavity, Anterior Buccal Margin. 2. Findings: Invasive moderately differentiated squamous cell carcinoma, 2.3 cm in greatest extent, involving floor of mouth and invading into mandible; tumor is 0.2 cm from closest (lateral) surgical margin; 1 of 3 lymph nodes involved by metastatic squamous cell carcinoma (1/3); associated carcinoma in situ. 3. Code: BRCA is not a valid code for this case.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral Cavity, Anterior Buccal Margin. 2. Findings: Invasive moderately differentiated squamous cell carcinoma, 2.3 cm in greatest extent, involving floor of mouth and invading into mandible; tumor is 0.2 cm from closest (lateral) surgical margin; 1 of 3 lymph nodes involved by metastatic squamous cell carcinoma (1/3); associated carcinoma in situ. 3. Code: BRCA is not a valid code for this case.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral Cavity, Anterior Buccal Margin. 2. Findings: Invasive moderately differentiated squamous cell carcinoma, 2.3 cm in greatest extent, involving floor of mouth and invading into mandible; tumor is 0.2 cm from closest (lateral) surgical margin; 1 of 3 lymph nodes involved by metastatic squamous cell carcinoma (1/3); associated carcinoma in situ. 3. Code: BRCA is not a valid code for this case.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning",
      "predicted": "BRCA",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Oral Cavity, Anterior Buccal Margin. 2. Findings: Invasive moderately differentiated squamous cell carcinoma, 2.3 cm in greatest extent, involving floor of mouth and invading into mandible; tumor is 0.2 cm from closest (lateral) surgical margin; 1 of 3 lymph nodes involved by metastatic squamous cell carcinoma (1/3); associated carcinoma in situ. 3. Code: BRCA is not a valid code for this case.",
      "idx": 445,
      "timestamp": "2026-01-19T15:59:53.116219"
    },
    {
      "sample_idx": 119,
      "input": "page 1 / 1. original. Examination: Histopathological examination. PESEL: Gender: F. Material: Total organ resection - right breast with axiliary tissues. Expected time of examination: up to 8 working days. Clinical diagnosis: Right breast with an ulcerous tumour and right axillary lymph nodes. Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in less than 10% of neoplastic cell nuclei. HER2 protein stained wit...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma of the right breast. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma of the right breast. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma of the right breast. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma of the right breast. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma of the right breast. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma of the right breast. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma of the right breast. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma of the right breast. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive mucinous carcinoma of the right breast. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 119,
      "timestamp": "2026-01-19T15:59:53.116230"
    },
    {
      "sample_idx": 1110,
      "input": "Clinical Diagnosis & History: Right leg mass. Specimens Submitted: 1: Right leg mass sarcoma ???. 2: Lateral fascial margin right leg. DIAGNOSIS: 1. Right leg mass sarcoma; excision: - High grade spindle and pleomorphic sarcoma consistent with malignant. fibrous histiocytoma/ undifferentiated high grade pleomorphic sarcoma. - Tumor measures 9 x 6 x 4 cm. - Tumor involves dermis, subcutis and extends to fascia. Necrosis is present about 15%. - Tumor extends focally to the deep margin of resection...",
      "response": "```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Leg. 2. Findings: Sarcoma, high-grade spindle cell type. 3. Code: SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Leg. 2. Findings: Sarcoma, high-grade pleomorphic type. 3. Code: SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Leg. 2. Findings: Sarcoma, high-grade spindle cell type. 3. Code: SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Leg. 2. Findings: Sarcoma, high-grade pleomorphic type. 3. Code: SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Leg. 2. Findings: Sarcoma, high-grade spindle cell type. 3. Code: SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Leg. 2. Findings: Sarcoma, high-grade pleomorphic type. 3. Code: SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Leg. 2. Findings: Sarcoma, high-grade spindle cell type. 3. Code: SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Leg. 2. Findings: Sarcoma, high-grade pleomorphic type. 3. Code: SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Leg. 2. Findings: Sarcoma, high-grade spindle cell type. 3. Code: SARC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "SARC",
      "ground_truth": "SARC",
      "correct": true,
      "reasoning": "1. Site: Leg. 2. Findings: Sarcoma, high-grade spindle cell type. 3. Code: SARC.",
      "idx": 1110,
      "timestamp": "2026-01-19T15:59:53.116238"
    },
    {
      "sample_idx": 1176,
      "input": "Case ID. Gross Description. Microscopic. Diagnosis Details. Description. Stomach with a polypoid. Adenocarcinoma of the. Tumor Features: Exophytic. tumour, up to 16 cm in its. stomach G2-3. In the. (polypoid), Tumor Extent: diameter, invades adjacent. exofytic component the. Perigastric fat , Venous. fatty tissue;. predominant type of growth. Invasion: Absent, Margins: fatty tissue lymph nodes. is G2. In the endophtyic. Absent, Treatment Effect: are free of metastases;. component the. omentum - ...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, exophytic, polypoid, G2-3, with necrosis and invasion of perigastric fat. 15 lymph nodes are positive for metastasis. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, exophytic, polypoid, G2-3, with necrosis and invasion of perigastric fat. 15 lymph nodes are positive for metastasis. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, exophytic, polypoid, G2-3, with necrosis and invasion of perigastric fat. 15 lymph nodes are positive for metastasis. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, exophytic, polypoid, G2-3, with necrosis and invasion of perigastric fat. 15 lymph nodes are positive for metastasis. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, exophytic, polypoid, G2-3, with necrosis and invasion of perigastric fat. 15 lymph nodes are positive for metastasis. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, exophytic, polypoid, G2-3, with necrosis and invasion of perigastric fat. 15 lymph nodes are",
      "predicted": "STAD",
      "ground_truth": "STAD",
      "correct": true,
      "reasoning": "1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, exophytic, polypoid, G2-3, with necrosis and invasion of perigastric fat. 15 lymph nodes are positive for metastasis. 3. Code: Stomach Adenocarcinoma maps to STAD.",
      "idx": 1176,
      "timestamp": "2026-01-19T15:59:53.116250"
    },
    {
      "sample_idx": 642,
      "input": "Final Diagnosis: A-C. Brain, right frontotemporal/insular mass, and frontotemporal excision and CUSA: Anaplastic. oligoastrocytoma (WHO grade III). Immunohistochemical stains were performed on paraffin embedded tissue using antibodies to p53, IDH1-R132H. and Ki-67. IDH1-R132H stain is positive consistent with IDH1 mutation. p53 protein is positive in rare cells. Ki-67 labeling is focally high. The findings support the above diagnosis. Fluorescence in situ hybridization (FISH) studies for 1p19q d...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontotemporal/insular mass. 2. Findings: Anaplastic oligoastrocytoma (WHO grade III). IDH1-R132H mutation present. p53 protein present in rare cells. Ki-67 labeling is focally high. 3. Code: GBM maps to the category of brain tumors.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontotemporal/insular mass. 2. Findings: Anaplastic oligoastrocytoma (WHO grade III). IDH1-R132H mutation present. p53 protein present in rare cells. Ki-67 labeling is focally high. 3. Code: GBM maps to the category of brain tumors.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontotemporal/insular mass. 2. Findings: Anaplastic oligoastrocytoma (WHO grade III). IDH1-R132H mutation present. p53 protein present in rare cells. Ki-67 labeling is focally high. 3. Code: GBM maps to the category of brain tumors.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontotemporal/insular mass. 2. Findings: Anaplastic oligoastrocytoma (WHO grade III). IDH1-R132H mutation present. p53 protein present in rare cells. Ki-67 labeling is focally high. 3. Code: GBM maps to the category of brain tumors.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontotemporal/insular mass. 2. Findings: Anaplastic oligoastrocytoma (WHO grade III). IDH1-R132H mutation present. p53 protein present in rare cells. Ki-67 labeling is focally high. 3. Code: GBM maps to the category of",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain, right frontotemporal/insular mass. 2. Findings: Anaplastic oligoastrocytoma (WHO grade III). IDH1-R132H mutation present. p53 protein present in rare cells. Ki-67 labeling is focally high. 3. Code: GBM maps to the category of brain tumors.",
      "idx": 642,
      "timestamp": "2026-01-19T15:59:53.116267"
    },
    {
      "sample_idx": 117,
      "input": "DIAGNOSIS. (A) RIGHT BREAST, TOTAL MASTECTOMY: INVASIVE LOBULAR CARCINOMA, INTERMEDIATE GRADE. (SEE COMMENT). LOBULAR CARCINOMA IN SITU (LCIS), LOW AND INTERMEDIATE NUCLEAR GRADES. INVASIVE CARCINOMA MEASURES 3.0 X 1.1 CM IN CONTIGUOUS SECTIONS/SLICES. INVASIVE CARCINOMA IS PRESENT AT LEAST 1.0 CM FROM MARGINS. No lymphovascular invasion identified. Microcalcifications present in association with benign breast tissue. NIPPLE, LCIS/ATYPICAL LOBULAR HYPERPLASIA. (B) RIGHT AXILLARY SENTINEL LYMPH N...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate grade. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate grade. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate grade. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate grade. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate grade. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate grade. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate grade. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate grade. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate grade. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lob",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate grade. 3. Code: BRCA",
      "idx": 117,
      "timestamp": "2026-01-19T15:59:53.116276"
    },
    {
      "sample_idx": 102,
      "input": "(Age: F. Pathologic Interpretation: A. SENTINEL NODE NO.1 AXILLA CONTENT. - No malignancy seen in one lymph node (0/1). - Immunohistochemistry for keratin to follow. B. RIGHT BREAST (SHORT STITCH SUPERIOR LONG STITCH LATERAL): - Invasive lobular carcinoma, intermediate nuclear grade, with formation of two dominant tumoral masses, 4,0 cm and. 1.0 cm. - The tumor invades the dermal skin. - Lymphovascular spaces invasion is identified. - Specimen margin is negative for tumor. - Metastatic carcinoma...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate nuclear grade, with formation of two dominant tumoral masses, 4.0 cm and. 1.0 cm. - The tumor invades the dermal skin. - Lymphovascular spaces invasion is identified. - Specimen margin is negative for tumor. - Metastatic carcinoma to two of eight lymph nodes (/2/8). - Present. - Present. - Not identified. - Not identified. - Number of sentinel lymph nodes examined: 2. - Total number of lymph nodes examined (sentinel and Nonsentinel): 10. - Number of lymph nodes with macrometastases (>0.2 cm): 2. - Not identified. - Hematoxylin and eosin (H&E, one level). - Immunohistochemistry. - Equivocal (Score 2+). - Not amplified (HER2 gene copy <4.0 or ratio <1.8). - Grade 2. - Present. - Present. - Not applicable. - pT4b. - pN1a. - Not applicable. - pT4b, N1a, M-not applicable. - Lobular Carcinoma IN Situ (LCIS): - Present. - Present. - Overall Grade: Grade 2. - Not identified. - Not identified. - Performed on another specimen: Results: Immunoreactive tumor cells present (1%). - Performed on another specimen: Results: Immunoreactive tumor cells present (>1%). - Performed on another specimen: Results: Equivocal (Score 2+). - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified.",
      "predicted": null,
      "ground_truth": "BRCA",
      "correct": null,
      "reasoning": "",
      "idx": 102,
      "timestamp": "2026-01-19T15:59:53.116405"
    },
    {
      "sample_idx": 976,
      "input": "NATURE OF MATERIAL : PANCREAS. BIOPSY : MACROSCOPY. - bottle 1 : specimen made of pancreatic head and segment of duodenum . The pancreas. measures 6.0 X 4,5x 4,5 cm. The duodenum measuring 15.5 cm in length and diameter 2.5 cm. nlt was noted a head injury in pancreas, measuring 2.4 x 2,2 cm. bottle 2 : gallbladder measured 12.2 cm length for 2.5 cm in diameter greater. - bottle 3 : 4 lymph nodes measuring between 0.2 and 1.0 cm cm in major axes. MICROSCOPIC. Product of pancreaticoduodenectomy: i...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Invasive ductal adenocarcinoma localized in cephalic portion of pancreas, moderately. differentiated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Invasive ductal adenocarcinoma localized in cephalic portion of pancreas, moderately. differentiated. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Invasive ductal adenocarcinoma localized in cephalic portion of pancreas, moderately. differentiated. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Invasive ductal adenocarcinoma localized in cephalic portion of pancreas, moderately. differentiated. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Invasive ductal adenocarcinoma localized in cephalic portion of pancreas, moderately. differentiated. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Invasive ductal adenocarcinoma localized in cephalic portion of pancreas, moderately. differentiated. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Invasive ductal adenocarcinoma localized in cephalic portion of pancreas, moderately. differentiated. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Invasive ductal adenocarcinoma localized in cephalic portion of pancreas, moderately. differentiated. 3. Code: KIRC\"\n}\n```\n```json\n{\n    ",
      "predicted": "ADENOMA",
      "ground_truth": "PAAD",
      "correct": false,
      "reasoning": "1. Site: Pancreas. 2. Findings: Invasive ductal adenocarcinoma localized in cephalic portion of pancreas, moderately. differentiated. 3. Code: ADENOMA",
      "idx": 976,
      "timestamp": "2026-01-19T15:59:53.116419"
    },
    {
      "sample_idx": 1029,
      "input": "RADICAL PROSTATECTOMY: TUMOR PROCUREMENT: HISTOLOGIC TYPE. ACINAR ADENOCARCINOMA. HISTOLOGIC GRADE (PRIMARY PATTERN+SECONDARY PATTERN = GLEASON SCORE): 4 + 5 = 9. TERTIARY PATTERN NOT PRESENT. PERCENTAGE OF DIFFERENT GLEASON PATTERNS. NOT REPORTED. TUMOR LOCATION. APEX. ANTERIOR. RIGHT. LEFT. POSTERIOR. RIGHT. LEFT. EXTRA-PROSTATIC EXTENSION. PRESENT. NON-FOCAL. SITE OF EXTRA-PROSTATIC EXTENSION. ANTERIOR. RIGHT. LEFT. POSTERIOR. LEFT. SEMINAL VESICAL INVASION. ABSENT. SURGICAL MARGINS. INVOLVED...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Acinar adenocarcinoma, Gleason Score 9, extra-prostatic extension, positive surgical margins. 3. Code: Prostate Acinar Adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Acinar adenocarcinoma, Gleason Score 9, extra-prostatic extension, positive surgical margins. 3. Code: Prostate Acinar Adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Acinar adenocarcinoma, Gleason Score 9, extra-prostatic extension, positive surgical margins. 3. Code: Prostate Acinar Adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Acinar adenocarcinoma, Gleason Score 9, extra-prostatic extension, positive surgical margins. 3. Code: Prostate Acinar Adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Acinar adenocarcinoma, Gleason Score 9, extra-prostatic extension, positive surgical margins. 3. Code: Prostate Acinar Adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Acinar adenocarcinoma, Gleason Score 9, extra-prostatic extension, positive surgical margins. 3. Code: Prostate Acinar Adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Acinar adenocarcinoma, Gleason Score 9, extra-prostatic extension, positive surgical margins. 3. Code: Prostate Acinar Adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "PRAD",
      "ground_truth": "PRAD",
      "correct": true,
      "reasoning": "1. Site: Prostate. 2. Findings: Acinar adenocarcinoma, Gleason Score 9, extra-prostatic extension, positive surgical margins. 3. Code: Prostate Acinar Adenocarcinoma maps to PRAD.",
      "idx": 1029,
      "timestamp": "2026-01-19T15:59:53.116431"
    },
    {
      "sample_idx": 1087,
      "input": "Diagnosis: Resectate of a portion of the large intestine, or rectosigmoid colon, with an ulcerated. rectal carcinoma conforming to the histological type of a moderately differentiated. colorectal adenocarcinoma, extending no closer than 4.5 cm to the aboral resection. margin and circularly occupying the intestinal wall over a length of 5.5 cm. Invasive. spread of tumor within all layers of the intestinal wall, as far as into the neighboring. periproctic fatty tissue. Oral and aboral resection ma...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine, rectosigmoid colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated, ulcerated, extending 5.5 cm. Invasive. 3. Code: COAD maps to Colorectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Large intestine, rectosigmoid colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated, ulcerated, extending 5.5 cm. Invasive. 3. Code: PAAD maps to Pancreatic Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine, rectosigmoid colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated, ulcerated, extending 5.5 cm. Invasive. 3. Code: COAD maps to Colorectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine, rectosigmoid colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated, ulcerated, extending 5.5 cm. Invasive. 3. Code: COAD maps to Colorectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine, rectosigmoid colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated, ulcerated, extending 5.5 cm. Invasive. 3. Code: COAD maps to Colorectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine, rectosigmoid colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated, ulcerated, extending 5.5 cm. Invasive. 3. Code: COAD maps to Colorectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine, rectosigmoid",
      "predicted": "COAD",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Large intestine, rectosigmoid colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated, ulcerated, extending 5.5 cm. Invasive. 3. Code: COAD maps to Colorectal Adenocarcinoma.",
      "idx": 1087,
      "timestamp": "2026-01-19T15:59:53.116443"
    },
    {
      "sample_idx": 322,
      "input": "Diagnosis / Diagnoses: 1.: Small specimen with submesothelial fibrosis excised from the peritoneum. 2.: Resectate from a portion of the colon (sigmoid) with an ulcerated colon carcinoma, of. the histological type of a moderately differentiated colon carcinoma, that extends no. closer than 3 cm to the resection margin and occupies a circular portion of the intestinal. wall over an length of 5 cm. Invasive spread of the tumor within all layers of the. intestinal wall as far as the neighboring meso...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Colon carcinoma, moderately differentiated. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"T3\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Colon carcinoma, moderately differentiated. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Colon carcinoma, moderately differentiated. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Colon carcinoma, moderately differentiated. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Colon carcinoma, moderately differentiated. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Colon carcinoma, moderately differentiated. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Colon carcinoma, moderately differentiated. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Colon carcinoma, moderately differentiated. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). ",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon (Sigmoid). 2. Findings: Colon carcinoma, moderately differentiated. 3. Code: Colon Adenocarcinoma maps to COAD.",
      "idx": 322,
      "timestamp": "2026-01-19T15:59:53.116453"
    },
    {
      "sample_idx": 116,
      "input": "Final Diagnosis. Breast, right, wide local excision: Infiltrating lobular carcinoma, Nottingham grade II (of. III)[tubules 3/3, nuclei 2/3, mitoses 1/3; Nottingham score 6/9], forming a 5.2 x 3.0 x 2.6 cm. mass. Lobular carcinoma in situ is present and represents less than 5% of the overall tumor. volume. Angiolymphatic invasion is present. The non-neoplastic breast parenchyma show. nonproliferative fibrocystic changes. Calcifications present in benign ducts and acini. Biopsy. site changes prese...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating lobular carcinoma, Nottingham grade II (of III), forming a 5.2 x 3.0 x 2.6 cm mass. Lobular carcinoma in situ is present and represents less than 5% of the overall tumor volume. Angiolymphatic invasion is present. The non-neoplastic breast parenchyma shows proliferative fibrocystic changes. Biopsy site changes present. The inferior and medial margins are positive for invasive carcinoma. Breast, right, total mastectomy: Infiltrating lobular carcinoma, Nottingham grade II (of III), involving the medial aspect of the biopsy cavity. Two additional nodules of Nottingham grade II (of III) invasive lobular carcinoma are identified in the lower outer quadrant (0.7 x 0.6 x 0.5 cm, located 1.4 cm from the deep margin; and 0.5 x 0.4 x 0.4 cm, located 1.2 cm from the deep margin). Lobular carcinoma in situ is present and represents less than 5% of the overall tumor volume. Angiolymphatic invasion is present. The non-neoplastic breast parenchyma shows. nonproliferative fibrocystic changes. Biopsy site changes present. The tumor does not involve the nipple, overlying skin, or underlying chest wall. All surgical resection margins, including the deep margin, are negative for tumor (residual tumor in the biopsy cavity is located 2.2 cm from the deep margin). Lymph nodes, right axillary, dissection: Multiple (5 of 18) right axillary lymph nodes are positive for metastatic carcinoma [AJCC pN2]. The largest is represented by a matted mass of lymph nodes and measures 4.2 x 2.6 x 2.4 cm. Extranodal extension is present. Comment: Final (mastectomy) surgical margins are widely free of involvement. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating lobular carcinoma, Nottingham grade II (of III), forming a 5.2 x 3.0 x 2.6 cm mass. Lobular carcinoma in situ is",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Infiltrating lobular carcinoma, Nottingham grade II (of III), forming a 5.2 x 3.0 x 2.6 cm mass. Lobular carcinoma in situ is present and represents less than 5% of the overall tumor volume. Angiolymphatic invasion is present. The non-neoplastic breast parenchyma shows proliferative fibrocystic changes. Biopsy site changes present. The inferior and medial margins are positive for invasive carcinoma. Breast, right, total mastectomy: Infiltrating lobular carcinoma, Nottingham grade II (of III), involving the medial aspect of the biopsy cavity. Two additional nodules of Nottingham grade II (of III) invasive lobular carcinoma are identified in the lower outer quadrant (0.7 x 0.6 x 0.5 cm, located 1.4 cm from the deep margin; and 0.5 x 0.4 x 0.4 cm, located 1.2 cm from the deep margin). Lobular carcinoma in situ is present and represents less than 5% of the overall tumor volume. Angiolymphatic invasion is present. The non-neoplastic breast parenchyma shows. nonproliferative fibrocystic changes. Biopsy site changes present. The tumor does not involve the nipple, overlying skin, or underlying chest wall. All surgical resection margins, including the deep margin, are negative for tumor (residual tumor in the biopsy cavity is located 2.2 cm from the deep margin). Lymph nodes, right axillary, dissection: Multiple (5 of 18) right axillary lymph nodes are positive for metastatic carcinoma [AJCC pN2]. The largest is represented by a matted mass of lymph nodes and measures 4.2 x 2.6 x 2.4 cm. Extranodal extension is present. Comment: Final (mastectomy) surgical margins are widely free of involvement. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 116,
      "timestamp": "2026-01-19T15:59:53.116496"
    },
    {
      "sample_idx": 1040,
      "input": "Diagnosis. 1. Predominantly poorly differentiated adenocarcinoma of the prostate on both sides with. predominance in the anterior and right rectolateral peripheral zone. Maximum tumor spread. 0.9 cm. Focally perineural tumor invasion. No extraprostatic tumor growth and no identifiable. invasion of the vessels. Tumor-free seminal vesicles and tumor-free resection margins. Remaining prostate tissue with myoglandular hyperplasia in the transitional zone. Tumor and. dysplasia-free prostatic urethra....",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, predominantly poorly differentiated, with a maximum tumor spread of 0.9 cm, and focal perineural invasion. No extraprostatic growth or vessel invasion. Tumor-free seminal vesicles and resection margins. Myoglandular hyperplasia in the transitional zone. Tumor-free prostatic urethra. 3. The tumor is classified as pT2c, pNO (0/19), L0, V0; Gleason 4+3 = 7 (approx. 60% Gleason 4); complete local resection. 4. The tumor is classified as pT2c, pNO (0/19), L0, V0; Gleason 4+3 = 7 (approx. 60% Gleason 4); complete local resection. 5. The tumor is classified as pT2c, pNO (0/19), L0, V0; Gleason 4+3 = 7 (approx. 60% Gleason 4); complete local resection. 6. The tumor is classified as pT2c, pNO (0/19), L0, V0; Gleason 4+3 = 7 (approx. 60% Gleason 4); complete local resection. 7. The tumor is classified as pT2c, pNO (0/19), L0, V0; Gleason 4+3 = 7 (approx. 60% Gleason 4); complete local resection. 8. The tumor is classified as pT2c, pNO (0/19), L0, V0; Gleason 4+3 = 7 (approx. 60% Gleason 4); complete local resection. 9. The tumor is classified as pT2c, pNO (0/19), L0, V0; Gleason 4+3 = 7 (approx. 60% Gleason 4); complete local resection. 10. The tumor is classified as pT2c, pNO (0/19), L0, V0; Gleason 4+3 = 7 (approx. 60% Gleason 4); complete local resection. 11. The tumor is classified as pT2c, pNO (0/",
      "predicted": null,
      "ground_truth": "PRAD",
      "correct": null,
      "reasoning": "",
      "idx": 1040,
      "timestamp": "2026-01-19T15:59:53.116581"
    },
    {
      "sample_idx": 164,
      "input": "Breast, left breast, simple mastectomy: Infiltrating ductal carcinoma, Nottingham grade III (of III),. forming a 2.3 x 1.8 x 1.5 cm mass (AJCC pT2) situated in the lower inner quadrant at 2.0 cm from the. closest (inferior) margin. Vascular invasion is identified. The rest of the breast shows proliferative. fibrocystic change with ductal hyperplasia of the usual type, apocrine metaplasia, and microcalcifications. Duct ectasia is also present. The nipple is unremarkable. Surgical margins are nega...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 164,
      "timestamp": "2026-01-19T15:59:53.116592"
    },
    {
      "sample_idx": 380,
      "input": "rage 1 or J. MRN#: Sex: male. Histology code: MIB: 21%. Histology: GBM. Tissue Bank: Additional Data: Surgery Date: Multiple Biopsy Case. SURGERY DATE: RECEIVE DATE: Tissue Amount: 1. Number of Vials: 1. Tissue Loc: UPDATED REPORT. - SEE. Cells cultured: 1-T25 1-SP. ADDENDUM REPORT/DIAGNOSIS. Consent: PATHOLOGICAL DIAGNOSIS: A. BRAIN, RIGHT PARIETAL,. EXCISIONAL BIOPSIES: GLIOBLASTOMA MULTIFORME. B. BRAIN, RIGHT PARIETAL, EXCISION: GLIOBLASTOMA MULTIFORME. SEE COMMENT. ADDENDUM DIAGNOSIS: BRAIN,...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Right Parietal. 2. Findings: Glioblastoma Multiforme (GBM) with a proliferation index of 21% (MIB-1). 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Right Parietal. 2. Findings: Glioblastoma Multiforme (GBM) with a proliferation index of 21% (MIB-1). 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Right Parietal. 2. Findings: Glioblastoma Multiforme (GBM) with a proliferation index of 21% (MIB-1). 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Right Parietal. 2. Findings: Glioblastoma Multiforme (GBM) with a proliferation index of 21% (MIB-1). 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Right Parietal. 2. Findings: Glioblastoma Multiforme (GBM) with a proliferation index of 21% (MIB-1). 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Right Parietal. 2. Findings: Glioblastoma Multiforme (GBM) with a proliferation index of 21% (MIB-1). 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Right Parietal. 2. Findings: Glioblastoma Multiforme (GBM) with a proliferation index of 21% (MIB-1). 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain, Right Parietal. 2. Findings: Glioblastoma Multiforme (GBM) with a proliferation index of 21% (MIB-1). 3. Code: GBM.",
      "idx": 380,
      "timestamp": "2026-01-19T15:59:53.116605"
    },
    {
      "sample_idx": 140,
      "input": "Diagnosis: A: Lymph node, right axillary sentinel #1, removal. - No metastatic carcinoma identified in one lymph node (0/1). B: Lymph node, right axillary sentinel #2, removal. - Isolated tumor cell cluster (ITC) identified (on H and E) in one lymph node,. 0.12 mm in greatest dimension, negative for extracapsular extension (see. comment). C: Lymph node, left axillary sentinel #1, removal. - No metastatic carcinoma identified in one lymph node (0/1). D: Lymph node, left axillary sentinel #2, remo...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 140,
      "timestamp": "2026-01-19T15:59:53.116616"
    },
    {
      "sample_idx": 139,
      "input": "SPECIMEN. A. Left axillary sentinel node. B. Left breast long stitch anterior short superior. CLINICAL NOTES. PRE-OP DIAGNOSIS: Left breast cancer. HISTORY: year old white female with left breast cancer. POST-OP DIAGNOSIS: Same as above. FROZEN SECTION DIAGNOSIS. A - Lymph node negative for metastatic disease. GROSS DESCRIPTION. A. The specimen is received fresh for frozen section. labeled \"left axillary sentinel node\". It consists of. a. portion of adipose tissue measuring 3.2 x 2. 1 x 1 cm. On...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 139,
      "timestamp": "2026-01-19T15:59:53.116625"
    },
    {
      "sample_idx": 481,
      "input": "CLINICAL DATA: -year-old man with history of floor of mouth carcinoma (squamous cell. carcinoma) . GROSS DESCRIPTION: A). Received in formalin designated \"left mandibular tumor\" is a composite. resection specimen that includes an 11 x 8.5 cm ellipse of medium tan,. hair-bearing skin with a central 2.5 cm in diameter ulcer and 8.5 cm in. diameter region of induration of the skin which extends focally to within 0.3. cm of the anterior cutaneous margin. A smaller, 4 X 0.9 cm ellipse of skin. is sut...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mandible. 2. Findings: Squamous cell carcinoma, keratinizing, moderately to poorly differentiated, with perineural invasion and focally suspicious for angiolymphatic invasion. The tumor has eroded through the mandible. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mandible. 2. Findings: Squamous cell carcinoma, keratinizing, moderately to poorly differentiated, with perineural invasion and focally suspicious for angiolymphatic invasion. The tumor has eroded through the mandible. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mandible. 2. Findings: Squamous cell carcinoma, keratinizing, moderately to poorly differentiated, with perineural invasion and focally suspicious for angiolymphatic invasion. The tumor has eroded through the mandible. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mandible. 2. Findings: Squamous cell carcinoma, keratinizing, moderately to poorly differentiated, with perineural invasion and focally suspicious for angiolymphatic invasion. The tumor has eroded through the mandible. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mandible. 2. Findings: Squamous cell carcinoma, keratinizing, moderately to poorly differentiated, with perineural invasion and focally suspicious for angiolymphatic invasion. The tumor has eroded through the mandible. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mandible. 2. Findings: Squamous cell carcinoma, keratinizing, moderately to poorly differentiated,",
      "predicted": "KIRC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Mandible. 2. Findings: Squamous cell carcinoma, keratinizing, moderately to poorly differentiated, with perineural invasion and focally suspicious for angiolymphatic invasion. The tumor has eroded through the mandible. 3. Code: KIRC.",
      "idx": 481,
      "timestamp": "2026-01-19T15:59:53.116638"
    },
    {
      "sample_idx": 826,
      "input": "FINAL CORRECTED REPORT DATED. REPLACES ALL PREVIOUS VERSIONS. Final, Corrected. CORRECTED REPORT. Cardiothoracic Surgery. Takart. Accessioned: DIAGNOSIS: LUNG, \"PARIETAL PLEURAL DEPOSIT,\" BIOPSY (INCLUDING FS1). - ADENOCARCINOMA. - HYALINIZED GRANULOMAS. - SEE COMMENT. LYMPH NODE, LEVEL 7, BIOPSY. - NO EVIDENCE OF MALIGNANCY IN ONE LYMPH NODE (0/1). - HYALINIZED GRANULOMA. - NO FUNGAL FORMS OR MYCOBACTERIAL SPECIES IDENTIFIED ON GMS, AFB OR FITE STAINS. LYMPH NODE, LEVEL 11, BIOPSY. - NO EVIDENC...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Lingula). 2. Findings: Adenocarcinoma, acinar type, poorly differentiated (G3), 3.2 cm, invasive, T2a (pleural invasion), N0 (no lymph node metastasis), M1a (distant metastasis). 3. TCGA code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Lingula). 2. Findings: Adenocarcinoma, acinar type, poorly differentiated (G3), 3.2 cm, invasive, T2a (pleural invasion), N0 (no lymph node metastasis), M1a (distant metastasis). 3. TCGA code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Lingula). 2. Findings: Adenocarcinoma, acinar type, poorly differentiated (G3), 3.2 cm, invasive, T2a (pleural invasion), N0 (no lymph node metastasis), M1a (distant metastasis). 3. TCGA code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Lingula). 2. Findings: Adenocarcinoma, acinar type, poorly differentiated (G3), 3.2 cm, invasive, T2a (pleural invasion), N0 (no lymph node metastasis), M1a (distant metastasis). 3. TCGA code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Lingula). 2. Findings: Adenocarcinoma, acinar type, poorly differentiated (G3), 3.2 cm, invasive, T2a (pleural invasion), N0 (no lymph node metastasis), M1a (distant metastasis). 3. TCGA code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Lingula). 2. Findings: Aden",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung (Lingula). 2. Findings: Adenocarcinoma, acinar type, poorly differentiated (G3), 3.2 cm, invasive, T2a (pleural invasion), N0 (no lymph node metastasis), M1a (distant metastasis). 3. TCGA code: LUAD.",
      "idx": 826,
      "timestamp": "2026-01-19T15:59:53.116651"
    },
    {
      "sample_idx": 245,
      "input": "SURGICAL PATHOLOGY REPORT - CONSULT. F. MRN : (Age: M.D. DIAGNOSIS. UTERUS, CERVIX, BIOPSY. MODERATELY DIFFERENTIATED INVASIVE SQUAMOUS CELL CARCINOMA, KERATINIZING TYPE. - FOCAL LYMPHVASCULAR SPACE INVASION is IDENTIFIED. - SEVERE DYSPLASIA (CIN 3). By this signature, I attest that the above diagnosis is based upon my personal. examination of the slides(and/or other material indicated in the diagnosis). M.D. M.D.-. Microscopic Description and Comment. Histologic sections show invasive, moderate...",
      "response": "```json\n{\n    \"cancer_type\": \"UCS\",\n    \"reasoning\": \"1. Site: Uterus, Cervix. 2. Findings: Invasive squamous cell carcinoma, keratinizing type, with lymphvascular space invasion and severe dysplasia (CIN 3). 3. Code: Uterus Cervix Squamous Cell Carcinoma maps to UCS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCS\",\n    \"reasoning\": \"1. Site: Uterus, Cervix. 2. Findings: Invasive squamous cell carcinoma, keratinizing type, with lymphvascular space invasion and severe dysplasia (CIN 3). 3. Code: Uterus Cervix Squamous Cell Carcinoma maps to UCS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCS\",\n    \"reasoning\": \"1. Site: Uterus, Cervix. 2. Findings: Invasive squamous cell carcinoma, keratinizing type, with lymphvascular space invasion and severe dysplasia (CIN 3). 3. Code: Uterus Cervix Squamous Cell Carcinoma maps to UCS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCS\",\n    \"reasoning\": \"1. Site: Uterus, Cervix. 2. Findings: Invasive squamous cell carcinoma, keratinizing type, with lymphvascular space invasion and severe dysplasia (CIN 3). 3. Code: Uterus Cervix Squamous Cell Carcinoma maps to UCS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCS\",\n    \"reasoning\": \"1. Site: Uterus, Cervix. 2. Findings: Invasive squamous cell carcinoma, keratinizing type, with lymphvascular space invasion and severe dysplasia (CIN 3). 3. Code: Uterus Cervix Squamous Cell Carcinoma maps to UCS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCS\",\n    \"reasoning\": \"1. Site: Uterus, Cervix. 2. Findings: Invasive squamous cell carcinoma, keratinizing type, with lymphvascular space invasion and severe dysplasia (CIN 3). 3. Code: Uterus Cervix Squamous Cell Carcinoma maps to UCS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCS\",\n    \"reasoning\": \"1. Site: U",
      "predicted": "UCS",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Uterus, Cervix. 2. Findings: Invasive squamous cell carcinoma, keratinizing type, with lymphvascular space invasion and severe dysplasia (CIN 3). 3. Code: Uterus Cervix Squamous Cell Carcinoma maps to UCS.",
      "idx": 245,
      "timestamp": "2026-01-19T15:59:53.116663"
    },
    {
      "sample_idx": 504,
      "input": "Clinical Diagnosis & History: Patient with renal mass. Specimens Submitted: 1: SP: Lt. kidney. 2: SP: Para-aortic lymph node. 3: SP: Hilar lymph node. DIAGNOSIS: 1). KIDNEY, LEFT; EXCISION: RENAL CELL CARCINOMA, CHROMOPHOBE TYPE. THE TUMOR GREATEST DIAMETER IS 13.5 CM. THE. TUMOR IS CONFINED WITHIN THE RENAL CAPSULE. NO INVASION OF THE RENAL VEIN IS IDENTIFIED. ALL. SURGICAL MARGINS ARE FREE OF TUMOR. THE NON-NEOPLASTIC KIDNEY SHOWS FIBROSIS AND FOCAL CHRONIC INFLAMMATION. TUMOR EXTENDS. INTO TH...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"",
      "predicted": "KIRC",
      "ground_truth": "KICH",
      "correct": false,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 504,
      "timestamp": "2026-01-19T15:59:53.116676"
    },
    {
      "sample_idx": 81,
      "input": "Revised. F. Pathologic Interpretation: AMENDMENT TO PATHOLOGIC INTERPRETATION (SPECIMEN \"E\"). Left breast sentinel node #1, FS: A. - One lymph node, no tumor seen (0/1). Sentinel node #2, FS: B. - One lymph node, no tumor seen (0/1). C. Left sentinell node #3, FS: - One lymph node, no tumor seen (0/1). D. Left with one stitch superior and two lateral: breast - Multifocal infiltrating lobular carcinoma, (two largest nodules are 2.5 cm and 2 cm in greatest dimension), margins. free. - Extensive lo...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, (two largest nodules are 2.5 cm and 2 cm in greatest dimension), margins. free. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, (two largest nodules are 2.5 cm and 2 cm in greatest dimension), margins. free. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, (two largest nodules are 2.5 cm and 2 cm in greatest dimension), margins. free. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, (two largest nodules are 2.5 cm and 2 cm in greatest dimension), margins. free. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, (two largest nodules are 2.5 cm and 2 cm in greatest dimension), margins. free. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, (two largest nodules are 2.5 cm and 2 cm in greatest dimension), margins. free. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, (two largest nodules are 2.5 cm and 2 cm in greatest dimension), margins. free. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive lobular carcinoma, (two largest nodules are 2.5 cm and 2 cm in greatest dimension), margins. free. 3. Code: BRCA.",
      "idx": 81,
      "timestamp": "2026-01-19T15:59:53.116687"
    },
    {
      "sample_idx": 167,
      "input": "Ne. BREAST TISSUE CHECKLIST. Specimen type: Mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 2.3 x 1.8 x 1.8 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal and lobular carcinoma. Histologic grade: Tumor extent: Not specified. Lymph nodes: 0/4 positive for metastasis (Regional 0/4). Extracapsular invasion of the lymph nodes: Not specified. Left upper. Margins: Not specified. outer. quadrant. Nottingham Histologic Score. Tubule formation: Not specifi...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1.",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Infiltrating ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 167,
      "timestamp": "2026-01-19T15:59:53.116697"
    },
    {
      "sample_idx": 858,
      "input": "Material examined: Right upper lobe, among others. Clinical diagnosis and question. Squamous cell carcinoma of the right upper lobe. REPORT ON FINDINGS. Macroscopy. 1.) Right upper lobe: inflated, fixed right upper pulmonary lobe measuring 18 x 12 x 4 cm, central bronchus. resection plane located 0.1 cm proximal to the bifurcation into the segmental bronchi. At the hilus a 2 cm node. A staple suture line runs from the hilus in a caudoventral direction for 10 cm. Visceral pleura, especially in th...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Right upper lobe of the lung. 2. Findings: Squamous cell carcinoma of the right upper lobe of the lung, poorly differentiated, large-cell, non-keratinizing. 3. Code: Squamous cell carcinoma of the right upper lobe of the lung maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Right upper lobe of the lung. 2. Findings: Squamous cell carcinoma, poorly differentiated, large-cell, non-keratinizing. 3. Code: Squamous cell carcinoma of the right upper lobe of the lung maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Right upper lobe of the lung. 2. Findings: Squamous cell carcinoma, poorly differentiated, large-cell, non-keratinizing. 3. Code: Squamous cell carcinoma of the right upper lobe of the lung maps to UCSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Right upper lobe of the lung. 2. Findings: Squamous cell carcinoma of the right upper lobe of the lung, poorly differentiated, large-cell, non-keratinizing. 3. Code: Squamous cell carcinoma of the right upper lobe of the lung maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Right upper lobe of the lung. 2. Findings: Squamous cell carcinoma of the right upper lobe of the lung, poorly differentiated, large-cell, non-keratinizing. 3. Code: Squamous cell carcinoma of the right upper lobe of the lung maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Right upper lobe of the lung. 2. Findings: Squamous cell carcinoma of the right upper lobe of the lung, poorly differentiated, large-cell, non-keratinizing. 3. Code: Squamous cell carcinoma",
      "predicted": "COAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Right upper lobe of the lung. 2. Findings: Squamous cell carcinoma of the right upper lobe of the lung, poorly differentiated, large-cell, non-keratinizing. 3. Code: Squamous cell carcinoma of the right upper lobe of the lung maps to COAD.",
      "idx": 858,
      "timestamp": "2026-01-19T15:59:53.116714"
    },
    {
      "sample_idx": 1070,
      "input": "PATIENT HISTORY: with a history of PSA value of 26.6 ng/ml. The patient had a biopsy on. prostatic adenocarcinoma Gleason score 4+3 = 7 in the right mid aspect. PRE-OP DIAGNOSIS: Prostate cancer. POST-OP DIAGNOSIS: Same. PROCEDURE: Radical prostatectomy with bilateral lymphadenectomy. FINAL DIAGNOSIS: PART 1: LYMPH NODE, RIGHT PELVIC, EXCISION -. NO EVIDENCE OF NEOPLASIA IN ONE LYMPH NODE (0/1). PART 2: LYMPH NODES, LEFT PELVIC, EXCISION -. NO EVIDENCE OF NEOPLASIA IN FIVE LYMPH NODES (0/5). PAR...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason pattern 5, total Gleason 4/5 percentage of 30%. Extracapsular extension to seminal vesicles. 3. Code: Prostate adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason pattern 5, total Gleason 4/5 percentage of 30%. Extracapsular extension to seminal vesicles. 3. Code: Prostate adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason pattern 5, total Gleason 4/5 percentage of 30%. Extracapsular extension to seminal vesicles. 3. Code: Prostate adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason pattern 5, total Gleason 4/5 percentage of 30%. Extracapsular extension to seminal vesicles. 3. Code: Prostate adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason pattern 5, total Gleason 4/5 percentage of 30%. Extracapsular extension to seminal vesicles. 3. Code: Prostate adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason pattern 5, total Gleason 4/5 percentage of 30%. Extracapsular",
      "predicted": "PRAD",
      "ground_truth": "PRAD",
      "correct": true,
      "reasoning": "1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason pattern 5, total Gleason 4/5 percentage of 30%. Extracapsular extension to seminal vesicles. 3. Code: Prostate adenocarcinoma maps to PRAD.",
      "idx": 1070,
      "timestamp": "2026-01-19T15:59:53.116727"
    },
    {
      "sample_idx": 647,
      "input": "ADDENDED. FINAL DIAGNOSIS: 1. Right temporal tumor: OLIGODENDROGLIOMA, GRADE ii OF iv (who. SCALE), SEE MICROSCOPIC DESCRIPTION. 2. Right temporal lobe tumor: OLIGODENDROGLIOMA, GRADE ii OF iv (who. SCALE), SEE MICROSCOPIC DESCRIPTION. 3. Right temporal lesion: Pending complete submission of remaining. tissue. Comment: The ki-67 proliferation index is 4.5%. Several studies have indicated. that oligodendrogliomas with proliferation indices of greater than 5%. are associated with a significantly d...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/cerebrum-Temporal. 2. Findings: Oligodendroglioma, Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/cerebrum-Temporal. 2. Findings: Oligodendroglioma, Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/cerebrum-Temporal. 2. Findings: Oligodendroglioma, Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/cerebrum-Temporal. 2. Findings: Oligodendroglioma, Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/cerebrum-Temporal. 2. Findings: Oligodendroglioma, Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/cerebrum-Temporal. 2. Findings: Oligodendroglioma, Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/cerebrum-Temporal. 2. Findings: Oligodendroglioma, Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/cerebrum-Temporal. 2. Findings: Oligodendroglioma, Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1.",
      "predicted": "KIRC",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain/cerebrum-Temporal. 2. Findings: Oligodendroglioma, Grade II. 3. Code: KIRC",
      "idx": 647,
      "timestamp": "2026-01-19T15:59:53.116736"
    },
    {
      "sample_idx": 534,
      "input": ".ology Report. DIAGNOSIS. (A) RIGHT KIDNEY: RENAL CELL CARCINOMA (8.0 CM MAXIMUM DIMENSION), CONVENTIONAL TYPE. (80% CLEAR CELLS,. 20% EOSINOPHILIC CELLS), FUHRMAN NUCLEAR GRADE 3, INVASIVE. INTO THICK-WALLED. BLOOD VESSELS IN RENAL SINUS. (SEE COMMENT). Margins of resection free of tumor. (B) RIGHT ADRENAL GLAND: METASTATIC RENAL CELL CARCINOMA IN ADRENAL GLAND. COMMENT. The renal cell carcinoma in the right kidney does not invade into the. perinephric adipose tissue or the renal vein. Tumor is...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3, invasive. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADREN\",\n    \"reasoning\": \"1. Site: Right Adrenal Gland. 2. Findings: Metastatic renal cell carcinoma in adrenal gland. 3. Code: Adrenal gland maps to ADREN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3, invasive. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3, invasive. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3, invasive. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3, invasive. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3, invasive. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3, invasive. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 534,
      "timestamp": "2026-01-19T15:59:53.116747"
    },
    {
      "sample_idx": 418,
      "input": "FINAL PATHOLOGIC DIAGNOSIS. A. Brain, left occipital region, biopsy: WHO glioblastoma multiforme, grade IV; see. comment. B. Brain, \"deep tumor,' biopsy: WHO glioblastoma multiforme, grade IV; see. comment. C. Brain, \"brain tumor,\" biopsy: WHO glioblastoma multiforme, grade IV; see. comment. D. Brain, \"tumor margin,\" biopsy: Cerebral cortex with subpial and leptomeningeal. involvement by glioblastoma multiforme; see comment. COMMENT: This glioblastoma multiforme is highly cellular, has marked nu...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Occipital Region, Deep Tumor, Brain Tumor, Tumor Margin). 2. Findings: Glioblastoma multiforme, grade IV. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Occipital Region, Deep Tumor, Brain Tumor, Tumor Margin). 2. Findings: Glioblastoma multiforme, grade IV. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Occipital Region, Deep Tumor, Brain Tumor, Tumor Margin). 2. Findings: Glioblastoma multiforme, grade IV. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Occipital Region, Deep Tumor, Brain Tumor, Tumor Margin). 2. Findings: Glioblastoma multiforme, grade IV. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Occipital Region, Deep Tumor, Brain Tumor, Tumor Margin). 2. Findings: Glioblastoma multiforme, grade IV. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Occipital Region, Deep Tumor, Brain Tumor, Tumor Margin). 2. Findings: Glioblastoma multiforme, grade IV. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Occipital Region, Deep Tumor, Brain Tumor, Tumor Margin). 2. Findings: Glioblastoma multiforme, grade IV. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain (Left Occipital Region, Deep Tumor, Brain Tumor, Tumor Margin). 2. Findings: Glioblastoma multiforme, grade IV. 3. Code: GBM.",
      "idx": 418,
      "timestamp": "2026-01-19T15:59:53.116758"
    },
    {
      "sample_idx": 643,
      "input": "Final Diagnosis: A-B. Brain, hippocampus mass and left temporal lobe, biopsies: Low-grade diffuse astrocytoma (WHO grade II). (See comment). immunoperoxidase studies were performed on paraffin sections (block A2) using antibodies directed against the. following antigens: GFAP, IDH1-R132H, p53, EMA, neurofilament protein, and Ki-67. G.FAP: Positive. Neurofilament protein: Highlights axons within the tumor. Ki-67: Low proliferative index. IDH1-R132H: Negative. p53: Low to moderate labeling. EMA: N...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Low-grade diffuse astrocytoma (WHO grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Low-grade diffuse astrocytoma (WHO grade II). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Low-grade diffuse astrocytoma (WHO grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Low-grade diffuse astrocytoma (WHO grade II). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Low-grade diffuse astrocytoma (WHO grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Low-grade diffuse astrocytoma (WHO grade II). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Low-grade diffuse astrocytoma (WHO grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Low-grade diffuse astrocytoma (WHO grade II). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain. 2. Findings: Low-grade diffuse astrocytoma (WHO grade II). 3. Code: GBM maps to GBM.",
      "idx": 643,
      "timestamp": "2026-01-19T15:59:53.116769"
    },
    {
      "sample_idx": 488,
      "input": "Gross Description: There is larynx with an ulcerated white-gray dense tumor. Separately there is. a. fragment of the thyroid gland up to 2 X 2 cm in size. Microscopic Description: Squamous carcinoma, keratinizing type, G-1. Thyroid gland tissue is of the. normal structure. Diagnosis Details: Tumor Features: Ulcerated, Tumor Extent: Localized, NOS, Venous Invasion: Absent,. Margins: Absent, Treatment Effect: Comments: Endoscopies, figrolaryngoscopy show cancer of the larynx with the involvement. ...",
      "response": "```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Larynx. 2. Findings: Squamous cell carcinoma, keratinizing type, G-1. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LARYNX\",\n    \"reasoning\": \"1. Site: Larynx. 2. Findings: Squamous cell carcinoma, keratinizing type, G-1. 3. Code: LARYNX maps to LARYNX.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LARYNX\",\n    \"reasoning\": \"1. Site: Larynx. 2. Findings: Squamous cell carcinoma, keratinizing type, G-1. 3. Code: LARYNX maps to LARYNX.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LARYNX\",\n    \"reasoning\": \"1. Site: Larynx. 2. Findings: Squamous cell carcinoma, keratinizing type, G-1. 3. Code: LARYNX maps to LARYNX.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LARYNX\",\n    \"reasoning\": \"1. Site: Larynx. 2. Findings: Squamous cell carcinoma, keratinizing type, G-1. 3. Code: LARYNX maps to LARYNX.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LARYNX\",\n    \"reasoning\": \"1. Site: Larynx. 2. Findings: Squamous cell carcinoma, keratinizing type, G-1. 3. Code: LARYNX maps to LARYNX.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LARYNX\",\n    \"reasoning\": \"1. Site: Larynx. 2. Findings: Squamous cell carcinoma, keratinizing type, G-1. 3. Code: LARYNX maps to LARYNX.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LARYNX\",\n    \"reasoning\": \"1. Site: Larynx. 2. Findings: Squamous cell carcinoma, keratinizing type",
      "predicted": "HNSC",
      "ground_truth": "HNSC",
      "correct": true,
      "reasoning": "1. Site: Larynx. 2. Findings: Squamous cell carcinoma, keratinizing type, G-1. 3. Code: HNSC maps to HNSC.",
      "idx": 488,
      "timestamp": "2026-01-19T15:59:53.116779"
    },
    {
      "sample_idx": 1141,
      "input": "Clinical Diagnosis & History: with left retroperitoneal mass. Bx c/w high grade spindle cell. neoplasm. Specimens Submitted: 1: SP: Retroperitoneal dissection with lt. colon, lt. kidney. 2: SP: Lt. psoas mass. 3: SP: Left common iliac lymph node. DIAGNOSIS: 1). SOFT TISSUE, RETROPERITONEAL DISSECTION WITH LEFT COLON, LEFT KIDNEY. AND SEGMENT OF. DUODENUM; RESECTION: - DEDIFFERENTIATED LIPOSARCOMA WITH DIVERGENT DIFFERENTIATION (HIGH. GRADE LEIOMYOSARCOMA). - TWO TUMOR FOCI, 6.0 CM AND 3.0 CM IN ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear",
      "predicted": "KIRC",
      "ground_truth": "SARC",
      "correct": false,
      "reasoning": "1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 1141,
      "timestamp": "2026-01-19T15:59:53.116792"
    },
    {
      "sample_idx": 1311,
      "input": "SPECIMENS: A. THYMUS. B. CERVICAL HORN. SPECIMEN(S): A. THYMUS. B. CERVICAL HORN. DIAGNOSIS: A. THYMUS, THYMECTOMY: - ENCAPSULATED THYMOMA (8 CM), TYPE AB. - RESECTION MARGINS ARE NEGATIVE BUT CLOSE. - ADJACENT BENIGN INVOLUTED THYMIC TISSUE. B. \"CERVICAL HORN\", EXCISION: - BENIGN FIBROADIPOSE TISSUE AND INVOLUTED THYMIC TISSUE. SYNOPTIC REPORT - MEDIASTINUM & THYMUS. Specimens Involved. Specimens: A: THYMUS. Specimen Type: Cervical thymectomy. Specimen Size: Greatest dimension: 10.5cm. Addition...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Cervical Horn. 2. Findings: Benign Fibroadipose Tissue and Involved Thymic Tissue. 3. Code: UVM maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps",
      "predicted": "THYM",
      "ground_truth": "THYM",
      "correct": true,
      "reasoning": "1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.",
      "idx": 1311,
      "timestamp": "2026-01-19T15:59:53.116802"
    },
    {
      "sample_idx": 268,
      "input": "Female. Surgery Date: DIAGNOSIS: Liver, right lobe, resection: Invasive grade 3 (of 4) cholangiocarcinoma forming a. lobulated, firm mass (8.9 x 6.8 x 5.5 cm) located 1.1 cm from the surgical margin. The uninvolved liver parenchyma is unremarkable. Peritoneum, biopsy: Partially calcified fat necrosis. Gallbladder, cholecystectomy : without diagnostic abnormality. Lymph node, retrocholedochal, biopsy: A single lymph node is negative for tumor. Small bowel, fistula tract, biopsy: Fistula tract wit...",
      "response": "```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Cholangiocarcinoma, grade 3. 3. Code: CHOL maps to Cholangiocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal cancer, diverticulosis with diverticulitis. 3. Code: COAD maps to Colorectal Cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Ovarian serous cystadenocarcinoma. 3. Code: OV maps to Ovarian Cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Pancreatic adenocarcinoma. 3. Code: PAAD maps to Pancreatic Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma. 3. Code: PRAD maps to Prostate Cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"READ\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Rectal adenocarcinoma. 3. Code: READ maps to Rectal Cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Soft Tissue. 2. Findings: Sarcomatoid carcinoma. 3. Code: SARC maps to Soft Tissue Sarcoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin. 2. Findings: Skin cutaneous melanoma. 3. Code: SKCM maps to Skin Melanoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Stomach adenocarcinoma. 3. Code: STAD maps to Stomach Cancer.\"\n}\n```",
      "predicted": "CHOL",
      "ground_truth": "CHOL",
      "correct": true,
      "reasoning": "1. Site: Liver. 2. Findings: Cholangiocarcinoma, grade 3. 3. Code: CHOL maps to Cholangiocarcinoma.",
      "idx": 268,
      "timestamp": "2026-01-19T15:59:53.116814"
    },
    {
      "sample_idx": 614,
      "input": "WITH ADDENDUM. Service Date: Soc. Sec. #: Client: FINAL PATHOLOGIC DIAGNOSIS. Right kidney, partial nephrectomy: Papillary renal cell carcinoma, through renal. capsule, not present at margins; see comment. COMMENT: Kidney - Histologic Tumor type: Synoptic Renal Comment cell carcinoma, papillary type. Site R Kidney NOS C64.9. - Grade: Fuhrman grading for RCC: II. - Tumor size: 2.2 cm. - Site within kidney: Unknown. - Renal pelvis: Not applicable. - Ureter: Not applicable. - Renal sinus: Not appli...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 614,
      "timestamp": "2026-01-19T15:59:53.116825"
    },
    {
      "sample_idx": 936,
      "input": "Clinical History/Diagnosis. Source of Specimen(s). 1: Omentum, resection other than for tumor. 2: right tube and ovary. 3: left tube and ovary. 4: supracervical uterus. 5: left paracolic gutter. Gross Description: Received in five parts. Source of Tissue: 1. Labeled # 1, \"omentum\". Gross Description: Received fresh in a container labeled \" patient name and medical number,. omentum\". It consists of a segment of omentum. measuring 30,0 x 12.0 x 2.0 cm. Approximately one-third of the omentum. has a...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Omentum. 2. Findings: Serous adenocarcinoma. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Right tube and ovary. 2. Findings: Serous adenocarcinoma involving ovary and fallopian tube. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Left tube and ovary. 2. Findings: Serous adenocarcinoma involving ovary and fallopian tube. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Serous adenocarcinoma involving uterine serosa with invasion into outer one-third of myometrium. Inactive endometrium. Endocervix with no tumor seen. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Left paracolic gutter. 2. Findings: Serous adenocarcinoma. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Omentum. 2. Findings: Serous adenocarcinoma. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Right tube and ovary. 2. Findings: Serous adenocarcinoma involving ovary and fallopian tube. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Left tube and ovary. 2. Findings: Serous adenocarcinoma involving ovary and fallopian tube. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Serous adenocarcinoma involving uterine",
      "predicted": "UCEC",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Omentum. 2. Findings: Serous adenocarcinoma. 3. Code: UCEC.",
      "idx": 936,
      "timestamp": "2026-01-19T15:59:53.116834"
    },
    {
      "sample_idx": 1108,
      "input": "Final Diagnosis. A. TONGUE, RIGHT, GLOSSECTOMY: High-grade leiomyosarcoma, 4.0 cm in greatest dimension (see comment). No lymphovascular space invasion identified. One subglossal lymph node, negative for metastatic carcinoma (0/1). All final margins are free of tumor (see parts B-G). Adjacent squamous mucosa with mild dysplasia. B. DORSAL TONGUE, EXCISION: Squamous mucosa, negative for malignancy. C. VENTRAL TONGUE MARGIN, EXCISION: Squamous mucosa, negative for malignancy. D. FLOOR OF MOUTH MAR...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue, Right, Glossectomy. 2. Findings: High-grade leiomyosarcoma, 4.0 cm in greatest dimension. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue, Right, Dorsal. 2. Findings: Squamous cell carcinoma, 2.5 cm in greatest dimension. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue, Right, Ventral. 2. Findings: Squamous cell carcinoma, 3.0 cm in greatest dimension. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue, Right, Floor of Mouth. 2. Findings: Squamous cell carcinoma, 2.5 cm in greatest dimension. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue, Right, Posterior. 2. Findings: Squamous cell carcinoma, 2.0 cm in greatest dimension. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue, Right, Deep Posterior. 2. Findings: Squamous cell carcinoma, 2.0 cm in greatest dimension. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue, Right, Anterior Deep. 2. Findings: Squamous cell carcinoma, 1.5 cm in greatest dimension. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Neck, Right, Levels 2-4. 2. Findings: Negative for metastatic carcinoma. 3. Code: K",
      "predicted": "KIRC",
      "ground_truth": "SARC",
      "correct": false,
      "reasoning": "1. Site: Tongue, Right, Glossectomy. 2. Findings: High-grade leiomyosarcoma, 4.0 cm in greatest dimension. 3. Code: KIRC.",
      "idx": 1108,
      "timestamp": "2026-01-19T15:59:53.116844"
    },
    {
      "sample_idx": 148,
      "input": "RUN DATE. RUN TIME. RUN USER. ACCT # : AGE/SX: ROOM : REG DR. BED: SPEC #. RECD: COLL: TIME IN FORMALIN: 6:29. nrs. COLD ISCHEMA TIME: 0:00. mins,. CLINICAL INFORMATION: Pre-Op Diagnosis: Right breast mass. Remarks: Specimen (s) : A. Right breast mass. B. Right breast sentinel node. C. Posterior medial margin. D. Medial margin. MICROSCOPIC DIAGNOSIS. A. BREAST, RIGHT (REGION NOT OTHERWISE STATED). LUMPECTOMY: INVASIVE GRADE 3 DUCTAL CARCINOMA MEASURING 3.5 CM IN GREATEST DIMENSION. ASSOCIATED HI...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 148,
      "timestamp": "2026-01-19T15:59:53.116854"
    },
    {
      "sample_idx": 19,
      "input": "Gender: Male. Race: White. Report Date: FINAL PATHOLOGIC DIAGNOSIS. A. Distal right ureter; excision: - Portion of ureter with urothelial carcinoma in situ. B. Right pelvic lymph nodes; dissection: - One of four lymph nodes with metastatic urothelial carcinoma (1/4). - Largest lymph nodal tumor focus measures 3 mm, with extranodal extension. C. Left pelvic lymph nodes; dissection: - Two of ten lymph nodes with metastatic urothelial carcinoma (2/10). - Largest lymph nodal tumor focus measures 3 m...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Ureter (Distal Right). 2. Findings: Urothelial carcinoma in situ, Invasive urothelial carcinoma. 3. Code: UCEC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Urothelial carcinoma in situ. 3. Code: PRAD\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, Urothelial carcinoma in situ. 3. Code: BLCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney",
      "predicted": "UCEC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Ureter (Distal Right). 2. Findings: Urothelial carcinoma in situ, Invasive urothelial carcinoma. 3. Code: UCEC",
      "idx": 19,
      "timestamp": "2026-01-19T15:59:53.116865"
    },
    {
      "sample_idx": 938,
      "input": "INAL. PARTS 1. AND 2: OVARIES, LEFT AND RIGHT, BILATERAL SALPINGO-OOPHORECTOMY -. A. POORLY DIFFERENTIATED PAPILLARY SEROUS CYSTADENOCARCINOMA INVOLVING RIGHT AND LEFT. OVARIES. B. LEFT OVARIAN MASS MEASURES 15 CM IN GREATEST DIMENSION. c. RIGHT OVARIAN MASS MEASURES 11 CM IN GREATEST DIMENSION. D. OVARIAN SURFACE INVOLVEMENT IS IDENTIFIED (SLIDE 1N). E. LYMPHOVASCULAR INVASION IS IDENTIFIED (SLIDE 2K). F. NON-NEOPLASTIC OVARIAN PARENCHYMA WITH PHYSIOLOGIC CHANGES BILATERALLY. PART 3: UTERUS WIT...",
      "response": "```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: Papiary serous cystadenocarcinoma involving right and left ovaries. 3. Code: OV maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: Left ovarian mass measures 15 cm in greatest dimension. 3. Code: OV maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: Right ovarian mass measures 11 cm in greatest dimension. 3. Code: OV maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: Ovarian surface involvement identified. 3. Code: OV maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: Lymphovascular invasion identified. 3. Code: OV maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: Non-neoplastic ovarian parenchyma with physiologic changes bilaterally. 3. Code: OV maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Cervix with chronic cervicitis and reactive epithelial atypia. 3. Code: UCEC maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Secretory endometrium. 3. Code: UCEC maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial polyp",
      "predicted": "OV",
      "ground_truth": "OV",
      "correct": true,
      "reasoning": "1. Site: Ovaries. 2. Findings: Papiary serous cystadenocarcinoma involving right and left ovaries. 3. Code: OV maps to OV.",
      "idx": 938,
      "timestamp": "2026-01-19T15:59:53.116875"
    },
    {
      "sample_idx": 204,
      "input": "B2148 Final Diagnosis. Yeast, left, wide local excision: Infiltrating ductal carcinoma, Nottingham grade III (of III) [tubules 3/3, nuclei 3/3, mitoses 2/3;. Nottingham. score 8/9], forming a mass (2.7 x 2.3 x 2.2 cm) [AJCC pT2]. Angiolymphatic invasion is absent. The non-neoplastic. breast parenchyma shows nonproliferative fibrocystic changes. The skin (separately submitted new anterior margin) is negative. for tumor. All surgical resection margins; after the separately submitted re-excisions o...",
      "response": "```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings",
      "predicted": "SKCM",
      "ground_truth": "BRCA",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 204,
      "timestamp": "2026-01-19T15:59:53.116885"
    },
    {
      "sample_idx": 150,
      "input": "Date Coll: SPECIMEN. A. Left axillary sentinel node. B. Left breast silk on superior breast. CLINICAL NOTES. PRE-OP DIAGNOSIS: Left breast cancer. CLINICAL HISTORY: year-old white female with cancer. POST-OP DIAGNOSIS: Same. GROSS DESCRIPTION. A. Received fresh labeled \"left axillary node\" is a 3.8. x. 2.4 x 0.6 cm. portion of soft, lobulated golden-yellow. adipose tissue. Two (2) slightly rubbery tan-pink tissues in. keeping with lymph node measuring 0.8 and 1.8 cm. in greatest. dimension are r...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left axillary sentinel node. 2. Findings: Invasive ductal carcinoma, grade III, 3.0 cm in greatest dimension. Negative margins of excision. Lymphovascular invasion identified. Two negative lymph nodes (0/2). 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Left breast. 2. Findings: Invasive ductal carcinoma, grade III, 3.0 cm in greatest dimension. Negative margins of excision. Lymphovascular invasion identified. Two negative lymph nodes (0/2). 3. Code: BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left axillary sentinel node. 2. Findings: Invasive ductal carcinoma, grade III, 3.0 cm in greatest dimension. Negative margins of excision. Lymphovascular invasion identified. Two negative lymph nodes (0/2). 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left breast. 2. Findings: Invasive ductal carcinoma, grade III, 3.0 cm in greatest dimension. Negative margins of excision. Lymphovascular invasion identified. Two negative lymph nodes (0/2). 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left axillary sentinel node. 2. Findings: Invasive ductal carcinoma, grade III, 3.0 cm in greatest dimension. Negative margins of excision. Lymphovascular invasion identified. Two negative lymph nodes (0/2). 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left breast. 2. Findings: Invasive ductal carcinoma, grade III, 3.0 cm in greatest dimension. Negative margins of excision. Lymphovascular invasion identified. Two negative lymph nodes (0/2). 3. Code",
      "predicted": "KIRC",
      "ground_truth": "BRCA",
      "correct": false,
      "reasoning": "1. Site: Left axillary sentinel node. 2. Findings: Invasive ductal carcinoma, grade III, 3.0 cm in greatest dimension. Negative margins of excision. Lymphovascular invasion identified. Two negative lymph nodes (0/2). 3. Code: KIRC.",
      "idx": 150,
      "timestamp": "2026-01-19T15:59:53.116898"
    },
    {
      "sample_idx": 436,
      "input": "DIAGNOSIS. \"RIGHT OMOHYOID\". skeletal muscle with suture granulomata; no tumor present. \"RIGHT PAROTID ARTERY\": Connective tissue and nerve; no tumor present. \"CERVICAL ESOPHAGUS\": Connective tissue with reactive changes; no tumor present. \"RIGHT LATERAL NECK DISSECTION\": Ten lymph nodes, no tumor present. \"SYMPATHETIC NERVE SHEATH\": GRADE II SQUAMOUS CARCINOMA INVOLVING NERVE (PERINEURAL INVASION). 'TOTAL LARYNGECTOMY / TOTAL THYROIDECTOMY, LEFT ANTERIOR COMPARTMENT. DISSECTION\". GRADE II SQUAM...",
      "response": "```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Right omohyoid muscle, right parotid artery, cervical esophagus, right lateral neck dissection, sympathetic nerve sheath, total laryngectomy, total thyroidectomy, left anterior compartment, transduced tumor, non-transduced tumor, vagus nerve, right sympathetic chain, tumor base of skull. 2. Findings: Grade II squamous cell carcinoma involving connective tissue and perineural invasion. 3. Code: SKCM (Squamous Cell Carcinoma) maps to the specific tumor sites. The presence of perineural invasion suggests a more aggressive tumor, which is common in squamous cell carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Right omohyoid muscle, right parotid artery, cervical esophagus, right lateral neck dissection, sympathetic nerve sheath, total laryngectomy, total thyroidectomy, left anterior compartment, transduced tumor, non-transduced tumor, vagus nerve, right sympathetic chain, tumor base of skull. 2. Findings: Grade II squamous cell carcinoma involving connective tissue and perineural invasion. 3. Code: SKCM (Squamous Cell Carcinoma) maps to the specific tumor sites. The presence of perineural invasion suggests a more aggressive tumor, which is common in squamous cell carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Right omohyoid muscle, right parotid artery, cervical esophagus, right lateral neck dissection, sympathetic nerve sheath, total laryngectomy, total thyroidectomy, left anterior compartment, transduced tumor, non-transduced tumor, vagus nerve, right sympathetic chain, tumor base of skull. 2. Findings: Grade II squamous cell carcinoma involving connective tissue and perineural invasion. 3. Code: SKCM (Squamous Cell Carcinoma) maps to the specific tumor sites. The presence of perineural invasion suggests a more aggressive tumor, which is common in squamous cell carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Right omohyoid muscle, right parotid artery, cervical esophagus, right lateral neck dissection, sympathetic nerve sheath, total laryngectomy, total thyroidectomy, left anterior compartment, transduced tumor, non-trans",
      "predicted": "SKCM",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Right omohyoid muscle, right parotid artery, cervical esophagus, right lateral neck dissection, sympathetic nerve sheath, total laryngectomy, total thyroidectomy, left anterior compartment, transduced tumor, non-transduced tumor, vagus nerve, right sympathetic chain, tumor base of skull. 2. Findings: Grade II squamous cell carcinoma involving connective tissue and perineural invasion. 3. Code: SKCM (Squamous Cell Carcinoma) maps to the specific tumor sites. The presence of perineural invasion suggests a more aggressive tumor, which is common in squamous cell carcinoma.",
      "idx": 436,
      "timestamp": "2026-01-19T15:59:53.116918"
    },
    {
      "sample_idx": 1036,
      "input": "DOS: SEX: Male. SURGICAL PATHOLOGY, COMPREHENSIVE. Not Released. I nqui ry: Sur gi e cal Pat hol ogyRepor t. Speci ren Dat e: In Lab Dat e: Report Dat e: Pat i ent : Encount er #: Locat i on: Age/ Sex: CLI N CAL I INFORMATI ON. Prostate cancer. I INTRACPERATI VE DI AGNOSI S: A. Thr ough E. Frozen section di agnosi s s: Soft tissue only. Reported to: GROSS. A. Recei ved fresh, the speci ren is label ed \"posterior apical'. and consists of a 0.2 x 0.2 x 0. cm pi ece of t an soft tissue. 100% submit...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate (Posterior Apical Margin). 2. Findings: Prostate adenocarcinoma, Gleason score 7 (3+4), bilateral. Extraprostatic extension, focal, left posterior margin (F17). Seminal vesicles and all surgical margins are negative for tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2",
      "predicted": "KIRC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate (Posterior Apical Margin). 2. Findings: Prostate adenocarcinoma, Gleason score 7 (3+4), bilateral. Extraprostatic extension, focal, left posterior margin (F17). Seminal vesicles and all surgical margins are negative for tumor. 3. Code: KIRC.",
      "idx": 1036,
      "timestamp": "2026-01-19T15:59:53.116933"
    },
    {
      "sample_idx": 1304,
      "input": "SURGICAL PATHOLOGY ----. MEDICAL RECORD. I. Laboratory: Accession No. Submitted by: Date obtained: Specimen (Received. A. THYMUS, FS. B. STATION 3 MEDIASTINAL LYMPH NODE. C. STATION 4L. D. THYMUS LYMPH NODE. E. MAMMARY FAT PAD. F. LEFT CHEST BIOPSY SITE. + SUPPLEMENTARY REPORT HAS BEEN ADDED +. REFER TO BOTTOM OF REPORT +. BRIEF CLINICAL HISTORY: PREOPERATIVE DIAGNOSIS: Thymoma. OPERATIVE FINDINGS: POSTOPERATIVE DIAGNOSIS: Thymoma. Laboratory: Accession No. Pathology Resident : GROSS DESCRIPTION...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thym",
      "predicted": "THYM",
      "ground_truth": "THYM",
      "correct": true,
      "reasoning": "1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM",
      "idx": 1304,
      "timestamp": "2026-01-19T15:59:53.116942"
    },
    {
      "sample_idx": 271,
      "input": "CONFIDENTIAL. Demographics (for. verification purposes). Date of Birth: Sex: M. Collected Date/Time. Received Date/Time. Specimen Description. A. Small bowel nodule. B. Mesenteric node. C. Gallbladder. D. Right lobe liver. Clinical Information. Mass in liver. Cholangiocarcinoma - query. Colon adenocarcinoma. Diagnosis. A. Small Bowel Nodule, Biopsy: Focal fibrosis, negative for malignancy. B. Mesenteric Node, Biopsy: One lymph node, negative for malignancy. C. Gallbladder, Cholecystectomy: Unrem...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Small bowel. 2. Findings: Small bowel nodule, biopsy shows focal fibrosis, negative for malignancy. 3. Code: Small Bowel Nodule maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mesenteric node. 2. Findings: Mesenteric node, biopsy shows one lymph node, negative for malignancy. 3. Code: Mesenteric Node maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Gallbladder. 2. Findings: Gallbladder, cholecystectomy shows unremarkable gallbladder, negative for malignancy. 3. Code: Gallbladder maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Right lobe liver. 2. Findings: Right lobe liver, wedge resection shows moderately differentiated cholangiocarcinoma. 7.7 x 6.0 x 5.5 cm. Less than 0.1 cm to the liver resection margin and the tumor focally involves the liver capsule. Positive perineural invasion. Surrounding background liver parenchyma shows moderate portal inflammation, likely due to mass effect. 3. Code: Right Lobe Liver maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Right lobe liver. 2. Findings: Right lobe liver, wedge resection shows moderately differentiated cholangiocarcinoma. 7.7 x 6.0 x 5.5 cm. Less than 0.1 cm to the liver resection margin and the tumor focally involves the liver capsule. Positive perineural invasion. Surrounding background liver parenchyma shows moderate portal inflammation, likely due to mass effect. 3. Code: Right Lobe Liver maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Right lobe liver. 2. Findings: Right lobe liver, wedge resection shows moderately differentiated cholangiocarcinoma. 7.7 x 6.0 x ",
      "predicted": "COAD",
      "ground_truth": "CHOL",
      "correct": false,
      "reasoning": "1. Site: Small bowel. 2. Findings: Small bowel nodule, biopsy shows focal fibrosis, negative for malignancy. 3. Code: Small Bowel Nodule maps to COAD.",
      "idx": 271,
      "timestamp": "2026-01-19T15:59:53.116953"
    },
    {
      "sample_idx": 714,
      "input": "Laboratory Services. PHN: ACB: Telephone: Encounter: Received Date/Time: Specimen Description. A. Gallbladder. B. Liver. C. Tumor thrombus - left hepatic vein. Clinical Information. Hepatocellular carcinoma. Diagnosis. A. Gallbladder, cholecystectomy: -Normal gallbladder with no pathologic abnormality. B. Liver, partial hepatectomy: -Moderately differentiated hepatocellular carcinoma. -Solitary, 11.0 cm in greatest dimension, 0.8 cm from the resection. margin. -Background liver negative for cirr...",
      "response": "```json\n{\n    \"cancer_type\": \"Hepatocellular carcinoma\",\n    \"reasoning\": \"1. Site: Gallbladder, Liver, Tumor Thrombus. 2. Findings: Hepatocellular carcinoma, moderately differentiated. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, moderately differentiated. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tumor Thrombus. 2. Findings: Hepatocellular carcinoma with necrosis. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, moderately differentiated. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Gallbladder. 2. Findings: Hepatocellular carcinoma, moderately differentiated. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, moderately differentiated. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, moderately differentiated. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, moderately differentiated. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular",
      "predicted": "Hepatocellular carcinoma",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Gallbladder, Liver, Tumor Thrombus. 2. Findings: Hepatocellular carcinoma, moderately differentiated. 3. Code: Hepatocellular carcinoma maps to KIRC.",
      "idx": 714,
      "timestamp": "2026-01-19T15:59:53.116965"
    },
    {
      "sample_idx": 1118,
      "input": "Report Status : Final. Type: surgicar. Specimen Type: Omentum. Procedure Date: Resident: PATHOLOGIC DIAGNOSIS: A. OMENTUM: HIGH GRADE SPINDLE CELL NEOPLASM SUGGESTIVE OF. DEDIFFERENTIATED LIPOSARCOMA (17.5 CM) involving adipose tissue. (See Note). Mitoses number 3 per 10 HPF. 50% necrosis is present. 30% hemorrhage is present. B. MESENTERY SARCOMA: HIGH GRADE SPINDLE CELL NEOPLASM SUGGESTIVE OF. DEDIFFERENTIATED LIPOSARCOMA (36.5 CM). Mitoses number 3 per 10 HPF. 50% necrosis is present. 30% hem...",
      "response": "```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Omentum and Mesentery. 2. Findings: High grade spindle cell neoplasm, suggestive of dedifferentiated liposarcoma. 3. Code: SARC (Sarcoma) maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Omentum and Mesentery. 2. Findings: High grade spindle cell neoplasm, suggestive of dedifferentiated liposarcoma. 3. Code: SARC (Sarcoma) maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Omentum and Mesentery. 2. Findings: High grade spindle cell neoplasm, suggestive of dedifferentiated liposarcoma. 3. Code: SARC (Sarcoma) maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Omentum and Mesentery. 2. Findings: High grade spindle cell neoplasm, suggestive of dedifferentiated liposarcoma. 3. Code: SARC (Sarcoma) maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Omentum and Mesentery. 2. Findings: High grade spindle cell neoplasm, suggestive of dedifferentiated liposarcoma. 3. Code: SARC (Sarcoma) maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Omentum and Mesentery. 2. Findings: High grade spindle cell neoplasm, suggestive of dedifferentiated liposarcoma. 3. Code: SARC (Sarcoma) maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Omentum and Mesentery. 2. Findings: High grade spindle cell neoplasm, suggestive of dedifferentiated liposarcoma. 3. Code: SARC (Sarcoma) maps to SARC",
      "predicted": "SARC",
      "ground_truth": "SARC",
      "correct": true,
      "reasoning": "1. Site: Omentum and Mesentery. 2. Findings: High grade spindle cell neoplasm, suggestive of dedifferentiated liposarcoma. 3. Code: SARC (Sarcoma) maps to SARC.",
      "idx": 1118,
      "timestamp": "2026-01-19T15:59:53.116975"
    },
    {
      "sample_idx": 500,
      "input": "MEDICAL RECORD. Revised Surgical Pathology Report. Revised Surgical Pathology Report. PROCEDURE DATE: SEX: M. SIGN-OUT DATE: ATTENDING: REQUESTING: CONTACT NO: ROOM: COPIES TO: REVISED REPORT. REASON FOR REVISION: A computer software error caused corruption in the original final report. This. incomplete, corrupted report was signed out so that a clean revised report could be created. This revised report. therefore represents the true original final report. DIAGNOSIS: Kidney, right (radical nephr...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",",
      "predicted": "KIRC",
      "ground_truth": "KICH",
      "correct": false,
      "reasoning": "1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 500,
      "timestamp": "2026-01-19T15:59:53.116986"
    },
    {
      "sample_idx": 756,
      "input": "Female. DIAGNOSIS. A. Liver, left, partial hepatectomy: Hepatocellular carcinoma,. moderately differentiated (grade 2 of 4), forming a single mass, 4.3. x 4.1 x 4.0 cm. The tumor is confined to the liver. The liver. parenchyma resection margin is negative for tumor (tumor free. margin, 1.4 cm) Macroscopic large vessel invasion is absent. Microscopic invasion is absent. No regional lymph nodes identified. B. Gallbladder, cholecystectomy Chronic cholecystitis and. cholelithiasis with two benign ly...",
      "response": "```json\n{\n    \"cancer_type\": \"Hepatocellular carcinoma\",\n    \"reasoning\": \"1. Site: Liver, Left. 2. Findings: Hepatocellular carcinoma, moderately differentiated (grade 2 of 4), forming a single mass. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Gallbladder. 2. Findings: Chronic cholecystitis, cholelithiasis with two benign lymph nodes. 3. Code: Gallbladder maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, moderately differentiated (grade 2 of 4), forming a single mass. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, moderately differentiated (grade 2 of 4), forming a single mass. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, moderately differentiated (grade 2 of 4), forming a single mass. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, moderately differentiated (grade 2 of 4), forming a single mass. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, moderately differentiated (grade 2 of 4), forming a single mass. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\":",
      "predicted": "Hepatocellular carcinoma",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Liver, Left. 2. Findings: Hepatocellular carcinoma, moderately differentiated (grade 2 of 4), forming a single mass. 3. Code: Hepatocellular carcinoma maps to KIRC.",
      "idx": 756,
      "timestamp": "2026-01-19T15:59:53.116998"
    },
    {
      "sample_idx": 583,
      "input": "Report Status: Amend/Addenda. Type: : Surgical Pathology. Specimen Type: Kidnev, partial or total resection. Procedure Date: PATHOLOGIC DIAGNOSIS: A/1) LEFT RADICAL NEPHRECTOMY: RENAL CELL CARCINOMA, clear cell type (11.3 cm), Fuhrman Grade II/IV. The tumor focally abuts but does not invade the renal capsule. No lymphovascular invasion seen. Renal vein is negative for tumor. Ureter (including margin) is negative for tumor. AJCC stage (6th edition) : T2 NO MX (see below). The non-neoplastic kidne...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 583,
      "timestamp": "2026-01-19T15:59:53.117010"
    },
    {
      "sample_idx": 1269,
      "input": "Diagnosis: A: Thyroid, total thyroidectomy. Tumor histologic type: papillary thyroid carcinoma, multifocal. Tumor size: there are 2 nodules of carcinoma, right upper pole. 2.5 cm in greatest dimension, right lower pole 1.7 cm in. greatest dimension. Tumor focality & laterality: multifocal, both tumors are in the. right thyroid. Tumor capsule: not present. Extent of invasion: Capsular Invasion: not identified. Lymphovascular invasion: not identified. Blood vascular invasion: not identified. Extra...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, multifocal. Tumor size: 2.5 cm and 1.7 cm. Tumor focality & laterality: right thyroid. Tumor capsule: not present. Extent of invasion: Capsular Invasion: not identified. Lymphovascular invasion: not identified. Blood vascular invasion: not identified. Extra thyroidal extension: not identified. Surgical margins: surgical margins free of tumor. Status of thyroid gland away from tumor: multinodular goiter. with extensive fibrosis and calcifciation. Lymph nodes: none present in specimen. Other significant findings: one parathyroid gland is present. (block A1), without pathologic abnormality. AJCC Pathologic TNM Stage: pT2 pNx. NOTE: This pathologic stage assessment is based on information. available at the time of this report, and is subject to change. pending clinical review and additional information. Clinical History. -year-old with thyroid cancer. Gross Description: Received is one appropriately labeled container, additionally. labeled \\\"total thyroid, stitch left superior pole\\\". Specimen fixation: formalin. Type of specimen: total thyroidectomy. Size and weight of specimen: 35.4 gm, 6.5 X 2.8 X 2.5 cm right. lobe, 6.3 X 3.0 X 1.3 cm left lobe and isthmus. Orientation Suture: left superior pole. Inking: anterior=blue, posterior=black, isthmus=yellow. Tumor location: right superior pole and right inferior pole. Focality: multifocal. Dominant tumor: present, right superior pole. Tumor description: The tumors are well circumscribed, solid,. fleshy, friable and pink/tan nodules. Tumor size: The dominate tumor nodule in the right upper pole is. 2.5 X 2.2 X 2.1 cm, and in the right lower pole is 1.7 x 1.3 X. 1.0 cm. Confinement / non-confinement: appears confined. Distance of tumor to capsule/inked surgical margins: Each tumor. nodule is within 0.1 cm of the blue inked anterior margin, and. 0. 1 cm of the black inked posterior margin. Appearance of thyroid gland away from tumor: dark red/brown and.",
      "predicted": null,
      "ground_truth": "THCA",
      "correct": null,
      "reasoning": "",
      "idx": 1269,
      "timestamp": "2026-01-19T15:59:53.117168"
    },
    {
      "sample_idx": 1286,
      "input": "SPECIMEN TAKEN: FINAL DIAGNOSIS. 1. RIGHT UPPER PARATHYROID (EXCISION): PARATHYROID AND. FIBROADIPOSE TISSUE (500MG). PARATHYROID ACCOUNTS FOR 40% OF. THE SPECIMEN. 2. RIGHT LOWER PARATHYROID (EXCISION): PARATHYROID TISSUE WITH. ADJACENT FIBROADIPOSE AND BENIGN THYROID TISSUE (450MG). PARATHYROID ACCOUNTS FOR 25% OF THE SPECIMEN. 3. BIOPSY LEFT LOWER PARATHYROID GLAND (BIOPSY): PARATHYROID. TISSUE. (6MG). NOTE: Tissue block exausted on frozen section. No frozen section control present. 4. THYROI...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid (Right Superior Lobe and Isthmus). 2. Findings: Papillary carcinoma, pT1b, margins uninvolved, venous/lymphatic invasion present, multinodular hyperplasia. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Parathyroid (Right Upper and Lower). 2. Findings: Parathyroid tissue, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ACC\",\n    \"reasoning\": \"1. Site: Parathyroid (Right Upper). 2. Findings: Parathyroid tissue, conventional (clear cell) type, Fuhrman Grade II. 3. Code: ACC maps to ACC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Parathyroid (Right Lower). 2. Findings: Parathyroid tissue, conventional (clear cell) type, Fuhrman Grade II. 3. Code: BRCA maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Parathyroid (Left Lower). 2. Findings: Parathyroid tissue, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, pT1b, margins uninvolved, venous/lymphatic invasion present, multinodular hyperplasia. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Parathyroid (Right Upper). 2. Findings: Parathyroid tissue, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```",
      "predicted": "THYM",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Thyroid (Right Superior Lobe and Isthmus). 2. Findings: Papillary carcinoma, pT1b, margins uninvolved, venous/lymphatic invasion present, multinodular hyperplasia. 3. Code: THYM maps to THYM.",
      "idx": 1286,
      "timestamp": "2026-01-19T15:59:53.117186"
    },
    {
      "sample_idx": 619,
      "input": "A description for each data field can be found in the 'Data description' worksheet (yellow tab). Sample Collection Details. Histology ai. Site of. Site of. Year of. Age at. Days to. Type. Preparatio. Tissue. Primary. Comments. Procedure. n. (Event). (yrs). TUMOUR. FF. RENL. BUFFY. FF. RENL. nd staging. Days to. Type of. Site of. Tumour. Histology. Grade/. Pathologic. Diagnosis. Procedure. Primary. Size (cm). Differentiat al T. (Histology). ion. RESECT. Right kidney. 14.5. Papillary renal ca., eo...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Papillary renal carcinoma, eosinophilic type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Papillary renal carcinoma, eosinophilic type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Papillary renal carcinoma, eosinophilic type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Papillary renal carcinoma, eosinophilic type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Papillary renal carcinoma, eosinophilic type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Papillary renal carcinoma, eosinophilic type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Papillary renal carcinoma, eosinophilic type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Papillary renal carcinoma, eosinophilic type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Right kidney. 2. Findings: Papillary renal carcinoma, eosinophilic type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 619,
      "timestamp": "2026-01-19T15:59:53.117197"
    },
    {
      "sample_idx": 16,
      "input": "M. Urology. Clinical Diagnosis & History: year old male with recurrent high grade T1 urothelial carcinoma. Specimens Submitted: 1: Urethral margin (fs). 2: Right distal pelvic lymph node. 3: Left distal pelvic lymph node. 4: Bladder, prostate, seminal vesicles and perivesicle lymph nodes; cystoprostatectomy. 5: Left distal ureter. 6: Right distal ureter. DIAGNOSIS: 1. Urethral margin; excision: - Benign urethra and prostate tissue. 2. Right distal pelvic lymph node: Lymph Node Dissection: Benign...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Urethra. 2. Findings: Urethral margin, benign. 3. Site: Right distal pelvic lymph node. 2. Findings: Lymph Node Dissection, Benign lymph nodes. 4. Site: Left distal pelvic lymph node. 2. Findings: Lymph Node Dissection, Benign lymph nodes. 5. Site: Bladder, prostate, seminal vesicles and perivesicle lymph nodes; cystoprostatectomy. 2. Findings: Invasive urothelial carcinoma, NOS. High grade. 6. Site: Left distal ureter. 2. Findings: Benign ureter. 7. Site: Right distal ureter. 2. Findings: Benign ureter. 8. Site: Bladder, prostate, seminal vesicles and perivesicle lymph nodes; cystoprostatectomy. 2. Findings: Tumor Type: Invasive urothelial carcinoma, NOS. Histologic Grade: High grade. Pattern of growth of the Non-Invasive component: In situ component not identified. Pattern of growth of the Invasive component: Infiltrating. Tumor Multicentricity: Not identified. Bladder Local Invasion: Deep half of muscularis propria. Extravesical Tumor Extension: Ureters uninvolved. Urethra uninvolved. Vascular Invasion: Identified. Perineural Invasion: Identified. Surgical Margins: Free of tumor. Non-Neoplastic Mucosa: Exhibiting ulceration. Exhibiting foreign body reaction. Prostate: Other See section b. Seminal Vesicles: Not involved. Perivesical Lymph Nodes: LN Not involved 1. The Pathologic Stage is (AJCC 2002): pT2b (Invades deep half of muscularis propria). PRO (No involvement of prostate). b. Tumor Type: Adenocarcinoma. of prostate. Gleason's Grade: Primary Gleason grade:3. Secondary Gleason grade:3. Total Gleason score:6. Tumor Location: Involves Right posterior. Involves Left posterior. Involves Left anterior. Dominant tumor mass located in: left anterior and posterior mid. Vascular Invasion: Not Identified. Perineural Invasion: Identified. Tumor Multicentricity: Multicentric foci of invasive carcinoma are present. High Grade Prostatic Intraepithelial Neoplasia: Identified. Capsule: Tumor invades into, but not beyond prostate capsule.",
      "predicted": null,
      "ground_truth": "BLCA",
      "correct": null,
      "reasoning": "",
      "idx": 16,
      "timestamp": "2026-01-19T15:59:53.117325"
    },
    {
      "sample_idx": 613,
      "input": "FINAL DIAGNOSIS: PART 1: FAT OVERLYING TUMOR, EXCISION -. A. BENIGN FIBROADIPOSE TISSUE. B. NO TUMOR SEEN. PART 2: CAPSULE OVERLYING TUMOR, EXCISION -. A. BENIGN FIBROADIPOSE TISSUE WITH CHRONIC INFLAMMATION. B. NO TUMOR SEEN. PART 3: LEFT KIDNEY TUMOR, PARTIAL NEPHRCTOMY -. A. PAPILLARY RENAL CELL CARCINOMA, TYPE 1, MAXIMAL FUHRMAN NUCLEAR GRADE 3 AND PREDOMINAIT. NUCLEAR GRADE 2 OUT OF 4 (See comment). B. TUMOR IS LIMITED TO THE KIDNEY AND MEASURES 2.2 x 1.9 x 0.8 CM. C. TUMOR IS FOCALLY PRESE...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Papillary renal cell carcinoma, type 1, maximal Fuhrman nuclear grade 3 and predominant. Nuclear grade 2 out of 4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Papillary renal cell carcinoma, type 1, maximal Fuhrman nuclear grade 3 and predominant. Nuclear grade 2 out of 4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Papillary renal cell carcinoma, type 1, maximal Fuhrman nuclear grade 3 and predominant. Nuclear grade 2 out of 4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Papillary renal cell carcinoma, type 1, maximal Fuhrman nuclear grade 3 and predominant. Nuclear grade 2 out of 4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Papillary renal cell carcinoma, type 1, maximal Fuhrman nuclear grade 3 and predominant. Nuclear grade 2 out of 4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Papillary renal cell carcinoma, type 1, maximal Fuhrman nuclear grade 3 and predominant. Nuclear grade 2 out of 4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Kidney. 2. Findings: Papillary renal cell carcinoma, type 1, maximal Fuhrman nuclear grade 3 and predominant. Nuclear grade 2 out of 4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 613,
      "timestamp": "2026-01-19T15:59:53.117340"
    },
    {
      "sample_idx": 212,
      "input": "Specimen #: Race: WHITE. Physician (s) : SPECIMEN: A: RIGHT BREAST B: SENTINEL NODE #1 C: SENTINEL NODE #2. D: SENTINEL NODE #3 E: SENTINEL NODE #4 F: left breast. FINAL DIAGNOSIS: A. RIGHT BREAST, SIMPLE MASTECTOMY. FIBROCYSTIC CHANGES TO INCLUDE FIBROADENOMAS, SCLEROSING ADENOSIS,. USUAL DUCTAL HYPERPLASIA, DUCT ECTASIA, CYSTIC CHANGE WITH APOCRINE. METAPLASIA. MICROCALCIFICATIONS IDENTIFIED IN BENIGN PROCESSES (A3) . SKIN AND NIPPLE WITH NO SIGNIFICANT PATHOLOGIC CHANGES. B. LYMPH NODE, SENTI...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, no special type, Nottingham Grade III, Nottingham Score 9/9. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, no special type, Nottingham Grade III, Nottingham Score 9/9. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, no special type, Nottingham Grade III, Nottingham Score 9/9. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, no special type, Nottingham Grade III, Nottingham Score 9/9. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, no special type, Nottingham Grade III, Nottingham Score 9/9. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, no special type, Nottingham Grade III, Nottingham Score 9/9. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, no special type, Nottingham Grade III, Nottingham Score 9/9. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, no special type, Nottingham Grade III, Nottingham Score 9/9. 3. Code",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, no special type, Nottingham Grade III, Nottingham Score 9/9. 3. Code: BRCA.",
      "idx": 212,
      "timestamp": "2026-01-19T15:59:53.117352"
    },
    {
      "sample_idx": 275,
      "input": "Addendum. Clinical Diagnosis & History. with transverse colon moderately differentiated. adenocarcinoma. Specimens Submitted: 1: SP: Right colon, hemicolectomy. DIAGNOSIS: 1. LARGE BOWEL; RIGHT HEMICOLECTOMY: - TUMOR TYPE: ADENOCARCINOMA. - HISTOLOGIC GRADE: MODERATELY DIFFERENTIATED. TUMOR LOCATION: ASCENDING COLON. - TUMOR SIZE: LENGTH IS 5.2 CM, WIDTH IS 4.1 CM, AND DEPTH IS 0.3 CM. - TUMOR INVASION: INVASION INTO MUSCULARIS PROPRIA. - GROSS TUMOR PERFORATION: NOT IDENTIFIED. - SEROSAL INVOLV...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: K",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Colon (Right Colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.",
      "idx": 275,
      "timestamp": "2026-01-19T15:59:53.117361"
    },
    {
      "sample_idx": 1369,
      "input": "LAB #: (Age. DOS: LOC: Specimen (source): I. OMENTUM BIOPSY; II. RIGHT PARACOLIC TISSUE; III. LEFT PARACOLIC TISSUE; IV. UTERUS, CERVIX, TUBES AND OVARIES; V. SIGMOID SEROSA; VI. OMENTUM; VII. LEFT COMMON NODE. Clinical Data: ENDOMETRIAL CANCER. FROZEN SECTION: I. Received for FS labeled \"omentum biopsy\" is fatty tissue with a nodular. mass measuring 4 x 3.5 x 2.5 cm. The cut surface is partially necrotic, gritty and gray. RS for FS in one. block. Tissue is formalin fixed and frozen and submitte...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1369,
      "timestamp": "2026-01-19T15:59:53.117371"
    },
    {
      "sample_idx": 236,
      "input": "Final Surgical Pathology Report. Procedure. Diagnosis. A. Uterus, cervix, endomyometrium, parametria and upper vagina,. hysterectomy: Squamous cell carcinoma of the cervix, poorly differentiated, with. direct extension into uterine wall, parametrial and upper vaginal. tissues, size of mass 4.8 cm. Surgical margins uninvolved. Ovaries, right and left, resection: No carcinoma identified. Fallopian tubes, right and left, resection: No carcinoma identified. B. Right pelvic lymph nodes, resection: Me...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, endomyometrium, parametria and upper vagina. 2. Findings: Squamous cell carcinoma of the cervix, poorly differentiated, with direct extension into uterine wall, parametrial and upper vaginal tissues. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Right pelvic lymph nodes. 2. Findings: Metastatic squamous cell carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Left pelvic lymph nodes. 2. Findings: No carcinoma identified. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Periaortic lymph nodes. 2. Findings: No carcinoma identified. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, endomyometrium, parametria and upper vagina. 2. Findings: Squamous cell carcinoma of the cervix, poorly differentiated, with direct extension into uterine wall, parametrial and upper vaginal tissues. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right pelvic lymph nodes. 2. Findings: Metastatic squamous cell carcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left pelvic lymph nodes. 2. Findings: No carcinoma identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Periaortic lymph nodes. 2. Findings: No carcinoma identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\":",
      "predicted": "KIRC",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Uterus, cervix, endomyometrium, parametria and upper vagina. 2. Findings: Squamous cell carcinoma of the cervix, poorly differentiated, with direct extension into uterine wall, parametrial and upper vaginal tissues. 3. Code: KIRC.",
      "idx": 236,
      "timestamp": "2026-01-19T15:59:53.117384"
    },
    {
      "sample_idx": 219,
      "input": "IP <DIS IN C. Specimen: spec Type: SURGICAL P. PREOPERATIVE DIAGNOSES. LEFT BREAST CANCER INVASIVE. OPERATION PERFORMED. DOCTOR (s) : PROCEDURE: MASTECTOMY MODIFIED RADICAL. TISSUE REMOVED. A. LT BREAST AND AXILLARY TISSUE. B. ADDITIONAL LYMPH NODES LT AXILLA. GROSS DESCRIPTION. PART A RECEIVED FRESH LABELED. LEFT BREAST AND AXILLARY. CONTENTS SUTURE AT 12 O'CLOCK, AND CONSISTS OF A MODIFIED RADICAL. MASTECTOMY SPECIMEN WITH OVERALL DIMENSIONS OF 31 x 20.5 x 5.8 CM. THE. NIPPLE IS UNREMARKABLE A...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 219,
      "timestamp": "2026-01-19T15:59:53.117394"
    },
    {
      "sample_idx": 1379,
      "input": "f3. CLINICAL HISTORY: Malignant neocorpus uteri. GROSS EXAMINATION: A. \"Uterus, cervix, bilateral tubes and ovaries (AF1-2)\", received fresh for. frozen section and placed in formalin at. is a 368 gram,. 11.1 x 7.5 x 7.2 cm uterus with attached left ovary (3 x 2.2 x 1.5 cm), left. fimbriated fallopian tube (8.6 cm long x 0.5 cm in diameter), right ovary (3.7. x 2.7 x 1.6 cm), and right fimbriated fallopian tube (7.1 cm long x 0.5 cm in. diameter) The uterus was received open from the OR, chisele...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Well-differentiated endometrioid adenocarcinoma, grade 1. Tumor limited to endometrium. 3. Code: UTERUS WITH CERVIX, BILATERAL OVARIES AND FALLOPIAN TUBES maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: HILUS CELL TUMOR, MITOTICALLY ACTIVE CELLULAR FIBROMA. 3. Code: Left ovarian nodule maps to BRCA. Right ovarian nodule maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pelvic Lymph Node. 2. Findings: No tumor seen in one lymph node (0/1). 3. Code: Left pelvic lymph node maps to KIRC. Right pelvic lymph node maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: 6.6 CM LEIOMYOMA. 3. Code: UTERUS WITH CERVIX, BILATERAL OVARIES AND FALLOPIAN TUBES maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: MITOTICALLY ACTIVE CELLULAR FIBROMA. 3. Code: Left ovarian nodule maps to BRCA. Right ovarian nodule maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: No tumor seen in one lymph node (0/1). 3. Code: Left pelvic lymph node maps to UCEC. Right pelvic lymph node maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: No tumor seen in two lymph nodes (0/",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus. 2. Findings: Well-differentiated endometrioid adenocarcinoma, grade 1. Tumor limited to endometrium. 3. Code: UTERUS WITH CERVIX, BILATERAL OVARIES AND FALLOPIAN TUBES maps to UCEC.",
      "idx": 1379,
      "timestamp": "2026-01-19T15:59:53.117410"
    },
    {
      "sample_idx": 557,
      "input": "DIAGNOSIS. (A) LEFT KIDNEY: RENAL CELL CARCINOMA (2.7 CM MAXIMUM DIMENSION), CONVENTIONAL TYPE. (100% CLEAR CELLS),. FUHRMAN NUCLEAR GRADE 3, CONFINED TO THE KIDNEY. Margins of resection free of tumor. Adrenal cortical adenoma (1.7 cm maximum dimension). COMMENT. The renal cell carcinoma in the left kidney does not invade into the. perinephric adipose tissue, renal sinus adipose tissue, or the renal. vein. There is no metastatic renal cell carcinoma in the adrenal gland. GROSS DESCRIPTION. (A) L...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADRENAL\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenal cortical adenoma. 3. Code: Adrenal cortical adenoma maps to ADRENAL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type,",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 557,
      "timestamp": "2026-01-19T15:59:53.117421"
    },
    {
      "sample_idx": 577,
      "input": "Clinical Diagnosis & History: ith incidentally diagnosed right renal mass. Specimens Submitted: 1: SP: Kidney, right posterior mid pole, partial nephrecimy. DIAGNOSIS: 1. SP: Kidney, right posterior mid pole, partial nephrectmy. Tumor Type: Renal cell carcinoma = Conventional (clear cell) type. Fuhrman Nuclear Grade;. Nuclear grade III/IV. Tumor Size: Greatest diameter is 5.0 cm. Local Invasion (for renal cortical types): Not Identified. Renal Vein Invasion: Not identified. Small vessel angiolym...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right posterior mid pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney (Right posterior mid pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 577,
      "timestamp": "2026-01-19T15:59:53.117432"
    },
    {
      "sample_idx": 431,
      "input": "Case imported from legacy computer system. The format of this report does not match the original case. For cases prior to. the section \"SPECIMEN\" may have been added. SUPPLEMENTAL REPORT. DIAGNOSIS: (B). HARD PALATE: Bone and mucosa, no tumor present. Entire report and diagnosis completed bv: DIAGNOSIS. BUCCAL FAT BIOPSY: Adipose tissue, no tumor present. BONE FROM POSTERIOR WALL OF MAXILLA: Tissue submitted for decalcification. Supplemental report will. follow. PARTIAL MAXILLECTOMY AND HEMIPALA...",
      "response": "```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Hard Palate, Maxilla, Maxillary Sinus, Nasal Cavity, Teeth. 2. Findings: Invasive Squamous Cell Carcinoma, Grade 2, presence of perineural invasion, invasion, thickness area of tumor 2.5 cm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Hard Palate, Maxilla, Maxillary Sinus, Nasal Cavity, Teeth. 2. Findings: Invasive Squamous Cell Carcinoma, Grade 2, presence of perineural invasion, invasion, thickness area of tumor 2.5 cm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Hard Palate, Maxilla, Maxillary Sinus, Nasal Cavity, Teeth. 2. Findings: Invasive Squamous Cell Carcinoma, Grade 2, presence of perineural invasion, invasion, thickness area of tumor 2.5 cm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Hard Palate, Maxilla, Maxillary Sinus, Nasal Cavity, Teeth. 2. Findings: Invasive Squamous Cell Carcinoma, Grade 2, presence of perineural invasion, invasion, thickness area of tumor 2.5 cm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Hard Palate, Maxilla, Maxillary Sinus, Nasal Cavity, Teeth. 2. Findings: Invasive Squamous Cell Carcinoma, Grade 2, presence of perineural invasion, invasion, thickness area of tumor 2.5 cm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Hard Palate, Maxilla",
      "predicted": "SKCM",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Hard Palate, Maxilla, Maxillary Sinus, Nasal Cavity, Teeth. 2. Findings: Invasive Squamous Cell Carcinoma, Grade 2, presence of perineural invasion, invasion, thickness area of tumor 2.5 cm. 3. Code: SKCM maps to SKCM.",
      "idx": 431,
      "timestamp": "2026-01-19T15:59:53.117445"
    },
    {
      "sample_idx": 702,
      "input": "Anatomic Pathology/Cytology Document State: (version). Update Date/Time: Service Date/Time: Male Provider: Responsible Staff: Surgical Pathologv Report. Med: Rec. : Phone Number : Client: Phy Location: CLINICAL HISTORY. year old man has had mental status change. and. on. imaging has a right temporoparietal, partially cystic, and with calcification. large tumor. OPERATIVE DIAGNOSES. Not Given. Operation/Specimen: A: Brain, biopsy. B: Brain, resection, perm. PATHOLOGICAL DIAGNOSIS: A. Brain, site ...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma with focal anaplastic transformation. 3. Code: STAD (Brain Tumor) maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma with focal anaplastic transformation. 3. Code: U23 (Brain Tumor) maps to U23.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma with focal anaplastic transformation. 3. Code: U23 (Brain Tumor) maps to U23.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma with focal anaplastic transformation. 3. Code: U23 (Brain Tumor) maps to U23.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma with focal anaplastic transformation. 3. Code: U23 (Brain Tumor) maps to U23.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma with focal anaplastic transformation. 3. Code: U23 (Brain Tumor) maps to U23.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma with focal anaplastic transformation. 3. Code: U23 (Brain Tumor) maps to U23.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23\",\n    \"reasoning\": \"1. Site: Brain. 2.",
      "predicted": "STAD",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain. 2. Findings: Oligodendroglioma with focal anaplastic transformation. 3. Code: STAD (Brain Tumor) maps to STAD.",
      "idx": 702,
      "timestamp": "2026-01-19T15:59:53.117454"
    },
    {
      "sample_idx": 416,
      "input": "Diagnosis: Right frontal glioblastoma. Discussion: In the area of cellular tumor, less than 10% of the cells are immunoreactive for MGMT. Many of these are recognizable as endothelial cells. The neoplastic cells are negative for. MGMT expression. Microscopic Description: Sections demonstrate gray and white matter with cellular and diffusely infiltrating. astrocytoma. Tumor cells demonstrate generally moderate cytologic atypia. In. multicellular areas, numerous scattered mitotic figures are seen....",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Frontal lobe of the brain (Right). 2. Findings: Glioblastoma, a type of astrocytoma. The report mentions a high number of mitotic figures and necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right frontal lobe of the brain. 2. Findings: Glioblastoma, a type of astrocytoma. The report mentions a high number of mitotic figures and necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right frontal lobe of the brain. 2. Findings: Glioblastoma, a type of astrocytoma. The report mentions a high number of mitotic figures and necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right frontal lobe of the brain. 2. Findings: Glioblastoma, a type of astrocytoma. The report mentions a high number of mitotic figures and necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right frontal lobe of the brain. 2. Findings: Glioblastoma, a type of astrocytoma. The report mentions a high number of mitotic figures and necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right frontal lobe of the brain. 2. Findings: Glioblastoma, a type of astrocytoma. The report mentions a high number of mitotic figures and necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right frontal lobe of the brain. 2.",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Frontal lobe of the brain (Right). 2. Findings: Glioblastoma, a type of astrocytoma. The report mentions a high number of mitotic figures and necrosis. 3. Code: Glioblastoma maps to GBM.",
      "idx": 416,
      "timestamp": "2026-01-19T15:59:53.117466"
    },
    {
      "sample_idx": 540,
      "input": "DIAGNOSIS. (A) RIGHT KIDNEY: RENAL CELL CARCINOMA (7.0 CM MAXIMUM DIMENSION), CONVENTIONAL TYPE. (95% CLEAR CELLS,. 5% EOSINOPHILIC CELLS), FUHRMAN NUCLEAR GRADE 3, CONFINED TO. THE KIDNEY. (SEE COMMENT). Margins of resection free of tumor. COMMENT. The renal cell carcinoma in the right kidney does not invade into the. perinephric adipose tissue, renal sinus adipose tissue, or the renal. vein. GROSS DESCRIPTION. (A) RIGHT KIDNEY - A radical nephrectomy specimen, which includes the. perinephric f...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney.",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 540,
      "timestamp": "2026-01-19T15:59:53.117476"
    },
    {
      "sample_idx": 1035,
      "input": "Margins Involvement: Yes. Left posterior (slide C21). Linear Distance: Microscopic (<1mm). Frozen Performed: Lymph Nodes: Positive Right 1 /5 Left 3 /. Other Pathologic Findings: Chronic inflammation. Pathological Staging (pTNM): p. T 3b. N 1. Mx. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. GROSS DESCRIPTION: A. RIGHT PELVIC LYMPH NODES. Received in formalin labeled with the patient's identification and \"right pelvic lymph node\" are pieces of. yellow-tan soft ti...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, with lymph node involvement (Right 1 / 5, Left 3). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, with lymph node involvement (Right 1 / 5, Left 3). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, with lymph node involvement (Right 1 / 5, Left 3). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, with lymph node involvement (Right 1 / 5, Left 3). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, with lymph node involvement (Right 1 / 5, Left 3). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, with lymph node involvement (Right 1 / 5, Left 3). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, with lymph node involvement (Right 1 / 5, Left 3). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```",
      "predicted": "KIRC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate. 2. Findings: Prostate cancer, with lymph node involvement (Right 1 / 5, Left 3). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 1035,
      "timestamp": "2026-01-19T15:59:53.117487"
    },
    {
      "sample_idx": 1249,
      "input": "Diagnosis: A: Thyroid, total thyroidectomy. Tumor histologic type: papillary thyroid carcinoma. Tumor size: 2.0 cm (gross), largest in any one slide 1.1 cm. Tumor growth pattern: papillary. Extent of invasion: Extra-capsular: not identified. Vascular: not identified. Tumor multicentricity: Multifocal. Surgical margins: Close, but negative (to <0.5 mm of the R lobe anterior margin (A1)). Background thyroid: Lymphocytic thyroiditis, nodular hyperplasia. Lymph nodes: Specimen A: metastatic papillar...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, multifocal. 3. Code: Thyroid maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma. 3. Code: Thyroid maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, multifocal. 3. Code: Thyroid maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, multifocal. 3. Code: Thyroid maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, multifocal. 3. Code: Thyroid maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, multifocal. 3. Code: Thyroid maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, multifocal. 3. Code: Thyroid maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, multifocal. 3. Code: Thyroid maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, multifocal. 3. Code: Thyroid maps to THYM.\"\n}\n```\n```json",
      "predicted": "THYM",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, multifocal. 3. Code: Thyroid maps to THYM.",
      "idx": 1249,
      "timestamp": "2026-01-19T15:59:53.117496"
    },
    {
      "sample_idx": 1279,
      "input": "UOD. Case type: Surgical Case. DIAGNOSIS. (A) TISSUE RIGHT INFERIOR THYROID POLE: Fragment of parathyroid tissue, no tumor present. (B) TISSUE, LEFT THYROID, SUPERIOR POLE: Fragment of parathyroid tissue, no tumor present. (C) TOTAL THYROID: PAPILLARY THYROID CARCINOMA, CONVENTIONAL TYPE. Location: Bilateral. Multi-focal: Yes. Size = 1.6 cm, left lobe and 0.4 cm right. Extrathyroidal extension: PRESENT (PART D). Lymph nodes: METASTATIC PAPILLARY THYROID CARCINOMA IN ONE LYMPH NODE (1/1). Locatio...",
      "response": "```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, conventional type. Location: Bilateral, multi-focal. Extrathyroidal extension: Present (part of the tumor). Lymph node involvement: Metastatic papillary thyroid carcinoma in one lymph node. 3. Code: TGCT corresponds to Thyroid Gland Tumors, which is a broad category that includes papillary thyroid carcinoma. The description of the tumor and its spread to lymph nodes aligns with the TGCT code.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, conventional type. Location: Bilateral, multi-focal. Extrathyroidal extension: Present (part of the tumor). Lymph node involvement: Metastatic papillary thyroid carcinoma in one lymph node. 3. Code: THCA corresponds to Thyroid Hormones, which is a broad category that includes thyroid gland tumors. The description of the tumor and its spread to lymph nodes aligns with the THCA code.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, conventional type. Location: Bilateral, multi-focal. Extrathyroidal extension: Present (part of the tumor). Lymph node involvement: Metastatic papillary thyroid carcinoma in one lymph node. 3. Code: UCSC corresponds to Uterine Corpus, which is a broad category that includes thyroid gland tumors. The description of the tumor and its spread to lymph nodes aligns with the UCSC code.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, conventional type. Location: Bilateral, multi-focal. Extrathyroidal extension: Present (part of the tumor). Lymph node involvement: Metastatic papillary thyroid carcinoma in one lymph node. 3. Code: UVM corresponds to Ureter, which is a broad category that includes thyroid gland tumors. The description of the tumor and its spread to lymph nodes aligns with the UVM code.\"\n}\n```\n```json\n{\n    \"cancer_type",
      "predicted": "TGCT",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, conventional type. Location: Bilateral, multi-focal. Extrathyroidal extension: Present (part of the tumor). Lymph node involvement: Metastatic papillary thyroid carcinoma in one lymph node. 3. Code: TGCT corresponds to Thyroid Gland Tumors, which is a broad category that includes papillary thyroid carcinoma. The description of the tumor and its spread to lymph nodes aligns with the TGCT code.",
      "idx": 1279,
      "timestamp": "2026-01-19T15:59:53.117514"
    },
    {
      "sample_idx": 104,
      "input": "SURGICAL REPORT. Sexc F. Date Collected: I. Date Received: M.R. Number. Doctor: Account Number. PRE-OPERATIVE DIAGNOSIS. RIGHT BREAST CANCER. POST-OPERATIVE DIAGNOSIS. RIGHT BREASTS CANCER. PROCEDURE. RIGHT SENTINEL LYMPH NODE BIOPSY. TISSUES. A. LYMPH NODE (S) - SENT NODE #1 \"FS. B. LYMPH NODE (S) - SENT NODE #2 FS. C. BREAST EXCISION,NEEDLE LOC,SIMPLE,MARGINS,ETC.- - RIGHT BREAST MASS. D. AXILLARY - AXILLARY CONTENTS. E. MARGINS - ADDITIONAL RIGHT BREAST TISSUE. F. MARGINS - ADDITIONAL LATERAL...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 104,
      "timestamp": "2026-01-19T15:59:53.117524"
    },
    {
      "sample_idx": 1375,
      "input": "CLINICAL HISTORY: Malignant neoplasm corpus uteri. GROSS EXAMINATION: A. \"Uterus, cervix, bilateral tubes and ovaries (AF1)\" received fresh for. frozen section is a 112 gram hysterectomy specimen with bilateral adnexa. The. uterine dimensions are 8.2 x 5.2 x 3.1 cm; the cervix is 2.7 cm in diameter. and the os diameter is 0.9 cm. The specimen is opened to demonstrate a 3.4. x. 2.5 x 2.2 cm exophytic, soft, friable mass involving the anterior and. posterior wall but sparing the fundus. The lesion...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma, FIGO grade 3, tumor size 3.4 x 2.5 x 2.2 cm, maximum depth of myometrial invasion 0.3 cm, no lymphatic/vascular invasion. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma, FIGO grade 3, tumor size 3.4 x 2.5 x 2.2 cm, maximum depth of myometrial invasion 0.3 cm, no lymphatic/vascular invasion. 3. Code: UCEC.",
      "idx": 1375,
      "timestamp": "2026-01-19T15:59:53.117536"
    },
    {
      "sample_idx": 1181,
      "input": "Gross. Microscopic. Diagnosis. Comments. Case ID. Description. Description. Details. Laterality. STOMACH TISSUE. Fundus. CHECKLIST. Specimen type: Gastrectomy. Tumor site: Fundus. Tumor size: 6 X 4.5 X 1.5. cm. Tumor features: None. specified. Histologic type: Adenocarcinoma, intestinal. type. Histologic grade: Moderately differentiated. Tumor extent: Adjacent. structures (specify) -. Lesser omentum. Lymph nodes: 2/7 positive. for metastasis. (Intraabdominal 2/7). Lymphatic invasion: Not. specif...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Fundus). 2. Findings: Adenocarcinoma, intestinal type. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Fundus). 2. Findings: Adenocarcinoma, intestinal type. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Fundus). 2. Findings: Adenocarcinoma, intestinal type. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Fundus). 2. Findings: Adenocarcinoma, intestinal type. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Fundus). 2. Findings: Adenocarcinoma, intestinal type. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Fundus). 2. Findings: Adenocarcinoma, intestinal type. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Fundus). 2. Findings: Adenocarcinoma, intestinal type. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Fundus). 2. Findings: Adenocarcinoma, intestinal type. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",",
      "predicted": "ADENOMA",
      "ground_truth": "STAD",
      "correct": false,
      "reasoning": "1. Site: Stomach (Fundus). 2. Findings: Adenocarcinoma, intestinal type. 3. Code: ADENOMA maps to ADENOMA.",
      "idx": 1181,
      "timestamp": "2026-01-19T15:59:53.117547"
    },
    {
      "sample_idx": 566,
      "input": "Clinical Diagnosis & History: Left kidney tumor. Left partial nephrectomy. Specimens Submitted: 1: SP: Left renal hilar lymph nodes. 2: SP: Left kidney mass. DIAGNOSIS: 1). LYMPH NODES, LEFT RENAL HILAR; EXCISION: - THREE BENIGN LYMPH NODES (0/3). 2). KIDNEY, LEFT; PARTIAL NEPHRECTOMY: - RENAL CELL CARCINOMA, CONVENTIONAL (CLEAR CELL) TYPE,. NUCLEAR GRADE II/IV. - THE PATTERN OF GROWTH IS ACINAR. .. THE TUMOR'S GREATEST DIAMETER IS 6.3 CM. - THE TUMOR IS CONFINED WITHIN THE RENAL CAPSULE. - ALL ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"K",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney (Left). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 566,
      "timestamp": "2026-01-19T15:59:53.117558"
    },
    {
      "sample_idx": 90,
      "input": "surgical Pathology Report. (Age. F. Pathologic Interpretation: A. SENTINEL NODE COUNT 0 AXILLA, FS: No malignancy seen in one lymph node (0/1). Immunohlstochemistry for keratin to follow. B. SENTINEL NODE COUNT 609 AXILLA, FS: No malignancy seen in one lymph node (0/1). Immunohistochemistry for keratin to follow. c. LEFT BREAST MASTECTOMY SINGLE SUTURE SUPERIOR, DOUBLE SUTURE MEDIAL: INVASIVE LOBULAR CARCINOMA, high nuclear grade, 7.0 cm (gross examination). Previous biopsy site. No lymphovascul...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, high nuclear grade, 7.0 cm (gross examination). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, high nuclear grade, 7.0 cm (gross examination). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, high nuclear grade, 7.0 cm (gross examination). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, high nuclear grade, 7.0 cm (gross examination). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, high nuclear grade, 7.0 cm (gross examination). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, high nuclear grade, 7.0 cm (gross examination). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, high nuclear grade, 7.0 cm (gross examination). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, high nuclear grade, 7.0 cm (gross examination). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive lobular carcinoma, high nuclear grade, 7.0 cm (gross examination). 3. Code: BRCA.",
      "idx": 90,
      "timestamp": "2026-01-19T15:59:53.117569"
    },
    {
      "sample_idx": 7,
      "input": "Procedure: adrenalectomy and nephrectomy. Gross description: 25 X 17 X 8.5cm with 18cm tumor. Reference Pathology only: Diagnosis: adrenocortical carcinoma, KI67 10%. Weiss score: 7. Hough score: 5.58. Van Slooten score: 22.7.",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Adrenal gland (Cortex). 2. Findings: Adrenocortical carcinoma, KI67 10%, Weiss score 7, Hough score 5.58, Van Slooten score 22.7. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Adrenal gland (Cortex). 2. Findings: Adrenocortical carcinoma, KI67 10%, Weiss score 7, Hough score 5.58, Van Slooten score 22.7. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Adrenal gland (Cortex). 2. Findings: Adrenocortical carcinoma, KI67 10%, Weiss score 7, Hough score 5.58, Van Slooten score 22.7. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Adrenal gland (Cortex). 2. Findings: Adrenocortical carcinoma, KI67 10%, Weiss score 7, Hough score 5.58, Van Slooten score 22.7. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Adrenal gland (Cortex). 2. Findings: Adrenocortical carcinoma, KI67 10%, Weiss score 7, Hough score 5.58, Van Slooten score 22.7. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Adrenal gland (Cortex",
      "predicted": "KIRC",
      "ground_truth": "ACC",
      "correct": false,
      "reasoning": "1. Site: Adrenal gland (Cortex). 2. Findings: Adrenocortical carcinoma, KI67 10%, Weiss score 7, Hough score 5.58, Van Slooten score 22.7. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 7,
      "timestamp": "2026-01-19T15:59:53.117580"
    },
    {
      "sample_idx": 683,
      "input": "Component. Tissue. Index. Ethnicity. Clinical. Tumor. Specimen. Specimen. Number of. Type of. Histological. of treatment. /. Anatomical Site. Specificati. Container. Amount/per. Grade. Matrix. Procureme. TNM Stage. TNM Stage. Format. container. description. TNM Stage. Treatment. Tumor cell. (Race). Diagnosis. containers. (Chemo. (source). (T). (N). (M). type. %. on. nt. (Source). Horm Th. Details). Brain,both w. Caucasia. male. Glioma. frantal lobes. Primary. Tumor. n (White). Tissue. OCT. block...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (both cerebral lobes). 2. Findings: Anaplastic astrocytoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Brain (both cerebral lobes). 2. Findings: Anaplastic astrocytoma. 3. Code: UVM maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Brain (both cerebral lobes). 2. Findings: Anaplastic astrocytoma. 3. Code: BLCA maps to BLCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (both cerebral lobes). 2. Findings: Anaplastic astrocytoma. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Brain (both cerebral lobes). 2. Findings: Anaplastic astrocytoma. 3. Code: UVM maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (both cerebral lobes). 2. Findings: Anaplastic astrocytoma. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (both cerebral lobes). 2. Findings: Anaplastic astrocytoma. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (both cerebral lobes). 2. Findings: Anaplastic astrocytoma. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain (both cerebral lobes). 2. Findings: Anaplastic astrocytoma. 3. Code: GBM maps to GBM.",
      "idx": 683,
      "timestamp": "2026-01-19T15:59:53.117589"
    },
    {
      "sample_idx": 267,
      "input": "Female. Surgery Date: DIAGNOSIS: A. Lymph nodes, hepatic hilar, biopsy: Multiple (4) lymph nodes are. negative for tumor. B. Hepatic duct, left margin, excision: Negative for tumor. c. Liver, left lobe, partial hepatectomy: Cholangiocarcinoma, moderately. differentiated (grade 2 of 4), forming two masses, ranging from 1.5 cm to 0.9 cm in. greatest microscopic dimension. Multiple additional microscopic foci of periductal. infiltrating carcinoma along the duct associated with moderate to severe dy...",
      "response": "```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Hepatic hilar lymph nodes, left hepatic duct margin, left lobe of liver. 2. Findings: Cholangiocarcinoma, moderately differentiated (grade 2 of 4), forming two masses, ranging from 1.5 cm to 0.9 cm in greatest microscopic dimension. Multiple additional microscopic foci of periductal infiltrating carcinoma along the duct associated with moderate to severe dysplasia are present. The tumor is confined to hepatic parenchyma. The hepatic parenchymal resection margin is negative for tumor (tumor-free margin, 4.5 cm grossly). Major vessel invasion is absent. Microscopic (small vessel) invasion is absent. No regional lymph nodes identified in specimen. The non-neoplastic hepatic parenchyma will be reviewed on permanent sections with special stains and the result will be reported in an addendum. D. Gallbladder, cholecystectomy: Benign gallbladder with chronic inflammation. 3. Code: CHOL (Cholangiocarcinoma) maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Hepatic hilar lymph nodes, left hepatic duct margin, left lobe of liver. 2. Findings: Cholangiocarcinoma, moderately differentiated (grade 2 of 4), forming two masses, ranging from 1.5 cm to 0.9 cm in greatest microscopic dimension. Multiple additional microscopic foci of periductal infiltrating carcinoma along the duct associated with moderate to severe dysplasia are present. The tumor is confined to hepatic parenchyma. The hepatic parenchymal resection margin is negative for tumor (tumor-free margin, 4.5 cm grossly). Major vessel invasion is absent. Microscopic (small vessel) invasion is absent. No regional lymph nodes identified in specimen. The non-neoplastic hepatic parenchyma will be reviewed on permanent sections with special stains and the result will be reported in an addendum. D. Gallbladder, cholecystectomy: Benign gallbladder with chronic inflammation. 3. Code: CHOL (Cholangiocarcinoma) maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Hepatic hilar lymph nodes, left hepatic duct margin, left lobe of liver. 2. Findings: Cholangiocarcinoma, moderately differentiated (grade ",
      "predicted": "CHOL",
      "ground_truth": "CHOL",
      "correct": true,
      "reasoning": "1. Site: Hepatic hilar lymph nodes, left hepatic duct margin, left lobe of liver. 2. Findings: Cholangiocarcinoma, moderately differentiated (grade 2 of 4), forming two masses, ranging from 1.5 cm to 0.9 cm in greatest microscopic dimension. Multiple additional microscopic foci of periductal infiltrating carcinoma along the duct associated with moderate to severe dysplasia are present. The tumor is confined to hepatic parenchyma. The hepatic parenchymal resection margin is negative for tumor (tumor-free margin, 4.5 cm grossly). Major vessel invasion is absent. Microscopic (small vessel) invasion is absent. No regional lymph nodes identified in specimen. The non-neoplastic hepatic parenchyma will be reviewed on permanent sections with special stains and the result will be reported in an addendum. D. Gallbladder, cholecystectomy: Benign gallbladder with chronic inflammation. 3. Code: CHOL (Cholangiocarcinoma) maps to CHOL.",
      "idx": 267,
      "timestamp": "2026-01-19T15:59:53.117617"
    },
    {
      "sample_idx": 536,
      "input": "Clinical Diagnosis & History: 4. Vith right renal mass. Specimens Submitted: 1: Kidney, right; partial nephrectomy. DIAGNOSIS: 1. Kidney, right; partial nephrectomy: Tumor Type: Renal cell carcinoma - Conventional (clear cell) type. Fuhrman Nuclear Grade: Nuclear grade III/IV. Tumor Size: Greatest diameter is 1.9 cm. Local Invasion (for renal cortical types): Not Identified. Renal Vein Invasion: Not applicable. Surgical Margins: Free of tumor. Non-Neoplastic Kidney: Unremarkable. Adrenal Gland: ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. Tumor Size: 1.9 cm. Local Invasion: Not identified. Renal Vein Invasion: Not applicable. Surgical Margins: Clear. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. Tumor Size: 1.9 cm. Local Invasion: Not identified. Renal Vein Invasion: Not applicable. Surgical Margins: Clear. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. Tumor Size: 1.9 cm. Local Invasion: Not identified. Renal Vein Invasion: Not applicable. Surgical Margins: Clear. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. Tumor Size: 1.9 cm. Local Invasion: Not identified. Renal Vein Invasion: Not applicable. Surgical Margins: Clear. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. Tumor Size: 1.9 cm. Local Invasion: Not identified. Renal Vein Invasion: Not applicable. Surgical Margins: Clear. 3. Code: Kidney Renal Clear Cell Carcinoma maps to",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. Tumor Size: 1.9 cm. Local Invasion: Not identified. Renal Vein Invasion: Not applicable. Surgical Margins: Clear. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 536,
      "timestamp": "2026-01-19T15:59:53.117632"
    },
    {
      "sample_idx": 1255,
      "input": "Date or Procedure: Clinical Diagnosis & History: year old male with FNA papillary on left thyroid nodule. Specimens Submitted: 1: SP: Right paratracheal lymph node (fs). 2: SP: Total thyroidectomy. DIAGNOSIS: 1. SP: Right paratracheal lymph node (fs): Lymph Node Dissection: Number of lymph nodes examined: 2. Number of lymph nodes with metastatic disease: 0. 2. SP: Total thyroldectomy: Tumor Type: Papillary microcarcinoma with tall cell features. Histologic Grade: Well differentiated. Mitotic Act...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Paratracheal lymph node. 2. Findings: Lymph node dissection reveals no metastatic disease. The total thyroidectomy shows a papillary microcarcinoma with tall cell features, well differentiated, grade II, with a separate focus of papillary microcarcinoma in the right lobe. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) does not map to this case, but KIRC is a valid TCGA code and the most appropriate given the presence of thyroid cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary microcarcinoma with tall cell features. 3. Code: BRCA (Breast Invasive Carcinoma) does not map to this case, but BRCA is a valid TCGA code and the most appropriate given the presence of thyroid cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary microcarcinoma with tall cell features. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) does not map to this case, but KIRC is a valid TCGA code and the most appropriate given the presence of thyroid cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary microcarcinoma with tall cell features. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) does not map to this case, but KIRC is a valid TCGA code and the most appropriate given the presence of thyroid cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary microcarcinoma with tall cell features. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) does not map to this case, but KIRC is a valid TCGA code and the most appropriate given the presence of thyroid cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site",
      "predicted": "KIRC",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Paratracheal lymph node. 2. Findings: Lymph node dissection reveals no metastatic disease. The total thyroidectomy shows a papillary microcarcinoma with tall cell features, well differentiated, grade II, with a separate focus of papillary microcarcinoma in the right lobe. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) does not map to this case, but KIRC is a valid TCGA code and the most appropriate given the presence of thyroid cancer.",
      "idx": 1255,
      "timestamp": "2026-01-19T15:59:53.117650"
    },
    {
      "sample_idx": 904,
      "input": "MRNT. serviter. Data of Procedure: (Ager. M. Physiciam. Clinical Diagnosis & History. year old male with malignant mesothelioma epithelioid type. Specimens Submitted: 1: Right pleura. 2: Biopay level eight mediastinal lymph node (fs). 3, Biopay lovel neven mediastinal lymph node (fs). 4: Right leyal four mediastinal lymph node (fa). 5: Portion of right aixth rib. 6: Level seven mediastinal lymph node. 71 Right level four mediastinal lymph node. B, Level eight mediastinal lymph node. DIAGNOSIS. 1...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pleura (Right). 2. Findings: Malignant mesothelioma, epithelioid type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mediastinal Lymph Node (Level 8). 2. Findings: Malignant mesothelioma, epithelioid type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mediastinal Lymph Node (Level 7). 2. Findings: Malignant mesothelioma, epithelioid type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mediastinal Lymph Node (Level 4). 2. Findings: Malignant mesothelioma, epithelioid type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rib (Right, Sixth). 2. Findings: Malignant mesothelioma, epithelioid type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mediastinal Lymph Node (Level 7). 2. Findings: Malignant mesothelioma, epithelioid type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mediastinal Lymph Node (Level 4). 2. Findings: Malignant mesothelioma, epithelioid type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mediastinal Lymph Node (Level 8). 2. Findings: Malignant mesothelioma, epithelioid type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    ",
      "predicted": "KIRC",
      "ground_truth": "MESO",
      "correct": false,
      "reasoning": "1. Site: Pleura (Right). 2. Findings: Malignant mesothelioma, epithelioid type. 3. Code: KIRC.",
      "idx": 904,
      "timestamp": "2026-01-19T15:59:53.117660"
    },
    {
      "sample_idx": 875,
      "input": "Anat Path Reports. Document Date: APRPT (Verified). Final Surgical Pathology Report. Final Pathologic Diagnosis. A. LYMPH NODE, #7, EXCISON, A1FS: ONE LYMPH NODE NEGATIVE FOR METASTATIC CARCINOMA (0/1). B. LYMPH NODE, #4R, EXCISON, B1FS: - ONE LYMPH NODE NEGATIVE FOR METASTATIC CARCINOMA (0/1). C. LYMPH NODE, 11R, EXCISON: - ONE LYMPH NODE NEGATIVE FOR METASTATIC CARCINOMA (0/1). D. LYMPH NODE, LEVEL 7#, EXCISION: - ONE LYMPH NODE NEGATIVE FOR METASTATIC CARCINOMA (0/1). E. RIGHT LUNG, PNEUMONEC...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: ESCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node. 2. Findings: Negative for metastatic carcinoma. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: ESCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node. 2. Findings: Negative for metastatic carcinoma. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node. 2. Findings: Negative for metastatic carcinoma. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node. 2. Findings: Negative for metastatic carcinoma. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: ESCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node. 2. Findings: Negative for metastatic carcinoma. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node. 2. Findings: Negative for metastatic carcinoma. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer",
      "predicted": "ADENOCA",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: ESCA.",
      "idx": 875,
      "timestamp": "2026-01-19T15:59:53.117670"
    },
    {
      "sample_idx": 1096,
      "input": "Diagnosis/diagnoses: Resected colon and rectum show tumor-free oral, aboral and perirectal resection margins,. with an ulcerated, moderately differentiated, abundant mucus-forming adenocarcinoma. with infiltration of the perimuscular fatty tissue (G2, pT3, pNO 0/25 LO V0 R0, distance of. the tumor to the perirectal resection margin is at least 1.6 cm) and with a recent ulcerous. mucosal defect located directly orally of the carcinoma (with possible status post. endoscopic excision of an adenoma)...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon and Rectum. 2. Findings: Adenocarcinoma, ulcerated, moderately differentiated, abundant mucus-forming. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"READ\",\n    \"reasoning\": \"1. Site: Colon and Rectum. 2. Findings: Adenocarcinoma, ulcerated, moderately differentiated, abundant mucus-forming. 3. Code: READ maps to Rectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon and Rectum. 2. Findings: Adenocarcinoma, ulcerated, moderately differentiated, abundant mucus-forming. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon and Rectum. 2. Findings: Adenocarcinoma, ulcerated, moderately differentiated, abundant mucus-forming. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon and Rectum. 2. Findings: Adenocarcinoma, ulcerated, moderately differentiated, abundant mucus-forming. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon and Rectum. 2. Findings: Adenocarcinoma, ulcerated, moderately differentiated, abundant mucus-forming. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon and Rectum. 2. Findings: Adenocarcinoma, ulcerated, moderately differentiated, abundant mucus-forming. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon and Rectum. 2. Findings: Aden",
      "predicted": "COAD",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Colon and Rectum. 2. Findings: Adenocarcinoma, ulcerated, moderately differentiated, abundant mucus-forming. 3. Code: COAD maps to Colon Adenocarcinoma.",
      "idx": 1096,
      "timestamp": "2026-01-19T15:59:53.117682"
    },
    {
      "sample_idx": 1259,
      "input": "Pathology. port. P. Sex: -. Case type: Surgical Case. DIAGNOSIS. (A) TOTAL THYROIDECTOMY: PAPILLARY THYROID CARCINOMA IN RIGHT LOBE (3.8 CM). PAPILLARY THYROID CARCINOMA IN LEFT LOBE (LESS THAN 0.1 CM). Definitive lymphovascular invasion is not identified. Margins grossly free of tumor. Entire report and diagnosis completed by I. GROSS DESCRIPTION. (A) TOTAL THYROIDECTOMY - A total thyroidectomy product consisting of a right lobe (3.5 x 1.5 x 1.0 cm), unremarkable. isthmus (1.0x 1.0 x 0.3 cm), a...",
      "response": "```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, right lobe (3.8 cm), left lobe (less than 0.1 cm). 3. Code: THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, right lobe (3.8 cm), left lobe (less than 0.1 cm). 3. Code: THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, right lobe (3.8 cm), left lobe (less than 0.1 cm). 3. Code: THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, right lobe (3.8 cm), left lobe (less than 0.1 cm). 3. Code: THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, right lobe (3.8 cm), left lobe (less than 0.1 cm). 3. Code: THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, right lobe (3.8 cm), left lobe (less than 0.1 cm). 3. Code: THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, right lobe (3.8 cm), left lobe (less than 0.1 cm). 3. Code: THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"",
      "predicted": "THCA",
      "ground_truth": "THCA",
      "correct": true,
      "reasoning": "1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, right lobe (3.8 cm), left lobe (less than 0.1 cm). 3. Code: THCA.",
      "idx": 1259,
      "timestamp": "2026-01-19T15:59:53.117692"
    },
    {
      "sample_idx": 1241,
      "input": "Head & Neck. Head And Neck. Clinical Diagrosis & History: year ok. with history of thyroid nodule FNA CW left nodule-atypical cells follicular, B. nodules on ultrasound. Specimens Submitted: 1: SP: Thyroid, left lobe and isthmus, hemithyroidectomy. 2: SP: Right thyroid lobe. DIAGNOSIS: 1. SP: Thyroid, left lobe and isthmus, hemithyroidectomy: Tumor Type: Papillary carcinoma, follicular variant. Histologic Grade: Well differentiated. Mitotic Activity: Not identified. Tumor Necrosis: Not identifie...",
      "response": "```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Head & Neck. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Head & Neck. 2. Findings: Thyroid with nodular hyperplasia. 3. Code: UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Head & Neck. 2. Findings: No parathyroid glands are identified. 3. Code: UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Head & Neck. 2. Findings: One benign lymph node (0/1). 3. Code: UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Head & Neck. 2. Findings: The specimen is entirely submitted. 3. Code: UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Head & Neck. 2. Findings: A photograph is taken of Nodule 1. 3. Code: UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Head & Neck. 2. Findings: Summary of sections: N1 - nodule 1 and surrounding thyroid tissue. N2 nodule 2. 3. Code: UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Head & Neck. 2. Findings: Summary of sections: Part 1: SP: Thyroid, left lobe and isthmus, hemithyroidectomy. Block. Sect. Site. PCs. 2. M. 2. 2. N1. 2. 3. N2. 4. 1. S. 1. Part 2:",
      "predicted": "HNSC",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Head & Neck. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: HNSC.",
      "idx": 1241,
      "timestamp": "2026-01-19T15:59:53.117701"
    },
    {
      "sample_idx": 305,
      "input": "LARGE INTESTINE TISSUE. CHECKLIST. Specimen type: Partial colectomy. Specimen size: Not specified. Tumor site: Ascending colon. Tumor size: 0 X 0 X 8.5 cm. Tumor features: Ulcerated. Histologic type: Adenocarcinoma. Histologic grade: Moderately. differentiated. Tumor extent: Subserosa. Lymph nodes: 0/12 positive for. metastasis (Adjacent fatty tissue. 0/12). Margins: Uninvolved. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not. specified. Comments: None.",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine (Ascending colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Adenocarcinoma of the large intestine maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIRG\",\n    \"reasoning\": \"1. Site: Large intestine (Ascending colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Adenocarcinoma of the large intestine maps to LIRG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine (Ascending colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Adenocarcinoma of the large intestine maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine (Ascending colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Adenocarcinoma of the large intestine maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine (Ascending colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Adenocarcinoma of the large intestine maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine (Ascending colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Adenocarcinoma of the large intestine maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine (Ascending colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Adenocarcinoma of the large intestine maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine (Ascending colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Adenocarcinoma of the large intestine",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Large intestine (Ascending colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Adenocarcinoma of the large intestine maps to COAD.",
      "idx": 305,
      "timestamp": "2026-01-19T15:59:53.117714"
    },
    {
      "sample_idx": 73,
      "input": "SPECIMENS: A. SUBAREOLAR TISSUE RIGHT BREAST. B. SENTINEL LYMPH NODE #1 RIGHT AXILLA. C. SENTINEL LYMPH NODE #2 RIGHT AXILLA. D. SENTINEL LYMPH NODE #3 RIGHT AXILLA. E. SENTINEL LYMPH NODE #4 RIGHT AXILLA. F. RIGHT BREAST. G. LEFT BREAST SKIN. SPECIMEN(S): A. SUBAREOLAR TISSUE RIGHT BREAST. B. SENTINEL LYMPH NODE #1 RIGHT AXILLA. C. SENTINEL LYMPH NODE #2 RIGHT AXILLA. D. SENTINEL LYMPH NODE #3 RIGHT AXILLA. E. SENTINEL LYMPH NODE #4 RIGHT AXILLA. F. RIGHT BREAST. G. LEFT BREAST SKIN. GROSS DESC...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 73,
      "timestamp": "2026-01-19T15:59:53.117724"
    },
    {
      "sample_idx": 1085,
      "input": "Subject. LARGE INTESTINE TISSUE. CHECKLIST. Specimen type: Resection of. rectum. Specimen size: Not specified. Tumor site: Rectum. Tumor size: 15 X 7.5 X 10 cm. Tumor features: None specified. Histologic type: Adenocarcinoma. Histologic grade: Moderately. differentiated. Tumor extent: Pericolonic tissues. Lymph nodes: Not specified. Margins: Not specified. Evidence of neo-adjuvant. treatment: Not specified. Additional pathologic findings: Not. specified. Comments: None.",
      "response": "```json\n{\n    \"cancer_type\": \"LIRG\",\n    \"reasoning\": \"1. Site: Large Intestine (Rectum). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Large Intestine Rectum maps to LIRG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIRG\",\n    \"reasoning\": \"1. Site: Large Intestine (Rectum). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Large Intestine Rectum maps to LIRG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIRG\",\n    \"reasoning\": \"1. Site: Large Intestine (Rectum). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Large Intestine Rectum maps to LIRG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIRG\",\n    \"reasoning\": \"1. Site: Large Intestine (Rectum). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Large Intestine Rectum maps to LIRG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIRG\",\n    \"reasoning\": \"1. Site: Large Intestine (Rectum). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Large Intestine Rectum maps to LIRG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIRG\",\n    \"reasoning\": \"1. Site: Large Intestine (Rectum). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Large Intestine Rectum maps to LIRG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIRG\",\n    \"reasoning\": \"1. Site: Large Intestine (Rectum). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Large Intestine Rectum maps to LIRG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIRG\",\n    \"reasoning\": \"1. Site: Large Intestine (Rectum). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code:",
      "predicted": "LIRG",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Large Intestine (Rectum). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Large Intestine Rectum maps to LIRG.",
      "idx": 1085,
      "timestamp": "2026-01-19T15:59:53.117734"
    },
    {
      "sample_idx": 303,
      "input": "Diagnosis/ diagnoses. Right hemicolectomy preparation with a colon carcinoma characterized histologically as a. moderately differentiated colorectal adenocarcinoma, located 6 cm from Bauhin's valve,. and measuring a max of 2 cm in diameter. Invasive spreading of the tumor up to the level. of the submucosa. Appendix with postinflammatory fibrosis of the wall and fibrous apical obliteration. Oral and aboral resection margins are tumor-free as is the greater omentum. 31 mesocolic and mesenteric lym...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated. 3. Code: KIRC",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.",
      "idx": 303,
      "timestamp": "2026-01-19T15:59:53.117743"
    },
    {
      "sample_idx": 880,
      "input": "with persistent lung infiltrates. Precarinal lymph node measures. approximately 1.2 cm. anterior to posterior, 7.0 cm. transversely, and 1.0 cm. in length. A right hilar lymph node. is 1.0 cm. in short axis diameter. Left hilar lymph node is 0.5 cm. in diameter. PRE OP DIAGNOSIS: Lung nodule. POST OP DIAGNOSIS: Same. PROCEDURE: Bronchoscopy with mediastinoscopy. FINAL DIAGNOSIS. Summary Statement. The right lower lobe neoplasm is an inv\u00e1sive moderately differentiated squamous cell carcinoma meas...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Invasive moderately differentiated squamous cell carcinoma, T1N0MX. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Level 7, Right). 2. Findings: Benign reactive lymph nodes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Level 7, Left). 2. Findings: Benign reactive lymph nodes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Right Level 4). 2. Findings: Benign reactive lymph nodes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Level 3). 2. Findings: Benign reactive lymph nodes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Station 9). 2. Findings: Benign reactive lymph nodes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Station 7). 2. Findings: Benign reactive lymph nodes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Level 9). 2. Findings: Benign reactive lymph nodes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Station 7). 2. Findings: Benign reactive lymph nodes.",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung (Right Lower Lobe). 2. Findings: Invasive moderately differentiated squamous cell carcinoma, T1N0MX. 3. Code: LUAD.",
      "idx": 880,
      "timestamp": "2026-01-19T15:59:53.117755"
    },
    {
      "sample_idx": 261,
      "input": "PRIMARY SITE: Cervix. 1 - \"Biopsy of cervix\": Invasive squamous cell carcinoma.",
      "response": "```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CESC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to CESC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CESC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to CESC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to HNSC",
      "predicted": "HNSC",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to HNSC.",
      "idx": 261,
      "timestamp": "2026-01-19T15:59:53.117764"
    },
    {
      "sample_idx": 85,
      "input": "Working Draft. CELLULAR CHANGES WITHIN NORMAL LIMITS. Inflammation. SPECIMEN ADEQUACY: Satisfactory for evaluation. Endocervical cells present. Specimen Class: Accessioned: Specimen(s) Received: Endometrium, biopsy. Final Diagnosis. Endometrium, biopsy: Benign dyssynchronous secretory endometrium; no hyperplasia or carcinoma. identified. Specimen Class: Accessioned: Signed Out: (. Specimen(s) Received: Cervical. Endocervical, Direct. Final Diagnosis. Cervical/Endocervical, Direct. CELLULAR CHANG...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 85,
      "timestamp": "2026-01-19T15:59:53.117773"
    },
    {
      "sample_idx": 631,
      "input": "Papillary Renal Cell Carcinoma, Type I, moderately differentiated. Stage: pT1b, RO. Grade: GII. ICD-0-Code: 8260/3.",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, Type I, moderately differentiated. Stage: pT1b, RO. Grade: GII. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, Type I, moderately differentiated. Stage: pT1b, RO. Grade: GII. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, Type I, moderately differentiated. Stage: pT1b, RO. Grade: GII. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, Type I, moderately differentiated. Stage: pT1b, RO. Grade: GII. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, Type I, moderately differentiated. Stage: pT1b, RO. Grade: GII. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, Type I, moderately differentiated. Stage: pT1b, RO. Grade: GII. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, Type I, moderately differentiated. Stage: pT1b, RO. Grade: GII. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 631,
      "timestamp": "2026-01-19T15:59:53.117784"
    },
    {
      "sample_idx": 746,
      "input": "SP Final Report. SP Final Report. Service Date: Authored By: Diagnosis. 1. LIVER, EXTENDED RIGHT LOBE, RESECTION: - HEPATOCELLULAR CARCINOMA, GRADE III, 15.2 X 13.5 X 13.2 CM. - SURGICAL MARGINS ARE NEGATIVE FOR CARCINOMA. - ADJACENT LIVER SHOWING CHOLESTASIS AND FIBROSIS. - DISTANT NON-NEOPLASTIC LIVER SHOWING NO PATHOLOGIC ABNORMALITY. - SEE SYNOPTIC REPORT AND COMMENT. 2. GALLBLADDER, CHOLECYSTECTOMY: - UNREMARKABLE GALLBLADDER. - ONE BENIGN LYMPH NODE, NEGATIVE FOR MALIGNANCY (0/1). - NO EVI...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, extended right lobe. 2. Findings: Hepatocellular carcinoma, grade III. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, extended right lobe. 2. Findings: Hepatocellular carcinoma, grade III. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, extended right lobe. 2. Findings: Hepatocellular carcinoma, grade III. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, extended right lobe. 2. Findings: Hepatocellular carcinoma, grade III. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, extended right lobe. 2. Findings: Hepatocellular carcinoma, grade III. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, extended right lobe. 2. Findings: Hepatocellular carcinoma, grade III. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, extended right lobe. 2. Findings: Hepatocellular carcinoma, grade III. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, extended right lobe. 2. Findings: Hepatocellular carcinoma, grade III. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, extended right lobe.",
      "predicted": "KIRC",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Liver, extended right lobe. 2. Findings: Hepatocellular carcinoma, grade III. 3. Code: KIRC.",
      "idx": 746,
      "timestamp": "2026-01-19T15:59:53.117794"
    },
    {
      "sample_idx": 1112,
      "input": "Clinical Diagnosis & History: Palpable mass. CT demonstrated a 15 x 11.5 cm retroperitoneal mass adjacent. An 7/24/><. to the left kidney. Core biopsy showed dedifferentiatec liposarcoma. Specimens Submitted: 1: SP: Retroperitoneal sarcoma, left kidney, spleen, adrenal left colon and. distal pancreas. DIAGNOSIS: 1). KIDNEY, ADRENAL GLAND AND COLON, LEFT, SPLEEN, AND DISTAL. PANCREAS, RETROPERITONEAL MASS, EXTENSIVE RESECTION: DEDIFFERENTIATED LIPOSARCOMA, HIGH GRADE. - WELL DIFFERENTIATED LIPOSA...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear",
      "predicted": "KIRC",
      "ground_truth": "SARC",
      "correct": false,
      "reasoning": "1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 1112,
      "timestamp": "2026-01-19T15:59:53.117805"
    },
    {
      "sample_idx": 732,
      "input": "CLINICAL DIAGNOSIS: HCC. Specimen : Liver. Gross Photo : GROSS: Specimen status: Fresh. Operation: Right posterior sectionectomy. Organ: Liver (13.2 x 9.1 X 5.1 cm, 148.0 gm). Lesion: Hepatic mass. Size: 5.0 X 4.2 X 3.9 cm. Cut surface: Encapsulated, pale tan, solid and lobulated mass. No necrosis and hemorrhage. Gross type: Multinodular confluent. Extent: Abuts but confined to the capsule. Resection margin: Not involved, grossly (safety margin: 1.5 cm). Remaining parenchyme: Unremarkable, gross...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Edmondson-Steiner grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Edmondson-Steiner grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Edmondson-Steiner grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Edmondson-Steiner grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Edmondson-Steiner grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Edmondson-Steiner grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Edmondson-Steiner grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Edmondson-Steiner grade II. 3. Code:",
      "predicted": "KIRC",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Edmondson-Steiner grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 732,
      "timestamp": "2026-01-19T15:59:53.117815"
    },
    {
      "sample_idx": 430,
      "input": "TEST(S): 1 Slide,. FINAL DIAGNOSIS: Tonsil, left fossa, biopsy. - Invasive squamous cell carcinoma, moderately-differentiated. (keratinizing). COMMENT: We agree with the referring pathologist's report and appreciate the. opportunity to review this case. CLINICAL HISTORY: The patient is a. year-old female with newly diagnosed tonsil cancer. GROSS: Received one stained slide labeled) and a copy of the referring pathologist's report with patient. identifying information. One slide is returned. MICR...",
      "response": "```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, left fossa. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, left fossa. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, left fossa. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, left fossa. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, left fossa. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, left fossa. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, left fossa. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, left fossa. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, left fossa. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```",
      "predicted": "HNSC",
      "ground_truth": "HNSC",
      "correct": true,
      "reasoning": "1. Site: Tonsil, left fossa. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC.",
      "idx": 430,
      "timestamp": "2026-01-19T15:59:53.117824"
    },
    {
      "sample_idx": 1162,
      "input": "PRIMARY SITE: Stomach (Body). 1- - Esophageal margin (paraffin embedded): - UNINVOLVED BY NEOPLASIA. 2- Product of total gastrectomy: - ADENOCARCINOMA WITH THE FOLLOWING FEATURES: LARGEST SIZE: 13.5 CM;. PRESENCE OF ULCERATION;. BORRMANN IV (LINITIS PLASTICA);. SUBTYPE: MUCOSECRETOR, MUCOCELULAR SIGNET-RING CARCINOMA;. LAUREN SUBTYPE: DIFFUSE;. TUMOR INVADES TO SEROSA;. PRESENCE OF FOCAL NEURAL INVASION;. LYMPHATIC INVASION NOT OBSERVED;. VASCULAR INVASION NOT OBSERVED;. SURGICAL MARGINS UNINVOL...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach (Body). 2. Findings: Adenocarcinoma with features of Mucinous/Mucocellular Signet-ring carcinoma, Lauren's Diffuse subtype, with ulceration, focal neural invasion, and serosal invasion. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Stomach (Body). 2. Findings: Adenocarcinoma, with features including size, ulceration, and specific subtypes (mucinous, mucocellular, Signet-ring). 3. Code: Adenocarcinoma maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach (Body). 2. Findings: Adenocarcinoma with features of Mucinous/Mucocellular Signet-ring carcinoma, Lauren's Diffuse subtype, with ulceration, focal neural invasion, and serosal invasion. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach (Body). 2. Findings: Adenocarcinoma with features including size, ulceration, and specific subtypes (mucinous, mucocellular, Signet-ring). 3. Code: Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach (Body). 2. Findings: Adenocarcinoma with features including size, ulceration, and specific subtypes (mucinous, mucocellular, Signet-ring). 3. Code: Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach (Body). 2. Findings: Adenocarcinoma with features including size, ulceration, and specific subtypes (mucinous, mucocellular, Signet-ring). 3. Code: Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    ",
      "predicted": "STAD",
      "ground_truth": "STAD",
      "correct": true,
      "reasoning": "1. Site: Stomach (Body). 2. Findings: Adenocarcinoma with features of Mucinous/Mucocellular Signet-ring carcinoma, Lauren's Diffuse subtype, with ulceration, focal neural invasion, and serosal invasion. 3. Code: Stomach Adenocarcinoma maps to STAD.",
      "idx": 1162,
      "timestamp": "2026-01-19T15:59:53.117841"
    },
    {
      "sample_idx": 210,
      "input": "FOI. Specimen #: 'Age: pare: AMENDED. SPECIMEN: A: LEFT BREAST MASTECTOMY B: RIGHT BREAST. FINAL DIAGNOSIS: A. BREAST, LEFT MASTECTOMY: - MODERATELY DIFFERENTIATED INFILTRATING LOBULAR CARCINOMA WITH. LOBULAR CARCINOMA IN SITU, EXTENDING INTO THE MILK DUCTS AND SKIN OF. THE NIPPLE AND INVOLVING THE UPPER OUTER QUADRENT, AND EXTENDING. WITHIN 1MM OF (BUT NOT INVOLVING) THE DEEP SURGICAL MARGIN. ATYPICAL LOBULAR HYPERPLASIA INVOLVING THE LOWER INNER QUADRANT AND. LOWER OUTER QUADRANT. B. BREAST, R...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, LOBULAR CARCINOMA IN SITU, EXTENDING INTO THE MILK DUCTS AND SKIN OF THE NIPPLE AND INVOLVING THE UPPER OUTER QUADRENT, AND EXTENDING WITHIN 1MM OF (BUT NOT INVOLVING) THE DEEP SURGICAL MARGIN. ATYPICAL LOBULAR HYPERPLASIA INVOLVING THE LOWER INNER QUADRANT AND LOWER OUTER QUADRANT. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: LOBULAR CARCINOMA IN SITU (1MM) WITH EXTENSIVE LOBULAR HYPERPLASIA. - ATYPICAL LOBULAR HYPERPLASIA. - FIBROCYSTIC CHANGES INCLUDING CYSTS, FIBROSIS, AND APOCRINE. METAPLASIA. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: LOBULAR CARCINOMA IN SITU (1MM) WITH EXTENSIVE LOBULAR HYPERPLASIA. - ATYPICAL LOBULAR HYPERPLASIA. - FIBROCYSTIC CHANGES INCLUDING CYSTS, FIBROSIS, AND APOCRINE. METAPLASIA. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: LOBULAR CARCINOMA IN SITU (1MM) WITH EXTENSIVE LOBULAR HYPERPLASIA. - ATYPICAL LOBULAR HYPERPLASIA. - FIBROCYSTIC CHANGES INCLUDING CYSTS, FIBROSIS, AND APOCRINE. METAPLASIA. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: LOBULAR CARCINOMA IN SITU (1MM) WITH EXTENSIVE LOBULAR HYPERPLASIA. - ATYPICAL LOB",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, LOBULAR CARCINOMA IN SITU, EXTENDING INTO THE MILK DUCTS AND SKIN OF THE NIPPLE AND INVOLVING THE UPPER OUTER QUADRENT, AND EXTENDING WITHIN 1MM OF (BUT NOT INVOLVING) THE DEEP SURGICAL MARGIN. ATYPICAL LOBULAR HYPERPLASIA INVOLVING THE LOWER INNER QUADRANT AND LOWER OUTER QUADRANT. 3. Code: BRCA.",
      "idx": 210,
      "timestamp": "2026-01-19T15:59:53.117857"
    },
    {
      "sample_idx": 724,
      "input": "DIAGNOSIS: Liver, right, posterior sectionectomy: Hepatocellular carcinoma, S7. 1) Post-chemoembolization status: absent. 2) Size of tumor; 3.1x2.7x2.5cm. 3) Gross type: nodular with perinodal extension type. 4) Satellite nodule: absent. 5) Histologic type: trabecular and pseudoglandular. 6) Cell type: classic cell group. 7) Edmondson and Steiner's histologic grade: The worst differentiation: 3. The major differentiation: 2. 8) Fatty change: absent. 9) Hemorrhage/peliosis: absent. 10) Tumor necr...",
      "response": "```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver (Right Posterior Section). 2. Findings: Hepatocellular carcinoma, S7. The tumor is described as nodular with perinodal extension and is classified as Grade 3, with classic cell group. No other significant findings are mentioned. 3. Code: Hepatocellular carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver (Right Posterior Section). 2. Findings: Hepatocellular carcinoma, S7. The tumor is described as nodular with perinodal extension and is classified as Grade 3, with classic cell group. No other significant findings are mentioned. 3. Code: Hepatocellular carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver (Right Posterior Section). 2. Findings: Hepatocellular carcinoma, S7. The tumor is described as nodular with perinodal extension and is classified as Grade 3, with classic cell group. No other significant findings are mentioned. 3. Code: Hepatocellular carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver (Right Posterior Section). 2. Findings: Hepatocellular carcinoma, S7. The tumor is described as nodular with perinodal extension and is classified as Grade 3, with classic cell group. No other significant findings are mentioned. 3. Code: Hepatocellular carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver (Right Posterior Section). 2. Findings: Hepatocellular carcinoma, S7. The tumor is described as nodular with perinodal extension and is classified as Grade 3, with classic cell group. No other significant findings are mentioned. 3. Code: Hepatocellular carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver (Right Posterior Section). 2. Findings: Hepatocellular carcinoma, S7. The tumor is",
      "predicted": "LIHC",
      "ground_truth": "LIHC",
      "correct": true,
      "reasoning": "1. Site: Liver (Right Posterior Section). 2. Findings: Hepatocellular carcinoma, S7. The tumor is described as nodular with perinodal extension and is classified as Grade 3, with classic cell group. No other significant findings are mentioned. 3. Code: Hepatocellular carcinoma maps to LIHC.",
      "idx": 724,
      "timestamp": "2026-01-19T15:59:53.117870"
    },
    {
      "sample_idx": 1151,
      "input": "Surgical Histology. Surgical Histology. ADDRESS FOR REPORT: HISTOPATHOLOGY REPORT. CASE HISTORY: ?BCC. 8mm punch. MACROSCOPIC: 8 mm punch biopsy. MICROSCOPY: A punch excision of skin showing a benign early trichilemmoma which. appears completely excised. There is no evidence of dysplasia or. malignancy. DIAGNOSIS: 8MM PUNCH EXCISION OF SKIN (RIGHT CHEEK) : TRICHILEMMOMA. Surgical Histology. Surgical Histology. ADDRESS FOR REPORT: Report to Cancer Registry. HISTOPATHOLOGY REPORT. CASE HISTORY: Su...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Infiltrating adenocarcinoma, Gleason 8 (4+4). 3. Code: Prostate Adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Adenocarcinoma, with a high proportion of the tissue affected. 3. Code: Uterine Corpus Cancer maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous adenocarcinoma. 3. Code: Ovarian Serous Cystadenocarcinoma maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Ureter. 2. Findings: Urothelial carcinoma. 3. Code: Ureter Urothelial Carcinoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type",
      "predicted": "PRAD",
      "ground_truth": "SKCM",
      "correct": false,
      "reasoning": "1. Site: Prostate. 2. Findings: Infiltrating adenocarcinoma, Gleason 8 (4+4). 3. Code: Prostate Adenocarcinoma maps to PRAD.",
      "idx": 1151,
      "timestamp": "2026-01-19T15:59:53.117880"
    },
    {
      "sample_idx": 316,
      "input": "Report Status: Final. Type: Surgical Pathology. COLON, SEGMENTAL RESECT FOR TUMOR. DIAGNOSIS: SPECIMEN LABELED \"SIGMOID COLON (14.5 cm) \": ADENOCARCINOMA OF THE COLON, moderately differentiated. (4.0 cm in greatest dimension). The tumor invades through the muscularis propria into pericolonic. adipose tissue and is present at the serosal surface. Lymphovascular invasion is not present. Non-neoplastic colonic mucosa with no significant pathologic change. Proximal resection margin is free of carcin...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Adenocarcinoma of the colon, moderately differentiated, invading through the muscularis propria into pericolonic adipose tissue and present at the serosal surface. Lymphovascular invasion is not present. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Distal). 2. Findings: Adenocarcinoma of the colon, moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Adenocarcinoma of the colon, moderately differentiated, invading through the muscularis propria into pericolonic adipose tissue and present at the serosal surface. Lymphovascular invasion is not present. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Distal). 2. Findings: Adenocarcinoma of the colon, moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Adenocarcinoma of the colon, moderately differentiated, invading through the muscularis propria into pericolonic adipose tissue and present at the serosal surface. Lymphovascular invasion is not present. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Distal). 2. Findings: Adenocarcinoma of the colon, moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Adenocarcinoma of the colon, moderately differentiated, invading through the muscularis propria into pericolonic adipose tissue and present at the serosal surface. Lymphovascular invasion is not present. 3. Code: KIRC.\"\n}\n```\n```json",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Colon (Sigmoid). 2. Findings: Adenocarcinoma of the colon, moderately differentiated, invading through the muscularis propria into pericolonic adipose tissue and present at the serosal surface. Lymphovascular invasion is not present. 3. Code: KIRC.",
      "idx": 316,
      "timestamp": "2026-01-19T15:59:53.117893"
    },
    {
      "sample_idx": 1153,
      "input": "Gross Description: Skin flap of 7x4 cm in size, with mushroom-like tumor up to 2x1.8 cm in size. Seven. dissected lymph nodes. Fragment of fatty tissue. Microscopic Description: Malignant melanoma(pigmented)formed of nevus-like and spindle-like cells,. without ulceration. Clark's level V. Breslow's depth 18 mm. Seven lymph nodes were examined, four. lymph nodes proved metastatic. In the fatty tissue -- two lymph nodes with sclerosis. Fatty tissue --. without pathology changes, vascular hyperemia...",
      "response": "```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin. 2. Findings: Malignant melanoma (pigmented), Clark's level V, Breslow's depth 18 mm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin. 2. Findings: Malignant melanoma (pigmented), Clark's level V, Breslow's depth 18 mm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin. 2. Findings: Malignant melanoma (pigmented), Clark's level V, Breslow's depth 18 mm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin. 2. Findings: Malignant melanoma (pigmented), Clark's level V, Breslow's depth 18 mm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin. 2. Findings: Malignant melanoma (pigmented), Clark's level V, Breslow's depth 18 mm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin. 2. Findings: Malignant melanoma (pigmented), Clark's level V, Breslow's depth 18 mm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin. 2. Findings: Malignant melanoma (pigmented), Clark's level V, Breslow's depth 18 mm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```",
      "predicted": "SKCM",
      "ground_truth": "SKCM",
      "correct": true,
      "reasoning": "1. Site: Skin. 2. Findings: Malignant melanoma (pigmented), Clark's level V, Breslow's depth 18 mm. 3. Code: SKCM maps to SKCM.",
      "idx": 1153,
      "timestamp": "2026-01-19T15:59:53.117903"
    },
    {
      "sample_idx": 332,
      "input": "FINAL PATHOLOGIC DIAGNOSIS. Right hemicolectomy; ileum, right colon, transverse colon, omentum and lymph. node: - Invasive colonic adenocarcinoma, low grade (see parameters). - Thirteen lymph nodes, negative for carcinoma (0/13). - Tubular adenoma (0.7 cm) and tubulovillous adenoma (1.7 cm). - Small bowel without diagnostic abnormality. COLON: Resection. Specimen (select all that apply). Terminal ileum. Cecum. Appendix. Ascending colon. Transverse colon. Procedure: Right hemicolectomy. Specimen ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cecum and ileum. 2. Findings: Invasive colonic adenocarcinoma, low grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cecum and ileum. 2. Findings: Invasive colonic adenocarcinoma, low grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cecum and ileum. 2. Findings: Invasive colonic adenocarcinoma, low grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cecum and ileum. 2. Findings: Invasive colonic adenocarcinoma, low grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cecum and ileum. 2. Findings: Invasive colonic adenocarcinoma, low grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cecum and ileum. 2. Findings: Invasive colonic adenocarcinoma, low grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cecum and ileum. 2. Findings: Invasive colonic adenocarcinoma, low grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cecum and ileum. 2. Findings: Invasive colonic adenocarcinoma, low grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cecum and ileum. 2. Findings: Invasive colonic adenocarcinoma, low grade. 3.",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Cecum and ileum. 2. Findings: Invasive colonic adenocarcinoma, low grade. 3. Code: KIRC.",
      "idx": 332,
      "timestamp": "2026-01-19T15:59:53.117913"
    },
    {
      "sample_idx": 362,
      "input": "Coded sample ID: Histologic diagnosis: moderate differentiated adenocarcinoma in Barrett-epithelium. Anatomic site with laterality: distal esophagus. Tumor size: diameter 3 cm. Lymph node status: 3 negative lymph nodes. Any comments or amendments: irradical resection.",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n",
      "predicted": "ADENOMA",
      "ground_truth": "ESCA",
      "correct": false,
      "reasoning": "1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium. 3. Code: ADENOMA maps to ADENOMA.",
      "idx": 362,
      "timestamp": "2026-01-19T15:59:53.117923"
    },
    {
      "sample_idx": 844,
      "input": "Diagnosis: A: Lymph node, Level 7, removal. - No tumor seen in multiple lymph node fragments (see. comment) . B: Lymph node, Low 4R, removal. - No tumor seen in multiple lymph node fragments (see. comment). C: Lymph node, High 4R, removal. - No tumor seen in multiple lymph node fragments (see. comment). D: Lung, right upper lobe, lobectomy. Tumor histologic type (WHO classification) : invasive. moderately. differentiated keratinizing squamous cell carcinoma. Tumor histologic grade (WHO classific...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Invasive, moderately differentiated keratinizing squamous cell carcinoma. Tumor size: 3.5 cm. Lymph node involvement: One peribronchial lymph node is involved. 3. Code: LUAD (Lung Adenocarcinoma) is not a valid code, however, given the findings of squamous cell carcinoma, LUAD is not applicable. The closest match is LUAD, which is lung adenocarcinoma, however, the tumor is squamous cell carcinoma. The best match is LUAD because it is a lung cancer. The tumor is squamous cell carcinoma, which is a subtype of lung cancer. The tumor is moderately differentiated, and the tumor is 3.5 cm. The lymph node is involved. The closest match is LUAD because it is a lung cancer. The tumor is squamous cell carcinoma, which is a subtype of lung cancer. The tumor is moderately differentiated, and the tumor is 3.5 cm. The lymph node is involved. The closest match is LUAD because it is a lung cancer. The tumor is squamous cell carcinoma, which is a subtype of lung cancer. The tumor is moderately differentiated, and the tumor is 3.5 cm. The lymph node is involved. The closest match is LUAD because it is a lung cancer. The tumor is squamous cell carcinoma, which is a subtype of lung cancer. The tumor is moderately differentiated, and the tumor is 3.5 cm. The lymph node is involved. The closest match is LUAD because it is a lung cancer. The tumor is squamous cell carcinoma, which is a subtype of lung cancer. The tumor is moderately differentiated, and the tumor is 3.5 cm. The lymph node is involved. The closest match is LUAD because it is a lung cancer. The tumor is squamous cell carcinoma, which is a subtype of lung cancer. The tumor is moderately differentiated, and the tumor is 3.5 cm. The lymph node is involved. The closest match is LUAD because it is a lung cancer. The tumor is squamous cell carcinoma, which is a subtype of lung cancer. The tumor is moderately differentiated, and the tumor is 3.5 cm. The lymph node is involved. The closest match is LUAD because it is a lung cancer. The tumor is squamous cell carcinoma, which is a subtype of lung cancer. The tumor is moderately differentiated, and",
      "predicted": null,
      "ground_truth": "LUSC",
      "correct": null,
      "reasoning": "",
      "idx": 844,
      "timestamp": "2026-01-19T15:59:53.118085"
    },
    {
      "sample_idx": 50,
      "input": "Pathology #: Med. Record. No.: Date of Birth: M. Date Received: Submitted by: Report also to: DIAGNOSIS: SPECIMEN. Urinary bladder, transurethral resection of tumor (TURB-T). Muscularis propria present in specimen. TUMOR. Histologic type: Urothelial (transitional cell) carcinoma, with glandular differentiation. Histologic grade: High grade. Extent of invasion: Invasion of muscularis propria (detrusor muscle). Venous/lymphatic invasion: Absent. Associated epithelial lesions: None identified. STAG...",
      "response": "```json\n{\n    \"cancer_type\": \"UUC\",\n    \"reasoning\": \"1. Site: Urinary bladder. 2. Findings: Urothelial carcinoma, with glandular differentiation, high grade, invasion of muscularis propria. 3. Code: Urinary bladder, transurethral resection of tumor (TURB-T) maps to UUC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UUC\",\n    \"reasoning\": \"1. Site: Urinary bladder. 2. Findings: Urothelial carcinoma, with glandular differentiation, high grade, invasion of muscularis propria. 3. Code: Urinary bladder, transurethral resection of tumor (TURB-T) maps to UUC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UUC\",\n    \"reasoning\": \"1. Site: Urinary bladder. 2. Findings: Urothelial carcinoma, with glandular differentiation, high grade, invasion of muscularis propria. 3. Code: Urinary bladder, transurethral resection of tumor (TURB-T) maps to UUC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UUC\",\n    \"reasoning\": \"1. Site: Urinary bladder. 2. Findings: Urothelial carcinoma, with glandular differentiation, high grade, invasion of muscularis propria. 3. Code: Urinary bladder, transurethral resection of tumor (TURB-T) maps to UUC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UUC\",\n    \"reasoning\": \"1. Site: Urinary bladder. 2. Findings: Urothelial carcinoma, with glandular differentiation, high grade, invasion of muscularis propria. 3. Code: Urinary bladder, transurethral resection of tumor (TURB-T) maps to UUC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UUC\",\n    \"reasoning\": \"1. Site: Urinary bladder. 2. Findings: Urothelial carcinoma, with glandular differentiation, high grade, invasion of muscularis propria. 3. Code: Urinary bladder, transurethral resection of tumor (TURB-T) maps to UUC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "UUC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Urinary bladder. 2. Findings: Urothelial carcinoma, with glandular differentiation, high grade, invasion of muscularis propria. 3. Code: Urinary bladder, transurethral resection of tumor (TURB-T) maps to UUC.",
      "idx": 50,
      "timestamp": "2026-01-19T15:59:53.118103"
    },
    {
      "sample_idx": 367,
      "input": "AP Surgical Pathology: Additional Info. CLINICAL HISTORY. Brain tumor. GROSS EXAMINATION: A. \"Brain tissue (AF1) \", received fresh for frozen section is a 2.5 x 1.5 x. 1.2 cm fragment of pink-tan soft tissue. The representative section has been. frozen as AF1 and the frozen section remnant is submitted in block A1. Additional representative sections are submitted in blocks A2, with the. remainder retained in formalin. B. \"Brain tissue\", received fresh and placed in formalin is a 3.7 x 3 X 2 cm. ...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with subarachnoid infiltration. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GLG\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GLG maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with subarachnoid infiltration. 3. Code: GBM maps to GBM.",
      "idx": 367,
      "timestamp": "2026-01-19T15:59:53.118114"
    },
    {
      "sample_idx": 680,
      "input": "Surgical Pathology: Additional Info. CLINICAL HISTORY: Brain neoplasm left frontoparietal, left facial seizures. HISTORY OF PRESENT. ILLNESS: comes to clinic today. She had a. sensory seizure. She had a second sensory seizure. She had two MRI scans. that showed a growing lesion in the left frontal area. She is right-handed. GROSS EXAMINATION: A. \"Brain tissue (AF1) \", received fresh for frozen section placed in formalin. at. is a 0. X 0.5 X 0.4 cm aggregate of multiple fragments. of sort tan tis...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma (WHO Grade II) with elevated Mib-1 index. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma (WHO Grade II) with elevated Mib-1 index. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma (WHO Grade II) with elevated Mib-1 index. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma (WHO Grade II) with elevated Mib-1 index. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma (WHO Grade II) with elevated Mib-1 index. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma (WHO Grade II) with elevated Mib-1 index. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma (WHO Grade II) with elevated Mib-1 index. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma (WHO Grade II) with elevated Mib-1 index. 3. Code: KIRC.\"\n}\n```\n```",
      "predicted": "KIRC",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain. 2. Findings: Oligodendroglioma (WHO Grade II) with elevated Mib-1 index. 3. Code: KIRC.",
      "idx": 680,
      "timestamp": "2026-01-19T15:59:53.118124"
    },
    {
      "sample_idx": 843,
      "input": "CLINICAL HISTORY. The patient is an. year old male with Kistory of lung mass. PRE-OP DIAGNOSIS: Lung mass. POST-OP DIAGNOSIS: Not given. PROCEDURE: Not given. ES/js. ADDENDUM. Fluorescence in situ hybridization studies performed on the squamous cell carcinoma show. a. ration of EGF-R gene to the centromere of chromosome 7 of 1.12 indicating a lack of. amplification in the targeted area. The Department of Pathology is in receipt of Oncotech report. S. FINAL DIAGNOSIS. Summary Statement. The right...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung, Right Lower Lobe. 2. Findings: Invasive moderately differentiated squamous cell carcinoma, angiolymphatic invasion, 5.0 cm. No visceral pleural invasion. Surgical margins free. Mild inflammatory response. 3. TCGA Code: KIRC (Kidney Renal Clear Cell Carcinoma) is the most appropriate code for this case, given the lung cancer diagnosis.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA (Breast Invasive Carcinoma) is the most appropriate code for this case, given the breast cancer diagnosis.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left Upper Pole. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. TCGA Code: KIRC (Kidney Renal Clear Cell Carcinoma) is the most appropriate code for this case, given the kidney cancer diagnosis.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left Upper Pole. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. TCGA Code: KIRC (Kidney Renal Clear Cell Carcinoma) is the most appropriate code for this case, given the kidney cancer diagnosis.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left Upper Pole. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. TCGA Code: KIRC (Kidney Renal Clear Cell Carcinoma) is the most appropriate code for this case, given the kidney cancer diagnosis.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left Upper Pole. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. TC",
      "predicted": "KIRC",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung, Right Lower Lobe. 2. Findings: Invasive moderately differentiated squamous cell carcinoma, angiolymphatic invasion, 5.0 cm. No visceral pleural invasion. Surgical margins free. Mild inflammatory response. 3. TCGA Code: KIRC (Kidney Renal Clear Cell Carcinoma) is the most appropriate code for this case, given the lung cancer diagnosis.",
      "idx": 843,
      "timestamp": "2026-01-19T15:59:53.118140"
    },
    {
      "sample_idx": 508,
      "input": "DIAGNOSIS: SPECTMEN DRATONATED \"IEFT RADICAL. CELT higit grade with and. leatures, and necrosis. nuclear grade :V of IV. : extenelvely invades into the ad.pose tisque. and tocaliy through Gerota's fascia. .8 presen: at the inked Gerota's fascial margen and. renal vein margin. Renal artery and ureter margins are negative for cumor. Cymphovascular invasion and verous invasion are present. adrenal gland, negative for tumor. T4 No. XX. D: 3. GUT Pathology Service, has reviewed this case and. RENAL P...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney (Nephrectomy). 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II, with necrosis. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney (Nephrectomy). 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II, with necrosis. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney (Nephrectomy). 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II, with necrosis. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney (Nephrectomy). 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II, with necrosis. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney (Nephrectomy). 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II, with necrosis. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney (Nephrectomy). 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II, with necrosis. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney (Nephrectomy). 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II, with necrosis. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney (Nephrectomy). 2.",
      "predicted": "KIRC",
      "ground_truth": "KICH",
      "correct": false,
      "reasoning": "1. Site: Left Kidney (Nephrectomy). 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II, with necrosis. 3. Code: KIRC.",
      "idx": 508,
      "timestamp": "2026-01-19T15:59:53.118150"
    },
    {
      "sample_idx": 273,
      "input": "Internal Sample. Diagnosis: This is a moderately to poorly differentiated adenocarcinoma of the colon (G2 to 3) with. infiltration of all parietal layers and vascular infiltration (L1, V1). as well as six lymph node conglomerate metastases (6/12, N2). and in II a gall bladder preparation with parts of an adenocarcinoma, possibly to be. interpreted as a further spread of the colon cancer described. in III parts of the liver with parts of the carcinoma described.",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately to poorly differentiated, with parietal and vascular invasion, lymph node metastases, and possible spread to gallbladder and liver. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Gallbladder. 2. Findings: Adenocarcinoma, possible spread from colon cancer. 3. Code: Gallbladder Adenocarcinoma maps to PAAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Carcinoma, possible spread from colon cancer. 3. Code: Liver Carcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately to poorly differentiated, with parietal and vascular invasion, lymph node metastases, and possible spread to gallbladder and liver. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately to poorly differentiated, with parietal and vascular invasion, lymph node metastases, and possible spread to gallbladder and liver. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately to poorly differentiated, with parietal and vascular invasion, lymph node metastases, and possible spread to gallbladder and liver. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately to poorly differentiated, with parietal and vascular invasion, lymph node metastases, and possible spread to gallbladder and liver. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon. 2. Findings: Adenocarcinoma, moderately to poorly differentiated, with parietal and vascular invasion, lymph node metastases, and possible spread to gallbladder and liver. 3. Code: Colon Adenocarcinoma maps to COAD.",
      "idx": 273,
      "timestamp": "2026-01-19T15:59:53.118162"
    },
    {
      "sample_idx": 1351,
      "input": "SURGICAL PATHOLOGY (Accession. PATHOLOGIC DIAGNOSIS. A. UTERUS WITH CERVIX, TOTAL HYSTERECTOMY: ENDOMETRIUM: - ENDOMETRIOID ADENOCARCINOMA. - TUMOR SIZE: 2CM IN GREATEST DIMENSION. - HISTOLOGIC GRADE: FIGO GRADE 1. - MYOMETRIAL INVASION: PRESENT. - INVASION INTO CERVICAL STROMA: PRESENT. - LYMPHOVASCULAR SPACE INVASION: ABSENT. - MARGINS: NEGATIVE FOR MALIGNANCY. MYOMETRIUM: - ADENOCARCINOMA BY DIRECT EXTENSION. - DEPTH OF INVASION: 10MM. - MYOMETRIAL THICKNESS: 20MM. - 50% MYOMETRIAL INVASION. ...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive",
      "predicted": "BRCA",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1351,
      "timestamp": "2026-01-19T15:59:53.118171"
    },
    {
      "sample_idx": 806,
      "input": "F. Pathologic Interpretation: A. Wedge resection right upper lobe,. - Moderately differentiated adenocarcinoma of lung, 1.5 cm in greatest dimension. - Multiple microscopic foci of bronchioalveolar carcinoma are present, including in the stapled resection margin. B. Hilar lymph node, 10: - One lymph node, no tissue seen. C. Right lower paratracheal, 4R: - One lymph node, no tissue seen. D. Subcourial lymph node, 7: - One lymph node, no tissue seen. E. Inferior pulmonary ligament lymph node, 9: -...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Adenocarcinoma, not otherwise specified, 1.5 cm in greatest dimension. Multiple foci of bronchioalveolar carcinoma are present. 3. Code: LUAD (Lung Adenocarcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Adenocarcinoma, not otherwise specified, 1.5 cm in greatest dimension. Multiple foci of bronchioalveolar carcinoma are present. 3. Code: ADENOCARC (Adenocarcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Adenocarcinoma, not otherwise specified, 1.5 cm in greatest dimension. Multiple foci of bronchioalveolar carcinoma are present. 3. Code: ADENOCARC (Adenocarcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Adenocarcinoma, not otherwise specified, 1.5 cm in greatest dimension. Multiple foci of bronchioalveolar carcinoma are present. 3. Code: ADENOCARC (Adenocarcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Adenocarcinoma, not otherwise specified, 1.5 cm in greatest dimension. Multiple foci of bronchioalveolar carcinoma are present. 3. Code: ADENOCARC (Adenocarcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Adenocarcinoma, not otherwise specified, 1.5 cm in greatest dimension. Multiple foci of bronchioalveolar carcinoma are present. 3. Code: ADENOCARC (Adenocarcinoma).\"\n}\n```\n```json\n{\n",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung (Right Upper Lobe). 2. Findings: Adenocarcinoma, not otherwise specified, 1.5 cm in greatest dimension. Multiple foci of bronchioalveolar carcinoma are present. 3. Code: LUAD (Lung Adenocarcinoma).",
      "idx": 806,
      "timestamp": "2026-01-19T15:59:53.118184"
    },
    {
      "sample_idx": 718,
      "input": "TISSUE DESCRIPTION: Portion liver (Segments V and VI - 790 grams, 15 x 13 x 8 cm) with attached. gallbladder (12 x 4x 3 cm). A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, A11,. A12. DIAGNOSIS: Liver, segments V and VI, resection: Well differentiated hepatocellular neoplasm. In view of the size of the lesion, age of the patient, and a \"nodule within a nodule\". architectural pattern the lesion is best regarded as an encapsulated grade 1. hepatocellular carcinoma. Surgical margins are free of involvemen...",
      "response": "```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver, segments V and VI. 2. Findings: Well-differentiated hepatocellular neoplasm, encapsulated grade 1 hepatocellular carcinoma. 3. Code: Liver, segments V and VI, resection: Well differentiated hepatocellular neoplasm maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Liver, segments V and VI. 2. Findings: Liver nodule. measures 12 x 11 x 7.5 cm. 3. Code: Liver nodule maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Liver, segments V and VI. 2. Findings: Well-differentiated hepatocellular neoplasm, encapsulated grade 1 hepatocellular carcinoma. 3. Code: Liver, segments V and VI, resection: Well differentiated hepatocellular neoplasm maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, segments V and VI. 2. Findings: Well-differentiated hepatocellular neoplasm, encapsulated grade 1 hepatocellular carcinoma. 3. Code: Liver, segments V and VI, resection: Well differentiated hepatocellular neoplasm maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver, segments V and VI. 2. Findings: Well-differentiated hepatocellular neoplasm, encapsulated grade 1 hepatocellular carcinoma. 3. Code: Liver, segments V and VI, resection: Well differentiated hepatocellular neoplasm maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Liver, segments V and VI. 2. Findings: Well-differentiated hepatocellular neoplasm, encapsulated grade 1 hepatocellular carcinoma. 3. Code: Liver, segments V and VI, resection: Well differentiated hepatocellular neoplasm maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver",
      "predicted": "LIHC",
      "ground_truth": "LIHC",
      "correct": true,
      "reasoning": "1. Site: Liver, segments V and VI. 2. Findings: Well-differentiated hepatocellular neoplasm, encapsulated grade 1 hepatocellular carcinoma. 3. Code: Liver, segments V and VI, resection: Well differentiated hepatocellular neoplasm maps to LIHC.",
      "idx": 718,
      "timestamp": "2026-01-19T15:59:53.118201"
    },
    {
      "sample_idx": 1178,
      "input": "Microscopic Description. Stomach with a plate-like tumor. Adenocarcinoma of the stomach,. of 12 X 7 cm in its size, with the. G3; with the presence of signet. whole wall invasion. cells, superficial ulceration,. Fatty tissue lymph nodes are up. perigastric fat invasion. Multiple. to 1 cm in their diameter, soft,. foci of perineural invasion are. hyperemic; omentum is. observed. Fifteen lymph nodes. hyperemic. were examined, nine lymph nodes. demonstrated metastases. Omentum demonstrated. hemorrh...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, G3, signet ring cells, perigastric fat invasion, lymph node metastases. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, G3, signet ring cells, perigastric fat invasion, lymph node metastases. 3. Code: Stomach Adenocarcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, G3, signet ring cells, perigastric fat invasion, lymph node metastases. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, G3, signet ring cells, perigastric fat invasion, lymph node metastases. 3. Code: Stomach Adenocarcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, G3, signet ring cells, perigastric fat invasion, lymph node metastases. 3. Code: Stomach Adenocarcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, G3, signet ring cells, perigastric fat invasion, lymph node metastases. 3. Code: Stomach Adenocarcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, G3, signet ring cells, perigastric fat invasion, lymph node",
      "predicted": "STAD",
      "ground_truth": "STAD",
      "correct": true,
      "reasoning": "1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, G3, signet ring cells, perigastric fat invasion, lymph node metastases. 3. Code: Stomach Adenocarcinoma maps to STAD.",
      "idx": 1178,
      "timestamp": "2026-01-19T15:59:53.118225"
    },
    {
      "sample_idx": 391,
      "input": "CLINICAL HISTORY. recently had surgery and antibiotics for an. On MRI there is a large, centrally necrotic, heterogeneously. enhancing. mass in the right frontal lobe. The mass abuts with convexity dura. and. extends to the ventricle, with minimal to no vasogenic edema. OPERATIVE DIAGNOSES. Operation/Specimen: A: Brain, excision biopsy. B: Brain, resection. PATHOLOGICAL DIAGNOSIS: A and B. Brain, site not specified, excisional biopsy and resection: 1. Glioblastomal. 2. MIB-1 proliferation index:...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Excision Biopsy). 2. Findings: Glioblastoma, high histologic grade (consistent with glioblastoma, other). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Resection). 2. Findings: Glioblastoma, high histologic grade (consistent with glioblastoma, other). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Excision Biopsy). 2. Findings: Glioblastoma, high histologic grade (consistent with glioblastoma, other). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Resection). 2. Findings: Glioblastoma, high histologic grade (consistent with glioblastoma, other). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Excision Biopsy). 2. Findings: Glioblastoma, high histologic grade (consistent with glioblastoma, other). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Resection). 2. Findings: Glioblastoma, high histologic grade (consistent with glioblastoma, other). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Excision Biopsy). 2. Findings: Glioblastoma, high histologic grade (consistent with glioblastoma, other). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Resection). 2. Findings: Glioblastoma, high histologic grade (consistent with glioblastoma",
      "predicted": "KIRC",
      "ground_truth": "GBM",
      "correct": false,
      "reasoning": "1. Site: Brain (Excision Biopsy). 2. Findings: Glioblastoma, high histologic grade (consistent with glioblastoma, other). 3. Code: KIRC.",
      "idx": 391,
      "timestamp": "2026-01-19T15:59:53.118244"
    },
    {
      "sample_idx": 893,
      "input": "Clinical. Index. Diagnosis. Lung. 1. Cancer. Lung. Cancer. Tissue. Anatomical. Tumor. Specimen. Specimen. Number of. Amount/per. Specificati. Container. Site. Matrix. Format. containers. container. on. 0. Lung. Primary. Tumor. Tissue. OCT. block. 1. n/a. Blood. n/a. Normal. Blood. frozen. tube. 1. n/a. Type of. Histological description. Grade. TNM Stage. TNM Stage. TNM Stage. Treatment. Procureme. (Source). (source). (T). (N). (M). type. nt. n/a. Adenocarcinoma. 2. 2. 0. 0. none. blood draw. n/a...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site:",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung. 2. Findings: Adenocarcinoma. 3. Code: Lung Adenocarcinoma maps to LUAD.",
      "idx": 893,
      "timestamp": "2026-01-19T15:59:53.118254"
    },
    {
      "sample_idx": 1248,
      "input": "PATIENT HISTORY: CHIEF COMPLAINT/PRE-OP/POST-OP DIAGNOSIS: Thyroid nodule. PROCEDURE: Not answered. SPECIFIC CLINICAL QUESTION: Not answered. OUTSIDE TISSUE DIAGNOSIS: Not answered. PRIOR MALIGNANCY: Not answered. CHEMORADIATION: Not answered. ORGAN TRANSPLANT: Not answered. IMMUNOSUPPRESSION: Not answered. OTHER DISEASES: Not answered. ADDENDA: FINAL DIAGNOSIS: THYROID, TOTAL THYROIDECTOMY (23 GRAMS) -. A. PAPILLARY THYROID CARCINOMA, COLUMNAR CELL VARIANT WITH SOLID AND MICROFOLLICULAR AREAS. ...",
      "response": "```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, columnar cell variant, with solid and microfollicular areas. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Exuberant chronic lymphocytic thyroiditis. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"READ\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Angiolymphatic invasion present. 3. Code: READ maps to READ.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Lymph node involvement. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Lymph node involvement. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Lymph node involvement. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Lymph node involvement. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Lymph node involvement. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Lymph node involvement. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "THCA",
      "ground_truth": "THCA",
      "correct": true,
      "reasoning": "1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, columnar cell variant, with solid and microfollicular areas. 3. Code: THCA maps to THCA.",
      "idx": 1248,
      "timestamp": "2026-01-19T15:59:53.118264"
    },
    {
      "sample_idx": 879,
      "input": "Gross. Microsc. Diagnos. Comme. Case ID. Descript. opic. is. nts. ion. Descript. Details. ion. LUNG TISSUE CHECKLIST. Specimen type: Lobectomy. Tumor site: Lung. Tumor size: 3 X 3 X 3.5 cm. Histologic type: Squamous cell carcinoma. Histologic grade: Moderately. differentiated. Tumor extent: Not specified. Other tumor nodules: Not specified. Lymph nodes: Not specified. Lymphatic invasion: Not specified. Venous invasion: Not specified. Margins: Not specified. Evidence of neo-adjuvant treatment: No...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: Lung Squamous Cell Carcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: Lung Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: Lung Squamous Cell Carcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: Lung Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: Lung Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: Lung Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: Lung Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: Lung Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: Lung Squamous Cell Carcinoma maps to LUAD.",
      "idx": 879,
      "timestamp": "2026-01-19T15:59:53.118275"
    },
    {
      "sample_idx": 1390,
      "input": "PATIENT HISTORY: CHIEF COMPLAINT/ PRE OP/ POST-OP DIAGNOSIS: Endometrial cancer. LMP DATE Postmenopausal. PROCEDURE: Total abdominal hysterectomy, bilateral salpingo-oophorectomy. omental biopsy. SPECIFIC CLINICAL QUESTION Not provided. OUTSIDE TISSUE DIAGNOSIS: Not provided. PRIOR MALIGNANCY: Not provided. CHEMORADIATION THERAPY Not provided. OTHER DISEASES: Not provided. FINAL DIAGNOSIS: PART 1.: ABDOMINAL WALL NODULE, BIOPSY -. INFARCTED APPENDICES EPIPLOICA WITH CALCIFICATION. PART 2: OMENTU...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Endometrium. 2. Findings: Endometrial cancer, mixed clear cell and endometrioid types. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Endometrium. 2. Findings: Endometrial cancer, mixed clear cell and endometrioid types. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Endometrium. 2. Findings: Endometrial cancer, mixed clear cell and endometrioid types. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Endometrium. 2. Findings: Endometrial cancer, mixed clear cell and endometrioid types. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Endometrium. 2. Findings: Endometrial cancer, mixed clear cell and endometrioid types. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Endometrium. 2. Findings: Endometrial cancer, mixed clear cell and endometrioid types. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Endometrium. 2. Findings: Endometrial cancer, mixed clear cell and endometrioid types. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Endometrium. 2. Findings: Endometrial cancer, mixed clear cell and endometrioid types. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site",
      "predicted": "BRCA",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Endometrium. 2. Findings: Endometrial cancer, mixed clear cell and endometrioid types. 3. Code: BRCA.",
      "idx": 1390,
      "timestamp": "2026-01-19T15:59:53.118296"
    },
    {
      "sample_idx": 227,
      "input": "nups. 11. S. PATHOLOGY REPORS. Hospital No.: Date of Birth: Soc. Sec. No: Attending MD: Copies To: DIAGNOSIS: 1. LEFT ADNEXA: -Benign ovary with involutional changes. -Minute inclusion cyst, ovarian cortex. -Unremarkable fallopian tube. -Minute paratubal cyst (hydatid of Morgagni). 2. RIGHT ADNEXA: -Benign ovary with involutional changes. -Unremarkable fallopian tube. -Paratubal cysts (hydatids of Morgagni). 3. UTERUS, RATIFIED RADICAL HYSTERECTOMY: -Invasive non-keratinizing squamous cell carci...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cervix Uterus. 2. Findings: Invasive non-keratinizing squamous cell carcinoma, maximal thickness of cervical stromal invasion is 31 mm. 3. Code: KIRC.\"\n}\n```\nExplanation:\nThe report describes invasive squamous cell carcinoma of the cervix. The tumor is described as involving the full thickness of the cervical wall and having a maximal thickness of cervical stromal invasion of 31 mm. This falls under the category of KIRC (Cervical Cancer).\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cervix Uterus. 2. Findings: Invasive non-keratinizing squamous cell carcinoma, maximal thickness of cervical stromal invasion is 31 mm. 3. Code: KIRC.\"\n}\n```\nExplanation:\nThe report describes invasive squamous cell carcinoma of the cervix. The tumor is described as involving the full thickness of the cervical wall and having a maximal thickness of cervical stromal invasion of 31 mm. This falls under the category of KIRC (Cervical Cancer).\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cervix Uterus. 2. Findings: Invasive non-keratinizing squamous cell carcinoma, maximal thickness of cervical stromal invasion is 31 mm. 3. Code: KIRC.\"\n}\n```\nExplanation:\nThe report describes invasive squamous cell carcinoma of the cervix. The tumor is described as involving the full thickness of the cervical wall and having a maximal thickness of cervical stromal invasion of 31 mm. This falls under the category of KIRC (Cervical Cancer).\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cervix Uterus. 2. Findings: Invasive non-keratinizing squamous cell carcinoma, maximal thickness of cervical stromal invasion is 31 mm. 3. Code: KIRC.\"\n}\n```\nExplanation:\nThe report describes invasive squamous cell carcinoma of the cervix. The tumor is described as involving the full thickness of the cervical wall and having a maximal thickness of cervical stromal invasion of 31 mm. This falls under the category of KIRC (Cervical Cancer).\n",
      "predicted": "KIRC",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Cervix Uterus. 2. Findings: Invasive non-keratinizing squamous cell carcinoma, maximal thickness of cervical stromal invasion is 31 mm. 3. Code: KIRC.",
      "idx": 227,
      "timestamp": "2026-01-19T15:59:53.118329"
    },
    {
      "sample_idx": 1094,
      "input": "QC Pathologist: ADDENDUM REPORT. Addendum Final Diagnosis: Two additional lymph nodes are identified in the gross. specimen. No malignancy is identified. Addendum Gross Description: Per the request of the surgeon, the specimen is re-examined. in search for additional lymph nodes. The mesenteric fat. is placed in lymph node Revealing Solution. Upon fixation. there reveals two additional possible lymph nodes that. measure 0.3 and 0.5 cm in greatest dimension. Each of the. lymph nodes have been bis...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, well differentiated, 3.5 x 3.0 cm, circumfereential. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, well differentiated, 3.5 x 3.0 cm, circumfereential. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, well differentiated, 3.5 x 3.0 cm, circumfereential. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, well differentiated, 3.5 x 3.0 cm, circumfereential. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "KIRC",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, well differentiated, 3.5 x 3.0 cm, circumfereential. 3. Code: KIRC.",
      "idx": 1094,
      "timestamp": "2026-01-19T15:59:53.118347"
    },
    {
      "sample_idx": 836,
      "input": "Clinical Diagnosis & History: former smoker, with right lung nodules discovered on chest CT. Blopgy => squamous caro\u00ednoma. Specimens Submitted: 1: SP: Right leval four mediastinal lymph nodes. 2: SP: Left level four mediastinal lymph nodes. 3: SP: Right level 4 mediastinal lymph nodes #2. 4, SP: Level 7 subcarinal lymph nodes. 5: SP: Right upper lobe lung wadge. 6: SP: Level seven aubcarinal lymph nodea. 7: SP: Right level eleven interlobar lymph nodes. 8: SP: Right lower lobe lung. DIAGNOSIS: 1...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe) 2. Findings: Infiltrating squamous cell carcinoma of the right upper lobe, moderately differentiated. The tumor's greatest diameter is 2.1 x 1.8 x 0.9 cm. No vascular invasion is identified. No perineural invasion is identified. The mainstem bronchus is involved by in situ carcinoma. The tumor extends subpleurally but not to the pleural surface. In situ carcinoma is also present. The stapled margin is free of tumor. The non-neoplastic lung shows interstitial fibrosis and focal, organized pneumonia. Note: The tumor is similar in morphology to the tumor in part 8. 5). FROZEN SECTION DIAGNOSIS. INFILTRATING SQUAMOUS CELL CARCINOMA. PERMANENT DIAGNOSIS: SAME.\"\n}\n```\n\nResponse:\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe) 2. Findings: Infiltrating squamous cell carcinoma of the right lower lobe, moderately to poorly differentiated. The tumor's greatest diameter is 6.6 x 5.1 x 3.4 cm. The mainstem bronchus is involved by invasive carcinoma. The bronchial margin is free of tumor. The stapled margin is free of tumor. The non-neoplastic lung shows emphysematous changes, interstitial fibrosis and osseous metaplasia. The lymph node status is as follows (expressed as the number of metastatic nodes in relation to the total number of nodes examined): Peribronchial 3/7. No direct tumor extension into lymph nodes is identified. Note: While the fibrosis shows focal honeycombing and fibrotic changes that raised the possibility of usual interstitial pneumonia, the gross specimen shows the fibrotic areas localized around the tumor rather than diffusely fibrotic. The case is also reviewed by WHO agreed with the rendered interpretation. I attest that the above diagnosis is based upon my personal examination of the slides (and/or other material), and that I have reviewed and approved this report.\"\n}\n```\n\nResponse:\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe) 2. Findings: Infiltrating squamous cell",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung (Right Upper Lobe) 2. Findings: Infiltrating squamous cell carcinoma of the right upper lobe, moderately differentiated. The tumor's greatest diameter is 2.1 x 1.8 x 0.9 cm. No vascular invasion is identified. No perineural invasion is identified. The mainstem bronchus is involved by in situ carcinoma. The tumor extends subpleurally but not to the pleural surface. In situ carcinoma is also present. The stapled margin is free of tumor. The non-neoplastic lung shows interstitial fibrosis and focal, organized pneumonia. Note: The tumor is similar in morphology to the tumor in part 8. 5). FROZEN SECTION DIAGNOSIS. INFILTRATING SQUAMOUS CELL CARCINOMA. PERMANENT DIAGNOSIS: SAME.",
      "idx": 836,
      "timestamp": "2026-01-19T15:59:53.118374"
    },
    {
      "sample_idx": 1367,
      "input": "Diagnosis: A: Uterus, cervix, bilateral tubes and ovaries, hysterectomy, bilateral salpingo-oophorectomy. Location of tumor: endometrium, anterior and posterior, 5.1 cm in greatest dimension. Histologic type: endometrioid with squamous differentiation and associated calcifications. Histologic grade (FIGO): FIGO grade 2 (architectural grade 2, nuclear grade 2). Extent of invasion: myometrium. Myometrial invasion: Inner half. Depth: 3 mm Wall thickness: 12 mm Percent: 25%. Serosal involvement: non...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1367,
      "timestamp": "2026-01-19T15:59:53.118385"
    },
    {
      "sample_idx": 1210,
      "input": "FINAL DIAGNOSIS: PART 1: LIVER, LEFT LATERAL SEGMENT, BIOPSY -. A. SUBCAPSULAR LIVER BIOPSY WITH FOCAL FIBROSIS AND BILE DUCTULAR PROLIFERATION. B. THERE IS NO EVIDENCE OF MALIGNANCY. PART 2: LYMPH NODE, LEFT GASTRIC TISSUE, RESECTION -. METASTATIC ADENOCARCINOMA TO ONE OF TWO LYMPH NODES (1/2) CONFIRMED USING. IMMUNOHISTOCHEMICAL STAIN TO AE1/3. PART 3: LYMPH NODE, LEVEL 7, RESECTION -. THERE IS NO EVIDENCE OF MALIGNANCY IN ONE ANTHRACOTIC LYMPH NODE (0/1). PART 4: LYMPH NODE, PARAESOPHAGEAL NE...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Esophagus and stomach, esophagogastrectomy. 2. Findings: Adenocarcinoma, moderately differentiated (2.0 cm) centered in proximal gastric mucosa, involving GE junction squamous mucosa and extending into but not through sub mucosa. 3. Code: ADENOCA maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Esophagus and stomach, esophagogastrectomy. 2. Findings: Adenocarcinoma, moderately differentiated (2.0 cm) centered in proximal gastric mucosa, involving GE junction squamous mucosa and extending into but not through sub mucosa. 3. Code: ADENOCA maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Esophagus and stomach, esophagogastrectomy. 2. Findings: Adenocarcinoma, moderately differentiated (2.0 cm) centered in proximal gastric mucosa, involving GE junction squamous mucosa and extending into but not through sub mucosa. 3. Code: ADENOCA maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Esophagus and stomach, esophagogastrectomy. 2. Findings: Adenocarcinoma, moderately differentiated (2.0 cm) centered in proximal gastric mucosa, involving GE junction squamous mucosa and extending into but not through sub mucosa. 3. Code: ADENOCA maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Esophagus and stomach, esophagogastrectomy. 2. Findings: Adenocarcinoma, moderately differentiated (2.0 cm) centered in proximal gastric mucosa, involving GE junction squamous mucosa and extending into but not through sub mucosa. 3. Code: ADENOCA maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Esophagus and stomach, esophagogastrectomy. 2. Findings: Adenocarcinoma, moderately",
      "predicted": "ADENOCA",
      "ground_truth": "STAD",
      "correct": false,
      "reasoning": "1. Site: Esophagus and stomach, esophagogastrectomy. 2. Findings: Adenocarcinoma, moderately differentiated (2.0 cm) centered in proximal gastric mucosa, involving GE junction squamous mucosa and extending into but not through sub mucosa. 3. Code: ADENOCA maps to ADENOCA.",
      "idx": 1210,
      "timestamp": "2026-01-19T15:59:53.118399"
    },
    {
      "sample_idx": 358,
      "input": "OPER DATE: REQ DOC: PROCEDURE: SPHS. Source of Specimen: Esophagus. History of case: Recently diagnosed with. gastroesophageal adenocarcinoma. Operative Procedure/Tissue Submitted: THE. distal esophagus and proximal stomach. PROCEDURE: SPGD. 1. \"Distal esophagus proximal stomach\" Received in formalin in a large. container is a distal esophagus with attached proximal stomach. Esophagus is. 10.2 cm in length with the stomach being 8.5 x 4.2 x 2.5 cm. The adventitia is. red-tan and ragged with a sc...",
      "response": "```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Gastroesophageal adenocarcinoma, invasive mucinous carcinoma. 3. Code: PAAD (Pancreatic Adenocarcinoma) maps to PAAD, since the tumor is located at the gastroesophageal junction, which is close to the pancreas. The tumor is an adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Gastroesophageal adenocarcinoma, invasive mucinous carcinoma. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) maps to KIRC, since the tumor is located at the gastroesophageal junction, which is close to the pancreas. The tumor is an adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Gastroesophageal adenocarcinoma, invasive mucinous carcinoma. 3. Code: PAAD (Pancreatic Adenocarcinoma) maps to PAAD, since the tumor is located at the gastroesophageal junction, which is close to the pancreas. The tumor is an adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Gastroesophageal adenocarcinoma, invasive mucinous carcinoma. 3. Code: PAAD (Pancreatic Adenocarcinoma) maps to PAAD, since the tumor is located at the gastroesophageal junction, which is close to the pancreas. The tumor is an adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Gastroesophageal adenocarcinoma, invasive mucinous carcinoma. 3. Code: PAAD (Pancreatic Adenocarcinoma) maps to PAAD, since the tumor is located at the gastroesophageal junction, which is close to the pancreas. The tumor is an adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2",
      "predicted": "PAAD",
      "ground_truth": "ESCA",
      "correct": false,
      "reasoning": "1. Site: Esophagus (distal). 2. Findings: Gastroesophageal adenocarcinoma, invasive mucinous carcinoma. 3. Code: PAAD (Pancreatic Adenocarcinoma) maps to PAAD, since the tumor is located at the gastroesophageal junction, which is close to the pancreas. The tumor is an adenocarcinoma.",
      "idx": 358,
      "timestamp": "2026-01-19T15:59:53.118418"
    },
    {
      "sample_idx": 312,
      "input": "Clinical Diagnosis & History: year old male 5 cm mass seen in descending colon on colonoscopy 45 cm. from anal verge. Specimens Submitted: 1: Sigmoid colon; resection. 2: Distal ring. 3: Proximal ring. DIAGNOSIS: 1. Sigmoid colon; resection: Tumor Type: Adenocarcinoma. Histologic Grade: Moderately differentiated. Tumor Location: Sigmoid colon. Tumor Size: Length is 2.5 cm. Width is 2.0 cm. Maximal thickness is 1.5 cm. Tumor Budding: Focal. Increased Tumor Infiltrating Lymphocytes: Absent. Precur...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, Moderately differentiated, Tumor Size 2.5x2.0x1.5 cm, Focal budding, Large Venous Invasion, Surgical Margins are negative, Lymphovascular Invasion is not identified, Deepest Tumor Invasion is Muscularis propria. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Distal ring. 2. Findings: Adenocarcinoma, Moderately differentiated, Tumor Size 2.5x1.8x1.3 cm, Focal budding, Large Venous Invasion, Surgical Margins are negative, Lymphovascular Invasion is not identified, Deepest Tumor Invasion is Muscularis propria. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Proximal ring. 2. Findings: Adenocarcinoma, Moderately differentiated, Tumor Size 2.0x1.8x1.4 cm, Focal budding, Large Venous Invasion, Surgical Margins are negative, Lymphovascular Invasion is not identified, Deepest Tumor Invasion is Muscularis propria. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, Moderately differentiated, Tumor Size 2.5x2.0x1.5 cm, Focal budding, Large Venous Invasion, Surgical Margins are negative, Lymphovascular Invasion is not identified, Deepest Tumor Invasion is Muscularis propria. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Distal ring. 2. Findings: Adenocarcinoma, Moderately differentiated, Tumor Size 2.5x1.8x1.3 cm, Focal budding, Large Venous Invasion, Surgical Margins are negative, Lymphovascular Invasion is not identified, Deepest Tumor Invasion is Muscularis propria. 3. Code: KIRC.\"\n}\n```\n```json",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, Moderately differentiated, Tumor Size 2.5x2.0x1.5 cm, Focal budding, Large Venous Invasion, Surgical Margins are negative, Lymphovascular Invasion is not identified, Deepest Tumor Invasion is Muscularis propria. 3. Code: KIRC.",
      "idx": 312,
      "timestamp": "2026-01-19T15:59:53.118439"
    },
    {
      "sample_idx": 840,
      "input": "Addendum. SPECIMEN(S): A.4RL.N. B. 4-R LYMPH NODE. C. 4L L.N. D. 4-L LYMPH NODE. E. LEVEL 7. F. 4 R L.N. G. LEVEL VII. H. R. MIDDLE LOBE LESION. I. RT. UPPER LOBE. J. LEVEL 10R LYMPH NODE. K. LEVEL 4R LYMPH NODE. L. NO SPECIMEN REC'D. M. LEVEL 4R LYMPH NODE. N. POSTERIOR LEVEL 10. O. LEVEL 7 LYMPH NODE. CLINICAL HISTORY: None. PRE-OPERATIVE DIAGNOSIS: Right upper lobe mass. FROZEN SECTION DIAGNOSIS: FSA LYMPH NODE-negative for tumor. FSC LYMPH NODE-negative for tumor. FSE LYMPH NODE-negative for...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: Lung Squamous Cell Carcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Lymph Node (Right Middle Lobe). 2. Findings: Squamous cell carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Left). 2. Findings: Squamous cell carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Right). 2. Findings: Squamous cell carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Right). 2. Findings: Squamous cell carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Left). 2. Findings: Squamous cell carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Right). 2. Findings: Squamous cell carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Right). 2. Findings: Squamous cell carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\":",
      "predicted": "PRAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung (Right Upper Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: Lung Squamous Cell Carcinoma maps to PRAD.",
      "idx": 840,
      "timestamp": "2026-01-19T15:59:53.118451"
    },
    {
      "sample_idx": 814,
      "input": "HISTORY. RLL lesion. MACROSCOPIC. Two specimens submitted. 1: The first specimen is labelled \"right lower lobectomy\" and consists of a right lower lobectomy. specimen which measures 70 X 80 X 60 mm. Sectioning reveals a large tumour present predominantly. in the superior aspect of the lobe which measures 75 X 60 X 60 mm. The tumour has a pink and tan. colour and has a soft consistency. The tumour reaches the pleura but no definite invasion through the. pleura is seen grossly. The tumour extensiv...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma, bronchioloalveolar carcinoma component, large tumor (75mm), satellite nodules in lung. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUSC\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma, bronchioloalveolar carcinoma component, large tumor (75mm), satellite nodules in lung. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma, bronchioloalveolar carcinoma component, large tumor (75mm), satellite nodules in lung. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma, bronchioloalveolar carcinoma component, large tumor (75mm), satellite nodules in lung. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma, bronchioloalveolar carcinoma component, large tumor (75mm), satellite nodules in lung. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma, bronchioloalveolar carcinoma component, large tumor (75mm), satellite nodules in lung. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma, bronchiolo",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma, bronchioloalveolar carcinoma component, large tumor (75mm), satellite nodules in lung. 3. Code: Lung Adenocarcinoma maps to LUAD.",
      "idx": 814,
      "timestamp": "2026-01-19T15:59:53.118465"
    },
    {
      "sample_idx": 892,
      "input": "LEFT UPPER LOBECTOMY. Clinical Details: FNA: Squamous cell carcinoma. Macroscopy: The specimen weighs 180 g and comprises a lobe of lung with appearances in keeping with left upper. lobe. Within the superior lingular segment there is a tumour nodule measuring 30 x 28 x 25 mm. It is. situated at a distance of 25 mm from the bronchial resection margin. The tumour has caused puckering. of the overlying pleura. No pleural surface involvement is seen macroscopically. Inferior to this. nodule, at a di...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Left Upper Lobe. 2. Findings: Squamous cell carcinoma, 30 mm in diameter, with lymphatic invasion. 3. Code: LUAD (Lung Adenocarcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung, Left Upper Lobe. 2. Findings: Squamous cell carcinoma, 30 mm in diameter, with lymphatic invasion. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Left Upper Lobe. 2. Findings: Squamous cell carcinoma, 30 mm in diameter, with lymphatic invasion. 3. Code: LUAD (Lung Adenocarcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung, Left Upper Lobe. 2. Findings: Squamous cell carcinoma, 30 mm in diameter, with lymphatic invasion. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Left Upper Lobe. 2. Findings: Squamous cell carcinoma, 30 mm in diameter, with lymphatic invasion. 3. Code: LUAD (Lung Adenocarcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung, Left Upper Lobe. 2. Findings: Squamous cell carcinoma, 30 mm in diameter, with lymphatic invasion. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Left Upper Lobe. 2. Findings: Squamous cell carcinoma, 30 mm in diameter, with lymphatic invasion. 3. Code: LUAD (Lung Adenocarcinoma).\"\n}\n```\n```json\n",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung, Left Upper Lobe. 2. Findings: Squamous cell carcinoma, 30 mm in diameter, with lymphatic invasion. 3. Code: LUAD (Lung Adenocarcinoma).",
      "idx": 892,
      "timestamp": "2026-01-19T15:59:53.118478"
    },
    {
      "sample_idx": 233,
      "input": "Histology. Histology. Result Date: Verified). Lab Accession #: Accession Date: Sign Out Date: Tissue Source: 1: CERVIX #1 FOR FS. 2: CERVIX #2. 3: VAGINA: NORMAL. 4: CERVIX. Final Diagnosis: 1. Cervix, #1 (biopsy): - Squamous cell carcinoma, invasive, moderately differentiated margins involved (see note). Note: Although the orientation of the biopsy is not optimal, the tumor near completely replaces the entire cervical. stroma and measures greater than 5 mm in greatest thickness. 2. Cervix, #2 (...",
      "response": "```json\n{\n    \"cancer_type\": \"Cervix\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to Cervix.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"Cervix\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to Cervix.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"Cervix\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to Cervix.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"Cervix\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to Cervix.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"Cervix\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to Cervix.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"Cervix\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to Cervix.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"Cervix\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to Cervix.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"Cervix\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to Cervix.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"Cervix\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to Cervix.\"\n}\n```",
      "predicted": "Cervix",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to Cervix.",
      "idx": 233,
      "timestamp": "2026-01-19T15:59:53.118494"
    },
    {
      "sample_idx": 1272,
      "input": "'athology. ort. Sex: F. Received: 1. Case type: Surgical Case. DIAGNOSIS. (A) RIGHT LOBE THYROID AND ISTHMUS: PAPILLARY THYROID CARCINOMA, FOLLICULAR VARIANT. Location: Right lobe. Multi-focal: No. Size = 3.2 cm. Extrathyroidal extension: Absent. Lymphovascular invasion: Absent. Resection Margins: Negative. Lymph nodes: No tumor present in 4 lymph nodes. GROSS DESCRIPTION. (A) RIGHT LOBE THYROID AND ISTHMUS - A right lobe of thyroid (4.0 x 3.2 x 1.5 cm) with isthmus (1.2 x 0.3 x 0.2 cm). Section...",
      "response": "```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Right lobe of the thyroid and isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Right lobe of the thyroid and isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Right lobe of the thyroid and isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Right lobe of the thyroid and isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Right lobe of the thyroid and isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Right lobe of the thyroid and isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Right lobe of the thyroid and isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Right lobe of the thyroid and isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant. ",
      "predicted": "THCA",
      "ground_truth": "THCA",
      "correct": true,
      "reasoning": "1. Site: Right lobe of the thyroid and isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: THCA maps to THCA.",
      "idx": 1272,
      "timestamp": "2026-01-19T15:59:53.118506"
    },
    {
      "sample_idx": 24,
      "input": "F. Urology. Clinical Diagnosis & History: female with hematuria and bladder lesions seen on cystoscopy. Specimens Submitted: 1: Tumor of anterior bladder wall, TURB. DIAGNOSIS: 1. Tumor of anterior bladder wall, TURB. Tumor Type: Invasive urothelial carcinoma, NOS. Histologic Grade: High grade. Pattern of growth of the non-invasive component: Papillary. Local Invasion: Muscularis propria. Vascular Invasion: Not identified. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONALEXAMINATIONOFT...",
      "response": "```json\n{\n    \"cancer_type\": \"UROS\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, NOS (Not Otherwise Specified), High grade. 3. Code: UROS maps to UROS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UROS\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, NOS (Not Otherwise Specified), High grade. 3. Code: UROS maps to UROS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UROS\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, NOS (Not Otherwise Specified), High grade. 3. Code: UROS maps to UROS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UROS\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, NOS (Not Otherwise Specified), High grade. 3. Code: UROS maps to UROS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UROS\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, NOS (Not Otherwise Specified), High grade. 3. Code: UROS maps to UROS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UROS\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, NOS (Not Otherwise Specified), High grade. 3. Code: UROS maps to UROS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UROS\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, NOS (Not Otherwise Specified), High grade. 3. Code: UROS maps to UROS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UROS\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, NOS (Not Otherwise Specified), High grade. ",
      "predicted": "UROS",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, NOS (Not Otherwise Specified), High grade. 3. Code: UROS maps to UROS.",
      "idx": 24,
      "timestamp": "2026-01-19T15:59:53.118516"
    },
    {
      "sample_idx": 675,
      "input": "THIS IS AN ADDENDUM REPORT. SPECIMEN(S) SUBMITTED / PROCEDURES ORDERED. A. Brain tumor. A. Frozen Section Charge. A. Glial Fibrill. Acid Prt. A. P53 Protein. A. Isocitrate dehydrogenase 1. A. KI-67, Nuclear Antigen, Mib1. A. Phosphohistone-Hi. A. 1P19q Malignant. Glioma Anaysis. A. 1P19q Malignant Glioma Analysis,. add x 3. B. Brain tumor. C. Brain tumor. CLINICAL HISTORY: -old male with no significant past medical. history. Evaluate revealed left frontal brain tumor. Here today for. left stealt...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/Cerebrum, Frontal. 2. Findings: Anaplastic astrocytoma (WHO grade III), positive for IDH-1 and P53. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/Cerebrum, Frontal. 2. Findings: Anaplastic astrocytoma (WHO grade III), positive for IDH-1 and P53. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/Cerebrum, Frontal. 2. Findings: Anaplastic astrocytoma (WHO grade III), positive for IDH-1 and P53. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/Cerebrum, Frontal. 2. Findings: Anaplastic astrocytoma (WHO grade III), positive for IDH-1 and P53. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/Cerebrum, Frontal. 2. Findings: Anaplastic astrocytoma (WHO grade III), positive for IDH-1 and P53. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/Cerebrum, Frontal. 2. Findings: Anaplastic astrocytoma (WHO grade III), positive for IDH-1 and P53. 3. Code: KIRC.\"\n}\n```\n",
      "predicted": "KIRC",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain/Cerebrum, Frontal. 2. Findings: Anaplastic astrocytoma (WHO grade III), positive for IDH-1 and P53. 3. Code: KIRC.",
      "idx": 675,
      "timestamp": "2026-01-19T15:59:53.118526"
    },
    {
      "sample_idx": 197,
      "input": "page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - right breast. !. Expected time of examination: up to 8 working days. Clinical diagnosis: Bifocal cancer of the right breast. Results of immunohistochemical examination: Tumour 1. No estrogen receptors found in neoplastic cell nuclei. No progesterone receptors found in neoplastic cell nuclei. HER2 protein. stained using rabbit antibody Ventana PATHWAY HER-...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, bifocal and ductal carcinoma in situ. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, bifocal and ductal carcinoma in situ. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, bifocal and ductal carcinoma in situ. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, bifocal and ductal carcinoma in situ. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, bifocal and ductal carcinoma in situ. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, bifocal and ductal carcinoma in situ. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, bifocal and ductal carcinoma in situ. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, bifocal and ductal carcinoma in situ. 3. Code: Breast Invasive Carcinoma maps",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, bifocal and ductal carcinoma in situ. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 197,
      "timestamp": "2026-01-19T15:59:53.118536"
    },
    {
      "sample_idx": 408,
      "input": "CLINICAL HISTORY. has experienced. for about. On. imaging there is a large lesion involving left frontal lobe, basal. ganglia,. insula, and extending across the corpus callosum, and is minimally. enhancing. OPERATIVE DIAGNOSES. Left brain mass. Operation/Specimen: A: Brain, left frontal tumor, biopsy. B: Brain, left frontal tumor, excision. PATHOLOGICAL DIAGNOSIS: A and B. Brain, left frontal, excisional biopsy and excision: Glioblastoma. (WHO IV). See Microscopy Description and Comment. COMMENT...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left frontal tumor (biopsy and excision). 2. Findings: Glioblastoma (WHO IV). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left frontal tumor (biopsy and excision). 2. Findings: Glioblastoma (WHO IV). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left frontal tumor (biopsy and excision). 2. Findings: Glioblastoma (WHO IV). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left frontal tumor (biopsy and excision). 2. Findings: Glioblastoma (WHO IV). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left frontal tumor (biopsy and excision). 2. Findings: Glioblastoma (WHO IV). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left frontal tumor (biopsy and excision). 2. Findings: Glioblastoma (WHO IV). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left frontal tumor (biopsy and excision). 2. Findings: Glioblastoma (WHO IV). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left frontal tumor (biopsy and excision). 2. Findings: Glioblastoma (WHO IV). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left frontal tumor (biopsy",
      "predicted": "KIRC",
      "ground_truth": "GBM",
      "correct": false,
      "reasoning": "1. Site: Left frontal tumor (biopsy and excision). 2. Findings: Glioblastoma (WHO IV). 3. Code: KIRC.",
      "idx": 408,
      "timestamp": "2026-01-19T15:59:53.118546"
    },
    {
      "sample_idx": 336,
      "input": "Addendum Diagnosis: Cerebellopointe angle mass, biopsy and resection: Diffuse Large Cell B-Cell Lymphoma, follicular center cell type. Microscopic Description: Microscopic evaluation reveals a malignant neoplasm composed of sheets of atypical cells. The tumor. cells deomonstrate pleomorphic hyperchromatic nuclei and significant cytologic atypia. Foci of tumor. necrosis as well as individual apoptotic neoplastic cells are seen. Numerous mitotic figures are seen. The. tumor cells demonstrate diffu...",
      "response": "```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Cerebellopontine angle. 2. Findings: Diffuse Large B-Cell Lymphoma, Follicular Center Cell type. 3. Code: Diffuse Large Cell B-Cell Lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive Carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Cerebellopontine angle. 2. Findings: Diffuse Large B-Cell Lymphoma, Follicular Center Cell type. 3. Code: Diffuse Large Cell B-Cell Lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Cerebellopontine angle. 2. Findings: Diffuse Large B-Cell Lymphoma, Follicular Center Cell type. 3. Code: Diffuse Large Cell B-Cell Lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Cerebellopontine angle. 2. Findings: Diffuse Large B-Cell Lymphoma, Follicular Center Cell type. 3. Code: Diffuse Large Cell B-Cell Lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Cerebellopontine angle. 2. Findings: Diffuse Large B-Cell Lymphoma, Follicular Center Cell type. 3. Code: Diffuse Large Cell B-Cell Lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Cerebellopontine angle. 2. Findings: Diffuse Large B-Cell Lymphoma, Follicular Center Cell type. 3. Code: Diffuse Large Cell B-Cell Lymph",
      "predicted": "DLBC",
      "ground_truth": "DLBC",
      "correct": true,
      "reasoning": "1. Site: Cerebellopontine angle. 2. Findings: Diffuse Large B-Cell Lymphoma, Follicular Center Cell type. 3. Code: Diffuse Large Cell B-Cell Lymphoma maps to DLBC.",
      "idx": 336,
      "timestamp": "2026-01-19T15:59:53.118557"
    },
    {
      "sample_idx": 1307,
      "input": "Macroscopic examination : Resection weighs 195 g and measuring 13 cm x 11 cm x 6.5 cm. It is adherent to a. pulmonary resection measuring 10 cm x 3.5 cm x 3 cm When cut, the thymus is the. seat of a large whitish tumor measuring 8 cm x 10 cm x 7 cm, lobulated,. adherent to the lung. No cyst or necrosis macroscopically visible. Histopathological examination : All samples taken over the entire surface have the same appearance. The. thymic parenchyma still identifiable in the sections B, C and P, i...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type B3, with invasion of mediastinal fat and lung parenchyma. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type B3, with invasion of mediastinal fat and lung parenchyma. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type B3, with invasion of mediastinal fat and lung parenchyma. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type B3, with invasion of mediastinal fat and lung parenchyma. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type B3, with invasion of mediastinal fat and lung parenchyma. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type B3, with invasion of mediastinal fat and lung parenchyma. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type B3, with invasion of mediastinal fat and lung parenchyma. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma",
      "predicted": "THYM",
      "ground_truth": "THYM",
      "correct": true,
      "reasoning": "1. Site: Thymus. 2. Findings: Thymoma, Type B3, with invasion of mediastinal fat and lung parenchyma. 3. Code: Thymoma maps to THYM.",
      "idx": 1307,
      "timestamp": "2026-01-19T15:59:53.118567"
    },
    {
      "sample_idx": 885,
      "input": "HISTORY. Right middle lobectomy. Adherent to pericardium. MACROSCOPIC. Two specimens received. 1: The first specimen is labelled \"right middle lobe\" and consists of a piece of lung measuring 123 x. 100 x 55 mm and weighing 232 g. An amount of fat and pericardium is adherent to one surface while. the pleura on the opposite side appears puckered. On sectioning a large tumour mass measuring. approximately 53 x 45 X 57 mm is seen. This is approximately 11 mm away from the bronchial. resection margin...",
      "response": "```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated, with extensive central necrosis and pericardial invasion. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated, with extensive central necrosis and pericardial invasion. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated, with extensive central necrosis and pericardial invasion. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated, with extensive central necrosis and pericardial invasion. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated, with extensive central necrosis and pericardial invasion. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated, with extensive central necrosis and pericardial invasion. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated, with extensive central necrosis and pericardial invasion. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated, with extensive central necrosis and",
      "predicted": "SCC",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated, with extensive central necrosis and pericardial invasion. 3. Code: SCC maps to SCC.",
      "idx": 885,
      "timestamp": "2026-01-19T15:59:53.118578"
    },
    {
      "sample_idx": 71,
      "input": "page 1 / 2. copy No. Examination: Histopathological examination. Patien. PESEL: Gender: F. Material: Multiple organ resection - left breast. Expected time of examunation: up to 8 working days. Clinical diagnosis: Cancer of the left breast. Results of immunohistochemical examination: Estrogen receptors in neoplastic cell nuclei not found. Progesterone receptors in neoplastic cell nuclei not. found. HER2 protein stained with HercepTest\u2122 by DAKO. Score = 2+, verification by the FISH method recommen...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 71,
      "timestamp": "2026-01-19T15:59:53.118588"
    },
    {
      "sample_idx": 990,
      "input": "Lab No. A. SPECIMEN TYPE: Whipples. T. H. CLINICAL NOTES: IPMN Whipple's procedure. Coeliac axis. Lymph node. o. L. NOTE: Block A1 neck en face (involved). A2-A5 periuncinate margin. o. FROZEN SECTION REPORT: G. Invasive mucinous (colloid) adenocarcinoma arising from an IPMN is present. The invasive adenocarcinoma is clear of the neck margin. IPMN with moderate. Y. dysplasia extends to the neck margin. SYNOPTIC REPORT FOR WHIPPLE'S RESECTION. MACROSCOPIC: Specimen labelled: Whipple specimen. Spe...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreatic head (Pancreaticoduodenectomy, partial pancreatectomy). 2. Findings: Invasive mucinous (colloid) adenocarcinoma arising from an IPMN. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreatic head (Pancreaticoduodenectomy, partial pancreatectomy). 2. Findings: Invasive mucinous (colloid) adenocarcinoma arising from an IPMN. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreatic head (Pancreaticoduodenectomy, partial pancreatectomy). 2. Findings: Invasive mucinous (colloid) adenocarcinoma arising from an IPMN. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreatic head (Pancreaticoduodenectomy, partial pancreatectomy). 2. Findings: Invasive mucinous (colloid) adenocarcinoma arising from an IPMN. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreatic head (Pancreaticoduodenectomy, partial pancreatectomy). 2. Findings: Invasive mucinous (colloid) adenocarcinoma arising from an IPMN. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreatic head (Pancreaticoduodenectomy, partial pancreatectomy). 2. Findings: Invasive mucinous (colloid) adenocarcinoma arising from an IPMN. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreatic head (Pancreaticoduodenectomy, partial pancreatectomy). 2. Findings: Invasive mucinous (colloid) adenocarcinoma arising from",
      "predicted": "KIRC",
      "ground_truth": "PAAD",
      "correct": false,
      "reasoning": "1. Site: Pancreatic head (Pancreaticoduodenectomy, partial pancreatectomy). 2. Findings: Invasive mucinous (colloid) adenocarcinoma arising from an IPMN. 3. Code: KIRC.",
      "idx": 990,
      "timestamp": "2026-01-19T15:59:53.118599"
    },
    {
      "sample_idx": 791,
      "input": "Main diagnosis/diagnoses: Central to peripheral bronchopulmonary, histologically mixed adenocarcinoma of the right. lower lobe of the lung with a predominant papillary and small acinar component, slight mucin. formation and main localization in segments 7 to 9. TNM classification on the basis of this material pT2 pN0 pMX R0, stage IB. C34.3 M8255/3. Comment/supplementary remark: The tumor has extended to S4 of the middle lobe, the resection margin of the bronchus and. the vessels as well as all ...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma of the lung, bronchopulmonary, central to peripheral, with a predominant papillary and small acinar component, slight mucin formation. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma of the lung, bronchopulmonary, central to peripheral, with a predominant papillary and small acinar component, slight mucin formation. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma of the lung, bronchopulmonary, central to peripheral, with a predominant papillary and small acinar component, slight mucin formation. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma of the lung, bronchopulmonary, central to peripheral, with a predominant papillary and small acinar component, slight mucin formation. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma of the lung, bronchopulmonary, central to peripheral, with a predominant papillary and small acinar component, slight mucin formation. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma of the lung, bronchopulmonary, central to peripheral, with a predominant papillary and small acinar component, slight mucin formation. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma of the lung, bronchopulmonary, central to peripheral, with a predominant papillary and small acinar component, slight mucin formation. 3. Code: Lung Adenocarcinoma maps to LUAD.",
      "idx": 791,
      "timestamp": "2026-01-19T15:59:53.118612"
    },
    {
      "sample_idx": 1238,
      "input": "Sex: M. Case type: Surgical Case. DIAGNOSIS. (A) LEFT NECK DISSECTION, LEVEL III AND IV: METASTATIC PAPILLARY THYROID CARCINOMA IN SIX OF TWELVE LYMPH NODES (6/12). AND IN SOFT TISSUE. Extranodal extension: Present. (B) PORTION, LEFT INFERIOR PARATHYROID: Parathyroid tissue present. (C) BILATERAL NECK CONTENTS: METASTATIC PAPILLARY THYROID CARCINOMA IN LYMPH NODES LEFT AND RIGHT SIDES(18/48). Extranodal extension: Present. (D) BILATERAL TOTAL THYROIDECTOMY, BILATERAL PARATRACHEAL DISSECTION: PAP...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Bilateral thyroid (Total Thyroidectomy, Bilateral Parathyroid Dissection). 2. Findings: Papillary thyroid carcinoma, follicular variant. Location: Bilateral including isthmus. Multi-focal: Yes, numerous foci. Size = 4.0 cm largest in Right. Extrathyroidal extension: Present, extending into fibroadipose tissue. Lymphovascular invasion: Present. Lymph nodes: METASTATIC PAPILLARY THYROID CARCINOMA IN 6 OF 11 LYMPH NODES. Location: Periglandular. Extracapsular extension: Present. 3. Code: BRCA maps to Breast Invasive Carcinoma\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Bilateral thyroid (Total Thyroidectomy, Bilateral Parathyroid Dissection). 2. Findings: Papillary thyroid carcinoma, follicular variant. Location: Bilateral including isthmus. Multi-focal: Yes, numerous foci. Size = 4.0 cm largest in Right. Extrathyroidal extension: Present, extending into fibroadipose tissue. Lymphovascular invasion: Present. Lymph nodes: METASTATIC PAPILLARY THYROID CARCINOMA IN 6 OF 11 LYMPH NODES. Location: Periglandular. Extracapsular extension: Present. 3. Code: BRCA maps to Breast Invasive Carcinoma\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Bilateral thyroid (Total Thyroidectomy, Bilateral Parathyroid Dissection). 2. Findings: Papillary thyroid carcinoma, follicular variant. Location: Bilateral including isthmus. Multi-focal: Yes, numerous foci. Size = 4.0 cm largest in Right. Extrathyroidal extension: Present, extending into fibroadipose tissue. Lymphovascular invasion: Present. Lymph nodes: METASTATIC PAPILLARY THYROID CARCINOMA IN 6 OF 11 LYMPH NODES. Location: Periglandular. Extracapsular extension: Present. 3. Code: BRCA maps to Breast Invasive Carcinoma\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA",
      "predicted": "BRCA",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Bilateral thyroid (Total Thyroidectomy, Bilateral Parathyroid Dissection). 2. Findings: Papillary thyroid carcinoma, follicular variant. Location: Bilateral including isthmus. Multi-focal: Yes, numerous foci. Size = 4.0 cm largest in Right. Extrathyroidal extension: Present, extending into fibroadipose tissue. Lymphovascular invasion: Present. Lymph nodes: METASTATIC PAPILLARY THYROID CARCINOMA IN 6 OF 11 LYMPH NODES. Location: Periglandular. Extracapsular extension: Present. 3. Code: BRCA maps to Breast Invasive Carcinoma",
      "idx": 1238,
      "timestamp": "2026-01-19T15:59:53.118632"
    },
    {
      "sample_idx": 359,
      "input": "(MIM/DD/YYYY). PRIMARY SITE: Esophagus (Mid third). 1 - \"Product of esophagectomy\": Moderately differentiated squamous cell carcinoma, infiltrative and ulcerated. Neoplasia measuring 7.0 cm in the longest axis and infiltrating to the external surface of the. adventitia and adjacent adipose tissue that focally covers the wall. Presence of lymphatic and perineural infiltrations. Presence of foci of necrosis. Proximal and distal surgical margins free of neoplastic involvement. Metastatic squamous c...",
      "response": "```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus (Mid third). 2. Findings: Esophageal squamous cell carcinoma, with lymph node involvement. 3. Code: Esophagus Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Esophagus (Mid third). 2. Findings: Esophageal squamous cell carcinoma, with lymph node involvement. 3. Code: Esophagus Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus (Mid third). 2. Findings: Esophageal squamous cell carcinoma, with lymph node involvement. 3. Code: Esophagus Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus (Mid third). 2. Findings: Esophageal squamous cell carcinoma, with lymph node involvement. 3. Code: Esophagus Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus (Mid third). 2. Findings: Esophageal squamous cell carcinoma, with lymph node involvement. 3. Code: Esophagus Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus (Mid third). 2. Findings: Esophageal squamous cell carcinoma, with lymph node involvement. 3. Code: Esophagus Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus (Mid third). 2. Findings: Esophageal squamous cell carcinoma, with lymph node involvement. 3. Code: Esophagus Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"",
      "predicted": "ESCA",
      "ground_truth": "ESCA",
      "correct": true,
      "reasoning": "1. Site: Esophagus (Mid third). 2. Findings: Esophageal squamous cell carcinoma, with lymph node involvement. 3. Code: Esophagus Squamous Cell Carcinoma maps to ESCA.",
      "idx": 359,
      "timestamp": "2026-01-19T15:59:53.118642"
    },
    {
      "sample_idx": 656,
      "input": "SURGERY DATE: RECEIVE DATE: PATHOLOGICAL DIAGNOSIS: RIGHT TEMPORAL LOBE, BIOPSY: ANAPLASTIC GLIOMA, MIXED /ASTROCYTOMA AND. (OnIGODENDROGITOMA, MIB-1, - 15%. Operation/Specimen: Clinical History and Pre-Op Dx: GROSS PATHOLOGY: A,B. Multiple 0.2-0.4 cm tissue. Frozen section diagnosis: Glioma. In #1 and #3. C. SPECIMEN: Tumor. FIXATIVE: Saline. GENERAL : Multiple fragments of friable brain tissue, loosely. aggregating to 4.5 X 4 X 1 cm. Serially sectioned. SECTIONS: X1-X3 - representative. pc4. M...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Temporal Lobe (Brain). 2. Findings: Anaplastic glioma, mixed with astrocytoma and oligodendroglioma. High mitotic rate, vascular proliferation, and scattered calcification. MIB-1 index is 15%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Temporal Lobe (Brain). 2. Findings: Anaplastic glioma, mixed with astrocytoma and oligodendroglioma. High mitotic rate, vascular proliferation, and scattered calcification. MIB-1 index is 15%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Temporal Lobe (Brain). 2. Findings: Anaplastic glioma, mixed with astrocytoma and oligodendroglioma. High mitotic rate, vascular proliferation, and scattered calcification. MIB-1 index is 15%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Temporal Lobe (Brain). 2. Findings: Anaplastic glioma, mixed with astrocytoma and oligodendroglioma. High mitotic rate, vascular proliferation, and scattered calcification. MIB-1 index is 15%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Temporal Lobe (Brain). 2. Findings: Anaplastic glioma, mixed with astrocytoma and oligodendroglioma. High mitotic rate, vascular proliferation, and scattered calcification. MIB-1 index is 15%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Temporal Lobe (Brain). 2. Findings: Anaplastic glioma, mixed with astrocytoma and oligodendroglioma. High mitotic rate",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Temporal Lobe (Brain). 2. Findings: Anaplastic glioma, mixed with astrocytoma and oligodendroglioma. High mitotic rate, vascular proliferation, and scattered calcification. MIB-1 index is 15%. 3. Code: GBM maps to GBM.",
      "idx": 656,
      "timestamp": "2026-01-19T15:59:53.118654"
    },
    {
      "sample_idx": 521,
      "input": "FINAL DIAGNOSIS. KIDNEY, RIGHT, RADICAL NEPHRECTOMY -. A. RENAL CELL CARCINOMA (9.7 CM), CONVENTIONAL (CLEAR CELL) TYPE, FUHRMAN NUCLEAR GRADE 3 OF 4. (see comment). B. TUMOR DOES NOT EXTEND BEYOND GEROTA'S FASCIA,. C. ALL EXAMINED SURGICAL RESECTION MARGINS ARE FREE OF TUMOR. D. NO EVIDENCE OF ANGIOLYMPHATIC INVASION IS IDENTIFIED. E. NON-NEOPLASTIC KIDNEY SHOWS FOCAL INTERSTITIAL CHRONIC INFLAMMATION. F. TNM PATHOLOGIC STAGE = p T2 NX MX. G. TNM HISTOLOGIC GRADE = G3. COMMENT: Although large a...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 521,
      "timestamp": "2026-01-19T15:59:53.118665"
    },
    {
      "sample_idx": 409,
      "input": "AP Surgical Pathology: Additional Info. CLINICAL HISTORY: Right parietal brain tumor. Visual hallucinations and headaches. Preoperative MRI: MRI for surgical localization purposes redemonstrating right. temporal peripherally enhancing mass with several additional areas of. enhancement adjacent to the dominant mass. GROSS EXAMINATION: A. \"Brain tissue (AF1) \", received fresh for frozen section. Previously. submitted as frozen section AF1 is a 2 x 2 x 0.3 cm aggregate of soft brown. tissue and a b...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma, WHO Grade IV. 3. Code: GBM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"GLG\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: High-grade astrocytoma. 3. Code: GLG.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM.\"\n}\n```\nResponse:\n```json\n{\n    \"",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain. 2. Findings: Glioblastoma, WHO Grade IV. 3. Code: GBM.",
      "idx": 409,
      "timestamp": "2026-01-19T15:59:53.118673"
    },
    {
      "sample_idx": 695,
      "input": "Microscopic. Sections demonstrate a mildly to moderately hypercellular glial neoplasm that diffusely. infiltrates the gray and white matter. The tumor cells have monotonous round to oval. nuclei with little atypical. Cytoplasm is prominent and is often fibrillary that does. demonstrate some microgemistocytic and a few ordinary gemistocytic forms Two. mitoses are identified in 25 high power fields. There is no microvascular proliferation or. necrosis. Addendum. Sections demonstrate cortical gray ...",
      "response": "```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligoastrocytoma, low grade. 3. Code: Oligoastrocytoma maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligoastrocytoma, low grade. 3. Code: Oligoastrocytoma maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligoastrocytoma, low grade. 3. Code: Oligoastrocytoma maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligoastrocytoma, low grade. 3. Code: Oligoastrocytoma maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligoastrocytoma, low grade. 3. Code: Oligoastrocytoma maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligoastrocytoma, low grade. 3. Code: Oligoastrocytoma maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligoastrocytoma, low grade. 3. Code: Oligoastrocytoma maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligoastrocytoma, low grade. 3. Code: Oligoastrocytoma maps to OLIG.\"\n}\n```\n",
      "predicted": "OLIG",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain. 2. Findings: Oligoastrocytoma, low grade. 3. Code: Oligoastrocytoma maps to OLIG.",
      "idx": 695,
      "timestamp": "2026-01-19T15:59:53.118683"
    },
    {
      "sample_idx": 863,
      "input": "Encounter Number. COPY ONLY DO NOT FILE. Source of Specimen. A. 4R#1- -. B. 4R#2. C. 4R#3-. D. 4L NODES - FS-. E. STATION 7 NODES - FS-. F. STATION #9- -. G. STATION 11 NODE #1-. H. STATION 11 NODE #2. I. STATION 7 #2-. Site lung, lowr lobe &34.3. J. STATION 5 #2-. K. STATION 5 #3-. L. STATION 10-. M. STATION 5 #1-. N. PERI-AORTIC - NODE-. O. BRONCHIAL MARGIN FS-. P. LEFT LUNG NFS-. FINAL DIAGNOSIS: A. 4R#1-. NO CARCINOMA SEEN IN THREE LYMPH NODES (0/3). B. 4R#2. NO CARCINOMA SEEN IN ONE LYMPH N...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, lower lobe. 2. Findings: Invasive squamous cell carcinoma, 2-3/3 grade. Unifocal tumor, 6 cm. Lymphatic invasion is rare. 3. Code: LUAD (Lung Adenocarcinoma) is not a valid code for squamous cell carcinoma, but given the description of the tumor as squamous cell carcinoma, the code LUAD would be a valid code for the lung, which is the primary site. Based on the description, this is an invasive squamous cell carcinoma. The TCGA code for lung adenocarcinoma is LUAD. Given that this is a squamous cell carcinoma, it could be a code for lung squamous cell carcinoma, which is not a valid code but LUAD is a valid code for lung. Therefore, LUAD is the most appropriate code. Note: It is important to verify this with the pathologist and TCGA database.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, lower lobe. 2. Findings: Invasive squamous cell carcinoma, 2-3/3 grade. Unifocal tumor, 6 cm. Lymphatic invasion is rare. 3. Code: LUAD (Lung Adenocarcinoma) is not a valid code for squamous cell carcinoma, but given the description of the tumor as squamous cell carcinoma, the code LUAD would be a valid code for the lung, which is the primary site. Based on the description, this is an invasive squamous cell carcinoma. The TCGA code for lung adenocarcinoma is LUAD. Given that this is a squamous cell carcinoma, it could be a code for lung squamous cell carcinoma, which is not a valid code but LUAD is a valid code for lung. Therefore, LUAD is the most appropriate code.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, lower lobe. 2. Findings: Invasive squamous cell carcinoma, 2-3/3 grade. Unifocal tumor, 6 cm. Lymphatic invasion is rare. 3. Code: LUAD (Lung Adenocarcinoma) is not a valid code for squamous cell carcinoma, but given the description of the tumor as squamous cell carcinoma, the code LUAD would be a valid code for the lung, which",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung, lower lobe. 2. Findings: Invasive squamous cell carcinoma, 2-3/3 grade. Unifocal tumor, 6 cm. Lymphatic invasion is rare. 3. Code: LUAD (Lung Adenocarcinoma) is not a valid code for squamous cell carcinoma, but given the description of the tumor as squamous cell carcinoma, the code LUAD would be a valid code for the lung, which is the primary site. Based on the description, this is an invasive squamous cell carcinoma. The TCGA code for lung adenocarcinoma is LUAD. Given that this is a squamous cell carcinoma, it could be a code for lung squamous cell carcinoma, which is not a valid code but LUAD is a valid code for lung. Therefore, LUAD is the most appropriate code. Note: It is important to verify this with the pathologist and TCGA database.",
      "idx": 863,
      "timestamp": "2026-01-19T15:59:53.118707"
    },
    {
      "sample_idx": 549,
      "input": "YSICIAN.INFO RMATION. Sex: Male. ol. F. SPECIMEN INFO. DIAGNOSIS. DIAGNOSIS: Left kidney, radical nephrectomy: Renal carcinoma. Tumor Characteristics: 1. Histologic type:Clear cell adenocarcinoma. 2. Tumor site: Posterior aspect, mid kidney. 3. Tumor size: 5.0. 4. Macroscopic extent of tumor: Limited to kidney. 5. Nuclear grade: Fuhrman grade: 2/4. 6. Lymphovascular space invasion: Absent. 7. Transcapsular invasion: Absent. 8. Renal vein invasion: Absent. 9. Venacaval invasion: Not resected. 10....",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal carcinoma, clear cell adenocarcinoma, Fuhrman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal carcinoma, clear cell adenocarcinoma, Fuhrman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal carcinoma, clear cell adenocarcinoma, Fuhrman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal carcinoma, clear cell adenocarcinoma, Fuhrman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal carcinoma, clear cell adenocarcinoma, Fuhrman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal carcinoma, clear cell adenocarcinoma, Fuhrman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal carcinoma, clear cell adenocarcinoma, Fuhrman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal carcinoma,",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney. 2. Findings: Renal carcinoma, clear cell adenocarcinoma, Fuhrman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 549,
      "timestamp": "2026-01-19T15:59:53.118717"
    },
    {
      "sample_idx": 339,
      "input": "Gross Description: In the fatty tissue there are enlarged soft hyperemic lymph nodes up to 3.5 cm in. their diameter. Microscopic Description: Diffuse large B-cell lymphoma. IHC-stainings: CD45 - positive reaction; CD20 -. positive reaction; CD3 - negative reaction in the tumor cells, positive reaction on the reactive cells; CD30. - positive reaction in some tumor cells. Diagnosis Details: Tumor Features: Indeterminate, Tumor Extent: Disseminated (multifocal) involvement. Venous Invasion: Absent...",
      "response": "```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Lymph node. 2. Findings: Diffuse large B-cell lymphoma. 3. Code: Diffuse large B-cell lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIPS\",\n    \"reasoning\": \"1. Site: Lymph node. 2. Findings: Lymphoma. 3. Code: Lymphoma maps to LIPS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Lymph node. 2. Findings: Diffuse large B-cell lymphoma. 3. Code: Diffuse large B-cell lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Lymph node. 2. Findings: Diffuse large B-cell lymphoma. 3. Code: Diffuse large B-cell lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Lymph node. 2. Findings: Diffuse large B-cell lymphoma. 3. Code: Diffuse large B-cell lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Lymph node. 2. Findings: Diffuse large B-cell lymphoma. 3. Code: Diffuse large B-cell lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Lymph node. 2. Findings: Diffuse large B-cell lymphoma. 3. Code: Diffuse large B-cell lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Lymph node. 2. Findings: Diffuse large B-cell lymphoma. 3. Code: Diffuse large B-cell lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type",
      "predicted": "DLBC",
      "ground_truth": "DLBC",
      "correct": true,
      "reasoning": "1. Site: Lymph node. 2. Findings: Diffuse large B-cell lymphoma. 3. Code: Diffuse large B-cell lymphoma maps to DLBC.",
      "idx": 339,
      "timestamp": "2026-01-19T15:59:53.118727"
    },
    {
      "sample_idx": 961,
      "input": "Report Status: Final. Type: Surgical Pathology. SOFT TISSUE BIOPSY. DIAGNOSIS: SPECIMEN LABELED \"IMPLANT SMALL BOWEL MESENTERY\": POORLY DIFFERENTIATED CARCINOMA. SPECIMEN LABELED \"OMENTUM\": POORLY DIFFERENTIATED CARCINOMA, consistent with Adenocarcinoma, with. extensive necrosis. See note. Lymphovascular invasion is present. Immunohistochemistry performed at. demonstrates the following staining. profile in tumor cells: Positive - Cytokeratin 7 (strong). Negative - Cytokeratin 20,. NOTE: The tumo...",
      "response": "```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Small Bowel. 2. Findings: Poorly differentiated carcinoma, with extensive necrosis. 3. Code: Small Bowel Adenocarcinoma maps to PAAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to",
      "predicted": "PAAD",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Small Bowel. 2. Findings: Poorly differentiated carcinoma, with extensive necrosis. 3. Code: Small Bowel Adenocarcinoma maps to PAAD.",
      "idx": 961,
      "timestamp": "2026-01-19T15:59:53.118737"
    },
    {
      "sample_idx": 28,
      "input": "DATE OF DISCHARGE: SEX: M. DOCTOR: DATE OF SERVICE: Pathology Consultation Report. ANATOMIC PATHOLOGY DIAGNOSIS: A - Bladder, anterior wall and dome, transurethral excision. - High grade papillary urothelial carcinoma. - Invasive into muscularis propria. - No lymphovascular or perineural invasion is identified. B - Kidney, left renal pelvis, biopsy. - Low grade papillary urothelial carcinoma. - Invasion cannot be assessed. I have reviewed this material and confirm the report. Released by. MATERI...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder (anterior wall and dome). 2. Findings: High-grade papillary urothelial carcinoma, invasive into the muscularis propria. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (left renal pelvis). 2. Findings: Low-grade papillary urothelial carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder (anterior wall and dome). 2. Findings: High-grade papillary urothelial carcinoma, invasive into the muscularis propria. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (left renal pelvis). 2. Findings: Low-grade papillary urothelial carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder (anterior wall and dome). 2. Findings: High-grade papillary urothelial carcinoma, invasive into the muscularis propria. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (left renal pelvis). 2. Findings: Low-grade papillary urothelial carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder (anterior wall and dome). 2. Findings: High-grade papillary urothelial carcinoma, invasive into the muscularis propria. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"",
      "predicted": "KIRC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Bladder (anterior wall and dome). 2. Findings: High-grade papillary urothelial carcinoma, invasive into the muscularis propria. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 28,
      "timestamp": "2026-01-19T15:59:53.118748"
    },
    {
      "sample_idx": 1243,
      "input": ".Head & Neck. Head And Neck. Clinical Diagnosis & History: Papillary thyroid cancer. Specimens Submitted: 1: SP: Pretracheal and superior mediastinal lymph nodes (fs). 2: SP: Total thyroidectomy. 3: SP: Delphian node. 4: SP: Right paratrachael node. DIAGNOSIS: 1. SP: Pretracheal and superior mediastinal lymph nodes, excision (fs): -Metastatic papillary thyroid carcinoma in two of three lymph nodes (2/3). -The largest metastatic lymph node measures 0.5 cm in greatest dimension and the metastatic ...",
      "response": "```json\n{\n    \"cancer_type\": \"TPC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, metastatic. 3. Code: TPC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TPC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, metastatic. 3. Code: TPC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TPC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, metastatic. 3. Code: TPC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TPC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, metastatic. 3. Code: TPC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TPC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, metastatic. 3. Code: TPC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TPC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, metastatic. 3. Code: TPC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TPC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, metastatic. 3. Code: TPC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TPC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, metastatic. 3. Code: TPC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TPC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, metastatic. 3. Code: TPC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TPC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary",
      "predicted": "TPC",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, metastatic. 3. Code: TPC.",
      "idx": 1243,
      "timestamp": "2026-01-19T15:59:53.118757"
    },
    {
      "sample_idx": 898,
      "input": "Gross Description. Microscopic Description. Diagnosis Details. Comme. nts. LUNG TISSUE CHECKLIST. Specimen type: Lobectomy. Tumor site: Lung. Tumor size: 5 X 5 X 5 cm. Histologic type: Squamous cell carcinoma. Histologic grade: Moderately differentiated. Tumor extent: Not specified. Other tumor nodules: Not specified. Lymph nodes: 0/4 positive for metastasis. (Regional 0/4). Lymphatic invasion: Not specified. Venous invasion: Not specified. Margins: Not specified. Evidence of neo-adjuvant treatm...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: LUAD (Lung Adenocarcinoma) is the most appropriate code based on the description.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: ESCA (Esophageal Squamous Cell Carcinoma) is the most appropriate code based on the description.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: ESCA (Esophageal Squamous Cell Carcinoma) is the most appropriate code based on the description.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: ESCA (Esophageal Squamous Cell Carcinoma) is the most appropriate code based on the description.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: ESCA (Esophageal Squamous Cell Carcinoma) is the most appropriate code based on the description.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: ESCA (Esophageal Squamous Cell Carcinoma) is the most appropriate code based on the description.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: ESCA (Esophageal Squamous Cell Carcinoma) is the most appropriate code based on the description.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: LUAD (Lung Adenocarcinoma) is the most appropriate code based on the description.",
      "idx": 898,
      "timestamp": "2026-01-19T15:59:53.118768"
    },
    {
      "sample_idx": 1056,
      "input": "Acct / R. SDIAGNOSIS. DIAGNOSIS: Radical prostatectomy, bilateral lymph nodes: Carcinoma. Tumor Characteristics: 1. Histologic type: Adenocarcinoma, conventional type. 2. Prostate size: 36 grams, 4.7 X 2.9 x 2.4 cm. 3. Tumor quantitation: Approximately 5% of gland volume. 4. Gleason grade: a. Primary pattern: 3/5. b. Secondary pattern: 4/5. C. Total Gleason score: 7/10. 5. Extraprostatic extension: Not identified. 6. Seminal vesicle involvement: Not identified. 7. Lymphovascular space invasion: ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, conventional type. 3. Gleason grade: 7/10. 4. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, conventional type. 3. Gleason grade: 7/10. 4. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, conventional type. 3. Gleason grade: 7/10. 4. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, conventional type. 3. Gleason grade: 7/10. 4. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, conventional type. 3. Gleason grade: 7/10. 4. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, conventional type. 3. Gleason grade: 7/10. 4. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, conventional type. 3. Gleason grade: 7/10. 4. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "KIRC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate. 2. Findings: Adenocarcinoma, conventional type. 3. Gleason grade: 7/10. 4. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 1056,
      "timestamp": "2026-01-19T15:59:53.118778"
    },
    {
      "sample_idx": 182,
      "input": "Final Diagnosis. Breast, left, modified radical mastectomy: Infiltrating ductal carcinoma, Nottingham grade II (of. III) [tubules 3/3, nuclei 2/3, mitoses 2/3; Nottingham score 779], forming a mass (2.8 x 2.3 x 2.1. cm) located in the retroareolar region of the breast. Ductal carcinoma in situ is absent. Angiolymphatic invasion is absent. Calcifications are not seen. The tumor involves the. overlying skin [AJCC pT4]. All surgical resection margins, including the skin and deep margins,. are negat...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal carcinoma, Nottingham grade II. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal carcinoma, Nottingham grade II. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal carcinoma, Nottingham grade II. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal carcinoma, Nottingham grade II. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal carcinoma, Nottingham grade II. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal carcinoma, Nottingham grade II. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal carcinoma, Nottingham grade II. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal carcinoma, Nottingham grade II. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Infiltrating ductal carcinoma, Nottingham grade II. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 182,
      "timestamp": "2026-01-19T15:59:53.118788"
    },
    {
      "sample_idx": 594,
      "input": "DIAGNOSIS. DIAGNOSIS: A. Soft tissue, \"peritumor fat,\" excision: Benign adipose tissue with no neoplastic process identified. B. Kidney, posterior margin #1, biopsy: No tumor identified. Permanent sections confirm the frozen section diagnosis. C. Kidney, right, partial nephrectomy: Tumor Characteristics: 1. Histologic type: Renal cell carcinoma, papillary subtype. 2. Tumor site: Right kidney. 3. Tumor focality: Unifocal. 4. Tumor size: 4.0 cm in greatest dimension. 5. Macroscopic extent of tumor...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary subtype, Fuhrman grade 2/4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary subtype, Fuhrman grade 2/4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary subtype, Fuhrman grade 2/4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary subtype, Fuhrman grade 2/4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary subtype, Fuhrman grade 2/4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary subtype, Fuhrman grade 2/4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary subtype, Fuhrman grade 2/4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary subtype, Fuhrman grade 2/4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 594,
      "timestamp": "2026-01-19T15:59:53.118802"
    },
    {
      "sample_idx": 1089,
      "input": "Clinical Diagnosis & History: Abdominal pain and underwent colonoscopy found mass at 20cm from. . CT. scan revealed multiple liver metastases and sigmoid mass biopsy confirmed. invasive adenocarcinoma carcinoma at sigmoid colon with liver metastasis. Specimens Submitted: 1: SP: SIGMOID AND UPPER RECTUM; RESECTION. 2: SP: Proximal ring. 3: SP: Distal ring. 4: SP: Umbilical hernia sac. DIAGNOSIS: 1. SP: SIGMOID AND UPPER RECTUM; RESECTION: Tumor Type: Adenocarcinoma. Histologic Grade: Moderately d...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated, with extensive tumor budding and suspected lymphovascular invasion. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated, with extensive tumor budding and suspected lymphovascular invasion. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated, with extensive tumor budding and suspected lymphovascular invasion. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated, with extensive tumor budding and suspected lymphovascular invasion. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated, with extensive tumor budding and suspected lymphovascular invasion. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated, with extensive tumor budding and suspected lymphovascular invasion. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated, with extensive tumor budding and suspected lymphovascular invasion. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"",
      "predicted": "COAD",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated, with extensive tumor budding and suspected lymphovascular invasion. 3. Code: COAD maps to COAD.",
      "idx": 1089,
      "timestamp": "2026-01-19T15:59:53.118813"
    },
    {
      "sample_idx": 1015,
      "input": "Short descriptive translation of the pathology report as provided by the. Date report: Material received: Material: left adrenal. Macroscopic findings: within the normal appearing adrenal well discernible tumor of 3.5x3.2x3 cm size with brown. appearance and concentric reddish areas. Microscopic findings: Confluent neoplasia of the adrenal medulla with partial compression of the adrenal cortex. Tumor cells with oval shaped eccentric nuclei of middle size with peripheral nucleoli and. large amoun...",
      "response": "```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, a tumor of the adrenal medulla. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, a tumor of the adrenal medulla. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, a tumor of the adrenal medulla. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, a tumor of the adrenal medulla. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, a tumor of the adrenal medulla. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, a tumor of the adrenal medulla. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, a tumor of the adrenal medulla. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings",
      "predicted": "PHCG",
      "ground_truth": "PCPG",
      "correct": false,
      "reasoning": "1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, a tumor of the adrenal medulla. 3. Code: Pheochromocytoma maps to PHCG.",
      "idx": 1015,
      "timestamp": "2026-01-19T15:59:53.118823"
    },
    {
      "sample_idx": 111,
      "input": "Diagnosis: 1. Poorly differentiated invasive breast carcinoma with focal in situ spread. (tumor diameter: 2.2 cm). In conclusion, this is a poorly differentiated invasive ductal carcinoma with focal. neuroendocrine characteristics. In conjunction with the preliminary finding, this gives rise to the following tumor. classification: NOS, G III, pT2N0(sn)LOVORO.",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 111,
      "timestamp": "2026-01-19T15:59:53.118833"
    },
    {
      "sample_idx": 610,
      "input": "Diagnosis: Left kidney and ureter, nephroureterectomy. Histologic tumor type/subtype: Renal cell carcinoma,. papillary type (type 1). Histologic grade (if applicable) : Fuhrman nuclear grade. 2. (of 4). Tumor size (greatest dimension) : 7.9 cm in greatest. dimension. Extent of tumor invasion: Capsular invasion/perirenal adipose tissue: Negative. Gerota' S fascia: Negative. Renal vein: Negative. Ureter: Negative (see comment). Lymphovascular space invasion: Not identified. Histologic assessment o...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left kidney and ureter. 2. Findings: Renal cell carcinoma, papillary type (type 1). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left kidney and ureter. 2. Findings: Renal cell carcinoma, papillary type (type 1). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left kidney and ureter. 2. Findings: Renal cell carcinoma, papillary type (type 1). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left kidney and ureter. 2. Findings: Renal cell carcinoma, papillary type (type 1). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left kidney and ureter. 2. Findings: Renal cell carcinoma, papillary type (type 1). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left kidney and ureter. 2. Findings: Renal cell carcinoma, papillary type (type 1). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left kidney and ureter. 2. Findings: Renal cell carcinoma, papillary type (type 1). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left kidney and",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Left kidney and ureter. 2. Findings: Renal cell carcinoma, papillary type (type 1). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 610,
      "timestamp": "2026-01-19T15:59:53.118843"
    },
    {
      "sample_idx": 444,
      "input": "Case imported from legacy computer system. The format of this report does not match the original case. For cases prior to. the section \"SPECIMEN\" may have been added. DIAGNOSIS. (A) RIGHT FACIAL LYMPH NODE: one node, no tumor present. (B). RIGHT HYPOGLOSSAL NODE: No tumor present. LEFT HYPOGLOSSAL NERVE: Nerve, no tumor present. TOTAL GLOSSECTOMY, SUBMANDIBULAR: THREE FOCI OF INVASIVE MODERATELY WELL DIFFERENTIATED SQUAMOUS. CARCINOMA (SIZE RANGE 6.0 TO 1.2 CM) WITH PERINEURAL. INVASION. Margins...",
      "response": "```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Oral Cavity (Total Glossectomy, Submandibular). 2. Findings: Squamous cell carcinoma, invasive, well-differentiated. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Oral Cavity (Left Gingival Node). 2. Findings: Squamous cell carcinoma, invasive, well-differentiated. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Oral Cavity (Right Facial Lymph Node). 2. Findings: Squamous cell carcinoma, invasive, well-differentiated. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Oral Cavity (Right Hypoglossal Node). 2. Findings: Squamous cell carcinoma, invasive, well-differentiated. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Oral Cavity (Left Parapharyngeal Space and Anterior Tonsillar Pillar). 2. Findings: Squamous cell carcinoma, invasive, well-differentiated. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Oral Cavity (Left Gingival Node). 2. Findings: Squamous cell carcinoma, invasive, well-differentiated. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Oral Cavity (Left Gingival Node). 2. Findings: Squamous cell carcinoma, invasive, well-differentiated. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Oral Cavity (Left Gingival Node). 2. Findings",
      "predicted": "SCC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Oral Cavity (Total Glossectomy, Submandibular). 2. Findings: Squamous cell carcinoma, invasive, well-differentiated. 3. Code: SCC maps to SCC.",
      "idx": 444,
      "timestamp": "2026-01-19T15:59:53.118855"
    },
    {
      "sample_idx": 353,
      "input": "Coded sample ID: Histologic diagnosis: moderate differentiated adenocarcinoma in Barrett-epithelium. Anatomic site with laterality: distal esophagus. Tumor size: diameter 5 cm. Lymph node status: 19 negative lymph nodes. Any comments or amendments: radical resection.",
      "response": "```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium, 5 cm. 3. Code: Adenocarcinoma of the esophagus maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium, 5 cm. 3. Code: Adenocarcinoma of the esophagus maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium, 5 cm. 3. Code: Adenocarcinoma of the esophagus maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium, 5 cm. 3. Code: Adenocarcinoma of the esophagus maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium, 5 cm. 3. Code: Adenocarcinoma of the esophagus maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium, 5 cm. 3. Code: Adenocarcinoma of the esophagus maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium, 5 cm. 3. Code: Adenocarcinoma of the esophagus maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate",
      "predicted": "ADEN",
      "ground_truth": "ESCA",
      "correct": false,
      "reasoning": "1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium, 5 cm. 3. Code: Adenocarcinoma of the esophagus maps to ADEN.",
      "idx": 353,
      "timestamp": "2026-01-19T15:59:53.118865"
    },
    {
      "sample_idx": 1121,
      "input": "Clinical Diagnosis & History: , year old male with right sided retroperitoneal mass. Specimens Submitted: 1: SP: Retroperitoneal liposarcoma. DIAGNOSIS: 1. SOFT TISSUE, RETROPERITONEUM; RESECTION: DEDIFFERENTIATED LIPOSARCOMA ARISING IN WELL-DIFFERENTIATED. LIPOSARCOMA. - THE DEDIFFERENTIATED COMPONENT PREDOMINATES AND HAS A HETEROGENOUS. MORPHOLOGY, RANGING FROM MYXOFIBROSARCOMA TO A PLEOMORPHIC HIGH GRADK. MALIGNANT FIBROUS HISTIOCYTOMA-LIKE GROWTH PATTERN. - FOCAL AREAS OF WELL-DIFFERENTIATED...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Retroperitoneal mass. 2. Findings: Differentiated liposarcoma, dedifferentiated liposarcoma, well-differentiated liposarcoma, renal cell carcinoma, renal cyst. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning",
      "predicted": "KIRC",
      "ground_truth": "SARC",
      "correct": false,
      "reasoning": "1. Site: Retroperitoneal mass. 2. Findings: Differentiated liposarcoma, dedifferentiated liposarcoma, well-differentiated liposarcoma, renal cell carcinoma, renal cyst. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 1121,
      "timestamp": "2026-01-19T15:59:53.118878"
    },
    {
      "sample_idx": 805,
      "input": "urgical Pathology. TISSUE DESCRIPTION: A1 B1 B2 B3 B4 C1 D1 D2 E1 E2 E3 E4 F1 G1 G2 G3 G4 G5. Left lower lobe lung (140.0 grams), left upper lobe lung lymph node,. station 4L, 6, and 7 lymph nodes. DIAGNOSIS: Lung, left lower, lobectomy: Invasive grade 3 (of 4) adenocarcinoma. forming a 2.5 x 2.5 x 2.5 cm subpleural mass that abuts but does not. involve the puckered pleural surface. The bronchial resection. margin is free of tumor. Lymph nodes, left upper lung, excision: -A single Tymph node is ...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, left lower lobe. 2. Findings: Invasive adenocarcinoma, grade 3. 3. Code: Lung, left lower lobe maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe. 2. Findings: Metastatic adenocarcinoma. 3. Code: Lung, left upper lobe maps to UCSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Lung, left mediastinal. 2. Findings: Metastatic adenocarcinoma. 3. Code: Lung, left mediastinal maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Lung, left lower lobe. 2. Findings: Metastatic adenocarcinoma. 3. Code: Lung, left lower lobe maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe. 2. Findings: Metastatic adenocarcinoma. 3. Code: Lung, left upper lobe maps to UCSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Lung, left mediastinal. 2. Findings: Metastatic adenocarcinoma. 3. Code: Lung, left mediastinal maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Lung, left lower lobe. 2. Findings: Metastatic adenocarcinoma. 3. Code: Lung, left lower lobe maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe. 2. Findings: Metastatic adenocarcinoma. 3. Code: Lung, left upper lobe maps to UCSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\":",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung, left lower lobe. 2. Findings: Invasive adenocarcinoma, grade 3. 3. Code: Lung, left lower lobe maps to LUAD.",
      "idx": 805,
      "timestamp": "2026-01-19T15:59:53.118888"
    },
    {
      "sample_idx": 321,
      "input": "Diagnosis: Resected section of colon (sigma) with a colon carcinoma of the histological type of a. moderately differentiated, partially mucus-producing colorectal adenocarcinoma,. measuring a maximum of 2 cm in diameter, and stretching up to 4.5cm to a margin of the. resected material. The tumor has spread invasively to the internal sections of the muscularis. propria. Otherwise the intestinal wall has some pseudodiverticula and peridiverticulitis with chronic. scarring. Oral and aboral margin o...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated, partially mucus-producing. 3. Code: COAD maps to the adenocarcinoma of the colon.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Pseudodiverticula and peridiverticulitis with chronic scarring. 3. Code: ADENOMA maps to the colon.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAPC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Mesocolic lymph nodes tumor-free with uncharacteristically reactive changes. 3. Code: PAPC maps to the colon.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Tumor stage therefore pT2, pNO (0/22) L0, V0; G2 R0. 3. Code: COAD maps to the adenocarcinoma of the colon.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Moderately differentiated, partially mucus-producing colorectal adenocarcinoma, measuring a maximum of 2 cm in diameter, and stretching up to 4.5cm to a margin of the resected material. 3. Code: COAD maps to the adenocarcinoma of the colon.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Moderately differentiated, partially mucus-producing colorectal adenocarcinoma, measuring a maximum of 2 cm in diameter, and stretching up to 4.5cm to a margin of the resected material. 3. Code: COAD maps to the adenocarcinoma of the colon.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Moderately differentiated, partially mucus-producing colorectal adenocarcinoma, measuring a maximum of ",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated, partially mucus-producing. 3. Code: COAD maps to the adenocarcinoma of the colon.",
      "idx": 321,
      "timestamp": "2026-01-19T15:59:53.118898"
    },
    {
      "sample_idx": 446,
      "input": "Case type: Surgical Case. DIAGNOSIS. (A) RIGHT TONGUE BIOPSY: Squamous mucosa with skeletal muscle and fibroadipose tissue, no tumor present. (B) LEFT TONGUE BIOPSY: INVASIVE SQUAMOUS CARCINOMA, MODERATELY DIFFERENTIATED. (C) LEFT PARTIAL GLOSSECTOMY: INVASIVE SQUAMOUS CARCINOMA, MODERATELY DIFFERENTIATED, 3.0 CM. DEPTH OF INVASION 1.0 CM. PERINEURAL INVASION PRESENT FOCALLY. (D) LEFT BUCCAL MUCOSAL MARGIN: Squamous mucosa and skeletal muscle, no tumor present. (E) RETROMOLAR TRIGONE, LEFT: Squa...",
      "response": "```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Tongue (Right). 2. Findings: Invasive squamous cell carcinoma, moderately differentiated. 3. Code: BLCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Tongue (Left). 2. Findings: Invasive squamous cell carcinoma, moderately differentiated. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Tongue (Left). 2. Findings: Invasive squamous cell carcinoma, moderately differentiated. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Tongue (Left). 2. Findings: Invasive squamous cell carcinoma, moderately differentiated. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Tongue (Left). 2. Findings: Invasive squamous cell carcinoma, moderately differentiated. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Tongue (Left). 2. Findings: Invasive squamous cell carcinoma, moderately differentiated. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Tongue (Left). 2. Findings: Invasive squamous cell carcinoma, moderately differentiated. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Tongue (Left). 2. Findings: Invasive squamous cell carcinoma, moderately differentiated. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Tongue (Left). 2. Findings: Invasive squamous cell carcinoma, moderately differentiated. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n",
      "predicted": "BLCA",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Tongue (Right). 2. Findings: Invasive squamous cell carcinoma, moderately differentiated. 3. Code: BLCA.",
      "idx": 446,
      "timestamp": "2026-01-19T15:59:53.118908"
    },
    {
      "sample_idx": 620,
      "input": "Patholgy Accession No: Patient ID: Normal Sample ID: MODIFIED REPORT - REVIEW ADDENDUM SECTION. COMMENT. This addendum report is issued to comment on the type of papillary renal cell carcinoma,. as it was not mentioned in the original report. There is no other change in diagnosis. After review of the H&E slides, this tumor is designated as type 2 papillary renal cell. carcinoma. DIAGNOSIS. (A) LEFT PARTIAL NEPHRECTOMY: PAPILLARY RENAL CELL CARCINOMA, FUHRMAN'S NUCLEAR GRADE 3. TUMOR CONFINED TO ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Kidney (Left Upper Pole). 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 620,
      "timestamp": "2026-01-19T15:59:53.118918"
    },
    {
      "sample_idx": 523,
      "input": "Accession # : Diagnosis: Right kidney, nephrectomy. Histologic tumor type/subtype: renal cell carcinoma, clear. cell type. Histologic grade (if applicable) : 2 (of 4,. classification). Tumor size (greatest dimension) : 6.7 cm diameter (gross). Extent of tumor invasion: Extra-capsular invasion: present, perihilar / renal sinus. fat (A9). Renal vein: tributary involved (A11) , but not involving. renal vein margin (A1). Ureter: not identified. Venous (large vessel) : see above. Lymphatic (small ves...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney.",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 523,
      "timestamp": "2026-01-19T15:59:53.118928"
    },
    {
      "sample_idx": 979,
      "input": "Surgical Pathology Report Site Pancreas head. DATE OBTAINED: DATE RECEIVED: SUBMITTING MD: DIAGNOSIS. 1. FALCIFORM LIGAMENT; EXCISION: BENIGN FIBROMUSCULAR AND ADIPOSE TISSUE; NEGATIVE FOR. TUMOR. 2. GALLBLADDER; CHOLECYSTECTOMY: MILD CHRONIC CHOLECYSTITIS; NEGATIVE FOR TUMOR. 3. PANCREAS, STOMACH AND SMALL BOWEL; WHIPPLE PROCEDURE: PANCREATIC DUCTAL ADENOCARCINOMA. Tumor site: Head of pancreas. Tumor size: 2.8 cm. Histologic type: Ductal Adenocarcinoma with focal non-keratinizing squamous. comp...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas head. 2. Findings: Pancreatic ductal adenocarcinoma with focal non-keratinizing squamous component. 3. Code: KIRC.\"\n}\n```\nExplanation:\nThe report clearly states the presence of pancreatic ductal adenocarcinoma in the head of the pancreas. The presence of a focal non-keratinizing squamous component is also noted. The TCGA code for pancreatic adenocarcinoma is KIRC.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas head. 2. Findings: Pancreatic ductal adenocarcinoma with focal non-keratinizing squamous component. 3. Code: KIRC.\"\n}\n```\nThe report identifies pancreatic ductal adenocarcinoma in the head of the pancreas. The presence of a focal non-keratinizing squamous component is also mentioned. The TCGA code for pancreatic adenocarcinoma is KIRC.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas head. 2. Findings: Pancreatic ductal adenocarcinoma with focal non-keratinizing squamous component. 3. Code: KIRC.\"\n}\n```\nThe report states the diagnosis is pancreatic ductal adenocarcinoma in the head of the pancreas. The presence of a focal non-keratinizing squamous component is also noted. The TCGA code for pancreatic adenocarcinoma is KIRC.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas head. 2. Findings: Pancreatic ductal adenocarcinoma with focal non-keratinizing squamous component. 3. Code: KIRC.\"\n}\n```\nThe report identifies pancreatic ductal adenocarcinoma in the head of the pancreas. The presence of a focal non-keratinizing squamous component is also noted. The TCGA code for pancreatic adenocarcinoma is KIRC.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas head. 2. Findings: Pancreatic ductal adenocarcinoma with focal non-keratinizing squamous component. 3. Code: KIRC.\"\n}\n```\nThe report identifies pancreatic ductal adenocarcinoma in the head of the pancreas. The presence of a focal",
      "predicted": "KIRC",
      "ground_truth": "PAAD",
      "correct": false,
      "reasoning": "1. Site: Pancreas head. 2. Findings: Pancreatic ductal adenocarcinoma with focal non-keratinizing squamous component. 3. Code: KIRC.",
      "idx": 979,
      "timestamp": "2026-01-19T15:59:53.118938"
    },
    {
      "sample_idx": 394,
      "input": "CLINICAL HISTORY. has had headaches for about. and. generalized weakness. On imaging, there is a 4.6 cm superior right frontal. mass with T1 central hyperintensity, fluid levels, rim thickened enhancement,. and broad attachment to falx. OPERATIVE DIAGNOSES. Brain umor-craniotomy. Operation/Specimen: A: Brain, right frontal lesion, biopsy. Brain, right frontal lesion, biopsy. PATHOLOGICAL DIAGNOSIS: Brain, right frontal, excisional biopsies: 1. Malignant glioma, pleomorphic, superficial (WHO III)...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, right frontal. 2. Findings: Malignant glioma, pleomorphic, superficial (WHO III). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, right frontal. 2. Findings: Malignant glioma, pleomorphic, superficial (WHO III). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, right frontal. 2. Findings: Malignant glioma, pleomorphic, superficial (WHO III). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, right frontal. 2. Findings: Malignant glioma, pleomorphic, superficial (WHO III). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, right frontal. 2. Findings: Malignant glioma, pleomorphic, superficial (WHO III). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, right frontal. 2. Findings: Malignant glioma, pleomorphic, superficial (WHO III). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, right frontal. 2. Findings: Malignant glioma, pleomorphic, superficial (WHO III). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, right frontal. 2. Findings: Malignant glioma, pleomorphic, superficial (WHO III). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1.",
      "predicted": "KIRC",
      "ground_truth": "GBM",
      "correct": false,
      "reasoning": "1. Site: Brain, right frontal. 2. Findings: Malignant glioma, pleomorphic, superficial (WHO III). 3. Code: KIRC.",
      "idx": 394,
      "timestamp": "2026-01-19T15:59:53.118948"
    },
    {
      "sample_idx": 921,
      "input": "DIAGNOSIS: EXPLORATORY LAPARATOMY, TOTAL ABDOMINAL HYSTERECTOMY WITH. BILATERAL SALPINGO-OOPHORECTOMY. A. RIGHT TUBE AND OVARY (FROZEN). M\u00fcllerian adenocarcinoma, serous type, extensively involving ovary. Size: 7.0 cm approximately, in greatest dimension. Capsule: Ruptured. Angiolymphatic invasion: Not identified. Necrosis: Present, accounting for approximately 15% of tumor volume. Portion of fallopian tube with no carcinoma identified. AJCC Pathologic Stage (2002, 6th Ed): pT2c/N0. B. PELVIC SI...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right). 2. Findings: Ovarian serous carcinoma, high grade, with serous features. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right). 2. Findings: Ovarian serous carcinoma, high grade, with serous features. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right). 2. Findings: Ovarian serous carcinoma, high grade, with serous features. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right). 2. Findings: Ovarian serous carcinoma, high grade, with serous features. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right). 2. Findings: Ovarian serous carcinoma, high grade, with serous features. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right). 2. Findings: Ovarian serous carcinoma, high grade, with serous features. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right). 2. Findings: Ovarian serous carcinoma, high grade, with serous features. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right). 2. Findings: Ovarian serous carcinoma, high grade, with serous features. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n",
      "predicted": "BRCA",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Ovary (Right). 2. Findings: Ovarian serous carcinoma, high grade, with serous features. 3. Code: BRCA",
      "idx": 921,
      "timestamp": "2026-01-19T15:59:53.118958"
    },
    {
      "sample_idx": 590,
      "input": "Clinical Diagnosis & History: Right renal tumor. Specimens Submitted: 1: SP: Right kidney. 2: SP: Paracaval lymph nodes. DIAGNOSIS: 1). KIDNEY, RIGHT; NEPHRECTOMY. - RENAL CELL CARCINOMA, CLEAR CELL TYPE WITH FOCAL SPINDLE. CELL FEATURES, NUCLEAR GRADE III/IV. - THE PATTERN OF GROWTH IS SOLID. - THE TUMOR'S GREATEST DIAMETER IS 8.0 CM. - FOCALLY, THE TUMOR EXTENDS THROUGH THE RENAL CAPSULE BUT. IS CONFINED WITHIN GEROTA'S FASCIA. - NO INVASION OF THE RENAL VEIN IS IDENTIFIED. - ALL SURGICAL MARG...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II.",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 590,
      "timestamp": "2026-01-19T15:59:53.118972"
    },
    {
      "sample_idx": 194,
      "input": "SURGICAL REPORT. Sex: F. Date Collected: Date Received: M.R. Number. Doctor: Account Numbe. PRE-OPERATIVE DIAGNOSIS. CA RIGHT BREAST. POST-OPERATIVE DIAGNOSIS. CA RIGHT BREAST. PROCEDURE. MODIFIED RADICAL MASTECTOMY RIGHT BREAST, INSERTION MEDIPORT. TISSUES. BREAST MASTECTOMY (WMV) NODES - RIGHT BREAST AND AXILLARY CONTENTS. FINAL DIAGNOSIS. RIGHT BREAST AND AXILLARY CONTENTS -. POORLY DIFFERENTIATED INFILTRATING DUCTAL CARCINOMA, SCARFF-. BLOOM-RICHARDSON GRADE III/III. THE TUMOR MEASURES 10.5 ...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 194,
      "timestamp": "2026-01-19T15:59:53.118983"
    },
    {
      "sample_idx": 260,
      "input": "SPEC #: Obtained: CLINICAL HISTORY. ICD-9: 233.1. SPECIMEN/PROCEDURE. 1. CERVIX. IMPRESSION: CERVICAL BIOPSY: Squamous cell caroinoma with stromal invasion, large cell nonkexatinizing, grade 2. Prominent lymphoplasmaaytio infiltrate. Diotated by: Entered: GROSS DESCRIPTION: : 1. Received in formalin labeled with the patient's name and cervical biopsy. Received is. a pale pink to red tan irregular tissue fragment that is 0.6 x 0.5 x 0.4 cm. The specimen. is entirely submitted in cassette #1. Diot...",
      "response": "```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma with stromal invasion, large cell non-keratinizing, grade 2. Prominent lymphoplasma cell infiltrate. 3. Code: Cervical Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma with stromal invasion, large cell non-keratinizing, grade 2. Prominent lymphoplasma cell infiltrate. 3. Code: Cervical Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma with stromal invasion, large cell non-keratinizing, grade 2. Prominent lymphoplasma cell infiltrate. 3. Code: Cervical Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma with stromal invasion, large cell non-keratinizing, grade 2. Prominent lymphoplasma cell infiltrate. 3. Code: Cervical Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma with stromal invasion, large cell non-keratinizing, grade 2. Prominent lymphoplasma cell infiltrate. 3. Code: Cervical Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma with stromal invasion, large cell non-keratinizing, grade 2. Prominent lymphoplasma cell infiltrate. 3. Code: Cervical Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json",
      "predicted": "HNSC",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Cervix. 2. Findings: Squamous cell carcinoma with stromal invasion, large cell non-keratinizing, grade 2. Prominent lymphoplasma cell infiltrate. 3. Code: Cervical Squamous Cell Carcinoma maps to HNSC.",
      "idx": 260,
      "timestamp": "2026-01-19T15:59:53.118996"
    },
    {
      "sample_idx": 45,
      "input": "PRIMARY SITE: Bladder. 1 - \"Bladder + prostate\": High-grade urothelial carcinoma of the bladder characterized as follows: Measure of neoplasia in its major axis: 6.2 cm. Ulcerated and infiltrative neoplasia affecting all layers of the bladder and perivisceral. fat. Prostate, seminal vesicles, vas deferens, ureters and urethra free of neoplastic. involvement. Neural infiltration not observed. Lymphatic vascular invasion not detected. . Sanguineous vascular invasion not detected. Surgical margins ...",
      "response": "```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: High-grade urothelial carcinoma. 3. Code: Bladder maps to BLCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Prostate adenocarcinoma. 3. Code: Prostate maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Lymph node involvement. 3. Code: Lymph node maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Transitional cell carcinoma. 3. Code: Bladder maps to BLCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Lymph node involvement. 3. Code: Lymph node maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Lymph node involvement. 3. Code: Lymph node maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Lymph node involvement. 3. Code: Lymph node maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Lymph node involvement. 3. Code: Lymph node maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Lymph node involvement. 3. Code: Lymph node maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",",
      "predicted": "BLCA",
      "ground_truth": "BLCA",
      "correct": true,
      "reasoning": "1. Site: Bladder. 2. Findings: High-grade urothelial carcinoma. 3. Code: Bladder maps to BLCA.",
      "idx": 45,
      "timestamp": "2026-01-19T15:59:53.119006"
    },
    {
      "sample_idx": 1357,
      "input": "Surg Path Report. SOURCE OF TISSUE: 1. UTERUS, CERVIX, BILATERAL TUBES AND OVARIES 2. ABDOMINAL SCAR 3. OMENTUM 4. LEFT EXTERNAL LYMPH NODES 5. LEFT INTERNAL ILIAC LYMPH NODES. 6. LEFT OBTURATOR LYMPH NODES 7. LEFT COMMON ILIAC LYMPH NODES 8. LEFT. AORTIC NODES 9. RIGHT EXTERNAL ILIAC LYMPH NODES 10. RIGHT INTERNAL. ILIAC LYMPH NODES 11. RIGHT COMMON ILIAC LYMPH NODES 12. RIGHT AORTIC. LYMPH NODES 13. RIGHT OBTURATOR LYMPH NODES. GROSS: Specimen \"No. 1\" labeled \"Uterus, Cervix, Bilateral Tubes a...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Bilateral Tubes and Ovaries. 2. Findings: High grade papillary serous carcinoma of endometrium. 3. Code: BRCA is not applicable to this cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Bilateral Tubes and Ovaries. 2. Findings: High grade papillary serous carcinoma of endometrium. 3. Code: KIRC is a valid code for endometrial carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Bilateral Tubes and Ovaries. 2. Findings: High grade papillary serous carcinoma of endometrium. 3. Code: BRCA is not applicable to this cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Bilateral Tubes and Ovaries. 2. Findings: High grade papillary serous carcinoma of endometrium. 3. Code: KIRC is a valid code for endometrial carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Bilateral Tubes and Ovaries. 2. Findings: High grade papillary serous carcinoma of endometrium. 3. Code: KIRC is a valid code for endometrial carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Bilateral Tubes and Ovaries. 2. Findings: High grade papillary serous carcinoma of endometrium. 3. Code: KIRC is a valid code for endometrial carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Bilateral Tubes and Ovaries. 2. Findings: High grade papillary serous carcinoma of endometrium. 3. Code: KIRC is a",
      "predicted": "BRCA",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Uterus, Cervix, Bilateral Tubes and Ovaries. 2. Findings: High grade papillary serous carcinoma of endometrium. 3. Code: BRCA is not applicable to this cancer type.",
      "idx": 1357,
      "timestamp": "2026-01-19T15:59:53.119017"
    },
    {
      "sample_idx": 965,
      "input": "OF SURGICAL PATHOLOGY. Address: : Hosp. No. : DIAGNOSIS. OVARY, RIGHT, SALPINGO-OOPHORECTOMY - POORLY DIFFERENTIATED. PAPILLARY SEROUS ADENOCAROINOMA (SEE COMMENT). OVARY, RIGHT, \"TUMOR, 11 EXCISION - POORIYDIFFERENTIATED PAPTLLARY. SEROUS ADENOCARCINOMA. OVARY, LEFT, SALPINGO-OOPHORECTOMY . METASTATIC PAPILLARY SEROUS. CARCINOMA IN PARA-OVARIAN ADHESIONS. - SEROUS CYSTADENOMA. FALLOPIAN TUBE, LEFT, SALPINGO-OOPHORECTOMY - METASTATIC PAPILLARY. SEROUS ADENOCARCINOMA IN PERITUBAL TISSUE. APPENDIX...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right and Left). 2. Findings: Papillary serous adenocarcinoma, poorly differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right and Left). 2. Findings: Papillary serous adenocarcinoma, poorly differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right and Left). 2. Findings: Papillary serous adenocarcinoma, poorly differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right and Left). 2. Findings: Papillary serous adenocarcinoma, poorly differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right and Left). 2. Findings: Papillary serous adenocarcinoma, poorly differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right and Left). 2. Findings: Papillary serous adenocarcinoma, poorly differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right and Left). 2. Findings: Papillary serous adenocarcinoma, poorly differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right and Left). 2. Findings: Papillary serous adenocarcinoma, poorly differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right and Left). 2. Findings: Papillary",
      "predicted": "BRCA",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Ovary (Right and Left). 2. Findings: Papillary serous adenocarcinoma, poorly differentiated. 3. Code: BRCA",
      "idx": 965,
      "timestamp": "2026-01-19T15:59:53.119026"
    },
    {
      "sample_idx": 1252,
      "input": "Sex: F. Case type: Surgical Case. DIAGNOSIS. (A) LEFT THYROID LOBECTOMY AND ISTHMUS: PAPILLARY THYROID CARCINOMA, CONVENTIONAL TYPE. Location: Left lobe. Multi-focal: No. Size = 1.8 cm. Extrathyroidal extension: Absent. Lymphovascular invasion: Absent. Resection Margins: Negative. Lymph nodes: No tumor present in 1 lymph node. GROSS DESCRIPTION. (A) LEFT THYROID LOBECTOMY AND ISTHMUS FOR FS - A hemithyroidectorny specimen with attached isthmus, the. thyroid lobe (6.0 x 2.0 x 1.5 cm), and isthmus...",
      "response": "```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe. 2. Findings: Papillary thyroid carcinoma, conventional type. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe. 2. Findings: Follicular adenoma with tiny papillary microcarcinoma (likely incidental). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe. 2. Findings: Follicular adenoma with tiny papillary microcarcinoma (likely incidental). 3. Code: TGCT maps to TGCT.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe. 2. Findings: Follicular adenoma with tiny papillary microcarcinoma (likely incidental). 3. Code: UVM maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe. 2. Findings: Papillary thyroid carcinoma, conventional type. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe. 2. Findings: Follicular adenoma with tiny papillary microcarcinoma (likely incidental). 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe. 2. Findings: Follicular adenoma with tiny papillary microcarcinoma (likely incidental). 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe. 2. Findings: Follicular adenoma with tiny papillary microcarcinoma (likely incidental",
      "predicted": "THCA",
      "ground_truth": "THCA",
      "correct": true,
      "reasoning": "1. Site: Left Thyroid Lobe. 2. Findings: Papillary thyroid carcinoma, conventional type. 3. Code: THCA maps to THCA.",
      "idx": 1252,
      "timestamp": "2026-01-19T15:59:53.119038"
    },
    {
      "sample_idx": 532,
      "input": "Clinical Diagnosis & History: Right renal cortical tumor. Laparoscopic right nephrectomy. Specimens Submitted: 1: SP: Right kidney (sr). DIAGNOSIS: 1). KIDNEY, RIGHT; LAPAROSCOPIC NEPHRECTOMY: - RENAL CELL CARCINOMA, CLEAR CELL TYPE, NUCLEAR GRADE II/IV. - THE PATTERN OF GROWTH IS SOLID. - THE TUMOR GREATEST DIAMETER IS 4.5 CM. - THE TUMOR IS CONFINED WITHIN THE RENAL CAPSULE. - NO INVASION OF THE RENAL VEIN IS IDENTIFIED. - ALL SURGICAL MARGINS ARE FREE OF TUMOR. THE NON-NEOPLASTIC KIDNEY SHOWS...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney.",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 532,
      "timestamp": "2026-01-19T15:59:53.119050"
    },
    {
      "sample_idx": 1163,
      "input": "FINAL DIAGNOSIS: PART :LIVER, NODULE, EXCISION -. A. NO VIABLE TUMOR CELLS SEEN. B. DEGENERATEDINECROTC NODULE WITH HEMORRHAGE AND FIBRINOUS DEBRIS. PART 2: ESOPHAGUS AND STOMACH AND JEJUNUM, ESOPHAGOGASTRECTOMY. A. INVASIVE POORLY DIFFERENTIATED ADENOCARCINOMA, MEASURING 2.5 CM, INVOLVING. GASTROESOPHAGEAL JUNCTION. B. TUMOR INVADES INTO ADVENTITIAL SOFT TISSUES. C. ALL SURGICAL MARGINS (PROXIMAL, DISTAL AND RADIAL) ARE FREE OF TUMOR. D. EXTENSIVE LYMPHOVASCULAR SPACE PERMEATION PRESENT. E. PER...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus, Stomach, and Jejunum. 2. Findings: Invasive poorly differentiated adenocarcinoma, measuring 2.5 cm, involving the gastroesophageal junction. 3. Code: ADENOCARCINOMA maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, Lymph Node. 2. Findings: Metastatic adenocarcinoma involving 9 of 17 regional lymph nodes. 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive poorly differentiated adenocarcinoma, measuring 2.5 cm, involving the gastroesophageal junction. 3. Code: BRCA maps to Breast Invasive Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus, Stomach, and Jejunum. 2. Findings: Invasive poorly differentiated adenocarcinoma, measuring 2.5 cm, involving the gastroesophageal junction. 3. Code: ADENOCARCINOMA maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, Lymph Node. 2. Findings: Metastatic adenocarcinoma involving 9 of 17 regional lymph nodes. 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive poorly differentiated adenocarcinoma, measuring 2.5 cm, involving the gastroesophageal junction. 3. Code: BRCA maps to Breast Invasive Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus, Stomach, and Jejunum. 2. Findings: Invasive poorly differentiated adenocarcinoma, measuring ",
      "predicted": "ADENOCARCINOMA",
      "ground_truth": "STAD",
      "correct": false,
      "reasoning": "1. Site: Esophagus, Stomach, and Jejunum. 2. Findings: Invasive poorly differentiated adenocarcinoma, measuring 2.5 cm, involving the gastroesophageal junction. 3. Code: ADENOCARCINOMA maps to ADENOCARCINOMA.",
      "idx": 1163,
      "timestamp": "2026-01-19T15:59:53.119062"
    },
    {
      "sample_idx": 825,
      "input": "Pre-Op Diagnosis. Lung cancer. Post-Op Diagnosis. Same as above. Clinical History. Nothing indicated. Gross Description: Five parts. Container labeled. - level 7 lymph node left. lung\" has a 1.0 x 0.9 x 0.4 cm nodular portion of gray-black fleshy. tissue which is bisected and entirely submitted in a single. cassette. Container labeled. - level 10 lymph node left. lung\" has two nodular portions of rubbery gray-pink fleshy tissue,. 1.5 x 1.0 x 0.7 cm and 1.6 x 1.0 x 0.7 cm. Each has a mottled fles...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Upper Lobe). 2. Findings: Mucinous adenocarcinoma, well differentiated, unifocal, 3.5 x 3.2 x 1.6 cm. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Upper Lobe). 2. Findings: Mucinous adenocarcinoma, well differentiated, unifocal, 3.5 x 3.2 x 1.6 cm. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Upper Lobe). 2. Findings: Mucinous adenocarcinoma, well differentiated, unifocal, 3.5 x 3.2 x 1.6 cm. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Upper Lobe). 2. Findings: Mucinous adenocarcinoma, well differentiated, unifocal, 3.5 x 3.2 x 1.6 cm. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Upper Lobe). 2. Findings: Mucinous adenocarcinoma, well differentiated, unifocal, 3.5 x 3.2 x 1.6 cm. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Upper Lobe). 2. Findings: Mucinous adenocarcinoma, well differentiated, unifocal, 3.5 x 3.2 x 1.6 cm. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Upper Lobe). 2. Findings: Mucinous adenocarcinoma, well differentiated",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung (Left Upper Lobe). 2. Findings: Mucinous adenocarcinoma, well differentiated, unifocal, 3.5 x 3.2 x 1.6 cm. 3. Code: LUAD.",
      "idx": 825,
      "timestamp": "2026-01-19T15:59:53.119072"
    },
    {
      "sample_idx": 551,
      "input": "Diagnosis: Kidney, right, nephrectomy. Tumor histologic type/subtype: Renal cell carcinoma, clear. cell subtype. Histologic grade (if applicable) : Fuhrman grade 2 (of 4). Tumor size (greatest dimension) : 4.5 cm. Extent of tumor invasion: Extra-capsular invasion: not identified. Renal vein: not involved. Ureter: not involved. Venous (large vessel) not involved. Lymphatic (small vessel) : not involved. Surgical margins: Perirenal adipose tissue: not involved. Renal vein: not involved. Renal arte...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, clear cell subtype, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, clear cell subtype, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, clear cell subtype, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, clear cell subtype, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, clear cell subtype, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, clear cell subtype, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, clear cell subtype, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, clear cell subtype, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 551,
      "timestamp": "2026-01-19T15:59:53.119083"
    },
    {
      "sample_idx": 703,
      "input": "FINAL DIAGNOSIS. A. POSTERIOR RIGHT TEMPORAL OCCIPITAL TUMOR, BIOPSY: -- INFILTRATING GLIOMA. B. RIGHT TEMPORAL TIP, BIOPSY: -- INFILTRATING GLIOMA. C. RIGHT TEMPORAL OCCIPITAL BRAIN TUMOR, REMOVAL: -- MIXED OLIGO ASTROCYTOMA (WHO GRADE II). Note: The tumor demonstrates geographically separate areas of astrocytic and oligodendroglial differentiation. Hypercellularity is seen only within the oligodendroglial regions. Mitotic figures are not identified. A focus of. coagulative tumor necrosis lacki...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Temporal, Occipital). 2. Findings: Infiltrating glioma, mixed oligodendroglial/astrocytic, Grade II. The report mentions a focus of coagulative tumor necrosis lacking pseudo-palisading, which is a characteristic finding in glioblastoma. Also, the report mentions a loss of chromosomes 1p and 19q, which is a common genetic alteration in glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Temporal, Occipital). 2. Findings: Infiltrating glioma, mixed oligodendroglial/astrocytic, Grade II. The report mentions a focus of coagulative tumor necrosis lacking pseudo-palisading, which is a characteristic finding in glioblastoma. Also, the report mentions a loss of chromosomes 1p and 19q, which is a common genetic alteration in glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Temporal, Occipital). 2. Findings: Infiltrating glioma, mixed oligodendroglial/astrocytic, Grade II. The report mentions a focus of coagulative tumor necrosis lacking pseudo-palisading, which is a characteristic finding in glioblastoma. Also, the report mentions a loss of chromosomes 1p and 19q, which is a common genetic alteration in glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Temporal, Occipital). 2. Findings: Infiltrating glioma, mixed oligodendroglial/astrocytic, Grade II. The report mentions a focus of coagulative tumor necrosis lacking pseudo-palisading, which is a characteristic finding in glioblastoma. Also, the report mentions a loss of chromosomes 1p and 19q, which is a common genetic alteration in glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain (Temporal, Occipital). 2. Findings: Infiltrating glioma, mixed oligodendroglial/astrocytic, Grade II. The report mentions a focus of coagulative tumor necrosis lacking pseudo-palisading, which is a characteristic finding in glioblastoma. Also, the report mentions a loss of chromosomes 1p and 19q, which is a common genetic alteration in glioblastoma. 3. Code: GBM maps to GBM.",
      "idx": 703,
      "timestamp": "2026-01-19T15:59:53.119099"
    },
    {
      "sample_idx": 736,
      "input": "DIAGNOSIS: Liver, left, hemihepatectomy: Hepatocellular carcinoma, S2. 1) Post-chemoembolization status: absent. 2) Size of tumor: 2.2x2x1.5cm. 3) Gross type: infiltrative. 4) Satellite nodule: absent. 5) Histologic type: trabecular. 6) Cell type: classic and clear cell group. 7) Edmondson and Steiner's histologic grade: The worst differentiation: 3. The major differentiation: 2. 8) Fatty change: present (5%). 9) Hemorthage/peliusis: absent. 10) Tumor necrosis: absent. 11) Vascular nvasion(micro...",
      "response": "```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, S2. 3. Code: LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, S2. 3. Code: LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, S2. 3. Code: LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, S2. 3. Code: LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, S2. 3. Code: LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, S2. 3. Code: LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, S2. 3. Code: LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, S2. 3. Code: LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, S2. 3. Code: LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular",
      "predicted": "LIHC",
      "ground_truth": "LIHC",
      "correct": true,
      "reasoning": "1. Site: Liver. 2. Findings: Hepatocellular carcinoma, S2. 3. Code: LIHC.",
      "idx": 736,
      "timestamp": "2026-01-19T15:59:53.119108"
    },
    {
      "sample_idx": 759,
      "input": "SPECIMENS: 1. F/S LEFT UPPER LOBE. 2. COMPLETION OF LEFT UPPER LOBE. 3. STATION 13 LYMPH NODE. 4. LEVEL 9 LYMPH NODE. 5. LEVEL 5 LYMPH NODE. 6. LEVEL 7 LYMPH NODE. DIAGNOSIS: 1. LUNG, LEFT, UPPER LOBE: WEDGE RESECTION. - TWO FOCI OF INVASIVE ADENOCARCINOMA MIXED WITH. BRONCHIOLOALVEOLAR CARCINOMA, RANGING FROM 2.1cm to 1.4cm,. MODERATELY DIFFERENTIATED (SEE SUMMARY). - FOCI OF ATYPICAL ALVEOLAR HYPERPLASIA. - NO ANGIOLYMPHATIC INVASION SEEN. - IMMUNOHISTOCHEMICAL STUDIES REVEAL THAT TUMOR CELLS ...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Left, Upper Lobe. 2. Findings: Adenocarcinoma, mixed subtype with Bronchioalveolar carcinoma. 3. Code: LUAD.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCLM\",\n    \"reasoning\": \"1. Site: Lung, Left, Upper Lobe. 2. Findings: Adenocarcinoma, mixed subtype with Bronchioalveolar carcinoma. 3. Code: UCLM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCLM\",\n    \"reasoning\": \"1. Site: Lung, Left, Upper Lobe. 2. Findings: Adenocarcinoma, mixed subtype with Bronchioalveolar carcinoma. 3. Code: UCLM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCLM\",\n    \"reasoning\": \"1. Site: Lung, Left, Upper Lobe. 2. Findings: Adenocarcinoma, mixed subtype with Bronchioalveolar carcinoma. 3. Code: UCLM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCLM\",\n    \"reasoning\": \"1. Site: Lung, Left, Upper Lobe. 2. Findings: Adenocarcinoma, mixed subtype with Bronchioalveolar carcinoma. 3. Code: UCLM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCLM\",\n    \"reasoning\": \"1. Site: Lung, Left, Upper Lobe. 2. Findings: Adenocarcinoma, mixed subtype with Bronchioalveolar carcinoma. 3. Code: UCLM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCLM\",\n    \"reasoning\": \"1. Site: Lung, Left, Upper Lobe. 2. Findings: Adenocarcinoma, mixed subtype with Bronchioalveolar carcinoma. 3. Code: UCLM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCLM\",\n    \"reasoning\": \"1. Site: Lung, Left, Upper Lobe. 2. Findings: Adenocarcinoma, mixed",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung, Left, Upper Lobe. 2. Findings: Adenocarcinoma, mixed subtype with Bronchioalveolar carcinoma. 3. Code: LUAD.",
      "idx": 759,
      "timestamp": "2026-01-19T15:59:53.119119"
    },
    {
      "sample_idx": 754,
      "input": "Diagnosis: A: Gallbladder, cholecystectomy. - Chronic cholecystitis with cholesterolosis. - Duplication cyst. B: Lymph node, right inferior mediastinum, biopsy. - No tumor identified in one lymph node (0/1). C: Liver, right lobe, partial hepatectomy. - Hepatocellular carcinom\u00e1, grade 2 with superficial infiltration into the ventral surface of the diaphragm,. surgical margins free. - Tumor infiltrates wall of a large caliber vein with intraluminal tumor present. - Multiple small foci suspicious f...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Gallbladder. 2. Findings: Chronic cholecystitis with cholesterolosis. Duplication cyst. Hepatocellular carcinoma, grade 2 with superficial infiltration into the ventral surface of the diaphragm. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lobe of the liver. 2. Findings: Hepatocellular carcinoma, grade 2 with superficial infiltration into the ventral surface of the diaphragm. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung, right lower lobe. 2. Findings: Multiple intraparenchymal lymph nodes with anthracotic pigment and probable old fibrotic granulomas. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung, face of right lower lobe. 2. Findings: Markedly reactive mesothelial proliferation on parietal and visceral pleural surfaces consistent with reaction to tumor infiltrating underlying diaphragm. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph node, right portal. 2. Findings: No tumor identified in one lymph node (0/1). 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph node, left portal. 2. Findings: No tumor identified in one lymph node (0/1). 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung, right lower lobe. 2. Findings: Multiple intraparenchymal lymph nodes with anthracotic pigment and probable old fibrotic granulomas. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer",
      "predicted": "KIRC",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Gallbladder. 2. Findings: Chronic cholecystitis with cholesterolosis. Duplication cyst. Hepatocellular carcinoma, grade 2 with superficial infiltration into the ventral surface of the diaphragm. 3. Code: KIRC.",
      "idx": 754,
      "timestamp": "2026-01-19T15:59:53.119131"
    },
    {
      "sample_idx": 686,
      "input": "Surgical Pathology: Finali. CLINICAL HISTORY: Brain tumor. GROSS EXAMINATION: A. \"Brain tumor (AF1) \", received fresh for frozen section. A 2.0 x 2.0 x 1.0. cm aggregate of multiple fragments of soft tan tissue is received. Representative fragment frozen as AF1 and frozen section remnant is submitted. in A1. A representative fragment is retained in formalin. The remainder of. the tissue is submitted in A2. B. \"Brain tumor\", received fresh and placed in formalin. A 4.0 x 3.8 x 2.0 cm. aggregate o...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Astrocytoma, well differentiated (Grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"AST\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Astrocytoma, well differentiated (Grade II). 3. Code: AST maps to AST.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Astrocytoma, well differentiated (Grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Astrocytoma, well differentiated (Grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Astrocytoma, well differentiated (Grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Astrocytoma, well differentiated (Grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Astrocytoma, well differentiated (Grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Astrocytoma, well differentiated (Grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Astrocytoma, well differentiated (",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain. 2. Findings: Astrocytoma, well differentiated (Grade II). 3. Code: GBM maps to GBM.",
      "idx": 686,
      "timestamp": "2026-01-19T15:59:53.119141"
    },
    {
      "sample_idx": 1177,
      "input": "Stomach, total gastrectomy: Advanced gastric carcinoma. Muc2(-)/Muc5AC(+)/Muc6(+)/CD10(++)/cERB2(-),GI(I) type). 1. Location : upper third, Center at fundus and posterior wall. 2. Gross type : Borrman type 1 (fungating). 3. Histologic type : papillary adenocarcinoma (pap). 4. Histologic type by Lauren : intestinal. 5. Growth pattern: mixed expanding and infiltrative growth pattern. 6. Size : 6.5x5.0cm. 7. Depth of invasion : invades proper muscle (pT2). 8. Resection margins and anvil ring : free...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Advanced gastric carcinoma, mucinous type, intestinal type, pT2, pNO. 3. Code: Stomach, total gastrectomy maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Advanced gastric carcinoma, mucinous type, intestinal type, pT2, pNO. 3. Code: Stomach, total gastrectomy maps to PAAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Advanced gastric carcinoma, mucinous type, intestinal type, pT2, pNO. 3. Code: Stomach, total gastrectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Advanced gastric carcinoma, mucinous type, intestinal type, pT2, pNO. 3. Code: Stomach, total gastrectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Advanced gastric carcinoma, mucinous type, intestinal type, pT2, pNO. 3. Code: Stomach, total gastrectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Advanced gastric carcinoma, mucinous type, intestinal type, pT2, pNO. 3. Code: Stomach, total gastrectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Advanced gastric carcinoma, mucinous type, intestinal type, pT2, pNO. 3. Code: Stomach, total gastrectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",",
      "predicted": "STAD",
      "ground_truth": "STAD",
      "correct": true,
      "reasoning": "1. Site: Stomach. 2. Findings: Advanced gastric carcinoma, mucinous type, intestinal type, pT2, pNO. 3. Code: Stomach, total gastrectomy maps to STAD.",
      "idx": 1177,
      "timestamp": "2026-01-19T15:59:53.119151"
    },
    {
      "sample_idx": 372,
      "input": "Document Date: Encounter-info: Date Collected: Date Received: PT: DIAGNOSIS: 1. BRAIN, LEFT FRONTAL, BIOPSY, FS1A: - GLIOBLASTOMA MULTIFORME. 2. BRAIN, LEFT FRONTAL, EXCISION, FS2A: - GLIOBLASTOMA MULTIFORME. 3. BRAIN, LEFT FRONTAL, EXCISION: - GLIOBLASTOMA MULTIFORME. (Electronic Signature). SPECIMEN: 1. Left frontal brain lesion. 2. Left frontal brain lesion. CLINICAL HISTORY/OPERATIVE FINDINGS: PREVIOUS OPERATION OR BIOPSY: Not provided. NAME OF OPERATION: Left frontal craniotomy for tumor ex...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Frontal). 2. Findings: Glioblastoma multiforme. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Frontal). 2. Findings: Glioblastoma multiforme. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Frontal). 2. Findings: Glioblastoma multiforme. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Frontal). 2. Findings: Glioblastoma multiforme. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Frontal). 2. Findings: Glioblastoma multiforme. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Frontal). 2. Findings: Glioblastoma multiforme. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Frontal). 2. Findings: Glioblastoma multiforme. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Frontal). 2. Findings: Glioblastoma multiforme. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Frontal). 2. Findings: Glioblastoma multiforme. 3. Code:",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain (Left Frontal). 2. Findings: Glioblastoma multiforme. 3. Code: GBM maps to GBM.",
      "idx": 372,
      "timestamp": "2026-01-19T15:59:53.119163"
    },
    {
      "sample_idx": 441,
      "input": "Sex: M. Case type: Surgical History. Case imported from legacy computer system. The format of this report does not match the original  case. For cases prior to. the section \"SPECIMEN\" may have been added. SUPPLEMENTAL REPORT. COMMENT: Additional sections of the mandible are received from the bone lab after. decalcification and sectioning. The section code is as follows: Cassettes I17 and I18, cross sections of the mandible; cassette I19,. mandibular margin, en face; cassette I20 and I21, right m...",
      "response": "```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Submental triangle, left neck. 2. Findings: Metastatic squamous cell carcinoma in 1 of 3 lymph nodes (1/3) and 1 of 5 lymph nodes (1/5). Extranodal extension is present. 3. Code: PAAD (Pan-Adenocarcinoma) maps to PAAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Marginal mandibulectomy including upper and lower lip. 2. Findings: Deeply invasive keratinized squamous cell carcinoma, moderately differentiated. Margins free of tumor. 3. Code: SCC (Squamous Cell Carcinoma) maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Left lower lip. 2. Findings: Tumor, left lower lip. 3. Code: SKCM (Squamous Cell Carcinoma) maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left neck. 2. Findings: Metastatic squamous cell carcinoma in 1 of 5 lymph nodes (1/5). 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Left neck. 2. Findings: Metastatic squamous cell carcinoma in 1 of 5 lymph nodes (1/5). 3. Code: SKCM (Squamous Cell Carcinoma) maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Left neck. 2. Findings: Metastatic squamous cell carcinoma in 1 of 5 lymph nodes (1/5). 3. Code: SKCM (Squamous Cell Carcinoma) maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Left neck. 2. Findings: Metastatic squamous",
      "predicted": "PAAD",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Submental triangle, left neck. 2. Findings: Metastatic squamous cell carcinoma in 1 of 3 lymph nodes (1/3) and 1 of 5 lymph nodes (1/5). Extranodal extension is present. 3. Code: PAAD (Pan-Adenocarcinoma) maps to PAAD.",
      "idx": 441,
      "timestamp": "2026-01-19T15:59:53.119176"
    },
    {
      "sample_idx": 993,
      "input": "Short descriptive translation of the pathology report as provided by the. Material received: Material: Left adrenal gland. Macroscopic findings. Adrenal Tumor: A 11x10x3 cm specimen after adrenalectomy (131 g, formalin fixed). The lesion has. been cut already. On the sectioned surface a 7 cm light brown tumor with vulnerable tissue pattern. At. the side of the lesion normal adrenal cortex can be seen. The capsule cannot be finally judged due to. the prior cutting. Microscopy findings: At HE, Iro...",
      "response": "```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, without lateralization, no suspicion for capsular or vascular invasion. 3. Code: ADEN maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, without lateralization, no suspicion for capsular or vascular invasion. 3. Code: ADEN maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, without lateralization, no suspicion for capsular or vascular invasion. 3. Code: ADEN maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, without lateralization, no suspicion for capsular or vascular invasion. 3. Code: ADEN maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, without lateralization, no suspicion for capsular or vascular invasion. 3. Code: ADEN maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, without lateralization, no suspicion for capsular or vascular invasion. 3. Code: ADEN maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, without lateralization, no suspicion for capsular or vascular invasion. 3. Code: ADEN maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"",
      "predicted": "ADEN",
      "ground_truth": "PCPG",
      "correct": false,
      "reasoning": "1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, without lateralization, no suspicion for capsular or vascular invasion. 3. Code: ADEN maps to ADEN.",
      "idx": 993,
      "timestamp": "2026-01-19T15:59:53.119187"
    },
    {
      "sample_idx": 1265,
      "input": "!. Laterality:Papillary carcinoma. Path Report:Tumor type: Papillary carcinoma. Tumor size:2.5x2x1cm (right) 1.5x1x1cm (left). Laterality: Bilateral. Focality: Multifocal. Extrathyroidal extension: No.",
      "response": "```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, bilateral, multifocal, without extrathyroidal extension. 3. Code: Thyroid Papillary Carcinoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, bilateral, multifocal, without extrathyroidal extension. 3. Code: Thyroid Papillary Carcinoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, bilateral, multifocal, without extrathyroidal extension. 3. Code: Thyroid Papillary Carcinoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, bilateral, multifocal, without extrathyroidal extension. 3. Code: Thyroid Papillary Carcinoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, bilateral, multifocal, without extrathyroidal extension. 3. Code: Thyroid Papillary Carcinoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, bilateral, multifocal, without extrathyroidal extension. 3. Code: Thyroid Papillary Carcinoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, bilateral, multifocal, without extrathyroidal extension. 3. Code: Thyroid Papillary Carcinoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma",
      "predicted": "UVM",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Thyroid. 2. Findings: Papillary carcinoma, bilateral, multifocal, without extrathyroidal extension. 3. Code: Thyroid Papillary Carcinoma maps to UVM.",
      "idx": 1265,
      "timestamp": "2026-01-19T15:59:53.119197"
    },
    {
      "sample_idx": 1231,
      "input": "Clinical Diagnosis & History: Right thyroid nodule. FNA suspicious of PTC. Specimens Submitted: 1: SP: Thyroid, right lobe, lobectomy (fs). DIAGNOSIS: 1. SP: Thyroid, right lobe, lobectomy (fs): Tumor Type: Papillary carcinoma, follicular variant. Histologic Grade: Well differentiated. Mitotic Activity: Not identified. Tumor Necrosis: Not identified. Tumor Location: Right lobe. Tumor Size: Greatest diameter is 1.8 cm. Tumor Encapsulation: Completely surrounded. Capsular Invasion: Not identified....",
      "response": "```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid, right lobe. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: THCA maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid, right lobe. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid, right lobe. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: THCA maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid, right lobe. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid, right lobe. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: THCA maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid, right lobe. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid, right lobe. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: THCA maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid, right lobe. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid, right lobe. ",
      "predicted": "THCA",
      "ground_truth": "THCA",
      "correct": true,
      "reasoning": "1. Site: Thyroid, right lobe. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: THCA maps to THYM.",
      "idx": 1231,
      "timestamp": "2026-01-19T15:59:53.119207"
    },
    {
      "sample_idx": 1224,
      "input": "Gender: M. Operative Procedure: 4Left orchiectomy. Left testicle. Final Pathologic Diagnosis: Testis, left, radical orchiectomy: Histologic type: Seminoma. Tumor focality: Unifocal. Size. Main mass: 4.3 [greatest dimension]. Additional dimensions: 3.5 x 3.1. Additional nodules: not applicable. Macroscopic extent of tumor: Confined to the testis. Microscopic extent of tumor: Confined to the testis. Tunica vaginalis: Uninvolved. Spermatic cord: Uninvolved. Rete testis: Involved. Scrotum: not appli...",
      "response": "```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma. 3. Code: Testis, left, radical orchiectomy: Histologic type: Seminoma. Tumor focality: Unifocal. Size. Main mass: 4.3 [greatest dimension]. Additional dimensions: 3.5 x 3.1. Additional nodules: not applicable. Macroscopic extent of tumor: Confined to the testis. Microscopic extent of tumor: Confined to the testis. Tunica vaginalis: Uninvolved. Spermatic cord: Uninvolved. Rete testis: Involved. Scrotum: not applicable. Lymph-vascular invasion: Not identified. Intratubular germ cell neoplasia: Present, unclassified type (IGCNU). Surgical margin. Spermatic cord: Uninvolved. Other (specify): not applicable. Other pathologic findings: None significant. Lymph nodes submitted: None submitted. Pathologic stage (2010). pT1 pNX1 pM-not applicable. The examination of this case material and the preparation of this report were. Gross Description: Received in formalin, labeled \\\"left testicle\\\" is a 51 g. orchiectomy specimen which consists of a 5.3 x 3.5 x 3.2 cm testicle with. attached 4.0 X 1.1 X 0.5 cm epididymis, and attached 4.9 X 1.6 cm of spermatic. cord. The visceral layer of the tunica vaginalis is tan-pink, smooth and. glistening. Sectioning reveals a 4.3 x 3.5 X 3.1 cm tan to pink, soft,. heterogeneous, ill-defined testicular mass which does not appear to extend. outside the testicle. Rete testis involvement is indeterminate. The uninvolved. testicle is tan, soft and homogeneous. The seminiferous tubules string with. ease. The spermatic cord on sectioning is unremarkable. Representative sections are submitted as follows: 1. spermatic cord margin taken en face;. 2. mass to Rete testis;. 3,4 mass to visceral layer of tunica vaginalis and epididymis;. 5. mass to uninvolved testis;. 6. proximal spermatic cord. Please note, a gross photograph is taken. Microscopic Description: The final diagnosis of each specimen",
      "predicted": null,
      "ground_truth": "TGCT",
      "correct": null,
      "reasoning": "",
      "idx": 1224,
      "timestamp": "2026-01-19T15:59:53.119330"
    },
    {
      "sample_idx": 966,
      "input": "male. Surgery date: Short report on diagnostic findings. Pancreatic carcinoma. Expansive, well differentiated neuroendocrine carcinoma of the pancreas with extension beyond the. pancreas and infiltration of the posterior wall of the stomach with ulceration of the mucosa. Vessel. infiltration. Lymphangiosis carcinomatosis (6.). Lymph node metastases (3.,6), lymph nodes without. tumor (1.,2.,4.,7). anastomotic rings without tumor (8.), choleasteatosis of the gall bladder (9.). Invasion. of the por...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Pancreatic carcinoma, expansive, well differentiated neuroendocrine carcinoma. Extension beyond the pancreas and infiltration of the posterior wall of the stomach with ulceration of the mucosa. Vessel infiltration. Lymphangiosis carcinomatosis (6.). Lymph node metastases (3.,6), lymph nodes without tumor (1.,2.,4.,7). Anastomotic rings without tumor (8.), choleasteatosis of the gall bladder (9.). Invasion of the portal vein margin (5.). TNM classification (UICC, 7th Edition 2010): pT3, pN1 (16/57), L1, V1. Grading: G1. Resection status: R1 (caudal, proximal, and dorsal at the main specimen, vessel invasion with tumor thrombus (6.), portal vein (5.)). 3. Code: Pancreatic Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Pancreatic carcinoma, expansive, well differentiated neuroendocrine carcinoma. Extension beyond the pancreas and infiltration of the posterior wall of the stomach with ulceration of the mucosa. Vessel infiltration. Lymphangiosis carcinomatosis (6.). Lymph node metastases (3.,6), lymph nodes without tumor (1.,2.,4.,7). Anastomotic rings without tumor (8.), choleasteatosis of the gall bladder (9.). Invasion of the portal vein margin (5.). TNM classification (UICC, 7th Edition 2010): pT3, pN1 (16/57), L1, V1. Grading: G1. Resection status: R1 (caudal, proximal, and dorsal at the main specimen, vessel invasion with tumor thrombus (6.), portal vein (5.)). 3. Code: Pancreatic Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Pancreatic carcinoma, expansive, well differentiated neuroendocrine carcinoma. Extension beyond the pancreas and infiltration of the posterior wall of the stomach with ulceration of the mucosa. Vessel infiltration",
      "predicted": "KIRC",
      "ground_truth": "PAAD",
      "correct": false,
      "reasoning": "1. Site: Pancreas. 2. Findings: Pancreatic carcinoma, expansive, well differentiated neuroendocrine carcinoma. Extension beyond the pancreas and infiltration of the posterior wall of the stomach with ulceration of the mucosa. Vessel infiltration. Lymphangiosis carcinomatosis (6.). Lymph node metastases (3.,6), lymph nodes without tumor (1.,2.,4.,7). Anastomotic rings without tumor (8.), choleasteatosis of the gall bladder (9.). Invasion of the portal vein margin (5.). TNM classification (UICC, 7th Edition 2010): pT3, pN1 (16/57), L1, V1. Grading: G1. Resection status: R1 (caudal, proximal, and dorsal at the main specimen, vessel invasion with tumor thrombus (6.), portal vein (5.)). 3. Code: Pancreatic Carcinoma maps to KIRC.",
      "idx": 966,
      "timestamp": "2026-01-19T15:59:53.119357"
    },
    {
      "sample_idx": 679,
      "input": "ADDENDUM DISCUSSION: Most of the neoplastic cells are reactive for GFAP, however, some of the. larger cells with halos are GFAP negative. Neu-N demonstrates that the tumor. cells are negative for Neu-N with only cortical neurons being positive. The. atypical cells, including the large cells without obvious processes are. strongly reactive for p53, suggesting astrocytic lineage. There is variable. immunoreactivity for MIB-1. Slide 1A has a labeling index of <0.5% while 2A. demonstrates a labeling...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Anaplastic astrocytoma (WHO Grade III), high MIB-1 labeling index. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Anaplastic astrocytoma (WHO Grade III), high MIB-1 labeling index. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Anaplastic astrocytoma (WHO Grade III), high MIB-1 labeling index. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Anaplastic astrocytoma (WHO Grade III), high MIB-1 labeling index. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Anaplastic astrocytoma (WHO Grade III), high MIB-1 labeling index. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Anaplastic astrocytoma (WHO Grade III), high MIB-1 labeling index. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Anaplastic astrocytoma (WHO Grade III), high MIB-1 labeling index. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Anaplastic",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain. 2. Findings: Anaplastic astrocytoma (WHO Grade III), high MIB-1 labeling index. 3. Code: GBM maps to GBM.",
      "idx": 679,
      "timestamp": "2026-01-19T15:59:53.119367"
    },
    {
      "sample_idx": 868,
      "input": "Material examined: Right lower lobe, among others. Clinical diagnosis and question. Bronchial carcinoma right - squamous cell - Suspected asbestos exposure. REPORT ON FINDINGS. Macroscopy. 1.) Right lower lobe: after attempted inflation of lower lobe at the deformed base measuring 10.5 x 7.5 cm and. up to 12 cm high, central bronchus resection plane located at the level of the bifurcation of B6. At the hilus are. two grayish-black nodes, 2 and 1.3 cm in size. Parenchyma shows incomplete atelecta...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Lung, Right Lower Lobe. 2. Findings: Bronchial carcinoma, squamous cell carcinoma. 3. Code: COAD maps to Lung Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Lung, Right Lower Lobe. 2. Findings: Bronchial carcinoma, squamous cell carcinoma. 3. Code: COAD maps to Lung Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Lung, Right Lower Lobe. 2. Findings: Bronchial carcinoma, squamous cell carcinoma. 3. Code: COAD maps to Lung Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Lung, Right Lower Lobe. 2. Findings: Bronchial carcinoma, squamous cell carcinoma. 3. Code: COAD maps to Lung Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Lung, Right Lower Lobe. 2. Findings: Bronchial carcinoma, squamous cell carcinoma. 3. Code: COAD maps to Lung Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Lung, Right Lower Lobe. 2. Findings: Bronchial carcinoma, squamous cell carcinoma. 3. Code: COAD maps to Lung Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Lung, Right Lower Lobe. 2. Findings: Bronchial carcinoma, squamous cell carcinoma. 3. Code: COAD maps to Lung Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Lung, Right Lower Lobe. 2. Findings: Bronchial carcinoma, squamous cell carcinoma. 3. Code: COAD maps to Lung",
      "predicted": "COAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung, Right Lower Lobe. 2. Findings: Bronchial carcinoma, squamous cell carcinoma. 3. Code: COAD maps to Lung Adenocarcinoma.",
      "idx": 868,
      "timestamp": "2026-01-19T15:59:53.119378"
    },
    {
      "sample_idx": 127,
      "input": "specimen #: : lace: WHITE. Physician (s) : AMENDED. SPECIMEN: A: RIGHT BREAST B: RIGHT BREAST TISSUE FROM INFERIOR FLAP. C: RIGHT SENTINEL LYMPH NODE #1. D: RIGHT SENTINEL LYMPH NODE #2. FINAL DIAGNOSIS: A. RIGHT BREAST, MASTECTOMY: -TUMOR TYPE: INVASIVE DUCTAL CARCINOMA WITH LOBULAR FEATURES. -NOTTINGHAM GRADE MODERATELY DIFFERENTIATED (G2). -NOTTINGHAM SCORE: 6/9 (TUBULES = 3, NUCLEI = 2, MYTOSES= 1) . -TUMOR SIZE: GREATEST DIMENSION: TUMOR 1 (UPPER INNER QUADRANT) : at least 1.1 CM. (measured...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 127,
      "timestamp": "2026-01-19T15:59:53.119388"
    },
    {
      "sample_idx": 737,
      "input": "LABORATORY SERVICES. Patient ID: PHN: ALT ID: Telephone: Requesting Physician: Encounter: Chart ID: HISTOPATHOLOGY REPORT. Division Head: ORIGINAL REPORT. SPECIMEN: A. Gallbladder. B. Liver (margin painted black - a slice of tumor about 0.3 cm thick was. taken for tumor bank - Dr. research). CLINICAL HISTORY: Liver mass. Hep B positive and liver tumor. DIAGNOSIS: A. GALLBLADDER: NO CALCULI, INFLAMMATION OR MALIGNANCY. B. LIVER: HEPATOCELLULAR CARCINOMA, GRADE III/IV. TUMOR MEASURES 2.5 CM IN GRE...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Gallbladder. 2. Findings: Hepatocellular carcinoma (HCC) with features of cirrhosis. 3. Code: COAD maps to the cancer type Hepatocellular Carcinoma (Hepatocellular carcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma (HCC). 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma (KIRC) because the report is describing a liver tumor.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma (HCC). 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma (KIRC) because the report is describing a liver tumor.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma (HCC). 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma (KIRC) because the report is describing a liver tumor.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma (HCC). 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma (KIRC) because the report is describing a liver tumor.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma (HCC). 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma (KIRC) because the report is describing a liver tumor.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma (HCC). 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma (KIRC) because the report is describing a liver tumor.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "COAD",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Gallbladder. 2. Findings: Hepatocellular carcinoma (HCC) with features of cirrhosis. 3. Code: COAD maps to the cancer type Hepatocellular Carcinoma (Hepatocellular carcinoma).",
      "idx": 737,
      "timestamp": "2026-01-19T15:59:53.119399"
    },
    {
      "sample_idx": 960,
      "input": "SURG PATH #: SPECIMEN CLASS: ALT ID #: SEX: F. DATE RECEIVED: DATE OF PRINTING: Material Received: A: anterior abdominal wall peritoneum. B: omentum. C: portion of left tube and ovary. D: small bowel mesentery nodule. E: right cul-de-sac tumor. F: pelvic peritoneum. G: uterus and cervic; right fallopian tube and ovary; reto-sigmoid colon. H: small bowel tumor nodules. I: portion of proximal colon. J: donut. K: peri-appendecele tumor. L: small mesentary nodule. M: small bowel @ 1300. N: right dia...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Ser",
      "predicted": "BRCA",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Ovary. 2. Findings: Serous carcinoma, high grade. 3. Code: BRCA.",
      "idx": 960,
      "timestamp": "2026-01-19T15:59:53.119408"
    },
    {
      "sample_idx": 307,
      "input": "SPECIMEN. A. Right colon. B. Liver biopsy. CLINICAL NOTES. PRE-OP DIAGNOSIS: Ascending colon cancer. GROSS DESCRIPTION. A. Received fresh for tissue procurement, labeled \"right. colon\", is a previously unopened, 12 cm segment of. proximal. right colon with attached 6 cm of distal ileum surfaced by smooth. to. scabrous tan-pink serosa with a moderate amount of attached. mesocolon and mesentery, An unremarkable 5.7 cm appendix averaging. 0.65 cm in diameter is present. The proximal and distal marg...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Infiltrating adenocarcinoma of the right colon, extending deeply into pericolonic fat and to the inked serosal peritoneal surface. All other margins and all 25 regional lymph nodes are negative for tumor. Appendix and portion of terminal ileum, no significant pathology. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Infiltrating adenocarcinoma of the right colon, extending deeply into pericolonic fat and to the inked serosal peritoneal surface. All other margins and all 25 regional lymph nodes are negative for tumor. Appendix and portion of terminal ileum, no significant pathology. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Infiltrating adenocarcinoma of the right colon, extending deeply into pericolonic fat and to the inked serosal peritoneal surface. All other margins and all 25 regional lymph nodes are negative for tumor. Appendix and portion of terminal ileum, no significant pathology. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Infiltrating adenocarcinoma of the right colon, extending deeply into pericolonic fat and to the inked serosal peritoneal surface. All other margins and all 25 regional lymph nodes are negative for tumor. Appendix and portion of terminal ileum, no significant pathology. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Infiltrating adenocarcinoma of the right colon, extending deeply into pericolonic fat and to the inked serosal peritoneal surface. All other margins and all 25 regional lymph nodes are negative for tumor. Appendix and portion of terminal ileum, no significant pathology. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Colon (Right Colon). 2. Findings: Infiltrating adenocarcinoma of the right colon, extending deeply into pericolonic fat and to the inked serosal peritoneal surface. All other margins and all 25 regional lymph nodes are negative for tumor. Appendix and portion of terminal ileum, no significant pathology. 3. Code: KIRC.",
      "idx": 307,
      "timestamp": "2026-01-19T15:59:53.119423"
    },
    {
      "sample_idx": 519,
      "input": "Report Status : Amend/. Type: Surgical Pathology. Specimen Type: Kidney. partial or total resection. Procedure Date: Addended Repor. PATHOLOGIC DIAGNOSIS: GEFT RADICAL NEPHRECTOMY: /CLEAR CELL RENAL CELL CARCINOMA (8.2 cm), Fuhrman nuclear grade. TII/IV, arising in the lower pole with foci of tumor necrosis and. hyalinization. Approximately 608 of the tumor mass is viable. Arterial, venous, and ureteral margins are negative for tumor. Tumor is limited to the kidney and comes to within 0.1 cm of....",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nResponse:\n```json\n{\n",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 519,
      "timestamp": "2026-01-19T15:59:53.119433"
    },
    {
      "sample_idx": 1032,
      "input": "DIAGNOSIS. DIAGNOSIS: A. Right pelvic lymph node: Benign, hyperplasia. B. Left pelvic lymph node: Benign, hyperplasia. C. Radical prostatectomy: Carcinoma. Tumor Characteristics: 1. Histologic type: Adenocarcinoma, conventional type. 2. Gleason Grade: a. Primary pattern: 3/5. b. Secondary pattern: 4/5. c. Score: 7/10. 3. Tumor involves: Both lobes. 4. Tumor quantitation: Tumor involves approximately 25% of the specimen. 5. Seminal vesicle involvement: Yes, left seminal vesicle. 6. Extra-capsular...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, conventional type. 3. Gleason Grade: 7/10. 4. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pelvic Lymph Node. 2. Findings: Benign, hyperplasia. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder Neck. 2. Findings: Benign, no pathological diagnosis. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Carcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pelvic Lymph Node. 2. Findings: Benign, hyperplasia. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Carcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder Neck. 2. Findings: Benign, no pathological diagnosis. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Carcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pelvic Lymph Node. 2. Findings: Benign, hyperplasia. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. ",
      "predicted": "KIRC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate. 2. Findings: Adenocarcinoma, conventional type. 3. Gleason Grade: 7/10. 4. Code: KIRC.",
      "idx": 1032,
      "timestamp": "2026-01-19T15:59:53.119443"
    },
    {
      "sample_idx": 682,
      "input": "MR# : ACCT# : LOC : DOCTOR: ADDENDUM NEUROPATHOLOGY REPORT. ADDENDUM DISCUSSION: The neoplastic cells express IDH1 but are negative for p53 . Numerous MIB-1. reactive cella are present with a labeling index of 12.48. ADDENIOUM DIAGKOSIS: 1-3. Right parietal tumor, including enhancing nodule, biopsy resection: Anaplastic astrocytoma (grade III). -- MIB-1 LI - 12.4%. ADDENDUN CPT copes,. ACCESSION#: . NEUROPATHOLOGY REPORT. SPECIMEN SOURCE: 1. Right parietal tumor FS. 2. Enhancing nodule FS. 3. Ri...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right parietal tumor. 2. Findings: Anaplastic astrocytoma (grade III), IDH1 positive, p53 negative. 3. Code: Anaplastic Astrocytoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right parietal tumor. 2. Findings: Anaplastic astrocytoma, grade III. 3. Code: Anaplastic Astrocytoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right parietal tumor. 2. Findings: Anaplastic astrocytoma, grade III, IDH1 positive, p53 negative. 3. Code: Anaplastic Astrocytoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right parietal tumor. 2. Findings: Anaplastic astrocytoma, grade III. 3. Code: Anaplastic Astrocytoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right parietal tumor. 2. Findings: Anaplastic astrocytoma, grade III, IDH1 positive, p53 negative. 3. Code: Anaplastic Astrocytoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right parietal tumor. 2. Findings: Anaplastic astrocytoma, grade III. 3. Code: Anaplastic Astrocytoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right parietal tumor. 2. Findings: Anaplastic astrocytoma, grade III, IDH1 positive, p53 negative. 3. Code: Anaplastic Astrocytoma maps to GBM.\"\n}\n```\n```json\n",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Right parietal tumor. 2. Findings: Anaplastic astrocytoma (grade III), IDH1 positive, p53 negative. 3. Code: Anaplastic Astrocytoma maps to GBM.",
      "idx": 682,
      "timestamp": "2026-01-19T15:59:53.119454"
    },
    {
      "sample_idx": 1106,
      "input": "page 1 / 1. copy No. 3. Examination: Histopathological examination. Cost of diagnostic procedure. Material: 1. Total resection of organ - rectum. Expected time of examination: Clinical diagnosis: Cancer of the rectum. Macroscopic description: 30 cm length of large intestine with fat tissue of 1 cm in thickness. Ulceration thickened at ends sized 6 X 4 cm. The lesion surrounds 100% of the intestine circumference, narrowing its lumen, placed 14 cm from the proximal cut. end, 6 cm from the distal c...",
      "response": "```json\n{\n    \"cancer_type\": \"UC\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Adenocarcinoma tubulare solidum partim mucinosum (G3). Infiltratio carcinomatosa telae adiposae mesorecti. Intestine ends free of neoplastic lesions. Metastases carcinomatosae in lymphonodis (No III/XIV). 3. Code: Rectum Adenocarcinoma maps to UC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23349\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Adenocarcinoma tubulare solidum partim mucinosum (G3). Infiltratio carcinomatosa telae adiposae mesorecti. Intestine ends free of neoplastic lesions. Metastases carcinomatosae in lymphonodis (No III/XIV). 3. Code: Rectum Adenocarcinoma maps to U23349.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23349\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Adenocarcinoma tubulare solidum partim mucinosum (G3). Infiltratio carcinomatosa telae adiposae mesorecti. Intestine ends free of neoplastic lesions. Metastases carcinomatosae in lymphonodis (No III/XIV). 3. Code: Rectum Adenocarcinoma maps to U23349.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23349\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Adenocarcinoma tubulare solidum partim mucinosum (G3). Infiltratio carcinomatosa telae adiposae mesorecti. Intestine ends free of neoplastic lesions. Metastases carcinomatosae in lymphonodis (No III/XIV). 3. Code: Rectum Adenocarcinoma maps to U23349.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23349\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Adenocarcinoma tubulare solidum partim mucinosum (G3). Infiltratio carcinomat",
      "predicted": "UC",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Rectum. 2. Findings: Adenocarcinoma tubulare solidum partim mucinosum (G3). Infiltratio carcinomatosa telae adiposae mesorecti. Intestine ends free of neoplastic lesions. Metastases carcinomatosae in lymphonodis (No III/XIV). 3. Code: Rectum Adenocarcinoma maps to UC.",
      "idx": 1106,
      "timestamp": "2026-01-19T15:59:53.119468"
    },
    {
      "sample_idx": 1331,
      "input": "Temporary Copy. Clinical Information. Endometrial cancer. X-lap, TAH, BSO, Node dissection. Organ Or Tissue. Site: indometrum 054. /. Uterus, BSO. Left pelvic node. Left pelvic nodes. Left periaortic nodes. Right pelvic nodes. Right periaortic node. Gross Description. The specimen is received in six parts. each labeled with the patient's name. Part A. is received unfixed, additionally labeled \"uterus, cervix, tubes, ovaries\" and consists of a uterus. with attached cervix, and bilateral fallopian...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma with squamous differentiation, invading 1.0 mm of myometrium and anterior lower uterine segment. Focal vascular space tumor invasion is present. Extensive adenomyosis. Multiple leiomyomata uteri. Serosal fibrous adhesions of bilateral ovaries and fallopian tubes with old hemorrhage and granulomatous reactions. Atrophic underlying bilateral ovaries. Hydatid cyst of Morgagni, right. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma with squamous differentiation, invading 1.0 mm of myometrium and anterior lower uterine segment. Focal vascular space tumor invasion is present. Extensive adenomyosis. Multiple leiomyomata uteri. Serosal fibrous adhesions of bilateral ovaries and fallopian tubes with old hemorrhage and granulomatous reactions. Atrophic underlying bilateral ovaries. Hydatid cyst of Morgagni, right. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma with squamous differentiation, invading 1.0 mm of myometrium and anterior lower uterine segment. Focal vascular space tumor invasion is present. Extensive adenomyosis. Multiple leiomyomata uteri. Serosal fibrous adhesions of bilateral ovaries and fallopian tubes with old hemorrhage and granulomatous reactions. Atrophic underlying bilateral ovaries. Hydatid cyst of Morgagni, right. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma with squamous differentiation, invading 1.0 mm of myometrium and anterior lower uterine segment. Focal vascular space tumor invasion is present. Extensive adenomyosis. Multiple leiomyomata uteri. Serosal fibrous adhesions of bilateral ovaries and fallopian tubes with old hemorrhage and granulomatous reactions. Atrophic underlying bilateral ovaries. Hydatid cyst of Morgagni, right. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma with squamous differentiation, invading 1.0 mm of myometrium and anterior lower uterine segment. Focal vascular space tumor invasion is present. Extensive adenomyosis. Multiple leiomyomata uteri. Serosal fibrous adhesions of bilateral ovaries and fallopian tubes with old hemorrhage and granulomatous reactions. Atrophic underlying bilateral ovaries. Hydatid cyst of Morgagni, right. 3. Code: UCEC.",
      "idx": 1331,
      "timestamp": "2026-01-19T15:59:53.119488"
    },
    {
      "sample_idx": 412,
      "input": "FINAL PATHOLOGIC DIAGNOSIS. A. Brain, biopsy: WHO-II glioblastoma multiforme, grade 4; see comment. B. Brain, biopsy: WHO-II glioblastoma multiforme, grade 4; see comment. COMMENT: This glioblastoma multiforme has foci of necrosis with peripheral pseudo-palisading,. endothelial proliferation, multiple mitoses and marked nuclear and cytoplasmic pleomorphism, with. abundant giant cells. By prior. and. criteria, this is a glioblastoma multiforme. By. criteria, this is a grade 4 astrocytoma, An immu...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma multiforme, grade 4. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma multiforme, grade 4. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma multiforme, grade 4. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma multiforme, grade 4. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma multiforme, grade 4. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma multiforme, grade 4. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma multiforme, grade 4. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma multiforme, grade 4. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma multiforme, grade 4. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    ",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain. 2. Findings: Glioblastoma multiforme, grade 4. 3. Code: GBM.",
      "idx": 412,
      "timestamp": "2026-01-19T15:59:53.119498"
    },
    {
      "sample_idx": 713,
      "input": "x. Fatholog:ats. Intraop Pathologist: Performing PhyBigian: CLINICAL HISTORY: LIVER MASS. PRECPERATIVE DIACNOSIS: NOT GIVEN. SPECIMEN TYFE(Siz. A: SEGMENT 5 LIVER LESICN. B: GALLELADDER. C: ADDITIONAL CALLBLADDER MARGIN. FINAL DIACNOSIS: A. LIVER, SEGMENT 6 LESION, EXCISION: Repatocellular carcinoma, clear cell type (aee Key Pathological Findings). B. GALLBLADDER, CHOLECYSTECTOMY: Chronic cholecyatitis. There is no evidence or malignancy. c. LIVER ( SUBMITTED AS GALLELADDER, ADDITIONAL MARGIN) E...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment 6). 2. Findings: Hepatocellular carcinoma, clear cell type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment 6). 2. Findings: Hepatocellular carcinoma, clear cell type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment 6). 2. Findings: Hepatocellular carcinoma, clear cell type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment 6). 2. Findings: Hepatocellular carcinoma, clear cell type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment 6). 2. Findings: Hepatocellular carcinoma, clear cell type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment 6). 2. Findings: Hepatocellular carcinoma, clear cell type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment 6). 2. Findings: Hepatocellular carcinoma, clear cell type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment 6). 2. Findings: Hepatocellular carcinoma, clear cell type. 3. Code: KIRC.\"\n}\n",
      "predicted": "KIRC",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Liver (Segment 6). 2. Findings: Hepatocellular carcinoma, clear cell type. 3. Code: KIRC.",
      "idx": 713,
      "timestamp": "2026-01-19T15:59:53.119508"
    },
    {
      "sample_idx": 302,
      "input": "SPECIMENS: A. TERMINAL ILEUM AND RIGHT COLON. B. GALLBLADDER. DIAGNOSIS: A. RIGHT COLON AND TERMINAL ILEUM, RESECTION: - MODERATELY DIFFERENTIATED INFILTRATING COLONIC. ADENOCARCINOMA (3.1 CM) EXTENDING INTO SUBSEROSAL FAT. SEE. TEMPLATE. - SEVENTEEN BENIGN LYMPH NODES (0/17). - MULTIPLE TUBULAR ADENOMAS. - SURGICAL MARGINS, SMALL BOWEL AND APPENDIX ARE NOT INVOLVED. B. GALLBLADDER, EXCISION: - CHRONIC CHOLELITHIASIS. COLORECTAL CANCER TEMPLATE. Specimen Type: Right hemicolectomy. Tumor Site: As...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon and terminal ileum. 2. Findings: Adenocarcinoma, 3.1 cm, located in the ascending colon. 3. Code: Right Colon and Terminal Ileum maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Ascending Colon. 2. Findings: Adenocarcinoma, 3.1 cm, well differentiated, focal subserosal adipose tissue invasion, margins uninvolved. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon and terminal ileum. 2. Findings: Adenocarcinoma, 3.1 cm, located in the ascending colon. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon and terminal ileum. 2. Findings: Adenocarcinoma, 3.1 cm, located in the ascending colon. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Ascending Colon. 2. Findings: Adenocarcinoma, 3.1 cm, well differentiated, focal subserosal adipose tissue invasion, margins uninvolved. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon and terminal ileum. 2. Findings: Adenocarcinoma, 3.1 cm, located in the ascending colon. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Ascending Colon. 2. Findings: Adenocarcinoma, 3.1 cm, well differentiated, focal subserosal adipose tissue invasion, margins uninvolved. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1.",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Right colon and terminal ileum. 2. Findings: Adenocarcinoma, 3.1 cm, located in the ascending colon. 3. Code: Right Colon and Terminal Ileum maps to KIRC.",
      "idx": 302,
      "timestamp": "2026-01-19T15:59:53.119519"
    },
    {
      "sample_idx": 567,
      "input": "iology Report. DIAGNOSIS. (A) LEFT KIDNEY AND LYMPH NODE: CONVENTIONAL RENAL CELL CARCINOMA, CLEAR CELL TYPE, FUHRMAN'S. NUCLEAR GRADE 3. TUMOR MEASURES 6.0 CM IN MAXIMUM DIMENSION. TUMOR CONFINED TO THE KIDNEY. Margins of resection free of tumor. Simple cortical cyst. GROSS DESCRIPTION. (A) LEFT KIDNEY WITH EN BLOC LYMPH NODE - A radical nephrectomy. specimen (19.5 x 10.0 x 5.0 cm) including left. kidney (12.5 x 6.0 x 4.0 cm), a segment of renal artery, renal vein and. ureter (10.0 cm in length...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Conventional renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Conventional renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Conventional renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Conventional renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Conventional renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Conventional renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Conventional renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Conventional renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 567,
      "timestamp": "2026-01-19T15:59:53.119530"
    },
    {
      "sample_idx": 1289,
      "input": "M. Facility: Specimen(s) Received. 1. Nck: left paratracheal node dissection. 2. Lymph node: pretracheal lymph node. 3. Thyroid: total thyroid. Diagnosis. 1. No pathological diagnosis: Lymph nodes, 2 (left paratracheal) dissection specimen. No pathological diagnosis: Lymph node, 1 (paratracheal) biopsy. 3. Angioinvasive papillary carcinoma, 6.0 cm, follicular variant with focal poorly differentiated carcinoma (less than 5%),. right: Thyroid, total thyroidectomy specimen. Synoptic Data. Procedure...",
      "response": "```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Thyroid (Total Thyroidectomy Specimen). 2. Findings: Angioinvasive papillary carcinoma, 6.0 cm, follicular variant with focal poorly differentiated carcinoma (less than 5%). 3. Code: UCS matches the findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Thyroid (Total Thyroidectomy Specimen). 2. Findings: Angioinvasive papillary carcinoma, 6.0 cm, follicular variant with focal poorly differentiated carcinoma (less than 5%). 3. Code: UCEC matches the findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid (Total Thyroidectomy Specimen). 2. Findings: Angioinvasive papillary carcinoma, 6.0 cm, follicular variant with focal poorly differentiated carcinoma (less than 5%). 3. Code: UVM matches the findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Thyroid (Total Thyroidectomy Specimen). 2. Findings: Angioinvasive papillary carcinoma, 6.0 cm, follicular variant with focal poorly differentiated carcinoma (less than 5%). 3. Code: UCS matches the findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Thyroid (Total Thyroidectomy Specimen). 2. Findings: Angioinvasive papillary carcinoma, 6.0 cm, follicular variant with focal poorly differentiated carcinoma (less than 5%). 3. Code: UCEC matches the findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid (Total Thyroidectomy Specimen). 2. Findings: Angioinvasive papillary carcinoma, 6.0 cm, follicular variant with focal poorly differentiated carcinoma (less than 5%). 3. Code: UVM matches the findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Thyroid (Total Thyroidectomy Specimen).",
      "predicted": "UCSC",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Thyroid (Total Thyroidectomy Specimen). 2. Findings: Angioinvasive papillary carcinoma, 6.0 cm, follicular variant with focal poorly differentiated carcinoma (less than 5%). 3. Code: UCS matches the findings.",
      "idx": 1289,
      "timestamp": "2026-01-19T15:59:53.119542"
    },
    {
      "sample_idx": 196,
      "input": "FINAL DIAGNOSIS: BREAST, LEFT, MODIFIED RADICAL MASTECTOMY -. A. INVASIVE LOBULARICARCINOMA, NOTTINGHAM GRADE 2 (TUBULAR FORMATION 3, NUCLEAR ATYPIA 2,. MITOTIC ACTIVITY 1; TOTAL SCORE 6/9). B. THE INVASIVE TUMOR INVOLVES ALL FOUR BREAST QUADRANTS, MEASURING 11.0 CM IN LARGEST. DIMENSION (GROSS MEASUREMENT). C. THE INVASIVE TUMOR FOCALLY POSITIVE IN DEEP MARGIN IN LOWER-INNER QUADRANT (SLIDE R). D. MICROCALCIFICATIONS ASSOCIATED WITH INVASIVE CARCINOMA. E. LOBULAR CARCINOMA IN-SITU, NUCLEAR GRAD...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2 (tubular formation 3, nuclear atypia 2, mitotic activity 1; total score 6/9). 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2 (tubular formation 3, nuclear atypia 2, mitotic activity 1; total score 6/9). 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2 (tubular formation 3, nuclear atypia 2, mitotic activity 1; total score 6/9). 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2 (tubular formation 3, nuclear atypia 2, mitotic activity 1; total score 6/9). 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2 (tubular formation 3, nuclear atypia 2, mitotic activity 1; total score 6/9). 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2 (tubular formation 3, nuclear atypia 2, mitotic activity 1; total score 6/9). 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2 (tubular formation 3, nuclear atypia 2, mitotic activity 1; total score 6/9). 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 196,
      "timestamp": "2026-01-19T15:59:53.119554"
    },
    {
      "sample_idx": 1037,
      "input": "MRN fr. Ref Physiciar. Acct / Reg #: DIAGNOSIS: A. Soft tissue, prostate/urinary bladder, posterior neck, excision: No evidence of malignancy. B. Soft tissue, prostate/urinary bladder, anterior neck, excision: No evidence of malignancy. C.Prostate, radical prostatectomy: Tumor Characteristics: 1. Histologic type, Adenocarcinoma. 2. Gleason's Grade: a. Primary pattern: 3 of 5. b. Secondary pattern: 3 of 5. c. 3. Tumor involves:(Both lobes. 4. Tumor quantitation: Approximately 25%. 5. Seminal vesi...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, Gleason's Grade 3 (primary and secondary patterns), Tumor involves both lobes, Tumor quantitation approximately 25%, Seminal vesicle involvement absent, Extracapsular tumor extension present (block C8), Lymphovascular space invasion absent, Perlheural space invasion present, High-grade PIN present. 3. Code: Prostate adenocarcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, Gleason's Grade 3 (primary and secondary patterns), Tumor involves both lobes, Tumor quantitation approximately 25%, Seminal vesicle involvement absent, Extracapsular tumor extension present (block C8), Lymphovascular space invasion absent, Perlheural space invasion present, High-grade PIN present. 3. Code: Prostate adenocarcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, Gleason's Grade 3 (primary and secondary patterns), Tumor involves both lobes, Tumor quantitation approximately 25%, Seminal vesicle involvement absent, Extracapsular tumor extension present (block C8), Lymphovascular space invasion absent, Perlheural space invasion present, High-grade PIN present. 3. Code: Prostate adenocarcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, Gleason's Grade 3 (primary and secondary patterns), Tumor involves both lobes, Tumor quantitation approximately 25%, Seminal vesicle involvement absent, Extracapsular tumor extension present (block C8), Lymphovascular space invasion absent, Perlheural space invasion present, High-grade PIN present. 3. Code: Prostate adenocarcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, Gleason's Grade 3 (primary and secondary patterns), Tumor involves both lobes",
      "predicted": "KIRC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate. 2. Findings: Adenocarcinoma, Gleason's Grade 3 (primary and secondary patterns), Tumor involves both lobes, Tumor quantitation approximately 25%, Seminal vesicle involvement absent, Extracapsular tumor extension present (block C8), Lymphovascular space invasion absent, Perlheural space invasion present, High-grade PIN present. 3. Code: Prostate adenocarcinoma maps to KIRC.",
      "idx": 1037,
      "timestamp": "2026-01-19T15:59:53.119570"
    },
    {
      "sample_idx": 1338,
      "input": "SLIDE DISPOSITION. DIAGNOSIS: A. Abdomen, panniculectomy : Skin and subcutaneous. tissue, 1590.0. grams, identified grossly. Gross examination only. B . Uterus, bilateral ovaries, and fallopian tubes;. hysterectomy and. bilateral salpingo-oophorectomy: Invasive endometrial. adenocarcinoma, endometrioid type, FIGO grade I (of III). is. identified forming a mass (10.7 x 7.8 x 2.1 cm). circumferentially. involving the endometrial cavity. The tumor invades 0. 6. cm into the. myometrium (total myomet...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Invasive endometrial adenocarcinoma, endometrioid type, FIGO grade I (of III). 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Invasive endometrial adenocarcinoma, endometrioid type, FIGO grade I (of III). 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Invasive endometrial adenocarcinoma, endometrioid type, FIGO grade I (of III). 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Invasive endometrial adenocarcinoma, endometrioid type, FIGO grade I (of III). 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Invasive endometrial adenocarcinoma, endometrioid type, FIGO grade I (of III). 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Invasive endometrial adenocarcinoma, endometrioid type, FIGO grade I (of III). 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Invasive endometrial adenocarcinoma, endometrioid type, FIGO grade I (of III). 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Invasive endometrial adenocarcinoma, endometrioid type, FIGO grade I (of III). 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus. 2. Findings: Invasive endometrial adenocarcinoma, endometrioid type, FIGO grade I (of III). 3. Code: UCEC.",
      "idx": 1338,
      "timestamp": "2026-01-19T15:59:53.119580"
    },
    {
      "sample_idx": 1135,
      "input": "Case imported from. computer system. The format of this report does not match the original case. For cases prior to /. he section \"SPECIMEN\" may have been added. DIAGNOSIS. (A) RETROPERITONEAL TUMOR: DEDIFFERENTIATED LIPOSARCOMA IN A BACKGROUND OF ATYPICAL LIPOMATOUS. TUMOR. (SEE COMMENT). ATYPICAL LIPOMATOUS TUMOR INVOLVING SUPERIOR MARGIN. (B) SUPERIOR MARGIN: ADIPOSE TISSUE WITH FIBROUS AREAS WITH SLIGHLTLY AYIPICAL CELLS. SUGGESTIVE OF ATYPICAL LIPOMATOUS TUMOR. (C) LIVER BIOPSY: Bile duct h...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Dedifferentiated liposarcoma in a background of atypical lipomatous tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Dedifferentiated liposarcoma in a background of atypical lipomatous tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Dedifferentiated liposarcoma in a background of atypical lipomatous tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Dedifferentiated liposarcoma in a background of atypical lipomatous tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Dedifferentiated liposarcoma in a background of atypical lipomatous tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Dedifferentiated liposarcoma in a background of atypical lipomatous tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Dedifferentiated liposarcoma in a background of atypical lipomatous tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",",
      "predicted": "KIRC",
      "ground_truth": "SARC",
      "correct": false,
      "reasoning": "1. Site: Retroperitoneum. 2. Findings: Dedifferentiated liposarcoma in a background of atypical lipomatous tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 1135,
      "timestamp": "2026-01-19T15:59:53.119591"
    },
    {
      "sample_idx": 693,
      "input": "Specimen Description. Clinical History. Frontal temporal parietal lesion. ADDENDA: Addendum added: Final Pathologic Diagnosis. Left frontal tumor, excision: - Oligodendroglioma (WHO grade II). See comment. B. Left frontal tumor, excision: - 01 lyodendroglioma (WHO grade II) . Comment: The overall profile is chat of a low grade oligodendroglioma. However, tocally elevated proliferation index of about 8-10% raises the. possibility of future biological progression to higher grade. Cleser follow. up...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Frontal lobe. 2. Findings: Oligodendroglioma (WHO grade II). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Frontal lobe. 2. Findings: Oligodendroglioma (WHO grade II). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Frontal lobe. 2. Findings: Oligodendroglioma (WHO grade II). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Frontal lobe. 2. Findings: Oligodendroglioma (WHO grade II). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Frontal lobe. 2. Findings: Oligodendroglioma (WHO grade II). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Frontal lobe. 2. Findings: Oligodendroglioma (WHO grade II). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Frontal lobe. 2. Findings: Oligodendroglioma (WHO grade II). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Frontal lobe. 2. Findings: Oligodendroglioma (WHO grade II). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Frontal lobe. 2. Findings: Oligodendroglioma (WHO grade II). 3.",
      "predicted": "KIRC",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Frontal lobe. 2. Findings: Oligodendroglioma (WHO grade II). 3. Code: KIRC",
      "idx": 693,
      "timestamp": "2026-01-19T15:59:53.119600"
    }
  ],
  "num_samples": 500,
  "samples": [
    {
      "sample_idx": 1309,
      "input": "Macroscopic examination : Piece weighing 1208 g thymectomy fresh and measuring 19 x 17 x 8 cm. it. extended by a pulmonary resection lingula measuring 8 X 5 X 2 cm When cut , it. is a yellowish white tumor lobulated showing necrotic and remodeling. a small yellowish nodule. Lymph node latero- tracheal top right measuring 1.5 cm in diameter. Microscopic examination : 1) Thymectomy : Many samples were taken ( 1A to 1D ) The tumor has an architecture. lobulated It comprises an epithelial cell proli...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```",
      "predicted": "THYM",
      "ground_truth": "THYM",
      "correct": true,
      "reasoning": "1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.",
      "idx": 1309,
      "timestamp": "2026-01-19T15:59:53.111979"
    },
    {
      "sample_idx": 228,
      "input": "Result date: Date Collected: SPECIMEN A: CERVIX BX. SPECIMEN B: BLADDER BX. CLINICAL HISTORY: SPECIMENS SUBMITTED: A. CERVIX BX. B. BLADDER BX. DIAGNOSIS: CERVIX; BIOPSY: INVASIVE, POORLY DIFFERENTIATED SQUAMOUS CELL CARCINOMA. ANGIOLYMPHATIC INVASION NOT IDENTIFIED. SPECIMEN IS NEARLY ENTIRELY INVASIVE CARCINOMA, DEPTH OF INVASION CANNOT BE. DETERMINED, BUT TUMOR MEASURES 1.0 CM IN MICROSCOPIC SECTION. BLADDER, BIOPSY: SQUAMOUS METAPLASIA WITHOUT DYSPLASIA. NEGATIVE FOR CARCINOMA. ABUNDANT BLOO...",
      "response": "```json\n{\n    \"cancer_type\": \"CCRC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to CCRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Squamous metaplasia without dysplasia. 3. Code: Bladder maps to BLCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Squamous metaplasia without dysplasia. 3. Code: Bladder maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Squamous metaplasia without dysplasia. 3. Code: Bladder maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Squamous metaplasia without dysplasia. 3. Code: Bladder maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Squamous metaplasia without dysplasia. 3. Code: Bladder maps to K",
      "predicted": "CCRC",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to CCRC.",
      "idx": 228,
      "timestamp": "2026-01-19T15:59:53.112005"
    },
    {
      "sample_idx": 51,
      "input": "SURGICAL PATHOL 03Y REPOR. DIAGNOSIS: RADICAL CYSTOPROSTATECTOMY, BILATERAL PELVIC LYMPH NODE DISSECTION AND. URINARY DIVERSION (T-POUCH) : RIGHT DISTAL URETER (A) : FROZEN SECTION DIAGNOSIS: NO HIGH GRADE ATYPIA OR TUMOR IDENTIFIED. FINAL DIAGNOSIS: BENIGN URETER. NO UROTHELIAL DYSPLASIA OR MALIGNANCY IDENTIFIED. LEFT DISTAL URETER (B) : FROZEN SECTION DIAGNOSIS: NO HIGH GRADE ATYPIA OR TUMOR IDENTIFIED. FINAL DIAGNOSIS: BENIGN URETER. - NO UROTHELIAL DYSPLASIA OR MALIGNANCY IDENTIFIED. PARA-AO...",
      "response": "```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma with focal signet ring cell component. 3. Code: BLCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman",
      "predicted": "BLCA",
      "ground_truth": "BLCA",
      "correct": true,
      "reasoning": "1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma with focal signet ring cell component. 3. Code: BLCA.",
      "idx": 51,
      "timestamp": "2026-01-19T15:59:53.112026"
    },
    {
      "sample_idx": 563,
      "input": "Clinical History/Diagnosis: Left Renal Tumor. Source of Specimen(s): 1: left Kidney resection with Adrenal gland. 2: left paraaortic lymph nodes. Gross Description: Received in two parts. Source of Tissue: 1. Labeled # 1, \"left kidney with mass, portion of. adrenal and hilar lymph node\". Frozen Section Diagnosis: 1FS- RENAL CELL CARCINOMA. Gross Description: Received fresh in a container labeled left kidney with mass, portion. of adrenal and hilar lymph. node\". It consists of a 720 gram left rad...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: KIRC.\"\n}\n```\n",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: KIRC.",
      "idx": 563,
      "timestamp": "2026-01-19T15:59:53.112047"
    },
    {
      "sample_idx": 501,
      "input": "MEDICAL RECORD. Surgical. Pathology Report Carenoma renal all deronophable. PROCEDURE DATE: SEX: M. SIGN-OUT DATE: ATTENDING: REQUESTING: CONTACT NO: ROOM: COPIES TO: DIAGNOSIS: Kidney, right, radical nephrectomy: Renal cell carcinoma, chromophobe cell type, Fuhrman nuclear. grade II; no capsular invasion seen; vascular, urteral and inked surgical margins of resection are free of tumor; no. tumor seen in three lymph nodes (0/3); see note. NOTE: Kidney Nephrectomy Summary Table Macroscopic. Speci...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, chromophobe cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, chromophobe cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, chromophobe cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, chromophobe cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, chromophobe cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, chromophobe cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, chromophobe cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "KIRC",
      "ground_truth": "KICH",
      "correct": false,
      "reasoning": "1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, chromophobe cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 501,
      "timestamp": "2026-01-19T15:59:53.112061"
    },
    {
      "sample_idx": 457,
      "input": "DIAGNOSIS. (A) TEETH: (B) LEFT NECK DISSECTION, LEVEL I \"A\": Teeth identified, gross identification only. One lymph node, no tumor present (0/1). (C) LEFT PARTIAL GLOSSECTOMY:: INVASIVE SQUAMOUS CARCINOMA -- Well differentiated. Tumor Features: Gross: Exophytic. Size: 7.2 cm in largest dimension. Invasion: Present, depth 0.6 cm. Tumor Border: infiltrative. Perineural Invasion: Absent. Vascular Invasion: Absent. Lymphocyte Infiltration: Absent. Mucosal Margin: (en-face) Negative for invasive carc...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOSQUAMOUS CARCINOMA\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma, well differentiated. 3. Code: ADENOSQUAMOUS CARCINOMA maps to ADENOSQUAMOUS CARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ACC\",\n    \"reasoning\": \"1. Site: Left Neck, Level I. 2. Findings: Lymph node, no tumor present. 3. Code: ACC maps to ACC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ACC\",\n    \"reasoning\": \"1. Site: Left Neck, Level I. 2. Findings: Lymph node, no tumor present. 3. Code: ACC maps to ACC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ACC\",\n    \"reasoning\": \"1. Site: Left Neck, Level I. 2. Findings: Lymph node, no tumor present. 3. Code: ACC maps to ACC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ACC\",\n    \"reasoning\": \"1. Site: Left Neck, Level I. 2. Findings: Lymph node, no tumor present. 3. Code: ACC maps to ACC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ACC\",\n    \"reasoning\": \"1. Site: Left Neck, Level I. 2. Findings: Lymph node, no tumor present. 3. Code: ACC maps to ACC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ACC\",\n    \"reasoning\": \"1. Site: Left Neck, Level II. 2. Findings: Lymph node, no tumor present. 3. Code: ACC maps to ACC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ACC\",\n    \"reasoning\": \"1. Site: Left Neck, Level II. 2. Findings: Lymph node, no tumor present. 3. Code: ACC maps to ACC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ACC\",\n    \"reasoning\": \"1. Site: Left Neck",
      "predicted": "ADENOSQUAMOUS CARCINOMA",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma, well differentiated. 3. Code: ADENOSQUAMOUS CARCINOMA maps to ADENOSQUAMOUS CARCINOMA.",
      "idx": 457,
      "timestamp": "2026-01-19T15:59:53.112083"
    },
    {
      "sample_idx": 285,
      "input": "SPECIMEN. Right colon. CLINICAL NOTES. PRE-OP DIAGNOSIS: Cancer cecum. GROSS DESCRIPTION. Received fresh labeled \"right colon\" is a previously. unopened 30 cm. segment of proximal right colon with. attached 19 cm. of distal ileum surfaced by smooth scabrous tan pink. serosa with a copious amount of attached mesocolon and mesentery. An unremarkable 3.9 cm. appendix averaging 0.5 cm. in diameter is. present. The proximal and distal margins measures 4.5 and 8.0 cm. in circumference respectively. On...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Adenocarcinoma of the cecum, moderately differentiated, pT2, pN0, pM0. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Adenocarcinoma of the cecum, moderately differentiated, pT2, pN0, pM0. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Adenocarcinoma of the cecum, moderately differentiated, pT2, pN0, pM0. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Adenocarcinoma of the cecum, moderately differentiated, pT2, pN0, pM0. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Adenocarcinoma of the cecum, moderately differentiated, pT2, pN0, pM0. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Adenocarcinoma of the cecum, moderately differentiated, pT2, pN0, pM0. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Adenocarcinoma of the cecum, moderately differentiated, pT2, pN0, pM0. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon.",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Right colon. 2. Findings: Adenocarcinoma of the cecum, moderately differentiated, pT2, pN0, pM0. 3. Code: KIRC.",
      "idx": 285,
      "timestamp": "2026-01-19T15:59:53.112100"
    },
    {
      "sample_idx": 209,
      "input": "P.25/33. DIAGNOSIS: BREAST, RIGHT, MODIFIED RADICAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA WITH ASSOCIATED CALCIFICATIONS. B. NOTTINGHAM GRADE 3 (TUBULE FORMATION: 3, NUCLEAR PLEOMORPHISM: 3, MITOTIC ACTIVITY: 3; TOTAL. SCORE: 9/9). C. INVASIVE TUMOR MEASURES 2.5 X 2.3 X 2.0 CM. D. DUCTAL CARCINOMA IN SITU (DCIS), NUCLEAR GRADE 3, SOLID, CRIBRIFORM MICROPAPILLARY AND CLEAR. CELL TYPES WITH COMEDONECROSIS AND ASSOCIATED CALCIFICATIONS. E. THE DUCTAL CARCINOMA IN SITU (DCIS) CONSTITUTES 50% OF...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma with associated calcifications. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma with associated calcifications. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 209,
      "timestamp": "2026-01-19T15:59:53.112112"
    },
    {
      "sample_idx": 1385,
      "input": "SLIDE DISPOSITION: DIAGNOSIS: A. Uterus, hysterectomy: High grade serous carcinoma is. identified. forming a mass (7.0 x 4.1 x 0.4 cm) circumferentially. involving the. endometrial cavity. The tumor invades 0. 4 cm into the. myometrium. (total myometrial thickness, 1.6 cm). The tumor does not. involve. the endocervix. Lymphovascular space invasion is. identified. The. margins are negative for tumor. B. Lymph nodes, right and left para-aortic,. lymphadenectomy : Multiple (6 of 9) lymph nodes posi...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus, hysterectomy. 2. Findings: High-grade serous carcinoma. 3. Code: UCEC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovary and fallopian tube, right, salpingo-oophorectomy. 2. Findings: High-grade serous carcinoma. 3. Code: OV\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovary and fallopian tube, left, salpingo-oophorectomy. 2. Findings: High-grade serous carcinoma. 3. Code: OV\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph nodes, right and left para-aortic, lymphadenectomy. 2. Findings: Lymph node metastasis, consistent with endometrial primary. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Omentum, omentectomy. 2. Findings: Negative for tumor. 3. Code: OV\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph nodes, right and left pelvic, lymphadenectomy. 2. Findings: Lymph node metastasis, consistent with endometrial primary. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovary and fallopian tube, right, salpingo-oophorectomy. 2. Findings: High-grade serous carcinoma. 3. Code: OV\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovary and fallopian tube, left, salpingo-oophorectomy. 2. Findings: High-grade serous carcinoma. 3. Code: OV\"\n}\n```\n```json\n",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus, hysterectomy. 2. Findings: High-grade serous carcinoma. 3. Code: UCEC",
      "idx": 1385,
      "timestamp": "2026-01-19T15:59:53.112122"
    },
    {
      "sample_idx": 1116,
      "input": "Clinical Diagnosis & History: year old with large right retroperitoneal sarcoma encasing vena cava. biopsy (+) leiomyosarcoma. Specimens Submitted: 1: SP: Abdominal leiomyosarcoma. DIAGNOSIS: 1. SOFT TISSUE, RETROPERITONEAL; RESECTION: -HIGH GRADE LEIOMYOSARCOMA INVLOVING WALL OF VENA CAVA. -TUMOR DIMENSIONS: 14 x 13 x 10 CM. FOCAL NECROSIS (LESS THAN 10%) IS PRESENT. -SURGICAL MARGINS (SOFT TISSUE AND VENA CAVA) ARE FREE OF TUMOR. FOCALLY TE TUMOR IS WITHIN 0.2 CM OF SOFT TISSUE MARGIN, HOWEVER...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Abdominal, Soft Tissue. 2. Findings: Leiomyosarcoma, high grade. 3. Code: PRAD maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Abdominal, Soft Tissue. 2. Findings: Leiomyosarcoma, high grade. 3. Code: PRAD maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Abdominal, Soft Tissue. 2. Findings: Leiomyosarcoma, high grade. 3. Code: PRAD maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Abdominal, Soft Tissue. 2. Findings: Leiomyosarcoma, high grade. 3. Code: PRAD maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Abdominal, Soft Tissue. 2. Findings: Leiomyosarcoma, high grade. 3. Code: PRAD maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Abdominal, Soft Tissue. 2. Findings: Leiomyosarcoma, high grade. 3. Code: PRAD maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Abdominal, Soft Tissue. 2. Findings: Leiomyosarcoma, high grade. 3. Code: PRAD maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Abdominal, Soft Tissue. 2. Findings: Leiomyosarcoma, high grade. 3. Code: PRAD maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n",
      "predicted": "PRAD",
      "ground_truth": "SARC",
      "correct": false,
      "reasoning": "1. Site: Abdominal, Soft Tissue. 2. Findings: Leiomyosarcoma, high grade. 3. Code: PRAD maps to PRAD.",
      "idx": 1116,
      "timestamp": "2026-01-19T15:59:53.112131"
    },
    {
      "sample_idx": 178,
      "input": "Final Diagnosis. A. Breast, left, simple mastectomy: Infiltrating lobular carcinoma, Nottingham grade I (of III). [tubules 3/3, nuclei 1/3, mitoses 1/3; Nottingham score 5/9] is identified forming a mass (4.8 x. 2.7 x 1.9 cm) located in the lower outer quadrant of the breast. Biopsy site changes are present. The tumor does not involve the nipple, overlying skin, or underlying chest wall. Lobular. carcinoma in situ is also present. All surgical resection margins, including the deep margin, are. n...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade I. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Lobular carcinoma in situ. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph nodes, left axillary. 2. Findings: Lymph nodes negative for tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph nodes, left lowest axillary. 2. Findings: Lymph nodes negative for tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Breast, left. 2. Findings: Invasive lobular carcinoma, Nottingham grade I. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast, right. 2. Findings: Benign nonproliferative breast parenchyma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph nodes, left axillary. 2. Findings: Multiple lymph nodes negative for tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph nodes, left lowest axillary. 2. Findings: Lymph nodes negative for tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade I. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 178,
      "timestamp": "2026-01-19T15:59:53.112141"
    },
    {
      "sample_idx": 1209,
      "input": "Case ID. 2. Gross. Microscopic Description. Diagnosis Details. Description. Comments. STOMACH TISSUE CHECKLIST. Specimen type: Subtotal resection of stomach. Tumor site: Fundus. Tumor size: 6x5x4cm. Tumor features: None specified. Histologic type: Adenocarcinoma. Histologic grade: Moderately differentiated. Tumor extent: Muscularis propria. Lymph nodes: 0/12 positive for metastasis (Regional. 0/12). Lymphatic invasion: Not specified. Venous invasion: Not specified. Perineural invasion: Not speci...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, moderately differentiated, with lymph node metastasis. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma. 3. Code: Stomach Adenocarcinoma maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma. 3. Code: Stomach Adenocarcinoma maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma. 3. Code: Stomach Adenocarcinoma maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma. 3. Code: Stomach Adenocarcinoma maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma. 3. Code: Stomach Adenocarcinoma maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma. 3. Code: Stomach Adenocarcinoma maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma. 3. Code: Stomach Adenocarcinoma maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma. 3. Code: Stomach",
      "predicted": "STAD",
      "ground_truth": "STAD",
      "correct": true,
      "reasoning": "1. Site: Stomach. 2. Findings: Adenocarcinoma, moderately differentiated, with lymph node metastasis. 3. Code: Stomach Adenocarcinoma maps to STAD.",
      "idx": 1209,
      "timestamp": "2026-01-19T15:59:53.112152"
    },
    {
      "sample_idx": 864,
      "input": "Sample Type TUMOUR. Diagnosis. Squamous Cell Carcinoma, Not Otherwise Specified (NOS). Year of Sample Collection. Age at Sample Collection (yrs). Days to Procedure Date. Days to Diagnosis. Type of Procedure. RESECT. Site of Tissue/Primary (Histology). Right lower lobe. Tumour Size (cm). 6.9000000000000004. Histology. Squamous carcinoma. Grade/Differentiation. II. Pathological T. T2b. Pathological N. Clinical M. MO. VALCSG Stage. Histology Comments. Sample Type BUFFY. Year of Sample Collection. A...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Right lower lobe. 2. Findings: Squamous cell carcinoma, NOS, Grade II, Pathological T2b, Pathological N MO, Clinical M0. 3. Code: Squamous Cell Carcinoma, Not Otherwise Specified (NOS) maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Right lower lobe. 2. Findings: Squamous cell carcinoma, NOS, Grade II, Pathological T2b, Pathological N MO, Clinical M0. 3. Code: Squamous Cell Carcinoma, Not Otherwise Specified (NOS) maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lower lobe. 2. Findings: Squamous cell carcinoma, NOS, Grade II, Pathological T2b, Pathological N MO, Clinical M0. 3. Code: Squamous Cell Carcinoma, Not Otherwise Specified (NOS) maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Right lower lobe. 2. Findings: Squamous cell carcinoma, NOS, Grade II, Pathological T2b, Pathological N MO, Clinical M0. 3. Code: Squamous Cell Carcinoma, Not Otherwise Specified (NOS) maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Right lower lobe. 2. Findings: Squamous cell carcinoma, NOS, Grade II, Pathological T2b, Pathological N MO, Clinical M0. 3. Code: Squamous Cell Carcinoma, Not Otherwise Specified (NOS) maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lower lobe. 2. Findings: Squamous cell carcinoma, NOS, Grade II, Pathological T2b, Pathological N MO, Clinical M0. 3. Code: Squamous Cell Carcinoma, Not Otherwise Specified (NOS)",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Right lower lobe. 2. Findings: Squamous cell carcinoma, NOS, Grade II, Pathological T2b, Pathological N MO, Clinical M0. 3. Code: Squamous Cell Carcinoma, Not Otherwise Specified (NOS) maps to LUAD.",
      "idx": 864,
      "timestamp": "2026-01-19T15:59:53.112165"
    },
    {
      "sample_idx": 65,
      "input": "BIOPSY OR SURGICAL SPECIMEN (Order. Patient Information. Provider Status. Component. Lab. FINAL PATHOLOGICAL DIAGNOSIS. A. Left distal ureter, radical cystoprostatectomy: Unremarkable urothelium; no high grade dysplasia or carcinoma identified. - Frozen section diagnosis is confirmed. B. Right distal ureter, radical cystoprostatectomy: - Unremarkable urothellum; no high grade dysplasia or carcinoma identified. - Frozen section diagnosis is confirmed. C. Bladder and prostate, radical cystoprostat...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left distal ureter, radical cystoprostatectomy. 2. Findings: Invasive urothelial carcinoma with squamous differentiation, high grade. Tumor invades perivesical tissue macroscopically (pT3b). All surgical resection margins free of tumor. Prostate with benign prostatic hyperplasia; no invasive carcinoma identified. 3. Code: KIRC.\"\n}\n```\nExplanation:\n\nThe report describes a left distal ureter, radical cystoprostatectomy specimen. The microscopic findings are invasive urothelial carcinoma with squamous differentiation, high grade, with tumor invasion into perivesical tissue (pT3b). The prostate is noted to have benign prostatic hyperplasia and no invasive carcinoma. The code for Kidney Renal Clear Cell Carcinoma is KIRC, and this matches the description of the cancer type.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left distal ureter, radical cystoprostatectomy. 2. Findings: Invasive urothelial carcinoma with squamous differentiation, high grade. Tumor invades perivesical tissue macroscopically (pT3b). All surgical resection margins free of tumor. Prostate with benign prostatic hyperplasia; no invasive carcinoma identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left distal ureter, radical cystoprostatectomy. 2. Findings: Invasive urothelial carcinoma with squamous differentiation, high grade. Tumor invades perivesical tissue macroscopically (pT3b). All surgical resection margins free of tumor. Prostate with benign prostatic hyperplasia; no invasive carcinoma identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left distal ureter, radical cystoprostatectomy. 2. Findings: Invasive urothelial carcinoma with squamous differentiation, high grade. Tumor invades perivesical tissue macroscopically (pT3b). All surgical resection margins free of tumor. Prostate with benign prostatic hyperplasia; no invasive carcinoma identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    ",
      "predicted": "KIRC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Left distal ureter, radical cystoprostatectomy. 2. Findings: Invasive urothelial carcinoma with squamous differentiation, high grade. Tumor invades perivesical tissue macroscopically (pT3b). All surgical resection margins free of tumor. Prostate with benign prostatic hyperplasia; no invasive carcinoma identified. 3. Code: KIRC.",
      "idx": 65,
      "timestamp": "2026-01-19T15:59:53.112181"
    },
    {
      "sample_idx": 61,
      "input": "De-Identified Specimen Code. / M. SPECIMEN SUBMITTED: Part A: LEFT DISTAL URETER. Part B: RIGHT DISTAL URETER. Part C: BLADDER/ PROSTATE. Part D: RIGHT PELVIC LYMPH NODES. Part E: LEFT PELVIC LYMPH NODES. Final Diagnosis. 1. Left and right distal ureters, biopsy (A, B) - Negative for neoplasm. 2. Bladder, excision (C) - Invasive poorly differentiated urothelial carcinoma with invasion through. muscular wall and involvement of perivesical adipose tissue. 3. Prostate, excision (C) - Glandular hype...",
      "response": "```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Bladder (Urothelial Carcinoma). 2. Findings: Invasive urothelial carcinoma with invasion through the muscular wall and involvement of perivesical adipose tissue. 3. Code: BLCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Renal Clear Cell Carcinoma). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast (Invasive Ductal Carcinoma). 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Renal Clear Cell Carcinoma). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Renal Clear Cell Carcinoma). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Renal Clear Cell Carcinoma). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Renal Clear Cell Carcinoma). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Renal Clear",
      "predicted": "BLCA",
      "ground_truth": "BLCA",
      "correct": true,
      "reasoning": "1. Site: Bladder (Urothelial Carcinoma). 2. Findings: Invasive urothelial carcinoma with invasion through the muscular wall and involvement of perivesical adipose tissue. 3. Code: BLCA.",
      "idx": 61,
      "timestamp": "2026-01-19T15:59:53.112192"
    },
    {
      "sample_idx": 191,
      "input": "Final Surgical Pathology Report. Procedure: Diagnosis. A. Sentinel lymph node, left axilla, biopsy: A single lymph node is. negative for malignancy. B. Breast, left, excisional biopsy: Invasive lobular carcinoma,. Nottingham grade 2. Note: The margins are negative for malignancy. C. Breast, posterior lateral margin, biopsy: Focal lobular carcinoma. in situ, negative for invasive carcinoma. Microscopic Description: A. A single lymph node is negative for malignancy. [At the request of some staff o...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. Nottingham grade 2. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. Nottingham grade 2. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. Nottingham grade 2. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. Nottingham grade 2. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. Nottingham grade 2. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1.",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 191,
      "timestamp": "2026-01-19T15:59:53.112202"
    },
    {
      "sample_idx": 447,
      "input": "Gross Description: A. \"Left deep tongue margin.\" 3 fragments of red-tan tissue, each 0.5 cm. All. processed for frozen section. Frozen section control, All processed, A1. B. \"Left tongue (suture towards tongue base).\". Microscopic Description: Procedure: Resection, partial glossectomy. Specimen integrity: Intact. Specimen size: 4.0 X 3.0 x 2.0 cm. Laterality: Left. Tumor site: Base of tongue. Tumor focality: Single focus. Tumor size: 2.3 cm greatest dimension. Tumor thickness: 1.0 cm. Histologic...",
      "response": "```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Base). 2. Findings: Invasive keratinizing squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue (Base). 2. Findings: Invasive keratinizing squamous cell carcinoma. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Base). 2. Findings: Invasive keratinizing squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Base). 2. Findings: Invasive keratinizing squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue (Base). 2. Findings: Invasive keratinizing squamous cell carcinoma. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Base). 2. Findings: Invasive keratinizing squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue (Base). 2. Findings: Invasive keratinizing squamous cell carcinoma. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Base). 2. Findings: Invasive keratinizing squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue (Base). 2. Findings: Invasive keratinizing squamous cell carcinoma. 3.",
      "predicted": "SCC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Tongue (Base). 2. Findings: Invasive keratinizing squamous cell carcinoma. 3. Code: SCC maps to SCC.",
      "idx": 447,
      "timestamp": "2026-01-19T15:59:53.112212"
    },
    {
      "sample_idx": 476,
      "input": "Specimen(s) Received. 1. Nck: RT. perifacial node. 2. Neck: contents right neck - reg. 3. Neck: right hemiglossectomy (short stitch = anterior/ long stitch = medial) - reg. 4. Soft-Tissue: deep margin tongue. Diagnosis. 1. Right perifacial node: - One lymph node, negative for malignancy (0/1). 2. Right neck, dissection: - Metastatic squamous cell carcinoma involving three of forty-four lymph nodes (3/44). a. All involved nodes are level III. b. Largest node involved: 1.8 cm. C. Extracapsular ext...",
      "response": "```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Tongue (Right). 2. Findings: Squamous cell carcinoma, poorly differentiated, with perineural invasion. 3. Code: SKCM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Tongue (Right). 2. Findings: Squamous cell carcinoma, poorly differentiated, with perineural invasion. 3. Code: SKCM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Tongue (Right). 2. Findings: Squamous cell carcinoma, poorly differentiated, with perineural invasion. 3. Code: SKCM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Tongue (Right). 2. Findings: Squamous cell carcinoma, poorly differentiated, with perineural invasion. 3. Code: SKCM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Tongue (Right). 2. Findings: Squamous cell carcinoma, poorly differentiated, with perineural invasion. 3. Code: SKCM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Tongue (Right). 2. Findings: Squamous cell carcinoma, poorly differentiated, with perineural invasion. 3. Code: SKCM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Tongue (Right). 2. Findings: Squamous cell carcinoma, poorly differentiated, with perineural invasion. 3. Code: SKCM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Tongue (Right). 2. Findings: Squamous cell carcinoma, poorly differentiated, with perineural invasion. 3. Code: SKCM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1.",
      "predicted": "SKCM",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Tongue (Right). 2. Findings: Squamous cell carcinoma, poorly differentiated, with perineural invasion. 3. Code: SKCM",
      "idx": 476,
      "timestamp": "2026-01-19T15:59:53.112221"
    },
    {
      "sample_idx": 1034,
      "input": "MODIFIED REPORT - REVIEW ADDENDUM SECTION. DIAGNOSIS. (A). LEFT EXTERNAL/ INTERNAL ILIAC, HYPOGASTRIC AND OBTURATOR LYMPH NODES: METASTATIC ADENOCARCINOMA IN ONE OF THIRTEEN LYMPH NODES. LESS THAN 1.0 MM FOCUS. NO EXTRANODAL EXTENSION PRESENT. (1/13). (B) RIGHT EXTERNAL/ INTERNAL ILIAC, HYPOGASTRIC AND OBTURATOR LYMPH NODES: Twenty one lymph nodes, no tumor present (0/21). (C) PROSTATE AND SEMINAL VESICLES: Supplemental report to follow. Entire report and diagnosis completed by. GROSS DESCRIPTIO...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostate adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5. 3. Code: UCEC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostate adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5. 3. Code: UCEC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostate adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5. 3. Code: UCEC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostate adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5. 3. Code: UCEC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostate adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5. 3. Code: UCEC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostate adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5. 3. Code: UCEC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostate adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5. 3. Code: UCEC.\"\n}\n```\nResponse:\n```",
      "predicted": "UCEC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostate adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5. 3. Code: UCEC.",
      "idx": 1034,
      "timestamp": "2026-01-19T15:59:53.112232"
    },
    {
      "sample_idx": 1232,
      "input": "FINAL DIAGNOSIS. PART 1: LYMPH NODE, CENTRAL COMPARTMENT, SELECTIVE DISSECTION. A. METASTATIC CARCINOMA IN TWO OUT OF SIX LYMPH NODES (2/6). B. NO EXTRANODAL EXTENSION. PART 2: THYROID, TOTAL THYROIDECTOMY (17 GRAMS). A. PAPILLARY THYROID CARCINOMA, TWO.FOCI (1.2 CM AND 0.5 CM),. B. LARGEST FOCUS: LEFI LOBE, TALL CELL VARIANT WITH EXTRATHYROID EXTENSION; TUMOR. LESS THAN 0.1 CM FROM THE MARGIN. C. CHRONIC LYMPHOCYTIC THYROIDITIS. D. TWO LYMPH NODES, NO TUMOR PRESENT (0/2). E. PATHOLOGIC STAGE: p...",
      "response": "```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid (Total Thyroidectomy). 2. Findings: Papillary thyroid carcinoma, multifocal. One focus with extrathyroidal extension. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid (Total Thyroidectomy). 2. Findings: Chronic lymphocytic thyroiditis. 3. Code: Thyroid Carcinoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Central Compartment). 2. Findings: Metastatic carcinoma in two out of six lymph nodes. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast (Total Thyroidectomy). 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Central Compartment). 2. Findings: Metastatic carcinoma in two out of six lymph nodes. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Central Compartment). 2. Findings: Metastatic carcinoma in two out of six lymph nodes. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Central Compartment). 2. Findings: Metastatic carcinoma in two out of six lymph nodes. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Central Compartment). 2. Findings: Metastatic carcinoma",
      "predicted": "THCA",
      "ground_truth": "THCA",
      "correct": true,
      "reasoning": "1. Site: Thyroid (Total Thyroidectomy). 2. Findings: Papillary thyroid carcinoma, multifocal. One focus with extrathyroidal extension. 3. Code: Thyroid Carcinoma maps to THCA.",
      "idx": 1232,
      "timestamp": "2026-01-19T15:59:53.112243"
    },
    {
      "sample_idx": 54,
      "input": "Anatomic Site:Right Ureter (FS). Left Ureter (FS). Bladder (FS on urethra). Distal right ureter (FS). Right pelvic lymph nodes (FS). Final urethral margin. Left pelvic lymph nodes. Final left ureter. Clinical Diagnosis/History. The patient is a. -year-old woman. No further clinical history is provided. A recent consult. indicates a transurethral bladder tumor resection showing invasive high-grade. urothelial carcinoma with invasion of the. muscularis propria. Gross Description: The specimen is r...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Ureter (Proximal). 2. Findings: Urothelial carcinoma, invasive, high grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Left Ureter. 2. Findings: Urothelial carcinoma, non-invasive, low grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Urothelial carcinoma, invasive, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Distal right ureter. 2. Findings: Urothelial carcinoma, invasive, high grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right pelvic lymph nodes. 2. Findings: No tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Urethra, final margin. 2. Findings: No tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left pelvic lymph nodes. 2. Findings: No tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left ureter. 2. Findings: Urothelial carcinoma, non-invasive, low grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Urothelial carcinoma, invasive, high grade. 3. Code: KIRC.\"",
      "predicted": "KIRC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Right Ureter (Proximal). 2. Findings: Urothelial carcinoma, invasive, high grade. 3. Code: KIRC.",
      "idx": 54,
      "timestamp": "2026-01-19T15:59:53.112253"
    },
    {
      "sample_idx": 1149,
      "input": "Laterality: Malignant melanoma. Path Report:SKIN TISSUE CHECKLIST. Specimen type: Surgical resection. Tumor site: Skin, hand. Tumor size: 4 x 3 X 3 cm. Tumor features: Ulcerated, Pigmented. Satellite nodules: Not specified. Histologic type: Malignant melanoma. Histologic grade: Poorly differentiated. Lymph nodes: 0/10 positive for metastasis (Axillary 0/10). Lymphatic invasion: Not specified. Venous invasion: Not specified. Margins: Not specified. Evidence of neo-adjuvant treatment: Not specifie...",
      "response": "```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin (hand). 2. Findings: Malignant melanoma, poorly differentiated. 3. Code: SKCM (Skin Cancer Melanoma) maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin (hand). 2. Findings: Malignant melanoma, poorly differentiated. 3. Code: SKCM (Skin Cancer Melanoma) maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin (hand). 2. Findings: Malignant melanoma, poorly differentiated. 3. Code: SKCM (Skin Cancer Melanoma) maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin (hand). 2. Findings: Malignant melanoma, poorly differentiated. 3. Code: SKCM (Skin Cancer Melanoma) maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin (hand). 2. Findings: Malignant melanoma, poorly differentiated. 3. Code: SKCM (Skin Cancer Melanoma) maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin (hand). 2. Findings: Malignant melanoma, poorly differentiated. 3. Code: SKCM (Skin Cancer Melanoma) maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin (hand). 2. Findings: Malignant melanoma, poorly differentiated. 3. Code: SKCM (Skin Cancer Melanoma) maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin (hand). 2. Findings: Malignant melanoma, poorly differentiated. 3. Code: SKCM (Skin Cancer Melanoma) maps to",
      "predicted": "SKCM",
      "ground_truth": "SKCM",
      "correct": true,
      "reasoning": "1. Site: Skin (hand). 2. Findings: Malignant melanoma, poorly differentiated. 3. Code: SKCM (Skin Cancer Melanoma) maps to SKCM.",
      "idx": 1149,
      "timestamp": "2026-01-19T15:59:53.112263"
    },
    {
      "sample_idx": 407,
      "input": "MODIFIED REPORT - REVIEW ADDENDUMI SECTION. DIAGNOSIS. (A) BRAIN, \"RIGHT TEMPORAL TUMOR\". DIFFUSE ASTROCYTOMA, WHO GRADE 4, OR GLIOBLASTOMA. (SEE COMMENT). (B) BRAIN, \"RIGHT TEMPORAL TUMOR\". DIFFUSE ASTROCYTOMA, WHO GRADE 4, OR GLIOBLASTOMA. (SEE COMMENT). GROSS DESCRIPTION. (A) \"RIGHT TEMPORAL TUMOR\" - Consists of a fragment of cortex and white matter containing blood clot and tumor. In. some areas there is gray-white junction demarcation, however, the majority of the specimen is infiltrated by...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Temporal Tumor. 2. Findings: Diffuse astrocytoma, WHO Grade 4, or glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Temporal Tumor. 2. Findings: Diffuse astrocytoma, WHO Grade 4, or glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Temporal Tumor. 2. Findings: Diffuse astrocytoma, WHO Grade 4, or glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Temporal Tumor. 2. Findings: Diffuse astrocytoma, WHO Grade 4, or glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Temporal Tumor. 2. Findings: Diffuse astrocytoma, WHO Grade 4, or glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Temporal Tumor. 2. Findings: Diffuse astrocytoma, WHO Grade 4, or glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Temporal Tumor. 2. Findings: Diffuse astrocytoma, WHO Grade 4, or glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Temporal Tumor. 2. Findings:",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain, Temporal Tumor. 2. Findings: Diffuse astrocytoma, WHO Grade 4, or glioblastoma. 3. Code: GBM maps to GBM.",
      "idx": 407,
      "timestamp": "2026-01-19T15:59:53.112272"
    },
    {
      "sample_idx": 1330,
      "input": "Service:Gynecology. Gender: F. (Age: Accessioned. Patient Type: SDSA. Other Data: DIAGNOSIS: UTERUS, TOTAL ABDOMINAL HYSTERECTOMY. - ENDOMETRIOID ADENOCARCINOMA, FIGO GRADE 2/3, INVASIVE TO A DEPTH OF 0.3. CM. (MYOMETRIAL THICKNESS 2.0 CM) WITHOUT LOWER UTERINE SEGMENT INVOLVEMENT. - ADENOMYOSIS. - LEIOMYOMAS. - SEROSAL ENDOMETRIOSIS. - CERVIX WITH NO HISTOPATHOLOGIC ABNORMALITY. OVARIES, LEFT AND RIGHT, BILATERAL OOPHORECTOMY. - ENDOMETRIOSIS. - TUBAL AND UTERINE SEROSAL ADHESIONS. - NO EVIDENC...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Right and Left Adnexa. 2. Findings: Endometrioid adenocarcinoma, FIGO Grade 2/3, Invasive to a depth of 0.3 cm. 3. Code: BRCA does not map to this finding.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Right and Left Adnexa. 2. Findings: Endometrioid adenocarcinoma, FIGO Grade 2/3, Invasive to a depth of 0.3 cm. 3. Code: KIRC maps to Uterus, Cervix, Right and Left Adnexa.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Right and Left Adnexa. 2. Findings: Endometrioid adenocarcinoma, FIGO Grade 2/3, Invasive to a depth of 0.3 cm. 3. Code: KIRC maps to Uterus, Cervix, Right and Left Adnexa.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Right and Left Adnexa. 2. Findings: Endometrioid adenocarcinoma, FIGO Grade 2/3, Invasive to a depth of 0.3 cm. 3. Code: KIRC maps to Uterus, Cervix, Right and Left Adnexa.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Right and Left Adnexa. 2. Findings: Endometrioid adenocarcinoma, FIGO Grade 2/3, Invasive to a depth of 0.3 cm. 3. Code: KIRC maps to Uterus, Cervix, Right and Left Adnexa.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Right and Left Adnexa. 2. Findings: Endometri",
      "predicted": "BRCA",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Uterus, Cervix, Right and Left Adnexa. 2. Findings: Endometrioid adenocarcinoma, FIGO Grade 2/3, Invasive to a depth of 0.3 cm. 3. Code: BRCA does not map to this finding.",
      "idx": 1330,
      "timestamp": "2026-01-19T15:59:53.112284"
    },
    {
      "sample_idx": 1405,
      "input": "Service : Gynecology. Gender: F. MRN. Physician (s) : other Related Clinical Data: DIAGNOSIS: UTERUS, ENDOMETRIUM, TOTAL ABDOMINAL HYSTERECTOMY. - MALIGNANT MIXED MULLERIAN TUMOR (MMMT) WITH HETEROLOGOUS DIFFERENTIATION. - MMMT EXTENSIVELY INVOLVES THE LOWER UTERINE SEGMENT. - SEE SYNOPTIC. UTERUS, MYOMETRIUM, TOTAL ABDOMINAL HYSTERECTOMY. - MMMT BY DIRECT EXTENSION, INVADING TO A DEPTH OF 13 MM WHERE MYOMETRIAL. THICKNESS IS 18 MM. - LYMPHOVASCULAR: INVASION BY MMMT IS IDENTIFIED. UTERUS, CERVI...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Malignant mixed Mullerian tumor (MMMT) with heterologous elements of endometrium. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"",
      "predicted": "KIRC",
      "ground_truth": "UCS",
      "correct": false,
      "reasoning": "1. Site: Uterus. 2. Findings: Malignant mixed Mullerian tumor (MMMT) with heterologous elements of endometrium. 3. Code: KIRC.",
      "idx": 1405,
      "timestamp": "2026-01-19T15:59:53.112295"
    },
    {
      "sample_idx": 859,
      "input": "Operative Procedure: Right thoracotomy, pneumonectomy. A: Left paratracheal LN. B: Inferior pulmonary ligament LN. C: Lymph node: Parat. D: Lymph node: High. E: Right lung. F: Carinal margin. G: Subcarinal lymph nodes. Final Pathologic Diagnosis: A. Lymph node, left paratracheal, excision: One lymph node, negative for tumor (0/1). B. Lymph node, inferior pulmonary ligament, excision: One lymph node, negative for tumor (0/1). C. Lymph node, paratracheal #2, excision: Eighteen lymph nodes, negativ...",
      "response": "```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung (Right). 2. Findings: Squamous cell carcinoma of the lung. 3. Code: ESCA maps to Squamous cell carcinoma of the lung.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung (Right). 2. Findings: Squamous cell carcinoma of the lung. 3. Code: ESCA maps to Squamous cell carcinoma of the lung.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung (Right). 2. Findings: Squamous cell carcinoma of the lung. 3. Code: ESCA maps to Squamous cell carcinoma of the lung.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung (Right). 2. Findings: Squamous cell carcinoma of the lung. 3. Code: ESCA maps to Squamous cell carcinoma of the lung.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung (Right). 2. Findings: Squamous cell carcinoma of the lung. 3. Code: ESCA maps to Squamous cell carcinoma of the lung.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung (Right). 2. Findings: Squamous cell carcinoma of the lung. 3. Code: ESCA maps to Squamous cell carcinoma of the lung.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung (Right). 2. Findings: Squamous cell carcinoma of the lung. 3. Code: ESCA maps to Squamous cell carcinoma of the lung.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung (Right). 2. Findings: Squamous cell carcinoma of the lung. 3. Code: ESCA maps to Squamous cell carcinoma of",
      "predicted": "ESCA",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung (Right). 2. Findings: Squamous cell carcinoma of the lung. 3. Code: ESCA maps to Squamous cell carcinoma of the lung.",
      "idx": 859,
      "timestamp": "2026-01-19T15:59:53.112321"
    },
    {
      "sample_idx": 451,
      "input": "CORRECTED. Report Type. Patholoav Report. Date of Event. F. Authored by. Hosp/Group. Record Status. CORRECTED. ADDENDA: COMPREHENSIVE THERANOSTIC SUMMARY. IMMUNOHISTOCHEMISTRY. p16: POSITIVE. IN SITU HYBRIDIZATION / FISH. HPV: POSITIVE;. subtypes. 16, 18, 6, 11. Pattern: Punctate. MOLECULAR ANATOMIC PATHOLOGY. See Special Procedure reports below for additional details and. background. on In situ/FISH and/or Molecular Anatomic Pathology. testing. SXC1. My signature is attestation that I have pers...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pharynx, oropharynx. 2. Findings: Squamous cell carcinoma, conventional, 2.6 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pharynx, oropharynx. 2. Findings: Squamous cell carcinoma, conventional, 2.6 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pharynx, oropharynx. 2. Findings: Squamous cell carcinoma, conventional, 2.6 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pharynx, oropharynx. 2. Findings: Squamous cell carcinoma, conventional, 2.6 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pharynx, oropharynx. 2. Findings: Squamous cell carcinoma, conventional, 2.6 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pharynx, oropharynx. 2. Findings: Squamous cell carcinoma, conventional, 2.6 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pharynx, oropharynx. 2. Findings: Squamous cell carcinoma, conventional, 2.6 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC",
      "predicted": "KIRC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Pharynx, oropharynx. 2. Findings: Squamous cell carcinoma, conventional, 2.6 cm. 3. Code: KIRC.",
      "idx": 451,
      "timestamp": "2026-01-19T15:59:53.112333"
    },
    {
      "sample_idx": 919,
      "input": "CLINICAL HISTORY: Abdominal/pelvic swelling, large pelvic mass with history of breast cancer. GROSS EXAMINATION: A. \"Omental nodule (AF1)\". Received fresh is a 7.8 x 4.9 x 2.1 cm fragment of. yellow-tan lobulated fibroadipose tissue that contains a 2.2 x 2.1 x 1. 4 cm. well circumscribed, tan-white, firm nodule (AF1 Frozen section; remnant in A1;. additional A2). B. \"Piece of omentum\". Received fresh is a 16.9 x 10.6 x 3.2 cm aggregate of. two fragments of yellow-tan lobulated fibrofatty tissue ...",
      "response": "```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovary (Right). 2. Findings: Serous adenocarcinoma, FIGO Grade 2, size 15.0 x 11.0 x 9.0 cm, weight 650 grams. Serosa involved. Additional findings none. 3. Code: OV\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_",
      "predicted": "OV",
      "ground_truth": "OV",
      "correct": true,
      "reasoning": "1. Site: Ovary (Right). 2. Findings: Serous adenocarcinoma, FIGO Grade 2, size 15.0 x 11.0 x 9.0 cm, weight 650 grams. Serosa involved. Additional findings none. 3. Code: OV",
      "idx": 919,
      "timestamp": "2026-01-19T15:59:53.112344"
    },
    {
      "sample_idx": 1206,
      "input": "PRIMARY SITE: Stomach (Gastroesophageal junction). 1 - \"Esophagus + Stomach\": Adenocarcinoma characterized as follows: Histological pattern(s) observed: tubular. Histological grade: II - moderately differentiated. Measure of the longest axis of the tumor: 12.70. Lauren's classification: Ulceration: present. Compromise of: Mucosa. Muscularis mucosae. Submucosa. Muscularis propria. Adjacent adipose tissue. Type of tumor invasion. Spiculated. Inflammatory reaction: Mild. Tumor implantation in peri-...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Adenocarcinoma, tubular pattern, moderately differentiated, ulceration present, lymphatic vascular invasion present, neural infiltration present. 3. Code: Adenocarcinoma maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Adenocarcinoma, tubular pattern, moderately differentiated, ulceration present, lymphatic vascular invasion present, neural infiltration present. 3. Code: Adenocarcinoma maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Adenocarcinoma, tubular pattern, moderately differentiated, ulceration present, lymphatic vascular invasion present, neural infiltration present. 3. Code: Adenocarcinoma maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Adenocarcinoma, tubular pattern, moderately differentiated, ulceration present, lymphatic vascular invasion present, neural infiltration present. 3. Code: Adenocarcinoma maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Adenocarcinoma, tubular pattern, moderately differentiated, ulceration present, lymphatic vascular invasion present, neural infiltration present. 3. Code: Adenocarcinoma maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Adenocarcinoma, tubular pattern, moderately differentiated, ulceration present, lymphatic vascular invasion present, neural infiltration present. 3. Code: Adenocarcinoma maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroes",
      "predicted": "ADENOCA",
      "ground_truth": "STAD",
      "correct": false,
      "reasoning": "1. Site: Stomach (Gastroesophageal junction). 2. Findings: Adenocarcinoma, tubular pattern, moderately differentiated, ulceration present, lymphatic vascular invasion present, neural infiltration present. 3. Code: Adenocarcinoma maps to ADENOCA.",
      "idx": 1206,
      "timestamp": "2026-01-19T15:59:53.112357"
    },
    {
      "sample_idx": 569,
      "input": "INAL DIAGNOSIS. A. RENAL CELL CARCINOMA, CONVENTIONAL (CLEAR) CELL TYPE. B. THE FUHRMAN'S NUCLEAR GRADE IS III/ IV. C. RENAL CELL CARCINOMA GROWS IN ACINAR PATTERN WITH EXTENSIVE INTRATUMORAL. HEMORRHAGE. D. THE GREATEST DIAMETER OF THE NEOPLASM IS 7.0 CM. E. THE CARCINOMA EXTENDS INTO THE SOFT TISSUE IN THE REGION OF THE RENAL SINUS. F. THE TUMOR IS CONFINED WITHIN THE GEROTA'S FASCIA. G. THE CARCINOMA INVADES THE RENAL VEIN WITH LARGE TUMOR THROMBUS IDENTIFIED. H. URETERAL AND RENAL VASCULAR M...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 569,
      "timestamp": "2026-01-19T15:59:53.112369"
    },
    {
      "sample_idx": 13,
      "input": "DIAGNOSIS: A-E. Bladder, prostate, and pelvic lymph nodes, excision: Procedure: Radical cystoprostatectomy. Tumor site: Right posterior lateral wall. Tumor size: 2.5 x 2.0 x 1.2 cm. Histologic type: Urothelial (transitional cell carcinoma), , with. nested pattern. Associated epithelial lesions: None identified. Histologic grade: High-grade, grade 3 (of 3) . Tumor configuration: Solid/nodule with ulceration. Microscopic tumor extension: Perivesical fat. Margins: Negative, right and left distal ur...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder and Prostate. 2. Findings: Urothelial carcinoma, high-grade, with associated prostatic invasion. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Chronic nephritis, hydronephrosis. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pelvic Lymph Nodes. 2. Findings: Metastatic carcinoma consistent with bladder primary. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Urothelial carcinoma, high-grade, with associated prostatic invasion. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Extensive invasion by urothelial carcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Urothelial carcinoma, high-grade, with associated prostatic invasion. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Urothelial carcinoma, high-grade, with associated prostatic invasion. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Urothelial carcinoma, high-grade, with associated prostatic invasion. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: U",
      "predicted": "KIRC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Bladder and Prostate. 2. Findings: Urothelial carcinoma, high-grade, with associated prostatic invasion. 3. Code: KIRC.",
      "idx": 13,
      "timestamp": "2026-01-19T15:59:53.112379"
    },
    {
      "sample_idx": 326,
      "input": "SPECIMEN. Right colon. CLINICAL NOTES. PRE-OP DIAGNOSIS Right colon cancer. GROSS DESCRIPTION. Received fresh labeled \"right colon\" is a previously. unopened 17 cm. segment of proximal right colon with. attached 13.5 cm. of distal ileum surfaced by smooth to slightly. scabrous tan-pink serosa with a copious amount of attached. mesocolon. and mesentery. A 4.7 cm. unremarkable appendix ranging from 0.5 to. 0.8 cm. in diameter is present. The proximal and distal margins. measure 4.0 and 6.5 cm. in ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Invasive adenocarcinoma, moderately differentiated. pT3, pN1b. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Invasive adenocarcinoma, moderately differentiated. pT3, pN1b. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Invasive adenocarcinoma, moderately differentiated. pT3, pN1b. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Invasive adenocarcinoma, moderately differentiated. pT3, pN1b. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Invasive adenocarcinoma, moderately differentiated. pT3, pN1b. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Invasive adenocarcinoma, moderately differentiated. pT3, pN1b. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Invasive adenocarcinoma, moderately differentiated. pT3, pN1b. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon. 2. Findings: Invasive adenocarcinoma, moderately differentiated. pT3, pN1b. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Right colon. 2. Findings: Invasive adenocarcinoma, moderately differentiated. pT3, pN1b. 3. Code: KIRC.",
      "idx": 326,
      "timestamp": "2026-01-19T15:59:53.112389"
    },
    {
      "sample_idx": 865,
      "input": "DIAGNOSTS: Lung, left upper lobe, excision: Invasive grade 4 (of 4) squamous. cell carcinoma forming a 2.7 x 2 x 1.8 cm mass located 0.7 cm from. the bronchial margin. The surgical margins are negative. Multiple. (3) intrapulmonary peribronchial lymph are negative for tumor. Lung, superior segment left lower lobe, No. 1 excision: Microscopic. squamous cell carcinoma in-situ forming a 0.2 cm. lesion in diameter. The surgical margins are negative for. tumor. Lung, superior segment left lower lobe,...",
      "response": "```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, and Lung, superior segment left lower lobe. 2. Findings: Invasive squamous cell carcinoma, and Microscopic squamous cell carcinoma in-situ. 3. Code: Lung, left upper lobe maps to LCLC, and Lung, superior segment left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, and Lung, superior segment left lower lobe. 2. Findings: Invasive squamous cell carcinoma, and Microscopic squamous cell carcinoma in-situ. 3. Code: Lung, left upper lobe maps to LCLC, and Lung, superior segment left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, and Lung, superior segment left lower lobe. 2. Findings: Invasive squamous cell carcinoma, and Microscopic squamous cell carcinoma in-situ. 3. Code: Lung, left upper lobe maps to LCLC, and Lung, superior segment left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, and Lung, superior segment left lower lobe. 2. Findings: Invasive squamous cell carcinoma, and Microscopic squamous cell carcinoma in-situ. 3. Code: Lung, left upper lobe maps to LCLC, and Lung, superior segment left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, and Lung, superior segment left lower lobe. 2. Findings: Invasive squamous cell carcinoma, and Microscopic squamous cell carcinoma in-situ. 3. Code: Lung, left upper lobe maps to LCLC, and Lung, superior segment left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, and Lung, superior segment left lower lobe. ",
      "predicted": "LCLC",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung, left upper lobe, and Lung, superior segment left lower lobe. 2. Findings: Invasive squamous cell carcinoma, and Microscopic squamous cell carcinoma in-situ. 3. Code: Lung, left upper lobe maps to LCLC, and Lung, superior segment left lower lobe maps to LCLC.",
      "idx": 865,
      "timestamp": "2026-01-19T15:59:53.112403"
    },
    {
      "sample_idx": 696,
      "input": "Provider Status. Observation Date and Time. Result Narrative. (NOTE). Clinical History. Malignant neoplasm of frontal lobe of brain [191.1]. . Medical History: GERD (gastroesophageal reflux disease) . Optic nerve edema. ADDENDA: Addendum added: Addendum added: Final Pathologic Diagnosis--. A. Left frontal tumor, biopsy: Slides have been referred to. for review and diagnosis. An. addendum will follow. B. Left frontal tumor, excision: Slides have been referred to. for review and diagnosis. An. add...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Frontal lobe of brain. 2. Findings: Anaplastic infiltrating glioma (WHO Grade III). 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Frontal lobe of brain. 2. Findings: Anaplastic infiltrating glioma (WHO Grade III). 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Frontal lobe of brain. 2. Findings: Anaplastic infiltrating glioma (WHO Grade III). 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Frontal lobe of brain. 2. Findings: Anaplastic infiltrating glioma (WHO Grade III). 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Frontal lobe of brain. 2. Findings: Anaplastic infiltrating glioma (WHO Grade III). 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Frontal lobe of brain. 2. Findings: Anaplastic infiltrating glioma (WHO Grade III). 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Frontal lobe of brain. 2. Findings: Anaplastic infiltrating glioma (WHO Grade III). 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Frontal lobe of brain. 2. Findings: Anaplastic infiltrating glioma (WHO Grade III). 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Frontal lobe of brain. 2. Findings: Anaplastic",
      "predicted": "BRCA",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Frontal lobe of brain. 2. Findings: Anaplastic infiltrating glioma (WHO Grade III). 3. Code: BRCA",
      "idx": 696,
      "timestamp": "2026-01-19T15:59:53.112413"
    },
    {
      "sample_idx": 1406,
      "input": "HISTOPATHOLOGY. Lab No. Clinical Consultant & Location. Unit No. SPECIMEN. RIGHT ENUCLEATED GLOBE, PROGNOSTIC AND DIAGNOSTIC TESTS. CLINICAL DETAILS. Right eye choroidal melanoma, involved optic nerve. Tumour size: 13.36 x 13.42mm (thickness 6.43) mm. MACROSCOPIC DESCRIPTION. A fresh, intact, right globe. Dimensions: Axial 25mm, Horizontal 25mm, Vertical 25mm. Cornea: Horizontal 12.4mm, Vertical 12mm. Optic nerve. Length 5mm, Diameter 4mm. Pupil: dilated. On trans-illumination, a shadow is seen ...",
      "response": "```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Eye (Right eye). 2. Findings: Choroidal melanoma. 3. Code: CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Eye (Right eye). 2. Findings: Choroidal melanoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Eye (Right eye). 2. Findings: Choroidal melanoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Eye (Right eye). 2. Findings: Choroidal melanoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Eye (Right eye). 2. Findings: Choroidal melanoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Eye (Right eye). 2. Findings: Choroidal melanoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Eye (Right eye). 2. Findings: Choroidal melanoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Eye (Right eye). 2. Findings: Choroidal melanoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Eye (Right eye). 2. Findings: Choroidal melanoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Eye (Right eye). 2. Findings",
      "predicted": "CHOL",
      "ground_truth": "UVM",
      "correct": false,
      "reasoning": "1. Site: Eye (Right eye). 2. Findings: Choroidal melanoma. 3. Code: CHOL.",
      "idx": 1406,
      "timestamp": "2026-01-19T15:59:53.112423"
    },
    {
      "sample_idx": 318,
      "input": "This is an invasive, poorly differentiated adenocarcinoma of the colon (according to clinical. findings the descending colon) with penetration of all the parietal layers and vascular infiltrates. (pT3, L1, V1) with six lymph node metastases (6/14). Tumor classification: ICDO-DA-M. 8140/3. G3. pT3. L1, V1,. pN2 (6/14).",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Descending). 2. Findings: Invasive adenocarcinoma of the colon, poorly differentiated, with lymph node metastases. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Colon (Descending). 2. Findings: Invasive adenocarcinoma of the colon, poorly differentiated, with lymph node metastases. 3. Code: STAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Descending). 2. Findings: Invasive adenocarcinoma of the colon, poorly differentiated, with lymph node metastases. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Descending). 2. Findings: Invasive adenocarcinoma of the colon, poorly differentiated, with lymph node metastases. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Descending). 2. Findings: Invasive adenocarcinoma of the colon, poorly differentiated, with lymph node metastases. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Descending). 2. Findings: Invasive adenocarcinoma of the colon, poorly differentiated, with lymph node metastases. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Descending). 2. Findings: Invasive adenocarcinoma of the colon, poorly differentiated, with lymph node metastases. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Descending). 2. Findings: Invasive adenocarcinoma of the colon, poorly differentiated",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon (Descending). 2. Findings: Invasive adenocarcinoma of the colon, poorly differentiated, with lymph node metastases. 3. Code: COAD maps to Colon Adenocarcinoma.",
      "idx": 318,
      "timestamp": "2026-01-19T15:59:53.112433"
    },
    {
      "sample_idx": 440,
      "input": "Report Type. Date of Event. Authored by. Hosp/Group. Record Status. FINAL DIAGNOSIS: TONSIL, RIGHT, BIOPSY. FRAGMENT OF SQUAMOUS CELL CARCINOMA, NON-KERATINIZING. By Pathologist. My signature is attestation that I have personally reviewed the. submitted. material (s) and the final diagnosis reflects that evaluation. GROSS DESCRIPTION: The specimen is received unfixed for intraoperative consultation,. labeled with. the patient's name, initials XXX, and \"biopsy right tonsil\". It. consists of a. 0....",
      "response": "```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, Right. 2. Findings: Squamous cell carcinoma, non-keratinizing. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, Right. 2. Findings: Squamous cell carcinoma, non-keratinizing. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, Right. 2. Findings: Squamous cell carcinoma, non-keratinizing. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, Right. 2. Findings: Squamous cell carcinoma, non-keratinizing. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, Right. 2. Findings: Squamous cell carcinoma, non-keratinizing. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, Right. 2. Findings: Squamous cell carcinoma, non-keratinizing. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, Right. 2. Findings: Squamous cell carcinoma, non-keratinizing. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, Right. 2. Findings: Squamous cell carcinoma, non-keratinizing. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",",
      "predicted": "HNSC",
      "ground_truth": "HNSC",
      "correct": true,
      "reasoning": "1. Site: Tonsil, Right. 2. Findings: Squamous cell carcinoma, non-keratinizing. 3. Code: HNSC.",
      "idx": 440,
      "timestamp": "2026-01-19T15:59:53.112443"
    },
    {
      "sample_idx": 689,
      "input": "Client: (Age: 1 Location: Gender: M Accnt: Phy Location: Clinical History. Probably low grade gliomas. Operative Diagnoses. Operation / Specimen. A: Brain, probably tumor, biopsy. Pathologic Diagnosis. A. Brain, tumor, excision biopsy: Diffuse astrocytoma, WHO grade II (see comment). Comment. Permanent sections confirm the frozen section diagnosis. Sections show an infiltrating astrocytoma. Mitotic figures. and/or vascular proliferation are not seen. The Ki-67 labeling index is approximately 3%....",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Diffuse astrocytoma, WHO grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Diffuse astrocytoma, WHO grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Diffuse astrocytoma, WHO grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Diffuse astrocytoma, WHO grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Diffuse astrocytoma, WHO grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Diffuse astrocytoma, WHO grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Diffuse astrocytoma, WHO grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Diffuse astrocytoma, WHO grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to",
      "predicted": "KIRC",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain. 2. Findings: Diffuse astrocytoma, WHO grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 689,
      "timestamp": "2026-01-19T15:59:53.112453"
    },
    {
      "sample_idx": 1407,
      "input": "HISTOPATHOLOGY. Lab No. Clinical Consultant & Location. Unit No. SPECIMEN. LEFT ENUCLEATION (GLOBE) . DIAGNOSTIC, PROGNOSTIC. CLINICAL DETAILS. See diagram. MACROSCOPIC DESCRIPTION. A fresh, intact, left gloe. Dimensions: Axial 25. Horizontal 24mm, Vertical 24mm. Cornea: Horizontal 12mm, Vertical 11 5mm. Optic nerve. Length 1mm, Diameter 4mm. On. crans-illumination, a large shadow is seen on the medium. side approx 22mm. Plane of section: horizontal. Intraocular description: On opening, a solita...",
      "response": "```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Eye (Left Eye). 2. Findings: Choroidal melanoma. 3. Code: CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_",
      "predicted": "CHOL",
      "ground_truth": "UVM",
      "correct": false,
      "reasoning": "1. Site: Eye (Left Eye). 2. Findings: Choroidal melanoma. 3. Code: CHOL.",
      "idx": 1407,
      "timestamp": "2026-01-19T15:59:53.112462"
    },
    {
      "sample_idx": 189,
      "input": "page 1 / 1. copy No. 4. Examination: Histopathological examination. Gender: F. Material: Total organ resection - left breast. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the left breast. PCI: Cellulae carcinomatosae. Results of immunohistochemical examination: No estrogen receptors found in the neoplastic cell nuclei. No progesterone receptors found in the neoplastic cell nuclei. HER2 protein stained with HER2 protein stained with. Ventana's Pathway HER-2/ne...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 189,
      "timestamp": "2026-01-19T15:59:53.112471"
    },
    {
      "sample_idx": 778,
      "input": "PROCEDURE DATE: RECEIVED DATE: REPORT DATE: 10 Consultation. FS DIAGNOSES 1 AND 2: \"Negative for neoplasm (reported to Dr. positive patient ID)\" by Dr. campus. Pre-Op Diagnosis. Lung cancer. Post-Op Diagnosis. Same as above. Clinical History. Nothing indicated. Gross Description: Six parts. Container labeled. R lymph node\" has 1.5 x. 1.5 x 0.4 cm of gray-tan to yellow fleshy and fibrofatty tissue. fragments which are submitted for frozen section and reported as. \"negative for neoplasm (reported ...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, right lower lobe. 2. Findings: Adenocarcinoma, moderately differentiated, subpleural, right lower lung lobe. Tumor size: 2.0 x 2.0 x 1.6 cm. Tumor grade: Moderately differentiated. Pleural invasion: Yes (tumor appears to focally involve overlying pleura in slide 5D). Lymphovascular space invasion: No. Surgical margin status: Tumor distance from bronchial margin: 2.8 cm. Tumor distance from stapled margin: Not applicable. Tumor distance from pleural surface: Less than 0.5 cm, focally involving pleura. microscopically. Lymph node status: See specimens 1, 2, 3, 4 and 6. Station 7 lymph node: Negative for tumor. Stage: T2N0. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, right lower lobe. 2. Findings: Adenocarcinoma, moderately differentiated, subpleural, right lower lung lobe. Tumor size: 2.0 x 2.0 x 1.6 cm. Tumor grade: Moderately differentiated. Pleural invasion: Yes (tumor appears to focally involve overlying pleura in slide 5D). Lymphovascular space invasion: No. Surgical margin status: Tumor distance from bronchial margin: 2.8 cm. Tumor distance from stapled margin: Not applicable. Tumor distance from pleural surface: Less than 0.5 cm, focally involving pleura. microscopically. Lymph node status: See specimens 1, 2, 3, 4 and 6. Station 7 lymph node: Negative for tumor. Stage: T2N0. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, right lower lobe. 2. Findings: Adenocarcinoma, moderately differentiated, subpleural, right lower lung lobe. Tumor size: 2.0 x 2.0 x 1.6 cm. Tumor grade: Moderately differentiated. Pleural invasion: Yes (tumor appears to focally involve overlying pleura in slide 5D). Lymph",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung, right lower lobe. 2. Findings: Adenocarcinoma, moderately differentiated, subpleural, right lower lung lobe. Tumor size: 2.0 x 2.0 x 1.6 cm. Tumor grade: Moderately differentiated. Pleural invasion: Yes (tumor appears to focally involve overlying pleura in slide 5D). Lymphovascular space invasion: No. Surgical margin status: Tumor distance from bronchial margin: 2.8 cm. Tumor distance from stapled margin: Not applicable. Tumor distance from pleural surface: Less than 0.5 cm, focally involving pleura. microscopically. Lymph node status: See specimens 1, 2, 3, 4 and 6. Station 7 lymph node: Negative for tumor. Stage: T2N0. 3. Code: LUAD.",
      "idx": 778,
      "timestamp": "2026-01-19T15:59:53.112493"
    },
    {
      "sample_idx": 198,
      "input": "page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. ender: F. Material: Total organ resection - left breast and axillary tissues. Unit in charge: (. Material received on: : Expected time of examination: up to 8 working days. Clinical diagnosis: Macroscopic breast'sized 24 x 19.5 x 5 cm removed with axillary tissues sized 10 x 7 x 2.5 cm and a skin flap of 24 x 12 and cm. 0 Tumour from sized the. description: Left 1.9 x 1.3 x 1.4 found in the subaurolar ...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 198,
      "timestamp": "2026-01-19T15:59:53.112503"
    },
    {
      "sample_idx": 735,
      "input": "TISSUE DESCRIPTION. Left lateral liver (250 grams, 18 x 9.5 X 5 cm). A1. A2,. DIAGNOSIS: Liver, left lateral, sectorectomy: Grade 2 (of 4). hepatocellular carcinoma, forming a 4 X 3 X 3 cm mass. The. surgical margins are negative for tumor by 5.0 cm. ADDENDUM. Special stains (reticulin and trichrome) demonstrate grade 1. chronic hepatitis and minimal periportal fibrosis. Sections of. tumor also demonstrate vascular invasion on permanent sections. TISSUE DESCRIPTION: Left lateral liver (250 grams...",
      "response": "```json\n{\n    \"cancer_type\": \"Hepatocellular Carcinoma\",\n    \"reasoning\": \"1. Site: Liver, left lateral. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Hepatocellular Carcinoma maps to HCB.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, left lateral. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Hepatocellular Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"Hepatocellular Carcinoma\",\n    \"reasoning\": \"1. Site: Liver, left lateral. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Hepatocellular Carcinoma maps to HCB.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, left lateral. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Hepatocellular Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, left lateral. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Hepatocellular Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, left lateral. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Hepatocellular Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, left lateral. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Hepatocellular Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, left lateral. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Hepatocellular Carcinoma maps to KIRC.\"\n}\n```\n```json",
      "predicted": "Hepatocellular Carcinoma",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Liver, left lateral. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Hepatocellular Carcinoma maps to HCB.",
      "idx": 735,
      "timestamp": "2026-01-19T15:59:53.112514"
    },
    {
      "sample_idx": 704,
      "input": "Service Date: Soc. Sec. #: Client: FINAL PATHOLOGIC DIAGNOSIS. A. Brain, left temporal lobe, excision: Anaplastic Astrocytoma, WHO grade III; see. comment. B. Brain, left temporal lobe, excision: Anaplastic Astrocytoma, WHO grade III; see. comment. COMMENT: H&E sections of this astrocytoma show multiple areas of increased cellularity and mitotic activity (up to. 4 MF/10 HPF), consistent with an anaplastic astrocytoma, WHO grade III. Immunohistochemistry for. IDH-1 (R132H mutant protein), p53, an...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Temporal Lobe). 2. Findings: Anaplastic Astrocytoma, WHO grade III. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Temporal Lobe). 2. Findings: Anaplastic Astrocytoma, WHO grade III. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Temporal Lobe). 2. Findings: Anaplastic Astrocytoma, WHO grade III. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Temporal Lobe). 2. Findings: Anaplastic Astrocytoma, WHO grade III. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Temporal Lobe). 2. Findings: Anaplastic Astrocytoma, WHO grade III. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Temporal Lobe). 2. Findings: Anaplastic Astrocytoma, WHO grade III. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Temporal Lobe). 2. Findings: Anaplastic Astrocytoma, WHO grade III. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Temporal Lobe). 2. Findings: Anaplastic Astrocytoma, WHO grade III. 3. Code: GBM maps",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain (Left Temporal Lobe). 2. Findings: Anaplastic Astrocytoma, WHO grade III. 3. Code: GBM maps to GBM.",
      "idx": 704,
      "timestamp": "2026-01-19T15:59:53.112523"
    },
    {
      "sample_idx": 1236,
      "input": "LABORATORY MEDICINE PROGRAM. Facility: Specimen(s) Received. 1. Thyroid: RIGHT HEMI THYROID STITCH UPPER POLE FOR TUMOUR BANK. Diagnosis. Papillary carcinoma, follicular variant 4.0 cm, right: Thyrold. No pathological diagnosis: Parathyroid, right. -Right hemithyroidectomy specimen. Comment. This case has been seen in consultation with Dr. and she agrees with the interpretation and diagnosis. Synoptic Data. Clinical History: Other: BRCA1 mutation. Procedure: Right hemithyroidectomy. Fresh. Speci...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, follicular variant, right lobe. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, follicular variant, right lobe. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, follicular variant, right lobe. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, follicular variant, right lobe. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, follicular variant, right lobe. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, follicular variant, right lobe. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, follicular variant, right lobe. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, follicular variant, right lobe. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1.",
      "predicted": "BRCA",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Thyroid. 2. Findings: Papillary carcinoma, follicular variant, right lobe. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1236,
      "timestamp": "2026-01-19T15:59:53.112533"
    },
    {
      "sample_idx": 541,
      "input": "SPECIMEN. Right kidney. CLINICAL NOTES. PRE-OP DIAGNOSIS: Right renal mass. GROSS DESCRIPTION. The specimen is received unfixed, labeled \"right kidney\". and consists of a radical nephrectomy specimen measuring. 16. x 9 x 7 cm. On cut section the specimen contains a kidney measuring. 12.5 x 7.7 cm. On the central portion of the kidney there is a. yellow tumor in the renal cortex measuring 5 x 3.2 cm. A portion of. the specimen is taken for research purposes. Sections after. fixation. RS-8. MICROS...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Clear cell type renal cell carcinoma, Furhman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Clear cell type renal cell carcinoma, Furhman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Clear cell type renal cell carcinoma, Furhman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Clear cell type renal cell carcinoma, Furhman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Clear cell type renal cell carcinoma, Furhman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Clear cell type renal cell carcinoma, Furhman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Clear cell type renal cell carcinoma, Furhman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Clear cell",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Right kidney. 2. Findings: Clear cell type renal cell carcinoma, Furhman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 541,
      "timestamp": "2026-01-19T15:59:53.112544"
    },
    {
      "sample_idx": 88,
      "input": "page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - right breast. Unit in charge: I. Material collected on: I. aterial received on: Expected time of examination: up to 8 working days. Clinical diagnosis: Macroscopic description: Right breast Sized 20 x 14 x 5 cm removed along with axillary tissues sized 10 x 5 x 3 cm and a skin flap of 18 x 10 cm. Tumour. found in the upper outer quadrant, located 3 cm fro...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 88,
      "timestamp": "2026-01-19T15:59:53.112553"
    },
    {
      "sample_idx": 940,
      "input": "FINAL DIAGNOSIS: PART 1: OMENTUM, OMENTECTOMY -. ADIPOSE TISSUE WITH REACTIVE LYMPHOID AGGREGATES, NO NEOPLASM IDENTIFIED. PART 2: ADNEXA, LEFT, SALPINGO-OOPHORECTOMY -. A. POORLY DIFFERENTIATED ADENOCARCINOMA OF LEFT OVARY, PREDOMINANTLY PAPILLARY SEROUS. TYPE WITH AREAS OF CLEAR CELL AND ENDOMETRIOID CARCINOMA, 18 CM. B. NEOPLASM EXTENDS THROUGH OVARIAN CAPSULE AND ONTO THE SURFACE. C. LYMPHOVASCULAR INVASION IDENTIFIED. D. PATHOLOGIC STAGE: pT2c, NX, MX. E. UNREMARKABLE FALLOPIAN TUBE. PART 3...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Papillary serous adenocarcinoma, moderately differentiated (6-7 pts). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Papillary serous adenocarcinoma, moderately differentiated (6-7 pts). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Papillary serous adenocarcinoma, moderately differentiated (6-7 pts). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Papillary serous adenocarcinoma, moderately differentiated (6-7 pts). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Papillary serous adenocarcinoma, moderately differentiated (6-7 pts). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Papillary serous adenocarcinoma, moderately differentiated (6-7 pts). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Papillary serous adenocarcinoma, moderately differentiated (6-7 pts). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Papillary serous adenocarcinoma, moderately differentiated (6-7 pts). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2.",
      "predicted": "BRCA",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Ovary. 2. Findings: Papillary serous adenocarcinoma, moderately differentiated (6-7 pts). 3. Code: BRCA.",
      "idx": 940,
      "timestamp": "2026-01-19T15:59:53.112563"
    },
    {
      "sample_idx": 1098,
      "input": "SPECIMEN. A. Sigmoid and upper rectum. B. Appendix. CLINICAL NOTES. PRE-OP DIAGNOSIS: Sigmoid cancer. GROSS DESCRIPTION. A. Received fresh, subsequently fixed in formalin labeled. \"sigmoid and upper rectum\" is a rectosigmoid colon,. partially covered with abundant yellow lobular fat. The specimen. is. 38.5. The proximal end is inked blue and is previously stapled. The. distal end is also stapled and is inked black. The serosa is. pink-tan smooth glistening and partially covered with abundant. ye...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid and upper rectum. 2. Findings: Invasive adenocarcinoma, moderately differentiated, invasive of visceral peritoneum. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Appendix. 2. Findings: Unremarkable appendix. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid and upper rectum. 2. Findings: Moderately differentiated invasive adenocarcinoma, invasive of visceral peritoneum. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid and upper rectum. 2. Findings: Moderately differentiated invasive adenocarcinoma, invasive of visceral peritoneum. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid and upper rectum. 2. Findings: Moderately differentiated invasive adenocarcinoma, invasive of visceral peritoneum. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid and upper rectum. 2. Findings: Moderately differentiated invasive adenocarcinoma, invasive of visceral peritoneum. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid and upper rectum. 2. Findings: Moderately differentiated invasive adenocarcinoma, invasive of visceral peritoneum. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid and upper rectum. 2. Findings: Moderately differentiated invasive adenocarcinoma, invasive of visceral peritoneum. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\":",
      "predicted": "KIRC",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Sigmoid and upper rectum. 2. Findings: Invasive adenocarcinoma, moderately differentiated, invasive of visceral peritoneum. 3. Code: KIRC.",
      "idx": 1098,
      "timestamp": "2026-01-19T15:59:53.112573"
    },
    {
      "sample_idx": 255,
      "input": "Component. (note). Accession # : PATHOLOGIC DIAGNOSIS. A. LYMPH NODE, LEFT PARAMETRIAL, BIOPSY: - ONE LYMPH NODE WITH NO EVIDENCE MALIGNANCY (0/1). B. UTERUS, CERVIX, RADICAL HYSTERECTOMY: - INVASIVE POORLY DIFFERENTIATED CERVICAL SQUAMOUS. CARCINOMA pT1b2N1. - TUMOR EXTENDS INTO LOWER UTERINE SEGMENT. - TUMOR NOT PRESENT AT INKED MARGINS. - LYMPHOVASCULAR SPACE INVASION IDENTIFIED. - PERINEURAL INVASION IDENTIFIED. - FOCAL SQUAMOUS CARCINOMA IN-SITU. - FOURTEEN LYMPH NODES WITH NO EVIDENCE OF M...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive poorly differentiated squamous cell carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix. 2. Findings: Invasive poorly differentiated squamous cell carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Lymph Node, Left Parametrial. 2. Findings: No evidence of malignancy. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix. 2. Findings: Invasive poorly differentiated squamous cell carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Lymph Node, Left Parametrial. 2. Findings: No evidence of malignancy. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Soft Tissue, Left Parametrium. 2. Findings: No evidence of malignancy. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Fallopian Tube and Ovary, Left. 2. Findings: Benign inclusion cyst. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Lymph Node, Left Parametrial. 2. Findings: No evidence of malignancy. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Soft Tissue, Left Parametrium. 2. Findings: No evidence of malignancy. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type",
      "predicted": "BRCA",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Cervix. 2. Findings: Invasive poorly differentiated squamous cell carcinoma. 3. Code: BRCA",
      "idx": 255,
      "timestamp": "2026-01-19T15:59:53.112582"
    },
    {
      "sample_idx": 775,
      "input": "Acct / Reg #: DIAGNOSIS. DIAGNOSIS: A. Lymph node, level 9L, excision: Total number of lymph nodes received: One (1). Total number of lymph nodes containing metastatic carcinoma: Zero (0). B. Lymph node, level 5, excision: Total number of lymph nodes received: One (1). Total number of lymph nodes containing metastatic carcinoma: Zero (0). Frozen section diagnosis confirmed. C. Lymph node, level 7, excision: Total number of lymph nodes received: Two (2). Total number of lymph nodes containing met...",
      "response": "```json\n{\n    \"cancer_type\": \"UCLM\",\n    \"reasoning\": \"1. Site: Lung (Left). 2. Findings: Adenocarcinoma, poorly differentiated, 4.5 cm, unifocal, pleural invasion, lymphovascular invasion, confined to lung, not identified. 3. Code: UCLM maps to UCLM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCLM\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated, 4.5 cm, unifocal, pleural invasion, lymphovascular invasion, confined to lung, not identified. 3. Code: UCLM maps to UCLM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCLM\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated, 4.5 cm, unifocal, pleural invasion, lymphovascular invasion, confined to lung, not identified. 3. Code: UCLM maps to UCLM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2",
      "predicted": "UCLM",
      "ground_truth": "LUAD",
      "correct": false,
      "reasoning": "1. Site: Lung (Left). 2. Findings: Adenocarcinoma, poorly differentiated, 4.5 cm, unifocal, pleural invasion, lymphovascular invasion, confined to lung, not identified. 3. Code: UCLM maps to UCLM.",
      "idx": 775,
      "timestamp": "2026-01-19T15:59:53.112594"
    },
    {
      "sample_idx": 161,
      "input": "BREAST TISSUE CHECKLIST. Specimen type: Radical mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 1.8 x 1 x 1 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal and lobular carcinoma. Histologic grade: Tumor extent: Not specified. Lymph nodes: 7/7 positive for metastasis (Regional 7/7). Right,Jupper. Extracapsular invasion of the lymph nodes: Not specified. inner. Margins: Not specified. quadrant. Nottingham Histologic Score. Tubule formation: Not speci...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal and lobular carcinoma",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 161,
      "timestamp": "2026-01-19T15:59:53.112603"
    },
    {
      "sample_idx": 1130,
      "input": "SPECIMEN(S): A: Left axillary sentinel lymph node. B: Left breast. C: Right breast. FINAL DIAGNOSIS: A. Lymph node, left axillary sentinel, biopsy. - No evidence of malignancy in one lymph node (0/1). B. Breast, left, mastectomy: - Leiomyosarcoma, intermediate grade. - Tumor measures 5.5 x 5.2 x 4.5 cm. - Biopsy site changes with hemorrhage. - Margin widely negative (all greater than 1.8 cm). - Fat necrosis. - Cysts with apocrine metaplasia. - See microscopic for discussion and tumor synoptic. C...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Leiomyosarcoma, intermediate grade. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left axillary sentinel lymph node. 2. Findings: Lymph node, left axillary sentinel, biopsy. No evidence of malignancy in one lymph node (0/1). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Right breast. 2. Findings: Simple ductal hyperplasia without atypia. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Simple ductal hyperplasia without atypia. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Simple ductal hyperplasia without atypia. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Simple ductal hyperplasia without atypia. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Simple ductal hyperplasia without atypia. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Simple ductal hyperplasia without atypia. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Simple ductal hyperplasia without atypia. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BR",
      "predicted": "BRCA",
      "ground_truth": "SARC",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Leiomyosarcoma, intermediate grade. 3. Code: BRCA",
      "idx": 1130,
      "timestamp": "2026-01-19T15:59:53.112612"
    },
    {
      "sample_idx": 600,
      "input": "AMENDEDICORRECTED REPORT: Amended date: Reason: Spelling / Typographical Edit. This report being amended is to make correction to a typographical error on diagnostic line 'C' of Part 2, \"THE GREATEST. DIMENSION OF THE NEOPLASM IS 3.0 cm\", which is corrected to read as, \"THE GREATEST DIMENSION OF THE. NEOPLASM IS 7.5 cm\". in the Final Diagnosis field. While it was correctly stated in the Case Synopsis field. This Amended/Corrected Report reflects NO change to the previously rendered diagnoses. Th...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left). 2. Findings: Papillary renal cell carcinoma, Type I, Fuhrman Grade II, Greatest dimension of the neoplasm is 7.5 cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left). 2. Findings: Papillary renal cell carcinoma, Type I, Fuhrman Grade II, Greatest dimension of the neoplasm is 7.5 cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left). 2. Findings: Papillary renal cell carcinoma, Type I, Fuhrman Grade II, Greatest dimension of the neoplasm is 7.5 cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left). 2. Findings: Papillary renal cell carcinoma, Type I, Fuhrman Grade II, Greatest dimension of the neoplasm is 7.5 cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left). 2. Findings: Papillary renal cell carcinoma, Type I, Fuhrman Grade II, Greatest dimension of the neoplasm is 7.5 cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left). 2. Findings: Papillary renal cell carcinoma, Type I, Fuhrman Grade II, Greatest dimension of the neoplasm is 7.5 cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Kidney (Left). 2. Findings: Papillary renal cell carcinoma, Type I, Fuhrman Grade II, Greatest dimension of the neoplasm is 7.5 cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 600,
      "timestamp": "2026-01-19T15:59:53.112624"
    },
    {
      "sample_idx": 1287,
      "input": "PATIENT HISTORY: CHIEF COMPLAINT/ PRE-OP/ POST-OP DIAGNOSIS: Metastatic thyroid cancer. PROCEDURE: Total thyroidectomy, excision lymph node. SPECIFIC CLINICAL QUESTION: Not 'answered. OUTSIDE TISSUE DIAGNOSIS: Not answered. PRIOR MALIGNANCY: Not answered. CHEMORADIATION THERAPY: Not answered. ORGAN TRANSPLANT: Not answered. IMMUNOSUPPRESSION: Not answered. OTHER DISEASES: Not answered. ADDENDA: Addendum. Molecular Anatomic Pathology Testing: Block 1D: A. HRAS codon 61 mutation IDENTIFIED. B. Mut...",
      "response": "```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Total thyroidectomy. 2. Findings: Angioinvasive follicular carcinoma, 2.8 cm. pT2, pNX, pM1. 3. Code: THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Total thyroidectomy. 2. Findings: Nodular thyroid hyperplasia. 3. Code: THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Total thyroidectomy. 2. Findings: Loss of heterozygosity at chromosome 22q. 3. Code: UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"READ\",\n    \"reasoning\": \"1. Site: Total thyroidectomy. 2. Findings: Loss of heterozygosity at chromosome 1p, 1p35.1, 1p36.21, 3p25.3, 3p26.3, 5q23.2, 5q23.3, 9p21.3, 9p22.2, 10q23.31, 10q23.31, 17p13.1, 17p13.1, 22q12.2, 22q12.2. 3. Code: READ.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Total thyroidectomy. 2. Findings: Nodular thyroid hyperplasia. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Total thyroidectomy. 2. Findings: pT2, pNX, pM1. 3. Code: OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Total thyroidectomy. 2. Findings: Angioinvasive follicular carcinoma, ",
      "predicted": "THCA",
      "ground_truth": "THCA",
      "correct": true,
      "reasoning": "1. Site: Total thyroidectomy. 2. Findings: Angioinvasive follicular carcinoma, 2.8 cm. pT2, pNX, pM1. 3. Code: THCA.",
      "idx": 1287,
      "timestamp": "2026-01-19T15:59:53.112639"
    },
    {
      "sample_idx": 1266,
      "input": "Case type: Surgical Case. DIAGNOSIS. 8340/3. (A) LEFT THYROID LOBE AND ISTHMUS: PAPILLARY THYROID CARCINOMA, FOLLICULAR VARIANT CQCF: carcinoma, papillary, theroid. Location: Left lobe. Multi-focal: No. Size = 2.2 cm. Extrathyroidal extension: Absent. Lymphovascular invasion: Present. Resection Margins: Negative. Lymph nodes: No lymph nodes present. GROSS DESCRIPTION. (A) LEFT THYROID LOBE AND ISTHMUS - A hemithyroidectomy specimen (4.0 : x 1.5 x 1.5 cm) contains a well-. circumscribed pink-tan ...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe and Isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant, Fuhrman Grade II, Extrathyroidal extension: Absent, Lymphovascular invasion: Present, Resection Margins: Negative, Lymph nodes: No lymph nodes present. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe and Isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant, Fuhrman Grade II, Extrathyroidal extension: Absent, Lymphovascular invasion: Present, Resection Margins: Negative, Lymph nodes: No lymph nodes present. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe and Isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant, Fuhrman Grade II, Extrathyroidal extension: Absent, Lymphovascular invasion: Present, Resection Margins: Negative, Lymph nodes: No lymph nodes present. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe and Isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant, Fuhrman Grade II, Extrathyroidal extension: Absent, Lymphovascular invasion: Present, Resection Margins: Negative, Lymph nodes: No lymph nodes present. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe and Isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant, Fuhrman Grade II, Extrathyroidal extension: Absent, Lymphovascular invasion: Present, Resection Margins: Negative, Lymph nodes: No lymph nodes present. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"",
      "predicted": "THYM",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Left Thyroid Lobe and Isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant, Fuhrman Grade II, Extrathyroidal extension: Absent, Lymphovascular invasion: Present, Resection Margins: Negative, Lymph nodes: No lymph nodes present. 3. Code: THYM maps to THYM.",
      "idx": 1266,
      "timestamp": "2026-01-19T15:59:53.112654"
    },
    {
      "sample_idx": 740,
      "input": "TISSUE DESCRIPTION. Right lobe liver (22 x 14.3 X 9.5 cm) and gallbladder (7.5 X 3.5. X 1.5 cm) and submitted en bloc (1,475 grams) . A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, A11, A12,. A13, A14, A15, A16, A17, A18, A19,A20, A21, A22, A23, A24, A25,. A26, A27, A28, A29, A30, A31, A32, A33, A34. DIAGNOSIS: Liver, right lobe, hepatectomy: Grade 2 (of 4) hepatocellular. carcinoma forming a 12 X 11 X 8 cm mass. No vascular invasion. is identified. Surgical margins are free by 1 cm. Gallbladder, hepa...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Right lobe). 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, right lobe, hepatectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Gallbladder. 2. Findings: Mild chronic cholecystitis. 3. Code: Gallbladder maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Right lobe). 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, right lobe, hepatectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Right lobe). 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, right lobe, hepatectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Right lobe). 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, right lobe, hepatectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Right lobe). 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, right lobe, hepatectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Right lobe). 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, right lobe, hepatectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Right lobe). 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, right",
      "predicted": "KIRC",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Liver (Right lobe). 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, right lobe, hepatectomy maps to KIRC.",
      "idx": 740,
      "timestamp": "2026-01-19T15:59:53.112664"
    },
    {
      "sample_idx": 1182,
      "input": "Case ID. Subject. STOMACH TISSUE CHECKLIST. Specimen type: Gastrectomy. Tumor site: Stomach. Tumor size: 8 X 5 X 1.7 cm. Tumor features: None specified. Histologic type: Adenocarcinoma. Histologic grade: Poorly differentiated. Tumor extent: Adjacent structures (specify) -. Esophagus, lesser omentum. Lymph nodes: 0/5 positive for metastasis. (Regional 0/5). Lymphatic invasion: Not specified. Venous invasion: Not specified. Perineural invasion: Not specified. Margins: Uninvolved. Evidence of neo-a...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site",
      "predicted": "ADENOMA",
      "ground_truth": "STAD",
      "correct": false,
      "reasoning": "1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: ADENOMA",
      "idx": 1182,
      "timestamp": "2026-01-19T15:59:53.112673"
    },
    {
      "sample_idx": 393,
      "input": "CLINICAL HISTORY. has experienced. On imaging. there is a large right temporoparietal mass with rim-enhancement and. prominent. associated vasogenic edema. OPERATIVE DIAGNOSES. Operation/Specimen A: Brain, right parietal tumor, excision biopsy. PATHOLOGICAL DIAGNOSIS: A and B. Brain, right parietal, excisional biopsies: A. Glioblastoma. B. MIB-1 proliferation index: > 8%. See Microscopy Description and Comment. COMMENT. The neoplasm is a glioblastoma with brisk mitotic activity, a high MIB-1. pr...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Right Parietal). 2. Findings: Glioblastoma, high grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Right Parietal). 2. Findings: Glioblastoma, high grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Right Parietal). 2. Findings: Glioblastoma, high grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Right Parietal). 2. Findings: Glioblastoma, high grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Right Parietal). 2. Findings: Glioblastoma, high grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Right Parietal). 2. Findings: Glioblastoma, high grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Right Parietal). 2. Findings: Glioblastoma, high grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Right Parietal). 2. Findings: Glioblastoma, high grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Right Parietal). 2. Findings: Glioblastoma, high grade. 3. Code: KIRC.\"\n}\n```",
      "predicted": "KIRC",
      "ground_truth": "GBM",
      "correct": false,
      "reasoning": "1. Site: Brain (Right Parietal). 2. Findings: Glioblastoma, high grade. 3. Code: KIRC.",
      "idx": 393,
      "timestamp": "2026-01-19T15:59:53.112683"
    },
    {
      "sample_idx": 142,
      "input": "SPECIMENS: A. SLN #1 RIGHT AXILLA. B. RIGHT BREAST. C. RIGHT BREAST UPPER OUTER QUADRANT. D. RIGHT BREAST LATERAL FLAP. E. LEFT BREAST AND AXILLARY TAIL. F. ADDITIONAL AXILLARY CONTENTS. SPECIMEN(S): A. SLN #1 RIGHT AXILLA. B. RIGHT BREAST. C. RIGHT BREAST UPPER OUTER QUADRANT. D. RIGHT BREAST LATERAL FLAP. E. LEFT BREAST AND AXILLARY TAIL. F. ADDITIONAL AXILLARY CONTENTS. GROSS DESCRIPTION: A. SLN #1 RIGHT AXILLA. Received fresh labeled with the patient's identification and \"SLN #1 right axilla...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, mainly pleomorphic type, SBR Grade 3, solid growth pattern, LCIS. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, mainly pleomorphic type, SBR Grade 3, solid growth pattern, LCIS. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, mainly pleomorphic type, SBR Grade 3, solid growth pattern, LCIS. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, mainly pleomorphic type, SBR Grade 3, solid growth pattern, LCIS. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, mainly pleomorphic type, SBR Grade 3, solid growth pattern, LCIS. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, mainly pleomorphic type, SBR Grade 3, solid growth pattern, LCIS. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, mainly pleomorphic type, SBR Grade 3, solid growth pattern, LCIS. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings:",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive lobular carcinoma, mainly pleomorphic type, SBR Grade 3, solid growth pattern, LCIS. 3. Code: BRCA.",
      "idx": 142,
      "timestamp": "2026-01-19T15:59:53.112692"
    },
    {
      "sample_idx": 93,
      "input": "IGA-EW-A2FW-01A-PR. Pathologic Interpretation: A. SENTINEL NODE # 1 COUNT. - No malignancy seen in one lymph node (0/1). . Keratin immunostain to follow. B. SUSPICIOUS LYMPH NODE RIGHT BREAST: - No malignancy seen in one lymph node (0/1). - Keratin immunostain to follow. c. SENTINEL NODE # 2 COUNT. - No malignancy seen in one lymph node (0/1). - Keratin immunostaln to follow. D. SENTINEL NODE # 3 COUNT. - No malignancy seen in one lymph node (0/1). - Keratin immunostain to follow. E. SENTINEL NO...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, poorly differentiated, Nottingham grade 2 (3 +2+1 = 6), papiliary type, 2.8 cm in greatest. dimension. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nExplanation:\nThe pathology report describes an invasive ductal carcinoma in the breast. The key findings are the presence of a poorly differentiated, high-grade invasive carcinoma with a Nottingham grade of 2 and a size of 2.8 cm. This aligns with the description of Breast Invasive Carcinoma in the provided TCGA codes. Therefore, the correct TCGA code is BRCA.\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, poorly differentiated, Nottingham grade 2 (3 +2+1 = 6), papiliary type, 2.8 cm in greatest. dimension. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, poorly differentiated, Nottingham grade 2 (3 +2+1 = 6), papiliary type, 2.8 cm in greatest. dimension. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, poorly differentiated, Nottingham grade 2 (3 +2+1 = 6), papiliary type, 2.8 cm in greatest. dimension. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, poorly differentiated, Nottingham grade 2 (3 +2+1 = 6), papiliary type, 2.8 cm in greatest. dimension. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, poorly differentiated, Nottingham grade 2 (3 +2+1 = 6), papiliary type, 2.8 cm in greatest. dimension. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 93,
      "timestamp": "2026-01-19T15:59:53.112704"
    },
    {
      "sample_idx": 466,
      "input": "SURGICAL PATHOLOGY REVISED REPORT. Diagnosis: A: Right palate lesion, biopsy. - Invasive moderately differentiated squamous cell carcinoma. Clinical History: -year-old male with a palate mass. Gross Description: Received is one appropriately labeled container, additionally. labeled \"right palate lesion. It holds multiple pale tan soft. tissue fragments in aggregate measuring 1.4 X 1.0 X 0.6 cm. Tissue is taken by Dr. in. for the. and the remaining tissue is submitted in block A1,. Addendum. Adde...",
      "response": "```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Palate. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Palate. 2. Findings: Squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Palate. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Palate. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Palate. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Palate. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Palate. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Palate. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Palate. 2. Findings: Invasive squamous cell carcinoma. 3. Code: H",
      "predicted": "HNSC",
      "ground_truth": "HNSC",
      "correct": true,
      "reasoning": "1. Site: Palate. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC maps to HNSC.",
      "idx": 466,
      "timestamp": "2026-01-19T15:59:53.112714"
    },
    {
      "sample_idx": 592,
      "input": "FINAL DIAGNOSIS: PART 1: BONE, BONE AND 12 TH BONE RIB, PARTIAL MARROW RESECTION: WITH NO EVIDENCE - OF MALIGNANCY. 3.8. CM. PART RADICAL. KIDNEY, 2: LEFT, NEPHRECTOMY CONVENTIONAL - (CLEAR CELL) TYPE, FUHRMAN NUCLEAR GRADE THE III/IV, RENAL SINUS. OR. A. RENAL GREATEST CELL DIMENSION. CARCINOMA, WITHIN THE RENAL CAPSULE, WITH NO EVIDENCE OF INVASION OF. B. TUMOR PERI-NEPHRIC IS NO CONFINED EVIDENCE ADIPOSE OF TISSUE. ANGIOLYMPHATIC TUMOR. INVASION. C. D. THERE ALL NON-NEOPLASTIC SURGICAL IS MAR...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 592,
      "timestamp": "2026-01-19T15:59:53.112724"
    },
    {
      "sample_idx": 163,
      "input": "FINAL DIAGNOSIS: PART 1: LEFT AXILLARY SENTINEL LYMPH NODE #1, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR TUMOR (0/1). PART 2: BREAST, LEFT, SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA, NOTTINGHAM GRADE 3, (TUBULE FORMATION - 3, NUCLEAR GRADE -. 3, MITOTIC RATE - 3, TOTAL SCORE: 9/9). B. INVASIVE CARCINOMA MEASURES 1.8 CM IN GREATEST DIMENSION (SLIDE 2B). C. DUCTAL CARCINOMA IN SITU (DCIS), NUCLEAR GRADE 3, SOLID AND MICROPAPILLARY TYPES WITH. COMEDO NECROSIS AND ASSOCIATED CALCIFICATIONS. ...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Grade 3. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Grade 3. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Grade 3. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Grade 3. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Grade 3. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Grade 3. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Grade 3. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Grade 3. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1.",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Grade 3. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 163,
      "timestamp": "2026-01-19T15:59:53.112734"
    },
    {
      "sample_idx": 1397,
      "input": "LOC: U#: AGE/SX: RM/BED: REG DR: TLOC: DIS: SPEC #: Obtained: CLINICAL HISTORY: GRADE II ENDOMETRIAL CANCER;. OUCI,. PECIMEN/PROCEDURE: 1. LYMPH NODE - RIGHT PELVIC; LAP.ASST'D VAGINAL HYSTERECTOMY/LNI. 2. LYMPH NODE - RIGHT PA'T AORTIC. 3. LYMPH NODE - RIGHT OCMMON ILIAC. 4. LYMPH NODE - LEFT PARA-AORTIC. 5. LYMPH NODE - LEFT PELVIC. 6. LYMPH NODE - LEFT COMMON ILIAC. 7. UTERUS - WITH CERVIX, BILATERAL TUBES AND OVARIES. IMPRESSION: 1). LYMPH NODES, RIGHT PELVIC, REGIONAL DISSECTION: Nine benig...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus (with cervix, bilateral tubes and ovaries). 2. Findings: Endometrial adenocarcinoma, endometrioid type, FIGO grade II, nuclear grade 2. The tumor involves the endometrium and extends into the myometrium. 3. Code: KIRC.\"\n}\n```\nExplanation:\n\n1.  **Anatomic Site:** The specimen is a uterus with cervix, bilateral tubes, and ovaries.\n2.  **Histological Findings:** The report describes endometrial adenocarcinoma, specifically endometrioid type, with a FIGO grade II and nuclear grade 2. It also mentions the tumor extending into the myometrium.\n3.  **TCGA Code Selection:** Based on the description, the most appropriate TCGA code is KIRC, which stands for Kidney Renal Clear Cell Carcinoma. This is because the report describes a tumor in the uterus, which is not a kidney. The report describes a tumor in the uterus.\nThe correct code is KIRC, which corresponds to Kidney Renal Clear Cell Carcinoma.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus (with cervix, bilateral tubes and ovaries). 2. Findings: Endometrial adenocarcinoma, endometrioid type, FIGO grade II, nuclear grade 2. The tumor involves the endometrium and extends into the myometrium. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus (with cervix, bilateral tubes and ovaries). 2. Findings: Endometrial adenocarcinoma, endometrioid type, FIGO grade II, nuclear grade 2. The tumor involves the endometrium and extends into the myometrium. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus (with cervix, bilateral tubes and ovaries). 2. Findings: Endometrial adenocarcinoma, endometrioid type, FIGO grade II, nuclear grade 2. The tumor involves the endometrium and extends into the myometrium. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type",
      "predicted": "KIRC",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Uterus (with cervix, bilateral tubes and ovaries). 2. Findings: Endometrial adenocarcinoma, endometrioid type, FIGO grade II, nuclear grade 2. The tumor involves the endometrium and extends into the myometrium. 3. Code: KIRC.",
      "idx": 1397,
      "timestamp": "2026-01-19T15:59:53.112748"
    },
    {
      "sample_idx": 206,
      "input": "AP Surgical Pathology: Final. CLINICAL HISTORY: Probable metastatic breast CA -. year-old white female presenting. with left femur fracture ? pathologic, has large 6 cm breast mass in left. breast. GROSS EXAMINATION: A. \"Left breast biopsy\", in formalin. An irregular fragment of yellow. fibro-adipose tissue measuring 5 x 2.5 x 2 cm in approximate dimensions. The. specimen has previously been sectioned and a portion submitted for ER-PR. evaluation. The margins of the specimen were not inked as th...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 206,
      "timestamp": "2026-01-19T15:59:53.112757"
    },
    {
      "sample_idx": 1374,
      "input": "Specimens Submitted: 1: SP: Uterus, cervix, bilateral tubes and ovaries (. 2: SP: Omentum. 3: SP: Right peri-aortic lymph node. 4: SP: Left peri-aortic lymph node. 5: SP: Left external iliac lymph node. 6 : SP: Left common iliac lymph node. 7: SP: Left obturator lymph node. 8: SP: Left hypogastric lymph node. 9: SP: Right external iliac lymph node. 10: SP: Right obturator lymph node. DIAGNOSIS: 1). UTERUS, CERVIX, VALLOPIAN TUBES AND OVARIES; TOTAL HYSTERECTOMY. AND BILATERAL SALPINGO-OOPHORECTO...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, bilateral tubes and ovaries. 2. Findings: Papillary serous carcinoma of the endometrium arising in an atrophic polyp. Tumor invades through more than half of the myometrial thickness. Vascular invasion is present. No endocervical invasion identified. 3. Code: UTERUS, CERVIX, VALLOPIAN TUBES AND OVARIES maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Omentum. 2. Findings: Benign fibroadipose tissue. 3. Code: OMENTUM maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right peri-aortic lymph node. 2. Findings: Four benign lymph nodes. 3. Code: LYMPH NODE, RIGHT PERICOLIC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left peri-aortic lymph node. 2. Findings: One benign lymph node. 3. Code: LYMPH NODE, LEFT PERIAORTIC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left external iliac lymph node. 2. Findings: Metastatic carcinoma in one of one lymph node. 3. Code: LYMPH NODE, LEFT EXTERNAL ILIAC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left common iliac lymph node. 2. Findings: Metastatic carcinoma in three of six lymph nodes. 3. Code: LYMPH NODE, LEFT COMMON ILIAC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left obturator lymph node. 2. Findings: Metastatic carcinoma in one or two lymph nodes. 3. Code: LYMPH NODE",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus, cervix, bilateral tubes and ovaries. 2. Findings: Papillary serous carcinoma of the endometrium arising in an atrophic polyp. Tumor invades through more than half of the myometrial thickness. Vascular invasion is present. No endocervical invasion identified. 3. Code: UTERUS, CERVIX, VALLOPIAN TUBES AND OVARIES maps to UCEC.",
      "idx": 1374,
      "timestamp": "2026-01-19T15:59:53.112772"
    },
    {
      "sample_idx": 1380,
      "input": "Client. History/Clinical Dx: Endometrial cancer. Postoperative Dx: Same, pending pathology examination. Specimen(s) Received: A: Uterus, cervix, tubes and ovaries. B: Left peivic lymph nodes. C: Left aortic lymph nodes. D: Right pelvic lymph nodes. E: Right caval lymph nodes. DIAGNOSIS: A. Uterus, cervix, tubes and ovaries: ENDOMETRIAL ADENOCARCINOMA. Tumor Information: Operative procedure: TAH-BSO with node sampling. Histologic type: Endometriold. Histologic grade(FIGO): Grade 1. Nuclear grade:...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, tubes and ovaries. 2. Findings: Endometrial adenocarcinoma, grade 1, nuclear grade 2, tumor size 2.4 x 2.0 x 1.8 cm. Extent of invasion: Less than 50% (2 mm of invasion). Lympho/vascular invasion: Not identified. Serosa: Free of tumor. Parametrium: Free of tumor. Cervical Involvement: Absent. Right adnexa: No evidence of tumor. Left adnexa: No evidence of tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"",
      "predicted": "KIRC",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Uterus, cervix, tubes and ovaries. 2. Findings: Endometrial adenocarcinoma, grade 1, nuclear grade 2, tumor size 2.4 x 2.0 x 1.8 cm. Extent of invasion: Less than 50% (2 mm of invasion). Lympho/vascular invasion: Not identified. Serosa: Free of tumor. Parametrium: Free of tumor. Cervical Involvement: Absent. Right adnexa: No evidence of tumor. Left adnexa: No evidence of tumor. 3. Code: KIRC.",
      "idx": 1380,
      "timestamp": "2026-01-19T15:59:53.112788"
    },
    {
      "sample_idx": 928,
      "input": "DIAGNOSIS: 1. SMALL BOWEL ADHESION, LYSIS: -Fibrous adhesion. -Necrotic cellular debris with fragments of high-grade. adenocarcinoma. 2. OMENTUM, PARTIAL OMENTECTOMY AND FROZEN SECTION #1: -Adenocarcinoma, high nuclear grade, consistent with mullerian. origin. 3. OVARY AND FALLOPIAN TUBE, LEFT, SALPINGO-OOPHORECTOMY: -Left ovary: -Papillary adenocarcinoma, high nuclear grade (nuclear grade. grade 3), consistent with mullerian-derived adenocarcinoma,. papillary serous type. -Left fallopian tube: ...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary and Fallopian Tube (Left). 2. Findings: Papillary adenocarcinoma, mullerian-derived, papillary serous type. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary and Fallopian Tube (Right). 2. Findings: Papillary adenocarcinoma, mullerian-derived, papillary serous type. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Diaphragm. 2. Findings: Papillary adenocarcinoma, mullerian-derived, papillary serous type. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Bladder Peritoneum. 2. Findings: Adenocarcinoma, papillary serous type, mullerian-derived. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary and Fallopian Tube (Left). 2. Findings: Papillary adenocarcinoma, mullerian-derived, papillary serous type. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary and Fallopian Tube (Right). 2. Findings: Papillary adenocarcinoma, mullerian-derived, papillary serous type. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Papillary adenocarcinoma, mullerian-derived, papillary serous type. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Left External Iliac Lymph Node. 2. Findings: Adenocarcinoma, papillary serous type, mullerian-derived. 3. Code: BRCA\"\n}\n```\n```json",
      "predicted": "BRCA",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Ovary and Fallopian Tube (Left). 2. Findings: Papillary adenocarcinoma, mullerian-derived, papillary serous type. 3. Code: BRCA",
      "idx": 928,
      "timestamp": "2026-01-19T15:59:53.112798"
    },
    {
      "sample_idx": 1301,
      "input": "Result date: Surgical Procedure. Contributor system: Surgical Procedure. SPECIMENS SUBMITTED: A. EXTENDED THYMECTOMY. DIAGNOSIS: A. MEDIASTINUM, THYMUS; THYMECTOMY: THYMOMA, TYPE B1 (PREDOMINANTLY CORTICAL). TUMOR SIZE: 5.8 cm. TUMOR INVASION. TUMOR CAPSULE/MEDIASTINAL FAT: INVASION INTO SURROUNDING FAT. PRESENT. PLEURA/PERICARDIUM: NOT PRESENT FOR EVALUATION. LUNG PARENCHYMA: NOT PRESENT FOR EVALUATION. DIAPHRAGM: NOT PRESENT FOR EVALUATION. LYMPH VASCULAR INVASION: NEGATIVE. IMPLANT/DISTANT ME...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, type B1 (predominantly cortical). 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, type B1 (predominantly cortical). 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, type B1 (predominantly cortical). 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, type B1 (predominantly cortical). 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, type B1 (predominantly cortical). 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, type B1 (predominantly cortical). 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, type B1 (predominantly cortical). 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, type B1 (predominantly cortical). 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "THYM",
      "ground_truth": "THYM",
      "correct": true,
      "reasoning": "1. Site: Thymus. 2. Findings: Thymoma, type B1 (predominantly cortical). 3. Code: Thymoma maps to THYM.",
      "idx": 1301,
      "timestamp": "2026-01-19T15:59:53.112808"
    },
    {
      "sample_idx": 747,
      "input": "TISSUE DESCRIPTION: Liver Segments I, II, III and IV (2280 grams, 20 x 19 x 11 cm), separately submitted. left portal lymph node (4.5 x 2.6 x 1.2 cm) and gallbladder (7.5 x 3.5 x 1 cm). A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, C6. DIAGNOSIS: Liver, Segments I, II, III and IV, resection: Grade 3 (of 4) hepatocellular carcinoma,. usual type, forming a single 18.5 x 18 x 11 cm mass. The tumor is located in. Segments I, II, III and IV. The tumor invades into but not through hepatic capsule. The tumor...",
      "response": "```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver, Segments I, II, III and IV. 2. Findings: Hepatocellular carcinoma, Grade 3 (of 4), usual type, forming a single mass. Vascular invasion identified. The tumor is not encapsulated. 30% necrosis. The non-neoplastic liver shows a mild nonspecific chronic inflammatory infiltrate in the portal tracts. The normal liver shows a mild nonspecific chronic inflammatory infiltrate in the portal tracts. but is otherwise unremarkable. The normal liver shows a mild nonspecific chronic inflammatory infiltrate in the portal tracts. but is otherwise unremarkable. Special stains show minimal amounts of hepatic iron of doubtful clinical significance. A PAS-D is unremarkable. 4. Code: Liver, Segments I, II, III and IV, resection maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, Segments I, II, III and IV. 2. Findings: Hepatocellular carcinoma, Grade 3 (of 4), usual type, forming a single mass. Vascular invasion identified. The tumor is not encapsulated. 30% necrosis. The non-neoplastic liver shows a mild nonspecific chronic inflammatory infiltrate in the portal tracts. The normal liver shows a mild nonspecific chronic inflammatory infiltrate in the portal tracts. but is otherwise unremarkable. Special stains show minimal amounts of hepatic iron of doubtful clinical significance. A PAS-D is unremarkable. 4. Code: Liver, Segments I, II, III and IV, resection maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver, Segments I, II, III and IV. 2. Findings: Hepatocellular carcinoma, Grade 3 (of 4), usual type, forming a single mass. Vascular invasion identified. The tumor is not encapsulated. 30% necrosis. The non-neoplastic liver shows a mild nonspecific chronic inflammatory infiltrate in the portal tracts. The normal liver shows a mild nonspecific chronic inflammatory infiltrate in the portal tracts. but is otherwise unremarkable. Special stains show minimal amounts of hepatic iron of doubtful clinical significance. A PAS-D is unremarkable. 4. Code: Liver, Segments I, II, III and IV, resection maps to LIHC.\"\n}",
      "predicted": "LIHC",
      "ground_truth": "LIHC",
      "correct": true,
      "reasoning": "1. Site: Liver, Segments I, II, III and IV. 2. Findings: Hepatocellular carcinoma, Grade 3 (of 4), usual type, forming a single mass. Vascular invasion identified. The tumor is not encapsulated. 30% necrosis. The non-neoplastic liver shows a mild nonspecific chronic inflammatory infiltrate in the portal tracts. The normal liver shows a mild nonspecific chronic inflammatory infiltrate in the portal tracts. but is otherwise unremarkable. The normal liver shows a mild nonspecific chronic inflammatory infiltrate in the portal tracts. but is otherwise unremarkable. Special stains show minimal amounts of hepatic iron of doubtful clinical significance. A PAS-D is unremarkable. 4. Code: Liver, Segments I, II, III and IV, resection maps to LIHC.",
      "idx": 747,
      "timestamp": "2026-01-19T15:59:53.112831"
    },
    {
      "sample_idx": 333,
      "input": "Date Coll: SPECIMEN. Right colon. CLINICAL NOTES. PRE-OP DIAGNOSIS: Carcinoma of the hepatic flexure. GROSS DESCRIPTION. Received fresh labeled \"right colon\" is a previously. unopened, 12 cm segment of proximal right colon with. attached 6 cm of distal ileum surfaced by smooth to scabrous. tan-pink serosa with a moderate amount of attached mesocolon,. mesentery and unremarkable omentum. An unremarkable 6.6 cm appendix. averaging 0.5 cm in diameter is present. The proximal and distal. margins mea...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with mucinous differentiation, pT3, pN0, pM0. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENCA\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with mucinous differentiation, pT3, pN0, pM0. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with mucinous differentiation, pT3, pN0, pM0. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with mucinous differentiation, pT3, pN0, pM0. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with mucinous differentiation, pT3, pN0, pM0. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with mucinous differentiation, pT3, pN0, pM0. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with mucinous differentiation, pT3, pN0, pM0. 3. Code: Colon Adenocarcinoma maps to CO",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with mucinous differentiation, pT3, pN0, pM0. 3. Code: Colon Adenocarcinoma maps to COAD.",
      "idx": 333,
      "timestamp": "2026-01-19T15:59:53.112844"
    },
    {
      "sample_idx": 758,
      "input": "PATIENT HISTORY: PRE-OP DIAGNOSIS: Pulmonary nodule. POST-OP DIAGNOSIS: Same. PROCEDURE: Bronchoscopy; Biopsy; Lavage; Right video assisted thoracic surgery: Apical posterior segmentectomy. with fiducials. FINAL DIAGNOSIS: PART 1: LUNG, RIGHT UPPER LOBE, BIOPSY -. BENIGN BRONCHIAL MUCOSA WITH MILD CHRONIC INFLAMMATION. PART 2: LYMPH NODE, LEVEL 4, BIOPSY -. BENIGN LYMPH NODE FRAGMENT. RART 3:LYMPH NODE, LEVEL 4R PRIME, BIOPSY -. BENIGN LYMPH NODE FRAGMENT. PART 4:LYMPH NODE, LEVEL 10, BIOPSY -. ...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right Upper Lobe. 2. Findings: Invasive adenocarcinoma, acinar type, Fuhrman Grade I. 3. Code: Lung, Right Upper Lobe maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right Upper Lobe. 2. Findings: Invasive adenocarcinoma, acinar type, Fuhrman Grade I. 3. Code: Lung, Right Upper Lobe maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right Upper Lobe. 2. Findings: Invasive adenocarcinoma, acinar type, Fuhrman Grade I. 3. Code: Lung, Right Upper Lobe maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right Upper Lobe. 2. Findings: Invasive adenocarcinoma, acinar type, Fuhrman Grade I. 3. Code: Lung, Right Upper Lobe maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right Upper Lobe. 2. Findings: Invasive adenocarcinoma, acinar type, Fuhrman Grade I. 3. Code: Lung, Right Upper Lobe maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right Upper Lobe. 2. Findings: Invasive adenocarcinoma, acinar type, Fuhrman Grade I. 3. Code: Lung, Right Upper Lobe maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right Upper Lobe. 2. Findings: Invasive adenocarcinoma, acinar type, Fuhrman Grade I. 3. Code: Lung, Right Upper Lobe maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung, Right Upper Lobe. 2. Findings: Invasive adenocarcinoma, acinar type, Fuhrman Grade I. 3. Code: Lung, Right Upper Lobe maps to LUAD.",
      "idx": 758,
      "timestamp": "2026-01-19T15:59:53.112855"
    },
    {
      "sample_idx": 727,
      "input": "CONFIDENTIAL. Demographics (for. verification purposes). Date or birth: Collected Date/Time. Received Date/Time. Specimen Description. A: Gallbladder. B: Right lobe liver. Clinical Information. Large right lobe liver Ca on CT KUB 16 x 12 x 14 cm. Infectious patient:No. Immunocompromised: No. History of neoplasm: No. Diagnosis. A: Gallbladder. Chronic cholecystitis. Cholelithiasis. B. Liver, Right Lobe, Excision: Hepatocellular carcinoma, grade II. Portal vascular inflammation of embolization. Re...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Gallbladder (A). 2. Findings: Chronic cholecystitis, Cholelithiasis, Hepatocellular carcinoma, grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lobe liver (B). 2. Findings: Hepatocellular carcinoma, grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lobe liver (B). 2. Findings: Hepatocellular carcinoma, grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lobe liver (B). 2. Findings: Hepatocellular carcinoma, grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lobe liver (B). 2. Findings: Hepatocellular carcinoma, grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lobe liver (B). 2. Findings: Hepatocellular carcinoma, grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lobe liver (B). 2. Findings: Hepatocellular carcinoma, grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lobe liver (B). 2. Findings: Hepatocellular carcinoma, grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lobe liver (B). 2. Findings: Hepatocellular carcinoma, grade II. 3",
      "predicted": "KIRC",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Gallbladder (A). 2. Findings: Chronic cholecystitis, Cholelithiasis, Hepatocellular carcinoma, grade II. 3. Code: KIRC.",
      "idx": 727,
      "timestamp": "2026-01-19T15:59:53.112865"
    },
    {
      "sample_idx": 429,
      "input": "ANEG Mouse X 1. ANEG Rab X 1. D. ACK5/6 X 1. D. AE1/3 X 1. D. HCOM X 1. D. ISHBNK X 1. ISHBNK X 1. D. H&E X 1. D. HPV X 1. D. IISH x 1. D. P16 X 1. D. P40 X 1. D. P63 X 1. D. H&E X 1. E. H&E X 1. F. H&E X 1. G. H&E X 1. H. H&E X 1. H&E x 1. Part 16: Left Neck Level 1B (Additional). Stain,. Block. H&E x 1. A. Part 17: Mandible and Tongue. Stain/. Block. H&E X 1. D. H&E X 1. E. H&E x 1. F. H&E x 1. G. H&E X 1. H. H&E X 1. H&E X 1. H&E X 1. K. H&E X 1. H&E X 1. M. H&E x 1. H&E x 1. H&E X 1. Patholo...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Oral Cavity. 2. Findings: Squamous cell carcinoma, conventional. 3. Code: PRAD maps to Prad.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Oral Cavity. 2. Findings: Squamous cell carcinoma, conventional. 3. Code: PRAD maps to Prad.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Oral Cavity. 2. Findings: Squamous cell carcinoma, conventional. 3. Code: PRAD maps to Prad.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Oral Cavity. 2. Findings: Squamous cell carcinoma, conventional. 3. Code: PRAD maps to Prad.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Oral Cavity. 2. Findings: Squamous cell carcinoma, conventional. 3. Code: PRAD maps to Prad.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Oral Cavity. 2. Findings: Squamous cell carcinoma, conventional. 3. Code: PRAD maps to Prad.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Oral Cavity. 2. Findings: Squamous cell carcinoma, conventional. 3. Code: PRAD maps to Prad.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Oral Cavity. 2. Findings: Squamous cell carcinoma, conventional. 3. Code: PRAD maps to Prad.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n",
      "predicted": "PRAD",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Oral Cavity. 2. Findings: Squamous cell carcinoma, conventional. 3. Code: PRAD maps to Prad.",
      "idx": 429,
      "timestamp": "2026-01-19T15:59:53.112875"
    },
    {
      "sample_idx": 546,
      "input": "Diagnosis: FSA: Kidney mass, right, biopsy. - Positive for renal cell carcinoma, conventional clear cell type. B: Kidney, right, nephrectomy. Histologic tumor type/subtype: renal cell carcinoma, conventional clear cell type. Sarcomatoid features: absent. Histologic grade (if applicable): Fuhrman nuclear grade 3 (of 4). Tumor size (greatest dimension): 10.1 cm. Tumor focality: focal. Extent of invasion: Capsular invasion/perirenal adipose tissue: not involved. Gerota's fascia: not involved. Renal...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional clear cell type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional clear cell type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional clear cell type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional clear cell type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional clear cell type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional clear cell type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional clear cell type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional clear cell type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional clear cell type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 546,
      "timestamp": "2026-01-19T15:59:53.112886"
    },
    {
      "sample_idx": 1327,
      "input": "Specimens Submitted: 1: SP: Anterior cul-de-sac. 2: SP: Uterus, cervix, bilateral tubes and ovries. 3: SP: Left exteral iliac lymph nodes. 4: SP: Left obturator lymph nodes. 5: SP: Left hypogastric lymph nodes. 6: SP: Left common iliac lymph nodes. 7: SP: Right external iliac lymph nodes. 8: SP: Right obturator lymph nodes. 9: SP: Right hypogastric lymph nodes. 10: SP: Left lateral external iliac lymph nodes. DIAGNOSIS: 1). CUL-DE-SAC, ANTERIOR, BIOPSY: - FIBROUS TISSUE WITH CALCIFICATIONS AND F...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, bilateral tubes and ovries. 2. Findings: Adenocarcinoma of endometrium, endometroid type. With mucinous features, FIGO Grade II 16-50% solid growth, nuclear grade II. 3. Code: Uterus, cervix, bilateral tubes and ovries maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left external iliac lymph nodes. 2. Findings: Lymph node metastasis, adenocarcinoma of endometrium. 3. Code: Left external iliac lymph nodes maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left obturator lymph nodes. 2. Findings: Lymph node metastasis, adenocarcinoma of endometrium. 3. Code: Left obturator lymph nodes maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left hypogastric lymph nodes. 2. Findings: Lymph node metastasis, adenocarcinoma of endometrium. 3. Code: Left hypogastric lymph nodes maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left common iliac lymph nodes. 2. Findings: Lymph node metastasis, adenocarcinoma of endometrium. 3. Code: Left common iliac lymph nodes maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right external iliac lymph nodes. 2. Findings: Lymph node metastasis, adenocarcinoma of endometrium. 3. Code: Right external iliac lymph nodes maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right obturator lymph nodes. 2. Findings: Lymph node metastasis, adenocarcinoma of endometrium. 3. Code: Right obturator lymph nodes maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus, cervix, bilateral tubes and ovries. 2. Findings: Adenocarcinoma of endometrium, endometroid type. With mucinous features, FIGO Grade II 16-50% solid growth, nuclear grade II. 3. Code: Uterus, cervix, bilateral tubes and ovries maps to UCEC.",
      "idx": 1327,
      "timestamp": "2026-01-19T15:59:53.112900"
    },
    {
      "sample_idx": 146,
      "input": "rage I or 2. Surgical Pathology: Additional. CLINICAL HISTORY: Mass right breast. GROSS EXAMINATION: A. \"Sentinel node hot and blue\". Received fresh is a 2 x 1.5 x 1 cm tan lymph. node which is bisected and submitted in block A1. A cytokeratin is. prospectively ordered. B. Requisition labeled with the patient's name and history number \"right. breast tissue:long stitch lateral, short superior, white inferior\". fresh is a 10 (A-P) x 8.5 (M-L) x 3 (S-I) cm breast biopsy specimen which has. been ink...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive adenocarcinoma of the breast, ductal type, Nottingham combined histologic grade 2, tubule formation score 2, nuclear pleomorphism score 2, mitotic rate score 1. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive adenocarcinoma of the breast, ductal type, Nottingham combined histologic grade 2, tubule formation score 2, nuclear pleomorphism score 2, mitotic rate score 1. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 146,
      "timestamp": "2026-01-19T15:59:53.112914"
    },
    {
      "sample_idx": 1247,
      "input": "PATIENT HISTORY: CHIEF COMPLAINT/PRE-OP/POST-OP DIAGNOSIS: Thyroid nodule. PROCEDURE: Not answered. SPECIFIC CLINICAL QUESTION: Not answered. OUTSIDE TISSUE DIAGNOSIS: Not answered. PRIOR MALIGNANCY: Not answered. CHEMORADIATION: Not answered. ORGAN TRANSPLANT: Not answered. IMMUNOSUPPRESSION: Not answered. OTHER DISEASES: Not answered. ADDENDA: Addendum. Molecular Anatomic Pathology Testing: Part 1: A. BRAF V600E mutation IDENTIFIED at low level (see note). B. Mutations in NRAS61, HRAS61, KRAS1...",
      "response": "```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: TGCT.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site:",
      "predicted": "TGCT",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: TGCT.",
      "idx": 1247,
      "timestamp": "2026-01-19T15:59:53.112923"
    },
    {
      "sample_idx": 1300,
      "input": "Patient Name: : Resulted: Facility: SPECIMEN (s) RECEIVED Sate Thymus C379. 1. Thymus thymus gland - stitch on rt upper pole. 2. Lymph node: Left Periphrenic node. DIAGNOSIS. 1. Thymectomy : - Two separate thymomas: WHO type AB thymoma, right side, 5.2 cm in greatest diameter. - Tumor shows extension outside fibrous capsule into. peritumoral adipose tissue. Adjacent painted margins negative for tumor. WHO type A thymoma, left side, 5 cm in greatest diameter. - Tumor completely encapsulated, no i...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Type AB thymoma, right side, 5.2 cm in greatest diameter. Type A thymoma, left side, 5 cm in greatest diameter. 3. Code: THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Type A thymoma (spindle cell, medullary). 3. Code: THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Type A thymoma (spindle cell, medullary). 3. Code: THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Type A thymoma (spindle cell, medullary). 3. Code: THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Type A thymoma (spindle cell, medullary). 3. Code: THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Type A thymoma (spindle cell, medullary). 3. Code: THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Type A thymoma (spindle cell, medullary). 3. Code: THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Type A thymoma (spindle cell, medullary). 3. Code: THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning",
      "predicted": "THYM",
      "ground_truth": "THYM",
      "correct": true,
      "reasoning": "1. Site: Thymus. 2. Findings: Type AB thymoma, right side, 5.2 cm in greatest diameter. Type A thymoma, left side, 5 cm in greatest diameter. 3. Code: THYM.",
      "idx": 1300,
      "timestamp": "2026-01-19T15:59:53.112934"
    },
    {
      "sample_idx": 350,
      "input": "DIAGNOSIS. (A) STOMACH, LESSER CURVATURE ULCER SCAR, BIOPSY: Gastric mucosa with focal active inflammation, fibrosis of the lamina propria and foveolar hyperplasia;. negative for carcinoma. (B) DISTAL ESOPHAGEAL TUMOR, BIOPSY: INVASIVE ADENOCARCINOMA, MODERATELY TO POORLY DIFFERENTIATED. COLUMNAR MUCOSA WITH HIGH GRADE DYSPLASIA. Entire report and diagnosis completed by. GROSS DESCRIPTION. (A) ULCER, SCAR, LESSER CURVATURE - Multiple tan-pink irregular fragments of tissue (1.0 X 0.7 x 0.2 cm in ...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Stomach (lesser curvature ulcer scar). 2. Findings: Invasive adenocarcinoma, moderately to poorly differentiated. 3. Code: Distal Esophageal Tumor maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Invasive adenocarcinoma, moderately to poorly differentiated. 3. Code: Distal Esophageal Tumor maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Invasive adenocarcinoma, moderately to poorly differentiated. 3. Code: Distal Esophageal Tumor maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Invasive adenocarcinoma, moderately to poorly differentiated. 3. Code: Distal Esophageal Tumor maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Invasive adenocarcinoma, moderately to poorly differentiated. 3. Code: Distal Esophageal Tumor maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Invasive adenocarcinoma, moderately to poorly differentiated. 3. Code: Distal Esophageal Tumor maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Invasive adenocarcinoma, moderately to poorly differentiated. 3. Code: Distal Esophageal Tumor maps to ADENOCARCINOMA.\"\n}\n```",
      "predicted": "ADENOCARCINOMA",
      "ground_truth": "ESCA",
      "correct": false,
      "reasoning": "1. Site: Stomach (lesser curvature ulcer scar). 2. Findings: Invasive adenocarcinoma, moderately to poorly differentiated. 3. Code: Distal Esophageal Tumor maps to ADENOCARCINOMA.",
      "idx": 350,
      "timestamp": "2026-01-19T15:59:53.112945"
    },
    {
      "sample_idx": 1093,
      "input": "Resident: Pathologis. PATHOLOGIC DIAGNOSIS: A. SPECIMEN LABELED \"RIGHT LIVER LOBE\" (INCLUDING FSA) : Liver with fibrotic nodule with cystic change suggestive of sclerosed. hemangioma. There is no evidence of malignancy. B. SPECIMEN LABELED \"OMENTAL BX\" (INCLUDING FSB) : Fibroadipose tissue with no tumor present. C,. SPECIMEN LABELED \"SIGMOID AND RECTUM\" (16.1 cm) : ADENOCARCINOMA, MODERATELY DIFFERENTIATED (4.5 cm in greatest. dimension). Tumor is located at the rectosigmoid junction, forms a fu...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid and Rectum). 2. Findings: Adenocarcinoma, moderately differentiated, 4.5 cm in greatest dimension. Tumor is located at the rectosigmoid junction, forms a fungating mass, is ulcerative and has an infiltrating border. Tumor invades through muscularis propria into pericolonic adipose. tissue. Proximal, distal, and radial resection margins are negative for tumor. Invasive tumor is 9.5 cm from proximal resection margin, 6.5 cm from. distal resection margin, and 3.0 cm from radial resection margin. Intramural and extramural lymphovascular invasion is identified. Extramural venous invasion is identified. Perineural invasion is identified. Peritumoral lymphoid response (involving Crohn's-like infiltrate) is not. present. Residual adenoma is absent. Other polyps identified include: 1 adenoma (1.5 cm). REGIONAL LYMPH NODES (POSITIVE/TOTAL) 4/11. AJCC Classification (6th Edition) : T3 N2 MX. D. SPECIMEN LABELED \\\"DISTAL DONUT\\\": Portion of colon with no significant pathologic change. E. SPECIMEN LABELED \\\"PROXIMAL DONUT\\\": Portion of colon with no significant pathologic change. CLINICAL DATA: History: Rectal Ca - on sigmoidoscopy. Liver cysts (multiple on CT) ? mets. Operation: Low anterior resection. Operative Findings None given. Clinical Diagnosis: Not provided. TISSUE SUBMITTED: A. Right liver lobe. B. Omental bx. C. Sigmoid + rectum. D. Distal donut. E. Proximal donut. O.R. CONSULTATION: SPECIMEN LABELED \\\"#1. RIGHT LOBE LIVER\\\" (FSA) : Liver with collapsed fibrous wall cyst with dystrophic calcifications. Negative for carcinoma. Page: 1 of 3. SPECIMEN LABELED \\\"#2. OMENTAL BX\\\" (FSB) : Fat necrosis. Negative for carcinoma. SPECIMEN LABELED \\\"#3. RECTUM AND SIGMOID\\\" (GROSS ONLY) : Tumor is 4.8 cm in greatest dimension and is located 9.5 cm from the. stapled margin and 6.5 cm from the open margin.",
      "predicted": null,
      "ground_truth": "READ",
      "correct": null,
      "reasoning": "",
      "idx": 1093,
      "timestamp": "2026-01-19T15:59:53.113152"
    },
    {
      "sample_idx": 1410,
      "input": "Left eye enucleation. Macroscopy. The eye ball mesures 25 by 25 by 23 mm and presents a posterior segment of optic. nerves measuring 5 mm. At the section, the tumor measures 18 mm main line. Samples have been frozen for genetic studies then the piece has been fixed and. included entirely. Microscopy. The tumor observed macroscopically corresponds to an uveal melanoma, mainly. composed of epithelio\u00efd cells. The cell cytoplasm is often pigmented with melanin. The cyto/nuclear atypia are severe. Pr...",
      "response": "```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Eye (Left eye). 2. Findings: Uveal melanoma, epithelioid cells predominant, size 18mm. The tumor is located at a large distance of the optic foramen and the optic nerve on its entire course. The tumor is located in the posterior segment of the eye. 3. Code: Uveal Melanoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Eye (Left eye). 2. Findings: Uveal melanoma, epithelioid cells predominant, size 18mm. The tumor is located at a large distance of the optic foramen and the optic nerve on its entire course. The tumor is located in the posterior segment of the eye. 3. Code: Uveal Melanoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Eye (Left eye). 2. Findings: Uveal melanoma, epithelioid cells predominant, size 18mm. The tumor is located at a large distance of the optic foramen and the optic nerve on its entire course. The tumor is located in the posterior segment of the eye. 3. Code: Uveal Melanoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Eye (Left eye). 2. Findings: Uveal melanoma, epithelioid cells predominant, size 18mm. The tumor is located at a large distance of the optic foramen and the optic nerve on its entire course. The tumor is located in the posterior segment of the eye. 3. Code: Uveal Melanoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Eye (Left eye). 2. Findings: Uveal melanoma, epithelioid cells predominant, size 18mm. The tumor is located at a large distance of the optic foramen and the optic nerve on its entire course. The tumor is located in the posterior segment of",
      "predicted": "UVM",
      "ground_truth": "UVM",
      "correct": true,
      "reasoning": "1. Site: Eye (Left eye). 2. Findings: Uveal melanoma, epithelioid cells predominant, size 18mm. The tumor is located at a large distance of the optic foramen and the optic nerve on its entire course. The tumor is located in the posterior segment of the eye. 3. Code: Uveal Melanoma maps to UVM.",
      "idx": 1410,
      "timestamp": "2026-01-19T15:59:53.113173"
    },
    {
      "sample_idx": 334,
      "input": "Diagnosis: Resected colon with a broad, ulcerated, moderately differentiated adenocarcinoma of. colorectal type, with infiltration of the pericolic adipose tissue, lymphangiosis. carcinomatosa with tumor and seven local lymph node metastases. Tumor-free colon. resection margins. Tumor-free mesenteric resection margin. The remaining mucous. membrane of the colon displaying a circumscribed, ulcerous defect with remains of a. tubular adenoma with moderate epithelial dysplasia, as well as a further ...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma of the colon, broad, ulcerated, moderately differentiated, with lymphangiosis carcinomatosa and lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"READ\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma of the colon, broad, ulcerated, moderately differentiated, with lymphangiosis carcinomatosa and lymph node metastases. 3. Code: Colon Adenocarcinoma maps to READ.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma of the colon, broad, ulcerated, moderately differentiated, with lymphangiosis carcinomatosa and lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma of the colon, broad, ulcerated, moderately differentiated, with lymphangiosis carcinomatosa and lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma of the colon, broad, ulcerated, moderately differentiated, with lymphangiosis carcinomatosa and lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma of the colon, broad, ulcerated, moderately differentiated, with lymphangiosis carcinomatosa and lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma of the colon, broad, ulcerated, moderately differentiated, with lymphangiosis carcin",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon. 2. Findings: Adenocarcinoma of the colon, broad, ulcerated, moderately differentiated, with lymphangiosis carcinomatosa and lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.",
      "idx": 334,
      "timestamp": "2026-01-19T15:59:53.113188"
    },
    {
      "sample_idx": 946,
      "input": "Specimen Type: A: RIGHT OVARY AND UTERUS. B: LEFT OVARY. C: Omentum. D: ANTERIOR ABDOMINAL WALL NODE. Clinical Details: Ovarian Debulking. Macroscopic Description: A). RIGHT OVARY AND UTERUS: The ovary weighs 53.3 grams and measures 6.5 X 5.5 X. 4.5 cm. The ovarian cyst wall is ruptured. The cut surface shows a multilocular cyst. with solid areas. The solid area shows tan coloured and brownish areas. The uterus. corpus measures 6 cm longitudinally, 3 cm transversally and 3.2 cm anteroposteriorly...",
      "response": "```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovary and Uterus. 2. Findings: Serous carcinoma, Grade II-III. 3. Code: OV maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MESO\",\n    \"reasoning\": \"1. Site: Omentum. 2. Findings: Metastatic serous carcinoma. 3. Code: MESO maps to MESO.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"READ\",\n    \"reasoning\": \"1. Site: Anterior abdominal wall nodule. 2. Findings: Metastatic serous carcinoma. 3. Code: READ maps to READ.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, Grade II-III. 3. Code: OV maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MESO\",\n    \"reasoning\": \"1. Site: Omentum. 2. Findings: Metastatic serous carcinoma. 3. Code: MESO maps to MESO.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"READ\",\n    \"reasoning\": \"1. Site: Anterior abdominal wall nodule. 2. Findings: Metastatic serous carcinoma. 3. Code: READ maps to READ.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, Grade II-III. 3. Code: OV maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MESO\",\n    \"reasoning\": \"1. Site: Omentum. 2. Findings: Metastatic serous carcinoma. 3. Code: MESO maps to MESO.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"READ\",\n    \"reasoning\": \"1. Site: Anterior abdominal wall nodule. 2. Findings: Metastatic serous carcinoma. 3. Code: READ maps to",
      "predicted": "OV",
      "ground_truth": "OV",
      "correct": true,
      "reasoning": "1. Site: Ovary and Uterus. 2. Findings: Serous carcinoma, Grade II-III. 3. Code: OV maps to OV.",
      "idx": 946,
      "timestamp": "2026-01-19T15:59:53.113198"
    },
    {
      "sample_idx": 777,
      "input": "SPECIMEN. A. Pericardial reflection node. B. Right upper and middle lobe. C. Lymph node level 11. D. Lymph node 4R. E. Lymph node 2R. F. Lymph node level 9. CLINICAL NOTES. Non-small cell lung cancer. FROZEN SECTION DIAGNOSIS. A) Lymph node, pericardial reflection node, excision - Metastatic. non small cell carcinoma. GROSS DESCRIPTION. A. Received fresh for frozen section labeled \"pericardial. reflection node\" are irregularly shaped fragments of tan tissue. that. measure 0.6 X 0.6 x 0.4 cm in a...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Lower Lobe, Left Upper Lobe). 2. Findings: Adenocarcinoma, poorly differentiated, 1.7cm, 1.8cm. Lymph node involvement: Level 5 lymph node shows metastasis (1/1). 3. Code: LUAD (Lung Adenocarcinoma) maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole, Left Lower Lobe). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole, Left Lower Lobe). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole, Left Lower Lobe). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole, Left Lower Lobe). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole, Left Lower Lobe).",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung (Left Lower Lobe, Left Upper Lobe). 2. Findings: Adenocarcinoma, poorly differentiated, 1.7cm, 1.8cm. Lymph node involvement: Level 5 lymph node shows metastasis (1/1). 3. Code: LUAD (Lung Adenocarcinoma) maps to LUAD.",
      "idx": 777,
      "timestamp": "2026-01-19T15:59:53.113211"
    },
    {
      "sample_idx": 552,
      "input": "REVISED REPORT (Revised information underlined). TISSUE DESCRIPTION: 13.5 cm segment right ureter and right kidney (400 grams, 13.5 x 8.3. x 7.5 cm) and lymph nodes from intra-aortocaval and retrocaval. regions. DIAGNOSIS: Kidney, right, radical nephrectomy: Grade 2 (of 4). renal cell carcinoma, clear cell type, forms a 9.3 x 7.5 x 6.5 cm. mass located in the mid portion of the kidney. The tumor is. confined to the kidney. A tumor thrombus is present in the renal. vein, 0.8 cm in greatest linear...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Grade 2 (of 4). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Grade 2 (of 4). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Grade 2 (of 4). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Grade 2 (of 4). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Grade 2 (of 4). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Grade 2 (of 4). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Grade 2 (of 4). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Grade 2 (of 4). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 552,
      "timestamp": "2026-01-19T15:59:53.113222"
    },
    {
      "sample_idx": 1310,
      "input": "Account. (Age: Clinical Diagnosis & History: year old female with incidental anterior mediastinal mass,Clinically. stage II thymoma. Specimens Submitted: 1: SP: Anterior mediastinal mass for tissue (fa). DIAGNOSIS: 1. ANTERIOR MEDIASTINUM, MASS; EXCISION (FS) 1. - THYMOMA, 2004 WHO TYPE A AND MICRONODULAR THYMOMA WITH LYMPHOID. STROMA (SEE NOTE). - TUMOR SIZE: 10 x 6 x 4.2 CM. - THERE IS EXTENSIVE NECROSIS. - THERE IS NO THYMIC CAPSULAR INVASION. - THE INKED MARGIN IS FREE OF TUMOR. NOTE: THE TU...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Anterior mediastinum. 2. Findings: Thymoma (Type A and micronodular thymoma). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Anterior mediastinum. 2. Findings: Thymoma (Type A and micronodular thymoma). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Anterior mediastinum. 2. Findings: Thymoma (Type A and micronodular thymoma). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Anterior mediastinum. 2. Findings: Thymoma (Type A and micronodular thymoma). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Anterior mediastinum. 2. Findings: Thymoma (Type A and micronodular thymoma). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Anterior mediastinum. 2. Findings: Thymoma (Type A and micronodular thymoma). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Anterior mediastinum. 2. Findings: Thymoma (Type A and micronodular thymoma). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Anterior mediastinum. 2. Findings: Thymoma (Type A and micronodular thymoma). 3. Code: THYM maps to THYM.\"\n}\n```\n",
      "predicted": "THYM",
      "ground_truth": "THYM",
      "correct": true,
      "reasoning": "1. Site: Anterior mediastinum. 2. Findings: Thymoma (Type A and micronodular thymoma). 3. Code: THYM maps to THYM.",
      "idx": 1310,
      "timestamp": "2026-01-19T15:59:53.113232"
    },
    {
      "sample_idx": 1140,
      "input": "Copies To: Date Received: Addendum - Please See End of Report. Reason for Addendum #1: Breast profile results. SPECIMEN(S) SUBMITTED: A. PERI CERVICAL TUMOR, B. PERI URETERAL TUMOR. C. UTERUS, D. PERI URETHRAL MASS, E. ROUND LIGAMENT. F. OMENTUM #1, G. OMENTUM #2. H. OMENTUM #3, I. RIGHT PELVIC PERITONEUM, J. RIGHT GUTTER,. K. LEFT GUTTER, L. LEFT RETROPERITONEUM, M. LEFT PELVIC LYMPH NODE, N. RIGHT PELVIC LYMPH NODE, o. RIGHT. COMMON ILLIAC LYMPH NODE, P. PERIAORTIC LYMPH NODE RIGHT. DIAGNOSIS:...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive",
      "predicted": "BRCA",
      "ground_truth": "SARC",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1140,
      "timestamp": "2026-01-19T15:59:53.113241"
    },
    {
      "sample_idx": 449,
      "input": "Specimen(s) Received. 1. Nck: left neck contents - Level I. 2. Neck: Left neck contents - Level Il. 3. Neck: Left neck contents - Level IV. 4. Neck: Left neck contents - Level III. 5. Oral Cavity: Hemiglossectomy. 6. Soft Tissue: Left posterior margin. 7. Soft Tissue: Left lateral margin. 8. Soft Tissue: Medial margin. 9. Oral Cavity: Revision glossectomy. 10. Surgical Waste. Diagnosis. 1. Left neck; level I: - Six lymph nodes, negative for malignancy (0/6). - Submandibular gland with no patholo...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue (Left Hemiglossectomy). 2. Findings: Squamous cell carcinoma, poorly differentiated, G3. Perineural invasion present. Margins uninvolved by tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue (Left Hemiglossectomy). 2. Findings: Squamous cell carcinoma, poorly differentiated, G3. Perineural invasion present. Margins uninvolved by tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue (Left Hemiglossectomy). 2. Findings: Squamous cell carcinoma, poorly differentiated, G3. Perineural invasion present. Margins uninvolved by tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue (Left Hemiglossectomy). 2. Findings: Squamous cell carcinoma, poorly differentiated, G3. Perineural invasion present. Margins uninvolved by tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue (Left Hemiglossectomy). 2. Findings: Squamous cell carcinoma, poorly differentiated, G3. Perineural invasion present. Margins uninvolved by tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue (Left Hemiglossectomy). 2. Findings: Squamous cell carcinoma, poorly differentiated, G3. Perineural invasion present. Margins uninvolved by tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue (Left Hemiglossectomy). 2. Findings: Squamous cell carcinoma, poorly differentiated, G3",
      "predicted": "KIRC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Tongue (Left Hemiglossectomy). 2. Findings: Squamous cell carcinoma, poorly differentiated, G3. Perineural invasion present. Margins uninvolved by tumor. 3. Code: KIRC.",
      "idx": 449,
      "timestamp": "2026-01-19T15:59:53.113252"
    },
    {
      "sample_idx": 664,
      "input": "Surgical Pathology Renort. CLINICAL HISTORY. man with recent onset seizure, has a left. parietal occipital tumor. OPERATIVE DIAGNOSES. Not Given. Operation/Specimen: A: Brain mass, biopsy. B: Brain, resection. PATHOLOGICAL DIAGNOSIS: A and B. Brain, parieto-occipital excision: Gemistocytic. astrocytoma,. diffusely infiltrating, anaplastic. MIB-1 proliferation index: 10%. See comment. COMMENT. The specimens contain cerebral cortex and adjacent white matter. diffusely. infiltrated by an astrocytic...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Parieto-occipital). 2. Findings: Gemistocytic astrocytoma, diffusely infiltrating, anaplastic. MIB-1 proliferation index: 10%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Gemistocytic astrocytoma, diffusely infiltrating, anaplastic. MIB-1 proliferation index: 10%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Gemistocytic astrocytoma, diffusely infiltrating, anaplastic. MIB-1 proliferation index: 10%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Gemistocytic astrocytoma, diffusely infiltrating, anaplastic. MIB-1 proliferation index: 10%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Gemistocytic astrocytoma, diffusely infiltrating, anaplastic. MIB-1 proliferation index: 10%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Gemistocytic astrocytoma, diffusely infiltrating, anaplastic. MIB-1 proliferation index: 10%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Gemistocytic astrocytoma, diffusely infiltrating, anaplastic. MIB-1 proliferation",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain (Parieto-occipital). 2. Findings: Gemistocytic astrocytoma, diffusely infiltrating, anaplastic. MIB-1 proliferation index: 10%. 3. Code: GBM maps to GBM.",
      "idx": 664,
      "timestamp": "2026-01-19T15:59:53.113267"
    },
    {
      "sample_idx": 114,
      "input": "Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Right Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: Frozen. Container: cryomold Type of Procurement: Radical mastectomy Grade: 3. T Stage: 2 N Stage: 0 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Cont...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 114,
      "timestamp": "2026-01-19T15:59:53.113277"
    },
    {
      "sample_idx": 469,
      "input": "Report Type. Date of Event. Authored by. Hosp/Group. Record Status. AL. PATIENT HISTORY: Clinical history: Laryngeal cancer. PRE-OP DIAGNOSIS: Laryngeal cancer. POST-OP DIAGNOSIS: Same. RE: None given. FINAL DIAGNOSIS: PART 1: LARYNX, LEFT THYROID LOBE, AND LYMPH NODES, TOTAL LARYNGECTOMY,. LEFT. THYROID LOBECTOMY AND BILATERAL NECK DISSECTION. A. INVASIVE SQUAMOUS CELL CARCINOMA (5.0 CM), POORLY. DIFFERENTIATED,. LEFT GLOTTIC WITH SUPRAGLOTTIC EXTENSION (TRANSGLOTTIC) INVOLVING: 1. ANTERIOR COM...",
      "response": "```json\n{\n    \"cancer_type\": \"LARY\",\n    \"reasoning\": \"1. Site: Larynx, Left Thyroid Lobe, and Lymph Nodes. 2. Findings: Invasive squamous cell carcinoma, 5.0 cm, poorly differentiated. Left glottic with supraglottic extension involving anterior commissure, paraglottic space, thyroid cartilage, left thyroid lobe. No perineural invasion. Left modified radical neck dissection: 6/6 lymph nodes involved. Right selective neck dissection: 0/17 lymph nodes involved. Right glottis with mild dysplasia and vocal cord muscle. Abscess. Left thyroid lobe with otherwise no significant abnormalities. 3. Code: LARY maps to LARY.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LARY\",\n    \"reasoning\": \"1. Site: Larynx, Left Thyroid Lobe, and Lymph Nodes. 2. Findings: Invasive squamous cell carcinoma, 5.0 cm, poorly differentiated. Left glottic with supraglottic extension involving anterior commissure, paraglottic space, thyroid cartilage, left thyroid lobe. No perineural invasion. Left modified radical neck dissection: 6/6 lymph nodes involved. Right selective neck dissection: 0/17 lymph nodes involved. Right glottis with mild dysplasia and vocal cord muscle. Abscess. Left thyroid lobe with otherwise no significant abnormalities. 3. Code: LARY maps to LARY.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LARY\",\n    \"reasoning\": \"1. Site: Larynx, Left Thyroid Lobe, and Lymph Nodes. 2. Findings: Invasive squamous cell carcinoma, 5.0 cm, poorly differentiated. Left glottic with supraglottic extension involving anterior commissure, paraglottic space, thyroid cartilage, left thyroid lobe. No perineural invasion. Left modified radical neck dissection: 6/6 lymph nodes involved. Right selective neck dissection: 0/17 lymph nodes involved. Right glottis with mild dysplasia and vocal cord muscle. Abscess. Left thyroid lobe with otherwise no significant abnormalities. 3. Code: LARY maps to LARY.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LARY\",\n    \"reasoning\": \"1. Site: Larynx, Left Thyroid Lobe, and",
      "predicted": "LARY",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Larynx, Left Thyroid Lobe, and Lymph Nodes. 2. Findings: Invasive squamous cell carcinoma, 5.0 cm, poorly differentiated. Left glottic with supraglottic extension involving anterior commissure, paraglottic space, thyroid cartilage, left thyroid lobe. No perineural invasion. Left modified radical neck dissection: 6/6 lymph nodes involved. Right selective neck dissection: 0/17 lymph nodes involved. Right glottis with mild dysplasia and vocal cord muscle. Abscess. Left thyroid lobe with otherwise no significant abnormalities. 3. Code: LARY maps to LARY.",
      "idx": 469,
      "timestamp": "2026-01-19T15:59:53.113304"
    },
    {
      "sample_idx": 1401,
      "input": "DIAGNOSIS. (A) UTERUS, CERVIX, BILATERAL OVARIES AND TUBES: UTERINE MALIGNANT MIXED MULLERIAN TUMOR; TUMOR INVADES 8.0 MM INTO A 24.0 MM THICK. MYOMETRIUM. (SEE COMMENT). LYMPHOVASCULAR INVASION IS PRESENT. Cervix with chronic inflammation and Nabothian cysts, no tumor present. Bilateral ovaries and fallopian tubes, no tumor present. (B) LEFT PELVIC LYMPH NODES: Two lymph nodes, no tumor present (0/2). (C) RIGHT COMMON LYMPH NODE: One lymph node, no tumor present (0/1). (D) LEFT PELVIC LYMPH NOD...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Uterine malignant mixed M\u00fcllerian tumor, tumor invades 8.0 mm into a 24.0 mm thick myometrium. 3. Code: Uterine Cancer maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Uterine malignant mixed M\u00fcllerian tumor, tumor invades 8.0 mm into a 24.0 mm thick myometrium. 3. Code: Uterine Cancer maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Uterine malignant mixed M\u00fcllerian tumor, tumor invades 8.0 mm into a 24.0 mm thick myometrium. 3. Code: Uterine Cancer maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Uterine malignant mixed M\u00fcllerian tumor, tumor invades 8.0 mm into a 24.0 mm thick myometrium. 3. Code: Uterine Cancer maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Uterine malignant mixed M\u00fcllerian tumor, tumor invades 8.0 mm into a 24.0 mm thick myometrium. 3. Code: Uterine Cancer maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Uterine malignant mixed M\u00fcllerian tumor, tumor invades 8.0 mm into a 24.0 mm thick myometrium. 3. Code: Uterine Cancer maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC",
      "predicted": "UCEC",
      "ground_truth": "UCS",
      "correct": false,
      "reasoning": "1. Site: Uterus. 2. Findings: Uterine malignant mixed M\u00fcllerian tumor, tumor invades 8.0 mm into a 24.0 mm thick myometrium. 3. Code: Uterine Cancer maps to UCEC.",
      "idx": 1401,
      "timestamp": "2026-01-19T15:59:53.113321"
    },
    {
      "sample_idx": 646,
      "input": "F. (157.0cm 53.3kg BSA: 1.52m\u00b2. MODIFIED REPORT - REVIEW ADDENDUM SECTION. DIAGNOSIS. (A) POSTERIOR PART RIGHT FRONTAL BRAIN TUMOR -. OLIGODENDROGLIOMA, GRADE Il (WHO). (B) ANTERIOR PORTION RIGHT FRONTAL BRAIN. OLIGODENDROGLIOMA, GRADE II (WHO). (C) CINGULATE GYRUS, RIGHT FRONTAL LOBE -. OLIGODENDROGLIOMA, GRADE II (WHO). See comment. COMMENT. The 1p/19q status of this tumor will be determined. GROSS DESCRIPTION. (A) POSTERIOR PART RIGHT FRONTAL BRAIN TUMOR - Specimen consists of a single piece ...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Frontal lobe). 2. Findings: Oligodendroglioma, Grade II. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain (Frontal lobe). 2. Findings: Oligodendroglioma, Grade II. 3. Code: OLIG maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain (Frontal lobe). 2. Findings: Oligodendroglioma, Grade II. 3. Code: OLIG maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain (Frontal lobe). 2. Findings: Oligodendroglioma, Grade II. 3. Code: OLIG maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain (Frontal lobe). 2. Findings: Oligodendroglioma, Grade II. 3. Code: OLIG maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain (Frontal lobe). 2. Findings: Oligodendroglioma, Grade II. 3. Code: OLIG maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain (Frontal lobe). 2. Findings: Oligodendroglioma, Grade II. 3. Code: OLIG maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain (Frontal lobe). 2. Findings: Oligodendroglioma, Grade II. 3. Code: OLIG maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain (Frontal lobe). 2. Findings: Oligodendroglioma, Grade II. 3. Code: GBM maps to GBM.",
      "idx": 646,
      "timestamp": "2026-01-19T15:59:53.113332"
    },
    {
      "sample_idx": 821,
      "input": "Result date: Clinical History. Left lung cancer. Specimen. # 1. 4R. Level 7. # 3. 4L. # 4. 2R. # 5. Left upper lobe wedge. # 6. Level 5. # 7. Level 6. Gross Examination. #1 Received fresh labeled 4R are fragments of yellow to black material, in. aggregate 0.8 X 0.5 X 0.3 cm. It is completely submitted as single frozen. sections. #2 Received fresh labeled level 7 are two fragments of gray-tan tissue, up to. 0.3 X 0.2 X 0.1 cm. Completely submitted as a single frozen section. #3 Received fresh lab...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Left upper lobe of lung. 2. Findings: Adenocarcinoma, moderately to poorly differentiated. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, wedge. 2. Findings: Adenocarcinoma, moderately to poorly differentiated. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, wedge. 2. Findings: Adenocarcinoma, moderately to poorly differentiated. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, wedge. 2. Findings: Adenocarcinoma, moderately to poorly differentiated. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, wedge. 2. Findings: Adenocarcinoma, moderately to poorly differentiated. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, wedge. 2. Findings: Adenocarcinoma, moderately to poorly differentiated. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, wedge. 2. Findings: Adenocarcinoma, moderately to poorly differentiated. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, wedge. 2. Findings: Adenocarcinoma, moderately to poorly differentiated. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe, wedge.",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Left upper lobe of lung. 2. Findings: Adenocarcinoma, moderately to poorly differentiated. 3. Code: LUAD.",
      "idx": 821,
      "timestamp": "2026-01-19T15:59:53.113342"
    },
    {
      "sample_idx": 548,
      "input": "Clinical Diagnosis & History: Laparoscopic right radical nephrectomy. Specimens Submitted: 1: SP: Right kidney and partial adrenal. DIAGNOSIS: 1). KIDNEY, RIGHT AND ADRENAL; NEPHRECTOMY: - RENAL CELL CARCINOMA, CLEAR CELL TYPE (CONVENTIONAL TYPE), NUCLEAR GRADE II/IV. - THE PATTERN OF GROWTH IS ACINAR AND SOLID. - THE TUMOR GREATEST DIAMETER IS 4.5 CM. - THE TUMOR EXTENDS THROUGH THE RENAL CAPSULE BUT IS CONFINED WITHIN GEROTA'S FASCIA. - NO INVASION OF THE RENAL VEIN IS IDENTIFIED. - ALL SURGIC...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 548,
      "timestamp": "2026-01-19T15:59:53.113352"
    },
    {
      "sample_idx": 135,
      "input": "Sex: I. MRN #: SPECIMEN INE. DIAGNOSIS. DIAGNOSIS: Right modified radical mastectomy with sentinel node mapping: Invasive lobular carcinoma. Lobular carcinoma was previously confirmed by negative e cadherin expression. Size: 5.3 cm. Architectural score: 3 of 3. Nuclear score: 2 of 3. Mitotic score: 1 of 3. Total score: 6 of 9 = grade 2. Carcinoma involves sections of the nipple but does not involve the overlying epidermis and is not seen in dermal lymphatics. Prognostic panel was performed on th...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 135,
      "timestamp": "2026-01-19T15:59:53.113362"
    },
    {
      "sample_idx": 432,
      "input": "DIAGNOSIS: 1) MOUTH, ANTERIOR FLOOR, MARGIN, EXCISION: SQUAMOUS MUCOSA, NEGATIVE FOR. MALIGNANCY. 2) MOUTH, POSTERIOR FLOOR, MARGIN, EXCISION: SQUAMOUS MUCOSA AND SALIVARY. GLAND, NEGATIVE FOR MALIGNANCY. 3) TONGUE, ANTERIOR MARGIN, EXCISION: SQUAMOUS MUCOSA, NEGATIVE FOR. MALIGNANCY. 4) TONGUE, POSTERIOR MARGIN, EXCISION: SQUAMOUS MUCOSA, NEGATIVE FOR. MALIGNANCY. 5) TONGUE, \"CANCER,\" LEFT, EXCISION: WELL-DIFFERENTIATED INVASIVE SQUAMOUS. CELL CARCINOMA, 1.5 CM IN GREATEST EXTENT, 0.7 CM TO DEE...",
      "response": "```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Tongue (Anterior and Posterior Margins), Floor of Mouth (Anterior Margin). 2. Findings: Squamous cell carcinoma. 3. Code: UCEC (Uterine Corpus Cancer) is the closest match as it is a cancer of the upper aerodigestive tract. Since there is no information about the uterine corpus, this is the closest match.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Tongue (Anterior and Posterior Margins), Floor of Mouth (Anterior Margin). 2. Findings: Squamous cell carcinoma. 3. Code: UCEC (Uterine Corpus Cancer) is the closest match as it is a cancer of the upper aerodigestive tract. Since there is no information about the uterine corpus, this is the closest match.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Tongue (Anterior and Posterior Margins), Floor of Mouth (Anterior Margin). 2. Findings: Squamous cell carcinoma. 3. Code: UCEC (Uterine Corpus Cancer) is the closest match as it is a cancer of the upper aerodigestive tract. Since there is no information about the uterine corpus, this is the closest match.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Tongue (Anterior and Posterior Margins), Floor of Mouth (Anterior Margin). 2. Findings: Squamous cell carcinoma. 3. Code: UCEC (Uterine Corpus Cancer) is the closest match as it is a cancer of the upper aerodigestive tract. Since there is no information about the uterine corpus, this is the closest match.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Tongue (Anterior and Posterior Margins), Floor of Mouth (Anterior Margin). 2. Findings: Squamous cell carcinoma. 3. Code: UCEC (Uterine Corpus Cancer) is the closest match as it is a cancer of the upper aerodigestive tract. Since there is",
      "predicted": "UCSC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Tongue (Anterior and Posterior Margins), Floor of Mouth (Anterior Margin). 2. Findings: Squamous cell carcinoma. 3. Code: UCEC (Uterine Corpus Cancer) is the closest match as it is a cancer of the upper aerodigestive tract. Since there is no information about the uterine corpus, this is the closest match.",
      "idx": 432,
      "timestamp": "2026-01-19T15:59:53.113377"
    },
    {
      "sample_idx": 1161,
      "input": "Diagnosis/diagnoses. Residual gastrectomy preparation of a stomach that had previously undergone B-II. gastrectomy showing tumor-free resection margins and the inclusion of a poorly. differentiated, highly mucigenous or mucinous adenocarcinoma with an extensive signet ring. cell component (so-called gastric carcinoma of the diffuse type) in the region of the lesser. curvature covering almost the entire gastric stump from the heart to the anastomosis, with. infiltration of the subserosa and two r...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach, lesser curvature. 2. Findings: Poorly differentiated, highly mucigenous/mucinous adenocarcinoma with signet ring cells. Extensive tumor coverage of the gastric stump. Subserosal infiltration. 2 regional lymph node metastases. 3. Code: ADENOMA. This is based on the pathology report which mentions the presence of a poorly differentiated, highly mucigenous/mucinous adenocarcinoma with signet ring cells. The report also mentions that it is in the stomach and that it has lymph node metastases. The code ADENOMA is not the best fit, but it is the closest valid code. This is a gastric carcinoma of the diffuse type. The report also mentions that the tumor is in the stomach, which is a valid cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach, lesser curvature. 2. Findings: Poorly differentiated, highly mucigenous/mucinous adenocarcinoma with signet ring cells. Extensive tumor coverage of the gastric stump. Subserosal infiltration. 2 regional lymph node metastases. 3. Code: ADENOMA. The report describes a poorly differentiated adenocarcinoma with signet ring cells and extensive tumor coverage. The presence of lymph node metastases is also mentioned. While the report mentions adenocarcinoma, the term 'adenoma' is not a valid TCGA code. The best code to use is ADENOMA, as the description is a very poor grade and highly aggressive adenocarcinoma. The report also mentions that it is in the stomach, which is a valid cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach, lesser curvature. 2. Findings: Poorly differentiated, highly mucigenous/mucinous adenocarcinoma with signet ring cells. Extensive tumor coverage of the gastric stump. Subserosal infiltration. 2 regional lymph node metastases. 3. Code: ADENOMA. The report describes a poorly differentiated adenocarcinoma with signet ring cells and extensive tumor coverage. The presence of lymph node metastases is also mentioned. While the report mentions adenocarcinoma, the term 'adenoma' is not a valid TCGA code. The best code to use is ADENOMA, as the description is a very poor grade and highly aggressive adenocarcinoma.",
      "predicted": "ADENOMA",
      "ground_truth": "STAD",
      "correct": false,
      "reasoning": "1. Site: Stomach, lesser curvature. 2. Findings: Poorly differentiated, highly mucigenous/mucinous adenocarcinoma with signet ring cells. Extensive tumor coverage of the gastric stump. Subserosal infiltration. 2 regional lymph node metastases. 3. Code: ADENOMA. This is based on the pathology report which mentions the presence of a poorly differentiated, highly mucigenous/mucinous adenocarcinoma with signet ring cells. The report also mentions that it is in the stomach and that it has lymph node metastases. The code ADENOMA is not the best fit, but it is the closest valid code. This is a gastric carcinoma of the diffuse type. The report also mentions that the tumor is in the stomach, which is a valid cancer type.",
      "idx": 1161,
      "timestamp": "2026-01-19T15:59:53.113400"
    },
    {
      "sample_idx": 644,
      "input": "Patier CResults. Anatomical Pathology results: Performed since. Atleast 1 Final Resalt. DOCTOR. :M. DOC. ADDRESS. COLL. DATE. DATE RECEIVED. WARD. CONSULTANT. H. SPECIMEN: A. Brain. B. Left parietal tumour. CLINICAL: Left parietal tumour glioma. MACROSCOPIC: A. Up to six soft smeared fragments 1mm to 5mm in size, pale grey in colour. INTRA-OPERATIVE ASSESSMENT - FROZEN SECTION: FSD. High grade alial tumour. Await permanent. rections for definitive. diagnosis. BLOCK KEY: l:tissue remaining from f...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: High grade glioma, Anaplastic astrocytoma, WHO III. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: High grade glioma, Anaplastic astrocytoma, WHO III. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: High grade glioma, Anaplastic astrocytoma, WHO III. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: High grade glioma, Anaplastic astrocytoma, WHO III. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: High grade glioma, Anaplastic astrocytoma, WHO III. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: High grade glioma, Anaplastic astrocytoma, WHO III. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: High grade glioma, Anaplastic astrocytoma, WHO III. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: High grade glioma, Anaplastic astrocytoma, WHO III. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain. 2. Findings: High grade glioma, Anaplastic astrocytoma, WHO III. 3. Code: GBM.",
      "idx": 644,
      "timestamp": "2026-01-19T15:59:53.113409"
    },
    {
      "sample_idx": 435,
      "input": "CLINICAL DATA: Right mandibular composite neck dissection, free flap. Diagnosis: FOM carcinoma. GROSS DESCRIPTION: A) Received fresh designated \". composite resection and right neck dissection\" is a 10 x 10 x. 6 cm specimen consisting of a right mandible consisting of the ramus and body with the posterior. and superior aspect of the ramus surgically transected (the ramus measures 3.6 cm IS). The. anterior mandible is intact and a portion of the mental protuberance is present just past the. midli...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (Esophagogastric junction). 2. Findings: Adenocarcinoma, moderately differentiated, with mucin production. 3. Code: ADENOCARCINOMA maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (Esophagogastric junction). 2. Findings: Adenocarcinoma, moderately differentiated, with mucin production. 3. Code: ADENOCARCINOMA maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (Esophagogastric junction). 2. Findings: Adenocarcinoma, moderately differentiated, with mucin production. 3. Code: ADENOCARCINOMA maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (Esophagogastric junction). 2. Findings: Adenocarcinoma, moderately differentiated, with mucin production. 3. Code: ADENOCARCINOMA maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (Esophagogastric junction). 2. Findings: Adenocarcinoma, moderately differentiated, with mucin production. 3. Code: ADENOCARCINOMA maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus (Esophagogastric junction). 2. Findings: Adenocarcinoma, moderately differentiated, with mucin production. 3. Code: ADENOCARCINOMA maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"",
      "predicted": "ADENOCARCINOMA",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Esophagus (Esophagogastric junction). 2. Findings: Adenocarcinoma, moderately differentiated, with mucin production. 3. Code: ADENOCARCINOMA maps to ADENOCARCINOMA.",
      "idx": 435,
      "timestamp": "2026-01-19T15:59:53.113420"
    },
    {
      "sample_idx": 1022,
      "input": "Sex: M. Results: SURGICAL PROCEDURE (Order. Result Narrative. Accession No: SPECIMEN SUBMITTED: A. LEFT PELVIC LYMPH NODE. B. RIGHT PELVIC LYMPH NODES. C. PROSTATE. OPERATION: Prostatectomy. CLINICAL DIAGNOSIS: Prostate cancer. GROSS DESCRIPTION: Three specimens are received each labeled with. the patient's name. and medical record number. The first specimen is additionally designated \"left pelvic lymph. node\" and consists of a single fragment of fibrofatty tissue. measuring 2.5 x 2.2 x 0.6 cm. ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, high-grade prostatic adenocarcinoma, with a component of the tumor demonstrating mucinous features. The carcinoma demonstrates extensive perineural invasion, multifocal extraprostatic extension, and involvement of the surgical margin at the right posterior prostatic margin. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Pelvic Lymph Node. 2. Findings: Lymph node, no carcinoma seen in one lymph node (0/1). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Pelvic Lymph Node. 2. Findings: Lymph node, no carcinoma seen in one lymph node (0/1). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, high-grade prostatic adenocarcinoma with focal mucinous features, involving the right posterior surgical margin. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, high-grade prostatic adenocarcinoma with focal mucinous features, involving the right posterior surgical margin. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, high-grade prostatic adenocarcinoma with focal mucinous features, involving the right posterior surgical margin. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, high-grade prostatic adenocarcinoma with focal mucinous features, involving the right posterior surgical margin. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning",
      "predicted": "KIRC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate. 2. Findings: Prostate cancer, high-grade prostatic adenocarcinoma, with a component of the tumor demonstrating mucinous features. The carcinoma demonstrates extensive perineural invasion, multifocal extraprostatic extension, and involvement of the surgical margin at the right posterior prostatic margin. 3. Code: KIRC",
      "idx": 1022,
      "timestamp": "2026-01-19T15:59:53.113435"
    },
    {
      "sample_idx": 810,
      "input": "23274921. SPECIMEN(S): A. LEVEL 7 SUBCARINAL. B. 4R RIGHT DISTAL PARATRACHEAL. C. 4R RIGHT DISTAL PARATRACHEAL. D. SUPERIOR SEGMENT RIGHT UPPER LOBE. E. 6TH RIB. F. RIGHT LUNG. G. 1OR LYMPH NODE. CLINICAL HISTORY: None given. PRE-OPERATIVE DIAGNOSIS: None given. INTRAOPERATIVE CONSULTATION DIAGNOSIS: FSA & B: Lymph nodes 4R and 7, biopsy: - Negative for carcinoma by. FSC: Lymph node 4R, biopsy: - Positive for adenocarcinoma. P.M. FSF: Right lung, pneumonectomy: - Bronchial margin negative for in...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right, Pneumonectomy. 2. Findings: Adenocarcinoma, moderately differentiated with focal poorly differentiated areas. 3. Code: LUAD\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right, Pneumonectomy. 2. Findings: Adenocarcinoma, moderately differentiated with focal poorly differentiated areas. 3. Code: LUAD\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right, Pneumonectomy. 2. Findings: Adenocarcinoma, moderately differentiated with focal poorly differentiated areas. 3. Code: LUAD\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right, Pneumonectomy. 2. Findings: Adenocarcinoma, moderately differentiated with focal poorly differentiated areas. 3. Code: LUAD\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right, Pneumonectomy. 2. Findings: Adenocarcinoma, moderately differentiated with focal poorly differentiated areas. 3. Code: LUAD\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right, Pneumonectomy. 2. Findings: Adenocarcinoma, moderately differentiated with focal poorly differentiated areas. 3. Code: LUAD\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right, Pneumonectomy. 2. Findings: Adenocarcinoma, moderately differentiated with focal poorly differentiated areas. 3. Code: LUAD\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Right, Pneumonectomy. 2. Findings: Adenocarcinoma, moderately differentiated with focal poorly differentiated areas. 3. Code: LUAD\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung, Right, Pneumonectomy. 2. Findings: Adenocarcinoma, moderately differentiated with focal poorly differentiated areas. 3. Code: LUAD",
      "idx": 810,
      "timestamp": "2026-01-19T15:59:53.113445"
    },
    {
      "sample_idx": 939,
      "input": "V3.00 110614. Instructions: The TCGA Missing Pathology Report Form should be completed for cases for which a pathology report is not. available. General Pathology Report Information. #. Data Element. Entry Alternatives. Working Instructions. Provide the tumor type of the case. 1. Tumor type: Indicate to which BCR location the case was originally sent. BCR specimen originally sent. NCH. 2. to: IGC. Biospecimen Core Resource (BCR). Date specimen received at. 3. BCR: ICD-0-3 Histology Code: Provide...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 939,
      "timestamp": "2026-01-19T15:59:53.113455"
    },
    {
      "sample_idx": 292,
      "input": "Diagnosis: Colon, ascending, right hemicolectomy. Tumor Histologic Type: adenocarcinoma, colon primary (see comment). Histologic Grade: low grade (grade 2 of 4, moderately differentiated). Tumor Size: 8.2 cm. Tumor Location: cecum. Depth of Invasion: through muscularis propria and into pericolonic adipose tissue, no definitive penetration or perforation of visceral. peritoneum identified. Lymphovascular Invasion: not identified. Perineural Invasion: not identified. Margins: negative. Proximal ma...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon, ascending, right hemicolectomy. 2. Findings: Adenocarcinoma, colon primary. 3. Code: KIRC\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon, ascending, right hemicolectomy. 2. Findings: Adenocarcinoma, colon primary, low grade (grade 2 of 4, moderately differentiated). 3. Code: KIRC\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon, ascending, right hemicolectomy. 2. Findings: Adenocarcinoma, colon primary, low grade (grade 2 of 4, moderately differentiated). 3. Code: KIRC\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon, ascending, right hemicolectomy. 2. Findings: Adenocarcinoma, colon primary, low grade (grade 2 of 4, moderately differentiated). 3. Code: KIRC\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon, ascending, right hemicolectomy. 2. Findings: Adenocarcinoma, colon primary, low grade (grade 2 of 4, moderately differentiated). 3. Code: KIRC\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon, ascending, right hemicolectomy. 2. Findings: Adenocarcinoma, colon primary, low grade (grade 2 of 4, moderately differentiated). 3. Code: KIRC\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon, ascending, right hemicolectomy. 2. Findings: Adenocarcinoma, colon primary, low grade (grade 2 of 4, moderately differentiated). 3. Code: KIRC\"\n",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Colon, ascending, right hemicolectomy. 2. Findings: Adenocarcinoma, colon primary. 3. Code: KIRC",
      "idx": 292,
      "timestamp": "2026-01-19T15:59:53.113464"
    },
    {
      "sample_idx": 542,
      "input": "PATIENT HISTORY: Not given. PRE-OP DIAGNOSIS: Left renal cancer. POST-OP DIAGNOSIS: Same. PROCEDURE: Left laparoscopic nephrectomy. FINAL DIAGNOSIS: KIDNEY, LEFT, LAPAROSCOPIC NEPHRECTOMY -. A. RENAL CELL CARCINOMA, CONVENTIONAL (CLEAR) CELL TYPE. B. FUHRMAN'S NUCLEAR GRADE IS 3 of 4. c. THE GREATEST DIAMETER OF THE NEOPLASM IS 7.2 CM. D. THE NEOPLASM IS CONFINED WITHIN THE RENAL CAPSULE. E. TUMOR INVADES INTO THE RENAL VEIN WITH INVOLVEMENT OF THE VESSEL WALL. F.-. ALL SURGICAL MARGINS ARE FREE...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney, Left. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 542,
      "timestamp": "2026-01-19T15:59:53.113475"
    },
    {
      "sample_idx": 1408,
      "input": "Right eye enucleation. Macroscopy. The eyeball measures 25 by 25 mm with a segment of optic nerve of 10 mm. There is a. posterior tumor close to the intraocular emergence of the optic nerve, pigmented, measuring. 15 mm main line. Samples have been made for cryopreservation . The specimen has been then. included entirely after fixation. Microscopy. Choroidal melanoma with fusiform cells measuring 15 by 12 mm. The lesion, very posterior,. is situated at the periphery, slightly distant from the int...",
      "response": "```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Right eye. 2. Findings: Choroidal melanoma with fusiform cells, measuring 15 x 12 mm. 3. Code: Choroidal melanoma maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Right eye. 2. Findings: Choroidal melanoma with fusiform cells, measuring 15 x 12 mm. 3. Code: Choroidal melanoma maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Right eye. 2. Findings: Choroidal melanoma with fusiform cells, measuring 15 x 12 mm. 3. Code: Choroidal melanoma maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Right eye. 2. Findings: Choroidal melanoma with fusiform cells, measuring 15 x 12 mm. 3. Code: Choroidal melanoma maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Right eye. 2. Findings: Choroidal melanoma with fusiform cells, measuring 15 x 12 mm. 3. Code: Choroidal melanoma maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Right eye. 2. Findings: Choroidal melanoma with fusiform cells, measuring 15 x 12 mm. 3. Code: Choroidal melanoma maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Right eye. 2. Findings: Choroidal melanoma with fusiform cells, measuring 15 x 12 mm. 3. Code: Choroidal melanoma maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"",
      "predicted": "CHOL",
      "ground_truth": "UVM",
      "correct": false,
      "reasoning": "1. Site: Right eye. 2. Findings: Choroidal melanoma with fusiform cells, measuring 15 x 12 mm. 3. Code: Choroidal melanoma maps to CHOL.",
      "idx": 1408,
      "timestamp": "2026-01-19T15:59:53.113492"
    },
    {
      "sample_idx": 505,
      "input": "Admit Date: Gender: Female. Birth Date: Attending: Surgical Pathology [OrderII: DIAGNOSIS: 1. Tumor, #1, left kidney (partial nephrectomy): Renal parenchyma. showing oncocytosis. Benign smooth muscle tumor. (leiomyoma). 2. Tumor, #2, left kidney (partial nephrectomy): Renal cell carcinoma,. chromophobe type (small). Furhman nuclear grade II. chromophobe type 8317/3. 3. Tumor, #3, left kidney (partial nephrectomy): Benign smooth muscle. tumor (leiomyoma). 4. Tumor, #4, left kidney (partial nephre...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Furhman nuclear grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Furhman nuclear grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Furhman nuclear grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Furhman nuclear grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Furhman nuclear grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Furhman nuclear grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Furhman nuclear grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Furhman nuclear grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\":",
      "predicted": "KIRC",
      "ground_truth": "KICH",
      "correct": false,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Furhman nuclear grade II. 3. Code: KIRC.",
      "idx": 505,
      "timestamp": "2026-01-19T15:59:53.113503"
    },
    {
      "sample_idx": 1393,
      "input": "Gander. Facility. Specimen(s) Received. 1. Lymph-Node: Left Iliac, external. 2. Uterus :Uterus cervix bilateral adnexal. 3. Lymph node Right pelvic Lymph nodes. 4. Lymph node Right common iliac node. 5. Lymph node :Left pelvic Lymph node. 6. Lymph node :Left para-aortic lymph node. Diagnosis. 1. Lymph nodes (left external iliac): - Positive for carcinoma, one of one node (1/1). 2. Uterus,cervix ovaries and tubes: Uterus: - ENDOMETRIAL CARCINOMA, ENDOMETRIOID TYPE, FIGO 3/3, pT1b N1. - Outer half...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Iliac, external lymph node. 2. Findings: Carcinoma, one of one node. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, bilateral adnexa. 2. Findings: Endometrioid adenocarcinoma, not otherwise characterized. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right pelvic Lymph nodes. 2. Findings: Carcinoma, four of twenty four nodes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right common iliac node. 2. Findings: Carcinoma, one of one node. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left pelvic Lymph node. 2. Findings: Carcinoma, seven lymph nodes, negative for carcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left para-aortic lymph node. 2. Findings: Carcinoma, three lymph node, negative for carcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, cervix, bilateral adnexa. 2. Findings: Endometrioid adenocarcinoma, not otherwise characterized. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right pelvic Lymph nodes. 2. Findings: Carcinoma, four of twenty four nodes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right common iliac",
      "predicted": "KIRC",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Left Iliac, external lymph node. 2. Findings: Carcinoma, one of one node. 3. Code: KIRC.",
      "idx": 1393,
      "timestamp": "2026-01-19T15:59:53.113514"
    },
    {
      "sample_idx": 1103,
      "input": "FINAL DIAGNOSIS: PART 1 : GASTROESOPHAGEAL JUNCTI\u00d3N, BIOPSY. A. REACTIVE SQUAMOUS AND GASTRIC TYPE MUCOSA. B. NEGATIVE FOR INTESTINAL METAPLASIA. Date of Event. PART 2: RECTUM, MASS, BIOPSY. INVASIVE MODERATELY DIFFERENTIATED ADENOCARCINOMA.",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Gastroesophageal junction, biopsy. 2. Findings: Reactive squamous and gastric type mucosa, negative for intestinal metaplasia. 2. Site: Rectum, mass, biopsy. 3. Findings: Invasive moderately differentiated adenocarcinoma. 3. Code: ADENOCARC maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Gastroesophageal junction, biopsy. 2. Findings: Reactive squamous and gastric type mucosa, negative for intestinal metaplasia. 2. Site: Rectum, mass, biopsy. 3. Findings: Invasive moderately differentiated adenocarcinoma. 3. Code: ADENOCARC maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Gastroesophageal junction, biopsy. 2. Findings: Reactive squamous and gastric type mucosa, negative for intestinal metaplasia. 2. Site: Rectum, mass, biopsy. 3. Findings: Invasive moderately differentiated adenocarcinoma. 3. Code: ADENOCARC maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Gastroesophageal junction, biopsy. 2. Findings: Reactive squamous and gastric type mucosa, negative for intestinal metaplasia. 2. Site: Rectum, mass, biopsy. 3. Findings: Invasive moderately differentiated adenocarcinoma. 3. Code: ADENOCARC maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Gastroesophageal junction, biopsy. 2. Findings: Reactive squamous and gastric type mucosa, negative for intestinal metaplasia. 2. Site: Rectum, mass, biopsy. 3. Findings: Invasive moderately differentiated adenocarcinoma. 3. Code: ADENOCARC maps to ADENOCARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site",
      "predicted": "ADENOCARC",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Gastroesophageal junction, biopsy. 2. Findings: Reactive squamous and gastric type mucosa, negative for intestinal metaplasia. 2. Site: Rectum, mass, biopsy. 3. Findings: Invasive moderately differentiated adenocarcinoma. 3. Code: ADENOCARC maps to ADENOCARC.",
      "idx": 1103,
      "timestamp": "2026-01-19T15:59:53.113528"
    },
    {
      "sample_idx": 538,
      "input": "Clinical Diagnosis & History: Patient with h/o right renal mass (right sided); renal cell cancer. Specimens Submitted: 1: SP: Right kidney, ureter and part of adrenal. 2: SP: Portion of right 11th rib. 3: SP: Right hilar lymph nodes. 4: SP: Fat at lower pole of kidney. DIAGNOSIS: 1). KIDNEY, RIGHT; RADICAL NEPHRECTOMY: - RENAL CELL CARCINOMA, CLEAR CELL TYPE, NUCLEAR GRADE II/IV. -THE PATTERN OF GROWTH IS PAPILLARY AND TUBULAR. - THE TUMOR GREATEST DIAMETER IS 6.5 CM. - THE TUMOR IS CONFINED WIT...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type,",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 538,
      "timestamp": "2026-01-19T15:59:53.113539"
    },
    {
      "sample_idx": 1197,
      "input": "Gender: F. Examination result No. Clinical diagnosis (suspicion) Gastric cancer. Date of admission: Material: 1) Material: stomach, Method of collection: Total organ resection. Histopathological diagnosis: Stomach adenocarcinoma, tubular and poorly differentiated (G3, pT2, pN2). Signs of vascular invasion. (8140/3. T-63000). codes according to ICD-O-3 or SNOMED. Macroscopic description: The specimen consisting of the stomach, after being incised along the greater curvature, sized 18,8x14,7 cm wi...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Stomach adenocarcinoma, tubular and poorly differentiated (G3, pT2, pN2). Signs of vascular invasion. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Stomach adenocarcinoma, tubular and poorly differentiated (G3, pT2, pN2). Signs of vascular invasion. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Stomach adenocarcinoma, tubular and poorly differentiated (G3, pT2, pN2). Signs of vascular invasion. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Stomach adenocarcinoma, tubular and poorly differentiated (G3, pT2, pN2). Signs of vascular invasion. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Stomach adenocarcinoma, tubular and poorly differentiated (G3, pT2, pN2). Signs of vascular invasion. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Stomach adenocarcinoma, tubular and poorly differentiated (G3, pT2, pN2). Signs of vascular invasion. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Stomach adenocarcinoma, tubular and poorly differentiated (G3, pT2, pN2). Signs of vascular invasion. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "ADENOMA",
      "ground_truth": "STAD",
      "correct": false,
      "reasoning": "1. Site: Stomach. 2. Findings: Stomach adenocarcinoma, tubular and poorly differentiated (G3, pT2, pN2). Signs of vascular invasion. 3. Code: ADENOMA.",
      "idx": 1197,
      "timestamp": "2026-01-19T15:59:53.113550"
    },
    {
      "sample_idx": 877,
      "input": "Clinical History/Diagnosis: Cancer left lung. Source of Specimen(s): A: Lung, wedge biopsy left lower lobe. B: Lymph Node, level 9L. Gross Description: Received in two parts. Source of Tissue: 1. Labeled #1 \"left lower lobe of lung wedge\". Gross Description: Received fresh is an 84.8 gm, 13.5 x 5.0 X 3.0 cm wedge. of lung. It is covered by a red-purple focally anthracotic stained pleura. having multiple staples along one margin. The pleural margins are inked. in black, the staples are removed an...",
      "response": "```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left lower lobe. 2. Findings: Invasive, poorly differentiated, squamous cell carcinoma. 3. Code: Lung, left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Level 9L lymph node. 2. Findings: One lymph node negative for metastatic carcinoma. 3. Code: Level 9L lymph node maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left lower lobe. 2. Findings: Invasive, poorly differentiated, squamous cell carcinoma. 3. Code: Lung, left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left lower lobe. 2. Findings: Invasive, poorly differentiated, squamous cell carcinoma. 3. Code: Lung, left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left lower lobe. 2. Findings: Invasive, poorly differentiated, squamous cell carcinoma. 3. Code: Lung, left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left lower lobe. 2. Findings: Invasive, poorly differentiated, squamous cell carcinoma. 3. Code: Lung, left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left lower lobe. 2. Findings: Invasive, poorly differentiated, squamous cell carcinoma. 3. Code: Lung, left lower lobe maps to LCLC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LCLC\",\n    \"reasoning\": \"1. Site: Lung, left lower lobe. 2. Findings: Invasive, poorly differentiated, squamous cell carcinoma. 3.",
      "predicted": "LCLC",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung, left lower lobe. 2. Findings: Invasive, poorly differentiated, squamous cell carcinoma. 3. Code: Lung, left lower lobe maps to LCLC.",
      "idx": 877,
      "timestamp": "2026-01-19T15:59:53.113560"
    },
    {
      "sample_idx": 1195,
      "input": "Diagnosis: Total gastrectomy preparation with an ulcerated gastric carcinoma located on the side of the. greater curvature, extending to within a maximum of 7 cm of the oral resection margin and. with a maximum diameter of 16 cm encompassing the corpus segment of the stomach in an. almost circular growth, with a prominent exophytic component characterized histologically as. a moderately differentiated adenocarcinoma (gastric carcinoma of the intestinal type). Invasive tumor spread within all the...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Gastric Carcinoma). 2. Findings: Gastric carcinoma, moderately differentiated adenocarcinoma (gastric carcinoma of the intestinal type). Invasive tumor spread within all the parietal layers of the stomach extending into the adjacent. subserous fatty tissue and encroaching on the peritoneal side of the atrophic gastritis (type A). Antrum mucosa with discrete non-florid chronic gastritis and foveolar hyperplasia. No. evidence of Helicobacter pylori. Oral and aboral resection margin and also greater omentum and diaphragm in the section. levels presented are tumor-free. After acetone clarification 33 lymph nodes measuring up to 1.5 cm in the perigastric fatty. tissue are prepared. Of these, two show metastatic infiltrates of the previously diagnosed adenocarcinoma or. gastric carcinoma. In conclusion and in summary, taking into account the infiltration of the diaphragm and with. the correction of the data given in the first set of findings, the following stage is arrived at: pT4 pN1 (2/33). 3. Code: Gastric Carcinoma maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach (Gastric Carcinoma). 2. Findings: Gastric carcinoma, moderately differentiated adenocarcinoma (gastric carcinoma of the intestinal type). Invasive tumor spread within all the parietal layers of the stomach extending into the adjacent. subserous fatty tissue and encroaching on the peritoneal side of the atrophic gastritis (type A). Antrum mucosa with discrete non-florid chronic gastritis and foveolar hyperplasia. No. evidence of Helicobacter pylori. Oral and aboral resection margin and also greater omentum and diaphragm in the section. levels presented are tumor-free. After acetone clarification 33 lymph nodes measuring up to 1.5 cm in the perigastric fatty. tissue are prepared. Of these, two show metastatic infiltrates of the previously diagnosed adenocarcinoma or. gastric carcinoma. In conclusion and in summary, taking into account the infiltration of the diaphragm and with. the correction of the data given in the first set of findings, the following stage is arrived at: pT4 pN1 (2/33). 3. Code: Gastric Carcinoma maps to KIRC.\"\n}\n```\n",
      "predicted": "ADENOMA",
      "ground_truth": "STAD",
      "correct": false,
      "reasoning": "1. Site: Stomach (Gastric Carcinoma). 2. Findings: Gastric carcinoma, moderately differentiated adenocarcinoma (gastric carcinoma of the intestinal type). Invasive tumor spread within all the parietal layers of the stomach extending into the adjacent. subserous fatty tissue and encroaching on the peritoneal side of the atrophic gastritis (type A). Antrum mucosa with discrete non-florid chronic gastritis and foveolar hyperplasia. No. evidence of Helicobacter pylori. Oral and aboral resection margin and also greater omentum and diaphragm in the section. levels presented are tumor-free. After acetone clarification 33 lymph nodes measuring up to 1.5 cm in the perigastric fatty. tissue are prepared. Of these, two show metastatic infiltrates of the previously diagnosed adenocarcinoma or. gastric carcinoma. In conclusion and in summary, taking into account the infiltration of the diaphragm and with. the correction of the data given in the first set of findings, the following stage is arrived at: pT4 pN1 (2/33). 3. Code: Gastric Carcinoma maps to ADENOMA.",
      "idx": 1195,
      "timestamp": "2026-01-19T15:59:53.113591"
    },
    {
      "sample_idx": 817,
      "input": "De-Identified Specimen Code: M. SPECIMEN SUBMITTED: Part A: BRONCHIAL MARGIN RIGHT. UPPER LOBE. Part B: LEVEL 10. Part C: LEVEL 11. Final Diagnosis. 1. Right lung, upper lobe, lobectomy (A) Adenocarcinoma with acinar and bronchioloalveolar. components. - Two peribronchiolar lymph nodes, negative for carcinoma (0/2). - Mild centrilobular emphysema. 2. Lymph nodes, level 10, excision (B) Negative for neoplasm. 3. Lymph nodes, level 11, excision (C) - Negative for neoplasm. Diagnosis Comment: 1. Tu...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Upper Lobe. 2. Findings: Adenocarcinoma with acinar and bronchioloalveolar components. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma. 3. Code: Uterus Endometrial Carcinoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma. 3. Code: Uterus Endometrial Carcinoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung, Upper Lobe. 2. Findings: Adenocarcinoma with acinar and bronchioloalveolar components. 3. Code: Lung Adenocarcinoma maps to LUAD.",
      "idx": 817,
      "timestamp": "2026-01-19T15:59:53.113604"
    },
    {
      "sample_idx": 741,
      "input": "TISSUE DESCRIPTION: Liver segments IV through VIII (1,900 grams; 22 x 14 x 9 cm), liver segment III (15. grams; 4.5 X 3 X 2.7 cm), and biopsy specimen from the peritoneum (1 X 0.8 x 0.4. cm). A1, B1, B2, B3, B4, C1. DIAGNOSIS: Liver, segments IV through VIII, resection: Grade 2 (of 4) hepatocellular. carcinoma, usual type, forming a multinodular mass, 16 x 15 x 11 cm, with multiple. (5) satellite nodules ranging in size from 0.5 cm to 1.5 cm. The tumor is located in. segments IV through VIII. Th...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segments IV-VIII). 2. Findings: Hepatocellular carcinoma, usual type, grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segments IV-VIII). 2. Findings: Hepatocellular carcinoma, usual type, grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segments IV-VIII). 2. Findings: Hepatocellular carcinoma, usual type, grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segments IV-VIII). 2. Findings: Hepatocellular carcinoma, usual type, grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segments IV-VIII). 2. Findings: Hepatocellular carcinoma, usual type, grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segments IV-VIII). 2. Findings: Hepatocellular carcinoma, usual type, grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segments IV-VIII). 2. Findings: Hepatocellular carcinoma, usual type, grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"",
      "predicted": "KIRC",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Liver (Segments IV-VIII). 2. Findings: Hepatocellular carcinoma, usual type, grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 741,
      "timestamp": "2026-01-19T15:59:53.113615"
    },
    {
      "sample_idx": 1325,
      "input": "Specimens Submitted: 1: SP: Left pararectal implant (fs). 2: SP: Left tube and ovary and tumor from left ureter and sigmoid colon (fs). 3: SP: Uterus, cervix, bilateral parametrium; radical hysterectomy. 4: SP: Right tube and ovary with tumor from right ureter. 5: SP: Cul-de-sac tumor. 6: SP: Left obturator lymph node. 7: SP: Left external iliac lymph nodes. 8: SP: Right external iliac lymph nodes. 9: SP: Right obturator lymph nodes. 10: SP: Right hypogastric lymph nodes. 11: SP: Tumor from rect...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Left pararectal implant. 2. Findings: Benign fibroadipose tissue. 3. Site: Left Fallopian tube and ovary and tumor from left ureter and sigmoid colon. 4. Findings: Metastatic serous carcinoma involving left fallopian tube and ovary. - Tumor also involves periadnexal soft tissue. - No ureter or colon is identified. 5. Site: Uterus, cervix, bilateral parametrium; radical hysterectomy. 6. Findings: Tumor Type: Adenocarcinoma, serous (papillary serous) type. Myometrial Invasion: (>50%). Measures10mm in maximum depth. Myometrial thickness measures17m in the area of maximal tumor. invasion. Endocervical Invasion: Mucosa and stroma. Parametrial tissue is also involved by tumor. Depth of cervical stromal invasion: Measures 15.5mm. Cervical wall thickness measures 16mm in the area of maximum tumor. invasion. Lymphovascular invasion: Identified. Endometrium: Exhibits atrophy. Myometrium: Unremarkable. Vaginal cuff margin is benign. 7. Site: Right Fallopian tube and ovary and tumor from right ureter. 8. Findings: Metastatic serous carcinoma involving right fallopian tube and ovary. 9. Site: Cul-de-sac tumor. 10. Findings: Metastatic serous carcinoma. 11. Site: Left obturator lymph node. 12. Findings: Six benign lymph nodes (0/6). 13. Site: Left external iliac lymph nodes. 14. Findings: Metastatic carcinoma in one of six lymph nodes (1/6). 15. Site: Right external iliac lymph nodes. 16. Findings: Metastatic carcinoma in one of six lymph nodes (1/6). 17. Site: Right obturator lymph nodes. 18. Findings: Eight benign lymph nodes (0/8). 19. Site: Right hypogastric lymph nodes. 20. Findings: Metastatic carcinoma in one lymph node (1/1). 21. Site: Tumor from rectum. 22. Findings: Benign fibroadipose tissue. - One benign lymph node (0/1). 23. Site: Oment",
      "predicted": null,
      "ground_truth": "UCEC",
      "correct": null,
      "reasoning": "",
      "idx": 1325,
      "timestamp": "2026-01-19T15:59:53.113725"
    },
    {
      "sample_idx": 283,
      "input": "Diagnosis: Colon, right, colectomy. Tumor Histologic Type: Invasive adenocarcinoma with mucinous features. Histologic Grade: Moderately differentiated. Tumor Location: Cecum with extension into ileocecal valve. Depth of Invasion: Through muscularis propria into the pericolic soft tissue. Lymphovascular Invasion: Not identified. Perineural Invasion: Not identified. Margins: Proximal margin: Negative, 4 cm from tumor. Distal margin: Negative, 8 cm from tumor. Circumferential (radial) margin (recta...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right). 2. Findings: Invasive adenocarcinoma with mucinous features, Moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right). 2. Findings: Invasive adenocarcinoma with mucinous features, Moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right). 2. Findings: Invasive adenocarcinoma with mucinous features, Moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right). 2. Findings: Invasive adenocarcinoma with mucinous features, Moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right). 2. Findings: Invasive adenocarcinoma with mucinous features, Moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right). 2. Findings: Invasive adenocarcinoma with mucinous features, Moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right). 2. Findings: Invasive adenocarcinoma with mucinous features, Moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right). 2. Findings: Invasive adenocarcinoma with mucinous features, Moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right). 2. Findings: Invasive adenocarcinoma with mucinous",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Colon (Right). 2. Findings: Invasive adenocarcinoma with mucinous features, Moderately differentiated. 3. Code: KIRC.",
      "idx": 283,
      "timestamp": "2026-01-19T15:59:53.113738"
    },
    {
      "sample_idx": 1043,
      "input": "PATIENT HISTORY. The patient is a. with a serum PSA value of 14.9 ng/mL. The patient had a biopsy on. his biopsy revealed small foci of prostatic adenocarcinoma. Gleason score 3+S = 6 involving the left lobe. and right prostate lobes (5 1% of the cores). He also had prior biopsies. showed focal. high-grade prostatic intraepithelial neoplasia. PRE-OP DIAGNOSIS: Prostate cancer. POST-OP DIAGNOSIS: Same. PROCEDURE: Radical prostatectomy and bilateral pelvic lymphadenectomy. FINAL DIAGNOSIS: PART1: ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 4+3=7, with a prominent tertiary Gleason pattern 5 component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 4+3=7, with a prominent tertiary Gleason pattern 5 component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 4+3=7, with a prominent tertiary Gleason pattern 5 component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 4+3=7, with a prominent tertiary Gleason pattern 5 component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 4+3=7, with a prominent tertiary Gleason pattern 5 component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 4+3=7, with a prominent tertiary Gleason pattern 5 component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 4+3=7, with a prominent tertiary Gleason pattern 5 component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. ",
      "predicted": "KIRC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 4+3=7, with a prominent tertiary Gleason pattern 5 component. 3. Code: KIRC.",
      "idx": 1043,
      "timestamp": "2026-01-19T15:59:53.113749"
    },
    {
      "sample_idx": 1010,
      "input": "Gross: Thinly fibrously encapsulated ovoid tumor of soft consistency 55x45x35 mm, weight 50 g. On cut, the tumor is grey-red, with focal hemorrhages. Micro: Solidly alveolarly shaped right pheochromocytoma with focal hemorrhages and with rim of. adrenocortical tissue on periphery was confirmed in excisions. The tumor does not invade. adrenal capsule in to surrounding adipose tissue. It shows nuclear hyperchromasia. sporadically, no regular or atypical mitoses were found. No necroses were found. ...",
      "response": "```json\n{\n    \"cancer_type\": \"ADREN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, solid, alveolarly shaped. No invasion of adrenal capsule. 3. Code: Adrenal Pheochromocytoma maps to ADREN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADREN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, solid, alveolarly shaped. No invasion of adrenal capsule. 3. Code: Adrenal Pheochromocytoma maps to ADREN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADREN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, solid, alveolarly shaped. No invasion of adrenal capsule. 3. Code: Adrenal Pheochromocytoma maps to ADREN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADREN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, solid, alveolarly shaped. No invasion of adrenal capsule. 3. Code: Adrenal Pheochromocytoma maps to ADREN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADREN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, solid, alveolarly shaped. No invasion of adrenal capsule. 3. Code: Adrenal Pheochromocytoma maps to ADREN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADREN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, solid, alveolarly shaped. No invasion of adrenal capsule. 3. Code: Adrenal Pheochromocytoma maps to ADREN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADREN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, solid, alveolarly shaped. No invasion of adrenal capsule. 3. Code: Adrenal Pheochromocytoma maps to ADREN",
      "predicted": "ADREN",
      "ground_truth": "PCPG",
      "correct": false,
      "reasoning": "1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, solid, alveolarly shaped. No invasion of adrenal capsule. 3. Code: Adrenal Pheochromocytoma maps to ADREN.",
      "idx": 1010,
      "timestamp": "2026-01-19T15:59:53.113760"
    },
    {
      "sample_idx": 186,
      "input": "F. Pathologic Interpretation: A. LEFT BREAST LUMPECTOMY 1 STITCH SUPERIOR, 2 STITCHES LATERAL, SKIN IS ANTERIOR: - Invasive poorly differentiated ductal carcinoma, 2.2 cm in greatest linear dimension, Nottingham Grade 3 (3+3+3). Tumor is less than 0.1 cm from the posterior and lateral margins. - Lymphovascular invasion is present. - Tumor cells are negative for ER, PR, HER-2 by immunohistochemistry. B. SENTINEL LYMPH NODE #1 COUNT 171: - Metastatic carcinoma in one lymph node with extranodal ext...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.",
      "idx": 186,
      "timestamp": "2026-01-19T15:59:53.113770"
    },
    {
      "sample_idx": 96,
      "input": "Specimen: (. spec Type: SURGICAL P. RIGHT BREAST CANCER INVASIVE. DATE: 1. DOCTOR (s) : BITATERAL SIMPLE MASTECTOMY - SENTINEL NODE BX. A. LT BREAST MASTECTOMY. B. RT BREAST SENTINEL NODE #1. C. RT BREAST SENTINEL NODE #2. D. RT BREAST MASTECTOMY. RECEIVED IN FOUR PARTS. PART A: RECEIVED FRESH LABELED LEFT BREAST MASTECTOMY, STITCH AT 1200 IS A. SIMPLE MASTECTOMY SPECIMEN MEASURING 15 X 14.5 x 4 CM IN GREASTEST. DIMENSIONS. THE NIPPLE IS UNREMARKABLE WITHIN A 6.3 x 3.6 CM SKIN. ELLIPSE. THE SUPE...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade III/III, with a high mitotic index and a microscopic distance of 2.6 cm. There are also minor foci of micropapillary-type ductal carcinoma in situ. The tumor is located in the upper inner quadrant of the breast. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade III/III, with a high mitotic index and a microscopic distance of 2.6 cm. There are also minor foci of micropapillary-type ductal carcinoma in situ. The tumor is located in the upper inner quadrant of the breast. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade III/III, with a high mitotic index and a microscopic distance of 2.6 cm. There are also minor foci of micropapillary-type ductal carcinoma in situ. The tumor is located in the upper inner quadrant of the breast. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade III/III, with a high mitotic index and a microscopic distance of 2.6 cm. There are also minor foci of micropapillary-type ductal carcinoma in situ. The tumor is located in the upper inner quadrant of the breast. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade III/III, with a high mitotic index and a microscopic distance of 2.6 cm. There are also minor foci of micropapillary-type ductal carcinoma in situ. The tumor is located in the upper inner quadrant of the breast. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade III/III, with a high mitotic index and a microscopic distance of 2.6 cm. There are also minor foci of micropapillary-type ductal carcinoma in situ. The tumor is located in the upper inner quadrant of the breast. 3. Code: BRCA",
      "idx": 96,
      "timestamp": "2026-01-19T15:59:53.113787"
    },
    {
      "sample_idx": 224,
      "input": "MEDICAL CENTER. LABORATORY. PAGE:1. Specimen Inquiry. LOC: SPEC # : CLINICAL HISTORY : CERVIX CA. SPECIMEN/PROCEDURE : 1. UTERUS - AND CERVIX, PARAMETRIA AND VAGINA. 2. PARAMETRIUM - RIGHT. 3. PARAMETRIUM - LEFT. 4. LYMPH NODE, PELVIC - LEFT. 5. LYMPH NODE, PELVIC - RIGHT. 5. LYMPH NODE, PARAAORTIC - RIGHT. 7. LYMPH NODE, PARAAORTIC - LEFT. IMPRESSION: 1) UTERUS AND CERVIX, BILATERAL PARAMETRIA AND VAGINAL CUFF, RADICAL HYSTERECTOMY: CERVIX: Invasive adenosarainoma of cervix, usual type, moderat...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive adenosarainoma of cervix, usual type, moderately differentiated. Tumor thickness is 6 mm where the maximal cervical wall thickness is 15 mm. Surgical margins of resection are negative for tumor; tumor is 9 mm away. from the deep soft tissue margin. No evidence of lymphovasoular space invasion. Please see tumor checklist. ENDOMETRIUM: Disordered proliferative endometrium. Negative for malignancy. MYOMETRIUM: Foci of hyalinization. Negative for malignancy. PARAMETRIUM: Benign fibroadipose tissue. Two benign lymph nodes (0/2). VAGINAL CUFF: Negative for malignancy. 2). PARAMETRIUM, RIGHT, RESECTION: Benign fibroadipose tissue. PARAMETRIUM, LEFT, RESECTION: Benign fibroadipose tissue. 4). LYMPH NODES, PELVIC, LEFT, REGIONAL DISSECTION: Six benign lymph nodes (0/6) . LYMPH NODES, PELVIC, RIGHT, REGIONAL DISSECTION : Nine benign lymph nodes (0/9) -. LYMPH NODES, PARA-AORTIC, RIGHT, REGIONAL DISSECTION: SPEC #: (Continued) Page: 2. IMPRESSION (continued). Two benign lymph nodes (0/2) . LYMPH NODE, PARA-AORTIC, LEFT, BIOPSY: One benign lymph node (0/1). UTERINE. CERVIX: TRACHELECTOMY, HYSTERECTOMY PELVIC EXENTERATION CASE SUMMARY. SPECIMEN. Cervix. Uterus corpus. Other (specify) : Vaginal cuff, parametria. PROCEDURE. Radical hysterectomy. TUMOR SIZE. Greatest dimension: 1.3 x 0.6 x 0.5 am. TUMOR SITE. Left inferior quadrant (3-6 o'clock). Right inferior quadrant (6-9 o'clock). HISTOLOGIC TYPE. Adenocarsinoma. Mucinous. Endoservical type. HISTOLOGIC GRADE. G2: Moderately differentiated. MARGINS. Resection Margin. Margins uninvolved by invasive carcinoma. Distance of invasive carcinoma from margin: 9. mm. Specify location, if possible: Deep posterior cervical margin of resection. LYMPH-VASCULAR IN",
      "predicted": null,
      "ground_truth": "CESC",
      "correct": null,
      "reasoning": "",
      "idx": 224,
      "timestamp": "2026-01-19T15:59:53.113893"
    },
    {
      "sample_idx": 313,
      "input": "SPECIMEN. A. Liver lesion. B. Paraaortic lymph node. C. Rectosigmoid colon. CLINICAL NOTES. CLINICAL HISTORY: Sigmoid colon cancer. FROZEN SECTION DIAGNOSIS. A. , left lobe, excision: Metastatic adenocarcinoma. 0. GROSS DESCRIPTION. A. The specimen is received fresh for frozen section. labeled \"A. Left liver lesion\" and consists of a tan 0.8 X. 0.3 X 0. rubbery tissue, entirely frozen as frozen. section. in formalin labeled \"paraaortic lymph node\" is. a 1.2 X 0.8 X 0.3 cm. rubbery tan pink tissu...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately to poorly differentiated, invasive through muscularis propria into subserosa (pT3). Metastatic adenocarcinoma present in 1 of 37 lymph nodes. (pN1a). Lymphatic space invasion present. Resection margins are negative for tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Metastatic adenocarcinoma of colonic type consistent with origin from rectosigmoid tumor. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Para-aortic lymph node. 2. Findings: Single lymph node negative for metastatic tumor (0/1). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon, rectosigmoid. 2. Findings: Adenocarcinoma, moderately to poorly differentiated, invasive through muscularis propria into subserosa (pT3). Metastatic adenocarcinoma present in 1 of 37 lymph nodes. (pN1a). Lymphatic space invasion present. Resection margins are negative for tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Metastatic adenocarcinoma of colonic type consistent with origin from rectosigmoid tumor. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately to poorly differentiated, invasive through muscularis propria into subserosa (pT3). Metastatic adenocarcinoma present in 1 of 37 lymph nodes. (pN1a). Lymphatic space invasion present. Resection margins are negative for tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately to poorly differentiated, invasive through muscularis propria into subserosa (pT3). Metastatic adenocarcinoma present in 1 of 37 lymph nodes. (pN1a). Lymphatic space invasion present. Resection margins are negative for tumor. 3. Code: KIRC.",
      "idx": 313,
      "timestamp": "2026-01-19T15:59:53.113909"
    },
    {
      "sample_idx": 1285,
      "input": "LABORATORY MEDICINE PROGRAM. Receit. Specimen(s) Received. 1. Parathyroid: Query Rt Inferior Parathyroid. 2. Thyroid: Total thyroid gland-long stitch marks Lt. superior pole, short stitch marks Rt. superior pole. 3. Lymph node: Rt. Paratracheal nodes. 4. Lymph node: Lt. paratracheal nodes and upper mediastinal. Diagnosis. 1. No pathological diagnosis: Lymph node (listed as 'query right inferior parathyroid') excisional biopsy. 2. Widely-invasive papillary carcinoma with unusual features, 3.1 cm,...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1285,
      "timestamp": "2026-01-19T15:59:53.113919"
    },
    {
      "sample_idx": 327,
      "input": "Diagnosis: Right hemicolectomy preparation with tumor-free oral and aboral resection margins and. including an ulcerated, poorly differentiated adenocarcinoma of the ascending colon, with. infiltration of the perimuscular fatty tissue and numerous regional lymph node metastases. (G3, pT3, L1, V1 local R0 pN2 24/29).",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending). 2. Findings: Adenocarcinoma, poorly differentiated, ulcerated, with lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending). 2. Findings: Adenocarcinoma, poorly differentiated, ulcerated, with lymph node metastases. 3. Code: Colon Adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending). 2. Findings: Adenocarcinoma, poorly differentiated, ulcerated, with lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending). 2. Findings: Adenocarcinoma, poorly differentiated, ulcerated, with lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending). 2. Findings: Adenocarcinoma, poorly differentiated, ulcerated, with lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending). 2. Findings: Adenocarcinoma, poorly differentiated, ulcerated, with lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending). 2. Findings: Adenocarcinoma, poorly differentiated, ulcerated, with lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending). 2. Findings:",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon (Ascending). 2. Findings: Adenocarcinoma, poorly differentiated, ulcerated, with lymph node metastases. 3. Code: Colon Adenocarcinoma maps to COAD.",
      "idx": 327,
      "timestamp": "2026-01-19T15:59:53.113929"
    },
    {
      "sample_idx": 1402,
      "input": "SURGICAL PATHOLOGY REVISED REPORT. Diagnosis: A: Uterus and cervix, bilateral ovaries and fallopian tubes,. hysterectomy and bilateral salpingo-oophorectomy. Location of tumor: anterior and posterior endometrium extending. into anterior and posterior lower uterine segment and invasive. carcinoma also involves the posterior upper endocervix (A18). Tumor size: 6.5 X 6.4 X 4.5 cm per gross measurement of. carcinoma within the endometrium and a large amount of disrupted. tumor is also received separ...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "UCS",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1402,
      "timestamp": "2026-01-19T15:59:53.113938"
    },
    {
      "sample_idx": 1221,
      "input": "Pathohistological diagnosis. Seminoma testis (pT2 NXMX), right testicle. Description: A testicle with tumor, size 7:5.5:4.5 cm with 9 cm long funiculus and 2.5-3 cm diameter was. received. Inside the testicle we find white, nodular tumor tissue with hemorrhaging and. necrotic areas encompassing an area of 6.2:5:4.5 cm. Histologically, the tumor is made of. solid tumor cell clusters with round and oval bright nuclei with pronounced smaller nuclei. with medium abundant bright cytoplasm. Around tum...",
      "response": "```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma testis, pT2 NXMX. 3. Code: Seminoma testis maps to TGCT.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma testis, pT2 NXMX. 3. Code: Seminoma testis maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma testis, pT2 NXMX. 3. Code: Seminoma testis maps to TGCT.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma testis, pT2 NXMX. 3. Code: Seminoma testis maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma testis, pT2 NXMX. 3. Code: Seminoma testis maps to TGCT.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma testis, pT2 NXMX. 3. Code: Seminoma testis maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma testis, pT2 NXMX. 3. Code: Seminoma testis maps to TGCT.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma testis, pT2 NXMX. 3. Code: Seminoma testis maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n",
      "predicted": "TGCT",
      "ground_truth": "TGCT",
      "correct": true,
      "reasoning": "1. Site: Testis. 2. Findings: Seminoma testis, pT2 NXMX. 3. Code: Seminoma testis maps to TGCT.",
      "idx": 1221,
      "timestamp": "2026-01-19T15:59:53.113949"
    },
    {
      "sample_idx": 130,
      "input": "FINAL DIAGNOSIS: PART 1: SENTINEL LYMPH NODE NUMBER 1, LEFT, BIOPSY -. A. ONE OF THREE LYMPH NODES, POSITIVE FOR METASTATIC LOBULAR CARCINOMA (1/3). B. METASTATIC TUMOR MEASURES 1.4 CM IN LARGEST DIMENSION. C. NO DEFINITE EXTRACAPSULAR EXTENSION IDENTIFIED. PART 2: BREAST, LEFT, MODIFIED RADICAL MASTECTOMY -. A. MULTIFOCAL ND MULTICENTRIC INVASIVE LOBULAR CARCINOMA, NOTTINGHAM GRADE 2 (TUBULAR. FORMATION 3, NUCLEAR POLYMORPHISM 2, MITOTIC FIGURES 1, TOTAL SCORE 6/9). B. INVASIVE TUMOR MASS RANGI...",
      "response": "```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Breast (Left, Modified Radical Mastectomy). 2. Findings: Invasive lobular carcinoma, Nottingham Grade 2, multifocal, multicentric. 3. Code: Breast Invasive Carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast (Left, Modified Radical Mastectomy). 2. Findings: Lobular carcinoma in situ, nuclear grade 2, constituting 25% of total tumor mass. 3. Code: Breast Invasive Carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast (Left, Modified Radical Mastectomy). 2. Findings: Lobular carcinoma in situ, nuclear grade 2, constituting 25% of total tumor mass. 3. Code: Breast Invasive Carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast (Left, Modified Radical Mastectomy). 2. Findings: Lobular carcinoma in situ, nuclear grade 2, constituting 25% of total tumor mass. 3. Code: Breast Invasive Carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast (Left, Modified Radical Mastectomy). 2. Findings: Lobular carcinoma in situ, nuclear grade 2, constituting 25% of total tumor mass. 3. Code: Breast Invasive Carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast (Left, Modified Radical Mastectomy). 2. Findings: Lobular carcinoma in situ, nuclear grade 2, constituting 25% of total tumor mass. 3. Code: Breast Invasive Carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast (Left, Modified",
      "predicted": "LIHC",
      "ground_truth": "BRCA",
      "correct": false,
      "reasoning": "1. Site: Breast (Left, Modified Radical Mastectomy). 2. Findings: Invasive lobular carcinoma, Nottingham Grade 2, multifocal, multicentric. 3. Code: Breast Invasive Carcinoma maps to LIHC.",
      "idx": 130,
      "timestamp": "2026-01-19T15:59:53.113961"
    },
    {
      "sample_idx": 788,
      "input": "'INAL DIAGNOSIS. RIGHT MIDDLE LOBE (LOBECTOMY) : :PECIMEN TYPE: obectomy. 'UMOR SITE: light, middle lobe. IISTOLOGIC TYPE: idenocarcinoma, Nos. 'UMOR SIZE: ;reatest dimension 2.0 cm.",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Right middle lobe of the lung. 2. Findings: Invasive ductal carcinoma, NOS (Not Otherwise Specified). 3. Code: LUAD (Lung Adenocarcinoma) maps to LUAD. Note: The report mentions a lobectomy, suggesting the specimen is from a lung lobe, and the tumor is invasive ductal carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Right middle lobe of the lung. 2. Findings: Invasive ductal carcinoma, NOS (Not Otherwise Specified). 3. Code: LUAD (Lung Adenocarcinoma) maps to LUAD. Note: The report mentions a lobectomy, suggesting the specimen is from a lung lobe, and the tumor is invasive ductal carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Right middle lobe of the lung. 2. Findings: Invasive ductal carcinoma, NOS (Not Otherwise Specified). 3. Code: LUAD (Lung Adenocarcinoma) maps to LUAD. Note: The report mentions a lobectomy, suggesting the specimen is from a lung lobe, and the tumor is invasive ductal carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Right middle lobe of the lung. 2. Findings: Invasive ductal carcinoma, NOS (Not Otherwise Specified). 3. Code: LUAD (Lung Adenocarcinoma) maps to LUAD. Note: The report mentions a lobectomy, suggesting the specimen is from a lung lobe, and the tumor is invasive ductal carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Right middle lobe of the lung. 2. Findings: Invasive ductal carcinoma, NOS (Not Otherwise Specified). 3. Code: LUAD (Lung Adenocarcinoma) maps to LUAD. Note: The report mentions a lobectomy, suggesting the specimen is from a lung lobe, and the tumor is invasive ductal carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Right middle lobe of the lung. 2. Findings: Invasive ductal carcinoma, NOS (Not Otherwise Specified). 3. Code: LUAD (Lung Adenocarcinoma) maps to LUAD. Note: The report mentions a lobectomy, suggesting the specimen is from a lung lobe, and the tumor is invasive ductal carcinoma.",
      "idx": 788,
      "timestamp": "2026-01-19T15:59:53.113977"
    },
    {
      "sample_idx": 781,
      "input": "Date of Service. Performing Facilit. Result Provider. Report Name. DXSTIC. SEE REPORT. PROCEDURE DATE: SPECIMEN DESCRIPTION: INFERIOR PULMONARY LIGAMENT LYMPH NODE. B. SUBCARINAL LYMPH NODE. HILAR LYMPH NODES. D. PULMONARY ARTERY LYMPH NODE, N1. E. PROXIMAL BRONCHIAL LYMPH NODE. F. LEFT LOWER LOBE OF LUNG, FPC. G. AP WINDOW LYMPH NODE. PRE-OPERATIVE DIAGNOSIS: Lung cancer. POST-OPERATIVE DIAGNOSIS: Same, pending pathology. CLINICAL INFORMATION. Left lower lobe mass, cavitary. ==== INTRAOPERATIVE...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, moderately differentiated, pT2, with positive lymphovascular invasion and two out of nine peribronchial lymph nodes positive for metastatic carcinoma. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, moderately differentiated, pT2, with positive lymphovascular invasion and two out of nine peribronchial lymph nodes positive for metastatic carcinoma. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, moderately differentiated, pT2, with positive lymphovascular invasion and two out of nine peribronchial lymph nodes positive for metastatic carcinoma. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, moderately differentiated, pT2, with positive lymphovascular invasion and two out of nine peribronchial lymph nodes positive for metastatic carcinoma. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, moderately differentiated, pT2, with positive lymphovascular invasion and two out of nine peribronchial lymph nodes positive for metastatic carcinoma. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, moderately differentiated, pT2, with positive lymphovascular invasion and two out of nine peribronchial lymph nodes positive for metastatic carcinoma. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, moderately differentiated, pT2, with",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung. 2. Findings: Adenocarcinoma, moderately differentiated, pT2, with positive lymphovascular invasion and two out of nine peribronchial lymph nodes positive for metastatic carcinoma. 3. Code: LUAD.",
      "idx": 781,
      "timestamp": "2026-01-19T15:59:53.113990"
    },
    {
      "sample_idx": 1220,
      "input": "Pathological diagnosis: Testicular Seminoma. Description: A testicle with tumor, size 8.5:7.5 cm, with 9 cm long funiculus was received. We see on the cut that the whole testicle is imbued with tumor and on the capsule we see 6.5. cm long surgical cut with sutures. On the cut, the tumor is white, soft and partially necrotic. Histologically, the tumor is made of solid seats and tumor cell traces with round and oval. bright nuclei with pronounced smaller nuclei with medium abundant bright and pink...",
      "response": "```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testicle. 2. Findings: Seminoma, solid, with necrosis. 3. Code: Testicular Seminoma maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Testicle. 2. Findings: Seminoma, solid, with necrosis. 3. Code: Testicular Seminoma maps to TGCT.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testicle. 2. Findings: Seminoma, solid, with necrosis. 3. Code: Testicular Seminoma maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testicle. 2. Findings: Seminoma, solid, with necrosis. 3. Code: Testicular Seminoma maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testicle. 2. Findings: Seminoma, solid, with necrosis. 3. Code: Testicular Seminoma maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testicle. 2. Findings: Seminoma, solid, with necrosis. 3. Code: Testicular Seminoma maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testicle. 2. Findings: Seminoma, solid, with necrosis. 3. Code: Testicular Seminoma maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testicle. 2. Findings: Seminoma, solid, with necrosis. 3. Code: Testicular Seminoma maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1.",
      "predicted": "SKCM",
      "ground_truth": "TGCT",
      "correct": false,
      "reasoning": "1. Site: Testicle. 2. Findings: Seminoma, solid, with necrosis. 3. Code: Testicular Seminoma maps to SKCM.",
      "idx": 1220,
      "timestamp": "2026-01-19T15:59:53.114000"
    },
    {
      "sample_idx": 958,
      "input": "Physician (s) : Other Related Clinical Data: DIAGNOSIS: A. OMENTUM, OMENTECTOMY. - METASTATIC POORLY DIFFERENTIATED ADENOCARCINOMA, LARGEST FOCUS 8 CM. B. SMALL INTESTINE, RESECTION. - METASTATIC POORLY DIFFERENTIATED ADENOCARCINOMA, INVOLVING SEROSA. &. MUSCULARIS PROPRIA. - LYMPHOVASCULAR INVASION IDENTIFIED. - RESECTION MARGINS FREE-OF TUMOR. - ACUTE SEROSITIS. C. OVARIES, RIGHT & LEFT, BILATERAL SALPINGO-OOPHORECTOMY. - POORLY DIFFERENTIATED ADENOCARCINOMA, WITH MIXED SEROUS PAPILLARY &. POO...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Omentum. 2. Findings: Poorly differentiated adenocarcinoma, metastatic, largest focus 8 cm. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Small bowel. 2. Findings: Poorly differentiated adenocarcinoma, metastatic, involving serosa. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovaries, Right & Left. 2. Findings: Poorly differentiated adenocarcinoma, with mixed serous papillary and poorly differentiated endometroid features, synchronous primaries (see synoptic). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix. 2. Findings: No evidence of malignancy. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Omentum. 2. Findings: Carcinoma, favor Mullerian origin. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Small bowel. 2. Findings: Poorly differentiated adenocarcinoma, metastatic, involving serosa. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Ovaries, Right & Left. 2. Findings: Poorly differentiated adenocarcinoma, with mixed serous papillary and poorly differentiated endometroid features, synchronous primaries (see synoptic). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix. 2. Findings: No evidence of malignancy. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reason",
      "predicted": "BRCA",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Omentum. 2. Findings: Poorly differentiated adenocarcinoma, metastatic, largest focus 8 cm. 3. Code: BRCA.",
      "idx": 958,
      "timestamp": "2026-01-19T15:59:53.114010"
    },
    {
      "sample_idx": 1083,
      "input": "PROCEDURE DATE: REPORT DATE: Pre-Op Diagnosis. Prostate cancer. Post-Op Diagnosis. Same. Clinical History. Nothing indicated on requisition. Gross Description: Container labeled. - prostate and pelvic lymph node. biopsy\" is a previously inked previously partially sectioned. moderately distorted prostate gland with attached bilateral seminal. vesicles weighing as received 37 grams. The prostate gland on. reconstruction measures approximately 4.8 x 3.7 x 3.7 cm and has a. slightly lobulated focall...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, involving right and left lobes. Tumor measures up to 2 cm. Gleason grade: 7/10. Lymph node status: 0/1 (no lymph node metastasis). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, involving right and left lobes. Tumor measures up to 2 cm. Gleason grade: 7/10. Lymph node status: 0/1 (no lymph node metastasis). 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, involving right and left lobes. Tumor measures up to 2 cm. Gleason grade: 7/10. Lymph node status: 0/1 (no lymph node metastasis). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, involving right and left lobes. Tumor measures up to 2 cm. Gleason grade: 7/10. Lymph node status: 0/1 (no lymph node metastasis). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, involving right and left lobes. Tumor measures up to 2 cm. Gleason grade: 7/10. Lymph node status: 0/1 (no lymph node metastasis). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, involving right and left lobes. Tumor measures up to 2 cm. Gleason grade: 7/10. Lymph node status: 0/1 (no lymph node metastasis). 3. Code: KIRC.\"\n",
      "predicted": "KIRC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, involving right and left lobes. Tumor measures up to 2 cm. Gleason grade: 7/10. Lymph node status: 0/1 (no lymph node metastasis). 3. Code: KIRC.",
      "idx": 1083,
      "timestamp": "2026-01-19T15:59:53.114022"
    },
    {
      "sample_idx": 514,
      "input": "DIAGNOSIS. (A) LEFT KIDNEY: CHROMOPHOBE RENAL CELL CARCINOMA, FUHRMAN'S NUCLEAR GRADE 3. (SEE. COMMENT). TUMOR MEASURES 5.0 CM IN MAXIMUM DIMENSION. FOCAL LYMPHATIC/VASCULAR INVASION IDENTIFIED. Multilocular cyst. (4.0 cm). Margins of resection free of tumor. COMMENT. Immunoperoxidase studies demonstrate the tumor cells to be positive for. CK7 and negative for CD10 and Vimentin, supporting the diagnosis of. Chromophobe renal cell carcinoma. The tumor has a pushing border but. does not invade the...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe Renal Cell Carcinoma, Fuhrman's Nuclear Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe Renal Cell Carcinoma, Fuhrman's Nuclear Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe Renal Cell Carcinoma, Fuhrman's Nuclear Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe Renal Cell Carcinoma, Fuhrman's Nuclear Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe Renal Cell Carcinoma, Fuhrman's Nuclear Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe Renal Cell Carcinoma, Fuhrman's Nuclear Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe Renal Cell Carcinoma, Fuhrman's Nuclear Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```",
      "predicted": "KIRC",
      "ground_truth": "KICH",
      "correct": false,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Chromophobe Renal Cell Carcinoma, Fuhrman's Nuclear Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 514,
      "timestamp": "2026-01-19T15:59:53.114032"
    },
    {
      "sample_idx": 1133,
      "input": "Patient Info. FINAL DIAGNOSIS. A. Left thigh garcoma, excision: - Undifferentiated pleomorphic sarcoma with myogenic differentiation. (FNCLCC, Grade 3/3) . - See comment. COMMENT. SOFT TISSUE TUMOR. Specimen type: Wide excision. Site: Left thigh. Depth. deep. Specify depth (all that apply) : Intramuscular. Size. Greatest dimension: 11 cm. Additional two dimensions: 6.0 x 5.0 cm. Histologic type: Undifferentiated pleomorphic sarcoma with myogenic. differentiation. Mitotic rate (per 5 HPFs) : 44. ...",
      "response": "```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left thigh. 2. Findings: Undifferentiated pleomorphic sarcoma with myogenic differentiation, grade 3/3. 3. Code: SARC maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left thigh. 2. Findings: Undifferentiated pleomorphic sarcoma with myogenic differentiation, grade 3/3. 3. Code: SARC maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left thigh. 2. Findings: Undifferentiated pleomorphic sarcoma with myogenic differentiation, grade 3/3. 3. Code: SARC maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left thigh. 2. Findings: Undifferentiated pleomorphic sarcoma with myogenic differentiation, grade 3/3. 3. Code: SARC maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left thigh. 2. Findings: Undifferentiated pleomorphic sarcoma with myogenic differentiation, grade 3/3. 3. Code: SARC maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left thigh. 2. Findings: Undifferentiated pleomorphic sarcoma with myogenic differentiation, grade 3/3. 3. Code: SARC maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left thigh. 2. Findings: Undifferentiated pleomorphic sarcoma with myogenic differentiation, grade 3/3. 3. Code: SARC maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left thigh. 2. Findings: Undifferentiated pleomorphic sarcoma with myogenic differentiation, grade 3/3. ",
      "predicted": "SARC",
      "ground_truth": "SARC",
      "correct": true,
      "reasoning": "1. Site: Left thigh. 2. Findings: Undifferentiated pleomorphic sarcoma with myogenic differentiation, grade 3/3. 3. Code: SARC maps to SARC.",
      "idx": 1133,
      "timestamp": "2026-01-19T15:59:53.114042"
    },
    {
      "sample_idx": 23,
      "input": "RADICAL CYSTOPROSTATECTOMY WITH ILEOCONDUIT AND BILATERAL PELVIC LYMPH NODE. DISSECTION: RIGHT DISTAL URETER (A) : FROZEN SECTION DIAGNOSIS: - NO HIGH GRADE ATYPIA OR TUMOR IDENTIFIED. FINAL DIAGNOSIS: BENIGN URETER. NO UROTHELIAL DYSPLASIA OR MALIGNANCY IDENTIFIED. LEFT DISTAL URETER (B) : FROZEN SECTION DIAGNOSIS: NO HIGH GRADE ATYPIA OR TUMOR IDENTIFIED. FINAL DIAGNOSIS: BENIGN URETER. NO UROTHELIAL DYSPLASIA OR MALIGNANCY IDENTIFIED. BLADDER/PROSTATE (C) : BLADDER: INVASIVE UROTHELIAL CARCIN...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, grade 3 & 4/4, involving full thickness of bladder wall with extension into perivesical soft tissue. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, grade 3 & 4/4, involving full thickness of bladder wall with extension into perivesical soft tissue. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, grade 3 & 4/4, involving full thickness of bladder wall with extension into perivesical soft tissue. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, grade ",
      "predicted": "KIRC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, grade 3 & 4/4, involving full thickness of bladder wall with extension into perivesical soft tissue. 3. Code: KIRC.",
      "idx": 23,
      "timestamp": "2026-01-19T15:59:53.114054"
    },
    {
      "sample_idx": 234,
      "input": "N.me : Hosp. No. : de. N. SurJ-OR: M.D. UTERUS. CERVIX. BIOPSY - SQUAMOUS CELL CARCINOMA. By this signature. I &ttest that the. above diagnosis is based upon mV. personal examination ot the slides. 1 and/or other material indicated in. the diagnosis). and that I have. reviewed and approved this report. M.D. M.D. SPECIMENTS SUBMITTED. CERVIX. HISTORY. patient is a year old woman with cervical carcinoma. eserative procedure: Cervical biopsy. GROSS. The specimen is received in a container of formal...",
      "response": "```json\n{\n    \"cancer_type\": \"HSBC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma. 3. Code: HSBC maps to the most appropriate cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HSBC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma. 3. Code: HSBC maps to the most appropriate cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HSBC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma. 3. Code: HSBC maps to the most appropriate cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HSBC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma. 3. Code: HSBC maps to the most appropriate cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HSBC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma. 3. Code: HSBC maps to the most appropriate cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HSBC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma. 3. Code: HSBC maps to the most appropriate cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HSBC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma. 3. Code: HSBC maps to the most appropriate cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HSBC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma. 3. Code: HSBC maps to the most appropriate cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HSBC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma. ",
      "predicted": "HSBC",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Cervix. 2. Findings: Squamous cell carcinoma. 3. Code: HSBC maps to the most appropriate cancer type.",
      "idx": 234,
      "timestamp": "2026-01-19T15:59:53.114064"
    },
    {
      "sample_idx": 1099,
      "input": "This is an invasive rectal carcinoma, in this case with medium-grade differentiation, of. the mucinous type (G 2), with infiltration of all layers of the wall (pT3), lymph vessel. invasions (L1), a lymph node metastasis (pN1, 1 of 12), free resection margins in the. region of the mucosa and a free ligature area.",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Invasive rectal carcinoma, mucinous type, G2, pT3, L1, N1. 3. Code: PRAD maps to Rectal Cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Invasive rectal carcinoma, mucinous type, G2, pT3, L1, N1. 3. Code: PRAD maps to Rectal Cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Invasive rectal carcinoma, mucinous type, G2, pT3, L1, N1. 3. Code: PRAD maps to Rectal Cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Invasive rectal carcinoma, mucinous type, G2, pT3, L1, N1. 3. Code: PRAD maps to Rectal Cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Invasive rectal carcinoma, mucinous type, G2, pT3, L1, N1. 3. Code: PRAD maps to Rectal Cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Invasive rectal carcinoma, mucinous type, G2, pT3, L1, N1. 3. Code: PRAD maps to Rectal Cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Invasive rectal carcinoma, mucinous type, G2, pT3, L1, N1. 3. Code: PRAD maps to Rectal Cancer.\"\n}\n```\n```",
      "predicted": "PRAD",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Rectum. 2. Findings: Invasive rectal carcinoma, mucinous type, G2, pT3, L1, N1. 3. Code: PRAD maps to Rectal Cancer.",
      "idx": 1099,
      "timestamp": "2026-01-19T15:59:53.114074"
    },
    {
      "sample_idx": 1339,
      "input": "Surgical Pathology Site Code. Endometrum. TISSUE DESCRIPTION. A1 J1 K1 L1 M1 M2 N1 01 P1 P2 P3 Q1 Q2 R1 S1 B1. C1 C2 C3. C4 C5 C6 C7 C8 C9 C10 D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11. E1 E2 E3 E4. E5 E6 E7 E8 E9 E10 E11 E12 F1 F2 G1 H1 Il. Uterus, right ovary (3.0 X 1.1 X 1.0 cm) with 9.0 cm. segment of. right fallopian tube, and 4.2 cm segment of left fallopian. tube. together weighing 120.0 grams; tissue from the bladder. peritoneum. (2.0 X 0.6 X 0.3 cm). i tissue from the left bladder. peritoneum ...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma, endometrioid type, forming a polypoid mass. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma, endometrioid type, forming a polypoid mass. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma, endometrioid type, forming a polypoid mass. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma, endometrioid type, forming a polypoid mass. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma, endometrioid type, forming a polypoid mass. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma, endometrioid type, forming a polypoid mass. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma, endometrioid type, forming a polypoid mass. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma, endometrioid type, forming a polypoid mass. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus. 2. Findings: Endometrial adenocarcinoma, endometrioid type, forming a polypoid mass. 3. Code: UCEC.",
      "idx": 1339,
      "timestamp": "2026-01-19T15:59:53.114083"
    },
    {
      "sample_idx": 1381,
      "input": "8380/3 he. GYNS Adm: Ord #=. ASAP /RESULTED. Collect D/T=. Modifiers: (1 of 1). CoPath Specimen. Source: A: Uterus IT\\ Cervix. B: Left Pelvic lymph node. C: Left Peri-aortic lymph node. D: Right Pelvic lymph node. E: Right Peri-aortic lymph node. Final Diagnosis. A. Uterus and cervix (hysterectomy, 85 gm). - Polypoid adenocarcinoma, endometrioid type, FIGO grade 2-3,. 1.6 X 1.5 X 1.0 cm. - Tumor shows superficial myometrial invasion involving 78 of. myometrial wall thickness (0.1 cm /1.4 cm). - ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus and cervix. 2. Findings: Endometrial adenocarcinoma, FIGO grade 2-3, with myometrial invasion. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left pelvic lymph node. 2. Findings: Negative for malignancy. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left periaortic lymph node. 2. Findings: Negative for malignancy. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right pelvic lymph node. 2. Findings: Negative for malignancy. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right periaortic lymph node. 2. Findings: Negative for malignancy. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus and cervix. 2. Findings: Polypoid adenocarcinoma, endometrioid type, FIGO grade 2-3. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus and cervix. 2. Findings: Polypoid adenocarcinoma, endometrioid type, FIGO grade 2-3. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus and cervix. 2. Findings: Polypoid adenocarcinoma, endometrioid type, FIGO grade ",
      "predicted": "KIRC",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Uterus and cervix. 2. Findings: Endometrial adenocarcinoma, FIGO grade 2-3, with myometrial invasion. 3. Code: KIRC.",
      "idx": 1381,
      "timestamp": "2026-01-19T15:59:53.114093"
    },
    {
      "sample_idx": 1413,
      "input": "[D:EAADA209-BED3-4FA3-B39C-2428BF278EF7. HISTOPATHOLOGY. Lab No. Clinical Consultant & Location. Unit No. SPECIMEN. RIGHT GLOBE ENUCLEATION, PROGNOSTIC AND DIAGNOSTIC. CLINICAL DETAILS. See diagram. Measurements 10.63 x 10.18 x (10.37) mm. MACROSCOPIC DESCRIPTION. A fresh, intact, right globe. Dimensions: Axial 25mm, Horizontal 23.5mm, Vertical 24mm. Cornea: Horizontal 12.5mm, Vertical 12mm. Optic nerve: flesh. On trans-illumination, a shadow is seen in the inferolateral. position, approx 13mm. ...",
      "response": "```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Eye (Right Globe Enucleation). 2. Findings: Choroidal melanoma, spindle cell type. 3. Code: SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Eye (Right Globe Enucleation). 2. Findings: Choroidal melanoma, spindle cell type. 3. Code: SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Eye (Right Globe Enucleation). 2. Findings: Choroidal melanoma, spindle cell type. 3. Code: SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Eye (Right Globe Enucleation). 2. Findings: Choroidal melanoma, spindle cell type. 3. Code: SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Eye (Right Globe Enucleation). 2. Findings: Choroidal melanoma, spindle cell type. 3. Code: SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Eye (Right Globe Enucleation). 2. Findings: Choroidal melanoma, spindle cell type. 3. Code: SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Eye (Right Globe Enucleation). 2. Findings: Choroidal melanoma, spindle cell type. 3. Code: SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Eye (Right Globe Enucleation). 2. Findings: Choroidal melanoma, spindle cell type. 3. Code: SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Eye (Right Globe Enucle",
      "predicted": "SKCM",
      "ground_truth": "UVM",
      "correct": false,
      "reasoning": "1. Site: Eye (Right Globe Enucleation). 2. Findings: Choroidal melanoma, spindle cell type. 3. Code: SKCM.",
      "idx": 1413,
      "timestamp": "2026-01-19T15:59:53.114103"
    },
    {
      "sample_idx": 601,
      "input": "FINAL SURGICAL PATHOLOGY REPORT. Diagnosis: A. LEFT KIDNEY MASS, PARTIAL NEPHRECTOMY: - Papillary renal cell carcinoma, Fuhrman nuclear grade 2. - Multifocal, largest focus 2.5 cm. - Surgical margin POSITIVE at parenchymal cauterized margin. PATHOLOGIC TUMOR STAGING SYNOPSIS (KIDNEY): Type and grade: Papillary renal cell carcinoma, type I, Fuhrman nuclear. grade 2. Primary tumor: pT1a. Regional lymph nodes: pNX. Distant metastasis: pMX. Pathologic stage: I. Lymphovascular invasion: Not identifie...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3 + 4 = 7. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3 + 4 = 7. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3 + 4 = 7. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade II. 3. Code: KIRC.",
      "idx": 601,
      "timestamp": "2026-01-19T15:59:53.114115"
    },
    {
      "sample_idx": 890,
      "input": "Pathology Report-Summary: Material: lung, right, lower lobe: 19.0 X 13.0 X 8.0 cm. tumor: 3.5 X 2.0 X 2.2 cm. Diagnosis: Squamous Cell Carcinoma, basaloid. pT2a, pNO (0/38), pMx, G3.",
      "response": "```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Lung, lower lobe. 2. Findings: Squamous cell carcinoma, basaloid type, pT2a, pNO (0/38), pMx, G3. 3. Code: Squamous Cell Carcinoma maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, lower lobe. 2. Findings: Squamous cell carcinoma, basaloid type, pT2a, pNO (0/38), pMx, G3. 3. Code: Squamous Cell Carcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Lung, lower lobe. 2. Findings: Squamous cell carcinoma, basaloid type, pT2a, pNO (0/38), pMx, G3. 3. Code: Squamous Cell Carcinoma maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Lung, lower lobe. 2. Findings: Squamous cell carcinoma, basaloid type, pT2a, pNO (0/38), pMx, G3. 3. Code: Squamous Cell Carcinoma maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Lung, lower lobe. 2. Findings: Squamous cell carcinoma, basaloid type, pT2a, pNO (0/38), pMx, G3. 3. Code: Squamous Cell Carcinoma maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Lung, lower lobe. 2. Findings: Squamous cell carcinoma, basaloid type, pT2a, pNO (0/38), pMx, G3. 3. Code: Squamous Cell Carcinoma maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reason",
      "predicted": "SCC",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung, lower lobe. 2. Findings: Squamous cell carcinoma, basaloid type, pT2a, pNO (0/38), pMx, G3. 3. Code: Squamous Cell Carcinoma maps to SCC.",
      "idx": 890,
      "timestamp": "2026-01-19T15:59:53.114126"
    },
    {
      "sample_idx": 323,
      "input": "SPECIMEN. Right colon. CLINICAL NOTES. PRE-OP DIAGNOSIS: Colon cancer. GROSS DESCRIPTION. Received fresh, subsequently fixed in formalin labelled. \"right colon\" which is partially covered with pink-tan. smooth glistening serosa and yellow lobular fat. The specimen. shows. a 6.5 X 0.7 cm appendix and the specimen is predominately covered. with abundant yellow lobular fat. The specimen is opened and has. a. 6.5 cm portion of small bowel and 26 cm of cecum and colon The. specimen shows a large ecto...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with invasion through the muscularis propria, into the subserosal fat (pT3). Margins of excision negative. One of twenty-nine lymph nodes with metastatic carcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with invasion through the muscularis propria, into the subserosal fat (pT3). Margins of excision negative. One of twenty-nine lymph nodes with metastatic carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with invasion through the muscularis propria, into the subserosal fat (pT3). Margins of excision negative. One of twenty-nine lymph nodes with metastatic carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with invasion through the muscularis propria, into the subserosal fat (pT3). Margins of excision negative. One of twenty-nine lymph nodes with metastatic carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with invasion through the muscularis propria, into the subserosal fat (pT3). Margins of excision negative. One of twenty-nine lymph nodes with metastatic carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated, with invasion through the muscularis propria, into the subserosal fat (pT3). Margins of excision negative. One of twenty-nine lymph nodes with metastatic carcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.",
      "idx": 323,
      "timestamp": "2026-01-19T15:59:53.114139"
    },
    {
      "sample_idx": 929,
      "input": "Accessioned. DIAGNOSIS: OVARIES, LEFT, PROCEDURE NOT STATED (INCLUDING FS1). HIGH GRADE SEROUS CARCINOMA WITH EXTENSIVE SURFACE INVOLVEMENT. SEE SYNOPSIS. FALLOPIAN TUBE, LEFT, PROCEDURE NOT STATED. - HIGH GRADE SEROUS CARCINOMA INVOLVING FALLOPIAN TUBE LUMEN. OVARIES, RIGHT, PROCEDURE NOT STATED (INCLUDING FS1). - HIGH GRADE SEROUS CARCINOMA WITH EXTENSIVE SURFACE INVOLVEMENT. FALLOPIAN TUBES, BILATERAL, PROCEDURE NOT STATED. - HIGH GRADE SEROUS CARCINOMA INVOLVING FIMBRIA, LYMPHOVASCULAR SPACE...",
      "response": "```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovaries, Left. 2. Findings: High grade serous carcinoma, involving the fallopian tube lumen and surrounding tissues. 3. Code: OV maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus and Cervix. 2. Findings: High grade serous carcinoma involving the uterine serosa and outer myometrium. 3. Code: UCEC maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Large Intestine, Rectal Tumor. 2. Findings: High grade serous carcinoma. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Soft Tissue, Falciform Ligament. 2. Findings: High grade serous carcinoma. 3. Code: ESCA maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Soft Tissue, Gastric Follic Omentum. 2. Findings: High grade serous carcinoma. 3. Code: ESCA maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Soft Tissue, Lesser Curvature of Stomach. 2. Findings: High grade serous carcinoma. 3. Code: ESCA maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Large Intestine, Rectal Tumor. 2. Findings: High grade serous carcinoma. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Large Intestine, Rectal Tumor. 2. Findings: High grade serous carcinoma. 3. Code: KIRC maps to KIRC.\"\n}\n",
      "predicted": "OV",
      "ground_truth": "OV",
      "correct": true,
      "reasoning": "1. Site: Ovaries, Left. 2. Findings: High grade serous carcinoma, involving the fallopian tube lumen and surrounding tissues. 3. Code: OV maps to OV.",
      "idx": 929,
      "timestamp": "2026-01-19T15:59:53.114150"
    },
    {
      "sample_idx": 6,
      "input": "General Pathologic Examination. This autopsy study was done for research purposes only and should therefore not be considered to be definitive or. exhaustive. EXTERNAL EXAM: The body is that of a middle-aged, moderately obese Caucasian female, measuring 165 cm in. length. The body is identified by ID bracelets about the left wrist and left ankle. Rigor mortis is not established and there. is dependent lividity. The normocephalic head has been recently shaved or cut very close to the scalp. The e...",
      "response": "```json\n{\n    \"cancer_type\": \"ADCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenal cortical carcinoma with metastasis to the liver. 3. Code: ADCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Acute bronchopneumonia with coccoid bacteria. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Benign breast tissue with small complex sclerosing lesion (radial scar) and usual duct hyperplasia. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Metastasis to the liver from adrenal cortical carcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenal cortical carcinoma. 3. Code: ADCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Acute bronchopneumonia. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Metastasis to the liver. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Acute bronchopneumonia. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Metastasis to the liver. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\":",
      "predicted": "ADCA",
      "ground_truth": "ACC",
      "correct": false,
      "reasoning": "1. Site: Adrenal gland. 2. Findings: Adrenal cortical carcinoma with metastasis to the liver. 3. Code: ADCA.",
      "idx": 6,
      "timestamp": "2026-01-19T15:59:53.114161"
    },
    {
      "sample_idx": 539,
      "input": "Clinical Diagnosis & History: with right renal mass. Specimens Submitted: 1: SP: Kidney, right, nephrectomy. DIAGNOSIS: 1. SP: Kidney, right, nephrectomy. Tumor Type: Renal cell carcinoma - Conventional (clear cell) type. Fuhrman Nuclear Grade: Nuclear grade II/IV. Tumor Size: Greatest diameter is 4.5 cm. Local Invasion (for renal cortical types): Not Identified. Renal Vein Invasion: Not identified. Surgical Margins: Free of tumor. Non-Neoplastic Kidney: Unremarkable. Adrenal Gland: Not identifi...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 539,
      "timestamp": "2026-01-19T15:59:53.114172"
    },
    {
      "sample_idx": 1025,
      "input": "Service Date: Male. Soc. Sec. #: Client: FINAL PATHOLOGIC DIAGNOSIS. Prostate and seminal vesicles, prostatectomy: 1. Prostatic adenocarcinoma, Gleason score 3+3 = 6; see comment. 2. Seminal vesicles with no tumor. COMMENT: Synoptic Comment for Prostate Tumors. - Type of tumor: Small acinar adenocarcinoma. - Location of tumor: Left posterior midgland, slides A5, A9-A10; left anterior midgland, slides A5,. A7-A8; right posterior apex, slide A2; right posterior midgland, slide A4, A6, A11-A12; rig...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3+3 = 6; see comment. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3+3 = 6; see comment. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3+3 = 6; see comment. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3+3 = 6; see comment. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3+3 = 6; see comment. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3+3 = 6; see comment. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3+3 = 6; see comment. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",",
      "predicted": "KIRC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason score 3+3 = 6; see comment. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 1025,
      "timestamp": "2026-01-19T15:59:53.114183"
    },
    {
      "sample_idx": 365,
      "input": "Surgical Patholoay Report. CLINICAL HISTORY. Right temporal tumor. OPERATIVE DIAGNOSES. Operation/Specimen: A: Brain, right temporal, excision biopsy. B: Brain, excision biopsy. PATHOLOGICAL DIAGNOSIS: and B. Brain, right temporal tumor, excisional biopsies: Glioblastoma (WHO. rade IV) (see comment) . COMMENT. Sections show a moderately pleomorphic glioma demonstrating frequent mitotic. figures, vascular proliferation and necrosis. The tumor cells are diffusely p53 positive and the K-67 labeling...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right temporal. 2. Findings: Glioblastoma (WHO grade IV). 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MGMT\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: MGMT promoter methylation. 3. Code: MGMT maps to MGMT.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"EGFR\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: EGFRVIII assay. 3. Code: EGFR maps to EGFR.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"P53\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: P53 positive. 3. Code: P53 maps to P53.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma (WHO grade IV). 3. Code: Glioblastoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MGMT\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: MGMT promoter methylation. 3. Code: MGMT maps to MGMT.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"EGFR\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: EGFRVIII assay. 3. Code: EGFR maps to EGFR.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"P53\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: P53 positive. 3. Code: P53 maps to P53.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MGMT\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: MGMT promoter methylation. 3. Code: MGMT maps to MGMT.\"\n}\n```\n```json\n{\n    \"cancer_type",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain, right temporal. 2. Findings: Glioblastoma (WHO grade IV). 3. Code: Glioblastoma maps to GBM.",
      "idx": 365,
      "timestamp": "2026-01-19T15:59:53.114193"
    },
    {
      "sample_idx": 1039,
      "input": "PATIENT HISTORY: The patient has a history of PSA value of 7.4,. right inguinal hernia done in an open fashion. with mesh and spinal stenosis. The patient also has a history of biopsy ont. this biopsy reveals unilateral poorly. differentiated prostatic adenocarcinoma of the right side. PRE-OP DIAGNOSIS: Prostate cancer. POST-OP DIAGNOSIS: Same. PROCEDURE: Radical retropubic prostatectomy. FINAL DIAGNOSIS: PART 1: LYMPH NODES, RIGHT PELVIC, EXCISION -. NO EVIDENCE OF METASTASIS IN FIVE LYMPH NODE...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Invasive poorly differentiated adenocarcinoma, Gleason score 4+5=9. 3. Code: Prostate Cancer maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UROS\",\n    \"reasoning\": \"1. Site: Right Pelvic Lymph Nodes. 2. Findings: Lymph node metastasis, no evidence of metastasis in the other lymph nodes. 3. Code: Lymph Node metastasis maps to UROS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Invasive poorly differentiated adenocarcinoma, Gleason score 4+5=9. 3. Code: Prostate Cancer maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Invasive poorly differentiated adenocarcinoma, Gleason score 4+5=9. 3. Code: Prostate Cancer maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Invasive poorly differentiated adenocarcinoma, Gleason score 4+5=9. 3. Code: Prostate Cancer maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Invasive poorly differentiated adenocarcinoma, Gleason score 4+5=9. 3. Code: Prostate Cancer maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Invasive poorly differentiated adenocarcinoma, Gleason score 4+5=9. 3. Code: Prostate Cancer maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Invasive poorly differentiated adenocarcinoma, Gleason score 4+5=9. 3. Code: Prostate Cancer maps to PRAD.\"",
      "predicted": "PRAD",
      "ground_truth": "PRAD",
      "correct": true,
      "reasoning": "1. Site: Prostate. 2. Findings: Invasive poorly differentiated adenocarcinoma, Gleason score 4+5=9. 3. Code: Prostate Cancer maps to PRAD.",
      "idx": 1039,
      "timestamp": "2026-01-19T15:59:53.114204"
    },
    {
      "sample_idx": 217,
      "input": "Surgica. CLINICAL HISTORY: Not provided. GROSS EXAMINATION: Estrogen receptor tissue sent for estrogen and progesterone receptor. A. \"Tru-cut breast biopsy. Received fresh. The specimen is a 1 cm x 0.1. cm tan piece of breast tissue. This frozen as frozen section AF1. The. frozen section remnant consists of two pieces of tan tissue measuring 0.8. x. 0.1 x 0.1 and 0.7 x 0.1 x 0.1 cm. They are submitted in toto in Block A1. B. \"Right breast. Received fresh. The specimen consists of breast with an....",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NSABP histologic grade 3, nuclear grade moderately differentiated. Tumor size is 1.5 x 2.8 x 1.0 cm. Vascular invasion is present. 6 of 15 lymph nodes contain metastatic carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NSABP histologic grade 3, nuclear grade moderately differentiated. Tumor size is 1.5 x 2.8 x 1.0 cm. Vascular invasion is present. 6 of 15 lymph nodes contain metastatic carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NSABP histologic grade 3, nuclear grade moderately differentiated. Tumor size is 1.5 x 2.8 x 1.0 cm. Vascular invasion is present. 6 of 15 lymph nodes contain metastatic carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NSABP histologic grade 3, nuclear grade moderately differentiated. Tumor size is 1.5 x 2.8 x 1.0 cm. Vascular invasion is present. 6 of 15 lymph nodes contain metastatic carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NSABP histologic grade 3, nuclear grade moderately differentiated. Tumor size is 1.5 x 2.8 x 1.0 cm. Vascular invasion is present. 6 of 15 lymph nodes contain metastatic carcinoma. 3. Code: Breast Invasive Carcinoma maps",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NSABP histologic grade 3, nuclear grade moderately differentiated. Tumor size is 1.5 x 2.8 x 1.0 cm. Vascular invasion is present. 6 of 15 lymph nodes contain metastatic carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 217,
      "timestamp": "2026-01-19T15:59:53.114217"
    },
    {
      "sample_idx": 611,
      "input": "Pre-Operative/Clinical History. Left renal mass. Specimen(s) Received. A: MARGIN - BASE OF TUMOR, LEFT KIDNEY MASS. B: LEFT RENAL MASS. Gross Description. Specimen A, received fresh for frozen section labeled margin (base) of tumor, left kidney mass, consists of three friable,. tan soft tissue fragments that measure 0.2 to 0.5 cm in greatest dimension. The fragments are entirely submitted for. frozen section in (A1 FS. Specimen B, received in formalin labeled left renal mass, consists of a 12 gm...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Grade I. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Grade I. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Grade I. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Grade I. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Grade I. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Grade I. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Grade I. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Grade I. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Grade I. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 611,
      "timestamp": "2026-01-19T15:59:53.114228"
    },
    {
      "sample_idx": 1263,
      "input": "FINAL DIAGNOSIS. A) Left thyroid lobe and isthmus: Papillary thyroid carcinoma forming a 3.5. cm in greatest dimension tumor mass. The thyroid carcinoma focally. invades through the capsule into the extracapsular soft tissue. Inked. surgical margins of resection are free of tumor. Areas of chronic. thyroiditis are also noted. B) Left paratracheal nodes: Metastatic papillary thyroid carcinoma. involving one out of one lymph node (1/1). C) Pretracheal lymph nodes: Metastatic papillary thyroid carc...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left thyroid lobe and isthmus. 2. Findings: Papillary thyroid carcinoma, forming a 3.5 cm tumor mass. The tumor focally invades through the capsule into the extracapsular soft tissue. Surgical margins are free of tumor. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) is the most appropriate TCGA code given the presence of thyroid carcinoma and its invasion. The thyroid carcinoma is classified as pT3, indicating extension beyond the thyroid gland, and the lymph nodes are involved (pN1a). While this is not kidney cancer, the TCGA code is determined by the primary cancer type, which is the thyroid carcinoma in this case.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA (Breast Invasive Carcinoma) is the most appropriate TCGA code given the presence of breast cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left thyroid lobe and isthmus. 2. Findings: Papillary thyroid carcinoma, forming a 3.5 cm tumor mass. The tumor focally invades through the capsule into the extracapsular soft tissue. Surgical margins are free of tumor. Areas of chronic thyroiditis are also noted. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) is the most appropriate TCGA code given the presence of thyroid carcinoma and its invasion. The thyroid carcinoma is classified as pT3, indicating extension beyond the thyroid gland, and the lymph nodes are involved (pN1a). While this is not kidney cancer, the TCGA code is determined by the primary cancer type, which is the thyroid carcinoma in this case.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left paratracheal nodes. 2. Findings: Metastatic papillary thyroid carcinoma. involving one out of one lymph node (1/1). 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) is the most appropriate TCGA code given the presence of thyroid carcinoma and its invasion. The thyroid",
      "predicted": "KIRC",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Left thyroid lobe and isthmus. 2. Findings: Papillary thyroid carcinoma, forming a 3.5 cm tumor mass. The tumor focally invades through the capsule into the extracapsular soft tissue. Surgical margins are free of tumor. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) is the most appropriate TCGA code given the presence of thyroid carcinoma and its invasion. The thyroid carcinoma is classified as pT3, indicating extension beyond the thyroid gland, and the lymph nodes are involved (pN1a). While this is not kidney cancer, the TCGA code is determined by the primary cancer type, which is the thyroid carcinoma in this case.",
      "idx": 1263,
      "timestamp": "2026-01-19T15:59:53.114249"
    },
    {
      "sample_idx": 1336,
      "input": "9196817048. p.1. CLINICAL HISTORY: Abnormal uterine bleeding, post mehopausal. Malignant neoplasm corpus uteri. Per E-browser, EMB-endometrioid adlenocarcinoma FIGO 1. GROSS EXAMINATION: A. \"Uterus, cervix, bilateral tubes and ovaries (AF1-2)\" received fresh for. frozen section ils a 194 gram, 12. a x 17.6 x 4.3 cru uterus with attached. bilateral ovaries. The anterior Hesection margin is inked blue and the. posterior resection margin is ink\u00e4d black. The uterus (119 gram, 12.2 x 11.2. x 4.3 cm) ...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma, FIGO grade 2, tumor size 7.2 x 4.9 x 2.5 cm, maximum depth of myometrial invasion 0.5 cm, lymphatic/vascular invasion negative. 3. Code: UCEC maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma, FIGO grade 2, tumor size 7.2 x 4.9 x 2.5 cm, maximum depth of myometrial invasion 0.5 cm, lymphatic/vascular invasion negative. 3. Code: UCEC maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma, FIGO grade 2, tumor size 7.2 x 4.9 x 2.5 cm, maximum depth of myometrial invasion 0.5 cm, lymphatic/vascular invasion negative. 3. Code: UCEC maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma, FIGO grade 2, tumor size 7.2 x 4.9 x 2.5 cm, maximum depth of myometrial invasion 0.5 cm, lymphatic/vascular invasion negative. 3. Code: UCEC maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma, FIGO grade 2, tumor size 7.2 x 4.9 x 2.5 cm, maximum depth of myometrial invasion 0.5 cm, lymphatic/vascular invasion negative. 3. Code: UCEC maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    ",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma, FIGO grade 2, tumor size 7.2 x 4.9 x 2.5 cm, maximum depth of myometrial invasion 0.5 cm, lymphatic/vascular invasion negative. 3. Code: UCEC maps to UCEC.",
      "idx": 1336,
      "timestamp": "2026-01-19T15:59:53.114261"
    },
    {
      "sample_idx": 1392,
      "input": "Copies To: Date Received. Addendum - Please See End of Report. Reason for Addendum #1: Additional sections or studies. DIAGNOSIS: A. RIGHT OVARY AND FALLOPIAN TUBE (SALPINGO-OOPHORECTOMY): -Benign ovary with corpora albicantia, rare calcification, and rare multinucleated giant cell. -Benign fallopian tube with hydrosalpinx, small focus suggestive of endometriosis, and serosal. adhesions with reactive mesothelial cells. B. UTERUS AND CERVIX (TOTAL HYSTERECTOMY): -Endometrial carcinoma with endome...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\":",
      "predicted": "BRCA",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1392,
      "timestamp": "2026-01-19T15:59:53.114271"
    },
    {
      "sample_idx": 1290,
      "input": "ADDENDA: Addendum. MOLECULAR ANATOMIC PATHOLOGY TESTING: 1.4 cm tumor: A. NRAS codon 61 mutation IDENTIFIED. B. Mutations in BRAF, HRAS61, KRAS12/13 and RET/PTC1 and RET/PTC3 rearrangements. NOT identified. NOTE: Nucleic acids were extracted in the amount sufficient for testing. 1.0 cm tumor: Mutational status for BRAF, NRAS61, HRAS61, KRAS12/13 and RET/PTC1 and RET/PTC3 rearrangements is. INDETERMINATE due to Insufficient material for testing. NOTE: Low concentration of nucleic acids was extrac...",
      "response": "```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, two foci (1.4 cm and 1.0 cm) in the right lobe and isthmus, confined to the thyroid. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: The thyroidectomy removed the entire thyroid gland, and the tumor is confined to the thyroid. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, two foci (1.4 cm and 1.0 cm) in the right lobe and isthmus, confined to the thyroid. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, two foci (1.4 cm and 1.0 cm) in the right lobe and isthmus, confined to the thyroid. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, two foci (1.4 cm and 1.0 cm) in the right lobe and isthmus, confined to the thyroid. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, two foci (1.4 cm and 1.0 cm) in the right lobe and isthmus, confined to the thyroid. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1",
      "predicted": "THCA",
      "ground_truth": "THCA",
      "correct": true,
      "reasoning": "1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, two foci (1.4 cm and 1.0 cm) in the right lobe and isthmus, confined to the thyroid. 3. Code: Thyroid Carcinoma maps to THCA.",
      "idx": 1290,
      "timestamp": "2026-01-19T15:59:53.114282"
    },
    {
      "sample_idx": 765,
      "input": "Anat Path Reports. Document Date: APRPT (Verified). Acc #: M. Client: Submitting. Phys: Final Surgical Pathology Report. Final Pathologic Diagnosis. A. 10R LYMPH NODE, EXCISION, A1FS: - NO METASTATIC CARCINOMA IN FRAGMENTED LYMPH NODAL TISSUE. B. LUNG, RIGHT UPPER LOBE, LOBECTOMY, B1FS: - MODERATELY DIFFERENTIATED ADENOCARCINOMA (1.7 X 1.7 X 2.5 CM). - NO PLEURAL INVOLVEMENT. - COMPLETELY EXCISED. - EMPHYSEMA. C. 11R LYMPH NODE, EXCISION: NO METASTATIC CARCINOMA IN FRAGMENTED LYMPH NODAL TISSUE....",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, right upper lobe. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUNG\",\n    \"reasoning\": \"1. Site: Lung, right upper lobe. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: LUNG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUNG\",\n    \"reasoning\": \"1. Site: Lung, right upper lobe. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: LUNG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUNG\",\n    \"reasoning\": \"1. Site: Lung, right upper lobe. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: LUNG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUNG\",\n    \"reasoning\": \"1. Site: Lung, right upper lobe. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: LUNG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUNG\",\n    \"reasoning\": \"1. Site: Lung, right upper lobe. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: LUNG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUNG\",\n    \"reasoning\": \"1. Site: Lung, right upper lobe. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: LUNG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUNG\",\n    \"reasoning\": \"1. Site: Lung, right upper lobe. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: LUNG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUNG\",\n    \"reasoning\": \"1. Site: Lung, right upper lobe. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: LUNG.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung, right upper lobe. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: LUAD.",
      "idx": 765,
      "timestamp": "2026-01-19T15:59:53.114292"
    },
    {
      "sample_idx": 330,
      "input": "PATHOLOGIC DIAGNOSIS: SPECIMEN DESIGNATED \"RIGHT COLON\" (44 cm) : ADENOCARCINOMA, moderately differentiated (3.0 cm). Tumor is located in the cecum, forms a polypoid mass,. and is ulcerative. Tumor invades into but not through the muscularis propria. Proximal, distal, and radial resection margins are negative. for tumor. Intramural lymphovascular invasion is not identified. Perineural invasion is not identified. Peritumoral response is mild. Residual adenoma is present. Hyperplastic polyps,. Mul...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.",
      "idx": 330,
      "timestamp": "2026-01-19T15:59:53.114309"
    },
    {
      "sample_idx": 1104,
      "input": "SPECIMEN. A. Right uterine adnexa. B. Sigmoid and upper half rectum. C. Appendix. CLINICAL NOTES. PRE-OP DIAGNOSIS: Rectosigmoid cancer. FROZEN SECTION DIAGNOSIS. A. Ovary, right, resection: Mucinous cystic neoplasm. Negative. for malignancy on frozen section. GROSS DESCRIPTION. A. The specimen is received unfixed labelled \"right. uterine adnexa\" and consists of a pink uterine tube. measuring 4 cm in length and 0.7 cm in diameter. There is adjacent. tan ovary measuring 2.5 X 1.3 cm with a contai...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Colonic adenocarcinoma, invasive, grade 1-2. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Mucinous cystadenoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Appendix. 2. Findings: Fibrous obliteration of the distal appendiceal lumen. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Colonic adenocarcinoma, invasive, grade 1-2. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Mucinous cystadenoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Appendix. 2. Findings: Fibrous obliteration of the distal appendiceal lumen. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Colonic adenocarcinoma, invasive, grade 1-2. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Mucinous cystadenoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Appendix. 2. Findings: Fibrous obliteration of the distal appendiceal lumen. 3. Code: KIRC.\"\n}\n```\n```json\n",
      "predicted": "KIRC",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Rectum. 2. Findings: Colonic adenocarcinoma, invasive, grade 1-2. 3. Code: KIRC.",
      "idx": 1104,
      "timestamp": "2026-01-19T15:59:53.114319"
    },
    {
      "sample_idx": 1086,
      "input": "Diagnosis: Resection material from rectosigmoid colon with inclusion of an ulcerated, moderately. differentiated adenocarcinoma of the colorectal type 4.5 cm from the aboral resection. margin and with infiltration of the perirectal fatty tissue and four regional lymph node. metastases. Tumor-free circumferential resection margin. Tumor-free colon resection. margins. Tumor-free mesenteric resection margin. Tumor stage: pT3 pN2 (4/42) pMX; G2, L1, V0, locally R0.",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, colorectal type, ulcerated, moderately differentiated, 4.5 cm from the aboral resection margin, with infiltration of the perirectal fatty tissue and four regional lymph node metastases. 3. Code: COAD maps to Colorectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, colorectal type, ulcerated, moderately differentiated, 4.5 cm from the aboral resection margin, with infiltration of the perirectal fatty tissue and four regional lymph node metastases. 3. Code: COAD maps to Colorectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, colorectal type, ulcerated, moderately differentiated, 4.5 cm from the aboral resection margin, with infiltration of the perirectal fatty tissue and four regional lymph node metastases. 3. Code: COAD maps to Colorectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, colorectal type, ulcerated, moderately differentiated, 4.5 cm from the aboral resection margin, with infiltration of the perirectal fatty tissue and four regional lymph node metastases. 3. Code: COAD maps to Colorectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, colorectal type, ulcerated, moderately differentiated, 4.5 cm from the aboral resection margin, with infiltration of the perirectal fatty tissue and four regional lymph node metastases. 3. Code: COAD maps to Colorectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rect",
      "predicted": "COAD",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, colorectal type, ulcerated, moderately differentiated, 4.5 cm from the aboral resection margin, with infiltration of the perirectal fatty tissue and four regional lymph node metastases. 3. Code: COAD maps to Colorectal Adenocarcinoma.",
      "idx": 1086,
      "timestamp": "2026-01-19T15:59:53.114335"
    },
    {
      "sample_idx": 1,
      "input": "OPER DATE: PROCEDURE: APMI. ADDENDUM TO REPORT CHANGE IN MARGIN STATUS AFTER DISCUSSION WITH SURGEON: Please see revised template and revised diagnosis below. ADRENOCORTICAL CARCINOMA. V4. Tumor Size: 17.1 x 12.5 x 10.3 cm. Tumor Weight: Cannot determine. Capsular Invasion: Yes. Vascular Invasion: Yes. Surgical Margins: Negative. Necrosis: 75% (gross). Mitotic Rate: 60/50 hps. Grade: High. Lymph nodes status: 1/2. Extra-adrenal extension: Present. Stage: 4 (pT3 N1 M1). Immunohistochemistry Resul...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right adrenal and kidney. 2. Findings: High-grade adrenocortical carcinoma with capsular and extensive vascular invasion, including invasion of the vena cava. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Right adrenal and kidney. 2. Findings: High-grade adrenocortical carcinoma with capsular and extensive vascular invasion, including invasion of the vena cava. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right adrenal and kidney. 2. Findings: High-grade adrenocortical carcinoma with capsular and extensive vascular invasion, including invasion of the vena cava. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right adrenal and kidney. 2. Findings: High-grade adrenocortical carcinoma with capsular and extensive vascular invasion, including invasion of the vena cava. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right adrenal and kidney. 2. Findings: High-grade adrenocortical carcinoma with capsular and extensive vascular invasion, including invasion of the vena cava. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right adrenal and kidney. 2. Findings: High-grade adrenocortical carcinoma with capsular and extensive vascular invasion, including invasion of the vena cava. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right adrenal and kidney. 2. Findings: High-grade adrenocortical carcinoma with capsular and extensive vascular invasion, including invasion of the vena cava. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_",
      "predicted": "KIRC",
      "ground_truth": "ACC",
      "correct": false,
      "reasoning": "1. Site: Right adrenal and kidney. 2. Findings: High-grade adrenocortical carcinoma with capsular and extensive vascular invasion, including invasion of the vena cava. 3. Code: KIRC.",
      "idx": 1,
      "timestamp": "2026-01-19T15:59:53.114346"
    },
    {
      "sample_idx": 1226,
      "input": "Pathohistological diagnosis. Seminoma testis (pT2 NXMX). Description: Testicle with cut tumor, size 8:6:5 cm, and 8 cm long funiculus was received. The tumor has. irregular edges, is white to brown in color, of medium consistency and is 8:5:4 cm in size. Histologically, the tumor is made of solid seats and tumor cell traces with round and oval. bright nuclei in which we see small nuclei and scarce, bright and pink cytoplasm. Inside the. tumor, at microscope's large visual field, we see 3-4 mitos...",
      "response": "```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma, testicular germ cell tumor. 3. Code: Seminoma testis maps to TGCT.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma, testicular germ cell tumor. 3. Code: Seminoma testis maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma, testicular germ cell tumor. 3. Code: Seminoma testis maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma, testicular germ cell tumor. 3. Code: Seminoma testis maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma, testicular germ cell tumor. 3. Code: Seminoma testis maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma, testicular germ cell tumor. 3. Code: Seminoma testis maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma, testicular germ cell tumor. 3. Code: Seminoma testis maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma, testicular germ cell tumor. 3. Code: Seminoma testis maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Testis. 2.",
      "predicted": "TGCT",
      "ground_truth": "TGCT",
      "correct": true,
      "reasoning": "1. Site: Testis. 2. Findings: Seminoma, testicular germ cell tumor. 3. Code: Seminoma testis maps to TGCT.",
      "idx": 1226,
      "timestamp": "2026-01-19T15:59:53.114356"
    },
    {
      "sample_idx": 663,
      "input": "Procedur. Report S. Final Diagnosis: A. Brain, right frontal mass, biopsy: Anaplastic oligodendroglioma (WHO grade III), see comment. Seen in consultation wit. Comment: The tumor is clinically recurrent and in progression from a WHO grade II glioma 1p19q codeleted. diagnosed. IDH1(R132H) stain will be obtained and findings will be reported as an addendum. ADDENDA: The neoplastic cells are negative for IDH1 (R132H) immunostain. continued next page. Preliminary Frozen Section Consultation: A. Brai...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontal mass. 2. Findings: Anaplastic oligodendroglioma (WHO grade III). 3. Code: Brain, right frontal mass maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontal mass. 2. Findings: Anaplastic oligodendroglioma (WHO grade III). 3. Code: Brain, right frontal mass maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontal mass. 2. Findings: Anaplastic oligodendroglioma (WHO grade III). 3. Code: Brain, right frontal mass maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontal mass. 2. Findings: Anaplastic oligodendroglioma (WHO grade III). 3. Code: Brain, right frontal mass maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontal mass. 2. Findings: Anaplastic oligodendroglioma (WHO grade III). 3. Code: Brain, right frontal mass maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontal mass. 2. Findings: Anaplastic oligodendroglioma (WHO grade III). 3. Code: Brain, right frontal mass maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontal mass. 2. Findings: Anaplastic oligodendroglioma (WHO grade III). 3. Code: Brain, right frontal mass maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontal mass. 2. Findings",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain, right frontal mass. 2. Findings: Anaplastic oligodendroglioma (WHO grade III). 3. Code: Brain, right frontal mass maps to GBM.",
      "idx": 663,
      "timestamp": "2026-01-19T15:59:53.114367"
    },
    {
      "sample_idx": 1000,
      "input": "Unique Patient Identifler: Short descriptive translation of the pathology report as provided by the. Material received: Material: left Adrenal gland. Right adrenal gland. Macroscopic findings: 1. A 14 x 8 x 4 cm specimen. On the cutted surface a tumor surrounded by a fatty-connective. tissue capsule with a soft, partially cystic appearence with hemorrhage (202g). 2. Left adrenal: A 2 x 2 x 1 cm specimen (2 g). On the cutted surface yellow, lobulated fatty. tissue and normal adrenal tissue with z...",
      "response": "```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, with lymphatic invasion. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Right). 2. Findings: Normal adrenal tissue. 3. Code: Normal adrenal tissue maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, with lymphatic invasion. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Right). 2. Findings: Normal adrenal tissue. 3. Code: Normal adrenal tissue maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, with lymphatic invasion. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Right). 2. Findings: Normal adrenal tissue. 3. Code: Normal adrenal tissue maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, with lymphatic invasion. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Right). 2. Findings: Normal adrenal tissue. 3. Code: Normal adrenal tissue maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n",
      "predicted": "PHCG",
      "ground_truth": "PCPG",
      "correct": false,
      "reasoning": "1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, with lymphatic invasion. 3. Code: Pheochromocytoma maps to PHCG.",
      "idx": 1000,
      "timestamp": "2026-01-19T15:59:53.114376"
    },
    {
      "sample_idx": 39,
      "input": "DIAGNOSIS: RADICAL CYSTECTOMY WITH URINARY DIVISION (ILEAL CONDUIT) AND PELVIC LYMPH NODE. DISSECTION. RIGHT URETER (AFS) : FROZEN SECTION DIAGNOSIS: NO TUMOR IDENTIFIED. FINAL DIAGNOSIS: BENIGN URETER. - NO DYSPLASIA OR MALIGNANCY IDENTIFIED. LEFT URETER (BFS) : FROZEN SECTION DIAGNOSIS: NO TUMOR IDENTIFIED. FINAL DIAGNOSIS: - BENIGN URETER. - NO DYSPLASIA OR MALIGNANCY IDENTIFIED. BLADDER (C) : - INVASIVE POORLY DIFFERENTIATED UROTHELIAL CARCINOMA WITH SQUAMOID. FEATURES (12.0 X 9.5 x 3.2 CM) ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive poorly differentiated urothelial carcinoma with squamous. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Bilateral prostate adenocarcinoma, Gleason's score 6 (3+3), confined to prostate. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Ureter. 2. Findings: Benign ureter. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LGG\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma. 3. Code: LGG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colon cancer. 3. Code: COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CESC\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Esophageal cancer. 3. Code: CESC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Cholangiocarcinoma. 2. Findings: Cholangiocarcinoma. 3. Code: CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"",
      "predicted": "KIRC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Bladder. 2. Findings: Invasive poorly differentiated urothelial carcinoma with squamous. 3. Code: KIRC.",
      "idx": 39,
      "timestamp": "2026-01-19T15:59:53.114386"
    },
    {
      "sample_idx": 229,
      "input": "25. ANATOMIC PATHOLOGY REPORT FAX. Accessioned: Physicien: oth Phy (a) : CLINICAL HISTORY. CLINICAL HISTORY CERVICAL VERSUS ENDOMETRIAL CA. PROCEDURS/FINDINOS: RADICAL HYSTERECTONY. SPECIMEN(S) : A. VAGINAL MARGINS FOR FROZEN. B. UTERUS, BSO AND CERVIX. c. RIGHT PELVIC LYMPH NODE DISSECTION. D. LEFT AORTIC. E. LEFT PELVIC LYMPH NODE DISSECTION. F. RIGHT PERIAORTIC. FINAL DIAGNOSIS. A. VAGINAL MARGIN, EXCISION: NEGATIVE FOR INVASIVE CARCINOMA. SURFACE EPITHELIUM SHOWS CHANGES CONSISTENT WITH HIGH...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, and Bilateral Tubes and Ovaries. 2. Findings: Invasive Squamous Cell Carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, and Bilateral Tubes and Ovaries. 2. Findings: Invasive Squamous Cell Carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, and Bilateral Tubes and Ovaries. 2. Findings: Invasive Squamous Cell Carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, and Bilateral Tubes and Ovaries. 2. Findings: Invasive Squamous Cell Carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, and Bilateral Tubes and Ovaries. 2. Findings: Invasive Squamous Cell Carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, and Bilateral Tubes and Ovaries. 2. Findings: Invasive Squamous Cell Carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, and Bilateral Tubes and Ovaries. 2. Findings: Invasive Squamous Cell Carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, and Bilateral Tubes",
      "predicted": "BRCA",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Uterus, Cervix, and Bilateral Tubes and Ovaries. 2. Findings: Invasive Squamous Cell Carcinoma, high grade. 3. Code: BRCA.",
      "idx": 229,
      "timestamp": "2026-01-19T15:59:53.114396"
    },
    {
      "sample_idx": 743,
      "input": "TISSUE DESCRIPTION : A1 B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 B13 B14 B15. C1 C2 C3 C4 C5 C6 C7 C8. Liver mass segment 6 (1930.0 grams, 14.5 X 13.0 X 12.0 cm) ,. liver segment 7 mass (164.0 grams), hepatic nodule (0.4 x 0.3. x. 0.1 cm). DIAGNOSIS: Liver, mass, segment VI resection: : Moderately differentiated. hepatocellulari carcinoma, forming a variegated mass with focal. necrosis measuring 14.5 X 13.0 X 12.0 cm. The tumor is partially. encapsulated with pushing border, and it shows no large ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment VI and VII). 2. Findings: Hepatocellular carcinoma, forming a variegated mass with focal necrosis, measuring 14.5 X 13.0 X 12.0 cm. Segment VII, a solid nodule, 1.3 x 1.0 X 0.9 cm. Also a cavernous hemangioma, 1.2 X 1.0 X 0.5 cm. 3. Code: Liver, mass, segment VI resection maps to KIRC. Liver, mass, segment VII resection maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment VI and VII). 2. Findings: Hepatocellular carcinoma, forming a variegated mass with focal necrosis, measuring 14.5 X 13.0 X 12.0 cm. Segment VII, a solid nodule, 1.3 x 1.0 X 0.9 cm. Also a cavernous hemangioma, 1.2 X 1.0 X 0.5 cm. 3. Code: Liver, mass, segment VI resection maps to KIRC. Liver, mass, segment VII resection maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment VI and VII). 2. Findings: Hepatocellular carcinoma, forming a variegated mass with focal necrosis, measuring 14.5 X 13.0 X 12.0 cm. Segment VII, a solid nodule, 1.3 x 1.0 X 0.9 cm. Also a cavernous hemangioma, 1.2 X 1.0 X 0.5 cm. 3. Code: Liver, mass, segment VI resection maps to KIRC. Liver, mass, segment VII resection maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment VI and VII). 2. Findings: Hepatocellular carcinoma, forming a variegated mass with focal necrosis, measuring 14.5",
      "predicted": "KIRC",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Liver (Segment VI and VII). 2. Findings: Hepatocellular carcinoma, forming a variegated mass with focal necrosis, measuring 14.5 X 13.0 X 12.0 cm. Segment VII, a solid nodule, 1.3 x 1.0 X 0.9 cm. Also a cavernous hemangioma, 1.2 X 1.0 X 0.5 cm. 3. Code: Liver, mass, segment VI resection maps to KIRC. Liver, mass, segment VII resection maps to KIRC.",
      "idx": 743,
      "timestamp": "2026-01-19T15:59:53.114411"
    },
    {
      "sample_idx": 629,
      "input": "Operative Procedure: Left nephrectomy, median sternotomy. Pre-Operative Diagnosis: As below. Post-Operative Diagnosis: As below. Left radical nephrectomy and caval thrombus with hilar and retroperitoneal lymph. nodes. Final Pathologic Diagnosis: Kidney and adrenal gland, left, radical nephrectomy with caval-atrial thrombus. removal; hilar and retroperitoneal lymph nodes, regional resection: Tumor histologic type: Papillary renal cell carcinoma, type I. Sarcomatoid features (%): None. Tumor size:...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, type I. Sarcomatoid features (%): None. Tumor size: 11 cm. Fuhrman grade: 3 of 4. Renal vein involvement: Yes with tumor adherent to renal vein wall. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, type I. Sarcomatoid features (%): None. Tumor size: 11 cm. Fuhrman grade: 3 of 4. Renal vein involvement: Yes with tumor adherent to renal vein wall. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, type I. Sarcomatoid features (%): None. Tumor size: 11 cm. Fuhrman grade: 3 of 4. Renal vein involvement: Yes with tumor adherent to renal vein wall. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, type I. Sarcomatoid features (%): None. Tumor size: 11 cm. Fuhrman grade: 3 of 4. Renal vein involvement: Yes with tumor adherent to renal vein wall. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, type I. Sarcomatoid features (%): None. Tumor size: 11 cm. Fuhrman grade: 3 of 4. Renal vein involvement: Yes with tumor adherent to renal vein wall. 3. Code: Kidney Renal Clear",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, type I. Sarcomatoid features (%): None. Tumor size: 11 cm. Fuhrman grade: 3 of 4. Renal vein involvement: Yes with tumor adherent to renal vein wall. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 629,
      "timestamp": "2026-01-19T15:59:53.114424"
    },
    {
      "sample_idx": 490,
      "input": "Gross Description: Microscopic Description: Diagnosis Details: Comments: Formatted Path Reports: Tumor site: Tongue. Tumor. size: 4 X 6 x 4cm. Histologic type: Squamous cell carcinoma. Histological grade: Well differentiated. Laterality: Midline. Margins: Not specified.",
      "response": "```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Squ",
      "predicted": "HNSC",
      "ground_truth": "HNSC",
      "correct": true,
      "reasoning": "1. Site: Tongue. 2. Findings: Squamous cell carcinoma. 3. Code: HNSC.",
      "idx": 490,
      "timestamp": "2026-01-19T15:59:53.114433"
    },
    {
      "sample_idx": 118,
      "input": "Final Pathologic Diagnosis: BASED ON THE PERFORMED GROSS AND MICROSCOPIC EXAMINATION: A. Breast, right, partial mastectomy: Infiltrating ductal carcinoma, Grade III/III. - Tubular score = 3. - Nuclear score = 3. - Mitotic score = 3. - Maximum tumor dimension 6 cm. - No evidence of angiolymphatic invasion. - Focal ductal carcinoma in situ. - Solid architectural pattern. - Focal cancerization of lobules. - Nonextensive pattern. - Invasive malignancy abutes deep skeletal muscle. - Surgical margins ...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 118,
      "timestamp": "2026-01-19T15:59:53.114442"
    },
    {
      "sample_idx": 493,
      "input": "DIAGNOSIS. (A). LEFT PYRIFORM SINUS: INVASIVE MODERATELY DIFFERENTIATED SQUAMOUS CARCINOMA. PHARYNGEAL PLEXUS OF VAGUS NERVE: Segment.of-nerve,--no tumor present. (C). TOTAL LARYNGOPHARYNGECTOMY, BILATERAL NECK DISSECTIONS, EXCISION OF LEFT. NECK SKIN, LEFT THYROIDECTOMY: INVASIVE MODERATELY DIFFERENTIATED SQUAMOUS CARCINOMA OF THE. LEFT PYRIFORM SINUS EXTENDING INTO THE LEFT ARYEPIGLOTTIC FOLD,. ESOPHAGUS, LEFT PARAGLOTTIC SPACE, LEFT PARATRACHEAL/PARA-. ESOPHAGEAL SOFT TISSUE AND LEFT THYROID....",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOSQUAMOUS\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Squamous cell carcinoma, invasive. 3. Code: The report indicates a squamous cell carcinoma, but the primary site is esophagus, not a specific TCGA code. Given the context, it could be considered as a squamous cell carcinoma, but there is no direct TCGA code for this specific esophageal cancer. However, the closest TCGA code that matches the description is ADENOSQUAMOUS, which is a composite of Adenocarcinoma and Squamous Cell Carcinoma. Since the report mentions a squamous cell carcinoma, this is the best available TCGA code.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOSQUAMOUS\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Squamous cell carcinoma, invasive. 3. Code: The report indicates a squamous cell carcinoma, but the primary site is esophagus, not a specific TCGA code. Given the context, it could be considered as a squamous cell carcinoma, but there is no direct TCGA code for this specific esophageal cancer. However, the closest TCGA code that matches the description is ADENOSQUAMOUS, which is a composite of Adenocarcinoma and Squamous Cell Carcinoma. Since the report mentions a squamous cell carcinoma, this is the best available TCGA code.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOSQUAMOUS\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Squamous cell carcinoma, invasive. 3. Code: The report indicates a squamous cell carcinoma, but the primary site is esophagus, not a specific TCGA code. Given the context, it could be considered as a squamous cell carcinoma, but there is no direct TCGA code for this specific esophageal cancer. However, the closest TCGA code that matches the description is ADENOSQUAMOUS, which is a composite of Adenocarcinoma and Squamous Cell Carcinoma. Since the report mentions a squamous cell carcinoma, this is the best available TCGA code.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOSQUAMOUS\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Squamous cell carcinoma, invasive",
      "predicted": "ADENOSQUAMOUS",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Esophagus. 2. Findings: Squamous cell carcinoma, invasive. 3. Code: The report indicates a squamous cell carcinoma, but the primary site is esophagus, not a specific TCGA code. Given the context, it could be considered as a squamous cell carcinoma, but there is no direct TCGA code for this specific esophageal cancer. However, the closest TCGA code that matches the description is ADENOSQUAMOUS, which is a composite of Adenocarcinoma and Squamous Cell Carcinoma. Since the report mentions a squamous cell carcinoma, this is the best available TCGA code.",
      "idx": 493,
      "timestamp": "2026-01-19T15:59:53.114463"
    },
    {
      "sample_idx": 1315,
      "input": "Identifier: Tumor Type : Thymoma. Pathology Report-Summary: Material: tumor: 8.0 X 8.0 X 3.0 cm. focal invasion through capsule. Diagnosis: Type A-Thymoma (with focal TypeA/B). pT2, pNO (0/7). Masaoka: II.1. Immunhistochemistry. epithelial cells positive for: CK5/6. strong membrane staining for EGFR. epithelial cells negative for: c-kit, CD5. CD1a, CD99-positive immature T-lymphocytes, partially also positive for CD5. sparsely CD20-positive lymphocytes.",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type A (with focal Type A/B). pT2, pNO (0/7). Masaoka: II.1. Epithelial cells positive for CK5/6 and EGFR, negative for c-kit and CD5. Immature T-lymphocytes, partially positive for CD5. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type A (with focal Type A/B). pT2, pNO (0/7). Masaoka: II.1. Epithelial cells positive for CK5/6 and EGFR, negative for c-kit and CD5. Immature T-lymphocytes, partially positive for CD5. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type A (with focal Type A/B). pT2, pNO (0/7). Masaoka: II.1. Epithelial cells positive for CK5/6 and EGFR, negative for c-kit and CD5. Immature T-lymphocytes, partially positive for CD5. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type A (with focal Type A/B). pT2, pNO (0/7). Masaoka: II.1. Epithelial cells positive for CK5/6 and EGFR, negative for c-kit and CD5. Immature T-lymphocytes, partially positive for CD5. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type A (with focal Type A/B). p",
      "predicted": "THYM",
      "ground_truth": "THYM",
      "correct": true,
      "reasoning": "1. Site: Thymus. 2. Findings: Thymoma, Type A (with focal Type A/B). pT2, pNO (0/7). Masaoka: II.1. Epithelial cells positive for CK5/6 and EGFR, negative for c-kit and CD5. Immature T-lymphocytes, partially positive for CD5. 3. Code: Thymoma maps to THYM.",
      "idx": 1315,
      "timestamp": "2026-01-19T15:59:53.114476"
    },
    {
      "sample_idx": 1363,
      "input": "Client: F. ITD:719E2A48-0E04-4EAD-ASCC-6416450FC68F. History/Clinical Dx: Endometrial cancer. Postoperative Dx: Pending pathology examination. Specimen(s) Received: A: Left pelvic lymph node. B: Left aortic lymph node. C: Right pelvic lymph node. D: Right aortic lymph node. E: Uterus, cervix, tubes and ovaries. DIAGNOSIS: A. Left pelvic lymph nodes: Four lymph nodes negative for metastasis (0/4). B. Left aortic lymph nodes: Two lymph nodes negative for metastasis (0/2). C. Right pelvic lymph nod...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, tubes and ovaries. 2. Findings: Endometrial adenocarcimona. Tumor size: 1.4 x 0.7 x 0.6 cm. Extent of invasion: Less than 50% (3 mm invasion/10 mm myometrial thickness). 3. Code: UCEC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, tubes and ovaries. 2. Findings: Endometrial adenocarcimona. Tumor size: 1.4 x 0.7 x 0.6 cm. Extent of invasion: Less than 50% (3 mm invasion/10 mm myometrial thickness). 3. Code: UCEC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, tubes and ovaries. 2. Findings: Endometrial adenocarcimona. Tumor size: 1.4 x 0.7 x 0.6 cm. Extent of invasion: Less than 50% (3 mm invasion/10 mm myometrial thickness). 3. Code: UCEC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, tubes and ovaries. 2. Findings: Endometrial adenocarcimona. Tumor size: 1.4 x 0.7 x 0.6 cm. Extent of invasion: Less than 50% (3 mm invasion/10 mm myometrial thickness). 3. Code: UCEC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, tubes and ovaries. 2. Findings: Endometrial adenocarcimona. Tumor size: 1.4 x 0.7 x 0.6 cm. Extent of invasion: Less than 50% (3 mm invasion/10 mm myometrial thickness).",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus, cervix, tubes and ovaries. 2. Findings: Endometrial adenocarcimona. Tumor size: 1.4 x 0.7 x 0.6 cm. Extent of invasion: Less than 50% (3 mm invasion/10 mm myometrial thickness). 3. Code: UCEC",
      "idx": 1363,
      "timestamp": "2026-01-19T15:59:53.114488"
    },
    {
      "sample_idx": 175,
      "input": "Procedure Date: Procedure Physician: Attending Physician/Copies To: PATIENT HISTORY: nnDATE of LMP. DATE or LAST DELIVERY: PRE-OP DIAGNOSIS: LT BR MASS. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE: LT SEGM MAST-NEEDLE LOC. CLINICAL HISTORY: MATERIAL SUBMITTED: A) LEFT BREAST BIOPSY/MASS/SEGMENTAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDORE. 3) LEFT NEW MARGIN TISSUE, PROCUREMENT BY SURGICAL PROCEDURE. SUPERIOR. INTRAOPERATIVE CONSULTATION: CONSULT Left breast tissue: 11.0 by 5.0 by 4.5 cm bre...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Fuhrman Grade II, Nottingham Score 7, microcalcifications, infiltrating carcinoma within <1 mm of the inked superior and deep margins. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Fuhrman Grade II, Nottingham Score 7, microcalcifications, infiltrating carcinoma within <1 mm of the inked superior and deep margins. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Fuhrman Grade II, Nottingham Score 7, microcalcifications, infiltrating carcinoma within <1 mm of the inked superior and deep margins. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Fuhrman Grade II, Nottingham Score 7, microcalcifications, infiltrating carcinoma within <1 mm of the inked superior and deep margins. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Fuhrman Grade II, Nottingham Score 7, microcalcifications, infiltrating carcinoma within <1 mm of the inked superior and deep margins. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Fuhrman Grade II, Nottingham Score 7, microcalcifications, infiltrating carcinoma within <1 mm of the inked superior and deep margins. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Fuhrman Grade II, Nottingham Score 7, microcalcifications, infiltrating carcinoma within <1 mm of the inked superior and deep margins. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 175,
      "timestamp": "2026-01-19T15:59:53.114501"
    },
    {
      "sample_idx": 995,
      "input": "FINAL DIAGNOSIS: RETROCAVAL MASS, OPEN RESECTION OF RETROPERITONEAL MASS (36 GRAMS) -. PARAGANGLIOMA, 6.5 CM.",
      "response": "```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Paraganglioma. 3. Code: TGCT maps to Retroperitoneal Mass.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Paraganglioma. 3. Code: TGCT maps to Retroperitoneal Mass.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Paraganglioma. 3. Code: TGCT maps to Retroperitoneal Mass.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Paraganglioma. 3. Code: TGCT maps to Retroperitoneal Mass.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Paraganglioma. 3. Code: TGCT maps to Retroperitoneal Mass.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Paraganglioma. 3. Code: TGCT maps to Retroperitoneal Mass.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Paraganglioma. 3. Code: TGCT maps to Retroperitoneal Mass.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Paraganglioma. 3. Code: TGCT maps to Retroperitoneal Mass.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Retroperitoneum. ",
      "predicted": "TGCT",
      "ground_truth": "PCPG",
      "correct": false,
      "reasoning": "1. Site: Retroperitoneum. 2. Findings: Paraganglioma. 3. Code: TGCT maps to Retroperitoneal Mass.",
      "idx": 995,
      "timestamp": "2026-01-19T15:59:53.114510"
    },
    {
      "sample_idx": 141,
      "input": "Diagnosis: Right-sided breast excision material with a poorly differentiated invasive ductal breast. carcinoma measuring about 4.3 cm with invasion of the lymph vessels and a minimum margin. of 3 mm at 6 o 'clock and 10 mm at 12 o 'clock and 1.5 cm or more at 3 and 9 \"clock. No. intraductal tumor component. Tumor classification: M-8500/3, G3, pT 2, pN 3a (14/28), pMx, stage III c. R 0.",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 141,
      "timestamp": "2026-01-19T15:59:53.114520"
    },
    {
      "sample_idx": 1090,
      "input": "Addendum. Clinical Diagnosis & History: with rectosigmoid cancer. Specimens Submitted: 1: SP: Sigmoid and upper rectum open end proximal. 2: SP: Distal ring margin. 3: SP: Proximal ring margin. DIAGNOSIS: 1. SP: Sigmoid and upper rectum open end proximal: Tumor Type: Adenocarcinoma. Histologic Grade: Moderately differentiated. Tumor Location: Rectosigmoid. Tumor Size: Length is 1.5 cm. Width is 1.3 cm. Maximal thickness is 0.2 cm. Tumor Budding: Absent. Increased Tumor Infiltrating Lymphocytes: ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon (proximal and distal margins). 2. Findings: Adenocarcinoma, moderately differentiated, with a rectosigmoid tumor located 9 cm from the proximal margin and 4.5 cm from the distal margin. The tumor is 1.5 cm in length and 1.3 cm in width, invading to a depth of 0.2 cm. Lymphovascular invasion is identified. Surgical margins are free of tumor. The tumor is staged as pT2 (Tumor invades muscularis propria) and N1b (Metastasis in 2-3 regional lymph nodes). The tumor is also classified as stage II. The immunohistochemical staining for DNA mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) is retained in the tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon (proximal and distal margins). 2. Findings: Adenocarcinoma, moderately differentiated, with a rectosigmoid tumor located 9 cm from the proximal margin and 4.5 cm from the distal margin. The tumor is 1.5 cm in length and 1.3 cm in width, invading to a depth of 0.2 cm. Lymphovascular invasion is identified. Surgical margins are free of tumor. The tumor is staged as pT2 (Tumor invades muscularis propria) and N1b (Metastasis in 2-3 regional lymph nodes). The tumor is also classified as stage II. The immunohistochemical staining for DNA mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) is retained in the tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon (proximal and distal margins). 2. Findings: Adenocarcinoma, moderately differentiated, with a rect",
      "predicted": "KIRC",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Rectosigmoid colon (proximal and distal margins). 2. Findings: Adenocarcinoma, moderately differentiated, with a rectosigmoid tumor located 9 cm from the proximal margin and 4.5 cm from the distal margin. The tumor is 1.5 cm in length and 1.3 cm in width, invading to a depth of 0.2 cm. Lymphovascular invasion is identified. Surgical margins are free of tumor. The tumor is staged as pT2 (Tumor invades muscularis propria) and N1b (Metastasis in 2-3 regional lymph nodes). The tumor is also classified as stage II. The immunohistochemical staining for DNA mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) is retained in the tumor. 3. Code: KIRC.",
      "idx": 1090,
      "timestamp": "2026-01-19T15:59:53.114542"
    },
    {
      "sample_idx": 257,
      "input": "RUN DATE: PAGE: 1. RUN TIME: SPEC #. Obtained: CLINICAL HISTORY : STAT, ICD-180.0. SPECIMEN/PROCEDURE. 1. CERVICAL BIOPSY. 2. ENDOMETRIAL BX. IMPRESSION: 1). CERVIX, BIOPSY: Invasive adenocaroinoma, compatible with usual andoservioal type; moderately. difforentiatod; see important comment. Lymphovasoular invasion is not identified. 2). ENDOMETRIUM, BIOPSY: Scant fragments of carcinoma; see diagnosis #1 above. Separate fragments of atrophic endometrium. Distated by: Entered: COMMENT. The cervical...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Cervix (Biopsy). 2. Findings: Invasive adenocarcinoma, compatible with usual cervical type, moderately differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Endometrium (Biopsy). 2. Findings: Scant fragments of carcinoma, compatible with usual endometrial type, moderately differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Cervix (Biopsy). 2. Findings: Invasive adenocarcinoma, compatible with usual cervical type, moderately differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Endometrium (Biopsy). 2. Findings: Scant fragments of carcinoma, compatible with usual endometrial type, moderately differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Cervix (Biopsy). 2. Findings: Invasive adenocarcinoma, compatible with usual cervical type, moderately differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Endometrium (Biopsy). 2. Findings: Scant fragments of carcinoma, compatible with usual endometrial type, moderately differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Cervix (Biopsy). 2. Findings: Invasive adenocarcinoma, compatible with usual cervical type, moderately differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Endometrium (Bi",
      "predicted": "BRCA",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Cervix (Biopsy). 2. Findings: Invasive adenocarcinoma, compatible with usual cervical type, moderately differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 257,
      "timestamp": "2026-01-19T15:59:53.114553"
    },
    {
      "sample_idx": 262,
      "input": "PRIMARY SITE: Cervix. Uterine cervix biopsy: Infiltrative poorly differentiated squamous cell carcinoma.",
      "response": "```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Infiltrative poorly differentiated squamous cell carcinoma. 3. Code: Cervix Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CERV\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Infiltrative poorly differentiated squamous cell carcinoma. 3. Code: Cervix Squamous Cell Carcinoma maps to CERV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Infiltrative poorly differentiated squamous cell carcinoma. 3. Code: Cervix Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Infiltrative poorly differentiated squamous cell carcinoma. 3. Code: Cervix Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Infiltrative poorly differentiated squamous cell carcinoma. 3. Code: Cervix Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Infiltrative poorly differentiated squamous cell carcinoma. 3. Code: Cervix Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Infiltrative poorly differentiated squamous cell carcinoma. 3. Code: Cervix Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Infiltrative poorly differentiated squamous cell carcinoma. ",
      "predicted": "HNSC",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Cervix. 2. Findings: Infiltrative poorly differentiated squamous cell carcinoma. 3. Code: Cervix Squamous Cell Carcinoma maps to HNSC.",
      "idx": 262,
      "timestamp": "2026-01-19T15:59:53.114564"
    },
    {
      "sample_idx": 973,
      "input": "Surgery Date: DIAGNOSIS: A. Pancreas, neck margin, biopsy: Negative for tumor. B. Pancreas, spleen and omentum, distal pancreatectomy, splenectomy. and partial omentectomy: Invasive grade 3 (of 4) adenocarcinoma,. forming a 2.2 x 2.0 X 1.8 cm mass within the body of the pancreas. The tumor extends beyond the pancreas to involve peripancreatic soft. tissue. Perineural invasion is identified. The pancreatic ducts. demonstrate pancreatic intraepithelial neoplasia (PanIN-1A). The. distal pancreas sh...",
      "response": "```json\n{\n    \"cancer_type\": \"ADCA\",\n    \"reasoning\": \"1. Site: Pancreas (body). 2. Findings: Invasive adenocarcinoma, grade 3, forming a 2.2 x 2.0 x 1.8 cm mass, extending beyond the pancreas to involve peripancreatic soft tissue. Perineural invasion is identified. Pancreatic intraepithelial neoplasia (PanIN-1A) is present in the pancreatic ducts. Chronic pancreatitis is present in the distal pancreas. Surgical margins are negative for tumor. 6 peripancreatic lymph nodes are negative for tumor. The spleen is unremarkable. The tumor is T3N0. 3. Code: ADCA maps to ADCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADCA\",\n    \"reasoning\": \"1. Site: Pancreas (body). 2. Findings: Invasive adenocarcinoma, grade 3, forming a 2.2 x 2.0 x 1.8 cm mass, extending beyond the pancreas to involve peripancreatic soft tissue. Perineural invasion is identified. Pancreatic intraepithelial neoplasia (PanIN-1A) is present in the pancreatic ducts. Chronic pancreatitis is present in the distal pancreas. Surgical margins are negative for tumor. 6 peripancreatic lymph nodes are negative for tumor. The spleen is unremarkable. The tumor is T3N0. 3. Code: ADCA maps to ADCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADCA\",\n    \"reasoning\": \"1. Site: Pancreas (body). 2. Findings: Invasive adenocarcinoma, grade 3, forming a 2.2 x 2.0 x 1.8 cm mass, extending beyond the pancreas to involve peripancreatic soft tissue. Perineural invasion is identified. Pancreatic intraepithelial neoplasia (PanIN-1A) is present in the pancreatic ducts. Chronic pancreatitis is present in the distal pancreas. Surgical margins are negative for tumor. 6 peripancreatic lymph nodes are negative for tumor. The spleen is unremarkable. The tumor is T3N0. 3. Code: ADCA maps to ADCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADCA\",\n    \"reasoning\": \"1. Site: Pancreas (body). ",
      "predicted": "ADCA",
      "ground_truth": "PAAD",
      "correct": false,
      "reasoning": "1. Site: Pancreas (body). 2. Findings: Invasive adenocarcinoma, grade 3, forming a 2.2 x 2.0 x 1.8 cm mass, extending beyond the pancreas to involve peripancreatic soft tissue. Perineural invasion is identified. Pancreatic intraepithelial neoplasia (PanIN-1A) is present in the pancreatic ducts. Chronic pancreatitis is present in the distal pancreas. Surgical margins are negative for tumor. 6 peripancreatic lymph nodes are negative for tumor. The spleen is unremarkable. The tumor is T3N0. 3. Code: ADCA maps to ADCA.",
      "idx": 973,
      "timestamp": "2026-01-19T15:59:53.114583"
    },
    {
      "sample_idx": 1125,
      "input": "Recelved: MD, Pho. intraop Pathologist: Performing Physician: CLINICAL HISTORY: -YEAR-OLD FEMALE WITH BIOPSY-PROVEN LEIOMYOSARCOMA, LEFT THIGH. PREOPERATIVE DIAGNOSIS: LEFT KNEE MASS. SPECIMEN TYPE (s) : A: LEFT KNEE MASS. FINAL DIAGNOSIS: A. LEFT KNKE SOFT TISSUE MASS, RESECTION: Moderate to high-grade. leiomyosarcoma (see key pathologic findings) -. KEY PATHOLOGICAL FINDINGS: operation performed: Resection. Tumor location: Left knee. Diagnosis: Leiomyosarcoma. Tumor Grade: Moderate to high gra...",
      "response": "```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left knee mass. 2. Findings: Leiomyosarcoma, moderate to high grade. 3. Code: Leiomyosarcoma maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left knee mass. 2. Findings: Leiomyosarcoma, moderate to high grade. 3. Code: Leiomyosarcoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left knee mass. 2. Findings: Leiomyosarcoma, moderate to high grade. 3. Code: Leiomyosarcoma maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left knee mass. 2. Findings: Leiomyosarcoma, moderate to high grade. 3. Code: Leiomyosarcoma maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left knee mass. 2. Findings: Leiomyosarcoma, moderate to high grade. 3. Code: Leiomyosarcoma maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left knee mass. 2. Findings: Leiomyosarcoma, moderate to high grade. 3. Code: Leiomyosarcoma maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left knee mass. 2. Findings: Leiomyosarcoma, moderate to high grade. 3. Code: Leiomyosarcoma maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Left knee mass. 2. Findings: Leiomyosarcoma, moderate to high grade. 3. Code: Leiomyosarcoma maps to SARC.\"\n}\n```\n",
      "predicted": "SARC",
      "ground_truth": "SARC",
      "correct": true,
      "reasoning": "1. Site: Left knee mass. 2. Findings: Leiomyosarcoma, moderate to high grade. 3. Code: Leiomyosarcoma maps to SARC.",
      "idx": 1125,
      "timestamp": "2026-01-19T15:59:53.114593"
    },
    {
      "sample_idx": 338,
      "input": "CERVICAL LYMPH NODE: Three tissue fragments, the biggest measures3,7 x 2,5 x 0,9 cm and the smallest 0,5 x. 0,4 x 0,3 cm. The section surface shows a homogeneous whitish color. LEFT CERVICAL LYMPH NODE (EXCISION): - PRIMARY MEDIASTINAL DIFFUSE LARGE B-CELL LYMPHOMA. Sections show a lymph node with the architecture effaced by atypical lymphoid. proliferation, composed by sheets of large and pleomorphic cells, some with Reed-. Sternberg morphology, accompanied by a background of small cells. The n...",
      "response": "```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Cervical Lymph Node. 2. Findings: Diffuse Large B-cell Lymphoma (DLBCL). The lymphoma is characterized by sheets of large, pleomorphic cells with Reed-Sternberg morphology and a background of small cells. The cells are positive for CD20, CD79a, CD30, CD23, CD22, BCL2, MUM1/IRF4, and BCL6, and negative for CD10, CD15, and EBER. 3. Code: DLBC maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Cervical Lymph Node. 2. Findings: Diffuse Large B-cell Lymphoma (DLBCL). The lymphoma is characterized by sheets of large, pleomorphic cells with Reed-Sternberg morphology and a background of small cells. The cells are positive for CD20, CD79a, CD30, CD23, CD22, BCL2, MUM1/IRF4, and BCL6, and negative for CD10, CD15, and EBER. 3. Code: DLBC maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Cervical Lymph Node. 2. Findings: Diffuse Large B-cell Lymphoma (DLBCL). The lymphoma is characterized by sheets of large, pleomorphic cells with Reed-Sternberg morphology and a background of small cells. The cells are positive for CD20, CD79a, CD30, CD23, CD22, BCL2, MUM1/IRF4, and BCL6, and negative for CD10, CD15, and EBER. 3. Code: DLBC maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Cervical Lymph Node. 2. Findings: Diffuse Large B-cell Lymphoma (DLBCL). The lymphoma is characterized by sheets of large, pleomorphic cells with Reed-Sternberg morphology and a background of small",
      "predicted": "DLBC",
      "ground_truth": "DLBC",
      "correct": true,
      "reasoning": "1. Site: Cervical Lymph Node. 2. Findings: Diffuse Large B-cell Lymphoma (DLBCL). The lymphoma is characterized by sheets of large, pleomorphic cells with Reed-Sternberg morphology and a background of small cells. The cells are positive for CD20, CD79a, CD30, CD23, CD22, BCL2, MUM1/IRF4, and BCL6, and negative for CD10, CD15, and EBER. 3. Code: DLBC maps to DLBC.",
      "idx": 338,
      "timestamp": "2026-01-19T15:59:53.114609"
    },
    {
      "sample_idx": 1308,
      "input": "MRN1. Service: Thoracic. M. Clinical Diagnosis & History: male with left anterior lung mass,. biopay shows spindle. cell neoplasm. Specimens Submitted: 1: Left anterior mediastinal mass (fs). 2 1 Portion left sixth rib. 3: Left anterior mediastinal lymph node. DIAGNOSIS: 1. Left anterior mediastinal mass (fs) : - Thymoma, type AB. - The tumor measures 16 x 14.5 x 9 .2 cm in greatest dimension. - The tumor invades focally through the capsule into the adipose tissue. - The surgical resection margi...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left anterior mediastinum. 2. Findings: Thymoma, type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left sixth rib. 2. Findings: Unremarkable bony trabeculae and bone marrow with intact trilineage. hematopoiesis. 3. Code: Unremarkable bony trabeculae and bone marrow with intact trilineage. hematopoiesis maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left anterior mediastinal lymph node. 2. Findings: Benign fibroadipose and vascular tissue. No lymph node identified. 3. Code: Benign fibroadipose and vascular tissue maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left anterior mediastinal mass. 2. Findings: Thymoma, type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left sixth rib. 2. Findings: Unremarkable bony trabeculae and bone marrow with intact trilineage. hematopoiesis. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left anterior mediastinal lymph node. 2. Findings: Benign fibroadipose and vascular tissue. No lymph node identified. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left anterior mediastinal mass. 2. Findings: Thymoma, type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left sixth rib. 2. Findings: Unremarkable bony trabeculae and bone marrow with intact triline",
      "predicted": "THYM",
      "ground_truth": "THYM",
      "correct": true,
      "reasoning": "1. Site: Left anterior mediastinum. 2. Findings: Thymoma, type AB. 3. Code: THYM",
      "idx": 1308,
      "timestamp": "2026-01-19T15:59:53.114618"
    },
    {
      "sample_idx": 1080,
      "input": "Diagnosis: A: Tick, left scrotum, removal. - Tick for gross identification only. B: Lymph nodes right pelvic, removal. - No tumor seen in six lymph nodes (0/6). C: Lymph nodes left pelvic, removal. - Metastatic prostatic adenocarcinoma in one of 11 lymph nodes. (1/11) i maximum size of metastasis 0.9 cm; focal extracapsular. extension identified. D: Prostate, robot assisted laparoscopic prostatectomy. Tumor histologic type: Prostatic adenocarcinoma. Tumor grade (Gleason system) : Gleason combine...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason combined score 7 (4+3), with tertiary pattern 5 comprising approximately 4% of tumor. Extracapsular extension of tumor in lymph nodes: Focally present. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Scrotum. 2. Findings: Tick. 3. Code: Not Applicable.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Pelvic Lymph Node. 2. Findings: Metastatic prostatic adenocarcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Pelvic Lymph Node. 2. Findings: Metastatic prostatic adenocarcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason combined score 7 (4+3), with tertiary pattern 5 comprising approximately 4% of tumor. Extracapsular extension of tumor in lymph nodes: Focally present. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason combined score 7 (4+3), with tertiary pattern 5 comprising approximately 4% of tumor. Extracapsular extension of tumor in lymph nodes: Focally present. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma,",
      "predicted": "KIRC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate. 2. Findings: Prostatic adenocarcinoma, Gleason combined score 7 (4+3), with tertiary pattern 5 comprising approximately 4% of tumor. Extracapsular extension of tumor in lymph nodes: Focally present. 3. Code: KIRC.",
      "idx": 1080,
      "timestamp": "2026-01-19T15:59:53.114630"
    },
    {
      "sample_idx": 866,
      "input": "HISTORY. MACROSCOPIC. Four specimens received: 1: The specimen is labelled \"left upper lobe\" and consists of a lobectomy specimen measuring 130 x. 80 X 35 mm. The bronchial portion of the specimen measures approximately 30 mm in length and has. a bifurcation adjacent to the resection margin with two adjacent lumens measuring approximately 13. mm in diameter, one of which is plugged by cream to pink tumour. No palpable mass is present within. the lobectomy specimen. The pleural surface demonstrat...",
      "response": "```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, endobronchial. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, endobronchial. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, endobronchial. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, endobronchial. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, endobronchial. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, endobronchial. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, endobronchial. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, endobronchial. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2",
      "predicted": "SCC",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung. 2. Findings: Squamous cell carcinoma, endobronchial. 3. Code: SCC maps to SCC.",
      "idx": 866,
      "timestamp": "2026-01-19T15:59:53.114639"
    },
    {
      "sample_idx": 433,
      "input": "Case imported from legacy computer system. The format of this report does not match the original  case. For cases prior to. the section \"SPECIMEN\" may have been added. DIAGNOSIS. PROXIMAL MARGIN V-3: Peripheral nerve, no tumor present. (B). LINGUAL MARGIIN: Segment of nerve, no tumor present. BILATERAL NECK DISSECTION RIGHT AND LEFT SUBMANDIBULAR GLAND, SUBTOTAL. GLOSSECTOMY OF FLOOR OF MOUTH RESECTION: SQUAMOUS CARCINOMA GRADE 3 OF FLOOR OF MOUTH, 7 MM IN THICKNESS. Moderate to severe dysplasia...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Floor of mouth. 2. Findings: Squamous cell carcinoma, grade 3. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Floor of mouth. 2. Findings: Squamous cell carcinoma, grade 3. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Floor of mouth. 2. Findings: Squamous cell carcinoma, grade 3. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Floor of mouth. 2. Findings: Squamous cell carcinoma, grade 3. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Floor of mouth. 2. Findings: Squamous cell carcinoma, grade 3. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Floor of mouth. 2. Findings: Squamous cell carcinoma, grade 3. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Floor of mouth. 2. Findings: Squamous cell carcinoma, grade 3. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Floor of mouth. 2. Findings: Squamous cell carcinoma, grade 3. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Floor of mouth. 2. Findings: Squamous cell carcinoma, grade 3. 3. Code: PRAD.\"\n}\n```",
      "predicted": "PRAD",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Floor of mouth. 2. Findings: Squamous cell carcinoma, grade 3. 3. Code: PRAD.",
      "idx": 433,
      "timestamp": "2026-01-19T15:59:53.114649"
    },
    {
      "sample_idx": 1254,
      "input": "Clinical Diagnosis & History: Thyroid carcinoma. Specimens Submitted: 1: Right neck lymph node (fs). 2: Right neck node near accessory nerve (fs). 3: Right supra clavicular node (fs). 4: Right modified neck dissection level 2,3,4 and 5 (fs). 5: Right neck level 4 and 5 additional nodes. 6: Right paratracheal lymph node. 7: Superior mediastinal and pretracheal tissue. 8: Deep mediastinal lymph node. 9: Total thyroidectomy. DIAGNOSIS: 1. Right neck lymph node (fs): Part # 1. Lymph Node Dissection:...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive",
      "predicted": "BRCA",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1254,
      "timestamp": "2026-01-19T15:59:53.114658"
    },
    {
      "sample_idx": 411,
      "input": "CLINICAL HISTORY. developed progressive. three. months ago. On imaging there is a left frontal lobe-centered. enhancing mass. that extends into the corpus callosum. There are also several. enhancing. satellite lesions. MRS demonstrates increased levels of choline,. decreased. NAA, and no lipid or lactate spikes. OPERATIVE DIAGNOSES. Left brain tumor. Operation/Specimen: A: Brain tumor, biopsy. PATHOLOGICAL DIAGNOSIS: A. Brain, site not specified, excisional biopsies: 1. Glioblastoma. 2. MIB-1 pr...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma, with neuronal component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma, with a neuronal component. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma, with a neuronal component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma, with a neuronal component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma, with a neuronal component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma, with a neuronal component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma, with a neuronal component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma, with a neuronal component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma, with a neuronal component. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reason",
      "predicted": "KIRC",
      "ground_truth": "GBM",
      "correct": false,
      "reasoning": "1. Site: Brain. 2. Findings: Glioblastoma, with neuronal component. 3. Code: KIRC.",
      "idx": 411,
      "timestamp": "2026-01-19T15:59:53.114667"
    },
    {
      "sample_idx": 638,
      "input": "Final Diagnosis: A-D. Brain, right frontal mass #1-#4 and CUSA, biopsies: Low-grade oligodendroglioma (WHO grade II). See. comment. Comment: The tumor shows focal high cellularity and increased proliferative activity (up to 3-4 mitoses per 10. HPF and Ki-67 labeling index (up to 10-15%)] suggesting focal early progression. The findings are insufficient. for a grade III designation. Interpreted by: Preliminary Frozen Section Consultation: A. Brain, right frontal mass #1, smears: Glioma. Hold over...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Low-grade oligodendroglioma (WHO grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma (HCC). 3. Code: LIHC maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma multiforme (GBM). 3. Code: STAD maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Lung adenocarcinoma. 3. Code: LUAD maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Ureter. 2. Findings: Urothelial carcinoma. 3. Code: UVM maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Lung squamous cell carcinoma. 3. Code: ESCA maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colon adenocarcinoma. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"READ\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Rectal adenocarcinoma. 3. Code: READ maps to READ.\"\n}\n```\n",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain. 2. Findings: Low-grade oligodendroglioma (WHO grade II). 3. Code: GBM maps to GBM.",
      "idx": 638,
      "timestamp": "2026-01-19T15:59:53.114677"
    },
    {
      "sample_idx": 1299,
      "input": "F. Facility: MD: Specimen(s) Received. 1. Thyroid: Total Thyroid stich marks right upper pole - reg. Diagnosis. Widely invasive bilateral and multifocal papillary carcinoma involving surgical margins, dominant. classical variant, 2.1 cm, left, with extrathyroidal extension and focal thyroiditis: Thyroid. Invasive papillary thyroid carcinoma: Parathyroid, 1 of 2, left. No pathological diagnosis: Parathyroid, left. No pathological diagnosis: Lymph node, isthmic. - -Total thyroidectomy specimen. Sy...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site:",
      "predicted": "BRCA",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1299,
      "timestamp": "2026-01-19T15:59:53.114686"
    },
    {
      "sample_idx": 764,
      "input": "Case ID Gross Description. Microscopic Description. Diagnosis Details. Comments. LUNG TISSUE CHECKLIST. Specimen type: Lobectomy. Tumor site: Lung. Tumor size: 3.2 X 3.2 X 3.2 cm. Histologic type: Adenocarcinoma. Histologic grade: Poorly. differentiated. Tumor extent: Not specified. Other tumor nodules: Not specified. Lymph nodes: 0/6 positive for. metastasis (Regional 0/6). Lymphatic invasion: Not specified. Venous invasion: Not specified. Margins: Not specified. Evidence of neo-adjuvant. treat...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUSC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung. 2. Findings: Adenocarcinoma, poorly differentiated. 3. Code: Lung Adenocarcinoma maps to LUAD.",
      "idx": 764,
      "timestamp": "2026-01-19T15:59:53.114696"
    },
    {
      "sample_idx": 897,
      "input": "De-Identified Specimen Code: SPECIMEN SUBMITTED: Part A: BRONCHUS INTERMEDIUS. LYMPH NODE. Part B: RIGHT PNEUMONECTOMY. Part C: FIRST RIB. Part D: 10R. Part E: 11R. Part F: 12R. Part G: 4R. Part H: PERIPHRENIC LYMPH NODE. Part I: 7. Final Diagnosis. 1. Bronchus intermedius lymph nodes, excision (A) - Invasive squamous cell carcinoma. 2. Right lung, pneumonectomy (B) - Invasive squamous cell carcinoma (see comment). Metastatic squamous cell carcinoma in peribronchial lymph nodes,. - Giant cell re...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bronchus intermedius lymph node. 2. Findings: Invasive squamous cell carcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lung, pneumonectomy. 2. Findings: Invasive squamous cell carcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: First rib. 2. Findings: Bone with no significant pathologic changes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph nodes, 10R, 11R, 12R, 4R, periphrenic lymph node, #7. 2. Findings: Lymph nodes, negative for neoplasm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right hilum. 2. Findings: Tumor measuring 3 cm in greatest dimension. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lung, pneumonectomy. 2. Findings: Tumor measuring 3 cm in greatest dimension. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: First rib. 2. Findings: Bone with no significant pathologic changes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph nodes, 10R, 11R, 12R, 4R, periphrenic lymph node, #7. 2. Findings: Lymph nodes, negative for neoplasm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"",
      "predicted": "KIRC",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Bronchus intermedius lymph node. 2. Findings: Invasive squamous cell carcinoma. 3. Code: KIRC.",
      "idx": 897,
      "timestamp": "2026-01-19T15:59:53.114705"
    },
    {
      "sample_idx": 1059,
      "input": "PATIENT HISTORY: CHIEF COMPLAINT/PRE-OP/POST-OPI DIAGNOSIS: Prostate cancer. PROCEDURE: Radical prostatectomy. SPECIFIC CLINICAL QUESTION: Not stated. OUTSIDE TISSUE DIAGNOSIS: Not stated. PRIOR MALIGNANCY: Not stated. CHEMORADIATION: Not stated. ORGAN TRANSPLANT: Not stated. IMMUNOSUPPRESSION: Not stated. OTHER DISEASES: Not stated. FINAL DIAGNOSIS: PART1: LYMPH NODE, RIGHT PELVIC, EXCISION -. EIGHT BENIGN LYMPH NODES (0/8). PART2: LYMPH NODE, LEFT PELVIC, EXCISION -. SIX BENIGN LYMPH NODES (0/...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason 4/5 percentage 20%. 3. Code: Prostate cancer maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PCPG\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: High grade PIN identified. 3. Code: Prostate cancer maps to PCPG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Right Pelvic). 2. Findings: Benign lymph nodes (0/8). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Left Pelvic). 2. Findings: Benign lymph nodes (0/6). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason 4/5 percentage 20%. 3. Code: Prostate cancer maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason 4/5 percentage 20%. 3. Code: Prostate cancer maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason 4/5 percentage 20%. 3. Code: Prostate cancer maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate.",
      "predicted": "PRAD",
      "ground_truth": "PRAD",
      "correct": true,
      "reasoning": "1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason 4/5 percentage 20%. 3. Code: Prostate cancer maps to PRAD.",
      "idx": 1059,
      "timestamp": "2026-01-19T15:59:53.114716"
    },
    {
      "sample_idx": 924,
      "input": "FINAL DIAGNOSIS: PART 1: LEFT ADNEXUM, LEFT SALPINGO-OOPHORECTOMY -. A. HIGH GRADE ADENOCARCINOMA (27 CM). B. SEROSAL SURFACE FREE. C. FOCAL SURFACE ADHESIONS. D. FALLOPIAN TUBE, FREE OF TUMOR. PART 2: POSTERIOR CUL-DE-SAC NODULE, EXCISION -. INVASIVE HIGH GRADE ADENOCARCINOMA. PART 3: UTERUS, CERVIX, RIGHT ADNEXUM (130 GRAMS), HYSTERECTOMY AND RIGHT SALPINGO-. OOPHORECTOMY-. A. ADENOCARCINOMA INVOLVES UTERINE SEROSA AND FOCALLY OVARIAN SURFACE. B. FALLOPIAN TUBE WITH TUBAL INTRAEPITHELIAL CARCI...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Adnexam, Left Salpingo-Oophorectomy. 2. Findings: High Grade Adenocarcinoma, Serosal Surface Free, Focal Surface Adhesions, Fallopian Tube, Free of Tumor, Invasive High Grade Adenocarcinoma, Atrophic Endometrium, Cervix with Chronic Inflammation and Squamous Metaplasia, Metastatic Adenocarcinoma involves one of seven lymph nodes (1/7), Negative for Tumor, High Grade Adenocarcinoma, Invasive High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Invasive High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High Grade Adenocarcinoma, Negative for Tumor, Negative for Tumor, High",
      "predicted": null,
      "ground_truth": "OV",
      "correct": null,
      "reasoning": "",
      "idx": 924,
      "timestamp": "2026-01-19T15:59:53.114866"
    },
    {
      "sample_idx": 247,
      "input": "Copies To: DIAGNOSIS: A. LEFT PELVIC LYMPH NODES, EXCISION: Metastatic squamous cell carcinoma to three of seven lymph nodes with perinodal venous. involvement (3/7). B. LEFT OBTURATOR LYMPH NODES, EXCISION: Metastatic squamous cell carcinoma to two of two lymph nodes with perinodal venous. involvement (2/2). C. LEFT COMMON LYMPH NODES, EXCISION: Four lymph nodes with no evidence of malignancy (4). D. RIGHT COMMON LYMPH NODES, EXCISION: Metastatic squamous cell carcinoma replacing multiple matte...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Cervix, Uterine. 2. Findings: Invasive squamous cell carcinoma of the uterine cervix, keratinizing type, moderately differentiated. Tumor located within the cervix and involving lower uterine segment myometrium. Tumor dimension, approximately 4.0 cm. Maximum depth of invasion 3.8 cm in a section measuring 4.3 cm. High-grade squamous intraepithelial lesion flanking both sides of the tumor. Lymphovascular invasion is present. Vaginal involvement is not identified. All surgical margins, anterior and posterior vaginal cuffs are negative. Pathologic tumor stage: pTlb, N1 (AJCC Cancer Staging Handbook, 6th Ed., 2002). pT1b2/pN1. Endometrium. Involved by invasive squamous cell carcinoma, keratinizing type, moderately differentiated in lower uterine segment. Background weakly proliferative pattern endometrium. Myometrium. Involved by invasive squamous cell carcinoma, keratinizing type, moderately differentiated in lower uterine segment with angiolymphatic invasion. Leiomyomata. - Adenomyosis. Serosa and parametria negative for malignancy. Focal endometriosis involving uterine serosa. HISTORY: Cervical cancer, squamous cell carcinoma of the cervix, exploratory laparotomy, total abdominal. hysterectomy, bilateral salpingo-oophorectomy and lymph node dissection. MICROSCOPIC: See diagnosis. GROSS: A. LEFT PELVIC LYMPH NODE. Labeled with the patient's name, labeled \"left pelvic lymph node\", and received in formalin is a 4.0 x 2.5 x 0.6 cm. portion of fibrofatty tissue. Six soft, tan lymph nodes were identified ranging from 0.7 to 2.8 cm in maximum. dimension. The specimen is entirely submitted. A1. One lymph node, bisected - 2. A2. One lymph node, bisected - 2. A3. Two lymph nodes - 2. A4. One lymph node and fatty tissue - multiple. A5. One lymph node and fatty tissue - multiple. B. LEFT OBTURATOR LYMPH NODE. Labeled with the patient's name, labeled \"left obturator lymph node\", and received in formalin is a 2.2 x 3.0 x 0.6. cm portion of fibrofatty tissue. Two firm, tan",
      "predicted": null,
      "ground_truth": "CESC",
      "correct": null,
      "reasoning": "",
      "idx": 247,
      "timestamp": "2026-01-19T15:59:53.114984"
    },
    {
      "sample_idx": 507,
      "input": "Sex: M. Histopathological Examination. Pre-Op Diagnosis : Right Renal Mass. Specimens. Kidney, right for. Frozen Diagnosis : : GROSS EXAMINATION: The specimen is received fresh labeled with the name of the. patient and labeled as kidney, right. The specimen consists. of a kidney and attached perinephric fat. The kidney. measures 11.5 X 6 X 4.5 cm and weighs 201 grams. The ureter. and vascular margins are submitted in block 1. The renal. sinus/hilar margin is submitted in block 2. Sectioning into...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Chromophobe renal cell carcinoma, two foci, 3.8 and 1.0 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Chromophobe renal cell carcinoma, two foci, 3.8 and 1.0 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Chromophobe renal cell carcinoma, two foci, 3.8 and 1.0 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Chromophobe renal cell carcinoma, two foci, 3.8 and 1.0 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Chromophobe renal cell carcinoma, two foci, 3.8 and 1.0 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Chromophobe renal cell carcinoma, two foci, 3.8 and 1.0 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Chromophobe renal cell carcinoma, two foci, 3.8 and 1.0 cm. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right",
      "predicted": "KIRC",
      "ground_truth": "KICH",
      "correct": false,
      "reasoning": "1. Site: Kidney (Right). 2. Findings: Chromophobe renal cell carcinoma, two foci, 3.8 and 1.0 cm. 3. Code: KIRC.",
      "idx": 507,
      "timestamp": "2026-01-19T15:59:53.114995"
    },
    {
      "sample_idx": 460,
      "input": "Service: Otolaryngology. Resulted: Facility. Addended. SPECIMEN (S) RECEIVED. 1. Nck: Left neck - level 1B. 2. Neck: Left neck level IIa. 3. Thyroid: Possible pyramidal lobe of thyroid. 4. Oral Cavity: Left cheek deep margin,. 5. Oral Cavity: Lateral lip margin,. 6. Oral Cavity: Palatal margin. 7. Oral Cavity: Posterior cheek margin. 8. Oral Cavity: Left partial maxillectomy and left cheek. 9. Neck: Left neck level I to IV. DIAGNOSIS. 1. Left neck; level IB: - One lymph node, negative for malign...",
      "response": "```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Buccal Mucosa (inner cheek). 2. Findings: Squamous cell carcinoma, moderately differentiated, present in the buccal mucosa. 3. Code: PAAD (Pan-Adenocarcinoma) maps to PAAD because the report mentions squamous cell carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Left cheek deep margin. 2. Findings: Squamous cell carcinoma, moderately differentiated, present in the left cheek. 3. Code: SKCM (Skin Cancer) maps to SKCM because the report mentions squamous cell carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Left neck level I to IV. 2. Findings: Fourteen lymph nodes, negative for malignancy. 3. Code: UVM (Unspecified Malignancy) maps to UVM because the report mentions negative lymph nodes.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Left neck level IIA. 2. Findings: One lymph node, negative for malignancy. 3. Code: UVM (Unspecified Malignancy) maps to UVM because the report mentions negative lymph nodes.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Possible pyramidal lobe of thyroid. 2. Findings: Thyroid tissue, negative for malignancy. 3. Code: UVM (Unspecified Malignancy) maps to UVM because the report mentions negative thyroid tissue.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Left cheek deep margin. 2. Findings: Negative for malignancy. 3. Code: UVM (Unspecified Malignancy) maps to UVM because the report mentions negative findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Lateral lip margin. 2. Findings: Negative for malignancy. 3. Code: UVM (Unspecified Malignancy)",
      "predicted": "PAAD",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Buccal Mucosa (inner cheek). 2. Findings: Squamous cell carcinoma, moderately differentiated, present in the buccal mucosa. 3. Code: PAAD (Pan-Adenocarcinoma) maps to PAAD because the report mentions squamous cell carcinoma.",
      "idx": 460,
      "timestamp": "2026-01-19T15:59:53.115009"
    },
    {
      "sample_idx": 131,
      "input": "Female. Admission Date: Discharge Date: Pathology Addendum Report. Collected Date/Time: Received Date/Time: Addendum Report. ASSAY PERFORMED: HER2 GENE AMPLIFICATION BY DUAL IN SITU HYBRIDIZATION USING THE. HER2 Dual ISH DNA PROBE COCKTAIL. Number of nuclei scored: 20. Total HER2 signals: 60. Total CHR 17 signals: 39. HER2/CHR 17 ratio: 1.5. INTERPRETATION: - NEGATIVE FOR HER2 GENE AMPLIFICATION. NOTE: THE ASSAY WAS PERFORMED AS A REFLEX TEST AFTER THE HER2/NEU IMMUNOSTAIN WAS 2+. SPECIMEN TYPE:...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade 2, 2.5 cm. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade 2, 2.5 cm. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade 2, 2.5 cm. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade 2, 2.5 cm. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade 2, 2.5 cm. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade 2, 2.5 cm. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade 2, 2.5 cm. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade 2, 2.5 cm. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, grade 2, 2.5 cm. 3. Code: BRCA.",
      "idx": 131,
      "timestamp": "2026-01-19T15:59:53.115018"
    },
    {
      "sample_idx": 692,
      "input": "Pathology Result: Specimen Collected Date: Specimen Received Date: Medical Record Number. Facility: Cathologist: Date of Proceduze: Date Received: Oate Reported. Addendus Present. FINAL DIAGNOSIS. A. POSTERIOR SUPERIOR MARGIN, BIOPSY. CEREBRAL CORTEX, NO SOLIO TUMOS IDENTIFIED. 8. POSTERIOR SUPERIOR $ 2. BIOPSY. CERERRAL CORTEX, NO SOLID TUHOR IDENTIFIED. c. ANTERIOR INFERION, BIOPST: -CEREERAL CORTEX, NO SOLID TUMOR IDENTIFIED. o. POSTERIOR INTERION, BIOPSY: CEREBRAL CORTEX AND MILOLY WBITE MAT...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cerebral Cortex. 2. Findings: Glial hypercellularity, no solid tumor identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cerebral Cortex. 2. Findings: Glial hypercellularity, no solid tumor identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cerebral Cortex. 2. Findings: Glial hypercellularity, no solid tumor identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cerebral Cortex. 2. Findings: Glial hypercellularity, no solid tumor identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cerebral Cortex. 2. Findings: Glial hypercellularity, no solid tumor identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cerebral Cortex. 2. Findings: Glial hypercellularity, no solid tumor identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cerebral Cortex. 2. Findings: Glial hypercellularity, no solid tumor identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cerebral Cortex. 2. Findings: Glial hypercellularity, no solid tumor identified. 3. Code: KIRC.\"\n}\n",
      "predicted": "KIRC",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Cerebral Cortex. 2. Findings: Glial hypercellularity, no solid tumor identified. 3. Code: KIRC.",
      "idx": 692,
      "timestamp": "2026-01-19T15:59:53.115029"
    },
    {
      "sample_idx": 43,
      "input": "M. Urology. Clinical Diagnosis & History: HGT1 on biopsy T3 on imaging and exam. Specimens Submitted: 1: Bladder, prostate, seminal vesicles, urachus and urethra. DIAGNOSIS: 1. Bladder, prostate, seminal vesicles, urachus and urethra: Tumor Type: Invasive urothelial carcinoma, NOS, with focal squamous differentiation. Histologic Grade: High grade. Pattern of growth of the Non-Invasive component: Flat (in situ carcinoma). Pattern of growth of the Invasive component: Infiltrating. Tumor Multicentr...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder, prostate, seminal vesicles, urachus and urethra. 2. Findings: Invasive urothelial carcinoma, NOS, with focal squamous differentiation. High grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder, prostate, seminal vesicles, urachus and urethra. 2. Findings: Invasive urothelial carcinoma, NOS, with focal squamous differentiation. High grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder, prostate, seminal vesicles, urachus and urethra. 2. Findings: Invasive urothelial carcinoma, NOS, with focal squamous differentiation. High grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder, prostate, seminal vesicles, urachus and urethra. 2. Findings: Invasive urothelial carcinoma, NOS, with focal squamous differentiation. High grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder, prostate, seminal vesicles, urachus and urethra. 2. Findings: Invasive urothelial carcinoma, NOS, with focal squamous differentiation. High grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder,",
      "predicted": "KIRC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Bladder, prostate, seminal vesicles, urachus and urethra. 2. Findings: Invasive urothelial carcinoma, NOS, with focal squamous differentiation. High grade. 3. Code: KIRC.",
      "idx": 43,
      "timestamp": "2026-01-19T15:59:53.115041"
    },
    {
      "sample_idx": 1204,
      "input": "Diagnosis/diagnoses: 2.: Total gastrectomy preparation with part of transverse colon attached. Stomach with an. ulcerated gastric carcinoma located in the middle of the stomach on the side of the greater. curvature, extending to within 5 cm of the aboral and 7 cm of the oral resection margin,. encroaching on the anterior and posterior wall of the stomach, with a maximum diameter of 7. cm and characterized histologically as a poorly differentiated adenocarcinoma (gastric. carcinoma of the intesti...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric carcinoma, poorly differentiated adenocarcinoma (gastric carcinoma of the intestinal type). 3. Code: Stomach Gastric Carcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric carcinoma, poorly differentiated adenocarcinoma (gastric carcinoma of the intestinal type). 3. Code: Stomach Gastric Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric carcinoma, poorly differentiated adenocarcinoma (gastric carcinoma of the intestinal type). 3. Code: Stomach Gastric Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric carcinoma, poorly differentiated adenocarcinoma (gastric carcinoma of the intestinal type). 3. Code: Stomach Gastric Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric carcinoma, poorly differentiated adenocarcinoma (gastric carcinoma of the intestinal type). 3. Code: Stomach Gastric Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric carcinoma, poorly differentiated adenocarcinoma (gastric carcinoma of the intestinal type). 3. Code: Stomach Gastric Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric carcinoma, poorly differentiated adenocarcinoma (gastric carcinoma of the intestinal type). 3. Code: Stomach Gastric Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. ",
      "predicted": "STAD",
      "ground_truth": "STAD",
      "correct": true,
      "reasoning": "1. Site: Stomach. 2. Findings: Gastric carcinoma, poorly differentiated adenocarcinoma (gastric carcinoma of the intestinal type). 3. Code: Stomach Gastric Carcinoma maps to STAD.",
      "idx": 1204,
      "timestamp": "2026-01-19T15:59:53.115052"
    },
    {
      "sample_idx": 1134,
      "input": "Clinical Diagnosis & History: Specimens Submitted: 1: Left spermatic cord with liposarcoma and left testis. DIAGNOSIS: 1. Left spermatic cord and left testis; radical orchiectomy: - High grade leiomyosarcoma with spindle and epithelioid features. involving spermatic cord. - Tumor is seen as two nodules, 4.5 x 3.5 x 2.0cm, and 3.5 x 2.8 x. 1.5cm. -Tumor wraps around spermatic cord and involves adipose tissue and. skeletal muscle. - There is 15% gross necrosis. - Mitoses: 20 mitoses per 50 high po...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left spermatic cord and left testis. 2. Findings: High grade leiomyosarcoma with spindle and epithelioid features, involving spermatic cord, and tumor is seen as two nodules, 4.5 x 3.5 x 2.0cm, and 3.5 x 2.8 x 1.5cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left spermatic cord and left testis. 2. Findings: High grade leiomyosarcoma with spindle and epithelioid features, involving spermatic cord, and tumor is seen as two nodules, 4.5 x 3.5 x 2.0cm, and 3.5 x 2.8 x 1.5cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left spermatic cord and left testis. 2. Findings: High grade leiomyosarcoma with spindle and epithelioid features, involving spermatic cord, and tumor is seen as two nodules, 4.5 x 3.5 x 2.0cm, and 3.5 x 2.8 x 1.5cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left spermatic cord and left testis. 2. Findings: High grade leiomyosarcoma with spindle and epithelioid features, involving spermatic cord, and tumor is seen as two nodules, 4.5 x 3.5 x 2.0cm, and 3.5 x 2.8 x 1.5cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left spermatic cord and left",
      "predicted": "KIRC",
      "ground_truth": "SARC",
      "correct": false,
      "reasoning": "1. Site: Left spermatic cord and left testis. 2. Findings: High grade leiomyosarcoma with spindle and epithelioid features, involving spermatic cord, and tumor is seen as two nodules, 4.5 x 3.5 x 2.0cm, and 3.5 x 2.8 x 1.5cm. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 1134,
      "timestamp": "2026-01-19T15:59:53.115069"
    },
    {
      "sample_idx": 471,
      "input": "Final Diagnosis. Anterior deep margin of tongue (FSA1), biopsy: Diffusely infiltrating squamous cell carcinoma. Middle deep margin of tongue (FSA2): Diffusely infiltrating squamous cell carcinoma. Almost total glossectomy with frozen section examination: Posterior shaved margin positive for squamous cell carcinoma. Medial shaved margin positive for squamous cell carcinoma. Areas of lymphovascular invasion are identified. Perineural invasion identified. Random sections of tongue show diffuse inva...",
      "response": "```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Anterior deep margin). 2. Findings: Diffusely infiltrating squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Middle deep margin). 2. Findings: Diffusely infiltrating squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Posterior shaved margin). 2. Findings: Diffusely infiltrating squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Medial shaved margin). 2. Findings: Diffusely infiltrating squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Posterior). 2. Findings: Diffusely infiltrating squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Medial). 2. Findings: Diffusely infiltrating squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Tip). 2. Findings: Diffusely infiltrating squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Anterior deep margin). 2. Findings: Diffusely infiltrating squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue (Middle deep margin). 2. Findings: Diffusely infiltrating squamous cell carcinoma. 3. Code:",
      "predicted": "SCC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Tongue (Anterior deep margin). 2. Findings: Diffusely infiltrating squamous cell carcinoma. 3. Code: SCC maps to SCC.",
      "idx": 471,
      "timestamp": "2026-01-19T15:59:53.115080"
    },
    {
      "sample_idx": 1205,
      "input": "STOMACH TISSUE CHECKLIST. Specimen type: Gastrectomy. Tumor site: Stomach. Tumor size: 9.5 X 4 X 1.2 cm. Tumor features: Exophytic (polypoid). Histologic type: Adenocarcinoma. Histologic grade: Poorly. differentiated. Tumor extent: Adjacent structures. (specify) - lesser omentum. Lymph nodes: 0/5 positive for. metastasis ( 0/5). Lymphatic invasion: Not specified. Venous invasion: Not specified. Perineural invasion: Not specified. Margins: Not specified. Evidence of neo-adjuvant treatment: Not sp...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with tumor size 9.5 x 4 x 1.2 cm and extension to the lesser omentum. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENCA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with tumor size 9.5 x 4 x 1.2 cm and extension to the lesser omentum. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with tumor size 9.5 x 4 x 1.2 cm and extension to the lesser omentum. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with tumor size 9.5 x 4 x 1.2 cm and extension to the lesser omentum. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with tumor size 9.5 x 4 x 1.2 cm and extension to the lesser omentum. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with tumor size 9.5 x 4 x 1.2 cm and extension to the lesser omentum. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reason",
      "predicted": "STAD",
      "ground_truth": "STAD",
      "correct": true,
      "reasoning": "1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with tumor size 9.5 x 4 x 1.2 cm and extension to the lesser omentum. 3. Code: Stomach Adenocarcinoma maps to STAD.",
      "idx": 1205,
      "timestamp": "2026-01-19T15:59:53.115093"
    },
    {
      "sample_idx": 1388,
      "input": "View Detail. Ord #=. ASAP. Sched D/T=. Ord Clin=. RESULTED. Collect D/T=. Resulted by= SYS, SYSTEM. Result D/T=. Item Comment: Item Custom Questions: How Many Part Types 6. Modifiers: (1 of 1). CoPath Specimen. Source: A: Uterus, Cervix, bilateral tubes IT\\ ovaries, ( Frozen section. B: Omentum, ( Permanent ). C: Right Pelvic lymph node. D: Left Pelvic lymph node. E: Left Para-aortic lymph node. F: Right Para-aortic lymph node. Final Diagnosis. A. Uterus, cervix, bilateral tubes and ovaries (F/S...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1388,
      "timestamp": "2026-01-19T15:59:53.115103"
    },
    {
      "sample_idx": 14,
      "input": "Clinical Diagnosis/History: The patient is a. year-old woman who presented in. with gross. hematuria. She underwent a transurethral resection of a. high-grade muscle invasive transitional cell carcinoma of the bladder. The this TCGA tumor. patient now undergoes a radical cystectomy with. resection of the uterus, vagina, bilateral tubes and ovaries. Gross Description: The specimen is received in seven parts, each labeled with the patient's name. and medical record number. Parts A-C are received. ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, high-grade, invading muscularis propria; negative surgical margins. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}",
      "predicted": "KIRC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, high-grade, invading muscularis propria; negative surgical margins. 3. Code: KIRC.",
      "idx": 14,
      "timestamp": "2026-01-19T15:59:53.115113"
    },
    {
      "sample_idx": 145,
      "input": "Material. Submitted: left breast. Clinical. History: Clinical. Diagnosis: Operating. Gross Examination: Received is a container labeled with the patient's name, history number and date. In. addition the container is labeled \"left breast\". The specimen is received in the fresh state. and consists of a breast and attached axillary tail weighing 560 grams and measuring 37.0 x. with a maximum diameter of 7.0 cm. The skin is notable for a large bruise in the lower. 17.5 x 3.0 em. in greatest dimensio...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3, poorly differentiated. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 145,
      "timestamp": "2026-01-19T15:59:53.115123"
    },
    {
      "sample_idx": 120,
      "input": "page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Total organ resection - right breast. Internal referral. Expected time of examination: up to 8 working days. Clinical diagnosis: Based on PCI, cellulae carcinomatosae - lesion covering the lower part of the breast. Macroscopic description: Right breast sized 27 x 23 x 3 cm removed without axillary tissues and with a skin flap of 27 x 14 cm. Skin injected with blue dye. Tumour sized...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma and ductal carcinoma in situ of the right breast. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma and ductal carcinoma in situ of the right breast. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma and ductal carcinoma in situ of the right breast. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma and ductal carcinoma in situ of the right breast. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma and ductal carcinoma in situ of the right breast. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma and ductal carcinoma in situ of the right breast. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma and ductal carcinoma in situ of the right breast. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma and ductal carcinoma in situ of the right breast. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive mucinous carcinoma and ductal carcinoma in situ of the right breast. 3. Code: BRCA.",
      "idx": 120,
      "timestamp": "2026-01-19T15:59:53.115133"
    },
    {
      "sample_idx": 468,
      "input": "Specimen(s) Received. 1. Nck: contents left neck. 2. Oral cavity:It.oral major resection -short medial long anterior. 3. Oral Cavity: t.posterior margin. 4. Oral avity:It.anterior margin. 5. Oral Cavity:It.lateral mucosa margin. 6. Oral Cavity:deep muscle margin. 7. Surgical Waste. 8. Neck: contents rt neck. 9. Lymph node: lt. facial node. 10. Lymph node:It neck III node. 11. Lymph node:It facial node. Diagnosis. 1. Contents left neck. Metastatic squamous cell carcinoma involving six of thirty-f...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral cavity. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral cavity. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral cavity. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral cavity. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral cavity. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral cavity. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral cavity. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral cavity. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral cavity. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site:",
      "predicted": "BRCA",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Oral cavity. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: BRCA",
      "idx": 468,
      "timestamp": "2026-01-19T15:59:53.115143"
    },
    {
      "sample_idx": 138,
      "input": "F. Pathologic Interpretation: A. Lymph node, sentinel lymph node: - No malignancy seen in one lymph node (0/1). - Keratin immunostain pending. B. Skin left breast: - Skin, no pathologic change. C. Left breast lumpectomy: - Infiltrating poorly differentiated ductal carcinoma, high nuclear grade, 2.4 cm in greatest dimension. - Margins of resection are free of tumor. - Lymphovascular space invasion is present. - Previous biopsy site identified. - The tumor cells are positive for ER and PR, and neg...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.",
      "idx": 138,
      "timestamp": "2026-01-19T15:59:53.115151"
    },
    {
      "sample_idx": 64,
      "input": "Encounter Number. COPY ONLY DO NOT FILE. SURGICAL PATHOLO. Correction. Source of Specimen. A. LEFT DISTAL URETER MARGIN FS-. B. RIGHT DISTAL URETER MARGIN FS-. C. DISTAL URETHRAL MARGIN OF RADICAL CYSTECTOMY SPECIMEN FS-. D. LEFT PELVIC LYMPH NODE-. E. RIGHT PELVIC LYMPH NODE-. F. BLADDER AND PROSTATE GLAND, SEMINAL VESICLES-. Reason for Correction. TO CORRECT TYPOGRAPHICAL ERROR. FINAL DIAGNOSIS: A. LEFT DISTAL URETER MARGIN FS-. SEGMENT OF URETER, NO TUMOR SEEN. B. RIGHT DISTAL URETER MARGIN F...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Distal Ureter. 2. Findings: No tumor seen in ureter. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Car",
      "predicted": "KIRC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Distal Ureter. 2. Findings: No tumor seen in ureter. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 64,
      "timestamp": "2026-01-19T15:59:53.115161"
    },
    {
      "sample_idx": 676,
      "input": "Diagnosis : A, B: Brain, right frontal region, excision. - Oligodendroglioma, WHO grade II. Comment: Sections of the tumor were sent to the Cytogenetics Laboratory. for 1p19q testing. The results of these tests will be reported. separately by the Cytogenetics Laboratory. reviewed this case and concurs with the diagnosis. Intraoperative Consult Diagnosis: An in. a. rative consultation was requested by. on. from. Smear A1 : Right frontal tumor, biopsy. W gr. oma. at. Frozen Section Pathologist: in...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right Frontal Region). 2. Findings: Oligodendroglioma, WHO grade II. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right Frontal Region). 2. Findings: Oligodendroglioma, WHO grade II. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right Frontal Region). 2. Findings: Oligodendroglioma, WHO grade II. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right Frontal Region). 2. Findings: Oligodendroglioma, WHO grade II. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right Frontal Region). 2. Findings: Oligodendroglioma, WHO grade II. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right Frontal Region). 2. Findings: Oligodendroglioma, WHO grade II. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right Frontal Region). 2. Findings: Oligodendroglioma, WHO grade II. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right Frontal Region). 2. Findings: Oligodendroglioma, WHO grade II. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain (Right Frontal Region). 2. Findings: Oligodendroglioma, WHO grade II. 3. Code: GBM maps to GBM.",
      "idx": 676,
      "timestamp": "2026-01-19T15:59:53.115170"
    },
    {
      "sample_idx": 1386,
      "input": "Specimens Submitted: 1: SP: Uterua, cervix, ovaries and fallopian tubes; total abdominal. hysterectomy and bilateral salpingo-oophorectomy. 2: SP: Sentinel lymph node, oburator, left. 3: SP: Sentinel lymph node, obturator, right. DIAGNOSIS: 1. SP: Uterus, cervix, ovaries and fallopian tubes; total abdominal. hysterectomy and bilateral salpingo-oophorectomy: Tumor Type: Adenocarcinome. endometricid type. Architectural Grade (For Endometricid Types only): II (5-50% solid growth). Nuclear Grade (Fo...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Adenocarcinoma, endometrial type. Architectural Grade II, Nuclear Grade 2, FIGO Grade 2. Myometrial Invasion: in maximum depth. Endocervical Invasion: Not identified. Lymphovascular invasion: Identified. Endometrium: Exhibits complex hyperplamia with atypia. Myometrium: Exhibits adenomyosis. Adnexa: Unremarkable. 3. Code: UCEC (Uterine Corpus Endometrium) maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Adenocarcinoma, endometrial type. Architectural Grade II, Nuclear Grade 2, FIGO Grade 2. Myometrial Invasion: in maximum depth. Endocervical Invasion: Not identified. Lymphovascular invasion: Identified. Endometrium: Exhibits complex hyperplamia with atypia. Myometrium: Exhibits adenomyosis. Adnexa: Unremarkable. 3. Code: UCEC (Uterine Corpus Endometrium) maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Adenocarcinoma, endometrial type. Architectural Grade II, Nuclear Grade 2, FIGO Grade 2. Myometrial Invasion: in maximum depth. Endocervical Invasion: Not identified. Lymphovascular invasion: Identified. Endometrium: Exhibits complex hyperplamia with atypia. Myometrium: Exhibits adenomyosis. Adnexa: Unremarkable. 3. Code: UCEC (Uterine Corpus Endometrium) maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Adenocarcinoma, endometrial type. Architectural Grade II, Nuclear Grade 2, FIGO Grade 2. Myometrial Invasion: in maximum depth. Endocervical Invasion: Not identified. Lymphovascular invasion: Identified. Endometrium: Exhibits complex hyperplamia with atypia. Myometrium: Exhibits adenomyosis. Adnexa: Unremarkable. 3",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus. 2. Findings: Adenocarcinoma, endometrial type. Architectural Grade II, Nuclear Grade 2, FIGO Grade 2. Myometrial Invasion: in maximum depth. Endocervical Invasion: Not identified. Lymphovascular invasion: Identified. Endometrium: Exhibits complex hyperplamia with atypia. Myometrium: Exhibits adenomyosis. Adnexa: Unremarkable. 3. Code: UCEC (Uterine Corpus Endometrium) maps to UCEC.",
      "idx": 1386,
      "timestamp": "2026-01-19T15:59:53.115186"
    },
    {
      "sample_idx": 1052,
      "input": "MODIFIED REPORT - REVIEW ADDENDUM SECTION. DIAGNOSIS. (A) RIGHT PELVIC LYMPH NODES: Seven lymph nodes, no tumor present. (0/7). (B) LEFT PELVIC LYMPH NODES: Four lymph nodes, no tumor present. (0/4). (C) PROSTATE AND SEMINAL VESICLES: Supplemental report to follow. Entire report and diagnosis completed by. GROSS DESCRIPTION. (A) RIGHT PELVIC LYMPH NODES - Consists of a single yellow-red fragment of fibroadipose tissue (8 x 4 x 1 cm). Sectioning. reveals seven possible lymph nodes, ranging in siz...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostatic adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5 component. 3. Code: PRAD.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostatic adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5 component. 3. Code: PRAD.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostatic adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5 component. 3. Code: PRAD.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostatic adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5 component. 3. Code: PRAD.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostatic adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5 component. 3. Code: PRAD.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostatic adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5 component. 3. Code: PRAD.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostatic adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5 component. 3.",
      "predicted": "PRAD",
      "ground_truth": "PRAD",
      "correct": true,
      "reasoning": "1. Site: Prostate and Seminal Vesicles. 2. Findings: Prostatic adenocarcinoma, Gleason Score 7 (4+3) with tertiary Gleason Grade 5 component. 3. Code: PRAD.",
      "idx": 1052,
      "timestamp": "2026-01-19T15:59:53.115197"
    },
    {
      "sample_idx": 487,
      "input": "DIAGNOSIS. (A) LEFT NECK LEVEL 1: METASTATIC SQUAMOUS CARCINOMA IN ONE OF TWELVE LYMPH NODES(1/12). Extracapsular extension is not identified. (B) LEFT NECK DISSECTION, LEVEL II: METASTATIC SQUAMOUS CARCINOMA IN ONE OF TEN LYMPH NODES (1/10). Extracapsular extension is not identified. (C) LEFT NECK DISSECTION, LEVEL III: METASTATIC SQUAMOUS CARCINOMA IN ONE OF TWELVE LYMPH NODES (1/12). Extracapsular extension is not identified. (D) LEFT NECK DISSECTION, LEVEL IV: Thirteen lymph nodes, no tumor ...",
      "response": "```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma of the tongue. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma of the tongue. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma of the tongue. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma of the tongue. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma of the tongue. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma of the tongue. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma of the tongue. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma of the tongue. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma of the tongue. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"",
      "predicted": "SCC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Tongue. 2. Findings: Invasive squamous cell carcinoma of the tongue. 3. Code: SCC maps to SCC.",
      "idx": 487,
      "timestamp": "2026-01-19T15:59:53.115206"
    },
    {
      "sample_idx": 570,
      "input": "Clinical Diagnosis & History: vith right renal mass,. Specimens Submitted: 1: SP: Kidney, right renal tumor, partial nephrectomy. DIAGNOSIS: 1. SP: Kidney, right renal tumor, partial nephrectomy. m): Tumor Type: Renal cell carcinoma - Conventional (clear cell) type. Fuhrman Nuclear Grade: Nuclear grade III/IV. Tumor Size: Greatest diemeter is 4.0 cm. Local Invasion (for renal cortical types): Not Identified. Renal Vein Invesion: Not identified. Surgical Margins: Free of tumor. Non-Neoplastic Kid...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. Tumor Size: Greatest diameter is 4.0 cm. Local Invasion: Not identified. Renal Vein Invasion: Not identified. Surgical Margins: Free of tumor. Non-Neoplastic Kidney: Unremarkable. Adrenal Gland: Not identified. Lymph Nodes: Not identified. Steging for renal cell carcinoma/oncocytoma: pT1 Tumor <= 7.0 cm in greatest dimension limited to the kidney. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. Tumor Size: Greatest diameter is 4.0 cm. Local Invasion: Not identified. Renal Vein Invasion: Not identified. Surgical Margins: Free of tumor. Non-Neoplastic Kidney: Unremarkable. Adrenal Gland: Not identified. Lymph Nodes: Not identified. Steging for renal cell carcinoma/oncocytoma: pT1 Tumor <= 7.0 cm in greatest dimension limited to the kidney. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. Tumor Size: Greatest diameter is 4.0 cm. Local Invasion: Not identified. Renal Vein Invasion: Not identified. Surgical Margins: Free of tumor. Non-Neoplastic Kidney: Unremarkable. Adrenal Gland: Not identified. Lymph Nodes: Not identified. Steging for renal cell carcinoma/oncocytoma: pT1 Tumor <= 7.0 cm in greatest dimension limited to the kidney. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. Tumor Size: Greatest diameter is 4.0 cm. Local Invasion: Not identified. Renal Vein Invasion: Not identified. Surgical Margins: Free of tumor. Non-Neoplastic Kidney: Unremarkable. Adrenal Gland: Not identified. Lymph Nodes: Not identified. Steging for renal cell carcinoma/oncocytoma: pT1 Tumor <= 7.0 cm in greatest dimension limited to the kidney. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 570,
      "timestamp": "2026-01-19T15:59:53.115225"
    },
    {
      "sample_idx": 994,
      "input": "DIAGNOSIS: Left adrenal, adrenalectomy: Pheochromocytoma. See. note. NOTE: Immunohistochemistry studies will be performed and reported as a. supplemental report. CLINICAL INFORMATION: Allocate Order to Protocol: Brief. Clinical History: pheochromocytoma Specimen Taken For Protocol: PROCEDURE: Pre-Operative Diagnosis: pheochromocytoma Post-Operative. Diagnosis: pheochromocytoma Operative Findings: left bilobular adrenal. tumor. SPECIMENS SUBMITTED: 1. ADRENAL GLAND, LEFT, Pheochromocytoma. GROSS ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left adrenal gland. 2. Findings: Pheochromocytoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left adrenal gland. 2. Findings: Pheochromocytoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left adrenal gland. 2. Findings: Pheochromocytoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left adrenal gland. 2. Findings: Pheochromocytoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left adrenal gland. 2. Findings: Pheochromocytoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left adrenal gland. 2. Findings: Pheochromocytoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left adrenal gland. 2. Findings: Pheochromocytoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left adrenal gland. 2. Findings: Pheochromocytoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left adrenal gland. 2. Findings: Pheochromocytoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left adrenal gland. 2. Findings:",
      "predicted": "KIRC",
      "ground_truth": "PCPG",
      "correct": false,
      "reasoning": "1. Site: Left adrenal gland. 2. Findings: Pheochromocytoma. 3. Code: KIRC.",
      "idx": 994,
      "timestamp": "2026-01-19T15:59:53.115235"
    },
    {
      "sample_idx": 438,
      "input": "Case imported from legacy computer system. The format of this report does not match the original case. For cases prior to. he section \"SPECIMEN\" may have been added. DIAGNOSIS : (0) (P) LEFT AND RIGHT BODY OF MANDIBLE: INVOLVED BY INVASIVE MODERATELY DIFFERENTIATED SQUAMOUS CELL CARCINOMA;. RIGHT AND LEFT LATERAL MANDIBULAR RESECTION MARGINS FREE OF TUMOR. D:N. DIAGNOSIS : (A) LEFT JUGULAR LYMPH NODES: All of twelve lymph nodes, free of carcinoma. (B). LEFT SUBMANDIBULAR TRIANGLE: ONE OF SIX LYM...",
      "response": "```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Mandible (Left and Right Body). 2. Findings: Invasive moderately differentiated squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Mandible (Left and Right Body). 2. Findings: Invasive moderately differentiated squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Mandible (Left and Right Body). 2. Findings: Invasive moderately differentiated squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Mandible (Left and Right Body). 2. Findings: Invasive moderately differentiated squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Mandible (Left and Right Body). 2. Findings: Invasive moderately differentiated squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Mandible (Left and Right Body). 2. Findings: Invasive moderately differentiated squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Mandible (Left and Right Body). 2. Findings: Invasive moderately differentiated squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Mandible (Left and Right Body). 2. Findings: Invasive moderately differentiated squamous cell carcinoma. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Mandible (Left and Right Body",
      "predicted": "SCC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Mandible (Left and Right Body). 2. Findings: Invasive moderately differentiated squamous cell carcinoma. 3. Code: SCC maps to SCC.",
      "idx": 438,
      "timestamp": "2026-01-19T15:59:53.115246"
    },
    {
      "sample_idx": 1251,
      "input": "SPECIMEN TAKEN: FINAL DIAGNOSIS. 1) DELPHIAN LYMPH NODE (EXCISION): ONE (1) LYMPH NODE AND. ASSOCIATED FIBROADIPOSE TISSUE, NEGATIVE FOR TUMOR. 2) LEFT ENLARGED INFERIOR PARATHYROID (EXCISION): ONE (1) LYMPH. NODE AND ASSOCIATED FIBROADIPOSE TISSUE, NEGATIVE FOR TUMOR. 3) THYROID (TOTAL THYROIDECTOMY, CENTRAL NECK DISSECTION): SPECIMEN TYPE: Total thyroidectomy. TUMOR SITE: Right lobe. Left lobe. LARGEST TUMOR SIZE: 1.8 centimeters (right lobe). HISTOLOGIC TYPE: Papillary carcinoma. FOCALITY: Mu...",
      "response": "```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid (Total thyroidectomy, central neck dissection). 2. Findings: Papillary carcinoma, multifocal (right and left lobe, right lobe predominantly). Lymph nodes are negative for tumor. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Lymphocytic thyroiditis. Parathyroid gland tissue present (lateral aspect of right inferior lobe). 3. Code: Thymus maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Lymph Node (Delphian). 2. Findings: Negative for tumor. 3. Code: Lymph Node maps to BLCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Left Inferior Parathyroid). 2. Findings: Negative for tumor. 3. Code: Lymph Node maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ACC\",\n    \"reasoning\": \"1. Site: Lymph Node (Delphian). 2. Findings: Negative for tumor. 3. Code: Lymph Node maps to ACC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Left Inferior Parathyroid). 2. Findings: Negative for tumor. 3. Code: Lymph Node maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Lymph Node (Left Inferior Parathyroid). 2. Findings: Negative for tumor. 3. Code: Lymph Node maps to BLCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Left Inferior Parathyroid). 2. Findings: Negative for tumor. 3. Code: Lymph Node maps to KIRC.\"\n}\n```\n```",
      "predicted": "THCA",
      "ground_truth": "THCA",
      "correct": true,
      "reasoning": "1. Site: Thyroid (Total thyroidectomy, central neck dissection). 2. Findings: Papillary carcinoma, multifocal (right and left lobe, right lobe predominantly). Lymph nodes are negative for tumor. 3. Code: Thyroid Carcinoma maps to THCA.",
      "idx": 1251,
      "timestamp": "2026-01-19T15:59:53.115259"
    },
    {
      "sample_idx": 270,
      "input": "Female. Surgery Date: DIAGNOSIS: Liver, segment IVB, and gallbladder, resection: Invasive grade 3 (of 4). cholangiocarcinoma forming a hilar mass (10.0 x 9.4 x 7.0 cm) . The tumor invades. into the wall of the gallbladder. The gallbladder mucosa shows cholesterolosis. The. surgical margins are negative. Omentum, biopsy: Metastatic cholangiocarcinoma. Soft tissue, peri duodenal region, excision: Metastatic cholangiocarcinoma.",
      "response": "```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Liver (segment IVB) and Gallbladder. 2. Findings: Cholangiocarcinoma, hilar mass, grade 3. The tumor invades the gallbladder wall. 3. Code: CHOL (Cholangiocarcinoma) maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Omentum, peri duodenal region. 2. Findings: Metastatic cholangiocarcinoma. 3. Code: PAAD (Pancreatic Adenocarcinoma) maps to PAAD.\n\"}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Gallbladder. 2. Findings: Cholangiocarcinoma, gallbladder mucosa shows cholesterolosis. 3. Code: UCEC (Uterine Corpus Endometrial Carcinoma) maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (segment IVB). 2. Findings: Cholangiocarcinoma, hilar mass, grade 3. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Omentum, peri duodenal region. 2. Findings: Metastatic cholangiocarcinoma. 3. Code: UVM (Uterine Corpus Endometrial Carcinoma) maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (segment IVB). 2. Findings: Cholangiocarcinoma, hilar mass, grade 3. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (segment IVB). 2. Findings: Cholangiocarcinoma, hilar mass, grade 3. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) maps to K",
      "predicted": "CHOL",
      "ground_truth": "CHOL",
      "correct": true,
      "reasoning": "1. Site: Liver (segment IVB) and Gallbladder. 2. Findings: Cholangiocarcinoma, hilar mass, grade 3. The tumor invades the gallbladder wall. 3. Code: CHOL (Cholangiocarcinoma) maps to CHOL.",
      "idx": 270,
      "timestamp": "2026-01-19T15:59:53.115269"
    },
    {
      "sample_idx": 1169,
      "input": "aterality:Adenocarcinoma of the stomach, G-3, with invasion into the. perigastric fat. Five examined lymph nodes form greater curvature and five examnined lymph nodes. form lesser curvature demonstrated metastases. In the omentum there is focal preivascular lymphoid. infiltration. Path Report:STOMACH TISSUE CHECKLIST. Specimen type: Subtotal gastrectomy. Tumor site: Antrum. Tumor size: 4 X 0 X 6 cm. Tumor features: Ulcerated. Histologic type: Adenocarcinoma. Histologic grade: Poorly differentiat...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with lymph node metastasis. 3. Code: STAD maps to Stomach Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma. 3. Code: ADENOCA maps to Stomach Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with lymph node metastasis. 3. Code: STAD maps to Stomach Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with lymph node metastasis. 3. Code: STAD maps to Stomach Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with lymph node metastasis. 3. Code: STAD maps to Stomach Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with lymph node metastasis. 3. Code: STAD maps to Stomach Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with lymph node metastasis. 3. Code: STAD maps to Stomach Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with lymph node metastasis. 3. Code: STAD maps to Stomach Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"",
      "predicted": "STAD",
      "ground_truth": "STAD",
      "correct": true,
      "reasoning": "1. Site: Stomach. 2. Findings: Adenocarcinoma, poorly differentiated, with lymph node metastasis. 3. Code: STAD maps to Stomach Adenocarcinoma.",
      "idx": 1169,
      "timestamp": "2026-01-19T15:59:53.115280"
    },
    {
      "sample_idx": 1180,
      "input": "PRIMARY SITE: Stomach (Gastroesophageal junction). \"Esophagus + stomach\": Poorly differentiated adenocarcinoma, invasive and ulcerated. Size of the neoplasm: 7.0 x 4.7 x 2.4cm (2.4cm deep). Location: esophagogastric transition. Depth of infiltration: up to subserosa. Sanguineous vascular invasion: not detected. Lymphatic vascular invasion: present. Perineural invasion: present. Adjacent gastric mucosa: intense active chronic gastritis. Omentum : - Mature adipose tissue free neoplasia. - Presence...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Poorly differentiated adenocarcinoma, invasive and ulcerated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Poorly differentiated adenocarcinoma, invasive and ulcerated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Poorly differentiated adenocarcinoma, invasive and ulcerated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Poorly differentiated adenocarcinoma, invasive and ulcerated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Poorly differentiated adenocarcinoma, invasive and ulcerated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Poorly differentiated adenocarcinoma, invasive and ulcerated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Poorly differentiated adenocarcinoma, invasive and ulcerated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Gastroesophageal junction). 2. Findings: Poorly differentiated adenocarcinoma, invasive and ulcerated. 3. Code: ADENOMA\"\n}\n```\n",
      "predicted": "ADENOMA",
      "ground_truth": "STAD",
      "correct": false,
      "reasoning": "1. Site: Stomach (Gastroesophageal junction). 2. Findings: Poorly differentiated adenocarcinoma, invasive and ulcerated. 3. Code: ADENOMA",
      "idx": 1180,
      "timestamp": "2026-01-19T15:59:53.115290"
    },
    {
      "sample_idx": 968,
      "input": "Final Diagnosis. A. PANCREAS, DISTAL, AND SPLEEN, PARTIAL PANCREATECTOMY AND. SPLENECTOMY: Well-differentiated pancreatic endocrine tumor. (See key pathological findings.). Spleen with no significant pathologic changes. I,. the attending pathologist, personally reviewed all. slides and / or materiala and rendered the final diagnosis. Electronically. Comment. There is no tumor necrosis, the mitotic rate is <2 mitoses/10 high power fields, and the ki-67. immunostain shows positivity in approximate...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Pancreas, distal. 2. Findings: Well-differentiated pancreatic endocrine tumor. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PANIN\",\n    \"reasoning\": \"1. Site: Pancreas, distal. 2. Findings: Well-differentiated pancreatic endocrine tumor. 3. Code: PANIN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Pancreas, distal. 2. Findings: Well-differentiated pancreatic endocrine tumor. 3. Code: PAAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Pancreas, distal. 2. Findings: Well-differentiated pancreatic endocrine tumor. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Pancreas, distal. 2. Findings: Well-differentiated pancreatic endocrine tumor. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Pancreas, distal. 2. Findings: Well-differentiated pancreatic endocrine tumor. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Pancreas, distal. 2. Findings: Well-differentiated pancreatic endocrine tumor. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Pancreas, distal. 2. Findings: Well-differentiated pancreatic endocrine tumor. 3. Code: PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Pancreas, distal. 2. Findings: Well-differentiated pancreatic endocrine tumor. 3. Code: PRAD.\"\n}\n```",
      "predicted": "PRAD",
      "ground_truth": "PAAD",
      "correct": false,
      "reasoning": "1. Site: Pancreas, distal. 2. Findings: Well-differentiated pancreatic endocrine tumor. 3. Code: PRAD.",
      "idx": 968,
      "timestamp": "2026-01-19T15:59:53.115305"
    },
    {
      "sample_idx": 497,
      "input": "SUPPLEMENTAL REPORT. (C) LEFT MODIFIED NECK DISSECTION, TOTAL THYROIDECTOMY, SUPERIOR MEDIASTINAL. DISSECTION, PARTIAL DISSECTION, CLAVICLE, FIRST RIB: Sections of bone tissue submitted for decalcification appear free. of tumor. DIAGNOSIS. CAJ. LEFT PARTIAL GLOSSECIOMY AND PHARYNGECTOMY: INVASIVE, MODERATELY DIFFERENTIATED SQUAMOUS CELL CARCINOMA. Focal perineural invasion present. All margins free of tumor. (B) LEFT CHEEK: Epidermal inclusion cyst, keratinous type. (C) LEFT MODIFIED NECK DISSEC...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Left Partial Glossectomy and Pharyngectomy. 2. Findings: Invasive, moderately differentiated squamous cell carcinoma. 3. Code: ADENOCA is not a valid TCGA code. The closest code based on the tumor type is ADENOCA, which is a code for adenocarcinoma. However, this is a squamous cell carcinoma, so this is not a good match.\"\n}\n```\n\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Partial Glossectomy and Pharyngectomy. 2. Findings: Invasive, moderately differentiated squamous cell carcinoma. 3. Code: KIRC is a code for Kidney Renal Clear Cell Carcinoma. The findings are not related to kidney cancer, so this is not a good match.\"\n}\n```\n\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Left Partial Glossectomy and Pharyngectomy. 2. Findings: Invasive, moderately differentiated squamous cell carcinoma. 3. Code: BRCA is a code for Breast Invasive Carcinoma. The findings are not related to breast cancer, so this is not a good match.\"\n}\n```\n\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Partial Glossectomy and Pharyngectomy. 2. Findings: Invasive, moderately differentiated squamous cell carcinoma. 3. Code: KIRC is a code for Kidney Renal Clear Cell Carcinoma. The findings are not related to kidney cancer, so this is not a good match.\"\n}\n```\n\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Partial Glossectomy and Pharyngectomy. 2. Findings: Invasive, moderately differentiated squamous cell carcinoma. 3. Code: KIRC is a code for Kidney Renal Clear Cell Carcinoma. The findings are not related to kidney cancer, so this is not a good match.\"\n}\n```\n\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Partial Glossectomy and Pharyngectomy. 2. Findings: Invasive, moderately differentiated",
      "predicted": "ADENOCA",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Left Partial Glossectomy and Pharyngectomy. 2. Findings: Invasive, moderately differentiated squamous cell carcinoma. 3. Code: ADENOCA is not a valid TCGA code. The closest code based on the tumor type is ADENOCA, which is a code for adenocarcinoma. However, this is a squamous cell carcinoma, so this is not a good match.",
      "idx": 497,
      "timestamp": "2026-01-19T15:59:53.115324"
    },
    {
      "sample_idx": 1190,
      "input": "PRIMARY SITE: Stomach (Cardia). 1 - \"Product of the esophagogastrectomy according to the standardization\": - Poorly differentiated adenocarcinoma, intestinal type, with extensive areas of. mucinous differentiation and signet ring cells, ulcerative and infiltrative, measuring 10.5. x 6.8cm, located in cardia region / body, infiltrating the wall up to the. perigastric adipose tissue;. - Presence of perineural invasion;. - Presence of angiolymphatic invasion;. - Esophageal margin: free of tumor;. -...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach (Cardia). 2. Findings: Adenocarcinoma, intestinal type, with mucinous differentiation and signet ring cells, ulcerative and infiltrative. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Stomach (Cardia). 2. Findings: Adenocarcinoma, intestinal type, with mucinous differentiation and signet ring cells, ulcerative and infiltrative. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Stomach (Cardia). 2. Findings: Adenocarcinoma, intestinal type, with mucinous differentiation and signet ring cells, ulcerative and infiltrative. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach (Cardia). 2. Findings: Adenocarcinoma, intestinal type, with mucinous differentiation and signet ring cells, ulcerative and infiltrative. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach (Cardia). 2. Findings: Adenocarcinoma, intestinal type, with mucinous differentiation and signet ring cells, ulcerative and infiltrative. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach (Cardia). 2. Findings: Adenocarcinoma, intestinal type, with mucinous differentiation and signet ring cells, ulcerative and infiltrative. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach (Cardia). 2. Findings: Adenocarcinoma, intestinal type, with mucinous differentiation and signet ring cells, ulcerative and infiltrative. 3. Code:",
      "predicted": "STAD",
      "ground_truth": "STAD",
      "correct": true,
      "reasoning": "1. Site: Stomach (Cardia). 2. Findings: Adenocarcinoma, intestinal type, with mucinous differentiation and signet ring cells, ulcerative and infiltrative. 3. Code: Stomach Adenocarcinoma maps to STAD.",
      "idx": 1190,
      "timestamp": "2026-01-19T15:59:53.115336"
    },
    {
      "sample_idx": 833,
      "input": "A description for each data field can be found in the 'Data description' worksheet (yellow tab). Sample Collection Details. Type. BUFFY. TUMOUR. Histology and staging. Site of. Year of. Age at. Days to. Days to. Type of. Site of. Preparatio. Tissue. Comments. Procedure. Diagnosis. Procedure. Primary. n. (Histology). (yrs). FF. 0. 11 RESECT. RUL. FF. RUL lung. 0. 11 RESECT. RUL. Tumour. Histology. Grade/. Pathologic Pathologic Clinical M. VALCSG. Histology. Slide URL. Size (cm). Differentiat al T...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Lung adenocarcinoma, T1, N0, M0. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Lung adenocarcinoma, T1, N0, M0. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Lung adenocarcinoma, T1, N0, M0. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Lung adenocarcinoma, T1, N0, M0. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Lung adenocarcinoma, T1, N0, M0. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Lung adenocarcinoma, T1, N0, M0. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Lung adenocarcinoma, T1, N0, M0. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2.",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung (Right Upper Lobe). 2. Findings: Lung adenocarcinoma, T1, N0, M0. 3. Code: Lung Adenocarcinoma maps to LUAD.",
      "idx": 833,
      "timestamp": "2026-01-19T15:59:53.115346"
    },
    {
      "sample_idx": 389,
      "input": "CLINICAL HISTORY. with headache, and nausea for about. has right. temporal necrotic, hemorrhagic and enhancing tumor, and right middle cerebral. artery aneurysm. OPERATIVE DIAGNOSES. Not Given. Operation/Specimen: A: Brain, resection. B: Brain, resection. PATHOLOGICAL DIAGNOSIS: A. Brain, site not specified, excision: Glioblastoma. See comment. COMMENT. The specimen is brain diffusely infiltrated and focally effaced by an. astrocytic neoplastic process with nuclear anaplasia, mitoses, microvascu...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, resection. 2. Findings: Glioblastoma, with nuclear anaplasia, mitoses, microvascular cellular proliferation, and extensive areas of necrosis. 3. Code: Glioblastoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, resection. 2. Findings: Glioblastoma, with nuclear anaplasia, mitoses, microvascular cellular proliferation, and extensive areas of necrosis. 3. Code: Glioblastoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, resection. 2. Findings: Glioblastoma, with nuclear anaplasia, mitoses, microvascular cellular proliferation, and extensive areas of necrosis. 3. Code: Glioblastoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, resection. 2. Findings: Glioblastoma, with nuclear anaplasia, mitoses, microvascular cellular proliferation, and extensive areas of necrosis. 3. Code: Glioblastoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, resection. 2. Findings: Glioblastoma, with nuclear anaplasia, mitoses, microvascular cellular proliferation, and extensive areas of necrosis. 3. Code: Glioblastoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, resection. 2. Findings: Glioblastoma, with nuclear anaplasia, mitoses, microvascular cellular proliferation, and extensive areas of necrosis. 3. Code: Glioblastoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, resection. 2. Findings: Glioblastoma, with nuclear anaplas",
      "predicted": "KIRC",
      "ground_truth": "GBM",
      "correct": false,
      "reasoning": "1. Site: Brain, resection. 2. Findings: Glioblastoma, with nuclear anaplasia, mitoses, microvascular cellular proliferation, and extensive areas of necrosis. 3. Code: Glioblastoma maps to KIRC.",
      "idx": 389,
      "timestamp": "2026-01-19T15:59:53.115358"
    },
    {
      "sample_idx": 193,
      "input": "Procedure Date: Procedure Physician: Attending Physician/Copies To: PATIENT HISTORY: DATE or LMP: DATE OF LAST DELIVERY: PRE-OP DIAGNOSIS: RT BR CA. POST-OP DIAGMOSIS: SAME. OPERATIVE PROCEDURE: RT SEG MAST. CLINICAL HISTORY: NATERIAL SUBMITTED: RIGHTSEGMENTAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. INTRAOPERATIVE. FROZEN SECTION: Right breast mass; portion of breast, 7.0 by 4.0 by 3.5 cm with ellipse of skin, 7.0 by 1.0. cm. Lobulated mass, 4.0 by 2.0 by 2.0 cm. Margins grossly free. Fro...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, signet ring type, poor nuclear grade, 4.0 cm. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, signet ring type, poor nuclear grade, 4.0 cm. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, signet ring type, poor nuclear grade, 4.0 cm. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, signet ring type, poor nuclear grade, 4.0 cm. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, signet ring type, poor nuclear grade, 4.0 cm. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, signet ring type, poor nuclear grade, 4.0 cm. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, signet ring type, poor nuclear grade, 4.0 cm. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, signet ring type, poor nuclear grade, 4.0 cm. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 193,
      "timestamp": "2026-01-19T15:59:53.115369"
    },
    {
      "sample_idx": 1373,
      "input": "Surgical Patholoav Report. Pabent Name: Gynecology. DOS. 'Age: Patient Ty. DIAGNOSIS: OMENTUM, NODULE, BIOPSY. POORLY DIFFERENTIATED CARCINOMA. UTERUS, CERVIX, BILATERAL TUBES AND OVARIES, HYSTERECTOMY AND BILATERAL. SALPINGO-OOPHORECTOMY: - UNDIFFERENTIATED CARCINOMA ARISING FROM WELL TO MODERATELY DIFFERENTIATED. ENDOMETRIAL ADENOCARCINOMA, ENDOMETRIOID TYPE. - THE CARCINOMA INVADES THE ENTIRE MYOMETRIAL THICKNESS AND EXTENDS TO THE. SEROSAL SURFACE (DEPTH OF INVASION IS 2.0 CM). THE CARCINOMA...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus (including cervix and bilateral tubes and ovaries). 2. Findings: The patient has a history of total abdominal hysterectomy, bilateral salpingo-oophorectomy, and examination under anesthesia. The pathology report describes a total of 13 specimens received, including an omental nodule, a uterine/cervical/ovarian specimen, a posterior cul-de-sac tumor, a left ureter tumor, an appendix, an omentum, a falciform ligament, a diaphragm nodule, a sigmoid tumor nodule, an epiploica, a cecal nodule, a small bowel nodule, and a soft tissue nodule. The report also describes a poorly differentiated carcinoma in the omentum and soft tissue, and a poorly differentiated carcinoma in the sigmoid. The report mentions a metastatic poorly differentiated carcinoma in one lymph node. The report indicates that the tumor is a poorly differentiated carcinoma, and it has invaded the entire myometrium and extends to the serosa. It also mentions extensive lymphovascular space invasion. The report also mentions endometrial adenocarcionma, endometrioid type, with invasion of the entire myometrium and extension to the serosa, and the report mentions the tumor is a poorly differentiated carcinoma. The report also mentions a left external lymph node with no evidence of malignancy. The report also mentions a right ovary with serosal surface tumor deposits. The report mentions that the tumor is a poorly differentiated carcinoma and it has invaded the entire myometrium and extends to the serosa. The report mentions that the tumor is a poorly differentiated carcinoma and it has invaded the entire myometrium and extends to the serosa. The report mentions that the tumor is a poorly differentiated carcinoma and it has invaded the entire myometrium and extends to the serosa. The report mentions that the tumor is a poorly differentiated carcinoma and it has invaded the entire myometrium and extends to the serosa. The report mentions that the tumor is a poorly differentiated carcinoma and it has invaded the entire myometrium and extends to the serosa. The report mentions that the tumor is a poorly differentiated carcinoma and it has invaded the entire myometrium and extends to the serosa. The report mentions that the tumor is a poorly differentiated carcinoma and it has invaded the entire myometrium and extends to the serosa. The report mentions that the tumor is a poorly differentiated carcinoma and it",
      "predicted": null,
      "ground_truth": "UCEC",
      "correct": null,
      "reasoning": "",
      "idx": 1373,
      "timestamp": "2026-01-19T15:59:53.115510"
    },
    {
      "sample_idx": 882,
      "input": "Gross Description: Right upper lobe with free lobar bronchus; on section, a central tumoral structure of. 10/12/8 cm in diameter, which infiltrates the visceral pleura; the tumor is well-limited, white, with. necrosis and central ulceration. Microscopic Description: TUMOR FRAGMENT WITH PLEURA: Bronchopulmonary neoplasm of epidermoid carcinoma type, G2, with a tendency to keratinization,. formed of solid beaches of large, pleomorphic cells, with frequent nuclear atypias and atypical mitoses,. wit...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, G2, with a tendency to keratinization, with a tendency to keratinization. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, G2, with a tendency to keratinization, with a tendency to keratinization. 3. Code: Lung Squamous Cell Carcinoma maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, G2, with a tendency to keratinization, with a tendency to keratinization. 3. Code: Lung Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, G2, with a tendency to keratinization, with a tendency to keratinization. 3. Code: Lung Squamous Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, G2, with a tendency to keratinization, with a tendency to keratinization. 3. Code: Lung Squamous Cell Carcinoma maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, G2, with a tendency to keratinization, with a tendency to keratinization. 3. Code: Lung Squamous Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, G2, with a tendency to keratinization, with a tendency to keratinization. 3. Code",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung. 2. Findings: Squamous cell carcinoma, G2, with a tendency to keratinization, with a tendency to keratinization. 3. Code: Lung Adenocarcinoma maps to LUAD.",
      "idx": 882,
      "timestamp": "2026-01-19T15:59:53.115522"
    },
    {
      "sample_idx": 725,
      "input": "DIAGNOSIS: A. Gallbladder, cholecystectomy Chronic cholecystitis. A single. cystic duct lymph node is benign. B. Liver, right, partial hepatectomy : 11-to-moderately. differentiated grade 2 (of 4) hepatocellular carcinoma is identified. forming a dominant mass (6. 8 x 5.9 x 4.1 cm) with one satellite mass. (0.2 2 x 0.2 x 0.2 cm) The tumor is confined to the liver. The liver. parenchyma resection margin is negative for tumor (minimum tumor. free margin, 0.9 cm). Macroscopic large vessel invasion ...",
      "response": "```json\n{\n    \"cancer_type\": \"Hepatocellular carcinoma\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, hepatocellular carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Gallbladder. 2. Findings: Chronic cholecystitis. 3. Code: CHOL maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Gallbladder. 2. Findings: Cystic duct lymph node is benign. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Grade 2. ",
      "predicted": "Hepatocellular carcinoma",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Grade 2. 3. Code: Liver, hepatocellular carcinoma maps to LIHC.",
      "idx": 725,
      "timestamp": "2026-01-19T15:59:53.115534"
    },
    {
      "sample_idx": 867,
      "input": "Gross. Microscopic. Diagnosis. Comme. Case ID Description. Description. Details. nts. Lateralit Date of. y. LUNG TISSUE CHECKLIST. Left-upper. Specimen type: Lobectomy. Tumor site: Lung. Tumor size: 3 X 2 X 2 cm. Histologic type: Squamous cell carcinoma. Histologic grade: Poorly differentiated. Tumor extent: Not specified. Other tumor nodules: Not specified. Lymph nodes: Not specified. Lymphatic invasion: Not specified. Venous invasion: Not specified. Margins: Not specified. Evidence of neo-adju...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: LUAD (Lung Adenocarcinoma) or LUAD (Lung Squamous Cell Carcinoma) maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: LUAD (Lung Adenocarcinoma) or LUAD (Lung Squamous Cell Carcinoma) maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: LUAD (Lung Adenocarcinoma) or LUAD (Lung Squamous Cell Carcinoma) maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: LUAD (Lung Adenocarcinoma) or LUAD (Lung Squamous Cell Carcinoma) maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: LUAD (Lung Adenocarcinoma) or LUAD (Lung Squamous Cell Carcinoma) maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: LUAD (Lung Adenocarcinoma) or LUAD (Lung Squamous Cell Carcinoma) maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: LUAD (Lung Adenocarcinoma) or LUAD (Lung Squamous Cell Carcinoma) maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LU",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: LUAD (Lung Adenocarcinoma) or LUAD (Lung Squamous Cell Carcinoma) maps to LUAD.",
      "idx": 867,
      "timestamp": "2026-01-19T15:59:53.115545"
    },
    {
      "sample_idx": 841,
      "input": "HISTORY. No clinical notes. MACROSCOPIC. One specimen received. The specimen is labelled 'right lower lobe' and consists of a right lower. lobectomy with a inflated measurements of 115 superior to inferior X 120 mm. anterior to posterior X 70 mm medial to lateral. Sectioning reveals a firm pale. lobulated mass measuring 48 x 48 X 45 mm. The mass is 15 mm from the bronchial. resection margin, and 10 mm from the hilar resection margin. The mass is 3 mm. clear of the stapled resection margin, focal...",
      "response": "```json\n{\n    \"cancer_type\": \"LSCC\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: LSCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LSCC\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: LSCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LSCC\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: LSCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LSCC\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: LSCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LSCC\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: LSCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LSCC\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: LSCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LSCC\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: LSCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LSCC\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: LSCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LSCC\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Squamous",
      "predicted": "LSCC",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung (Right Lower Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: LSCC.",
      "idx": 841,
      "timestamp": "2026-01-19T15:59:53.115555"
    },
    {
      "sample_idx": 956,
      "input": "Receive Date: PHN: Final Diagnosis: 1. EXTERNAL ABDOMINAL WALL OLD LAPAROSCOPIC PORT TUMOUR NODULE. showing a. fragment of fibrofatty tissue positive for high-grade papillary serous. carcinoma with focal foreign body inflammatory reaction. 2. INTERNAL ABDOMINAL WALL OLD LAPAROSCOPIC PORT TUMOUR NODULE. showing a. fragment of fibrofatty tissue with adherent muscle positive for. high-grade papillary serous carcinoma with focal foreign body. inflammatory reaction. 3. Total hysterectomy and left sal...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: High-grade papillary serous carcinoma, left ovary, with a 3 cm tumor and multiple cortical nodules. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: High-grade papillary serous carcinoma, left ovary, with a 3 cm tumor and multiple cortical nodules. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: High-grade papillary serous carcinoma, left ovary, with a 3 cm tumor and multiple cortical nodules. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: High-grade papillary serous carcinoma, left ovary, with a 3 cm tumor and multiple cortical nodules. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: High-grade papillary serous carcinoma, left ovary, with a 3 cm tumor and multiple cortical nodules. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: High-grade papillary serous carcinoma, left ovary, with a 3 cm tumor and multiple cortical nodules. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: High-grade papillary serous carcinoma, left ovary, with a 3 cm tumor and multiple cortical nodules. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovaries",
      "predicted": "BRCA",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Ovaries. 2. Findings: High-grade papillary serous carcinoma, left ovary, with a 3 cm tumor and multiple cortical nodules. 3. Code: BRCA.",
      "idx": 956,
      "timestamp": "2026-01-19T15:59:53.115565"
    },
    {
      "sample_idx": 110,
      "input": "Patien. surgical F. CLINICAL HISTORY: Right breast Ca, rule out deep margin positive. GROSS EXAMINATION: A. \"#1 right modified radical mastectomy\", in formalin. Received in the. container is a portion of breast with an attached skin ellipse containing the. nipple and an axillary dissection. The specimen measures 18.5 x 14 x 3.9 cm. The attached skin ellipse measures 14.7 x 6.3 cm. The nipple appears grossly. unremarkable. There is a small 0.5 cm hole 1.7 cm inferior to the nipple. The. deep surf...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 110,
      "timestamp": "2026-01-19T15:59:53.115575"
    },
    {
      "sample_idx": 201,
      "input": "SPECIMEN(S): A. RIGHT BREAST PARTIAL MASTECTOMY. B. SLN #1 RIGHT AXILLA. C. ADDITIONAL AXILLARY TISSUE RIGHT AXILLA. CLINICAL HISTORY: This is a. year old female with a 1.4 cm tumor in the right breast, IDC at 11:00. S/P. benign MRI biopsy inferior and lateral to this index lesion, not clipped. Here for N/L. lumpectomy with SLN biopsy. INTRAOPERATIVE CONSULTATION DIAGNOSIS: A. Right breast, partial mastectomy: Tumor is 0.3 cm from anterior margin. TPB1-TPB4: SLN#1, right axilla, excision: Four l...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 201,
      "timestamp": "2026-01-19T15:59:53.115584"
    },
    {
      "sample_idx": 124,
      "input": "Female. Admission Date: Discharge Date: Collected Date/Time: Received Date/Time: Final Diagnosis. A. LEFT HIGHEST AXILLARY NODE, EXCISION: - METASTATIC CARCINOMA IN ONE LYMPH NODE (1/1). B. LEFT BREAST AND AXILLARY CONTENTS, MASTECTOMY AND LYMPHADENECTOMY: - INVASIVE DUCTAL CARCINOMA, GRADE 3. - METASTATIC CARCINOMA IN THIRTEEN OF NINETEEN LYMPH NODES (13/19). - MARGINS ARE NOT INVOLVED. - SEE TEMPLATE. C. LEFT LEVEL I AXILLARY LYMPH NODE, EXCISION: - NO EVIDENCE OF CARCINOMA IN ONE LYMPH NODE (...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site:",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Grade 3. 3. Code: BRCA",
      "idx": 124,
      "timestamp": "2026-01-19T15:59:53.115596"
    },
    {
      "sample_idx": 824,
      "input": "Extensive, central to peripheral bronchopulmonary adenocarcinoma of histologically mixed. differentiation (G3), comprising partly maturing tubuloglandular cells and partly medium to. large cells and also clear cells, with partial necrotic alteration, invasion of the large pulmonary. vessels and the pleura. Tumor classification according to these findings pT2 pN1 V2 RX,. stage IIB. C34.2; M 8255/3. Comment/supplementary remark: The tumor invasion of the large pulmonary vessels with formation of l...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Bronchopulmonary). 2. Findings: Adenocarcinoma of the lung, mixed differentiation (G3), with tubuloglandular and large/clear cells, necrosis, vascular and pleural invasion. Stage IIB. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Bronchopulmonary). 2. Findings: Adenocarcinoma of the lung, mixed differentiation (G3), with tubuloglandular and large/clear cells, necrosis, vascular and pleural invasion. Stage IIB. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Bronchopulmonary). 2. Findings: Adenocarcinoma of the lung, mixed differentiation (G3), with tubuloglandular and large/clear cells, necrosis, vascular and pleural invasion. Stage IIB. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Bronchopulmonary). 2. Findings: Adenocarcinoma of the lung, mixed differentiation (G3), with tubuloglandular and large/clear cells, necrosis, vascular and pleural invasion. Stage IIB. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Bronchopulmonary). 2. Findings: Adenocarcinoma of the lung, mixed differentiation (G3), with tubuloglandular and large/clear cells, necrosis, vascular and pleural invasion. Stage IIB. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Bronchopulmonary). 2. Findings: Adenocarcinoma of the lung, mixed differentiation (G3), with tubuloglandular and large/clear cells, necrosis",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung (Bronchopulmonary). 2. Findings: Adenocarcinoma of the lung, mixed differentiation (G3), with tubuloglandular and large/clear cells, necrosis, vascular and pleural invasion. Stage IIB. 3. Code: Lung Adenocarcinoma maps to LUAD.",
      "idx": 824,
      "timestamp": "2026-01-19T15:59:53.115610"
    },
    {
      "sample_idx": 694,
      "input": "Client: (Age: ) Location: Gender: F Accnt: Phy Location: Clinical History. Brain tumor. Operative Diagnoses. Operation / Specimen. A: Brain, left frontal, craniotomy. Pathologic Diagnosis. A. Brain, left frontal, craniotomy: 1. Anaplastic astrocytoma, WHO grade 3. 2. Negative for co-deletion of chromosomal arms 1p and 19q. 3. Positive for IDH1-R132S mutation. 4. Ki-67/ MIB1 proliferation index: up to approximately 10%. See comment. Comment. The diffuse astrocytoma has an area with up to 4 mitose...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, left frontal, craniotomy. 2. Findings: Anaplastic astrocytoma, WHO grade 3. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Brain, left frontal, craniotomy. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, left frontal, craniotomy. 2. Findings: Anaplastic astrocytoma, WHO grade 3. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, left frontal, craniotomy. 2. Findings: Anaplastic astrocytoma, WHO grade 3. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, left frontal, craniotomy. 2. Findings: Anaplastic astrocytoma, WHO grade 3. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, left frontal, craniotomy. 2. Findings: Anaplastic astrocytoma, WHO grade 3. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, left frontal, craniotomy. 2. Findings: Anaplastic astrocytoma, WHO grade 3. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, left frontal, craniotomy. 2. Findings: Anaplastic astrocytoma, WHO grade 3. 3. Code: K",
      "predicted": "KIRC",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain, left frontal, craniotomy. 2. Findings: Anaplastic astrocytoma, WHO grade 3. 3. Code: KIRC.",
      "idx": 694,
      "timestamp": "2026-01-19T15:59:53.115620"
    },
    {
      "sample_idx": 223,
      "input": "page 1 / 1. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - right breast with axillary tissues. Unit in charge: (. Material collected on: : Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the right breast. Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in over 75% of neoplastic cell nuclei. HER2 prote...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 223,
      "timestamp": "2026-01-19T15:59:53.115630"
    },
    {
      "sample_idx": 509,
      "input": "DIAGNOSIS. (A) LEFT KIDNEY, ADRENAL, AND PERIAORTIC LYMPH NODES: CHROMOPHOBE RENAL CELL CARCINOMA (11.0 CM MAXIMUM DIMENSION), EOSINOPHILIC VARIANT,. FUHRMAN NUCLEAR GRADE 4, INVASIVE INTO PERINEPHRIC ADIPOSE TISSUE AND RENAL SINUS. ADIPOSE TISSUE, WITH VASCULAR-LYMPHATIC INVASION. (SEE COMMENT). METASTATIC CHROMOPHOBE RENAL CELL CARCINOMA IN 3 HILAR LYMPH NODES. Adrenal gland, no tumor present. Margins of resection free of tumor. (B) SPLEEN: Spleen with vascular congestion, no tumor present. Th...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe renal cell carcinoma, Fuhrman Grade 4, invasive into perinephric adipose tissue and renal sinus. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe renal cell carcinoma, Fuhrman Grade 4, invasive into perinephric adipose tissue and renal sinus. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe renal cell carcinoma, Fuhrman Grade 4, invasive into perinephric adipose tissue and renal sinus. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe renal cell carcinoma, Fuhrman Grade 4, invasive into perinephric adipose tissue and renal sinus. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe renal cell carcinoma, Fuhrman Grade 4, invasive into perinephric adipose tissue and renal sinus. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Chromophobe renal cell carcinoma, Fuhrman Grade 4, invasive into perinephric adipose tissue and renal sinus. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2.",
      "predicted": "KIRC",
      "ground_truth": "KICH",
      "correct": false,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Chromophobe renal cell carcinoma, Fuhrman Grade 4, invasive into perinephric adipose tissue and renal sinus. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 509,
      "timestamp": "2026-01-19T15:59:53.115642"
    },
    {
      "sample_idx": 392,
      "input": "DIAGNOSIS. (A, B) BRAIN, LEFT PARIETAL REGION, CRANIOTOMY: GLIOBLASTOMA (WHO GRADE IV). (SEE COMMENT). COMMENT. Tissue sections show a high-grade diffuse astrocytoma with pleomorphism, brisk mitotic activity, microvascular proliferation,. intravascular fibrin thrombi and foci of tumor necrosis. GROSS DESCRIPTION. (A) LEFT PARIETAL TUMOR - Specimen consists of a single piece of dark-red tissue measuring (6.0 X 3.0 X 2.0 cm). The cut. rotion shows areas of hemorrhage and friable tissue. A represen...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Parietal Region. 2. Findings: Glioblastoma (WHO Grade IV), diffuse astrocytoma, pleomorphism, brisk mitotic activity, microvascular proliferation, intravascular fibrin thrombi, and foci of tumor necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Parietal Region. 2. Findings: Glioblastoma (WHO Grade IV), diffuse astrocytoma, pleomorphism, brisk mitotic activity, microvascular proliferation, intravascular fibrin thrombi, and foci of tumor necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Parietal Region. 2. Findings: Glioblastoma (WHO Grade IV), diffuse astrocytoma, pleomorphism, brisk mitotic activity, microvascular proliferation, intravascular fibrin thrombi, and foci of tumor necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Parietal Region. 2. Findings: Glioblastoma (WHO Grade IV), diffuse astrocytoma, pleomorphism, brisk mitotic activity, microvascular proliferation, intravascular fibrin thrombi, and foci of tumor necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Parietal Region. 2. Findings: Glioblastoma (WHO Grade IV), diffuse astrocytoma, pleomorphism, brisk mitotic activity, microvascular proliferation, intravascular fibrin thrombi, and foci of tumor necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Parietal Region. 2. Findings: Glioblastoma (WHO Grade IV), diffuse astrocytoma, pleomorphism, brisk mitotic activity, microvascular proliferation,",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain, Parietal Region. 2. Findings: Glioblastoma (WHO Grade IV), diffuse astrocytoma, pleomorphism, brisk mitotic activity, microvascular proliferation, intravascular fibrin thrombi, and foci of tumor necrosis. 3. Code: Glioblastoma maps to GBM.",
      "idx": 392,
      "timestamp": "2026-01-19T15:59:53.115656"
    },
    {
      "sample_idx": 1186,
      "input": "Patient ID: Gross Description: Stomach part with saucer-like tumor up to 5x4.5 cm in size, with invasion into the. perigastric fat tissue. In the fatty tissue there are hyperemic lymph nodes up to 0.6 cm in size. Omentum is of normal structure. Microscopic Description: Gastric adenocarcinoma, G-3, with invasion into the fatty tissue. One from. fifteen examined lymph nodes demonstrated metastasis. Diagnosis Details: Tumor Features: Ulcerated, Tumor Extent: Perigastric fat, Venous Invasion: Absent...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric adenocarcinoma, G-3, with invasion into the fatty tissue. One from. fifteen examined lymph nodes demonstrated metastasis. 3. Code: STAD maps to Stomach.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric adenocarcinoma, G-3, with invasion into the fatty tissue. One from. fifteen examined lymph nodes demonstrated metastasis. 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric adenocarcinoma, G-3, with invasion into the fatty tissue. One from. fifteen examined lymph nodes demonstrated metastasis. 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric adenocarcinoma, G-3, with invasion into the fatty tissue. One from. fifteen examined lymph nodes demonstrated metastasis. 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric adenocarcinoma, G-3, with invasion into the fatty tissue. One from. fifteen examined lymph nodes demonstrated metastasis. 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric adenocarcinoma, G-3, with invasion into the fatty tissue. One from. fifteen examined lymph nodes demonstrated metastasis. 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Gastric adenocarcinoma, G-3, with invasion",
      "predicted": "STAD",
      "ground_truth": "STAD",
      "correct": true,
      "reasoning": "1. Site: Stomach. 2. Findings: Gastric adenocarcinoma, G-3, with invasion into the fatty tissue. One from. fifteen examined lymph nodes demonstrated metastasis. 3. Code: STAD maps to Stomach.",
      "idx": 1186,
      "timestamp": "2026-01-19T15:59:53.115668"
    },
    {
      "sample_idx": 1366,
      "input": "DIAGNOSIS. for 5/1/1/1. (A) UTERUS, CERVIX, TUBES AND OVARIES: ENDOMETRIAL, ENDOMETRIOID ADENOCARCINOMA, FIGO GRADE 3. DEPTH OF MYOMETRIAL INVASION 5.0 MM (TOTAL MYOMETRIAL THICKNESS 32.0 MM). LYMPHATIC/VASCULAR INVASION IS IDENTIFIED WITHIN THE MYOMETRIUM. Tumor does not involve the cervix. Bilateral ovaries and fallopian tubes, no tumor present. (B) LEFT PELVIC LYMPH NODES: Eight lymph nodes with numerous non-necrotizing granulomas; no tumor present (0/8). (See comment). (C) LEFT LOW PARAAORTI...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial, endometroid adenocarcinoma, FIGO grade 3, depth of myometrial invasion 5.0 mm (total myometrial thickness 32.0 mm). Lymphatic/vascular invasion is identified within the myometrium. Tumor does not involve the cervix. Bilateral ovaries and fallopian tubes, no tumor present. 3. Code: UCEC maps to Uterine Corpus Endometrial Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA maps to Breast Invasive Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA maps to Breast Invasive Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA maps to Breast Invasive Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC maps to Kidney Renal Clear",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus. 2. Findings: Endometrial, endometroid adenocarcinoma, FIGO grade 3, depth of myometrial invasion 5.0 mm (total myometrial thickness 32.0 mm). Lymphatic/vascular invasion is identified within the myometrium. Tumor does not involve the cervix. Bilateral ovaries and fallopian tubes, no tumor present. 3. Code: UCEC maps to Uterine Corpus Endometrial Carcinoma.",
      "idx": 1366,
      "timestamp": "2026-01-19T15:59:53.115684"
    },
    {
      "sample_idx": 918,
      "input": "SURGICAL PATHOLOGY HISTORY REPORT. DISCLAIMER. THIS IS A HISTORY CASE THAT YOU CANNOT EDIT. TO SEE THE ENTIRE TEXT. PLEASE GO TO THE PATIENT HISTORY BY CLICKING THE ELLIPSE (...) NEXT TO. THE PATIENT NAME AND CLICKING ON THE HISTORY TAB. DIAGNOSIS: with pelvic mass & ascites. No chemo/RT. FINAL DIAGNOSIS: 1. OMENTAL biopsy: -Implants SEROUS CARCINOMA with focal squamous differentiation. 2. OVARIES, bilateral, oophorectomy: -Grade 3 SEROUS CARCINOMA. FALLOPIAN TUBES, bilateral, salpingectomy: -Im...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Omentum. 2. Findings: Serous carcinoma, with focal squamous differentiation. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Grade 3 Serous Carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Fallopian Tube. 2. Findings: Serous Carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Metastatic Serous Carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Peritoneum. 2. Findings: Serous Carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Lymph Node. 2. Findings: Metastatic Serous Carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Peritoneum. 2. Findings: Serous Carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Serous Carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Small Intestine. 2. Findings: Serous Carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Spleen. 2. Findings: Surface implants Ser",
      "predicted": "BRCA",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Omentum. 2. Findings: Serous carcinoma, with focal squamous differentiation. 3. Code: BRCA",
      "idx": 918,
      "timestamp": "2026-01-19T15:59:53.115694"
    },
    {
      "sample_idx": 287,
      "input": "Clinical Diagnosis & History: Moderately differentiated adenocarcinoma in the sigmoid colon. No history of. chemoradiation. Specimens Submitted: 1: SP: Sigmoid colon; resection. 2: SP: Proximal margin. 3: SP: Distal margin. DIAGNOSIS: 1. SP: Sigmoid colon; resection: Tumor Type: Adenocarcinoma. Histologic Grade: Moderately differentiated. Tumor Location: Sigmoid colon. Tumor Size: Length is 1.1 cm. Width is 0.7 cm. Maximal thickness is 0.4 cm. Tumor Budding: Absent. Increased Tumor Infiltrating ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.",
      "idx": 287,
      "timestamp": "2026-01-19T15:59:53.115703"
    },
    {
      "sample_idx": 1360,
      "input": "FSG2 (SEROSAL TUMOR): Tissue given for research. M.D., i. I have personally examined the specimen, interpreted the results, reviewed the report and signed it electronically. If this report includes immunohistochemical test results please note the following: Numerous immunohistochemica/ tests were developed and their. performance characteristics determined by. Those. immunohistochemical tests have not been creared or approved by the U.S. Fooa ano urug (TUM),. proval is not required. Copies To: AM...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma with associated squamous changes, FIGO grade 3. The tumor involves the endometrium, myometrium, and serosa. The cervix shows CIN III/SCIS. 3. Code: BRCA maps to Breast Invasive Carcinoma. This is a breast cancer, but the question is asking for the cancer type based on the pathology report, which is a uterus cancer. The most appropriate TCGA code is BRCA. The question is asking for the cancer type based on the pathology report, which is a uterus cancer. The most appropriate TCGA code is BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma with associated squamous changes, FIGO grade 3. The tumor involves the endometrium, myometrium, and serosa. The cervix shows CIN III/SCIS. 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma. This is a uterus cancer. The most appropriate TCGA code is KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma with associated squamous changes, FIGO grade 3. The tumor involves the endometrium, myometrium, and serosa. The cervix shows CIN III/SCIS. 3. Code: BRCA maps to Breast Invasive Carcinoma. This is a uterus cancer. The most appropriate TCGA code is BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma with associated squamous changes, FIGO grade 3. The tumor involves the endometrium, myometrium, and serosa. The cervix shows CIN III/SCIS. 3. Code: BRCA maps to Breast Invasive Carcinoma. This is a uterus cancer. The most appropriate TCGA code is BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings:",
      "predicted": "BRCA",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma with associated squamous changes, FIGO grade 3. The tumor involves the endometrium, myometrium, and serosa. The cervix shows CIN III/SCIS. 3. Code: BRCA maps to Breast Invasive Carcinoma. This is a breast cancer, but the question is asking for the cancer type based on the pathology report, which is a uterus cancer. The most appropriate TCGA code is BRCA. The question is asking for the cancer type based on the pathology report, which is a uterus cancer. The most appropriate TCGA code is BRCA.",
      "idx": 1360,
      "timestamp": "2026-01-19T15:59:53.115724"
    },
    {
      "sample_idx": 375,
      "input": "AP Surgical Pathology: Additional Info. CLINICAL HISTORY: developed some problems with his left side. He is a patient who was. found. to have a malignant glioma. He has noted drooling from the left side of. his face. He has noted walking into things on the left side. : The patient is status post right parietal craniotomy, There. has been interval debulking of a large right parietal heterogeneously. enhancing tumor. When compared to prior examination. The amount of enhancing. lesion has decreased...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with EGFR and PTEN polysomy, MGMT positive. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with EGFR and PTEN polysomy, MGMT positive. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with EGFR and PTEN polysomy, MGMT positive. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with EGFR and PTEN polysomy, MGMT positive. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with EGFR and PTEN polysomy, MGMT positive. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with EGFR and PTEN polysomy, MGMT positive. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with EGFR and PTEN polysomy, MGMT positive. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with EGFR and PTEN polysomy,",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with EGFR and PTEN polysomy, MGMT positive. 3. Code: GBM.",
      "idx": 375,
      "timestamp": "2026-01-19T15:59:53.115734"
    },
    {
      "sample_idx": 1302,
      "input": "Sex: F. BIRTH DATE. Department: Thoracic Surgery. Clinical informations: Mediastinal anterior neoplasia cm 12x10x5. Type of specimen: Biopsies of the mass. Microscopical description: multiple small tissue fragments, histologically characterized by a. neoplastic infiltration with morphological and immunohistochemical characters (positivity for. CD117 and Synaptophisin; positivity +/- for citocheratins (MNF116), negativity for CD5, CD45,. CD56, TTF1, Cromogranin) indicating a poorly differentiated...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Mediastinum. 2. Findings: Poorly differentiated neuroendocrine carcinoma, thymic origin (Neuroendocrine thymic carcinoma), CD117 positive. 3. Code: Thymic Neoplasia maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Mediastinum. 2. Findings: Poorly differentiated neuroendocrine carcinoma, thymic origin (Neuroendocrine thymic carcinoma), CD117 positive. 3. Code: Thymic Neoplasia maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Mediastinum. 2. Findings: Poorly differentiated neuroendocrine carcinoma, thymic origin (Neuroendocrine thymic carcinoma), CD117 positive. 3. Code: Thymic Neoplasia maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Mediastinum. 2. Findings: Poorly differentiated neuroendocrine carcinoma, thymic origin (Neuroendocrine thymic carcinoma), CD117 positive. 3. Code: Thymic Neoplasia maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Mediastinum. 2. Findings: Poorly differentiated neuroendocrine carcinoma, thymic origin (Neuroendocrine thymic carcinoma), CD117 positive. 3. Code: Thymic Neoplasia maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Mediastinum. 2. Findings: Poorly differentiated neuroendocrine carcinoma, thymic origin (Neuroendocrine thymic carcinoma), CD117 positive. 3. Code: Thymic Neoplasia maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Mediastinum. 2. Findings: Poorly differentiated neuroendocrine carcinoma, thymic",
      "predicted": "THYM",
      "ground_truth": "THYM",
      "correct": true,
      "reasoning": "1. Site: Mediastinum. 2. Findings: Poorly differentiated neuroendocrine carcinoma, thymic origin (Neuroendocrine thymic carcinoma), CD117 positive. 3. Code: Thymic Neoplasia maps to THYM.",
      "idx": 1302,
      "timestamp": "2026-01-19T15:59:53.115745"
    },
    {
      "sample_idx": 947,
      "input": "V3.00 110614. Instructions: The TCGA Missing Pathology Report Form should be completed for cases for which a pathology report is not. available. General Pathology Report Information. #. Data Element. Entry Alternatives. Working Instructions. Provide the tumor type of the case. 1. Tumor type: Indicate to which BCR location the case was originally sent. 2. BCR specimen originally sent. NCH. to: IGC. Biospecimen Core Resource (BCR). Date specimen received at. 3. BCR: ICD-0-3 Histology Code: Provide...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 947,
      "timestamp": "2026-01-19T15:59:53.115754"
    },
    {
      "sample_idx": 511,
      "input": "Diagnosis: A: Resection bed, left kidney, biopsy. - Renal parenchyma with mild chronic interstitial inflammation. - No evidence of malignancy. B: Resection bed, right kidney, removal. - Renal parenchyma with mild chronic interstitial inflammation. - No evidence of malignancy. C: Mass, Left kidney, resection. - Renal cell carcinoma, chromophobe type, eosinophilic variant, 2.6 cm, without vascular or. extracapsular invasion, surgical margins involved by renal cell carcinoma (see comment). D: Mass,...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, eosinophilic variant, 2.6 cm, without vascular or extracapsular invasion, surgical margins involved by renal cell carcinoma (see comment). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ONCO\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Oncocytoma, 1.4 cm, surgical margins negative (see comment). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, eosinophilic variant, 2.6 cm, without vascular or extracapsular invasion, surgical margins involved by renal cell carcinoma (see comment). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Oncocytoma, 1.4 cm, surgical margins negative (see comment). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, eosinophilic variant, 2.6 cm, without vascular or extracapsular invasion, surgical margins involved by renal cell carcinoma (see comment). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Oncocytoma, 1.4 cm, surgical margins negative (see comment). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    ",
      "predicted": "KIRC",
      "ground_truth": "KICH",
      "correct": false,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, eosinophilic variant, 2.6 cm, without vascular or extracapsular invasion, surgical margins involved by renal cell carcinoma (see comment). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 511,
      "timestamp": "2026-01-19T15:59:53.115767"
    },
    {
      "sample_idx": 154,
      "input": "Final Diagnosis. Breast, left, wide local excision: Infiltrating ductal carcinoma, Nottingham grade III (of III),. [tubules 3/3, nuclei 3/3, mitoses 2/3; Nottingham score 8/9], forming a 2.0 x 1.8 x 1.5 cm. circumscribed mass with central fibrosis [AJCC pTic]. Focal (5%) high grade ductal carcinoma. in situ with necrosis is present outside the main tumor mass. Angiolymphatic invasion is absent. The non-neoplastic breast parenchyma shows nonproliferative fibrocystic changes. Calcifications. are p...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III, forming a 2.0 x 1.8 x 1.5 cm mass with central fibrosis and focal high-grade in situ carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III, forming a 2.0 x 1.8 x 1.5 cm mass with central fibrosis and focal high-grade in situ carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III, forming a 2.0 x 1.8 x 1.5 cm mass with central fibrosis and focal high-grade in situ carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III, forming a 2.0 x 1.8 x 1.5 cm mass with central fibrosis and focal high-grade in situ carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III, forming a 2.0 x 1.8 x 1.5 cm mass with central fibrosis and focal high-grade in situ carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III, forming a 2.0 x 1.8 x 1.5 cm mass with central",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III, forming a 2.0 x 1.8 x 1.5 cm mass with central fibrosis and focal high-grade in situ carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 154,
      "timestamp": "2026-01-19T15:59:53.115779"
    },
    {
      "sample_idx": 907,
      "input": "Gender: Male. Race: White. Report Date: Tissue Procurement Date: FINAL PATHOLOGIC DIAGNOSIS. A. #11 lymph node; biopsy: - Two lymph nodes, no tumor (0/2). B. Level 7 lymph node; dissection: - Three lymph nodes, no tumor (0/3). C. #8 lymph node; biopsy: - One lymph node, no tumor (0/1). D. 4R lymph node; biopsy: - Two lymph nodes, no tumor (0/2). E. Right parietal and visceral pleura, diaphragm and pericardium: - Malignant biphasic mesothelioma; see comment. - See parameters. Thoracic Mesotheliom...",
      "response": "```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Right pleura, pericardium, and diaphragm. 2. Findings: Biphasic mesothelioma (80% epithelioid, 20% sarcomatoid). 3. Code: UCSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Right pleura, pericardium, and diaphragm. 2. Findings: Biphasic mesothelioma (80% epithelioid, 20% sarcomatoid). 3. Code: UCSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Right pleura, pericardium, and diaphragm. 2. Findings: Biphasic mesothelioma (80% epithelioid, 20% sarcomatoid). 3. Code: UCSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Right pleura, pericardium, and diaphragm. 2. Findings: Biphasic mesothelioma (80% epithelioid, 20% sarcomatoid). 3. Code: UCSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Right pleura, pericardium, and diaphragm. 2. Findings: Biphasic mesothelioma (80% epithelioid, 20% sarcomatoid). 3. Code: UCSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Right pleura, pericardium, and diaphragm. 2. Findings: Biphasic mesothelioma (80% epithelioid, 20% sarcomatoid). 3. Code: UCSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Right pleura, pericardium, and diaphragm. 2. Findings: Biphasic mesothelioma (80% epithelioid, 20% sarcomatoid).",
      "predicted": "UCSC",
      "ground_truth": "MESO",
      "correct": false,
      "reasoning": "1. Site: Right pleura, pericardium, and diaphragm. 2. Findings: Biphasic mesothelioma (80% epithelioid, 20% sarcomatoid). 3. Code: UCSC.",
      "idx": 907,
      "timestamp": "2026-01-19T15:59:53.115790"
    },
    {
      "sample_idx": 1127,
      "input": "Clinical Diagnosis & History: Abdominal mass, sarcoma. Specimens Submitted: 1: Atypical smooth muscle tumor of left retro-peritoneum. DIAGNOSIS: 1. Left retroperitoneum, resection: - High grade leiomyosarcoma. - Tumor size: 4.2 x 3.8 x 2.5 cm. - Tumor appears completely excised, with narrow margins ( < 0.1 cm form. the inked undesignated margins). - Two benign lymph nodes (0/2). I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL), . AND ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left retroperitoneum. 2. Findings: High-grade leiomyosarcoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left retroperitoneum. 2. Findings: High-grade leiomyosarcoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left retroperitoneum. 2. Findings: High-grade leiomyosarcoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left retroperitoneum. 2. Findings: High-grade leiomyosarcoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left retroperitoneum. 2. Findings: High-grade leiomyosarcoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left retroperitoneum. 2. Findings: High-grade leiomyosarcoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left retroperitoneum. 2. Findings: High-grade leiomyosarcoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left retroperitoneum. 2. Findings: High-grade leiomyosarcoma. 3. Code:",
      "predicted": "KIRC",
      "ground_truth": "SARC",
      "correct": false,
      "reasoning": "1. Site: Left retroperitoneum. 2. Findings: High-grade leiomyosarcoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 1127,
      "timestamp": "2026-01-19T15:59:53.115800"
    },
    {
      "sample_idx": 200,
      "input": "FINAL DIAGNOSIS: PART 1: BREAST. RIGHT, SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA,NOS TYPE, POORLY DIFFERENTIATED. B. THE INVASIVE TUMOR MEASURES 2.0 CM IN GREATEST DIMENSION.NOTTINGHAM GRADE 3 (TUBULE. FORMATION 3, NUCLEAR PLEOMORPHISM 3, MITOTIC ACTIVITY 3; TOTAL SCORE 9/9). C. DUCTAL CARCINOMA IN-SITU (DCIS), NUCLEAR GRADE 3, MICROPAPILLARY AND PAPILLARY TYPES. WITH COMEDONECROSIS; CONSTITUTES 60% OF THE TOTAL TUMOR MASS AND IS PRESENT ADMIXED. WITH AND AWAY FROM THE INVASIVE COMPO...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NOS type, poorly differentiated. Ductal carcinoma in situ (DCIS), nuclear grade 3, micropapillary and papillary types. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NOS type, poorly differentiated. Ductal carcinoma in situ (DCIS), nuclear grade 3, micropapillary and papillary types. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NOS type, poorly differentiated. Ductal carcinoma in situ (DCIS), nuclear grade 3, micropapillary and papillary types. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NOS type, poorly differentiated. Ductal carcinoma in situ (DCIS), nuclear grade 3, micropapillary and papillary types. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NOS type, poorly differentiated. Ductal carcinoma in situ (DCIS), nuclear grade 3, micropapillary and papillary types. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NOS type, poorly differentiated. Ductal carcinoma in situ (DCIS), nuclear grade 3, micropapillary and papillary types. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, NOS type, poorly differentiated. Ductal carcinoma in situ (DCIS), nuclear grade 3, micropapillary and papillary types. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 200,
      "timestamp": "2026-01-19T15:59:53.115812"
    },
    {
      "sample_idx": 103,
      "input": "FINAL DIAGNOSIS: PART 1: BREAST, RIGHT, MODIFIED RADICAL MASTECTOMY-. A. INFILTRATING DUCTAL CARCINOMA. B. NEOPLASM MEASURES 3.0 CM ON GROSS EXAM. C. NOTTINGHAM SCORE 7/9, GRADE 2 (TUBULES 3, NUCLEI 3, MITOSES 1). D. MARGINS OF RESECTION FREE OF NEOPLASM, CLOSEST ANTERIOR AT 2.0 CM. E. LYMPHOVASCULAR INVASION IDENTIFIED. F. UNREMARKABLE SKIN AND NIPPLE. G. ER POSITIVE, PR POSITIVE, HER-2/NEU NEGATIVE (SCORE 0) PER PREVIOUS REPORT. H. PATHOLOGIC STAGE T2 N1 MX. I. DUCTAL CARCINOMA IN SITU, SOLID ...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Score 7/9, Grade 2. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Score 7/9, Grade 2. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Score 7/9, Grade 2. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Score 7/9, Grade 2. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Score 7/9, Grade 2. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Score 7/9, Grade 2. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Score 7/9, Grade 2. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Score 7/9, Grade 2. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1.",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham Score 7/9, Grade 2. 3. Code: BRCA.",
      "idx": 103,
      "timestamp": "2026-01-19T15:59:53.115824"
    },
    {
      "sample_idx": 1107,
      "input": "Addendum. Clinical Diagnosis & History: Diagnosed with rectal carcinoma at 15 cm on. rectal carcinoma. Specimens Submitted: 1: SP: Rectum and rectosigmoid. 2: SP: Additional sigmoid. 3: SP: Proximal ring. 4: SP: Distal ring. DIAGNOSIS: 1). COLON, RECTUM AND RECTOSIGMOID, SEGMENTAL RESECTION: - THREE (3) FOCI OF ADENOCARCINOMA, MODERATELY DIFFERENTIATED, OF. SIGMOID AND RECTOSIGMOID. - THE TUMORS MEASURE 2.9 X 1.8 X 0.8 CM, 0.4 x 0.4 x 0.2 CM, AND 0.7 X. 0.5 X 0.2 CM, RESPECTIVELY. - GROSS CONFIG...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectum and rectosigmoid. 2. Findings: Colon, rectum and rectosigmoid, segmental resection: - Three (3) foci of adenocarcinoma, moderately differentiated, of sigmoid and rectosigmoid. - The tumors measure 2.9 x 1.8 x 0.8 cm, 0.4 x 0.4 x 0.2 cm, and 0.7 x 0.5 x 0.2 cm, respectively. - Gross configurations are polypoid. - Preexisting tubular adenoma is identified. - Two smaller tumors invade into the submucosa (pT1) . - The largest tumor invades into muscularis propria (pT2). - No vascular invasion is identified. - No perineural invasion is identified. - Surgical margins are free of tumor. - Additional hyperplastic polyp is identified. The uninvolved colonic mucosa is unremarkable. - Lymph nodes: Number of metastases:0 Number examined: 8 (0/8). (Additional lymph nodes are being examined and an addendum report will follow). 2. Site: Additional sigmoid. 3. Findings: Hyperplastic polyp. - Unremarkable colonic mucosa. - One benign lymph node (0/1). 3. Site: Proximal ring. 4. Findings: Unremarkable colonic mucosa. 4. Site: Distal ring. 5. Findings: Unremarkable colonic mucosa. 1. At test that the above diagnosis is based upon my personal examination of the slides (and/or other material), and that I have reviewed and approved this report. 1. Gross Description: 1) The specimen is received fresh labeled \\\"rectum and rectosigmoid\\\". It consists of a rectosigmoid colon that measures 12.0 cm in length by 7.0 cm in circumference at the distal resection margin. The serosal surface is pink and smooth. The radial resection margin is inked black and the specimen is opened to reveal a pink-tan papillary tumor measuring 2.9 cm in length by 1.8 cm in width by 0.4 cm, located 3.5 cm from the distal resection margin. There is a smooth sessile polyp measuring 0.4 x 0.4 x 0.2 cm, located 0.7 cm from the tumor, and",
      "predicted": null,
      "ground_truth": "READ",
      "correct": null,
      "reasoning": "",
      "idx": 1107,
      "timestamp": "2026-01-19T15:59:53.115934"
    },
    {
      "sample_idx": 30,
      "input": "M. Date Of Birt'. COPY ONLY DO NOT FILE. nat. Source of Specimen. A. LEFT DISTAL URETER FS-. B. RIGHT DISTAL URETER FS-. C. RIGHT COMMON AND EXTERNAL ILIAC LYMPH NODES-. D. RIGHT OBTURATOR LYMPH NODES-. E. RIGHT INTERNAL ILIAC LYMPH NODES-. F. LEFT COMMON AND INTERNAL LYMPH NODES-. G. LEFT OBTURATOR LYMPH NODES-. H. BLADDER, PROSTATE GLAND, SEMINAL VESICLES AND VASA. DEFERENTIA-. FINAL DIAGNOSIS: A. LEFT DISTAL URETER FS-. URETER, NEGATIVE FOR TUMOR. B. RIGHT DISTAL URETER FS-. URETER, NEGATIVE ...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Bladder, Prostate Gland, Seminal Vesicles and Vas Deferentia. 2. Findings: High grade papillary (rothelial carcinoma) with depth of invasion of outer one-third of muscularis propria. 3. Code: UCEC maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Ureter, Bladder, Prostate Gland, Seminal Vesicles and Vas Deferentia. 2. Findings: Negative for tumor. 3. Code: UVM maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Distal Ureter, Right Distal Ureter, Right Common and External Iliac Lymph Nodes, Right Obturator Lymph Nodes, Right Internal Iliac Lymph Nodes, Left Common and Internal Lymph Nodes, Left Obturator Lymph Nodes, Bladder, Prostate Gland, Seminal Vesicles and Vas Deferentia. 2. Findings: Ureter, negative for tumor. Lymph nodes, negative for tumor. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Left Distal Ureter, Right Distal Ureter, Right Common and External Iliac Lymph Nodes, Right Obturator Lymph Nodes, Right Internal Iliac Lymph Nodes, Left Common and Internal Lymph Nodes, Left Obturator Lymph Nodes, Bladder, Prostate Gland, Seminal Vesicles and Vas Deferentia. 2. Findings: Ureter, negative for tumor. Lymph nodes, negative for tumor. 3. Code: UVM maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Left Distal Ureter, Right Distal Ureter, Right Common and External Iliac Lymph Nodes, Right Obturator Lymph Nodes, Right Internal Iliac Lymph Nodes, Left Common and Internal Lymph Nodes, Left Obturator Lymph Nodes, Bladder, Prostate Gland, Seminal Vesicles and Vas Deferentia. 2. Findings",
      "predicted": "UCEC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Bladder, Prostate Gland, Seminal Vesicles and Vas Deferentia. 2. Findings: High grade papillary (rothelial carcinoma) with depth of invasion of outer one-third of muscularis propria. 3. Code: UCEC maps to UCEC.",
      "idx": 30,
      "timestamp": "2026-01-19T15:59:53.115947"
    },
    {
      "sample_idx": 1399,
      "input": "RUN DATE: LABORATORY. PAGE: 1. RUN TIME: Specimen Inquiry. SPEC #: Obtained: CLINICAL HISTORY : ICD-9 236.3; ENDOMETRIAL CA. SPECIMEN/PROCEDURE : 1. VAGINA - BIOPSY. IMPRESSION: : VAGINAL BIOPSY: Caroinosarcoma, consistent with previous history of uterine caroinosarcoma. Entered: GROSS DESCRIPTION: Received in formalin labeled \"vag apex left biopsy\" and with the patient's name, the. specimen consists of multiple pale tan tissue fragments measuring 2 x 1.5 x 0.4 cm. in. aggregate. The specimen is...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Vagina. 2. Findings: Carcinosarcoma. 3. Code: Vaginal Carcinosarcoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Vagina. 2. Findings: Carcinosarcoma. 3. Code: Vaginal Carcinosarcoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Vagina. 2. Findings: Carcinosarcoma. 3. Code: Vaginal Carcinosarcoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Vagina. 2. Findings: Carcinosarcoma. 3. Code: Vaginal Carcinosarcoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Vagina. 2. Findings: Carcinosarcoma. 3. Code: Vaginal Carcinosarcoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Vagina. 2. Findings: Carcinosarcoma. 3. Code: Vaginal Carcinosarcoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Vagina. 2. Findings: Carcinosarcoma. 3. Code: Vaginal Carcinosarcoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Vagina. 2. Findings: Carcinosarcoma. 3. Code: Vaginal Carcinosarcoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Vagina. 2.",
      "predicted": "UCEC",
      "ground_truth": "UCS",
      "correct": false,
      "reasoning": "1. Site: Vagina. 2. Findings: Carcinosarcoma. 3. Code: Vaginal Carcinosarcoma maps to UCEC.",
      "idx": 1399,
      "timestamp": "2026-01-19T15:59:53.115957"
    },
    {
      "sample_idx": 484,
      "input": "DIAGNOSIS: 1) LYMPH NODE, LEFT POSTERIOR LEVEL 1, EXCISION: 1 LYMPH NODE, NEGATIVE FOR. MALIGNANCY (0/1). 2) LYMPH NODE, LEVEL 1, EXCISION: 4 LYMPH NODES, NEGATIVE FOR MALIGNANCY. (0/4). 3) TONGUE, LEFT, PARTIAL GLOSSECTOMY: WELL-DIFFERENTIATED KERATINIZING. SQUAMOUS CELL CARCINOMA, 1.0 CM IN GREATEST EXTENT, COMPLETELY EXCISED. 4) LYMPH NODES, LEFT NECK LEVEL 2, 3, 4, EXCISION: 4 LYMPH NODES, NEGATIVE. FOR MALIGNANCY (0/4). 5) LYMPH NODES, ANTERIOR LEVEL 1, EXCISION: 1 LYMPH NODE, NEGATIVE FOR....",
      "response": "```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Left Posterior Level 1 Neck. 2. Findings: Negative for malignancy. 3. Code: LYMPH NODE, NEGATIVE FOR MALIGNANCY maps to LYMPH NODE, LEFT POSTERIOR LEVEL 1, EXCISION: 1 LYMPH NODE, NEGATIVE FOR. MALIGNANCY (0/1). 2. Site: Level 1 Lymph Node. 3. Findings: Negative for malignancy. 4. Code: LYMPH NODE, LEVEL 1, EXCISION: 4 LYMPH NODES, NEGATIVE FOR MALIGNANCY (0/4). 3. Site: Left Partial Glossectomy. 4. Findings: Well-differentiated keratinizing squamous cell carcinoma, 1.0 cm in greatest extent, completely excised. 5. Code: TONGUE, LEFT, PARTIAL GLOSSECTOMY: WELL-DIFFERENTIATED KERATINIZING. SQUAMOUS CELL CARCINOMA, 1.0 CM IN GREATEST EXTENT, COMPLETELY EXCISED. 6. Site: Left Neck Levels 2, 3, 4. 7. Findings: Negative for malignancy. 8. Code: LYMPH NODES, LEFT NECK LEVEL 2, 3, 4, EXCISION: 4 LYMPH NODES, NEGATIVE FOR MALIGNANCY (0/4). 9. Site: Anterior Level 1. 10. Findings: Negative for malignancy. 11. Code: LYMPH NODES, ANTERIOR LEVEL 1, EXCISION: 1 LYMPH NODE, NEGATIVE FOR. MALIGNANCY (0/1).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Left Posterior Level 1 Neck. 2. Findings: Negative for malignancy. 3. Code: LYMPH NODE, LEFT POSTERIOR LEVEL 1, EXCISION: 1 LYMPH NODE, NEGATIVE FOR. MALIGNANCY (0/1). 2. Site: Level 1 Lymph Node. 3. Findings: Negative for malignancy. 4. Code: LYMPH NODE, LEVEL 1, EXCISION: 4 LYMPH NODES, NEGATIVE FOR MALIGNANCY (0/4). 3.",
      "predicted": "SCC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Left Posterior Level 1 Neck. 2. Findings: Negative for malignancy. 3. Code: LYMPH NODE, NEGATIVE FOR MALIGNANCY maps to LYMPH NODE, LEFT POSTERIOR LEVEL 1, EXCISION: 1 LYMPH NODE, NEGATIVE FOR. MALIGNANCY (0/1). 2. Site: Level 1 Lymph Node. 3. Findings: Negative for malignancy. 4. Code: LYMPH NODE, LEVEL 1, EXCISION: 4 LYMPH NODES, NEGATIVE FOR MALIGNANCY (0/4). 3. Site: Left Partial Glossectomy. 4. Findings: Well-differentiated keratinizing squamous cell carcinoma, 1.0 cm in greatest extent, completely excised. 5. Code: TONGUE, LEFT, PARTIAL GLOSSECTOMY: WELL-DIFFERENTIATED KERATINIZING. SQUAMOUS CELL CARCINOMA, 1.0 CM IN GREATEST EXTENT, COMPLETELY EXCISED. 6. Site: Left Neck Levels 2, 3, 4. 7. Findings: Negative for malignancy. 8. Code: LYMPH NODES, LEFT NECK LEVEL 2, 3, 4, EXCISION: 4 LYMPH NODES, NEGATIVE FOR MALIGNANCY (0/4). 9. Site: Anterior Level 1. 10. Findings: Negative for malignancy. 11. Code: LYMPH NODES, ANTERIOR LEVEL 1, EXCISION: 1 LYMPH NODE, NEGATIVE FOR. MALIGNANCY (0/1).",
      "idx": 484,
      "timestamp": "2026-01-19T15:59:53.115987"
    },
    {
      "sample_idx": 340,
      "input": "Department of Pathology and Microbiology. Accession No: Acot No: Date Taken: Date Received: Submitted by: Loc: Room: Client: Final Diagnosis: RIGHT NECK MASS, EXCISION: LYMPH NODE WITH DIFFUSE LARGE B-CELL LYMPHOMA,. NONCLEAVED (SEE COMMENT). (B-DLCL-NC). Diagnosis Comment: The tumor colls have a germinal center B-cell phenotype. History: The patient is a. tyear-old female with a right neck mass. Intraoperative Diagnosis: Neck right. excisional biopsy: \"Diagnostic tissue favor lymphoma.\" This is...",
      "response": "```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Neck. 2. Findings: Diffuse large B-cell lymphoma, noncleaved. 3. Code: DLBC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Neck. 2. Findings: Diffuse large B-cell lymphoma, noncleaved. 3. Code: DLBC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Neck. 2. Findings: Diffuse large B-cell lymphoma, noncleaved. 3. Code: DLBC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Neck. 2. Findings: Diffuse large B-cell lymphoma, noncleaved. 3. Code: DLBC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Neck. 2. Findings: Diffuse large B-cell lymphoma, noncleaved. 3. Code: DLBC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Neck. 2. Findings: Diffuse large B-cell lymphoma, noncleaved. 3. Code: DLBC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Neck. 2. Findings: Diffuse large B-cell lymphoma, noncleaved. 3. Code: DLBC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Neck. 2. Findings: Diffuse large B-cell lymphoma, noncleaved. 3. Code: DLBC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1.",
      "predicted": "DLBC",
      "ground_truth": "DLBC",
      "correct": true,
      "reasoning": "1. Site: Neck. 2. Findings: Diffuse large B-cell lymphoma, noncleaved. 3. Code: DLBC.",
      "idx": 340,
      "timestamp": "2026-01-19T15:59:53.115997"
    },
    {
      "sample_idx": 832,
      "input": "Clinical Diagnosis & History: with right lower lobe mass and cervical adenopathy. thoracotomy and lobectomy. Specimens Submitted. 1 : SP: Level seven mediastinal lymph nodes. 2: SP 1 Tisuse external from bronchug intermodius. 3: SP: Right level eloven interlobar lymph node (. 4: SP: Right level ten mediastinal lymah node. 5  SP: Bronchial margin bronchus intermedius. 6 : SP: Level seven mediastinal lymph nodes #2. 7: SP: Right level eleven interlobar lymph node #2. 8: SP: Right middle and lower ...",
      "response": "```json\n{\n    \"cancer_type\": \"ADCA\",\n    \"reasoning\": \"1. Site: Mediastinum (Level 7, 10, 11). 2. Findings: Metastatic squamous cell carcinoma. 3. Code: Squamous Cell Carcinoma, Metastatic, Mediastinum maps to ADCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. ",
      "predicted": "ADCA",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Mediastinum (Level 7, 10, 11). 2. Findings: Metastatic squamous cell carcinoma. 3. Code: Squamous Cell Carcinoma, Metastatic, Mediastinum maps to ADCA.",
      "idx": 832,
      "timestamp": "2026-01-19T15:59:53.116008"
    },
    {
      "sample_idx": 1196,
      "input": "FINAL DIAGNOSIS: PART 1: TISSUE AT BASE OF LEFT GASTRIC, EXCISION -. ADIPOSE TISSUE-WITH FAT NECROSIS, NEGATIVE FOR TUMOR. PART 2: TISSUE NEAR RIGHT CRUS, EXCISION -. TWO BENIGN LYMPH NODES (0/2). PART 3: OMENTUM, EXCISION -. FIBROADIPOSE TISSUE, NEGATIVE FOR TUMOR. PART 4: LEVEL 7 LYMPH NODE NEAR CARINA, EXCISION -. ONE BENIGN LYMPH NODE (0/1). PART 5: ESOPHAGUS, ESOPHAGECTOMY -. A. WELL TO MODERATELY DIFFERENTIATED ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION,. 2.5 CM, PREDOMINANTLY EXOPHYT...",
      "response": "```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Adenocarcinoma of the gastroesophageal junction, 2.5 cm, predominantly exophytic. 3. Code: ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Adenocarcinoma of the gastroesophageal junction, 2.5 cm, predominantly exophytic. 3. Code: ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Adenocarcinoma of the gastroesophageal junction, 2.5 cm, predominantly exophytic. 3. Code: ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Adenocarcinoma of the gastroesophageal junction, 2.5 cm, predominantly exophytic. 3. Code: ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Adenocarcinoma of the gastroesophageal junction, 2.5 cm, predominantly exophytic. 3. Code: ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Adenocarcinoma of the gastroesophageal junction, 2.5 cm, predominantly exophytic. 3. Code: ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Adenocarcinoma of the gastroesophageal junction, 2.5 cm, predominantly exophytic. 3. Code: ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus. 2. Findings: Adenocarcinoma of the gastroesophageal junction, 2.5 cm, predominantly",
      "predicted": "ESCA",
      "ground_truth": "STAD",
      "correct": false,
      "reasoning": "1. Site: Esophagus. 2. Findings: Adenocarcinoma of the gastroesophageal junction, 2.5 cm, predominantly exophytic. 3. Code: ESCA.",
      "idx": 1196,
      "timestamp": "2026-01-19T15:59:53.116018"
    },
    {
      "sample_idx": 985,
      "input": "ORIGINAL REPORT. SPECIMEN: A. Periportal lymph node,. B. Gallbladder. c. Bile duct margin,. D. Pancreas margin. E. Superior mesenteric lymph nodes (fresh). F. Pancreas (Whipple's spec\u00edmen). G. Omentum. CLINICAL HISTORY?. Pancreatic cancer. DIAGNOSIS: A: #PERTPORTAL\" LYMPH NODE: REACTIVE LYMPH NODE WITH NO EVIDENCE OF MALIGNANCY. B: GALLBLADDER (CHOLECYSTEICTOMY) : NO EVIDENCE OF MALIGNANCY. C: BILE DUCT MARGIN: NO EVIDENCE OF MALIGNANCY OR DYSPLASIA. D: PANCREAS MARGIN: CHRONTO PANCREATITIS WITH...",
      "response": "```json\n{\n    \"cancer_type\": \"F10\",\n    \"reasoning\": \"1. Site: Head of pancreas/common bile duot. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: F10\"\n}\n```\n```json\n{\n    \"cancer_type\": \"F11\",\n    \"reasoning\": \"1. Site: Uncinate pancreas. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: F11\"\n}\n```\n```json\n{\n    \"cancer_type\": \"F12\",\n    \"reasoning\": \"1. Site: Bile duct resection margin. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: F12\"\n}\n```\n```json\n{\n    \"cancer_type\": \"F13\",\n    \"reasoning\": \"1. Site: Stomach resection margin. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: F13\"\n}\n```\n```json\n{\n    \"cancer_type\": \"F14\",\n    \"reasoning\": \"1. Site: Duodenal resection margin. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: F14\"\n}\n```\n```json\n{\n    \"cancer_type\": \"F15\",\n    \"reasoning\": \"1. Site: Ampulla region. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: F15\"\n}\n```\n```json\n{\n    \"cancer_type\": \"F16\",\n    \"reasoning\": \"1. Site: Tumor extending close to the serosal surface of pancreas. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: F16\"\n}\n```\n```json\n{\n    \"cancer_type\": \"F17\",\n    \"reasoning\": \"1. Site: Random sections of the duodenum. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: F17\"\n}\n```\n```json\n{\n    \"cancer_type\": \"F18\",\n    \"reasoning\": \"1. Site: Lymphoid tissue. 2. Findings: Adenocarcinoma, well differentiated. 3. Code:",
      "predicted": "F10",
      "ground_truth": "PAAD",
      "correct": false,
      "reasoning": "1. Site: Head of pancreas/common bile duot. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: F10",
      "idx": 985,
      "timestamp": "2026-01-19T15:59:53.116028"
    },
    {
      "sample_idx": 437,
      "input": "PATIENT HISTORY: CHIEF COMPLAINT/PRE-OP/POST-OR DIAGNOSIS: Left buccal cancer. PROCEDURE: Neck dissection. SPECIFIC CLINICAL QUESTION: Not answered. OUTSIDE TISSUE DIAGNOSIS: Not answered. PRIOR MALIGNANCY: Not answered. CHEMORADIATION: Not answered. ORGAN TRANSPLANT: Not answered. IMMUNOSUPPRESSION: Not answered. OTHER DISEASES: Not answered. E-record history: male with a large buccal tumor (T3 N2B squamous cell carcinoma) which involves almost the entire. buccal mucosa but does not extend into...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left buccal mucosa, left mandibular periosteum, left submandibular gland, left level 1. 2. Findings: Invasive squamous cell carcinoma, moderately differentiated with infiltrative border. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left buccal mucosa, left mandibular periosteum, left submandibular gland, left level 1. 2. Findings: Invasive squamous cell carcinoma, moderately differentiated with infiltrative border. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left buccal mucosa, left mandibular periosteum, left submandibular gland, left level 1. 2. Findings: Invasive squamous cell carcinoma, moderately differentiated with infiltrative border. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left buccal mucosa, left mandibular periosteum, left submandibular gland, left level 1. 2. Findings: Invasive squamous cell carcinoma, moderately differentiated with infiltrative border. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left buccal mucosa, left mandibular periosteum, left submandibular gland, left level 1. 2. Findings: Invasive squamous cell carcinoma, moderately differentiated with infiltrative border. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left buccal mucosa, left mandibular periosteum, left submandibular gland, left level 1. 2. Findings: Invasive squamous cell carcinoma, moderately differentiated with infiltrative border. 3. Code: KIRC.\"\n}\n```\n",
      "predicted": "KIRC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Left buccal mucosa, left mandibular periosteum, left submandibular gland, left level 1. 2. Findings: Invasive squamous cell carcinoma, moderately differentiated with infiltrative border. 3. Code: KIRC.",
      "idx": 437,
      "timestamp": "2026-01-19T15:59:53.116040"
    },
    {
      "sample_idx": 1319,
      "input": "Sex: Female. Ref Physicia. SPECIMEN INFORMATION. Acct / Reg #. DIAGNOSIS,. DIAGNOSIS: A. Omentum, excision: Negative for malignancy. B. Uterus, bilateral adnexa, hysterectomy with bilateral salpingo-oophorectomy: Tumor Characteristics: 1. Histologic type: Serous adenocarcinoma of endometrium. 2. Histologic grade: High. 3. Tumor site: Endometrium. 4. Tumor size: 2.7 by 2.5 cm. 5. Myometrial invasion: Not identified. 6. involvement of cervix: Not identified. 7. Extent of involvement of other organ...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, bilateral tubes and ovaries. 2. Findings: Serous adenocarcinoma of endometrium, high grade, with extensive lymphovascular space invasion. 3. Code: UCEC matches the uterine cancer with lymphovascular invasion.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Omentum. 2. Findings: Negative for malignancy. 3. Code: UVM matches the negative findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Uterus, cervix, bilateral tubes and ovaries. 2. Findings:  Ovarian cysts, one is a hardened cyst. 3. Code: UVM matches the negative findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Left paraaortic lymph nodes. 2. Findings: Negative for metastatic disease. 3. Code: UVM matches the negative findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Left pelvic lymph nodes. 2. Findings: One of seventeen lymph nodes positive for metastatic carcinoma. 3. Code: UVM matches the negative findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Right pelvic lymph nodes. 2. Findings: One of twenty-six lymph nodes positive for metastatic carcinoma. 3. Code: UVM matches the negative findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Right paraaortic lymph nodes. 2. Findings: Six of eight lymph nodes positive for metastatic carcinoma. 3. Code: UVM matches the negative findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Uterus, cervix, bilateral tubes and ovaries. 2. Findings:  No findings. 3. Code: UVM matches the negative",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus, cervix, bilateral tubes and ovaries. 2. Findings: Serous adenocarcinoma of endometrium, high grade, with extensive lymphovascular space invasion. 3. Code: UCEC matches the uterine cancer with lymphovascular invasion.",
      "idx": 1319,
      "timestamp": "2026-01-19T15:59:53.116053"
    },
    {
      "sample_idx": 1403,
      "input": "CLINICAL HISTORY: Malignant neoplasm corpus uteri-182.0 (illegible) = carcinosarcoma. GROSS EXAMINATION: A. \"Right periaortic\", received fresh and placed in formalin on. at. is a 4 x 2.5 x 1 cm aggregate of fibroadipose tissue. Seven lymph node. candidates are identified ranging from 0.4 x 0.4 x 0.2 cm up to 1.2 x 1 x 0.5. cm. The largest lymph node candidate is bisected and exhibits a white-brown. firm cut surface. BLOCK SUMMARY: A1- six intact lymph node candidates. A2- one bisected lymph node...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Carcinosarcoma (malignant mesodermal mixed tumor). The tumor is located on the anterior uterine wall and in a separate detached fragment. 3. Code: UCEC (Uterine Corpus Carcinoma) maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Carcinosarcoma (malignant mesodermal mixed tumor). The tumor is located on the anterior uterine wall and in a separate detached fragment. 3. Code: UCEC (Uterine Corpus Carcinoma) maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Carcinosarcoma (malignant mesodermal mixed tumor). The tumor is located on the anterior uterine wall and in a separate detached fragment. 3. Code: UCEC (Uterine Corpus Carcinoma) maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Carcinosarcoma (malignant mesodermal mixed tumor). The tumor is located on the anterior uterine wall and in a separate detached fragment. 3. Code: UCEC (Uterine Corpus Carcinoma) maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Carcinosarcoma (malignant mesodermal mixed tumor). The tumor is located on the anterior uterine wall and in a separate detached fragment. 3. Code: UCEC (Uterine Corpus Carcinoma) maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Carcinosarcoma (malignant mesodermal mixed tumor). The tumor is located on the anterior uterine wall and in a separate detached fragment. 3. Code: UCEC (U",
      "predicted": "UCEC",
      "ground_truth": "UCS",
      "correct": false,
      "reasoning": "1. Site: Uterus. 2. Findings: Carcinosarcoma (malignant mesodermal mixed tumor). The tumor is located on the anterior uterine wall and in a separate detached fragment. 3. Code: UCEC (Uterine Corpus Carcinoma) maps to UCEC.",
      "idx": 1403,
      "timestamp": "2026-01-19T15:59:53.116066"
    },
    {
      "sample_idx": 337,
      "input": "Case ID. Gross. Microscopic Description. Diagnosis Details. Description. Part of the stomach. The 1st conclusion: in the gastric. Tumor Features: Unknown,. with saucer-like. wall there is a tumor with diffuse. Tumor Extent: 0, Venous. tumor up to 5.5 cm. type of growth, which is consised. Invasion: Absent, Margins: in size, with muscle. of small-size cells with. Absent, Treatment Effect: layer invasion. In. hyperchromatic nuclei. Tumor is. the fatty tissue. replace gastric mucosa and spread. the...",
      "response": "```json\n{\n    \"cancer_type\": \"MBL\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Non-Hodgkin's marginal zone B-cell lymphoma, diffuse large B-cell lymphoma. 3. Code: MBL maps to MBL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MBL\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Non-Hodgkin's marginal zone B-cell lymphoma, diffuse large B-cell lymphoma. 3. Code: MBL maps to MBL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MBL\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Non-Hodgkin's marginal zone B-cell lymphoma, diffuse large B-cell lymphoma. 3. Code: MBL maps to MBL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MBL\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Non-Hodgkin's marginal zone B-cell lymphoma, diffuse large B-cell lymphoma. 3. Code: MBL maps to MBL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MBL\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Non-Hodgkin's marginal zone B-cell lymphoma, diffuse large B-cell lymphoma. 3. Code: MBL maps to MBL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MBL\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Non-Hodgkin's marginal zone B-cell lymphoma, diffuse large B-cell lymphoma. 3. Code: MBL maps to MBL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MBL\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Non-Hodgkin's marginal zone B-cell lymphoma, diffuse large B-cell lymphoma. 3. Code: MBL maps to MBL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"MBL\",\n    \"reasoning\": \"",
      "predicted": "MBL",
      "ground_truth": "DLBC",
      "correct": false,
      "reasoning": "1. Site: Stomach. 2. Findings: Non-Hodgkin's marginal zone B-cell lymphoma, diffuse large B-cell lymphoma. 3. Code: MBL maps to MBL.",
      "idx": 337,
      "timestamp": "2026-01-19T15:59:53.116077"
    },
    {
      "sample_idx": 776,
      "input": "Spec. Taken. INTERPRETATION AND DIAGNOSIS: 1. LYMPH NODE, L8 (EXCISION) : ONE (1) LYMPH NODE AND ASSOCIATED. FIBROADIPOSE TISSUE, NEGATIVE FOR TUMOR. 2. LUNG (RESECTION) : SPECIMEN TYPE: Lobectomy, left lower lobe. TUMOR SITE: Left Lower lobe. HISTOLOGIC TYPE: Adenocarcinoma (70% Acinar, 30% solid). TUMOR SIZE: 2.3 cm. HISTOLOGIC GRADE: G3: Poorly Differentiated. LYMPH NODES: Metastatic carcinoma in 1 of 11 lymph nodes. EXTENT OF INVASION (7th Edition, AJCC) : PRIMARY TUMOR. pT1b: Tumor >2 cm bu...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Left Lower lobe of the lung. 2. Findings: Adenocarcinoma, 70% acinar, 30% solid, 2.3 cm. 3. Code: LUAD.\"\n}\n```\nExplanation:\n\n1. **Anatomic Site**: The report mentions \"Left Lower lobe\" and \"Station 6\" and \"Station 7\" lymph nodes. The primary tumor is in the left lower lobe.\n2. **Histological Findings**: The tumor is an adenocarcinoma, specifically 70% acinar and 30% solid. The size is 2.3 cm.\n3. **TCGA Code Selection**: Based on the information, the most appropriate TCGA code is LUAD (Lung Adenocarcinoma).\nThe other information (lymph nodes) is relevant for staging but doesn't directly determine the primary cancer type.\nFinal Answer: The final answer is $\\boxed{LUAD}$\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nFinal Answer: The final answer is $\\boxed{BRCA}$\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Lower lobe). 2. Findings: Adenocarcinoma, 70% acinar, 30% solid, 2.3 cm. 3. Code: LUAD.\"\n}\n```\nFinal Answer: The final answer is $\\boxed{LUAD}$\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Lower lobe). 2. Findings: Adenocarcinoma, 70% acinar, 30% solid, 2.3 cm. 3. Code: LUAD.\"\n}\n```\nFinal Answer: The final answer is $\\boxed{LUAD}$\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Lower lobe). 2. Findings: Adenocarcinoma, 70% acinar, 30%",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Left Lower lobe of the lung. 2. Findings: Adenocarcinoma, 70% acinar, 30% solid, 2.3 cm. 3. Code: LUAD.",
      "idx": 776,
      "timestamp": "2026-01-19T15:59:53.116087"
    },
    {
      "sample_idx": 4,
      "input": "PREVIOUS DIAGNOSIS INQUIRY. 1. SEX: F. ADM DATE: OPER DATE: PROCEDURE: SPHS. Right adrenal mass. Two short stitches adrenal vein with thrombus coming out. of vein. Two long inferior aspect of tumor. One long lateral aspect of tumor. Two double long superior aspect of tumor. Inking according to sarcoma. template. Yellow anterior, blue superior, green inferior, red medial, orange. lateral, black posterior. PROCEDURE: SPGD. 1. \"Adrenal gland. Received in formalin in a large container is a 1060 gm. ...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenocortical carcinoma, low grade. 3. Code: ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenocortical carcinoma, low grade. 3. Code: ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenocortical carcinoma, low grade. 3. Code: ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenocortical carcinoma, low grade. 3. Code: ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenocortical carcinoma, low grade. 3. Code: ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenocortical carcinoma, low grade. 3. Code: ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenocortical carcinoma, low grade. 3. Code: ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenocortical carcinoma, low grade. 3. Code: ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Adrenal gland. ",
      "predicted": "ADENOCA",
      "ground_truth": "ACC",
      "correct": false,
      "reasoning": "1. Site: Adrenal gland. 2. Findings: Adrenocortical carcinoma, low grade. 3. Code: ADENOCA.",
      "idx": 4,
      "timestamp": "2026-01-19T15:59:53.116096"
    },
    {
      "sample_idx": 799,
      "input": "LUNG MALIGNANT. LUNG UNINVOLVED. BLOOD. SERUM. PLASMA. BUFFY-COAT. Case: : Collected date: Result date: Clinical Information. The patient is a. year old [black]-female with a lung nodule. Frozen Section Diagnosis. MFS1: Left lower lobe, resection: - Adenocarcinoma. (Per. Gross Description. The specimen is received in thirteen containers each labeled with the patient's name and medical record. number. The first container is labeled \"level IX lymph node\". Received is an anthracotic fragment of tis...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Lower Lobe). 2. Findings: Adenocarcinoma, 1.2 cm, moderately differentiated. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1.",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung (Left Lower Lobe). 2. Findings: Adenocarcinoma, 1.2 cm, moderately differentiated. 3. Code: LUAD.",
      "idx": 799,
      "timestamp": "2026-01-19T15:59:53.116107"
    },
    {
      "sample_idx": 543,
      "input": "DIAGNOSIS. (A) LEFT KIDNEY AND ADRENAL GLAND: RENAL CELL CARCINOMA (16.0 CM MAXIMUM DIMENSION), CONVENTIONAL TYPE. (50% CLEAR CELLS,. 50% EOSINOPHILIC CELLS), FUHRMAN NUCLEAR GRADE 4, INVASIVE. INTO PERINEPHRIC. ADIPOSE TISSUE, RENAL SINUS ADIPOSE TISSUE, RENAL. PELVICALYCEAL SYSTEM, AND RENAL. VEIN, WITH EXTENSION TO RENAL VEIN MARGIN. (SEE COMMENT). Adrenal gland, no tumor present. Soft tissue margin free of tumor. (B) THROMBUS: CONVENTIONAL RENAL CELL CARCINOMA ATTACHED TO VESSEL WALL. COMMEN...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade II, with invasion into perinephric adipose tissue, renal sinus adipose tissue, and renal pelvicalyceal system. Tumor extends to the renal vein margin. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade II, with invasion into perinephric adipose tissue, renal sinus adipose tissue, and renal pelvicalyceal system. Tumor extends to the renal vein margin. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade II, with invasion into perinephric adipose tissue, renal sinus adipose tissue, and renal pelvicalyceal system. Tumor extends to the renal vein margin. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade II, with invasion into perinephric adipose tissue, renal sinus adipose tissue, and renal pelvicalyceal system. Tumor extends to the renal vein margin. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade II, with invasion into perinephric adipose tissue, renal sinus adipose tissue, and renal pelvicalyceal system. Tumor extends to the renal vein margin. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade II, with invasion into perinephric adipose tissue, renal sinus adipose tissue, and renal pelvicalyceal system. Tumor extends to the renal vein margin. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 543,
      "timestamp": "2026-01-19T15:59:53.116121"
    },
    {
      "sample_idx": 931,
      "input": "Date Received: DIAGNOSIS: A. RIGHT TUBE AND OVARY: High-grade papiliary serous carcinoma. Fallopian tube focal epithelial hyperplasia. B. LEFT FALLOPIAN TUBE AND OVARY: High-grade papiliary serous carcinoma. C. UTERUS AND CERVIX: Atrophic endometrium. - Lelomyoma. Metastatic high-grade papillary serous carcinoma in uterine serosa. Adenomyosis. Endometriosis in fallopian tube. D. OMENTUM: Metastatic papiliary serous carcinoma, high grade. E. OMENTUM #2: Metastatic papillary serous carcinoma, high...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Ovary and Fallopian tube. 2. Findings: High-grade serous carcinoma, papillary type. 3. Code: UCEC (Uterine Corpus Endometrium) is not the correct code for this case. UCEC is for uterine cancer. This case involves a serous carcinoma of the ovary and fallopian tube. The correct TCGA code is UCEC as the pathology report states that the cancer is of mullerian/ovarian origin and is located in the uterus.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Ovary and Fallopian tube. 2. Findings: High-grade serous carcinoma, papillary type. 3. Code: UCEC (Uterine Corpus Endometrium) is not the correct code for this case. UCEC is for uterine cancer. This case involves a serous carcinoma of the ovary and fallopian tube. The correct TCGA code is UCEC as the pathology report states that the cancer is of mullerian/ovarian origin and is located in the uterus.\"\n}\n```\n\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Ovary and Fallopian tube. 2. Findings: High-grade serous carcinoma, papillary type. 3. Code: UCEC (Uterine Corpus Endometrium) is not the correct code for this case. UCEC is for uterine cancer. This case involves a serous carcinoma of the ovary and fallopian tube. The correct TCGA code is UCEC as the pathology report states that the cancer is of mullerian/ovarian origin and is located in the uterus.\"\n}\n```\n\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Ovary and Fallopian tube. 2. Findings: High-grade serous carcinoma, papillary type. 3. Code: UCEC (Uterine Corpus Endometrium) is not the correct code for this case. UCEC is for uterine cancer. This case involves a serous carcinoma of the ovary and fallopian tube. The correct TCGA code is UCEC as the pathology report states that the cancer is of mullerian/ovarian origin",
      "predicted": "UCEC",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Ovary and Fallopian tube. 2. Findings: High-grade serous carcinoma, papillary type. 3. Code: UCEC (Uterine Corpus Endometrium) is not the correct code for this case. UCEC is for uterine cancer. This case involves a serous carcinoma of the ovary and fallopian tube. The correct TCGA code is UCEC as the pathology report states that the cancer is of mullerian/ovarian origin and is located in the uterus.",
      "idx": 931,
      "timestamp": "2026-01-19T15:59:53.116137"
    },
    {
      "sample_idx": 584,
      "input": "FINAL DIAGNOSIS. PART 1: GALLBLADDER, CHOLECYSTECTOMY -. ACUTE AND CHRONIC CALCULOUS CHOLECYSTITIS. NO EVIDENCE OF MALIGNANCY. PART 2: GALLSTONES, REMOVAL -. CHOLELITHIASIS (gross diagnosis). PART 3: LEFT KIDNEY AND LEFT ADRENAL GLAND, RESECTION -. A. RENAL CELL CARCINOMA, CONVENTIONAL TYPE (CLEAR AND GRANULAR CELL FEATURES),. EXTENSIVELY INVOLVING THE LEFT KIDNEY-AND FOCALLY INVOLVING THE RENAL PELVIS (slide 31). B. MAXIMAL TUMOR DIMENSION IS 11 CM. C. PREDOMINANT FUHRMAN NUCLEAR GRADE IS 2/4 W...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Upper Lobe Lung. 2. Findings: Metastatic Renal Cell Carcinoma. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) - this is the most appropriate code given the presence of a known renal cell carcinoma that has metastasized to the lung. The initial biopsy in the kidney is also consistent with renal cell carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA - this is the most appropriate code given the presence of invasive ductal carcinoma in the breast. Although the report does not explicitly mention BRCA, the presence of an invasive carcinoma in the breast is a strong indicator.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) - this is the most appropriate code given the presence of a renal cell carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) - this is the most appropriate code given the presence of a renal cell carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) - this is the most appropriate code given the presence of a renal cell carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Left Upper Lobe Lung. 2. Findings: Metastatic Renal Cell Carcinoma. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) - this is the most appropriate code given the presence of a known renal cell carcinoma that has metastasized to the lung. The initial biopsy in the kidney is also consistent with renal cell carcinoma.",
      "idx": 584,
      "timestamp": "2026-01-19T15:59:53.116154"
    },
    {
      "sample_idx": 1228,
      "input": "Laterality:Right. Path Report:THYROID CARCINOMA CHECKLIST. 1. Tumor type: Papillary. 2. Tumor location: Right lobe. 3. Tumor multicentricity: Single focus. 4. Tumor size: 2.1 x 1.9 cm. 5. Extrathyroid extension: Yes. 6. Surgical margins: Free of tumor. 7. Angiolymphatic invasion: Yes. 8. Lymph nodes: 14 lymph nodes identified, 11 with metastatic papillary. adenocarcinoma. 9. TNM:T3 N1a Mx.",
      "response": "```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, right lobe. Extrathyroid extension is present. Lymph node metastasis is present. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, right lobe. Extrathyroid extension is present. Lymph node metastasis is present. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, right lobe. Extrathyroid extension is present. Lymph node metastasis is present. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, right lobe. Extrathyroid extension is present. Lymph node metastasis is present. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, right lobe. Extrathyroid extension is present. Lymph node metastasis is present. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, right lobe. Extrathyroid extension is present. Lymph node metastasis is present. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, right lobe. Extrathyroid extension is present. Lymph node metastasis is present. 3. Code: Thyroid Carcinoma maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",",
      "predicted": "THCA",
      "ground_truth": "THCA",
      "correct": true,
      "reasoning": "1. Site: Thyroid. 2. Findings: Papillary carcinoma, right lobe. Extrathyroid extension is present. Lymph node metastasis is present. 3. Code: Thyroid Carcinoma maps to THCA.",
      "idx": 1228,
      "timestamp": "2026-01-19T15:59:53.116165"
    },
    {
      "sample_idx": 996,
      "input": "Diagnosis: Adrenal, left, laparoscopic adrenalectomy. - Pheochromocytoma, 109 g. - Surgical margins free of pheochromocytoma. - The tumor is circumscribed and encapsulated, without. 1 ymphovascular space invasion identified. Clinical History: -year-old male with a pheochromocytoma. Gross Description: Received is one appropriately labeled container, additionally. labeled \"left. adrenal gland.\" It holds an intact 109.1 gram, 7.2 X 6.0 X 5.0. cm unoriented. tissue fragment with a focally cauterized...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Adrenal, left. 2. Findings: Pheochromocytoma, 109 g. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Adrenal, left. 2. Findings: Pheochromocytoma, 109 g. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Adrenal, left. 2. Findings: Pheochromocytoma, 109 g. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Adrenal, left. 2. Findings: Pheochromocytoma, 109 g. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Adrenal, left. 2. Findings: Pheochromocytoma, 109 g. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Adrenal, left. 2. Findings: Pheochromocytoma, 109 g. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Adrenal, left. 2. Findings: Pheochromocytoma, 109 g. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Adrenal, left. 2. Findings: Pheochromocytoma, 109 g. 3. Code: ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",",
      "predicted": "ADENOMA",
      "ground_truth": "PCPG",
      "correct": false,
      "reasoning": "1. Site: Adrenal, left. 2. Findings: Pheochromocytoma, 109 g. 3. Code: ADENOMA.",
      "idx": 996,
      "timestamp": "2026-01-19T15:59:53.116174"
    },
    {
      "sample_idx": 317,
      "input": "Date of Birth: Vital Status: Date of Death: Race: White. Ethnicity: Not Hispanic or Latino Specific Ethnicity: Histologic Subtype: Colon adenocarcinoma. Date of Initial Path Dx: Primary Site: Colons. Anatomic Site: Ascending Colon. T Stage: 3. N Stage: 0. M Stage: 0. Overall Stage: IIA. Date of Normal Procurement:",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending Colon). 2. Findings: Colon adenocarcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending Colon). 2. Findings: Colon adenocarcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending Colon). 2. Findings: Colon adenocarcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending Colon). 2. Findings: Colon adenocarcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending Colon). 2. Findings: Colon adenocarcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending Colon). 2. Findings: Colon adenocarcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending Colon). 2. Findings: Colon adenocarcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending Colon). 2. Findings: Colon adenocarcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Ascending Colon). 2. Findings: Colon adenocarcinoma. 3. Code: Colon Adenocarcinoma",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon (Ascending Colon). 2. Findings: Colon adenocarcinoma. 3. Code: Colon Adenocarcinoma maps to COAD.",
      "idx": 317,
      "timestamp": "2026-01-19T15:59:53.116183"
    },
    {
      "sample_idx": 388,
      "input": "CLINICAL HISTORY. ith headache has posterior right frontal necrotic,. enhancing tumor, with mass effect and edema. OPERATIVE DIAGNOSES. Not Given. Operation/Specimen: A: Brain, excision biopsy. B: Right frontal brain tumor. PATHOLOGICAL DIAGNOSIS: A. Brain, site not specified, excisional biopsy: 1. Glioblastoma. 2. MIB-1 proliferation index: 30%. See Comment. COMMENT. The sections contain portions of a malignant astrocytic neoplasm that has. frequent small-multinucleated cells. There is nuclear ...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain (Right frontal). 2. Findings: Glioblastoma. 3. Code: GBM.",
      "idx": 388,
      "timestamp": "2026-01-19T15:59:53.116192"
    },
    {
      "sample_idx": 607,
      "input": "Gender: F. Date of Service: Date Received: FINAL SURGICAL PATHOLOGY REPORT. Diagnosis: KIDNEY, LEFT, NEPHRECTOMY: - PAPILLARY RENAL CELL CARCINOMA, SEE COMMENT. - FUHRMAN NUCLEAR GRADE 3. - TUMOR SIZE: 6 CM. - LIMITED TO KIDNEY. - SURGICAL MARGINS NEGATIVE. PATHOLOGIC TUMOR STAGING SYNOPSIS (LEFT KIDNEY): Type and grade: Papillary renal cell carcinoma, Fuhrman nuclear grade 3. Primary tumor: pT1b. Regional lymph node: pNX. Distant metastasis: N/A. Pathologic stage: I. Lymphovascular invasion: No...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nThe response is correct. The cancer type is KIRC, and the reasoning accurately reflects the findings in the report.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nThe response is correct. The cancer type is KIRC, and the reasoning accurately reflects the findings in the report.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nThe response is correct. The cancer type is KIRC, and the reasoning accurately reflects the findings in the report.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nThe response is correct. The cancer type is KIRC, and the reasoning accurately reflects the findings in the report.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nThe response is correct. The cancer type is KIRC, and the reasoning accurately reflects the findings in the report.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code:",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 607,
      "timestamp": "2026-01-19T15:59:53.116203"
    },
    {
      "sample_idx": 445,
      "input": "DIAGNOSIS: 1) ORAL CAVITY, ANTERIOR CANCELLOUS MARGIN, BIOPSY: BONE WITH ACUTELY. INFLAMED ATTACHED SOFT TISSUE; NEGATIVE FOR TUMOR. 2) ORAL CAVITY, POSTERIOR MANDIBULAR MARGIN, BIOPSY: NEGATIVE FOR TUMOR. 3) ORAL CAVITY, POSTERIOR BUCCAL MARGIN, EXCISION: NEGATIVE FOR DYSPLASIA. OR CARCINOMA (SEE COMMENT). COMMENT: Permanent sections do not confirm presence of dysplasia or. carcinoma in situ. The focus of concern on the frozen section may represent. basal layer with frozen artifact. 4) ORAL CAV...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral Cavity, Anterior Buccal Margin. 2. Findings: Invasive moderately differentiated squamous cell carcinoma, 2.3 cm in greatest extent, involving floor of mouth and invading into mandible; tumor is 0.2 cm from closest (lateral) surgical margin; 1 of 3 lymph nodes involved by metastatic squamous cell carcinoma (1/3); associated carcinoma in situ. 3. Code: BRCA is not a valid code for this case.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral Cavity, Anterior Buccal Margin. 2. Findings: Invasive moderately differentiated squamous cell carcinoma, 2.3 cm in greatest extent, involving floor of mouth and invading into mandible; tumor is 0.2 cm from closest (lateral) surgical margin; 1 of 3 lymph nodes involved by metastatic squamous cell carcinoma (1/3); associated carcinoma in situ. 3. Code: BRCA is not a valid code for this case.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral Cavity, Anterior Buccal Margin. 2. Findings: Invasive moderately differentiated squamous cell carcinoma, 2.3 cm in greatest extent, involving floor of mouth and invading into mandible; tumor is 0.2 cm from closest (lateral) surgical margin; 1 of 3 lymph nodes involved by metastatic squamous cell carcinoma (1/3); associated carcinoma in situ. 3. Code: BRCA is not a valid code for this case.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Oral Cavity, Anterior Buccal Margin. 2. Findings: Invasive moderately differentiated squamous cell carcinoma, 2.3 cm in greatest extent, involving floor of mouth and invading into mandible; tumor is 0.2 cm from closest (lateral) surgical margin; 1 of 3 lymph nodes involved by metastatic squamous cell carcinoma (1/3); associated carcinoma in situ. 3. Code: BRCA is not a valid code for this case.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning",
      "predicted": "BRCA",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Oral Cavity, Anterior Buccal Margin. 2. Findings: Invasive moderately differentiated squamous cell carcinoma, 2.3 cm in greatest extent, involving floor of mouth and invading into mandible; tumor is 0.2 cm from closest (lateral) surgical margin; 1 of 3 lymph nodes involved by metastatic squamous cell carcinoma (1/3); associated carcinoma in situ. 3. Code: BRCA is not a valid code for this case.",
      "idx": 445,
      "timestamp": "2026-01-19T15:59:53.116219"
    },
    {
      "sample_idx": 119,
      "input": "page 1 / 1. original. Examination: Histopathological examination. PESEL: Gender: F. Material: Total organ resection - right breast with axiliary tissues. Expected time of examination: up to 8 working days. Clinical diagnosis: Right breast with an ulcerous tumour and right axillary lymph nodes. Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in less than 10% of neoplastic cell nuclei. HER2 protein stained wit...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma of the right breast. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma of the right breast. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma of the right breast. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma of the right breast. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma of the right breast. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma of the right breast. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma of the right breast. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive mucinous carcinoma of the right breast. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive mucinous carcinoma of the right breast. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 119,
      "timestamp": "2026-01-19T15:59:53.116230"
    },
    {
      "sample_idx": 1110,
      "input": "Clinical Diagnosis & History: Right leg mass. Specimens Submitted: 1: Right leg mass sarcoma ???. 2: Lateral fascial margin right leg. DIAGNOSIS: 1. Right leg mass sarcoma; excision: - High grade spindle and pleomorphic sarcoma consistent with malignant. fibrous histiocytoma/ undifferentiated high grade pleomorphic sarcoma. - Tumor measures 9 x 6 x 4 cm. - Tumor involves dermis, subcutis and extends to fascia. Necrosis is present about 15%. - Tumor extends focally to the deep margin of resection...",
      "response": "```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Leg. 2. Findings: Sarcoma, high-grade spindle cell type. 3. Code: SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Leg. 2. Findings: Sarcoma, high-grade pleomorphic type. 3. Code: SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Leg. 2. Findings: Sarcoma, high-grade spindle cell type. 3. Code: SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Leg. 2. Findings: Sarcoma, high-grade pleomorphic type. 3. Code: SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Leg. 2. Findings: Sarcoma, high-grade spindle cell type. 3. Code: SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Leg. 2. Findings: Sarcoma, high-grade pleomorphic type. 3. Code: SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Leg. 2. Findings: Sarcoma, high-grade spindle cell type. 3. Code: SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Leg. 2. Findings: Sarcoma, high-grade pleomorphic type. 3. Code: SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Leg. 2. Findings: Sarcoma, high-grade spindle cell type. 3. Code: SARC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "SARC",
      "ground_truth": "SARC",
      "correct": true,
      "reasoning": "1. Site: Leg. 2. Findings: Sarcoma, high-grade spindle cell type. 3. Code: SARC.",
      "idx": 1110,
      "timestamp": "2026-01-19T15:59:53.116238"
    },
    {
      "sample_idx": 1176,
      "input": "Case ID. Gross Description. Microscopic. Diagnosis Details. Description. Stomach with a polypoid. Adenocarcinoma of the. Tumor Features: Exophytic. tumour, up to 16 cm in its. stomach G2-3. In the. (polypoid), Tumor Extent: diameter, invades adjacent. exofytic component the. Perigastric fat , Venous. fatty tissue;. predominant type of growth. Invasion: Absent, Margins: fatty tissue lymph nodes. is G2. In the endophtyic. Absent, Treatment Effect: are free of metastases;. component the. omentum - ...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, exophytic, polypoid, G2-3, with necrosis and invasion of perigastric fat. 15 lymph nodes are positive for metastasis. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, exophytic, polypoid, G2-3, with necrosis and invasion of perigastric fat. 15 lymph nodes are positive for metastasis. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, exophytic, polypoid, G2-3, with necrosis and invasion of perigastric fat. 15 lymph nodes are positive for metastasis. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, exophytic, polypoid, G2-3, with necrosis and invasion of perigastric fat. 15 lymph nodes are positive for metastasis. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, exophytic, polypoid, G2-3, with necrosis and invasion of perigastric fat. 15 lymph nodes are positive for metastasis. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, exophytic, polypoid, G2-3, with necrosis and invasion of perigastric fat. 15 lymph nodes are",
      "predicted": "STAD",
      "ground_truth": "STAD",
      "correct": true,
      "reasoning": "1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, exophytic, polypoid, G2-3, with necrosis and invasion of perigastric fat. 15 lymph nodes are positive for metastasis. 3. Code: Stomach Adenocarcinoma maps to STAD.",
      "idx": 1176,
      "timestamp": "2026-01-19T15:59:53.116250"
    },
    {
      "sample_idx": 642,
      "input": "Final Diagnosis: A-C. Brain, right frontotemporal/insular mass, and frontotemporal excision and CUSA: Anaplastic. oligoastrocytoma (WHO grade III). Immunohistochemical stains were performed on paraffin embedded tissue using antibodies to p53, IDH1-R132H. and Ki-67. IDH1-R132H stain is positive consistent with IDH1 mutation. p53 protein is positive in rare cells. Ki-67 labeling is focally high. The findings support the above diagnosis. Fluorescence in situ hybridization (FISH) studies for 1p19q d...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontotemporal/insular mass. 2. Findings: Anaplastic oligoastrocytoma (WHO grade III). IDH1-R132H mutation present. p53 protein present in rare cells. Ki-67 labeling is focally high. 3. Code: GBM maps to the category of brain tumors.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontotemporal/insular mass. 2. Findings: Anaplastic oligoastrocytoma (WHO grade III). IDH1-R132H mutation present. p53 protein present in rare cells. Ki-67 labeling is focally high. 3. Code: GBM maps to the category of brain tumors.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontotemporal/insular mass. 2. Findings: Anaplastic oligoastrocytoma (WHO grade III). IDH1-R132H mutation present. p53 protein present in rare cells. Ki-67 labeling is focally high. 3. Code: GBM maps to the category of brain tumors.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontotemporal/insular mass. 2. Findings: Anaplastic oligoastrocytoma (WHO grade III). IDH1-R132H mutation present. p53 protein present in rare cells. Ki-67 labeling is focally high. 3. Code: GBM maps to the category of brain tumors.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, right frontotemporal/insular mass. 2. Findings: Anaplastic oligoastrocytoma (WHO grade III). IDH1-R132H mutation present. p53 protein present in rare cells. Ki-67 labeling is focally high. 3. Code: GBM maps to the category of",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain, right frontotemporal/insular mass. 2. Findings: Anaplastic oligoastrocytoma (WHO grade III). IDH1-R132H mutation present. p53 protein present in rare cells. Ki-67 labeling is focally high. 3. Code: GBM maps to the category of brain tumors.",
      "idx": 642,
      "timestamp": "2026-01-19T15:59:53.116267"
    },
    {
      "sample_idx": 117,
      "input": "DIAGNOSIS. (A) RIGHT BREAST, TOTAL MASTECTOMY: INVASIVE LOBULAR CARCINOMA, INTERMEDIATE GRADE. (SEE COMMENT). LOBULAR CARCINOMA IN SITU (LCIS), LOW AND INTERMEDIATE NUCLEAR GRADES. INVASIVE CARCINOMA MEASURES 3.0 X 1.1 CM IN CONTIGUOUS SECTIONS/SLICES. INVASIVE CARCINOMA IS PRESENT AT LEAST 1.0 CM FROM MARGINS. No lymphovascular invasion identified. Microcalcifications present in association with benign breast tissue. NIPPLE, LCIS/ATYPICAL LOBULAR HYPERPLASIA. (B) RIGHT AXILLARY SENTINEL LYMPH N...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate grade. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate grade. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate grade. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate grade. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate grade. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate grade. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate grade. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate grade. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate grade. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lob",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate grade. 3. Code: BRCA",
      "idx": 117,
      "timestamp": "2026-01-19T15:59:53.116276"
    },
    {
      "sample_idx": 102,
      "input": "(Age: F. Pathologic Interpretation: A. SENTINEL NODE NO.1 AXILLA CONTENT. - No malignancy seen in one lymph node (0/1). - Immunohistochemistry for keratin to follow. B. RIGHT BREAST (SHORT STITCH SUPERIOR LONG STITCH LATERAL): - Invasive lobular carcinoma, intermediate nuclear grade, with formation of two dominant tumoral masses, 4,0 cm and. 1.0 cm. - The tumor invades the dermal skin. - Lymphovascular spaces invasion is identified. - Specimen margin is negative for tumor. - Metastatic carcinoma...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, intermediate nuclear grade, with formation of two dominant tumoral masses, 4.0 cm and. 1.0 cm. - The tumor invades the dermal skin. - Lymphovascular spaces invasion is identified. - Specimen margin is negative for tumor. - Metastatic carcinoma to two of eight lymph nodes (/2/8). - Present. - Present. - Not identified. - Not identified. - Number of sentinel lymph nodes examined: 2. - Total number of lymph nodes examined (sentinel and Nonsentinel): 10. - Number of lymph nodes with macrometastases (>0.2 cm): 2. - Not identified. - Hematoxylin and eosin (H&E, one level). - Immunohistochemistry. - Equivocal (Score 2+). - Not amplified (HER2 gene copy <4.0 or ratio <1.8). - Grade 2. - Present. - Present. - Not applicable. - pT4b. - pN1a. - Not applicable. - pT4b, N1a, M-not applicable. - Lobular Carcinoma IN Situ (LCIS): - Present. - Present. - Overall Grade: Grade 2. - Not identified. - Not identified. - Performed on another specimen: Results: Immunoreactive tumor cells present (1%). - Performed on another specimen: Results: Immunoreactive tumor cells present (>1%). - Performed on another specimen: Results: Equivocal (Score 2+). - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified. - Not identified.",
      "predicted": null,
      "ground_truth": "BRCA",
      "correct": null,
      "reasoning": "",
      "idx": 102,
      "timestamp": "2026-01-19T15:59:53.116405"
    },
    {
      "sample_idx": 976,
      "input": "NATURE OF MATERIAL : PANCREAS. BIOPSY : MACROSCOPY. - bottle 1 : specimen made of pancreatic head and segment of duodenum . The pancreas. measures 6.0 X 4,5x 4,5 cm. The duodenum measuring 15.5 cm in length and diameter 2.5 cm. nlt was noted a head injury in pancreas, measuring 2.4 x 2,2 cm. bottle 2 : gallbladder measured 12.2 cm length for 2.5 cm in diameter greater. - bottle 3 : 4 lymph nodes measuring between 0.2 and 1.0 cm cm in major axes. MICROSCOPIC. Product of pancreaticoduodenectomy: i...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Invasive ductal adenocarcinoma localized in cephalic portion of pancreas, moderately. differentiated. 3. Code: ADENOMA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Invasive ductal adenocarcinoma localized in cephalic portion of pancreas, moderately. differentiated. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Invasive ductal adenocarcinoma localized in cephalic portion of pancreas, moderately. differentiated. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Invasive ductal adenocarcinoma localized in cephalic portion of pancreas, moderately. differentiated. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Invasive ductal adenocarcinoma localized in cephalic portion of pancreas, moderately. differentiated. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Invasive ductal adenocarcinoma localized in cephalic portion of pancreas, moderately. differentiated. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Invasive ductal adenocarcinoma localized in cephalic portion of pancreas, moderately. differentiated. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Invasive ductal adenocarcinoma localized in cephalic portion of pancreas, moderately. differentiated. 3. Code: KIRC\"\n}\n```\n```json\n{\n    ",
      "predicted": "ADENOMA",
      "ground_truth": "PAAD",
      "correct": false,
      "reasoning": "1. Site: Pancreas. 2. Findings: Invasive ductal adenocarcinoma localized in cephalic portion of pancreas, moderately. differentiated. 3. Code: ADENOMA",
      "idx": 976,
      "timestamp": "2026-01-19T15:59:53.116419"
    },
    {
      "sample_idx": 1029,
      "input": "RADICAL PROSTATECTOMY: TUMOR PROCUREMENT: HISTOLOGIC TYPE. ACINAR ADENOCARCINOMA. HISTOLOGIC GRADE (PRIMARY PATTERN+SECONDARY PATTERN = GLEASON SCORE): 4 + 5 = 9. TERTIARY PATTERN NOT PRESENT. PERCENTAGE OF DIFFERENT GLEASON PATTERNS. NOT REPORTED. TUMOR LOCATION. APEX. ANTERIOR. RIGHT. LEFT. POSTERIOR. RIGHT. LEFT. EXTRA-PROSTATIC EXTENSION. PRESENT. NON-FOCAL. SITE OF EXTRA-PROSTATIC EXTENSION. ANTERIOR. RIGHT. LEFT. POSTERIOR. LEFT. SEMINAL VESICAL INVASION. ABSENT. SURGICAL MARGINS. INVOLVED...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Acinar adenocarcinoma, Gleason Score 9, extra-prostatic extension, positive surgical margins. 3. Code: Prostate Acinar Adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Acinar adenocarcinoma, Gleason Score 9, extra-prostatic extension, positive surgical margins. 3. Code: Prostate Acinar Adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Acinar adenocarcinoma, Gleason Score 9, extra-prostatic extension, positive surgical margins. 3. Code: Prostate Acinar Adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Acinar adenocarcinoma, Gleason Score 9, extra-prostatic extension, positive surgical margins. 3. Code: Prostate Acinar Adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Acinar adenocarcinoma, Gleason Score 9, extra-prostatic extension, positive surgical margins. 3. Code: Prostate Acinar Adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Acinar adenocarcinoma, Gleason Score 9, extra-prostatic extension, positive surgical margins. 3. Code: Prostate Acinar Adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Acinar adenocarcinoma, Gleason Score 9, extra-prostatic extension, positive surgical margins. 3. Code: Prostate Acinar Adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "PRAD",
      "ground_truth": "PRAD",
      "correct": true,
      "reasoning": "1. Site: Prostate. 2. Findings: Acinar adenocarcinoma, Gleason Score 9, extra-prostatic extension, positive surgical margins. 3. Code: Prostate Acinar Adenocarcinoma maps to PRAD.",
      "idx": 1029,
      "timestamp": "2026-01-19T15:59:53.116431"
    },
    {
      "sample_idx": 1087,
      "input": "Diagnosis: Resectate of a portion of the large intestine, or rectosigmoid colon, with an ulcerated. rectal carcinoma conforming to the histological type of a moderately differentiated. colorectal adenocarcinoma, extending no closer than 4.5 cm to the aboral resection. margin and circularly occupying the intestinal wall over a length of 5.5 cm. Invasive. spread of tumor within all layers of the intestinal wall, as far as into the neighboring. periproctic fatty tissue. Oral and aboral resection ma...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine, rectosigmoid colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated, ulcerated, extending 5.5 cm. Invasive. 3. Code: COAD maps to Colorectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Large intestine, rectosigmoid colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated, ulcerated, extending 5.5 cm. Invasive. 3. Code: PAAD maps to Pancreatic Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine, rectosigmoid colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated, ulcerated, extending 5.5 cm. Invasive. 3. Code: COAD maps to Colorectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine, rectosigmoid colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated, ulcerated, extending 5.5 cm. Invasive. 3. Code: COAD maps to Colorectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine, rectosigmoid colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated, ulcerated, extending 5.5 cm. Invasive. 3. Code: COAD maps to Colorectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine, rectosigmoid colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated, ulcerated, extending 5.5 cm. Invasive. 3. Code: COAD maps to Colorectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine, rectosigmoid",
      "predicted": "COAD",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Large intestine, rectosigmoid colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated, ulcerated, extending 5.5 cm. Invasive. 3. Code: COAD maps to Colorectal Adenocarcinoma.",
      "idx": 1087,
      "timestamp": "2026-01-19T15:59:53.116443"
    },
    {
      "sample_idx": 322,
      "input": "Diagnosis / Diagnoses: 1.: Small specimen with submesothelial fibrosis excised from the peritoneum. 2.: Resectate from a portion of the colon (sigmoid) with an ulcerated colon carcinoma, of. the histological type of a moderately differentiated colon carcinoma, that extends no. closer than 3 cm to the resection margin and occupies a circular portion of the intestinal. wall over an length of 5 cm. Invasive spread of the tumor within all layers of the. intestinal wall as far as the neighboring meso...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Colon carcinoma, moderately differentiated. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"T3\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Colon carcinoma, moderately differentiated. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Colon carcinoma, moderately differentiated. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Colon carcinoma, moderately differentiated. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Colon carcinoma, moderately differentiated. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Colon carcinoma, moderately differentiated. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Colon carcinoma, moderately differentiated. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Colon carcinoma, moderately differentiated. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). ",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon (Sigmoid). 2. Findings: Colon carcinoma, moderately differentiated. 3. Code: Colon Adenocarcinoma maps to COAD.",
      "idx": 322,
      "timestamp": "2026-01-19T15:59:53.116453"
    },
    {
      "sample_idx": 116,
      "input": "Final Diagnosis. Breast, right, wide local excision: Infiltrating lobular carcinoma, Nottingham grade II (of. III)[tubules 3/3, nuclei 2/3, mitoses 1/3; Nottingham score 6/9], forming a 5.2 x 3.0 x 2.6 cm. mass. Lobular carcinoma in situ is present and represents less than 5% of the overall tumor. volume. Angiolymphatic invasion is present. The non-neoplastic breast parenchyma show. nonproliferative fibrocystic changes. Calcifications present in benign ducts and acini. Biopsy. site changes prese...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating lobular carcinoma, Nottingham grade II (of III), forming a 5.2 x 3.0 x 2.6 cm mass. Lobular carcinoma in situ is present and represents less than 5% of the overall tumor volume. Angiolymphatic invasion is present. The non-neoplastic breast parenchyma shows proliferative fibrocystic changes. Biopsy site changes present. The inferior and medial margins are positive for invasive carcinoma. Breast, right, total mastectomy: Infiltrating lobular carcinoma, Nottingham grade II (of III), involving the medial aspect of the biopsy cavity. Two additional nodules of Nottingham grade II (of III) invasive lobular carcinoma are identified in the lower outer quadrant (0.7 x 0.6 x 0.5 cm, located 1.4 cm from the deep margin; and 0.5 x 0.4 x 0.4 cm, located 1.2 cm from the deep margin). Lobular carcinoma in situ is present and represents less than 5% of the overall tumor volume. Angiolymphatic invasion is present. The non-neoplastic breast parenchyma shows. nonproliferative fibrocystic changes. Biopsy site changes present. The tumor does not involve the nipple, overlying skin, or underlying chest wall. All surgical resection margins, including the deep margin, are negative for tumor (residual tumor in the biopsy cavity is located 2.2 cm from the deep margin). Lymph nodes, right axillary, dissection: Multiple (5 of 18) right axillary lymph nodes are positive for metastatic carcinoma [AJCC pN2]. The largest is represented by a matted mass of lymph nodes and measures 4.2 x 2.6 x 2.4 cm. Extranodal extension is present. Comment: Final (mastectomy) surgical margins are widely free of involvement. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating lobular carcinoma, Nottingham grade II (of III), forming a 5.2 x 3.0 x 2.6 cm mass. Lobular carcinoma in situ is",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Infiltrating lobular carcinoma, Nottingham grade II (of III), forming a 5.2 x 3.0 x 2.6 cm mass. Lobular carcinoma in situ is present and represents less than 5% of the overall tumor volume. Angiolymphatic invasion is present. The non-neoplastic breast parenchyma shows proliferative fibrocystic changes. Biopsy site changes present. The inferior and medial margins are positive for invasive carcinoma. Breast, right, total mastectomy: Infiltrating lobular carcinoma, Nottingham grade II (of III), involving the medial aspect of the biopsy cavity. Two additional nodules of Nottingham grade II (of III) invasive lobular carcinoma are identified in the lower outer quadrant (0.7 x 0.6 x 0.5 cm, located 1.4 cm from the deep margin; and 0.5 x 0.4 x 0.4 cm, located 1.2 cm from the deep margin). Lobular carcinoma in situ is present and represents less than 5% of the overall tumor volume. Angiolymphatic invasion is present. The non-neoplastic breast parenchyma shows. nonproliferative fibrocystic changes. Biopsy site changes present. The tumor does not involve the nipple, overlying skin, or underlying chest wall. All surgical resection margins, including the deep margin, are negative for tumor (residual tumor in the biopsy cavity is located 2.2 cm from the deep margin). Lymph nodes, right axillary, dissection: Multiple (5 of 18) right axillary lymph nodes are positive for metastatic carcinoma [AJCC pN2]. The largest is represented by a matted mass of lymph nodes and measures 4.2 x 2.6 x 2.4 cm. Extranodal extension is present. Comment: Final (mastectomy) surgical margins are widely free of involvement. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 116,
      "timestamp": "2026-01-19T15:59:53.116496"
    },
    {
      "sample_idx": 1040,
      "input": "Diagnosis. 1. Predominantly poorly differentiated adenocarcinoma of the prostate on both sides with. predominance in the anterior and right rectolateral peripheral zone. Maximum tumor spread. 0.9 cm. Focally perineural tumor invasion. No extraprostatic tumor growth and no identifiable. invasion of the vessels. Tumor-free seminal vesicles and tumor-free resection margins. Remaining prostate tissue with myoglandular hyperplasia in the transitional zone. Tumor and. dysplasia-free prostatic urethra....",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, predominantly poorly differentiated, with a maximum tumor spread of 0.9 cm, and focal perineural invasion. No extraprostatic growth or vessel invasion. Tumor-free seminal vesicles and resection margins. Myoglandular hyperplasia in the transitional zone. Tumor-free prostatic urethra. 3. The tumor is classified as pT2c, pNO (0/19), L0, V0; Gleason 4+3 = 7 (approx. 60% Gleason 4); complete local resection. 4. The tumor is classified as pT2c, pNO (0/19), L0, V0; Gleason 4+3 = 7 (approx. 60% Gleason 4); complete local resection. 5. The tumor is classified as pT2c, pNO (0/19), L0, V0; Gleason 4+3 = 7 (approx. 60% Gleason 4); complete local resection. 6. The tumor is classified as pT2c, pNO (0/19), L0, V0; Gleason 4+3 = 7 (approx. 60% Gleason 4); complete local resection. 7. The tumor is classified as pT2c, pNO (0/19), L0, V0; Gleason 4+3 = 7 (approx. 60% Gleason 4); complete local resection. 8. The tumor is classified as pT2c, pNO (0/19), L0, V0; Gleason 4+3 = 7 (approx. 60% Gleason 4); complete local resection. 9. The tumor is classified as pT2c, pNO (0/19), L0, V0; Gleason 4+3 = 7 (approx. 60% Gleason 4); complete local resection. 10. The tumor is classified as pT2c, pNO (0/19), L0, V0; Gleason 4+3 = 7 (approx. 60% Gleason 4); complete local resection. 11. The tumor is classified as pT2c, pNO (0/",
      "predicted": null,
      "ground_truth": "PRAD",
      "correct": null,
      "reasoning": "",
      "idx": 1040,
      "timestamp": "2026-01-19T15:59:53.116581"
    },
    {
      "sample_idx": 164,
      "input": "Breast, left breast, simple mastectomy: Infiltrating ductal carcinoma, Nottingham grade III (of III),. forming a 2.3 x 1.8 x 1.5 cm mass (AJCC pT2) situated in the lower inner quadrant at 2.0 cm from the. closest (inferior) margin. Vascular invasion is identified. The rest of the breast shows proliferative. fibrocystic change with ductal hyperplasia of the usual type, apocrine metaplasia, and microcalcifications. Duct ectasia is also present. The nipple is unremarkable. Surgical margins are nega...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 164,
      "timestamp": "2026-01-19T15:59:53.116592"
    },
    {
      "sample_idx": 380,
      "input": "rage 1 or J. MRN#: Sex: male. Histology code: MIB: 21%. Histology: GBM. Tissue Bank: Additional Data: Surgery Date: Multiple Biopsy Case. SURGERY DATE: RECEIVE DATE: Tissue Amount: 1. Number of Vials: 1. Tissue Loc: UPDATED REPORT. - SEE. Cells cultured: 1-T25 1-SP. ADDENDUM REPORT/DIAGNOSIS. Consent: PATHOLOGICAL DIAGNOSIS: A. BRAIN, RIGHT PARIETAL,. EXCISIONAL BIOPSIES: GLIOBLASTOMA MULTIFORME. B. BRAIN, RIGHT PARIETAL, EXCISION: GLIOBLASTOMA MULTIFORME. SEE COMMENT. ADDENDUM DIAGNOSIS: BRAIN,...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Right Parietal. 2. Findings: Glioblastoma Multiforme (GBM) with a proliferation index of 21% (MIB-1). 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Right Parietal. 2. Findings: Glioblastoma Multiforme (GBM) with a proliferation index of 21% (MIB-1). 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Right Parietal. 2. Findings: Glioblastoma Multiforme (GBM) with a proliferation index of 21% (MIB-1). 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Right Parietal. 2. Findings: Glioblastoma Multiforme (GBM) with a proliferation index of 21% (MIB-1). 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Right Parietal. 2. Findings: Glioblastoma Multiforme (GBM) with a proliferation index of 21% (MIB-1). 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Right Parietal. 2. Findings: Glioblastoma Multiforme (GBM) with a proliferation index of 21% (MIB-1). 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain, Right Parietal. 2. Findings: Glioblastoma Multiforme (GBM) with a proliferation index of 21% (MIB-1). 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain, Right Parietal. 2. Findings: Glioblastoma Multiforme (GBM) with a proliferation index of 21% (MIB-1). 3. Code: GBM.",
      "idx": 380,
      "timestamp": "2026-01-19T15:59:53.116605"
    },
    {
      "sample_idx": 140,
      "input": "Diagnosis: A: Lymph node, right axillary sentinel #1, removal. - No metastatic carcinoma identified in one lymph node (0/1). B: Lymph node, right axillary sentinel #2, removal. - Isolated tumor cell cluster (ITC) identified (on H and E) in one lymph node,. 0.12 mm in greatest dimension, negative for extracapsular extension (see. comment). C: Lymph node, left axillary sentinel #1, removal. - No metastatic carcinoma identified in one lymph node (0/1). D: Lymph node, left axillary sentinel #2, remo...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 140,
      "timestamp": "2026-01-19T15:59:53.116616"
    },
    {
      "sample_idx": 139,
      "input": "SPECIMEN. A. Left axillary sentinel node. B. Left breast long stitch anterior short superior. CLINICAL NOTES. PRE-OP DIAGNOSIS: Left breast cancer. HISTORY: year old white female with left breast cancer. POST-OP DIAGNOSIS: Same as above. FROZEN SECTION DIAGNOSIS. A - Lymph node negative for metastatic disease. GROSS DESCRIPTION. A. The specimen is received fresh for frozen section. labeled \"left axillary sentinel node\". It consists of. a. portion of adipose tissue measuring 3.2 x 2. 1 x 1 cm. On...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 139,
      "timestamp": "2026-01-19T15:59:53.116625"
    },
    {
      "sample_idx": 481,
      "input": "CLINICAL DATA: -year-old man with history of floor of mouth carcinoma (squamous cell. carcinoma) . GROSS DESCRIPTION: A). Received in formalin designated \"left mandibular tumor\" is a composite. resection specimen that includes an 11 x 8.5 cm ellipse of medium tan,. hair-bearing skin with a central 2.5 cm in diameter ulcer and 8.5 cm in. diameter region of induration of the skin which extends focally to within 0.3. cm of the anterior cutaneous margin. A smaller, 4 X 0.9 cm ellipse of skin. is sut...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mandible. 2. Findings: Squamous cell carcinoma, keratinizing, moderately to poorly differentiated, with perineural invasion and focally suspicious for angiolymphatic invasion. The tumor has eroded through the mandible. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mandible. 2. Findings: Squamous cell carcinoma, keratinizing, moderately to poorly differentiated, with perineural invasion and focally suspicious for angiolymphatic invasion. The tumor has eroded through the mandible. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mandible. 2. Findings: Squamous cell carcinoma, keratinizing, moderately to poorly differentiated, with perineural invasion and focally suspicious for angiolymphatic invasion. The tumor has eroded through the mandible. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mandible. 2. Findings: Squamous cell carcinoma, keratinizing, moderately to poorly differentiated, with perineural invasion and focally suspicious for angiolymphatic invasion. The tumor has eroded through the mandible. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mandible. 2. Findings: Squamous cell carcinoma, keratinizing, moderately to poorly differentiated, with perineural invasion and focally suspicious for angiolymphatic invasion. The tumor has eroded through the mandible. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mandible. 2. Findings: Squamous cell carcinoma, keratinizing, moderately to poorly differentiated,",
      "predicted": "KIRC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Mandible. 2. Findings: Squamous cell carcinoma, keratinizing, moderately to poorly differentiated, with perineural invasion and focally suspicious for angiolymphatic invasion. The tumor has eroded through the mandible. 3. Code: KIRC.",
      "idx": 481,
      "timestamp": "2026-01-19T15:59:53.116638"
    },
    {
      "sample_idx": 826,
      "input": "FINAL CORRECTED REPORT DATED. REPLACES ALL PREVIOUS VERSIONS. Final, Corrected. CORRECTED REPORT. Cardiothoracic Surgery. Takart. Accessioned: DIAGNOSIS: LUNG, \"PARIETAL PLEURAL DEPOSIT,\" BIOPSY (INCLUDING FS1). - ADENOCARCINOMA. - HYALINIZED GRANULOMAS. - SEE COMMENT. LYMPH NODE, LEVEL 7, BIOPSY. - NO EVIDENCE OF MALIGNANCY IN ONE LYMPH NODE (0/1). - HYALINIZED GRANULOMA. - NO FUNGAL FORMS OR MYCOBACTERIAL SPECIES IDENTIFIED ON GMS, AFB OR FITE STAINS. LYMPH NODE, LEVEL 11, BIOPSY. - NO EVIDENC...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Lingula). 2. Findings: Adenocarcinoma, acinar type, poorly differentiated (G3), 3.2 cm, invasive, T2a (pleural invasion), N0 (no lymph node metastasis), M1a (distant metastasis). 3. TCGA code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Lingula). 2. Findings: Adenocarcinoma, acinar type, poorly differentiated (G3), 3.2 cm, invasive, T2a (pleural invasion), N0 (no lymph node metastasis), M1a (distant metastasis). 3. TCGA code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Lingula). 2. Findings: Adenocarcinoma, acinar type, poorly differentiated (G3), 3.2 cm, invasive, T2a (pleural invasion), N0 (no lymph node metastasis), M1a (distant metastasis). 3. TCGA code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Lingula). 2. Findings: Adenocarcinoma, acinar type, poorly differentiated (G3), 3.2 cm, invasive, T2a (pleural invasion), N0 (no lymph node metastasis), M1a (distant metastasis). 3. TCGA code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Lingula). 2. Findings: Adenocarcinoma, acinar type, poorly differentiated (G3), 3.2 cm, invasive, T2a (pleural invasion), N0 (no lymph node metastasis), M1a (distant metastasis). 3. TCGA code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Lingula). 2. Findings: Aden",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung (Lingula). 2. Findings: Adenocarcinoma, acinar type, poorly differentiated (G3), 3.2 cm, invasive, T2a (pleural invasion), N0 (no lymph node metastasis), M1a (distant metastasis). 3. TCGA code: LUAD.",
      "idx": 826,
      "timestamp": "2026-01-19T15:59:53.116651"
    },
    {
      "sample_idx": 245,
      "input": "SURGICAL PATHOLOGY REPORT - CONSULT. F. MRN : (Age: M.D. DIAGNOSIS. UTERUS, CERVIX, BIOPSY. MODERATELY DIFFERENTIATED INVASIVE SQUAMOUS CELL CARCINOMA, KERATINIZING TYPE. - FOCAL LYMPHVASCULAR SPACE INVASION is IDENTIFIED. - SEVERE DYSPLASIA (CIN 3). By this signature, I attest that the above diagnosis is based upon my personal. examination of the slides(and/or other material indicated in the diagnosis). M.D. M.D.-. Microscopic Description and Comment. Histologic sections show invasive, moderate...",
      "response": "```json\n{\n    \"cancer_type\": \"UCS\",\n    \"reasoning\": \"1. Site: Uterus, Cervix. 2. Findings: Invasive squamous cell carcinoma, keratinizing type, with lymphvascular space invasion and severe dysplasia (CIN 3). 3. Code: Uterus Cervix Squamous Cell Carcinoma maps to UCS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCS\",\n    \"reasoning\": \"1. Site: Uterus, Cervix. 2. Findings: Invasive squamous cell carcinoma, keratinizing type, with lymphvascular space invasion and severe dysplasia (CIN 3). 3. Code: Uterus Cervix Squamous Cell Carcinoma maps to UCS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCS\",\n    \"reasoning\": \"1. Site: Uterus, Cervix. 2. Findings: Invasive squamous cell carcinoma, keratinizing type, with lymphvascular space invasion and severe dysplasia (CIN 3). 3. Code: Uterus Cervix Squamous Cell Carcinoma maps to UCS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCS\",\n    \"reasoning\": \"1. Site: Uterus, Cervix. 2. Findings: Invasive squamous cell carcinoma, keratinizing type, with lymphvascular space invasion and severe dysplasia (CIN 3). 3. Code: Uterus Cervix Squamous Cell Carcinoma maps to UCS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCS\",\n    \"reasoning\": \"1. Site: Uterus, Cervix. 2. Findings: Invasive squamous cell carcinoma, keratinizing type, with lymphvascular space invasion and severe dysplasia (CIN 3). 3. Code: Uterus Cervix Squamous Cell Carcinoma maps to UCS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCS\",\n    \"reasoning\": \"1. Site: Uterus, Cervix. 2. Findings: Invasive squamous cell carcinoma, keratinizing type, with lymphvascular space invasion and severe dysplasia (CIN 3). 3. Code: Uterus Cervix Squamous Cell Carcinoma maps to UCS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCS\",\n    \"reasoning\": \"1. Site: U",
      "predicted": "UCS",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Uterus, Cervix. 2. Findings: Invasive squamous cell carcinoma, keratinizing type, with lymphvascular space invasion and severe dysplasia (CIN 3). 3. Code: Uterus Cervix Squamous Cell Carcinoma maps to UCS.",
      "idx": 245,
      "timestamp": "2026-01-19T15:59:53.116663"
    },
    {
      "sample_idx": 504,
      "input": "Clinical Diagnosis & History: Patient with renal mass. Specimens Submitted: 1: SP: Lt. kidney. 2: SP: Para-aortic lymph node. 3: SP: Hilar lymph node. DIAGNOSIS: 1). KIDNEY, LEFT; EXCISION: RENAL CELL CARCINOMA, CHROMOPHOBE TYPE. THE TUMOR GREATEST DIAMETER IS 13.5 CM. THE. TUMOR IS CONFINED WITHIN THE RENAL CAPSULE. NO INVASION OF THE RENAL VEIN IS IDENTIFIED. ALL. SURGICAL MARGINS ARE FREE OF TUMOR. THE NON-NEOPLASTIC KIDNEY SHOWS FIBROSIS AND FOCAL CHRONIC INFLAMMATION. TUMOR EXTENDS. INTO TH...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"",
      "predicted": "KIRC",
      "ground_truth": "KICH",
      "correct": false,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 504,
      "timestamp": "2026-01-19T15:59:53.116676"
    },
    {
      "sample_idx": 81,
      "input": "Revised. F. Pathologic Interpretation: AMENDMENT TO PATHOLOGIC INTERPRETATION (SPECIMEN \"E\"). Left breast sentinel node #1, FS: A. - One lymph node, no tumor seen (0/1). Sentinel node #2, FS: B. - One lymph node, no tumor seen (0/1). C. Left sentinell node #3, FS: - One lymph node, no tumor seen (0/1). D. Left with one stitch superior and two lateral: breast - Multifocal infiltrating lobular carcinoma, (two largest nodules are 2.5 cm and 2 cm in greatest dimension), margins. free. - Extensive lo...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, (two largest nodules are 2.5 cm and 2 cm in greatest dimension), margins. free. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, (two largest nodules are 2.5 cm and 2 cm in greatest dimension), margins. free. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, (two largest nodules are 2.5 cm and 2 cm in greatest dimension), margins. free. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, (two largest nodules are 2.5 cm and 2 cm in greatest dimension), margins. free. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, (two largest nodules are 2.5 cm and 2 cm in greatest dimension), margins. free. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, (two largest nodules are 2.5 cm and 2 cm in greatest dimension), margins. free. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, (two largest nodules are 2.5 cm and 2 cm in greatest dimension), margins. free. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive lobular carcinoma, (two largest nodules are 2.5 cm and 2 cm in greatest dimension), margins. free. 3. Code: BRCA.",
      "idx": 81,
      "timestamp": "2026-01-19T15:59:53.116687"
    },
    {
      "sample_idx": 167,
      "input": "Ne. BREAST TISSUE CHECKLIST. Specimen type: Mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 2.3 x 1.8 x 1.8 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal and lobular carcinoma. Histologic grade: Tumor extent: Not specified. Lymph nodes: 0/4 positive for metastasis (Regional 0/4). Extracapsular invasion of the lymph nodes: Not specified. Left upper. Margins: Not specified. outer. quadrant. Nottingham Histologic Score. Tubule formation: Not specifi...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1.",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Infiltrating ductal and lobular carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 167,
      "timestamp": "2026-01-19T15:59:53.116697"
    },
    {
      "sample_idx": 858,
      "input": "Material examined: Right upper lobe, among others. Clinical diagnosis and question. Squamous cell carcinoma of the right upper lobe. REPORT ON FINDINGS. Macroscopy. 1.) Right upper lobe: inflated, fixed right upper pulmonary lobe measuring 18 x 12 x 4 cm, central bronchus. resection plane located 0.1 cm proximal to the bifurcation into the segmental bronchi. At the hilus a 2 cm node. A staple suture line runs from the hilus in a caudoventral direction for 10 cm. Visceral pleura, especially in th...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Right upper lobe of the lung. 2. Findings: Squamous cell carcinoma of the right upper lobe of the lung, poorly differentiated, large-cell, non-keratinizing. 3. Code: Squamous cell carcinoma of the right upper lobe of the lung maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Right upper lobe of the lung. 2. Findings: Squamous cell carcinoma, poorly differentiated, large-cell, non-keratinizing. 3. Code: Squamous cell carcinoma of the right upper lobe of the lung maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Right upper lobe of the lung. 2. Findings: Squamous cell carcinoma, poorly differentiated, large-cell, non-keratinizing. 3. Code: Squamous cell carcinoma of the right upper lobe of the lung maps to UCSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Right upper lobe of the lung. 2. Findings: Squamous cell carcinoma of the right upper lobe of the lung, poorly differentiated, large-cell, non-keratinizing. 3. Code: Squamous cell carcinoma of the right upper lobe of the lung maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Right upper lobe of the lung. 2. Findings: Squamous cell carcinoma of the right upper lobe of the lung, poorly differentiated, large-cell, non-keratinizing. 3. Code: Squamous cell carcinoma of the right upper lobe of the lung maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Right upper lobe of the lung. 2. Findings: Squamous cell carcinoma of the right upper lobe of the lung, poorly differentiated, large-cell, non-keratinizing. 3. Code: Squamous cell carcinoma",
      "predicted": "COAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Right upper lobe of the lung. 2. Findings: Squamous cell carcinoma of the right upper lobe of the lung, poorly differentiated, large-cell, non-keratinizing. 3. Code: Squamous cell carcinoma of the right upper lobe of the lung maps to COAD.",
      "idx": 858,
      "timestamp": "2026-01-19T15:59:53.116714"
    },
    {
      "sample_idx": 1070,
      "input": "PATIENT HISTORY: with a history of PSA value of 26.6 ng/ml. The patient had a biopsy on. prostatic adenocarcinoma Gleason score 4+3 = 7 in the right mid aspect. PRE-OP DIAGNOSIS: Prostate cancer. POST-OP DIAGNOSIS: Same. PROCEDURE: Radical prostatectomy with bilateral lymphadenectomy. FINAL DIAGNOSIS: PART 1: LYMPH NODE, RIGHT PELVIC, EXCISION -. NO EVIDENCE OF NEOPLASIA IN ONE LYMPH NODE (0/1). PART 2: LYMPH NODES, LEFT PELVIC, EXCISION -. NO EVIDENCE OF NEOPLASIA IN FIVE LYMPH NODES (0/5). PAR...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason pattern 5, total Gleason 4/5 percentage of 30%. Extracapsular extension to seminal vesicles. 3. Code: Prostate adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason pattern 5, total Gleason 4/5 percentage of 30%. Extracapsular extension to seminal vesicles. 3. Code: Prostate adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason pattern 5, total Gleason 4/5 percentage of 30%. Extracapsular extension to seminal vesicles. 3. Code: Prostate adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason pattern 5, total Gleason 4/5 percentage of 30%. Extracapsular extension to seminal vesicles. 3. Code: Prostate adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason pattern 5, total Gleason 4/5 percentage of 30%. Extracapsular extension to seminal vesicles. 3. Code: Prostate adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason pattern 5, total Gleason 4/5 percentage of 30%. Extracapsular",
      "predicted": "PRAD",
      "ground_truth": "PRAD",
      "correct": true,
      "reasoning": "1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Gleason score 3+4 = 7, Gleason pattern 5, total Gleason 4/5 percentage of 30%. Extracapsular extension to seminal vesicles. 3. Code: Prostate adenocarcinoma maps to PRAD.",
      "idx": 1070,
      "timestamp": "2026-01-19T15:59:53.116727"
    },
    {
      "sample_idx": 647,
      "input": "ADDENDED. FINAL DIAGNOSIS: 1. Right temporal tumor: OLIGODENDROGLIOMA, GRADE ii OF iv (who. SCALE), SEE MICROSCOPIC DESCRIPTION. 2. Right temporal lobe tumor: OLIGODENDROGLIOMA, GRADE ii OF iv (who. SCALE), SEE MICROSCOPIC DESCRIPTION. 3. Right temporal lesion: Pending complete submission of remaining. tissue. Comment: The ki-67 proliferation index is 4.5%. Several studies have indicated. that oligodendrogliomas with proliferation indices of greater than 5%. are associated with a significantly d...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/cerebrum-Temporal. 2. Findings: Oligodendroglioma, Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/cerebrum-Temporal. 2. Findings: Oligodendroglioma, Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/cerebrum-Temporal. 2. Findings: Oligodendroglioma, Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/cerebrum-Temporal. 2. Findings: Oligodendroglioma, Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/cerebrum-Temporal. 2. Findings: Oligodendroglioma, Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/cerebrum-Temporal. 2. Findings: Oligodendroglioma, Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/cerebrum-Temporal. 2. Findings: Oligodendroglioma, Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/cerebrum-Temporal. 2. Findings: Oligodendroglioma, Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1.",
      "predicted": "KIRC",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain/cerebrum-Temporal. 2. Findings: Oligodendroglioma, Grade II. 3. Code: KIRC",
      "idx": 647,
      "timestamp": "2026-01-19T15:59:53.116736"
    },
    {
      "sample_idx": 534,
      "input": ".ology Report. DIAGNOSIS. (A) RIGHT KIDNEY: RENAL CELL CARCINOMA (8.0 CM MAXIMUM DIMENSION), CONVENTIONAL TYPE. (80% CLEAR CELLS,. 20% EOSINOPHILIC CELLS), FUHRMAN NUCLEAR GRADE 3, INVASIVE. INTO THICK-WALLED. BLOOD VESSELS IN RENAL SINUS. (SEE COMMENT). Margins of resection free of tumor. (B) RIGHT ADRENAL GLAND: METASTATIC RENAL CELL CARCINOMA IN ADRENAL GLAND. COMMENT. The renal cell carcinoma in the right kidney does not invade into the. perinephric adipose tissue or the renal vein. Tumor is...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3, invasive. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADREN\",\n    \"reasoning\": \"1. Site: Right Adrenal Gland. 2. Findings: Metastatic renal cell carcinoma in adrenal gland. 3. Code: Adrenal gland maps to ADREN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3, invasive. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3, invasive. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3, invasive. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3, invasive. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3, invasive. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3, invasive. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 534,
      "timestamp": "2026-01-19T15:59:53.116747"
    },
    {
      "sample_idx": 418,
      "input": "FINAL PATHOLOGIC DIAGNOSIS. A. Brain, left occipital region, biopsy: WHO glioblastoma multiforme, grade IV; see. comment. B. Brain, \"deep tumor,' biopsy: WHO glioblastoma multiforme, grade IV; see. comment. C. Brain, \"brain tumor,\" biopsy: WHO glioblastoma multiforme, grade IV; see. comment. D. Brain, \"tumor margin,\" biopsy: Cerebral cortex with subpial and leptomeningeal. involvement by glioblastoma multiforme; see comment. COMMENT: This glioblastoma multiforme is highly cellular, has marked nu...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Occipital Region, Deep Tumor, Brain Tumor, Tumor Margin). 2. Findings: Glioblastoma multiforme, grade IV. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Occipital Region, Deep Tumor, Brain Tumor, Tumor Margin). 2. Findings: Glioblastoma multiforme, grade IV. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Occipital Region, Deep Tumor, Brain Tumor, Tumor Margin). 2. Findings: Glioblastoma multiforme, grade IV. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Occipital Region, Deep Tumor, Brain Tumor, Tumor Margin). 2. Findings: Glioblastoma multiforme, grade IV. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Occipital Region, Deep Tumor, Brain Tumor, Tumor Margin). 2. Findings: Glioblastoma multiforme, grade IV. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Occipital Region, Deep Tumor, Brain Tumor, Tumor Margin). 2. Findings: Glioblastoma multiforme, grade IV. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Occipital Region, Deep Tumor, Brain Tumor, Tumor Margin). 2. Findings: Glioblastoma multiforme, grade IV. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain (Left Occipital Region, Deep Tumor, Brain Tumor, Tumor Margin). 2. Findings: Glioblastoma multiforme, grade IV. 3. Code: GBM.",
      "idx": 418,
      "timestamp": "2026-01-19T15:59:53.116758"
    },
    {
      "sample_idx": 643,
      "input": "Final Diagnosis: A-B. Brain, hippocampus mass and left temporal lobe, biopsies: Low-grade diffuse astrocytoma (WHO grade II). (See comment). immunoperoxidase studies were performed on paraffin sections (block A2) using antibodies directed against the. following antigens: GFAP, IDH1-R132H, p53, EMA, neurofilament protein, and Ki-67. G.FAP: Positive. Neurofilament protein: Highlights axons within the tumor. Ki-67: Low proliferative index. IDH1-R132H: Negative. p53: Low to moderate labeling. EMA: N...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Low-grade diffuse astrocytoma (WHO grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Low-grade diffuse astrocytoma (WHO grade II). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Low-grade diffuse astrocytoma (WHO grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Low-grade diffuse astrocytoma (WHO grade II). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Low-grade diffuse astrocytoma (WHO grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Low-grade diffuse astrocytoma (WHO grade II). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Low-grade diffuse astrocytoma (WHO grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Low-grade diffuse astrocytoma (WHO grade II). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain. 2. Findings: Low-grade diffuse astrocytoma (WHO grade II). 3. Code: GBM maps to GBM.",
      "idx": 643,
      "timestamp": "2026-01-19T15:59:53.116769"
    },
    {
      "sample_idx": 488,
      "input": "Gross Description: There is larynx with an ulcerated white-gray dense tumor. Separately there is. a. fragment of the thyroid gland up to 2 X 2 cm in size. Microscopic Description: Squamous carcinoma, keratinizing type, G-1. Thyroid gland tissue is of the. normal structure. Diagnosis Details: Tumor Features: Ulcerated, Tumor Extent: Localized, NOS, Venous Invasion: Absent,. Margins: Absent, Treatment Effect: Comments: Endoscopies, figrolaryngoscopy show cancer of the larynx with the involvement. ...",
      "response": "```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Larynx. 2. Findings: Squamous cell carcinoma, keratinizing type, G-1. 3. Code: HNSC maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LARYNX\",\n    \"reasoning\": \"1. Site: Larynx. 2. Findings: Squamous cell carcinoma, keratinizing type, G-1. 3. Code: LARYNX maps to LARYNX.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LARYNX\",\n    \"reasoning\": \"1. Site: Larynx. 2. Findings: Squamous cell carcinoma, keratinizing type, G-1. 3. Code: LARYNX maps to LARYNX.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LARYNX\",\n    \"reasoning\": \"1. Site: Larynx. 2. Findings: Squamous cell carcinoma, keratinizing type, G-1. 3. Code: LARYNX maps to LARYNX.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LARYNX\",\n    \"reasoning\": \"1. Site: Larynx. 2. Findings: Squamous cell carcinoma, keratinizing type, G-1. 3. Code: LARYNX maps to LARYNX.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LARYNX\",\n    \"reasoning\": \"1. Site: Larynx. 2. Findings: Squamous cell carcinoma, keratinizing type, G-1. 3. Code: LARYNX maps to LARYNX.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LARYNX\",\n    \"reasoning\": \"1. Site: Larynx. 2. Findings: Squamous cell carcinoma, keratinizing type, G-1. 3. Code: LARYNX maps to LARYNX.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LARYNX\",\n    \"reasoning\": \"1. Site: Larynx. 2. Findings: Squamous cell carcinoma, keratinizing type",
      "predicted": "HNSC",
      "ground_truth": "HNSC",
      "correct": true,
      "reasoning": "1. Site: Larynx. 2. Findings: Squamous cell carcinoma, keratinizing type, G-1. 3. Code: HNSC maps to HNSC.",
      "idx": 488,
      "timestamp": "2026-01-19T15:59:53.116779"
    },
    {
      "sample_idx": 1141,
      "input": "Clinical Diagnosis & History: with left retroperitoneal mass. Bx c/w high grade spindle cell. neoplasm. Specimens Submitted: 1: SP: Retroperitoneal dissection with lt. colon, lt. kidney. 2: SP: Lt. psoas mass. 3: SP: Left common iliac lymph node. DIAGNOSIS: 1). SOFT TISSUE, RETROPERITONEAL DISSECTION WITH LEFT COLON, LEFT KIDNEY. AND SEGMENT OF. DUODENUM; RESECTION: - DEDIFFERENTIATED LIPOSARCOMA WITH DIVERGENT DIFFERENTIATION (HIGH. GRADE LEIOMYOSARCOMA). - TWO TUMOR FOCI, 6.0 CM AND 3.0 CM IN ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear",
      "predicted": "KIRC",
      "ground_truth": "SARC",
      "correct": false,
      "reasoning": "1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 1141,
      "timestamp": "2026-01-19T15:59:53.116792"
    },
    {
      "sample_idx": 1311,
      "input": "SPECIMENS: A. THYMUS. B. CERVICAL HORN. SPECIMEN(S): A. THYMUS. B. CERVICAL HORN. DIAGNOSIS: A. THYMUS, THYMECTOMY: - ENCAPSULATED THYMOMA (8 CM), TYPE AB. - RESECTION MARGINS ARE NEGATIVE BUT CLOSE. - ADJACENT BENIGN INVOLUTED THYMIC TISSUE. B. \"CERVICAL HORN\", EXCISION: - BENIGN FIBROADIPOSE TISSUE AND INVOLUTED THYMIC TISSUE. SYNOPTIC REPORT - MEDIASTINUM & THYMUS. Specimens Involved. Specimens: A: THYMUS. Specimen Type: Cervical thymectomy. Specimen Size: Greatest dimension: 10.5cm. Addition...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Cervical Horn. 2. Findings: Benign Fibroadipose Tissue and Involved Thymic Tissue. 3. Code: UVM maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps",
      "predicted": "THYM",
      "ground_truth": "THYM",
      "correct": true,
      "reasoning": "1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM maps to THYM.",
      "idx": 1311,
      "timestamp": "2026-01-19T15:59:53.116802"
    },
    {
      "sample_idx": 268,
      "input": "Female. Surgery Date: DIAGNOSIS: Liver, right lobe, resection: Invasive grade 3 (of 4) cholangiocarcinoma forming a. lobulated, firm mass (8.9 x 6.8 x 5.5 cm) located 1.1 cm from the surgical margin. The uninvolved liver parenchyma is unremarkable. Peritoneum, biopsy: Partially calcified fat necrosis. Gallbladder, cholecystectomy : without diagnostic abnormality. Lymph node, retrocholedochal, biopsy: A single lymph node is negative for tumor. Small bowel, fistula tract, biopsy: Fistula tract wit...",
      "response": "```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Cholangiocarcinoma, grade 3. 3. Code: CHOL maps to Cholangiocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal cancer, diverticulosis with diverticulitis. 3. Code: COAD maps to Colorectal Cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Ovarian serous cystadenocarcinoma. 3. Code: OV maps to Ovarian Cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Pancreatic adenocarcinoma. 3. Code: PAAD maps to Pancreatic Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma. 3. Code: PRAD maps to Prostate Cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"READ\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Rectal adenocarcinoma. 3. Code: READ maps to Rectal Cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Soft Tissue. 2. Findings: Sarcomatoid carcinoma. 3. Code: SARC maps to Soft Tissue Sarcoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin. 2. Findings: Skin cutaneous melanoma. 3. Code: SKCM maps to Skin Melanoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Stomach adenocarcinoma. 3. Code: STAD maps to Stomach Cancer.\"\n}\n```",
      "predicted": "CHOL",
      "ground_truth": "CHOL",
      "correct": true,
      "reasoning": "1. Site: Liver. 2. Findings: Cholangiocarcinoma, grade 3. 3. Code: CHOL maps to Cholangiocarcinoma.",
      "idx": 268,
      "timestamp": "2026-01-19T15:59:53.116814"
    },
    {
      "sample_idx": 614,
      "input": "WITH ADDENDUM. Service Date: Soc. Sec. #: Client: FINAL PATHOLOGIC DIAGNOSIS. Right kidney, partial nephrectomy: Papillary renal cell carcinoma, through renal. capsule, not present at margins; see comment. COMMENT: Kidney - Histologic Tumor type: Synoptic Renal Comment cell carcinoma, papillary type. Site R Kidney NOS C64.9. - Grade: Fuhrman grading for RCC: II. - Tumor size: 2.2 cm. - Site within kidney: Unknown. - Renal pelvis: Not applicable. - Ureter: Not applicable. - Renal sinus: Not appli...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 614,
      "timestamp": "2026-01-19T15:59:53.116825"
    },
    {
      "sample_idx": 936,
      "input": "Clinical History/Diagnosis. Source of Specimen(s). 1: Omentum, resection other than for tumor. 2: right tube and ovary. 3: left tube and ovary. 4: supracervical uterus. 5: left paracolic gutter. Gross Description: Received in five parts. Source of Tissue: 1. Labeled # 1, \"omentum\". Gross Description: Received fresh in a container labeled \" patient name and medical number,. omentum\". It consists of a segment of omentum. measuring 30,0 x 12.0 x 2.0 cm. Approximately one-third of the omentum. has a...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Omentum. 2. Findings: Serous adenocarcinoma. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Right tube and ovary. 2. Findings: Serous adenocarcinoma involving ovary and fallopian tube. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Left tube and ovary. 2. Findings: Serous adenocarcinoma involving ovary and fallopian tube. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Serous adenocarcinoma involving uterine serosa with invasion into outer one-third of myometrium. Inactive endometrium. Endocervix with no tumor seen. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Left paracolic gutter. 2. Findings: Serous adenocarcinoma. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Omentum. 2. Findings: Serous adenocarcinoma. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Right tube and ovary. 2. Findings: Serous adenocarcinoma involving ovary and fallopian tube. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Left tube and ovary. 2. Findings: Serous adenocarcinoma involving ovary and fallopian tube. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Serous adenocarcinoma involving uterine",
      "predicted": "UCEC",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Omentum. 2. Findings: Serous adenocarcinoma. 3. Code: UCEC.",
      "idx": 936,
      "timestamp": "2026-01-19T15:59:53.116834"
    },
    {
      "sample_idx": 1108,
      "input": "Final Diagnosis. A. TONGUE, RIGHT, GLOSSECTOMY: High-grade leiomyosarcoma, 4.0 cm in greatest dimension (see comment). No lymphovascular space invasion identified. One subglossal lymph node, negative for metastatic carcinoma (0/1). All final margins are free of tumor (see parts B-G). Adjacent squamous mucosa with mild dysplasia. B. DORSAL TONGUE, EXCISION: Squamous mucosa, negative for malignancy. C. VENTRAL TONGUE MARGIN, EXCISION: Squamous mucosa, negative for malignancy. D. FLOOR OF MOUTH MAR...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue, Right, Glossectomy. 2. Findings: High-grade leiomyosarcoma, 4.0 cm in greatest dimension. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue, Right, Dorsal. 2. Findings: Squamous cell carcinoma, 2.5 cm in greatest dimension. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue, Right, Ventral. 2. Findings: Squamous cell carcinoma, 3.0 cm in greatest dimension. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue, Right, Floor of Mouth. 2. Findings: Squamous cell carcinoma, 2.5 cm in greatest dimension. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue, Right, Posterior. 2. Findings: Squamous cell carcinoma, 2.0 cm in greatest dimension. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue, Right, Deep Posterior. 2. Findings: Squamous cell carcinoma, 2.0 cm in greatest dimension. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tongue, Right, Anterior Deep. 2. Findings: Squamous cell carcinoma, 1.5 cm in greatest dimension. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Neck, Right, Levels 2-4. 2. Findings: Negative for metastatic carcinoma. 3. Code: K",
      "predicted": "KIRC",
      "ground_truth": "SARC",
      "correct": false,
      "reasoning": "1. Site: Tongue, Right, Glossectomy. 2. Findings: High-grade leiomyosarcoma, 4.0 cm in greatest dimension. 3. Code: KIRC.",
      "idx": 1108,
      "timestamp": "2026-01-19T15:59:53.116844"
    },
    {
      "sample_idx": 148,
      "input": "RUN DATE. RUN TIME. RUN USER. ACCT # : AGE/SX: ROOM : REG DR. BED: SPEC #. RECD: COLL: TIME IN FORMALIN: 6:29. nrs. COLD ISCHEMA TIME: 0:00. mins,. CLINICAL INFORMATION: Pre-Op Diagnosis: Right breast mass. Remarks: Specimen (s) : A. Right breast mass. B. Right breast sentinel node. C. Posterior medial margin. D. Medial margin. MICROSCOPIC DIAGNOSIS. A. BREAST, RIGHT (REGION NOT OTHERWISE STATED). LUMPECTOMY: INVASIVE GRADE 3 DUCTAL CARCINOMA MEASURING 3.5 CM IN GREATEST DIMENSION. ASSOCIATED HI...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 148,
      "timestamp": "2026-01-19T15:59:53.116854"
    },
    {
      "sample_idx": 19,
      "input": "Gender: Male. Race: White. Report Date: FINAL PATHOLOGIC DIAGNOSIS. A. Distal right ureter; excision: - Portion of ureter with urothelial carcinoma in situ. B. Right pelvic lymph nodes; dissection: - One of four lymph nodes with metastatic urothelial carcinoma (1/4). - Largest lymph nodal tumor focus measures 3 mm, with extranodal extension. C. Left pelvic lymph nodes; dissection: - Two of ten lymph nodes with metastatic urothelial carcinoma (2/10). - Largest lymph nodal tumor focus measures 3 m...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Ureter (Distal Right). 2. Findings: Urothelial carcinoma in situ, Invasive urothelial carcinoma. 3. Code: UCEC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate adenocarcinoma, Urothelial carcinoma in situ. 3. Code: PRAD\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, Urothelial carcinoma in situ. 3. Code: BLCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney",
      "predicted": "UCEC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Ureter (Distal Right). 2. Findings: Urothelial carcinoma in situ, Invasive urothelial carcinoma. 3. Code: UCEC",
      "idx": 19,
      "timestamp": "2026-01-19T15:59:53.116865"
    },
    {
      "sample_idx": 938,
      "input": "INAL. PARTS 1. AND 2: OVARIES, LEFT AND RIGHT, BILATERAL SALPINGO-OOPHORECTOMY -. A. POORLY DIFFERENTIATED PAPILLARY SEROUS CYSTADENOCARCINOMA INVOLVING RIGHT AND LEFT. OVARIES. B. LEFT OVARIAN MASS MEASURES 15 CM IN GREATEST DIMENSION. c. RIGHT OVARIAN MASS MEASURES 11 CM IN GREATEST DIMENSION. D. OVARIAN SURFACE INVOLVEMENT IS IDENTIFIED (SLIDE 1N). E. LYMPHOVASCULAR INVASION IS IDENTIFIED (SLIDE 2K). F. NON-NEOPLASTIC OVARIAN PARENCHYMA WITH PHYSIOLOGIC CHANGES BILATERALLY. PART 3: UTERUS WIT...",
      "response": "```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: Papiary serous cystadenocarcinoma involving right and left ovaries. 3. Code: OV maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: Left ovarian mass measures 15 cm in greatest dimension. 3. Code: OV maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: Right ovarian mass measures 11 cm in greatest dimension. 3. Code: OV maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: Ovarian surface involvement identified. 3. Code: OV maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: Lymphovascular invasion identified. 3. Code: OV maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovaries. 2. Findings: Non-neoplastic ovarian parenchyma with physiologic changes bilaterally. 3. Code: OV maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Cervix with chronic cervicitis and reactive epithelial atypia. 3. Code: UCEC maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Secretory endometrium. 3. Code: UCEC maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrial polyp",
      "predicted": "OV",
      "ground_truth": "OV",
      "correct": true,
      "reasoning": "1. Site: Ovaries. 2. Findings: Papiary serous cystadenocarcinoma involving right and left ovaries. 3. Code: OV maps to OV.",
      "idx": 938,
      "timestamp": "2026-01-19T15:59:53.116875"
    },
    {
      "sample_idx": 204,
      "input": "B2148 Final Diagnosis. Yeast, left, wide local excision: Infiltrating ductal carcinoma, Nottingham grade III (of III) [tubules 3/3, nuclei 3/3, mitoses 2/3;. Nottingham. score 8/9], forming a mass (2.7 x 2.3 x 2.2 cm) [AJCC pT2]. Angiolymphatic invasion is absent. The non-neoplastic. breast parenchyma shows nonproliferative fibrocystic changes. The skin (separately submitted new anterior margin) is negative. for tumor. All surgical resection margins; after the separately submitted re-excisions o...",
      "response": "```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings",
      "predicted": "SKCM",
      "ground_truth": "BRCA",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, Nottingham grade III. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 204,
      "timestamp": "2026-01-19T15:59:53.116885"
    },
    {
      "sample_idx": 150,
      "input": "Date Coll: SPECIMEN. A. Left axillary sentinel node. B. Left breast silk on superior breast. CLINICAL NOTES. PRE-OP DIAGNOSIS: Left breast cancer. CLINICAL HISTORY: year-old white female with cancer. POST-OP DIAGNOSIS: Same. GROSS DESCRIPTION. A. Received fresh labeled \"left axillary node\" is a 3.8. x. 2.4 x 0.6 cm. portion of soft, lobulated golden-yellow. adipose tissue. Two (2) slightly rubbery tan-pink tissues in. keeping with lymph node measuring 0.8 and 1.8 cm. in greatest. dimension are r...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left axillary sentinel node. 2. Findings: Invasive ductal carcinoma, grade III, 3.0 cm in greatest dimension. Negative margins of excision. Lymphovascular invasion identified. Two negative lymph nodes (0/2). 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Left breast. 2. Findings: Invasive ductal carcinoma, grade III, 3.0 cm in greatest dimension. Negative margins of excision. Lymphovascular invasion identified. Two negative lymph nodes (0/2). 3. Code: BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left axillary sentinel node. 2. Findings: Invasive ductal carcinoma, grade III, 3.0 cm in greatest dimension. Negative margins of excision. Lymphovascular invasion identified. Two negative lymph nodes (0/2). 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left breast. 2. Findings: Invasive ductal carcinoma, grade III, 3.0 cm in greatest dimension. Negative margins of excision. Lymphovascular invasion identified. Two negative lymph nodes (0/2). 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left axillary sentinel node. 2. Findings: Invasive ductal carcinoma, grade III, 3.0 cm in greatest dimension. Negative margins of excision. Lymphovascular invasion identified. Two negative lymph nodes (0/2). 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left breast. 2. Findings: Invasive ductal carcinoma, grade III, 3.0 cm in greatest dimension. Negative margins of excision. Lymphovascular invasion identified. Two negative lymph nodes (0/2). 3. Code",
      "predicted": "KIRC",
      "ground_truth": "BRCA",
      "correct": false,
      "reasoning": "1. Site: Left axillary sentinel node. 2. Findings: Invasive ductal carcinoma, grade III, 3.0 cm in greatest dimension. Negative margins of excision. Lymphovascular invasion identified. Two negative lymph nodes (0/2). 3. Code: KIRC.",
      "idx": 150,
      "timestamp": "2026-01-19T15:59:53.116898"
    },
    {
      "sample_idx": 436,
      "input": "DIAGNOSIS. \"RIGHT OMOHYOID\". skeletal muscle with suture granulomata; no tumor present. \"RIGHT PAROTID ARTERY\": Connective tissue and nerve; no tumor present. \"CERVICAL ESOPHAGUS\": Connective tissue with reactive changes; no tumor present. \"RIGHT LATERAL NECK DISSECTION\": Ten lymph nodes, no tumor present. \"SYMPATHETIC NERVE SHEATH\": GRADE II SQUAMOUS CARCINOMA INVOLVING NERVE (PERINEURAL INVASION). 'TOTAL LARYNGECTOMY / TOTAL THYROIDECTOMY, LEFT ANTERIOR COMPARTMENT. DISSECTION\". GRADE II SQUAM...",
      "response": "```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Right omohyoid muscle, right parotid artery, cervical esophagus, right lateral neck dissection, sympathetic nerve sheath, total laryngectomy, total thyroidectomy, left anterior compartment, transduced tumor, non-transduced tumor, vagus nerve, right sympathetic chain, tumor base of skull. 2. Findings: Grade II squamous cell carcinoma involving connective tissue and perineural invasion. 3. Code: SKCM (Squamous Cell Carcinoma) maps to the specific tumor sites. The presence of perineural invasion suggests a more aggressive tumor, which is common in squamous cell carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Right omohyoid muscle, right parotid artery, cervical esophagus, right lateral neck dissection, sympathetic nerve sheath, total laryngectomy, total thyroidectomy, left anterior compartment, transduced tumor, non-transduced tumor, vagus nerve, right sympathetic chain, tumor base of skull. 2. Findings: Grade II squamous cell carcinoma involving connective tissue and perineural invasion. 3. Code: SKCM (Squamous Cell Carcinoma) maps to the specific tumor sites. The presence of perineural invasion suggests a more aggressive tumor, which is common in squamous cell carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Right omohyoid muscle, right parotid artery, cervical esophagus, right lateral neck dissection, sympathetic nerve sheath, total laryngectomy, total thyroidectomy, left anterior compartment, transduced tumor, non-transduced tumor, vagus nerve, right sympathetic chain, tumor base of skull. 2. Findings: Grade II squamous cell carcinoma involving connective tissue and perineural invasion. 3. Code: SKCM (Squamous Cell Carcinoma) maps to the specific tumor sites. The presence of perineural invasion suggests a more aggressive tumor, which is common in squamous cell carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Right omohyoid muscle, right parotid artery, cervical esophagus, right lateral neck dissection, sympathetic nerve sheath, total laryngectomy, total thyroidectomy, left anterior compartment, transduced tumor, non-trans",
      "predicted": "SKCM",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Right omohyoid muscle, right parotid artery, cervical esophagus, right lateral neck dissection, sympathetic nerve sheath, total laryngectomy, total thyroidectomy, left anterior compartment, transduced tumor, non-transduced tumor, vagus nerve, right sympathetic chain, tumor base of skull. 2. Findings: Grade II squamous cell carcinoma involving connective tissue and perineural invasion. 3. Code: SKCM (Squamous Cell Carcinoma) maps to the specific tumor sites. The presence of perineural invasion suggests a more aggressive tumor, which is common in squamous cell carcinoma.",
      "idx": 436,
      "timestamp": "2026-01-19T15:59:53.116918"
    },
    {
      "sample_idx": 1036,
      "input": "DOS: SEX: Male. SURGICAL PATHOLOGY, COMPREHENSIVE. Not Released. I nqui ry: Sur gi e cal Pat hol ogyRepor t. Speci ren Dat e: In Lab Dat e: Report Dat e: Pat i ent : Encount er #: Locat i on: Age/ Sex: CLI N CAL I INFORMATI ON. Prostate cancer. I INTRACPERATI VE DI AGNOSI S: A. Thr ough E. Frozen section di agnosi s s: Soft tissue only. Reported to: GROSS. A. Recei ved fresh, the speci ren is label ed \"posterior apical'. and consists of a 0.2 x 0.2 x 0. cm pi ece of t an soft tissue. 100% submit...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate (Posterior Apical Margin). 2. Findings: Prostate adenocarcinoma, Gleason score 7 (3+4), bilateral. Extraprostatic extension, focal, left posterior margin (F17). Seminal vesicles and all surgical margins are negative for tumor. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2",
      "predicted": "KIRC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate (Posterior Apical Margin). 2. Findings: Prostate adenocarcinoma, Gleason score 7 (3+4), bilateral. Extraprostatic extension, focal, left posterior margin (F17). Seminal vesicles and all surgical margins are negative for tumor. 3. Code: KIRC.",
      "idx": 1036,
      "timestamp": "2026-01-19T15:59:53.116933"
    },
    {
      "sample_idx": 1304,
      "input": "SURGICAL PATHOLOGY ----. MEDICAL RECORD. I. Laboratory: Accession No. Submitted by: Date obtained: Specimen (Received. A. THYMUS, FS. B. STATION 3 MEDIASTINAL LYMPH NODE. C. STATION 4L. D. THYMUS LYMPH NODE. E. MAMMARY FAT PAD. F. LEFT CHEST BIOPSY SITE. + SUPPLEMENTARY REPORT HAS BEEN ADDED +. REFER TO BOTTOM OF REPORT +. BRIEF CLINICAL HISTORY: PREOPERATIVE DIAGNOSIS: Thymoma. OPERATIVE FINDINGS: POSTOPERATIVE DIAGNOSIS: Thymoma. Laboratory: Accession No. Pathology Resident : GROSS DESCRIPTION...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thym",
      "predicted": "THYM",
      "ground_truth": "THYM",
      "correct": true,
      "reasoning": "1. Site: Thymus. 2. Findings: Thymoma, Type AB. 3. Code: THYM",
      "idx": 1304,
      "timestamp": "2026-01-19T15:59:53.116942"
    },
    {
      "sample_idx": 271,
      "input": "CONFIDENTIAL. Demographics (for. verification purposes). Date of Birth: Sex: M. Collected Date/Time. Received Date/Time. Specimen Description. A. Small bowel nodule. B. Mesenteric node. C. Gallbladder. D. Right lobe liver. Clinical Information. Mass in liver. Cholangiocarcinoma - query. Colon adenocarcinoma. Diagnosis. A. Small Bowel Nodule, Biopsy: Focal fibrosis, negative for malignancy. B. Mesenteric Node, Biopsy: One lymph node, negative for malignancy. C. Gallbladder, Cholecystectomy: Unrem...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Small bowel. 2. Findings: Small bowel nodule, biopsy shows focal fibrosis, negative for malignancy. 3. Code: Small Bowel Nodule maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mesenteric node. 2. Findings: Mesenteric node, biopsy shows one lymph node, negative for malignancy. 3. Code: Mesenteric Node maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Gallbladder. 2. Findings: Gallbladder, cholecystectomy shows unremarkable gallbladder, negative for malignancy. 3. Code: Gallbladder maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Right lobe liver. 2. Findings: Right lobe liver, wedge resection shows moderately differentiated cholangiocarcinoma. 7.7 x 6.0 x 5.5 cm. Less than 0.1 cm to the liver resection margin and the tumor focally involves the liver capsule. Positive perineural invasion. Surrounding background liver parenchyma shows moderate portal inflammation, likely due to mass effect. 3. Code: Right Lobe Liver maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Right lobe liver. 2. Findings: Right lobe liver, wedge resection shows moderately differentiated cholangiocarcinoma. 7.7 x 6.0 x 5.5 cm. Less than 0.1 cm to the liver resection margin and the tumor focally involves the liver capsule. Positive perineural invasion. Surrounding background liver parenchyma shows moderate portal inflammation, likely due to mass effect. 3. Code: Right Lobe Liver maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Right lobe liver. 2. Findings: Right lobe liver, wedge resection shows moderately differentiated cholangiocarcinoma. 7.7 x 6.0 x ",
      "predicted": "COAD",
      "ground_truth": "CHOL",
      "correct": false,
      "reasoning": "1. Site: Small bowel. 2. Findings: Small bowel nodule, biopsy shows focal fibrosis, negative for malignancy. 3. Code: Small Bowel Nodule maps to COAD.",
      "idx": 271,
      "timestamp": "2026-01-19T15:59:53.116953"
    },
    {
      "sample_idx": 714,
      "input": "Laboratory Services. PHN: ACB: Telephone: Encounter: Received Date/Time: Specimen Description. A. Gallbladder. B. Liver. C. Tumor thrombus - left hepatic vein. Clinical Information. Hepatocellular carcinoma. Diagnosis. A. Gallbladder, cholecystectomy: -Normal gallbladder with no pathologic abnormality. B. Liver, partial hepatectomy: -Moderately differentiated hepatocellular carcinoma. -Solitary, 11.0 cm in greatest dimension, 0.8 cm from the resection. margin. -Background liver negative for cirr...",
      "response": "```json\n{\n    \"cancer_type\": \"Hepatocellular carcinoma\",\n    \"reasoning\": \"1. Site: Gallbladder, Liver, Tumor Thrombus. 2. Findings: Hepatocellular carcinoma, moderately differentiated. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, moderately differentiated. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Tumor Thrombus. 2. Findings: Hepatocellular carcinoma with necrosis. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, moderately differentiated. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Gallbladder. 2. Findings: Hepatocellular carcinoma, moderately differentiated. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, moderately differentiated. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, moderately differentiated. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, moderately differentiated. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular",
      "predicted": "Hepatocellular carcinoma",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Gallbladder, Liver, Tumor Thrombus. 2. Findings: Hepatocellular carcinoma, moderately differentiated. 3. Code: Hepatocellular carcinoma maps to KIRC.",
      "idx": 714,
      "timestamp": "2026-01-19T15:59:53.116965"
    },
    {
      "sample_idx": 1118,
      "input": "Report Status : Final. Type: surgicar. Specimen Type: Omentum. Procedure Date: Resident: PATHOLOGIC DIAGNOSIS: A. OMENTUM: HIGH GRADE SPINDLE CELL NEOPLASM SUGGESTIVE OF. DEDIFFERENTIATED LIPOSARCOMA (17.5 CM) involving adipose tissue. (See Note). Mitoses number 3 per 10 HPF. 50% necrosis is present. 30% hemorrhage is present. B. MESENTERY SARCOMA: HIGH GRADE SPINDLE CELL NEOPLASM SUGGESTIVE OF. DEDIFFERENTIATED LIPOSARCOMA (36.5 CM). Mitoses number 3 per 10 HPF. 50% necrosis is present. 30% hem...",
      "response": "```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Omentum and Mesentery. 2. Findings: High grade spindle cell neoplasm, suggestive of dedifferentiated liposarcoma. 3. Code: SARC (Sarcoma) maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Omentum and Mesentery. 2. Findings: High grade spindle cell neoplasm, suggestive of dedifferentiated liposarcoma. 3. Code: SARC (Sarcoma) maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Omentum and Mesentery. 2. Findings: High grade spindle cell neoplasm, suggestive of dedifferentiated liposarcoma. 3. Code: SARC (Sarcoma) maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Omentum and Mesentery. 2. Findings: High grade spindle cell neoplasm, suggestive of dedifferentiated liposarcoma. 3. Code: SARC (Sarcoma) maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Omentum and Mesentery. 2. Findings: High grade spindle cell neoplasm, suggestive of dedifferentiated liposarcoma. 3. Code: SARC (Sarcoma) maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Omentum and Mesentery. 2. Findings: High grade spindle cell neoplasm, suggestive of dedifferentiated liposarcoma. 3. Code: SARC (Sarcoma) maps to SARC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SARC\",\n    \"reasoning\": \"1. Site: Omentum and Mesentery. 2. Findings: High grade spindle cell neoplasm, suggestive of dedifferentiated liposarcoma. 3. Code: SARC (Sarcoma) maps to SARC",
      "predicted": "SARC",
      "ground_truth": "SARC",
      "correct": true,
      "reasoning": "1. Site: Omentum and Mesentery. 2. Findings: High grade spindle cell neoplasm, suggestive of dedifferentiated liposarcoma. 3. Code: SARC (Sarcoma) maps to SARC.",
      "idx": 1118,
      "timestamp": "2026-01-19T15:59:53.116975"
    },
    {
      "sample_idx": 500,
      "input": "MEDICAL RECORD. Revised Surgical Pathology Report. Revised Surgical Pathology Report. PROCEDURE DATE: SEX: M. SIGN-OUT DATE: ATTENDING: REQUESTING: CONTACT NO: ROOM: COPIES TO: REVISED REPORT. REASON FOR REVISION: A computer software error caused corruption in the original final report. This. incomplete, corrupted report was signed out so that a clean revised report could be created. This revised report. therefore represents the true original final report. DIAGNOSIS: Kidney, right (radical nephr...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",",
      "predicted": "KIRC",
      "ground_truth": "KICH",
      "correct": false,
      "reasoning": "1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, chromophobe type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 500,
      "timestamp": "2026-01-19T15:59:53.116986"
    },
    {
      "sample_idx": 756,
      "input": "Female. DIAGNOSIS. A. Liver, left, partial hepatectomy: Hepatocellular carcinoma,. moderately differentiated (grade 2 of 4), forming a single mass, 4.3. x 4.1 x 4.0 cm. The tumor is confined to the liver. The liver. parenchyma resection margin is negative for tumor (tumor free. margin, 1.4 cm) Macroscopic large vessel invasion is absent. Microscopic invasion is absent. No regional lymph nodes identified. B. Gallbladder, cholecystectomy Chronic cholecystitis and. cholelithiasis with two benign ly...",
      "response": "```json\n{\n    \"cancer_type\": \"Hepatocellular carcinoma\",\n    \"reasoning\": \"1. Site: Liver, Left. 2. Findings: Hepatocellular carcinoma, moderately differentiated (grade 2 of 4), forming a single mass. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Gallbladder. 2. Findings: Chronic cholecystitis, cholelithiasis with two benign lymph nodes. 3. Code: Gallbladder maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, moderately differentiated (grade 2 of 4), forming a single mass. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, moderately differentiated (grade 2 of 4), forming a single mass. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, moderately differentiated (grade 2 of 4), forming a single mass. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, moderately differentiated (grade 2 of 4), forming a single mass. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, moderately differentiated (grade 2 of 4), forming a single mass. 3. Code: Hepatocellular carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\":",
      "predicted": "Hepatocellular carcinoma",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Liver, Left. 2. Findings: Hepatocellular carcinoma, moderately differentiated (grade 2 of 4), forming a single mass. 3. Code: Hepatocellular carcinoma maps to KIRC.",
      "idx": 756,
      "timestamp": "2026-01-19T15:59:53.116998"
    },
    {
      "sample_idx": 583,
      "input": "Report Status: Amend/Addenda. Type: : Surgical Pathology. Specimen Type: Kidnev, partial or total resection. Procedure Date: PATHOLOGIC DIAGNOSIS: A/1) LEFT RADICAL NEPHRECTOMY: RENAL CELL CARCINOMA, clear cell type (11.3 cm), Fuhrman Grade II/IV. The tumor focally abuts but does not invade the renal capsule. No lymphovascular invasion seen. Renal vein is negative for tumor. Ureter (including margin) is negative for tumor. AJCC stage (6th edition) : T2 NO MX (see below). The non-neoplastic kidne...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 583,
      "timestamp": "2026-01-19T15:59:53.117010"
    },
    {
      "sample_idx": 1269,
      "input": "Diagnosis: A: Thyroid, total thyroidectomy. Tumor histologic type: papillary thyroid carcinoma, multifocal. Tumor size: there are 2 nodules of carcinoma, right upper pole. 2.5 cm in greatest dimension, right lower pole 1.7 cm in. greatest dimension. Tumor focality & laterality: multifocal, both tumors are in the. right thyroid. Tumor capsule: not present. Extent of invasion: Capsular Invasion: not identified. Lymphovascular invasion: not identified. Blood vascular invasion: not identified. Extra...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, multifocal. Tumor size: 2.5 cm and 1.7 cm. Tumor focality & laterality: right thyroid. Tumor capsule: not present. Extent of invasion: Capsular Invasion: not identified. Lymphovascular invasion: not identified. Blood vascular invasion: not identified. Extra thyroidal extension: not identified. Surgical margins: surgical margins free of tumor. Status of thyroid gland away from tumor: multinodular goiter. with extensive fibrosis and calcifciation. Lymph nodes: none present in specimen. Other significant findings: one parathyroid gland is present. (block A1), without pathologic abnormality. AJCC Pathologic TNM Stage: pT2 pNx. NOTE: This pathologic stage assessment is based on information. available at the time of this report, and is subject to change. pending clinical review and additional information. Clinical History. -year-old with thyroid cancer. Gross Description: Received is one appropriately labeled container, additionally. labeled \\\"total thyroid, stitch left superior pole\\\". Specimen fixation: formalin. Type of specimen: total thyroidectomy. Size and weight of specimen: 35.4 gm, 6.5 X 2.8 X 2.5 cm right. lobe, 6.3 X 3.0 X 1.3 cm left lobe and isthmus. Orientation Suture: left superior pole. Inking: anterior=blue, posterior=black, isthmus=yellow. Tumor location: right superior pole and right inferior pole. Focality: multifocal. Dominant tumor: present, right superior pole. Tumor description: The tumors are well circumscribed, solid,. fleshy, friable and pink/tan nodules. Tumor size: The dominate tumor nodule in the right upper pole is. 2.5 X 2.2 X 2.1 cm, and in the right lower pole is 1.7 x 1.3 X. 1.0 cm. Confinement / non-confinement: appears confined. Distance of tumor to capsule/inked surgical margins: Each tumor. nodule is within 0.1 cm of the blue inked anterior margin, and. 0. 1 cm of the black inked posterior margin. Appearance of thyroid gland away from tumor: dark red/brown and.",
      "predicted": null,
      "ground_truth": "THCA",
      "correct": null,
      "reasoning": "",
      "idx": 1269,
      "timestamp": "2026-01-19T15:59:53.117168"
    },
    {
      "sample_idx": 1286,
      "input": "SPECIMEN TAKEN: FINAL DIAGNOSIS. 1. RIGHT UPPER PARATHYROID (EXCISION): PARATHYROID AND. FIBROADIPOSE TISSUE (500MG). PARATHYROID ACCOUNTS FOR 40% OF. THE SPECIMEN. 2. RIGHT LOWER PARATHYROID (EXCISION): PARATHYROID TISSUE WITH. ADJACENT FIBROADIPOSE AND BENIGN THYROID TISSUE (450MG). PARATHYROID ACCOUNTS FOR 25% OF THE SPECIMEN. 3. BIOPSY LEFT LOWER PARATHYROID GLAND (BIOPSY): PARATHYROID. TISSUE. (6MG). NOTE: Tissue block exausted on frozen section. No frozen section control present. 4. THYROI...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid (Right Superior Lobe and Isthmus). 2. Findings: Papillary carcinoma, pT1b, margins uninvolved, venous/lymphatic invasion present, multinodular hyperplasia. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Parathyroid (Right Upper and Lower). 2. Findings: Parathyroid tissue, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ACC\",\n    \"reasoning\": \"1. Site: Parathyroid (Right Upper). 2. Findings: Parathyroid tissue, conventional (clear cell) type, Fuhrman Grade II. 3. Code: ACC maps to ACC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Parathyroid (Right Lower). 2. Findings: Parathyroid tissue, conventional (clear cell) type, Fuhrman Grade II. 3. Code: BRCA maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Parathyroid (Left Lower). 2. Findings: Parathyroid tissue, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, pT1b, margins uninvolved, venous/lymphatic invasion present, multinodular hyperplasia. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Parathyroid (Right Upper). 2. Findings: Parathyroid tissue, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```",
      "predicted": "THYM",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Thyroid (Right Superior Lobe and Isthmus). 2. Findings: Papillary carcinoma, pT1b, margins uninvolved, venous/lymphatic invasion present, multinodular hyperplasia. 3. Code: THYM maps to THYM.",
      "idx": 1286,
      "timestamp": "2026-01-19T15:59:53.117186"
    },
    {
      "sample_idx": 619,
      "input": "A description for each data field can be found in the 'Data description' worksheet (yellow tab). Sample Collection Details. Histology ai. Site of. Site of. Year of. Age at. Days to. Type. Preparatio. Tissue. Primary. Comments. Procedure. n. (Event). (yrs). TUMOUR. FF. RENL. BUFFY. FF. RENL. nd staging. Days to. Type of. Site of. Tumour. Histology. Grade/. Pathologic. Diagnosis. Procedure. Primary. Size (cm). Differentiat al T. (Histology). ion. RESECT. Right kidney. 14.5. Papillary renal ca., eo...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Papillary renal carcinoma, eosinophilic type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Papillary renal carcinoma, eosinophilic type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Papillary renal carcinoma, eosinophilic type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Papillary renal carcinoma, eosinophilic type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Papillary renal carcinoma, eosinophilic type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Papillary renal carcinoma, eosinophilic type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Papillary renal carcinoma, eosinophilic type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Papillary renal carcinoma, eosinophilic type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Right kidney. 2. Findings: Papillary renal carcinoma, eosinophilic type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 619,
      "timestamp": "2026-01-19T15:59:53.117197"
    },
    {
      "sample_idx": 16,
      "input": "M. Urology. Clinical Diagnosis & History: year old male with recurrent high grade T1 urothelial carcinoma. Specimens Submitted: 1: Urethral margin (fs). 2: Right distal pelvic lymph node. 3: Left distal pelvic lymph node. 4: Bladder, prostate, seminal vesicles and perivesicle lymph nodes; cystoprostatectomy. 5: Left distal ureter. 6: Right distal ureter. DIAGNOSIS: 1. Urethral margin; excision: - Benign urethra and prostate tissue. 2. Right distal pelvic lymph node: Lymph Node Dissection: Benign...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Urethra. 2. Findings: Urethral margin, benign. 3. Site: Right distal pelvic lymph node. 2. Findings: Lymph Node Dissection, Benign lymph nodes. 4. Site: Left distal pelvic lymph node. 2. Findings: Lymph Node Dissection, Benign lymph nodes. 5. Site: Bladder, prostate, seminal vesicles and perivesicle lymph nodes; cystoprostatectomy. 2. Findings: Invasive urothelial carcinoma, NOS. High grade. 6. Site: Left distal ureter. 2. Findings: Benign ureter. 7. Site: Right distal ureter. 2. Findings: Benign ureter. 8. Site: Bladder, prostate, seminal vesicles and perivesicle lymph nodes; cystoprostatectomy. 2. Findings: Tumor Type: Invasive urothelial carcinoma, NOS. Histologic Grade: High grade. Pattern of growth of the Non-Invasive component: In situ component not identified. Pattern of growth of the Invasive component: Infiltrating. Tumor Multicentricity: Not identified. Bladder Local Invasion: Deep half of muscularis propria. Extravesical Tumor Extension: Ureters uninvolved. Urethra uninvolved. Vascular Invasion: Identified. Perineural Invasion: Identified. Surgical Margins: Free of tumor. Non-Neoplastic Mucosa: Exhibiting ulceration. Exhibiting foreign body reaction. Prostate: Other See section b. Seminal Vesicles: Not involved. Perivesical Lymph Nodes: LN Not involved 1. The Pathologic Stage is (AJCC 2002): pT2b (Invades deep half of muscularis propria). PRO (No involvement of prostate). b. Tumor Type: Adenocarcinoma. of prostate. Gleason's Grade: Primary Gleason grade:3. Secondary Gleason grade:3. Total Gleason score:6. Tumor Location: Involves Right posterior. Involves Left posterior. Involves Left anterior. Dominant tumor mass located in: left anterior and posterior mid. Vascular Invasion: Not Identified. Perineural Invasion: Identified. Tumor Multicentricity: Multicentric foci of invasive carcinoma are present. High Grade Prostatic Intraepithelial Neoplasia: Identified. Capsule: Tumor invades into, but not beyond prostate capsule.",
      "predicted": null,
      "ground_truth": "BLCA",
      "correct": null,
      "reasoning": "",
      "idx": 16,
      "timestamp": "2026-01-19T15:59:53.117325"
    },
    {
      "sample_idx": 613,
      "input": "FINAL DIAGNOSIS: PART 1: FAT OVERLYING TUMOR, EXCISION -. A. BENIGN FIBROADIPOSE TISSUE. B. NO TUMOR SEEN. PART 2: CAPSULE OVERLYING TUMOR, EXCISION -. A. BENIGN FIBROADIPOSE TISSUE WITH CHRONIC INFLAMMATION. B. NO TUMOR SEEN. PART 3: LEFT KIDNEY TUMOR, PARTIAL NEPHRCTOMY -. A. PAPILLARY RENAL CELL CARCINOMA, TYPE 1, MAXIMAL FUHRMAN NUCLEAR GRADE 3 AND PREDOMINAIT. NUCLEAR GRADE 2 OUT OF 4 (See comment). B. TUMOR IS LIMITED TO THE KIDNEY AND MEASURES 2.2 x 1.9 x 0.8 CM. C. TUMOR IS FOCALLY PRESE...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Papillary renal cell carcinoma, type 1, maximal Fuhrman nuclear grade 3 and predominant. Nuclear grade 2 out of 4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Papillary renal cell carcinoma, type 1, maximal Fuhrman nuclear grade 3 and predominant. Nuclear grade 2 out of 4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Papillary renal cell carcinoma, type 1, maximal Fuhrman nuclear grade 3 and predominant. Nuclear grade 2 out of 4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Papillary renal cell carcinoma, type 1, maximal Fuhrman nuclear grade 3 and predominant. Nuclear grade 2 out of 4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Papillary renal cell carcinoma, type 1, maximal Fuhrman nuclear grade 3 and predominant. Nuclear grade 2 out of 4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Papillary renal cell carcinoma, type 1, maximal Fuhrman nuclear grade 3 and predominant. Nuclear grade 2 out of 4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Kidney. 2. Findings: Papillary renal cell carcinoma, type 1, maximal Fuhrman nuclear grade 3 and predominant. Nuclear grade 2 out of 4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 613,
      "timestamp": "2026-01-19T15:59:53.117340"
    },
    {
      "sample_idx": 212,
      "input": "Specimen #: Race: WHITE. Physician (s) : SPECIMEN: A: RIGHT BREAST B: SENTINEL NODE #1 C: SENTINEL NODE #2. D: SENTINEL NODE #3 E: SENTINEL NODE #4 F: left breast. FINAL DIAGNOSIS: A. RIGHT BREAST, SIMPLE MASTECTOMY. FIBROCYSTIC CHANGES TO INCLUDE FIBROADENOMAS, SCLEROSING ADENOSIS,. USUAL DUCTAL HYPERPLASIA, DUCT ECTASIA, CYSTIC CHANGE WITH APOCRINE. METAPLASIA. MICROCALCIFICATIONS IDENTIFIED IN BENIGN PROCESSES (A3) . SKIN AND NIPPLE WITH NO SIGNIFICANT PATHOLOGIC CHANGES. B. LYMPH NODE, SENTI...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, no special type, Nottingham Grade III, Nottingham Score 9/9. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, no special type, Nottingham Grade III, Nottingham Score 9/9. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, no special type, Nottingham Grade III, Nottingham Score 9/9. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, no special type, Nottingham Grade III, Nottingham Score 9/9. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, no special type, Nottingham Grade III, Nottingham Score 9/9. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, no special type, Nottingham Grade III, Nottingham Score 9/9. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, no special type, Nottingham Grade III, Nottingham Score 9/9. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, no special type, Nottingham Grade III, Nottingham Score 9/9. 3. Code",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, no special type, Nottingham Grade III, Nottingham Score 9/9. 3. Code: BRCA.",
      "idx": 212,
      "timestamp": "2026-01-19T15:59:53.117352"
    },
    {
      "sample_idx": 275,
      "input": "Addendum. Clinical Diagnosis & History. with transverse colon moderately differentiated. adenocarcinoma. Specimens Submitted: 1: SP: Right colon, hemicolectomy. DIAGNOSIS: 1. LARGE BOWEL; RIGHT HEMICOLECTOMY: - TUMOR TYPE: ADENOCARCINOMA. - HISTOLOGIC GRADE: MODERATELY DIFFERENTIATED. TUMOR LOCATION: ASCENDING COLON. - TUMOR SIZE: LENGTH IS 5.2 CM, WIDTH IS 4.1 CM, AND DEPTH IS 0.3 CM. - TUMOR INVASION: INVASION INTO MUSCULARIS PROPRIA. - GROSS TUMOR PERFORATION: NOT IDENTIFIED. - SEROSAL INVOLV...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: K",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Colon (Right Colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: KIRC.",
      "idx": 275,
      "timestamp": "2026-01-19T15:59:53.117361"
    },
    {
      "sample_idx": 1369,
      "input": "LAB #: (Age. DOS: LOC: Specimen (source): I. OMENTUM BIOPSY; II. RIGHT PARACOLIC TISSUE; III. LEFT PARACOLIC TISSUE; IV. UTERUS, CERVIX, TUBES AND OVARIES; V. SIGMOID SEROSA; VI. OMENTUM; VII. LEFT COMMON NODE. Clinical Data: ENDOMETRIAL CANCER. FROZEN SECTION: I. Received for FS labeled \"omentum biopsy\" is fatty tissue with a nodular. mass measuring 4 x 3.5 x 2.5 cm. The cut surface is partially necrotic, gritty and gray. RS for FS in one. block. Tissue is formalin fixed and frozen and submitte...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1369,
      "timestamp": "2026-01-19T15:59:53.117371"
    },
    {
      "sample_idx": 236,
      "input": "Final Surgical Pathology Report. Procedure. Diagnosis. A. Uterus, cervix, endomyometrium, parametria and upper vagina,. hysterectomy: Squamous cell carcinoma of the cervix, poorly differentiated, with. direct extension into uterine wall, parametrial and upper vaginal. tissues, size of mass 4.8 cm. Surgical margins uninvolved. Ovaries, right and left, resection: No carcinoma identified. Fallopian tubes, right and left, resection: No carcinoma identified. B. Right pelvic lymph nodes, resection: Me...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, endomyometrium, parametria and upper vagina. 2. Findings: Squamous cell carcinoma of the cervix, poorly differentiated, with direct extension into uterine wall, parametrial and upper vaginal tissues. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Right pelvic lymph nodes. 2. Findings: Metastatic squamous cell carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Left pelvic lymph nodes. 2. Findings: No carcinoma identified. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Periaortic lymph nodes. 2. Findings: No carcinoma identified. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, cervix, endomyometrium, parametria and upper vagina. 2. Findings: Squamous cell carcinoma of the cervix, poorly differentiated, with direct extension into uterine wall, parametrial and upper vaginal tissues. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right pelvic lymph nodes. 2. Findings: Metastatic squamous cell carcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left pelvic lymph nodes. 2. Findings: No carcinoma identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Periaortic lymph nodes. 2. Findings: No carcinoma identified. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\":",
      "predicted": "KIRC",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Uterus, cervix, endomyometrium, parametria and upper vagina. 2. Findings: Squamous cell carcinoma of the cervix, poorly differentiated, with direct extension into uterine wall, parametrial and upper vaginal tissues. 3. Code: KIRC.",
      "idx": 236,
      "timestamp": "2026-01-19T15:59:53.117384"
    },
    {
      "sample_idx": 219,
      "input": "IP <DIS IN C. Specimen: spec Type: SURGICAL P. PREOPERATIVE DIAGNOSES. LEFT BREAST CANCER INVASIVE. OPERATION PERFORMED. DOCTOR (s) : PROCEDURE: MASTECTOMY MODIFIED RADICAL. TISSUE REMOVED. A. LT BREAST AND AXILLARY TISSUE. B. ADDITIONAL LYMPH NODES LT AXILLA. GROSS DESCRIPTION. PART A RECEIVED FRESH LABELED. LEFT BREAST AND AXILLARY. CONTENTS SUTURE AT 12 O'CLOCK, AND CONSISTS OF A MODIFIED RADICAL. MASTECTOMY SPECIMEN WITH OVERALL DIMENSIONS OF 31 x 20.5 x 5.8 CM. THE. NIPPLE IS UNREMARKABLE A...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 219,
      "timestamp": "2026-01-19T15:59:53.117394"
    },
    {
      "sample_idx": 1379,
      "input": "f3. CLINICAL HISTORY: Malignant neocorpus uteri. GROSS EXAMINATION: A. \"Uterus, cervix, bilateral tubes and ovaries (AF1-2)\", received fresh for. frozen section and placed in formalin at. is a 368 gram,. 11.1 x 7.5 x 7.2 cm uterus with attached left ovary (3 x 2.2 x 1.5 cm), left. fimbriated fallopian tube (8.6 cm long x 0.5 cm in diameter), right ovary (3.7. x 2.7 x 1.6 cm), and right fimbriated fallopian tube (7.1 cm long x 0.5 cm in. diameter) The uterus was received open from the OR, chisele...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Well-differentiated endometrioid adenocarcinoma, grade 1. Tumor limited to endometrium. 3. Code: UTERUS WITH CERVIX, BILATERAL OVARIES AND FALLOPIAN TUBES maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: HILUS CELL TUMOR, MITOTICALLY ACTIVE CELLULAR FIBROMA. 3. Code: Left ovarian nodule maps to BRCA. Right ovarian nodule maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pelvic Lymph Node. 2. Findings: No tumor seen in one lymph node (0/1). 3. Code: Left pelvic lymph node maps to KIRC. Right pelvic lymph node maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: 6.6 CM LEIOMYOMA. 3. Code: UTERUS WITH CERVIX, BILATERAL OVARIES AND FALLOPIAN TUBES maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: MITOTICALLY ACTIVE CELLULAR FIBROMA. 3. Code: Left ovarian nodule maps to BRCA. Right ovarian nodule maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: No tumor seen in one lymph node (0/1). 3. Code: Left pelvic lymph node maps to UCEC. Right pelvic lymph node maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: No tumor seen in two lymph nodes (0/",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus. 2. Findings: Well-differentiated endometrioid adenocarcinoma, grade 1. Tumor limited to endometrium. 3. Code: UTERUS WITH CERVIX, BILATERAL OVARIES AND FALLOPIAN TUBES maps to UCEC.",
      "idx": 1379,
      "timestamp": "2026-01-19T15:59:53.117410"
    },
    {
      "sample_idx": 557,
      "input": "DIAGNOSIS. (A) LEFT KIDNEY: RENAL CELL CARCINOMA (2.7 CM MAXIMUM DIMENSION), CONVENTIONAL TYPE. (100% CLEAR CELLS),. FUHRMAN NUCLEAR GRADE 3, CONFINED TO THE KIDNEY. Margins of resection free of tumor. Adrenal cortical adenoma (1.7 cm maximum dimension). COMMENT. The renal cell carcinoma in the left kidney does not invade into the. perinephric adipose tissue, renal sinus adipose tissue, or the renal. vein. There is no metastatic renal cell carcinoma in the adrenal gland. GROSS DESCRIPTION. (A) L...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADRENAL\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Adrenal cortical adenoma. 3. Code: Adrenal cortical adenoma maps to ADRENAL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional type,",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 557,
      "timestamp": "2026-01-19T15:59:53.117421"
    },
    {
      "sample_idx": 577,
      "input": "Clinical Diagnosis & History: ith incidentally diagnosed right renal mass. Specimens Submitted: 1: SP: Kidney, right posterior mid pole, partial nephrecimy. DIAGNOSIS: 1. SP: Kidney, right posterior mid pole, partial nephrectmy. Tumor Type: Renal cell carcinoma = Conventional (clear cell) type. Fuhrman Nuclear Grade;. Nuclear grade III/IV. Tumor Size: Greatest diameter is 5.0 cm. Local Invasion (for renal cortical types): Not Identified. Renal Vein Invasion: Not identified. Small vessel angiolym...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right posterior mid pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney (Right posterior mid pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 577,
      "timestamp": "2026-01-19T15:59:53.117432"
    },
    {
      "sample_idx": 431,
      "input": "Case imported from legacy computer system. The format of this report does not match the original case. For cases prior to. the section \"SPECIMEN\" may have been added. SUPPLEMENTAL REPORT. DIAGNOSIS: (B). HARD PALATE: Bone and mucosa, no tumor present. Entire report and diagnosis completed bv: DIAGNOSIS. BUCCAL FAT BIOPSY: Adipose tissue, no tumor present. BONE FROM POSTERIOR WALL OF MAXILLA: Tissue submitted for decalcification. Supplemental report will. follow. PARTIAL MAXILLECTOMY AND HEMIPALA...",
      "response": "```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Hard Palate, Maxilla, Maxillary Sinus, Nasal Cavity, Teeth. 2. Findings: Invasive Squamous Cell Carcinoma, Grade 2, presence of perineural invasion, invasion, thickness area of tumor 2.5 cm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Hard Palate, Maxilla, Maxillary Sinus, Nasal Cavity, Teeth. 2. Findings: Invasive Squamous Cell Carcinoma, Grade 2, presence of perineural invasion, invasion, thickness area of tumor 2.5 cm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Hard Palate, Maxilla, Maxillary Sinus, Nasal Cavity, Teeth. 2. Findings: Invasive Squamous Cell Carcinoma, Grade 2, presence of perineural invasion, invasion, thickness area of tumor 2.5 cm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Hard Palate, Maxilla, Maxillary Sinus, Nasal Cavity, Teeth. 2. Findings: Invasive Squamous Cell Carcinoma, Grade 2, presence of perineural invasion, invasion, thickness area of tumor 2.5 cm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Hard Palate, Maxilla, Maxillary Sinus, Nasal Cavity, Teeth. 2. Findings: Invasive Squamous Cell Carcinoma, Grade 2, presence of perineural invasion, invasion, thickness area of tumor 2.5 cm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Hard Palate, Maxilla",
      "predicted": "SKCM",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Hard Palate, Maxilla, Maxillary Sinus, Nasal Cavity, Teeth. 2. Findings: Invasive Squamous Cell Carcinoma, Grade 2, presence of perineural invasion, invasion, thickness area of tumor 2.5 cm. 3. Code: SKCM maps to SKCM.",
      "idx": 431,
      "timestamp": "2026-01-19T15:59:53.117445"
    },
    {
      "sample_idx": 702,
      "input": "Anatomic Pathology/Cytology Document State: (version). Update Date/Time: Service Date/Time: Male Provider: Responsible Staff: Surgical Pathologv Report. Med: Rec. : Phone Number : Client: Phy Location: CLINICAL HISTORY. year old man has had mental status change. and. on. imaging has a right temporoparietal, partially cystic, and with calcification. large tumor. OPERATIVE DIAGNOSES. Not Given. Operation/Specimen: A: Brain, biopsy. B: Brain, resection, perm. PATHOLOGICAL DIAGNOSIS: A. Brain, site ...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma with focal anaplastic transformation. 3. Code: STAD (Brain Tumor) maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma with focal anaplastic transformation. 3. Code: U23 (Brain Tumor) maps to U23.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma with focal anaplastic transformation. 3. Code: U23 (Brain Tumor) maps to U23.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma with focal anaplastic transformation. 3. Code: U23 (Brain Tumor) maps to U23.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma with focal anaplastic transformation. 3. Code: U23 (Brain Tumor) maps to U23.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma with focal anaplastic transformation. 3. Code: U23 (Brain Tumor) maps to U23.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma with focal anaplastic transformation. 3. Code: U23 (Brain Tumor) maps to U23.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23\",\n    \"reasoning\": \"1. Site: Brain. 2.",
      "predicted": "STAD",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain. 2. Findings: Oligodendroglioma with focal anaplastic transformation. 3. Code: STAD (Brain Tumor) maps to STAD.",
      "idx": 702,
      "timestamp": "2026-01-19T15:59:53.117454"
    },
    {
      "sample_idx": 416,
      "input": "Diagnosis: Right frontal glioblastoma. Discussion: In the area of cellular tumor, less than 10% of the cells are immunoreactive for MGMT. Many of these are recognizable as endothelial cells. The neoplastic cells are negative for. MGMT expression. Microscopic Description: Sections demonstrate gray and white matter with cellular and diffusely infiltrating. astrocytoma. Tumor cells demonstrate generally moderate cytologic atypia. In. multicellular areas, numerous scattered mitotic figures are seen....",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Frontal lobe of the brain (Right). 2. Findings: Glioblastoma, a type of astrocytoma. The report mentions a high number of mitotic figures and necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right frontal lobe of the brain. 2. Findings: Glioblastoma, a type of astrocytoma. The report mentions a high number of mitotic figures and necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right frontal lobe of the brain. 2. Findings: Glioblastoma, a type of astrocytoma. The report mentions a high number of mitotic figures and necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right frontal lobe of the brain. 2. Findings: Glioblastoma, a type of astrocytoma. The report mentions a high number of mitotic figures and necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right frontal lobe of the brain. 2. Findings: Glioblastoma, a type of astrocytoma. The report mentions a high number of mitotic figures and necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right frontal lobe of the brain. 2. Findings: Glioblastoma, a type of astrocytoma. The report mentions a high number of mitotic figures and necrosis. 3. Code: Glioblastoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right frontal lobe of the brain. 2.",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Frontal lobe of the brain (Right). 2. Findings: Glioblastoma, a type of astrocytoma. The report mentions a high number of mitotic figures and necrosis. 3. Code: Glioblastoma maps to GBM.",
      "idx": 416,
      "timestamp": "2026-01-19T15:59:53.117466"
    },
    {
      "sample_idx": 540,
      "input": "DIAGNOSIS. (A) RIGHT KIDNEY: RENAL CELL CARCINOMA (7.0 CM MAXIMUM DIMENSION), CONVENTIONAL TYPE. (95% CLEAR CELLS,. 5% EOSINOPHILIC CELLS), FUHRMAN NUCLEAR GRADE 3, CONFINED TO. THE KIDNEY. (SEE COMMENT). Margins of resection free of tumor. COMMENT. The renal cell carcinoma in the right kidney does not invade into the. perinephric adipose tissue, renal sinus adipose tissue, or the renal. vein. GROSS DESCRIPTION. (A) RIGHT KIDNEY - A radical nephrectomy specimen, which includes the. perinephric f...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right Kidney.",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Right Kidney. 2. Findings: Renal cell carcinoma, conventional type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 540,
      "timestamp": "2026-01-19T15:59:53.117476"
    },
    {
      "sample_idx": 1035,
      "input": "Margins Involvement: Yes. Left posterior (slide C21). Linear Distance: Microscopic (<1mm). Frozen Performed: Lymph Nodes: Positive Right 1 /5 Left 3 /. Other Pathologic Findings: Chronic inflammation. Pathological Staging (pTNM): p. T 3b. N 1. Mx. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. GROSS DESCRIPTION: A. RIGHT PELVIC LYMPH NODES. Received in formalin labeled with the patient's identification and \"right pelvic lymph node\" are pieces of. yellow-tan soft ti...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, with lymph node involvement (Right 1 / 5, Left 3). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, with lymph node involvement (Right 1 / 5, Left 3). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, with lymph node involvement (Right 1 / 5, Left 3). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, with lymph node involvement (Right 1 / 5, Left 3). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, with lymph node involvement (Right 1 / 5, Left 3). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, with lymph node involvement (Right 1 / 5, Left 3). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Prostate cancer, with lymph node involvement (Right 1 / 5, Left 3). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```",
      "predicted": "KIRC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate. 2. Findings: Prostate cancer, with lymph node involvement (Right 1 / 5, Left 3). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 1035,
      "timestamp": "2026-01-19T15:59:53.117487"
    },
    {
      "sample_idx": 1249,
      "input": "Diagnosis: A: Thyroid, total thyroidectomy. Tumor histologic type: papillary thyroid carcinoma. Tumor size: 2.0 cm (gross), largest in any one slide 1.1 cm. Tumor growth pattern: papillary. Extent of invasion: Extra-capsular: not identified. Vascular: not identified. Tumor multicentricity: Multifocal. Surgical margins: Close, but negative (to <0.5 mm of the R lobe anterior margin (A1)). Background thyroid: Lymphocytic thyroiditis, nodular hyperplasia. Lymph nodes: Specimen A: metastatic papillar...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, multifocal. 3. Code: Thyroid maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma. 3. Code: Thyroid maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, multifocal. 3. Code: Thyroid maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, multifocal. 3. Code: Thyroid maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, multifocal. 3. Code: Thyroid maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, multifocal. 3. Code: Thyroid maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, multifocal. 3. Code: Thyroid maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, multifocal. 3. Code: Thyroid maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, multifocal. 3. Code: Thyroid maps to THYM.\"\n}\n```\n```json",
      "predicted": "THYM",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, multifocal. 3. Code: Thyroid maps to THYM.",
      "idx": 1249,
      "timestamp": "2026-01-19T15:59:53.117496"
    },
    {
      "sample_idx": 1279,
      "input": "UOD. Case type: Surgical Case. DIAGNOSIS. (A) TISSUE RIGHT INFERIOR THYROID POLE: Fragment of parathyroid tissue, no tumor present. (B) TISSUE, LEFT THYROID, SUPERIOR POLE: Fragment of parathyroid tissue, no tumor present. (C) TOTAL THYROID: PAPILLARY THYROID CARCINOMA, CONVENTIONAL TYPE. Location: Bilateral. Multi-focal: Yes. Size = 1.6 cm, left lobe and 0.4 cm right. Extrathyroidal extension: PRESENT (PART D). Lymph nodes: METASTATIC PAPILLARY THYROID CARCINOMA IN ONE LYMPH NODE (1/1). Locatio...",
      "response": "```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, conventional type. Location: Bilateral, multi-focal. Extrathyroidal extension: Present (part of the tumor). Lymph node involvement: Metastatic papillary thyroid carcinoma in one lymph node. 3. Code: TGCT corresponds to Thyroid Gland Tumors, which is a broad category that includes papillary thyroid carcinoma. The description of the tumor and its spread to lymph nodes aligns with the TGCT code.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, conventional type. Location: Bilateral, multi-focal. Extrathyroidal extension: Present (part of the tumor). Lymph node involvement: Metastatic papillary thyroid carcinoma in one lymph node. 3. Code: THCA corresponds to Thyroid Hormones, which is a broad category that includes thyroid gland tumors. The description of the tumor and its spread to lymph nodes aligns with the THCA code.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, conventional type. Location: Bilateral, multi-focal. Extrathyroidal extension: Present (part of the tumor). Lymph node involvement: Metastatic papillary thyroid carcinoma in one lymph node. 3. Code: UCSC corresponds to Uterine Corpus, which is a broad category that includes thyroid gland tumors. The description of the tumor and its spread to lymph nodes aligns with the UCSC code.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, conventional type. Location: Bilateral, multi-focal. Extrathyroidal extension: Present (part of the tumor). Lymph node involvement: Metastatic papillary thyroid carcinoma in one lymph node. 3. Code: UVM corresponds to Ureter, which is a broad category that includes thyroid gland tumors. The description of the tumor and its spread to lymph nodes aligns with the UVM code.\"\n}\n```\n```json\n{\n    \"cancer_type",
      "predicted": "TGCT",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, conventional type. Location: Bilateral, multi-focal. Extrathyroidal extension: Present (part of the tumor). Lymph node involvement: Metastatic papillary thyroid carcinoma in one lymph node. 3. Code: TGCT corresponds to Thyroid Gland Tumors, which is a broad category that includes papillary thyroid carcinoma. The description of the tumor and its spread to lymph nodes aligns with the TGCT code.",
      "idx": 1279,
      "timestamp": "2026-01-19T15:59:53.117514"
    },
    {
      "sample_idx": 104,
      "input": "SURGICAL REPORT. Sexc F. Date Collected: I. Date Received: M.R. Number. Doctor: Account Number. PRE-OPERATIVE DIAGNOSIS. RIGHT BREAST CANCER. POST-OPERATIVE DIAGNOSIS. RIGHT BREASTS CANCER. PROCEDURE. RIGHT SENTINEL LYMPH NODE BIOPSY. TISSUES. A. LYMPH NODE (S) - SENT NODE #1 \"FS. B. LYMPH NODE (S) - SENT NODE #2 FS. C. BREAST EXCISION,NEEDLE LOC,SIMPLE,MARGINS,ETC.- - RIGHT BREAST MASS. D. AXILLARY - AXILLARY CONTENTS. E. MARGINS - ADDITIONAL RIGHT BREAST TISSUE. F. MARGINS - ADDITIONAL LATERAL...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 104,
      "timestamp": "2026-01-19T15:59:53.117524"
    },
    {
      "sample_idx": 1375,
      "input": "CLINICAL HISTORY: Malignant neoplasm corpus uteri. GROSS EXAMINATION: A. \"Uterus, cervix, bilateral tubes and ovaries (AF1)\" received fresh for. frozen section is a 112 gram hysterectomy specimen with bilateral adnexa. The. uterine dimensions are 8.2 x 5.2 x 3.1 cm; the cervix is 2.7 cm in diameter. and the os diameter is 0.9 cm. The specimen is opened to demonstrate a 3.4. x. 2.5 x 2.2 cm exophytic, soft, friable mass involving the anterior and. posterior wall but sparing the fundus. The lesion...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma, FIGO grade 3, tumor size 3.4 x 2.5 x 2.2 cm, maximum depth of myometrial invasion 0.3 cm, no lymphatic/vascular invasion. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma, FIGO grade 3, tumor size 3.4 x 2.5 x 2.2 cm, maximum depth of myometrial invasion 0.3 cm, no lymphatic/vascular invasion. 3. Code: UCEC.",
      "idx": 1375,
      "timestamp": "2026-01-19T15:59:53.117536"
    },
    {
      "sample_idx": 1181,
      "input": "Gross. Microscopic. Diagnosis. Comments. Case ID. Description. Description. Details. Laterality. STOMACH TISSUE. Fundus. CHECKLIST. Specimen type: Gastrectomy. Tumor site: Fundus. Tumor size: 6 X 4.5 X 1.5. cm. Tumor features: None. specified. Histologic type: Adenocarcinoma, intestinal. type. Histologic grade: Moderately differentiated. Tumor extent: Adjacent. structures (specify) -. Lesser omentum. Lymph nodes: 2/7 positive. for metastasis. (Intraabdominal 2/7). Lymphatic invasion: Not. specif...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Fundus). 2. Findings: Adenocarcinoma, intestinal type. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Fundus). 2. Findings: Adenocarcinoma, intestinal type. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Fundus). 2. Findings: Adenocarcinoma, intestinal type. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Fundus). 2. Findings: Adenocarcinoma, intestinal type. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Fundus). 2. Findings: Adenocarcinoma, intestinal type. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Fundus). 2. Findings: Adenocarcinoma, intestinal type. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Fundus). 2. Findings: Adenocarcinoma, intestinal type. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Stomach (Fundus). 2. Findings: Adenocarcinoma, intestinal type. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",",
      "predicted": "ADENOMA",
      "ground_truth": "STAD",
      "correct": false,
      "reasoning": "1. Site: Stomach (Fundus). 2. Findings: Adenocarcinoma, intestinal type. 3. Code: ADENOMA maps to ADENOMA.",
      "idx": 1181,
      "timestamp": "2026-01-19T15:59:53.117547"
    },
    {
      "sample_idx": 566,
      "input": "Clinical Diagnosis & History: Left kidney tumor. Left partial nephrectomy. Specimens Submitted: 1: SP: Left renal hilar lymph nodes. 2: SP: Left kidney mass. DIAGNOSIS: 1). LYMPH NODES, LEFT RENAL HILAR; EXCISION: - THREE BENIGN LYMPH NODES (0/3). 2). KIDNEY, LEFT; PARTIAL NEPHRECTOMY: - RENAL CELL CARCINOMA, CONVENTIONAL (CLEAR CELL) TYPE,. NUCLEAR GRADE II/IV. - THE PATTERN OF GROWTH IS ACINAR. .. THE TUMOR'S GREATEST DIAMETER IS 6.3 CM. - THE TUMOR IS CONFINED WITHIN THE RENAL CAPSULE. - ALL ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"K",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney (Left). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 566,
      "timestamp": "2026-01-19T15:59:53.117558"
    },
    {
      "sample_idx": 90,
      "input": "surgical Pathology Report. (Age. F. Pathologic Interpretation: A. SENTINEL NODE COUNT 0 AXILLA, FS: No malignancy seen in one lymph node (0/1). Immunohlstochemistry for keratin to follow. B. SENTINEL NODE COUNT 609 AXILLA, FS: No malignancy seen in one lymph node (0/1). Immunohistochemistry for keratin to follow. c. LEFT BREAST MASTECTOMY SINGLE SUTURE SUPERIOR, DOUBLE SUTURE MEDIAL: INVASIVE LOBULAR CARCINOMA, high nuclear grade, 7.0 cm (gross examination). Previous biopsy site. No lymphovascul...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, high nuclear grade, 7.0 cm (gross examination). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, high nuclear grade, 7.0 cm (gross examination). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, high nuclear grade, 7.0 cm (gross examination). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, high nuclear grade, 7.0 cm (gross examination). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, high nuclear grade, 7.0 cm (gross examination). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, high nuclear grade, 7.0 cm (gross examination). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, high nuclear grade, 7.0 cm (gross examination). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, high nuclear grade, 7.0 cm (gross examination). 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive lobular carcinoma, high nuclear grade, 7.0 cm (gross examination). 3. Code: BRCA.",
      "idx": 90,
      "timestamp": "2026-01-19T15:59:53.117569"
    },
    {
      "sample_idx": 7,
      "input": "Procedure: adrenalectomy and nephrectomy. Gross description: 25 X 17 X 8.5cm with 18cm tumor. Reference Pathology only: Diagnosis: adrenocortical carcinoma, KI67 10%. Weiss score: 7. Hough score: 5.58. Van Slooten score: 22.7.",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Adrenal gland (Cortex). 2. Findings: Adrenocortical carcinoma, KI67 10%, Weiss score 7, Hough score 5.58, Van Slooten score 22.7. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Adrenal gland (Cortex). 2. Findings: Adrenocortical carcinoma, KI67 10%, Weiss score 7, Hough score 5.58, Van Slooten score 22.7. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Adrenal gland (Cortex). 2. Findings: Adrenocortical carcinoma, KI67 10%, Weiss score 7, Hough score 5.58, Van Slooten score 22.7. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Adrenal gland (Cortex). 2. Findings: Adrenocortical carcinoma, KI67 10%, Weiss score 7, Hough score 5.58, Van Slooten score 22.7. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Adrenal gland (Cortex). 2. Findings: Adrenocortical carcinoma, KI67 10%, Weiss score 7, Hough score 5.58, Van Slooten score 22.7. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Adrenal gland (Cortex",
      "predicted": "KIRC",
      "ground_truth": "ACC",
      "correct": false,
      "reasoning": "1. Site: Adrenal gland (Cortex). 2. Findings: Adrenocortical carcinoma, KI67 10%, Weiss score 7, Hough score 5.58, Van Slooten score 22.7. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 7,
      "timestamp": "2026-01-19T15:59:53.117580"
    },
    {
      "sample_idx": 683,
      "input": "Component. Tissue. Index. Ethnicity. Clinical. Tumor. Specimen. Specimen. Number of. Type of. Histological. of treatment. /. Anatomical Site. Specificati. Container. Amount/per. Grade. Matrix. Procureme. TNM Stage. TNM Stage. Format. container. description. TNM Stage. Treatment. Tumor cell. (Race). Diagnosis. containers. (Chemo. (source). (T). (N). (M). type. %. on. nt. (Source). Horm Th. Details). Brain,both w. Caucasia. male. Glioma. frantal lobes. Primary. Tumor. n (White). Tissue. OCT. block...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (both cerebral lobes). 2. Findings: Anaplastic astrocytoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Brain (both cerebral lobes). 2. Findings: Anaplastic astrocytoma. 3. Code: UVM maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Brain (both cerebral lobes). 2. Findings: Anaplastic astrocytoma. 3. Code: BLCA maps to BLCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (both cerebral lobes). 2. Findings: Anaplastic astrocytoma. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Brain (both cerebral lobes). 2. Findings: Anaplastic astrocytoma. 3. Code: UVM maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (both cerebral lobes). 2. Findings: Anaplastic astrocytoma. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (both cerebral lobes). 2. Findings: Anaplastic astrocytoma. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (both cerebral lobes). 2. Findings: Anaplastic astrocytoma. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain (both cerebral lobes). 2. Findings: Anaplastic astrocytoma. 3. Code: GBM maps to GBM.",
      "idx": 683,
      "timestamp": "2026-01-19T15:59:53.117589"
    },
    {
      "sample_idx": 267,
      "input": "Female. Surgery Date: DIAGNOSIS: A. Lymph nodes, hepatic hilar, biopsy: Multiple (4) lymph nodes are. negative for tumor. B. Hepatic duct, left margin, excision: Negative for tumor. c. Liver, left lobe, partial hepatectomy: Cholangiocarcinoma, moderately. differentiated (grade 2 of 4), forming two masses, ranging from 1.5 cm to 0.9 cm in. greatest microscopic dimension. Multiple additional microscopic foci of periductal. infiltrating carcinoma along the duct associated with moderate to severe dy...",
      "response": "```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Hepatic hilar lymph nodes, left hepatic duct margin, left lobe of liver. 2. Findings: Cholangiocarcinoma, moderately differentiated (grade 2 of 4), forming two masses, ranging from 1.5 cm to 0.9 cm in greatest microscopic dimension. Multiple additional microscopic foci of periductal infiltrating carcinoma along the duct associated with moderate to severe dysplasia are present. The tumor is confined to hepatic parenchyma. The hepatic parenchymal resection margin is negative for tumor (tumor-free margin, 4.5 cm grossly). Major vessel invasion is absent. Microscopic (small vessel) invasion is absent. No regional lymph nodes identified in specimen. The non-neoplastic hepatic parenchyma will be reviewed on permanent sections with special stains and the result will be reported in an addendum. D. Gallbladder, cholecystectomy: Benign gallbladder with chronic inflammation. 3. Code: CHOL (Cholangiocarcinoma) maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Hepatic hilar lymph nodes, left hepatic duct margin, left lobe of liver. 2. Findings: Cholangiocarcinoma, moderately differentiated (grade 2 of 4), forming two masses, ranging from 1.5 cm to 0.9 cm in greatest microscopic dimension. Multiple additional microscopic foci of periductal infiltrating carcinoma along the duct associated with moderate to severe dysplasia are present. The tumor is confined to hepatic parenchyma. The hepatic parenchymal resection margin is negative for tumor (tumor-free margin, 4.5 cm grossly). Major vessel invasion is absent. Microscopic (small vessel) invasion is absent. No regional lymph nodes identified in specimen. The non-neoplastic hepatic parenchyma will be reviewed on permanent sections with special stains and the result will be reported in an addendum. D. Gallbladder, cholecystectomy: Benign gallbladder with chronic inflammation. 3. Code: CHOL (Cholangiocarcinoma) maps to CHOL.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CHOL\",\n    \"reasoning\": \"1. Site: Hepatic hilar lymph nodes, left hepatic duct margin, left lobe of liver. 2. Findings: Cholangiocarcinoma, moderately differentiated (grade ",
      "predicted": "CHOL",
      "ground_truth": "CHOL",
      "correct": true,
      "reasoning": "1. Site: Hepatic hilar lymph nodes, left hepatic duct margin, left lobe of liver. 2. Findings: Cholangiocarcinoma, moderately differentiated (grade 2 of 4), forming two masses, ranging from 1.5 cm to 0.9 cm in greatest microscopic dimension. Multiple additional microscopic foci of periductal infiltrating carcinoma along the duct associated with moderate to severe dysplasia are present. The tumor is confined to hepatic parenchyma. The hepatic parenchymal resection margin is negative for tumor (tumor-free margin, 4.5 cm grossly). Major vessel invasion is absent. Microscopic (small vessel) invasion is absent. No regional lymph nodes identified in specimen. The non-neoplastic hepatic parenchyma will be reviewed on permanent sections with special stains and the result will be reported in an addendum. D. Gallbladder, cholecystectomy: Benign gallbladder with chronic inflammation. 3. Code: CHOL (Cholangiocarcinoma) maps to CHOL.",
      "idx": 267,
      "timestamp": "2026-01-19T15:59:53.117617"
    },
    {
      "sample_idx": 536,
      "input": "Clinical Diagnosis & History: 4. Vith right renal mass. Specimens Submitted: 1: Kidney, right; partial nephrectomy. DIAGNOSIS: 1. Kidney, right; partial nephrectomy: Tumor Type: Renal cell carcinoma - Conventional (clear cell) type. Fuhrman Nuclear Grade: Nuclear grade III/IV. Tumor Size: Greatest diameter is 1.9 cm. Local Invasion (for renal cortical types): Not Identified. Renal Vein Invasion: Not applicable. Surgical Margins: Free of tumor. Non-Neoplastic Kidney: Unremarkable. Adrenal Gland: ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. Tumor Size: 1.9 cm. Local Invasion: Not identified. Renal Vein Invasion: Not applicable. Surgical Margins: Clear. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. Tumor Size: 1.9 cm. Local Invasion: Not identified. Renal Vein Invasion: Not applicable. Surgical Margins: Clear. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. Tumor Size: 1.9 cm. Local Invasion: Not identified. Renal Vein Invasion: Not applicable. Surgical Margins: Clear. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. Tumor Size: 1.9 cm. Local Invasion: Not identified. Renal Vein Invasion: Not applicable. Surgical Margins: Clear. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. Tumor Size: 1.9 cm. Local Invasion: Not identified. Renal Vein Invasion: Not applicable. Surgical Margins: Clear. 3. Code: Kidney Renal Clear Cell Carcinoma maps to",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade III/IV. Tumor Size: 1.9 cm. Local Invasion: Not identified. Renal Vein Invasion: Not applicable. Surgical Margins: Clear. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 536,
      "timestamp": "2026-01-19T15:59:53.117632"
    },
    {
      "sample_idx": 1255,
      "input": "Date or Procedure: Clinical Diagnosis & History: year old male with FNA papillary on left thyroid nodule. Specimens Submitted: 1: SP: Right paratracheal lymph node (fs). 2: SP: Total thyroidectomy. DIAGNOSIS: 1. SP: Right paratracheal lymph node (fs): Lymph Node Dissection: Number of lymph nodes examined: 2. Number of lymph nodes with metastatic disease: 0. 2. SP: Total thyroldectomy: Tumor Type: Papillary microcarcinoma with tall cell features. Histologic Grade: Well differentiated. Mitotic Act...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Paratracheal lymph node. 2. Findings: Lymph node dissection reveals no metastatic disease. The total thyroidectomy shows a papillary microcarcinoma with tall cell features, well differentiated, grade II, with a separate focus of papillary microcarcinoma in the right lobe. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) does not map to this case, but KIRC is a valid TCGA code and the most appropriate given the presence of thyroid cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary microcarcinoma with tall cell features. 3. Code: BRCA (Breast Invasive Carcinoma) does not map to this case, but BRCA is a valid TCGA code and the most appropriate given the presence of thyroid cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary microcarcinoma with tall cell features. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) does not map to this case, but KIRC is a valid TCGA code and the most appropriate given the presence of thyroid cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary microcarcinoma with tall cell features. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) does not map to this case, but KIRC is a valid TCGA code and the most appropriate given the presence of thyroid cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary microcarcinoma with tall cell features. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) does not map to this case, but KIRC is a valid TCGA code and the most appropriate given the presence of thyroid cancer.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site",
      "predicted": "KIRC",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Paratracheal lymph node. 2. Findings: Lymph node dissection reveals no metastatic disease. The total thyroidectomy shows a papillary microcarcinoma with tall cell features, well differentiated, grade II, with a separate focus of papillary microcarcinoma in the right lobe. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) does not map to this case, but KIRC is a valid TCGA code and the most appropriate given the presence of thyroid cancer.",
      "idx": 1255,
      "timestamp": "2026-01-19T15:59:53.117650"
    },
    {
      "sample_idx": 904,
      "input": "MRNT. serviter. Data of Procedure: (Ager. M. Physiciam. Clinical Diagnosis & History. year old male with malignant mesothelioma epithelioid type. Specimens Submitted: 1: Right pleura. 2: Biopay level eight mediastinal lymph node (fs). 3, Biopay lovel neven mediastinal lymph node (fs). 4: Right leyal four mediastinal lymph node (fa). 5: Portion of right aixth rib. 6: Level seven mediastinal lymph node. 71 Right level four mediastinal lymph node. B, Level eight mediastinal lymph node. DIAGNOSIS. 1...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pleura (Right). 2. Findings: Malignant mesothelioma, epithelioid type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mediastinal Lymph Node (Level 8). 2. Findings: Malignant mesothelioma, epithelioid type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mediastinal Lymph Node (Level 7). 2. Findings: Malignant mesothelioma, epithelioid type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mediastinal Lymph Node (Level 4). 2. Findings: Malignant mesothelioma, epithelioid type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rib (Right, Sixth). 2. Findings: Malignant mesothelioma, epithelioid type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mediastinal Lymph Node (Level 7). 2. Findings: Malignant mesothelioma, epithelioid type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mediastinal Lymph Node (Level 4). 2. Findings: Malignant mesothelioma, epithelioid type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Mediastinal Lymph Node (Level 8). 2. Findings: Malignant mesothelioma, epithelioid type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    ",
      "predicted": "KIRC",
      "ground_truth": "MESO",
      "correct": false,
      "reasoning": "1. Site: Pleura (Right). 2. Findings: Malignant mesothelioma, epithelioid type. 3. Code: KIRC.",
      "idx": 904,
      "timestamp": "2026-01-19T15:59:53.117660"
    },
    {
      "sample_idx": 875,
      "input": "Anat Path Reports. Document Date: APRPT (Verified). Final Surgical Pathology Report. Final Pathologic Diagnosis. A. LYMPH NODE, #7, EXCISON, A1FS: ONE LYMPH NODE NEGATIVE FOR METASTATIC CARCINOMA (0/1). B. LYMPH NODE, #4R, EXCISON, B1FS: - ONE LYMPH NODE NEGATIVE FOR METASTATIC CARCINOMA (0/1). C. LYMPH NODE, 11R, EXCISON: - ONE LYMPH NODE NEGATIVE FOR METASTATIC CARCINOMA (0/1). D. LYMPH NODE, LEVEL 7#, EXCISION: - ONE LYMPH NODE NEGATIVE FOR METASTATIC CARCINOMA (0/1). E. RIGHT LUNG, PNEUMONEC...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: ESCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node. 2. Findings: Negative for metastatic carcinoma. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: ESCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node. 2. Findings: Negative for metastatic carcinoma. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node. 2. Findings: Negative for metastatic carcinoma. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node. 2. Findings: Negative for metastatic carcinoma. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: ESCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node. 2. Findings: Negative for metastatic carcinoma. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node. 2. Findings: Negative for metastatic carcinoma. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer",
      "predicted": "ADENOCA",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: ESCA.",
      "idx": 875,
      "timestamp": "2026-01-19T15:59:53.117670"
    },
    {
      "sample_idx": 1096,
      "input": "Diagnosis/diagnoses: Resected colon and rectum show tumor-free oral, aboral and perirectal resection margins,. with an ulcerated, moderately differentiated, abundant mucus-forming adenocarcinoma. with infiltration of the perimuscular fatty tissue (G2, pT3, pNO 0/25 LO V0 R0, distance of. the tumor to the perirectal resection margin is at least 1.6 cm) and with a recent ulcerous. mucosal defect located directly orally of the carcinoma (with possible status post. endoscopic excision of an adenoma)...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon and Rectum. 2. Findings: Adenocarcinoma, ulcerated, moderately differentiated, abundant mucus-forming. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"READ\",\n    \"reasoning\": \"1. Site: Colon and Rectum. 2. Findings: Adenocarcinoma, ulcerated, moderately differentiated, abundant mucus-forming. 3. Code: READ maps to Rectal Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon and Rectum. 2. Findings: Adenocarcinoma, ulcerated, moderately differentiated, abundant mucus-forming. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon and Rectum. 2. Findings: Adenocarcinoma, ulcerated, moderately differentiated, abundant mucus-forming. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon and Rectum. 2. Findings: Adenocarcinoma, ulcerated, moderately differentiated, abundant mucus-forming. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon and Rectum. 2. Findings: Adenocarcinoma, ulcerated, moderately differentiated, abundant mucus-forming. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon and Rectum. 2. Findings: Adenocarcinoma, ulcerated, moderately differentiated, abundant mucus-forming. 3. Code: COAD maps to Colon Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon and Rectum. 2. Findings: Aden",
      "predicted": "COAD",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Colon and Rectum. 2. Findings: Adenocarcinoma, ulcerated, moderately differentiated, abundant mucus-forming. 3. Code: COAD maps to Colon Adenocarcinoma.",
      "idx": 1096,
      "timestamp": "2026-01-19T15:59:53.117682"
    },
    {
      "sample_idx": 1259,
      "input": "Pathology. port. P. Sex: -. Case type: Surgical Case. DIAGNOSIS. (A) TOTAL THYROIDECTOMY: PAPILLARY THYROID CARCINOMA IN RIGHT LOBE (3.8 CM). PAPILLARY THYROID CARCINOMA IN LEFT LOBE (LESS THAN 0.1 CM). Definitive lymphovascular invasion is not identified. Margins grossly free of tumor. Entire report and diagnosis completed by I. GROSS DESCRIPTION. (A) TOTAL THYROIDECTOMY - A total thyroidectomy product consisting of a right lobe (3.5 x 1.5 x 1.0 cm), unremarkable. isthmus (1.0x 1.0 x 0.3 cm), a...",
      "response": "```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, right lobe (3.8 cm), left lobe (less than 0.1 cm). 3. Code: THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, right lobe (3.8 cm), left lobe (less than 0.1 cm). 3. Code: THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, right lobe (3.8 cm), left lobe (less than 0.1 cm). 3. Code: THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, right lobe (3.8 cm), left lobe (less than 0.1 cm). 3. Code: THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, right lobe (3.8 cm), left lobe (less than 0.1 cm). 3. Code: THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, right lobe (3.8 cm), left lobe (less than 0.1 cm). 3. Code: THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, right lobe (3.8 cm), left lobe (less than 0.1 cm). 3. Code: THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"",
      "predicted": "THCA",
      "ground_truth": "THCA",
      "correct": true,
      "reasoning": "1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, right lobe (3.8 cm), left lobe (less than 0.1 cm). 3. Code: THCA.",
      "idx": 1259,
      "timestamp": "2026-01-19T15:59:53.117692"
    },
    {
      "sample_idx": 1241,
      "input": "Head & Neck. Head And Neck. Clinical Diagrosis & History: year ok. with history of thyroid nodule FNA CW left nodule-atypical cells follicular, B. nodules on ultrasound. Specimens Submitted: 1: SP: Thyroid, left lobe and isthmus, hemithyroidectomy. 2: SP: Right thyroid lobe. DIAGNOSIS: 1. SP: Thyroid, left lobe and isthmus, hemithyroidectomy: Tumor Type: Papillary carcinoma, follicular variant. Histologic Grade: Well differentiated. Mitotic Activity: Not identified. Tumor Necrosis: Not identifie...",
      "response": "```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Head & Neck. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Head & Neck. 2. Findings: Thyroid with nodular hyperplasia. 3. Code: UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Head & Neck. 2. Findings: No parathyroid glands are identified. 3. Code: UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Head & Neck. 2. Findings: One benign lymph node (0/1). 3. Code: UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Head & Neck. 2. Findings: The specimen is entirely submitted. 3. Code: UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Head & Neck. 2. Findings: A photograph is taken of Nodule 1. 3. Code: UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Head & Neck. 2. Findings: Summary of sections: N1 - nodule 1 and surrounding thyroid tissue. N2 nodule 2. 3. Code: UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Head & Neck. 2. Findings: Summary of sections: Part 1: SP: Thyroid, left lobe and isthmus, hemithyroidectomy. Block. Sect. Site. PCs. 2. M. 2. 2. N1. 2. 3. N2. 4. 1. S. 1. Part 2:",
      "predicted": "HNSC",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Head & Neck. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: HNSC.",
      "idx": 1241,
      "timestamp": "2026-01-19T15:59:53.117701"
    },
    {
      "sample_idx": 305,
      "input": "LARGE INTESTINE TISSUE. CHECKLIST. Specimen type: Partial colectomy. Specimen size: Not specified. Tumor site: Ascending colon. Tumor size: 0 X 0 X 8.5 cm. Tumor features: Ulcerated. Histologic type: Adenocarcinoma. Histologic grade: Moderately. differentiated. Tumor extent: Subserosa. Lymph nodes: 0/12 positive for. metastasis (Adjacent fatty tissue. 0/12). Margins: Uninvolved. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not. specified. Comments: None.",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine (Ascending colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Adenocarcinoma of the large intestine maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIRG\",\n    \"reasoning\": \"1. Site: Large intestine (Ascending colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Adenocarcinoma of the large intestine maps to LIRG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine (Ascending colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Adenocarcinoma of the large intestine maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine (Ascending colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Adenocarcinoma of the large intestine maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine (Ascending colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Adenocarcinoma of the large intestine maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine (Ascending colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Adenocarcinoma of the large intestine maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine (Ascending colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Adenocarcinoma of the large intestine maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Large intestine (Ascending colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Adenocarcinoma of the large intestine",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Large intestine (Ascending colon). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Adenocarcinoma of the large intestine maps to COAD.",
      "idx": 305,
      "timestamp": "2026-01-19T15:59:53.117714"
    },
    {
      "sample_idx": 73,
      "input": "SPECIMENS: A. SUBAREOLAR TISSUE RIGHT BREAST. B. SENTINEL LYMPH NODE #1 RIGHT AXILLA. C. SENTINEL LYMPH NODE #2 RIGHT AXILLA. D. SENTINEL LYMPH NODE #3 RIGHT AXILLA. E. SENTINEL LYMPH NODE #4 RIGHT AXILLA. F. RIGHT BREAST. G. LEFT BREAST SKIN. SPECIMEN(S): A. SUBAREOLAR TISSUE RIGHT BREAST. B. SENTINEL LYMPH NODE #1 RIGHT AXILLA. C. SENTINEL LYMPH NODE #2 RIGHT AXILLA. D. SENTINEL LYMPH NODE #3 RIGHT AXILLA. E. SENTINEL LYMPH NODE #4 RIGHT AXILLA. F. RIGHT BREAST. G. LEFT BREAST SKIN. GROSS DESC...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 73,
      "timestamp": "2026-01-19T15:59:53.117724"
    },
    {
      "sample_idx": 1085,
      "input": "Subject. LARGE INTESTINE TISSUE. CHECKLIST. Specimen type: Resection of. rectum. Specimen size: Not specified. Tumor site: Rectum. Tumor size: 15 X 7.5 X 10 cm. Tumor features: None specified. Histologic type: Adenocarcinoma. Histologic grade: Moderately. differentiated. Tumor extent: Pericolonic tissues. Lymph nodes: Not specified. Margins: Not specified. Evidence of neo-adjuvant. treatment: Not specified. Additional pathologic findings: Not. specified. Comments: None.",
      "response": "```json\n{\n    \"cancer_type\": \"LIRG\",\n    \"reasoning\": \"1. Site: Large Intestine (Rectum). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Large Intestine Rectum maps to LIRG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIRG\",\n    \"reasoning\": \"1. Site: Large Intestine (Rectum). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Large Intestine Rectum maps to LIRG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIRG\",\n    \"reasoning\": \"1. Site: Large Intestine (Rectum). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Large Intestine Rectum maps to LIRG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIRG\",\n    \"reasoning\": \"1. Site: Large Intestine (Rectum). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Large Intestine Rectum maps to LIRG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIRG\",\n    \"reasoning\": \"1. Site: Large Intestine (Rectum). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Large Intestine Rectum maps to LIRG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIRG\",\n    \"reasoning\": \"1. Site: Large Intestine (Rectum). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Large Intestine Rectum maps to LIRG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIRG\",\n    \"reasoning\": \"1. Site: Large Intestine (Rectum). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Large Intestine Rectum maps to LIRG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIRG\",\n    \"reasoning\": \"1. Site: Large Intestine (Rectum). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code:",
      "predicted": "LIRG",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Large Intestine (Rectum). 2. Findings: Adenocarcinoma, moderately differentiated. 3. Code: Large Intestine Rectum maps to LIRG.",
      "idx": 1085,
      "timestamp": "2026-01-19T15:59:53.117734"
    },
    {
      "sample_idx": 303,
      "input": "Diagnosis/ diagnoses. Right hemicolectomy preparation with a colon carcinoma characterized histologically as a. moderately differentiated colorectal adenocarcinoma, located 6 cm from Bauhin's valve,. and measuring a max of 2 cm in diameter. Invasive spreading of the tumor up to the level. of the submucosa. Appendix with postinflammatory fibrosis of the wall and fibrous apical obliteration. Oral and aboral resection margins are tumor-free as is the greater omentum. 31 mesocolic and mesenteric lym...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated. 3. Code: KIRC",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated. 3. Code: COAD maps to COAD.",
      "idx": 303,
      "timestamp": "2026-01-19T15:59:53.117743"
    },
    {
      "sample_idx": 880,
      "input": "with persistent lung infiltrates. Precarinal lymph node measures. approximately 1.2 cm. anterior to posterior, 7.0 cm. transversely, and 1.0 cm. in length. A right hilar lymph node. is 1.0 cm. in short axis diameter. Left hilar lymph node is 0.5 cm. in diameter. PRE OP DIAGNOSIS: Lung nodule. POST OP DIAGNOSIS: Same. PROCEDURE: Bronchoscopy with mediastinoscopy. FINAL DIAGNOSIS. Summary Statement. The right lower lobe neoplasm is an inv\u00e1sive moderately differentiated squamous cell carcinoma meas...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Invasive moderately differentiated squamous cell carcinoma, T1N0MX. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Level 7, Right). 2. Findings: Benign reactive lymph nodes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Level 7, Left). 2. Findings: Benign reactive lymph nodes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Right Level 4). 2. Findings: Benign reactive lymph nodes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Level 3). 2. Findings: Benign reactive lymph nodes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Station 9). 2. Findings: Benign reactive lymph nodes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Station 7). 2. Findings: Benign reactive lymph nodes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Level 9). 2. Findings: Benign reactive lymph nodes. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Station 7). 2. Findings: Benign reactive lymph nodes.",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung (Right Lower Lobe). 2. Findings: Invasive moderately differentiated squamous cell carcinoma, T1N0MX. 3. Code: LUAD.",
      "idx": 880,
      "timestamp": "2026-01-19T15:59:53.117755"
    },
    {
      "sample_idx": 261,
      "input": "PRIMARY SITE: Cervix. 1 - \"Biopsy of cervix\": Invasive squamous cell carcinoma.",
      "response": "```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CESC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to CESC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"CESC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to CESC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to HNSC",
      "predicted": "HNSC",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to HNSC.",
      "idx": 261,
      "timestamp": "2026-01-19T15:59:53.117764"
    },
    {
      "sample_idx": 85,
      "input": "Working Draft. CELLULAR CHANGES WITHIN NORMAL LIMITS. Inflammation. SPECIMEN ADEQUACY: Satisfactory for evaluation. Endocervical cells present. Specimen Class: Accessioned: Specimen(s) Received: Endometrium, biopsy. Final Diagnosis. Endometrium, biopsy: Benign dyssynchronous secretory endometrium; no hyperplasia or carcinoma. identified. Specimen Class: Accessioned: Signed Out: (. Specimen(s) Received: Cervical. Endocervical, Direct. Final Diagnosis. Cervical/Endocervical, Direct. CELLULAR CHANG...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 85,
      "timestamp": "2026-01-19T15:59:53.117773"
    },
    {
      "sample_idx": 631,
      "input": "Papillary Renal Cell Carcinoma, Type I, moderately differentiated. Stage: pT1b, RO. Grade: GII. ICD-0-Code: 8260/3.",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, Type I, moderately differentiated. Stage: pT1b, RO. Grade: GII. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, Type I, moderately differentiated. Stage: pT1b, RO. Grade: GII. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, Type I, moderately differentiated. Stage: pT1b, RO. Grade: GII. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, Type I, moderately differentiated. Stage: pT1b, RO. Grade: GII. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, Type I, moderately differentiated. Stage: pT1b, RO. Grade: GII. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, Type I, moderately differentiated. Stage: pT1b, RO. Grade: GII. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, Type I, moderately differentiated. Stage: pT1b, RO. Grade: GII. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 631,
      "timestamp": "2026-01-19T15:59:53.117784"
    },
    {
      "sample_idx": 746,
      "input": "SP Final Report. SP Final Report. Service Date: Authored By: Diagnosis. 1. LIVER, EXTENDED RIGHT LOBE, RESECTION: - HEPATOCELLULAR CARCINOMA, GRADE III, 15.2 X 13.5 X 13.2 CM. - SURGICAL MARGINS ARE NEGATIVE FOR CARCINOMA. - ADJACENT LIVER SHOWING CHOLESTASIS AND FIBROSIS. - DISTANT NON-NEOPLASTIC LIVER SHOWING NO PATHOLOGIC ABNORMALITY. - SEE SYNOPTIC REPORT AND COMMENT. 2. GALLBLADDER, CHOLECYSTECTOMY: - UNREMARKABLE GALLBLADDER. - ONE BENIGN LYMPH NODE, NEGATIVE FOR MALIGNANCY (0/1). - NO EVI...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, extended right lobe. 2. Findings: Hepatocellular carcinoma, grade III. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, extended right lobe. 2. Findings: Hepatocellular carcinoma, grade III. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, extended right lobe. 2. Findings: Hepatocellular carcinoma, grade III. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, extended right lobe. 2. Findings: Hepatocellular carcinoma, grade III. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, extended right lobe. 2. Findings: Hepatocellular carcinoma, grade III. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, extended right lobe. 2. Findings: Hepatocellular carcinoma, grade III. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, extended right lobe. 2. Findings: Hepatocellular carcinoma, grade III. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, extended right lobe. 2. Findings: Hepatocellular carcinoma, grade III. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, extended right lobe.",
      "predicted": "KIRC",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Liver, extended right lobe. 2. Findings: Hepatocellular carcinoma, grade III. 3. Code: KIRC.",
      "idx": 746,
      "timestamp": "2026-01-19T15:59:53.117794"
    },
    {
      "sample_idx": 1112,
      "input": "Clinical Diagnosis & History: Palpable mass. CT demonstrated a 15 x 11.5 cm retroperitoneal mass adjacent. An 7/24/><. to the left kidney. Core biopsy showed dedifferentiatec liposarcoma. Specimens Submitted: 1: SP: Retroperitoneal sarcoma, left kidney, spleen, adrenal left colon and. distal pancreas. DIAGNOSIS: 1). KIDNEY, ADRENAL GLAND AND COLON, LEFT, SPLEEN, AND DISTAL. PANCREAS, RETROPERITONEAL MASS, EXTENSIVE RESECTION: DEDIFFERENTIATED LIPOSARCOMA, HIGH GRADE. - WELL DIFFERENTIATED LIPOSA...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear",
      "predicted": "KIRC",
      "ground_truth": "SARC",
      "correct": false,
      "reasoning": "1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 1112,
      "timestamp": "2026-01-19T15:59:53.117805"
    },
    {
      "sample_idx": 732,
      "input": "CLINICAL DIAGNOSIS: HCC. Specimen : Liver. Gross Photo : GROSS: Specimen status: Fresh. Operation: Right posterior sectionectomy. Organ: Liver (13.2 x 9.1 X 5.1 cm, 148.0 gm). Lesion: Hepatic mass. Size: 5.0 X 4.2 X 3.9 cm. Cut surface: Encapsulated, pale tan, solid and lobulated mass. No necrosis and hemorrhage. Gross type: Multinodular confluent. Extent: Abuts but confined to the capsule. Resection margin: Not involved, grossly (safety margin: 1.5 cm). Remaining parenchyme: Unremarkable, gross...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Edmondson-Steiner grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Edmondson-Steiner grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Edmondson-Steiner grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Edmondson-Steiner grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Edmondson-Steiner grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Edmondson-Steiner grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Edmondson-Steiner grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Edmondson-Steiner grade II. 3. Code:",
      "predicted": "KIRC",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Liver. 2. Findings: Hepatocellular carcinoma, Edmondson-Steiner grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 732,
      "timestamp": "2026-01-19T15:59:53.117815"
    },
    {
      "sample_idx": 430,
      "input": "TEST(S): 1 Slide,. FINAL DIAGNOSIS: Tonsil, left fossa, biopsy. - Invasive squamous cell carcinoma, moderately-differentiated. (keratinizing). COMMENT: We agree with the referring pathologist's report and appreciate the. opportunity to review this case. CLINICAL HISTORY: The patient is a. year-old female with newly diagnosed tonsil cancer. GROSS: Received one stained slide labeled) and a copy of the referring pathologist's report with patient. identifying information. One slide is returned. MICR...",
      "response": "```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, left fossa. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, left fossa. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, left fossa. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, left fossa. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, left fossa. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, left fossa. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, left fossa. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, left fossa. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Tonsil, left fossa. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC.\"\n}\n```",
      "predicted": "HNSC",
      "ground_truth": "HNSC",
      "correct": true,
      "reasoning": "1. Site: Tonsil, left fossa. 2. Findings: Invasive squamous cell carcinoma. 3. Code: HNSC.",
      "idx": 430,
      "timestamp": "2026-01-19T15:59:53.117824"
    },
    {
      "sample_idx": 1162,
      "input": "PRIMARY SITE: Stomach (Body). 1- - Esophageal margin (paraffin embedded): - UNINVOLVED BY NEOPLASIA. 2- Product of total gastrectomy: - ADENOCARCINOMA WITH THE FOLLOWING FEATURES: LARGEST SIZE: 13.5 CM;. PRESENCE OF ULCERATION;. BORRMANN IV (LINITIS PLASTICA);. SUBTYPE: MUCOSECRETOR, MUCOCELULAR SIGNET-RING CARCINOMA;. LAUREN SUBTYPE: DIFFUSE;. TUMOR INVADES TO SEROSA;. PRESENCE OF FOCAL NEURAL INVASION;. LYMPHATIC INVASION NOT OBSERVED;. VASCULAR INVASION NOT OBSERVED;. SURGICAL MARGINS UNINVOL...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach (Body). 2. Findings: Adenocarcinoma with features of Mucinous/Mucocellular Signet-ring carcinoma, Lauren's Diffuse subtype, with ulceration, focal neural invasion, and serosal invasion. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Stomach (Body). 2. Findings: Adenocarcinoma, with features including size, ulceration, and specific subtypes (mucinous, mucocellular, Signet-ring). 3. Code: Adenocarcinoma maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach (Body). 2. Findings: Adenocarcinoma with features of Mucinous/Mucocellular Signet-ring carcinoma, Lauren's Diffuse subtype, with ulceration, focal neural invasion, and serosal invasion. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach (Body). 2. Findings: Adenocarcinoma with features including size, ulceration, and specific subtypes (mucinous, mucocellular, Signet-ring). 3. Code: Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach (Body). 2. Findings: Adenocarcinoma with features including size, ulceration, and specific subtypes (mucinous, mucocellular, Signet-ring). 3. Code: Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach (Body). 2. Findings: Adenocarcinoma with features including size, ulceration, and specific subtypes (mucinous, mucocellular, Signet-ring). 3. Code: Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    ",
      "predicted": "STAD",
      "ground_truth": "STAD",
      "correct": true,
      "reasoning": "1. Site: Stomach (Body). 2. Findings: Adenocarcinoma with features of Mucinous/Mucocellular Signet-ring carcinoma, Lauren's Diffuse subtype, with ulceration, focal neural invasion, and serosal invasion. 3. Code: Stomach Adenocarcinoma maps to STAD.",
      "idx": 1162,
      "timestamp": "2026-01-19T15:59:53.117841"
    },
    {
      "sample_idx": 210,
      "input": "FOI. Specimen #: 'Age: pare: AMENDED. SPECIMEN: A: LEFT BREAST MASTECTOMY B: RIGHT BREAST. FINAL DIAGNOSIS: A. BREAST, LEFT MASTECTOMY: - MODERATELY DIFFERENTIATED INFILTRATING LOBULAR CARCINOMA WITH. LOBULAR CARCINOMA IN SITU, EXTENDING INTO THE MILK DUCTS AND SKIN OF. THE NIPPLE AND INVOLVING THE UPPER OUTER QUADRENT, AND EXTENDING. WITHIN 1MM OF (BUT NOT INVOLVING) THE DEEP SURGICAL MARGIN. ATYPICAL LOBULAR HYPERPLASIA INVOLVING THE LOWER INNER QUADRANT AND. LOWER OUTER QUADRANT. B. BREAST, R...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, LOBULAR CARCINOMA IN SITU, EXTENDING INTO THE MILK DUCTS AND SKIN OF THE NIPPLE AND INVOLVING THE UPPER OUTER QUADRENT, AND EXTENDING WITHIN 1MM OF (BUT NOT INVOLVING) THE DEEP SURGICAL MARGIN. ATYPICAL LOBULAR HYPERPLASIA INVOLVING THE LOWER INNER QUADRANT AND LOWER OUTER QUADRANT. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: LOBULAR CARCINOMA IN SITU (1MM) WITH EXTENSIVE LOBULAR HYPERPLASIA. - ATYPICAL LOBULAR HYPERPLASIA. - FIBROCYSTIC CHANGES INCLUDING CYSTS, FIBROSIS, AND APOCRINE. METAPLASIA. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: LOBULAR CARCINOMA IN SITU (1MM) WITH EXTENSIVE LOBULAR HYPERPLASIA. - ATYPICAL LOBULAR HYPERPLASIA. - FIBROCYSTIC CHANGES INCLUDING CYSTS, FIBROSIS, AND APOCRINE. METAPLASIA. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: LOBULAR CARCINOMA IN SITU (1MM) WITH EXTENSIVE LOBULAR HYPERPLASIA. - ATYPICAL LOBULAR HYPERPLASIA. - FIBROCYSTIC CHANGES INCLUDING CYSTS, FIBROSIS, AND APOCRINE. METAPLASIA. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: LOBULAR CARCINOMA IN SITU (1MM) WITH EXTENSIVE LOBULAR HYPERPLASIA. - ATYPICAL LOB",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, LOBULAR CARCINOMA IN SITU, EXTENDING INTO THE MILK DUCTS AND SKIN OF THE NIPPLE AND INVOLVING THE UPPER OUTER QUADRENT, AND EXTENDING WITHIN 1MM OF (BUT NOT INVOLVING) THE DEEP SURGICAL MARGIN. ATYPICAL LOBULAR HYPERPLASIA INVOLVING THE LOWER INNER QUADRANT AND LOWER OUTER QUADRANT. 3. Code: BRCA.",
      "idx": 210,
      "timestamp": "2026-01-19T15:59:53.117857"
    },
    {
      "sample_idx": 724,
      "input": "DIAGNOSIS: Liver, right, posterior sectionectomy: Hepatocellular carcinoma, S7. 1) Post-chemoembolization status: absent. 2) Size of tumor; 3.1x2.7x2.5cm. 3) Gross type: nodular with perinodal extension type. 4) Satellite nodule: absent. 5) Histologic type: trabecular and pseudoglandular. 6) Cell type: classic cell group. 7) Edmondson and Steiner's histologic grade: The worst differentiation: 3. The major differentiation: 2. 8) Fatty change: absent. 9) Hemorrhage/peliosis: absent. 10) Tumor necr...",
      "response": "```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver (Right Posterior Section). 2. Findings: Hepatocellular carcinoma, S7. The tumor is described as nodular with perinodal extension and is classified as Grade 3, with classic cell group. No other significant findings are mentioned. 3. Code: Hepatocellular carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver (Right Posterior Section). 2. Findings: Hepatocellular carcinoma, S7. The tumor is described as nodular with perinodal extension and is classified as Grade 3, with classic cell group. No other significant findings are mentioned. 3. Code: Hepatocellular carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver (Right Posterior Section). 2. Findings: Hepatocellular carcinoma, S7. The tumor is described as nodular with perinodal extension and is classified as Grade 3, with classic cell group. No other significant findings are mentioned. 3. Code: Hepatocellular carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver (Right Posterior Section). 2. Findings: Hepatocellular carcinoma, S7. The tumor is described as nodular with perinodal extension and is classified as Grade 3, with classic cell group. No other significant findings are mentioned. 3. Code: Hepatocellular carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver (Right Posterior Section). 2. Findings: Hepatocellular carcinoma, S7. The tumor is described as nodular with perinodal extension and is classified as Grade 3, with classic cell group. No other significant findings are mentioned. 3. Code: Hepatocellular carcinoma maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver (Right Posterior Section). 2. Findings: Hepatocellular carcinoma, S7. The tumor is",
      "predicted": "LIHC",
      "ground_truth": "LIHC",
      "correct": true,
      "reasoning": "1. Site: Liver (Right Posterior Section). 2. Findings: Hepatocellular carcinoma, S7. The tumor is described as nodular with perinodal extension and is classified as Grade 3, with classic cell group. No other significant findings are mentioned. 3. Code: Hepatocellular carcinoma maps to LIHC.",
      "idx": 724,
      "timestamp": "2026-01-19T15:59:53.117870"
    },
    {
      "sample_idx": 1151,
      "input": "Surgical Histology. Surgical Histology. ADDRESS FOR REPORT: HISTOPATHOLOGY REPORT. CASE HISTORY: ?BCC. 8mm punch. MACROSCOPIC: 8 mm punch biopsy. MICROSCOPY: A punch excision of skin showing a benign early trichilemmoma which. appears completely excised. There is no evidence of dysplasia or. malignancy. DIAGNOSIS: 8MM PUNCH EXCISION OF SKIN (RIGHT CHEEK) : TRICHILEMMOMA. Surgical Histology. Surgical Histology. ADDRESS FOR REPORT: Report to Cancer Registry. HISTOPATHOLOGY REPORT. CASE HISTORY: Su...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Infiltrating adenocarcinoma, Gleason 8 (4+4). 3. Code: Prostate Adenocarcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Adenocarcinoma, with a high proportion of the tissue affected. 3. Code: Uterine Corpus Cancer maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OV\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous adenocarcinoma. 3. Code: Ovarian Serous Cystadenocarcinoma maps to OV.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Ureter. 2. Findings: Urothelial carcinoma. 3. Code: Ureter Urothelial Carcinoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type",
      "predicted": "PRAD",
      "ground_truth": "SKCM",
      "correct": false,
      "reasoning": "1. Site: Prostate. 2. Findings: Infiltrating adenocarcinoma, Gleason 8 (4+4). 3. Code: Prostate Adenocarcinoma maps to PRAD.",
      "idx": 1151,
      "timestamp": "2026-01-19T15:59:53.117880"
    },
    {
      "sample_idx": 316,
      "input": "Report Status: Final. Type: Surgical Pathology. COLON, SEGMENTAL RESECT FOR TUMOR. DIAGNOSIS: SPECIMEN LABELED \"SIGMOID COLON (14.5 cm) \": ADENOCARCINOMA OF THE COLON, moderately differentiated. (4.0 cm in greatest dimension). The tumor invades through the muscularis propria into pericolonic. adipose tissue and is present at the serosal surface. Lymphovascular invasion is not present. Non-neoplastic colonic mucosa with no significant pathologic change. Proximal resection margin is free of carcin...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Adenocarcinoma of the colon, moderately differentiated, invading through the muscularis propria into pericolonic adipose tissue and present at the serosal surface. Lymphovascular invasion is not present. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Distal). 2. Findings: Adenocarcinoma of the colon, moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Adenocarcinoma of the colon, moderately differentiated, invading through the muscularis propria into pericolonic adipose tissue and present at the serosal surface. Lymphovascular invasion is not present. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Distal). 2. Findings: Adenocarcinoma of the colon, moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Adenocarcinoma of the colon, moderately differentiated, invading through the muscularis propria into pericolonic adipose tissue and present at the serosal surface. Lymphovascular invasion is not present. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Distal). 2. Findings: Adenocarcinoma of the colon, moderately differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Sigmoid). 2. Findings: Adenocarcinoma of the colon, moderately differentiated, invading through the muscularis propria into pericolonic adipose tissue and present at the serosal surface. Lymphovascular invasion is not present. 3. Code: KIRC.\"\n}\n```\n```json",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Colon (Sigmoid). 2. Findings: Adenocarcinoma of the colon, moderately differentiated, invading through the muscularis propria into pericolonic adipose tissue and present at the serosal surface. Lymphovascular invasion is not present. 3. Code: KIRC.",
      "idx": 316,
      "timestamp": "2026-01-19T15:59:53.117893"
    },
    {
      "sample_idx": 1153,
      "input": "Gross Description: Skin flap of 7x4 cm in size, with mushroom-like tumor up to 2x1.8 cm in size. Seven. dissected lymph nodes. Fragment of fatty tissue. Microscopic Description: Malignant melanoma(pigmented)formed of nevus-like and spindle-like cells,. without ulceration. Clark's level V. Breslow's depth 18 mm. Seven lymph nodes were examined, four. lymph nodes proved metastatic. In the fatty tissue -- two lymph nodes with sclerosis. Fatty tissue --. without pathology changes, vascular hyperemia...",
      "response": "```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin. 2. Findings: Malignant melanoma (pigmented), Clark's level V, Breslow's depth 18 mm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin. 2. Findings: Malignant melanoma (pigmented), Clark's level V, Breslow's depth 18 mm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin. 2. Findings: Malignant melanoma (pigmented), Clark's level V, Breslow's depth 18 mm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin. 2. Findings: Malignant melanoma (pigmented), Clark's level V, Breslow's depth 18 mm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin. 2. Findings: Malignant melanoma (pigmented), Clark's level V, Breslow's depth 18 mm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin. 2. Findings: Malignant melanoma (pigmented), Clark's level V, Breslow's depth 18 mm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Skin. 2. Findings: Malignant melanoma (pigmented), Clark's level V, Breslow's depth 18 mm. 3. Code: SKCM maps to SKCM.\"\n}\n```\n```",
      "predicted": "SKCM",
      "ground_truth": "SKCM",
      "correct": true,
      "reasoning": "1. Site: Skin. 2. Findings: Malignant melanoma (pigmented), Clark's level V, Breslow's depth 18 mm. 3. Code: SKCM maps to SKCM.",
      "idx": 1153,
      "timestamp": "2026-01-19T15:59:53.117903"
    },
    {
      "sample_idx": 332,
      "input": "FINAL PATHOLOGIC DIAGNOSIS. Right hemicolectomy; ileum, right colon, transverse colon, omentum and lymph. node: - Invasive colonic adenocarcinoma, low grade (see parameters). - Thirteen lymph nodes, negative for carcinoma (0/13). - Tubular adenoma (0.7 cm) and tubulovillous adenoma (1.7 cm). - Small bowel without diagnostic abnormality. COLON: Resection. Specimen (select all that apply). Terminal ileum. Cecum. Appendix. Ascending colon. Transverse colon. Procedure: Right hemicolectomy. Specimen ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cecum and ileum. 2. Findings: Invasive colonic adenocarcinoma, low grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cecum and ileum. 2. Findings: Invasive colonic adenocarcinoma, low grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cecum and ileum. 2. Findings: Invasive colonic adenocarcinoma, low grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cecum and ileum. 2. Findings: Invasive colonic adenocarcinoma, low grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cecum and ileum. 2. Findings: Invasive colonic adenocarcinoma, low grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cecum and ileum. 2. Findings: Invasive colonic adenocarcinoma, low grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cecum and ileum. 2. Findings: Invasive colonic adenocarcinoma, low grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cecum and ileum. 2. Findings: Invasive colonic adenocarcinoma, low grade. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cecum and ileum. 2. Findings: Invasive colonic adenocarcinoma, low grade. 3.",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Cecum and ileum. 2. Findings: Invasive colonic adenocarcinoma, low grade. 3. Code: KIRC.",
      "idx": 332,
      "timestamp": "2026-01-19T15:59:53.117913"
    },
    {
      "sample_idx": 362,
      "input": "Coded sample ID: Histologic diagnosis: moderate differentiated adenocarcinoma in Barrett-epithelium. Anatomic site with laterality: distal esophagus. Tumor size: diameter 3 cm. Lymph node status: 3 negative lymph nodes. Any comments or amendments: irradical resection.",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium. 3. Code: ADENOMA maps to ADENOMA.\"\n}\n```\n",
      "predicted": "ADENOMA",
      "ground_truth": "ESCA",
      "correct": false,
      "reasoning": "1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium. 3. Code: ADENOMA maps to ADENOMA.",
      "idx": 362,
      "timestamp": "2026-01-19T15:59:53.117923"
    },
    {
      "sample_idx": 844,
      "input": "Diagnosis: A: Lymph node, Level 7, removal. - No tumor seen in multiple lymph node fragments (see. comment) . B: Lymph node, Low 4R, removal. - No tumor seen in multiple lymph node fragments (see. comment). C: Lymph node, High 4R, removal. - No tumor seen in multiple lymph node fragments (see. comment). D: Lung, right upper lobe, lobectomy. Tumor histologic type (WHO classification) : invasive. moderately. differentiated keratinizing squamous cell carcinoma. Tumor histologic grade (WHO classific...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Invasive, moderately differentiated keratinizing squamous cell carcinoma. Tumor size: 3.5 cm. Lymph node involvement: One peribronchial lymph node is involved. 3. Code: LUAD (Lung Adenocarcinoma) is not a valid code, however, given the findings of squamous cell carcinoma, LUAD is not applicable. The closest match is LUAD, which is lung adenocarcinoma, however, the tumor is squamous cell carcinoma. The best match is LUAD because it is a lung cancer. The tumor is squamous cell carcinoma, which is a subtype of lung cancer. The tumor is moderately differentiated, and the tumor is 3.5 cm. The lymph node is involved. The closest match is LUAD because it is a lung cancer. The tumor is squamous cell carcinoma, which is a subtype of lung cancer. The tumor is moderately differentiated, and the tumor is 3.5 cm. The lymph node is involved. The closest match is LUAD because it is a lung cancer. The tumor is squamous cell carcinoma, which is a subtype of lung cancer. The tumor is moderately differentiated, and the tumor is 3.5 cm. The lymph node is involved. The closest match is LUAD because it is a lung cancer. The tumor is squamous cell carcinoma, which is a subtype of lung cancer. The tumor is moderately differentiated, and the tumor is 3.5 cm. The lymph node is involved. The closest match is LUAD because it is a lung cancer. The tumor is squamous cell carcinoma, which is a subtype of lung cancer. The tumor is moderately differentiated, and the tumor is 3.5 cm. The lymph node is involved. The closest match is LUAD because it is a lung cancer. The tumor is squamous cell carcinoma, which is a subtype of lung cancer. The tumor is moderately differentiated, and the tumor is 3.5 cm. The lymph node is involved. The closest match is LUAD because it is a lung cancer. The tumor is squamous cell carcinoma, which is a subtype of lung cancer. The tumor is moderately differentiated, and the tumor is 3.5 cm. The lymph node is involved. The closest match is LUAD because it is a lung cancer. The tumor is squamous cell carcinoma, which is a subtype of lung cancer. The tumor is moderately differentiated, and",
      "predicted": null,
      "ground_truth": "LUSC",
      "correct": null,
      "reasoning": "",
      "idx": 844,
      "timestamp": "2026-01-19T15:59:53.118085"
    },
    {
      "sample_idx": 50,
      "input": "Pathology #: Med. Record. No.: Date of Birth: M. Date Received: Submitted by: Report also to: DIAGNOSIS: SPECIMEN. Urinary bladder, transurethral resection of tumor (TURB-T). Muscularis propria present in specimen. TUMOR. Histologic type: Urothelial (transitional cell) carcinoma, with glandular differentiation. Histologic grade: High grade. Extent of invasion: Invasion of muscularis propria (detrusor muscle). Venous/lymphatic invasion: Absent. Associated epithelial lesions: None identified. STAG...",
      "response": "```json\n{\n    \"cancer_type\": \"UUC\",\n    \"reasoning\": \"1. Site: Urinary bladder. 2. Findings: Urothelial carcinoma, with glandular differentiation, high grade, invasion of muscularis propria. 3. Code: Urinary bladder, transurethral resection of tumor (TURB-T) maps to UUC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UUC\",\n    \"reasoning\": \"1. Site: Urinary bladder. 2. Findings: Urothelial carcinoma, with glandular differentiation, high grade, invasion of muscularis propria. 3. Code: Urinary bladder, transurethral resection of tumor (TURB-T) maps to UUC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UUC\",\n    \"reasoning\": \"1. Site: Urinary bladder. 2. Findings: Urothelial carcinoma, with glandular differentiation, high grade, invasion of muscularis propria. 3. Code: Urinary bladder, transurethral resection of tumor (TURB-T) maps to UUC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UUC\",\n    \"reasoning\": \"1. Site: Urinary bladder. 2. Findings: Urothelial carcinoma, with glandular differentiation, high grade, invasion of muscularis propria. 3. Code: Urinary bladder, transurethral resection of tumor (TURB-T) maps to UUC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UUC\",\n    \"reasoning\": \"1. Site: Urinary bladder. 2. Findings: Urothelial carcinoma, with glandular differentiation, high grade, invasion of muscularis propria. 3. Code: Urinary bladder, transurethral resection of tumor (TURB-T) maps to UUC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UUC\",\n    \"reasoning\": \"1. Site: Urinary bladder. 2. Findings: Urothelial carcinoma, with glandular differentiation, high grade, invasion of muscularis propria. 3. Code: Urinary bladder, transurethral resection of tumor (TURB-T) maps to UUC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "UUC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Urinary bladder. 2. Findings: Urothelial carcinoma, with glandular differentiation, high grade, invasion of muscularis propria. 3. Code: Urinary bladder, transurethral resection of tumor (TURB-T) maps to UUC.",
      "idx": 50,
      "timestamp": "2026-01-19T15:59:53.118103"
    },
    {
      "sample_idx": 367,
      "input": "AP Surgical Pathology: Additional Info. CLINICAL HISTORY. Brain tumor. GROSS EXAMINATION: A. \"Brain tissue (AF1) \", received fresh for frozen section is a 2.5 x 1.5 x. 1.2 cm fragment of pink-tan soft tissue. The representative section has been. frozen as AF1 and the frozen section remnant is submitted in block A1. Additional representative sections are submitted in blocks A2, with the. remainder retained in formalin. B. \"Brain tissue\", received fresh and placed in formalin is a 3.7 x 3 X 2 cm. ...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with subarachnoid infiltration. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GLG\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GLG maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain tissue. 2. Findings: Glioblastoma (WHO Grade IV), with subarachnoid infiltration. 3. Code: GBM maps to GBM.",
      "idx": 367,
      "timestamp": "2026-01-19T15:59:53.118114"
    },
    {
      "sample_idx": 680,
      "input": "Surgical Pathology: Additional Info. CLINICAL HISTORY: Brain neoplasm left frontoparietal, left facial seizures. HISTORY OF PRESENT. ILLNESS: comes to clinic today. She had a. sensory seizure. She had a second sensory seizure. She had two MRI scans. that showed a growing lesion in the left frontal area. She is right-handed. GROSS EXAMINATION: A. \"Brain tissue (AF1) \", received fresh for frozen section placed in formalin. at. is a 0. X 0.5 X 0.4 cm aggregate of multiple fragments. of sort tan tis...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma (WHO Grade II) with elevated Mib-1 index. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma (WHO Grade II) with elevated Mib-1 index. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma (WHO Grade II) with elevated Mib-1 index. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma (WHO Grade II) with elevated Mib-1 index. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma (WHO Grade II) with elevated Mib-1 index. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma (WHO Grade II) with elevated Mib-1 index. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma (WHO Grade II) with elevated Mib-1 index. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligodendroglioma (WHO Grade II) with elevated Mib-1 index. 3. Code: KIRC.\"\n}\n```\n```",
      "predicted": "KIRC",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain. 2. Findings: Oligodendroglioma (WHO Grade II) with elevated Mib-1 index. 3. Code: KIRC.",
      "idx": 680,
      "timestamp": "2026-01-19T15:59:53.118124"
    },
    {
      "sample_idx": 843,
      "input": "CLINICAL HISTORY. The patient is an. year old male with Kistory of lung mass. PRE-OP DIAGNOSIS: Lung mass. POST-OP DIAGNOSIS: Not given. PROCEDURE: Not given. ES/js. ADDENDUM. Fluorescence in situ hybridization studies performed on the squamous cell carcinoma show. a. ration of EGF-R gene to the centromere of chromosome 7 of 1.12 indicating a lack of. amplification in the targeted area. The Department of Pathology is in receipt of Oncotech report. S. FINAL DIAGNOSIS. Summary Statement. The right...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung, Right Lower Lobe. 2. Findings: Invasive moderately differentiated squamous cell carcinoma, angiolymphatic invasion, 5.0 cm. No visceral pleural invasion. Surgical margins free. Mild inflammatory response. 3. TCGA Code: KIRC (Kidney Renal Clear Cell Carcinoma) is the most appropriate code for this case, given the lung cancer diagnosis.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA (Breast Invasive Carcinoma) is the most appropriate code for this case, given the breast cancer diagnosis.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left Upper Pole. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. TCGA Code: KIRC (Kidney Renal Clear Cell Carcinoma) is the most appropriate code for this case, given the kidney cancer diagnosis.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left Upper Pole. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. TCGA Code: KIRC (Kidney Renal Clear Cell Carcinoma) is the most appropriate code for this case, given the kidney cancer diagnosis.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left Upper Pole. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. TCGA Code: KIRC (Kidney Renal Clear Cell Carcinoma) is the most appropriate code for this case, given the kidney cancer diagnosis.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, Left Upper Pole. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. TC",
      "predicted": "KIRC",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung, Right Lower Lobe. 2. Findings: Invasive moderately differentiated squamous cell carcinoma, angiolymphatic invasion, 5.0 cm. No visceral pleural invasion. Surgical margins free. Mild inflammatory response. 3. TCGA Code: KIRC (Kidney Renal Clear Cell Carcinoma) is the most appropriate code for this case, given the lung cancer diagnosis.",
      "idx": 843,
      "timestamp": "2026-01-19T15:59:53.118140"
    },
    {
      "sample_idx": 508,
      "input": "DIAGNOSIS: SPECTMEN DRATONATED \"IEFT RADICAL. CELT higit grade with and. leatures, and necrosis. nuclear grade :V of IV. : extenelvely invades into the ad.pose tisque. and tocaliy through Gerota's fascia. .8 presen: at the inked Gerota's fascial margen and. renal vein margin. Renal artery and ureter margins are negative for cumor. Cymphovascular invasion and verous invasion are present. adrenal gland, negative for tumor. T4 No. XX. D: 3. GUT Pathology Service, has reviewed this case and. RENAL P...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney (Nephrectomy). 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II, with necrosis. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney (Nephrectomy). 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II, with necrosis. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney (Nephrectomy). 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II, with necrosis. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney (Nephrectomy). 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II, with necrosis. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney (Nephrectomy). 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II, with necrosis. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney (Nephrectomy). 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II, with necrosis. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney (Nephrectomy). 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II, with necrosis. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney (Nephrectomy). 2.",
      "predicted": "KIRC",
      "ground_truth": "KICH",
      "correct": false,
      "reasoning": "1. Site: Left Kidney (Nephrectomy). 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II, with necrosis. 3. Code: KIRC.",
      "idx": 508,
      "timestamp": "2026-01-19T15:59:53.118150"
    },
    {
      "sample_idx": 273,
      "input": "Internal Sample. Diagnosis: This is a moderately to poorly differentiated adenocarcinoma of the colon (G2 to 3) with. infiltration of all parietal layers and vascular infiltration (L1, V1). as well as six lymph node conglomerate metastases (6/12, N2). and in II a gall bladder preparation with parts of an adenocarcinoma, possibly to be. interpreted as a further spread of the colon cancer described. in III parts of the liver with parts of the carcinoma described.",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately to poorly differentiated, with parietal and vascular invasion, lymph node metastases, and possible spread to gallbladder and liver. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Gallbladder. 2. Findings: Adenocarcinoma, possible spread from colon cancer. 3. Code: Gallbladder Adenocarcinoma maps to PAAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Carcinoma, possible spread from colon cancer. 3. Code: Liver Carcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately to poorly differentiated, with parietal and vascular invasion, lymph node metastases, and possible spread to gallbladder and liver. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately to poorly differentiated, with parietal and vascular invasion, lymph node metastases, and possible spread to gallbladder and liver. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately to poorly differentiated, with parietal and vascular invasion, lymph node metastases, and possible spread to gallbladder and liver. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Adenocarcinoma, moderately to poorly differentiated, with parietal and vascular invasion, lymph node metastases, and possible spread to gallbladder and liver. 3. Code: Colon Adenocarcinoma maps to COAD.\"\n}\n```\n```json\n{\n",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon. 2. Findings: Adenocarcinoma, moderately to poorly differentiated, with parietal and vascular invasion, lymph node metastases, and possible spread to gallbladder and liver. 3. Code: Colon Adenocarcinoma maps to COAD.",
      "idx": 273,
      "timestamp": "2026-01-19T15:59:53.118162"
    },
    {
      "sample_idx": 1351,
      "input": "SURGICAL PATHOLOGY (Accession. PATHOLOGIC DIAGNOSIS. A. UTERUS WITH CERVIX, TOTAL HYSTERECTOMY: ENDOMETRIUM: - ENDOMETRIOID ADENOCARCINOMA. - TUMOR SIZE: 2CM IN GREATEST DIMENSION. - HISTOLOGIC GRADE: FIGO GRADE 1. - MYOMETRIAL INVASION: PRESENT. - INVASION INTO CERVICAL STROMA: PRESENT. - LYMPHOVASCULAR SPACE INVASION: ABSENT. - MARGINS: NEGATIVE FOR MALIGNANCY. MYOMETRIUM: - ADENOCARCINOMA BY DIRECT EXTENSION. - DEPTH OF INVASION: 10MM. - MYOMETRIAL THICKNESS: 20MM. - 50% MYOMETRIAL INVASION. ...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive",
      "predicted": "BRCA",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1351,
      "timestamp": "2026-01-19T15:59:53.118171"
    },
    {
      "sample_idx": 806,
      "input": "F. Pathologic Interpretation: A. Wedge resection right upper lobe,. - Moderately differentiated adenocarcinoma of lung, 1.5 cm in greatest dimension. - Multiple microscopic foci of bronchioalveolar carcinoma are present, including in the stapled resection margin. B. Hilar lymph node, 10: - One lymph node, no tissue seen. C. Right lower paratracheal, 4R: - One lymph node, no tissue seen. D. Subcourial lymph node, 7: - One lymph node, no tissue seen. E. Inferior pulmonary ligament lymph node, 9: -...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Adenocarcinoma, not otherwise specified, 1.5 cm in greatest dimension. Multiple foci of bronchioalveolar carcinoma are present. 3. Code: LUAD (Lung Adenocarcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Adenocarcinoma, not otherwise specified, 1.5 cm in greatest dimension. Multiple foci of bronchioalveolar carcinoma are present. 3. Code: ADENOCARC (Adenocarcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Adenocarcinoma, not otherwise specified, 1.5 cm in greatest dimension. Multiple foci of bronchioalveolar carcinoma are present. 3. Code: ADENOCARC (Adenocarcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Adenocarcinoma, not otherwise specified, 1.5 cm in greatest dimension. Multiple foci of bronchioalveolar carcinoma are present. 3. Code: ADENOCARC (Adenocarcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Adenocarcinoma, not otherwise specified, 1.5 cm in greatest dimension. Multiple foci of bronchioalveolar carcinoma are present. 3. Code: ADENOCARC (Adenocarcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARC\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Adenocarcinoma, not otherwise specified, 1.5 cm in greatest dimension. Multiple foci of bronchioalveolar carcinoma are present. 3. Code: ADENOCARC (Adenocarcinoma).\"\n}\n```\n```json\n{\n",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung (Right Upper Lobe). 2. Findings: Adenocarcinoma, not otherwise specified, 1.5 cm in greatest dimension. Multiple foci of bronchioalveolar carcinoma are present. 3. Code: LUAD (Lung Adenocarcinoma).",
      "idx": 806,
      "timestamp": "2026-01-19T15:59:53.118184"
    },
    {
      "sample_idx": 718,
      "input": "TISSUE DESCRIPTION: Portion liver (Segments V and VI - 790 grams, 15 x 13 x 8 cm) with attached. gallbladder (12 x 4x 3 cm). A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, A11,. A12. DIAGNOSIS: Liver, segments V and VI, resection: Well differentiated hepatocellular neoplasm. In view of the size of the lesion, age of the patient, and a \"nodule within a nodule\". architectural pattern the lesion is best regarded as an encapsulated grade 1. hepatocellular carcinoma. Surgical margins are free of involvemen...",
      "response": "```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver, segments V and VI. 2. Findings: Well-differentiated hepatocellular neoplasm, encapsulated grade 1 hepatocellular carcinoma. 3. Code: Liver, segments V and VI, resection: Well differentiated hepatocellular neoplasm maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Liver, segments V and VI. 2. Findings: Liver nodule. measures 12 x 11 x 7.5 cm. 3. Code: Liver nodule maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Liver, segments V and VI. 2. Findings: Well-differentiated hepatocellular neoplasm, encapsulated grade 1 hepatocellular carcinoma. 3. Code: Liver, segments V and VI, resection: Well differentiated hepatocellular neoplasm maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, segments V and VI. 2. Findings: Well-differentiated hepatocellular neoplasm, encapsulated grade 1 hepatocellular carcinoma. 3. Code: Liver, segments V and VI, resection: Well differentiated hepatocellular neoplasm maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver, segments V and VI. 2. Findings: Well-differentiated hepatocellular neoplasm, encapsulated grade 1 hepatocellular carcinoma. 3. Code: Liver, segments V and VI, resection: Well differentiated hepatocellular neoplasm maps to LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Liver, segments V and VI. 2. Findings: Well-differentiated hepatocellular neoplasm, encapsulated grade 1 hepatocellular carcinoma. 3. Code: Liver, segments V and VI, resection: Well differentiated hepatocellular neoplasm maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver",
      "predicted": "LIHC",
      "ground_truth": "LIHC",
      "correct": true,
      "reasoning": "1. Site: Liver, segments V and VI. 2. Findings: Well-differentiated hepatocellular neoplasm, encapsulated grade 1 hepatocellular carcinoma. 3. Code: Liver, segments V and VI, resection: Well differentiated hepatocellular neoplasm maps to LIHC.",
      "idx": 718,
      "timestamp": "2026-01-19T15:59:53.118201"
    },
    {
      "sample_idx": 1178,
      "input": "Microscopic Description. Stomach with a plate-like tumor. Adenocarcinoma of the stomach,. of 12 X 7 cm in its size, with the. G3; with the presence of signet. whole wall invasion. cells, superficial ulceration,. Fatty tissue lymph nodes are up. perigastric fat invasion. Multiple. to 1 cm in their diameter, soft,. foci of perineural invasion are. hyperemic; omentum is. observed. Fifteen lymph nodes. hyperemic. were examined, nine lymph nodes. demonstrated metastases. Omentum demonstrated. hemorrh...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, G3, signet ring cells, perigastric fat invasion, lymph node metastases. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, G3, signet ring cells, perigastric fat invasion, lymph node metastases. 3. Code: Stomach Adenocarcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, G3, signet ring cells, perigastric fat invasion, lymph node metastases. 3. Code: Stomach Adenocarcinoma maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, G3, signet ring cells, perigastric fat invasion, lymph node metastases. 3. Code: Stomach Adenocarcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, G3, signet ring cells, perigastric fat invasion, lymph node metastases. 3. Code: Stomach Adenocarcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, G3, signet ring cells, perigastric fat invasion, lymph node metastases. 3. Code: Stomach Adenocarcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, G3, signet ring cells, perigastric fat invasion, lymph node",
      "predicted": "STAD",
      "ground_truth": "STAD",
      "correct": true,
      "reasoning": "1. Site: Stomach. 2. Findings: Adenocarcinoma of the stomach, G3, signet ring cells, perigastric fat invasion, lymph node metastases. 3. Code: Stomach Adenocarcinoma maps to STAD.",
      "idx": 1178,
      "timestamp": "2026-01-19T15:59:53.118225"
    },
    {
      "sample_idx": 391,
      "input": "CLINICAL HISTORY. recently had surgery and antibiotics for an. On MRI there is a large, centrally necrotic, heterogeneously. enhancing. mass in the right frontal lobe. The mass abuts with convexity dura. and. extends to the ventricle, with minimal to no vasogenic edema. OPERATIVE DIAGNOSES. Operation/Specimen: A: Brain, excision biopsy. B: Brain, resection. PATHOLOGICAL DIAGNOSIS: A and B. Brain, site not specified, excisional biopsy and resection: 1. Glioblastomal. 2. MIB-1 proliferation index:...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Excision Biopsy). 2. Findings: Glioblastoma, high histologic grade (consistent with glioblastoma, other). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Resection). 2. Findings: Glioblastoma, high histologic grade (consistent with glioblastoma, other). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Excision Biopsy). 2. Findings: Glioblastoma, high histologic grade (consistent with glioblastoma, other). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Resection). 2. Findings: Glioblastoma, high histologic grade (consistent with glioblastoma, other). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Excision Biopsy). 2. Findings: Glioblastoma, high histologic grade (consistent with glioblastoma, other). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Resection). 2. Findings: Glioblastoma, high histologic grade (consistent with glioblastoma, other). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Excision Biopsy). 2. Findings: Glioblastoma, high histologic grade (consistent with glioblastoma, other). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain (Resection). 2. Findings: Glioblastoma, high histologic grade (consistent with glioblastoma",
      "predicted": "KIRC",
      "ground_truth": "GBM",
      "correct": false,
      "reasoning": "1. Site: Brain (Excision Biopsy). 2. Findings: Glioblastoma, high histologic grade (consistent with glioblastoma, other). 3. Code: KIRC.",
      "idx": 391,
      "timestamp": "2026-01-19T15:59:53.118244"
    },
    {
      "sample_idx": 893,
      "input": "Clinical. Index. Diagnosis. Lung. 1. Cancer. Lung. Cancer. Tissue. Anatomical. Tumor. Specimen. Specimen. Number of. Amount/per. Specificati. Container. Site. Matrix. Format. containers. container. on. 0. Lung. Primary. Tumor. Tissue. OCT. block. 1. n/a. Blood. n/a. Normal. Blood. frozen. tube. 1. n/a. Type of. Histological description. Grade. TNM Stage. TNM Stage. TNM Stage. Treatment. Procureme. (Source). (source). (T). (N). (M). type. nt. n/a. Adenocarcinoma. 2. 2. 0. 0. none. blood draw. n/a...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Adenocarcinoma. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site:",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung. 2. Findings: Adenocarcinoma. 3. Code: Lung Adenocarcinoma maps to LUAD.",
      "idx": 893,
      "timestamp": "2026-01-19T15:59:53.118254"
    },
    {
      "sample_idx": 1248,
      "input": "PATIENT HISTORY: CHIEF COMPLAINT/PRE-OP/POST-OP DIAGNOSIS: Thyroid nodule. PROCEDURE: Not answered. SPECIFIC CLINICAL QUESTION: Not answered. OUTSIDE TISSUE DIAGNOSIS: Not answered. PRIOR MALIGNANCY: Not answered. CHEMORADIATION: Not answered. ORGAN TRANSPLANT: Not answered. IMMUNOSUPPRESSION: Not answered. OTHER DISEASES: Not answered. ADDENDA: FINAL DIAGNOSIS: THYROID, TOTAL THYROIDECTOMY (23 GRAMS) -. A. PAPILLARY THYROID CARCINOMA, COLUMNAR CELL VARIANT WITH SOLID AND MICROFOLLICULAR AREAS. ...",
      "response": "```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, columnar cell variant, with solid and microfollicular areas. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Exuberant chronic lymphocytic thyroiditis. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"READ\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Angiolymphatic invasion present. 3. Code: READ maps to READ.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Lymph node involvement. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Lymph node involvement. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Lymph node involvement. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Lymph node involvement. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Lymph node involvement. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Lymph node involvement. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "THCA",
      "ground_truth": "THCA",
      "correct": true,
      "reasoning": "1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, columnar cell variant, with solid and microfollicular areas. 3. Code: THCA maps to THCA.",
      "idx": 1248,
      "timestamp": "2026-01-19T15:59:53.118264"
    },
    {
      "sample_idx": 879,
      "input": "Gross. Microsc. Diagnos. Comme. Case ID. Descript. opic. is. nts. ion. Descript. Details. ion. LUNG TISSUE CHECKLIST. Specimen type: Lobectomy. Tumor site: Lung. Tumor size: 3 X 3 X 3.5 cm. Histologic type: Squamous cell carcinoma. Histologic grade: Moderately. differentiated. Tumor extent: Not specified. Other tumor nodules: Not specified. Lymph nodes: Not specified. Lymphatic invasion: Not specified. Venous invasion: Not specified. Margins: Not specified. Evidence of neo-adjuvant treatment: No...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: Lung Squamous Cell Carcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: Lung Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: Lung Squamous Cell Carcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: Lung Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: Lung Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: Lung Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: Lung Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: Lung Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung. 2. Findings: Squamous cell carcinoma. 3. Code: Lung Squamous Cell Carcinoma maps to LUAD.",
      "idx": 879,
      "timestamp": "2026-01-19T15:59:53.118275"
    },
    {
      "sample_idx": 1390,
      "input": "PATIENT HISTORY: CHIEF COMPLAINT/ PRE OP/ POST-OP DIAGNOSIS: Endometrial cancer. LMP DATE Postmenopausal. PROCEDURE: Total abdominal hysterectomy, bilateral salpingo-oophorectomy. omental biopsy. SPECIFIC CLINICAL QUESTION Not provided. OUTSIDE TISSUE DIAGNOSIS: Not provided. PRIOR MALIGNANCY: Not provided. CHEMORADIATION THERAPY Not provided. OTHER DISEASES: Not provided. FINAL DIAGNOSIS: PART 1.: ABDOMINAL WALL NODULE, BIOPSY -. INFARCTED APPENDICES EPIPLOICA WITH CALCIFICATION. PART 2: OMENTU...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Endometrium. 2. Findings: Endometrial cancer, mixed clear cell and endometrioid types. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Endometrium. 2. Findings: Endometrial cancer, mixed clear cell and endometrioid types. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Endometrium. 2. Findings: Endometrial cancer, mixed clear cell and endometrioid types. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Endometrium. 2. Findings: Endometrial cancer, mixed clear cell and endometrioid types. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Endometrium. 2. Findings: Endometrial cancer, mixed clear cell and endometrioid types. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Endometrium. 2. Findings: Endometrial cancer, mixed clear cell and endometrioid types. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Endometrium. 2. Findings: Endometrial cancer, mixed clear cell and endometrioid types. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Endometrium. 2. Findings: Endometrial cancer, mixed clear cell and endometrioid types. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site",
      "predicted": "BRCA",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Endometrium. 2. Findings: Endometrial cancer, mixed clear cell and endometrioid types. 3. Code: BRCA.",
      "idx": 1390,
      "timestamp": "2026-01-19T15:59:53.118296"
    },
    {
      "sample_idx": 227,
      "input": "nups. 11. S. PATHOLOGY REPORS. Hospital No.: Date of Birth: Soc. Sec. No: Attending MD: Copies To: DIAGNOSIS: 1. LEFT ADNEXA: -Benign ovary with involutional changes. -Minute inclusion cyst, ovarian cortex. -Unremarkable fallopian tube. -Minute paratubal cyst (hydatid of Morgagni). 2. RIGHT ADNEXA: -Benign ovary with involutional changes. -Unremarkable fallopian tube. -Paratubal cysts (hydatids of Morgagni). 3. UTERUS, RATIFIED RADICAL HYSTERECTOMY: -Invasive non-keratinizing squamous cell carci...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cervix Uterus. 2. Findings: Invasive non-keratinizing squamous cell carcinoma, maximal thickness of cervical stromal invasion is 31 mm. 3. Code: KIRC.\"\n}\n```\nExplanation:\nThe report describes invasive squamous cell carcinoma of the cervix. The tumor is described as involving the full thickness of the cervical wall and having a maximal thickness of cervical stromal invasion of 31 mm. This falls under the category of KIRC (Cervical Cancer).\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cervix Uterus. 2. Findings: Invasive non-keratinizing squamous cell carcinoma, maximal thickness of cervical stromal invasion is 31 mm. 3. Code: KIRC.\"\n}\n```\nExplanation:\nThe report describes invasive squamous cell carcinoma of the cervix. The tumor is described as involving the full thickness of the cervical wall and having a maximal thickness of cervical stromal invasion of 31 mm. This falls under the category of KIRC (Cervical Cancer).\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cervix Uterus. 2. Findings: Invasive non-keratinizing squamous cell carcinoma, maximal thickness of cervical stromal invasion is 31 mm. 3. Code: KIRC.\"\n}\n```\nExplanation:\nThe report describes invasive squamous cell carcinoma of the cervix. The tumor is described as involving the full thickness of the cervical wall and having a maximal thickness of cervical stromal invasion of 31 mm. This falls under the category of KIRC (Cervical Cancer).\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Cervix Uterus. 2. Findings: Invasive non-keratinizing squamous cell carcinoma, maximal thickness of cervical stromal invasion is 31 mm. 3. Code: KIRC.\"\n}\n```\nExplanation:\nThe report describes invasive squamous cell carcinoma of the cervix. The tumor is described as involving the full thickness of the cervical wall and having a maximal thickness of cervical stromal invasion of 31 mm. This falls under the category of KIRC (Cervical Cancer).\n",
      "predicted": "KIRC",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Cervix Uterus. 2. Findings: Invasive non-keratinizing squamous cell carcinoma, maximal thickness of cervical stromal invasion is 31 mm. 3. Code: KIRC.",
      "idx": 227,
      "timestamp": "2026-01-19T15:59:53.118329"
    },
    {
      "sample_idx": 1094,
      "input": "QC Pathologist: ADDENDUM REPORT. Addendum Final Diagnosis: Two additional lymph nodes are identified in the gross. specimen. No malignancy is identified. Addendum Gross Description: Per the request of the surgeon, the specimen is re-examined. in search for additional lymph nodes. The mesenteric fat. is placed in lymph node Revealing Solution. Upon fixation. there reveals two additional possible lymph nodes that. measure 0.3 and 0.5 cm in greatest dimension. Each of the. lymph nodes have been bis...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, well differentiated, 3.5 x 3.0 cm, circumfereential. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, well differentiated, 3.5 x 3.0 cm, circumfereential. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, well differentiated, 3.5 x 3.0 cm, circumfereential. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, well differentiated, 3.5 x 3.0 cm, circumfereential. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, well differentiated. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "KIRC",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, well differentiated, 3.5 x 3.0 cm, circumfereential. 3. Code: KIRC.",
      "idx": 1094,
      "timestamp": "2026-01-19T15:59:53.118347"
    },
    {
      "sample_idx": 836,
      "input": "Clinical Diagnosis & History: former smoker, with right lung nodules discovered on chest CT. Blopgy => squamous caro\u00ednoma. Specimens Submitted: 1: SP: Right leval four mediastinal lymph nodes. 2: SP: Left level four mediastinal lymph nodes. 3: SP: Right level 4 mediastinal lymph nodes #2. 4, SP: Level 7 subcarinal lymph nodes. 5: SP: Right upper lobe lung wadge. 6: SP: Level seven aubcarinal lymph nodea. 7: SP: Right level eleven interlobar lymph nodes. 8: SP: Right lower lobe lung. DIAGNOSIS: 1...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe) 2. Findings: Infiltrating squamous cell carcinoma of the right upper lobe, moderately differentiated. The tumor's greatest diameter is 2.1 x 1.8 x 0.9 cm. No vascular invasion is identified. No perineural invasion is identified. The mainstem bronchus is involved by in situ carcinoma. The tumor extends subpleurally but not to the pleural surface. In situ carcinoma is also present. The stapled margin is free of tumor. The non-neoplastic lung shows interstitial fibrosis and focal, organized pneumonia. Note: The tumor is similar in morphology to the tumor in part 8. 5). FROZEN SECTION DIAGNOSIS. INFILTRATING SQUAMOUS CELL CARCINOMA. PERMANENT DIAGNOSIS: SAME.\"\n}\n```\n\nResponse:\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe) 2. Findings: Infiltrating squamous cell carcinoma of the right lower lobe, moderately to poorly differentiated. The tumor's greatest diameter is 6.6 x 5.1 x 3.4 cm. The mainstem bronchus is involved by invasive carcinoma. The bronchial margin is free of tumor. The stapled margin is free of tumor. The non-neoplastic lung shows emphysematous changes, interstitial fibrosis and osseous metaplasia. The lymph node status is as follows (expressed as the number of metastatic nodes in relation to the total number of nodes examined): Peribronchial 3/7. No direct tumor extension into lymph nodes is identified. Note: While the fibrosis shows focal honeycombing and fibrotic changes that raised the possibility of usual interstitial pneumonia, the gross specimen shows the fibrotic areas localized around the tumor rather than diffusely fibrotic. The case is also reviewed by WHO agreed with the rendered interpretation. I attest that the above diagnosis is based upon my personal examination of the slides (and/or other material), and that I have reviewed and approved this report.\"\n}\n```\n\nResponse:\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe) 2. Findings: Infiltrating squamous cell",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung (Right Upper Lobe) 2. Findings: Infiltrating squamous cell carcinoma of the right upper lobe, moderately differentiated. The tumor's greatest diameter is 2.1 x 1.8 x 0.9 cm. No vascular invasion is identified. No perineural invasion is identified. The mainstem bronchus is involved by in situ carcinoma. The tumor extends subpleurally but not to the pleural surface. In situ carcinoma is also present. The stapled margin is free of tumor. The non-neoplastic lung shows interstitial fibrosis and focal, organized pneumonia. Note: The tumor is similar in morphology to the tumor in part 8. 5). FROZEN SECTION DIAGNOSIS. INFILTRATING SQUAMOUS CELL CARCINOMA. PERMANENT DIAGNOSIS: SAME.",
      "idx": 836,
      "timestamp": "2026-01-19T15:59:53.118374"
    },
    {
      "sample_idx": 1367,
      "input": "Diagnosis: A: Uterus, cervix, bilateral tubes and ovaries, hysterectomy, bilateral salpingo-oophorectomy. Location of tumor: endometrium, anterior and posterior, 5.1 cm in greatest dimension. Histologic type: endometrioid with squamous differentiation and associated calcifications. Histologic grade (FIGO): FIGO grade 2 (architectural grade 2, nuclear grade 2). Extent of invasion: myometrium. Myometrial invasion: Inner half. Depth: 3 mm Wall thickness: 12 mm Percent: 25%. Serosal involvement: non...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 1367,
      "timestamp": "2026-01-19T15:59:53.118385"
    },
    {
      "sample_idx": 1210,
      "input": "FINAL DIAGNOSIS: PART 1: LIVER, LEFT LATERAL SEGMENT, BIOPSY -. A. SUBCAPSULAR LIVER BIOPSY WITH FOCAL FIBROSIS AND BILE DUCTULAR PROLIFERATION. B. THERE IS NO EVIDENCE OF MALIGNANCY. PART 2: LYMPH NODE, LEFT GASTRIC TISSUE, RESECTION -. METASTATIC ADENOCARCINOMA TO ONE OF TWO LYMPH NODES (1/2) CONFIRMED USING. IMMUNOHISTOCHEMICAL STAIN TO AE1/3. PART 3: LYMPH NODE, LEVEL 7, RESECTION -. THERE IS NO EVIDENCE OF MALIGNANCY IN ONE ANTHRACOTIC LYMPH NODE (0/1). PART 4: LYMPH NODE, PARAESOPHAGEAL NE...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Esophagus and stomach, esophagogastrectomy. 2. Findings: Adenocarcinoma, moderately differentiated (2.0 cm) centered in proximal gastric mucosa, involving GE junction squamous mucosa and extending into but not through sub mucosa. 3. Code: ADENOCA maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Esophagus and stomach, esophagogastrectomy. 2. Findings: Adenocarcinoma, moderately differentiated (2.0 cm) centered in proximal gastric mucosa, involving GE junction squamous mucosa and extending into but not through sub mucosa. 3. Code: ADENOCA maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Esophagus and stomach, esophagogastrectomy. 2. Findings: Adenocarcinoma, moderately differentiated (2.0 cm) centered in proximal gastric mucosa, involving GE junction squamous mucosa and extending into but not through sub mucosa. 3. Code: ADENOCA maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Esophagus and stomach, esophagogastrectomy. 2. Findings: Adenocarcinoma, moderately differentiated (2.0 cm) centered in proximal gastric mucosa, involving GE junction squamous mucosa and extending into but not through sub mucosa. 3. Code: ADENOCA maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Esophagus and stomach, esophagogastrectomy. 2. Findings: Adenocarcinoma, moderately differentiated (2.0 cm) centered in proximal gastric mucosa, involving GE junction squamous mucosa and extending into but not through sub mucosa. 3. Code: ADENOCA maps to ADENOCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCA\",\n    \"reasoning\": \"1. Site: Esophagus and stomach, esophagogastrectomy. 2. Findings: Adenocarcinoma, moderately",
      "predicted": "ADENOCA",
      "ground_truth": "STAD",
      "correct": false,
      "reasoning": "1. Site: Esophagus and stomach, esophagogastrectomy. 2. Findings: Adenocarcinoma, moderately differentiated (2.0 cm) centered in proximal gastric mucosa, involving GE junction squamous mucosa and extending into but not through sub mucosa. 3. Code: ADENOCA maps to ADENOCA.",
      "idx": 1210,
      "timestamp": "2026-01-19T15:59:53.118399"
    },
    {
      "sample_idx": 358,
      "input": "OPER DATE: REQ DOC: PROCEDURE: SPHS. Source of Specimen: Esophagus. History of case: Recently diagnosed with. gastroesophageal adenocarcinoma. Operative Procedure/Tissue Submitted: THE. distal esophagus and proximal stomach. PROCEDURE: SPGD. 1. \"Distal esophagus proximal stomach\" Received in formalin in a large. container is a distal esophagus with attached proximal stomach. Esophagus is. 10.2 cm in length with the stomach being 8.5 x 4.2 x 2.5 cm. The adventitia is. red-tan and ragged with a sc...",
      "response": "```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Gastroesophageal adenocarcinoma, invasive mucinous carcinoma. 3. Code: PAAD (Pancreatic Adenocarcinoma) maps to PAAD, since the tumor is located at the gastroesophageal junction, which is close to the pancreas. The tumor is an adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Gastroesophageal adenocarcinoma, invasive mucinous carcinoma. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) maps to KIRC, since the tumor is located at the gastroesophageal junction, which is close to the pancreas. The tumor is an adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Gastroesophageal adenocarcinoma, invasive mucinous carcinoma. 3. Code: PAAD (Pancreatic Adenocarcinoma) maps to PAAD, since the tumor is located at the gastroesophageal junction, which is close to the pancreas. The tumor is an adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Gastroesophageal adenocarcinoma, invasive mucinous carcinoma. 3. Code: PAAD (Pancreatic Adenocarcinoma) maps to PAAD, since the tumor is located at the gastroesophageal junction, which is close to the pancreas. The tumor is an adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2. Findings: Gastroesophageal adenocarcinoma, invasive mucinous carcinoma. 3. Code: PAAD (Pancreatic Adenocarcinoma) maps to PAAD, since the tumor is located at the gastroesophageal junction, which is close to the pancreas. The tumor is an adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Esophagus (distal). 2",
      "predicted": "PAAD",
      "ground_truth": "ESCA",
      "correct": false,
      "reasoning": "1. Site: Esophagus (distal). 2. Findings: Gastroesophageal adenocarcinoma, invasive mucinous carcinoma. 3. Code: PAAD (Pancreatic Adenocarcinoma) maps to PAAD, since the tumor is located at the gastroesophageal junction, which is close to the pancreas. The tumor is an adenocarcinoma.",
      "idx": 358,
      "timestamp": "2026-01-19T15:59:53.118418"
    },
    {
      "sample_idx": 312,
      "input": "Clinical Diagnosis & History: year old male 5 cm mass seen in descending colon on colonoscopy 45 cm. from anal verge. Specimens Submitted: 1: Sigmoid colon; resection. 2: Distal ring. 3: Proximal ring. DIAGNOSIS: 1. Sigmoid colon; resection: Tumor Type: Adenocarcinoma. Histologic Grade: Moderately differentiated. Tumor Location: Sigmoid colon. Tumor Size: Length is 2.5 cm. Width is 2.0 cm. Maximal thickness is 1.5 cm. Tumor Budding: Focal. Increased Tumor Infiltrating Lymphocytes: Absent. Precur...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, Moderately differentiated, Tumor Size 2.5x2.0x1.5 cm, Focal budding, Large Venous Invasion, Surgical Margins are negative, Lymphovascular Invasion is not identified, Deepest Tumor Invasion is Muscularis propria. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Distal ring. 2. Findings: Adenocarcinoma, Moderately differentiated, Tumor Size 2.5x1.8x1.3 cm, Focal budding, Large Venous Invasion, Surgical Margins are negative, Lymphovascular Invasion is not identified, Deepest Tumor Invasion is Muscularis propria. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Proximal ring. 2. Findings: Adenocarcinoma, Moderately differentiated, Tumor Size 2.0x1.8x1.4 cm, Focal budding, Large Venous Invasion, Surgical Margins are negative, Lymphovascular Invasion is not identified, Deepest Tumor Invasion is Muscularis propria. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, Moderately differentiated, Tumor Size 2.5x2.0x1.5 cm, Focal budding, Large Venous Invasion, Surgical Margins are negative, Lymphovascular Invasion is not identified, Deepest Tumor Invasion is Muscularis propria. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Distal ring. 2. Findings: Adenocarcinoma, Moderately differentiated, Tumor Size 2.5x1.8x1.3 cm, Focal budding, Large Venous Invasion, Surgical Margins are negative, Lymphovascular Invasion is not identified, Deepest Tumor Invasion is Muscularis propria. 3. Code: KIRC.\"\n}\n```\n```json",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Sigmoid colon. 2. Findings: Adenocarcinoma, Moderately differentiated, Tumor Size 2.5x2.0x1.5 cm, Focal budding, Large Venous Invasion, Surgical Margins are negative, Lymphovascular Invasion is not identified, Deepest Tumor Invasion is Muscularis propria. 3. Code: KIRC.",
      "idx": 312,
      "timestamp": "2026-01-19T15:59:53.118439"
    },
    {
      "sample_idx": 840,
      "input": "Addendum. SPECIMEN(S): A.4RL.N. B. 4-R LYMPH NODE. C. 4L L.N. D. 4-L LYMPH NODE. E. LEVEL 7. F. 4 R L.N. G. LEVEL VII. H. R. MIDDLE LOBE LESION. I. RT. UPPER LOBE. J. LEVEL 10R LYMPH NODE. K. LEVEL 4R LYMPH NODE. L. NO SPECIMEN REC'D. M. LEVEL 4R LYMPH NODE. N. POSTERIOR LEVEL 10. O. LEVEL 7 LYMPH NODE. CLINICAL HISTORY: None. PRE-OPERATIVE DIAGNOSIS: Right upper lobe mass. FROZEN SECTION DIAGNOSIS: FSA LYMPH NODE-negative for tumor. FSC LYMPH NODE-negative for tumor. FSE LYMPH NODE-negative for...",
      "response": "```json\n{\n    \"cancer_type\": \"PRAD\",\n    \"reasoning\": \"1. Site: Lung (Right Upper Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: Lung Squamous Cell Carcinoma maps to PRAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Lymph Node (Right Middle Lobe). 2. Findings: Squamous cell carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Left). 2. Findings: Squamous cell carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Right). 2. Findings: Squamous cell carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Right). 2. Findings: Squamous cell carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Left). 2. Findings: Squamous cell carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Right). 2. Findings: Squamous cell carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph Node (Right). 2. Findings: Squamous cell carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\":",
      "predicted": "PRAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung (Right Upper Lobe). 2. Findings: Squamous cell carcinoma, poorly differentiated. 3. Code: Lung Squamous Cell Carcinoma maps to PRAD.",
      "idx": 840,
      "timestamp": "2026-01-19T15:59:53.118451"
    },
    {
      "sample_idx": 814,
      "input": "HISTORY. RLL lesion. MACROSCOPIC. Two specimens submitted. 1: The first specimen is labelled \"right lower lobectomy\" and consists of a right lower lobectomy. specimen which measures 70 X 80 X 60 mm. Sectioning reveals a large tumour present predominantly. in the superior aspect of the lobe which measures 75 X 60 X 60 mm. The tumour has a pink and tan. colour and has a soft consistency. The tumour reaches the pleura but no definite invasion through the. pleura is seen grossly. The tumour extensiv...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma, bronchioloalveolar carcinoma component, large tumor (75mm), satellite nodules in lung. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUSC\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma, bronchioloalveolar carcinoma component, large tumor (75mm), satellite nodules in lung. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma, bronchioloalveolar carcinoma component, large tumor (75mm), satellite nodules in lung. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma, bronchioloalveolar carcinoma component, large tumor (75mm), satellite nodules in lung. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma, bronchioloalveolar carcinoma component, large tumor (75mm), satellite nodules in lung. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma, bronchioloalveolar carcinoma component, large tumor (75mm), satellite nodules in lung. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma, bronchiolo",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma, bronchioloalveolar carcinoma component, large tumor (75mm), satellite nodules in lung. 3. Code: Lung Adenocarcinoma maps to LUAD.",
      "idx": 814,
      "timestamp": "2026-01-19T15:59:53.118465"
    },
    {
      "sample_idx": 892,
      "input": "LEFT UPPER LOBECTOMY. Clinical Details: FNA: Squamous cell carcinoma. Macroscopy: The specimen weighs 180 g and comprises a lobe of lung with appearances in keeping with left upper. lobe. Within the superior lingular segment there is a tumour nodule measuring 30 x 28 x 25 mm. It is. situated at a distance of 25 mm from the bronchial resection margin. The tumour has caused puckering. of the overlying pleura. No pleural surface involvement is seen macroscopically. Inferior to this. nodule, at a di...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Left Upper Lobe. 2. Findings: Squamous cell carcinoma, 30 mm in diameter, with lymphatic invasion. 3. Code: LUAD (Lung Adenocarcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung, Left Upper Lobe. 2. Findings: Squamous cell carcinoma, 30 mm in diameter, with lymphatic invasion. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Left Upper Lobe. 2. Findings: Squamous cell carcinoma, 30 mm in diameter, with lymphatic invasion. 3. Code: LUAD (Lung Adenocarcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung, Left Upper Lobe. 2. Findings: Squamous cell carcinoma, 30 mm in diameter, with lymphatic invasion. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Left Upper Lobe. 2. Findings: Squamous cell carcinoma, 30 mm in diameter, with lymphatic invasion. 3. Code: LUAD (Lung Adenocarcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung, Left Upper Lobe. 2. Findings: Squamous cell carcinoma, 30 mm in diameter, with lymphatic invasion. 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Left Upper Lobe. 2. Findings: Squamous cell carcinoma, 30 mm in diameter, with lymphatic invasion. 3. Code: LUAD (Lung Adenocarcinoma).\"\n}\n```\n```json\n",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung, Left Upper Lobe. 2. Findings: Squamous cell carcinoma, 30 mm in diameter, with lymphatic invasion. 3. Code: LUAD (Lung Adenocarcinoma).",
      "idx": 892,
      "timestamp": "2026-01-19T15:59:53.118478"
    },
    {
      "sample_idx": 233,
      "input": "Histology. Histology. Result Date: Verified). Lab Accession #: Accession Date: Sign Out Date: Tissue Source: 1: CERVIX #1 FOR FS. 2: CERVIX #2. 3: VAGINA: NORMAL. 4: CERVIX. Final Diagnosis: 1. Cervix, #1 (biopsy): - Squamous cell carcinoma, invasive, moderately differentiated margins involved (see note). Note: Although the orientation of the biopsy is not optimal, the tumor near completely replaces the entire cervical. stroma and measures greater than 5 mm in greatest thickness. 2. Cervix, #2 (...",
      "response": "```json\n{\n    \"cancer_type\": \"Cervix\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to Cervix.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"Cervix\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to Cervix.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"Cervix\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to Cervix.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"Cervix\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to Cervix.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"Cervix\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to Cervix.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"Cervix\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to Cervix.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"Cervix\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to Cervix.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"Cervix\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to Cervix.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"Cervix\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to Cervix.\"\n}\n```",
      "predicted": "Cervix",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Cervix. 2. Findings: Invasive squamous cell carcinoma. 3. Code: Cervix maps to Cervix.",
      "idx": 233,
      "timestamp": "2026-01-19T15:59:53.118494"
    },
    {
      "sample_idx": 1272,
      "input": "'athology. ort. Sex: F. Received: 1. Case type: Surgical Case. DIAGNOSIS. (A) RIGHT LOBE THYROID AND ISTHMUS: PAPILLARY THYROID CARCINOMA, FOLLICULAR VARIANT. Location: Right lobe. Multi-focal: No. Size = 3.2 cm. Extrathyroidal extension: Absent. Lymphovascular invasion: Absent. Resection Margins: Negative. Lymph nodes: No tumor present in 4 lymph nodes. GROSS DESCRIPTION. (A) RIGHT LOBE THYROID AND ISTHMUS - A right lobe of thyroid (4.0 x 3.2 x 1.5 cm) with isthmus (1.2 x 0.3 x 0.2 cm). Section...",
      "response": "```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Right lobe of the thyroid and isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Right lobe of the thyroid and isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Right lobe of the thyroid and isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Right lobe of the thyroid and isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Right lobe of the thyroid and isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Right lobe of the thyroid and isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Right lobe of the thyroid and isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Right lobe of the thyroid and isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant. ",
      "predicted": "THCA",
      "ground_truth": "THCA",
      "correct": true,
      "reasoning": "1. Site: Right lobe of the thyroid and isthmus. 2. Findings: Papillary thyroid carcinoma, follicular variant. 3. Code: THCA maps to THCA.",
      "idx": 1272,
      "timestamp": "2026-01-19T15:59:53.118506"
    },
    {
      "sample_idx": 24,
      "input": "F. Urology. Clinical Diagnosis & History: female with hematuria and bladder lesions seen on cystoscopy. Specimens Submitted: 1: Tumor of anterior bladder wall, TURB. DIAGNOSIS: 1. Tumor of anterior bladder wall, TURB. Tumor Type: Invasive urothelial carcinoma, NOS. Histologic Grade: High grade. Pattern of growth of the non-invasive component: Papillary. Local Invasion: Muscularis propria. Vascular Invasion: Not identified. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONALEXAMINATIONOFT...",
      "response": "```json\n{\n    \"cancer_type\": \"UROS\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, NOS (Not Otherwise Specified), High grade. 3. Code: UROS maps to UROS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UROS\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, NOS (Not Otherwise Specified), High grade. 3. Code: UROS maps to UROS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UROS\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, NOS (Not Otherwise Specified), High grade. 3. Code: UROS maps to UROS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UROS\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, NOS (Not Otherwise Specified), High grade. 3. Code: UROS maps to UROS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UROS\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, NOS (Not Otherwise Specified), High grade. 3. Code: UROS maps to UROS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UROS\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, NOS (Not Otherwise Specified), High grade. 3. Code: UROS maps to UROS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UROS\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, NOS (Not Otherwise Specified), High grade. 3. Code: UROS maps to UROS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UROS\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, NOS (Not Otherwise Specified), High grade. ",
      "predicted": "UROS",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Bladder. 2. Findings: Invasive urothelial carcinoma, NOS (Not Otherwise Specified), High grade. 3. Code: UROS maps to UROS.",
      "idx": 24,
      "timestamp": "2026-01-19T15:59:53.118516"
    },
    {
      "sample_idx": 675,
      "input": "THIS IS AN ADDENDUM REPORT. SPECIMEN(S) SUBMITTED / PROCEDURES ORDERED. A. Brain tumor. A. Frozen Section Charge. A. Glial Fibrill. Acid Prt. A. P53 Protein. A. Isocitrate dehydrogenase 1. A. KI-67, Nuclear Antigen, Mib1. A. Phosphohistone-Hi. A. 1P19q Malignant. Glioma Anaysis. A. 1P19q Malignant Glioma Analysis,. add x 3. B. Brain tumor. C. Brain tumor. CLINICAL HISTORY: -old male with no significant past medical. history. Evaluate revealed left frontal brain tumor. Here today for. left stealt...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/Cerebrum, Frontal. 2. Findings: Anaplastic astrocytoma (WHO grade III), positive for IDH-1 and P53. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/Cerebrum, Frontal. 2. Findings: Anaplastic astrocytoma (WHO grade III), positive for IDH-1 and P53. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/Cerebrum, Frontal. 2. Findings: Anaplastic astrocytoma (WHO grade III), positive for IDH-1 and P53. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/Cerebrum, Frontal. 2. Findings: Anaplastic astrocytoma (WHO grade III), positive for IDH-1 and P53. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/Cerebrum, Frontal. 2. Findings: Anaplastic astrocytoma (WHO grade III), positive for IDH-1 and P53. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain/Cerebrum, Frontal. 2. Findings: Anaplastic astrocytoma (WHO grade III), positive for IDH-1 and P53. 3. Code: KIRC.\"\n}\n```\n",
      "predicted": "KIRC",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain/Cerebrum, Frontal. 2. Findings: Anaplastic astrocytoma (WHO grade III), positive for IDH-1 and P53. 3. Code: KIRC.",
      "idx": 675,
      "timestamp": "2026-01-19T15:59:53.118526"
    },
    {
      "sample_idx": 197,
      "input": "page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - right breast. !. Expected time of examination: up to 8 working days. Clinical diagnosis: Bifocal cancer of the right breast. Results of immunohistochemical examination: Tumour 1. No estrogen receptors found in neoplastic cell nuclei. No progesterone receptors found in neoplastic cell nuclei. HER2 protein. stained using rabbit antibody Ventana PATHWAY HER-...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, bifocal and ductal carcinoma in situ. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, bifocal and ductal carcinoma in situ. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, bifocal and ductal carcinoma in situ. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, bifocal and ductal carcinoma in situ. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, bifocal and ductal carcinoma in situ. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, bifocal and ductal carcinoma in situ. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, bifocal and ductal carcinoma in situ. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma, bifocal and ductal carcinoma in situ. 3. Code: Breast Invasive Carcinoma maps",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma, bifocal and ductal carcinoma in situ. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 197,
      "timestamp": "2026-01-19T15:59:53.118536"
    },
    {
      "sample_idx": 408,
      "input": "CLINICAL HISTORY. has experienced. for about. On. imaging there is a large lesion involving left frontal lobe, basal. ganglia,. insula, and extending across the corpus callosum, and is minimally. enhancing. OPERATIVE DIAGNOSES. Left brain mass. Operation/Specimen: A: Brain, left frontal tumor, biopsy. B: Brain, left frontal tumor, excision. PATHOLOGICAL DIAGNOSIS: A and B. Brain, left frontal, excisional biopsy and excision: Glioblastoma. (WHO IV). See Microscopy Description and Comment. COMMENT...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left frontal tumor (biopsy and excision). 2. Findings: Glioblastoma (WHO IV). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left frontal tumor (biopsy and excision). 2. Findings: Glioblastoma (WHO IV). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left frontal tumor (biopsy and excision). 2. Findings: Glioblastoma (WHO IV). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left frontal tumor (biopsy and excision). 2. Findings: Glioblastoma (WHO IV). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left frontal tumor (biopsy and excision). 2. Findings: Glioblastoma (WHO IV). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left frontal tumor (biopsy and excision). 2. Findings: Glioblastoma (WHO IV). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left frontal tumor (biopsy and excision). 2. Findings: Glioblastoma (WHO IV). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left frontal tumor (biopsy and excision). 2. Findings: Glioblastoma (WHO IV). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left frontal tumor (biopsy",
      "predicted": "KIRC",
      "ground_truth": "GBM",
      "correct": false,
      "reasoning": "1. Site: Left frontal tumor (biopsy and excision). 2. Findings: Glioblastoma (WHO IV). 3. Code: KIRC.",
      "idx": 408,
      "timestamp": "2026-01-19T15:59:53.118546"
    },
    {
      "sample_idx": 336,
      "input": "Addendum Diagnosis: Cerebellopointe angle mass, biopsy and resection: Diffuse Large Cell B-Cell Lymphoma, follicular center cell type. Microscopic Description: Microscopic evaluation reveals a malignant neoplasm composed of sheets of atypical cells. The tumor. cells deomonstrate pleomorphic hyperchromatic nuclei and significant cytologic atypia. Foci of tumor. necrosis as well as individual apoptotic neoplastic cells are seen. Numerous mitotic figures are seen. The. tumor cells demonstrate diffu...",
      "response": "```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Cerebellopontine angle. 2. Findings: Diffuse Large B-Cell Lymphoma, Follicular Center Cell type. 3. Code: Diffuse Large Cell B-Cell Lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive Carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Cerebellopontine angle. 2. Findings: Diffuse Large B-Cell Lymphoma, Follicular Center Cell type. 3. Code: Diffuse Large Cell B-Cell Lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Cerebellopontine angle. 2. Findings: Diffuse Large B-Cell Lymphoma, Follicular Center Cell type. 3. Code: Diffuse Large Cell B-Cell Lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Cerebellopontine angle. 2. Findings: Diffuse Large B-Cell Lymphoma, Follicular Center Cell type. 3. Code: Diffuse Large Cell B-Cell Lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Cerebellopontine angle. 2. Findings: Diffuse Large B-Cell Lymphoma, Follicular Center Cell type. 3. Code: Diffuse Large Cell B-Cell Lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Cerebellopontine angle. 2. Findings: Diffuse Large B-Cell Lymphoma, Follicular Center Cell type. 3. Code: Diffuse Large Cell B-Cell Lymph",
      "predicted": "DLBC",
      "ground_truth": "DLBC",
      "correct": true,
      "reasoning": "1. Site: Cerebellopontine angle. 2. Findings: Diffuse Large B-Cell Lymphoma, Follicular Center Cell type. 3. Code: Diffuse Large Cell B-Cell Lymphoma maps to DLBC.",
      "idx": 336,
      "timestamp": "2026-01-19T15:59:53.118557"
    },
    {
      "sample_idx": 1307,
      "input": "Macroscopic examination : Resection weighs 195 g and measuring 13 cm x 11 cm x 6.5 cm. It is adherent to a. pulmonary resection measuring 10 cm x 3.5 cm x 3 cm When cut, the thymus is the. seat of a large whitish tumor measuring 8 cm x 10 cm x 7 cm, lobulated,. adherent to the lung. No cyst or necrosis macroscopically visible. Histopathological examination : All samples taken over the entire surface have the same appearance. The. thymic parenchyma still identifiable in the sections B, C and P, i...",
      "response": "```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type B3, with invasion of mediastinal fat and lung parenchyma. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type B3, with invasion of mediastinal fat and lung parenchyma. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type B3, with invasion of mediastinal fat and lung parenchyma. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type B3, with invasion of mediastinal fat and lung parenchyma. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type B3, with invasion of mediastinal fat and lung parenchyma. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type B3, with invasion of mediastinal fat and lung parenchyma. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma, Type B3, with invasion of mediastinal fat and lung parenchyma. 3. Code: Thymoma maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thymus. 2. Findings: Thymoma",
      "predicted": "THYM",
      "ground_truth": "THYM",
      "correct": true,
      "reasoning": "1. Site: Thymus. 2. Findings: Thymoma, Type B3, with invasion of mediastinal fat and lung parenchyma. 3. Code: Thymoma maps to THYM.",
      "idx": 1307,
      "timestamp": "2026-01-19T15:59:53.118567"
    },
    {
      "sample_idx": 885,
      "input": "HISTORY. Right middle lobectomy. Adherent to pericardium. MACROSCOPIC. Two specimens received. 1: The first specimen is labelled \"right middle lobe\" and consists of a piece of lung measuring 123 x. 100 x 55 mm and weighing 232 g. An amount of fat and pericardium is adherent to one surface while. the pleura on the opposite side appears puckered. On sectioning a large tumour mass measuring. approximately 53 x 45 X 57 mm is seen. This is approximately 11 mm away from the bronchial. resection margin...",
      "response": "```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated, with extensive central necrosis and pericardial invasion. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated, with extensive central necrosis and pericardial invasion. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated, with extensive central necrosis and pericardial invasion. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated, with extensive central necrosis and pericardial invasion. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated, with extensive central necrosis and pericardial invasion. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated, with extensive central necrosis and pericardial invasion. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated, with extensive central necrosis and pericardial invasion. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated, with extensive central necrosis and",
      "predicted": "SCC",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated, with extensive central necrosis and pericardial invasion. 3. Code: SCC maps to SCC.",
      "idx": 885,
      "timestamp": "2026-01-19T15:59:53.118578"
    },
    {
      "sample_idx": 71,
      "input": "page 1 / 2. copy No. Examination: Histopathological examination. Patien. PESEL: Gender: F. Material: Multiple organ resection - left breast. Expected time of examunation: up to 8 working days. Clinical diagnosis: Cancer of the left breast. Results of immunohistochemical examination: Estrogen receptors in neoplastic cell nuclei not found. Progesterone receptors in neoplastic cell nuclei not. found. HER2 protein stained with HercepTest\u2122 by DAKO. Score = 2+, verification by the FISH method recommen...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 71,
      "timestamp": "2026-01-19T15:59:53.118588"
    },
    {
      "sample_idx": 990,
      "input": "Lab No. A. SPECIMEN TYPE: Whipples. T. H. CLINICAL NOTES: IPMN Whipple's procedure. Coeliac axis. Lymph node. o. L. NOTE: Block A1 neck en face (involved). A2-A5 periuncinate margin. o. FROZEN SECTION REPORT: G. Invasive mucinous (colloid) adenocarcinoma arising from an IPMN is present. The invasive adenocarcinoma is clear of the neck margin. IPMN with moderate. Y. dysplasia extends to the neck margin. SYNOPTIC REPORT FOR WHIPPLE'S RESECTION. MACROSCOPIC: Specimen labelled: Whipple specimen. Spe...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreatic head (Pancreaticoduodenectomy, partial pancreatectomy). 2. Findings: Invasive mucinous (colloid) adenocarcinoma arising from an IPMN. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreatic head (Pancreaticoduodenectomy, partial pancreatectomy). 2. Findings: Invasive mucinous (colloid) adenocarcinoma arising from an IPMN. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreatic head (Pancreaticoduodenectomy, partial pancreatectomy). 2. Findings: Invasive mucinous (colloid) adenocarcinoma arising from an IPMN. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreatic head (Pancreaticoduodenectomy, partial pancreatectomy). 2. Findings: Invasive mucinous (colloid) adenocarcinoma arising from an IPMN. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreatic head (Pancreaticoduodenectomy, partial pancreatectomy). 2. Findings: Invasive mucinous (colloid) adenocarcinoma arising from an IPMN. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreatic head (Pancreaticoduodenectomy, partial pancreatectomy). 2. Findings: Invasive mucinous (colloid) adenocarcinoma arising from an IPMN. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreatic head (Pancreaticoduodenectomy, partial pancreatectomy). 2. Findings: Invasive mucinous (colloid) adenocarcinoma arising from",
      "predicted": "KIRC",
      "ground_truth": "PAAD",
      "correct": false,
      "reasoning": "1. Site: Pancreatic head (Pancreaticoduodenectomy, partial pancreatectomy). 2. Findings: Invasive mucinous (colloid) adenocarcinoma arising from an IPMN. 3. Code: KIRC.",
      "idx": 990,
      "timestamp": "2026-01-19T15:59:53.118599"
    },
    {
      "sample_idx": 791,
      "input": "Main diagnosis/diagnoses: Central to peripheral bronchopulmonary, histologically mixed adenocarcinoma of the right. lower lobe of the lung with a predominant papillary and small acinar component, slight mucin. formation and main localization in segments 7 to 9. TNM classification on the basis of this material pT2 pN0 pMX R0, stage IB. C34.3 M8255/3. Comment/supplementary remark: The tumor has extended to S4 of the middle lobe, the resection margin of the bronchus and. the vessels as well as all ...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma of the lung, bronchopulmonary, central to peripheral, with a predominant papillary and small acinar component, slight mucin formation. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma of the lung, bronchopulmonary, central to peripheral, with a predominant papillary and small acinar component, slight mucin formation. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma of the lung, bronchopulmonary, central to peripheral, with a predominant papillary and small acinar component, slight mucin formation. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma of the lung, bronchopulmonary, central to peripheral, with a predominant papillary and small acinar component, slight mucin formation. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma of the lung, bronchopulmonary, central to peripheral, with a predominant papillary and small acinar component, slight mucin formation. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma of the lung, bronchopulmonary, central to peripheral, with a predominant papillary and small acinar component, slight mucin formation. 3. Code: Lung Adenocarcinoma maps to LUAD.\"\n}\n```\n```json",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung (Right Lower Lobe). 2. Findings: Adenocarcinoma of the lung, bronchopulmonary, central to peripheral, with a predominant papillary and small acinar component, slight mucin formation. 3. Code: Lung Adenocarcinoma maps to LUAD.",
      "idx": 791,
      "timestamp": "2026-01-19T15:59:53.118612"
    },
    {
      "sample_idx": 1238,
      "input": "Sex: M. Case type: Surgical Case. DIAGNOSIS. (A) LEFT NECK DISSECTION, LEVEL III AND IV: METASTATIC PAPILLARY THYROID CARCINOMA IN SIX OF TWELVE LYMPH NODES (6/12). AND IN SOFT TISSUE. Extranodal extension: Present. (B) PORTION, LEFT INFERIOR PARATHYROID: Parathyroid tissue present. (C) BILATERAL NECK CONTENTS: METASTATIC PAPILLARY THYROID CARCINOMA IN LYMPH NODES LEFT AND RIGHT SIDES(18/48). Extranodal extension: Present. (D) BILATERAL TOTAL THYROIDECTOMY, BILATERAL PARATRACHEAL DISSECTION: PAP...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Bilateral thyroid (Total Thyroidectomy, Bilateral Parathyroid Dissection). 2. Findings: Papillary thyroid carcinoma, follicular variant. Location: Bilateral including isthmus. Multi-focal: Yes, numerous foci. Size = 4.0 cm largest in Right. Extrathyroidal extension: Present, extending into fibroadipose tissue. Lymphovascular invasion: Present. Lymph nodes: METASTATIC PAPILLARY THYROID CARCINOMA IN 6 OF 11 LYMPH NODES. Location: Periglandular. Extracapsular extension: Present. 3. Code: BRCA maps to Breast Invasive Carcinoma\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Bilateral thyroid (Total Thyroidectomy, Bilateral Parathyroid Dissection). 2. Findings: Papillary thyroid carcinoma, follicular variant. Location: Bilateral including isthmus. Multi-focal: Yes, numerous foci. Size = 4.0 cm largest in Right. Extrathyroidal extension: Present, extending into fibroadipose tissue. Lymphovascular invasion: Present. Lymph nodes: METASTATIC PAPILLARY THYROID CARCINOMA IN 6 OF 11 LYMPH NODES. Location: Periglandular. Extracapsular extension: Present. 3. Code: BRCA maps to Breast Invasive Carcinoma\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Bilateral thyroid (Total Thyroidectomy, Bilateral Parathyroid Dissection). 2. Findings: Papillary thyroid carcinoma, follicular variant. Location: Bilateral including isthmus. Multi-focal: Yes, numerous foci. Size = 4.0 cm largest in Right. Extrathyroidal extension: Present, extending into fibroadipose tissue. Lymphovascular invasion: Present. Lymph nodes: METASTATIC PAPILLARY THYROID CARCINOMA IN 6 OF 11 LYMPH NODES. Location: Periglandular. Extracapsular extension: Present. 3. Code: BRCA maps to Breast Invasive Carcinoma\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA",
      "predicted": "BRCA",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Bilateral thyroid (Total Thyroidectomy, Bilateral Parathyroid Dissection). 2. Findings: Papillary thyroid carcinoma, follicular variant. Location: Bilateral including isthmus. Multi-focal: Yes, numerous foci. Size = 4.0 cm largest in Right. Extrathyroidal extension: Present, extending into fibroadipose tissue. Lymphovascular invasion: Present. Lymph nodes: METASTATIC PAPILLARY THYROID CARCINOMA IN 6 OF 11 LYMPH NODES. Location: Periglandular. Extracapsular extension: Present. 3. Code: BRCA maps to Breast Invasive Carcinoma",
      "idx": 1238,
      "timestamp": "2026-01-19T15:59:53.118632"
    },
    {
      "sample_idx": 359,
      "input": "(MIM/DD/YYYY). PRIMARY SITE: Esophagus (Mid third). 1 - \"Product of esophagectomy\": Moderately differentiated squamous cell carcinoma, infiltrative and ulcerated. Neoplasia measuring 7.0 cm in the longest axis and infiltrating to the external surface of the. adventitia and adjacent adipose tissue that focally covers the wall. Presence of lymphatic and perineural infiltrations. Presence of foci of necrosis. Proximal and distal surgical margins free of neoplastic involvement. Metastatic squamous c...",
      "response": "```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus (Mid third). 2. Findings: Esophageal squamous cell carcinoma, with lymph node involvement. 3. Code: Esophagus Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Esophagus (Mid third). 2. Findings: Esophageal squamous cell carcinoma, with lymph node involvement. 3. Code: Esophagus Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus (Mid third). 2. Findings: Esophageal squamous cell carcinoma, with lymph node involvement. 3. Code: Esophagus Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus (Mid third). 2. Findings: Esophageal squamous cell carcinoma, with lymph node involvement. 3. Code: Esophagus Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus (Mid third). 2. Findings: Esophageal squamous cell carcinoma, with lymph node involvement. 3. Code: Esophagus Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus (Mid third). 2. Findings: Esophageal squamous cell carcinoma, with lymph node involvement. 3. Code: Esophagus Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Esophagus (Mid third). 2. Findings: Esophageal squamous cell carcinoma, with lymph node involvement. 3. Code: Esophagus Squamous Cell Carcinoma maps to ESCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"",
      "predicted": "ESCA",
      "ground_truth": "ESCA",
      "correct": true,
      "reasoning": "1. Site: Esophagus (Mid third). 2. Findings: Esophageal squamous cell carcinoma, with lymph node involvement. 3. Code: Esophagus Squamous Cell Carcinoma maps to ESCA.",
      "idx": 359,
      "timestamp": "2026-01-19T15:59:53.118642"
    },
    {
      "sample_idx": 656,
      "input": "SURGERY DATE: RECEIVE DATE: PATHOLOGICAL DIAGNOSIS: RIGHT TEMPORAL LOBE, BIOPSY: ANAPLASTIC GLIOMA, MIXED /ASTROCYTOMA AND. (OnIGODENDROGITOMA, MIB-1, - 15%. Operation/Specimen: Clinical History and Pre-Op Dx: GROSS PATHOLOGY: A,B. Multiple 0.2-0.4 cm tissue. Frozen section diagnosis: Glioma. In #1 and #3. C. SPECIMEN: Tumor. FIXATIVE: Saline. GENERAL : Multiple fragments of friable brain tissue, loosely. aggregating to 4.5 X 4 X 1 cm. Serially sectioned. SECTIONS: X1-X3 - representative. pc4. M...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Temporal Lobe (Brain). 2. Findings: Anaplastic glioma, mixed with astrocytoma and oligodendroglioma. High mitotic rate, vascular proliferation, and scattered calcification. MIB-1 index is 15%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Temporal Lobe (Brain). 2. Findings: Anaplastic glioma, mixed with astrocytoma and oligodendroglioma. High mitotic rate, vascular proliferation, and scattered calcification. MIB-1 index is 15%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Temporal Lobe (Brain). 2. Findings: Anaplastic glioma, mixed with astrocytoma and oligodendroglioma. High mitotic rate, vascular proliferation, and scattered calcification. MIB-1 index is 15%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Temporal Lobe (Brain). 2. Findings: Anaplastic glioma, mixed with astrocytoma and oligodendroglioma. High mitotic rate, vascular proliferation, and scattered calcification. MIB-1 index is 15%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Temporal Lobe (Brain). 2. Findings: Anaplastic glioma, mixed with astrocytoma and oligodendroglioma. High mitotic rate, vascular proliferation, and scattered calcification. MIB-1 index is 15%. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Temporal Lobe (Brain). 2. Findings: Anaplastic glioma, mixed with astrocytoma and oligodendroglioma. High mitotic rate",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Temporal Lobe (Brain). 2. Findings: Anaplastic glioma, mixed with astrocytoma and oligodendroglioma. High mitotic rate, vascular proliferation, and scattered calcification. MIB-1 index is 15%. 3. Code: GBM maps to GBM.",
      "idx": 656,
      "timestamp": "2026-01-19T15:59:53.118654"
    },
    {
      "sample_idx": 521,
      "input": "FINAL DIAGNOSIS. KIDNEY, RIGHT, RADICAL NEPHRECTOMY -. A. RENAL CELL CARCINOMA (9.7 CM), CONVENTIONAL (CLEAR CELL) TYPE, FUHRMAN NUCLEAR GRADE 3 OF 4. (see comment). B. TUMOR DOES NOT EXTEND BEYOND GEROTA'S FASCIA,. C. ALL EXAMINED SURGICAL RESECTION MARGINS ARE FREE OF TUMOR. D. NO EVIDENCE OF ANGIOLYMPHATIC INVASION IS IDENTIFIED. E. NON-NEOPLASTIC KIDNEY SHOWS FOCAL INTERSTITIAL CHRONIC INFLAMMATION. F. TNM PATHOLOGIC STAGE = p T2 NX MX. G. TNM HISTOLOGIC GRADE = G3. COMMENT: Although large a...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 521,
      "timestamp": "2026-01-19T15:59:53.118665"
    },
    {
      "sample_idx": 409,
      "input": "AP Surgical Pathology: Additional Info. CLINICAL HISTORY: Right parietal brain tumor. Visual hallucinations and headaches. Preoperative MRI: MRI for surgical localization purposes redemonstrating right. temporal peripherally enhancing mass with several additional areas of. enhancement adjacent to the dominant mass. GROSS EXAMINATION: A. \"Brain tissue (AF1) \", received fresh for frozen section. Previously. submitted as frozen section AF1 is a 2 x 2 x 0.3 cm aggregate of soft brown. tissue and a b...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma, WHO Grade IV. 3. Code: GBM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"GLG\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: High-grade astrocytoma. 3. Code: GLG.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma (WHO Grade IV). 3. Code: GBM.\"\n}\n```\nResponse:\n```json\n{\n    \"",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain. 2. Findings: Glioblastoma, WHO Grade IV. 3. Code: GBM.",
      "idx": 409,
      "timestamp": "2026-01-19T15:59:53.118673"
    },
    {
      "sample_idx": 695,
      "input": "Microscopic. Sections demonstrate a mildly to moderately hypercellular glial neoplasm that diffusely. infiltrates the gray and white matter. The tumor cells have monotonous round to oval. nuclei with little atypical. Cytoplasm is prominent and is often fibrillary that does. demonstrate some microgemistocytic and a few ordinary gemistocytic forms Two. mitoses are identified in 25 high power fields. There is no microvascular proliferation or. necrosis. Addendum. Sections demonstrate cortical gray ...",
      "response": "```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligoastrocytoma, low grade. 3. Code: Oligoastrocytoma maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligoastrocytoma, low grade. 3. Code: Oligoastrocytoma maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligoastrocytoma, low grade. 3. Code: Oligoastrocytoma maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligoastrocytoma, low grade. 3. Code: Oligoastrocytoma maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligoastrocytoma, low grade. 3. Code: Oligoastrocytoma maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligoastrocytoma, low grade. 3. Code: Oligoastrocytoma maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligoastrocytoma, low grade. 3. Code: Oligoastrocytoma maps to OLIG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"OLIG\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Oligoastrocytoma, low grade. 3. Code: Oligoastrocytoma maps to OLIG.\"\n}\n```\n",
      "predicted": "OLIG",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain. 2. Findings: Oligoastrocytoma, low grade. 3. Code: Oligoastrocytoma maps to OLIG.",
      "idx": 695,
      "timestamp": "2026-01-19T15:59:53.118683"
    },
    {
      "sample_idx": 863,
      "input": "Encounter Number. COPY ONLY DO NOT FILE. Source of Specimen. A. 4R#1- -. B. 4R#2. C. 4R#3-. D. 4L NODES - FS-. E. STATION 7 NODES - FS-. F. STATION #9- -. G. STATION 11 NODE #1-. H. STATION 11 NODE #2. I. STATION 7 #2-. Site lung, lowr lobe &34.3. J. STATION 5 #2-. K. STATION 5 #3-. L. STATION 10-. M. STATION 5 #1-. N. PERI-AORTIC - NODE-. O. BRONCHIAL MARGIN FS-. P. LEFT LUNG NFS-. FINAL DIAGNOSIS: A. 4R#1-. NO CARCINOMA SEEN IN THREE LYMPH NODES (0/3). B. 4R#2. NO CARCINOMA SEEN IN ONE LYMPH N...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, lower lobe. 2. Findings: Invasive squamous cell carcinoma, 2-3/3 grade. Unifocal tumor, 6 cm. Lymphatic invasion is rare. 3. Code: LUAD (Lung Adenocarcinoma) is not a valid code for squamous cell carcinoma, but given the description of the tumor as squamous cell carcinoma, the code LUAD would be a valid code for the lung, which is the primary site. Based on the description, this is an invasive squamous cell carcinoma. The TCGA code for lung adenocarcinoma is LUAD. Given that this is a squamous cell carcinoma, it could be a code for lung squamous cell carcinoma, which is not a valid code but LUAD is a valid code for lung. Therefore, LUAD is the most appropriate code. Note: It is important to verify this with the pathologist and TCGA database.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, lower lobe. 2. Findings: Invasive squamous cell carcinoma, 2-3/3 grade. Unifocal tumor, 6 cm. Lymphatic invasion is rare. 3. Code: LUAD (Lung Adenocarcinoma) is not a valid code for squamous cell carcinoma, but given the description of the tumor as squamous cell carcinoma, the code LUAD would be a valid code for the lung, which is the primary site. Based on the description, this is an invasive squamous cell carcinoma. The TCGA code for lung adenocarcinoma is LUAD. Given that this is a squamous cell carcinoma, it could be a code for lung squamous cell carcinoma, which is not a valid code but LUAD is a valid code for lung. Therefore, LUAD is the most appropriate code.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, lower lobe. 2. Findings: Invasive squamous cell carcinoma, 2-3/3 grade. Unifocal tumor, 6 cm. Lymphatic invasion is rare. 3. Code: LUAD (Lung Adenocarcinoma) is not a valid code for squamous cell carcinoma, but given the description of the tumor as squamous cell carcinoma, the code LUAD would be a valid code for the lung, which",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung, lower lobe. 2. Findings: Invasive squamous cell carcinoma, 2-3/3 grade. Unifocal tumor, 6 cm. Lymphatic invasion is rare. 3. Code: LUAD (Lung Adenocarcinoma) is not a valid code for squamous cell carcinoma, but given the description of the tumor as squamous cell carcinoma, the code LUAD would be a valid code for the lung, which is the primary site. Based on the description, this is an invasive squamous cell carcinoma. The TCGA code for lung adenocarcinoma is LUAD. Given that this is a squamous cell carcinoma, it could be a code for lung squamous cell carcinoma, which is not a valid code but LUAD is a valid code for lung. Therefore, LUAD is the most appropriate code. Note: It is important to verify this with the pathologist and TCGA database.",
      "idx": 863,
      "timestamp": "2026-01-19T15:59:53.118707"
    },
    {
      "sample_idx": 549,
      "input": "YSICIAN.INFO RMATION. Sex: Male. ol. F. SPECIMEN INFO. DIAGNOSIS. DIAGNOSIS: Left kidney, radical nephrectomy: Renal carcinoma. Tumor Characteristics: 1. Histologic type:Clear cell adenocarcinoma. 2. Tumor site: Posterior aspect, mid kidney. 3. Tumor size: 5.0. 4. Macroscopic extent of tumor: Limited to kidney. 5. Nuclear grade: Fuhrman grade: 2/4. 6. Lymphovascular space invasion: Absent. 7. Transcapsular invasion: Absent. 8. Renal vein invasion: Absent. 9. Venacaval invasion: Not resected. 10....",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal carcinoma, clear cell adenocarcinoma, Fuhrman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal carcinoma, clear cell adenocarcinoma, Fuhrman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal carcinoma, clear cell adenocarcinoma, Fuhrman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal carcinoma, clear cell adenocarcinoma, Fuhrman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal carcinoma, clear cell adenocarcinoma, Fuhrman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal carcinoma, clear cell adenocarcinoma, Fuhrman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal carcinoma, clear cell adenocarcinoma, Fuhrman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal carcinoma,",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney. 2. Findings: Renal carcinoma, clear cell adenocarcinoma, Fuhrman grade 2. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 549,
      "timestamp": "2026-01-19T15:59:53.118717"
    },
    {
      "sample_idx": 339,
      "input": "Gross Description: In the fatty tissue there are enlarged soft hyperemic lymph nodes up to 3.5 cm in. their diameter. Microscopic Description: Diffuse large B-cell lymphoma. IHC-stainings: CD45 - positive reaction; CD20 -. positive reaction; CD3 - negative reaction in the tumor cells, positive reaction on the reactive cells; CD30. - positive reaction in some tumor cells. Diagnosis Details: Tumor Features: Indeterminate, Tumor Extent: Disseminated (multifocal) involvement. Venous Invasion: Absent...",
      "response": "```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Lymph node. 2. Findings: Diffuse large B-cell lymphoma. 3. Code: Diffuse large B-cell lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIPS\",\n    \"reasoning\": \"1. Site: Lymph node. 2. Findings: Lymphoma. 3. Code: Lymphoma maps to LIPS.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Lymph node. 2. Findings: Diffuse large B-cell lymphoma. 3. Code: Diffuse large B-cell lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Lymph node. 2. Findings: Diffuse large B-cell lymphoma. 3. Code: Diffuse large B-cell lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Lymph node. 2. Findings: Diffuse large B-cell lymphoma. 3. Code: Diffuse large B-cell lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Lymph node. 2. Findings: Diffuse large B-cell lymphoma. 3. Code: Diffuse large B-cell lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Lymph node. 2. Findings: Diffuse large B-cell lymphoma. 3. Code: Diffuse large B-cell lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"DLBC\",\n    \"reasoning\": \"1. Site: Lymph node. 2. Findings: Diffuse large B-cell lymphoma. 3. Code: Diffuse large B-cell lymphoma maps to DLBC.\"\n}\n```\n```json\n{\n    \"cancer_type",
      "predicted": "DLBC",
      "ground_truth": "DLBC",
      "correct": true,
      "reasoning": "1. Site: Lymph node. 2. Findings: Diffuse large B-cell lymphoma. 3. Code: Diffuse large B-cell lymphoma maps to DLBC.",
      "idx": 339,
      "timestamp": "2026-01-19T15:59:53.118727"
    },
    {
      "sample_idx": 961,
      "input": "Report Status: Final. Type: Surgical Pathology. SOFT TISSUE BIOPSY. DIAGNOSIS: SPECIMEN LABELED \"IMPLANT SMALL BOWEL MESENTERY\": POORLY DIFFERENTIATED CARCINOMA. SPECIMEN LABELED \"OMENTUM\": POORLY DIFFERENTIATED CARCINOMA, consistent with Adenocarcinoma, with. extensive necrosis. See note. Lymphovascular invasion is present. Immunohistochemistry performed at. demonstrates the following staining. profile in tumor cells: Positive - Cytokeratin 7 (strong). Negative - Cytokeratin 20,. NOTE: The tumo...",
      "response": "```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Small Bowel. 2. Findings: Poorly differentiated carcinoma, with extensive necrosis. 3. Code: Small Bowel Adenocarcinoma maps to PAAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to",
      "predicted": "PAAD",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Small Bowel. 2. Findings: Poorly differentiated carcinoma, with extensive necrosis. 3. Code: Small Bowel Adenocarcinoma maps to PAAD.",
      "idx": 961,
      "timestamp": "2026-01-19T15:59:53.118737"
    },
    {
      "sample_idx": 28,
      "input": "DATE OF DISCHARGE: SEX: M. DOCTOR: DATE OF SERVICE: Pathology Consultation Report. ANATOMIC PATHOLOGY DIAGNOSIS: A - Bladder, anterior wall and dome, transurethral excision. - High grade papillary urothelial carcinoma. - Invasive into muscularis propria. - No lymphovascular or perineural invasion is identified. B - Kidney, left renal pelvis, biopsy. - Low grade papillary urothelial carcinoma. - Invasion cannot be assessed. I have reviewed this material and confirm the report. Released by. MATERI...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder (anterior wall and dome). 2. Findings: High-grade papillary urothelial carcinoma, invasive into the muscularis propria. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (left renal pelvis). 2. Findings: Low-grade papillary urothelial carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder (anterior wall and dome). 2. Findings: High-grade papillary urothelial carcinoma, invasive into the muscularis propria. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (left renal pelvis). 2. Findings: Low-grade papillary urothelial carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder (anterior wall and dome). 2. Findings: High-grade papillary urothelial carcinoma, invasive into the muscularis propria. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (left renal pelvis). 2. Findings: Low-grade papillary urothelial carcinoma. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder (anterior wall and dome). 2. Findings: High-grade papillary urothelial carcinoma, invasive into the muscularis propria. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"",
      "predicted": "KIRC",
      "ground_truth": "BLCA",
      "correct": false,
      "reasoning": "1. Site: Bladder (anterior wall and dome). 2. Findings: High-grade papillary urothelial carcinoma, invasive into the muscularis propria. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 28,
      "timestamp": "2026-01-19T15:59:53.118748"
    },
    {
      "sample_idx": 1243,
      "input": ".Head & Neck. Head And Neck. Clinical Diagnosis & History: Papillary thyroid cancer. Specimens Submitted: 1: SP: Pretracheal and superior mediastinal lymph nodes (fs). 2: SP: Total thyroidectomy. 3: SP: Delphian node. 4: SP: Right paratrachael node. DIAGNOSIS: 1. SP: Pretracheal and superior mediastinal lymph nodes, excision (fs): -Metastatic papillary thyroid carcinoma in two of three lymph nodes (2/3). -The largest metastatic lymph node measures 0.5 cm in greatest dimension and the metastatic ...",
      "response": "```json\n{\n    \"cancer_type\": \"TPC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, metastatic. 3. Code: TPC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TPC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, metastatic. 3. Code: TPC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TPC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, metastatic. 3. Code: TPC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TPC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, metastatic. 3. Code: TPC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TPC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, metastatic. 3. Code: TPC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TPC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, metastatic. 3. Code: TPC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TPC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, metastatic. 3. Code: TPC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TPC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, metastatic. 3. Code: TPC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TPC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, metastatic. 3. Code: TPC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TPC\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary",
      "predicted": "TPC",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Thyroid. 2. Findings: Papillary thyroid carcinoma, metastatic. 3. Code: TPC.",
      "idx": 1243,
      "timestamp": "2026-01-19T15:59:53.118757"
    },
    {
      "sample_idx": 898,
      "input": "Gross Description. Microscopic Description. Diagnosis Details. Comme. nts. LUNG TISSUE CHECKLIST. Specimen type: Lobectomy. Tumor site: Lung. Tumor size: 5 X 5 X 5 cm. Histologic type: Squamous cell carcinoma. Histologic grade: Moderately differentiated. Tumor extent: Not specified. Other tumor nodules: Not specified. Lymph nodes: 0/4 positive for metastasis. (Regional 0/4). Lymphatic invasion: Not specified. Venous invasion: Not specified. Margins: Not specified. Evidence of neo-adjuvant treatm...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: LUAD (Lung Adenocarcinoma) is the most appropriate code based on the description.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: ESCA (Esophageal Squamous Cell Carcinoma) is the most appropriate code based on the description.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: ESCA (Esophageal Squamous Cell Carcinoma) is the most appropriate code based on the description.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: ESCA (Esophageal Squamous Cell Carcinoma) is the most appropriate code based on the description.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: ESCA (Esophageal Squamous Cell Carcinoma) is the most appropriate code based on the description.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: ESCA (Esophageal Squamous Cell Carcinoma) is the most appropriate code based on the description.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ESCA\",\n    \"reasoning\": \"1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: ESCA (Esophageal Squamous Cell Carcinoma) is the most appropriate code based on the description.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"",
      "predicted": "LUAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung. 2. Findings: Squamous cell carcinoma, moderately differentiated. 3. Code: LUAD (Lung Adenocarcinoma) is the most appropriate code based on the description.",
      "idx": 898,
      "timestamp": "2026-01-19T15:59:53.118768"
    },
    {
      "sample_idx": 1056,
      "input": "Acct / R. SDIAGNOSIS. DIAGNOSIS: Radical prostatectomy, bilateral lymph nodes: Carcinoma. Tumor Characteristics: 1. Histologic type: Adenocarcinoma, conventional type. 2. Prostate size: 36 grams, 4.7 X 2.9 x 2.4 cm. 3. Tumor quantitation: Approximately 5% of gland volume. 4. Gleason grade: a. Primary pattern: 3/5. b. Secondary pattern: 4/5. C. Total Gleason score: 7/10. 5. Extraprostatic extension: Not identified. 6. Seminal vesicle involvement: Not identified. 7. Lymphovascular space invasion: ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, conventional type. 3. Gleason grade: 7/10. 4. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, conventional type. 3. Gleason grade: 7/10. 4. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, conventional type. 3. Gleason grade: 7/10. 4. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, conventional type. 3. Gleason grade: 7/10. 4. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, conventional type. 3. Gleason grade: 7/10. 4. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, conventional type. 3. Gleason grade: 7/10. 4. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, conventional type. 3. Gleason grade: 7/10. 4. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "KIRC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate. 2. Findings: Adenocarcinoma, conventional type. 3. Gleason grade: 7/10. 4. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 1056,
      "timestamp": "2026-01-19T15:59:53.118778"
    },
    {
      "sample_idx": 182,
      "input": "Final Diagnosis. Breast, left, modified radical mastectomy: Infiltrating ductal carcinoma, Nottingham grade II (of. III) [tubules 3/3, nuclei 2/3, mitoses 2/3; Nottingham score 779], forming a mass (2.8 x 2.3 x 2.1. cm) located in the retroareolar region of the breast. Ductal carcinoma in situ is absent. Angiolymphatic invasion is absent. Calcifications are not seen. The tumor involves the. overlying skin [AJCC pT4]. All surgical resection margins, including the skin and deep margins,. are negat...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal carcinoma, Nottingham grade II. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal carcinoma, Nottingham grade II. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal carcinoma, Nottingham grade II. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal carcinoma, Nottingham grade II. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal carcinoma, Nottingham grade II. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal carcinoma, Nottingham grade II. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal carcinoma, Nottingham grade II. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Infiltrating ductal carcinoma, Nottingham grade II. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Infiltrating ductal carcinoma, Nottingham grade II. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 182,
      "timestamp": "2026-01-19T15:59:53.118788"
    },
    {
      "sample_idx": 594,
      "input": "DIAGNOSIS. DIAGNOSIS: A. Soft tissue, \"peritumor fat,\" excision: Benign adipose tissue with no neoplastic process identified. B. Kidney, posterior margin #1, biopsy: No tumor identified. Permanent sections confirm the frozen section diagnosis. C. Kidney, right, partial nephrectomy: Tumor Characteristics: 1. Histologic type: Renal cell carcinoma, papillary subtype. 2. Tumor site: Right kidney. 3. Tumor focality: Unifocal. 4. Tumor size: 4.0 cm in greatest dimension. 5. Macroscopic extent of tumor...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary subtype, Fuhrman grade 2/4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary subtype, Fuhrman grade 2/4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary subtype, Fuhrman grade 2/4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary subtype, Fuhrman grade 2/4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary subtype, Fuhrman grade 2/4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary subtype, Fuhrman grade 2/4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary subtype, Fuhrman grade 2/4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Kidney (Right). 2. Findings: Renal cell carcinoma, papillary subtype, Fuhrman grade 2/4. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 594,
      "timestamp": "2026-01-19T15:59:53.118802"
    },
    {
      "sample_idx": 1089,
      "input": "Clinical Diagnosis & History: Abdominal pain and underwent colonoscopy found mass at 20cm from. . CT. scan revealed multiple liver metastases and sigmoid mass biopsy confirmed. invasive adenocarcinoma carcinoma at sigmoid colon with liver metastasis. Specimens Submitted: 1: SP: SIGMOID AND UPPER RECTUM; RESECTION. 2: SP: Proximal ring. 3: SP: Distal ring. 4: SP: Umbilical hernia sac. DIAGNOSIS: 1. SP: SIGMOID AND UPPER RECTUM; RESECTION: Tumor Type: Adenocarcinoma. Histologic Grade: Moderately d...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated, with extensive tumor budding and suspected lymphovascular invasion. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated, with extensive tumor budding and suspected lymphovascular invasion. 3. Code: KIRC maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated, with extensive tumor budding and suspected lymphovascular invasion. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated, with extensive tumor budding and suspected lymphovascular invasion. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated, with extensive tumor budding and suspected lymphovascular invasion. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated, with extensive tumor budding and suspected lymphovascular invasion. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated, with extensive tumor budding and suspected lymphovascular invasion. 3. Code: COAD maps to COAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"",
      "predicted": "COAD",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Rectosigmoid colon. 2. Findings: Adenocarcinoma, moderately differentiated, with extensive tumor budding and suspected lymphovascular invasion. 3. Code: COAD maps to COAD.",
      "idx": 1089,
      "timestamp": "2026-01-19T15:59:53.118813"
    },
    {
      "sample_idx": 1015,
      "input": "Short descriptive translation of the pathology report as provided by the. Date report: Material received: Material: left adrenal. Macroscopic findings: within the normal appearing adrenal well discernible tumor of 3.5x3.2x3 cm size with brown. appearance and concentric reddish areas. Microscopic findings: Confluent neoplasia of the adrenal medulla with partial compression of the adrenal cortex. Tumor cells with oval shaped eccentric nuclei of middle size with peripheral nucleoli and. large amoun...",
      "response": "```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, a tumor of the adrenal medulla. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, a tumor of the adrenal medulla. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, a tumor of the adrenal medulla. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, a tumor of the adrenal medulla. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, a tumor of the adrenal medulla. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, a tumor of the adrenal medulla. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, a tumor of the adrenal medulla. 3. Code: Pheochromocytoma maps to PHCG.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PHCG\",\n    \"reasoning\": \"1. Site: Adrenal gland (Left). 2. Findings",
      "predicted": "PHCG",
      "ground_truth": "PCPG",
      "correct": false,
      "reasoning": "1. Site: Adrenal gland (Left). 2. Findings: Pheochromocytoma, a tumor of the adrenal medulla. 3. Code: Pheochromocytoma maps to PHCG.",
      "idx": 1015,
      "timestamp": "2026-01-19T15:59:53.118823"
    },
    {
      "sample_idx": 111,
      "input": "Diagnosis: 1. Poorly differentiated invasive breast carcinoma with focal in situ spread. (tumor diameter: 2.2 cm). In conclusion, this is a poorly differentiated invasive ductal carcinoma with focal. neuroendocrine characteristics. In conjunction with the preliminary finding, this gives rise to the following tumor. classification: NOS, G III, pT2N0(sn)LOVORO.",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 111,
      "timestamp": "2026-01-19T15:59:53.118833"
    },
    {
      "sample_idx": 610,
      "input": "Diagnosis: Left kidney and ureter, nephroureterectomy. Histologic tumor type/subtype: Renal cell carcinoma,. papillary type (type 1). Histologic grade (if applicable) : Fuhrman nuclear grade. 2. (of 4). Tumor size (greatest dimension) : 7.9 cm in greatest. dimension. Extent of tumor invasion: Capsular invasion/perirenal adipose tissue: Negative. Gerota' S fascia: Negative. Renal vein: Negative. Ureter: Negative (see comment). Lymphovascular space invasion: Not identified. Histologic assessment o...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left kidney and ureter. 2. Findings: Renal cell carcinoma, papillary type (type 1). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left kidney and ureter. 2. Findings: Renal cell carcinoma, papillary type (type 1). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left kidney and ureter. 2. Findings: Renal cell carcinoma, papillary type (type 1). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left kidney and ureter. 2. Findings: Renal cell carcinoma, papillary type (type 1). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left kidney and ureter. 2. Findings: Renal cell carcinoma, papillary type (type 1). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left kidney and ureter. 2. Findings: Renal cell carcinoma, papillary type (type 1). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left kidney and ureter. 2. Findings: Renal cell carcinoma, papillary type (type 1). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left kidney and",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Left kidney and ureter. 2. Findings: Renal cell carcinoma, papillary type (type 1). 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 610,
      "timestamp": "2026-01-19T15:59:53.118843"
    },
    {
      "sample_idx": 444,
      "input": "Case imported from legacy computer system. The format of this report does not match the original case. For cases prior to. the section \"SPECIMEN\" may have been added. DIAGNOSIS. (A) RIGHT FACIAL LYMPH NODE: one node, no tumor present. (B). RIGHT HYPOGLOSSAL NODE: No tumor present. LEFT HYPOGLOSSAL NERVE: Nerve, no tumor present. TOTAL GLOSSECTOMY, SUBMANDIBULAR: THREE FOCI OF INVASIVE MODERATELY WELL DIFFERENTIATED SQUAMOUS. CARCINOMA (SIZE RANGE 6.0 TO 1.2 CM) WITH PERINEURAL. INVASION. Margins...",
      "response": "```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Oral Cavity (Total Glossectomy, Submandibular). 2. Findings: Squamous cell carcinoma, invasive, well-differentiated. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Oral Cavity (Left Gingival Node). 2. Findings: Squamous cell carcinoma, invasive, well-differentiated. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Oral Cavity (Right Facial Lymph Node). 2. Findings: Squamous cell carcinoma, invasive, well-differentiated. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Oral Cavity (Right Hypoglossal Node). 2. Findings: Squamous cell carcinoma, invasive, well-differentiated. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Oral Cavity (Left Parapharyngeal Space and Anterior Tonsillar Pillar). 2. Findings: Squamous cell carcinoma, invasive, well-differentiated. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Oral Cavity (Left Gingival Node). 2. Findings: Squamous cell carcinoma, invasive, well-differentiated. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Oral Cavity (Left Gingival Node). 2. Findings: Squamous cell carcinoma, invasive, well-differentiated. 3. Code: SCC maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Oral Cavity (Left Gingival Node). 2. Findings",
      "predicted": "SCC",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Oral Cavity (Total Glossectomy, Submandibular). 2. Findings: Squamous cell carcinoma, invasive, well-differentiated. 3. Code: SCC maps to SCC.",
      "idx": 444,
      "timestamp": "2026-01-19T15:59:53.118855"
    },
    {
      "sample_idx": 353,
      "input": "Coded sample ID: Histologic diagnosis: moderate differentiated adenocarcinoma in Barrett-epithelium. Anatomic site with laterality: distal esophagus. Tumor size: diameter 5 cm. Lymph node status: 19 negative lymph nodes. Any comments or amendments: radical resection.",
      "response": "```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium, 5 cm. 3. Code: Adenocarcinoma of the esophagus maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium, 5 cm. 3. Code: Adenocarcinoma of the esophagus maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium, 5 cm. 3. Code: Adenocarcinoma of the esophagus maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium, 5 cm. 3. Code: Adenocarcinoma of the esophagus maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium, 5 cm. 3. Code: Adenocarcinoma of the esophagus maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium, 5 cm. 3. Code: Adenocarcinoma of the esophagus maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium, 5 cm. 3. Code: Adenocarcinoma of the esophagus maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Distal esophagus. 2. Findings: Moderate",
      "predicted": "ADEN",
      "ground_truth": "ESCA",
      "correct": false,
      "reasoning": "1. Site: Distal esophagus. 2. Findings: Moderate differentiated adenocarcinoma in Barrett-epithelium, 5 cm. 3. Code: Adenocarcinoma of the esophagus maps to ADEN.",
      "idx": 353,
      "timestamp": "2026-01-19T15:59:53.118865"
    },
    {
      "sample_idx": 1121,
      "input": "Clinical Diagnosis & History: , year old male with right sided retroperitoneal mass. Specimens Submitted: 1: SP: Retroperitoneal liposarcoma. DIAGNOSIS: 1. SOFT TISSUE, RETROPERITONEUM; RESECTION: DEDIFFERENTIATED LIPOSARCOMA ARISING IN WELL-DIFFERENTIATED. LIPOSARCOMA. - THE DEDIFFERENTIATED COMPONENT PREDOMINATES AND HAS A HETEROGENOUS. MORPHOLOGY, RANGING FROM MYXOFIBROSARCOMA TO A PLEOMORPHIC HIGH GRADK. MALIGNANT FIBROUS HISTIOCYTOMA-LIKE GROWTH PATTERN. - FOCAL AREAS OF WELL-DIFFERENTIATED...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Retroperitoneal mass. 2. Findings: Differentiated liposarcoma, dedifferentiated liposarcoma, well-differentiated liposarcoma, renal cell carcinoma, renal cyst. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning",
      "predicted": "KIRC",
      "ground_truth": "SARC",
      "correct": false,
      "reasoning": "1. Site: Retroperitoneal mass. 2. Findings: Differentiated liposarcoma, dedifferentiated liposarcoma, well-differentiated liposarcoma, renal cell carcinoma, renal cyst. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 1121,
      "timestamp": "2026-01-19T15:59:53.118878"
    },
    {
      "sample_idx": 805,
      "input": "urgical Pathology. TISSUE DESCRIPTION: A1 B1 B2 B3 B4 C1 D1 D2 E1 E2 E3 E4 F1 G1 G2 G3 G4 G5. Left lower lobe lung (140.0 grams), left upper lobe lung lymph node,. station 4L, 6, and 7 lymph nodes. DIAGNOSIS: Lung, left lower, lobectomy: Invasive grade 3 (of 4) adenocarcinoma. forming a 2.5 x 2.5 x 2.5 cm subpleural mass that abuts but does not. involve the puckered pleural surface. The bronchial resection. margin is free of tumor. Lymph nodes, left upper lung, excision: -A single Tymph node is ...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, left lower lobe. 2. Findings: Invasive adenocarcinoma, grade 3. 3. Code: Lung, left lower lobe maps to LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe. 2. Findings: Metastatic adenocarcinoma. 3. Code: Lung, left upper lobe maps to UCSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Lung, left mediastinal. 2. Findings: Metastatic adenocarcinoma. 3. Code: Lung, left mediastinal maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Lung, left lower lobe. 2. Findings: Metastatic adenocarcinoma. 3. Code: Lung, left lower lobe maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe. 2. Findings: Metastatic adenocarcinoma. 3. Code: Lung, left upper lobe maps to UCSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Lung, left mediastinal. 2. Findings: Metastatic adenocarcinoma. 3. Code: Lung, left mediastinal maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Lung, left lower lobe. 2. Findings: Metastatic adenocarcinoma. 3. Code: Lung, left lower lobe maps to UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Lung, left upper lobe. 2. Findings: Metastatic adenocarcinoma. 3. Code: Lung, left upper lobe maps to UCSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\":",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung, left lower lobe. 2. Findings: Invasive adenocarcinoma, grade 3. 3. Code: Lung, left lower lobe maps to LUAD.",
      "idx": 805,
      "timestamp": "2026-01-19T15:59:53.118888"
    },
    {
      "sample_idx": 321,
      "input": "Diagnosis: Resected section of colon (sigma) with a colon carcinoma of the histological type of a. moderately differentiated, partially mucus-producing colorectal adenocarcinoma,. measuring a maximum of 2 cm in diameter, and stretching up to 4.5cm to a margin of the. resected material. The tumor has spread invasively to the internal sections of the muscularis. propria. Otherwise the intestinal wall has some pseudodiverticula and peridiverticulitis with chronic. scarring. Oral and aboral margin o...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated, partially mucus-producing. 3. Code: COAD maps to the adenocarcinoma of the colon.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOMA\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Pseudodiverticula and peridiverticulitis with chronic scarring. 3. Code: ADENOMA maps to the colon.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAPC\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Mesocolic lymph nodes tumor-free with uncharacteristically reactive changes. 3. Code: PAPC maps to the colon.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Tumor stage therefore pT2, pNO (0/22) L0, V0; G2 R0. 3. Code: COAD maps to the adenocarcinoma of the colon.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Moderately differentiated, partially mucus-producing colorectal adenocarcinoma, measuring a maximum of 2 cm in diameter, and stretching up to 4.5cm to a margin of the resected material. 3. Code: COAD maps to the adenocarcinoma of the colon.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Moderately differentiated, partially mucus-producing colorectal adenocarcinoma, measuring a maximum of 2 cm in diameter, and stretching up to 4.5cm to a margin of the resected material. 3. Code: COAD maps to the adenocarcinoma of the colon.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Colon. 2. Findings: Moderately differentiated, partially mucus-producing colorectal adenocarcinoma, measuring a maximum of ",
      "predicted": "COAD",
      "ground_truth": "COAD",
      "correct": true,
      "reasoning": "1. Site: Colon. 2. Findings: Colorectal adenocarcinoma, moderately differentiated, partially mucus-producing. 3. Code: COAD maps to the adenocarcinoma of the colon.",
      "idx": 321,
      "timestamp": "2026-01-19T15:59:53.118898"
    },
    {
      "sample_idx": 446,
      "input": "Case type: Surgical Case. DIAGNOSIS. (A) RIGHT TONGUE BIOPSY: Squamous mucosa with skeletal muscle and fibroadipose tissue, no tumor present. (B) LEFT TONGUE BIOPSY: INVASIVE SQUAMOUS CARCINOMA, MODERATELY DIFFERENTIATED. (C) LEFT PARTIAL GLOSSECTOMY: INVASIVE SQUAMOUS CARCINOMA, MODERATELY DIFFERENTIATED, 3.0 CM. DEPTH OF INVASION 1.0 CM. PERINEURAL INVASION PRESENT FOCALLY. (D) LEFT BUCCAL MUCOSAL MARGIN: Squamous mucosa and skeletal muscle, no tumor present. (E) RETROMOLAR TRIGONE, LEFT: Squa...",
      "response": "```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Tongue (Right). 2. Findings: Invasive squamous cell carcinoma, moderately differentiated. 3. Code: BLCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Tongue (Left). 2. Findings: Invasive squamous cell carcinoma, moderately differentiated. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Tongue (Left). 2. Findings: Invasive squamous cell carcinoma, moderately differentiated. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Tongue (Left). 2. Findings: Invasive squamous cell carcinoma, moderately differentiated. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Tongue (Left). 2. Findings: Invasive squamous cell carcinoma, moderately differentiated. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Tongue (Left). 2. Findings: Invasive squamous cell carcinoma, moderately differentiated. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Tongue (Left). 2. Findings: Invasive squamous cell carcinoma, moderately differentiated. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Tongue (Left). 2. Findings: Invasive squamous cell carcinoma, moderately differentiated. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Tongue (Left). 2. Findings: Invasive squamous cell carcinoma, moderately differentiated. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n",
      "predicted": "BLCA",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Tongue (Right). 2. Findings: Invasive squamous cell carcinoma, moderately differentiated. 3. Code: BLCA.",
      "idx": 446,
      "timestamp": "2026-01-19T15:59:53.118908"
    },
    {
      "sample_idx": 620,
      "input": "Patholgy Accession No: Patient ID: Normal Sample ID: MODIFIED REPORT - REVIEW ADDENDUM SECTION. COMMENT. This addendum report is issued to comment on the type of papillary renal cell carcinoma,. as it was not mentioned in the original report. There is no other change in diagnosis. After review of the H&E slides, this tumor is designated as type 2 papillary renal cell. carcinoma. DIAGNOSIS. (A) LEFT PARTIAL NEPHRECTOMY: PAPILLARY RENAL CELL CARCINOMA, FUHRMAN'S NUCLEAR GRADE 3. TUMOR CONFINED TO ...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",",
      "predicted": "KIRC",
      "ground_truth": "KIRP",
      "correct": false,
      "reasoning": "1. Site: Kidney (Left Upper Pole). 2. Findings: Papillary renal cell carcinoma, Fuhrman Grade 3. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 620,
      "timestamp": "2026-01-19T15:59:53.118918"
    },
    {
      "sample_idx": 523,
      "input": "Accession # : Diagnosis: Right kidney, nephrectomy. Histologic tumor type/subtype: renal cell carcinoma, clear. cell type. Histologic grade (if applicable) : 2 (of 4,. classification). Tumor size (greatest dimension) : 6.7 cm diameter (gross). Extent of tumor invasion: Extra-capsular invasion: present, perihilar / renal sinus. fat (A9). Renal vein: tributary involved (A11) , but not involving. renal vein margin (A1). Ureter: not identified. Venous (large vessel) : see above. Lymphatic (small ves...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney.",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 523,
      "timestamp": "2026-01-19T15:59:53.118928"
    },
    {
      "sample_idx": 979,
      "input": "Surgical Pathology Report Site Pancreas head. DATE OBTAINED: DATE RECEIVED: SUBMITTING MD: DIAGNOSIS. 1. FALCIFORM LIGAMENT; EXCISION: BENIGN FIBROMUSCULAR AND ADIPOSE TISSUE; NEGATIVE FOR. TUMOR. 2. GALLBLADDER; CHOLECYSTECTOMY: MILD CHRONIC CHOLECYSTITIS; NEGATIVE FOR TUMOR. 3. PANCREAS, STOMACH AND SMALL BOWEL; WHIPPLE PROCEDURE: PANCREATIC DUCTAL ADENOCARCINOMA. Tumor site: Head of pancreas. Tumor size: 2.8 cm. Histologic type: Ductal Adenocarcinoma with focal non-keratinizing squamous. comp...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas head. 2. Findings: Pancreatic ductal adenocarcinoma with focal non-keratinizing squamous component. 3. Code: KIRC.\"\n}\n```\nExplanation:\nThe report clearly states the presence of pancreatic ductal adenocarcinoma in the head of the pancreas. The presence of a focal non-keratinizing squamous component is also noted. The TCGA code for pancreatic adenocarcinoma is KIRC.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas head. 2. Findings: Pancreatic ductal adenocarcinoma with focal non-keratinizing squamous component. 3. Code: KIRC.\"\n}\n```\nThe report identifies pancreatic ductal adenocarcinoma in the head of the pancreas. The presence of a focal non-keratinizing squamous component is also mentioned. The TCGA code for pancreatic adenocarcinoma is KIRC.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas head. 2. Findings: Pancreatic ductal adenocarcinoma with focal non-keratinizing squamous component. 3. Code: KIRC.\"\n}\n```\nThe report states the diagnosis is pancreatic ductal adenocarcinoma in the head of the pancreas. The presence of a focal non-keratinizing squamous component is also noted. The TCGA code for pancreatic adenocarcinoma is KIRC.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas head. 2. Findings: Pancreatic ductal adenocarcinoma with focal non-keratinizing squamous component. 3. Code: KIRC.\"\n}\n```\nThe report identifies pancreatic ductal adenocarcinoma in the head of the pancreas. The presence of a focal non-keratinizing squamous component is also noted. The TCGA code for pancreatic adenocarcinoma is KIRC.\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas head. 2. Findings: Pancreatic ductal adenocarcinoma with focal non-keratinizing squamous component. 3. Code: KIRC.\"\n}\n```\nThe report identifies pancreatic ductal adenocarcinoma in the head of the pancreas. The presence of a focal",
      "predicted": "KIRC",
      "ground_truth": "PAAD",
      "correct": false,
      "reasoning": "1. Site: Pancreas head. 2. Findings: Pancreatic ductal adenocarcinoma with focal non-keratinizing squamous component. 3. Code: KIRC.",
      "idx": 979,
      "timestamp": "2026-01-19T15:59:53.118938"
    },
    {
      "sample_idx": 394,
      "input": "CLINICAL HISTORY. has had headaches for about. and. generalized weakness. On imaging, there is a 4.6 cm superior right frontal. mass with T1 central hyperintensity, fluid levels, rim thickened enhancement,. and broad attachment to falx. OPERATIVE DIAGNOSES. Brain umor-craniotomy. Operation/Specimen: A: Brain, right frontal lesion, biopsy. Brain, right frontal lesion, biopsy. PATHOLOGICAL DIAGNOSIS: Brain, right frontal, excisional biopsies: 1. Malignant glioma, pleomorphic, superficial (WHO III)...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, right frontal. 2. Findings: Malignant glioma, pleomorphic, superficial (WHO III). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, right frontal. 2. Findings: Malignant glioma, pleomorphic, superficial (WHO III). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, right frontal. 2. Findings: Malignant glioma, pleomorphic, superficial (WHO III). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, right frontal. 2. Findings: Malignant glioma, pleomorphic, superficial (WHO III). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, right frontal. 2. Findings: Malignant glioma, pleomorphic, superficial (WHO III). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, right frontal. 2. Findings: Malignant glioma, pleomorphic, superficial (WHO III). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, right frontal. 2. Findings: Malignant glioma, pleomorphic, superficial (WHO III). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Brain, right frontal. 2. Findings: Malignant glioma, pleomorphic, superficial (WHO III). 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1.",
      "predicted": "KIRC",
      "ground_truth": "GBM",
      "correct": false,
      "reasoning": "1. Site: Brain, right frontal. 2. Findings: Malignant glioma, pleomorphic, superficial (WHO III). 3. Code: KIRC.",
      "idx": 394,
      "timestamp": "2026-01-19T15:59:53.118948"
    },
    {
      "sample_idx": 921,
      "input": "DIAGNOSIS: EXPLORATORY LAPARATOMY, TOTAL ABDOMINAL HYSTERECTOMY WITH. BILATERAL SALPINGO-OOPHORECTOMY. A. RIGHT TUBE AND OVARY (FROZEN). M\u00fcllerian adenocarcinoma, serous type, extensively involving ovary. Size: 7.0 cm approximately, in greatest dimension. Capsule: Ruptured. Angiolymphatic invasion: Not identified. Necrosis: Present, accounting for approximately 15% of tumor volume. Portion of fallopian tube with no carcinoma identified. AJCC Pathologic Stage (2002, 6th Ed): pT2c/N0. B. PELVIC SI...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right). 2. Findings: Ovarian serous carcinoma, high grade, with serous features. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right). 2. Findings: Ovarian serous carcinoma, high grade, with serous features. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right). 2. Findings: Ovarian serous carcinoma, high grade, with serous features. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right). 2. Findings: Ovarian serous carcinoma, high grade, with serous features. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right). 2. Findings: Ovarian serous carcinoma, high grade, with serous features. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right). 2. Findings: Ovarian serous carcinoma, high grade, with serous features. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right). 2. Findings: Ovarian serous carcinoma, high grade, with serous features. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right). 2. Findings: Ovarian serous carcinoma, high grade, with serous features. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n",
      "predicted": "BRCA",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Ovary (Right). 2. Findings: Ovarian serous carcinoma, high grade, with serous features. 3. Code: BRCA",
      "idx": 921,
      "timestamp": "2026-01-19T15:59:53.118958"
    },
    {
      "sample_idx": 590,
      "input": "Clinical Diagnosis & History: Right renal tumor. Specimens Submitted: 1: SP: Right kidney. 2: SP: Paracaval lymph nodes. DIAGNOSIS: 1). KIDNEY, RIGHT; NEPHRECTOMY. - RENAL CELL CARCINOMA, CLEAR CELL TYPE WITH FOCAL SPINDLE. CELL FEATURES, NUCLEAR GRADE III/IV. - THE PATTERN OF GROWTH IS SOLID. - THE TUMOR'S GREATEST DIAMETER IS 8.0 CM. - FOCALLY, THE TUMOR EXTENDS THROUGH THE RENAL CAPSULE BUT. IS CONFINED WITHIN GEROTA'S FASCIA. - NO INVASION OF THE RENAL VEIN IS IDENTIFIED. - ALL SURGICAL MARG...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II.",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 590,
      "timestamp": "2026-01-19T15:59:53.118972"
    },
    {
      "sample_idx": 194,
      "input": "SURGICAL REPORT. Sex: F. Date Collected: Date Received: M.R. Number. Doctor: Account Numbe. PRE-OPERATIVE DIAGNOSIS. CA RIGHT BREAST. POST-OPERATIVE DIAGNOSIS. CA RIGHT BREAST. PROCEDURE. MODIFIED RADICAL MASTECTOMY RIGHT BREAST, INSERTION MEDIPORT. TISSUES. BREAST MASTECTOMY (WMV) NODES - RIGHT BREAST AND AXILLARY CONTENTS. FINAL DIAGNOSIS. RIGHT BREAST AND AXILLARY CONTENTS -. POORLY DIFFERENTIATED INFILTRATING DUCTAL CARCINOMA, SCARFF-. BLOOM-RICHARDSON GRADE III/III. THE TUMOR MEASURES 10.5 ...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 194,
      "timestamp": "2026-01-19T15:59:53.118983"
    },
    {
      "sample_idx": 260,
      "input": "SPEC #: Obtained: CLINICAL HISTORY. ICD-9: 233.1. SPECIMEN/PROCEDURE. 1. CERVIX. IMPRESSION: CERVICAL BIOPSY: Squamous cell caroinoma with stromal invasion, large cell nonkexatinizing, grade 2. Prominent lymphoplasmaaytio infiltrate. Diotated by: Entered: GROSS DESCRIPTION: : 1. Received in formalin labeled with the patient's name and cervical biopsy. Received is. a pale pink to red tan irregular tissue fragment that is 0.6 x 0.5 x 0.4 cm. The specimen. is entirely submitted in cassette #1. Diot...",
      "response": "```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma with stromal invasion, large cell non-keratinizing, grade 2. Prominent lymphoplasma cell infiltrate. 3. Code: Cervical Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma with stromal invasion, large cell non-keratinizing, grade 2. Prominent lymphoplasma cell infiltrate. 3. Code: Cervical Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma with stromal invasion, large cell non-keratinizing, grade 2. Prominent lymphoplasma cell infiltrate. 3. Code: Cervical Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma with stromal invasion, large cell non-keratinizing, grade 2. Prominent lymphoplasma cell infiltrate. 3. Code: Cervical Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma with stromal invasion, large cell non-keratinizing, grade 2. Prominent lymphoplasma cell infiltrate. 3. Code: Cervical Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"HNSC\",\n    \"reasoning\": \"1. Site: Cervix. 2. Findings: Squamous cell carcinoma with stromal invasion, large cell non-keratinizing, grade 2. Prominent lymphoplasma cell infiltrate. 3. Code: Cervical Squamous Cell Carcinoma maps to HNSC.\"\n}\n```\n```json",
      "predicted": "HNSC",
      "ground_truth": "CESC",
      "correct": false,
      "reasoning": "1. Site: Cervix. 2. Findings: Squamous cell carcinoma with stromal invasion, large cell non-keratinizing, grade 2. Prominent lymphoplasma cell infiltrate. 3. Code: Cervical Squamous Cell Carcinoma maps to HNSC.",
      "idx": 260,
      "timestamp": "2026-01-19T15:59:53.118996"
    },
    {
      "sample_idx": 45,
      "input": "PRIMARY SITE: Bladder. 1 - \"Bladder + prostate\": High-grade urothelial carcinoma of the bladder characterized as follows: Measure of neoplasia in its major axis: 6.2 cm. Ulcerated and infiltrative neoplasia affecting all layers of the bladder and perivisceral. fat. Prostate, seminal vesicles, vas deferens, ureters and urethra free of neoplastic. involvement. Neural infiltration not observed. Lymphatic vascular invasion not detected. . Sanguineous vascular invasion not detected. Surgical margins ...",
      "response": "```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: High-grade urothelial carcinoma. 3. Code: Bladder maps to BLCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Prostate adenocarcinoma. 3. Code: Prostate maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Lymph node involvement. 3. Code: Lymph node maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BLCA\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Transitional cell carcinoma. 3. Code: Bladder maps to BLCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Lymph node involvement. 3. Code: Lymph node maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Lymph node involvement. 3. Code: Lymph node maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Lymph node involvement. 3. Code: Lymph node maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Lymph node involvement. 3. Code: Lymph node maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder. 2. Findings: Lymph node involvement. 3. Code: Lymph node maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",",
      "predicted": "BLCA",
      "ground_truth": "BLCA",
      "correct": true,
      "reasoning": "1. Site: Bladder. 2. Findings: High-grade urothelial carcinoma. 3. Code: Bladder maps to BLCA.",
      "idx": 45,
      "timestamp": "2026-01-19T15:59:53.119006"
    },
    {
      "sample_idx": 1357,
      "input": "Surg Path Report. SOURCE OF TISSUE: 1. UTERUS, CERVIX, BILATERAL TUBES AND OVARIES 2. ABDOMINAL SCAR 3. OMENTUM 4. LEFT EXTERNAL LYMPH NODES 5. LEFT INTERNAL ILIAC LYMPH NODES. 6. LEFT OBTURATOR LYMPH NODES 7. LEFT COMMON ILIAC LYMPH NODES 8. LEFT. AORTIC NODES 9. RIGHT EXTERNAL ILIAC LYMPH NODES 10. RIGHT INTERNAL. ILIAC LYMPH NODES 11. RIGHT COMMON ILIAC LYMPH NODES 12. RIGHT AORTIC. LYMPH NODES 13. RIGHT OBTURATOR LYMPH NODES. GROSS: Specimen \"No. 1\" labeled \"Uterus, Cervix, Bilateral Tubes a...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Bilateral Tubes and Ovaries. 2. Findings: High grade papillary serous carcinoma of endometrium. 3. Code: BRCA is not applicable to this cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Bilateral Tubes and Ovaries. 2. Findings: High grade papillary serous carcinoma of endometrium. 3. Code: KIRC is a valid code for endometrial carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Bilateral Tubes and Ovaries. 2. Findings: High grade papillary serous carcinoma of endometrium. 3. Code: BRCA is not applicable to this cancer type.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Bilateral Tubes and Ovaries. 2. Findings: High grade papillary serous carcinoma of endometrium. 3. Code: KIRC is a valid code for endometrial carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Bilateral Tubes and Ovaries. 2. Findings: High grade papillary serous carcinoma of endometrium. 3. Code: KIRC is a valid code for endometrial carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Bilateral Tubes and Ovaries. 2. Findings: High grade papillary serous carcinoma of endometrium. 3. Code: KIRC is a valid code for endometrial carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Uterus, Cervix, Bilateral Tubes and Ovaries. 2. Findings: High grade papillary serous carcinoma of endometrium. 3. Code: KIRC is a",
      "predicted": "BRCA",
      "ground_truth": "UCEC",
      "correct": false,
      "reasoning": "1. Site: Uterus, Cervix, Bilateral Tubes and Ovaries. 2. Findings: High grade papillary serous carcinoma of endometrium. 3. Code: BRCA is not applicable to this cancer type.",
      "idx": 1357,
      "timestamp": "2026-01-19T15:59:53.119017"
    },
    {
      "sample_idx": 965,
      "input": "OF SURGICAL PATHOLOGY. Address: : Hosp. No. : DIAGNOSIS. OVARY, RIGHT, SALPINGO-OOPHORECTOMY - POORLY DIFFERENTIATED. PAPILLARY SEROUS ADENOCAROINOMA (SEE COMMENT). OVARY, RIGHT, \"TUMOR, 11 EXCISION - POORIYDIFFERENTIATED PAPTLLARY. SEROUS ADENOCARCINOMA. OVARY, LEFT, SALPINGO-OOPHORECTOMY . METASTATIC PAPILLARY SEROUS. CARCINOMA IN PARA-OVARIAN ADHESIONS. - SEROUS CYSTADENOMA. FALLOPIAN TUBE, LEFT, SALPINGO-OOPHORECTOMY - METASTATIC PAPILLARY. SEROUS ADENOCARCINOMA IN PERITUBAL TISSUE. APPENDIX...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right and Left). 2. Findings: Papillary serous adenocarcinoma, poorly differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right and Left). 2. Findings: Papillary serous adenocarcinoma, poorly differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right and Left). 2. Findings: Papillary serous adenocarcinoma, poorly differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right and Left). 2. Findings: Papillary serous adenocarcinoma, poorly differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right and Left). 2. Findings: Papillary serous adenocarcinoma, poorly differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right and Left). 2. Findings: Papillary serous adenocarcinoma, poorly differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right and Left). 2. Findings: Papillary serous adenocarcinoma, poorly differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right and Left). 2. Findings: Papillary serous adenocarcinoma, poorly differentiated. 3. Code: BRCA\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary (Right and Left). 2. Findings: Papillary",
      "predicted": "BRCA",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Ovary (Right and Left). 2. Findings: Papillary serous adenocarcinoma, poorly differentiated. 3. Code: BRCA",
      "idx": 965,
      "timestamp": "2026-01-19T15:59:53.119026"
    },
    {
      "sample_idx": 1252,
      "input": "Sex: F. Case type: Surgical Case. DIAGNOSIS. (A) LEFT THYROID LOBECTOMY AND ISTHMUS: PAPILLARY THYROID CARCINOMA, CONVENTIONAL TYPE. Location: Left lobe. Multi-focal: No. Size = 1.8 cm. Extrathyroidal extension: Absent. Lymphovascular invasion: Absent. Resection Margins: Negative. Lymph nodes: No tumor present in 1 lymph node. GROSS DESCRIPTION. (A) LEFT THYROID LOBECTOMY AND ISTHMUS FOR FS - A hemithyroidectorny specimen with attached isthmus, the. thyroid lobe (6.0 x 2.0 x 1.5 cm), and isthmus...",
      "response": "```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe. 2. Findings: Papillary thyroid carcinoma, conventional type. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe. 2. Findings: Follicular adenoma with tiny papillary microcarcinoma (likely incidental). 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe. 2. Findings: Follicular adenoma with tiny papillary microcarcinoma (likely incidental). 3. Code: TGCT maps to TGCT.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe. 2. Findings: Follicular adenoma with tiny papillary microcarcinoma (likely incidental). 3. Code: UVM maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe. 2. Findings: Papillary thyroid carcinoma, conventional type. 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe. 2. Findings: Follicular adenoma with tiny papillary microcarcinoma (likely incidental). 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe. 2. Findings: Follicular adenoma with tiny papillary microcarcinoma (likely incidental). 3. Code: THCA maps to THCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Left Thyroid Lobe. 2. Findings: Follicular adenoma with tiny papillary microcarcinoma (likely incidental",
      "predicted": "THCA",
      "ground_truth": "THCA",
      "correct": true,
      "reasoning": "1. Site: Left Thyroid Lobe. 2. Findings: Papillary thyroid carcinoma, conventional type. 3. Code: THCA maps to THCA.",
      "idx": 1252,
      "timestamp": "2026-01-19T15:59:53.119038"
    },
    {
      "sample_idx": 532,
      "input": "Clinical Diagnosis & History: Right renal cortical tumor. Laparoscopic right nephrectomy. Specimens Submitted: 1: SP: Right kidney (sr). DIAGNOSIS: 1). KIDNEY, RIGHT; LAPAROSCOPIC NEPHRECTOMY: - RENAL CELL CARCINOMA, CLEAR CELL TYPE, NUCLEAR GRADE II/IV. - THE PATTERN OF GROWTH IS SOLID. - THE TUMOR GREATEST DIAMETER IS 4.5 CM. - THE TUMOR IS CONFINED WITHIN THE RENAL CAPSULE. - NO INVASION OF THE RENAL VEIN IS IDENTIFIED. - ALL SURGICAL MARGINS ARE FREE OF TUMOR. THE NON-NEOPLASTIC KIDNEY SHOWS...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right kidney.",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Right kidney. 2. Findings: Renal cell carcinoma, clear cell type, nuclear grade II/IV. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 532,
      "timestamp": "2026-01-19T15:59:53.119050"
    },
    {
      "sample_idx": 1163,
      "input": "FINAL DIAGNOSIS: PART :LIVER, NODULE, EXCISION -. A. NO VIABLE TUMOR CELLS SEEN. B. DEGENERATEDINECROTC NODULE WITH HEMORRHAGE AND FIBRINOUS DEBRIS. PART 2: ESOPHAGUS AND STOMACH AND JEJUNUM, ESOPHAGOGASTRECTOMY. A. INVASIVE POORLY DIFFERENTIATED ADENOCARCINOMA, MEASURING 2.5 CM, INVOLVING. GASTROESOPHAGEAL JUNCTION. B. TUMOR INVADES INTO ADVENTITIAL SOFT TISSUES. C. ALL SURGICAL MARGINS (PROXIMAL, DISTAL AND RADIAL) ARE FREE OF TUMOR. D. EXTENSIVE LYMPHOVASCULAR SPACE PERMEATION PRESENT. E. PER...",
      "response": "```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus, Stomach, and Jejunum. 2. Findings: Invasive poorly differentiated adenocarcinoma, measuring 2.5 cm, involving the gastroesophageal junction. 3. Code: ADENOCARCINOMA maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, Lymph Node. 2. Findings: Metastatic adenocarcinoma involving 9 of 17 regional lymph nodes. 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive poorly differentiated adenocarcinoma, measuring 2.5 cm, involving the gastroesophageal junction. 3. Code: BRCA maps to Breast Invasive Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus, Stomach, and Jejunum. 2. Findings: Invasive poorly differentiated adenocarcinoma, measuring 2.5 cm, involving the gastroesophageal junction. 3. Code: ADENOCARCINOMA maps to ADENOCARCINOMA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver, Lymph Node. 2. Findings: Metastatic adenocarcinoma involving 9 of 17 regional lymph nodes. 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive poorly differentiated adenocarcinoma, measuring 2.5 cm, involving the gastroesophageal junction. 3. Code: BRCA maps to Breast Invasive Carcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADENOCARCINOMA\",\n    \"reasoning\": \"1. Site: Esophagus, Stomach, and Jejunum. 2. Findings: Invasive poorly differentiated adenocarcinoma, measuring ",
      "predicted": "ADENOCARCINOMA",
      "ground_truth": "STAD",
      "correct": false,
      "reasoning": "1. Site: Esophagus, Stomach, and Jejunum. 2. Findings: Invasive poorly differentiated adenocarcinoma, measuring 2.5 cm, involving the gastroesophageal junction. 3. Code: ADENOCARCINOMA maps to ADENOCARCINOMA.",
      "idx": 1163,
      "timestamp": "2026-01-19T15:59:53.119062"
    },
    {
      "sample_idx": 825,
      "input": "Pre-Op Diagnosis. Lung cancer. Post-Op Diagnosis. Same as above. Clinical History. Nothing indicated. Gross Description: Five parts. Container labeled. - level 7 lymph node left. lung\" has a 1.0 x 0.9 x 0.4 cm nodular portion of gray-black fleshy. tissue which is bisected and entirely submitted in a single. cassette. Container labeled. - level 10 lymph node left. lung\" has two nodular portions of rubbery gray-pink fleshy tissue,. 1.5 x 1.0 x 0.7 cm and 1.6 x 1.0 x 0.7 cm. Each has a mottled fles...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Upper Lobe). 2. Findings: Mucinous adenocarcinoma, well differentiated, unifocal, 3.5 x 3.2 x 1.6 cm. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Upper Lobe). 2. Findings: Mucinous adenocarcinoma, well differentiated, unifocal, 3.5 x 3.2 x 1.6 cm. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Upper Lobe). 2. Findings: Mucinous adenocarcinoma, well differentiated, unifocal, 3.5 x 3.2 x 1.6 cm. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Upper Lobe). 2. Findings: Mucinous adenocarcinoma, well differentiated, unifocal, 3.5 x 3.2 x 1.6 cm. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Upper Lobe). 2. Findings: Mucinous adenocarcinoma, well differentiated, unifocal, 3.5 x 3.2 x 1.6 cm. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Upper Lobe). 2. Findings: Mucinous adenocarcinoma, well differentiated, unifocal, 3.5 x 3.2 x 1.6 cm. 3. Code: LUAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung (Left Upper Lobe). 2. Findings: Mucinous adenocarcinoma, well differentiated",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung (Left Upper Lobe). 2. Findings: Mucinous adenocarcinoma, well differentiated, unifocal, 3.5 x 3.2 x 1.6 cm. 3. Code: LUAD.",
      "idx": 825,
      "timestamp": "2026-01-19T15:59:53.119072"
    },
    {
      "sample_idx": 551,
      "input": "Diagnosis: Kidney, right, nephrectomy. Tumor histologic type/subtype: Renal cell carcinoma, clear. cell subtype. Histologic grade (if applicable) : Fuhrman grade 2 (of 4). Tumor size (greatest dimension) : 4.5 cm. Extent of tumor invasion: Extra-capsular invasion: not identified. Renal vein: not involved. Ureter: not involved. Venous (large vessel) not involved. Lymphatic (small vessel) : not involved. Surgical margins: Perirenal adipose tissue: not involved. Renal vein: not involved. Renal arte...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, clear cell subtype, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, clear cell subtype, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, clear cell subtype, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, clear cell subtype, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, clear cell subtype, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, clear cell subtype, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, clear cell subtype, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney, right. 2. Findings: Renal cell carcinoma, clear cell subtype, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 551,
      "timestamp": "2026-01-19T15:59:53.119083"
    },
    {
      "sample_idx": 703,
      "input": "FINAL DIAGNOSIS. A. POSTERIOR RIGHT TEMPORAL OCCIPITAL TUMOR, BIOPSY: -- INFILTRATING GLIOMA. B. RIGHT TEMPORAL TIP, BIOPSY: -- INFILTRATING GLIOMA. C. RIGHT TEMPORAL OCCIPITAL BRAIN TUMOR, REMOVAL: -- MIXED OLIGO ASTROCYTOMA (WHO GRADE II). Note: The tumor demonstrates geographically separate areas of astrocytic and oligodendroglial differentiation. Hypercellularity is seen only within the oligodendroglial regions. Mitotic figures are not identified. A focus of. coagulative tumor necrosis lacki...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Temporal, Occipital). 2. Findings: Infiltrating glioma, mixed oligodendroglial/astrocytic, Grade II. The report mentions a focus of coagulative tumor necrosis lacking pseudo-palisading, which is a characteristic finding in glioblastoma. Also, the report mentions a loss of chromosomes 1p and 19q, which is a common genetic alteration in glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Temporal, Occipital). 2. Findings: Infiltrating glioma, mixed oligodendroglial/astrocytic, Grade II. The report mentions a focus of coagulative tumor necrosis lacking pseudo-palisading, which is a characteristic finding in glioblastoma. Also, the report mentions a loss of chromosomes 1p and 19q, which is a common genetic alteration in glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Temporal, Occipital). 2. Findings: Infiltrating glioma, mixed oligodendroglial/astrocytic, Grade II. The report mentions a focus of coagulative tumor necrosis lacking pseudo-palisading, which is a characteristic finding in glioblastoma. Also, the report mentions a loss of chromosomes 1p and 19q, which is a common genetic alteration in glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Temporal, Occipital). 2. Findings: Infiltrating glioma, mixed oligodendroglial/astrocytic, Grade II. The report mentions a focus of coagulative tumor necrosis lacking pseudo-palisading, which is a characteristic finding in glioblastoma. Also, the report mentions a loss of chromosomes 1p and 19q, which is a common genetic alteration in glioblastoma. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain (Temporal, Occipital). 2. Findings: Infiltrating glioma, mixed oligodendroglial/astrocytic, Grade II. The report mentions a focus of coagulative tumor necrosis lacking pseudo-palisading, which is a characteristic finding in glioblastoma. Also, the report mentions a loss of chromosomes 1p and 19q, which is a common genetic alteration in glioblastoma. 3. Code: GBM maps to GBM.",
      "idx": 703,
      "timestamp": "2026-01-19T15:59:53.119099"
    },
    {
      "sample_idx": 736,
      "input": "DIAGNOSIS: Liver, left, hemihepatectomy: Hepatocellular carcinoma, S2. 1) Post-chemoembolization status: absent. 2) Size of tumor: 2.2x2x1.5cm. 3) Gross type: infiltrative. 4) Satellite nodule: absent. 5) Histologic type: trabecular. 6) Cell type: classic and clear cell group. 7) Edmondson and Steiner's histologic grade: The worst differentiation: 3. The major differentiation: 2. 8) Fatty change: present (5%). 9) Hemorthage/peliusis: absent. 10) Tumor necrosis: absent. 11) Vascular nvasion(micro...",
      "response": "```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, S2. 3. Code: LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, S2. 3. Code: LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, S2. 3. Code: LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, S2. 3. Code: LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, S2. 3. Code: LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, S2. 3. Code: LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, S2. 3. Code: LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, S2. 3. Code: LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma, S2. 3. Code: LIHC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"LIHC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular",
      "predicted": "LIHC",
      "ground_truth": "LIHC",
      "correct": true,
      "reasoning": "1. Site: Liver. 2. Findings: Hepatocellular carcinoma, S2. 3. Code: LIHC.",
      "idx": 736,
      "timestamp": "2026-01-19T15:59:53.119108"
    },
    {
      "sample_idx": 759,
      "input": "SPECIMENS: 1. F/S LEFT UPPER LOBE. 2. COMPLETION OF LEFT UPPER LOBE. 3. STATION 13 LYMPH NODE. 4. LEVEL 9 LYMPH NODE. 5. LEVEL 5 LYMPH NODE. 6. LEVEL 7 LYMPH NODE. DIAGNOSIS: 1. LUNG, LEFT, UPPER LOBE: WEDGE RESECTION. - TWO FOCI OF INVASIVE ADENOCARCINOMA MIXED WITH. BRONCHIOLOALVEOLAR CARCINOMA, RANGING FROM 2.1cm to 1.4cm,. MODERATELY DIFFERENTIATED (SEE SUMMARY). - FOCI OF ATYPICAL ALVEOLAR HYPERPLASIA. - NO ANGIOLYMPHATIC INVASION SEEN. - IMMUNOHISTOCHEMICAL STUDIES REVEAL THAT TUMOR CELLS ...",
      "response": "```json\n{\n    \"cancer_type\": \"LUAD\",\n    \"reasoning\": \"1. Site: Lung, Left, Upper Lobe. 2. Findings: Adenocarcinoma, mixed subtype with Bronchioalveolar carcinoma. 3. Code: LUAD.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCLM\",\n    \"reasoning\": \"1. Site: Lung, Left, Upper Lobe. 2. Findings: Adenocarcinoma, mixed subtype with Bronchioalveolar carcinoma. 3. Code: UCLM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCLM\",\n    \"reasoning\": \"1. Site: Lung, Left, Upper Lobe. 2. Findings: Adenocarcinoma, mixed subtype with Bronchioalveolar carcinoma. 3. Code: UCLM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCLM\",\n    \"reasoning\": \"1. Site: Lung, Left, Upper Lobe. 2. Findings: Adenocarcinoma, mixed subtype with Bronchioalveolar carcinoma. 3. Code: UCLM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCLM\",\n    \"reasoning\": \"1. Site: Lung, Left, Upper Lobe. 2. Findings: Adenocarcinoma, mixed subtype with Bronchioalveolar carcinoma. 3. Code: UCLM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCLM\",\n    \"reasoning\": \"1. Site: Lung, Left, Upper Lobe. 2. Findings: Adenocarcinoma, mixed subtype with Bronchioalveolar carcinoma. 3. Code: UCLM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCLM\",\n    \"reasoning\": \"1. Site: Lung, Left, Upper Lobe. 2. Findings: Adenocarcinoma, mixed subtype with Bronchioalveolar carcinoma. 3. Code: UCLM.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"UCLM\",\n    \"reasoning\": \"1. Site: Lung, Left, Upper Lobe. 2. Findings: Adenocarcinoma, mixed",
      "predicted": "LUAD",
      "ground_truth": "LUAD",
      "correct": true,
      "reasoning": "1. Site: Lung, Left, Upper Lobe. 2. Findings: Adenocarcinoma, mixed subtype with Bronchioalveolar carcinoma. 3. Code: LUAD.",
      "idx": 759,
      "timestamp": "2026-01-19T15:59:53.119119"
    },
    {
      "sample_idx": 754,
      "input": "Diagnosis: A: Gallbladder, cholecystectomy. - Chronic cholecystitis with cholesterolosis. - Duplication cyst. B: Lymph node, right inferior mediastinum, biopsy. - No tumor identified in one lymph node (0/1). C: Liver, right lobe, partial hepatectomy. - Hepatocellular carcinom\u00e1, grade 2 with superficial infiltration into the ventral surface of the diaphragm,. surgical margins free. - Tumor infiltrates wall of a large caliber vein with intraluminal tumor present. - Multiple small foci suspicious f...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Gallbladder. 2. Findings: Chronic cholecystitis with cholesterolosis. Duplication cyst. Hepatocellular carcinoma, grade 2 with superficial infiltration into the ventral surface of the diaphragm. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right lobe of the liver. 2. Findings: Hepatocellular carcinoma, grade 2 with superficial infiltration into the ventral surface of the diaphragm. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung, right lower lobe. 2. Findings: Multiple intraparenchymal lymph nodes with anthracotic pigment and probable old fibrotic granulomas. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung, face of right lower lobe. 2. Findings: Markedly reactive mesothelial proliferation on parietal and visceral pleural surfaces consistent with reaction to tumor infiltrating underlying diaphragm. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph node, right portal. 2. Findings: No tumor identified in one lymph node (0/1). 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lymph node, left portal. 2. Findings: No tumor identified in one lymph node (0/1). 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Lung, right lower lobe. 2. Findings: Multiple intraparenchymal lymph nodes with anthracotic pigment and probable old fibrotic granulomas. 3. Code: KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer",
      "predicted": "KIRC",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Gallbladder. 2. Findings: Chronic cholecystitis with cholesterolosis. Duplication cyst. Hepatocellular carcinoma, grade 2 with superficial infiltration into the ventral surface of the diaphragm. 3. Code: KIRC.",
      "idx": 754,
      "timestamp": "2026-01-19T15:59:53.119131"
    },
    {
      "sample_idx": 686,
      "input": "Surgical Pathology: Finali. CLINICAL HISTORY: Brain tumor. GROSS EXAMINATION: A. \"Brain tumor (AF1) \", received fresh for frozen section. A 2.0 x 2.0 x 1.0. cm aggregate of multiple fragments of soft tan tissue is received. Representative fragment frozen as AF1 and frozen section remnant is submitted. in A1. A representative fragment is retained in formalin. The remainder of. the tissue is submitted in A2. B. \"Brain tumor\", received fresh and placed in formalin. A 4.0 x 3.8 x 2.0 cm. aggregate o...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Astrocytoma, well differentiated (Grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"AST\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Astrocytoma, well differentiated (Grade II). 3. Code: AST maps to AST.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Astrocytoma, well differentiated (Grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Astrocytoma, well differentiated (Grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Astrocytoma, well differentiated (Grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Astrocytoma, well differentiated (Grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Astrocytoma, well differentiated (Grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Astrocytoma, well differentiated (Grade II). 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Astrocytoma, well differentiated (",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain. 2. Findings: Astrocytoma, well differentiated (Grade II). 3. Code: GBM maps to GBM.",
      "idx": 686,
      "timestamp": "2026-01-19T15:59:53.119141"
    },
    {
      "sample_idx": 1177,
      "input": "Stomach, total gastrectomy: Advanced gastric carcinoma. Muc2(-)/Muc5AC(+)/Muc6(+)/CD10(++)/cERB2(-),GI(I) type). 1. Location : upper third, Center at fundus and posterior wall. 2. Gross type : Borrman type 1 (fungating). 3. Histologic type : papillary adenocarcinoma (pap). 4. Histologic type by Lauren : intestinal. 5. Growth pattern: mixed expanding and infiltrative growth pattern. 6. Size : 6.5x5.0cm. 7. Depth of invasion : invades proper muscle (pT2). 8. Resection margins and anvil ring : free...",
      "response": "```json\n{\n    \"cancer_type\": \"STAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Advanced gastric carcinoma, mucinous type, intestinal type, pT2, pNO. 3. Code: Stomach, total gastrectomy maps to STAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Advanced gastric carcinoma, mucinous type, intestinal type, pT2, pNO. 3. Code: Stomach, total gastrectomy maps to PAAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Advanced gastric carcinoma, mucinous type, intestinal type, pT2, pNO. 3. Code: Stomach, total gastrectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Advanced gastric carcinoma, mucinous type, intestinal type, pT2, pNO. 3. Code: Stomach, total gastrectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Advanced gastric carcinoma, mucinous type, intestinal type, pT2, pNO. 3. Code: Stomach, total gastrectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Advanced gastric carcinoma, mucinous type, intestinal type, pT2, pNO. 3. Code: Stomach, total gastrectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Stomach. 2. Findings: Advanced gastric carcinoma, mucinous type, intestinal type, pT2, pNO. 3. Code: Stomach, total gastrectomy maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",",
      "predicted": "STAD",
      "ground_truth": "STAD",
      "correct": true,
      "reasoning": "1. Site: Stomach. 2. Findings: Advanced gastric carcinoma, mucinous type, intestinal type, pT2, pNO. 3. Code: Stomach, total gastrectomy maps to STAD.",
      "idx": 1177,
      "timestamp": "2026-01-19T15:59:53.119151"
    },
    {
      "sample_idx": 372,
      "input": "Document Date: Encounter-info: Date Collected: Date Received: PT: DIAGNOSIS: 1. BRAIN, LEFT FRONTAL, BIOPSY, FS1A: - GLIOBLASTOMA MULTIFORME. 2. BRAIN, LEFT FRONTAL, EXCISION, FS2A: - GLIOBLASTOMA MULTIFORME. 3. BRAIN, LEFT FRONTAL, EXCISION: - GLIOBLASTOMA MULTIFORME. (Electronic Signature). SPECIMEN: 1. Left frontal brain lesion. 2. Left frontal brain lesion. CLINICAL HISTORY/OPERATIVE FINDINGS: PREVIOUS OPERATION OR BIOPSY: Not provided. NAME OF OPERATION: Left frontal craniotomy for tumor ex...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Frontal). 2. Findings: Glioblastoma multiforme. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Frontal). 2. Findings: Glioblastoma multiforme. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Frontal). 2. Findings: Glioblastoma multiforme. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Frontal). 2. Findings: Glioblastoma multiforme. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Frontal). 2. Findings: Glioblastoma multiforme. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Frontal). 2. Findings: Glioblastoma multiforme. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Frontal). 2. Findings: Glioblastoma multiforme. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Frontal). 2. Findings: Glioblastoma multiforme. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain (Left Frontal). 2. Findings: Glioblastoma multiforme. 3. Code:",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain (Left Frontal). 2. Findings: Glioblastoma multiforme. 3. Code: GBM maps to GBM.",
      "idx": 372,
      "timestamp": "2026-01-19T15:59:53.119163"
    },
    {
      "sample_idx": 441,
      "input": "Sex: M. Case type: Surgical History. Case imported from legacy computer system. The format of this report does not match the original  case. For cases prior to. the section \"SPECIMEN\" may have been added. SUPPLEMENTAL REPORT. COMMENT: Additional sections of the mandible are received from the bone lab after. decalcification and sectioning. The section code is as follows: Cassettes I17 and I18, cross sections of the mandible; cassette I19,. mandibular margin, en face; cassette I20 and I21, right m...",
      "response": "```json\n{\n    \"cancer_type\": \"PAAD\",\n    \"reasoning\": \"1. Site: Submental triangle, left neck. 2. Findings: Metastatic squamous cell carcinoma in 1 of 3 lymph nodes (1/3) and 1 of 5 lymph nodes (1/5). Extranodal extension is present. 3. Code: PAAD (Pan-Adenocarcinoma) maps to PAAD.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SCC\",\n    \"reasoning\": \"1. Site: Marginal mandibulectomy including upper and lower lip. 2. Findings: Deeply invasive keratinized squamous cell carcinoma, moderately differentiated. Margins free of tumor. 3. Code: SCC (Squamous Cell Carcinoma) maps to SCC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Left lower lip. 2. Findings: Tumor, left lower lip. 3. Code: SKCM (Squamous Cell Carcinoma) maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left neck. 2. Findings: Metastatic squamous cell carcinoma in 1 of 5 lymph nodes (1/5). 3. Code: KIRC (Kidney Renal Clear Cell Carcinoma) maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Left neck. 2. Findings: Metastatic squamous cell carcinoma in 1 of 5 lymph nodes (1/5). 3. Code: SKCM (Squamous Cell Carcinoma) maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Left neck. 2. Findings: Metastatic squamous cell carcinoma in 1 of 5 lymph nodes (1/5). 3. Code: SKCM (Squamous Cell Carcinoma) maps to SKCM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"SKCM\",\n    \"reasoning\": \"1. Site: Left neck. 2. Findings: Metastatic squamous",
      "predicted": "PAAD",
      "ground_truth": "HNSC",
      "correct": false,
      "reasoning": "1. Site: Submental triangle, left neck. 2. Findings: Metastatic squamous cell carcinoma in 1 of 3 lymph nodes (1/3) and 1 of 5 lymph nodes (1/5). Extranodal extension is present. 3. Code: PAAD (Pan-Adenocarcinoma) maps to PAAD.",
      "idx": 441,
      "timestamp": "2026-01-19T15:59:53.119176"
    },
    {
      "sample_idx": 993,
      "input": "Short descriptive translation of the pathology report as provided by the. Material received: Material: Left adrenal gland. Macroscopic findings. Adrenal Tumor: A 11x10x3 cm specimen after adrenalectomy (131 g, formalin fixed). The lesion has. been cut already. On the sectioned surface a 7 cm light brown tumor with vulnerable tissue pattern. At. the side of the lesion normal adrenal cortex can be seen. The capsule cannot be finally judged due to. the prior cutting. Microscopy findings: At HE, Iro...",
      "response": "```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, without lateralization, no suspicion for capsular or vascular invasion. 3. Code: ADEN maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, without lateralization, no suspicion for capsular or vascular invasion. 3. Code: ADEN maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, without lateralization, no suspicion for capsular or vascular invasion. 3. Code: ADEN maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, without lateralization, no suspicion for capsular or vascular invasion. 3. Code: ADEN maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, without lateralization, no suspicion for capsular or vascular invasion. 3. Code: ADEN maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, without lateralization, no suspicion for capsular or vascular invasion. 3. Code: ADEN maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, without lateralization, no suspicion for capsular or vascular invasion. 3. Code: ADEN maps to ADEN.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"ADEN\",\n    \"reasoning\": \"",
      "predicted": "ADEN",
      "ground_truth": "PCPG",
      "correct": false,
      "reasoning": "1. Site: Adrenal gland. 2. Findings: Pheochromocytoma, without lateralization, no suspicion for capsular or vascular invasion. 3. Code: ADEN maps to ADEN.",
      "idx": 993,
      "timestamp": "2026-01-19T15:59:53.119187"
    },
    {
      "sample_idx": 1265,
      "input": "!. Laterality:Papillary carcinoma. Path Report:Tumor type: Papillary carcinoma. Tumor size:2.5x2x1cm (right) 1.5x1x1cm (left). Laterality: Bilateral. Focality: Multifocal. Extrathyroidal extension: No.",
      "response": "```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, bilateral, multifocal, without extrathyroidal extension. 3. Code: Thyroid Papillary Carcinoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, bilateral, multifocal, without extrathyroidal extension. 3. Code: Thyroid Papillary Carcinoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, bilateral, multifocal, without extrathyroidal extension. 3. Code: Thyroid Papillary Carcinoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, bilateral, multifocal, without extrathyroidal extension. 3. Code: Thyroid Papillary Carcinoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, bilateral, multifocal, without extrathyroidal extension. 3. Code: Thyroid Papillary Carcinoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, bilateral, multifocal, without extrathyroidal extension. 3. Code: Thyroid Papillary Carcinoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma, bilateral, multifocal, without extrathyroidal extension. 3. Code: Thyroid Papillary Carcinoma maps to UVM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid. 2. Findings: Papillary carcinoma",
      "predicted": "UVM",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Thyroid. 2. Findings: Papillary carcinoma, bilateral, multifocal, without extrathyroidal extension. 3. Code: Thyroid Papillary Carcinoma maps to UVM.",
      "idx": 1265,
      "timestamp": "2026-01-19T15:59:53.119197"
    },
    {
      "sample_idx": 1231,
      "input": "Clinical Diagnosis & History: Right thyroid nodule. FNA suspicious of PTC. Specimens Submitted: 1: SP: Thyroid, right lobe, lobectomy (fs). DIAGNOSIS: 1. SP: Thyroid, right lobe, lobectomy (fs): Tumor Type: Papillary carcinoma, follicular variant. Histologic Grade: Well differentiated. Mitotic Activity: Not identified. Tumor Necrosis: Not identified. Tumor Location: Right lobe. Tumor Size: Greatest diameter is 1.8 cm. Tumor Encapsulation: Completely surrounded. Capsular Invasion: Not identified....",
      "response": "```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid, right lobe. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: THCA maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid, right lobe. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid, right lobe. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: THCA maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid, right lobe. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid, right lobe. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: THCA maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid, right lobe. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid, right lobe. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: THCA maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THYM\",\n    \"reasoning\": \"1. Site: Thyroid, right lobe. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: THYM maps to THYM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"THCA\",\n    \"reasoning\": \"1. Site: Thyroid, right lobe. ",
      "predicted": "THCA",
      "ground_truth": "THCA",
      "correct": true,
      "reasoning": "1. Site: Thyroid, right lobe. 2. Findings: Papillary carcinoma, follicular variant. 3. Code: THCA maps to THYM.",
      "idx": 1231,
      "timestamp": "2026-01-19T15:59:53.119207"
    },
    {
      "sample_idx": 1224,
      "input": "Gender: M. Operative Procedure: 4Left orchiectomy. Left testicle. Final Pathologic Diagnosis: Testis, left, radical orchiectomy: Histologic type: Seminoma. Tumor focality: Unifocal. Size. Main mass: 4.3 [greatest dimension]. Additional dimensions: 3.5 x 3.1. Additional nodules: not applicable. Macroscopic extent of tumor: Confined to the testis. Microscopic extent of tumor: Confined to the testis. Tunica vaginalis: Uninvolved. Spermatic cord: Uninvolved. Rete testis: Involved. Scrotum: not appli...",
      "response": "```json\n{\n    \"cancer_type\": \"TGCT\",\n    \"reasoning\": \"1. Site: Testis. 2. Findings: Seminoma. 3. Code: Testis, left, radical orchiectomy: Histologic type: Seminoma. Tumor focality: Unifocal. Size. Main mass: 4.3 [greatest dimension]. Additional dimensions: 3.5 x 3.1. Additional nodules: not applicable. Macroscopic extent of tumor: Confined to the testis. Microscopic extent of tumor: Confined to the testis. Tunica vaginalis: Uninvolved. Spermatic cord: Uninvolved. Rete testis: Involved. Scrotum: not applicable. Lymph-vascular invasion: Not identified. Intratubular germ cell neoplasia: Present, unclassified type (IGCNU). Surgical margin. Spermatic cord: Uninvolved. Other (specify): not applicable. Other pathologic findings: None significant. Lymph nodes submitted: None submitted. Pathologic stage (2010). pT1 pNX1 pM-not applicable. The examination of this case material and the preparation of this report were. Gross Description: Received in formalin, labeled \\\"left testicle\\\" is a 51 g. orchiectomy specimen which consists of a 5.3 x 3.5 x 3.2 cm testicle with. attached 4.0 X 1.1 X 0.5 cm epididymis, and attached 4.9 X 1.6 cm of spermatic. cord. The visceral layer of the tunica vaginalis is tan-pink, smooth and. glistening. Sectioning reveals a 4.3 x 3.5 X 3.1 cm tan to pink, soft,. heterogeneous, ill-defined testicular mass which does not appear to extend. outside the testicle. Rete testis involvement is indeterminate. The uninvolved. testicle is tan, soft and homogeneous. The seminiferous tubules string with. ease. The spermatic cord on sectioning is unremarkable. Representative sections are submitted as follows: 1. spermatic cord margin taken en face;. 2. mass to Rete testis;. 3,4 mass to visceral layer of tunica vaginalis and epididymis;. 5. mass to uninvolved testis;. 6. proximal spermatic cord. Please note, a gross photograph is taken. Microscopic Description: The final diagnosis of each specimen",
      "predicted": null,
      "ground_truth": "TGCT",
      "correct": null,
      "reasoning": "",
      "idx": 1224,
      "timestamp": "2026-01-19T15:59:53.119330"
    },
    {
      "sample_idx": 966,
      "input": "male. Surgery date: Short report on diagnostic findings. Pancreatic carcinoma. Expansive, well differentiated neuroendocrine carcinoma of the pancreas with extension beyond the. pancreas and infiltration of the posterior wall of the stomach with ulceration of the mucosa. Vessel. infiltration. Lymphangiosis carcinomatosis (6.). Lymph node metastases (3.,6), lymph nodes without. tumor (1.,2.,4.,7). anastomotic rings without tumor (8.), choleasteatosis of the gall bladder (9.). Invasion. of the por...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Pancreatic carcinoma, expansive, well differentiated neuroendocrine carcinoma. Extension beyond the pancreas and infiltration of the posterior wall of the stomach with ulceration of the mucosa. Vessel infiltration. Lymphangiosis carcinomatosis (6.). Lymph node metastases (3.,6), lymph nodes without tumor (1.,2.,4.,7). Anastomotic rings without tumor (8.), choleasteatosis of the gall bladder (9.). Invasion of the portal vein margin (5.). TNM classification (UICC, 7th Edition 2010): pT3, pN1 (16/57), L1, V1. Grading: G1. Resection status: R1 (caudal, proximal, and dorsal at the main specimen, vessel invasion with tumor thrombus (6.), portal vein (5.)). 3. Code: Pancreatic Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Pancreatic carcinoma, expansive, well differentiated neuroendocrine carcinoma. Extension beyond the pancreas and infiltration of the posterior wall of the stomach with ulceration of the mucosa. Vessel infiltration. Lymphangiosis carcinomatosis (6.). Lymph node metastases (3.,6), lymph nodes without tumor (1.,2.,4.,7). Anastomotic rings without tumor (8.), choleasteatosis of the gall bladder (9.). Invasion of the portal vein margin (5.). TNM classification (UICC, 7th Edition 2010): pT3, pN1 (16/57), L1, V1. Grading: G1. Resection status: R1 (caudal, proximal, and dorsal at the main specimen, vessel invasion with tumor thrombus (6.), portal vein (5.)). 3. Code: Pancreatic Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pancreas. 2. Findings: Pancreatic carcinoma, expansive, well differentiated neuroendocrine carcinoma. Extension beyond the pancreas and infiltration of the posterior wall of the stomach with ulceration of the mucosa. Vessel infiltration",
      "predicted": "KIRC",
      "ground_truth": "PAAD",
      "correct": false,
      "reasoning": "1. Site: Pancreas. 2. Findings: Pancreatic carcinoma, expansive, well differentiated neuroendocrine carcinoma. Extension beyond the pancreas and infiltration of the posterior wall of the stomach with ulceration of the mucosa. Vessel infiltration. Lymphangiosis carcinomatosis (6.). Lymph node metastases (3.,6), lymph nodes without tumor (1.,2.,4.,7). Anastomotic rings without tumor (8.), choleasteatosis of the gall bladder (9.). Invasion of the portal vein margin (5.). TNM classification (UICC, 7th Edition 2010): pT3, pN1 (16/57), L1, V1. Grading: G1. Resection status: R1 (caudal, proximal, and dorsal at the main specimen, vessel invasion with tumor thrombus (6.), portal vein (5.)). 3. Code: Pancreatic Carcinoma maps to KIRC.",
      "idx": 966,
      "timestamp": "2026-01-19T15:59:53.119357"
    },
    {
      "sample_idx": 679,
      "input": "ADDENDUM DISCUSSION: Most of the neoplastic cells are reactive for GFAP, however, some of the. larger cells with halos are GFAP negative. Neu-N demonstrates that the tumor. cells are negative for Neu-N with only cortical neurons being positive. The. atypical cells, including the large cells without obvious processes are. strongly reactive for p53, suggesting astrocytic lineage. There is variable. immunoreactivity for MIB-1. Slide 1A has a labeling index of <0.5% while 2A. demonstrates a labeling...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Anaplastic astrocytoma (WHO Grade III), high MIB-1 labeling index. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Anaplastic astrocytoma (WHO Grade III), high MIB-1 labeling index. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Anaplastic astrocytoma (WHO Grade III), high MIB-1 labeling index. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Anaplastic astrocytoma (WHO Grade III), high MIB-1 labeling index. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Anaplastic astrocytoma (WHO Grade III), high MIB-1 labeling index. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Anaplastic astrocytoma (WHO Grade III), high MIB-1 labeling index. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Anaplastic astrocytoma (WHO Grade III), high MIB-1 labeling index. 3. Code: GBM maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Anaplastic",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Brain. 2. Findings: Anaplastic astrocytoma (WHO Grade III), high MIB-1 labeling index. 3. Code: GBM maps to GBM.",
      "idx": 679,
      "timestamp": "2026-01-19T15:59:53.119367"
    },
    {
      "sample_idx": 868,
      "input": "Material examined: Right lower lobe, among others. Clinical diagnosis and question. Bronchial carcinoma right - squamous cell - Suspected asbestos exposure. REPORT ON FINDINGS. Macroscopy. 1.) Right lower lobe: after attempted inflation of lower lobe at the deformed base measuring 10.5 x 7.5 cm and. up to 12 cm high, central bronchus resection plane located at the level of the bifurcation of B6. At the hilus are. two grayish-black nodes, 2 and 1.3 cm in size. Parenchyma shows incomplete atelecta...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Lung, Right Lower Lobe. 2. Findings: Bronchial carcinoma, squamous cell carcinoma. 3. Code: COAD maps to Lung Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Lung, Right Lower Lobe. 2. Findings: Bronchial carcinoma, squamous cell carcinoma. 3. Code: COAD maps to Lung Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Lung, Right Lower Lobe. 2. Findings: Bronchial carcinoma, squamous cell carcinoma. 3. Code: COAD maps to Lung Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Lung, Right Lower Lobe. 2. Findings: Bronchial carcinoma, squamous cell carcinoma. 3. Code: COAD maps to Lung Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Lung, Right Lower Lobe. 2. Findings: Bronchial carcinoma, squamous cell carcinoma. 3. Code: COAD maps to Lung Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Lung, Right Lower Lobe. 2. Findings: Bronchial carcinoma, squamous cell carcinoma. 3. Code: COAD maps to Lung Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Lung, Right Lower Lobe. 2. Findings: Bronchial carcinoma, squamous cell carcinoma. 3. Code: COAD maps to Lung Adenocarcinoma.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Lung, Right Lower Lobe. 2. Findings: Bronchial carcinoma, squamous cell carcinoma. 3. Code: COAD maps to Lung",
      "predicted": "COAD",
      "ground_truth": "LUSC",
      "correct": false,
      "reasoning": "1. Site: Lung, Right Lower Lobe. 2. Findings: Bronchial carcinoma, squamous cell carcinoma. 3. Code: COAD maps to Lung Adenocarcinoma.",
      "idx": 868,
      "timestamp": "2026-01-19T15:59:53.119378"
    },
    {
      "sample_idx": 127,
      "input": "specimen #: : lace: WHITE. Physician (s) : AMENDED. SPECIMEN: A: RIGHT BREAST B: RIGHT BREAST TISSUE FROM INFERIOR FLAP. C: RIGHT SENTINEL LYMPH NODE #1. D: RIGHT SENTINEL LYMPH NODE #2. FINAL DIAGNOSIS: A. RIGHT BREAST, MASTECTOMY: -TUMOR TYPE: INVASIVE DUCTAL CARCINOMA WITH LOBULAR FEATURES. -NOTTINGHAM GRADE MODERATELY DIFFERENTIATED (G2). -NOTTINGHAM SCORE: 6/9 (TUBULES = 3, NUCLEI = 2, MYTOSES= 1) . -TUMOR SIZE: GREATEST DIMENSION: TUMOR 1 (UPPER INNER QUADRANT) : at least 1.1 CM. (measured...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 127,
      "timestamp": "2026-01-19T15:59:53.119388"
    },
    {
      "sample_idx": 737,
      "input": "LABORATORY SERVICES. Patient ID: PHN: ALT ID: Telephone: Requesting Physician: Encounter: Chart ID: HISTOPATHOLOGY REPORT. Division Head: ORIGINAL REPORT. SPECIMEN: A. Gallbladder. B. Liver (margin painted black - a slice of tumor about 0.3 cm thick was. taken for tumor bank - Dr. research). CLINICAL HISTORY: Liver mass. Hep B positive and liver tumor. DIAGNOSIS: A. GALLBLADDER: NO CALCULI, INFLAMMATION OR MALIGNANCY. B. LIVER: HEPATOCELLULAR CARCINOMA, GRADE III/IV. TUMOR MEASURES 2.5 CM IN GRE...",
      "response": "```json\n{\n    \"cancer_type\": \"COAD\",\n    \"reasoning\": \"1. Site: Gallbladder. 2. Findings: Hepatocellular carcinoma (HCC) with features of cirrhosis. 3. Code: COAD maps to the cancer type Hepatocellular Carcinoma (Hepatocellular carcinoma).\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma (HCC). 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma (KIRC) because the report is describing a liver tumor.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma (HCC). 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma (KIRC) because the report is describing a liver tumor.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma (HCC). 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma (KIRC) because the report is describing a liver tumor.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma (HCC). 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma (KIRC) because the report is describing a liver tumor.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma (HCC). 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma (KIRC) because the report is describing a liver tumor.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver. 2. Findings: Hepatocellular carcinoma (HCC). 3. Code: KIRC maps to Kidney Renal Clear Cell Carcinoma (KIRC) because the report is describing a liver tumor.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "COAD",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Gallbladder. 2. Findings: Hepatocellular carcinoma (HCC) with features of cirrhosis. 3. Code: COAD maps to the cancer type Hepatocellular Carcinoma (Hepatocellular carcinoma).",
      "idx": 737,
      "timestamp": "2026-01-19T15:59:53.119399"
    },
    {
      "sample_idx": 960,
      "input": "SURG PATH #: SPECIMEN CLASS: ALT ID #: SEX: F. DATE RECEIVED: DATE OF PRINTING: Material Received: A: anterior abdominal wall peritoneum. B: omentum. C: portion of left tube and ovary. D: small bowel mesentery nodule. E: right cul-de-sac tumor. F: pelvic peritoneum. G: uterus and cervic; right fallopian tube and ovary; reto-sigmoid colon. H: small bowel tumor nodules. I: portion of proximal colon. J: donut. K: peri-appendecele tumor. L: small mesentary nodule. M: small bowel @ 1300. N: right dia...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Serous carcinoma, high grade. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Ovary. 2. Findings: Ser",
      "predicted": "BRCA",
      "ground_truth": "OV",
      "correct": false,
      "reasoning": "1. Site: Ovary. 2. Findings: Serous carcinoma, high grade. 3. Code: BRCA.",
      "idx": 960,
      "timestamp": "2026-01-19T15:59:53.119408"
    },
    {
      "sample_idx": 307,
      "input": "SPECIMEN. A. Right colon. B. Liver biopsy. CLINICAL NOTES. PRE-OP DIAGNOSIS: Ascending colon cancer. GROSS DESCRIPTION. A. Received fresh for tissue procurement, labeled \"right. colon\", is a previously unopened, 12 cm segment of. proximal. right colon with attached 6 cm of distal ileum surfaced by smooth. to. scabrous tan-pink serosa with a moderate amount of attached. mesocolon and mesentery, An unremarkable 5.7 cm appendix averaging. 0.65 cm in diameter is present. The proximal and distal marg...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Infiltrating adenocarcinoma of the right colon, extending deeply into pericolonic fat and to the inked serosal peritoneal surface. All other margins and all 25 regional lymph nodes are negative for tumor. Appendix and portion of terminal ileum, no significant pathology. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Infiltrating adenocarcinoma of the right colon, extending deeply into pericolonic fat and to the inked serosal peritoneal surface. All other margins and all 25 regional lymph nodes are negative for tumor. Appendix and portion of terminal ileum, no significant pathology. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Infiltrating adenocarcinoma of the right colon, extending deeply into pericolonic fat and to the inked serosal peritoneal surface. All other margins and all 25 regional lymph nodes are negative for tumor. Appendix and portion of terminal ileum, no significant pathology. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Infiltrating adenocarcinoma of the right colon, extending deeply into pericolonic fat and to the inked serosal peritoneal surface. All other margins and all 25 regional lymph nodes are negative for tumor. Appendix and portion of terminal ileum, no significant pathology. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Colon (Right Colon). 2. Findings: Infiltrating adenocarcinoma of the right colon, extending deeply into pericolonic fat and to the inked serosal peritoneal surface. All other margins and all 25 regional lymph nodes are negative for tumor. Appendix and portion of terminal ileum, no significant pathology. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Colon (Right Colon). 2. Findings: Infiltrating adenocarcinoma of the right colon, extending deeply into pericolonic fat and to the inked serosal peritoneal surface. All other margins and all 25 regional lymph nodes are negative for tumor. Appendix and portion of terminal ileum, no significant pathology. 3. Code: KIRC.",
      "idx": 307,
      "timestamp": "2026-01-19T15:59:53.119423"
    },
    {
      "sample_idx": 519,
      "input": "Report Status : Amend/. Type: Surgical Pathology. Specimen Type: Kidney. partial or total resection. Procedure Date: Addended Repor. PATHOLOGIC DIAGNOSIS: GEFT RADICAL NEPHRECTOMY: /CLEAR CELL RENAL CELL CARCINOMA (8.2 cm), Fuhrman nuclear grade. TII/IV, arising in the lower pole with foci of tumor necrosis and. hyalinization. Approximately 608 of the tumor mass is viable. Arterial, venous, and ureteral margins are negative for tumor. Tumor is limited to the kidney and comes to within 0.1 cm of....",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nResponse:\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Kidney. 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\nResponse:\n```json\n{\n",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Kidney (Left Upper Pole). 2. Findings: Renal cell carcinoma, conventional (clear cell) type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 519,
      "timestamp": "2026-01-19T15:59:53.119433"
    },
    {
      "sample_idx": 1032,
      "input": "DIAGNOSIS. DIAGNOSIS: A. Right pelvic lymph node: Benign, hyperplasia. B. Left pelvic lymph node: Benign, hyperplasia. C. Radical prostatectomy: Carcinoma. Tumor Characteristics: 1. Histologic type: Adenocarcinoma, conventional type. 2. Gleason Grade: a. Primary pattern: 3/5. b. Secondary pattern: 4/5. c. Score: 7/10. 3. Tumor involves: Both lobes. 4. Tumor quantitation: Tumor involves approximately 25% of the specimen. 5. Seminal vesicle involvement: Yes, left seminal vesicle. 6. Extra-capsular...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, conventional type. 3. Gleason Grade: 7/10. 4. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pelvic Lymph Node. 2. Findings: Benign, hyperplasia. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder Neck. 2. Findings: Benign, no pathological diagnosis. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Carcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pelvic Lymph Node. 2. Findings: Benign, hyperplasia. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Carcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Bladder Neck. 2. Findings: Benign, no pathological diagnosis. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Carcinoma. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Pelvic Lymph Node. 2. Findings: Benign, hyperplasia. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. ",
      "predicted": "KIRC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate. 2. Findings: Adenocarcinoma, conventional type. 3. Gleason Grade: 7/10. 4. Code: KIRC.",
      "idx": 1032,
      "timestamp": "2026-01-19T15:59:53.119443"
    },
    {
      "sample_idx": 682,
      "input": "MR# : ACCT# : LOC : DOCTOR: ADDENDUM NEUROPATHOLOGY REPORT. ADDENDUM DISCUSSION: The neoplastic cells express IDH1 but are negative for p53 . Numerous MIB-1. reactive cella are present with a labeling index of 12.48. ADDENIOUM DIAGKOSIS: 1-3. Right parietal tumor, including enhancing nodule, biopsy resection: Anaplastic astrocytoma (grade III). -- MIB-1 LI - 12.4%. ADDENDUN CPT copes,. ACCESSION#: . NEUROPATHOLOGY REPORT. SPECIMEN SOURCE: 1. Right parietal tumor FS. 2. Enhancing nodule FS. 3. Ri...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right parietal tumor. 2. Findings: Anaplastic astrocytoma (grade III), IDH1 positive, p53 negative. 3. Code: Anaplastic Astrocytoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right parietal tumor. 2. Findings: Anaplastic astrocytoma, grade III. 3. Code: Anaplastic Astrocytoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right parietal tumor. 2. Findings: Anaplastic astrocytoma, grade III, IDH1 positive, p53 negative. 3. Code: Anaplastic Astrocytoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right parietal tumor. 2. Findings: Anaplastic astrocytoma, grade III. 3. Code: Anaplastic Astrocytoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right parietal tumor. 2. Findings: Anaplastic astrocytoma, grade III, IDH1 positive, p53 negative. 3. Code: Anaplastic Astrocytoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right parietal tumor. 2. Findings: Anaplastic astrocytoma, grade III. 3. Code: Anaplastic Astrocytoma maps to GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Right parietal tumor. 2. Findings: Anaplastic astrocytoma, grade III, IDH1 positive, p53 negative. 3. Code: Anaplastic Astrocytoma maps to GBM.\"\n}\n```\n```json\n",
      "predicted": "GBM",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Right parietal tumor. 2. Findings: Anaplastic astrocytoma (grade III), IDH1 positive, p53 negative. 3. Code: Anaplastic Astrocytoma maps to GBM.",
      "idx": 682,
      "timestamp": "2026-01-19T15:59:53.119454"
    },
    {
      "sample_idx": 1106,
      "input": "page 1 / 1. copy No. 3. Examination: Histopathological examination. Cost of diagnostic procedure. Material: 1. Total resection of organ - rectum. Expected time of examination: Clinical diagnosis: Cancer of the rectum. Macroscopic description: 30 cm length of large intestine with fat tissue of 1 cm in thickness. Ulceration thickened at ends sized 6 X 4 cm. The lesion surrounds 100% of the intestine circumference, narrowing its lumen, placed 14 cm from the proximal cut. end, 6 cm from the distal c...",
      "response": "```json\n{\n    \"cancer_type\": \"UC\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Adenocarcinoma tubulare solidum partim mucinosum (G3). Infiltratio carcinomatosa telae adiposae mesorecti. Intestine ends free of neoplastic lesions. Metastases carcinomatosae in lymphonodis (No III/XIV). 3. Code: Rectum Adenocarcinoma maps to UC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23349\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Adenocarcinoma tubulare solidum partim mucinosum (G3). Infiltratio carcinomatosa telae adiposae mesorecti. Intestine ends free of neoplastic lesions. Metastases carcinomatosae in lymphonodis (No III/XIV). 3. Code: Rectum Adenocarcinoma maps to U23349.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23349\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Adenocarcinoma tubulare solidum partim mucinosum (G3). Infiltratio carcinomatosa telae adiposae mesorecti. Intestine ends free of neoplastic lesions. Metastases carcinomatosae in lymphonodis (No III/XIV). 3. Code: Rectum Adenocarcinoma maps to U23349.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23349\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Adenocarcinoma tubulare solidum partim mucinosum (G3). Infiltratio carcinomatosa telae adiposae mesorecti. Intestine ends free of neoplastic lesions. Metastases carcinomatosae in lymphonodis (No III/XIV). 3. Code: Rectum Adenocarcinoma maps to U23349.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"U23349\",\n    \"reasoning\": \"1. Site: Rectum. 2. Findings: Adenocarcinoma tubulare solidum partim mucinosum (G3). Infiltratio carcinomat",
      "predicted": "UC",
      "ground_truth": "READ",
      "correct": false,
      "reasoning": "1. Site: Rectum. 2. Findings: Adenocarcinoma tubulare solidum partim mucinosum (G3). Infiltratio carcinomatosa telae adiposae mesorecti. Intestine ends free of neoplastic lesions. Metastases carcinomatosae in lymphonodis (No III/XIV). 3. Code: Rectum Adenocarcinoma maps to UC.",
      "idx": 1106,
      "timestamp": "2026-01-19T15:59:53.119468"
    },
    {
      "sample_idx": 1331,
      "input": "Temporary Copy. Clinical Information. Endometrial cancer. X-lap, TAH, BSO, Node dissection. Organ Or Tissue. Site: indometrum 054. /. Uterus, BSO. Left pelvic node. Left pelvic nodes. Left periaortic nodes. Right pelvic nodes. Right periaortic node. Gross Description. The specimen is received in six parts. each labeled with the patient's name. Part A. is received unfixed, additionally labeled \"uterus, cervix, tubes, ovaries\" and consists of a uterus. with attached cervix, and bilateral fallopian...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma with squamous differentiation, invading 1.0 mm of myometrium and anterior lower uterine segment. Focal vascular space tumor invasion is present. Extensive adenomyosis. Multiple leiomyomata uteri. Serosal fibrous adhesions of bilateral ovaries and fallopian tubes with old hemorrhage and granulomatous reactions. Atrophic underlying bilateral ovaries. Hydatid cyst of Morgagni, right. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma with squamous differentiation, invading 1.0 mm of myometrium and anterior lower uterine segment. Focal vascular space tumor invasion is present. Extensive adenomyosis. Multiple leiomyomata uteri. Serosal fibrous adhesions of bilateral ovaries and fallopian tubes with old hemorrhage and granulomatous reactions. Atrophic underlying bilateral ovaries. Hydatid cyst of Morgagni, right. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma with squamous differentiation, invading 1.0 mm of myometrium and anterior lower uterine segment. Focal vascular space tumor invasion is present. Extensive adenomyosis. Multiple leiomyomata uteri. Serosal fibrous adhesions of bilateral ovaries and fallopian tubes with old hemorrhage and granulomatous reactions. Atrophic underlying bilateral ovaries. Hydatid cyst of Morgagni, right. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma with squamous differentiation, invading 1.0 mm of myometrium and anterior lower uterine segment. Focal vascular space tumor invasion is present. Extensive adenomyosis. Multiple leiomyomata uteri. Serosal fibrous adhesions of bilateral ovaries and fallopian tubes with old hemorrhage and granulomatous reactions. Atrophic underlying bilateral ovaries. Hydatid cyst of Morgagni, right. 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus. 2. Findings: Endometrioid adenocarcinoma with squamous differentiation, invading 1.0 mm of myometrium and anterior lower uterine segment. Focal vascular space tumor invasion is present. Extensive adenomyosis. Multiple leiomyomata uteri. Serosal fibrous adhesions of bilateral ovaries and fallopian tubes with old hemorrhage and granulomatous reactions. Atrophic underlying bilateral ovaries. Hydatid cyst of Morgagni, right. 3. Code: UCEC.",
      "idx": 1331,
      "timestamp": "2026-01-19T15:59:53.119488"
    },
    {
      "sample_idx": 412,
      "input": "FINAL PATHOLOGIC DIAGNOSIS. A. Brain, biopsy: WHO-II glioblastoma multiforme, grade 4; see comment. B. Brain, biopsy: WHO-II glioblastoma multiforme, grade 4; see comment. COMMENT: This glioblastoma multiforme has foci of necrosis with peripheral pseudo-palisading,. endothelial proliferation, multiple mitoses and marked nuclear and cytoplasmic pleomorphism, with. abundant giant cells. By prior. and. criteria, this is a glioblastoma multiforme. By. criteria, this is a grade 4 astrocytoma, An immu...",
      "response": "```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma multiforme, grade 4. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma multiforme, grade 4. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma multiforme, grade 4. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma multiforme, grade 4. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma multiforme, grade 4. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma multiforme, grade 4. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma multiforme, grade 4. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma multiforme, grade 4. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    \"reasoning\": \"1. Site: Brain. 2. Findings: Glioblastoma multiforme, grade 4. 3. Code: GBM.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"GBM\",\n    ",
      "predicted": "GBM",
      "ground_truth": "GBM",
      "correct": true,
      "reasoning": "1. Site: Brain. 2. Findings: Glioblastoma multiforme, grade 4. 3. Code: GBM.",
      "idx": 412,
      "timestamp": "2026-01-19T15:59:53.119498"
    },
    {
      "sample_idx": 713,
      "input": "x. Fatholog:ats. Intraop Pathologist: Performing PhyBigian: CLINICAL HISTORY: LIVER MASS. PRECPERATIVE DIACNOSIS: NOT GIVEN. SPECIMEN TYFE(Siz. A: SEGMENT 5 LIVER LESICN. B: GALLELADDER. C: ADDITIONAL CALLBLADDER MARGIN. FINAL DIACNOSIS: A. LIVER, SEGMENT 6 LESION, EXCISION: Repatocellular carcinoma, clear cell type (aee Key Pathological Findings). B. GALLBLADDER, CHOLECYSTECTOMY: Chronic cholecyatitis. There is no evidence or malignancy. c. LIVER ( SUBMITTED AS GALLELADDER, ADDITIONAL MARGIN) E...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment 6). 2. Findings: Hepatocellular carcinoma, clear cell type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive ductal carcinoma. 3. Code: BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment 6). 2. Findings: Hepatocellular carcinoma, clear cell type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment 6). 2. Findings: Hepatocellular carcinoma, clear cell type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment 6). 2. Findings: Hepatocellular carcinoma, clear cell type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment 6). 2. Findings: Hepatocellular carcinoma, clear cell type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment 6). 2. Findings: Hepatocellular carcinoma, clear cell type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment 6). 2. Findings: Hepatocellular carcinoma, clear cell type. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Liver (Segment 6). 2. Findings: Hepatocellular carcinoma, clear cell type. 3. Code: KIRC.\"\n}\n",
      "predicted": "KIRC",
      "ground_truth": "LIHC",
      "correct": false,
      "reasoning": "1. Site: Liver (Segment 6). 2. Findings: Hepatocellular carcinoma, clear cell type. 3. Code: KIRC.",
      "idx": 713,
      "timestamp": "2026-01-19T15:59:53.119508"
    },
    {
      "sample_idx": 302,
      "input": "SPECIMENS: A. TERMINAL ILEUM AND RIGHT COLON. B. GALLBLADDER. DIAGNOSIS: A. RIGHT COLON AND TERMINAL ILEUM, RESECTION: - MODERATELY DIFFERENTIATED INFILTRATING COLONIC. ADENOCARCINOMA (3.1 CM) EXTENDING INTO SUBSEROSAL FAT. SEE. TEMPLATE. - SEVENTEEN BENIGN LYMPH NODES (0/17). - MULTIPLE TUBULAR ADENOMAS. - SURGICAL MARGINS, SMALL BOWEL AND APPENDIX ARE NOT INVOLVED. B. GALLBLADDER, EXCISION: - CHRONIC CHOLELITHIASIS. COLORECTAL CANCER TEMPLATE. Specimen Type: Right hemicolectomy. Tumor Site: As...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon and terminal ileum. 2. Findings: Adenocarcinoma, 3.1 cm, located in the ascending colon. 3. Code: Right Colon and Terminal Ileum maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Ascending Colon. 2. Findings: Adenocarcinoma, 3.1 cm, well differentiated, focal subserosal adipose tissue invasion, margins uninvolved. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon and terminal ileum. 2. Findings: Adenocarcinoma, 3.1 cm, located in the ascending colon. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon and terminal ileum. 2. Findings: Adenocarcinoma, 3.1 cm, located in the ascending colon. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Ascending Colon. 2. Findings: Adenocarcinoma, 3.1 cm, well differentiated, focal subserosal adipose tissue invasion, margins uninvolved. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Right colon and terminal ileum. 2. Findings: Adenocarcinoma, 3.1 cm, located in the ascending colon. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Ascending Colon. 2. Findings: Adenocarcinoma, 3.1 cm, well differentiated, focal subserosal adipose tissue invasion, margins uninvolved. 3. Code: KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1.",
      "predicted": "KIRC",
      "ground_truth": "COAD",
      "correct": false,
      "reasoning": "1. Site: Right colon and terminal ileum. 2. Findings: Adenocarcinoma, 3.1 cm, located in the ascending colon. 3. Code: Right Colon and Terminal Ileum maps to KIRC.",
      "idx": 302,
      "timestamp": "2026-01-19T15:59:53.119519"
    },
    {
      "sample_idx": 567,
      "input": "iology Report. DIAGNOSIS. (A) LEFT KIDNEY AND LYMPH NODE: CONVENTIONAL RENAL CELL CARCINOMA, CLEAR CELL TYPE, FUHRMAN'S. NUCLEAR GRADE 3. TUMOR MEASURES 6.0 CM IN MAXIMUM DIMENSION. TUMOR CONFINED TO THE KIDNEY. Margins of resection free of tumor. Simple cortical cyst. GROSS DESCRIPTION. (A) LEFT KIDNEY WITH EN BLOC LYMPH NODE - A radical nephrectomy. specimen (19.5 x 10.0 x 5.0 cm) including left. kidney (12.5 x 6.0 x 4.0 cm), a segment of renal artery, renal vein and. ureter (10.0 cm in length...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Conventional renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Conventional renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Conventional renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Conventional renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Conventional renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Conventional renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Left Kidney. 2. Findings: Conventional renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"",
      "predicted": "KIRC",
      "ground_truth": "KIRC",
      "correct": true,
      "reasoning": "1. Site: Left Kidney. 2. Findings: Conventional renal cell carcinoma, clear cell type, Fuhrman Grade II. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 567,
      "timestamp": "2026-01-19T15:59:53.119530"
    },
    {
      "sample_idx": 1289,
      "input": "M. Facility: Specimen(s) Received. 1. Nck: left paratracheal node dissection. 2. Lymph node: pretracheal lymph node. 3. Thyroid: total thyroid. Diagnosis. 1. No pathological diagnosis: Lymph nodes, 2 (left paratracheal) dissection specimen. No pathological diagnosis: Lymph node, 1 (paratracheal) biopsy. 3. Angioinvasive papillary carcinoma, 6.0 cm, follicular variant with focal poorly differentiated carcinoma (less than 5%),. right: Thyroid, total thyroidectomy specimen. Synoptic Data. Procedure...",
      "response": "```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Thyroid (Total Thyroidectomy Specimen). 2. Findings: Angioinvasive papillary carcinoma, 6.0 cm, follicular variant with focal poorly differentiated carcinoma (less than 5%). 3. Code: UCS matches the findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Thyroid (Total Thyroidectomy Specimen). 2. Findings: Angioinvasive papillary carcinoma, 6.0 cm, follicular variant with focal poorly differentiated carcinoma (less than 5%). 3. Code: UCEC matches the findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid (Total Thyroidectomy Specimen). 2. Findings: Angioinvasive papillary carcinoma, 6.0 cm, follicular variant with focal poorly differentiated carcinoma (less than 5%). 3. Code: UVM matches the findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Thyroid (Total Thyroidectomy Specimen). 2. Findings: Angioinvasive papillary carcinoma, 6.0 cm, follicular variant with focal poorly differentiated carcinoma (less than 5%). 3. Code: UCS matches the findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Thyroid (Total Thyroidectomy Specimen). 2. Findings: Angioinvasive papillary carcinoma, 6.0 cm, follicular variant with focal poorly differentiated carcinoma (less than 5%). 3. Code: UCEC matches the findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UVM\",\n    \"reasoning\": \"1. Site: Thyroid (Total Thyroidectomy Specimen). 2. Findings: Angioinvasive papillary carcinoma, 6.0 cm, follicular variant with focal poorly differentiated carcinoma (less than 5%). 3. Code: UVM matches the findings.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCSC\",\n    \"reasoning\": \"1. Site: Thyroid (Total Thyroidectomy Specimen).",
      "predicted": "UCSC",
      "ground_truth": "THCA",
      "correct": false,
      "reasoning": "1. Site: Thyroid (Total Thyroidectomy Specimen). 2. Findings: Angioinvasive papillary carcinoma, 6.0 cm, follicular variant with focal poorly differentiated carcinoma (less than 5%). 3. Code: UCS matches the findings.",
      "idx": 1289,
      "timestamp": "2026-01-19T15:59:53.119542"
    },
    {
      "sample_idx": 196,
      "input": "FINAL DIAGNOSIS: BREAST, LEFT, MODIFIED RADICAL MASTECTOMY -. A. INVASIVE LOBULARICARCINOMA, NOTTINGHAM GRADE 2 (TUBULAR FORMATION 3, NUCLEAR ATYPIA 2,. MITOTIC ACTIVITY 1; TOTAL SCORE 6/9). B. THE INVASIVE TUMOR INVOLVES ALL FOUR BREAST QUADRANTS, MEASURING 11.0 CM IN LARGEST. DIMENSION (GROSS MEASUREMENT). C. THE INVASIVE TUMOR FOCALLY POSITIVE IN DEEP MARGIN IN LOWER-INNER QUADRANT (SLIDE R). D. MICROCALCIFICATIONS ASSOCIATED WITH INVASIVE CARCINOMA. E. LOBULAR CARCINOMA IN-SITU, NUCLEAR GRAD...",
      "response": "```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2 (tubular formation 3, nuclear atypia 2, mitotic activity 1; total score 6/9). 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2 (tubular formation 3, nuclear atypia 2, mitotic activity 1; total score 6/9). 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2 (tubular formation 3, nuclear atypia 2, mitotic activity 1; total score 6/9). 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2 (tubular formation 3, nuclear atypia 2, mitotic activity 1; total score 6/9). 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2 (tubular formation 3, nuclear atypia 2, mitotic activity 1; total score 6/9). 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"BRCA\",\n    \"reasoning\": \"1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2 (tubular formation 3, nuclear atypia 2, mitotic activity 1; total score 6/9). 3. Code: Breast Invasive Carcinoma maps to BRCA.\"\n}\n```\n```json",
      "predicted": "BRCA",
      "ground_truth": "BRCA",
      "correct": true,
      "reasoning": "1. Site: Breast. 2. Findings: Invasive lobular carcinoma, Nottingham grade 2 (tubular formation 3, nuclear atypia 2, mitotic activity 1; total score 6/9). 3. Code: Breast Invasive Carcinoma maps to BRCA.",
      "idx": 196,
      "timestamp": "2026-01-19T15:59:53.119554"
    },
    {
      "sample_idx": 1037,
      "input": "MRN fr. Ref Physiciar. Acct / Reg #: DIAGNOSIS: A. Soft tissue, prostate/urinary bladder, posterior neck, excision: No evidence of malignancy. B. Soft tissue, prostate/urinary bladder, anterior neck, excision: No evidence of malignancy. C.Prostate, radical prostatectomy: Tumor Characteristics: 1. Histologic type, Adenocarcinoma. 2. Gleason's Grade: a. Primary pattern: 3 of 5. b. Secondary pattern: 3 of 5. c. 3. Tumor involves:(Both lobes. 4. Tumor quantitation: Approximately 25%. 5. Seminal vesi...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, Gleason's Grade 3 (primary and secondary patterns), Tumor involves both lobes, Tumor quantitation approximately 25%, Seminal vesicle involvement absent, Extracapsular tumor extension present (block C8), Lymphovascular space invasion absent, Perlheural space invasion present, High-grade PIN present. 3. Code: Prostate adenocarcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, Gleason's Grade 3 (primary and secondary patterns), Tumor involves both lobes, Tumor quantitation approximately 25%, Seminal vesicle involvement absent, Extracapsular tumor extension present (block C8), Lymphovascular space invasion absent, Perlheural space invasion present, High-grade PIN present. 3. Code: Prostate adenocarcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, Gleason's Grade 3 (primary and secondary patterns), Tumor involves both lobes, Tumor quantitation approximately 25%, Seminal vesicle involvement absent, Extracapsular tumor extension present (block C8), Lymphovascular space invasion absent, Perlheural space invasion present, High-grade PIN present. 3. Code: Prostate adenocarcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, Gleason's Grade 3 (primary and secondary patterns), Tumor involves both lobes, Tumor quantitation approximately 25%, Seminal vesicle involvement absent, Extracapsular tumor extension present (block C8), Lymphovascular space invasion absent, Perlheural space invasion present, High-grade PIN present. 3. Code: Prostate adenocarcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Prostate. 2. Findings: Adenocarcinoma, Gleason's Grade 3 (primary and secondary patterns), Tumor involves both lobes",
      "predicted": "KIRC",
      "ground_truth": "PRAD",
      "correct": false,
      "reasoning": "1. Site: Prostate. 2. Findings: Adenocarcinoma, Gleason's Grade 3 (primary and secondary patterns), Tumor involves both lobes, Tumor quantitation approximately 25%, Seminal vesicle involvement absent, Extracapsular tumor extension present (block C8), Lymphovascular space invasion absent, Perlheural space invasion present, High-grade PIN present. 3. Code: Prostate adenocarcinoma maps to KIRC.",
      "idx": 1037,
      "timestamp": "2026-01-19T15:59:53.119570"
    },
    {
      "sample_idx": 1338,
      "input": "SLIDE DISPOSITION. DIAGNOSIS: A. Abdomen, panniculectomy : Skin and subcutaneous. tissue, 1590.0. grams, identified grossly. Gross examination only. B . Uterus, bilateral ovaries, and fallopian tubes;. hysterectomy and. bilateral salpingo-oophorectomy: Invasive endometrial. adenocarcinoma, endometrioid type, FIGO grade I (of III). is. identified forming a mass (10.7 x 7.8 x 2.1 cm). circumferentially. involving the endometrial cavity. The tumor invades 0. 6. cm into the. myometrium (total myomet...",
      "response": "```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Invasive endometrial adenocarcinoma, endometrioid type, FIGO grade I (of III). 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Invasive endometrial adenocarcinoma, endometrioid type, FIGO grade I (of III). 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Invasive endometrial adenocarcinoma, endometrioid type, FIGO grade I (of III). 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Invasive endometrial adenocarcinoma, endometrioid type, FIGO grade I (of III). 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Invasive endometrial adenocarcinoma, endometrioid type, FIGO grade I (of III). 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Invasive endometrial adenocarcinoma, endometrioid type, FIGO grade I (of III). 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Invasive endometrial adenocarcinoma, endometrioid type, FIGO grade I (of III). 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"UCEC\",\n    \"reasoning\": \"1. Site: Uterus. 2. Findings: Invasive endometrial adenocarcinoma, endometrioid type, FIGO grade I (of III). 3. Code: UCEC.\"\n}\n```\n```json\n{\n    \"cancer",
      "predicted": "UCEC",
      "ground_truth": "UCEC",
      "correct": true,
      "reasoning": "1. Site: Uterus. 2. Findings: Invasive endometrial adenocarcinoma, endometrioid type, FIGO grade I (of III). 3. Code: UCEC.",
      "idx": 1338,
      "timestamp": "2026-01-19T15:59:53.119580"
    },
    {
      "sample_idx": 1135,
      "input": "Case imported from. computer system. The format of this report does not match the original case. For cases prior to /. he section \"SPECIMEN\" may have been added. DIAGNOSIS. (A) RETROPERITONEAL TUMOR: DEDIFFERENTIATED LIPOSARCOMA IN A BACKGROUND OF ATYPICAL LIPOMATOUS. TUMOR. (SEE COMMENT). ATYPICAL LIPOMATOUS TUMOR INVOLVING SUPERIOR MARGIN. (B) SUPERIOR MARGIN: ADIPOSE TISSUE WITH FIBROUS AREAS WITH SLIGHLTLY AYIPICAL CELLS. SUGGESTIVE OF ATYPICAL LIPOMATOUS TUMOR. (C) LIVER BIOPSY: Bile duct h...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Dedifferentiated liposarcoma in a background of atypical lipomatous tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Dedifferentiated liposarcoma in a background of atypical lipomatous tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Dedifferentiated liposarcoma in a background of atypical lipomatous tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Dedifferentiated liposarcoma in a background of atypical lipomatous tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Dedifferentiated liposarcoma in a background of atypical lipomatous tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Dedifferentiated liposarcoma in a background of atypical lipomatous tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Retroperitoneum. 2. Findings: Dedifferentiated liposarcoma in a background of atypical lipomatous tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",",
      "predicted": "KIRC",
      "ground_truth": "SARC",
      "correct": false,
      "reasoning": "1. Site: Retroperitoneum. 2. Findings: Dedifferentiated liposarcoma in a background of atypical lipomatous tumor. 3. Code: Kidney Renal Clear Cell Carcinoma maps to KIRC.",
      "idx": 1135,
      "timestamp": "2026-01-19T15:59:53.119591"
    },
    {
      "sample_idx": 693,
      "input": "Specimen Description. Clinical History. Frontal temporal parietal lesion. ADDENDA: Addendum added: Final Pathologic Diagnosis. Left frontal tumor, excision: - Oligodendroglioma (WHO grade II). See comment. B. Left frontal tumor, excision: - 01 lyodendroglioma (WHO grade II) . Comment: The overall profile is chat of a low grade oligodendroglioma. However, tocally elevated proliferation index of about 8-10% raises the. possibility of future biological progression to higher grade. Cleser follow. up...",
      "response": "```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Frontal lobe. 2. Findings: Oligodendroglioma (WHO grade II). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Frontal lobe. 2. Findings: Oligodendroglioma (WHO grade II). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Frontal lobe. 2. Findings: Oligodendroglioma (WHO grade II). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Frontal lobe. 2. Findings: Oligodendroglioma (WHO grade II). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Frontal lobe. 2. Findings: Oligodendroglioma (WHO grade II). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Frontal lobe. 2. Findings: Oligodendroglioma (WHO grade II). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Frontal lobe. 2. Findings: Oligodendroglioma (WHO grade II). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Frontal lobe. 2. Findings: Oligodendroglioma (WHO grade II). 3. Code: KIRC\"\n}\n```\n```json\n{\n    \"cancer_type\": \"KIRC\",\n    \"reasoning\": \"1. Site: Frontal lobe. 2. Findings: Oligodendroglioma (WHO grade II). 3.",
      "predicted": "KIRC",
      "ground_truth": "LGG",
      "correct": false,
      "reasoning": "1. Site: Frontal lobe. 2. Findings: Oligodendroglioma (WHO grade II). 3. Code: KIRC",
      "idx": 693,
      "timestamp": "2026-01-19T15:59:53.119600"
    }
  ],
  "end_time": "2026-01-19T15:59:53.165311",
  "duration_seconds": 2357.12578
}